[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fU33KjU01FeZmXlQxShtRI4ymonyyvwdBF2j9L_IscJA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"Novartis Pharmaceuticals",[4],2647,false,333,730,4527742,277,281,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Breast Cancer",68,{"name":18,"count":19},"Asthma",63,{"name":21,"count":22},"Hypertension",44,{"name":24,"count":25},"Chronic Obstructive Pulmonary Disease",42,{"name":27,"count":28},"Multiple Sclerosis",39,{"name":30,"count":31},"Diabetes Mellitus, Type 2",34,{"name":33,"count":34},"Chronic Spontaneous Urticaria",27,{"name":36,"count":37},"Melanoma",26,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT02381886","A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations","2016-12-07","IDH305",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT01892722","Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis","2017-07-14","Interferon beta-1a",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04516369","Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy","2022-04-05","voretigene neparvovec",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT04765657","Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)","2022-06-09","inclisiran sodium",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT03814746","Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients","2022-08-31","Crizanlizumab",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT04689828","177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","2022-10-02","177Lu-PSMA-617",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT04179175","Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa","2023-05-26","secukinumab",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04603495","Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)","2023-08-23","Pelabresib",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT04971226","A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","2023-11-28","Imatinib",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT04589650","Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum","2024-03-20","Alpelisib",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,495,714,1052,1355,1560,1658,2340,2611,2751,3016,3184,3660,3904,3986,4024,4147,4206,4238,4264,4291,5158,5284,5362,5384,5414,5451,5476,5494,5512,5530,5554,5580,5768,5935,6110,6247,6409,6467,6616,6678,6721,6833,6890,6922,6999,7074,7118,7151,7185,7219,7241,7282,7304,7326,7348,7377,7557,7613,7743,7810,7854,8029,8138,8249,8287,8313,8357,8402,8428,8450,8481,8505,8523,8541,8559,8577,8605,8623,8641,8667,8685,8708,8733,8751,8777,8795,8815,8833,8851,8869,8887,8905,8923,8941,8965,8990,9008,9031,9049,9256,9282,9315,9398,9448,9478,9541,9577,9622,9681,9727,9758,9784,9810,9895,9964,9994,10026,10159,10220,10271,10311,10349,10383,10418,10449,10471,10560,10678,10781,10848,10886,10932,10954,10979,11080,11165,11229,11267,11305,11341,11378,11410,11445,11467,11492,11525,11547,11569,11595,11617,11642,11669,11687,11705,11731,11749,11773,11791,11809,11832,11850,11868,11886,11910,11928,11946,11971,11989,12013,12031,12049,12067,12085,12111,12129,12147,12165,12189,12207,12230,12255,12273,12291,12309,12327,12345,12363,12381,12404,12428,12453,12471,12496,12521,12544,12568,12594,12612,12636,12654,12672,12690,12708,12726,12744,12769,12793,12811,12829,12847,12865,12883,12901,12919,12937,12955,13057,13170,13212,13253,13543,13565,13668,13694,13822,13893,13947,13982,14008,14039,14061,14089,14116,14134,14152,14170,14194,14212,14230,14248,14266,14284,14302,14320,14342,14369,14387,14405,14423,14441,14463,14486,14504,14522,14547,14571,14598,14616,14634,14652,14675,14705,14731,14757,14784,14812,14836,14861,14879,14897,14915,14933,14951,14969,14987,15005,15028,15351,15523,15704,15894,16052,16192,16317,16449,16598,16714,16854,16978,17086,17177,17264,17381,17484,17576,17633,17733,17833,17912,17963,18049,18112,18158,18210,18260,18322,18383,18421,18462,18500,18541,18608,18642,18676,18713,18768,18819,18853,18915,18951,19015,19048,19083,19131,19167,19193,19231,19257,19298,19339,19367,19407,19433,19469,19499,19534,19570,19596,19625,19651,19686,19708,19730,19752,19777,19799,19826,19853,19886,19916,19947,19973,19999,20021,20046,20075,20105,20130,20155,20181,20202,20225,20243,20261,20279,20297,20315,20333,20351,20380,20398,20416,20434,20452,20470,20488,20506,20529,20551,20572,20594,20612,20637,20655,20678,20701,20719,20737,20758,20776,20794,20812,20830,20848,20866,20889,20912,20930,20948,20966,20987,21005,21023,21041,21064,21086,21104,21122,21140,21158,21182,21200,21218,21240,21258,21279,21297,21321,21339,21361,21383,21401,21419,21437,21455,21479,21497,21521,21539,21557,21575,21597,21623,21641,21659,21677,21699,21723,21744,21769,21787,21805,21823,21841,21862,21880,21898,21922,21940,21958,21976,21994,22018,22040,22058,22076,22094,22116,22134,22152,22174,22192,22210,22228,22249,22267,22285,22303,22326,22348,22366,22384,22402,22423,22441,22463,22481,22499,22517,22535,22557,22578,22596,22619,22637,22655,22676,22699,22717,22743,22761,22779,22797,23000,23136,23227,23349,23459,23565,23646,23692,23754,23818,23888,23934,23981,24022,24060,24109,24157,24221,24261,24310,24344,24394,24428,24462,24512,24560,24609,24656,24702,24740,24779,24809,24847,24877,24907,24942,24968,25007,25033,25077,25103,25144,25183,25209,25235,25261,25294,25327,25349,25375,25406,25428,25450,25479,25504,25530,25560,25588,25619,25649,25671,25700,25730,25763,25791,25813,25843,25868,25897,25919,25948,25974,26007,26033,26056,26084,26111,26133,26155,26177,26199,26221,26243,26268,26290,26312,26336,26361,26383,26408,26426,26450,26468,26491,26509,26531,26549,26567,26591,26609,26627,26645,26669,26687,26712,26730,26748,26770,26793,26811,26837,26855,26873,26896,26914,26932,26954,26977,26999,27017,27035,27056,27079,27101,27119,27140,27162,27180,27198,27216,27242,27260,27278,27296,27318,27336,27359,27377,27395,27418,27440,27458,27476,27494,27512,27536,27561,27579,27597,27615,27633,27651,27669,27687,27713,27731,27749,27767,27785,27803,27821,27839,27864,27882,27907,27925,27943,27961,27984,28002,28020,28046,28064,28082,28100,28118,28140,28158,28181,28199,28217,28235,28258,28276,28294,28312,28330,28348,28371,28389,28412,28430,28448,28466,28484,28502,28525,28543,28561,28579,28597,28615,28638,28660,28685,28703,28721,28739,28765,28783,28806,28824,28842,28860,28878,28896,28914,28932,28950,28972,28990,29008,29032,29050,29068,29086,29110,29128,29146,29169,29187,29210,29228,29255,29278,29296,29316,29334,29357,29375,29393,29411,29429,29447,29465,29489,29507,29525,29543,29564,29587,29605,29623,29647,29670,29688,29712,29730,29748,29766,29784,29802,29820,29838,29856,29881,29899,29917,29935,29958,29982,30000,30022,30045,30068,30086,30104,30125,30148,30166,30184,30202,30220,30238,30256,30274,30292,30316,30337,30355,30373,30391,30413,30431,30449,30467,30494,30512,30530,30548,30573,30591,30609,30627,30645,30663,30681,30699,30720,30738,30763,30781,30806,30824,30842,30867,30885,30907,30925,30943,30964,30989,31007,31025,31051,31069,31091,31115,31133,31266,31375,31472,31571,31648,31709,31775,31833,31908,31972,32041,32092,32160,32212,32263,32327,32367,32407,32441,32475,32521,32569,32621,32660,32718,32776,32821,32866,32901,32940,32986,33022,33071,33106,33154,33190,33220,33252,33288,33314,33356,33386,33418,33457,33493,33515,33544,33576,33606,33632,33661,33688,33719,33741,33773,33805,33832,33859,33881,33924,33955,33977,33999,34029,34059,34081,34111,34140,34166,34188,34210,34241,34263,34295,34326,34348,34382,34404,34426,34448,34477,34506,34541,34563,34587,34605,34623,34641,34666,34684,34706,34724,34745,34767,34785,34803,34821,34839,34862,34880,34898,34922,34945,34963,34981,34999,35020,35038,35063,35081,35099,35121,35139,35161,35179,35205,35223,35241,35259,35277,35295,35318,35341,35359,35377,35401,35419,35442,35460,35482,35500,35524,35542,35560,35584,35602,35620,35638,35663,35681,35705,35723,35746,35770,35788,35813,35831,35849,35867,35885,35907,35925,35947,35969,35987,36005,36023,36048,36066,36089,36107,36125,36143,36164,36189,36210,36232,36250,36272,36290,36314,36332,36350,36374,36399,36417,36438,36460,36478,36496,36514,36542,36560,36578,36596,36614,36632,36650,36668,36693,36711,36729,36747,36771,36789,36807,36828,36853,36876,36894,36920,36938,36956,36974,36992,37015,37033,37056,37074,37092,37110,37132,37153,37176,37194,37212,37230,37248,37266,37284,37306,37324,37348,37366,37392,37410,37433,37456,37478,37496,37520,37541,37559,37583,37601,37619,37637,37655,37673,37691,37709,37727,37750,37768,37786,37804,37827,37845,37863,37886,37904,37922,37944,37962,37980,37998,38016,38034,38052,38070,38094,38112,38141,38159,38177,38195,38213,38231,38249,38267,38285,38309,38327,38345,38363,38381,38399,38417,38435,38457,38475,38496,38518,38536,38554,38575,38600,38618,38640,38658,38676,38700,38718,38736,38754,38779,38797,38820,38838,38861,38887,38905,38923,38941,38963,38981,39005,39023,39041,39063,39089,39107,39125,39143,39161,39184,39202,39226,39244,39262,39280,39298,39316,39339,39357,39375,39399,39421,39439,39457,39475,39497,39515,39533,39555,39576,39594,39612,39634,39652,39670,39688,39706,39724,39742,39764,39787,39805,39823,39845,39863,39886,39904,39922,39940,39958,39976,39999,40017,40035,40053,40071,40089,40111,40135,40153,40171,40194,40212,40230,40252,40270,40292,40315,40333,40351,40369,40387,40410,40428,40446,40469,40487,40505,40523,40551,40569,40587,40605,40623,40641,40659,40680,40703,40721,40739,40761,40779,40806,40824,40842,40860,40878,40896,40914,40932,40970,41000,41026,41060,41089,41123,41154,41183,41209,41231,41258,41280,41307,41337,41359,41381,41415,41441,41463,41488,41506,41524,41542,41560,41578,41600,41621,41639,41657,41681,41699,41717,41735,41757,41778,41799,41820,41844,41862,41880,41901,41919,41940,41961,41984,42002,42025,42048,42066,42084,42105,42126,42148,42170,42191,42212,42233,42251,42269,42287,42308,42326,42348,42366,42384,42408,42426,42444,42462,42483,42506,42524,42547,42565,42588,42609,42632,42654,42676,42698,42720,42743,42766,42784,42802,42824,42842,42866,42884,42902,42920,42941,42959,42977,42995,43018,43036,43054,43072,43090,43108,43130,43148,43170,43191,43213,43236,43254,43275,43297,43318,43341,43359,43377,43395,43419,43437,43455,43473,43494,43515,43533,43558,43576,43594,43616,43638,43656,43677,43698,43721,43739,43762,43780,43798,43816,43834,43852,43870,43892,43910,43928,43953,43971,43989,44007,44025,44047,44070,44088,44106,44128,44150,44168,44190,44208,44231,44255,44273,44291,44314,44332,44355,44373,44397,44415,44436,44454,44472,44813,45023,45275,45503,45733,45862,46005,46087,46141,46218,46301,46336,46376,46398,46424,46455,46477,46503,46532,46556,46584,46606,46633,46655,46677,46699,46717,46735,46753,46771,46794,46815,46839,46857,46881,46905,46928,46949,46967,46993,47011,47029,47051,47073,47096,47114,47137,47155,47176,47194,47212,47230,47248],{"intervention":98,"totalTrials":99,"cells":100},"Ribociclib",33,{"EARLY_PHASE1":101,"PHASE1":104,"PHASE2":214,"PHASE3":318,"PHASE4":425,"NA":438},{"trials":102,"activeCount":103},[],0,{"trials":105,"activeCount":213,"soonestReadout":149},[106,120,131,144,161,174,185,197],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":116},"NCT05870579","[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer","RECRUITING",[91],"2026-12-30","2032-04-05","2023-11-13",48,[15],[117,118,98,119],"[68Ga]Ga-NeoB","[177Lu]Lu-NeoB","Fulvestrant",{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":125,"start":126,"enrollment":34,"conditions":127,"interventions":129},"NCT02292550","Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.","COMPLETED",[91],"2018-09-26","2015-05-14",[128],"Non-small Cell Lung Cancer",[98,130],"Ceritinib",{"nctId":132,"briefTitle":133,"status":134,"phases":135,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":141},"NCT05429502","Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors","TERMINATED",[91],"2025-02-26","2022-12-27",12,[140],"Neuroblastoma",[142,143,98],"Topotecan","Temozolomide",{"nctId":145,"briefTitle":146,"status":147,"phases":148,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":154},"NCT03333343","Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC","ACTIVE_NOT_RECRUITING",[91],"2026-10-05","2018-01-29",105,[153],"EGFR-mutant Non-small Cell Lung Cancer",[155,156,157,158,159,160],"EGF816","trametinib","ribociclib","LXH254","INC280","gefitinib",{"nctId":162,"briefTitle":163,"status":134,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":172},"NCT02703571","Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors",[91],"2019-09-24","2016-06-29",95,[169,170,171],"Solid Tumors for Phase Ib","Pancreatic Cancer for Phase II","Colorectal Cancer for Phase II",[157,173],"Trametinib",{"nctId":175,"briefTitle":176,"status":134,"phases":177,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},"NCT02974725","A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma",[91],"2024-04-24","2017-02-24",241,[182,36],"Non-Small Cell Lung Cancer",[158,184,173,98],"LTT462",{"nctId":186,"briefTitle":187,"status":123,"phases":188,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":194},"NCT01857193","Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer",[91],"2018-03-14","2020-04-16","2013-09-06",132,[15],[157,195,196],"Exemestane","Everolimus",{"nctId":198,"briefTitle":199,"status":134,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":210},"NCT04000529","Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies",[91],"2024-01-15","2019-07-30",122,[205,206,207,208,209],"Non-small Cell Lung Carcinoma","Head and Neck Squamous Cell Carcinoma","Esophageal SCC","Gastrointestinal Stromal Tumors","Colorectal Cancer",[211,212,98],"TNO155","Spartalizumab",2,{"trials":215,"activeCount":317,"soonestReadout":220},[216,237,251,265,275,286,295,308],{"nctId":217,"briefTitle":218,"status":147,"phases":219,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":234},"NCT05358249","Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",[91,92],"2026-07-29","2026-07-30","2022-10-24",74,[225,226,227,182,228,229,209,230,231,232,233],"KRAS G12C Mutant Solid Tumors","Carcinoma, Non-Small Cell Lung","Carcinoma, Non-Small-Cell Lung","Non-Small Cell Lung Carcinoma","Nonsmall Cell Lung Cancer","Colorectal Carcinoma","Colorectal Neoplasms","Colorectal Tumors","Neoplasms, Colorectal",[235,156,98,236],"JDQ443","cetuximab",{"nctId":238,"briefTitle":239,"status":123,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":246},"NCT03671330","Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.",[92],"2022-04-25","2025-05-09","2018-08-29",327,[15],[247,98,248,249,250],"Ribociclib Placebo","NSAI: Letrozole or Anastrazole","Letrozole","Goserelin",{"nctId":252,"briefTitle":253,"status":123,"phases":254,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":260},"NCT03839823","Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer",[92],"2022-04-12","2023-05-10","2019-02-25",222,[15],[261,262,263,98,264,250],"Docetaxel \u002F Capecitabine","Capecitabine \u002F Vinorelbine","Paclitaxel \u002F Gemcitabine","Letrozole OR Anastrozole",{"nctId":266,"briefTitle":267,"status":123,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":273},"NCT03078751","Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+\u002FHER2- High Risk Early Breast Cancer",[92],"2020-03-09","2017-06-20",54,[15],[98,274],"Adjuvant endocrine therapy",{"nctId":276,"briefTitle":277,"status":123,"phases":278,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":284},"NCT03822468","Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",[92],"2021-06-11","2024-08-30","2019-06-11",376,[15],[98,285,249,250],"Anastrozole",{"nctId":287,"briefTitle":288,"status":147,"phases":289,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":294},"NCT04417621","Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma",[92],"2027-02-02","2020-10-30",134,[36],[158,184,173,98],{"nctId":296,"briefTitle":297,"status":109,"phases":298,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":305},"NCT06726148","Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+\u002FHER2- Breast Cancer and Other Advanced Solid Tumors",[91,92],"2028-09-25","2025-04-03",280,[303,304],"Advanced HR+\u002FHER2- Breast Cancer","Advanced CCNE1-amplified Solid Tumors",[306,157,307],"ECI830","fulvestrant",{"nctId":309,"briefTitle":310,"status":123,"phases":311,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":316},"NCT02732119","Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced\u002FMetastatic Breast Cancer Post Progression on CDK 4\u002F6 Inhibitor.",[91,92],"2020-02-25","2016-06-14",104,[15],[98,196,195],3,{"trials":319,"activeCount":213,"soonestReadout":324},[320,333,346,357,366,377,387,396,407,416],{"nctId":321,"briefTitle":322,"status":109,"phases":323,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":330},"NCT05827081","Phase IIIb Study of Ribociclib + ET in Early Breast Cancer",[93],"2029-09-07","2030-09-20","2024-02-28",1400,[329],"Early Breast Cancer",[98,249,331,250,332,195],"Ansastrozole","Leuprolide",{"nctId":334,"briefTitle":335,"status":123,"phases":336,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":343},"NCT03096847","Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer",[93],"2018-12-11","2020-02-06","2016-10-24",502,[342],"Advanced Metastatic Breast Cancer",[157,344,345],"letrozole","goserelin",{"nctId":347,"briefTitle":348,"status":123,"phases":349,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":355},"NCT02278120","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",[93],"2017-08-21","2023-04-20","2014-11-20",672,[342],[98,356,249,285,250],"Tamoxifen",{"nctId":358,"briefTitle":359,"status":147,"phases":360,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":365},"NCT03701334","A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+\u002FHER2- Early Breast Cancer",[93],"2030-05-29","2018-12-07",5101,[329],[98],{"nctId":367,"briefTitle":368,"status":123,"phases":369,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":376},"NCT02422615","Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.",[93],"2017-11-03","2023-01-11","2015-06-09",726,[375],"Advanced Breast Cancer",[98,119],{"nctId":378,"briefTitle":379,"status":123,"phases":380,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":386},"NCT02941926","Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre\u002FPostmenopausal Women With HR+ HER2- aBC",[93],"2019-11-08","2022-11-09","2016-11-30",3246,[15],[98,249,250,332],{"nctId":388,"briefTitle":389,"status":390,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":103,"conditions":394,"interventions":395},"NCT03081234","Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+\u002FHER2- Intermediate Risk Early Breast Cancer","WITHDRAWN",[93],"2025-11-17","2018-03-31",[15],[98,274],{"nctId":397,"briefTitle":398,"status":123,"phases":399,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":406},"NCT01958021","Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer",[93],"2016-01-29","2023-03-16","2013-12-17",668,[405],"Advanced, Metastatic Breast Cancer",[98,249],{"nctId":408,"briefTitle":409,"status":123,"phases":410,"primaryCompletion":411,"completion":411,"start":412,"enrollment":413,"conditions":414,"interventions":415},"NCT03439046","Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant",[93],"2023-12-11","2018-02-02",287,[15],[98,249,88,119],{"nctId":417,"briefTitle":418,"status":134,"phases":419,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":424},"NCT03050398","A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4\u002F6 Therapy\u002FLEE011\u002FRibociclib",[93],"2019-03-08","2017-06-07",8,[15],[98,344],{"trials":426,"activeCount":437,"soonestReadout":431},[427],{"nctId":428,"briefTitle":429,"status":147,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":292,"conditions":434,"interventions":436},"NCT05161195","Roll-over Study to Allow Continued Access to Ribociclib",[94],"2030-06-28","2030-08-14","2022-07-07",[435],"Metastatic Breast Cancer",[98,249,285,250,356,119],1,{"trials":439,"activeCount":317,"soonestReadout":444},[440,450,461,470,479,488],{"nctId":441,"briefTitle":442,"status":109,"phases":443,"primaryCompletion":444,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":449},"NCT06797531","RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+\u002FHER2- Early Breast Cancer in Saudi Arabia",[],"2028-11-30","2025-08-27",177,[448],"HR+\u002FHER2- Early Breast Cancer",[157],{"nctId":451,"briefTitle":452,"status":123,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":458},"NCT05153135","Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+\u002FHER2- Breast Cancer Treated With CDK4\u002F6 Inhibitors",[],"2020-07-31","2020-05-08",4320,[435],[98,459,460],"Palbociclib","Abemaciclib",{"nctId":462,"briefTitle":463,"status":109,"phases":464,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":469},"NCT06905301","Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice",[],"2029-12-31","2026-01-23",240,[15],[98,249,285],{"nctId":471,"briefTitle":472,"status":109,"phases":473,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":478},"NCT06930859","Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia",[],"2032-12-31","2025-12-03",2766,[15],[98,249,285],{"nctId":480,"briefTitle":481,"status":123,"phases":482,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":487},"NCT05569187","Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer",[],"2021-10-29","2021-03-23",76,[15],[98],{"nctId":489,"briefTitle":490,"status":491,"phases":492,"conditions":493,"interventions":494},"NCT05038631","Managed Access Programs for LEE011, Ribociclib","AVAILABLE",[],[15],[98],{"intervention":119,"totalTrials":496,"cells":497},23,{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":549,"PHASE3":638,"PHASE4":697,"NA":712},{"trials":499,"activeCount":103},[],{"trials":501,"activeCount":213,"soonestReadout":111},[502,506,518,528,538],{"nctId":107,"briefTitle":108,"status":109,"phases":503,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":504,"interventions":505},[91],[15],[117,118,98,119],{"nctId":507,"briefTitle":508,"status":123,"phases":509,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":514},"NCT02088684","Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer",[91],"2018-04-17","2014-05-19",70,[15],[515,516,307,517],"LEE011","BYL719","BKM120",{"nctId":519,"briefTitle":520,"status":109,"phases":521,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":526},"NCT07604571","Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+\u002FHER2- Breast Cancer",[91],"2032-06-08","2026-05-28",194,[303],[527,119,249],"IEV407",{"nctId":529,"briefTitle":530,"status":123,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":535,"interventions":537},"NCT02333370","A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",[91],"2022-09-29","2015-02-04",88,[536],"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",[515,249,356,119,345],{"nctId":539,"briefTitle":540,"status":123,"phases":541,"primaryCompletion":542,"completion":190,"start":543,"enrollment":544,"conditions":545,"interventions":548},"NCT01219699","A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",[91],"2015-02-05","2010-10-05",221,[546,547],"Advanced Solid Tumors With an Alteration of the PIK3CA Gene","Estrogen Receptor Positive Breast Cancer",[516,119],{"trials":550,"activeCount":637,"soonestReadout":555},[551,561,571,579,590,602,613,623,633],{"nctId":552,"briefTitle":553,"status":147,"phases":554,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":560},"NCT04544189","Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer",[92],"2027-01-29","2021-01-20",69,[559],"Breast Neoplasms",[88,119],{"nctId":562,"briefTitle":563,"status":123,"phases":564,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":570},"NCT03056755","Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments",[92],"2021-06-14","2024-11-12","2017-08-29",383,[15],[88,119,249,250,332],{"nctId":572,"briefTitle":573,"status":134,"phases":574,"primaryCompletion":575,"completion":575,"start":576,"enrollment":213,"conditions":577,"interventions":578},"NCT04862143","Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant",[92],"2022-09-19","2022-03-08",[375],[88,119,250],{"nctId":580,"briefTitle":581,"status":109,"phases":582,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":588},"NCT07288359","Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+\u002FHER2- Breast Cancer and Other Advanced Solid Tumors",[91,92],"2031-05-09","2025-12-29",205,[303,304,587],"Metastatic Castration-resistant Prostate Cancer",[589,119,249],"GVV858",{"nctId":591,"briefTitle":592,"status":593,"phases":594,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":598,"interventions":600},"NCT07570966","Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+\u002FHER2- Breast Cancer and Other Advanced Solid Tumors","NOT_YET_RECRUITING",[91,92],"2031-08-01","2026-06-30",217,[303,304,599],"Metastatic Castration-resistant Prostate Cancer (mCRPC)",[601,119,249],"ERW316",{"nctId":603,"briefTitle":604,"status":134,"phases":605,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":609,"interventions":610},"NCT01528345","Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",[92],"2015-04","2012-04",97,[435],[611,119,612],"Dovitinib","Dovitinib Placebo",{"nctId":614,"briefTitle":615,"status":134,"phases":616,"primaryCompletion":256,"completion":256,"start":617,"enrollment":213,"conditions":618,"interventions":619},"NCT04899349","Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant",[92],"2022-04-06",[15],[88,119,620,621,622],"Metformin XR","Dapagliflozin + metformin XR","Dapagliflozin",{"nctId":624,"briefTitle":625,"status":147,"phases":626,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":632},"NCT04524000","Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer",[92],"2027-02-26","2027-02-27","2021-01-08",24,[375],[88,119],{"nctId":296,"briefTitle":297,"status":109,"phases":634,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":635,"interventions":636},[91,92],[303,304],[306,157,307],5,{"trials":639,"activeCount":437,"soonestReadout":688},[640,650,660,670,680,684,693],{"nctId":641,"briefTitle":642,"status":123,"phases":643,"primaryCompletion":644,"completion":644,"start":645,"enrollment":138,"conditions":646,"interventions":648},"NCT02116803","An Open Label Multi-center Extension Study to Evaluate Long-term Safety\u002F Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective",[92,93],"2016-11-28","2014-05-28",[647],"Solid Tumors",[649,307],"dovitinib",{"nctId":651,"briefTitle":652,"status":123,"phases":653,"primaryCompletion":654,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":659},"NCT02437318","Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.",[93],"2018-06-12","2023-06-09","2015-07-23",572,[15],[119,88],{"nctId":661,"briefTitle":662,"status":123,"phases":663,"primaryCompletion":664,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":669},"NCT01610284","Phase III Study of BKM120\u002FPlacebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor",[93],"2015-04-29","2019-04-19","2012-08-07",1147,[15],[119,517],{"nctId":671,"briefTitle":672,"status":134,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":679},"NCT01633060","A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",[93],"2016-05-23","2017-09-21","2012-10-03",432,[435],[119,517],{"nctId":367,"briefTitle":368,"status":123,"phases":681,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":682,"interventions":683},[93],[375],[98,119],{"nctId":685,"briefTitle":686,"status":147,"phases":687,"primaryCompletion":688,"completion":627,"start":689,"enrollment":690,"conditions":691,"interventions":692},"NCT05038735","Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4\u002F6 Inhibitor and an Aromatase Inhibitor.",[93],"2027-01-28","2021-12-17",210,[15],[88,119],{"nctId":408,"briefTitle":409,"status":123,"phases":694,"primaryCompletion":411,"completion":411,"start":412,"enrollment":413,"conditions":695,"interventions":696},[93],[15],[98,249,88,119],{"trials":698,"activeCount":437,"soonestReadout":431},[699,703],{"nctId":428,"briefTitle":429,"status":147,"phases":700,"primaryCompletion":431,"completion":432,"start":433,"enrollment":292,"conditions":701,"interventions":702},[94],[435],[98,249,285,250,356,119],{"nctId":704,"briefTitle":705,"status":123,"phases":706,"primaryCompletion":707,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":711},"NCT05631795","Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment",[94],"2025-06-12","2022-08-09",40,[375],[88,119],{"trials":713,"activeCount":103},[],{"intervention":249,"totalTrials":22,"cells":715},{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":739,"PHASE3":858,"PHASE4":982,"NA":1042},{"trials":717,"activeCount":103},[],{"trials":719,"activeCount":437,"soonestReadout":522},[720,724,728],{"nctId":519,"briefTitle":520,"status":109,"phases":721,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":722,"interventions":723},[91],[303],[527,119,249],{"nctId":529,"briefTitle":530,"status":123,"phases":725,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":726,"interventions":727},[91],[536],[515,249,356,119,345],{"nctId":729,"briefTitle":730,"status":123,"phases":731,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":735,"interventions":737},"NCT02154776","Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.",[91],"2016-10-26","2014-06-27",13,[736],"Advanced or Metastatic Breast Cancer",[515,738,249],"Buparlisib",{"trials":740,"activeCount":317,"soonestReadout":627},[741,750,763,767,779,783,787,796,800,808,817,821,831,840,849],{"nctId":742,"briefTitle":743,"status":123,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":709,"conditions":747,"interventions":749},"NCT00240942","Letrozole in the Treatment of Severe and Recurrent Endometriosis",[92],"2006-06","2002-10",[748],"Severe and Recurrent Endometriosis",[249],{"nctId":751,"briefTitle":752,"status":123,"phases":753,"primaryCompletion":754,"completion":755,"start":756,"enrollment":757,"conditions":758,"interventions":760},"NCT01698918","Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",[92],"2015-12-17","2021-01-13","2013-03-07",202,[759],"Hormone Receptor Positive Breast Cancer",[196,249,195,761,762],"Alcohol-free dexamethasone mouth rinse","Standard of care to treat stomatitis",{"nctId":562,"briefTitle":563,"status":123,"phases":764,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":765,"interventions":766},[92],[15],[88,119,249,250,332],{"nctId":768,"briefTitle":769,"status":123,"phases":770,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":775,"interventions":778},"NCT01231659","Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer",[92],"2012-11-20","2017-04-30","2011-08-09",72,[776,777,435],"Postmenopausal Women","Locally Advanced Metastatic Breast Cancer",[196,249],{"nctId":580,"briefTitle":581,"status":109,"phases":780,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":781,"interventions":782},[91,92],[303,304,587],[589,119,249],{"nctId":238,"briefTitle":239,"status":123,"phases":784,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":785,"interventions":786},[92],[15],[247,98,248,249,250],{"nctId":788,"briefTitle":789,"status":123,"phases":790,"primaryCompletion":745,"start":791,"enrollment":792,"conditions":793,"interventions":795},"NCT00333086","A Study of Letrozole in the Treatment of Endometrial Cancer",[92],"2000-01",36,[794],"Recurrent and Metastatic Endometrial Cancer",[249],{"nctId":591,"briefTitle":592,"status":593,"phases":797,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":798,"interventions":799},[91,92],[303,304,599],[601,119,249],{"nctId":801,"briefTitle":802,"status":147,"phases":803,"primaryCompletion":627,"completion":627,"start":804,"enrollment":805,"conditions":806,"interventions":807},"NCT01872260","Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",[91,92],"2013-10-22",255,[15],[515,249,516],{"nctId":809,"briefTitle":810,"status":134,"phases":811,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":815,"interventions":816},"NCT01919229","A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)",[92],"2014-09","2013-10",14,[329],[515,344],{"nctId":276,"briefTitle":277,"status":123,"phases":818,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":819,"interventions":820},[92],[15],[98,285,249,250],{"nctId":822,"briefTitle":823,"status":123,"phases":824,"primaryCompletion":825,"completion":825,"start":826,"enrollment":827,"conditions":828,"interventions":830},"NCT00237211","Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer",[92],"2006-10","2001-06",31,[829],"Postmenopausal Women With Advanced Breast Cancer",[249],{"nctId":832,"briefTitle":833,"status":123,"phases":834,"primaryCompletion":835,"start":836,"enrollment":837,"conditions":838,"interventions":839},"NCT00247663","Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer",[92],"2005-12","1999-12",17,[829],[249],{"nctId":841,"briefTitle":842,"status":123,"phases":843,"primaryCompletion":844,"start":845,"enrollment":846,"conditions":847,"interventions":848},"NCT00237198","Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment",[92],"2006-07","2004-03",47,[829],[249],{"nctId":850,"briefTitle":851,"status":123,"phases":852,"primaryCompletion":853,"start":854,"enrollment":37,"conditions":855,"interventions":857},"NCT00171808","Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer",[92],"2010-05","2005-04",[856],"Endometrial Cancer",[249],{"trials":859,"activeCount":437,"soonestReadout":324},[860,869,876,887,891,900,909,913,922,930,934,945,956,960,970,974,978],{"nctId":861,"briefTitle":862,"status":123,"phases":863,"primaryCompletion":864,"start":865,"enrollment":866,"conditions":867,"interventions":868},"NCT00332852","Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer",[93],"2010-07","2006-03",655,[15],[249],{"nctId":870,"briefTitle":871,"status":123,"phases":872,"primaryCompletion":812,"completion":812,"start":835,"enrollment":873,"conditions":874,"interventions":875},"NCT00248170","Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer",[93],4172,[15],[249,285],{"nctId":877,"briefTitle":878,"status":123,"phases":879,"primaryCompletion":880,"completion":880,"start":881,"enrollment":882,"conditions":883,"interventions":885},"NCT00171340","Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.",[93],"2010-02","2003-05",1065,[884,15],"Bone Loss",[886,249],"Zoledronic acid",{"nctId":321,"briefTitle":322,"status":109,"phases":888,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":889,"interventions":890},[93],[329],[98,249,331,250,332,195],{"nctId":892,"briefTitle":893,"status":123,"phases":894,"primaryCompletion":895,"completion":895,"start":854,"enrollment":896,"conditions":897,"interventions":899},"NCT00171704","A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer",[93],"2011-03",263,[898],"Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women",[249,356],{"nctId":901,"briefTitle":902,"status":123,"phases":903,"primaryCompletion":904,"start":905,"enrollment":906,"conditions":907,"interventions":908},"NCT00535418","Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers",[92,93],"2002-07","2000-06",35,[15],[249],{"nctId":334,"briefTitle":335,"status":123,"phases":910,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":911,"interventions":912},[93],[342],[157,344,345],{"nctId":914,"briefTitle":915,"status":123,"phases":916,"primaryCompletion":917,"start":918,"enrollment":919,"conditions":920,"interventions":921},"NCT00329940","Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer",[93],"2008-01","2005-11",200,[15],[249],{"nctId":923,"briefTitle":924,"status":123,"phases":925,"primaryCompletion":926,"start":845,"enrollment":927,"conditions":928,"interventions":929},"NCT00171314","The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer",[93],"2010-11",527,[15],[886,249],{"nctId":347,"briefTitle":348,"status":123,"phases":931,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":932,"interventions":933},[93],[342],[98,356,249,285,250],{"nctId":935,"briefTitle":936,"status":123,"phases":937,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":943},"NCT00073528","Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer",[93],"2008-06-03","2018-03-22","2003-12-09",1286,[559],[944,249],"Lapatinib",{"nctId":946,"briefTitle":947,"status":123,"phases":948,"primaryCompletion":949,"completion":949,"start":950,"enrollment":951,"conditions":952,"interventions":954},"NCT00050011","Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and\u002For Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy",[93],"2009-01","2002-09",602,[559,953],"Osteoporosis",[955,249],"Zoledronic Acid",{"nctId":378,"briefTitle":379,"status":123,"phases":957,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":958,"interventions":959},[93],[15],[98,249,250,332],{"nctId":961,"briefTitle":962,"status":123,"phases":963,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":968,"interventions":969},"NCT00330317","Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer",[93],"2010-03","2010-11-16","2006-02",300,[15],[344],{"nctId":397,"briefTitle":398,"status":123,"phases":971,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":972,"interventions":973},[93],[405],[98,249],{"nctId":408,"briefTitle":409,"status":123,"phases":975,"primaryCompletion":411,"completion":411,"start":412,"enrollment":413,"conditions":976,"interventions":977},[93],[15],[98,249,88,119],{"nctId":417,"briefTitle":418,"status":134,"phases":979,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":980,"interventions":981},[93],[15],[98,344],{"trials":983,"activeCount":437,"soonestReadout":431},[984,992,1000,1010,1020,1029,1038],{"nctId":985,"briefTitle":986,"status":123,"phases":987,"primaryCompletion":988,"start":989,"enrollment":709,"conditions":990,"interventions":991},"NCT00237224","Open Label Study of Postmenopausal Women With ER and \u002For PgR Positive Breast Cancer Treated With Letrozole",[94],"2007-02","2003-02",[15],[249],{"nctId":993,"briefTitle":994,"status":134,"phases":995,"primaryCompletion":996,"start":997,"enrollment":734,"conditions":998,"interventions":999},"NCT00241046","Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment",[94],"2005-03","2002-04",[435],[249],{"nctId":1001,"briefTitle":1002,"status":134,"phases":1003,"primaryCompletion":1004,"completion":1004,"start":1005,"enrollment":1006,"conditions":1007,"interventions":1008},"NCT00375752","Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer",[94],"2010-12-16","2006-06-01",168,[559],[249,1009],"Zolendronic Acid",{"nctId":1011,"briefTitle":1012,"status":134,"phases":1013,"primaryCompletion":1014,"start":1015,"enrollment":1016,"conditions":1017,"interventions":1018},"NCT00171847","Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer",[94],"2008-10","2003-03",93,[435],[249,1019,249],"Trastuzumab plus Letrozole",{"nctId":1021,"briefTitle":1022,"status":123,"phases":1023,"primaryCompletion":1024,"completion":1024,"start":1025,"enrollment":1026,"conditions":1027,"interventions":1028},"NCT00688909","Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer",[94],"2009-06","2008-03",261,[15],[344],{"nctId":1030,"briefTitle":1031,"status":123,"phases":1032,"primaryCompletion":949,"completion":1033,"start":1015,"enrollment":1034,"conditions":1035,"interventions":1037},"NCT00237133","Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women",[94],"2009-01-21",112,[1036],"Locally Advanced Breast Cancer",[249],{"nctId":428,"briefTitle":429,"status":147,"phases":1039,"primaryCompletion":431,"completion":432,"start":433,"enrollment":292,"conditions":1040,"interventions":1041},[94],[435],[98,249,285,250,356,119],{"trials":1043,"activeCount":213,"soonestReadout":465},[1044,1048],{"nctId":462,"briefTitle":463,"status":109,"phases":1045,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":1046,"interventions":1047},[],[15],[98,249,285],{"nctId":471,"briefTitle":472,"status":109,"phases":1049,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":1050,"interventions":1051},[],[15],[98,249,285],{"intervention":173,"totalTrials":1053,"cells":1054},29,{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1092,"PHASE3":1226,"PHASE4":1294,"NA":1321},{"trials":1056,"activeCount":103},[],{"trials":1058,"activeCount":437,"soonestReadout":149},[1059,1069,1080,1084,1088],{"nctId":1060,"briefTitle":1061,"status":123,"phases":1062,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1067},"NCT02705963","A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors",[91],"2019-08-29","2016-10-20",19,[647],[173,173,1068],"Oral Contraceptive",{"nctId":1070,"briefTitle":1071,"status":134,"phases":1072,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":203,"conditions":1075,"interventions":1077},"NCT04294160","A Study of Select Drug Combinations in Adult Patients With Advanced\u002FMetastatic BRAF V600 Colorectal Cancer",[91],"2024-09-25","2020-07-22",[1076],"BRAF V600 Colorectal Cancer",[1078,184,173,158,211,212,1079],"Dabrafenib","Tislelizumab",{"nctId":145,"briefTitle":146,"status":147,"phases":1081,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":1082,"interventions":1083},[91],[153],[155,156,157,158,159,160],{"nctId":162,"briefTitle":163,"status":134,"phases":1085,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":1086,"interventions":1087},[91],[169,170,171],[157,173],{"nctId":175,"briefTitle":176,"status":134,"phases":1089,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":1090,"interventions":1091},[91],[182,36],[158,184,173,98],{"trials":1093,"activeCount":317,"soonestReadout":220},[1094,1105,1115,1123,1132,1136,1170,1180,1184,1197,1206,1217],{"nctId":1095,"briefTitle":1096,"status":123,"phases":1097,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1103},"NCT01750918","BRAF\u002FMEK\u002FEGFR Inhibitor Combination Study in Colorectal Cancer (CRC)",[91,92],"2020-06-18","2012-12-19",166,[1102],"Cancer",[1078,173,1104],"Panitumumab",{"nctId":1106,"briefTitle":1107,"status":123,"phases":1108,"primaryCompletion":1109,"completion":1110,"start":1111,"enrollment":1112,"conditions":1113,"interventions":1114},"NCT02083354","Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma",[92],"2018-02-23","2021-04-19","2014-03-18",77,[1102,36],[1078,173],{"nctId":1116,"briefTitle":1117,"status":123,"phases":1118,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":709,"conditions":1121,"interventions":1122},"NCT04452877","A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC",[92],"2024-11-07","2020-08-19",[227],[1078,173],{"nctId":1124,"briefTitle":1125,"status":123,"phases":1126,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":446,"conditions":1130,"interventions":1131},"NCT01336634","Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.",[92],"2015-10-01","2021-01-07","2011-08-05",[1102],[1078,173],{"nctId":217,"briefTitle":218,"status":147,"phases":1133,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":1134,"interventions":1135},[91,92],[225,226,227,182,228,229,209,230,231,232,233],[235,156,98,236],{"nctId":1137,"briefTitle":1138,"status":123,"phases":1139,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":1143,"conditions":1144,"interventions":1167},"NCT02684058","Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors",[92],"2021-08-23","2023-04-28","2017-12-28",151,[1145,1146,1147,1148,1149,1150,1151,1152,1153,1154,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],"Diffuse Astrocytoma","Anaplastic Astrocytoma","Astrocytoma","Oligodendroglioma, Childhood","Anaplastic Oligodendroglioma","Glioblastoma","Pilocytic Astrocytoma","Giant Cell Astrocytoma","Pleomorphic Xanthoastrocytoma","Anaplastic Pleomorphic Xanthoastrocytoma","Angiocentric Glioma","Chordoid Glioma of Third Ventricle","Gangliocytoma","Ganglioglioma","Anaplastic Ganglioglioma","Dysplastic Gangliocytoma of Cerebrellum","Desmoplastic Infantile Astrocytoma and Ganglioglioma","Papillary Glioneuronal Tumor","Rosette-forming Glioneurona Tumor","Central Neurocytoma","Extraventricular Neurocytoma","Cerebellar Iponeurocytoma",[1078,156,1168,1169],"Carboplatin","Vincristine",{"nctId":1171,"briefTitle":1172,"status":390,"phases":1173,"primaryCompletion":1174,"completion":1175,"start":1176,"enrollment":103,"conditions":1177,"interventions":1179},"NCT02672358","Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC",[92],"2019-09-02","2020-12-07","2018-09-03",[1178],"Non-Small-Cell Lung Cancer",[1078,173],{"nctId":287,"briefTitle":288,"status":147,"phases":1181,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":1182,"interventions":1183},[92],[36],[158,184,173,98],{"nctId":1185,"briefTitle":1186,"status":593,"phases":1187,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":709,"conditions":1191,"interventions":1194},"NCT07468071","Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments",[91,92],"2029-06-15","2029-09-17","2026-06-15",[1192,1193],"Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer","Advanced Solid Tumors Harboring the KRAS G12C Mutation",[1195,211,156,236,1196],"Opnurasib","tislelizumab",{"nctId":1198,"briefTitle":1199,"status":123,"phases":1200,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1205},"NCT02034110","Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers",[92],"2021-12-10","2014-03-12",206,[1102],[1078,173],{"nctId":1207,"briefTitle":1208,"status":123,"phases":1209,"primaryCompletion":1210,"completion":1211,"start":1212,"enrollment":1213,"conditions":1214,"interventions":1216},"NCT02039947","Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain",[92],"2017-05-12","2018-02-14","2014-02-21",127,[1215],"Melanoma and Brain Metastases",[1078,173],{"nctId":1218,"briefTitle":1219,"status":123,"phases":1220,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":1223,"conditions":1224,"interventions":1225},"NCT02124772","Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",[91,92],"2020-12-29","2015-01-15",139,[1102],[173,1078],{"trials":1227,"activeCount":437,"soonestReadout":1275},[1228,1238,1249,1260,1271,1284],{"nctId":1229,"briefTitle":1230,"status":134,"phases":1231,"primaryCompletion":1232,"completion":1233,"start":1234,"enrollment":1235,"conditions":1236,"interventions":1237},"NCT02967692","A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",[93],"2020-08-11","2024-08-21","2017-02-17",568,[36],[212,1078,173],{"nctId":1239,"briefTitle":1240,"status":123,"phases":1241,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":1246,"interventions":1247},"NCT01584648","A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma",[93],"2013-08-26","2019-02-28","2012-05-04",423,[36],[1078,173,1248],"Trametinib placebo",{"nctId":1250,"briefTitle":1251,"status":123,"phases":1252,"primaryCompletion":1253,"completion":1254,"start":1255,"enrollment":1256,"conditions":1257,"interventions":1258},"NCT01597908","Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E\u002FK Cutaneous Melanoma",[93],"2014-04-17","2019-04-25","2012-06-04",704,[36],[1078,1259,173],"Vemurafenib",{"nctId":1261,"briefTitle":1262,"status":123,"phases":1263,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1269},"NCT01682083","Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).",[93],"2017-06-30","2023-07-31","2013-01-08",870,[36],[1078,173,1270],"Placebos",{"nctId":1272,"briefTitle":1273,"status":147,"phases":1274,"primaryCompletion":1275,"completion":1276,"start":1277,"enrollment":1278,"conditions":1279,"interventions":1281},"NCT04940052","Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer",[93],"2025-01-22","2027-05-17","2021-11-15",153,[1280],"Differentiated Thyroid Cancer (DTC)",[1078,173,1282,1283],"Trametinib Placebo","Dabrafenib placebo",{"nctId":1285,"briefTitle":1286,"status":123,"phases":1287,"primaryCompletion":1288,"completion":1289,"start":243,"enrollment":1290,"conditions":1291,"interventions":1293},"NCT03551626","Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes",[93],"2020-10-05","2021-09-16",552,[1292],"Malignant Melanoma",[1078,173],{"trials":1295,"activeCount":213,"soonestReadout":1300},[1296,1309],{"nctId":1297,"briefTitle":1298,"status":109,"phases":1299,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":1302,"conditions":1303,"interventions":1307},"NCT03975829","Pediatric Long-Term Follow-up and Rollover Study",[94],"2026-11-05","2019-11-04",165,[1145,1146,1147,1148,1149,1150,1151,1152,1153,1154,1155,1156,1157,1158,1159,1160,1161,1162,1304,1164,1165,1305,1306],"Rosette-forming Glioneuronal Tumor","Cerebellar Liponeurocytoma","Neurofibromatosis Type 1",[1308,156],"dabrafenib",{"nctId":1310,"briefTitle":1311,"status":109,"phases":1312,"primaryCompletion":1313,"completion":1313,"start":1142,"enrollment":1314,"conditions":1315,"interventions":1320},"NCT03340506","Dabrafenib and\u002For Trametinib Rollover Study",[94],"2032-12-28",100,[36,1316,1317,1318,1319],"Non Small Cell Lung Cancer","Solid Tumor","Rare Cancers","High Grade Glioma",[1308,156],{"trials":1322,"activeCount":437,"soonestReadout":1350},[1323,1331,1338,1346],{"nctId":1324,"briefTitle":1325,"status":1326,"phases":1327,"conditions":1328,"interventions":1329},"NCT04489433","Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma","NO_LONGER_AVAILABLE",[],[36],[1330,1078,173],"Dabrafenib and Trametinib",{"nctId":1332,"briefTitle":1333,"status":1326,"phases":1334,"conditions":1335,"interventions":1337},"NCT04544202","Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection",[],[36,1336],"Adjuvant",[1330,1078,173],{"nctId":1339,"briefTitle":1340,"status":123,"phases":1341,"primaryCompletion":1342,"completion":1342,"start":1343,"enrollment":28,"conditions":1344,"interventions":1345},"NCT04961619","Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.",[],"2024-12-05","2021-12-01",[36],[1308,156],{"nctId":1347,"briefTitle":1348,"status":147,"phases":1349,"primaryCompletion":1350,"completion":1350,"start":1351,"enrollment":1352,"conditions":1353,"interventions":1354},"NCT04666272","Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection",[],"2028-02-04","2020-12-31",78,[36],[1308,156],{"intervention":1356,"totalTrials":837,"cells":1357},"Inclisiran",{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1391,"PHASE4":1517,"NA":1541},{"trials":1359,"activeCount":103},[],{"trials":1361,"activeCount":103},[],{"trials":1363,"activeCount":437,"soonestReadout":1381},[1364,1377],{"nctId":1365,"briefTitle":1366,"status":123,"phases":1367,"primaryCompletion":689,"completion":689,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1375},"NCT03060577","An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol",[92],"2017-04-27",382,[1371,1372,1373,1374],"Atherosclerotic Cardiovascular Disease","Symptomatic Atherosclerosis","Type2 Diabetes","Familial Hypercholesterolemia",[1356,1376],"Evolocumab",{"nctId":1378,"briefTitle":1379,"status":593,"phases":1380,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1387},"NCT07610278","A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia",[92],"2027-04-28","2028-01-28","2026-06-03",120,[1386],"Hypercholesterolaemia",[1388,1356,1389,1390],"QCZ484","QCZ484 placebo","Inclisiran placebo",{"trials":1392,"activeCount":637,"soonestReadout":1474},[1393,1404,1416,1427,1437,1448,1460,1470,1478,1489,1499,1508],{"nctId":1394,"briefTitle":1395,"status":123,"phases":1396,"primaryCompletion":1397,"completion":1397,"start":1398,"enrollment":1399,"conditions":1400,"interventions":1402},"NCT05763875","Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.",[93],"2024-06-20","2023-03-15",350,[1401],"Hypercholesterolemia",[1356,1403],"Ezetimibe",{"nctId":1405,"briefTitle":1406,"status":109,"phases":1407,"primaryCompletion":1408,"completion":1409,"start":1410,"enrollment":1411,"conditions":1412,"interventions":1414},"NCT06813911","Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD",[93],"2028-02-03","2028-02-29","2025-04-30",340,[1413],"Atherosclerotic Cardiovascular Disease (ASCVD)",[1415,1356],"Pelacarsen",{"nctId":1417,"briefTitle":1418,"status":109,"phases":1419,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":1423,"conditions":1424,"interventions":1426},"NCT06597019","Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia",[93],"2028-03-21","2029-04-15","2024-12-09",60,[1425],"Familial Hypercholesterolemia - Heterozygous",[1356],{"nctId":1428,"briefTitle":1429,"status":123,"phases":1430,"primaryCompletion":1431,"completion":1432,"start":1433,"enrollment":1434,"conditions":1435,"interventions":1436},"NCT04652726","Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia",[93],"2023-11-09","2024-11-27","2021-01-27",141,[1425],[1356],{"nctId":1438,"briefTitle":1439,"status":123,"phases":1440,"primaryCompletion":1441,"completion":1442,"start":1443,"enrollment":1444,"conditions":1445,"interventions":1447},"NCT05888103","Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.",[93],"2024-04-02","2024-10-24","2023-07-11",207,[1446],"Primary Hypercholesterolemia or Mixed Dyslipidemia",[1356],{"nctId":1449,"briefTitle":1450,"status":123,"phases":1451,"primaryCompletion":1452,"completion":1452,"start":1453,"enrollment":1454,"conditions":1455,"interventions":1458},"NCT04807400","Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support",[93],"2023-01-13","2021-07-07",892,[1371,1456,1457],"Atherosclerotic Cardiovascular Disease Risk Equivelents","Elevated Low Density Lipoprotein Cholesterol",[1356,1459],"Background lipid lowering therapy",{"nctId":1461,"briefTitle":1462,"status":123,"phases":1463,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":1466,"conditions":1467,"interventions":1469},"NCT04873934","Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome",[93],"2024-08-07","2021-06-24",400,[1468],"Acute Coronary Syndrome",[1356],{"nctId":1471,"briefTitle":1472,"status":109,"phases":1473,"primaryCompletion":1474,"completion":1474,"start":1475,"enrollment":967,"conditions":1476,"interventions":1477},"NCT07102628","Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes",[93],"2027-02-11","2025-10-03",[1468],[1356],{"nctId":1479,"briefTitle":1480,"status":109,"phases":1481,"primaryCompletion":1482,"completion":1483,"start":1484,"enrollment":1485,"conditions":1486,"interventions":1488},"NCT05682378","Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies",[93],"2032-03-25","2032-03-28","2023-02-10",195,[1487],"Heterozygous or Homozygous Familial Hypercholesterolemia",[1356],{"nctId":1490,"briefTitle":1491,"status":109,"phases":1492,"primaryCompletion":1493,"completion":1421,"start":1494,"enrollment":1495,"conditions":1496,"interventions":1498},"NCT06597006","Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia",[93],"2028-03-23","2025-02-28",9,[1497],"Familial Hypercholesterolemia - Homozygous",[1356],{"nctId":1500,"briefTitle":1501,"status":123,"phases":1502,"primaryCompletion":1503,"completion":1504,"start":1505,"enrollment":734,"conditions":1506,"interventions":1507},"NCT04659863","Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia",[93],"2023-10-30","2024-11-18","2021-02-16",[1497],[1356],{"nctId":1509,"briefTitle":1510,"status":123,"phases":1511,"primaryCompletion":1512,"completion":1512,"start":1513,"enrollment":1514,"conditions":1515,"interventions":1516},"NCT04929249","A Randomized Study to Evaluate the Effect of an \"Inclisiran First\" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)",[93],"2023-09-15","2021-06-25",450,[1371],[1356],{"trials":1518,"activeCount":437,"soonestReadout":111},[1519,1530],{"nctId":1520,"briefTitle":1521,"status":123,"phases":1522,"primaryCompletion":1523,"completion":1523,"start":566,"enrollment":1524,"conditions":1525,"interventions":1528},"NCT06386419","A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia",[94],"2026-01-13",65,[1526,1527],"Primary Hypercholesterolemia","Mixed Dyslipidemia",[1529],"inclisiran",{"nctId":1531,"briefTitle":1532,"status":109,"phases":1533,"primaryCompletion":111,"completion":1534,"start":1535,"enrollment":1536,"conditions":1537,"interventions":1539},"NCT06372925","Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction",[94],"2027-01-26","2024-07-09",318,[1538],"Plaque, Atherosclerotic",[1540,1529],"atorvastatin",{"trials":1542,"activeCount":437,"soonestReadout":1547},[1543],{"nctId":1544,"briefTitle":1545,"status":109,"phases":1546,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":1550,"interventions":1551},"NCT06858332","Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia",[],"2027-09-30","2025-04-15",2382,[1371],[1552,1553,1554,1403,1555,1556,1557,1558,1376,1559,1356],"Atorvastatin","Simvastatin","Rozuvastatin","Niacin","Ciprofibrate","Fenofibrate","Bezafibrate","Alirocumab",{"intervention":1561,"totalTrials":1562,"cells":1563},"AAA617",7,{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1580,"PHASE3":1631,"PHASE4":1643,"NA":1656},{"trials":1565,"activeCount":103},[],{"trials":1567,"activeCount":437,"soonestReadout":1572},[1568],{"nctId":1569,"briefTitle":1570,"status":109,"phases":1571,"primaryCompletion":1572,"completion":1572,"start":1573,"enrollment":1574,"conditions":1575,"interventions":1577},"NCT06531499","A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study",[91],"2028-11-24","2024-11-11",106,[1576],"Metastatic Castration-Resistant Prostate Cancer",[1561,1578,1579],"Gonadotropin-releasing hormone (GnRH) analogues","Gonadotropin-releasing hormone (GnRH) antagonists",{"trials":1581,"activeCount":1630,"soonestReadout":1609},[1582,1593,1605,1616],{"nctId":1583,"briefTitle":1584,"status":147,"phases":1585,"primaryCompletion":1586,"completion":1586,"start":1587,"enrollment":1562,"conditions":1588,"interventions":1590},"NCT06894511","An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC",[92],"2026-10-15","2025-09-11",[1589],"Metastatic Castration Resistant Prostate Cancer (mCRPC)",[1561,1591,1592],"ARPI: Abiraterone","ARPI: Enzalutamide",{"nctId":1594,"briefTitle":1595,"status":147,"phases":1596,"primaryCompletion":1597,"completion":1598,"start":1599,"enrollment":1600,"conditions":1601,"interventions":1603},"NCT07047118","A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)",[92],"2027-07-16","2028-05-14","2025-07-03",138,[1602],"Prostatic Cancer, Castration-Resistant",[1604,1561],"JSB462",{"nctId":1606,"briefTitle":1607,"status":109,"phases":1608,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":1611,"conditions":1612,"interventions":1614},"NCT06004661","Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function",[92],"2026-06-17","2024-04-04",20,[1613],"Metastatic Castration-Resistant Prostate Cancer (mCRPC)",[1561,1615],"68Ga-PSMA-11",{"nctId":1617,"briefTitle":1618,"status":147,"phases":1619,"primaryCompletion":1620,"completion":1620,"start":1621,"enrollment":1622,"conditions":1623,"interventions":1625},"NCT05849298","A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC",[92],"2026-12-23","2024-01-03",49,[1624],"Prostatic Neoplasm",[1561,1626,1627,1628,1629],"AAA517","Piflufolastat F 18","ARPI","ADT",4,{"trials":1632,"activeCount":437,"soonestReadout":1637},[1633],{"nctId":1634,"briefTitle":1635,"status":109,"phases":1636,"primaryCompletion":1637,"completion":1638,"start":1639,"enrollment":1514,"conditions":1640,"interventions":1642},"NCT05939414","An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.",[93],"2028-04-25","2031-10-03","2024-03-12",[1641],"Oligometastatic Prostate Cancer (OMPC)",[1561],{"trials":1644,"activeCount":437,"soonestReadout":1649},[1645],{"nctId":1646,"briefTitle":1647,"status":109,"phases":1648,"primaryCompletion":1649,"completion":1650,"start":1651,"enrollment":1652,"conditions":1653,"interventions":1655},"NCT05803941","Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer",[94],"2033-07-20","2033-07-21","2023-08-14",700,[1654],"Prostate Cancer",[1561],{"trials":1657,"activeCount":103},[],{"intervention":1659,"totalTrials":1660,"cells":1661},"Secukinumab",71,{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1708,"PHASE3":1754,"PHASE4":2204,"NA":2271},{"trials":1663,"activeCount":103},[],{"trials":1665,"activeCount":437,"soonestReadout":1702},[1666,1677,1687,1698],{"nctId":1667,"briefTitle":1668,"status":123,"phases":1669,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":1672,"conditions":1673,"interventions":1676},"NCT01539213","Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg",[91],"2013-01","2012-02",16,[1674,1675],"Healthy","Psoriasis",[73],{"nctId":1678,"briefTitle":1679,"status":123,"phases":1680,"primaryCompletion":1681,"completion":1681,"start":1682,"enrollment":167,"conditions":1683,"interventions":1685},"NCT01828086","Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis",[91],"2015-10","2013-06",[1684],"Chronic Plaque-type Psoriasis",[1686,1659],"CJM112",{"nctId":1688,"briefTitle":1689,"status":123,"phases":1690,"primaryCompletion":1691,"completion":1692,"start":1693,"enrollment":1524,"conditions":1694,"interventions":1697},"NCT06130540","Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR",[91],"2025-03-12","2025-04-02","2024-03-27",[1695,1696],"Giant Cell Arteritis","Polymyalgia Rheumatica",[1659],{"nctId":1699,"briefTitle":1700,"status":109,"phases":1701,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":1611,"conditions":1705,"interventions":1707},"NCT06751238","Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).",[91],"2032-11-30","2032-12-01","2025-09-24",[1706],"Juvenile Psoriatic Arthritis",[1659],{"trials":1709,"activeCount":103},[1710,1719,1727,1736,1743],{"nctId":1711,"briefTitle":1712,"status":123,"phases":1713,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":544,"conditions":1716,"interventions":1718},"NCT01359943","Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate",[92],"2013-12","2011-10",[1717],"Rheumatoid Arthritis",[73],{"nctId":1720,"briefTitle":1721,"status":123,"phases":1722,"primaryCompletion":1723,"completion":1723,"start":1724,"enrollment":1314,"conditions":1725,"interventions":1726},"NCT01426789","A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients",[92],"2014-02","2011-08",[1717],[1659],{"nctId":1728,"briefTitle":1729,"status":123,"phases":1730,"primaryCompletion":1731,"completion":1731,"start":1732,"enrollment":792,"conditions":1733,"interventions":1735},"NCT01537432","Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients",[92],"2014-12","2012-01",[1734],"Psoriasis, Plaque-type Psoriasis",[73],{"nctId":1737,"briefTitle":1738,"status":134,"phases":1739,"primaryCompletion":812,"completion":812,"start":1723,"enrollment":637,"conditions":1740,"interventions":1742},"NCT02044848","Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus",[92],[1741],"Type 1 Diabetes Mellitus",[1659],{"nctId":1744,"briefTitle":1745,"status":123,"phases":1746,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":1751,"interventions":1753},"NCT03344640","Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy",[92],"2019-08-02","2019-10-17","2017-12-15",96,[1752],"Tendinopathy",[73],{"trials":1755,"activeCount":213,"soonestReadout":72},[1756,1765,1776,1784,1792,1802,1813,1823,1832,1842,1853,1864,1872,1883,1894,1905,1915,1926,1935,1947,1957,1967,1976,1987,1994,2001,2012,2022,2029,2040,2051,2060,2070,2080,2088,2097,2107,2116,2124,2133,2143,2152,2160,2170,2179,2188,2195],{"nctId":1757,"briefTitle":1758,"status":134,"phases":1759,"primaryCompletion":1760,"completion":1760,"start":1761,"enrollment":1762,"conditions":1763,"interventions":1764},"NCT01770379","Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.",[93],"2015-05","2012-10",242,[1717],[1659],{"nctId":1766,"briefTitle":1767,"status":123,"phases":1768,"primaryCompletion":1769,"completion":1769,"start":1770,"enrollment":1771,"conditions":1772,"interventions":1774},"NCT02826603","Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis",[93],"2018-07-09","2016-06-22",1114,[1773],"Plaque Psoriasis",[1659,1775],"Ustekinumab",{"nctId":1777,"briefTitle":1778,"status":123,"phases":1779,"primaryCompletion":1780,"completion":1780,"start":1781,"enrollment":1143,"conditions":1782,"interventions":1783},"NCT02559622","Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab",[93],"2016-04","2014-04",[1675],[1659,1659],{"nctId":1785,"briefTitle":1786,"status":123,"phases":1787,"primaryCompletion":1788,"completion":1788,"start":606,"enrollment":757,"conditions":1789,"interventions":1790},"NCT02474082","Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.",[93],"2016-06",[1675],[1659,1791],"Fumaric acid",{"nctId":1793,"briefTitle":1794,"status":134,"phases":1795,"primaryCompletion":1796,"completion":1796,"start":1797,"enrollment":1798,"conditions":1799,"interventions":1801},"NCT04181762","Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis",[93],"2023-09-13","2020-07-07",275,[1800],"Lupus Nephritis",[73],{"nctId":1803,"briefTitle":1804,"status":123,"phases":1805,"primaryCompletion":1806,"completion":1807,"start":1808,"enrollment":1809,"conditions":1810,"interventions":1812},"NCT03713619","This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).",[93],"2021-10-01","2022-07-26","2019-01-31",544,[1811],"Hidradenitis Suppurativa",[73],{"nctId":1814,"briefTitle":1815,"status":123,"phases":1816,"primaryCompletion":1817,"completion":1817,"start":1818,"enrollment":1819,"conditions":1820,"interventions":1822},"NCT01392326","Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",[93],"2014-10","2011-09",606,[1821],"Psoriatic Arthritis",[1659,1659],{"nctId":1824,"briefTitle":1825,"status":147,"phases":1826,"primaryCompletion":1827,"completion":1827,"start":1828,"enrollment":1829,"conditions":1830,"interventions":1831},"NCT06331312","Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)",[93],"2028-08-22","2024-06-28",161,[1696],[1659],{"nctId":1833,"briefTitle":1834,"status":123,"phases":1835,"primaryCompletion":1836,"completion":1837,"start":1838,"enrollment":1839,"conditions":1840,"interventions":1841},"NCT01752634","Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis",[93],"2014-05-12","2019-01-09","2013-04-14",397,[1821],[1659],{"nctId":1843,"briefTitle":1844,"status":123,"phases":1845,"primaryCompletion":1846,"completion":1847,"start":1848,"enrollment":1849,"conditions":1850,"interventions":1852},"NCT02696031","Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis",[93],"2019-07-01","2021-03-11","2016-04-29",555,[1851],"Non-radiographic Spondyloarthritis",[1659],{"nctId":1854,"briefTitle":1855,"status":123,"phases":1856,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":1861,"interventions":1863},"NCT02896127","Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis",[93],"2018-05-14","2019-03-19","2016-10-18",458,[1862],"Ankylosing Spondyloarthritis",[1659],{"nctId":1865,"briefTitle":1866,"status":123,"phases":1867,"primaryCompletion":1868,"completion":1868,"start":1869,"enrollment":1384,"conditions":1870,"interventions":1871},"NCT02595970","Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis",[93],"2017-02-09","2015-05-20",[1675],[1659],{"nctId":1873,"briefTitle":1874,"status":123,"phases":1875,"primaryCompletion":1876,"completion":1877,"start":1878,"enrollment":1879,"conditions":1880,"interventions":1882},"NCT02008916","16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients",[93],"2015-02-23","2017-12-11","2014-01-14",226,[1881],"Spondylitis, Ankylosing",[1659],{"nctId":1884,"briefTitle":1885,"status":123,"phases":1886,"primaryCompletion":1887,"completion":1888,"start":1889,"enrollment":1890,"conditions":1891,"interventions":1893},"NCT04732117","Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis",[93],"2024-04-03","2025-02-14","2021-07-21",137,[1892],"Non-radiographic Axial Spondyloarthritis",[1659],{"nctId":1895,"briefTitle":1896,"status":123,"phases":1897,"primaryCompletion":1898,"completion":1899,"start":1900,"enrollment":1901,"conditions":1902,"interventions":1904},"NCT03031782","Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)",[93],"2020-10-07","2020-11-09","2017-05-23",86,[1706,1903],"Enthesitis-related Arthritis",[73],{"nctId":1906,"briefTitle":1907,"status":134,"phases":1908,"primaryCompletion":1909,"completion":1910,"start":1911,"enrollment":1423,"conditions":1912,"interventions":1914},"NCT05758415","Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy",[93],"2024-10-17","2024-12-11","2023-08-02",[1913],"Rotator Cuff Tendinopathy",[1659],{"nctId":1916,"briefTitle":1917,"status":123,"phases":1918,"primaryCompletion":1919,"completion":1920,"start":1921,"enrollment":1922,"conditions":1923,"interventions":1925},"NCT02294227","16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis",[93],"2016-02-16","2017-12-19","2015-05-29",341,[1924],"Arthritis, Psoriatic",[1659],{"nctId":1927,"briefTitle":1928,"status":123,"phases":1929,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1932,"conditions":1933,"interventions":1934},"NCT04632927","Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment",[93],"2024-10-22","2020-12-21",119,[1821],[1659,1775],{"nctId":1936,"briefTitle":1937,"status":123,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":1942,"interventions":1945},"NCT02771210","Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site",[93],"2019-12-11","2016-08-30",204,[1821,1943,1944],"Axial Spondyloarthritis","Enthesitis",[1659,1946],"Secukinumab Placebo",{"nctId":1948,"briefTitle":1949,"status":123,"phases":1950,"primaryCompletion":1951,"completion":1951,"start":1952,"enrollment":1953,"conditions":1954,"interventions":1956},"NCT02394561","A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)",[93],"2017-06-08","2015-04-10",434,[1955],"Plaque Type Psorisis",[1659],{"nctId":1958,"briefTitle":1959,"status":123,"phases":1960,"primaryCompletion":1961,"completion":1962,"start":1963,"enrollment":1964,"conditions":1965,"interventions":1966},"NCT02404350","Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis",[93],"2017-08-16","2019-01-24","2015-08-31",997,[1821],[1659],{"nctId":1968,"briefTitle":1969,"status":123,"phases":1970,"primaryCompletion":1971,"completion":1972,"start":1939,"enrollment":927,"conditions":1973,"interventions":1975},"NCT04156620","Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA",[93],"2022-02-17","2022-12-20",[1974],"Ankylosing Spondylitis",[1659],{"nctId":1977,"briefTitle":1978,"status":123,"phases":1979,"primaryCompletion":1980,"completion":1981,"start":1982,"enrollment":1983,"conditions":1984,"interventions":1986},"NCT01649375","16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis",[93],"2014-08-04","2018-09-18","2012-10-18",219,[1985],"Anklyosing Spondylitis",[1659,1659],{"nctId":1988,"briefTitle":1989,"status":123,"phases":1990,"primaryCompletion":1731,"completion":1731,"start":1715,"enrollment":1991,"conditions":1992,"interventions":1993},"NCT01358175","16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis",[93],371,[1974],[1659,1659],{"nctId":70,"briefTitle":71,"status":147,"phases":1995,"primaryCompletion":72,"completion":1996,"start":1997,"enrollment":1998,"conditions":1999,"interventions":2000},[93],"2026-07-15","2020-03-18",703,[1811],[73,73],{"nctId":2002,"briefTitle":2003,"status":123,"phases":2004,"primaryCompletion":2005,"completion":2005,"start":2006,"enrollment":2007,"conditions":2008,"interventions":2010},"NCT02721966","Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement",[93],"2019-06-26","2016-10-03",503,[2009],"Axial Psoratic Arthritis",[1659,2011],"Secukinumab and Placebo",{"nctId":2013,"briefTitle":2014,"status":123,"phases":2015,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":2019,"conditions":2020,"interventions":2021},"NCT01989468","24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis",[93],"2015-05-27","2018-03-28","2014-04-10",414,[1821],[1659],{"nctId":2023,"briefTitle":1907,"status":134,"phases":2024,"primaryCompletion":1909,"completion":2025,"start":2026,"enrollment":99,"conditions":2027,"interventions":2028},"NCT05722522",[93],"2024-12-13","2023-08-10",[1913],[1659],{"nctId":2030,"briefTitle":2031,"status":123,"phases":2032,"primaryCompletion":2033,"completion":2033,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2038},"NCT01358578","Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis",[93],"2013-07","2011-06",1306,[2037],"Chronic Plaque Psoriasis",[73,2039],"etanercept",{"nctId":2041,"briefTitle":2042,"status":134,"phases":2043,"primaryCompletion":2044,"completion":2044,"start":2045,"enrollment":2046,"conditions":2047,"interventions":2050},"NCT04737330","A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)",[93],"2023-05-16","2021-11-29",28,[2048,2049],"Thyroid Eye Disease","Graves Orbitopathy",[1659],{"nctId":2052,"briefTitle":2053,"status":123,"phases":2054,"primaryCompletion":2055,"completion":2055,"start":2056,"enrollment":2057,"conditions":2058,"interventions":2059},"NCT01961609","Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.",[93],"2016-07-12","2013-10-09",235,[1675],[1659],{"nctId":2061,"briefTitle":2062,"status":123,"phases":2063,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":2066,"conditions":2067,"interventions":2069},"NCT02474069","Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis",[93],"2016-09-15","2015-02-08",772,[2068],"Moderate to Severe Plaque-type Psoriasis",[1659],{"nctId":2071,"briefTitle":2072,"status":390,"phases":2073,"primaryCompletion":2074,"completion":2075,"start":2076,"enrollment":103,"conditions":2077,"interventions":2079},"NCT05206591","Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).",[93],"2028-03-20","2028-06-12","2022-08-16",[2078],"Active Peripheral Spondyloarthritis (pSpA)",[1659],{"nctId":2081,"briefTitle":2082,"status":123,"phases":2083,"primaryCompletion":2084,"completion":2084,"start":2085,"enrollment":192,"conditions":2086,"interventions":2087},"NCT02362789","Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers",[93],"2016-07-15","2015-01-04",[1675],[1659],{"nctId":2089,"briefTitle":2090,"status":123,"phases":2091,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":2094,"conditions":2095,"interventions":2096},"NCT01863732","Extension in AS: Sustainability of Benefits, Safety and Tolerability",[93],"2018-03-16","2013-11-06",274,[1881],[1659],{"nctId":2098,"briefTitle":2099,"status":123,"phases":2100,"primaryCompletion":2101,"completion":2101,"start":2102,"enrollment":2103,"conditions":2104,"interventions":2105},"NCT02745080","Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis",[93],"2019-12-30","2017-04-03",853,[1821],[1659,2106],"Adalimumab",{"nctId":2108,"briefTitle":2109,"status":123,"phases":2110,"primaryCompletion":1119,"completion":1119,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2115},"NCT03769168","An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)",[93],"2019-06-07",55,[1706,2114],"Enthesitis Related Arthritis",[1659],{"nctId":2117,"briefTitle":2118,"status":123,"phases":2119,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":138,"conditions":2122,"interventions":2123},"NCT01952015","Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)",[93],"2016-03-15","2013-08-21",[1675],[1659],{"nctId":2125,"briefTitle":2126,"status":123,"phases":2127,"primaryCompletion":2128,"completion":2128,"start":2129,"enrollment":2130,"conditions":2131,"interventions":2132},"NCT01892436","Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis",[93],"2018-01-11","2013-09-30",460,[1821],[1659],{"nctId":2134,"briefTitle":2135,"status":123,"phases":2136,"primaryCompletion":2137,"completion":2138,"start":2139,"enrollment":2140,"conditions":2141,"interventions":2142},"NCT02409667","Plaque Psoriasis Efficacy and Safety With Secukinumab",[93],"2017-03-14","2017-05-08","2015-05-07",16487,[1773],[1659],{"nctId":2144,"briefTitle":2145,"status":123,"phases":2146,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":2149,"conditions":2150,"interventions":2151},"NCT05569174","Study of Efficacy and Safety of AIN457\u002FSecukinumab in Patients With Rotator Cuff Tendinopathy",[93],"2024-12-18","2022-12-02",62,[1752],[1659],{"nctId":2153,"briefTitle":2154,"status":123,"phases":2155,"primaryCompletion":2156,"completion":2156,"start":2157,"enrollment":667,"conditions":2158,"interventions":2159},"NCT01544595","Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab",[93],"2017-06-26","2012-06-19",[2068],[1659],{"nctId":2161,"briefTitle":2162,"status":123,"phases":2163,"primaryCompletion":2164,"completion":2164,"start":2165,"enrollment":2166,"conditions":2167,"interventions":2169},"NCT01807520","Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis",[93],"2017-01-03","2013-06-20",198,[2168],"Moderate to Severe Nail Psoriasis",[1659],{"nctId":2171,"briefTitle":2172,"status":123,"phases":2173,"primaryCompletion":2174,"completion":2175,"start":2176,"enrollment":1399,"conditions":2177,"interventions":2178},"NCT02159053","16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis",[93],"2016-02-23","2018-01-02","2015-05-18",[1881],[1659,1659],{"nctId":2180,"briefTitle":2181,"status":123,"phases":2182,"primaryCompletion":2183,"completion":2184,"start":257,"enrollment":2185,"conditions":2186,"interventions":2187},"NCT03713632","Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)",[93],"2021-09-23","2022-07-19",545,[1811],[1659],{"nctId":2189,"briefTitle":2190,"status":134,"phases":2191,"primaryCompletion":77,"completion":77,"start":2192,"enrollment":827,"conditions":2193,"interventions":2194},"NCT05232864","Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis",[93],"2022-08-22",[1800],[1659],{"nctId":2196,"briefTitle":2197,"status":123,"phases":2198,"primaryCompletion":2199,"completion":2199,"start":2200,"enrollment":2201,"conditions":2202,"interventions":2203},"NCT01377012","Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents",[93],"2015-09-09","2011-08-30",637,[1717],[1659],{"trials":2205,"activeCount":213,"soonestReadout":2256},[2206,2216,2227,2235,2243,2252,2261],{"nctId":2207,"briefTitle":2208,"status":593,"phases":2209,"primaryCompletion":2210,"completion":2211,"start":2212,"enrollment":792,"conditions":2213,"interventions":2215},"NCT07489573","Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa",[94],"2029-09-25","2029-11-05","2026-08-21",[2214],"Hidradenitis Suppurativa (HS)",[1659],{"nctId":2217,"briefTitle":2218,"status":123,"phases":2219,"primaryCompletion":2220,"completion":2221,"start":2222,"enrollment":2223,"conditions":2224,"interventions":2226},"NCT03440736","Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome",[94],"2021-11-30","2022-06-03","2018-02-28",781,[1675,2225],"Metabolic Syndrome",[1659],{"nctId":2228,"briefTitle":2229,"status":123,"phases":2230,"primaryCompletion":2231,"completion":2231,"start":2232,"enrollment":31,"conditions":2233,"interventions":2234},"NCT02547714","Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A",[94],"2016-05-02","2015-06-16",[1773],[1659],{"nctId":2236,"briefTitle":2237,"status":123,"phases":2238,"primaryCompletion":2017,"completion":2017,"start":2239,"enrollment":2240,"conditions":2241,"interventions":2242},"NCT02752776","A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.",[94],"2016-03-17",1660,[1773],[1659],{"nctId":2244,"briefTitle":2245,"status":123,"phases":2246,"primaryCompletion":2220,"completion":2247,"start":2248,"enrollment":2249,"conditions":2250,"interventions":2251},"NCT03020199","Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis",[94],"2023-06-16","2017-03-27",196,[1773],[1659],{"nctId":2253,"briefTitle":2254,"status":147,"phases":2255,"primaryCompletion":2256,"completion":2257,"start":2258,"enrollment":467,"conditions":2259,"interventions":2260},"NCT05622708","A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission",[94],"2028-02-08","2028-04-04","2023-03-28",[1892],[1659,1659],{"nctId":2262,"briefTitle":2263,"status":123,"phases":2264,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":2269,"interventions":2270},"NCT03055494","Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients",[94],"2018-04-25","2019-02-26","2017-04-18",102,[1773],[1659],{"trials":2272,"activeCount":213,"soonestReadout":2286},[2273,2282,2289,2297,2306,2315,2321,2331],{"nctId":2274,"briefTitle":2275,"status":123,"phases":2276,"primaryCompletion":2277,"completion":2277,"start":2278,"enrollment":2279,"conditions":2280,"interventions":2281},"NCT05677542","Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study",[],"2021-12-31","2021-06-02",758,[1943,1821],[73],{"nctId":2283,"briefTitle":2284,"status":109,"phases":2285,"primaryCompletion":2286,"completion":2286,"start":1692,"enrollment":512,"conditions":2287,"interventions":2288},"NCT06905288","Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.",[],"2026-12-31",[1974],[1659],{"nctId":2290,"briefTitle":2291,"status":123,"phases":2292,"primaryCompletion":2293,"completion":2293,"start":556,"enrollment":2294,"conditions":2295,"interventions":2296},"NCT05650060","Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis",[],"2021-12-23",163,[1773],[1659],{"nctId":2298,"briefTitle":2299,"status":123,"phases":2300,"primaryCompletion":2301,"completion":2301,"start":2302,"enrollment":2303,"conditions":2304,"interventions":2305},"NCT05320159","Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)",[],"2021-03-31","2021-02-03",17743,[1675],[1659],{"nctId":2307,"briefTitle":2308,"status":123,"phases":2309,"primaryCompletion":2310,"completion":2310,"start":2311,"enrollment":2312,"conditions":2313,"interventions":2314},"NCT04894890","A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China",[],"2023-12-15","2021-09-26",1002,[1675],[73],{"nctId":2316,"briefTitle":2317,"status":491,"phases":2318,"conditions":2319,"interventions":2320},"NCT05583604","Managed Access Programs for AIN457, Secukinumab",[],[2214],[73],{"nctId":2322,"briefTitle":2323,"status":109,"phases":2324,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":485,"conditions":2327,"interventions":2330},"NCT07243782","Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea",[],"2027-06-15","2025-12-22",[1811,2328,2329],"Pediatric Plaque Psoriasis","Juvenile Idiopathic Arthritis",[1659],{"nctId":2332,"briefTitle":2333,"status":123,"phases":2334,"primaryCompletion":2335,"completion":2335,"start":2336,"enrollment":2337,"conditions":2338,"interventions":2339},"NCT05513014","Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis",[],"2021-08-31","2021-03-21",1518,[1675],[1659],{"intervention":2341,"totalTrials":2342,"cells":2343},"Ruxolitinib",25,{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2396,"PHASE3":2461,"PHASE4":2548,"NA":2585},{"trials":2345,"activeCount":103},[],{"trials":2347,"activeCount":437,"soonestReadout":2376},[2348,2362,2372,2385],{"nctId":2349,"briefTitle":2350,"status":123,"phases":2351,"primaryCompletion":2352,"completion":2352,"start":2353,"enrollment":2354,"conditions":2355,"interventions":2359},"NCT01433445","Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis",[91],"2020-06-22","2011-11-01",61,[2356,2357,2358],"Idiopathic Myelofibrosis","Post Essential Thrombocythemia Myelofibrosis","Post Polycythemia-Vera Myelofibrosis",[2360,2361],"panobinostat","ruxolitinib",{"nctId":2363,"briefTitle":2364,"status":123,"phases":2365,"primaryCompletion":1899,"completion":1899,"start":2366,"enrollment":2367,"conditions":2368,"interventions":2370},"NCT02370706","Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis",[91],"2015-05-21",15,[2369],"Myelofibrosis",[2371,2341,515],"PIM447",{"nctId":2373,"briefTitle":2374,"status":109,"phases":2375,"primaryCompletion":2376,"completion":2377,"start":2378,"enrollment":2379,"conditions":2380,"interventions":2384},"NCT07340138","Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis",[91],"2026-11-16","2030-12-18","2026-04-15",6,[2381,2382,2383],"Primary Myelofibrosis (PMF)","Post-polycythemia Vera Myelofibrosis (Post-PV MF)","Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)",[78,2341],{"nctId":2386,"briefTitle":2387,"status":123,"phases":2388,"primaryCompletion":2389,"completion":2390,"start":2391,"enrollment":637,"conditions":2392,"interventions":2394},"NCT02253277","Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients",[91],"2018-03-06","2018-04-03","2015-02-18",[2393],"Chronic Myeloid Leukemia",[2395,2341],"Nilotinib",{"trials":2397,"activeCount":103},[2398,2412,2421,2434,2443,2454],{"nctId":2399,"briefTitle":2400,"status":134,"phases":2401,"primaryCompletion":2402,"completion":2403,"start":2404,"enrollment":2405,"conditions":2406,"interventions":2407},"NCT04097821","Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients",[91,92],"2023-05-03","2024-08-28","2019-09-26",45,[2369],[2341,2408,63,2409,2410,2411],"Siremadlin","Sabatolimab","Rineterkib","NIS793",{"nctId":2413,"briefTitle":2414,"status":123,"phases":2415,"primaryCompletion":1847,"completion":2416,"start":2417,"enrollment":2405,"conditions":2418,"interventions":2420},"NCT03491215","Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease",[91,92],"2023-02-02","2019-02-21",[2419],"Acute Graft Versus Host Disease",[2341],{"nctId":2422,"briefTitle":2423,"status":123,"phases":2424,"primaryCompletion":2425,"completion":2426,"start":2427,"enrollment":2428,"conditions":2429,"interventions":2433},"NCT02966353","Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.",[92],"2018-07-24","2019-02-15","2017-03-31",51,[2430,2431,2432],"Primary Myelofibrosis","Post-Polycythemia Vera-Myelofibrosis","Post-Essential Thrombocythemia Myelofibrosis",[2361],{"nctId":2435,"briefTitle":2436,"status":123,"phases":2437,"primaryCompletion":2438,"completion":2438,"start":645,"enrollment":2439,"conditions":2440,"interventions":2442},"NCT02049450","Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.",[92],"2016-04-12",30,[2441],"Thalassemia Major",[2361],{"nctId":2444,"briefTitle":2445,"status":123,"phases":2446,"primaryCompletion":2447,"completion":2447,"start":2448,"enrollment":1384,"conditions":2449,"interventions":2453},"NCT01392443","Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF",[92],"2017-10-31","2010-10-14",[2450,2451,2452],"Primary Myelofibrosis (MF)","Post-Polycythemia Vera (PV) MF","Post-Essential Thrombocythemia (ET) MF",[2341],{"nctId":2455,"briefTitle":2456,"status":134,"phases":2457,"primaryCompletion":2458,"completion":2458,"start":812,"enrollment":317,"conditions":2459,"interventions":2460},"NCT02091752","A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib\u002FJakavi After Treatment Interruption Due to Loss of Response and\u002For Adverse Event (ReTreatment Trial)",[92],"2015-02",[2430],[2341],{"trials":2462,"activeCount":213,"soonestReadout":77},[2463,2472,2483,2495,2505,2512,2521,2529,2539],{"nctId":2464,"briefTitle":2465,"status":123,"phases":2466,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":1829,"conditions":2469,"interventions":2471},"NCT02292446","Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.",[93],"2017-12-29","2014-11-21",[2470],"Polycythemia Vera",[2341],{"nctId":2473,"briefTitle":2474,"status":109,"phases":2475,"primaryCompletion":2476,"completion":2477,"start":2478,"enrollment":2130,"conditions":2479,"interventions":2482},"NCT07357727","A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)",[93],"2028-05-17","2030-12-27","2026-05-27",[2381,2480,2481],"Post-polycythemia Vera Myelofibrosis (PPV-MF)","Post-essential Thrombocythemia Myelofibrosis (PET-MF)",[78,2341],{"nctId":2484,"briefTitle":2485,"status":123,"phases":2486,"primaryCompletion":2487,"completion":2488,"start":2489,"enrollment":2490,"conditions":2491,"interventions":2493},"NCT02913261","Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation",[93],"2019-06-24","2021-04-23","2017-03-10",310,[2492],"Corticosteroid Refractory Acute Graft vs Host Disease",[2341,2494],"Best Available Therapy",{"nctId":2496,"briefTitle":2497,"status":123,"phases":2498,"primaryCompletion":2499,"completion":2500,"start":2501,"enrollment":2502,"conditions":2503,"interventions":2504},"NCT02038036","Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.",[93],"2015-09-29","2020-04-07","2014-03-25",149,[2470],[2494,2341],{"nctId":2506,"briefTitle":2507,"status":123,"phases":2508,"primaryCompletion":2509,"completion":606,"start":1781,"enrollment":2428,"conditions":2510,"interventions":2511},"NCT02087059","A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis",[93],"2015-03",[2450],[2341],{"nctId":2513,"briefTitle":2514,"status":123,"phases":2515,"primaryCompletion":2516,"completion":2516,"start":2517,"enrollment":677,"conditions":2518,"interventions":2520},"NCT04362137","Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm",[93],"2020-10-17","2020-05-02",[2519],"Cytokine Storm (Covid-19)",[2341],{"nctId":2522,"briefTitle":2523,"status":123,"phases":2524,"primaryCompletion":2525,"completion":2525,"start":2526,"enrollment":1983,"conditions":2527,"interventions":2528},"NCT00934544","Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial",[93],"2015-03-04","2009-07-01",[2369],[2341,2494],{"nctId":2530,"briefTitle":2531,"status":134,"phases":2532,"primaryCompletion":2533,"completion":2533,"start":2534,"enrollment":1622,"conditions":2535,"interventions":2537},"NCT02598297","Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.",[93],"2017-10-23","2016-02-03",[2536],"Myelofibrosis With High Molecular Risk Mutations",[2341,2538],"Ruxolitinib Placebo",{"nctId":75,"briefTitle":76,"status":147,"phases":2540,"primaryCompletion":77,"completion":2541,"start":2542,"enrollment":2543,"conditions":2544,"interventions":2547},[93],"2027-06-30","2021-04-09",430,[2369,2430,2545,2546],"Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis",[78,2341],{"trials":2549,"activeCount":317,"soonestReadout":2554},[2550,2560,2572],{"nctId":2551,"briefTitle":2552,"status":109,"phases":2553,"primaryCompletion":2554,"completion":2555,"start":2556,"enrollment":792,"conditions":2557,"interventions":2559},"NCT06462469","Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease",[94],"2027-01-04","2028-02-17","2024-07-04",[2558],"Steroid-refractory Acute Graft Versus Host Disease",[2341],{"nctId":2561,"briefTitle":2562,"status":147,"phases":2563,"primaryCompletion":2564,"completion":2564,"start":2565,"enrollment":2566,"conditions":2567,"interventions":2571},"NCT02386800","CINC424A2X01B Rollover Protocol",[94],"2027-09-16","2015-03-05",279,[2430,2470,2568,2569,2570],"Graft Versus Host Disease","Acute Myeloid Leukemia","Thalassemia",[2361,2360],{"nctId":2573,"briefTitle":2574,"status":109,"phases":2575,"primaryCompletion":2576,"completion":2577,"start":2578,"enrollment":2579,"conditions":2580,"interventions":2584},"NCT06824103","Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease",[94],"2029-11-29","2031-05-23","2025-09-09",50,[2581,2582,2583],"Graft vs. Host Disease","Chronic Graft vs. Host Disease","Corticosteroid-refractory Chronic Graft vs. Host Disease",[2341],{"trials":2586,"activeCount":103},[2587,2593,2600],{"nctId":2588,"briefTitle":2589,"status":1326,"phases":2590,"conditions":2591,"interventions":2592},"NCT05269771","MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera",[],[2470],[2341],{"nctId":2594,"briefTitle":2595,"status":1326,"phases":2596,"conditions":2597,"interventions":2599},"NCT04337359","Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe\u002FVery Severe COVID-19 Illness",[],[2598],"Severe\u002FVery Severe COVID-19 Illness",[2341],{"nctId":2601,"briefTitle":2602,"status":491,"phases":2603,"conditions":2604,"interventions":2610},"NCT04745637","Managed Access Programs for INC424, Ruxolitinib",[],[2381,2605,2606,2598,2607,2608,2609],"Post Polycythemia Myelofibrosis (PPV MF)","Thrombocythemia Myelofibrosis (PET-MF)","Polycythemia Vera (PV)","Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD)","Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)",[2341],{"intervention":1078,"totalTrials":37,"cells":2612},{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2641,"PHASE3":2689,"PHASE4":2715,"NA":2725},{"trials":2614,"activeCount":103},[],{"trials":2616,"activeCount":103},[2617,2627,2637],{"nctId":2618,"briefTitle":2619,"status":134,"phases":2620,"primaryCompletion":2621,"completion":2622,"start":2623,"enrollment":637,"conditions":2624,"interventions":2626},"NCT02873650","Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment",[91],"2018-10-12","2019-04-08","2016-12-20",[2625],"Hepatic Impairment",[1308],{"nctId":2628,"briefTitle":2629,"status":123,"phases":2630,"primaryCompletion":2631,"completion":2631,"start":2632,"enrollment":2633,"conditions":2634,"interventions":2636},"NCT02852239","Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment",[91],"2019-09-27","2016-12-19",22,[2635],"Renal Impairment",[1308],{"nctId":1070,"briefTitle":1071,"status":134,"phases":2638,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":203,"conditions":2639,"interventions":2640},[91],[1076],[1078,184,173,158,211,212,1079],{"trials":2642,"activeCount":103},[2643,2647,2651,2655,2659,2663,2667,2671,2675,2679],{"nctId":1095,"briefTitle":1096,"status":123,"phases":2644,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":2645,"interventions":2646},[91,92],[1102],[1078,173,1104],{"nctId":1106,"briefTitle":1107,"status":123,"phases":2648,"primaryCompletion":1109,"completion":1110,"start":1111,"enrollment":1112,"conditions":2649,"interventions":2650},[92],[1102,36],[1078,173],{"nctId":1116,"briefTitle":1117,"status":123,"phases":2652,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":709,"conditions":2653,"interventions":2654},[92],[227],[1078,173],{"nctId":1124,"briefTitle":1125,"status":123,"phases":2656,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":446,"conditions":2657,"interventions":2658},[92],[1102],[1078,173],{"nctId":1137,"briefTitle":1138,"status":123,"phases":2660,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":1143,"conditions":2661,"interventions":2662},[92],[1145,1146,1147,1148,1149,1150,1151,1152,1153,1154,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],[1078,156,1168,1169],{"nctId":1171,"briefTitle":1172,"status":390,"phases":2664,"primaryCompletion":1174,"completion":1175,"start":1176,"enrollment":103,"conditions":2665,"interventions":2666},[92],[1178],[1078,173],{"nctId":1198,"briefTitle":1199,"status":123,"phases":2668,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":2669,"interventions":2670},[92],[1102],[1078,173],{"nctId":1207,"briefTitle":1208,"status":123,"phases":2672,"primaryCompletion":1210,"completion":1211,"start":1212,"enrollment":1213,"conditions":2673,"interventions":2674},[92],[1215],[1078,173],{"nctId":1218,"briefTitle":1219,"status":123,"phases":2676,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":1223,"conditions":2677,"interventions":2678},[91,92],[1102],[173,1078],{"nctId":2680,"briefTitle":2681,"status":123,"phases":2682,"primaryCompletion":2683,"completion":2683,"start":2684,"enrollment":2685,"conditions":2686,"interventions":2688},"NCT01677741","A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects",[91,92],"2020-12-04","2013-05-23",85,[2687],"Neoplasms, Brain",[1078],{"trials":2690,"activeCount":437,"soonestReadout":1275},[2691,2695,2699,2703,2707,2711],{"nctId":1229,"briefTitle":1230,"status":134,"phases":2692,"primaryCompletion":1232,"completion":1233,"start":1234,"enrollment":1235,"conditions":2693,"interventions":2694},[93],[36],[212,1078,173],{"nctId":1239,"briefTitle":1240,"status":123,"phases":2696,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":2697,"interventions":2698},[93],[36],[1078,173,1248],{"nctId":1250,"briefTitle":1251,"status":123,"phases":2700,"primaryCompletion":1253,"completion":1254,"start":1255,"enrollment":1256,"conditions":2701,"interventions":2702},[93],[36],[1078,1259,173],{"nctId":1261,"briefTitle":1262,"status":123,"phases":2704,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":1267,"conditions":2705,"interventions":2706},[93],[36],[1078,173,1270],{"nctId":1272,"briefTitle":1273,"status":147,"phases":2708,"primaryCompletion":1275,"completion":1276,"start":1277,"enrollment":1278,"conditions":2709,"interventions":2710},[93],[1280],[1078,173,1282,1283],{"nctId":1285,"briefTitle":1286,"status":123,"phases":2712,"primaryCompletion":1288,"completion":1289,"start":243,"enrollment":1290,"conditions":2713,"interventions":2714},[93],[1292],[1078,173],{"trials":2716,"activeCount":213,"soonestReadout":1300},[2717,2721],{"nctId":1297,"briefTitle":1298,"status":109,"phases":2718,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":1302,"conditions":2719,"interventions":2720},[94],[1145,1146,1147,1148,1149,1150,1151,1152,1153,1154,1155,1156,1157,1158,1159,1160,1161,1162,1304,1164,1165,1305,1306],[1308,156],{"nctId":1310,"briefTitle":1311,"status":109,"phases":2722,"primaryCompletion":1313,"completion":1313,"start":1142,"enrollment":1314,"conditions":2723,"interventions":2724},[94],[36,1316,1317,1318,1319],[1308,156],{"trials":2726,"activeCount":437,"soonestReadout":1350},[2727,2731,2739,2743,2747],{"nctId":1324,"briefTitle":1325,"status":1326,"phases":2728,"conditions":2729,"interventions":2730},[],[36],[1330,1078,173],{"nctId":2732,"briefTitle":2733,"status":1326,"phases":2734,"conditions":2735,"interventions":2737},"NCT04507919","Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer",[],[2736],"Small Cell Lung Carcinoma",[1078,2738],"Trametininb",{"nctId":1332,"briefTitle":1333,"status":1326,"phases":2740,"conditions":2741,"interventions":2742},[],[36,1336],[1330,1078,173],{"nctId":1339,"briefTitle":1340,"status":123,"phases":2744,"primaryCompletion":1342,"completion":1342,"start":1343,"enrollment":28,"conditions":2745,"interventions":2746},[],[36],[1308,156],{"nctId":1347,"briefTitle":1348,"status":147,"phases":2748,"primaryCompletion":1350,"completion":1350,"start":1351,"enrollment":1352,"conditions":2749,"interventions":2750},[],[36],[1308,156],{"intervention":2752,"totalTrials":630,"cells":2753},"Ofatumumab",{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2767,"PHASE3":2801,"PHASE4":2923,"NA":2985},{"trials":2755,"activeCount":103},[],{"trials":2757,"activeCount":103},[2758],{"nctId":2759,"briefTitle":2760,"status":123,"phases":2761,"primaryCompletion":2762,"completion":2762,"start":1670,"enrollment":2439,"conditions":2763,"interventions":2764},"NCT01691807","Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma",[91],"2015-12",[1102],[2765,2766],"ofatumumab","bendamustine",{"trials":2768,"activeCount":103},[2769,2780,2789],{"nctId":2770,"briefTitle":2771,"status":123,"phases":2772,"primaryCompletion":2773,"completion":2774,"start":2775,"enrollment":2776,"conditions":2777,"interventions":2779},"NCT03249714","Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab",[92],"2019-12-26","2020-07-29","2018-03-15",64,[2778],"Relapsing Multiple Sclerosis",[2752],{"nctId":2781,"briefTitle":2782,"status":123,"phases":2783,"primaryCompletion":2623,"completion":2623,"start":2784,"enrollment":1622,"conditions":2785,"interventions":2787},"NCT01294579","Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)",[92],"2011-05-17",[2786],"Lymphoma, Non-Hodgkin",[2752,2788],"Bendamustine",{"nctId":2790,"briefTitle":2791,"status":123,"phases":2792,"primaryCompletion":2793,"completion":2794,"start":2795,"enrollment":2796,"conditions":2797,"interventions":2800},"NCT01520922","Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)",[92],"2013-02","2015-11","2012-03",99,[2798,2799],"Chronic Lymphocytic Leukemia (CLL)","Leukaemia, Lymphocytic, Chronic",[2752,2788],{"trials":2802,"activeCount":213,"soonestReadout":2829},[2803,2813,2825,2838,2848,2860,2870,2880,2894,2904,2914],{"nctId":2804,"briefTitle":2805,"status":123,"phases":2806,"primaryCompletion":2807,"completion":2808,"start":2809,"enrollment":2810,"conditions":2811,"interventions":2812},"NCT04486716","A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis",[93],"2023-11-20","2024-10-21","2020-10-19",111,[2778],[2752],{"nctId":2814,"briefTitle":2815,"status":134,"phases":2816,"primaryCompletion":2817,"completion":2818,"start":2819,"enrollment":2820,"conditions":2821,"interventions":2822},"NCT00748189","Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia",[93],"2013-03-20","2018-05-17","2008-12-22",447,[2799],[2823,2824],"chlorambucil,","ofatumumab (GSK1841157)",{"nctId":2826,"briefTitle":2827,"status":147,"phases":2828,"primaryCompletion":2829,"completion":2830,"start":2831,"enrollment":2832,"conditions":2833,"interventions":2835},"NCT04926818","Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis",[93],"2026-03-25","2031-02-28","2021-10-05",129,[2834],"Multiple Sclerosis (MS)",[2836,2752,2837],"Fingolimod","Siponimod",{"nctId":2839,"briefTitle":2840,"status":134,"phases":2841,"primaryCompletion":2842,"completion":2843,"start":2844,"enrollment":2845,"conditions":2846,"interventions":2847},"NCT01039376","Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy",[93],"2017-02-20","2018-06-26","2010-05-06",480,[2799],[2752],{"nctId":2849,"briefTitle":2850,"status":134,"phases":2851,"primaryCompletion":2852,"completion":2853,"start":2854,"enrollment":2855,"conditions":2856,"interventions":2858},"NCT01077518","Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy",[93],"2018-01-03","2018-12-26","2010-08-26",346,[2857],"Lymphoma, Follicular",[2752,2788,2859,2788],"Ofatumumab and Bendamustine infusions",{"nctId":2861,"briefTitle":2862,"status":123,"phases":2863,"primaryCompletion":2864,"completion":2865,"start":2866,"enrollment":2867,"conditions":2868,"interventions":2869},"NCT04353492","An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab",[93],"2024-10-09","2025-03-11","2020-07-14",562,[2778],[2752],{"nctId":2871,"briefTitle":2872,"status":134,"phases":2873,"primaryCompletion":2632,"completion":2632,"start":2874,"enrollment":2875,"conditions":2876,"interventions":2878},"NCT01200589","Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy",[93],"2010-10-11",438,[2877],"Non-Hodgkin's Lymphoma",[2752,2879,2752,2879],"Rituximab",{"nctId":2881,"briefTitle":2882,"status":147,"phases":2883,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":2886,"conditions":2887,"interventions":2888},"NCT03650114","Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",[93],"2028-09-30","2018-12-28",1882,[2778],[2752,2889,2890,2891,2892,2893],"Tetanus toxoid","13-valent pneumococcal conjugate vaccine","23-valent pneumococcal polysaccharide vaccine","Seasonal Quadrivalent influenza vaccine","Keyhole limpet hemocyanin (KLH) neo-antigen",{"nctId":2895,"briefTitle":2896,"status":123,"phases":2897,"primaryCompletion":1111,"completion":2898,"start":2899,"enrollment":203,"conditions":2900,"interventions":2902},"NCT01313689","Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia",[93],"2017-04-24","2011-04-14",[2901],"Leukaemia",[2752,2903],"Physicians' Choice",{"nctId":2905,"briefTitle":2906,"status":123,"phases":2907,"primaryCompletion":2908,"completion":2908,"start":2909,"enrollment":2910,"conditions":2911,"interventions":2912},"NCT04788615","Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS",[93],"2025-11-04","2021-07-23",185,[27],[2752,2913],"First line DMT",{"nctId":2915,"briefTitle":2916,"status":134,"phases":2917,"primaryCompletion":2918,"completion":2128,"start":2919,"enrollment":906,"conditions":2920,"interventions":2922},"NCT01920477","Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris",[93],"2016-04-13","2013-08-13",[2921],"Pemphigus Vulgaris",[2752],{"trials":2924,"activeCount":437,"soonestReadout":2946},[2925,2933,2942,2953,2964,2974],{"nctId":2926,"briefTitle":2927,"status":123,"phases":2928,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":2796,"conditions":2931,"interventions":2932},"NCT05199571","Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China",[94],"2025-02-13","2022-07-22",[2778],[2752],{"nctId":2934,"briefTitle":2935,"status":123,"phases":2936,"primaryCompletion":2937,"completion":2938,"start":2939,"enrollment":31,"conditions":2940,"interventions":2941},"NCT04869358","Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab",[94],"2022-05-10","2023-06-13","2021-05-27",[2778],[2752],{"nctId":2943,"briefTitle":2944,"status":147,"phases":2945,"primaryCompletion":2946,"completion":2946,"start":2947,"enrollment":2948,"conditions":2949,"interventions":2951},"NCT05090371","A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation",[94],"2027-04-13","2022-03-02",136,[2950],"Relapsing-Remitting Multiple Sclerosis",[2752,2952],"Disease modifying treatment",{"nctId":2954,"briefTitle":2955,"status":134,"phases":2956,"primaryCompletion":2957,"completion":2957,"start":2958,"enrollment":630,"conditions":2959,"interventions":2961},"NCT04878211","A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab",[94],"2023-04-14","2021-06-10",[2960],"Relapsing Multiple Sclerosis (RMS)",[2752,2962,2963],"mRNA COVID-19 vaccine","interferon or glatiramer acetate",{"nctId":2965,"briefTitle":2966,"status":123,"phases":2967,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":19,"conditions":2970,"interventions":2971},"NCT04667117","A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab",[94],"2023-07-06","2021-01-14",[2778],[2972,2752,2973],"Quadrivalent influenza vaccine","iDMT",{"nctId":2975,"briefTitle":2976,"status":123,"phases":2977,"primaryCompletion":2978,"completion":2979,"start":2980,"enrollment":2981,"conditions":2982,"interventions":2984},"NCT05084638","Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.",[94],"2025-02-04","2026-02-11","2022-01-25",180,[2983],"Relapse Remitting Multiple Sclerosis",[2752],{"trials":2986,"activeCount":437,"soonestReadout":596},[2987,2996,3006],{"nctId":2988,"briefTitle":2989,"status":147,"phases":2990,"primaryCompletion":596,"completion":596,"start":2991,"enrollment":2992,"conditions":2993,"interventions":2995},"NCT06345157","ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients",[],"2024-07-30",379,[2994],"Multiple Sclerosis, Relapsing-Remitting",[2752],{"nctId":2997,"briefTitle":2998,"status":123,"phases":2999,"primaryCompletion":3000,"completion":3000,"start":3001,"enrollment":3002,"conditions":3003,"interventions":3004},"NCT06121349","WOE of Anti-CD20 Therapies",[],"2025-06-13","2023-12-04",157,[27],[3005,2765],"ocrelizumab",{"nctId":3007,"briefTitle":3008,"status":123,"phases":3009,"primaryCompletion":3010,"completion":3010,"start":3011,"enrollment":213,"conditions":3012,"interventions":3014},"NCT04676555","Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis",[],"2021-10-21","2021-05-11",[3013],"Relapsing Forms of Multiple Sclerosis",[3015,2752],"Ocrelizumab",{"intervention":3017,"totalTrials":734,"cells":3018},"Standard of Care",{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3023,"PHASE3":3132,"PHASE4":3170,"NA":3182},{"trials":3020,"activeCount":103},[],{"trials":3022,"activeCount":103},[],{"trials":3024,"activeCount":437,"soonestReadout":3117},[3025,3037,3048,3058,3069,3080,3091,3103,3113],{"nctId":3026,"briefTitle":3027,"status":123,"phases":3028,"primaryCompletion":3029,"completion":3030,"start":3031,"enrollment":3032,"conditions":3033,"interventions":3035},"NCT04382053","Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia",[92],"2020-12-10","2020-12-24","2020-05-27",143,[3034],"COVID-19 Pneumonia, Impaired Respiratory Function",[3036,3017],"DFV890",{"nctId":3038,"briefTitle":3039,"status":123,"phases":3040,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":3043,"conditions":3044,"interventions":3046},"NCT03804879","Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy",[92],"2021-05-03","2018-12-17",83,[3045],"Diabetic Nephropathy",[3047,3017],"Nidufexor",{"nctId":3049,"briefTitle":3050,"status":123,"phases":3051,"primaryCompletion":3052,"completion":3052,"start":3053,"enrollment":630,"conditions":3054,"interventions":3055},"NCT04589663","Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to \u003C 12 Years Old With Asthma",[92],"2022-04-11","2021-06-07",[18],[3056,3057,3017],"Mometasone furoate","QMF149",{"nctId":3059,"briefTitle":3060,"status":123,"phases":3061,"primaryCompletion":3062,"completion":3062,"start":3063,"enrollment":3064,"conditions":3065,"interventions":3067},"NCT04053764","Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease",[92],"2023-03-20","2019-12-10",58,[3066],"Sickle Cell Disease (SCD)",[3068,3017],"Crizanlizuamb",{"nctId":3070,"briefTitle":3071,"status":123,"phases":3072,"primaryCompletion":3073,"completion":3074,"start":3075,"enrollment":1672,"conditions":3076,"interventions":3078},"NCT03439839","Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",[92],"2020-04-22","2022-02-28","2018-04-09",[3077],"Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis",[3079,3017],"iptacopan",{"nctId":3081,"briefTitle":3082,"status":123,"phases":3083,"primaryCompletion":3084,"completion":3085,"start":3086,"enrollment":3087,"conditions":3088,"interventions":3089},"NCT04382651","Study of Efficacy and Safety of MAS825 in Patients With COVID-19",[92],"2021-01-06","2021-04-21","2020-06-11",140,[3034],[3090,3017],"MAS825",{"nctId":3092,"briefTitle":3093,"status":134,"phases":3094,"primaryCompletion":3095,"completion":3096,"start":3097,"enrollment":3098,"conditions":3099,"interventions":3101},"NCT05497284","To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF",[92],"2024-08-26","2024-09-26","2022-11-10",46,[3100],"Idiopathic Pulmonary Fibrosis",[3102,3017],"LTP001",{"nctId":3104,"briefTitle":3105,"status":134,"phases":3106,"primaryCompletion":3107,"completion":3108,"start":3109,"enrollment":2439,"conditions":3110,"interventions":3111},"NCT03287414","Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis",[92],"2020-11-25","2022-02-14","2017-12-20",[3100],[3112,3017],"VAY736",{"nctId":3114,"briefTitle":3115,"status":109,"phases":3116,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":3120,"conditions":3121,"interventions":3123},"NCT07206056","An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)",[91,92],"2029-11-09","2030-12-01","2025-10-15",188,[3122],"Progressive Metastatic Castrate Resistant Prostate Cancer",[3124,3125,3126,3127,3128,3129,3130,3131,3017],"Tulmimetostat DL1 QD","Tulmimetostat DL2 QD","Tulmimetostat DL3 QD","Tulmimetostat Doses 1 or 2 QD","Tulmimetostat RP2D QD","JSB462 Dose 1 QD","JSB462 Dose 2 QD","JSB462 QD",{"trials":3133,"activeCount":437,"soonestReadout":3163},[3134,3146,3159],{"nctId":3135,"briefTitle":3136,"status":134,"phases":3137,"primaryCompletion":3138,"completion":3139,"start":3140,"enrollment":3141,"conditions":3142,"interventions":3144},"NCT02064868","Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients",[93],"2017-03-26","2017-04-25","2014-01-31",2666,[3143],"Acute Heart Failure (AHF)",[3145,3017],"Serelaxin",{"nctId":3147,"briefTitle":3148,"status":123,"phases":3149,"primaryCompletion":3150,"completion":3151,"start":3152,"enrollment":3153,"conditions":3154,"interventions":3156},"NCT01327846","Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)",[93],"2017-03-28","2019-04-14","2011-04-11",10066,[3155],"Atherosclerosis",[3157,3158],"Canakinumab","Standard of care",{"nctId":3160,"briefTitle":3161,"status":109,"phases":3162,"primaryCompletion":3163,"completion":3164,"start":3165,"enrollment":3166,"conditions":3167,"interventions":3168},"NCT06855277","Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC",[93],"2028-09-29","2032-11-04","2025-07-01",940,[1654],[3169,1628,3017],"AAA817",{"trials":3171,"activeCount":437,"soonestReadout":3176},[3172],{"nctId":3173,"briefTitle":3174,"status":147,"phases":3175,"primaryCompletion":3176,"completion":3176,"start":3177,"enrollment":3178,"conditions":3179,"interventions":3181},"NCT06941792","Inclisiran Effectiveness in China: a Pragmatic Randomized Trial",[94],"2027-04-30","2025-06-17",1590,[3180],"Coronary Heart Disease",[58,3017],{"trials":3183,"activeCount":103},[],{"intervention":2395,"totalTrials":271,"cells":3185},{"EARLY_PHASE1":3186,"PHASE1":3188,"PHASE2":3237,"PHASE3":3364,"PHASE4":3515,"NA":3625},{"trials":3187,"activeCount":103},[],{"trials":3189,"activeCount":103},[3190,3198,3206,3213,3219,3233],{"nctId":3191,"briefTitle":3192,"status":123,"phases":3193,"primaryCompletion":3194,"start":3195,"enrollment":34,"conditions":3196,"interventions":3197},"NCT00418626","Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function",[91],"2007-09","2006-11",[1674],[2395],{"nctId":3199,"briefTitle":3200,"status":123,"phases":3201,"primaryCompletion":3202,"completion":3202,"start":2899,"enrollment":2367,"conditions":3203,"interventions":3205},"NCT01077544","A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)",[91],"2015-07-01",[2393,3204],"Acute Lymphoblastic Leukemia",[2395],{"nctId":3207,"briefTitle":3208,"status":123,"phases":3209,"primaryCompletion":3210,"start":745,"enrollment":630,"conditions":3211,"interventions":3212},"NCT00418769","Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers",[91],"2006-08",[1674],[2395],{"nctId":3214,"briefTitle":3215,"status":123,"phases":3216,"primaryCompletion":3195,"start":825,"enrollment":138,"conditions":3217,"interventions":3218},"NCT00418756","Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects",[91],[1674],[2395],{"nctId":3220,"briefTitle":3221,"status":123,"phases":3222,"primaryCompletion":3223,"completion":3224,"start":3225,"enrollment":3226,"conditions":3227,"interventions":3230},"NCT02081378","A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL",[91],"2021-06-03","2023-03-14","2014-04-24",326,[3228,3229],"Chronic Myelogenous Leukemia","Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia",[3231,2395,83,3232],"Asciminib","Dasatinib",{"nctId":2386,"briefTitle":2387,"status":123,"phases":3234,"primaryCompletion":2389,"completion":2390,"start":2391,"enrollment":637,"conditions":3235,"interventions":3236},[91],[2393],[2395,2341],{"trials":3238,"activeCount":103},[3239,3250,3258,3267,3275,3283,3291,3300,3307,3315,3326,3339,3347,3355],{"nctId":3240,"briefTitle":3241,"status":123,"phases":3242,"primaryCompletion":3243,"completion":3243,"start":854,"enrollment":3244,"conditions":3245,"interventions":3249},"NCT00109707","A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies",[91,92],"2012-09",507,[3228,3246,3247,3248],"Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)","Hypereosinophilic Syndrome","Systemic Mastocytosis",[2395],{"nctId":3251,"briefTitle":3252,"status":123,"phases":3253,"primaryCompletion":3254,"start":3255,"enrollment":25,"conditions":3256,"interventions":3257},"NCT00384228","A Phase l\u002Fll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL",[91,92],"2007-01","2005-05",[3228,3246],[2395],{"nctId":3259,"briefTitle":3260,"status":123,"phases":3261,"primaryCompletion":3262,"completion":3262,"start":3263,"enrollment":2367,"conditions":3264,"interventions":3265},"NCT01863745","Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment",[92],"2023-10-02","2013-06-25",[208],[3266],"nilotinib",{"nctId":3268,"briefTitle":3269,"status":123,"phases":3270,"primaryCompletion":3271,"start":3272,"enrollment":25,"conditions":3273,"interventions":3274},"NCT01279473","Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse\u002FRefractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)",[91,92],"2009-12","2005-08",[3228,3204],[2395],{"nctId":3276,"briefTitle":3277,"status":123,"phases":3278,"primaryCompletion":1818,"completion":1818,"start":3279,"enrollment":213,"conditions":3280,"interventions":3282},"NCT01110668","Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)",[92],"2008-09",[3281],"Gastrointestinal Stromal Tumor",[2395],{"nctId":3284,"briefTitle":3285,"status":123,"phases":3286,"primaryCompletion":3119,"completion":3119,"start":3287,"enrollment":3288,"conditions":3289,"interventions":3290},"NCT03874858","A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia",[92],"2019-03-22",124,[2393],[2395,2395,3231],{"nctId":3292,"briefTitle":3293,"status":123,"phases":3294,"primaryCompletion":3295,"completion":3296,"start":3297,"enrollment":2294,"conditions":3298,"interventions":3299},"NCT01698905","Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)",[92],"2015-11-26","2025-01-29","2012-12-20",[2393],[3266],{"nctId":3301,"briefTitle":3302,"status":134,"phases":3303,"primaryCompletion":1670,"completion":1670,"start":864,"enrollment":496,"conditions":3304,"interventions":3306},"NCT01179737","Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)",[92],[3305],"Pulmonary Arterial Hypertension",[2395],{"nctId":3308,"briefTitle":3309,"status":123,"phases":3310,"primaryCompletion":3311,"completion":3311,"start":3312,"enrollment":1034,"conditions":3313,"interventions":3314},"NCT01274351","Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)",[92],"2019-08-01","2011-01-25",[3228],[2395],{"nctId":3316,"briefTitle":3317,"status":123,"phases":3318,"primaryCompletion":3319,"completion":3320,"start":3321,"enrollment":3322,"conditions":3323,"interventions":3325},"NCT01844765","Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.",[92],"2016-06-01","2020-08-28","2013-08-20",59,[3324],"Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia",[3266],{"nctId":3327,"briefTitle":3328,"status":123,"phases":3329,"primaryCompletion":3330,"completion":136,"start":3331,"enrollment":314,"conditions":3332,"interventions":3336},"NCT03578367","Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.",[92],"2021-11-08","2018-11-22",[3333,3228,3334,3335],"CML","Leukemia, Myeloid Chronic","Hematologic Diseases",[3337,83,2395,3338],"Asciminib add-on","Asciminib 80mg QD",{"nctId":3340,"briefTitle":3341,"status":134,"phases":3342,"primaryCompletion":2795,"completion":2795,"start":1014,"enrollment":3343,"conditions":3344,"interventions":3346},"NCT00644878","Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib",[92],18,[3345],"Chronic Myelogenous Leukemia - Chronic Phase",[2395],{"nctId":3348,"briefTitle":3349,"status":123,"phases":3350,"primaryCompletion":1731,"completion":1731,"start":3351,"enrollment":2112,"conditions":3352,"interventions":3353},"NCT01028222","A Study of AMNN107 in the Treatment of Metastatic and\u002For Inoperable Melanoma Harboring a c-Kit Mutation",[92],"2010-06",[36],[2395,3354],"DTIC",{"nctId":3356,"briefTitle":3357,"status":123,"phases":3358,"primaryCompletion":3359,"completion":3360,"start":3361,"enrollment":3322,"conditions":3362,"interventions":3363},"NCT01744665","A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation",[92],"2018-09-28","2018-09-29","2013-08-12",[3333],[3266],{"trials":3365,"activeCount":213,"soonestReadout":82},[3366,3378,3387,3396,3405,3414,3424,3434,3443,3451,3461,3469,3478,3486,3494,3501,3507],{"nctId":3367,"briefTitle":3368,"status":123,"phases":3369,"primaryCompletion":3370,"completion":3371,"start":3372,"enrollment":3373,"conditions":3374,"interventions":3376},"NCT00471497","A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)",[93],"2009-09-02","2019-08-21","2007-07-31",846,[3375],"Myelogenous Leukemia, Chronic",[3266,3377],"imatinib",{"nctId":3379,"briefTitle":3380,"status":123,"phases":3381,"primaryCompletion":3382,"completion":3382,"start":3383,"enrollment":3384,"conditions":3385,"interventions":3386},"NCT01254188","Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients",[93],"2014-11","2011-04",421,[2393],[2395],{"nctId":80,"briefTitle":81,"status":147,"phases":3388,"primaryCompletion":82,"completion":3389,"start":3390,"enrollment":3391,"conditions":3392,"interventions":3394},[93],"2031-01-18","2021-10-06",405,[3393],"Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive",[83,2395,3395,3232,3231],"Bosutinib",{"nctId":3397,"briefTitle":3398,"status":123,"phases":3399,"primaryCompletion":1817,"completion":1817,"start":3400,"enrollment":3401,"conditions":3402,"interventions":3404},"NCT00785785","A Study of Nilotinib Versus Imatinib in GIST Patients",[93],"2009-03",644,[3403],"Gastrointestinal Stromal Tumor (GIST)",[2395,3377],{"nctId":3406,"briefTitle":3407,"status":123,"phases":3408,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":3411,"conditions":3412,"interventions":3413},"NCT00802841","Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib",[93],"2014-07","2009-05",191,[3228],[3266,3377],{"nctId":3415,"briefTitle":3416,"status":123,"phases":3417,"primaryCompletion":3418,"completion":3418,"start":3419,"enrollment":3420,"conditions":3421,"interventions":3423},"NCT02272777","A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase",[93],"2017-01-30","2014-07-17",225,[3422],"Leukemia",[83,2395],{"nctId":3425,"briefTitle":3426,"status":147,"phases":3427,"primaryCompletion":3428,"completion":3429,"start":3430,"enrollment":1235,"conditions":3431,"interventions":3433},"NCT05456191","A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)",[93],"2025-05-15","2031-07-07","2022-11-21",[3432],"Philadelphia Chromosome-Positive Chronic Myeloid Leukemia",[3231,2395],{"nctId":3435,"briefTitle":3436,"status":134,"phases":3437,"primaryCompletion":3438,"completion":3438,"start":3439,"enrollment":1611,"conditions":3440,"interventions":3442},"NCT02108951","Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.",[93],"2016-08-10","2014-07-07",[3441],"Philidelphia Positive Chronic Myeloid Leukaemia",[2395],{"nctId":3444,"briefTitle":3445,"status":134,"phases":3446,"primaryCompletion":1014,"completion":1014,"start":3447,"enrollment":2379,"conditions":3448,"interventions":3450},"NCT00519090","Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)",[93],"2007-10",[3449],"Myelogenous Leukemia",[83,2395],{"nctId":3452,"briefTitle":3453,"status":123,"phases":3454,"primaryCompletion":3455,"completion":3455,"start":3456,"enrollment":3457,"conditions":3458,"interventions":3460},"NCT01743989","A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.",[93],"2020-07-08","2013-04-15",620,[3459],"Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)",[2395],{"nctId":3462,"briefTitle":3463,"status":134,"phases":3464,"primaryCompletion":3465,"completion":3465,"start":754,"enrollment":1562,"conditions":3466,"interventions":3468},"NCT02115386","Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib",[93],"2016-10-31",[3467],"Philadelphia Positive (Ph+) Chronic Myeloid Leukemia",[2395],{"nctId":3470,"briefTitle":3471,"status":123,"phases":3472,"primaryCompletion":3473,"completion":2034,"start":3474,"enrollment":3475,"conditions":3476,"interventions":3477},"NCT00471328","Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib",[93],"2008-08","2007-03",248,[208],[2395],{"nctId":3479,"briefTitle":3480,"status":134,"phases":3481,"primaryCompletion":3482,"completion":3482,"start":1024,"enrollment":3483,"conditions":3484,"interventions":3485},"NCT00751036","Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg",[93],"2012-08",94,[208],[2395,83],{"nctId":3487,"briefTitle":3488,"status":123,"phases":3489,"primaryCompletion":3409,"completion":3409,"start":3490,"enrollment":3491,"conditions":3492,"interventions":3493},"NCT01289028","Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.",[93],"2008-11",125,[208],[2395],{"nctId":3495,"briefTitle":3496,"status":123,"phases":3497,"primaryCompletion":1817,"completion":1817,"start":3383,"enrollment":3498,"conditions":3499,"interventions":3500},"NCT01275196","Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients",[93],267,[2393],[2395,83],{"nctId":3502,"briefTitle":3503,"status":123,"phases":3504,"primaryCompletion":3383,"completion":3383,"start":949,"enrollment":2379,"conditions":3505,"interventions":3506},"NCT01126892","A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",[93],[2393],[2395],{"nctId":3508,"briefTitle":3509,"status":123,"phases":3510,"primaryCompletion":3511,"completion":3511,"start":1024,"enrollment":1444,"conditions":3512,"interventions":3514},"NCT00760877","Nilotinib Versus Standard Imatinib (400\u002F600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)",[93],"2015-07",[3513],"CHRONIC MYELOGENOUS LEUKEMIA",[2395,83],{"trials":3516,"activeCount":437,"soonestReadout":3575},[3517,3524,3537,3547,3555,3564,3571,3583,3590,3600,3608,3617],{"nctId":3518,"briefTitle":3519,"status":123,"phases":3520,"primaryCompletion":2147,"completion":2147,"start":3521,"enrollment":31,"conditions":3522,"interventions":3523},"NCT00756509","Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib",[94],"2008-08-29",[208],[2395],{"nctId":3525,"briefTitle":3526,"status":123,"phases":3527,"primaryCompletion":3528,"completion":3528,"start":3529,"enrollment":3530,"conditions":3531,"interventions":3536},"NCT01735955","Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study",[94],"2023-07-07","2013-03-29",57,[3532,3533,3534,3535],"Chronic Myelogenous Leukemia (CML)","Metastatic Gastrointestinal Stromal Tumors (GIST)","Acute Lymphoblastic Leukemia (ALL)","Receptor Tyrosine Kinase (KIT) Mutated Melanoma",[2395],{"nctId":3538,"briefTitle":3539,"status":123,"phases":3540,"primaryCompletion":3541,"completion":3542,"start":3543,"enrollment":3544,"conditions":3545,"interventions":3546},"NCT02546674","Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.",[94],"2021-02-23","2021-03-25","2016-02-18",171,[2393],[2395],{"nctId":3548,"briefTitle":3549,"status":123,"phases":3550,"primaryCompletion":3551,"start":3552,"enrollment":1065,"conditions":3553,"interventions":3554},"NCT01368523","Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial",[94],"2010-01","2008-12",[3228],[3266],{"nctId":3556,"briefTitle":3557,"status":123,"phases":3558,"primaryCompletion":1714,"completion":3559,"start":3271,"enrollment":2405,"conditions":3560,"interventions":3563},"NCT01043874","Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response",[94],"2014-01",[3561,3562],"Philadelphia Chromosome Positive","Chronic Myelogenous Leukemia in Chronic Phase",[2395],{"nctId":3565,"briefTitle":3566,"status":123,"phases":3567,"primaryCompletion":1732,"completion":1732,"start":3473,"enrollment":3568,"conditions":3569,"interventions":3570},"NCT00786812","Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",[94],89,[2393],[2395],{"nctId":3572,"briefTitle":3573,"status":109,"phases":3574,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":3577,"conditions":3578,"interventions":3580},"NCT04877522","Asciminib Roll-over Study",[94],"2030-08-30","2022-08-30",347,[3228,3579],"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",[3581,83,2395,3395,3232,3582],"Asciminib single agent","Asciminib single agent pediatric formulation",{"nctId":3584,"briefTitle":3585,"status":123,"phases":3586,"primaryCompletion":3382,"completion":3382,"start":926,"enrollment":3587,"conditions":3588,"interventions":3589},"NCT01227577","CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib",[94],128,[3562],[2395],{"nctId":3591,"briefTitle":3592,"status":134,"phases":3593,"primaryCompletion":3594,"completion":3594,"start":3595,"enrollment":317,"conditions":3596,"interventions":3599},"NCT01131325","Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations",[94],"2011-05-12","2010-10-21",[3333,3597,3598],"Philadelphia Chromosome Positive (Ph+)","Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels",[3266],{"nctId":3601,"briefTitle":3602,"status":123,"phases":3603,"primaryCompletion":3604,"completion":3604,"start":3271,"enrollment":3605,"conditions":3606,"interventions":3607},"NCT00980018","An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment",[94],"2012-12",52,[3228],[2395],{"nctId":3609,"briefTitle":3610,"status":123,"phases":3611,"primaryCompletion":3243,"completion":3243,"start":3612,"enrollment":1016,"conditions":3613,"interventions":3616},"NCT01206088","Tasigna in Glivec-resistant or Intolerant Patients in CML",[94],"2009-02",[3333,2395,3614,3615],"Imatinib Resistant","Imatinib Intolerant",[3266],{"nctId":3618,"briefTitle":3619,"status":123,"phases":3620,"primaryCompletion":3409,"completion":3409,"start":853,"enrollment":3621,"conditions":3622,"interventions":3624},"NCT01061177","Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & \u002For BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase",[94],1090,[3623],"CML in Chronic Phase",[2395],{"trials":3626,"activeCount":103},[3627,3633,3640,3646,3653],{"nctId":3628,"briefTitle":3629,"status":1326,"phases":3630,"conditions":3631,"interventions":3632},"NCT04559555","MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[],[3534],[2395],{"nctId":3634,"briefTitle":3635,"status":3636,"phases":3637,"primaryCompletion":3383,"start":3279,"conditions":3638,"interventions":3639},"NCT00905593","Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase","APPROVED_FOR_MARKETING",[],[2393],[2395],{"nctId":3641,"briefTitle":3642,"status":1326,"phases":3643,"conditions":3644,"interventions":3645},"NCT04518644","Nilotinib, for Patients With CML-CP or CML-AP",[],[3532],[2395],{"nctId":3647,"briefTitle":3648,"status":1326,"phases":3649,"conditions":3650,"interventions":3652},"NCT04498871","MAP to Provide Access to Nilotinib, for Patients With HES",[],[3651],"Hypereosinophilic Syndrome (HES)",[2395],{"nctId":3654,"briefTitle":3655,"status":1326,"phases":3656,"start":3657,"conditions":3658,"interventions":3659},"NCT00413270","Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant",[],"2006-12",[3228],[3266],{"intervention":2836,"totalTrials":34,"cells":3661},{"EARLY_PHASE1":3662,"PHASE1":3664,"PHASE2":3666,"PHASE3":3668,"PHASE4":3735,"NA":3874},{"trials":3663,"activeCount":103},[],{"trials":3665,"activeCount":103},[],{"trials":3667,"activeCount":103},[],{"trials":3669,"activeCount":213,"soonestReadout":47},[3670,3676,3688,3697,3701,3708,3717,3726],{"nctId":45,"briefTitle":46,"status":147,"phases":3671,"primaryCompletion":47,"completion":3672,"start":3673,"enrollment":467,"conditions":3674,"interventions":3675},[93],"2030-02-18","2013-07-26",[27],[48,2836],{"nctId":3677,"briefTitle":3678,"status":134,"phases":3679,"primaryCompletion":3680,"completion":3680,"start":3681,"enrollment":3682,"conditions":3683,"interventions":3685},"NCT01633112","MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone",[93],"2018-04-30","2012-08-09",1064,[3684],"Relapsing-remitting Multiple Sclerosis (RRMS)",[3686,3687],"fingolimod","glatiramer acetate",{"nctId":3689,"briefTitle":3690,"status":123,"phases":3691,"primaryCompletion":3692,"completion":3692,"start":3693,"enrollment":3694,"conditions":3695,"interventions":3696},"NCT01201356","Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis",[93],"2018-10-19","2010-09-13",4125,[3013],[2836],{"nctId":2826,"briefTitle":2827,"status":147,"phases":3698,"primaryCompletion":2829,"completion":2830,"start":2831,"enrollment":2832,"conditions":3699,"interventions":3700},[93],[2834],[2836,2752,2837],{"nctId":3702,"briefTitle":3703,"status":123,"phases":3704,"primaryCompletion":1781,"completion":1781,"start":1671,"enrollment":3705,"conditions":3706,"interventions":3707},"NCT01497262","Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis",[93],162,[27],[2836],{"nctId":3709,"briefTitle":3710,"status":134,"phases":3711,"primaryCompletion":3712,"completion":3712,"start":1818,"enrollment":3713,"conditions":3714,"interventions":3716},"NCT01499667","Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod",[93],"2012-11",142,[3715],"Relapsing Remitting Multiple Sclerosis (RRMS)",[2836],{"nctId":3718,"briefTitle":3719,"status":123,"phases":3720,"primaryCompletion":3721,"completion":3721,"start":3722,"enrollment":1574,"conditions":3723,"interventions":3725},"NCT01625182","Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.",[93],"2016-09-03","2012-12-22",[3724],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy",[2836],{"nctId":3727,"briefTitle":3728,"status":390,"phases":3729,"primaryCompletion":3730,"completion":3730,"start":3731,"enrollment":103,"conditions":3732,"interventions":3734},"NCT01941004","Safety and Efficacy of Fingolimod in MS Patients in China",[93],"2017-05","2014-06",[3733],"Multiple Sclerosis (Relapsing Remitting)",[3686],{"trials":3736,"activeCount":437,"soonestReadout":1547},[3737,3747,3755,3764,3770,3780,3788,3795,3807,3815,3822,3831,3841,3850,3857,3865],{"nctId":3738,"briefTitle":3739,"status":123,"phases":3740,"primaryCompletion":1682,"completion":1682,"start":1732,"enrollment":3741,"conditions":3742,"interventions":3744},"NCT01534182","Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)",[94],298,[3743],"Relapsing Remitting Multiple Sclerosis",[2836,3745,3746],"Interferon beta - 1a","Glatiramer acetate",{"nctId":3748,"briefTitle":3749,"status":123,"phases":3750,"primaryCompletion":3751,"completion":3751,"start":3752,"enrollment":3577,"conditions":3753,"interventions":3754},"NCT01498887","Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy",[94],"2015-12-26","2011-12-24",[3743],[2836],{"nctId":3756,"briefTitle":3757,"status":123,"phases":3758,"primaryCompletion":3759,"completion":3759,"start":3760,"enrollment":2820,"conditions":3761,"interventions":3763},"NCT01310166","Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis",[94],"2012-07","2011-02",[3762],"Relapsing-remitting Multiple Sclerosis",[2836],{"nctId":3765,"briefTitle":3766,"status":390,"phases":3767,"primaryCompletion":3731,"completion":3731,"start":1682,"enrollment":103,"conditions":3768,"interventions":3769},"NCT01621269","ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon",[94],[27],[2836],{"nctId":3771,"briefTitle":3772,"status":123,"phases":3773,"primaryCompletion":3774,"completion":3774,"start":3775,"enrollment":3776,"conditions":3777,"interventions":3779},"NCT01705236","A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®",[94],"2019-02-18","2012-08-20",87,[3778],"Relapsing Remitting Multiple Sclerosis RRMS",[2836],{"nctId":3781,"briefTitle":3782,"status":123,"phases":3783,"primaryCompletion":3731,"completion":3731,"start":3784,"enrollment":2354,"conditions":3785,"interventions":3786},"NCT01317004","Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change",[94],"2011-05",[3743],[2836,3787],"Standard MS DMT",{"nctId":3789,"briefTitle":3790,"status":123,"phases":3791,"primaryCompletion":606,"completion":606,"start":1761,"enrollment":25,"conditions":3792,"interventions":3794},"NCT01578330","A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720",[94],[27,3793],"Relapsing-Remitting",[2836],{"nctId":3796,"briefTitle":3797,"status":134,"phases":3798,"primaryCompletion":3799,"completion":3799,"start":3800,"enrollment":271,"conditions":3801,"interventions":3803},"NCT01436643","Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression",[94],"2013-09","2011-11",[3802,3762],"Depression",[3804,3805,3806,2836],"Venlafaxine","Fluoxetine","Citalopram",{"nctId":3808,"briefTitle":3809,"status":123,"phases":3810,"primaryCompletion":3811,"completion":3811,"start":3812,"enrollment":2379,"conditions":3813,"interventions":3814},"NCT02232061","Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks",[94],"2020-01-24","2014-09-29",[27],[2836],{"nctId":3816,"briefTitle":3817,"status":109,"phases":3818,"primaryCompletion":1547,"completion":1547,"start":3819,"enrollment":2439,"conditions":3820,"interventions":3821},"NCT04480853","Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis",[94],"2020-10-12",[27],[2836],{"nctId":3823,"briefTitle":3824,"status":123,"phases":3825,"primaryCompletion":3826,"completion":3827,"start":3828,"enrollment":1369,"conditions":3829,"interventions":3830},"NCT03257358","A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod",[94],"2019-03-05","2019-06-28","2017-09-19",[2778],[2836],{"nctId":3832,"briefTitle":3833,"status":123,"phases":3834,"primaryCompletion":3835,"completion":3835,"start":3836,"enrollment":3837,"conditions":3838,"interventions":3839},"NCT01623596","Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.",[94],"2015-07-13","2012-06-08",881,[3743],[2836,3840],"Disease Modifying therapy",{"nctId":3842,"briefTitle":3843,"status":123,"phases":3844,"primaryCompletion":3482,"completion":3482,"start":3845,"enrollment":3846,"conditions":3847,"interventions":3848},"NCT01216072","A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg\u002FDay vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",[94],"2010-08",1053,[3013],[2836,3849],"Standard MS DMTs",{"nctId":3851,"briefTitle":3852,"status":123,"phases":3853,"primaryCompletion":1682,"completion":1682,"start":1724,"enrollment":3854,"conditions":3855,"interventions":3856},"NCT01420055","Fingolimod -Response According to Coping - Evaluation",[94],189,[2994],[3686],{"nctId":3858,"briefTitle":3859,"status":123,"phases":3860,"primaryCompletion":3861,"completion":3861,"start":3784,"enrollment":1143,"conditions":3862,"interventions":3863},"NCT01333501","Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms",[94],"2015-09",[27],[2836,3864],"Interferon beta 1b",{"nctId":3866,"briefTitle":3867,"status":123,"phases":3868,"primaryCompletion":3869,"completion":3869,"start":3870,"enrollment":3871,"conditions":3872,"interventions":3873},"NCT02720107","Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)",[94],"2016-11-14","2016-05-12",133,[3762],[3686],{"trials":3875,"activeCount":103},[3876,3885,3895],{"nctId":3877,"briefTitle":3878,"status":123,"phases":3879,"primaryCompletion":3880,"completion":3880,"start":3881,"enrollment":3882,"conditions":3883,"interventions":3884},"NCT05141669","Impact of Fingolimod Adherence on Outcomes",[],"2020-11-20","2020-05-18",694,[27],[2836],{"nctId":3886,"briefTitle":3887,"status":123,"phases":3888,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":3891,"conditions":3892,"interventions":3893},"NCT01442194","Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies",[],"2020-07-10","2011-08-01",3076,[27],[3894,2836],"other disease-modifying therapy",{"nctId":3896,"briefTitle":3897,"status":123,"phases":3898,"primaryCompletion":3899,"completion":3899,"start":3900,"enrollment":3901,"conditions":3902,"interventions":3903},"NCT01285479","The Gilenya Pregnancy Registry",[],"2024-05-29","2011-10-15",312,[27],[2836],{"intervention":63,"totalTrials":1495,"cells":3905},{"EARLY_PHASE1":3906,"PHASE1":3908,"PHASE2":3910,"PHASE3":3942,"PHASE4":3960,"NA":3978},{"trials":3907,"activeCount":103},[],{"trials":3909,"activeCount":103},[],{"trials":3911,"activeCount":103},[3912,3921,3925,3933],{"nctId":3913,"briefTitle":3914,"status":123,"phases":3915,"primaryCompletion":2258,"completion":3916,"start":3917,"enrollment":792,"conditions":3918,"interventions":3920},"NCT03938454","A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism",[92],"2023-11-29","2019-10-16",[3919],"Priapism",[63],{"nctId":2399,"briefTitle":2400,"status":134,"phases":3922,"primaryCompletion":2402,"completion":2403,"start":2404,"enrollment":2405,"conditions":3923,"interventions":3924},[91,92],[2369],[2341,2408,63,2409,2410,2411],{"nctId":3926,"briefTitle":3927,"status":123,"phases":3928,"primaryCompletion":3929,"completion":3929,"start":1920,"enrollment":3530,"conditions":3930,"interventions":3931},"NCT03264989","Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)",[92],"2023-06-26",[3066],[3932],"crizanlizumab",{"nctId":3934,"briefTitle":3935,"status":123,"phases":3936,"primaryCompletion":3937,"completion":3937,"start":3938,"enrollment":3939,"conditions":3940,"interventions":3941},"NCT03474965","Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients",[92],"2024-11-06","2018-10-01",117,[3066],[63],{"trials":3943,"activeCount":213,"soonestReadout":62},[3944,3954],{"nctId":3945,"briefTitle":3946,"status":109,"phases":3947,"primaryCompletion":3948,"completion":3949,"start":1442,"enrollment":3950,"conditions":3951,"interventions":3953},"NCT06439082","A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg\u002Fkg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)",[93],"2029-03-23","2030-04-19",315,[3952],"Sickle Cell Disease",[63],{"nctId":60,"briefTitle":61,"status":147,"phases":3955,"primaryCompletion":62,"completion":3956,"start":3957,"enrollment":805,"conditions":3958,"interventions":3959},[93],"2026-11-23","2019-07-26",[3066],[63],{"trials":3961,"activeCount":437,"soonestReadout":3974},[3962,3970],{"nctId":3963,"briefTitle":3964,"status":123,"phases":3965,"primaryCompletion":3966,"completion":3966,"start":3967,"enrollment":3087,"conditions":3968,"interventions":3969},"NCT04662931","An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients",[94],"2024-02-14","2021-07-14",[3066],[3932],{"nctId":3971,"briefTitle":3972,"status":109,"phases":3973,"primaryCompletion":3974,"completion":3974,"start":2958,"enrollment":3975,"conditions":3976,"interventions":3977},"NCT04657822","Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study",[94],"2031-06-10",130,[3952],[63],{"trials":3979,"activeCount":103},[3980],{"nctId":3981,"briefTitle":3982,"status":491,"phases":3983,"conditions":3984,"interventions":3985},"NCT03720626","Managed Access Programs for SEG101, Crizanlizumab",[],[3952],[3932],{"intervention":285,"totalTrials":2379,"cells":3987},{"EARLY_PHASE1":3988,"PHASE1":3990,"PHASE2":3992,"PHASE3":3998,"PHASE4":4008,"NA":4014},{"trials":3989,"activeCount":103},[],{"trials":3991,"activeCount":103},[],{"trials":3993,"activeCount":103},[3994],{"nctId":276,"briefTitle":277,"status":123,"phases":3995,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":3996,"interventions":3997},[92],[15],[98,285,249,250],{"trials":3999,"activeCount":103},[4000,4004],{"nctId":870,"briefTitle":871,"status":123,"phases":4001,"primaryCompletion":812,"completion":812,"start":835,"enrollment":873,"conditions":4002,"interventions":4003},[93],[15],[249,285],{"nctId":347,"briefTitle":348,"status":123,"phases":4005,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":4006,"interventions":4007},[93],[342],[98,356,249,285,250],{"trials":4009,"activeCount":437,"soonestReadout":431},[4010],{"nctId":428,"briefTitle":429,"status":147,"phases":4011,"primaryCompletion":431,"completion":432,"start":433,"enrollment":292,"conditions":4012,"interventions":4013},[94],[435],[98,249,285,250,356,119],{"trials":4015,"activeCount":213,"soonestReadout":465},[4016,4020],{"nctId":462,"briefTitle":463,"status":109,"phases":4017,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":4018,"interventions":4019},[],[15],[98,249,285],{"nctId":471,"briefTitle":472,"status":109,"phases":4021,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":4022,"interventions":4023},[],[15],[98,249,285],{"intervention":83,"totalTrials":1065,"cells":4025},{"EARLY_PHASE1":4026,"PHASE1":4028,"PHASE2":4041,"PHASE3":4075,"PHASE4":4139,"NA":4145},{"trials":4027,"activeCount":103},[],{"trials":4029,"activeCount":103},[4030,4037],{"nctId":4031,"briefTitle":4032,"status":123,"phases":4033,"primaryCompletion":4034,"completion":4034,"start":745,"enrollment":1672,"conditions":4035,"interventions":4036},"NCT00422825","Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib",[91],"2006-09",[1674],[3377],{"nctId":3220,"briefTitle":3221,"status":123,"phases":4038,"primaryCompletion":3223,"completion":3224,"start":3225,"enrollment":3226,"conditions":4039,"interventions":4040},[91],[3228,3229],[3231,2395,83,3232],{"trials":4042,"activeCount":103},[4043,4053,4057,4066],{"nctId":4044,"briefTitle":4045,"status":123,"phases":4046,"primaryCompletion":4047,"start":4048,"enrollment":4049,"conditions":4050,"interventions":4052},"NCT00940563","A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors",[92],"2004-08","2002-03",135,[4051],"Advanced Gastrointestinal Stromal Tumors",[83],{"nctId":3327,"briefTitle":3328,"status":123,"phases":4054,"primaryCompletion":3330,"completion":136,"start":3331,"enrollment":314,"conditions":4055,"interventions":4056},[92],[3333,3228,3334,3335],[3337,83,2395,3338],{"nctId":4058,"briefTitle":4059,"status":123,"phases":4060,"primaryCompletion":3272,"completion":3272,"start":4061,"enrollment":2579,"conditions":4062,"interventions":4063},"NCT00154336","A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.",[92],"2004-07",[1717],[83,4064,4065],"Methotrexate","Imatinib Placebo",{"nctId":4067,"briefTitle":4068,"status":123,"phases":4069,"primaryCompletion":4070,"completion":4070,"start":4071,"enrollment":2112,"conditions":4072,"interventions":4074},"NCT00150072","Efficacy and Safety of Imatinib in Chordoma",[92],"2008-04","2004-10",[4073],"Chordoma",[3377],{"trials":4076,"activeCount":437,"soonestReadout":82},[4077,4085,4089,4096,4100,4104,4108,4112,4123,4127,4131,4135],{"nctId":4078,"briefTitle":4079,"status":134,"phases":4080,"primaryCompletion":1781,"completion":1781,"start":4081,"enrollment":4082,"conditions":4083,"interventions":4084},"NCT01117987","Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)",[93],"2010-04",144,[3305],[83],{"nctId":3367,"briefTitle":3368,"status":123,"phases":4086,"primaryCompletion":3370,"completion":3371,"start":3372,"enrollment":3373,"conditions":4087,"interventions":4088},[93],[3375],[3266,3377],{"nctId":4090,"briefTitle":4091,"status":134,"phases":4092,"primaryCompletion":4093,"completion":4093,"start":2034,"enrollment":837,"conditions":4094,"interventions":4095},"NCT01392495","Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)",[93],"2014-03",[3305],[83],{"nctId":80,"briefTitle":81,"status":147,"phases":4097,"primaryCompletion":82,"completion":3389,"start":3390,"enrollment":3391,"conditions":4098,"interventions":4099},[93],[3393],[83,2395,3395,3232,3231],{"nctId":3397,"briefTitle":3398,"status":123,"phases":4101,"primaryCompletion":1817,"completion":1817,"start":3400,"enrollment":3401,"conditions":4102,"interventions":4103},[93],[3403],[2395,3377],{"nctId":3406,"briefTitle":3407,"status":123,"phases":4105,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":3411,"conditions":4106,"interventions":4107},[93],[3228],[3266,3377],{"nctId":3415,"briefTitle":3416,"status":123,"phases":4109,"primaryCompletion":3418,"completion":3418,"start":3419,"enrollment":3420,"conditions":4110,"interventions":4111},[93],[3422],[83,2395],{"nctId":4113,"briefTitle":4114,"status":123,"phases":4115,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":4119,"interventions":4120},"NCT01392469","Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants",[93],"2012-10-25","2011-04-20",21,[3305],[83,4121,4122],"Sildenafil","Bosentan",{"nctId":3444,"briefTitle":3445,"status":134,"phases":4124,"primaryCompletion":1014,"completion":1014,"start":3447,"enrollment":2379,"conditions":4125,"interventions":4126},[93],[3449],[83,2395],{"nctId":3479,"briefTitle":3480,"status":134,"phases":4128,"primaryCompletion":3482,"completion":3482,"start":1024,"enrollment":3483,"conditions":4129,"interventions":4130},[93],[208],[2395,83],{"nctId":3495,"briefTitle":3496,"status":123,"phases":4132,"primaryCompletion":1817,"completion":1817,"start":3383,"enrollment":3498,"conditions":4133,"interventions":4134},[93],[2393],[2395,83],{"nctId":3508,"briefTitle":3509,"status":123,"phases":4136,"primaryCompletion":3511,"completion":3511,"start":1024,"enrollment":1444,"conditions":4137,"interventions":4138},[93],[3513],[2395,83],{"trials":4140,"activeCount":437,"soonestReadout":3575},[4141],{"nctId":3572,"briefTitle":3573,"status":109,"phases":4142,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":3577,"conditions":4143,"interventions":4144},[94],[3228,3579],[3581,83,2395,3395,3232,3582],{"trials":4146,"activeCount":103},[],{"intervention":250,"totalTrials":4148,"cells":4149},11,{"EARLY_PHASE1":4150,"PHASE1":4152,"PHASE2":4158,"PHASE3":4180,"PHASE4":4198,"NA":4204},{"trials":4151,"activeCount":103},[],{"trials":4153,"activeCount":103},[4154],{"nctId":529,"briefTitle":530,"status":123,"phases":4155,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":4156,"interventions":4157},[91],[536],[515,249,356,119,345],{"trials":4159,"activeCount":103},[4160,4164,4168,4172,4176],{"nctId":562,"briefTitle":563,"status":123,"phases":4161,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":4162,"interventions":4163},[92],[15],[88,119,249,250,332],{"nctId":572,"briefTitle":573,"status":134,"phases":4165,"primaryCompletion":575,"completion":575,"start":576,"enrollment":213,"conditions":4166,"interventions":4167},[92],[375],[88,119,250],{"nctId":238,"briefTitle":239,"status":123,"phases":4169,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":4170,"interventions":4171},[92],[15],[247,98,248,249,250],{"nctId":252,"briefTitle":253,"status":123,"phases":4173,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":4174,"interventions":4175},[92],[15],[261,262,263,98,264,250],{"nctId":276,"briefTitle":277,"status":123,"phases":4177,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":4178,"interventions":4179},[92],[15],[98,285,249,250],{"trials":4181,"activeCount":437,"soonestReadout":324},[4182,4186,4190,4194],{"nctId":321,"briefTitle":322,"status":109,"phases":4183,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":4184,"interventions":4185},[93],[329],[98,249,331,250,332,195],{"nctId":334,"briefTitle":335,"status":123,"phases":4187,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":4188,"interventions":4189},[93],[342],[157,344,345],{"nctId":347,"briefTitle":348,"status":123,"phases":4191,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":4192,"interventions":4193},[93],[342],[98,356,249,285,250],{"nctId":378,"briefTitle":379,"status":123,"phases":4195,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":4196,"interventions":4197},[93],[15],[98,249,250,332],{"trials":4199,"activeCount":437,"soonestReadout":431},[4200],{"nctId":428,"briefTitle":429,"status":147,"phases":4201,"primaryCompletion":431,"completion":432,"start":433,"enrollment":292,"conditions":4202,"interventions":4203},[94],[435],[98,249,285,250,356,119],{"trials":4205,"activeCount":103},[],{"intervention":3395,"totalTrials":317,"cells":4207},{"EARLY_PHASE1":4208,"PHASE1":4210,"PHASE2":4212,"PHASE3":4214,"PHASE4":4230,"NA":4236},{"trials":4209,"activeCount":103},[],{"trials":4211,"activeCount":103},[],{"trials":4213,"activeCount":103},[],{"trials":4215,"activeCount":437,"soonestReadout":82},[4216,4226],{"nctId":4217,"briefTitle":4218,"status":123,"phases":4219,"primaryCompletion":4220,"completion":4221,"start":4222,"enrollment":4223,"conditions":4224,"interventions":4225},"NCT03106779","Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs",[93],"2020-05-25","2024-12-04","2017-10-26",233,[3228],[3231,3395],{"nctId":80,"briefTitle":81,"status":147,"phases":4227,"primaryCompletion":82,"completion":3389,"start":3390,"enrollment":3391,"conditions":4228,"interventions":4229},[93],[3393],[83,2395,3395,3232,3231],{"trials":4231,"activeCount":437,"soonestReadout":3575},[4232],{"nctId":3572,"briefTitle":3573,"status":109,"phases":4233,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":3577,"conditions":4234,"interventions":4235},[94],[3228,3579],[3581,83,2395,3395,3232,3582],{"trials":4237,"activeCount":103},[],{"intervention":3232,"totalTrials":317,"cells":4239},{"EARLY_PHASE1":4240,"PHASE1":4242,"PHASE2":4248,"PHASE3":4250,"PHASE4":4256,"NA":4262},{"trials":4241,"activeCount":103},[],{"trials":4243,"activeCount":103},[4244],{"nctId":3220,"briefTitle":3221,"status":123,"phases":4245,"primaryCompletion":3223,"completion":3224,"start":3225,"enrollment":3226,"conditions":4246,"interventions":4247},[91],[3228,3229],[3231,2395,83,3232],{"trials":4249,"activeCount":103},[],{"trials":4251,"activeCount":437,"soonestReadout":82},[4252],{"nctId":80,"briefTitle":81,"status":147,"phases":4253,"primaryCompletion":82,"completion":3389,"start":3390,"enrollment":3391,"conditions":4254,"interventions":4255},[93],[3393],[83,2395,3395,3232,3231],{"trials":4257,"activeCount":437,"soonestReadout":3575},[4258],{"nctId":3572,"briefTitle":3573,"status":109,"phases":4259,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":3577,"conditions":4260,"interventions":4261},[94],[3228,3579],[3581,83,2395,3395,3232,3582],{"trials":4263,"activeCount":103},[],{"intervention":3581,"totalTrials":213,"cells":4265},{"EARLY_PHASE1":4266,"PHASE1":4268,"PHASE2":4270,"PHASE3":4281,"PHASE4":4283,"NA":4289},{"trials":4267,"activeCount":103},[],{"trials":4269,"activeCount":103},[],{"trials":4271,"activeCount":437,"soonestReadout":4276},[4272],{"nctId":4273,"briefTitle":4274,"status":109,"phases":4275,"primaryCompletion":4276,"completion":4276,"start":4277,"enrollment":2579,"conditions":4278,"interventions":4280},"NCT07354074","Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP",[92],"2033-02-23","2026-04-28",[3228,4279],"Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive",[3581],{"trials":4282,"activeCount":103},[],{"trials":4284,"activeCount":437,"soonestReadout":3575},[4285],{"nctId":3572,"briefTitle":3573,"status":109,"phases":4286,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":3577,"conditions":4287,"interventions":4288},[94],[3228,3579],[3581,83,2395,3395,3232,3582],{"trials":4290,"activeCount":103},[],{"intervention":196,"totalTrials":2796,"cells":4292},{"EARLY_PHASE1":4293,"PHASE1":4295,"PHASE2":4394,"PHASE3":4614,"PHASE4":4929,"NA":5135},{"trials":4294,"activeCount":103},[],{"trials":4296,"activeCount":103},[4297,4306,4313,4322,4331,4339,4347,4354,4368,4376,4380],{"nctId":4298,"briefTitle":4299,"status":123,"phases":4300,"primaryCompletion":1781,"completion":1781,"start":4301,"enrollment":814,"conditions":4302,"interventions":4304},"NCT01217177","A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer",[91],"2011-12",[4303],"Locally Advanced Cervical Cancer",[4305],"everolimus",{"nctId":4307,"briefTitle":4308,"status":123,"phases":4309,"primaryCompletion":3351,"completion":3351,"start":988,"enrollment":2579,"conditions":4310,"interventions":4312},"NCT00426530","Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer",[91],[559,4311],"Neoplasm Metastasis",[4305],{"nctId":4314,"briefTitle":4315,"status":123,"phases":4316,"primaryCompletion":4093,"completion":4093,"start":4317,"enrollment":534,"conditions":4318,"interventions":4319},"NCT00426556","Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer",[91],"2007-07",[435],[196,4320,4321],"Trastuzumab","Paclitaxel",{"nctId":4323,"briefTitle":4324,"status":123,"phases":4325,"primaryCompletion":3319,"completion":3319,"start":4326,"enrollment":827,"conditions":4327,"interventions":4329},"NCT01854606","Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma",[91],"2013-12-05",[4328],"CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma",[4330,196],"AEB071",{"nctId":4332,"briefTitle":4333,"status":123,"phases":4334,"primaryCompletion":926,"start":4335,"enrollment":31,"conditions":4336,"interventions":4338},"NCT00968591","Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency",[91],"2009-11",[4337],"Hepatic Insufficiency",[196],{"nctId":4340,"briefTitle":4341,"status":123,"phases":4342,"primaryCompletion":926,"start":4343,"enrollment":1611,"conditions":4344,"interventions":4346},"NCT00466466","Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients",[91],"2007-04",[4345],"Small-Cell Lung Cancer",[196],{"nctId":4348,"briefTitle":4349,"status":123,"phases":4350,"primaryCompletion":1714,"completion":1714,"start":853,"enrollment":2776,"conditions":4351,"interventions":4353},"NCT01152801","Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer",[91],[4352],"Metastatic Renal Cell Carcinoma",[196],{"nctId":4355,"briefTitle":4356,"status":123,"phases":4357,"primaryCompletion":4358,"completion":4358,"start":4359,"enrollment":4360,"conditions":4361,"interventions":4365},"NCT02077933","Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",[91],"2019-04-12","2014-05-14",79,[4362,559,4363,4364],"Neoplasms","Kidney Neoplasms","Pancreatic Neuroendocine Neoplasms (pNETs)",[4366,4305,4367],"alpelisib","exemestane",{"nctId":4369,"briefTitle":4370,"status":123,"phases":4371,"primaryCompletion":4372,"completion":4372,"start":3657,"enrollment":114,"conditions":4373,"interventions":4374},"NCT00434174","Safety of Everolimus and Pemetrexed in Lung Cancer Patients",[91],"2010-12",[1316],[196,4375],"Pemetrexed",{"nctId":186,"briefTitle":187,"status":123,"phases":4377,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":4378,"interventions":4379},[91],[15],[157,195,196],{"nctId":4381,"briefTitle":4382,"status":123,"phases":4383,"primaryCompletion":4384,"completion":4384,"start":4385,"enrollment":3741,"conditions":4386,"interventions":4388},"NCT02890069","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",[91],"2022-02-22","2016-10-14",[4387],"Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma",[4389,4390,196,4391,4392,4393],"PDR001","LCL161","Panobinostat","QBM076","HDM201",{"trials":4395,"activeCount":103},[4396,4406,4415,4426,4433,4441,4452,4461,4470,4479,4483,4490,4494,4501,4510,4520,4528,4536,4545,4552,4562,4578,4587,4594,4602,4610],{"nctId":4397,"briefTitle":4398,"status":123,"phases":4399,"primaryCompletion":1760,"completion":1760,"start":4400,"enrollment":4401,"conditions":4402,"interventions":4404},"NCT00903175","Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma",[92],"2009-10",471,[4403],"Renal Cell Carcinoma",[4305,4405],"sunitinib",{"nctId":4407,"briefTitle":4408,"status":134,"phases":4409,"primaryCompletion":4410,"completion":4410,"start":2034,"enrollment":1524,"conditions":4411,"interventions":4413},"NCT01379521","Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC",[92],"2015-06",[4412],"Hepatocellular Carcinoma",[4305,4414],"everolimus placebo",{"nctId":4416,"briefTitle":4417,"status":123,"phases":4418,"primaryCompletion":4419,"completion":4419,"start":4420,"enrollment":3288,"conditions":4421,"interventions":4423},"NCT01563354","3-arm Trial to Evaluate Pasireotide LAR\u002FEverolimus Alone\u002Fin Combination in Patients With Lung\u002FThymus NET - LUNA Trial",[92],"2020-02-10","2013-08-16",[4422],"Neuroendocrine Carcinoma of the Lung and Thymus",[4424,196,4425],"Pasireotide LAR","Pasireotide LAR and Everolimus Combination",{"nctId":4427,"briefTitle":4428,"status":123,"phases":4429,"primaryCompletion":3210,"completion":3210,"start":4047,"conditions":4430,"interventions":4431},"NCT00093639","Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate",[91,92],[3422],[4305,4432],"imatinib mesylate",{"nctId":4434,"briefTitle":4435,"status":123,"phases":4436,"primaryCompletion":949,"start":4437,"enrollment":271,"conditions":4438,"interventions":4440},"NCT00519324","Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer",[92],"2007-08",[4439],"Advanced Gastric Cancer",[196],{"nctId":4442,"briefTitle":4443,"status":123,"phases":4444,"primaryCompletion":4445,"completion":4446,"start":4447,"enrollment":4448,"conditions":4449,"interventions":4450},"NCT01783444","A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.",[92],"2018-07-02","2018-07-30","2013-02-26",309,[15],[4451,195,196],"Capecitabine",{"nctId":4453,"briefTitle":4454,"status":134,"phases":4455,"primaryCompletion":864,"start":3612,"enrollment":1672,"conditions":4456,"interventions":4459},"NCT00857259","The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration",[92],[4457,4458],"Choroidal Neo-Vascular Age-onset Macular Degeneration","Age-related Macular Degeneration",[196,4460],"Ranibizumab",{"nctId":4462,"briefTitle":4463,"status":123,"phases":4464,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":3064,"conditions":4467,"interventions":4469},"NCT00702052","Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy",[92],"2012-04-20","2008-08-22",[4468],"Lymphoma, Mantle- Cell",[196],{"nctId":4471,"briefTitle":4472,"status":123,"phases":4473,"primaryCompletion":4474,"completion":4474,"start":4475,"enrollment":1660,"conditions":4476,"interventions":4478},"NCT00767819","Treatment of Patients With RAD001 With Progressive Sarcoma",[92],"2017-05-17","2008-03-31",[4477],"Progressive Sarcoma",[196],{"nctId":751,"briefTitle":752,"status":123,"phases":4480,"primaryCompletion":754,"completion":755,"start":756,"enrollment":757,"conditions":4481,"interventions":4482},[92],[759],[196,249,195,761,762],{"nctId":4484,"briefTitle":4485,"status":134,"phases":4486,"primaryCompletion":606,"completion":606,"start":607,"enrollment":1495,"conditions":4487,"interventions":4489},"NCT01365468","Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)",[92],[4488],"Plexiform Neurofibroma Associated With Neurofibromatosis Type 1",[196],{"nctId":768,"briefTitle":769,"status":123,"phases":4491,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":4492,"interventions":4493},[92],[776,777,435],[196,249],{"nctId":4495,"briefTitle":4496,"status":123,"phases":4497,"primaryCompletion":3400,"completion":3400,"start":3657,"enrollment":4498,"conditions":4499,"interventions":4500},"NCT00419159","Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy",[92],199,[209],[196],{"nctId":4502,"briefTitle":4503,"status":134,"phases":4504,"primaryCompletion":4505,"completion":4505,"start":4437,"enrollment":4506,"conditions":4507,"interventions":4509},"NCT00515086","Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)",[92],"2009-08",41,[4508],"Glioblastoma Multiforme",[196],{"nctId":4511,"briefTitle":4512,"status":123,"phases":4513,"primaryCompletion":4514,"completion":4514,"start":4515,"enrollment":4516,"conditions":4517,"interventions":4518},"NCT02069093","Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer",[92],"2016-03","2014-05",92,[375],[4519,196,195],"Dexamethasone based mouthwash",{"nctId":4521,"briefTitle":4522,"status":123,"phases":4523,"primaryCompletion":4524,"completion":4524,"start":3551,"enrollment":630,"conditions":4525,"interventions":4527},"NCT01059318","A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis",[92],"2012-06",[4526],"Lymphangioleiomyomatosis",[196],{"nctId":4529,"briefTitle":4530,"status":134,"phases":4531,"primaryCompletion":2458,"completion":2458,"start":2034,"enrollment":4532,"conditions":4533,"interventions":4535},"NCT01374451","Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET",[92],160,[4534],"Islet Cell Tumor",[196,4424],{"nctId":4537,"briefTitle":4538,"status":123,"phases":4539,"primaryCompletion":745,"completion":745,"start":4540,"enrollment":1672,"conditions":4541,"interventions":4543},"NCT00107237","AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme",[91,92],"2003-10",[4542],"Brain and Central Nervous System Tumors",[4544,4305],"AEE788",{"nctId":4546,"briefTitle":4547,"status":123,"phases":4548,"primaryCompletion":1254,"completion":1254,"start":4549,"enrollment":1630,"conditions":4550,"interventions":4551},"NCT02017860","Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.",[92],"2014-01-16",[4362],[196],{"nctId":4553,"briefTitle":4554,"status":134,"phases":4555,"primaryCompletion":3551,"completion":3551,"start":4556,"enrollment":4557,"conditions":4558,"interventions":4560},"NCT00582738","Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection",[92],"2007-12",43,[4559],"Recurrent Hepatitis C",[4561,196],"CsA-TAC",{"nctId":4563,"briefTitle":4564,"status":123,"phases":4565,"primaryCompletion":4566,"completion":4566,"start":4567,"enrollment":4568,"conditions":4569,"interventions":4577},"NCT00688623","RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe",[92],"2016-11-07","2009-06-24",73,[4570,4571,4572,4573,4574,4575,4576],"Advanced and Metastatic Silent Neuro-Endocrine Tumors","Carcinoma","Neuroendocrine","Non Functioning Neuroendocrine Tumors (NETs)","Non Syndromic Neuroendocrine Tumors","Carcinoids","Non Functioning",[196],{"nctId":4579,"briefTitle":4580,"status":123,"phases":4581,"primaryCompletion":241,"completion":241,"start":4582,"enrollment":4583,"conditions":4584,"interventions":4585},"NCT03312738","A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor",[92],"2017-09-15",159,[375],[196,195,4586],"Everolimus Placebo",{"nctId":4588,"briefTitle":4589,"status":123,"phases":4590,"primaryCompletion":3382,"completion":3382,"start":3271,"enrollment":3530,"conditions":4591,"interventions":4593},"NCT01022996","Study of RAD001 in Patients With Relapsed\u002FRefractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and\u002For After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.",[92],[4592],"Hodgkin Lymphoma",[196],{"nctId":4595,"briefTitle":4596,"status":123,"phases":4597,"primaryCompletion":4598,"completion":4598,"start":3447,"enrollment":4118,"conditions":4599,"interventions":4601},"NCT00560963","Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine",[91,92],"2011-01",[4600],"Advanced or Metastatic Pancreatic Adenocarcinoma",[4305],{"nctId":4603,"briefTitle":4604,"status":134,"phases":4605,"primaryCompletion":812,"completion":812,"start":1761,"enrollment":2149,"conditions":4606,"interventions":4608},"NCT01628913","Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors",[92],[4607],"Pancreatic Neuroendocrine Tumors (pNET)",[4609,196],"BEZ235",{"nctId":309,"briefTitle":310,"status":123,"phases":4611,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":4612,"interventions":4613},[91,92],[15],[98,196,195],{"trials":4615,"activeCount":437,"soonestReadout":4785},[4616,4629,4638,4650,4657,4665,4673,4683,4694,4703,4713,4720,4728,4736,4746,4756,4771,4781,4790,4797,4806,4814,4822,4832,4841,4851,4858,4868,4876,4884,4892,4905,4915,4921],{"nctId":4617,"briefTitle":4618,"status":123,"phases":4619,"primaryCompletion":4620,"completion":4620,"start":4621,"enrollment":4622,"conditions":4623,"interventions":4625},"NCT00300274","Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection",[93],"2011-07","2006-01",721,[4624],"Graft Rejection",[4305,4626,4627,4628],"mycophenolate mofetil","cyclosporine","corticosteroids",{"nctId":4630,"briefTitle":4631,"status":123,"phases":4632,"primaryCompletion":4633,"completion":4633,"start":4634,"enrollment":4635,"conditions":4636,"interventions":4637},"NCT00863655","Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole",[93],"2014-12-04","2009-06-03",724,[15],[196,195,4586],{"nctId":4639,"briefTitle":4640,"status":123,"phases":4641,"primaryCompletion":4642,"completion":4642,"start":918,"enrollment":4643,"conditions":4644,"interventions":4646},"NCT00267189","RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency",[93],"2007-11",145,[4645],"Liver Transplantation",[196,4647,4648,4649],"Calcineurin inhibitors","Mycophenolate acid","Steroids",{"nctId":4651,"briefTitle":4652,"status":123,"phases":4653,"primaryCompletion":3604,"start":4034,"enrollment":1611,"conditions":4654,"interventions":4656},"NCT00464399","Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients",[93],[4655],"De Novo Renal Transplantation",[4305],{"nctId":4658,"briefTitle":4659,"status":123,"phases":4660,"primaryCompletion":880,"completion":4093,"start":4317,"enrollment":4661,"conditions":4662,"interventions":4664},"NCT00510068","Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors",[93],410,[4663],"Advanced Neuroendocrine Tumors of Pancreatic Origin",[196,4586],{"nctId":4666,"briefTitle":4667,"status":123,"phases":4668,"primaryCompletion":4669,"completion":4669,"start":4524,"enrollment":4670,"conditions":4671,"interventions":4672},"NCT01626222","4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer",[93],"2013-11",301,[435],[195,196],{"nctId":4674,"briefTitle":4675,"status":123,"phases":4676,"primaryCompletion":4677,"completion":4677,"start":4678,"enrollment":4679,"conditions":4680,"interventions":4682},"NCT00790036","Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy",[93],"2016-06-15","2009-07-24",742,[4681],"Diffuse Large B-cell Lymphoma",[196,4586],{"nctId":4684,"briefTitle":4685,"status":123,"phases":4686,"primaryCompletion":4687,"completion":4687,"start":4688,"enrollment":4689,"conditions":4690,"interventions":4692},"NCT01114529","Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients",[93],"2014-10-30","2010-08-09",828,[4691],"Kidney Transplantation",[196,4693],"Prograf or Neoral",{"nctId":4695,"briefTitle":4696,"status":123,"phases":4697,"primaryCompletion":3272,"start":4698,"enrollment":4699,"conditions":4700,"interventions":4702},"NCT00531440","This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.",[93],"2001-11",256,[4701],"Renal Transplantation",[196],{"nctId":4704,"briefTitle":4705,"status":123,"phases":4706,"primaryCompletion":2034,"completion":2794,"start":4707,"enrollment":4708,"conditions":4709,"interventions":4712},"NCT00790400","Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)",[93],"2009-04",118,[4710,4711],"Tuberous Sclerosis Complex (TSC)","Lymphangioleiomyomatosis (LAM)",[196,4586],{"nctId":4714,"briefTitle":4715,"status":123,"phases":4716,"primaryCompletion":813,"completion":813,"start":4081,"enrollment":4717,"conditions":4718,"interventions":4719},"NCT01035229","Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.",[93],546,[4571],[196,4586],{"nctId":4721,"briefTitle":4722,"status":123,"phases":4723,"primaryCompletion":895,"completion":1817,"start":4505,"enrollment":3939,"conditions":4724,"interventions":4727},"NCT00789828","Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)",[93],[4725,4726],"Tuberous Sclerosis","Subependymal Giant Cell Astrocytoma",[196],{"nctId":4729,"briefTitle":4730,"status":123,"phases":4731,"primaryCompletion":918,"start":4732,"enrollment":4733,"conditions":4734,"interventions":4735},"NCT00170833","Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients",[93],"2003-11",80,[4701],[196],{"nctId":4737,"briefTitle":4738,"status":123,"phases":4739,"primaryCompletion":4740,"start":4741,"enrollment":4742,"conditions":4743,"interventions":4745},"NCT00150046","Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients",[93],"2007-05","2004-12",176,[4744],"Heart Transplantation",[196],{"nctId":4747,"briefTitle":4748,"status":123,"phases":4749,"primaryCompletion":4410,"completion":4410,"start":4317,"enrollment":4750,"conditions":4751,"interventions":4752},"NCT00514514","Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen",[93],802,[4691],[196,4753,4754,4755],"Myfortic","Sandimmun Optoral","Simulect®",{"nctId":4757,"briefTitle":4758,"status":123,"phases":4759,"primaryCompletion":4760,"completion":4760,"start":4761,"enrollment":4762,"conditions":4763,"interventions":4764},"NCT01843348","12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients",[93],"2016-03-23","2012-12-27",612,[4691,4701],[196,4765,4766,4767,4768,4769,4770],"Tacrolimus","Cyclosporin A","Enteric Coated Mycophenolate Sodium","Mycophenolate mofetil","Corticosteroids","Simulect",{"nctId":4772,"briefTitle":4773,"status":123,"phases":4774,"primaryCompletion":4410,"completion":4410,"start":4400,"enrollment":4775,"conditions":4776,"interventions":4778},"NCT01007942","Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2\u002FNeu Positive Women With Locally Advanced or Metastatic Breast Cancer",[93],569,[4777,435],"HER2\u002FNeu Over-expressing Locally Advanced Breast Cancer",[4305,4779,4780],"vinorelbine","trastuzumab",{"nctId":4782,"briefTitle":4783,"status":147,"phases":4784,"primaryCompletion":4785,"completion":4786,"start":1951,"enrollment":1203,"conditions":4787,"interventions":4789},"NCT02962414","Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment",[93],"2027-08-04","2027-08-13",[4788],"Tuberous Sclerosis Complex",[4305],{"nctId":4791,"briefTitle":4792,"status":123,"phases":4793,"primaryCompletion":607,"completion":607,"start":917,"enrollment":4794,"conditions":4795,"interventions":4796},"NCT00622869","Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients",[93],719,[4645],[4765,4765,4765,196,196,4769],{"nctId":4798,"briefTitle":4799,"status":123,"phases":4800,"primaryCompletion":2509,"completion":2509,"start":3604,"enrollment":3120,"conditions":4801,"interventions":4802},"NCT01625377","A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients",[93],[4645],[4803,4305,4804,4805,4769],"tacrolimus","Basiliximab","Mycophenolic Acid",{"nctId":4807,"briefTitle":4808,"status":123,"phases":4809,"primaryCompletion":844,"start":4810,"conditions":4811,"interventions":4813},"NCT00170794","Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.",[93],"2004-09",[4812],"Cardiac Transplantation",[196],{"nctId":4815,"briefTitle":4816,"status":123,"phases":4817,"primaryCompletion":4818,"completion":4818,"start":4819,"enrollment":1352,"conditions":4820,"interventions":4821},"NCT02115113","REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy",[93],"2016-09-30","2014-03-28",[4645],[196,4765],{"nctId":4823,"briefTitle":4824,"status":123,"phases":4825,"primaryCompletion":4081,"completion":1682,"start":3657,"enrollment":4826,"conditions":4827,"interventions":4830},"NCT00412061","Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor",[93],429,[4828,4829],"Carcinoid Tumor","Malignant Carcinoid Syndrome",[4831,196],"Octreotide",{"nctId":4833,"briefTitle":4834,"status":123,"phases":4835,"primaryCompletion":1670,"completion":1670,"start":3210,"enrollment":4836,"conditions":4837,"interventions":4838},"NCT00378014","Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy",[93],276,[4645],[4305,4839,4840],"basiliximab","CNI",{"nctId":4842,"briefTitle":4843,"status":123,"phases":4844,"primaryCompletion":3559,"completion":3559,"start":4845,"enrollment":4846,"conditions":4847,"interventions":4848},"NCT00879333","Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)",[93],"2009-07",656,[4439],[196,4849,4850],"Everolimus placebo","Best Supportive Care",{"nctId":4852,"briefTitle":4853,"status":123,"phases":4854,"primaryCompletion":3272,"start":4698,"enrollment":4855,"conditions":4856,"interventions":4857},"NCT00531063","This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus",[93],237,[4701],[196],{"nctId":4859,"briefTitle":4860,"status":123,"phases":4861,"primaryCompletion":4862,"completion":4862,"start":4863,"enrollment":3975,"conditions":4864,"interventions":4866},"NCT01404325","Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients",[93],"2017-01-05","2012-02-01",[4865],"Lung Transplantation",[4867,196],"standard therapy",{"nctId":4869,"briefTitle":4870,"status":123,"phases":4871,"primaryCompletion":2762,"completion":2762,"start":3800,"enrollment":568,"conditions":4872,"interventions":4873},"NCT01410448","Everolimus in de Novo Kidney Transplant Recipients",[93],[4691],[196,4874,4875,4649],"Mycophenolate sodium","Cyclosporine",{"nctId":4877,"briefTitle":4878,"status":123,"phases":4879,"primaryCompletion":4880,"completion":4880,"start":4881,"enrollment":4498,"conditions":4882,"interventions":4883},"NCT00098007","A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients",[93],"2007-01-08","2004-08-09",[4744],[196],{"nctId":4885,"briefTitle":4886,"status":123,"phases":4887,"primaryCompletion":4888,"completion":4888,"start":3529,"enrollment":2057,"conditions":4889,"interventions":4891},"NCT03176238","Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",[93],"2019-01-29",[4890],"Post Menopausal Breast Cancer",[4305,4367],{"nctId":4893,"briefTitle":4894,"status":123,"phases":4895,"primaryCompletion":4896,"completion":4897,"start":4898,"enrollment":4899,"conditions":4900,"interventions":4904},"NCT01524783","Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)",[93],"2014-11-28","2020-08-07","2012-03-30",302,[4901,4902,4903],"Advanced NET of GI Origin","Advanced NET of Lung Origin","Neuroendocrine Tumors",[196],{"nctId":4906,"briefTitle":4907,"status":123,"phases":4908,"primaryCompletion":4909,"completion":4909,"start":4910,"enrollment":4911,"conditions":4912,"interventions":4914},"NCT01150097","Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients",[93],"2013-05-03","2010-03-31",284,[4913],"Liver Transplant Recipient",[4765,196,4765,196,4765,4769],{"nctId":4916,"briefTitle":4917,"status":123,"phases":4918,"primaryCompletion":854,"start":4047,"conditions":4919,"interventions":4920},"NCT00097968","Safety\u002FEfficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy",[93],[4624],[4305],{"nctId":4922,"briefTitle":4923,"status":123,"phases":4924,"primaryCompletion":4925,"completion":2533,"start":4926,"enrollment":4794,"conditions":4927,"interventions":4928},"NCT00876395","Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer",[93],"2014-05-30","2009-09-10",[15],[196,4320,4321],{"trials":4930,"activeCount":437,"soonestReadout":5010},[4931,4939,4948,4954,4963,4971,4980,4988,4997,5006,5015,5022,5029,5037,5044,5050,5058,5066,5076,5085,5093,5102,5110,5118,5127],{"nctId":4932,"briefTitle":4933,"status":123,"phases":4934,"primaryCompletion":813,"completion":813,"start":3657,"enrollment":4935,"conditions":4936,"interventions":4938},"NCT00414440","Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease",[94],431,[4937],"Autosomal Dominant Polycystic Kidney Disease",[196],{"nctId":4940,"briefTitle":4941,"status":123,"phases":4942,"primaryCompletion":4943,"completion":4943,"start":4944,"enrollment":2354,"conditions":4945,"interventions":4947},"NCT02842749","Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China",[94],"2024-02-22","2016-03-14",[4946],"Pancreatic Neuroendocrine Tumors",[4305],{"nctId":4949,"briefTitle":4950,"status":123,"phases":4951,"primaryCompletion":3195,"completion":3657,"start":4047,"conditions":4952,"interventions":4953},"NCT00170859","Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients",[94],[4744],[196],{"nctId":4955,"briefTitle":4956,"status":123,"phases":4957,"primaryCompletion":4958,"completion":4958,"start":4959,"enrollment":4960,"conditions":4961,"interventions":4962},"NCT01551212","Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients",[94],"2017-08-08","2012-05-24",339,[4645],[196,4765,4769],{"nctId":4964,"briefTitle":4965,"status":134,"phases":4966,"primaryCompletion":4967,"completion":4967,"start":918,"enrollment":1016,"conditions":4968,"interventions":4969},"NCT00332839","Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.",[94],"2013-03",[4701],[196,4766,4765,4970,4769],"Enteric Coated - Mycophenolate Sodium",{"nctId":4972,"briefTitle":4973,"status":123,"phases":4974,"primaryCompletion":1714,"completion":1714,"start":4975,"enrollment":4976,"conditions":4977,"interventions":4978},"NCT01017029","Everolimus in de Novo Heart Transplant Recipients",[94],"2009-09",182,[4812],[196,4979],"Mycophenolate mofetil + Everolimus",{"nctId":4981,"briefTitle":4982,"status":123,"phases":4983,"primaryCompletion":4093,"completion":4093,"start":3845,"enrollment":1660,"conditions":4984,"interventions":4986},"NCT01169701","24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients",[94],[4985],"Renal Transplant",[196,4765,4987],"Mycophenolic acid",{"nctId":4989,"briefTitle":4990,"status":123,"phases":4991,"primaryCompletion":3604,"completion":3604,"start":4335,"enrollment":4992,"conditions":4993,"interventions":4995},"NCT01266148","SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance",[94],115,[4994],"Renal Function and Chronic Allograft Vasculopathy",[4875,4768,4769,196,4996],"Anti Thymocyte Globulin",{"nctId":4998,"briefTitle":4999,"status":123,"phases":5000,"primaryCompletion":5001,"completion":5001,"start":5002,"enrollment":2367,"conditions":5003,"interventions":5005},"NCT02338609","Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus",[94],"2023-12-18","2014-12-17",[5004],"Growth and Development",[196],{"nctId":5007,"briefTitle":5008,"status":147,"phases":5009,"primaryCompletion":5010,"completion":5010,"start":5011,"enrollment":1630,"conditions":5012,"interventions":5014},"NCT05252585","A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)",[94],"2026-10-10","2023-05-01",[5013],"Renal Angiomyolipoma",[196],{"nctId":5016,"briefTitle":5017,"status":123,"phases":5018,"primaryCompletion":1682,"completion":1682,"start":3271,"enrollment":792,"conditions":5019,"interventions":5021},"NCT00965094","Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients",[94],[5020],"Chronic Renal Failure",[196,4765,4804,4767,4769],{"nctId":5023,"briefTitle":5024,"status":123,"phases":5025,"primaryCompletion":865,"start":5026,"enrollment":1611,"conditions":5027,"interventions":5028},"NCT00170820","Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen",[94],"2005-02",[4701],[196],{"nctId":5030,"briefTitle":5031,"status":123,"phases":5032,"primaryCompletion":880,"completion":880,"start":835,"enrollment":5033,"conditions":5034,"interventions":5036},"NCT00377962","Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation",[94],282,[5035],"Disorder Related to Cardiac Transplantation",[196,4987,4647,4649],{"nctId":5038,"briefTitle":5039,"status":123,"phases":5040,"primaryCompletion":813,"completion":813,"start":2795,"enrollment":271,"conditions":5041,"interventions":5043},"NCT01594268","A Prospective, Open Label Study of CERtican in KIdney Transplantation",[94],[5042],"Kidney Transplant",[196],{"nctId":5045,"briefTitle":5046,"status":390,"phases":5047,"primaryCompletion":3473,"completion":3473,"start":3473,"enrollment":103,"conditions":5048,"interventions":5049},"NCT01269684","Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients",[94],[4691],[196],{"nctId":5051,"briefTitle":5052,"status":123,"phases":5053,"primaryCompletion":4400,"completion":4400,"start":5026,"enrollment":5054,"conditions":5055,"interventions":5056},"NCT00170846","ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients",[94],394,[4701],[196,5057,4648,4649],"Calcineurin Inhibitors",{"nctId":5059,"briefTitle":5060,"status":123,"phases":5061,"primaryCompletion":5062,"start":5063,"enrollment":1223,"conditions":5064,"interventions":5065},"NCT00154297","Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients",[94],"2008-06","2005-06",[4701],[196],{"nctId":5067,"briefTitle":5068,"status":123,"phases":5069,"primaryCompletion":5070,"completion":5070,"start":5071,"enrollment":3705,"conditions":5072,"interventions":5073},"NCT00862979","A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients",[94],"2017-03-06","2009-02-24",[4744],[196,5074,4803,5075,4626,4769],"cyclosporine A","Enteric coated mycophenolate sodium",{"nctId":5077,"briefTitle":5078,"status":123,"phases":5079,"primaryCompletion":4524,"completion":4524,"start":865,"enrollment":5080,"conditions":5081,"interventions":5083},"NCT00371826","SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus",[94],126,[5082],"Renal Transplanted Recipients",[196,4875,5084,4874],"Methylprednisone\u002Fprednisone",{"nctId":5086,"briefTitle":5087,"status":123,"phases":5088,"primaryCompletion":5089,"completion":5089,"start":5090,"enrollment":709,"conditions":5091,"interventions":5092},"NCT03525834","Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.",[94],"2020-09-25","2018-11-09",[5013],[196],{"nctId":5094,"briefTitle":5095,"status":123,"phases":5096,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":5100,"interventions":5101},"NCT01595009","An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)",[94],"2016-08-09","2011-04-27",246,[4903],[196],{"nctId":5103,"briefTitle":5104,"status":123,"phases":5105,"primaryCompletion":3320,"completion":3320,"start":5106,"enrollment":31,"conditions":5107,"interventions":5108},"NCT01789281","Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.",[94],"2013-05-14",[4362],[196,5109],"Sandostatin LAR Depot",{"nctId":5111,"briefTitle":5112,"status":123,"phases":5113,"primaryCompletion":5114,"completion":5114,"start":1025,"enrollment":1941,"conditions":5115,"interventions":5117},"NCT00634920","Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients",[94],"2013-05",[5116],"Renal Function",[4305,5074,4767,4628,4804],{"nctId":5119,"briefTitle":5120,"status":123,"phases":5121,"primaryCompletion":5122,"completion":5122,"start":5123,"enrollment":1053,"conditions":5124,"interventions":5126},"NCT01514448","Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib",[94],"2016-04-01","2012-05-21",[5125],"Metastatic Renal Cell Carcinoma (mRCC)",[196],{"nctId":5128,"briefTitle":5129,"status":123,"phases":5130,"primaryCompletion":5131,"completion":5131,"start":5132,"enrollment":167,"conditions":5133,"interventions":5134},"NCT02864706","SCHEDULE Follow Up Visit 5-7 yr",[94],"2017-09-25","2016-01-18",[4744],[196,4875,4768,4769],{"trials":5136,"activeCount":103},[5137,5144,5151],{"nctId":5138,"briefTitle":5139,"status":1326,"phases":5140,"conditions":5141,"interventions":5143},"NCT05108740","MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer",[],[5142],"Advanced Hormone Receptor Positive (HR+) Breast Cancer",[4305],{"nctId":5145,"briefTitle":5146,"status":1326,"phases":5147,"conditions":5148,"interventions":5150},"NCT00655252","Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy",[],[5149],"Metastatic Renal Cell Cancer",[196],{"nctId":5152,"briefTitle":5153,"status":1326,"phases":5154,"conditions":5155,"interventions":5157},"NCT00149981","A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation",[],[5156],"Organ Transplantation",[4305],{"intervention":130,"totalTrials":138,"cells":5159},{"EARLY_PHASE1":5160,"PHASE1":5162,"PHASE2":5208,"PHASE3":5240,"PHASE4":5263,"NA":5274},{"trials":5161,"activeCount":103},[],{"trials":5163,"activeCount":437,"soonestReadout":5183},[5164,5168,5179,5188,5197],{"nctId":121,"briefTitle":122,"status":123,"phases":5165,"primaryCompletion":125,"completion":125,"start":126,"enrollment":34,"conditions":5166,"interventions":5167},[91],[128],[98,130],{"nctId":5169,"briefTitle":5170,"status":123,"phases":5171,"primaryCompletion":5172,"completion":5173,"start":5174,"enrollment":5175,"conditions":5176,"interventions":5177},"NCT02299505","Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)",[91],"2016-06-16","2020-03-06","2015-04-09",306,[182],[5178],"ceritinib",{"nctId":5180,"briefTitle":5181,"status":147,"phases":5182,"primaryCompletion":5183,"completion":5183,"start":2016,"enrollment":3530,"conditions":5184,"interventions":5186},"NCT02393625","Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer",[91],"2027-04-09",[5185],"ALK-positive NSCLC",[130,5187],"Nivolumab",{"nctId":5189,"briefTitle":5190,"status":123,"phases":5191,"primaryCompletion":5192,"completion":5192,"start":5193,"enrollment":3043,"conditions":5194,"interventions":5196},"NCT01742286","Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)",[91],"2019-04-26","2013-08-28",[5195],"ALK-activated Tumors",[130],{"nctId":5198,"briefTitle":5199,"status":123,"phases":5200,"primaryCompletion":5201,"completion":5201,"start":5202,"enrollment":99,"conditions":5203,"interventions":5205},"NCT02422589","A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",[91],"2017-12-12","2015-10-23",[5204],"ALK-positive Advanced Tumors",[5178,5206,5207],"warfarin","midazolam",{"trials":5209,"activeCount":103},[5210,5221,5230],{"nctId":5211,"briefTitle":5212,"status":134,"phases":5213,"primaryCompletion":5214,"completion":5214,"start":5215,"enrollment":2633,"conditions":5216,"interventions":5220},"NCT02465528","Ceritinib Rare Indications Study in ALK+ Tumors",[92],"2018-08-20","2016-05-06",[5217,5218,5219,1150],"Tumors With Aberrations in ALK","Anaplastic Large Cell Lymphoma","Inflammatory Myofibroblastic Tumor",[130],{"nctId":5222,"briefTitle":5223,"status":134,"phases":5224,"primaryCompletion":5225,"completion":5225,"start":5226,"enrollment":846,"conditions":5227,"interventions":5229},"NCT02186821","Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)",[92],"2017-12-13","2014-09-17",[5228],"Tumors With Aberrations in ALK or ROS1",[130],{"nctId":5231,"briefTitle":5232,"status":123,"phases":5233,"primaryCompletion":5234,"completion":5234,"start":5235,"enrollment":5236,"conditions":5237,"interventions":5239},"NCT02336451","A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and\u002For to Leptomeninges",[92],"2019-02-06","2015-04-01",156,[5238],"ALK-positive Non-small Cell Lung Cancer",[130],{"trials":5241,"activeCount":103},[5242,5253],{"nctId":5243,"briefTitle":5244,"status":123,"phases":5245,"primaryCompletion":5246,"completion":5247,"start":5248,"enrollment":5249,"conditions":5250,"interventions":5251},"NCT01828112","LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib",[93],"2016-01-26","2023-11-10","2013-06-28",231,[182],[130,4375,5252],"Docetaxel",{"nctId":5254,"briefTitle":5255,"status":123,"phases":5256,"primaryCompletion":5257,"completion":5258,"start":5259,"enrollment":282,"conditions":5260,"interventions":5261},"NCT01828099","LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer",[93],"2016-06-24","2024-01-07","2013-07-09",[182],[130,4375,5262,1168],"Cisplatin",{"trials":5264,"activeCount":437,"soonestReadout":5269},[5265],{"nctId":5266,"briefTitle":5267,"status":147,"phases":5268,"primaryCompletion":5269,"completion":5269,"start":5270,"enrollment":4223,"conditions":5271,"interventions":5273},"NCT02584933","Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study",[94],"2027-06-09","2015-12-11",[5272],"ALK Positive Malignancies",[5178],{"trials":5275,"activeCount":103},[5276],{"nctId":5277,"briefTitle":5278,"status":1326,"phases":5279,"conditions":5280,"interventions":5283},"NCT05100134","Managed Access Programs for LDK378, Ceritinib",[],[5281,5282],"Anaplastic Lymphoma Kinase (ALK)- Positive Tumors","Non-small Cell Lung Cancer (NSCLC)",[5178],{"intervention":5285,"totalTrials":1562,"cells":5286},"Inclisiran sodium",{"EARLY_PHASE1":5287,"PHASE1":5289,"PHASE2":5291,"PHASE3":5303,"PHASE4":5325,"NA":5352},{"trials":5288,"activeCount":103},[],{"trials":5290,"activeCount":103},[],{"trials":5292,"activeCount":103},[5293],{"nctId":5294,"briefTitle":5295,"status":123,"phases":5296,"primaryCompletion":5297,"completion":5298,"start":5299,"enrollment":3901,"conditions":5300,"interventions":5302},"NCT04666298","Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C",[92],"2022-04-18","2022-10-19","2021-01-29",[1401,5301],"Heterozygous Familial Hypercholesterolemia",[5285],{"trials":5304,"activeCount":437,"soonestReadout":57},[5305,5318],{"nctId":5306,"briefTitle":5307,"status":123,"phases":5308,"primaryCompletion":5309,"completion":5309,"start":5310,"enrollment":5311,"conditions":5312,"interventions":5316},"NCT03814187","Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C",[93],"2023-02-13","2019-04-16",3275,[5313,5314,5301,5315],"ASCVD","Elevated Cholesterol","Homozygous Familial Hypercholesterolemia",[5317],"Inclisiran Sodium",{"nctId":55,"briefTitle":56,"status":147,"phases":5319,"primaryCompletion":57,"completion":5320,"start":5321,"enrollment":5322,"conditions":5323,"interventions":5324},[93],"2026-12-28","2021-03-01",345,[1401],[58],{"trials":5326,"activeCount":437,"soonestReadout":3176},[5327,5331,5342],{"nctId":3173,"briefTitle":3174,"status":147,"phases":5328,"primaryCompletion":3176,"completion":3176,"start":3177,"enrollment":3178,"conditions":5329,"interventions":5330},[94],[3180],[58,3017],{"nctId":5332,"briefTitle":5333,"status":123,"phases":5334,"primaryCompletion":5335,"completion":5336,"start":5337,"enrollment":5338,"conditions":5339,"interventions":5340},"NCT06431763","A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.",[94],"2025-12-01","2026-01-02","2024-06-21",402,[1401],[5285,5341],"BPA",{"nctId":5343,"briefTitle":5344,"status":123,"phases":5345,"primaryCompletion":5346,"completion":5347,"start":5348,"enrollment":5349,"conditions":5350,"interventions":5351},"NCT05192941","Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia",[94],"2024-06-11","2025-03-19","2022-04-08",1770,[1401],[5317],{"trials":5353,"activeCount":103},[5354],{"nctId":5355,"briefTitle":5356,"status":123,"phases":5357,"primaryCompletion":2310,"completion":2310,"start":5358,"enrollment":5359,"conditions":5360,"interventions":5361},"NCT05974345","In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease",[],"2023-11-03",204691,[1371],[5285,1403,1376],{"intervention":1540,"totalTrials":213,"cells":5363},{"EARLY_PHASE1":5364,"PHASE1":5366,"PHASE2":5368,"PHASE3":5370,"PHASE4":5372,"NA":5378},{"trials":5365,"activeCount":103},[],{"trials":5367,"activeCount":103},[],{"trials":5369,"activeCount":103},[],{"trials":5371,"activeCount":103},[],{"trials":5373,"activeCount":437,"soonestReadout":111},[5374],{"nctId":1531,"briefTitle":1532,"status":109,"phases":5375,"primaryCompletion":111,"completion":1534,"start":1535,"enrollment":1536,"conditions":5376,"interventions":5377},[94],[1538],[1540,1529],{"trials":5379,"activeCount":437,"soonestReadout":1547},[5380],{"nctId":1544,"briefTitle":1545,"status":109,"phases":5381,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":5382,"interventions":5383},[],[1371],[1552,1553,1554,1403,1555,1556,1557,1558,1376,1559,1356],{"intervention":356,"totalTrials":1630,"cells":5385},{"EARLY_PHASE1":5386,"PHASE1":5388,"PHASE2":5394,"PHASE3":5396,"PHASE4":5406,"NA":5412},{"trials":5387,"activeCount":103},[],{"trials":5389,"activeCount":103},[5390],{"nctId":529,"briefTitle":530,"status":123,"phases":5391,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":5392,"interventions":5393},[91],[536],[515,249,356,119,345],{"trials":5395,"activeCount":103},[],{"trials":5397,"activeCount":103},[5398,5402],{"nctId":892,"briefTitle":893,"status":123,"phases":5399,"primaryCompletion":895,"completion":895,"start":854,"enrollment":896,"conditions":5400,"interventions":5401},[93],[898],[249,356],{"nctId":347,"briefTitle":348,"status":123,"phases":5403,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":5404,"interventions":5405},[93],[342],[98,356,249,285,250],{"trials":5407,"activeCount":437,"soonestReadout":431},[5408],{"nctId":428,"briefTitle":429,"status":147,"phases":5409,"primaryCompletion":431,"completion":432,"start":433,"enrollment":292,"conditions":5410,"interventions":5411},[94],[435],[98,249,285,250,356,119],{"trials":5413,"activeCount":103},[],{"intervention":5415,"totalTrials":213,"cells":5416},"Usual care",{"EARLY_PHASE1":5417,"PHASE1":5419,"PHASE2":5421,"PHASE3":5423,"PHASE4":5425,"NA":5449},{"trials":5418,"activeCount":103},[],{"trials":5420,"activeCount":103},[],{"trials":5422,"activeCount":103},[],{"trials":5424,"activeCount":103},[],{"trials":5426,"activeCount":437,"soonestReadout":5431},[5427,5438],{"nctId":5428,"briefTitle":5429,"status":109,"phases":5430,"primaryCompletion":5431,"completion":5432,"start":5433,"enrollment":5434,"conditions":5435,"interventions":5436},"NCT06501443","LATAM LOWERS LDL-C",[94],"2026-11-27","2026-11-29","2025-02-11",520,[1386],[5415,5437],"KJX839",{"nctId":5439,"briefTitle":5440,"status":123,"phases":5441,"primaryCompletion":4620,"completion":4620,"start":4845,"enrollment":5442,"conditions":5443,"interventions":5444},"NCT00902304","Valsartan Intensified Primary Care Reduction of Blood Pressure Study",[94],2337,[21],[5445,5446,5415,5447,5448],"Valsartan and hydrochlorothiazide (HCTZ) - monotherapy","Valsartan and amlodipine","Valsartan","Valsartan and hydrochlorothiazide (HCTZ) - combination arm",{"trials":5450,"activeCount":103},[],{"intervention":5452,"totalTrials":437,"cells":5453},"Onasemnogene Abeparvovec-brve",{"EARLY_PHASE1":5454,"PHASE1":5456,"PHASE2":5458,"PHASE3":5460,"PHASE4":5462,"NA":5474},{"trials":5455,"activeCount":103},[],{"trials":5457,"activeCount":103},[],{"trials":5459,"activeCount":103},[],{"trials":5461,"activeCount":103},[],{"trials":5463,"activeCount":437,"soonestReadout":5468},[5464],{"nctId":5465,"briefTitle":5466,"status":593,"phases":5467,"primaryCompletion":5468,"completion":5469,"start":5470,"enrollment":792,"conditions":5471,"interventions":5473},"NCT07448610","ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)",[94],"2032-05-03","2032-06-30","2026-07-01",[5472],"Spinal Muscular Atrophy",[5452],{"trials":5475,"activeCount":103},[],{"intervention":5437,"totalTrials":437,"cells":5477},{"EARLY_PHASE1":5478,"PHASE1":5480,"PHASE2":5482,"PHASE3":5484,"PHASE4":5486,"NA":5492},{"trials":5479,"activeCount":103},[],{"trials":5481,"activeCount":103},[],{"trials":5483,"activeCount":103},[],{"trials":5485,"activeCount":103},[],{"trials":5487,"activeCount":437,"soonestReadout":5431},[5488],{"nctId":5428,"briefTitle":5429,"status":109,"phases":5489,"primaryCompletion":5431,"completion":5432,"start":5433,"enrollment":5434,"conditions":5490,"interventions":5491},[94],[1386],[5415,5437],{"trials":5493,"activeCount":103},[],{"intervention":3582,"totalTrials":437,"cells":5495},{"EARLY_PHASE1":5496,"PHASE1":5498,"PHASE2":5500,"PHASE3":5502,"PHASE4":5504,"NA":5510},{"trials":5497,"activeCount":103},[],{"trials":5499,"activeCount":103},[],{"trials":5501,"activeCount":103},[],{"trials":5503,"activeCount":103},[],{"trials":5505,"activeCount":437,"soonestReadout":3575},[5506],{"nctId":3572,"briefTitle":3573,"status":109,"phases":5507,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":3577,"conditions":5508,"interventions":5509},[94],[3228,3579],[3581,83,2395,3395,3232,3582],{"trials":5511,"activeCount":103},[],{"intervention":2952,"totalTrials":437,"cells":5513},{"EARLY_PHASE1":5514,"PHASE1":5516,"PHASE2":5518,"PHASE3":5520,"PHASE4":5522,"NA":5528},{"trials":5515,"activeCount":103},[],{"trials":5517,"activeCount":103},[],{"trials":5519,"activeCount":103},[],{"trials":5521,"activeCount":103},[],{"trials":5523,"activeCount":437,"soonestReadout":2946},[5524],{"nctId":2943,"briefTitle":2944,"status":147,"phases":5525,"primaryCompletion":2946,"completion":2946,"start":2947,"enrollment":2948,"conditions":5526,"interventions":5527},[94],[2950],[2752,2952],{"trials":5529,"activeCount":103},[],{"intervention":5531,"totalTrials":437,"cells":5532},"Ofatunumab",{"EARLY_PHASE1":5533,"PHASE1":5535,"PHASE2":5537,"PHASE3":5539,"PHASE4":5541,"NA":5552},{"trials":5534,"activeCount":103},[],{"trials":5536,"activeCount":103},[],{"trials":5538,"activeCount":103},[],{"trials":5540,"activeCount":103},[],{"trials":5542,"activeCount":437,"soonestReadout":5547},[5543],{"nctId":5544,"briefTitle":5545,"status":147,"phases":5546,"primaryCompletion":5547,"completion":5548,"start":5549,"enrollment":630,"conditions":5550,"interventions":5551},"NCT06444113","Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis",[94],"2026-05-18","2026-10-29","2024-11-25",[27],[5531],{"trials":5553,"activeCount":103},[],{"intervention":5555,"totalTrials":437,"cells":5556},"Secukinumab s.c.",{"EARLY_PHASE1":5557,"PHASE1":5559,"PHASE2":5561,"PHASE3":5563,"PHASE4":5565,"NA":5578},{"trials":5558,"activeCount":103},[],{"trials":5560,"activeCount":103},[],{"trials":5562,"activeCount":103},[],{"trials":5564,"activeCount":103},[],{"trials":5566,"activeCount":437,"soonestReadout":5571},[5567],{"nctId":5568,"briefTitle":5569,"status":109,"phases":5570,"primaryCompletion":5571,"completion":5572,"start":5573,"enrollment":5574,"conditions":5575,"interventions":5577},"NCT04638647","Secukinumab Open Label Roll-over Extension Protocol",[94],"2030-01-29","2030-04-04","2020-12-22",1000,[5576],"Autoimmunity, Inflammation",[5555],{"trials":5579,"activeCount":103},[],{"intervention":4391,"totalTrials":2633,"cells":5581},{"EARLY_PHASE1":5582,"PHASE1":5584,"PHASE2":5627,"PHASE3":5727,"PHASE4":5748,"NA":5754},{"trials":5583,"activeCount":103},[],{"trials":5585,"activeCount":103},[5586,5590,5600,5608,5616,5623],{"nctId":2349,"briefTitle":2350,"status":123,"phases":5587,"primaryCompletion":2352,"completion":2352,"start":2353,"enrollment":2354,"conditions":5588,"interventions":5589},[91],[2356,2357,2358],[2360,2361],{"nctId":5591,"briefTitle":5592,"status":123,"phases":5593,"primaryCompletion":4515,"completion":4515,"start":3482,"enrollment":5594,"conditions":5595,"interventions":5599},"NCT01613976","A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients",[91],10,[5596,5597,5598],"Myelodysplastic Syndromes (MDS)","Chronic Myelomonocytic Leukemia (CMML)","Acute Myeloid Leukemia (AML)",[4391],{"nctId":5601,"briefTitle":5602,"status":123,"phases":5603,"primaryCompletion":3551,"completion":3551,"start":3279,"enrollment":1562,"conditions":5604,"interventions":5607},"NCT00670553","A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer",[91],[1654,5605,5606],"Head & Neck Cancer","Esophageal Cancer",[2360],{"nctId":5609,"briefTitle":5610,"status":123,"phases":5611,"primaryCompletion":3731,"completion":3731,"start":964,"enrollment":5612,"conditions":5613,"interventions":5615},"NCT00997399","Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function",[91],37,[5614],"Advanced Solid Tumors",[2360],{"nctId":5617,"briefTitle":5618,"status":123,"phases":5619,"primaryCompletion":4515,"completion":4515,"start":5620,"enrollment":3098,"conditions":5621,"interventions":5622},"NCT01242774","Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients \u003C 65 Years Old With Acute Myeloid Leukemia (AML)",[91],"2010-10",[5598],[4391],{"nctId":4381,"briefTitle":4382,"status":123,"phases":5624,"primaryCompletion":4384,"completion":4384,"start":4385,"enrollment":3741,"conditions":5625,"interventions":5626},[91],[4387],[4389,4390,196,4391,4392,4393],{"trials":5628,"activeCount":103},[5629,5640,5650,5659,5669,5677,5684,5692,5700,5709,5715],{"nctId":5630,"briefTitle":5631,"status":390,"phases":5632,"primaryCompletion":5633,"completion":5633,"start":5634,"enrollment":103,"conditions":5635,"interventions":5637},"NCT02756663","Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma",[92],"2021-02","2016-12",[5636],"Multiple Myeloma",[2360,5638,5639],"carfilzomib","dexamethasone",{"nctId":5641,"briefTitle":5642,"status":123,"phases":5643,"primaryCompletion":1723,"completion":1723,"start":3351,"enrollment":2112,"conditions":5644,"interventions":5648},"NCT01083602","Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma",[92],[5645,5646,5647],"Relapsed and Bortezomib Refractory Multiple Myeloma","Refractory Multiple Myeloma","Multiple Myeloma in Relapse",[2360,5649,5639],"bortezomib",{"nctId":5651,"briefTitle":5652,"status":134,"phases":5653,"primaryCompletion":4975,"completion":5654,"start":5655,"enrollment":1495,"conditions":5656,"interventions":5658},"NCT00490776","Study of Oral LBH589 in Adult Participants With Refractory\u002FResistant Cutaneous T-Cell Lymphoma (CTCL)",[92],"2009-09-22","2007-07-05",[5657],"Cutaneous T-Cell Lymphoma",[4391],{"nctId":5660,"briefTitle":5661,"status":134,"phases":5662,"primaryCompletion":5663,"completion":5663,"start":5664,"enrollment":906,"conditions":5665,"interventions":5668},"NCT00931762","A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis",[92],"2011-08-29","2009-08-31",[2430,5666,5667],"Post-Polycythemia Vera","Post-Essential Thrombocytopenia",[4391],{"nctId":5670,"briefTitle":5671,"status":123,"phases":5672,"primaryCompletion":3361,"completion":3361,"start":5673,"enrollment":2832,"conditions":5674,"interventions":5676},"NCT00742027","Phase II Study of Oral Panobinostat in Adult Participants With Relapsed\u002FRefractory Classical Hodgkin's Lymphoma",[92],"2008-09-16",[5675],"Classical Hodgkin's Lymphoma",[4391],{"nctId":5678,"briefTitle":5679,"status":134,"phases":5680,"primaryCompletion":3784,"completion":3784,"start":4070,"enrollment":5681,"conditions":5682,"interventions":5683},"NCT00567879","A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab",[91,92],56,[15],[4391,4320],{"nctId":5685,"briefTitle":5686,"status":123,"phases":5687,"primaryCompletion":5688,"completion":5688,"start":5689,"enrollment":906,"conditions":5690,"interventions":5691},"NCT00667862","Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer",[92],"2010-11-05","2008-03-18",[1654],[4391],{"nctId":5693,"briefTitle":5694,"status":134,"phases":5695,"primaryCompletion":3552,"start":5696,"enrollment":1630,"conditions":5697,"interventions":5699},"NCT00699296","Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia\u002FLymphoma",[92],"2008-05",[5657,5698],"Leukemia-Lymphoma, Adult T-Cell",[4391],{"nctId":5701,"briefTitle":5702,"status":123,"phases":5703,"primaryCompletion":5704,"completion":5704,"start":5705,"enrollment":1495,"conditions":5706,"interventions":5708},"NCT01802879","Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator",[92],"2018-11-19","2013-06-24",[5707],"Hematologic Neoplasms",[4391],{"nctId":5710,"briefTitle":5711,"status":123,"phases":5712,"primaryCompletion":1682,"completion":1682,"start":3254,"enrollment":1223,"conditions":5713,"interventions":5714},"NCT00425555","Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma",[92],[5657],[4391],{"nctId":5716,"briefTitle":5717,"status":123,"phases":5718,"primaryCompletion":5719,"completion":5719,"start":5720,"enrollment":5721,"conditions":5722,"interventions":5725},"NCT00946647","A Phase Ib\u002FIIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).",[91,92],"2019-04-29","2009-12-02",113,[5723,5724,2569],"Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia",[4391,5726],"5-Azacytidine",{"trials":5728,"activeCount":103},[5729,5737],{"nctId":5730,"briefTitle":5731,"status":123,"phases":5732,"primaryCompletion":5733,"completion":5733,"start":3351,"enrollment":4506,"conditions":5734,"interventions":5736},"NCT01034163","A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)",[93],"2012-05",[5735],"Hodgkin's Lymphoma",[4391],{"nctId":5738,"briefTitle":5739,"status":123,"phases":5740,"primaryCompletion":5741,"completion":5741,"start":5742,"enrollment":5743,"conditions":5744,"interventions":5745},"NCT01023308","Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma",[93],"2015-07-30","2009-12-21",767,[5636],[4391,5746,5747],"Bortezomib","Dexamethasone",{"trials":5749,"activeCount":437,"soonestReadout":2564},[5750],{"nctId":2561,"briefTitle":2562,"status":147,"phases":5751,"primaryCompletion":2564,"completion":2564,"start":2565,"enrollment":2566,"conditions":5752,"interventions":5753},[94],[2430,2470,2568,2569,2570],[2361,2360],{"trials":5755,"activeCount":103},[5756,5762],{"nctId":5757,"briefTitle":5758,"status":1326,"phases":5759,"conditions":5760,"interventions":5761},"NCT02568943","An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma",[],[5636],[4391],{"nctId":5763,"briefTitle":5764,"status":1326,"phases":5765,"conditions":5766,"interventions":5767},"NCT02204553","Expanded Treatment Prot of Panobinostat in Combo w\u002F Bortez and Dex in Pts w\u002F Relapsed and\u002For Refractory Multiple Myeloma",[],[5636],[4391],{"intervention":5769,"totalTrials":1672,"cells":5770},"Ianalumab",{"EARLY_PHASE1":5771,"PHASE1":5773,"PHASE2":5794,"PHASE3":5846,"PHASE4":5924,"NA":5926},{"trials":5772,"activeCount":103},[],{"trials":5774,"activeCount":103},[5775,5786],{"nctId":5776,"briefTitle":5777,"status":390,"phases":5778,"primaryCompletion":5779,"completion":5780,"start":5549,"enrollment":103,"conditions":5781,"interventions":5784},"NCT06411639","Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases",[91],"2025-12-17","2028-06-24",[5782,5783],"Sjogren Disease","Systemic Lupus Erythematosus",[5785],"ianalumab",{"nctId":5787,"briefTitle":5788,"status":123,"phases":5789,"primaryCompletion":5790,"completion":5790,"start":5791,"enrollment":114,"conditions":5792,"interventions":5793},"NCT03574545","Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis",[91],"2024-07-18","2018-12-19",[1717],[5785],{"trials":5795,"activeCount":1630,"soonestReadout":5818},[5796,5805,5814,5824,5834],{"nctId":5797,"briefTitle":5798,"status":109,"phases":5799,"primaryCompletion":5800,"completion":5801,"start":2864,"enrollment":919,"conditions":5802,"interventions":5804},"NCT06470048","A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis",[92],"2027-07-06","2030-07-15",[5803],"Diffuse Cutaneous Systemic Sclerosis",[5769],{"nctId":5806,"briefTitle":5807,"status":109,"phases":5808,"primaryCompletion":3575,"completion":3575,"start":5809,"enrollment":1423,"conditions":5810,"interventions":5813},"NCT07039422","Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab",[92],"2026-06-26",[5811,5812],"Primary Immune Thrombocytopenia","Warm Autoimmune Hemolytic Anemia",[5769],{"nctId":5815,"briefTitle":5816,"status":147,"phases":5817,"primaryCompletion":5818,"completion":5819,"start":5820,"enrollment":4506,"conditions":5821,"interventions":5823},"NCT05885555","A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies",[92],"2025-02-05","2029-03-19","2023-08-16",[5822],"Primary Immune Thrombocytopenia (ITP)",[5769],{"nctId":5825,"briefTitle":5826,"status":123,"phases":5827,"primaryCompletion":5828,"completion":5829,"start":5830,"enrollment":4118,"conditions":5831,"interventions":5833},"NCT05124925","Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.",[92],"2024-06-26","2026-01-05","2022-07-27",[5832],"Sjogren Syndrome",[5769],{"nctId":5835,"briefTitle":5836,"status":109,"phases":5837,"primaryCompletion":5838,"completion":5839,"start":5840,"enrollment":5841,"conditions":5842,"interventions":5844},"NCT07421167","A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)",[92],"2027-03-03","2027-03-31","2026-11-11",164,[5822,5843],"Primary Evans Syndrome (ES)",[5785,5845],"thrombopoietin receptor agonist",{"trials":5847,"activeCount":422,"soonestReadout":5890},[5848,5858,5867,5875,5886,5896,5906,5915],{"nctId":5849,"briefTitle":5850,"status":147,"phases":5851,"primaryCompletion":5852,"completion":5853,"start":5854,"enrollment":5855,"conditions":5856,"interventions":5857},"NCT05639114","Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)",[93],"2027-03-24","2029-03-21","2023-03-02",436,[5783],[5769],{"nctId":5859,"briefTitle":5860,"status":109,"phases":5861,"primaryCompletion":5862,"completion":5863,"start":5864,"enrollment":3950,"conditions":5865,"interventions":5866},"NCT06711887","Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)",[93],"2030-07-16","2032-07-16","2025-05-19",[1800],[5769],{"nctId":5868,"briefTitle":5869,"status":147,"phases":5870,"primaryCompletion":5548,"completion":5871,"start":5872,"enrollment":1879,"conditions":5873,"interventions":5874},"NCT05653349","Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)",[93],"2028-12-06","2023-02-03",[5822],[5769,4769],{"nctId":5876,"briefTitle":5877,"status":147,"phases":5878,"primaryCompletion":5879,"completion":5880,"start":5881,"enrollment":5882,"conditions":5883,"interventions":5885},"NCT05648968","A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia",[93],"2026-02-20","2028-12-19","2022-12-30",90,[5884],"Warm Autoimmune Hemolytic Anemia (wAIHA)",[5769],{"nctId":5887,"briefTitle":5888,"status":147,"phases":5889,"primaryCompletion":5890,"completion":5891,"start":2416,"enrollment":5892,"conditions":5893,"interventions":5894},"NCT05653219","A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids",[93],"2025-06-19","2028-04-08",152,[5811],[5769,5895],"Eltrombopag",{"nctId":5897,"briefTitle":5898,"status":147,"phases":5899,"primaryCompletion":5900,"completion":5901,"start":5902,"enrollment":5903,"conditions":5904,"interventions":5905},"NCT05624749","Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)",[93],"2027-04-12","2029-04-09","2023-04-21",288,[5783],[5785],{"nctId":5907,"briefTitle":5908,"status":147,"phases":5909,"primaryCompletion":5910,"completion":5910,"start":5911,"enrollment":4762,"conditions":5912,"interventions":5914},"NCT05985915","A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.",[93],"2033-04-22","2023-10-27",[5913],"Sjogrens Syndrome",[5769],{"nctId":5916,"briefTitle":5917,"status":109,"phases":5918,"primaryCompletion":5919,"completion":112,"start":5920,"enrollment":5921,"conditions":5922,"interventions":5923},"NCT06133972","Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).",[93],"2030-04-08","2024-05-21",550,[5783],[5769],{"trials":5925,"activeCount":103},[],{"trials":5927,"activeCount":103},[5928],{"nctId":5929,"briefTitle":5930,"status":491,"phases":5931,"conditions":5932,"interventions":5934},"NCT07244289","Managed Access Programs for VAY736, Ianalumab",[],[5811,5933],"Sjögren's Syndrome",[5785],{"intervention":5936,"totalTrials":3343,"cells":5937},"Iptacopan",{"EARLY_PHASE1":5938,"PHASE1":5940,"PHASE2":5951,"PHASE3":6007,"PHASE4":6090,"NA":6092},{"trials":5939,"activeCount":103},[],{"trials":5941,"activeCount":103},[5942],{"nctId":5943,"briefTitle":5944,"status":123,"phases":5945,"primaryCompletion":5946,"completion":5946,"start":5947,"enrollment":5948,"conditions":5949,"interventions":5950},"NCT05078580","Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.",[91],"2022-06-20","2021-11-10",38,[2625],[5936,5936,5936,5936],{"trials":5952,"activeCount":1630,"soonestReadout":6001},[5953,5963,5973,5977,5986,5997],{"nctId":5954,"briefTitle":5955,"status":147,"phases":5956,"primaryCompletion":5957,"completion":5958,"start":1971,"enrollment":5959,"conditions":5960,"interventions":5962},"NCT05230537","A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration",[92],"2026-10-01","2026-10-02",170,[5961],"Age-Related Macular Degeneration",[5936],{"nctId":5964,"briefTitle":5965,"status":109,"phases":5966,"primaryCompletion":5967,"completion":5967,"start":5968,"enrollment":1611,"conditions":5969,"interventions":5972},"NCT06797518","Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN",[92],"2027-11-27","2025-02-21",[5970,5971],"Glomerulonephritis, IGA","Immunoglobulin A Nephropathy",[5936],{"nctId":3070,"briefTitle":3071,"status":123,"phases":5974,"primaryCompletion":3073,"completion":3074,"start":3075,"enrollment":1672,"conditions":5975,"interventions":5976},[92],[3077],[3079,3017],{"nctId":5978,"briefTitle":5979,"status":147,"phases":5980,"primaryCompletion":111,"completion":111,"start":5981,"enrollment":5982,"conditions":5983,"interventions":5985},"NCT06388941","Iptacopan in Patients With ANCA Associated Vasculitis",[92],"2024-08-05",84,[5984],"Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis",[5936,2879],{"nctId":5987,"briefTitle":5988,"status":134,"phases":5989,"primaryCompletion":5990,"completion":5991,"start":5992,"enrollment":1065,"conditions":5993,"interventions":5996},"NCT05086744","Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders",[92],"2023-09-20","2024-05-17","2021-12-21",[5994,5995],"Immune Thrombocytopenia (ITP)","Cold Agglutinin Disease (CAD)",[5936],{"nctId":5998,"briefTitle":5999,"status":109,"phases":6000,"primaryCompletion":6001,"completion":6002,"start":6003,"enrollment":467,"conditions":6004,"interventions":6005},"NCT05268289","Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +\u002F- V",[92],"2026-03-19","2028-09-28","2022-08-10",[1800],[5936,5936,6006],"Iptacopan + placebo",{"trials":6008,"activeCount":2379,"soonestReadout":555},[6009,6018,6028,6037,6046,6055,6065,6072,6082],{"nctId":6010,"briefTitle":6011,"status":109,"phases":6012,"primaryCompletion":555,"completion":555,"start":6013,"enrollment":6014,"conditions":6015,"interventions":6017},"NCT04817618","Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.",[93],"2021-07-28",98,[6016],"C3G",[3079],{"nctId":6019,"briefTitle":6020,"status":147,"phases":6021,"primaryCompletion":6022,"completion":6022,"start":6023,"enrollment":6024,"conditions":6025,"interventions":6027},"NCT04747613","Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria",[93],"2027-10-18","2021-07-27",208,[6026],"Paroxysmal Nocturnal Hemoglobinuria",[5936],{"nctId":6029,"briefTitle":6030,"status":109,"phases":6031,"primaryCompletion":431,"completion":6032,"start":6033,"enrollment":827,"conditions":6034,"interventions":6036},"NCT06994845","Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN",[93],"2030-06-30","2025-11-27",[6035],"Primary Immunoglobulin A Nephropathy (IgAN)",[3079],{"nctId":6038,"briefTitle":6039,"status":123,"phases":6040,"primaryCompletion":6041,"completion":6041,"start":6042,"enrollment":31,"conditions":6043,"interventions":6045},"NCT04889430","Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy",[93],"2026-04-11","2022-01-17",[6044],"Atypical Hemolytic Uremic Syndrome",[5936],{"nctId":6047,"briefTitle":6048,"status":109,"phases":6049,"primaryCompletion":6050,"completion":6051,"start":3262,"enrollment":1574,"conditions":6052,"interventions":6054},"NCT05755386","Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN",[93],"2028-10-27","2029-05-31",[6053],"IC-MPGN",[3079],{"nctId":6056,"briefTitle":6057,"status":109,"phases":6058,"primaryCompletion":3176,"completion":6059,"start":6060,"enrollment":6061,"conditions":6062,"interventions":6064},"NCT06517758","A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.",[93],"2032-05-27","2024-07-31",146,[6063],"Generalized Myasthenia Gravis",[5936],{"nctId":6066,"briefTitle":6067,"status":123,"phases":6068,"primaryCompletion":1909,"completion":1909,"start":6069,"enrollment":3605,"conditions":6070,"interventions":6071},"NCT05630001","Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.",[93],"2023-04-24",[6026],[5936],{"nctId":6073,"briefTitle":6074,"status":123,"phases":6075,"primaryCompletion":6076,"completion":6077,"start":6078,"enrollment":709,"conditions":6079,"interventions":6081},"NCT04820530","Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy",[93],"2022-11-02","2023-04-18","2021-07-19",[6080],"Paroxysmal Nocturnal Hemoglobinuria (PNH)",[5936],{"nctId":6083,"briefTitle":6084,"status":109,"phases":6085,"primaryCompletion":6086,"completion":6087,"start":326,"enrollment":2579,"conditions":6088,"interventions":6089},"NCT05935215","Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)",[93],"2028-07-21","2029-07-19",[6044],[5936],{"trials":6091,"activeCount":103},[],{"trials":6093,"activeCount":437,"soonestReadout":6098},[6094,6103],{"nctId":6095,"briefTitle":6096,"status":147,"phases":6097,"primaryCompletion":6098,"completion":6098,"start":6099,"enrollment":919,"conditions":6100,"interventions":6102},"NCT06903234","Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry",[],"2029-10-01","2025-03-31",[6101],"Hemoglobinuria, Paroxysmal",[5936],{"nctId":6104,"briefTitle":6105,"status":491,"phases":6106,"conditions":6107,"interventions":6109},"NCT05222412","Managed Access Programs for LNP023, Iptacopan",[],[6108,6080],"C3 Glomerulopathy (C3G)",[5936],{"intervention":6111,"totalTrials":734,"cells":6112},"Remibrutinib",{"EARLY_PHASE1":6113,"PHASE1":6115,"PHASE2":6128,"PHASE3":6157,"PHASE4":6237,"NA":6239},{"trials":6114,"activeCount":103},[],{"trials":6116,"activeCount":103},[6117],{"nctId":6118,"briefTitle":6119,"status":123,"phases":6120,"primaryCompletion":6121,"completion":6122,"start":6123,"enrollment":1672,"conditions":6124,"interventions":6126},"NCT07032272","A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.",[91],"2025-10-12","2025-10-14","2025-07-23",[6125],"Autoimmune and Chronic Inflammatory Diseases",[6127],"remibrutinib",{"trials":6129,"activeCount":437,"soonestReadout":6151},[6130,6138,6147],{"nctId":6131,"briefTitle":6132,"status":123,"phases":6133,"primaryCompletion":2865,"completion":2865,"start":6134,"enrollment":485,"conditions":6135,"interventions":6137},"NCT05432388","Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts",[92],"2022-10-12",[6136],"Allergy, Peanut",[6127],{"nctId":6139,"briefTitle":6140,"status":134,"phases":6141,"primaryCompletion":6142,"completion":6142,"start":6143,"enrollment":4568,"conditions":6144,"interventions":6146},"NCT04035668","A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome",[92],"2021-11-23","2019-07-12",[6145],"Sjögren Syndrome",[6111],{"nctId":6148,"briefTitle":6149,"status":109,"phases":6150,"primaryCompletion":6151,"completion":6152,"start":6153,"enrollment":22,"conditions":6154,"interventions":6156},"NCT06865651","Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria",[92],"2027-08-23","2027-09-28","2025-05-22",[6155],"Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)",[6111],{"trials":6158,"activeCount":422,"soonestReadout":6212},[6159,6169,6179,6189,6198,6208,6219,6230],{"nctId":6160,"briefTitle":6161,"status":147,"phases":6162,"primaryCompletion":6163,"completion":1188,"start":6164,"enrollment":6165,"conditions":6166,"interventions":6168},"NCT05976243","A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines",[93],"2026-05-22","2023-12-07",362,[6167],"Chronic Inducible Urticaria",[6111],{"nctId":6170,"briefTitle":6171,"status":109,"phases":6172,"primaryCompletion":6173,"completion":6173,"start":6174,"enrollment":6175,"conditions":6176,"interventions":6178},"NCT07456891","Remibrutinib Open Label Roll-over Post-trial Access Protocol",[93],"2033-01-30","2026-04-16",212,[6177],"Indication of the Parent Protocol",[6111],{"nctId":6180,"briefTitle":6181,"status":147,"phases":6182,"primaryCompletion":6183,"completion":6184,"start":6185,"enrollment":5574,"conditions":6186,"interventions":6187},"NCT05147220","Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)",[93],"2026-07-23","2030-10-30","2021-12-16",[2778],[6111,6188],"Teriflunomide",{"nctId":6190,"briefTitle":6191,"status":109,"phases":6192,"primaryCompletion":6193,"completion":6194,"start":6195,"enrollment":2981,"conditions":6196,"interventions":6197},"NCT06744920","A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis",[93],"2028-02-25","2033-02-26","2025-02-07",[6063],[6111,6111],{"nctId":6199,"briefTitle":6200,"status":109,"phases":6201,"primaryCompletion":6202,"completion":1276,"start":6203,"enrollment":1466,"conditions":6204,"interventions":6206},"NCT06868212","A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines",[93],"2027-02-22","2025-07-11",[6205],"Chronic Spontaneous Urticaria (CSU)",[6111,6207],"Dupilumab",{"nctId":6209,"briefTitle":6210,"status":147,"phases":6211,"primaryCompletion":6212,"completion":6213,"start":6214,"enrollment":6215,"conditions":6216,"interventions":6217},"NCT06042478","Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.",[93],"2025-09-17","2027-07-20","2023-11-15",470,[33],[6111,6218],"Omalizumab",{"nctId":6220,"briefTitle":6221,"status":109,"phases":6222,"primaryCompletion":6223,"completion":6224,"start":6225,"enrollment":6226,"conditions":6227,"interventions":6229},"NCT07225504","A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis",[93],"2030-12-03","2034-01-02","2025-11-11",1275,[6228],"Secondary Progressive Multiple Sclerosis (SPMS)",[6111,6111],{"nctId":6231,"briefTitle":6181,"status":147,"phases":6232,"primaryCompletion":6183,"completion":6184,"start":6233,"enrollment":6234,"conditions":6235,"interventions":6236},"NCT05156281",[93],"2021-12-13",1007,[2778],[6111,6188],{"trials":6238,"activeCount":103},[],{"trials":6240,"activeCount":103},[6241],{"nctId":6242,"briefTitle":6243,"status":491,"phases":6244,"conditions":6245,"interventions":6246},"NCT05170724","Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria",[],[33],[6111],{"intervention":88,"totalTrials":2633,"cells":6248},{"EARLY_PHASE1":6249,"PHASE1":6251,"PHASE2":6276,"PHASE3":6330,"PHASE4":6387,"NA":6393},{"trials":6250,"activeCount":103},[],{"trials":6252,"activeCount":103},[6253,6264,6268],{"nctId":6254,"briefTitle":6255,"status":123,"phases":6256,"primaryCompletion":6257,"completion":6257,"start":6258,"enrollment":709,"conditions":6259,"interventions":6262},"NCT02058381","A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer",[91],"2018-06-19","2014-05-06",[6260,6261],"Pre-menopausal Breast Cancer","PI3K Pathway Inhibition",[4366,6263],"buparlisib",{"nctId":4355,"briefTitle":4356,"status":123,"phases":6265,"primaryCompletion":4358,"completion":4358,"start":4359,"enrollment":4360,"conditions":6266,"interventions":6267},[91],[4362,559,4363,4364],[4366,4305,4367],{"nctId":6269,"briefTitle":6270,"status":123,"phases":6271,"primaryCompletion":6272,"completion":6272,"start":6273,"enrollment":496,"conditions":6274,"interventions":6275},"NCT02624557","Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.",[91],"2017-10-01","2015-12-21",[2625],[88],{"trials":6277,"activeCount":637,"soonestReadout":87},[6278,6284,6288,6292,6296,6300,6309,6318,6322],{"nctId":85,"briefTitle":86,"status":147,"phases":6279,"primaryCompletion":87,"completion":6280,"start":1110,"enrollment":1203,"conditions":6281,"interventions":6283},[92],"2031-01-09",[6282],"PIK3CA-related Overgrowth Spectrum (PROS)",[88],{"nctId":552,"briefTitle":553,"status":147,"phases":6285,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":6286,"interventions":6287},[92],[559],[88,119],{"nctId":562,"briefTitle":563,"status":123,"phases":6289,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":6290,"interventions":6291},[92],[15],[88,119,249,250,332],{"nctId":572,"briefTitle":573,"status":134,"phases":6293,"primaryCompletion":575,"completion":575,"start":576,"enrollment":213,"conditions":6294,"interventions":6295},[92],[375],[88,119,250],{"nctId":614,"briefTitle":615,"status":134,"phases":6297,"primaryCompletion":256,"completion":256,"start":617,"enrollment":213,"conditions":6298,"interventions":6299},[92],[15],[88,119,620,621,622],{"nctId":6301,"briefTitle":6302,"status":123,"phases":6303,"primaryCompletion":6304,"completion":6305,"start":6306,"enrollment":1411,"conditions":6307,"interventions":6308},"NCT01923168","Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",[92],"2017-07-07","2017-07-08","2014-03-11",[15],[4366,6263],{"nctId":6310,"briefTitle":6311,"status":109,"phases":6312,"primaryCompletion":6313,"completion":6314,"start":6315,"enrollment":314,"conditions":6316,"interventions":6317},"NCT06997588","EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)",[92],"2028-08-02","2030-09-30","2025-10-09",[6282],[88],{"nctId":624,"briefTitle":625,"status":147,"phases":6319,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":6320,"interventions":6321},[92],[375],[88,119],{"nctId":6323,"briefTitle":6324,"status":147,"phases":6325,"primaryCompletion":6326,"completion":6326,"start":6327,"enrollment":4506,"conditions":6328,"interventions":6329},"NCT04980833","Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)",[92],"2027-08-20","2022-01-27",[6282],[88],{"trials":6331,"activeCount":317,"soonestReadout":688},[6332,6343,6354,6358,6367,6379,6383],{"nctId":6333,"briefTitle":6334,"status":134,"phases":6335,"primaryCompletion":6336,"completion":6337,"start":6338,"enrollment":1890,"conditions":6339,"interventions":6341},"NCT04251533","Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss",[93],"2023-05-31","2026-02-05","2020-06-08",[6340],"Triple Negative Breast Neoplasms",[4366,6342],"nab-paclitaxel",{"nctId":6344,"briefTitle":6345,"status":109,"phases":6346,"primaryCompletion":6347,"completion":6348,"start":6349,"enrollment":6350,"conditions":6351,"interventions":6353},"NCT05948943","Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.",[92,93],"2028-05-31","2033-05-02","2023-11-24",232,[6352],"Lymphatic Malformations",[88],{"nctId":651,"briefTitle":652,"status":123,"phases":6355,"primaryCompletion":654,"completion":655,"start":656,"enrollment":657,"conditions":6356,"interventions":6357},[93],[15],[119,88],{"nctId":6359,"briefTitle":6360,"status":147,"phases":6361,"primaryCompletion":627,"completion":627,"start":6362,"enrollment":1065,"conditions":6363,"interventions":6365},"NCT04208178","Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation",[93],"2020-07-16",[6364],"Advanced HER2+Breast Cancer",[88,4320,6366],"Pertuzumab",{"nctId":6368,"briefTitle":6369,"status":134,"phases":6370,"primaryCompletion":5902,"completion":6371,"start":6372,"enrollment":6373,"conditions":6374,"interventions":6376},"NCT04729387","Alpelisib Plus Olaparib in Platinum-resistant\u002FRefractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected",[93],"2026-01-19","2021-07-22",358,[6375],"Ovarian Cancer",[88,6377,4321,6378],"Olaparib","Pegylated liposomal doxorubicin",{"nctId":685,"briefTitle":686,"status":147,"phases":6380,"primaryCompletion":688,"completion":627,"start":689,"enrollment":690,"conditions":6381,"interventions":6382},[93],[15],[88,119],{"nctId":408,"briefTitle":409,"status":123,"phases":6384,"primaryCompletion":411,"completion":411,"start":412,"enrollment":413,"conditions":6385,"interventions":6386},[93],[15],[98,249,88,119],{"trials":6388,"activeCount":103},[6389],{"nctId":704,"briefTitle":705,"status":123,"phases":6390,"primaryCompletion":707,"completion":707,"start":708,"enrollment":709,"conditions":6391,"interventions":6392},[94],[375],[88,119],{"trials":6394,"activeCount":103},[6395,6402],{"nctId":6396,"briefTitle":6397,"status":1326,"phases":6398,"conditions":6399,"interventions":6401},"NCT03706573","Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer",[],[6400],"HR+ Advanced or Metastatic Breast Cancer",[4366],{"nctId":6403,"briefTitle":6404,"status":491,"phases":6405,"conditions":6406,"interventions":6408},"NCT04085653","Managed Access Programs for BYL719, Alpelisib",[],[6407,15],"PIK3CA-Related Overgrowth Spectrum (PROS)",[4366],{"intervention":78,"totalTrials":2379,"cells":6410},{"EARLY_PHASE1":6411,"PHASE1":6413,"PHASE2":6442,"PHASE3":6444,"PHASE4":6463,"NA":6465},{"trials":6412,"activeCount":103},[],{"trials":6414,"activeCount":317,"soonestReadout":2376},[6415,6425,6429],{"nctId":6416,"briefTitle":6417,"status":109,"phases":6418,"primaryCompletion":6419,"completion":6313,"start":6420,"enrollment":630,"conditions":6421,"interventions":6423},"NCT07422610","Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment",[91],"2028-06-28","2026-04-24",[6422],"Advanced Malignancies and Hepatic Impairment",[6424],"pelabresib",{"nctId":2373,"briefTitle":2374,"status":109,"phases":6426,"primaryCompletion":2376,"completion":2377,"start":2378,"enrollment":2379,"conditions":6427,"interventions":6428},[91],[2381,2382,2383],[78,2341],{"nctId":6430,"briefTitle":6431,"status":593,"phases":6432,"primaryCompletion":6433,"completion":6434,"start":6435,"enrollment":630,"conditions":6436,"interventions":6438},"NCT07340190","A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies",[91],"2028-03-09","2028-04-07","2026-05-29",[6437],"Advanced Malignancies",[6424,6439,5207,6440,6441],"repaglinide","drospirenone","ethinyl estradiol",{"trials":6443,"activeCount":103},[],{"trials":6445,"activeCount":317,"soonestReadout":77},[6446,6455,6459],{"nctId":6447,"briefTitle":6448,"status":109,"phases":6449,"primaryCompletion":6450,"completion":2541,"start":6451,"enrollment":2579,"conditions":6452,"interventions":6454},"NCT06401356","An Extension Study for Patients Previously Enrolled in Studies With Pelabresib",[93],"2027-06-02","2024-08-13",[6453,1317,6437],"Hematologic Malignancy",[78],{"nctId":2473,"briefTitle":2474,"status":109,"phases":6456,"primaryCompletion":2476,"completion":2477,"start":2478,"enrollment":2130,"conditions":6457,"interventions":6458},[93],[2381,2480,2481],[78,2341],{"nctId":75,"briefTitle":76,"status":147,"phases":6460,"primaryCompletion":77,"completion":2541,"start":2542,"enrollment":2543,"conditions":6461,"interventions":6462},[93],[2369,2430,2545,2546],[78,2341],{"trials":6464,"activeCount":103},[],{"trials":6466,"activeCount":103},[],{"intervention":3112,"totalTrials":2367,"cells":6468},{"EARLY_PHASE1":6469,"PHASE1":6471,"PHASE2":6507,"PHASE3":6572,"PHASE4":6612,"NA":6614},{"trials":6470,"activeCount":103},[],{"trials":6472,"activeCount":103},[6473,6480,6490,6499],{"nctId":6474,"briefTitle":6475,"status":134,"phases":6476,"primaryCompletion":3712,"completion":3712,"start":3759,"enrollment":317,"conditions":6477,"interventions":6479},"NCT02137889","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients",[91],[6478],"Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",[3112],{"nctId":6481,"briefTitle":6482,"status":134,"phases":6483,"primaryCompletion":6484,"completion":6484,"start":6485,"enrollment":3343,"conditions":6486,"interventions":6488},"NCT04903197","Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma",[91],"2025-02-24","2022-01-24",[6487],"Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma",[3112,6489],"lenalidomide",{"nctId":6491,"briefTitle":6492,"status":123,"phases":6493,"primaryCompletion":6494,"completion":6494,"start":6495,"enrollment":1524,"conditions":6496,"interventions":6497},"NCT02675803","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients",[91],"2018-01-22","2010-12-20",[1717],[3112,6498],"VAY736 placebo",{"nctId":6500,"briefTitle":6501,"status":134,"phases":6502,"primaryCompletion":6503,"completion":6503,"start":3075,"enrollment":28,"conditions":6504,"interventions":6505},"NCT03400176","VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib",[91],"2023-09-29",[2798],[3112,6506],"ibrutinib",{"trials":6508,"activeCount":437,"soonestReadout":4221},[6509,6521,6532,6541,6551,6560,6564],{"nctId":6510,"briefTitle":6511,"status":123,"phases":6512,"primaryCompletion":5830,"completion":6513,"start":5791,"enrollment":6514,"conditions":6515,"interventions":6517},"NCT03656562","Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients",[92],"2025-04-28",107,[6516],"Systemic Lupus Erythematosus (SLE)",[3112,6518,6519,6520],"VAY736 Placebo","CFZ533","CFZ533 Placebo",{"nctId":6522,"briefTitle":6523,"status":147,"phases":6524,"primaryCompletion":4221,"completion":6525,"start":6526,"enrollment":3475,"conditions":6527,"interventions":6528},"NCT03827798","Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa",[92],"2026-12-11","2019-02-27",[1811],[6519,6529,3090,6530,6531,3112],"LYS006","LOU064 25mg","LOU064 100mg",{"nctId":6533,"briefTitle":6534,"status":134,"phases":6535,"primaryCompletion":6536,"completion":6537,"start":6538,"enrollment":422,"conditions":6539,"interventions":6540},"NCT02038049","A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis",[92],"2015-05-05","2018-09-13","2013-12-20",[2983],[3112],{"nctId":6542,"briefTitle":6543,"status":123,"phases":6544,"primaryCompletion":6545,"completion":2183,"start":6546,"enrollment":6547,"conditions":6548,"interventions":6550},"NCT02962895","Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)",[92],"2020-06-30","2017-06-27",190,[6549],"Primary Sjogren Syndrome",[3112],{"nctId":6552,"briefTitle":6553,"status":123,"phases":6554,"primaryCompletion":6555,"completion":6555,"start":6556,"enrollment":34,"conditions":6557,"interventions":6559},"NCT02149420","PD of VAY736 in Patients With Primary Sjögren's Syndrome",[92],"2018-02-07","2014-05-23",[6558],"Primary Sjögren's Syndrome",[3112],{"nctId":3104,"briefTitle":3105,"status":134,"phases":6561,"primaryCompletion":3107,"completion":3108,"start":3109,"enrollment":2439,"conditions":6562,"interventions":6563},[92],[3100],[3112,3017],{"nctId":6565,"briefTitle":6566,"status":134,"phases":6567,"primaryCompletion":6568,"completion":6568,"start":6569,"enrollment":734,"conditions":6570,"interventions":6571},"NCT01930175","Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris",[92],"2019-09-25","2013-12-18",[2921],[3112],{"trials":6573,"activeCount":317,"soonestReadout":6587},[6574,6583,6592,6602],{"nctId":6575,"briefTitle":6576,"status":123,"phases":6577,"primaryCompletion":6578,"completion":5779,"start":6579,"enrollment":16,"conditions":6580,"interventions":6582},"NCT03217422","ADCC Mediated B-Cell dEpletion and BAFF-R Blockade",[92,93],"2023-12-28","2018-02-15",[6581],"Autoimmune Hepatitis",[3112],{"nctId":6584,"briefTitle":6585,"status":147,"phases":6586,"primaryCompletion":6587,"completion":6588,"start":6589,"enrollment":1798,"conditions":6590,"interventions":6591},"NCT05350072","Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome",[93],"2025-05-07","2026-06-02","2022-07-28",[5832],[3112],{"nctId":6593,"briefTitle":6594,"status":147,"phases":6595,"primaryCompletion":6596,"completion":6597,"start":6598,"enrollment":6599,"conditions":6600,"interventions":6601},"NCT05349214","Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome",[93],"2025-05-13","2027-05-13","2022-08-04",506,[5832],[3112],{"nctId":6603,"briefTitle":6604,"status":593,"phases":6605,"primaryCompletion":6606,"completion":6607,"start":1996,"enrollment":6608,"conditions":6609,"interventions":6611},"NCT07621809","Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden",[93],"2029-08-14","2033-08-13",570,[6610],"Sjögren´s Disease",[3112],{"trials":6613,"activeCount":103},[],{"trials":6615,"activeCount":103},[],{"intervention":235,"totalTrials":637,"cells":6617},{"EARLY_PHASE1":6618,"PHASE1":6620,"PHASE2":6630,"PHASE3":6662,"PHASE4":6674,"NA":6676},{"trials":6619,"activeCount":103},[],{"trials":6621,"activeCount":103},[6622],{"nctId":6623,"briefTitle":6624,"status":123,"phases":6625,"primaryCompletion":6626,"completion":6626,"start":6627,"enrollment":99,"conditions":6628,"interventions":6629},"NCT05329623","A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.",[91],"2024-04-07","2022-05-03",[2736],[235],{"trials":6631,"activeCount":317,"soonestReadout":6640},[6632,6636,6645],{"nctId":217,"briefTitle":218,"status":147,"phases":6633,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":6634,"interventions":6635},[91,92],[225,226,227,182,228,229,209,230,231,232,233],[235,156,98,236],{"nctId":6637,"briefTitle":6638,"status":147,"phases":6639,"primaryCompletion":6640,"completion":2286,"start":6641,"enrollment":167,"conditions":6642,"interventions":6644},"NCT05445843","Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression \u003C 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.",[92],"2024-11-04","2022-12-06",[6643],"Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression \u003C1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation",[235],{"nctId":6646,"briefTitle":6647,"status":147,"phases":6648,"primaryCompletion":6649,"completion":6649,"start":6650,"enrollment":6651,"conditions":6652,"interventions":6661},"NCT04699188","Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",[91,92],"2027-01-25","2021-02-24",344,[225,227,6653,6654,6655,6656,6657,6658,6659,6660],"Carcinoma, Colorectal","Cancer of Lung","Cancer of the Lung","Lung Cancer","Neoplasms, Lung","Neoplasms, Pulmonary","Pulmonary Cancer","Pulmonary Neoplasms",[235,211,1196],{"trials":6663,"activeCount":437,"soonestReadout":6668},[6664],{"nctId":6665,"briefTitle":6666,"status":147,"phases":6667,"primaryCompletion":6668,"completion":6669,"start":6670,"enrollment":167,"conditions":6671,"interventions":6672},"NCT05132075","Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer",[93],"2026-08-25","2026-09-23","2022-06-15",[182],[235,6673],"docetaxel",{"trials":6675,"activeCount":103},[],{"trials":6677,"activeCount":103},[],{"intervention":1615,"totalTrials":1630,"cells":6679},{"EARLY_PHASE1":6680,"PHASE1":6682,"PHASE2":6684,"PHASE3":6697,"PHASE4":6717,"NA":6719},{"trials":6681,"activeCount":103},[],{"trials":6683,"activeCount":103},[],{"trials":6685,"activeCount":213,"soonestReadout":5991},[6686,6690],{"nctId":1606,"briefTitle":1607,"status":109,"phases":6687,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":1611,"conditions":6688,"interventions":6689},[92],[1613],[1561,1615],{"nctId":6691,"briefTitle":6692,"status":147,"phases":6693,"primaryCompletion":5991,"completion":596,"start":2044,"enrollment":2149,"conditions":6694,"interventions":6695},"NCT05670106","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC",[92],[1613],[6696,1615],"[177Lu]Lu-PSMA-617",{"trials":6698,"activeCount":213,"soonestReadout":67},[6699,6708],{"nctId":65,"briefTitle":66,"status":147,"phases":6700,"primaryCompletion":67,"completion":6701,"start":6702,"enrollment":6703,"conditions":6704,"interventions":6706},[93],"2026-09-30","2021-06-15",469,[6705],"Prostatic Neoplasms",[68,1615,6707],"ARDT",{"nctId":6709,"briefTitle":6710,"status":147,"phases":6711,"primaryCompletion":6712,"completion":1474,"start":6713,"enrollment":6714,"conditions":6715,"interventions":6716},"NCT04720157","An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",[93],"2025-01-13","2021-06-09",1140,[6705],[68,1615,6707,1629],{"trials":6718,"activeCount":103},[],{"trials":6720,"activeCount":103},[],{"intervention":6722,"totalTrials":4148,"cells":6723},"LNP023",{"EARLY_PHASE1":6724,"PHASE1":6726,"PHASE2":6728,"PHASE3":6771,"PHASE4":6821,"NA":6823},{"trials":6725,"activeCount":103},[],{"trials":6727,"activeCount":103},[],{"trials":6729,"activeCount":103},[6730,6738,6747,6755,6763],{"nctId":6731,"briefTitle":6732,"status":123,"phases":6733,"primaryCompletion":6734,"completion":6734,"start":2199,"enrollment":5594,"conditions":6735,"interventions":6736},"NCT02534909","Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria",[92],"2022-05-24",[6026],[6737,6722],"LFG316",{"nctId":6739,"briefTitle":6740,"status":134,"phases":6741,"primaryCompletion":6742,"completion":6742,"start":6743,"enrollment":5612,"conditions":6744,"interventions":6746},"NCT04154787","Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy",[92],"2023-01-20","2019-11-23",[6745],"Idiopathic Membranous Nephropathy",[6722,2879],{"nctId":6748,"briefTitle":6749,"status":123,"phases":6750,"primaryCompletion":2488,"completion":2488,"start":6751,"enrollment":34,"conditions":6752,"interventions":6754},"NCT03832114","Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted",[92],"2019-02-20",[6753],"Glomerulonephritis",[6722],{"nctId":6756,"briefTitle":6757,"status":123,"phases":6758,"primaryCompletion":1221,"completion":6759,"start":6555,"enrollment":1034,"conditions":6760,"interventions":6762},"NCT03373461","Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation",[92],"2021-06-22",[6761],"IgA Nephropathy",[6722],{"nctId":6764,"briefTitle":6765,"status":123,"phases":6766,"primaryCompletion":2500,"completion":6767,"start":6768,"enrollment":734,"conditions":6769,"interventions":6770},"NCT03896152","Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria",[92],"2022-02-09","2019-04-05",[6026],[6722],{"trials":6772,"activeCount":317,"soonestReadout":6815},[6773,6783,6792,6803,6811],{"nctId":6774,"briefTitle":6775,"status":109,"phases":6776,"primaryCompletion":6777,"completion":6777,"start":6778,"enrollment":3420,"conditions":6779,"interventions":6782},"NCT03955445","Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN",[93],"2036-05-30","2019-10-03",[6780,6781],"C3 Glomerulopathy","Immune-complex-membranoproliferative Glomerulonephritis",[6722],{"nctId":6784,"briefTitle":6785,"status":109,"phases":6786,"primaryCompletion":6787,"completion":6788,"start":6789,"enrollment":138,"conditions":6790,"interventions":6791},"NCT06934967","Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients",[93],"2031-11-19","2031-12-19","2025-10-28",[6080],[6722],{"nctId":6793,"briefTitle":6794,"status":123,"phases":6795,"primaryCompletion":6796,"completion":6797,"start":6798,"enrollment":608,"conditions":6799,"interventions":6800},"NCT04558918","Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment",[93],"2022-09-26","2023-03-06","2021-01-25",[6080],[6722,6801,6802],"Eculizumab","Ravulizumab",{"nctId":6804,"briefTitle":6805,"status":123,"phases":6806,"primaryCompletion":6807,"completion":6807,"start":6798,"enrollment":6808,"conditions":6809,"interventions":6810},"NCT04578834","Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients",[93],"2025-09-19",518,[6761],[6722],{"nctId":6812,"briefTitle":6813,"status":147,"phases":6814,"primaryCompletion":6815,"completion":6815,"start":6816,"enrollment":6817,"conditions":6818,"interventions":6820},"NCT04557462","A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan\u002FLNP023 in Participants With Primary IgA Nephropathy",[93],"2030-12-04","2021-09-20",448,[6819],"Primary IgA Nephropathy",[6722],{"trials":6822,"activeCount":103},[],{"trials":6824,"activeCount":437,"soonestReadout":6829},[6825],{"nctId":6826,"briefTitle":6827,"status":109,"phases":6828,"primaryCompletion":6829,"completion":6829,"start":6830,"enrollment":4733,"conditions":6831,"interventions":6832},"NCT06931691","A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China",[],"2027-04-21","2025-06-10",[6026],[6722],{"intervention":1415,"totalTrials":2379,"cells":6834},{"EARLY_PHASE1":6835,"PHASE1":6837,"PHASE2":6845,"PHASE3":6847,"PHASE4":6879,"NA":6881},{"trials":6836,"activeCount":103},[],{"trials":6838,"activeCount":103},[6839],{"nctId":6840,"briefTitle":6841,"status":123,"phases":6842,"primaryCompletion":5298,"completion":5298,"start":6142,"enrollment":837,"conditions":6843,"interventions":6844},"NCT05026996","Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants",[91],[2625],[1415],{"trials":6846,"activeCount":103},[],{"trials":6848,"activeCount":1630,"soonestReadout":1408},[6849,6853,6863,6871],{"nctId":1405,"briefTitle":1406,"status":109,"phases":6850,"primaryCompletion":1408,"completion":1409,"start":1410,"enrollment":1411,"conditions":6851,"interventions":6852},[93],[1413],[1415,1356],{"nctId":6854,"briefTitle":6855,"status":109,"phases":6856,"primaryCompletion":6857,"completion":6857,"start":6858,"enrollment":6859,"conditions":6860,"interventions":6862},"NCT07517263","An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)",[93],"2030-01-09","2026-05-11",5700,[6861],"Cardiovascular Disease and Lipoprotein(a)",[1415],{"nctId":6864,"briefTitle":6865,"status":147,"phases":6866,"primaryCompletion":6867,"completion":6867,"start":6503,"enrollment":4506,"conditions":6868,"interventions":6870},"NCT05900141","An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)",[93],"2028-08-24",[6869],"Hyperlipoproteinemia (a)",[1415],{"nctId":6872,"briefTitle":6873,"status":109,"phases":6874,"primaryCompletion":6875,"completion":6875,"start":5864,"enrollment":6876,"conditions":6877,"interventions":6878},"NCT06875973","Pelacarsen Roll-over Extension Program",[93],"2030-12-08",599,[1371],[1415],{"trials":6880,"activeCount":103},[],{"trials":6882,"activeCount":103},[6883],{"nctId":6884,"briefTitle":6885,"status":491,"phases":6886,"conditions":6887,"interventions":6889},"NCT07000695","Managed Access Programs for TQJ230, Pelacarsen",[],[6888],"Atherosclerotic Cardiovascular Disease, ASCVD",[1415],{"intervention":6707,"totalTrials":317,"cells":6891},{"EARLY_PHASE1":6892,"PHASE1":6894,"PHASE2":6896,"PHASE3":6908,"PHASE4":6918,"NA":6920},{"trials":6893,"activeCount":103},[],{"trials":6895,"activeCount":103},[],{"trials":6897,"activeCount":437,"soonestReadout":6902},[6898],{"nctId":6899,"briefTitle":6900,"status":147,"phases":6901,"primaryCompletion":6902,"completion":6903,"start":6904,"enrollment":19,"conditions":6905,"interventions":6906},"NCT05658003","A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer",[92],"2024-12-02","2027-01-13","2023-05-05",[1613],[6696,6707,6907],"[68Ga]Ga-PSMA-11",{"trials":6909,"activeCount":213,"soonestReadout":67},[6910,6914],{"nctId":65,"briefTitle":66,"status":147,"phases":6911,"primaryCompletion":67,"completion":6701,"start":6702,"enrollment":6703,"conditions":6912,"interventions":6913},[93],[6705],[68,1615,6707],{"nctId":6709,"briefTitle":6710,"status":147,"phases":6915,"primaryCompletion":6712,"completion":1474,"start":6713,"enrollment":6714,"conditions":6916,"interventions":6917},[93],[6705],[68,1615,6707,1629],{"trials":6919,"activeCount":103},[],{"trials":6921,"activeCount":103},[],{"intervention":3231,"totalTrials":5594,"cells":6923},{"EARLY_PHASE1":6924,"PHASE1":6926,"PHASE2":6940,"PHASE3":6965,"PHASE4":6979,"NA":6990},{"trials":6925,"activeCount":103},[],{"trials":6927,"activeCount":103},[6928,6936],{"nctId":6929,"briefTitle":6930,"status":123,"phases":6931,"primaryCompletion":6932,"completion":3151,"start":6933,"enrollment":814,"conditions":6934,"interventions":6935},"NCT03605277","Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers",[91],"2019-03-18","2018-11-16",[2635],[3231],{"nctId":3220,"briefTitle":3221,"status":123,"phases":6937,"primaryCompletion":3223,"completion":3224,"start":3225,"enrollment":3226,"conditions":6938,"interventions":6939},[91],[3228,3229],[3231,2395,83,3232],{"trials":6941,"activeCount":437,"soonestReadout":6950},[6942,6946,6956],{"nctId":3284,"briefTitle":3285,"status":123,"phases":6943,"primaryCompletion":3119,"completion":3119,"start":3287,"enrollment":3288,"conditions":6944,"interventions":6945},[92],[2393],[2395,2395,3231],{"nctId":6947,"briefTitle":6948,"status":147,"phases":6949,"primaryCompletion":6950,"completion":6951,"start":6952,"enrollment":31,"conditions":6953,"interventions":6954},"NCT05384587","Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia",[92],"2025-08-13","2027-10-17","2022-11-11",[3345],[6955],"asciminib",{"nctId":6957,"briefTitle":6958,"status":123,"phases":6959,"primaryCompletion":6960,"completion":1504,"start":6961,"enrollment":5982,"conditions":6962,"interventions":6964},"NCT04795427","Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors",[92],"2023-05-29","2021-12-06",[6963],"Leukemia, Chronic Myelogenous",[6955],{"trials":6966,"activeCount":213,"soonestReadout":82},[6967,6971,6975],{"nctId":4217,"briefTitle":4218,"status":123,"phases":6968,"primaryCompletion":4220,"completion":4221,"start":4222,"enrollment":4223,"conditions":6969,"interventions":6970},[93],[3228],[3231,3395],{"nctId":80,"briefTitle":81,"status":147,"phases":6972,"primaryCompletion":82,"completion":3389,"start":3390,"enrollment":3391,"conditions":6973,"interventions":6974},[93],[3393],[83,2395,3395,3232,3231],{"nctId":3425,"briefTitle":3426,"status":147,"phases":6976,"primaryCompletion":3428,"completion":3429,"start":3430,"enrollment":1235,"conditions":6977,"interventions":6978},[93],[3432],[3231,2395],{"trials":6980,"activeCount":103},[6981],{"nctId":6982,"briefTitle":6983,"status":123,"phases":6984,"primaryCompletion":6985,"completion":6985,"start":6986,"enrollment":2685,"conditions":6987,"interventions":6989},"NCT06427811","Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation",[94],"2026-03-18","2024-11-28",[6988],"Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase",[3231],{"trials":6991,"activeCount":103},[6992],{"nctId":6993,"briefTitle":6994,"status":491,"phases":6995,"conditions":6996,"interventions":6998},"NCT04360005","Managed Access Programs for ABL001, Asciminib",[],[6997],"Chronic Myeloid Leukemia in Chronic Phase",[3231],{"intervention":7000,"totalTrials":1562,"cells":7001},"LOU064",{"EARLY_PHASE1":7002,"PHASE1":7004,"PHASE2":7015,"PHASE3":7026,"PHASE4":7070,"NA":7072},{"trials":7003,"activeCount":103},[],{"trials":7005,"activeCount":103},[7006],{"nctId":7007,"briefTitle":7008,"status":123,"phases":7009,"primaryCompletion":7010,"completion":7010,"start":7011,"enrollment":2910,"conditions":7012,"interventions":7014},"NCT03918980","Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064",[91],"2020-01-27","2016-08-18",[7013],"Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis",[7000],{"trials":7016,"activeCount":103},[7017],{"nctId":7018,"briefTitle":7019,"status":123,"phases":7020,"primaryCompletion":7021,"completion":7021,"start":7022,"enrollment":7023,"conditions":7024,"interventions":7025},"NCT04109313","An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU",[92],"2022-09-09","2019-10-24",229,[33],[7000],{"trials":7027,"activeCount":213,"soonestReadout":3095},[7028,7037,7045,7053,7062],{"nctId":7029,"briefTitle":7030,"status":123,"phases":7031,"primaryCompletion":7032,"completion":7033,"start":7034,"enrollment":1660,"conditions":7035,"interventions":7036},"NCT05048342","A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines",[93],"2023-12-08","2023-12-09","2022-01-15",[33],[7000],{"nctId":7038,"briefTitle":7039,"status":123,"phases":7040,"primaryCompletion":5001,"completion":7041,"start":1343,"enrollment":7042,"conditions":7043,"interventions":7044},"NCT05032157","A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines",[93],"2024-01-05",455,[33],[7000,7000],{"nctId":7046,"briefTitle":7047,"status":123,"phases":7048,"primaryCompletion":7049,"completion":7049,"start":7050,"enrollment":4082,"conditions":7051,"interventions":7052},"NCT05795153","A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.",[93],"2024-04-25","2023-04-05",[33],[7000],{"nctId":7054,"briefTitle":7055,"status":147,"phases":7056,"primaryCompletion":3095,"completion":7057,"start":7058,"enrollment":7059,"conditions":7060,"interventions":7061},"NCT05513001","An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib",[93],"2027-08-02","2022-12-09",696,[33],[7000,7000],{"nctId":7063,"briefTitle":7064,"status":109,"phases":7065,"primaryCompletion":7066,"completion":7067,"start":1443,"enrollment":1314,"conditions":7068,"interventions":7069},"NCT05677451","24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - \u003C18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up",[93],"2026-11-06","2032-03-30",[33],[7000],{"trials":7071,"activeCount":103},[],{"trials":7073,"activeCount":103},[],{"intervention":6188,"totalTrials":1630,"cells":7075},{"EARLY_PHASE1":7076,"PHASE1":7078,"PHASE2":7080,"PHASE3":7082,"PHASE4":7114,"NA":7116},{"trials":7077,"activeCount":103},[],{"trials":7079,"activeCount":103},[],{"trials":7081,"activeCount":103},[],{"trials":7083,"activeCount":213,"soonestReadout":6183},[7084,7088,7099,7103],{"nctId":6180,"briefTitle":6181,"status":147,"phases":7085,"primaryCompletion":6183,"completion":6184,"start":6185,"enrollment":5574,"conditions":7086,"interventions":7087},[93],[2778],[6111,6188],{"nctId":7089,"briefTitle":7090,"status":123,"phases":7091,"primaryCompletion":7092,"completion":7093,"start":7094,"enrollment":7095,"conditions":7096,"interventions":7097},"NCT02792218","Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis",[93],"2019-07-05","2020-07-20","2016-09-20",930,[2778],[7098,6188],"Ofatumumab subcutaneous",{"nctId":6231,"briefTitle":6181,"status":147,"phases":7100,"primaryCompletion":6183,"completion":6184,"start":6233,"enrollment":6234,"conditions":7101,"interventions":7102},[93],[2778],[6111,6188],{"nctId":7104,"briefTitle":7105,"status":123,"phases":7106,"primaryCompletion":7107,"completion":7108,"start":7109,"enrollment":7110,"conditions":7111,"interventions":7113},"NCT02792231","Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.",[93],"2019-07-10","2020-10-22","2016-08-26",955,[7112],"Relapsing Multiple Scelrosis",[7098,6188],{"trials":7115,"activeCount":103},[],{"trials":7117,"activeCount":103},[],{"intervention":7119,"totalTrials":213,"cells":7120},"Inclisiran sodium 300 mg",{"EARLY_PHASE1":7121,"PHASE1":7123,"PHASE2":7125,"PHASE3":7127,"PHASE4":7147,"NA":7149},{"trials":7122,"activeCount":103},[],{"trials":7124,"activeCount":103},[],{"trials":7126,"activeCount":103},[],{"trials":7128,"activeCount":213,"soonestReadout":7141},[7129,7137],{"nctId":7130,"briefTitle":7131,"status":147,"phases":7132,"primaryCompletion":7133,"completion":7133,"start":6142,"enrollment":7134,"conditions":7135,"interventions":7136},"NCT05030428","Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease",[93],"2027-10-13",17004,[1371],[7119],{"nctId":7138,"briefTitle":7139,"status":147,"phases":7140,"primaryCompletion":7141,"completion":7141,"start":7142,"enrollment":7143,"conditions":7144,"interventions":7146},"NCT05360446","Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events",[93],"2026-10-26","2022-07-08",608,[7145],"Coronary Artery Disease",[7119],{"trials":7148,"activeCount":103},[],{"trials":7150,"activeCount":103},[],{"intervention":7152,"totalTrials":213,"cells":7153},"Votoplam",{"EARLY_PHASE1":7154,"PHASE1":7156,"PHASE2":7158,"PHASE3":7169,"PHASE4":7181,"NA":7183},{"trials":7155,"activeCount":103},[],{"trials":7157,"activeCount":103},[],{"trials":7159,"activeCount":437,"soonestReadout":7164},[7160],{"nctId":7161,"briefTitle":7162,"status":147,"phases":7163,"primaryCompletion":7164,"completion":7164,"start":7165,"enrollment":4082,"conditions":7166,"interventions":7168},"NCT06254482","An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)",[92],"2029-07-16","2023-08-25",[7167],"Huntington Disease",[7152],{"trials":7170,"activeCount":437,"soonestReadout":7175},[7171],{"nctId":7172,"briefTitle":7173,"status":109,"phases":7174,"primaryCompletion":7175,"completion":7176,"start":7177,"enrollment":7178,"conditions":7179,"interventions":7180},"NCT07326709","A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease",[93],"2030-04-02","2030-04-30","2026-03-24",770,[7167],[7152],{"trials":7182,"activeCount":103},[],{"trials":7184,"activeCount":103},[],{"intervention":7186,"totalTrials":213,"cells":7187},"Remibrutinib Dose A",{"EARLY_PHASE1":7188,"PHASE1":7190,"PHASE2":7192,"PHASE3":7194,"PHASE4":7215,"NA":7217},{"trials":7189,"activeCount":103},[],{"trials":7191,"activeCount":103},[],{"trials":7193,"activeCount":103},[],{"trials":7195,"activeCount":213,"soonestReadout":1276},[7196,7206],{"nctId":7197,"briefTitle":7198,"status":147,"phases":7199,"primaryCompletion":1276,"completion":7200,"start":7201,"enrollment":7202,"conditions":7203,"interventions":7204},"NCT06799000","A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)",[93],"2027-10-04","2025-01-31",588,[1811],[7186,7205],"Remibrutinib Dose B",{"nctId":7207,"briefTitle":7208,"status":109,"phases":7209,"primaryCompletion":7210,"completion":7211,"start":7212,"enrollment":1849,"conditions":7213,"interventions":7214},"NCT06840392","A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa",[93],"2027-10-29","2028-02-07","2025-03-20",[1811],[7186,7205],{"trials":7216,"activeCount":103},[],{"trials":7218,"activeCount":103},[],{"intervention":7205,"totalTrials":213,"cells":7220},{"EARLY_PHASE1":7221,"PHASE1":7223,"PHASE2":7225,"PHASE3":7227,"PHASE4":7237,"NA":7239},{"trials":7222,"activeCount":103},[],{"trials":7224,"activeCount":103},[],{"trials":7226,"activeCount":103},[],{"trials":7228,"activeCount":213,"soonestReadout":1276},[7229,7233],{"nctId":7197,"briefTitle":7198,"status":147,"phases":7230,"primaryCompletion":1276,"completion":7200,"start":7201,"enrollment":7202,"conditions":7231,"interventions":7232},[93],[1811],[7186,7205],{"nctId":7207,"briefTitle":7208,"status":109,"phases":7234,"primaryCompletion":7210,"completion":7211,"start":7212,"enrollment":1849,"conditions":7235,"interventions":7236},[93],[1811],[7186,7205],{"trials":7238,"activeCount":103},[],{"trials":7240,"activeCount":103},[],{"intervention":7242,"totalTrials":213,"cells":7243},"zigakibart",{"EARLY_PHASE1":7244,"PHASE1":7246,"PHASE2":7248,"PHASE3":7261,"PHASE4":7278,"NA":7280},{"trials":7245,"activeCount":103},[],{"trials":7247,"activeCount":103},[],{"trials":7249,"activeCount":437,"soonestReadout":7254},[7250],{"nctId":7251,"briefTitle":7252,"status":109,"phases":7253,"primaryCompletion":7254,"completion":7255,"start":7256,"enrollment":7257,"conditions":7258,"interventions":7260},"NCT07146906","A Study to Assess the Effects of Zigakibart on IgA Nephropathy.",[92],"2030-07-12","2030-10-18","2026-03-26",32,[7259],"Immunoglobulin A Nephropathy (IgAN)",[7242],{"trials":7262,"activeCount":437,"soonestReadout":7267},[7263],{"nctId":7264,"briefTitle":7265,"status":109,"phases":7266,"primaryCompletion":7267,"completion":7267,"start":7268,"enrollment":7269,"conditions":7270,"interventions":7277},"NCT06858319","Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.",[93],"2031-06-25","2025-07-28",220,[7271,7272,7273,6753,7274,5970,7275,7276],"Kidney Diseases","Kidney Diseases, Chronic","Urological Diseases","Glomerular Disease","Glomerulopathy","Immunoglobulin Disease",[7242],{"trials":7279,"activeCount":103},[],{"trials":7281,"activeCount":103},[],{"intervention":68,"totalTrials":213,"cells":7283},{"EARLY_PHASE1":7284,"PHASE1":7286,"PHASE2":7288,"PHASE3":7290,"PHASE4":7300,"NA":7302},{"trials":7285,"activeCount":103},[],{"trials":7287,"activeCount":103},[],{"trials":7289,"activeCount":103},[],{"trials":7291,"activeCount":213,"soonestReadout":67},[7292,7296],{"nctId":65,"briefTitle":66,"status":147,"phases":7293,"primaryCompletion":67,"completion":6701,"start":6702,"enrollment":6703,"conditions":7294,"interventions":7295},[93],[6705],[68,1615,6707],{"nctId":6709,"briefTitle":6710,"status":147,"phases":7297,"primaryCompletion":6712,"completion":1474,"start":6713,"enrollment":6714,"conditions":7298,"interventions":7299},[93],[6705],[68,1615,6707,1629],{"trials":7301,"activeCount":103},[],{"trials":7303,"activeCount":103},[],{"intervention":1629,"totalTrials":213,"cells":7305},{"EARLY_PHASE1":7306,"PHASE1":7308,"PHASE2":7310,"PHASE3":7316,"PHASE4":7322,"NA":7324},{"trials":7307,"activeCount":103},[],{"trials":7309,"activeCount":103},[],{"trials":7311,"activeCount":437,"soonestReadout":1620},[7312],{"nctId":1617,"briefTitle":1618,"status":147,"phases":7313,"primaryCompletion":1620,"completion":1620,"start":1621,"enrollment":1622,"conditions":7314,"interventions":7315},[92],[1624],[1561,1626,1627,1628,1629],{"trials":7317,"activeCount":437,"soonestReadout":6712},[7318],{"nctId":6709,"briefTitle":6710,"status":147,"phases":7319,"primaryCompletion":6712,"completion":1474,"start":6713,"enrollment":6714,"conditions":7320,"interventions":7321},[93],[6705],[68,1615,6707,1629],{"trials":7323,"activeCount":103},[],{"trials":7325,"activeCount":103},[],{"intervention":1628,"totalTrials":213,"cells":7327},{"EARLY_PHASE1":7328,"PHASE1":7330,"PHASE2":7332,"PHASE3":7338,"PHASE4":7344,"NA":7346},{"trials":7329,"activeCount":103},[],{"trials":7331,"activeCount":103},[],{"trials":7333,"activeCount":437,"soonestReadout":1620},[7334],{"nctId":1617,"briefTitle":1618,"status":147,"phases":7335,"primaryCompletion":1620,"completion":1620,"start":1621,"enrollment":1622,"conditions":7336,"interventions":7337},[92],[1624],[1561,1626,1627,1628,1629],{"trials":7339,"activeCount":437,"soonestReadout":3163},[7340],{"nctId":3160,"briefTitle":3161,"status":109,"phases":7341,"primaryCompletion":3163,"completion":3164,"start":3165,"enrollment":3166,"conditions":7342,"interventions":7343},[93],[1654],[3169,1628,3017],{"trials":7345,"activeCount":103},[],{"trials":7347,"activeCount":103},[],{"intervention":3169,"totalTrials":213,"cells":7349},{"EARLY_PHASE1":7350,"PHASE1":7352,"PHASE2":7354,"PHASE3":7356,"PHASE4":7373,"NA":7375},{"trials":7351,"activeCount":103},[],{"trials":7353,"activeCount":103},[],{"trials":7355,"activeCount":103},[],{"trials":7357,"activeCount":213,"soonestReadout":7362},[7358,7369],{"nctId":7359,"briefTitle":7360,"status":109,"phases":7361,"primaryCompletion":7362,"completion":7363,"start":7364,"enrollment":7365,"conditions":7366,"interventions":7367},"NCT06780670","Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy",[92,93],"2028-06-27","2033-07-19","2025-02-27",443,[1654],[7368,3169,3169,3169],"Investigators choice of SoC",{"nctId":3160,"briefTitle":3161,"status":109,"phases":7370,"primaryCompletion":3163,"completion":3164,"start":3165,"enrollment":3166,"conditions":7371,"interventions":7372},[93],[1654],[3169,1628,3017],{"trials":7374,"activeCount":103},[],{"trials":7376,"activeCount":103},[],{"intervention":5895,"totalTrials":3343,"cells":7378},{"EARLY_PHASE1":7379,"PHASE1":7381,"PHASE2":7383,"PHASE3":7492,"PHASE4":7528,"NA":7538},{"trials":7380,"activeCount":103},[],{"trials":7382,"activeCount":103},[],{"trials":7384,"activeCount":437,"soonestReadout":7448},[7385,7393,7404,7416,7424,7431,7444,7453,7462,7473,7483],{"nctId":7386,"briefTitle":7387,"status":123,"phases":7388,"primaryCompletion":7389,"completion":7389,"start":7390,"enrollment":37,"conditions":7391,"interventions":7392},"NCT04346654","A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP",[92],"2023-09-22","2020-10-09",[5994],[5895,5747],{"nctId":7394,"briefTitle":7395,"status":123,"phases":7396,"primaryCompletion":7397,"completion":7398,"start":7399,"enrollment":151,"conditions":7400,"interventions":7402},"NCT03524612","A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP",[92],"2021-10-22","2022-10-03","2018-11-02",[7401],"Immune Thrombocytopenic Purpura (ITP)",[7403],"eltrombopag",{"nctId":7405,"briefTitle":7406,"status":123,"phases":7407,"primaryCompletion":7408,"completion":7409,"start":7410,"enrollment":5594,"conditions":7411,"interventions":7413},"NCT02404025","Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin\u002FCyclosporine A in Naive Aplastic Anemia (AA) Subjects",[92],"2016-07-05","2017-09-06","2015-05-12",[7412],"Aplastic Anemia",[5895,7414,7415],"Rabbit ATG","CsA",{"nctId":7417,"briefTitle":7418,"status":134,"phases":7419,"primaryCompletion":7420,"completion":7420,"start":3042,"enrollment":5594,"conditions":7421,"interventions":7423},"NCT03718533","Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function",[92],"2020-11-03",[7422],"Poor Graft Function",[5895],{"nctId":7425,"briefTitle":7426,"status":123,"phases":7427,"primaryCompletion":2509,"completion":2762,"start":1818,"enrollment":3705,"conditions":7428,"interventions":7430},"NCT01440374","A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia",[92],[7429],"Thrombocytopaenia",[7403],{"nctId":7432,"briefTitle":7433,"status":123,"phases":7434,"primaryCompletion":7435,"completion":7436,"start":7437,"enrollment":7438,"conditions":7439,"interventions":7441},"NCT01890746","A Safety and Efficacy Study of Eltrombopag in Subjects With AML",[92],"2015-03-13","2017-01-25","2013-09-05",148,[7440],"Acute Leukaemia",[7442,7443,5895],"Daunorubicin","Cytarabine",{"nctId":7445,"briefTitle":7446,"status":147,"phases":7447,"primaryCompletion":7448,"completion":7449,"start":7450,"enrollment":792,"conditions":7451,"interventions":7452},"NCT04797000","Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence",[92],"2025-04-26","2026-12-09","2021-05-25",[5723],[5895],{"nctId":7454,"briefTitle":7455,"status":123,"phases":7456,"primaryCompletion":7457,"completion":7458,"start":7459,"enrollment":1611,"conditions":7460,"interventions":7461},"NCT03988608","Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.",[92],"2021-07-16","2023-05-17","2019-12-09",[7412],[5895],{"nctId":7463,"briefTitle":7464,"status":123,"phases":7465,"primaryCompletion":7466,"completion":7467,"start":7468,"enrollment":792,"conditions":7469,"interventions":7471},"NCT04328727","Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia",[92],"2022-06-10","2024-12-06","2020-11-04",[7470],"Severe Aplastic Anemia (SAA)",[7403,7472,5074],"rabbit anti-thymocyte globulin",{"nctId":7474,"briefTitle":7475,"status":123,"phases":7476,"primaryCompletion":7477,"completion":7478,"start":7479,"enrollment":2428,"conditions":7480,"interventions":7481},"NCT03025698","A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia",[92],"2022-04-22","2025-01-27","2017-09-30",[7412],[5895,7482,7415],"hATG",{"nctId":7484,"briefTitle":7485,"status":123,"phases":7486,"primaryCompletion":7420,"completion":7487,"start":7488,"enrollment":271,"conditions":7489,"interventions":7491},"NCT02998645","Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia",[92],"2022-05-30","2017-05-11",[7490],"Severe Aplastic Anemia",[7403,4875],{"trials":7493,"activeCount":437,"soonestReadout":5890},[7494,7504,7514,7518],{"nctId":7495,"briefTitle":7496,"status":123,"phases":7497,"primaryCompletion":7498,"completion":3331,"start":7499,"enrollment":7500,"conditions":7501,"interventions":7503},"NCT01762761","Eltrombopag Phase III Study In Chinese Chronic ITP Patients",[93],"2014-06-05","2013-02-18",155,[7502],"Purpura, Thrombocytopenic, Idiopathic and Hepatitis C",[7403],{"nctId":7505,"briefTitle":7506,"status":134,"phases":7507,"primaryCompletion":7508,"completion":7508,"start":7509,"enrollment":7510,"conditions":7511,"interventions":7512},"NCT02158936","A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)",[93],"2016-04-30","2014-06-10",356,[7429],[5895,7513],"Azacitidine",{"nctId":5887,"briefTitle":5888,"status":147,"phases":7515,"primaryCompletion":5890,"completion":5891,"start":2416,"enrollment":5892,"conditions":7516,"interventions":7517},[93],[5811],[5769,5895],{"nctId":7519,"briefTitle":7520,"status":123,"phases":7521,"primaryCompletion":7522,"completion":7522,"start":7523,"enrollment":1495,"conditions":7524,"interventions":7526},"NCT02201290","A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",[93],"2017-07-04","2013-06-18",[7525],"Purpura, Thrombocytopenic, Idiopathic",[5895,7527],"Eltrombopag PfOS",{"trials":7529,"activeCount":103},[7530],{"nctId":7531,"briefTitle":7532,"status":123,"phases":7533,"primaryCompletion":7534,"completion":7534,"start":7535,"enrollment":2633,"conditions":7536,"interventions":7537},"NCT01957176","A Rollover Study to Provide Continued Treatment With Eltrombopag",[94],"2022-02-23","2013-10-15",[7429],[5895],{"trials":7539,"activeCount":103},[7540,7547],{"nctId":7541,"briefTitle":7542,"status":491,"phases":7543,"conditions":7544,"interventions":7546},"NCT04837703","Managed Access Programs for ETB115, Eltrombopag",[],[7545],"Thrombocytopenia",[5895],{"nctId":7548,"briefTitle":7549,"status":123,"phases":7550,"primaryCompletion":7551,"completion":7551,"start":7552,"enrollment":7553,"conditions":7554,"interventions":7556},"NCT01416311","Drug Use Investigation for REVOLADE (ITP)",[],"2020-10-16","2010-12-21",5797,[7555],"Purpura, Thrombocytopaenic, Idiopathic",[5895],{"intervention":7558,"totalTrials":637,"cells":7559},"CTL019",{"EARLY_PHASE1":7560,"PHASE1":7562,"PHASE2":7564,"PHASE3":7585,"PHASE4":7601,"NA":7603},{"trials":7561,"activeCount":103},[],{"trials":7563,"activeCount":103},[],{"trials":7565,"activeCount":437,"soonestReadout":7570},[7566,7575],{"nctId":7567,"briefTitle":7568,"status":147,"phases":7569,"primaryCompletion":7570,"completion":7570,"start":2487,"enrollment":7571,"conditions":7572,"interventions":7574},"NCT03876769","Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients",[92],"2027-10-19",121,[7573],"B-Cell Acute Lymphoblastic Leukemia",[7558],{"nctId":7576,"briefTitle":7577,"status":123,"phases":7578,"primaryCompletion":7579,"completion":7580,"start":7581,"enrollment":4733,"conditions":7582,"interventions":7584},"NCT02435849","Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients",[92],"2020-01-21","2022-11-17","2015-04-08",[7583],"B-cell Acute Lymphoblastic Leukemia",[7558],{"trials":7586,"activeCount":437,"soonestReadout":5839},[7587,7594],{"nctId":7588,"briefTitle":7589,"status":109,"phases":7590,"primaryCompletion":5839,"completion":5839,"start":7591,"enrollment":919,"conditions":7592,"interventions":7593},"NCT04094311","Study of Out of Specification for Tisagenlecleucel",[93],"2019-11-21",[7583,4681],[7558],{"nctId":7595,"briefTitle":7596,"status":123,"phases":7597,"primaryCompletion":7598,"completion":7598,"start":2898,"enrollment":557,"conditions":7599,"interventions":7600},"NCT03123939","Phase III B in Acute Lymphoblastic Leukemia",[93],"2020-10-13",[3204],[7558],{"trials":7602,"activeCount":103},[],{"trials":7604,"activeCount":103},[7605],{"nctId":7606,"briefTitle":7607,"status":491,"phases":7608,"conditions":7609,"interventions":7612},"NCT03601442","Managed Access Programs for CTL019, Tisagenlecleucel",[],[7610,3422,7611],"Lymphoma","Off-label Indications",[7558],{"intervention":4769,"totalTrials":1065,"cells":7614},{"EARLY_PHASE1":7615,"PHASE1":7617,"PHASE2":7619,"PHASE3":7652,"PHASE4":7686,"NA":7741},{"trials":7616,"activeCount":103},[],{"trials":7618,"activeCount":103},[],{"trials":7620,"activeCount":103},[7621,7629,7638],{"nctId":7622,"briefTitle":7623,"status":123,"phases":7624,"primaryCompletion":7625,"completion":7625,"start":542,"enrollment":3322,"conditions":7626,"interventions":7627},"NCT02217410","CCFZ533X2201 - PoC Study in de Novo Renal Transplantation",[91,92],"2017-11-29",[4691],[6519,4765,4768,4769,7628],"anti-IL2 Induction",{"nctId":7630,"briefTitle":7631,"status":123,"phases":7632,"primaryCompletion":4967,"completion":4967,"start":2795,"enrollment":1672,"conditions":7633,"interventions":7634},"NCT01596062","Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)",[92],[4701],[4755,7635,7636,7637,4769],"Neoral®","Certican®","Myfortic®",{"nctId":7639,"briefTitle":7640,"status":123,"phases":7641,"primaryCompletion":483,"completion":483,"start":7642,"enrollment":7643,"conditions":7644,"interventions":7645},"NCT03663335","Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients",[92],"2018-11-28",418,[4691],[7646,7647,4769,4765,7648,7649,7650,7651],"CFZ533 - Cohort 1\u002FCohort 2","Mycophenolate Mofetil","Induction therapy: basiliximab","Induction therapy: rabbit anti-thymocyte globulin","Maintenance population: EC-MPS","Maintenance population: MMF",{"trials":7653,"activeCount":437,"soonestReadout":5548},[7654,7658,7666,7670,7674,7678,7682],{"nctId":4617,"briefTitle":4618,"status":123,"phases":7655,"primaryCompletion":4620,"completion":4620,"start":4621,"enrollment":4622,"conditions":7656,"interventions":7657},[93],[4624],[4305,4626,4627,4628],{"nctId":7659,"briefTitle":7660,"status":123,"phases":7661,"primaryCompletion":4524,"completion":4524,"start":4975,"enrollment":524,"conditions":7662,"interventions":7664},"NCT01079143","Progression of Renal Interstitial Fibrosis \u002F Tubular Atrophy (IF\u002FTA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients",[93],[7663],"Renal Interstitial Fibrosis",[7636,7665,4753,4755,4769],"Neoral",{"nctId":5868,"briefTitle":5869,"status":147,"phases":7667,"primaryCompletion":5548,"completion":5871,"start":5872,"enrollment":1879,"conditions":7668,"interventions":7669},[93],[5822],[5769,4769],{"nctId":4757,"briefTitle":4758,"status":123,"phases":7671,"primaryCompletion":4760,"completion":4760,"start":4761,"enrollment":4762,"conditions":7672,"interventions":7673},[93],[4691,4701],[196,4765,4766,4767,4768,4769,4770],{"nctId":4791,"briefTitle":4792,"status":123,"phases":7675,"primaryCompletion":607,"completion":607,"start":917,"enrollment":4794,"conditions":7676,"interventions":7677},[93],[4645],[4765,4765,4765,196,196,4769],{"nctId":4798,"briefTitle":4799,"status":123,"phases":7679,"primaryCompletion":2509,"completion":2509,"start":3604,"enrollment":3120,"conditions":7680,"interventions":7681},[93],[4645],[4803,4305,4804,4805,4769],{"nctId":4906,"briefTitle":4907,"status":123,"phases":7683,"primaryCompletion":4909,"completion":4909,"start":4910,"enrollment":4911,"conditions":7684,"interventions":7685},[93],[4913],[4765,196,4765,196,4765,4769],{"trials":7687,"activeCount":103},[7688,7692,7696,7700,7704,7712,7716,7733,7737],{"nctId":4955,"briefTitle":4956,"status":123,"phases":7689,"primaryCompletion":4958,"completion":4958,"start":4959,"enrollment":4960,"conditions":7690,"interventions":7691},[94],[4645],[196,4765,4769],{"nctId":4964,"briefTitle":4965,"status":134,"phases":7693,"primaryCompletion":4967,"completion":4967,"start":918,"enrollment":1016,"conditions":7694,"interventions":7695},[94],[4701],[196,4766,4765,4970,4769],{"nctId":4989,"briefTitle":4990,"status":123,"phases":7697,"primaryCompletion":3604,"completion":3604,"start":4335,"enrollment":4992,"conditions":7698,"interventions":7699},[94],[4994],[4875,4768,4769,196,4996],{"nctId":5016,"briefTitle":5017,"status":123,"phases":7701,"primaryCompletion":1682,"completion":1682,"start":3271,"enrollment":792,"conditions":7702,"interventions":7703},[94],[5020],[196,4765,4804,4767,4769],{"nctId":7705,"briefTitle":7706,"status":134,"phases":7707,"primaryCompletion":4967,"completion":4967,"start":4845,"enrollment":1444,"conditions":7708,"interventions":7709},"NCT00956293","Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program",[94],[4701],[4804,7710,7711,4766,4769],"Enteric Coated Mycophenolic Acid","RAD001",{"nctId":5067,"briefTitle":5068,"status":123,"phases":7713,"primaryCompletion":5070,"completion":5070,"start":5071,"enrollment":3705,"conditions":7714,"interventions":7715},[94],[4744],[196,5074,4803,5075,4626,4769],{"nctId":7717,"briefTitle":7718,"status":123,"phases":7719,"primaryCompletion":7720,"completion":7721,"start":7722,"enrollment":7723,"conditions":7724,"interventions":7729},"NCT01950819","Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)",[94],"2017-02-01","2018-01-17","2013-12-03",2037,[7725,7726,7727,7728,4701],"End Stage Renal Disease (ESRD)","Chronic Kidney Disease (CKD)","Hemodialysis","Renal Replacement Therapy",[7730,4769,7731,7732],"Induction therapy","EVR+rCNI","MPA+sCNI",{"nctId":5111,"briefTitle":5112,"status":123,"phases":7734,"primaryCompletion":5114,"completion":5114,"start":1025,"enrollment":1941,"conditions":7735,"interventions":7736},[94],[5116],[4305,5074,4767,4628,4804],{"nctId":5128,"briefTitle":5129,"status":123,"phases":7738,"primaryCompletion":5131,"completion":5131,"start":5132,"enrollment":167,"conditions":7739,"interventions":7740},[94],[4744],[196,4875,4768,4769],{"trials":7742,"activeCount":103},[],{"intervention":195,"totalTrials":138,"cells":7744},{"EARLY_PHASE1":7745,"PHASE1":7747,"PHASE2":7757,"PHASE3":7779,"PHASE4":7797,"NA":7808},{"trials":7746,"activeCount":103},[],{"trials":7748,"activeCount":103},[7749,7753],{"nctId":4355,"briefTitle":4356,"status":123,"phases":7750,"primaryCompletion":4358,"completion":4358,"start":4359,"enrollment":4360,"conditions":7751,"interventions":7752},[91],[4362,559,4363,4364],[4366,4305,4367],{"nctId":186,"briefTitle":187,"status":123,"phases":7754,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":7755,"interventions":7756},[91],[15],[157,195,196],{"trials":7758,"activeCount":103},[7759,7763,7767,7771,7775],{"nctId":4442,"briefTitle":4443,"status":123,"phases":7760,"primaryCompletion":4445,"completion":4446,"start":4447,"enrollment":4448,"conditions":7761,"interventions":7762},[92],[15],[4451,195,196],{"nctId":751,"briefTitle":752,"status":123,"phases":7764,"primaryCompletion":754,"completion":755,"start":756,"enrollment":757,"conditions":7765,"interventions":7766},[92],[759],[196,249,195,761,762],{"nctId":4511,"briefTitle":4512,"status":123,"phases":7768,"primaryCompletion":4514,"completion":4514,"start":4515,"enrollment":4516,"conditions":7769,"interventions":7770},[92],[375],[4519,196,195],{"nctId":4579,"briefTitle":4580,"status":123,"phases":7772,"primaryCompletion":241,"completion":241,"start":4582,"enrollment":4583,"conditions":7773,"interventions":7774},[92],[375],[196,195,4586],{"nctId":309,"briefTitle":310,"status":123,"phases":7776,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":7777,"interventions":7778},[91,92],[15],[98,196,195],{"trials":7780,"activeCount":437,"soonestReadout":324},[7781,7785,7789,7793],{"nctId":4630,"briefTitle":4631,"status":123,"phases":7782,"primaryCompletion":4633,"completion":4633,"start":4634,"enrollment":4635,"conditions":7783,"interventions":7784},[93],[15],[196,195,4586],{"nctId":4666,"briefTitle":4667,"status":123,"phases":7786,"primaryCompletion":4669,"completion":4669,"start":4524,"enrollment":4670,"conditions":7787,"interventions":7788},[93],[435],[195,196],{"nctId":321,"briefTitle":322,"status":109,"phases":7790,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":7791,"interventions":7792},[93],[329],[98,249,331,250,332,195],{"nctId":4885,"briefTitle":4886,"status":123,"phases":7794,"primaryCompletion":4888,"completion":4888,"start":3529,"enrollment":2057,"conditions":7795,"interventions":7796},[93],[4890],[4305,4367],{"trials":7798,"activeCount":103},[7799],{"nctId":7800,"briefTitle":7801,"status":123,"phases":7802,"primaryCompletion":7803,"completion":7803,"start":7804,"enrollment":3605,"conditions":7805,"interventions":7807},"NCT01743560","An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis",[94],"2016-08-15","2013-01-31",[7806],"Oestrogen Receptor Positive Advanced Breast Cancer",[7711,195],{"trials":7809,"activeCount":103},[],{"intervention":7811,"totalTrials":317,"cells":7812},"Budesonide",{"EARLY_PHASE1":7813,"PHASE1":7815,"PHASE2":7817,"PHASE3":7819,"PHASE4":7830,"NA":7852},{"trials":7814,"activeCount":103},[],{"trials":7816,"activeCount":103},[],{"trials":7818,"activeCount":103},[],{"trials":7820,"activeCount":437,"soonestReadout":7825},[7821],{"nctId":7822,"briefTitle":7823,"status":109,"phases":7824,"primaryCompletion":7825,"completion":7826,"start":7827,"enrollment":919,"conditions":7828,"interventions":7829},"NCT05562466","A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate\u002FMometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma",[93],"2028-02-01","2028-05-30","2023-05-11",[18],[3057,7811],{"trials":7831,"activeCount":103},[7832,7843],{"nctId":7833,"briefTitle":7834,"status":134,"phases":7835,"primaryCompletion":7836,"completion":7837,"start":7838,"enrollment":1034,"conditions":7839,"interventions":7841},"NCT01912872","Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma",[94],"2015-08-06","2016-01-08","2013-11-11",[7840],"Severe IgE-mediated Asthma",[6218,7811,7842,7811,7842],"Formoterol",{"nctId":7844,"briefTitle":7845,"status":123,"phases":7846,"primaryCompletion":5246,"completion":5246,"start":4925,"enrollment":258,"conditions":7847,"interventions":7848},"NCT02055352","Study to Evaluate Efficacy\u002FSafety of Combination Budesonide\u002FIndacaterol vs Fluticasone\u002FSalmeterol in Patients With COPD",[94],[24],[7811,7849,7850,7851],"Fluticasone","Indacaterol","Salmeterol",{"trials":7853,"activeCount":103},[],{"intervention":4320,"totalTrials":1611,"cells":7855},{"EARLY_PHASE1":7856,"PHASE1":7858,"PHASE2":7896,"PHASE3":7943,"PHASE4":8025,"NA":8027},{"trials":7857,"activeCount":103},[],{"trials":7859,"activeCount":103},[7860,7873,7877,7887],{"nctId":7861,"briefTitle":7862,"status":123,"phases":7863,"primaryCompletion":7864,"completion":7865,"start":7866,"enrollment":827,"conditions":7867,"interventions":7869},"NCT00367471","Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.",[91],"2010-12-22","2019-09-12","2006-12-07",[7868],"Neoplasms, Breast",[7870,7871,4780,7872],"lapatinib","carboplatin","paclitaxel",{"nctId":4314,"briefTitle":4315,"status":123,"phases":7874,"primaryCompletion":4093,"completion":4093,"start":4317,"enrollment":534,"conditions":7875,"interventions":7876},[91],[435],[196,4320,4321],{"nctId":7878,"briefTitle":7879,"status":123,"phases":7880,"primaryCompletion":7881,"completion":7881,"start":7882,"enrollment":2776,"conditions":7883,"interventions":7885},"NCT01602406","Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer",[91],"2017-08-02","2012-09-21",[7884],"Advanced HER2-positive Breast Cancer or Gastric Cancer",[7886,4320],"LJM716",{"nctId":7888,"briefTitle":7889,"status":123,"phases":7890,"primaryCompletion":3845,"start":3552,"enrollment":2367,"conditions":7891,"interventions":7893},"NCT00788931","A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer",[91],[7892,435],"HER-2 Positive Breast Cancer",[7894,7895,4780,7872],"IV LBH589","Oral LBH589",{"trials":7897,"activeCount":103},[7898,7907,7914,7918,7927,7935],{"nctId":7899,"briefTitle":7900,"status":134,"phases":7901,"primaryCompletion":7902,"completion":7902,"start":7903,"enrollment":25,"conditions":7904,"interventions":7905},"NCT02213042","Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer",[92],"2020-06-04","2014-10-24",[7868],[944,4320,7906],"Aromatase Inhibitors",{"nctId":7908,"briefTitle":7909,"status":134,"phases":7910,"primaryCompletion":1682,"completion":1682,"start":3800,"enrollment":4118,"conditions":7911,"interventions":7912},"NCT01402401","Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients",[92],[4439],[7913,4320],"AUY922",{"nctId":5678,"briefTitle":5679,"status":134,"phases":7915,"primaryCompletion":3784,"completion":3784,"start":4070,"enrollment":5681,"conditions":7916,"interventions":7917},[91,92],[15],[4391,4320],{"nctId":7919,"briefTitle":7920,"status":123,"phases":7921,"primaryCompletion":2391,"completion":2391,"start":7922,"enrollment":2579,"conditions":7923,"interventions":7925},"NCT01816594","NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer",[92],"2013-09-03",[7924],"HER2-positive Newly Diagnosed, Primary Breast Cancer",[517,4320,4321,7926],"BKM120 Placebo",{"nctId":7928,"briefTitle":7929,"status":123,"phases":7930,"primaryCompletion":813,"completion":813,"start":7931,"enrollment":2405,"conditions":7932,"interventions":7934},"NCT01271920","Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab",[91,92],"2010-09",[7933],"Advanced HER2-positive Breast Cancer",[7913,4320],{"nctId":7936,"briefTitle":7937,"status":134,"phases":7938,"primaryCompletion":7939,"completion":7939,"start":853,"enrollment":774,"conditions":7940,"interventions":7942},"NCT01132664","Phase 1b\u002F2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer",[91,92],"2014-08",[435,7941],"HER2+ Breast Cancer",[517,4320,4451],{"trials":7944,"activeCount":437,"soonestReadout":627},[7945,7956,7967,7977,7987,7991,7999,8003,8012,8016],{"nctId":7946,"briefTitle":7947,"status":123,"phases":7948,"primaryCompletion":7949,"completion":939,"start":7950,"enrollment":7951,"conditions":7952,"interventions":7954},"NCT00820222","Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer",[93],"2012-06-11","2009-04-14",540,[7953],"Metastases, Brain",[7955,7870,4780],"capecitabine",{"nctId":7957,"briefTitle":7958,"status":123,"phases":7959,"primaryCompletion":7960,"completion":7961,"start":7962,"enrollment":7963,"conditions":7964,"interventions":7965},"NCT01160211","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",[93],"2016-03-11","2022-06-06","2011-05-05",369,[7868],[944,4320,7966,944],"Aromatase Inhibitor",{"nctId":7968,"briefTitle":7969,"status":123,"phases":7970,"primaryCompletion":7971,"completion":5830,"start":7972,"enrollment":7973,"conditions":7974,"interventions":7975},"NCT00667251","Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2\u002FNeu-Positive Metastatic Breast Cancer",[93],"2012-08-01","2008-10-07",652,[15],[4780,6673,7976,7872],"lapatinib ditosylate",{"nctId":7978,"briefTitle":7979,"status":123,"phases":7980,"primaryCompletion":7981,"completion":7982,"start":7983,"enrollment":7984,"conditions":7985,"interventions":7986},"NCT00490139","ALTTO (Adjuvant Lapatinib And\u002FOr Trastuzumab Treatment Optimisation) Study; BIG 2-06\u002FN063D",[93],"2013-12-06","2021-07-01","2007-05-16",8381,[7868],[944,4320],{"nctId":4772,"briefTitle":4773,"status":123,"phases":7988,"primaryCompletion":4410,"completion":4410,"start":4400,"enrollment":4775,"conditions":7989,"interventions":7990},[93],[4777,435],[4305,4779,4780],{"nctId":7992,"briefTitle":7993,"status":134,"phases":7994,"primaryCompletion":1212,"completion":7995,"start":7996,"enrollment":5612,"conditions":7997,"interventions":7998},"NCT00968968","Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone",[93],"2018-03-30","2010-01-20",[1102],[944,4320],{"nctId":6359,"briefTitle":6360,"status":147,"phases":8000,"primaryCompletion":627,"completion":627,"start":6362,"enrollment":1065,"conditions":8001,"interventions":8002},[93],[6364],[88,4320,6366],{"nctId":8004,"briefTitle":8005,"status":123,"phases":8006,"primaryCompletion":8007,"completion":8008,"start":8009,"enrollment":7042,"conditions":8010,"interventions":8011},"NCT00553358","Neo ALTTO (Neoadjuvant Lapatinib and\u002For Trastuzumab Treatment Optimisation) Study",[93],"2010-05-27","2019-12-23","2008-01-05",[7868],[944,4320,4321],{"nctId":4922,"briefTitle":4923,"status":123,"phases":8013,"primaryCompletion":4925,"completion":2533,"start":4926,"enrollment":4794,"conditions":8014,"interventions":8015},[93],[15],[196,4320,4321],{"nctId":8017,"briefTitle":8018,"status":134,"phases":8019,"primaryCompletion":8020,"completion":8021,"start":8022,"enrollment":19,"conditions":8023,"interventions":8024},"NCT00272987","ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib",[93],"2009-07-31","2019-10-21","2005-12-13",[7868],[7870,7872,4780],{"trials":8026,"activeCount":103},[],{"trials":8028,"activeCount":103},[],{"intervention":5252,"totalTrials":734,"cells":8030},{"EARLY_PHASE1":8031,"PHASE1":8033,"PHASE2":8052,"PHASE3":8094,"PHASE4":8134,"NA":8136},{"trials":8032,"activeCount":103},[],{"trials":8034,"activeCount":103},[8035,8044],{"nctId":8036,"briefTitle":8037,"status":123,"phases":8038,"primaryCompletion":8039,"completion":8039,"start":3673,"enrollment":114,"conditions":8040,"interventions":8042},"NCT01822613","Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)",[91],"2016-06-03",[8041],"Esophageal Squamous Cell Carcinoma",[7886,516,4321,5252,8043],"Irinotecan",{"nctId":8045,"briefTitle":8046,"status":134,"phases":8047,"primaryCompletion":8048,"completion":8048,"start":813,"enrollment":34,"conditions":8049,"interventions":8051},"NCT01911325","Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients",[91],"2015-08",[8050],"Squamous Non-small Cell Lung Cancer",[738,5252],{"trials":8053,"activeCount":103},[8054,8063,8071,8080,8087],{"nctId":8055,"briefTitle":8056,"status":123,"phases":8057,"primaryCompletion":3243,"completion":3243,"start":4034,"enrollment":2910,"conditions":8058,"interventions":8060},"NCT00411528","Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer",[92],[8059],"Metastatic Hormone Refractory Prostate Cancer",[8061,8062,6673],"Patupilone","prednisone",{"nctId":8064,"briefTitle":8065,"status":123,"phases":8066,"primaryCompletion":8067,"completion":8067,"start":2853,"enrollment":3343,"conditions":8068,"interventions":8069},"NCT03647488","Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer",[92],"2020-09-07",[227],[8070,212,5252],"Capmatinib",{"nctId":8072,"briefTitle":8073,"status":134,"phases":8074,"primaryCompletion":8075,"completion":8075,"start":8076,"enrollment":3322,"conditions":8077,"interventions":8079},"NCT01646125","An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",[92],"2015-11-04","2012-11-23",[8078],"Advanced Non Small Cell Lung Cancer (NSCLC)",[7913,5252,4375],{"nctId":8081,"briefTitle":8082,"status":123,"phases":8083,"primaryCompletion":5733,"completion":5733,"start":4081,"enrollment":16,"conditions":8084,"interventions":8086},"NCT01084330","Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer",[92],[4439,8085],"Gastro-esophageal Junction Cancer",[7913,5252,8043],{"nctId":8088,"briefTitle":8089,"status":134,"phases":8090,"primaryCompletion":3195,"start":8091,"enrollment":437,"conditions":8092,"interventions":8093},"NCT00258765","Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.",[92],"2006-05",[1654],[955,5252],{"trials":8095,"activeCount":437,"soonestReadout":6668},[8096,8104,8108,8116,8126,8130],{"nctId":8097,"briefTitle":8098,"status":134,"phases":8099,"primaryCompletion":8100,"completion":8101,"start":5089,"enrollment":2633,"conditions":8102,"interventions":8103},"NCT04427072","Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation",[93],"2023-02-15","2023-11-06",[227],[8070,5252],{"nctId":7968,"briefTitle":7969,"status":123,"phases":8105,"primaryCompletion":7971,"completion":5830,"start":7972,"enrollment":7973,"conditions":8106,"interventions":8107},[93],[15],[4780,6673,7976,7872],{"nctId":8109,"briefTitle":8110,"status":134,"phases":8111,"primaryCompletion":4372,"start":3552,"enrollment":8112,"conditions":8113,"interventions":8114},"NCT00738387","A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb\u002FIV) Non-small Cell Lung Cancer",[93],900,[182],[8115,6673],"ASA404",{"nctId":8117,"briefTitle":8118,"status":134,"phases":8119,"primaryCompletion":629,"completion":8120,"start":8121,"enrollment":8122,"conditions":8123,"interventions":8125},"NCT03626545","Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy",[93],"2021-12-20","2019-01-23",245,[8124],"Non-Small-Cell Lung",[3157,5252],{"nctId":5243,"briefTitle":5244,"status":123,"phases":8127,"primaryCompletion":5246,"completion":5247,"start":5248,"enrollment":5249,"conditions":8128,"interventions":8129},[93],[182],[130,4375,5252],{"nctId":6665,"briefTitle":6666,"status":147,"phases":8131,"primaryCompletion":6668,"completion":6669,"start":6670,"enrollment":167,"conditions":8132,"interventions":8133},[93],[182],[235,6673],{"trials":8135,"activeCount":103},[],{"trials":8137,"activeCount":103},[],{"intervention":8139,"totalTrials":5594,"cells":8140},"Tisagenlecleucel",{"EARLY_PHASE1":8141,"PHASE1":8143,"PHASE2":8162,"PHASE3":8220,"PHASE4":8245,"NA":8247},{"trials":8142,"activeCount":103},[],{"trials":8144,"activeCount":103},[8145,8154],{"nctId":8146,"briefTitle":8147,"status":123,"phases":8148,"primaryCompletion":8149,"completion":8149,"start":8150,"enrollment":138,"conditions":8151,"interventions":8152},"NCT03630159","Study of Tisagenlecleucel in Combination With Pembrolizumab in r\u002Fr Diffuse Large B-cell Lymphoma Patients",[91],"2021-07-20","2018-10-09",[4681],[8139,8153],"Pembrolizumab",{"nctId":8155,"briefTitle":8156,"status":134,"phases":8157,"primaryCompletion":8158,"completion":8158,"start":281,"enrollment":5594,"conditions":8159,"interventions":8160},"NCT03876028","Study of Tisagenlecleucel in Combination With Ibrutinib in r\u002Fr Diffuse Large B-cell Lymphoma Patients",[91],"2021-11-01",[4681],[8139,8161],"Ibrutinib",{"trials":8163,"activeCount":103},[8164,8174,8184,8195,8205,8213],{"nctId":8165,"briefTitle":8166,"status":123,"phases":8167,"primaryCompletion":6023,"completion":8168,"start":2426,"enrollment":31,"conditions":8169,"interventions":8171},"NCT03610724","Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients",[92],"2023-04-26",[8170],"Non-Hodgkin Lymphoma",[8139,8172,8173],"lymphodepleting chemotherapy","Bridging Therapy",{"nctId":8175,"briefTitle":8176,"status":123,"phases":8177,"primaryCompletion":8178,"completion":8178,"start":8179,"enrollment":4992,"conditions":8180,"interventions":8182},"NCT02445248","Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients",[92],"2022-12-22","2015-07-29",[8181],"Diffuse Large B-cell Lymphoma (DLBCL)",[8139,8183],"Lymphodepleting chemotherapy",{"nctId":8185,"briefTitle":8186,"status":123,"phases":8187,"primaryCompletion":8188,"completion":8189,"start":8190,"enrollment":6014,"conditions":8191,"interventions":8193},"NCT03568461","Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma",[92],"2020-11-24","2025-05-28","2018-11-12",[8192],"Follicular Lymphoma",[8194],"tisagenlecleucel",{"nctId":8196,"briefTitle":8197,"status":390,"phases":8198,"primaryCompletion":8199,"completion":8200,"start":8201,"enrollment":103,"conditions":8202,"interventions":8204},"NCT04456023","Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)",[92],"2022-10-31","2027-09-27","2022-01-31",[8203],"Diffuse Large B-Cell Lymphoma (DLBCL)",[8139],{"nctId":8206,"briefTitle":8207,"status":390,"phases":8208,"primaryCompletion":8209,"completion":8210,"start":2220,"enrollment":103,"conditions":8211,"interventions":8212},"NCT04156659","Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL",[92],"2022-11-30","2027-11-30",[7583],[8139],{"nctId":8214,"briefTitle":8215,"status":134,"phases":8216,"primaryCompletion":8217,"completion":8217,"start":2809,"enrollment":637,"conditions":8218,"interventions":8219},"NCT04225676","Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)",[92],"2021-10-19",[3204],[8139],{"trials":8221,"activeCount":437,"soonestReadout":8237},[8222,8233],{"nctId":8223,"briefTitle":8224,"status":390,"phases":8225,"primaryCompletion":8226,"completion":8227,"start":8228,"enrollment":103,"conditions":8229,"interventions":8230},"NCT03628053","Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed\u002FRefractory B-cell Precursor Acute Lymphoblastic Leukemia",[93],"2025-10-08","2026-01-07","2020-06-05",[3204],[8139,8231,8232],"Blinatumomab","Inotuzumab",{"nctId":8234,"briefTitle":8235,"status":147,"phases":8236,"primaryCompletion":8237,"completion":8238,"start":3262,"enrollment":8239,"conditions":8240,"interventions":8242},"NCT05888493","A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r\u002Fr Follicular Lymphoma",[93],"2028-07-25","2031-02-20",109,[8241],"Follicular Lymphoma (FL)",[8139,8243,8244,8183],"Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.","Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles",{"trials":8246,"activeCount":103},[],{"trials":8248,"activeCount":103},[],{"intervention":3057,"totalTrials":1630,"cells":8250},{"EARLY_PHASE1":8251,"PHASE1":8253,"PHASE2":8255,"PHASE3":8269,"PHASE4":8283,"NA":8285},{"trials":8252,"activeCount":103},[],{"trials":8254,"activeCount":103},[],{"trials":8256,"activeCount":103},[8257,8261],{"nctId":3049,"briefTitle":3050,"status":123,"phases":8258,"primaryCompletion":3052,"completion":3052,"start":3053,"enrollment":630,"conditions":8259,"interventions":8260},[92],[18],[3056,3057,3017],{"nctId":8262,"briefTitle":8263,"status":123,"phases":8264,"primaryCompletion":3799,"completion":3799,"start":3712,"enrollment":8265,"conditions":8266,"interventions":8268},"NCT01636076","Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate\u002FFluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],629,[8267],"COPD",[3057,7851],{"trials":8270,"activeCount":437,"soonestReadout":7825},[8271,8279],{"nctId":8272,"briefTitle":8273,"status":123,"phases":8274,"primaryCompletion":8275,"completion":8276,"start":3139,"enrollment":2428,"conditions":8277,"interventions":8278},"NCT03100500","A Long-term Safety Study of QMF149 in Japanese Participants With Asthma",[93],"2018-07-19","2019-02-12",[18],[3057],{"nctId":7822,"briefTitle":7823,"status":109,"phases":8280,"primaryCompletion":7825,"completion":7826,"start":7827,"enrollment":919,"conditions":8281,"interventions":8282},[93],[18],[3057,7811],{"trials":8284,"activeCount":103},[],{"trials":8286,"activeCount":103},[],{"intervention":8183,"totalTrials":317,"cells":8288},{"EARLY_PHASE1":8289,"PHASE1":8291,"PHASE2":8293,"PHASE3":8303,"PHASE4":8309,"NA":8311},{"trials":8290,"activeCount":103},[],{"trials":8292,"activeCount":103},[],{"trials":8294,"activeCount":103},[8295,8299],{"nctId":8165,"briefTitle":8166,"status":123,"phases":8296,"primaryCompletion":6023,"completion":8168,"start":2426,"enrollment":31,"conditions":8297,"interventions":8298},[92],[8170],[8139,8172,8173],{"nctId":8175,"briefTitle":8176,"status":123,"phases":8300,"primaryCompletion":8178,"completion":8178,"start":8179,"enrollment":4992,"conditions":8301,"interventions":8302},[92],[8181],[8139,8183],{"trials":8304,"activeCount":437,"soonestReadout":8237},[8305],{"nctId":8234,"briefTitle":8235,"status":147,"phases":8306,"primaryCompletion":8237,"completion":8238,"start":3262,"enrollment":8239,"conditions":8307,"interventions":8308},[93],[8241],[8139,8243,8244,8183],{"trials":8310,"activeCount":103},[],{"trials":8312,"activeCount":103},[],{"intervention":8314,"totalTrials":317,"cells":8315},"QVM149",{"EARLY_PHASE1":8316,"PHASE1":8318,"PHASE2":8320,"PHASE3":8322,"PHASE4":8353,"NA":8355},{"trials":8317,"activeCount":103},[],{"trials":8319,"activeCount":103},[],{"trials":8321,"activeCount":103},[],{"trials":8323,"activeCount":437,"soonestReadout":8345},[8324,8334,8341],{"nctId":8325,"briefTitle":8326,"status":123,"phases":8327,"primaryCompletion":6143,"completion":8328,"start":8329,"enrollment":8330,"conditions":8331,"interventions":8332},"NCT03158311","Study to Compare QVM149 and Free Triple Combination of Salmeterol\u002FFluticasone + Tiotropium",[93],"2019-07-19","2018-02-05",1426,[18],[8314,8333],"Salmeterol\u002Ffluticasone plus tiotropium",{"nctId":8335,"briefTitle":8336,"status":123,"phases":8337,"primaryCompletion":1981,"completion":2622,"start":8338,"enrollment":1750,"conditions":8339,"interventions":8340},"NCT03100825","A Long-term Safety Study of QVM149 in Japanese Patients With Asthma",[93],"2017-04-28",[18],[8314],{"nctId":8342,"briefTitle":8343,"status":593,"phases":8344,"primaryCompletion":8345,"completion":8346,"start":6435,"enrollment":8347,"conditions":8348,"interventions":8349},"NCT05776927","A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate \u002F Glycopyrronium Bromide \u002F Mometasone Furoate) Versus Salmeterol Xinafoate\u002FFluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.",[93],"2028-12-21","2029-12-24",304,[18],[8314,8350,8351,8352],"Salmeterol Xinafoate \u002F Fluticasone Propionate","Run-In Medication","Rescue Medication",{"trials":8354,"activeCount":103},[],{"trials":8356,"activeCount":103},[],{"intervention":8358,"totalTrials":317,"cells":8359},"Octreotide LAR",{"EARLY_PHASE1":8360,"PHASE1":8362,"PHASE2":8364,"PHASE3":8377,"PHASE4":8398,"NA":8400},{"trials":8361,"activeCount":103},[],{"trials":8363,"activeCount":103},[],{"trials":8365,"activeCount":103},[8366],{"nctId":8367,"briefTitle":8368,"status":123,"phases":8369,"primaryCompletion":3279,"completion":3279,"start":8370,"enrollment":2776,"conditions":8371,"interventions":8375},"NCT00332696","Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis",[92],"2005-09",[8372,8373,8374],"Peritoneal Neoplasms","Intestinal Obstruction","Carcinomatosis",[8358,4831,8376],"methylprednisolone",{"trials":8378,"activeCount":437,"soonestReadout":8391},[8379,8387],{"nctId":8380,"briefTitle":8381,"status":123,"phases":8382,"primaryCompletion":996,"completion":996,"start":8383,"enrollment":1314,"conditions":8384,"interventions":8386},"NCT00225979","Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly",[93],"2002-11",[8385],"Acromegaly",[8358],{"nctId":8388,"briefTitle":8389,"status":109,"phases":8390,"primaryCompletion":8391,"completion":8392,"start":8393,"enrollment":467,"conditions":8394,"interventions":8397},"NCT06784752","Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET",[93],"2028-12-08","2034-01-23","2025-05-30",[8395,8396],"Somatostatin Receptor Positive (SSTR+)","Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)",[8358],{"trials":8399,"activeCount":103},[],{"trials":8401,"activeCount":103},[],{"intervention":332,"totalTrials":317,"cells":8403},{"EARLY_PHASE1":8404,"PHASE1":8406,"PHASE2":8408,"PHASE3":8414,"PHASE4":8424,"NA":8426},{"trials":8405,"activeCount":103},[],{"trials":8407,"activeCount":103},[],{"trials":8409,"activeCount":103},[8410],{"nctId":562,"briefTitle":563,"status":123,"phases":8411,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":8412,"interventions":8413},[92],[15],[88,119,249,250,332],{"trials":8415,"activeCount":437,"soonestReadout":324},[8416,8420],{"nctId":321,"briefTitle":322,"status":109,"phases":8417,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":8418,"interventions":8419},[93],[329],[98,249,331,250,332,195],{"nctId":378,"briefTitle":379,"status":123,"phases":8421,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":8422,"interventions":8423},[93],[15],[98,249,250,332],{"trials":8425,"activeCount":103},[],{"trials":8427,"activeCount":103},[],{"intervention":1248,"totalTrials":213,"cells":8429},{"EARLY_PHASE1":8430,"PHASE1":8432,"PHASE2":8434,"PHASE3":8436,"PHASE4":8446,"NA":8448},{"trials":8431,"activeCount":103},[],{"trials":8433,"activeCount":103},[],{"trials":8435,"activeCount":103},[],{"trials":8437,"activeCount":437,"soonestReadout":1275},[8438,8442],{"nctId":1239,"briefTitle":1240,"status":123,"phases":8439,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":8440,"interventions":8441},[93],[36],[1078,173,1248],{"nctId":1272,"briefTitle":1273,"status":147,"phases":8443,"primaryCompletion":1275,"completion":1276,"start":1277,"enrollment":1278,"conditions":8444,"interventions":8445},[93],[1280],[1078,173,1282,1283],{"trials":8447,"activeCount":103},[],{"trials":8449,"activeCount":103},[],{"intervention":8451,"totalTrials":213,"cells":8452},"TQJ230",{"EARLY_PHASE1":8453,"PHASE1":8455,"PHASE2":8457,"PHASE3":8459,"PHASE4":8477,"NA":8479},{"trials":8454,"activeCount":103},[],{"trials":8456,"activeCount":103},[],{"trials":8458,"activeCount":103},[],{"trials":8460,"activeCount":437,"soonestReadout":596},[8461,8469],{"nctId":8462,"briefTitle":8463,"status":123,"phases":8464,"primaryCompletion":2829,"completion":2829,"start":178,"enrollment":8465,"conditions":8466,"interventions":8468},"NCT06267560","Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black\u002FAfrican American and Hispanic Participants With Elevated Lp(a) and Established ASCVD",[93],422,[8467],"Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease",[8451],{"nctId":8470,"briefTitle":8471,"status":147,"phases":8472,"primaryCompletion":596,"completion":596,"start":8473,"enrollment":8474,"conditions":8475,"interventions":8476},"NCT04023552","Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD",[93],"2019-12-12",8323,[6861],[8451],{"trials":8478,"activeCount":103},[],{"trials":8480,"activeCount":103},[],{"intervention":8482,"totalTrials":437,"cells":8483},"Remibrutinib oral treatment",{"EARLY_PHASE1":8484,"PHASE1":8486,"PHASE2":8488,"PHASE3":8490,"PHASE4":8501,"NA":8503},{"trials":8485,"activeCount":103},[],{"trials":8487,"activeCount":103},[],{"trials":8489,"activeCount":103},[],{"trials":8491,"activeCount":437,"soonestReadout":8496},[8492],{"nctId":8493,"briefTitle":8494,"status":109,"phases":8495,"primaryCompletion":8496,"completion":8497,"start":6123,"enrollment":8498,"conditions":8499,"interventions":8500},"NCT06846281","Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.",[93],"2029-07-24","2031-06-24",360,[2778],[8482,3015],{"trials":8502,"activeCount":103},[],{"trials":8504,"activeCount":103},[],{"intervention":48,"totalTrials":437,"cells":8506},{"EARLY_PHASE1":8507,"PHASE1":8509,"PHASE2":8511,"PHASE3":8513,"PHASE4":8519,"NA":8521},{"trials":8508,"activeCount":103},[],{"trials":8510,"activeCount":103},[],{"trials":8512,"activeCount":103},[],{"trials":8514,"activeCount":437,"soonestReadout":47},[8515],{"nctId":45,"briefTitle":46,"status":147,"phases":8516,"primaryCompletion":47,"completion":3672,"start":3673,"enrollment":467,"conditions":8517,"interventions":8518},[93],[27],[48,2836],{"trials":8520,"activeCount":103},[],{"trials":8522,"activeCount":103},[],{"intervention":8350,"totalTrials":437,"cells":8524},{"EARLY_PHASE1":8525,"PHASE1":8527,"PHASE2":8529,"PHASE3":8531,"PHASE4":8537,"NA":8539},{"trials":8526,"activeCount":103},[],{"trials":8528,"activeCount":103},[],{"trials":8530,"activeCount":103},[],{"trials":8532,"activeCount":437,"soonestReadout":8345},[8533],{"nctId":8342,"briefTitle":8343,"status":593,"phases":8534,"primaryCompletion":8345,"completion":8346,"start":6435,"enrollment":8347,"conditions":8535,"interventions":8536},[93],[18],[8314,8350,8351,8352],{"trials":8538,"activeCount":103},[],{"trials":8540,"activeCount":103},[],{"intervention":8351,"totalTrials":437,"cells":8542},{"EARLY_PHASE1":8543,"PHASE1":8545,"PHASE2":8547,"PHASE3":8549,"PHASE4":8555,"NA":8557},{"trials":8544,"activeCount":103},[],{"trials":8546,"activeCount":103},[],{"trials":8548,"activeCount":103},[],{"trials":8550,"activeCount":437,"soonestReadout":8345},[8551],{"nctId":8342,"briefTitle":8343,"status":593,"phases":8552,"primaryCompletion":8345,"completion":8346,"start":6435,"enrollment":8347,"conditions":8553,"interventions":8554},[93],[18],[8314,8350,8351,8352],{"trials":8556,"activeCount":103},[],{"trials":8558,"activeCount":103},[],{"intervention":8352,"totalTrials":437,"cells":8560},{"EARLY_PHASE1":8561,"PHASE1":8563,"PHASE2":8565,"PHASE3":8567,"PHASE4":8573,"NA":8575},{"trials":8562,"activeCount":103},[],{"trials":8564,"activeCount":103},[],{"trials":8566,"activeCount":103},[],{"trials":8568,"activeCount":437,"soonestReadout":8345},[8569],{"nctId":8342,"briefTitle":8343,"status":593,"phases":8570,"primaryCompletion":8345,"completion":8346,"start":6435,"enrollment":8347,"conditions":8571,"interventions":8572},[93],[18],[8314,8350,8351,8352],{"trials":8574,"activeCount":103},[],{"trials":8576,"activeCount":103},[],{"intervention":8578,"totalTrials":437,"cells":8579},"Drug: Atrasentan",{"EARLY_PHASE1":8580,"PHASE1":8582,"PHASE2":8584,"PHASE3":8586,"PHASE4":8601,"NA":8603},{"trials":8581,"activeCount":103},[],{"trials":8583,"activeCount":103},[],{"trials":8585,"activeCount":103},[],{"trials":8587,"activeCount":437,"soonestReadout":8592},[8588],{"nctId":8589,"briefTitle":8590,"status":593,"phases":8591,"primaryCompletion":8592,"completion":8593,"start":8594,"enrollment":2046,"conditions":8595,"interventions":8600},"NCT07498335","Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN",[93],"2031-09-15","2032-12-13","2026-08-26",[8596,8597,6761,5971,8598,8599],"Berger Disease","Bergers Disease","Primary IgAN","Nephritis IgA Type, Nephropathy IgA Type",[8578],{"trials":8602,"activeCount":103},[],{"trials":8604,"activeCount":103},[],{"intervention":8243,"totalTrials":437,"cells":8606},{"EARLY_PHASE1":8607,"PHASE1":8609,"PHASE2":8611,"PHASE3":8613,"PHASE4":8619,"NA":8621},{"trials":8608,"activeCount":103},[],{"trials":8610,"activeCount":103},[],{"trials":8612,"activeCount":103},[],{"trials":8614,"activeCount":437,"soonestReadout":8237},[8615],{"nctId":8234,"briefTitle":8235,"status":147,"phases":8616,"primaryCompletion":8237,"completion":8238,"start":3262,"enrollment":8239,"conditions":8617,"interventions":8618},[93],[8241],[8139,8243,8244,8183],{"trials":8620,"activeCount":103},[],{"trials":8622,"activeCount":103},[],{"intervention":8244,"totalTrials":437,"cells":8624},{"EARLY_PHASE1":8625,"PHASE1":8627,"PHASE2":8629,"PHASE3":8631,"PHASE4":8637,"NA":8639},{"trials":8626,"activeCount":103},[],{"trials":8628,"activeCount":103},[],{"trials":8630,"activeCount":103},[],{"trials":8632,"activeCount":437,"soonestReadout":8237},[8633],{"nctId":8234,"briefTitle":8235,"status":147,"phases":8634,"primaryCompletion":8237,"completion":8238,"start":3262,"enrollment":8239,"conditions":8635,"interventions":8636},[93],[8241],[8139,8243,8244,8183],{"trials":8638,"activeCount":103},[],{"trials":8640,"activeCount":103},[],{"intervention":8642,"totalTrials":437,"cells":8643},"onasemnogene abeparvovec",{"EARLY_PHASE1":8644,"PHASE1":8646,"PHASE2":8648,"PHASE3":8650,"PHASE4":8663,"NA":8665},{"trials":8645,"activeCount":103},[],{"trials":8647,"activeCount":103},[],{"trials":8649,"activeCount":103},[],{"trials":8651,"activeCount":437,"soonestReadout":8656},[8652],{"nctId":8653,"briefTitle":8654,"status":109,"phases":8655,"primaryCompletion":8656,"completion":8657,"start":8658,"enrollment":8659,"conditions":8660,"interventions":8662},"NCT05335876","Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials",[93],"2030-09-26","2031-02-27","2022-12-19",175,[8661],"Spinal Muscular Atrophy (SMA)",[8642],{"trials":8664,"activeCount":103},[],{"trials":8666,"activeCount":103},[],{"intervention":331,"totalTrials":437,"cells":8668},{"EARLY_PHASE1":8669,"PHASE1":8671,"PHASE2":8673,"PHASE3":8675,"PHASE4":8681,"NA":8683},{"trials":8670,"activeCount":103},[],{"trials":8672,"activeCount":103},[],{"trials":8674,"activeCount":103},[],{"trials":8676,"activeCount":437,"soonestReadout":324},[8677],{"nctId":321,"briefTitle":322,"status":109,"phases":8678,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":8679,"interventions":8680},[93],[329],[98,249,331,250,332,195],{"trials":8682,"activeCount":103},[],{"trials":8684,"activeCount":103},[],{"intervention":8686,"totalTrials":437,"cells":8687},"Iptcaopan 200 mg",{"EARLY_PHASE1":8688,"PHASE1":8690,"PHASE2":8692,"PHASE3":8694,"PHASE4":8704,"NA":8706},{"trials":8689,"activeCount":103},[],{"trials":8691,"activeCount":103},[],{"trials":8693,"activeCount":103},[],{"trials":8695,"activeCount":437,"soonestReadout":5863},[8696],{"nctId":8697,"briefTitle":8698,"status":109,"phases":8699,"primaryCompletion":5863,"completion":8700,"start":8701,"enrollment":1524,"conditions":8702,"interventions":8703},"NCT05795140","Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS",[93],"2032-07-27","2024-05-08",[6044],[8686],{"trials":8705,"activeCount":103},[],{"trials":8707,"activeCount":103},[],{"intervention":8709,"totalTrials":437,"cells":8710},"Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL",{"EARLY_PHASE1":8711,"PHASE1":8713,"PHASE2":8715,"PHASE3":8717,"PHASE4":8729,"NA":8731},{"trials":8712,"activeCount":103},[],{"trials":8714,"activeCount":103},[],{"trials":8716,"activeCount":103},[],{"trials":8718,"activeCount":437,"soonestReadout":8723},[8719],{"nctId":8720,"briefTitle":8721,"status":147,"phases":8722,"primaryCompletion":8723,"completion":8723,"start":8724,"enrollment":8725,"conditions":8726,"interventions":8728},"NCT05739383","A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.",[93],"2029-04-16","2023-03-09",14012,[8727],"Primary Prevention of Atherosclerotic Cardiovascular Disease",[8709],{"trials":8730,"activeCount":103},[],{"trials":8732,"activeCount":103},[],{"intervention":1283,"totalTrials":437,"cells":8734},{"EARLY_PHASE1":8735,"PHASE1":8737,"PHASE2":8739,"PHASE3":8741,"PHASE4":8747,"NA":8749},{"trials":8736,"activeCount":103},[],{"trials":8738,"activeCount":103},[],{"trials":8740,"activeCount":103},[],{"trials":8742,"activeCount":437,"soonestReadout":1275},[8743],{"nctId":1272,"briefTitle":1273,"status":147,"phases":8744,"primaryCompletion":1275,"completion":1276,"start":1277,"enrollment":1278,"conditions":8745,"interventions":8746},[93],[1280],[1078,173,1282,1283],{"trials":8748,"activeCount":103},[],{"trials":8750,"activeCount":103},[],{"intervention":8752,"totalTrials":437,"cells":8753},"ianalumab s.c. q4w",{"EARLY_PHASE1":8754,"PHASE1":8756,"PHASE2":8758,"PHASE3":8760,"PHASE4":8773,"NA":8775},{"trials":8755,"activeCount":103},[],{"trials":8757,"activeCount":103},[],{"trials":8759,"activeCount":103},[],{"trials":8761,"activeCount":437,"soonestReadout":8766},[8762],{"nctId":8763,"briefTitle":8764,"status":147,"phases":8765,"primaryCompletion":8766,"completion":8767,"start":8768,"enrollment":8769,"conditions":8770,"interventions":8771},"NCT05126277","Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis",[93],"2027-06-22","2031-02-11","2022-07-14",452,[1800],[8752,8772],"ianalumab s.c. q12w",{"trials":8774,"activeCount":103},[],{"trials":8776,"activeCount":103},[],{"intervention":8772,"totalTrials":437,"cells":8778},{"EARLY_PHASE1":8779,"PHASE1":8781,"PHASE2":8783,"PHASE3":8785,"PHASE4":8791,"NA":8793},{"trials":8780,"activeCount":103},[],{"trials":8782,"activeCount":103},[],{"trials":8784,"activeCount":103},[],{"trials":8786,"activeCount":437,"soonestReadout":8766},[8787],{"nctId":8763,"briefTitle":8764,"status":147,"phases":8788,"primaryCompletion":8766,"completion":8767,"start":8768,"enrollment":8769,"conditions":8789,"interventions":8790},[93],[1800],[8752,8772],{"trials":8792,"activeCount":103},[],{"trials":8794,"activeCount":103},[],{"intervention":53,"totalTrials":437,"cells":8796},{"EARLY_PHASE1":8797,"PHASE1":8799,"PHASE2":8801,"PHASE3":8803,"PHASE4":8811,"NA":8813},{"trials":8798,"activeCount":103},[],{"trials":8800,"activeCount":103},[],{"trials":8802,"activeCount":103},[],{"trials":8804,"activeCount":437,"soonestReadout":52},[8805],{"nctId":50,"briefTitle":51,"status":147,"phases":8806,"primaryCompletion":52,"completion":8807,"start":8188,"enrollment":1630,"conditions":8808,"interventions":8810},[93],"2026-06-22",[8809],"Biallelic RPE65 Mutation-associated Retinal Dystrophy",[53],{"trials":8812,"activeCount":103},[],{"trials":8814,"activeCount":103},[],{"intervention":6207,"totalTrials":437,"cells":8816},{"EARLY_PHASE1":8817,"PHASE1":8819,"PHASE2":8821,"PHASE3":8823,"PHASE4":8829,"NA":8831},{"trials":8818,"activeCount":103},[],{"trials":8820,"activeCount":103},[],{"trials":8822,"activeCount":103},[],{"trials":8824,"activeCount":437,"soonestReadout":6202},[8825],{"nctId":6199,"briefTitle":6200,"status":109,"phases":8826,"primaryCompletion":6202,"completion":1276,"start":6203,"enrollment":1466,"conditions":8827,"interventions":8828},[93],[6205],[6111,6207],{"trials":8830,"activeCount":103},[],{"trials":8832,"activeCount":103},[],{"intervention":6366,"totalTrials":437,"cells":8834},{"EARLY_PHASE1":8835,"PHASE1":8837,"PHASE2":8839,"PHASE3":8841,"PHASE4":8847,"NA":8849},{"trials":8836,"activeCount":103},[],{"trials":8838,"activeCount":103},[],{"trials":8840,"activeCount":103},[],{"trials":8842,"activeCount":437,"soonestReadout":627},[8843],{"nctId":6359,"briefTitle":6360,"status":147,"phases":8844,"primaryCompletion":627,"completion":627,"start":6362,"enrollment":1065,"conditions":8845,"interventions":8846},[93],[6364],[88,4320,6366],{"trials":8848,"activeCount":103},[],{"trials":8850,"activeCount":103},[],{"intervention":2889,"totalTrials":437,"cells":8852},{"EARLY_PHASE1":8853,"PHASE1":8855,"PHASE2":8857,"PHASE3":8859,"PHASE4":8865,"NA":8867},{"trials":8854,"activeCount":103},[],{"trials":8856,"activeCount":103},[],{"trials":8858,"activeCount":103},[],{"trials":8860,"activeCount":437,"soonestReadout":2884},[8861],{"nctId":2881,"briefTitle":2882,"status":147,"phases":8862,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":2886,"conditions":8863,"interventions":8864},[93],[2778],[2752,2889,2890,2891,2892,2893],{"trials":8866,"activeCount":103},[],{"trials":8868,"activeCount":103},[],{"intervention":2890,"totalTrials":437,"cells":8870},{"EARLY_PHASE1":8871,"PHASE1":8873,"PHASE2":8875,"PHASE3":8877,"PHASE4":8883,"NA":8885},{"trials":8872,"activeCount":103},[],{"trials":8874,"activeCount":103},[],{"trials":8876,"activeCount":103},[],{"trials":8878,"activeCount":437,"soonestReadout":2884},[8879],{"nctId":2881,"briefTitle":2882,"status":147,"phases":8880,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":2886,"conditions":8881,"interventions":8882},[93],[2778],[2752,2889,2890,2891,2892,2893],{"trials":8884,"activeCount":103},[],{"trials":8886,"activeCount":103},[],{"intervention":2891,"totalTrials":437,"cells":8888},{"EARLY_PHASE1":8889,"PHASE1":8891,"PHASE2":8893,"PHASE3":8895,"PHASE4":8901,"NA":8903},{"trials":8890,"activeCount":103},[],{"trials":8892,"activeCount":103},[],{"trials":8894,"activeCount":103},[],{"trials":8896,"activeCount":437,"soonestReadout":2884},[8897],{"nctId":2881,"briefTitle":2882,"status":147,"phases":8898,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":2886,"conditions":8899,"interventions":8900},[93],[2778],[2752,2889,2890,2891,2892,2893],{"trials":8902,"activeCount":103},[],{"trials":8904,"activeCount":103},[],{"intervention":2892,"totalTrials":437,"cells":8906},{"EARLY_PHASE1":8907,"PHASE1":8909,"PHASE2":8911,"PHASE3":8913,"PHASE4":8919,"NA":8921},{"trials":8908,"activeCount":103},[],{"trials":8910,"activeCount":103},[],{"trials":8912,"activeCount":103},[],{"trials":8914,"activeCount":437,"soonestReadout":2884},[8915],{"nctId":2881,"briefTitle":2882,"status":147,"phases":8916,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":2886,"conditions":8917,"interventions":8918},[93],[2778],[2752,2889,2890,2891,2892,2893],{"trials":8920,"activeCount":103},[],{"trials":8922,"activeCount":103},[],{"intervention":2893,"totalTrials":437,"cells":8924},{"EARLY_PHASE1":8925,"PHASE1":8927,"PHASE2":8929,"PHASE3":8931,"PHASE4":8937,"NA":8939},{"trials":8926,"activeCount":103},[],{"trials":8928,"activeCount":103},[],{"trials":8930,"activeCount":103},[],{"trials":8932,"activeCount":437,"soonestReadout":2884},[8933],{"nctId":2881,"briefTitle":2882,"status":147,"phases":8934,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":2886,"conditions":8935,"interventions":8936},[93],[2778],[2752,2889,2890,2891,2892,2893],{"trials":8938,"activeCount":103},[],{"trials":8940,"activeCount":103},[],{"intervention":8942,"totalTrials":437,"cells":8943},"Previously treated CAR-T patients",{"EARLY_PHASE1":8944,"PHASE1":8946,"PHASE2":8948,"PHASE3":8950,"PHASE4":8961,"NA":8963},{"trials":8945,"activeCount":103},[],{"trials":8947,"activeCount":103},[],{"trials":8949,"activeCount":103},[],{"trials":8951,"activeCount":437,"soonestReadout":8956},[8952],{"nctId":8953,"briefTitle":8954,"status":109,"phases":8955,"primaryCompletion":8956,"completion":8956,"start":8957,"enrollment":327,"conditions":8958,"interventions":8960},"NCT02445222","CAR-T Long Term Follow Up (LTFU) Study",[93],"2036-02-22","2015-11-02",[8959],"Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program",[8942],{"trials":8962,"activeCount":103},[],{"trials":8964,"activeCount":103},[],{"intervention":8966,"totalTrials":437,"cells":8967},"Ofatumumab approved dose",{"EARLY_PHASE1":8968,"PHASE1":8970,"PHASE2":8972,"PHASE3":8974,"PHASE4":8986,"NA":8988},{"trials":8969,"activeCount":103},[],{"trials":8971,"activeCount":103},[],{"trials":8973,"activeCount":103},[],{"trials":8975,"activeCount":437,"soonestReadout":8980},[8976],{"nctId":8977,"briefTitle":8978,"status":147,"phases":8979,"primaryCompletion":8980,"completion":8981,"start":8982,"enrollment":2249,"conditions":8983,"interventions":8984},"NCT06869785","Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab",[93],"2026-01-28","2030-03-23","2025-03-13",[2960],[8966,8985],"Ofatumumab new dose",{"trials":8987,"activeCount":103},[],{"trials":8989,"activeCount":103},[],{"intervention":8985,"totalTrials":437,"cells":8991},{"EARLY_PHASE1":8992,"PHASE1":8994,"PHASE2":8996,"PHASE3":8998,"PHASE4":9004,"NA":9006},{"trials":8993,"activeCount":103},[],{"trials":8995,"activeCount":103},[],{"trials":8997,"activeCount":103},[],{"trials":8999,"activeCount":437,"soonestReadout":8980},[9000],{"nctId":8977,"briefTitle":8978,"status":147,"phases":9001,"primaryCompletion":8980,"completion":8981,"start":8982,"enrollment":2249,"conditions":9002,"interventions":9003},[93],[2960],[8966,8985],{"trials":9005,"activeCount":103},[],{"trials":9007,"activeCount":103},[],{"intervention":9009,"totalTrials":437,"cells":9010},"BION-1301",{"EARLY_PHASE1":9011,"PHASE1":9013,"PHASE2":9015,"PHASE3":9017,"PHASE4":9027,"NA":9029},{"trials":9012,"activeCount":103},[],{"trials":9014,"activeCount":103},[],{"trials":9016,"activeCount":103},[],{"trials":9018,"activeCount":437,"soonestReadout":9023},[9019],{"nctId":9020,"briefTitle":9021,"status":147,"phases":9022,"primaryCompletion":9023,"completion":9024,"start":2968,"enrollment":568,"conditions":9025,"interventions":9026},"NCT05852938","A Study of Zigakibart in Adults With IgA Nephropathy",[93],"2027-08-10","2028-01-25",[6761,5971],[9009],{"trials":9028,"activeCount":103},[],{"trials":9030,"activeCount":103},[],{"intervention":7368,"totalTrials":437,"cells":9032},{"EARLY_PHASE1":9033,"PHASE1":9035,"PHASE2":9037,"PHASE3":9039,"PHASE4":9045,"NA":9047},{"trials":9034,"activeCount":103},[],{"trials":9036,"activeCount":103},[],{"trials":9038,"activeCount":103},[],{"trials":9040,"activeCount":437,"soonestReadout":7362},[9041],{"nctId":7359,"briefTitle":7360,"status":109,"phases":9042,"primaryCompletion":7362,"completion":7363,"start":7364,"enrollment":7365,"conditions":9043,"interventions":9044},[92,93],[1654],[7368,3169,3169,3169],{"trials":9046,"activeCount":103},[],{"trials":9048,"activeCount":103},[],{"intervention":6218,"totalTrials":2342,"cells":9050},{"EARLY_PHASE1":9051,"PHASE1":9053,"PHASE2":9055,"PHASE3":9082,"PHASE4":9199,"NA":9237},{"trials":9052,"activeCount":103},[],{"trials":9054,"activeCount":103},[],{"trials":9056,"activeCount":103},[9057,9065,9073],{"nctId":9058,"briefTitle":9059,"status":123,"phases":9060,"primaryCompletion":9061,"completion":9061,"start":3604,"enrollment":4401,"conditions":9062,"interventions":9063},"NCT01716754","Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma",[92],"2016-01",[18],[9064,6218],"QGE031",{"nctId":9066,"briefTitle":9067,"status":123,"phases":9068,"primaryCompletion":813,"completion":813,"start":3712,"enrollment":5612,"conditions":9069,"interventions":9071},"NCT01703312","A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma",[91,92],[9070],"Allergic Asthma",[9064,9072],"omalizumab",{"nctId":9074,"briefTitle":9075,"status":123,"phases":9076,"primaryCompletion":9077,"completion":9078,"start":9079,"enrollment":1369,"conditions":9080,"interventions":9081},"NCT02477332","Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU",[92],"2016-11-02","2017-06-12","2015-07-15",[33],[9064,6218],{"trials":9083,"activeCount":437,"soonestReadout":6212},[9084,9092,9100,9110,9118,9125,9131,9139,9143,9149,9159,9165,9173,9182,9192],{"nctId":9085,"briefTitle":9086,"status":123,"phases":9087,"primaryCompletion":813,"completion":813,"start":7931,"enrollment":9088,"conditions":9089,"interventions":9091},"NCT01202903","Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy",[93],616,[9090],"Persistent Allergic Asthma",[6218],{"nctId":9093,"briefTitle":9094,"status":123,"phases":9095,"primaryCompletion":1025,"completion":1025,"start":9096,"enrollment":9097,"conditions":9098,"interventions":9099},"NCT00079937","Efficacy and Safety of Omalizumab in Children (6 - \u003C 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma",[93],"2004-04",628,[18],[6218,7849],{"nctId":9101,"briefTitle":9102,"status":123,"phases":9103,"primaryCompletion":9104,"completion":9104,"start":9105,"enrollment":9106,"conditions":9107,"interventions":9109},"NCT01723072","Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy",[93],"2014-05-09","2013-01-23",91,[33,9108],"Angioedema",[6218],{"nctId":9111,"briefTitle":9112,"status":123,"phases":9113,"primaryCompletion":9096,"completion":9096,"start":9114,"enrollment":9115,"conditions":9116,"interventions":9117},"NCT00046748","Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma",[93],"2001-12",484,[18],[6218],{"nctId":9119,"briefTitle":9120,"status":123,"phases":9121,"primaryCompletion":3473,"completion":3473,"start":966,"enrollment":3587,"conditions":9122,"interventions":9123},"NCT00396409","Efficacy\u002F Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis",[93],[9070],[9124,6218],"Depigoid",{"nctId":9126,"briefTitle":9127,"status":123,"phases":9128,"primaryCompletion":1714,"completion":1714,"start":895,"enrollment":5948,"conditions":9129,"interventions":9130},"NCT01328886","Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children",[93],[9070],[6218],{"nctId":9132,"briefTitle":9133,"status":123,"phases":9134,"primaryCompletion":9135,"completion":165,"start":9136,"enrollment":7643,"conditions":9137,"interventions":9138},"NCT03328897","Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria",[93],"2019-07-23","2017-04-26",[33],[6218],{"nctId":6209,"briefTitle":6210,"status":147,"phases":9140,"primaryCompletion":6212,"completion":6213,"start":6214,"enrollment":6215,"conditions":9141,"interventions":9142},[93],[33],[6111,6218],{"nctId":9144,"briefTitle":9145,"status":123,"phases":9146,"primaryCompletion":3760,"completion":3760,"start":4975,"enrollment":4360,"conditions":9147,"interventions":9148},"NCT01007149","Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma",[93],[18],[9072],{"nctId":9150,"briefTitle":9151,"status":123,"phases":9152,"primaryCompletion":9153,"completion":9154,"start":1749,"enrollment":9155,"conditions":9156,"interventions":9158},"NCT03369704","Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients",[93],"2018-05-11","2018-10-20",337,[9157],"Seasonal Allergic Rhinitis",[6218],{"nctId":9160,"briefTitle":9161,"status":123,"phases":9162,"primaryCompletion":1671,"completion":1671,"start":3351,"enrollment":2428,"conditions":9163,"interventions":9164},"NCT01155700","Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)",[93],[9070],[9072],{"nctId":9166,"briefTitle":9167,"status":123,"phases":9168,"primaryCompletion":2762,"completion":2762,"start":1731,"enrollment":9169,"conditions":9170,"interventions":9172},"NCT02329223","Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients",[93],218,[9171],"Chronic Spontaneous Uriticaria",[6218],{"nctId":9174,"briefTitle":9175,"status":123,"phases":9176,"primaryCompletion":9177,"completion":9177,"start":9178,"enrollment":9179,"conditions":9180,"interventions":9181},"NCT02161562","OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients",[93],"2016-11-03","2014-08-01",314,[33],[9072,9072],{"nctId":9183,"briefTitle":9184,"status":123,"phases":9185,"primaryCompletion":7457,"completion":9186,"start":9187,"enrollment":9188,"conditions":9189,"interventions":9190},"NCT03580369","A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines",[93],"2022-06-14","2018-10-17",1072,[33],[9191,6218],"Ligelizumab",{"nctId":9193,"briefTitle":9194,"status":123,"phases":9195,"primaryCompletion":6759,"completion":9186,"start":9154,"enrollment":9196,"conditions":9197,"interventions":9198},"NCT03580356","A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.",[93],1078,[33],[9191,6218],{"trials":9200,"activeCount":103},[9201,9211,9217,9221,9228],{"nctId":9202,"briefTitle":9203,"status":123,"phases":9204,"primaryCompletion":9205,"completion":9205,"start":9206,"enrollment":2948,"conditions":9207,"interventions":9209},"NCT02550106","Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment",[94],"2016-01-11","2015-04-22",[9208],"CHRONIC SPONTANEOUS URTICARIA",[9210],"OMALIZUMAB",{"nctId":9212,"briefTitle":9213,"status":123,"phases":9214,"primaryCompletion":1025,"completion":1025,"start":3657,"enrollment":827,"conditions":9215,"interventions":9216},"NCT00454051","Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma",[94],[18],[6218],{"nctId":7833,"briefTitle":7834,"status":134,"phases":9218,"primaryCompletion":7836,"completion":7837,"start":7838,"enrollment":1034,"conditions":9219,"interventions":9220},[94],[7840],[6218,7811,7842,7811,7842],{"nctId":9222,"briefTitle":9223,"status":123,"phases":9224,"primaryCompletion":964,"completion":964,"start":3400,"enrollment":9225,"conditions":9226,"interventions":9227},"NCT00870584","Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma",[94],271,[9090],[6218],{"nctId":9229,"briefTitle":9230,"status":134,"phases":9231,"primaryCompletion":864,"completion":864,"start":3490,"enrollment":814,"conditions":9232,"interventions":9235},"NCT00787917","An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)",[94],[9233,9234],"Cystic Fibrosis","Allergic Bronchopulmonary Aspergillosis",[6218,9236],"Itraconazole",{"trials":9238,"activeCount":103},[9239,9248],{"nctId":9240,"briefTitle":9241,"status":123,"phases":9242,"primaryCompletion":9243,"completion":9243,"start":9244,"enrollment":9245,"conditions":9246,"interventions":9247},"NCT05157087","XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States",[],"2020-12-01","2020-03-01",16246,[18],[6218],{"nctId":9249,"briefTitle":9250,"status":123,"phases":9251,"primaryCompletion":9252,"completion":9252,"start":9253,"enrollment":919,"conditions":9254,"interventions":9255},"NCT05424523","Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.",[],"2021-06-28","2021-02-25",[9070],[6218],{"intervention":3015,"totalTrials":317,"cells":9257},{"EARLY_PHASE1":9258,"PHASE1":9260,"PHASE2":9262,"PHASE3":9264,"PHASE4":9270,"NA":9272},{"trials":9259,"activeCount":103},[],{"trials":9261,"activeCount":103},[],{"trials":9263,"activeCount":103},[],{"trials":9265,"activeCount":437,"soonestReadout":8496},[9266],{"nctId":8493,"briefTitle":8494,"status":109,"phases":9267,"primaryCompletion":8496,"completion":8497,"start":6123,"enrollment":8498,"conditions":9268,"interventions":9269},[93],[2778],[8482,3015],{"trials":9271,"activeCount":103},[],{"trials":9273,"activeCount":103},[9274,9278],{"nctId":2997,"briefTitle":2998,"status":123,"phases":9275,"primaryCompletion":3000,"completion":3000,"start":3001,"enrollment":3002,"conditions":9276,"interventions":9277},[],[27],[3005,2765],{"nctId":3007,"briefTitle":3008,"status":123,"phases":9279,"primaryCompletion":3010,"completion":3010,"start":3011,"enrollment":213,"conditions":9280,"interventions":9281},[],[3013],[3015,2752],{"intervention":2837,"totalTrials":317,"cells":9283},{"EARLY_PHASE1":9284,"PHASE1":9286,"PHASE2":9288,"PHASE3":9290,"PHASE4":9305,"NA":9307},{"trials":9285,"activeCount":103},[],{"trials":9287,"activeCount":103},[],{"trials":9289,"activeCount":103},[],{"trials":9291,"activeCount":437,"soonestReadout":2829},[9292,9296],{"nctId":2826,"briefTitle":2827,"status":147,"phases":9293,"primaryCompletion":2829,"completion":2830,"start":2831,"enrollment":2832,"conditions":9294,"interventions":9295},[93],[2834],[2836,2752,2837],{"nctId":9297,"briefTitle":9298,"status":123,"phases":9299,"primaryCompletion":9300,"completion":9300,"start":9301,"enrollment":2910,"conditions":9302,"interventions":9304},"NCT03623243","Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients",[93],"2022-07-06","2019-02-14",[27,2778,9303],"Advancing Multiple Sclerosis",[2837],{"trials":9306,"activeCount":103},[],{"trials":9308,"activeCount":103},[9309],{"nctId":9310,"briefTitle":9311,"status":1326,"phases":9312,"conditions":9313,"interventions":9314},"NCT04540861","Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease",[],[27],[2837],{"intervention":9316,"totalTrials":1562,"cells":9317},"rapcabtagene autoleucel",{"EARLY_PHASE1":9318,"PHASE1":9320,"PHASE2":9322,"PHASE3":9392,"PHASE4":9394,"NA":9396},{"trials":9319,"activeCount":103},[],{"trials":9321,"activeCount":103},[],{"trials":9323,"activeCount":1562,"soonestReadout":9366},[9324,9336,9346,9355,9362,9373,9382],{"nctId":9325,"briefTitle":9326,"status":109,"phases":9327,"primaryCompletion":9328,"completion":9329,"start":9330,"enrollment":9331,"conditions":9332,"interventions":9334},"NCT06665256","Phase 2 Study of Rapcabtagene Autoleucel in Myositis",[92],"2029-03-09","2032-11-29","2024-12-17",123,[9333],"Idiopathic Inflammatory Myopathies",[9335],"Rapcabtagene autoleucel",{"nctId":9337,"briefTitle":9338,"status":109,"phases":9339,"primaryCompletion":9340,"completion":9341,"start":8982,"enrollment":5080,"conditions":9342,"interventions":9344},"NCT06868290","Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA",[92],"2029-06-07","2030-05-24",[9343],"ANCA Associated Vasculitis (AAV)",[9335,9345],"Glucocorticoids",{"nctId":9347,"briefTitle":9348,"status":109,"phases":9349,"primaryCompletion":9350,"completion":9350,"start":9351,"enrollment":2046,"conditions":9352,"interventions":9354},"NCT06675864","Open-label, Multi-center, Phase I\u002FII Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)",[91,92],"2030-06-14","2024-12-12",[9353],"Progressive Multiple Sclerosis",[9316],{"nctId":9356,"briefTitle":9357,"status":109,"phases":9358,"primaryCompletion":9359,"completion":9359,"start":6484,"enrollment":2046,"conditions":9360,"interventions":9361},"NCT06617793","An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis",[91,92],"2030-10-01",[2778],[9316],{"nctId":9363,"briefTitle":9364,"status":109,"phases":9365,"primaryCompletion":9366,"completion":9367,"start":9368,"enrollment":9369,"conditions":9370,"interventions":9372},"NCT06581198","A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE\u002FLN)",[92],"2028-02-14","2032-02-06","2024-09-04",179,[9371,1800],"Lupus Erythematosus, Systemic",[9316],{"nctId":9374,"briefTitle":9375,"status":109,"phases":9376,"primaryCompletion":9377,"completion":9377,"start":9378,"enrollment":34,"conditions":9379,"interventions":9381},"NCT07048197","A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease",[91,92],"2028-11-01","2025-06-20",[9380],"Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)",[9335],{"nctId":9383,"briefTitle":9384,"status":109,"phases":9385,"primaryCompletion":444,"completion":9386,"start":9387,"enrollment":1750,"conditions":9388,"interventions":9390},"NCT06655896","Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis",[92],"2032-08-30","2024-10-29",[9389],"Scleroderma, Diffuse",[9316,9391],"rituximab",{"trials":9393,"activeCount":103},[],{"trials":9395,"activeCount":103},[],{"trials":9397,"activeCount":103},[],{"intervention":117,"totalTrials":1630,"cells":9399},{"EARLY_PHASE1":9400,"PHASE1":9402,"PHASE2":9432,"PHASE3":9442,"PHASE4":9444,"NA":9446},{"trials":9401,"activeCount":103},[],{"trials":9403,"activeCount":317,"soonestReadout":9412},[9404,9408,9423],{"nctId":107,"briefTitle":108,"status":109,"phases":9405,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":9406,"interventions":9407},[91],[15],[117,118,98,119],{"nctId":9409,"briefTitle":9410,"status":147,"phases":9411,"primaryCompletion":9412,"completion":9412,"start":9413,"enrollment":827,"conditions":9414,"interventions":9416},"NCT06379217","NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.",[91],"2026-08-24","2024-07-29",[9415],"Metastatic Neuroendocrine Prostate Cancer",[6907,9417,117,6696,9418,118,9419,1578,9420,9421,9422],"[68Ga]GA-DOTA-TATE","[177Lu]Lu-DOTA-TATE","L-Lysine HCl-L-Arginine HCl, 2.5 %,","GnRH antagonists","Antiemetics & antinauseants","Metoclopramide",{"nctId":9424,"briefTitle":9425,"status":147,"phases":9426,"primaryCompletion":9427,"completion":9427,"start":9428,"enrollment":25,"conditions":9429,"interventions":9431},"NCT05739942","Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma",[91],"2028-11-08","2024-05-15",[9430],"Newly Diagnosed and Recurrent Glioblastoma",[118,117],{"trials":9433,"activeCount":437,"soonestReadout":9438},[9434],{"nctId":9435,"briefTitle":9436,"status":109,"phases":9437,"primaryCompletion":9438,"completion":9438,"start":9439,"enrollment":3064,"conditions":9440,"interventions":9441},"NCT06247995","A Phase I\u002FII, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4\u002F6 Inhibitor.",[91,92],"2031-09-09","2024-08-14",[15],[117,118,4451],{"trials":9443,"activeCount":103},[],{"trials":9445,"activeCount":103},[],{"trials":9447,"activeCount":103},[],{"intervention":118,"totalTrials":1630,"cells":9449},{"EARLY_PHASE1":9450,"PHASE1":9452,"PHASE2":9466,"PHASE3":9472,"PHASE4":9474,"NA":9476},{"trials":9451,"activeCount":103},[],{"trials":9453,"activeCount":317,"soonestReadout":9412},[9454,9458,9462],{"nctId":107,"briefTitle":108,"status":109,"phases":9455,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":9456,"interventions":9457},[91],[15],[117,118,98,119],{"nctId":9409,"briefTitle":9410,"status":147,"phases":9459,"primaryCompletion":9412,"completion":9412,"start":9413,"enrollment":827,"conditions":9460,"interventions":9461},[91],[9415],[6907,9417,117,6696,9418,118,9419,1578,9420,9421,9422],{"nctId":9424,"briefTitle":9425,"status":147,"phases":9463,"primaryCompletion":9427,"completion":9427,"start":9428,"enrollment":25,"conditions":9464,"interventions":9465},[91],[9430],[118,117],{"trials":9467,"activeCount":437,"soonestReadout":9438},[9468],{"nctId":9435,"briefTitle":9436,"status":109,"phases":9469,"primaryCompletion":9438,"completion":9438,"start":9439,"enrollment":3064,"conditions":9470,"interventions":9471},[91,92],[15],[117,118,4451],{"trials":9473,"activeCount":103},[],{"trials":9475,"activeCount":103},[],{"trials":9477,"activeCount":103},[],{"intervention":9479,"totalTrials":1630,"cells":9480},"Enzalutamide",{"EARLY_PHASE1":9481,"PHASE1":9483,"PHASE2":9496,"PHASE3":9535,"PHASE4":9537,"NA":9539},{"trials":9482,"activeCount":103},[],{"trials":9484,"activeCount":437,"soonestReadout":9489},[9485],{"nctId":9486,"briefTitle":9487,"status":109,"phases":9488,"primaryCompletion":9489,"completion":9489,"start":9490,"enrollment":6024,"conditions":9491,"interventions":9492},"NCT07570979","A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer",[91],"2030-06-03","2026-05-25",[599],[9493,9479,9494,9495],"INR731","Abiraterone","Androgen deprivation therapy",{"trials":9497,"activeCount":317,"soonestReadout":9502},[9498,9509,9524],{"nctId":9499,"briefTitle":9500,"status":109,"phases":9501,"primaryCompletion":9502,"completion":9503,"start":9504,"enrollment":9331,"conditions":9505,"interventions":9507},"NCT07226986","A Phase Ib\u002FII Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC",[91,92],"2028-07-10","2029-09-13","2025-12-05",[9506],"PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy",[9508,9479,9494],"AMO959",{"nctId":9510,"briefTitle":9511,"status":109,"phases":9512,"primaryCompletion":9513,"completion":9513,"start":9514,"enrollment":1798,"conditions":9515,"interventions":9522},"NCT04104776","A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas",[91,92],"2030-02-27","2019-09-18",[9516,9517,9518,9519,9520,856,9521,587],"Advanced Solid Tumor","Diffuse Large B Cell Lymphoma","Lymphoma, T-Cell","Mesothelioma, Malignant","Prostatic Neoplasms, Castration-Resistant","Ovarian Clear Cell Carcinoma",[9523,9479],"Tulmimetostat",{"nctId":9525,"briefTitle":9526,"status":109,"phases":9527,"primaryCompletion":9528,"completion":9529,"start":9530,"enrollment":9531,"conditions":9532,"interventions":9534},"NCT06991556","An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",[92],"2032-03-29","2035-10-19","2025-07-07",150,[9533],"Metastatic Hormone-sensitive Prostate Cancer",[1604,9494,9479],{"trials":9536,"activeCount":103},[],{"trials":9538,"activeCount":103},[],{"trials":9540,"activeCount":103},[],{"intervention":9494,"totalTrials":1630,"cells":9542},{"EARLY_PHASE1":9543,"PHASE1":9545,"PHASE2":9551,"PHASE3":9571,"PHASE4":9573,"NA":9575},{"trials":9544,"activeCount":103},[],{"trials":9546,"activeCount":437,"soonestReadout":9489},[9547],{"nctId":9486,"briefTitle":9487,"status":109,"phases":9548,"primaryCompletion":9489,"completion":9489,"start":9490,"enrollment":6024,"conditions":9549,"interventions":9550},[91],[599],[9493,9479,9494,9495],{"trials":9552,"activeCount":317,"soonestReadout":9502},[9553,9563,9567],{"nctId":9554,"briefTitle":9555,"status":109,"phases":9556,"primaryCompletion":9557,"completion":9557,"start":1523,"enrollment":9558,"conditions":9559,"interventions":9561},"NCT07190300","TulmiSTAR-02: A Phase I\u002FII Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",[91,92],"2032-08-02",181,[9560],"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",[9523,9562,9494],"Darolutamide",{"nctId":9499,"briefTitle":9500,"status":109,"phases":9564,"primaryCompletion":9502,"completion":9503,"start":9504,"enrollment":9331,"conditions":9565,"interventions":9566},[91,92],[9506],[9508,9479,9494],{"nctId":9525,"briefTitle":9526,"status":109,"phases":9568,"primaryCompletion":9528,"completion":9529,"start":9530,"enrollment":9531,"conditions":9569,"interventions":9570},[92],[9533],[1604,9494,9479],{"trials":9572,"activeCount":103},[],{"trials":9574,"activeCount":103},[],{"trials":9576,"activeCount":103},[],{"intervention":9578,"totalTrials":1630,"cells":9579},"[68Ga]Ga-DOTA-TATE",{"EARLY_PHASE1":9580,"PHASE1":9582,"PHASE2":9595,"PHASE3":9606,"PHASE4":9618,"NA":9620},{"trials":9581,"activeCount":103},[],{"trials":9583,"activeCount":213,"soonestReadout":475},[9584,9588],{"nctId":9409,"briefTitle":9410,"status":147,"phases":9585,"primaryCompletion":9412,"completion":9412,"start":9413,"enrollment":827,"conditions":9586,"interventions":9587},[91],[9415],[6907,9417,117,6696,9418,118,9419,1578,9420,9421,9422],{"nctId":9589,"briefTitle":9590,"status":147,"phases":9591,"primaryCompletion":475,"completion":9592,"start":2937,"enrollment":1524,"conditions":9593,"interventions":9594},"NCT05109728","A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.",[91],"2027-07-31",[1150],[9418,9578],{"trials":9596,"activeCount":437,"soonestReadout":9328},[9597],{"nctId":9598,"briefTitle":9599,"status":147,"phases":9600,"primaryCompletion":9328,"completion":3948,"start":9601,"enrollment":630,"conditions":9602,"interventions":9604},"NCT05142696","A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab",[91,92],"2022-07-13",[9603],"Extensive Stage Small Cell Lung Cancer",[9418,9605,9578],"Atezolizumab",{"trials":9607,"activeCount":103},[9608],{"nctId":9609,"briefTitle":9610,"status":123,"phases":9611,"primaryCompletion":9612,"completion":9612,"start":9613,"enrollment":1660,"conditions":9614,"interventions":9616},"NCT06240741","A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan",[93],"2024-12-27","2024-03-21",[9615],"Neuroendocrine Neoplasms",[9578,9617],"68Ge\u002F68Ga Generator",{"trials":9619,"activeCount":103},[],{"trials":9621,"activeCount":103},[],{"intervention":3090,"totalTrials":2379,"cells":9623},{"EARLY_PHASE1":9624,"PHASE1":9626,"PHASE2":9636,"PHASE3":9675,"PHASE4":9677,"NA":9679},{"trials":9625,"activeCount":103},[],{"trials":9627,"activeCount":103},[9628],{"nctId":9629,"briefTitle":9630,"status":123,"phases":9631,"primaryCompletion":9632,"completion":9632,"start":2111,"enrollment":4733,"conditions":9633,"interventions":9635},"NCT04665154","A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers",[91],"2022-08-03",[9634],"Healthy Volunteers",[3090],{"trials":9637,"activeCount":317,"soonestReadout":4221},[9638,9642,9651,9655,9664],{"nctId":6522,"briefTitle":6523,"status":147,"phases":9639,"primaryCompletion":4221,"completion":6525,"start":6526,"enrollment":3475,"conditions":9640,"interventions":9641},[92],[1811],[6519,6529,3090,6530,6531,3112],{"nctId":9643,"briefTitle":9644,"status":147,"phases":9645,"primaryCompletion":6122,"completion":9646,"start":9647,"enrollment":837,"conditions":9648,"interventions":9650},"NCT04641442","Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations",[92],"2032-04-07","2020-12-18",[9649],"NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations",[3090],{"nctId":3081,"briefTitle":3082,"status":123,"phases":9652,"primaryCompletion":3084,"completion":3085,"start":3086,"enrollment":3087,"conditions":9653,"interventions":9654},[92],[3034],[3090,3017],{"nctId":9656,"briefTitle":9657,"status":109,"phases":9658,"primaryCompletion":9659,"completion":9659,"start":9660,"enrollment":1611,"conditions":9661,"interventions":9663},"NCT07203001","A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease",[92],"2029-05-24","2025-11-03",[9662],"Still´s Disease",[3090],{"nctId":9665,"briefTitle":9666,"status":123,"phases":9667,"primaryCompletion":9668,"completion":6640,"start":9669,"enrollment":827,"conditions":9670,"interventions":9672},"NCT06097663","A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)",[92],"2024-10-27","2024-02-15",[3180,9671],"Clonal Hematopoiesis of Indeterminate Potential (CHIP)",[3090,9673,3036,9674],"MAS825 Placebo","DFV890 placebo",{"trials":9676,"activeCount":103},[],{"trials":9678,"activeCount":103},[],{"trials":9680,"activeCount":103},[],{"intervention":1388,"totalTrials":1630,"cells":9682},{"EARLY_PHASE1":9683,"PHASE1":9685,"PHASE2":9695,"PHASE3":9721,"PHASE4":9723,"NA":9725},{"trials":9684,"activeCount":103},[],{"trials":9686,"activeCount":103},[9687],{"nctId":9688,"briefTitle":9689,"status":123,"phases":9690,"primaryCompletion":1073,"completion":3165,"start":9691,"enrollment":5681,"conditions":9692,"interventions":9694},"NCT06905327","A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects",[91],"2023-03-08",[9693],"Mild Hypertension",[1388],{"trials":9696,"activeCount":317,"soonestReadout":555},[9697,9708,9712],{"nctId":9698,"briefTitle":9699,"status":109,"phases":9700,"primaryCompletion":9701,"completion":9702,"start":9703,"enrollment":9704,"conditions":9705,"interventions":9707},"NCT07543120","An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.",[92],"2031-05-31","2031-11-30","2026-05-07",323,[9706],"Hypertension (HTN)",[1388],{"nctId":1378,"briefTitle":1379,"status":593,"phases":9709,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":9710,"interventions":9711},[92],[1386],[1388,1356,1389,1390],{"nctId":9713,"briefTitle":9714,"status":147,"phases":9715,"primaryCompletion":555,"completion":9716,"start":9717,"enrollment":9718,"conditions":9719,"interventions":9720},"NCT06857955","A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients",[92],"2028-04-05","2025-03-26",385,[21],[1388],{"trials":9722,"activeCount":103},[],{"trials":9724,"activeCount":103},[],{"trials":9726,"activeCount":103},[],{"intervention":1604,"totalTrials":317,"cells":9728},{"EARLY_PHASE1":9729,"PHASE1":9731,"PHASE2":9742,"PHASE3":9752,"PHASE4":9754,"NA":9756},{"trials":9730,"activeCount":103},[],{"trials":9732,"activeCount":437,"soonestReadout":9737},[9733],{"nctId":9734,"briefTitle":9735,"status":109,"phases":9736,"primaryCompletion":9737,"completion":9737,"start":9738,"enrollment":2367,"conditions":9739,"interventions":9741},"NCT07174063","A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer",[91],"2027-06-18","2025-11-14",[9740],"Metastatic Prostate Cancer (mCRPC)",[1604],{"trials":9743,"activeCount":213,"soonestReadout":1597},[9744,9748],{"nctId":1594,"briefTitle":1595,"status":147,"phases":9745,"primaryCompletion":1597,"completion":1598,"start":1599,"enrollment":1600,"conditions":9746,"interventions":9747},[92],[1602],[1604,1561],{"nctId":9525,"briefTitle":9526,"status":109,"phases":9749,"primaryCompletion":9528,"completion":9529,"start":9530,"enrollment":9531,"conditions":9750,"interventions":9751},[92],[9533],[1604,9494,9479],{"trials":9753,"activeCount":103},[],{"trials":9755,"activeCount":103},[],{"trials":9757,"activeCount":103},[],{"intervention":6696,"totalTrials":317,"cells":9759},{"EARLY_PHASE1":9760,"PHASE1":9762,"PHASE2":9768,"PHASE3":9778,"PHASE4":9780,"NA":9782},{"trials":9761,"activeCount":103},[],{"trials":9763,"activeCount":437,"soonestReadout":9412},[9764],{"nctId":9409,"briefTitle":9410,"status":147,"phases":9765,"primaryCompletion":9412,"completion":9412,"start":9413,"enrollment":827,"conditions":9766,"interventions":9767},[91],[9415],[6907,9417,117,6696,9418,118,9419,1578,9420,9421,9422],{"trials":9769,"activeCount":213,"soonestReadout":5991},[9770,9774],{"nctId":6899,"briefTitle":6900,"status":147,"phases":9771,"primaryCompletion":6902,"completion":6903,"start":6904,"enrollment":19,"conditions":9772,"interventions":9773},[92],[1613],[6696,6707,6907],{"nctId":6691,"briefTitle":6692,"status":147,"phases":9775,"primaryCompletion":5991,"completion":596,"start":2044,"enrollment":2149,"conditions":9776,"interventions":9777},[92],[1613],[6696,1615],{"trials":9779,"activeCount":103},[],{"trials":9781,"activeCount":103},[],{"trials":9783,"activeCount":103},[],{"intervention":9418,"totalTrials":317,"cells":9785},{"EARLY_PHASE1":9786,"PHASE1":9788,"PHASE2":9798,"PHASE3":9804,"PHASE4":9806,"NA":9808},{"trials":9787,"activeCount":103},[],{"trials":9789,"activeCount":213,"soonestReadout":475},[9790,9794],{"nctId":9409,"briefTitle":9410,"status":147,"phases":9791,"primaryCompletion":9412,"completion":9412,"start":9413,"enrollment":827,"conditions":9792,"interventions":9793},[91],[9415],[6907,9417,117,6696,9418,118,9419,1578,9420,9421,9422],{"nctId":9589,"briefTitle":9590,"status":147,"phases":9795,"primaryCompletion":475,"completion":9592,"start":2937,"enrollment":1524,"conditions":9796,"interventions":9797},[91],[1150],[9418,9578],{"trials":9799,"activeCount":437,"soonestReadout":9328},[9800],{"nctId":9598,"briefTitle":9599,"status":147,"phases":9801,"primaryCompletion":9328,"completion":3948,"start":9601,"enrollment":630,"conditions":9802,"interventions":9803},[91,92],[9603],[9418,9605,9578],{"trials":9805,"activeCount":103},[],{"trials":9807,"activeCount":103},[],{"trials":9809,"activeCount":103},[],{"intervention":7443,"totalTrials":1562,"cells":9811},{"EARLY_PHASE1":9812,"PHASE1":9814,"PHASE2":9826,"PHASE3":9871,"PHASE4":9891,"NA":9893},{"trials":9813,"activeCount":103},[],{"trials":9815,"activeCount":103},[9816],{"nctId":9817,"briefTitle":9818,"status":123,"phases":9819,"primaryCompletion":2034,"completion":2034,"start":9820,"enrollment":557,"conditions":9821,"interventions":9822},"NCT00093600","PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",[91],"2004-02",[5598],[9823,9824,9825],"cytarabine","daunorubicin hydrochloride","midostaurin",{"trials":9827,"activeCount":213,"soonestReadout":6371},[9828,9842,9853,9857],{"nctId":9829,"briefTitle":9830,"status":593,"phases":9831,"primaryCompletion":9832,"completion":9833,"start":221,"enrollment":2579,"conditions":9834,"interventions":9837},"NCT07387926","Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse\u002FRefractory (r\u002Fr) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)",[91,92],"2033-07-18","2036-06-18",[3204,9835,9836],"Leukemia, Lymphoblastic, Acute, Philadelphia-Positive","Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[9838,9839,5747,1169,8231,4064,7443,9840,9841],"Asciminib Adult formulation","Asciminib Pediatric formulation","Hydrocortisone","Prednisolone",{"nctId":9843,"briefTitle":9844,"status":390,"phases":9845,"primaryCompletion":6372,"completion":2938,"start":9846,"enrollment":103,"conditions":9847,"interventions":9849},"NCT03760445","HDM201 Added to CT in R\u002FR or Newly Diagnosed AML",[91,92],"2019-11-15",[9848],"Leukemia, Myeloid, Acute",[4393,9823,9850,9825,9851,9852,5207],"anthracycline","liposomal cytarabine\u002Fdaunorubicin","posaconazole",{"nctId":7432,"briefTitle":7433,"status":123,"phases":9854,"primaryCompletion":7435,"completion":7436,"start":7437,"enrollment":7438,"conditions":9855,"interventions":9856},[92],[7440],[7442,7443,5895],{"nctId":9858,"briefTitle":9859,"status":147,"phases":9860,"primaryCompletion":6371,"completion":9861,"start":9862,"enrollment":2633,"conditions":9863,"interventions":9865},"NCT03591510","A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML",[92],"2029-05-18","2019-03-13",[9864],"FLT3-mutated Acute Myeloid Leukemia",[9866,9867,7443,9868,9869,9870],"Midostaurin","Fludarabine","Daunorubicin or idarubicin","Mitoxantrone","Etoposide",{"trials":9872,"activeCount":103},[9873,9882],{"nctId":9874,"briefTitle":9875,"status":123,"phases":9876,"primaryCompletion":9877,"completion":9877,"start":9878,"enrollment":4670,"conditions":9879,"interventions":9880},"NCT03379727","Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.",[93],"2021-07-09","2018-02-13",[2569],[9866,7443,9881],"anthracycline ((daunorubicin or idarubicin): Induction Phase only",{"nctId":9883,"briefTitle":9884,"status":123,"phases":9885,"primaryCompletion":2795,"completion":2795,"start":905,"enrollment":9886,"conditions":9887,"interventions":9888},"NCT00333840","Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",[93],1106,[3228],[9889,9890,9823],"imatinib mesilate","interferon-alpha",{"trials":9892,"activeCount":103},[],{"trials":9894,"activeCount":103},[],{"intervention":1079,"totalTrials":1562,"cells":9896},{"EARLY_PHASE1":9897,"PHASE1":9899,"PHASE2":9916,"PHASE3":9949,"PHASE4":9960,"NA":9962},{"trials":9898,"activeCount":103},[],{"trials":9900,"activeCount":103},[9901,9905],{"nctId":1070,"briefTitle":1071,"status":134,"phases":9902,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":203,"conditions":9903,"interventions":9904},[91],[1076],[1078,184,173,158,211,212,1079],{"nctId":9906,"briefTitle":9907,"status":134,"phases":9908,"primaryCompletion":9909,"completion":9909,"start":9910,"enrollment":1423,"conditions":9911,"interventions":9914},"NCT04261439","A Phase I\u002FIb Study of NIZ985 Alone and in Combination With Spartalizumab",[91],"2023-12-27","2020-02-27",[9912,9913],"In Escalation: All Patients With Solid Tumors and Lymphoma","In Expansion: Melanoma, Non-small Cell Lung Cancer",[9915,212,1079],"NIZ985",{"trials":9917,"activeCount":213,"soonestReadout":6649},[9918,9929,9933,9937],{"nctId":9919,"briefTitle":9920,"status":134,"phases":9921,"primaryCompletion":9922,"completion":9922,"start":1277,"enrollment":1941,"conditions":9923,"interventions":9925},"NCT04952753","Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC",[92],"2025-01-20",[9924],"Metastatic Colorectal Cancer",[2411,9926,9927,9928,1079],"Bevacizumab","Modified FOLFOX6","FOLFIRI",{"nctId":1185,"briefTitle":1186,"status":593,"phases":9930,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":709,"conditions":9931,"interventions":9932},[91,92],[1192,1193],[1195,211,156,236,1196],{"nctId":6646,"briefTitle":6647,"status":147,"phases":9934,"primaryCompletion":6649,"completion":6649,"start":6650,"enrollment":6651,"conditions":9935,"interventions":9936},[91,92],[225,227,6653,6654,6655,6656,6657,6658,6659,6660],[235,211,1196],{"nctId":9938,"briefTitle":9939,"status":390,"phases":9940,"primaryCompletion":9941,"completion":9942,"start":1512,"enrollment":103,"conditions":9943,"interventions":9945},"NCT05809895","Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer",[92],"2029-07-17","2029-07-18",[9944],"Triple Negative Breast Cancer",[9946,1079,4321,9947,1168,8153,9948],"Ociperlimab","Nab-paclitaxel","Gemcitabine",{"trials":9950,"activeCount":103},[9951],{"nctId":9952,"briefTitle":9953,"status":390,"phases":9954,"primaryCompletion":9955,"completion":9956,"start":9957,"enrollment":103,"conditions":9958,"interventions":9959},"NCT05791097","Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.",[93],"2027-12-24","2027-12-26","2023-07-28",[5282],[9946,1079,8153,1168,5262,4375,4321,9947],{"trials":9961,"activeCount":103},[],{"trials":9963,"activeCount":103},[],{"intervention":2879,"totalTrials":1630,"cells":9965},{"EARLY_PHASE1":9966,"PHASE1":9968,"PHASE2":9970,"PHASE3":9984,"PHASE4":9990,"NA":9992},{"trials":9967,"activeCount":103},[],{"trials":9969,"activeCount":103},[],{"trials":9971,"activeCount":213,"soonestReadout":111},[9972,9976,9980],{"nctId":5978,"briefTitle":5979,"status":147,"phases":9973,"primaryCompletion":111,"completion":111,"start":5981,"enrollment":5982,"conditions":9974,"interventions":9975},[92],[5984],[5936,2879],{"nctId":6739,"briefTitle":6740,"status":134,"phases":9977,"primaryCompletion":6742,"completion":6742,"start":6743,"enrollment":5612,"conditions":9978,"interventions":9979},[92],[6745],[6722,2879],{"nctId":9383,"briefTitle":9384,"status":109,"phases":9981,"primaryCompletion":444,"completion":9386,"start":9387,"enrollment":1750,"conditions":9982,"interventions":9983},[92],[9389],[9316,9391],{"trials":9985,"activeCount":103},[9986],{"nctId":2871,"briefTitle":2872,"status":134,"phases":9987,"primaryCompletion":2632,"completion":2632,"start":2874,"enrollment":2875,"conditions":9988,"interventions":9989},[93],[2877],[2752,2879,2752,2879],{"trials":9991,"activeCount":103},[],{"trials":9993,"activeCount":103},[],{"intervention":6907,"totalTrials":317,"cells":9995},{"EARLY_PHASE1":9996,"PHASE1":9998,"PHASE2":10004,"PHASE3":10010,"PHASE4":10022,"NA":10024},{"trials":9997,"activeCount":103},[],{"trials":9999,"activeCount":437,"soonestReadout":9412},[10000],{"nctId":9409,"briefTitle":9410,"status":147,"phases":10001,"primaryCompletion":9412,"completion":9412,"start":9413,"enrollment":827,"conditions":10002,"interventions":10003},[91],[9415],[6907,9417,117,6696,9418,118,9419,1578,9420,9421,9422],{"trials":10005,"activeCount":437,"soonestReadout":6902},[10006],{"nctId":6899,"briefTitle":6900,"status":147,"phases":10007,"primaryCompletion":6902,"completion":6903,"start":6904,"enrollment":19,"conditions":10008,"interventions":10009},[92],[1613],[6696,6707,6907],{"trials":10011,"activeCount":103},[10012],{"nctId":10013,"briefTitle":10014,"status":123,"phases":10015,"primaryCompletion":10016,"completion":10016,"start":10017,"enrollment":6547,"conditions":10018,"interventions":10020},"NCT04838613","Study of Diagnostic Performance of [18F]CTT1057 in BCR",[93],"2023-11-23","2021-09-30",[6705,1654,10019],"Recurrence",[10021,6907],"[18F]CTT1057",{"trials":10023,"activeCount":103},[],{"trials":10025,"activeCount":103},[],{"intervention":515,"totalTrials":837,"cells":10027},{"EARLY_PHASE1":10028,"PHASE1":10030,"PHASE2":10107,"PHASE3":10153,"PHASE4":10155,"NA":10157},{"trials":10029,"activeCount":103},[],{"trials":10031,"activeCount":103},[10032,10041,10051,10058,10062,10071,10075,10084,10092,10096,10100],{"nctId":10033,"briefTitle":10034,"status":123,"phases":10035,"primaryCompletion":10036,"completion":9153,"start":5202,"enrollment":5948,"conditions":10037,"interventions":10040},"NCT02431481","Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011",[91],"2017-09-14",[10038,10039],"Normal Renal Function","Impaired Renal Function",[515],{"nctId":10042,"briefTitle":10043,"status":123,"phases":10044,"primaryCompletion":10045,"completion":10045,"start":10046,"enrollment":2439,"conditions":10047,"interventions":10050},"NCT02388620","Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011",[91],"2017-01-09","2015-03-25",[10048,10049],"Normal Hepatic Function","Impaired Hepatic Function",[515],{"nctId":10052,"briefTitle":10053,"status":123,"phases":10054,"primaryCompletion":10055,"completion":10055,"start":5114,"enrollment":837,"conditions":10056,"interventions":10057},"NCT01898845","A Phase I Study of LEE011 in Asian Patients",[91],"2015-01",[5614],[515],{"nctId":2363,"briefTitle":2364,"status":123,"phases":10059,"primaryCompletion":1899,"completion":1899,"start":2366,"enrollment":2367,"conditions":10060,"interventions":10061},[91],[2369],[2371,2341,515],{"nctId":10063,"briefTitle":10064,"status":134,"phases":10065,"primaryCompletion":10066,"completion":10066,"start":10067,"enrollment":7257,"conditions":10068,"interventions":10070},"NCT01747876","Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma",[91],"2017-06-29","2013-05-28",[10069,140],"Malignant Rhabdoid Tumors (MRT)",[515],{"nctId":507,"briefTitle":508,"status":123,"phases":10072,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":10073,"interventions":10074},[91],[15],[515,516,307,517],{"nctId":10076,"briefTitle":10077,"status":134,"phases":10078,"primaryCompletion":10079,"completion":10079,"start":313,"enrollment":4498,"conditions":10080,"interventions":10082},"NCT02734615","Phase I\u002FIb Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers",[91],"2021-09-13",[10081],"Advanced or Metastatic ER+ Breast Cancer",[10083,515,516],"LSZ102",{"nctId":10085,"briefTitle":10086,"status":123,"phases":10087,"primaryCompletion":10088,"completion":10088,"start":7552,"enrollment":5236,"conditions":10089,"interventions":10091},"NCT01237236","A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.",[91],"2017-03-09",[9516,10090],"Lymphomas",[515],{"nctId":529,"briefTitle":530,"status":123,"phases":10093,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":10094,"interventions":10095},[91],[536],[515,249,356,119,345],{"nctId":729,"briefTitle":730,"status":123,"phases":10097,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":10098,"interventions":10099},[91],[736],[515,738,249],{"nctId":10101,"briefTitle":10102,"status":123,"phases":10103,"primaryCompletion":3917,"completion":3917,"start":7435,"enrollment":223,"conditions":10104,"interventions":10106},"NCT02343172","Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma",[91],[10105],"Liposarcoma",[4393,515],{"trials":10108,"activeCount":213,"soonestReadout":10113},[10109,10118,10127,10131,10135,10145],{"nctId":10110,"briefTitle":10111,"status":147,"phases":10112,"primaryCompletion":10113,"completion":10113,"start":10114,"enrollment":2633,"conditions":10115,"interventions":10117},"NCT02934568","Ribociclib (LEE011) Rollover Study for Continued Access",[92],"2027-02-01","2016-12-15",[10116],"Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies",[515],{"nctId":10119,"briefTitle":10120,"status":123,"phases":10121,"primaryCompletion":5881,"completion":5881,"start":10122,"enrollment":2249,"conditions":10123,"interventions":10124},"NCT03484923","Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma",[92],"2018-09-10",[36],[4389,10125,159,10126,515],"LAG525","ACZ885",{"nctId":801,"briefTitle":802,"status":147,"phases":10128,"primaryCompletion":627,"completion":627,"start":804,"enrollment":805,"conditions":10129,"interventions":10130},[91,92],[15],[515,249,516],{"nctId":809,"briefTitle":810,"status":134,"phases":10132,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":10133,"interventions":10134},[92],[329],[515,344],{"nctId":10136,"briefTitle":10137,"status":123,"phases":10138,"primaryCompletion":10139,"completion":10139,"start":10140,"enrollment":5594,"conditions":10141,"interventions":10143},"NCT02300987","A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression",[92],"2018-02-21","2015-02-26",[10142],"Teratoma",[515,10144],"LEE011 Placebo",{"nctId":10146,"briefTitle":10147,"status":123,"phases":10148,"primaryCompletion":7721,"completion":7721,"start":10149,"enrollment":1574,"conditions":10150,"interventions":10152},"NCT02187783","LEE011 for Patients With CDK4\u002F6 Pathway Activated Tumors (SIGNATURE)",[92],"2014-08-25",[10151],"Tumors With CDK4\u002F6 Pathway Activation",[515],{"trials":10154,"activeCount":103},[],{"trials":10156,"activeCount":103},[],{"trials":10158,"activeCount":103},[],{"intervention":211,"totalTrials":1562,"cells":10160},{"EARLY_PHASE1":10161,"PHASE1":10163,"PHASE2":10204,"PHASE3":10214,"PHASE4":10216,"NA":10218},{"trials":10162,"activeCount":103},[],{"trials":10164,"activeCount":103},[10165,10173,10189,10193,10200],{"nctId":10166,"briefTitle":10167,"status":390,"phases":10168,"primaryCompletion":10169,"completion":10169,"start":10170,"enrollment":103,"conditions":10171,"interventions":10172},"NCT05490030","Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants",[91],"2025-06-26","2025-03-06",[2625],[211],{"nctId":10174,"briefTitle":10175,"status":134,"phases":10176,"primaryCompletion":10177,"completion":10177,"start":10178,"enrollment":10179,"conditions":10180,"interventions":10187},"NCT03114319","Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors",[91],"2025-07-04","2017-05-26",227,[10181,10182,10183,10184,36,10185,10186],"Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)","KRAS G12-mutant NSCLC","Esophageal Squamous Cell Cancer (SCC)","Head\u002FNeck SCC","Advanced Gastrointestinal Stromal Tumors (GIST)","Advanced NRAS\u002FBRAFT wt Cutaneous Melanoma",[211,10188],"TNO155 in combination with EGF816",{"nctId":1070,"briefTitle":1071,"status":134,"phases":10190,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":203,"conditions":10191,"interventions":10192},[91],[1076],[1078,184,173,158,211,212,1079],{"nctId":10194,"briefTitle":10195,"status":390,"phases":10196,"primaryCompletion":10197,"completion":10197,"start":5347,"enrollment":103,"conditions":10198,"interventions":10199},"NCT05541159","Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants",[91],"2025-07-15",[2635],[211],{"nctId":198,"briefTitle":199,"status":134,"phases":10201,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":10202,"interventions":10203},[91],[205,206,207,208,209],[211,212,98],{"trials":10205,"activeCount":213,"soonestReadout":6649},[10206,10210],{"nctId":1185,"briefTitle":1186,"status":593,"phases":10207,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":709,"conditions":10208,"interventions":10209},[91,92],[1192,1193],[1195,211,156,236,1196],{"nctId":6646,"briefTitle":6647,"status":147,"phases":10211,"primaryCompletion":6649,"completion":6649,"start":6650,"enrollment":6651,"conditions":10212,"interventions":10213},[91,92],[225,227,6653,6654,6655,6656,6657,6658,6659,6660],[235,211,1196],{"trials":10215,"activeCount":103},[],{"trials":10217,"activeCount":103},[],{"trials":10219,"activeCount":103},[],{"intervention":236,"totalTrials":637,"cells":10221},{"EARLY_PHASE1":10222,"PHASE1":10224,"PHASE2":10235,"PHASE3":10265,"PHASE4":10267,"NA":10269},{"trials":10223,"activeCount":103},[],{"trials":10225,"activeCount":103},[10226],{"nctId":10227,"briefTitle":10228,"status":134,"phases":10229,"primaryCompletion":10230,"completion":10230,"start":10231,"enrollment":734,"conditions":10232,"interventions":10234},"NCT02205398","Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",[91],"2017-01-20","2014-07-28",[10233,9924],"Squamous Cell Carcinoma of Head and Neck (SCCHN)",[159,236],{"trials":10236,"activeCount":213,"soonestReadout":220},[10237,10241,10254,10261],{"nctId":217,"briefTitle":218,"status":147,"phases":10238,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":10239,"interventions":10240},[91,92],[225,226,227,182,228,229,209,230,231,232,233],[235,156,98,236],{"nctId":10242,"briefTitle":10243,"status":134,"phases":10244,"primaryCompletion":10245,"completion":10245,"start":10246,"enrollment":9369,"conditions":10247,"interventions":10250},"NCT01602315","A Phase Ib\u002FII Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[91,92],"2016-09-16","2012-11-12",[10248,10249],"Recurrent Head and Neck Squamous Cell Carcinoma","Metastatic Head and Neck Squamous Cell Carcinoma",[10251,10252,236,10253],"BYL719 as film-coated (FC) whole","BYL719 as dispersible","BYL719 drink suspension",{"nctId":10255,"briefTitle":10256,"status":390,"phases":10257,"primaryCompletion":10258,"completion":10258,"start":2509,"enrollment":103,"conditions":10259,"interventions":10260},"NCT02143622","Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients",[91,92],"2018-08",[206],[7886,236],{"nctId":1185,"briefTitle":1186,"status":593,"phases":10262,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":709,"conditions":10263,"interventions":10264},[91,92],[1192,1193],[1195,211,156,236,1196],{"trials":10266,"activeCount":103},[],{"trials":10268,"activeCount":103},[],{"trials":10270,"activeCount":103},[],{"intervention":158,"totalTrials":637,"cells":10272},{"EARLY_PHASE1":10273,"PHASE1":10275,"PHASE2":10299,"PHASE3":10305,"PHASE4":10307,"NA":10309},{"trials":10274,"activeCount":103},[],{"trials":10276,"activeCount":437,"soonestReadout":149},[10277,10287,10291,10295],{"nctId":10278,"briefTitle":10279,"status":134,"phases":10280,"primaryCompletion":10281,"completion":10282,"start":5132,"enrollment":3713,"conditions":10283,"interventions":10286},"NCT02607813","Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations",[91],"2022-02-18","2022-02-19",[10284,6375,36,10285],"NSCLC","Other Solid Tumors",[158,4389],{"nctId":1070,"briefTitle":1071,"status":134,"phases":10288,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":203,"conditions":10289,"interventions":10290},[91],[1076],[1078,184,173,158,211,212,1079],{"nctId":145,"briefTitle":146,"status":147,"phases":10292,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":10293,"interventions":10294},[91],[153],[155,156,157,158,159,160],{"nctId":175,"briefTitle":176,"status":134,"phases":10296,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":10297,"interventions":10298},[91],[182,36],[158,184,173,98],{"trials":10300,"activeCount":437,"soonestReadout":290},[10301],{"nctId":287,"briefTitle":288,"status":147,"phases":10302,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":10303,"interventions":10304},[92],[36],[158,184,173,98],{"trials":10306,"activeCount":103},[],{"trials":10308,"activeCount":103},[],{"trials":10310,"activeCount":103},[],{"intervention":10312,"totalTrials":317,"cells":10313},"Gefitinib",{"EARLY_PHASE1":10314,"PHASE1":10316,"PHASE2":10322,"PHASE3":10343,"PHASE4":10345,"NA":10347},{"trials":10315,"activeCount":103},[],{"trials":10317,"activeCount":437,"soonestReadout":149},[10318],{"nctId":145,"briefTitle":146,"status":147,"phases":10319,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":10320,"interventions":10321},[91],[153],[155,156,157,158,159,160],{"trials":10323,"activeCount":437,"soonestReadout":10336},[10324,10332],{"nctId":10325,"briefTitle":10326,"status":123,"phases":10327,"primaryCompletion":10328,"completion":3031,"start":10329,"enrollment":1829,"conditions":10330,"interventions":10331},"NCT01610336","A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment",[92],"2016-06-10","2012-04-05",[128],[159,10312],{"nctId":10333,"briefTitle":10334,"status":147,"phases":10335,"primaryCompletion":10336,"completion":10336,"start":10337,"enrollment":1053,"conditions":10338,"interventions":10340},"NCT03040973","Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone",[92],"2027-07-30","2017-08-23",[10339],"Advanced Solid Tumors Which Are cMET-dependent",[8070,10341,10312,10342],"Nazartinib","Osimertinib",{"trials":10344,"activeCount":103},[],{"trials":10346,"activeCount":103},[],{"trials":10348,"activeCount":103},[],{"intervention":10350,"totalTrials":213,"cells":10351},"GIA632",{"EARLY_PHASE1":10352,"PHASE1":10354,"PHASE2":10356,"PHASE3":10377,"PHASE4":10379,"NA":10381},{"trials":10353,"activeCount":103},[],{"trials":10355,"activeCount":103},[],{"trials":10357,"activeCount":213,"soonestReadout":1276},[10358,10367],{"nctId":10359,"briefTitle":10360,"status":147,"phases":10361,"primaryCompletion":1276,"completion":10362,"start":10363,"enrollment":31,"conditions":10364,"interventions":10366},"NCT07220577","Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis",[92],"2027-09-06","2025-11-10",[10365],"Atopic Dermatitis",[10350],{"nctId":10368,"briefTitle":10369,"status":109,"phases":10370,"primaryCompletion":10371,"completion":10372,"start":10373,"enrollment":690,"conditions":10374,"interventions":10376},"NCT07431177","A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo",[92],"2028-06-06","2030-01-28","2026-03-09",[10375],"Non-segmental Vitiligo",[10350],{"trials":10378,"activeCount":103},[],{"trials":10380,"activeCount":103},[],{"trials":10382,"activeCount":103},[],{"intervention":10384,"totalTrials":213,"cells":10385},"VHB937",{"EARLY_PHASE1":10386,"PHASE1":10388,"PHASE2":10390,"PHASE3":10412,"PHASE4":10414,"NA":10416},{"trials":10387,"activeCount":103},[],{"trials":10389,"activeCount":103},[],{"trials":10391,"activeCount":213,"soonestReadout":10407},[10392,10403],{"nctId":10393,"briefTitle":10394,"status":109,"phases":10395,"primaryCompletion":10396,"completion":10397,"start":10398,"enrollment":10399,"conditions":10400,"interventions":10402},"NCT07094516","A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease",[92],"2028-09-14","2030-12-31","2025-08-07",407,[10401],"Alzheimer's Disease",[10384,10384],{"nctId":10404,"briefTitle":10405,"status":147,"phases":10406,"primaryCompletion":10407,"completion":9502,"start":1909,"enrollment":10408,"conditions":10409,"interventions":10411},"NCT06643481","A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)",[92],"2026-09-21",251,[10410],"Amyotrophic Lateral Sclerosis (ALS)",[10384],{"trials":10413,"activeCount":103},[],{"trials":10415,"activeCount":103},[],{"trials":10417,"activeCount":103},[],{"intervention":10419,"totalTrials":213,"cells":10420},"YTB323",{"EARLY_PHASE1":10421,"PHASE1":10423,"PHASE2":10425,"PHASE3":10443,"PHASE4":10445,"NA":10447},{"trials":10422,"activeCount":103},[],{"trials":10424,"activeCount":103},[],{"trials":10426,"activeCount":213,"soonestReadout":10439},[10427,10435],{"nctId":10428,"briefTitle":10429,"status":109,"phases":10430,"primaryCompletion":10431,"completion":10431,"start":10432,"enrollment":2367,"conditions":10433,"interventions":10434},"NCT06704269","Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis",[91,92],"2029-10-26","2025-04-22",[6063],[10419],{"nctId":10436,"briefTitle":10437,"status":147,"phases":10438,"primaryCompletion":10439,"completion":10439,"start":10440,"enrollment":4118,"conditions":10441,"interventions":10442},"NCT05798117","An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus",[91,92],"2026-09-24","2023-02-28",[5783,1800],[10419],{"trials":10444,"activeCount":103},[],{"trials":10446,"activeCount":103},[],{"trials":10448,"activeCount":103},[],{"intervention":9523,"totalTrials":213,"cells":10450},{"EARLY_PHASE1":10451,"PHASE1":10453,"PHASE2":10455,"PHASE3":10465,"PHASE4":10467,"NA":10469},{"trials":10452,"activeCount":103},[],{"trials":10454,"activeCount":103},[],{"trials":10456,"activeCount":213,"soonestReadout":9513},[10457,10461],{"nctId":9554,"briefTitle":9555,"status":109,"phases":10458,"primaryCompletion":9557,"completion":9557,"start":1523,"enrollment":9558,"conditions":10459,"interventions":10460},[91,92],[9560],[9523,9562,9494],{"nctId":9510,"briefTitle":9511,"status":109,"phases":10462,"primaryCompletion":9513,"completion":9513,"start":9514,"enrollment":1798,"conditions":10463,"interventions":10464},[91,92],[9516,9517,9518,9519,9520,856,9521,587],[9523,9479],{"trials":10466,"activeCount":103},[],{"trials":10468,"activeCount":103},[],{"trials":10470,"activeCount":103},[],{"intervention":5639,"totalTrials":4148,"cells":10472},{"EARLY_PHASE1":10473,"PHASE1":10475,"PHASE2":10477,"PHASE3":10542,"PHASE4":10548,"NA":10558},{"trials":10474,"activeCount":103},[],{"trials":10476,"activeCount":103},[],{"trials":10478,"activeCount":437,"soonestReadout":9832},[10479,10483,10487,10491,10495,10503,10513,10522,10532],{"nctId":5630,"briefTitle":5631,"status":390,"phases":10480,"primaryCompletion":5633,"completion":5633,"start":5634,"enrollment":103,"conditions":10481,"interventions":10482},[92],[5636],[2360,5638,5639],{"nctId":7386,"briefTitle":7387,"status":123,"phases":10484,"primaryCompletion":7389,"completion":7389,"start":7390,"enrollment":37,"conditions":10485,"interventions":10486},[92],[5994],[5895,5747],{"nctId":5641,"briefTitle":5642,"status":123,"phases":10488,"primaryCompletion":1723,"completion":1723,"start":3351,"enrollment":2112,"conditions":10489,"interventions":10490},[92],[5645,5646,5647],[2360,5649,5639],{"nctId":9829,"briefTitle":9830,"status":593,"phases":10492,"primaryCompletion":9832,"completion":9833,"start":221,"enrollment":2579,"conditions":10493,"interventions":10494},[91,92],[3204,9835,9836],[9838,9839,5747,1169,8231,4064,7443,9840,9841],{"nctId":10496,"briefTitle":10497,"status":123,"phases":10498,"primaryCompletion":4598,"completion":4598,"start":10499,"enrollment":1053,"conditions":10500,"interventions":10502},"NCT00708292","A Phase I-Ib\u002FII Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.",[91,92],"2008-07",[10501],"Relapsed or Refractory Multiple Myeloma",[7913,5746,5747],{"nctId":10504,"briefTitle":10505,"status":134,"phases":10506,"primaryCompletion":10507,"completion":10507,"start":313,"enrollment":2379,"conditions":10508,"interventions":10509},"NCT02720510","A Trial Evaluating Efficacy & Safety of RVD +\u002F- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)",[92],"2017-05-22",[5636],[10510,10511,5639,10512],"Revlimid","Velcade","Farydak",{"nctId":10514,"briefTitle":10515,"status":123,"phases":10516,"primaryCompletion":5114,"completion":5114,"start":1732,"enrollment":1495,"conditions":10517,"interventions":10519},"NCT01337752","Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency",[92],[5636,10518],"Renal Insufficiency",[10520,10521,5649,5639],"BHQ880","BHQ880 Placebo",{"nctId":10523,"briefTitle":10524,"status":123,"phases":10525,"primaryCompletion":4410,"completion":8048,"start":988,"enrollment":10526,"conditions":10527,"interventions":10528},"NCT00427999","Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer",[92],67,[1654],[4432,10529,10530,10531,5639],"Treosulfane","etoricoxib","pioglitazone",{"nctId":10533,"briefTitle":10534,"status":123,"phases":10535,"primaryCompletion":2467,"completion":10536,"start":10537,"enrollment":827,"conditions":10538,"interventions":10540},"NCT02290431","Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed\u002FRefractory Multiple Myeloma",[92],"2018-12-25","2014-12-16",[10539],"Relapse\u002FRefractory Multiple Myeloma",[10541,5649,5639],"LBH589",{"trials":10543,"activeCount":103},[10544],{"nctId":5738,"briefTitle":5739,"status":123,"phases":10545,"primaryCompletion":5741,"completion":5741,"start":5742,"enrollment":5743,"conditions":10546,"interventions":10547},[93],[5636],[4391,5746,5747],{"trials":10549,"activeCount":103},[10550],{"nctId":10551,"briefTitle":10552,"status":123,"phases":10553,"primaryCompletion":1817,"completion":1817,"start":5733,"enrollment":8659,"conditions":10554,"interventions":10556},"NCT01580020","Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO",[94],[10555],"Retinal Vein Occlusion",[10557,5747],"RFB002",{"trials":10559,"activeCount":103},[],{"intervention":212,"totalTrials":734,"cells":10561},{"EARLY_PHASE1":10562,"PHASE1":10564,"PHASE2":10612,"PHASE3":10668,"PHASE4":10674,"NA":10676},{"trials":10563,"activeCount":103},[],{"trials":10565,"activeCount":103},[10566,10579,10591,10600,10604,10608],{"nctId":10567,"briefTitle":10568,"status":134,"phases":10569,"primaryCompletion":10570,"completion":10570,"start":1808,"enrollment":2776,"conditions":10571,"interventions":10573},"NCT03742349","Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).",[91],"2023-02-06",[10572],"Triple Negative Breast Cancer (TNBC)",[10574,10125,10575,10576,10577,10578],"spartalizumab","NIR178","capmatinib","MCS110","canakinumab",{"nctId":10580,"briefTitle":10581,"status":390,"phases":10582,"primaryCompletion":10583,"completion":10583,"start":10584,"enrollment":103,"conditions":10585,"interventions":10588},"NCT04283526","Study of Select Combinations in Adults With Myelofibrosis",[91],"2024-04-11","2020-11-30",[2430,2369,10586,2432,10587],"PMF","Post-Polycythemia Vera Myelofibrosis",[10589,2411,212,10590],"MBG453","Decitabine",{"nctId":10592,"briefTitle":10593,"status":123,"phases":10594,"primaryCompletion":10595,"completion":10595,"start":10596,"enrollment":5594,"conditions":10597,"interventions":10598},"NCT03081494","Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer",[91],"2019-05-07","2017-06-09",[9924],[10574,10599],"regorafenib",{"nctId":1070,"briefTitle":1071,"status":134,"phases":10601,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":203,"conditions":10602,"interventions":10603},[91],[1076],[1078,184,173,158,211,212,1079],{"nctId":198,"briefTitle":199,"status":134,"phases":10605,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":10606,"interventions":10607},[91],[205,206,207,208,209],[211,212,98],{"nctId":9906,"briefTitle":9907,"status":134,"phases":10609,"primaryCompletion":9909,"completion":9909,"start":9910,"enrollment":1423,"conditions":10610,"interventions":10611},[91],[9912,9913],[9915,212,1079],{"trials":10613,"activeCount":437,"soonestReadout":9366},[10614,10623,10633,10637,10645,10656],{"nctId":10615,"briefTitle":10616,"status":134,"phases":10617,"primaryCompletion":10618,"completion":10619,"start":1120,"enrollment":827,"conditions":10620,"interventions":10621},"NCT04323436","Study of Capmatinib and Spartalizumab\u002FPlacebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations",[92],"2022-12-14","2023-01-26",[227],[212,8070,10622],"spartalizumab placebo",{"nctId":10624,"briefTitle":10625,"status":134,"phases":10626,"primaryCompletion":10627,"completion":10628,"start":7551,"enrollment":5841,"conditions":10629,"interventions":10631},"NCT04390763","Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)",[92],"2024-04-26","2024-05-02",[10630],"Metastatic Pancreatic Ductal Adenocarcinoma",[2411,212,10632,6342],"gemcitabine",{"nctId":8064,"briefTitle":8065,"status":123,"phases":10634,"primaryCompletion":8067,"completion":8067,"start":2853,"enrollment":3343,"conditions":10635,"interventions":10636},[92],[227],[8070,212,5252],{"nctId":10638,"briefTitle":10639,"status":123,"phases":10640,"primaryCompletion":10641,"completion":1465,"start":4677,"enrollment":3568,"conditions":10642,"interventions":10644},"NCT02795429","Phase Ib\u002FII Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC",[91,92],"2021-06-01",[10643],"Advanced Hepatocellular Carcinoma",[212,8070],{"nctId":10646,"briefTitle":10647,"status":123,"phases":10648,"primaryCompletion":10649,"completion":10650,"start":10651,"enrollment":203,"conditions":10652,"interventions":10654},"NCT02605967","Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma",[92],"2019-11-05","2021-02-19","2016-04-20",[10653],"Nasopharyngeal Carcinoma",[212,10655],"Investigator choice of chemotherapy",{"nctId":10657,"briefTitle":10658,"status":147,"phases":10659,"primaryCompletion":9366,"completion":9366,"start":5309,"enrollment":99,"conditions":10660,"interventions":10662},"NCT05201066","Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.",[92],[5723,10661],"Leukemia, Myelomonocytic, Chronic",[10663,10574,10664,10665,10666,10667],"decitabine","sabatolimab","azacitidine","venetoclax","INQOVI",{"trials":10669,"activeCount":103},[10670],{"nctId":1229,"briefTitle":1230,"status":134,"phases":10671,"primaryCompletion":1232,"completion":1233,"start":1234,"enrollment":1235,"conditions":10672,"interventions":10673},[93],[36],[212,1078,173],{"trials":10675,"activeCount":103},[],{"trials":10677,"activeCount":103},[],{"intervention":7513,"totalTrials":4148,"cells":10679},{"EARLY_PHASE1":10680,"PHASE1":10682,"PHASE2":10704,"PHASE3":10763,"PHASE4":10777,"NA":10779},{"trials":10681,"activeCount":103},[],{"trials":10683,"activeCount":103},[10684,10693],{"nctId":10685,"briefTitle":10686,"status":123,"phases":10687,"primaryCompletion":10688,"completion":10688,"start":10689,"enrollment":814,"conditions":10690,"interventions":10691},"NCT05155709","A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.",[91],"2024-04-17","2022-05-17",[2569],[10692,10666,10665],"siremadlin",{"nctId":10694,"briefTitle":10695,"status":123,"phases":10696,"primaryCompletion":10697,"completion":10697,"start":10698,"enrollment":180,"conditions":10699,"interventions":10703},"NCT03066648","Study of PDR001 and\u002For MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS",[91],"2023-09-08","2017-07-06",[3422,10700,9848,5723,10701,10702,3335,5724],"Leukemia, Myeloid","Preleukemia","Bone Marrow Diseases",[10590,4389,10589,7513],{"trials":10705,"activeCount":437,"soonestReadout":9366},[10706,10715,10723,10732,10740,10744,10753],{"nctId":10707,"briefTitle":10708,"status":134,"phases":10709,"primaryCompletion":10710,"completion":10710,"start":10711,"enrollment":1611,"conditions":10712,"interventions":10714},"NCT04812548","A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants",[92],"2023-05-08","2021-05-31",[10713],"Myelodysplastic Syndrome (MDS)",[10664,10665,10666],{"nctId":10716,"briefTitle":10717,"status":390,"phases":10718,"primaryCompletion":10431,"completion":10431,"start":10719,"enrollment":103,"conditions":10720,"interventions":10721},"NCT05367401","A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants",[91,92],"2024-12-20",[5723,2569],[2409,10722,7513],"Magrolimab",{"nctId":10724,"briefTitle":10725,"status":134,"phases":10726,"primaryCompletion":10727,"completion":10727,"start":10728,"enrollment":5882,"conditions":10729,"interventions":10730},"NCT04150029","A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy",[92],"2024-10-25","2020-09-01",[2569],[10589,10731,7513],"Venetoclax",{"nctId":10733,"briefTitle":10734,"status":134,"phases":10735,"primaryCompletion":10736,"completion":10736,"start":10737,"enrollment":630,"conditions":10738,"interventions":10739},"NCT04623216","Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.",[91,92],"2024-08-22","2021-09-14",[2569],[2409,7513],{"nctId":10657,"briefTitle":10658,"status":147,"phases":10741,"primaryCompletion":9366,"completion":9366,"start":5309,"enrollment":99,"conditions":10742,"interventions":10743},[92],[5723,10661],[10663,10574,10664,10665,10666,10667],{"nctId":10745,"briefTitle":10746,"status":134,"phases":10747,"primaryCompletion":10748,"completion":10749,"start":10750,"enrollment":28,"conditions":10751,"interventions":10752},"NCT04878432","STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS",[92],"2023-10-26","2024-09-01","2022-03-17",[10713],[10589,7513,10590,10667],{"nctId":10754,"briefTitle":10755,"status":134,"phases":10756,"primaryCompletion":10757,"completion":10757,"start":10758,"enrollment":437,"conditions":10759,"interventions":10761},"NCT02159040","Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.",[92],"2015-06-26","2014-09-11",[10760],"High Risk MDS",[7513,10762],"Azacitidine plus Deferasirox",{"trials":10764,"activeCount":103},[10765,10769],{"nctId":7505,"briefTitle":7506,"status":134,"phases":10766,"primaryCompletion":7508,"completion":7508,"start":7509,"enrollment":7510,"conditions":10767,"interventions":10768},[93],[7429],[5895,7513],{"nctId":10770,"briefTitle":10771,"status":134,"phases":10772,"primaryCompletion":10773,"completion":10773,"start":6338,"enrollment":10774,"conditions":10775,"interventions":10776},"NCT04266301","Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)",[93],"2024-10-02",530,[5723,10661],[2409,7513],{"trials":10778,"activeCount":103},[],{"trials":10780,"activeCount":103},[],{"intervention":4451,"totalTrials":422,"cells":10782},{"EARLY_PHASE1":10783,"PHASE1":10785,"PHASE2":10787,"PHASE3":10818,"PHASE4":10844,"NA":10846},{"trials":10784,"activeCount":103},[],{"trials":10786,"activeCount":103},[],{"trials":10788,"activeCount":437,"soonestReadout":9438},[10789,10793,10803,10810,10814],{"nctId":4442,"briefTitle":4443,"status":123,"phases":10790,"primaryCompletion":4445,"completion":4446,"start":4447,"enrollment":4448,"conditions":10791,"interventions":10792},[92],[15],[4451,195,196],{"nctId":10794,"briefTitle":10795,"status":123,"phases":10796,"primaryCompletion":10797,"completion":10798,"start":10799,"enrollment":1034,"conditions":10800,"interventions":10801},"NCT01013740","Lapatinib in Combination With Vinorelbine",[92],"2012-08-21","2016-03-01","2009-11-25",[1102],[10802,944,4451],"Vinorelbine",{"nctId":10804,"briefTitle":10805,"status":134,"phases":10806,"primaryCompletion":10807,"completion":10807,"start":5002,"enrollment":2149,"conditions":10808,"interventions":10809},"NCT02294786","Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer",[92],"2017-10-19",[1102],[944,4451,4831],{"nctId":7936,"briefTitle":7937,"status":134,"phases":10811,"primaryCompletion":7939,"completion":7939,"start":853,"enrollment":774,"conditions":10812,"interventions":10813},[91,92],[435,7941],[517,4320,4451],{"nctId":9435,"briefTitle":9436,"status":109,"phases":10815,"primaryCompletion":9438,"completion":9438,"start":9439,"enrollment":3064,"conditions":10816,"interventions":10817},[91,92],[15],[117,118,4451],{"trials":10819,"activeCount":103},[10820,10829,10833],{"nctId":10821,"briefTitle":10822,"status":134,"phases":10823,"primaryCompletion":10824,"completion":10825,"start":10826,"enrollment":3605,"conditions":10827,"interventions":10828},"NCT00508274","Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China",[93],"2015-12-02","2020-07-01","2007-07-18",[7868],[7870,7955],{"nctId":7946,"briefTitle":7947,"status":123,"phases":10830,"primaryCompletion":7949,"completion":939,"start":7950,"enrollment":7951,"conditions":10831,"interventions":10832},[93],[7953],[7955,7870,4780],{"nctId":10834,"briefTitle":10835,"status":123,"phases":10836,"primaryCompletion":10837,"completion":10838,"start":10839,"enrollment":2185,"conditions":10840,"interventions":10842},"NCT00680901","LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib",[93],"2012-09-24","2024-10-03","2008-06-04",[10841],"Neoplasms, Gastrointestinal Tract",[944,4451,10843],"Oxaliplatin",{"trials":10845,"activeCount":103},[],{"trials":10847,"activeCount":103},[],{"intervention":2409,"totalTrials":2379,"cells":10849},{"EARLY_PHASE1":10850,"PHASE1":10852,"PHASE2":10854,"PHASE3":10876,"PHASE4":10882,"NA":10884},{"trials":10851,"activeCount":103},[],{"trials":10853,"activeCount":103},[],{"trials":10855,"activeCount":437,"soonestReadout":9366},[10856,10860,10864,10868,10872],{"nctId":2399,"briefTitle":2400,"status":134,"phases":10857,"primaryCompletion":2402,"completion":2403,"start":2404,"enrollment":2405,"conditions":10858,"interventions":10859},[91,92],[2369],[2341,2408,63,2409,2410,2411],{"nctId":10707,"briefTitle":10708,"status":134,"phases":10861,"primaryCompletion":10710,"completion":10710,"start":10711,"enrollment":1611,"conditions":10862,"interventions":10863},[92],[10713],[10664,10665,10666],{"nctId":10716,"briefTitle":10717,"status":390,"phases":10865,"primaryCompletion":10431,"completion":10431,"start":10719,"enrollment":103,"conditions":10866,"interventions":10867},[91,92],[5723,2569],[2409,10722,7513],{"nctId":10733,"briefTitle":10734,"status":134,"phases":10869,"primaryCompletion":10736,"completion":10736,"start":10737,"enrollment":630,"conditions":10870,"interventions":10871},[91,92],[2569],[2409,7513],{"nctId":10657,"briefTitle":10658,"status":147,"phases":10873,"primaryCompletion":9366,"completion":9366,"start":5309,"enrollment":99,"conditions":10874,"interventions":10875},[92],[5723,10661],[10663,10574,10664,10665,10666,10667],{"trials":10877,"activeCount":103},[10878],{"nctId":10770,"briefTitle":10771,"status":134,"phases":10879,"primaryCompletion":10773,"completion":10773,"start":6338,"enrollment":10774,"conditions":10880,"interventions":10881},[93],[5723,10661],[2409,7513],{"trials":10883,"activeCount":103},[],{"trials":10885,"activeCount":103},[],{"intervention":10887,"totalTrials":317,"cells":10888},"KLU156",{"EARLY_PHASE1":10889,"PHASE1":10891,"PHASE2":10893,"PHASE3":10915,"PHASE4":10928,"NA":10930},{"trials":10890,"activeCount":103},[],{"trials":10892,"activeCount":103},[],{"trials":10894,"activeCount":437,"soonestReadout":10910},[10895,10906],{"nctId":10896,"briefTitle":10897,"status":123,"phases":10898,"primaryCompletion":10899,"completion":5347,"start":10900,"enrollment":1423,"conditions":10901,"interventions":10903},"NCT07235033","Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)",[92],"2025-03-05","2024-01-23",[10902],"Uncomplicated Plasmodium Falciparum Malaria",[10904,10905,10887],"KAE609","SoC",{"nctId":10907,"briefTitle":10908,"status":109,"phases":10909,"primaryCompletion":10910,"completion":10911,"start":10900,"enrollment":244,"conditions":10912,"interventions":10913},"NCT05750628","Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria",[92],"2026-06-09","2026-06-23",[10902],[10914,10904,10905,10887],"INE963",{"trials":10916,"activeCount":103},[10917],{"nctId":10918,"briefTitle":10919,"status":123,"phases":10920,"primaryCompletion":10921,"completion":10922,"start":10923,"enrollment":10924,"conditions":10925,"interventions":10926},"NCT05842954","Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria",[93],"2025-06-27","2025-11-25","2024-03-07",1720,[10902],[10887,10927],"Coartem",{"trials":10929,"activeCount":103},[],{"trials":10931,"activeCount":103},[],{"intervention":8231,"totalTrials":213,"cells":10933},{"EARLY_PHASE1":10934,"PHASE1":10936,"PHASE2":10938,"PHASE3":10944,"PHASE4":10950,"NA":10952},{"trials":10935,"activeCount":103},[],{"trials":10937,"activeCount":103},[],{"trials":10939,"activeCount":437,"soonestReadout":9832},[10940],{"nctId":9829,"briefTitle":9830,"status":593,"phases":10941,"primaryCompletion":9832,"completion":9833,"start":221,"enrollment":2579,"conditions":10942,"interventions":10943},[91,92],[3204,9835,9836],[9838,9839,5747,1169,8231,4064,7443,9840,9841],{"trials":10945,"activeCount":103},[10946],{"nctId":8223,"briefTitle":8224,"status":390,"phases":10947,"primaryCompletion":8226,"completion":8227,"start":8228,"enrollment":103,"conditions":10948,"interventions":10949},[93],[3204],[8139,8231,8232],{"trials":10951,"activeCount":103},[],{"trials":10953,"activeCount":103},[],{"intervention":10342,"totalTrials":213,"cells":10955},{"EARLY_PHASE1":10956,"PHASE1":10958,"PHASE2":10960,"PHASE3":10966,"PHASE4":10975,"NA":10977},{"trials":10957,"activeCount":103},[],{"trials":10959,"activeCount":103},[],{"trials":10961,"activeCount":437,"soonestReadout":10336},[10962],{"nctId":10333,"briefTitle":10334,"status":147,"phases":10963,"primaryCompletion":10336,"completion":10336,"start":10337,"enrollment":1053,"conditions":10964,"interventions":10965},[92],[10339],[8070,10341,10312,10342],{"trials":10967,"activeCount":103},[10968],{"nctId":10969,"briefTitle":10970,"status":134,"phases":10971,"primaryCompletion":137,"completion":137,"start":10972,"enrollment":2379,"conditions":10973,"interventions":10974},"NCT04816214","Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy",[93],"2021-09-22",[227],[8070,10342,4375,5262,1168],{"trials":10976,"activeCount":103},[],{"trials":10978,"activeCount":103},[],{"intervention":516,"totalTrials":138,"cells":10980},{"EARLY_PHASE1":10981,"PHASE1":10983,"PHASE2":11044,"PHASE3":11074,"PHASE4":11076,"NA":11078},{"trials":10982,"activeCount":103},[],{"trials":10984,"activeCount":103},[10985,10989,10998,11006,11013,11017,11021,11030,11040],{"nctId":8036,"briefTitle":8037,"status":123,"phases":10986,"primaryCompletion":8039,"completion":8039,"start":3673,"enrollment":114,"conditions":10987,"interventions":10988},[91],[8041],[7886,516,4321,5252,8043],{"nctId":10990,"briefTitle":10991,"status":123,"phases":10992,"primaryCompletion":10993,"completion":10993,"start":10994,"enrollment":1065,"conditions":10995,"interventions":10997},"NCT02051751","A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer",[91],"2016-08-19","2014-03-05",[10996],"Neoplasms, Breast Neoplasms, Head and Neck Neoplasms",[516,4321],{"nctId":10999,"briefTitle":11000,"status":123,"phases":11001,"primaryCompletion":11002,"completion":11002,"start":11003,"enrollment":99,"conditions":11004,"interventions":11005},"NCT01387321","A Study of BYL719 in Adult Patients With Advanced Solid Malignancies",[91],"2015-11-25","2011-09-22",[9516],[516],{"nctId":11007,"briefTitle":11008,"status":123,"phases":11009,"primaryCompletion":4093,"completion":4093,"start":3604,"enrollment":3343,"conditions":11010,"interventions":11012},"NCT01613950","PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer",[91],[11011],"Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein",[7913,516],{"nctId":507,"briefTitle":508,"status":123,"phases":11014,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":11015,"interventions":11016},[91],[15],[515,516,307,517],{"nctId":10076,"briefTitle":10077,"status":134,"phases":11018,"primaryCompletion":10079,"completion":10079,"start":313,"enrollment":4498,"conditions":11019,"interventions":11020},[91],[10081],[10083,515,516],{"nctId":11022,"briefTitle":11023,"status":123,"phases":11024,"primaryCompletion":11025,"completion":11025,"start":813,"enrollment":2149,"conditions":11026,"interventions":11028},"NCT01928459","Phase 1b Trial of BGJ398\u002FBYL719 in Solid Tumors",[91],"2016-08",[5614,11027],"Metastatic Solid Tumors",[11029,516],"BGJ398",{"nctId":11031,"briefTitle":11032,"status":123,"phases":11033,"primaryCompletion":11034,"completion":11034,"start":11035,"enrollment":1611,"conditions":11036,"interventions":11038},"NCT02144038","Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma",[91],"2015-10-28","2014-07-23",[11037],"Relapsed and Refractory Multiple Myeloma",[11039,516],"LGH447",{"nctId":539,"briefTitle":540,"status":123,"phases":11041,"primaryCompletion":542,"completion":190,"start":543,"enrollment":544,"conditions":11042,"interventions":11043},[91],[546,547],[516,119],{"trials":11045,"activeCount":437,"soonestReadout":627},[11046,11058,11062],{"nctId":11047,"briefTitle":11048,"status":134,"phases":11049,"primaryCompletion":11050,"completion":11051,"start":11052,"enrollment":846,"conditions":11053,"interventions":11056},"NCT01708161","A Phase Ib\u002FII Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors",[91,92],"2014-12-26","2017-06-01","2012-11-27",[11054,11055],"PIK3CA Mutated Advanced Solid Tumors","PIK3CA Amplified Advanced Solid Tumors",[516,11057],"AMG 479",{"nctId":801,"briefTitle":802,"status":147,"phases":11059,"primaryCompletion":627,"completion":627,"start":804,"enrollment":805,"conditions":11060,"interventions":11061},[91,92],[15],[515,249,516],{"nctId":11063,"briefTitle":11064,"status":123,"phases":11065,"primaryCompletion":11066,"completion":11066,"start":11067,"enrollment":11068,"conditions":11069,"interventions":11071},"NCT02276027","A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer",[92],"2019-10-15","2015-01-20",66,[11070],"Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma",[516,159,11072,11073],"LDK378","MEK162",{"trials":11075,"activeCount":103},[],{"trials":11077,"activeCount":103},[],{"trials":11079,"activeCount":103},[],{"intervention":6519,"totalTrials":5594,"cells":11081},{"EARLY_PHASE1":11082,"PHASE1":11084,"PHASE2":11095,"PHASE3":11159,"PHASE4":11161,"NA":11163},{"trials":11083,"activeCount":103},[],{"trials":11085,"activeCount":103},[11086],{"nctId":11087,"briefTitle":11088,"status":123,"phases":11089,"primaryCompletion":11090,"completion":11090,"start":11091,"enrollment":11092,"conditions":11093,"interventions":11094},"NCT02089087","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients",[91],"2017-02-03","2013-01-07",75,[1717],[6519],{"trials":11096,"activeCount":437,"soonestReadout":4221},[11097,11101,11105,11115,11123,11130,11139,11143,11151],{"nctId":6510,"briefTitle":6511,"status":123,"phases":11098,"primaryCompletion":5830,"completion":6513,"start":5791,"enrollment":6514,"conditions":11099,"interventions":11100},[92],[6516],[3112,6518,6519,6520],{"nctId":6522,"briefTitle":6523,"status":147,"phases":11102,"primaryCompletion":4221,"completion":6525,"start":6526,"enrollment":3475,"conditions":11103,"interventions":11104},[92],[1811],[6519,6529,3090,6530,6531,3112],{"nctId":11106,"briefTitle":11107,"status":123,"phases":11108,"primaryCompletion":11109,"completion":11110,"start":11111,"enrollment":11112,"conditions":11113,"interventions":11114},"NCT03905525","Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome",[92],"2022-09-28","2023-06-06","2019-10-01",273,[6145],[6519],{"nctId":11116,"briefTitle":11117,"status":123,"phases":11118,"primaryCompletion":11119,"completion":11119,"start":11120,"enrollment":3530,"conditions":11121,"interventions":11122},"NCT03610516","Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.",[92],"2023-06-29","2018-09-12",[1800],[6519],{"nctId":11124,"briefTitle":11125,"status":123,"phases":11126,"primaryCompletion":201,"completion":11127,"start":381,"enrollment":22,"conditions":11128,"interventions":11129},"NCT04129528","Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects",[92],"2024-06-04",[1741],[6519],{"nctId":11131,"briefTitle":11132,"status":134,"phases":11133,"primaryCompletion":351,"completion":351,"start":11134,"enrollment":2832,"conditions":11135,"interventions":11137},"NCT03781414","Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension",[92],"2019-10-07",[11136],"Liver Transplant Rejection",[6519,11138],"Tacrolimus - MMF - corticosteroids",{"nctId":7622,"briefTitle":7623,"status":123,"phases":11140,"primaryCompletion":7625,"completion":7625,"start":542,"enrollment":3322,"conditions":11141,"interventions":11142},[91,92],[4691],[6519,4765,4768,4769,7628],{"nctId":11144,"briefTitle":11145,"status":123,"phases":11146,"primaryCompletion":2898,"completion":2898,"start":11147,"enrollment":2367,"conditions":11148,"interventions":11150},"NCT02713256","A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease",[92],"2016-04-19",[11149],"Graves' Disease",[6519],{"nctId":11152,"briefTitle":11153,"status":123,"phases":11154,"primaryCompletion":11155,"completion":1920,"start":2499,"enrollment":22,"conditions":11156,"interventions":11158},"NCT02565576","Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis",[92],"2017-07-31",[11157],"Myasthenia Gravis, Generalized",[6519],{"trials":11160,"activeCount":103},[],{"trials":11162,"activeCount":103},[],{"trials":11164,"activeCount":103},[],{"intervention":10904,"totalTrials":422,"cells":11166},{"EARLY_PHASE1":11167,"PHASE1":11169,"PHASE2":11187,"PHASE3":11223,"PHASE4":11225,"NA":11227},{"trials":11168,"activeCount":103},[],{"trials":11170,"activeCount":103},[11171,11179],{"nctId":11172,"briefTitle":11173,"status":123,"phases":11174,"primaryCompletion":11175,"completion":11175,"start":1074,"enrollment":3530,"conditions":11176,"interventions":11178},"NCT04321252","Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects",[91],"2020-11-10",[11177],"Malaria",[10904],{"nctId":11180,"briefTitle":11181,"status":134,"phases":11182,"primaryCompletion":3861,"completion":3861,"start":3511,"enrollment":422,"conditions":11183,"interventions":11185},"NCT02543086","Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos",[91],[11184],"Plasmodium Falciparum Malaria",[10904,11186],"Piperaquine Phosphate",{"trials":11188,"activeCount":437,"soonestReadout":10910},[11189,11193,11200,11206,11213,11219],{"nctId":10896,"briefTitle":10897,"status":123,"phases":11190,"primaryCompletion":10899,"completion":5347,"start":10900,"enrollment":1423,"conditions":11191,"interventions":11192},[92],[10902],[10904,10905,10887],{"nctId":11194,"briefTitle":11195,"status":123,"phases":11196,"primaryCompletion":6743,"completion":6743,"start":11197,"enrollment":3120,"conditions":11198,"interventions":11199},"NCT03334747","Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.",[92],"2017-11-16",[11177],[10904,10927],{"nctId":11201,"briefTitle":11202,"status":123,"phases":11203,"primaryCompletion":4524,"completion":4524,"start":1732,"enrollment":34,"conditions":11204,"interventions":11205},"NCT01524341","Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection",[92],[11177],[10904],{"nctId":11207,"briefTitle":11208,"status":123,"phases":11209,"primaryCompletion":7939,"completion":7939,"start":2033,"enrollment":4148,"conditions":11210,"interventions":11212},"NCT01860989","A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection",[92],[11211],"Cure Rate",[10904,10904,10904,10904],{"nctId":11214,"briefTitle":11215,"status":123,"phases":11216,"primaryCompletion":2509,"completion":2509,"start":3559,"enrollment":2342,"conditions":11217,"interventions":11218},"NCT01836458","A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection",[92],[11177],[10904],{"nctId":10907,"briefTitle":10908,"status":109,"phases":11220,"primaryCompletion":10910,"completion":10911,"start":10900,"enrollment":244,"conditions":11221,"interventions":11222},[92],[10902],[10914,10904,10905,10887],{"trials":11224,"activeCount":103},[],{"trials":11226,"activeCount":103},[],{"trials":11228,"activeCount":103},[],{"intervention":10666,"totalTrials":637,"cells":11230},{"EARLY_PHASE1":11231,"PHASE1":11233,"PHASE2":11247,"PHASE3":11261,"PHASE4":11263,"NA":11265},{"trials":11232,"activeCount":103},[],{"trials":11234,"activeCount":103},[11235,11239],{"nctId":10685,"briefTitle":10686,"status":123,"phases":11236,"primaryCompletion":10688,"completion":10688,"start":10689,"enrollment":814,"conditions":11237,"interventions":11238},[91],[2569],[10692,10666,10665],{"nctId":11240,"briefTitle":11241,"status":134,"phases":11242,"primaryCompletion":11243,"completion":11243,"start":2487,"enrollment":3605,"conditions":11244,"interventions":11246},"NCT03940352","HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)",[91],"2024-08-20",[5598,11245],"High-risk Myelodysplastic Syndrome (MDS)",[4393,10589,10731],{"trials":11248,"activeCount":437,"soonestReadout":9366},[11249,11253,11257],{"nctId":10707,"briefTitle":10708,"status":134,"phases":11250,"primaryCompletion":10710,"completion":10710,"start":10711,"enrollment":1611,"conditions":11251,"interventions":11252},[92],[10713],[10664,10665,10666],{"nctId":10724,"briefTitle":10725,"status":134,"phases":11254,"primaryCompletion":10727,"completion":10727,"start":10728,"enrollment":5882,"conditions":11255,"interventions":11256},[92],[2569],[10589,10731,7513],{"nctId":10657,"briefTitle":10658,"status":147,"phases":11258,"primaryCompletion":9366,"completion":9366,"start":5309,"enrollment":99,"conditions":11259,"interventions":11260},[92],[5723,10661],[10663,10574,10664,10665,10666,10667],{"trials":11262,"activeCount":103},[],{"trials":11264,"activeCount":103},[],{"trials":11266,"activeCount":103},[],{"intervention":10590,"totalTrials":637,"cells":11268},{"EARLY_PHASE1":11269,"PHASE1":11271,"PHASE2":11281,"PHASE3":11299,"PHASE4":11301,"NA":11303},{"trials":11270,"activeCount":103},[],{"trials":11272,"activeCount":103},[11273,11277],{"nctId":10580,"briefTitle":10581,"status":390,"phases":11274,"primaryCompletion":10583,"completion":10583,"start":10584,"enrollment":103,"conditions":11275,"interventions":11276},[91],[2430,2369,10586,2432,10587],[10589,2411,212,10590],{"nctId":10694,"briefTitle":10695,"status":123,"phases":11278,"primaryCompletion":10697,"completion":10697,"start":10698,"enrollment":180,"conditions":11279,"interventions":11280},[91],[3422,10700,9848,5723,10701,10702,3335,5724],[10590,4389,10589,7513],{"trials":11282,"activeCount":437,"soonestReadout":9366},[11283,11291,11295],{"nctId":11284,"briefTitle":11285,"status":134,"phases":11286,"primaryCompletion":3576,"completion":3576,"start":11287,"enrollment":11288,"conditions":11289,"interventions":11290},"NCT02608268","Phase I-Ib\u002FII Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",[91,92],"2015-11-23",252,[6437],[10589,4389,10590],{"nctId":10657,"briefTitle":10658,"status":147,"phases":11292,"primaryCompletion":9366,"completion":9366,"start":5309,"enrollment":99,"conditions":11293,"interventions":11294},[92],[5723,10661],[10663,10574,10664,10665,10666,10667],{"nctId":10745,"briefTitle":10746,"status":134,"phases":11296,"primaryCompletion":10748,"completion":10749,"start":10750,"enrollment":28,"conditions":11297,"interventions":11298},[92],[10713],[10589,7513,10590,10667],{"trials":11300,"activeCount":103},[],{"trials":11302,"activeCount":103},[],{"trials":11304,"activeCount":103},[],{"intervention":184,"totalTrials":1630,"cells":11306},{"EARLY_PHASE1":11307,"PHASE1":11309,"PHASE2":11329,"PHASE3":11335,"PHASE4":11337,"NA":11339},{"trials":11308,"activeCount":103},[],{"trials":11310,"activeCount":103},[11311,11315,11319],{"nctId":1070,"briefTitle":1071,"status":134,"phases":11312,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":203,"conditions":11313,"interventions":11314},[91],[1076],[1078,184,173,158,211,212,1079],{"nctId":175,"briefTitle":176,"status":134,"phases":11316,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":11317,"interventions":11318},[91],[182,36],[158,184,173,98],{"nctId":11320,"briefTitle":11321,"status":134,"phases":11322,"primaryCompletion":11323,"completion":11323,"start":11324,"enrollment":1524,"conditions":11325,"interventions":11328},"NCT02711345","A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.",[91],"2018-11-21","2016-04-15",[11326,11327,36,10285],"Ovarian Neoplasms","Non-Small-Cell Lung Carcinoma",[184],{"trials":11330,"activeCount":437,"soonestReadout":290},[11331],{"nctId":287,"briefTitle":288,"status":147,"phases":11332,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":11333,"interventions":11334},[92],[36],[158,184,173,98],{"trials":11336,"activeCount":103},[],{"trials":11338,"activeCount":103},[],{"trials":11340,"activeCount":103},[],{"intervention":6529,"totalTrials":317,"cells":11342},{"EARLY_PHASE1":11343,"PHASE1":11345,"PHASE2":11347,"PHASE3":11372,"PHASE4":11374,"NA":11376},{"trials":11344,"activeCount":103},[],{"trials":11346,"activeCount":103},[],{"trials":11348,"activeCount":437,"soonestReadout":4221},[11349,11353,11362],{"nctId":6522,"briefTitle":6523,"status":147,"phases":11350,"primaryCompletion":4221,"completion":6525,"start":6526,"enrollment":3475,"conditions":11351,"interventions":11352},[92],[1811],[6519,6529,3090,6530,6531,3112],{"nctId":11354,"briefTitle":11355,"status":134,"phases":11356,"primaryCompletion":11357,"completion":11357,"start":11358,"enrollment":496,"conditions":11359,"interventions":11361},"NCT04074590","Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis",[92],"2022-11-07","2020-02-03",[11360],"Colitis, Ulcerative",[6529],{"nctId":11363,"briefTitle":11364,"status":134,"phases":11365,"primaryCompletion":11366,"completion":11366,"start":7902,"enrollment":4506,"conditions":11367,"interventions":11370},"NCT04147195","Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)",[92],"2022-01-06",[11368,11369],"Non-alcoholic Fatty Liver Disease","Nonalcoholic Steatohepatitis",[6529,11371],"Tropifexor",{"trials":11373,"activeCount":103},[],{"trials":11375,"activeCount":103},[],{"trials":11377,"activeCount":103},[],{"intervention":8161,"totalTrials":317,"cells":11379},{"EARLY_PHASE1":11380,"PHASE1":11382,"PHASE2":11392,"PHASE3":11404,"PHASE4":11406,"NA":11408},{"trials":11381,"activeCount":103},[],{"trials":11383,"activeCount":103},[11384,11388],{"nctId":6500,"briefTitle":6501,"status":134,"phases":11385,"primaryCompletion":6503,"completion":6503,"start":3075,"enrollment":28,"conditions":11386,"interventions":11387},[91],[2798],[3112,6506],{"nctId":8155,"briefTitle":8156,"status":134,"phases":11389,"primaryCompletion":8158,"completion":8158,"start":281,"enrollment":5594,"conditions":11390,"interventions":11391},[91],[4681],[8139,8161],{"trials":11393,"activeCount":437,"soonestReadout":2541},[11394],{"nctId":11395,"briefTitle":11396,"status":147,"phases":11397,"primaryCompletion":2541,"completion":2541,"start":2005,"enrollment":597,"conditions":11398,"interventions":11402},"NCT03960840","Phase I\u002FII Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r\u002Fr ALL and 1L HR LBCL",[91,92],[11399,11400,4681,3204,11401],"Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Large B-cell Lymphoma",[11403,8161],"Rapcabtagene autoleucel single agent",{"trials":11405,"activeCount":103},[],{"trials":11407,"activeCount":103},[],{"trials":11409,"activeCount":103},[],{"intervention":9841,"totalTrials":317,"cells":11411},{"EARLY_PHASE1":11412,"PHASE1":11414,"PHASE2":11416,"PHASE3":11439,"PHASE4":11441,"NA":11443},{"trials":11413,"activeCount":103},[],{"trials":11415,"activeCount":103},[],{"trials":11417,"activeCount":437,"soonestReadout":9832},[11418,11422,11430],{"nctId":9829,"briefTitle":9830,"status":593,"phases":11419,"primaryCompletion":9832,"completion":9833,"start":221,"enrollment":2579,"conditions":11420,"interventions":11421},[91,92],[3204,9835,9836],[9838,9839,5747,1169,8231,4064,7443,9840,9841],{"nctId":11423,"briefTitle":11424,"status":123,"phases":11425,"primaryCompletion":4335,"start":949,"enrollment":630,"conditions":11426,"interventions":11427},"NCT00920933","Effect of AIN457 on Ozone-induced Airway Neutrophilia Compared to Placebo and Corticosteroid in Healthy Subjects",[91,92],[1674],[11428,11429],"AIN457","prednisolone",{"nctId":11431,"briefTitle":11432,"status":123,"phases":11433,"primaryCompletion":11434,"completion":11434,"start":11435,"enrollment":3605,"conditions":11436,"interventions":11437},"NCT03765788","A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis",[92],"2021-06-08","2019-01-30",[1695],[11438,9841],"Secukinumab 300 mg, s.c.",{"trials":11440,"activeCount":103},[],{"trials":11442,"activeCount":103},[],{"trials":11444,"activeCount":103},[],{"intervention":10905,"totalTrials":213,"cells":11446},{"EARLY_PHASE1":11447,"PHASE1":11449,"PHASE2":11451,"PHASE3":11461,"PHASE4":11463,"NA":11465},{"trials":11448,"activeCount":103},[],{"trials":11450,"activeCount":103},[],{"trials":11452,"activeCount":437,"soonestReadout":10910},[11453,11457],{"nctId":10896,"briefTitle":10897,"status":123,"phases":11454,"primaryCompletion":10899,"completion":5347,"start":10900,"enrollment":1423,"conditions":11455,"interventions":11456},[92],[10902],[10904,10905,10887],{"nctId":10907,"briefTitle":10908,"status":109,"phases":11458,"primaryCompletion":10910,"completion":10911,"start":10900,"enrollment":244,"conditions":11459,"interventions":11460},[92],[10902],[10914,10904,10905,10887],{"trials":11462,"activeCount":103},[],{"trials":11464,"activeCount":103},[],{"trials":11466,"activeCount":103},[],{"intervention":10341,"totalTrials":213,"cells":11468},{"EARLY_PHASE1":11469,"PHASE1":11471,"PHASE2":11473,"PHASE3":11486,"PHASE4":11488,"NA":11490},{"trials":11470,"activeCount":103},[],{"trials":11472,"activeCount":103},[],{"trials":11474,"activeCount":437,"soonestReadout":10336},[11475,11479],{"nctId":10333,"briefTitle":10334,"status":147,"phases":11476,"primaryCompletion":10336,"completion":10336,"start":10337,"enrollment":1053,"conditions":11477,"interventions":11478},[92],[10339],[8070,10341,10312,10342],{"nctId":11480,"briefTitle":11481,"status":134,"phases":11482,"primaryCompletion":11175,"completion":11175,"start":11483,"enrollment":446,"conditions":11484,"interventions":11485},"NCT02335944","Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.",[91,92],"2015-01-13",[1316],[8070,10341],{"trials":11487,"activeCount":103},[],{"trials":11489,"activeCount":103},[],{"trials":11491,"activeCount":103},[],{"intervention":11493,"totalTrials":213,"cells":11494},"EDI048",{"EARLY_PHASE1":11495,"PHASE1":11497,"PHASE2":11507,"PHASE3":11519,"PHASE4":11521,"NA":11523},{"trials":11496,"activeCount":103},[],{"trials":11498,"activeCount":103},[11499],{"nctId":11500,"briefTitle":11501,"status":123,"phases":11502,"primaryCompletion":2147,"completion":2147,"start":11503,"enrollment":11504,"conditions":11505,"interventions":11506},"NCT05275855","First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers",[91],"2022-04-29",110,[9634],[11493],{"trials":11508,"activeCount":437,"soonestReadout":11513},[11509],{"nctId":11510,"briefTitle":11511,"status":109,"phases":11512,"primaryCompletion":11513,"completion":11513,"start":11514,"enrollment":1750,"conditions":11515,"interventions":11517},"NCT07249463","Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults",[92],"2027-03-02","2025-12-08",[11516],"Cryptosporidiosis",[11518,11493],"Cryptosporidium parvum oocysts",{"trials":11520,"activeCount":103},[],{"trials":11522,"activeCount":103},[],{"trials":11524,"activeCount":103},[],{"intervention":1169,"totalTrials":213,"cells":11526},{"EARLY_PHASE1":11527,"PHASE1":11529,"PHASE2":11531,"PHASE3":11541,"PHASE4":11543,"NA":11545},{"trials":11528,"activeCount":103},[],{"trials":11530,"activeCount":103},[],{"trials":11532,"activeCount":437,"soonestReadout":9832},[11533,11537],{"nctId":9829,"briefTitle":9830,"status":593,"phases":11534,"primaryCompletion":9832,"completion":9833,"start":221,"enrollment":2579,"conditions":11535,"interventions":11536},[91,92],[3204,9835,9836],[9838,9839,5747,1169,8231,4064,7443,9840,9841],{"nctId":1137,"briefTitle":1138,"status":123,"phases":11538,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":1143,"conditions":11539,"interventions":11540},[92],[1145,1146,1147,1148,1149,1150,1151,1152,1153,1154,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],[1078,156,1168,1169],{"trials":11542,"activeCount":103},[],{"trials":11544,"activeCount":103},[],{"trials":11546,"activeCount":103},[],{"intervention":4064,"totalTrials":213,"cells":11548},{"EARLY_PHASE1":11549,"PHASE1":11551,"PHASE2":11553,"PHASE3":11563,"PHASE4":11565,"NA":11567},{"trials":11550,"activeCount":103},[],{"trials":11552,"activeCount":103},[],{"trials":11554,"activeCount":437,"soonestReadout":9832},[11555,11559],{"nctId":9829,"briefTitle":9830,"status":593,"phases":11556,"primaryCompletion":9832,"completion":9833,"start":221,"enrollment":2579,"conditions":11557,"interventions":11558},[91,92],[3204,9835,9836],[9838,9839,5747,1169,8231,4064,7443,9840,9841],{"nctId":4058,"briefTitle":4059,"status":123,"phases":11560,"primaryCompletion":3272,"completion":3272,"start":4061,"enrollment":2579,"conditions":11561,"interventions":11562},[92],[1717],[83,4064,4065],{"trials":11564,"activeCount":103},[],{"trials":11566,"activeCount":103},[],{"trials":11568,"activeCount":103},[],{"intervention":11518,"totalTrials":213,"cells":11570},{"EARLY_PHASE1":11571,"PHASE1":11573,"PHASE2":11583,"PHASE3":11589,"PHASE4":11591,"NA":11593},{"trials":11572,"activeCount":103},[],{"trials":11574,"activeCount":103},[11575],{"nctId":11576,"briefTitle":11577,"status":123,"phases":11578,"primaryCompletion":11357,"completion":137,"start":11579,"enrollment":2439,"conditions":11580,"interventions":11582},"NCT05036668","Study of Efficacy and Safety of ABO809 in Healthy Participants",[91],"2022-04-07",[11581],"Cryptosporidium Infection, Cryptosporidiosis",[11518],{"trials":11584,"activeCount":437,"soonestReadout":11513},[11585],{"nctId":11510,"briefTitle":11511,"status":109,"phases":11586,"primaryCompletion":11513,"completion":11513,"start":11514,"enrollment":1750,"conditions":11587,"interventions":11588},[92],[11516],[11518,11493],{"trials":11590,"activeCount":103},[],{"trials":11592,"activeCount":103},[],{"trials":11594,"activeCount":103},[],{"intervention":10667,"totalTrials":213,"cells":11596},{"EARLY_PHASE1":11597,"PHASE1":11599,"PHASE2":11601,"PHASE3":11611,"PHASE4":11613,"NA":11615},{"trials":11598,"activeCount":103},[],{"trials":11600,"activeCount":103},[],{"trials":11602,"activeCount":437,"soonestReadout":9366},[11603,11607],{"nctId":10657,"briefTitle":10658,"status":147,"phases":11604,"primaryCompletion":9366,"completion":9366,"start":5309,"enrollment":99,"conditions":11605,"interventions":11606},[92],[5723,10661],[10663,10574,10664,10665,10666,10667],{"nctId":10745,"briefTitle":10746,"status":134,"phases":11608,"primaryCompletion":10748,"completion":10749,"start":10750,"enrollment":28,"conditions":11609,"interventions":11610},[92],[10713],[10589,7513,10590,10667],{"trials":11612,"activeCount":103},[],{"trials":11614,"activeCount":103},[],{"trials":11616,"activeCount":103},[],{"intervention":10914,"totalTrials":213,"cells":11618},{"EARLY_PHASE1":11619,"PHASE1":11621,"PHASE2":11623,"PHASE3":11636,"PHASE4":11638,"NA":11640},{"trials":11620,"activeCount":103},[],{"trials":11622,"activeCount":103},[],{"trials":11624,"activeCount":437,"soonestReadout":10910},[11625,11632],{"nctId":11626,"briefTitle":11627,"status":123,"phases":11628,"primaryCompletion":11629,"completion":5968,"start":10900,"enrollment":3605,"conditions":11630,"interventions":11631},"NCT07235020","Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria",[92],"2025-01-30",[10902],[10914],{"nctId":10907,"briefTitle":10908,"status":109,"phases":11633,"primaryCompletion":10910,"completion":10911,"start":10900,"enrollment":244,"conditions":11634,"interventions":11635},[92],[10902],[10914,10904,10905,10887],{"trials":11637,"activeCount":103},[],{"trials":11639,"activeCount":103},[],{"trials":11641,"activeCount":103},[],{"intervention":11643,"totalTrials":437,"cells":11644},"VAY736 1ml PFS",{"EARLY_PHASE1":11645,"PHASE1":11647,"PHASE2":11649,"PHASE3":11663,"PHASE4":11665,"NA":11667},{"trials":11646,"activeCount":103},[],{"trials":11648,"activeCount":103},[],{"trials":11650,"activeCount":437,"soonestReadout":11655},[11651],{"nctId":11652,"briefTitle":11653,"status":147,"phases":11654,"primaryCompletion":11655,"completion":11656,"start":11657,"enrollment":7500,"conditions":11658,"interventions":11660},"NCT06293365","Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector\u002F2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease",[92],"2025-06-05","2029-01-16","2024-07-02",[11659,5783,1717],"Sjögrens Disease",[11643,11661,11662],"VAY736 2 ml PFS","VAY736 2ml AI",{"trials":11664,"activeCount":103},[],{"trials":11666,"activeCount":103},[],{"trials":11668,"activeCount":103},[],{"intervention":11661,"totalTrials":437,"cells":11670},{"EARLY_PHASE1":11671,"PHASE1":11673,"PHASE2":11675,"PHASE3":11681,"PHASE4":11683,"NA":11685},{"trials":11672,"activeCount":103},[],{"trials":11674,"activeCount":103},[],{"trials":11676,"activeCount":437,"soonestReadout":11655},[11677],{"nctId":11652,"briefTitle":11653,"status":147,"phases":11678,"primaryCompletion":11655,"completion":11656,"start":11657,"enrollment":7500,"conditions":11679,"interventions":11680},[92],[11659,5783,1717],[11643,11661,11662],{"trials":11682,"activeCount":103},[],{"trials":11684,"activeCount":103},[],{"trials":11686,"activeCount":103},[],{"intervention":11662,"totalTrials":437,"cells":11688},{"EARLY_PHASE1":11689,"PHASE1":11691,"PHASE2":11693,"PHASE3":11699,"PHASE4":11701,"NA":11703},{"trials":11690,"activeCount":103},[],{"trials":11692,"activeCount":103},[],{"trials":11694,"activeCount":437,"soonestReadout":11655},[11695],{"nctId":11652,"briefTitle":11653,"status":147,"phases":11696,"primaryCompletion":11655,"completion":11656,"start":11657,"enrollment":7500,"conditions":11697,"interventions":11698},[92],[11659,5783,1717],[11643,11661,11662],{"trials":11700,"activeCount":103},[],{"trials":11702,"activeCount":103},[],{"trials":11704,"activeCount":103},[],{"intervention":11706,"totalTrials":437,"cells":11707},"Asciminib Pediatric formulation group",{"EARLY_PHASE1":11708,"PHASE1":11710,"PHASE2":11712,"PHASE3":11725,"PHASE4":11727,"NA":11729},{"trials":11709,"activeCount":103},[],{"trials":11711,"activeCount":103},[],{"trials":11713,"activeCount":437,"soonestReadout":11718},[11714],{"nctId":11715,"briefTitle":11716,"status":109,"phases":11717,"primaryCompletion":11718,"completion":11719,"start":11720,"enrollment":31,"conditions":11721,"interventions":11723},"NCT04925479","Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia",[91,92],"2026-06-16","2031-11-01","2021-12-27",[11722],"Myeloid Leukemia, Philadelphia Positive",[11706,11724],"Asciminib Adult formulation group",{"trials":11726,"activeCount":103},[],{"trials":11728,"activeCount":103},[],{"trials":11730,"activeCount":103},[],{"intervention":11724,"totalTrials":437,"cells":11732},{"EARLY_PHASE1":11733,"PHASE1":11735,"PHASE2":11737,"PHASE3":11743,"PHASE4":11745,"NA":11747},{"trials":11734,"activeCount":103},[],{"trials":11736,"activeCount":103},[],{"trials":11738,"activeCount":437,"soonestReadout":11718},[11739],{"nctId":11715,"briefTitle":11716,"status":109,"phases":11740,"primaryCompletion":11718,"completion":11719,"start":11720,"enrollment":31,"conditions":11741,"interventions":11742},[91,92],[11722],[11706,11724],{"trials":11744,"activeCount":103},[],{"trials":11746,"activeCount":103},[],{"trials":11748,"activeCount":103},[],{"intervention":11750,"totalTrials":437,"cells":11751},"DYP688",{"EARLY_PHASE1":11752,"PHASE1":11754,"PHASE2":11756,"PHASE3":11767,"PHASE4":11769,"NA":11771},{"trials":11753,"activeCount":103},[],{"trials":11755,"activeCount":103},[],{"trials":11757,"activeCount":437,"soonestReadout":11762},[11758],{"nctId":11759,"briefTitle":11760,"status":147,"phases":11761,"primaryCompletion":11762,"completion":11762,"start":11763,"enrollment":11068,"conditions":11764,"interventions":11766},"NCT05415072","A Phase I\u002FII Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ\u002F11 Mutant Melanomas",[91,92],"2027-10-01","2022-07-04",[11765],"Metastatic Uveal Melanoma",[11750],{"trials":11768,"activeCount":103},[],{"trials":11770,"activeCount":103},[],{"trials":11772,"activeCount":103},[],{"intervention":6530,"totalTrials":437,"cells":11774},{"EARLY_PHASE1":11775,"PHASE1":11777,"PHASE2":11779,"PHASE3":11785,"PHASE4":11787,"NA":11789},{"trials":11776,"activeCount":103},[],{"trials":11778,"activeCount":103},[],{"trials":11780,"activeCount":437,"soonestReadout":4221},[11781],{"nctId":6522,"briefTitle":6523,"status":147,"phases":11782,"primaryCompletion":4221,"completion":6525,"start":6526,"enrollment":3475,"conditions":11783,"interventions":11784},[92],[1811],[6519,6529,3090,6530,6531,3112],{"trials":11786,"activeCount":103},[],{"trials":11788,"activeCount":103},[],{"trials":11790,"activeCount":103},[],{"intervention":6531,"totalTrials":437,"cells":11792},{"EARLY_PHASE1":11793,"PHASE1":11795,"PHASE2":11797,"PHASE3":11803,"PHASE4":11805,"NA":11807},{"trials":11794,"activeCount":103},[],{"trials":11796,"activeCount":103},[],{"trials":11798,"activeCount":437,"soonestReadout":4221},[11799],{"nctId":6522,"briefTitle":6523,"status":147,"phases":11800,"primaryCompletion":4221,"completion":6525,"start":6526,"enrollment":3475,"conditions":11801,"interventions":11802},[92],[1811],[6519,6529,3090,6530,6531,3112],{"trials":11804,"activeCount":103},[],{"trials":11806,"activeCount":103},[],{"trials":11808,"activeCount":103},[],{"intervention":11810,"totalTrials":437,"cells":11811},"225Ac-PSMA-R2",{"EARLY_PHASE1":11812,"PHASE1":11814,"PHASE2":11816,"PHASE3":11826,"PHASE4":11828,"NA":11830},{"trials":11813,"activeCount":103},[],{"trials":11815,"activeCount":103},[],{"trials":11817,"activeCount":437,"soonestReadout":11822},[11818],{"nctId":11819,"briefTitle":11820,"status":147,"phases":11821,"primaryCompletion":11822,"completion":2211,"start":11823,"enrollment":99,"conditions":11824,"interventions":11825},"NCT05983198","Phase I\u002FII Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With\u002FWithout Prior 177Lu-PSMA RLT",[91,92],"2026-11-19","2023-11-07",[1654],[11810],{"trials":11827,"activeCount":103},[],{"trials":11829,"activeCount":103},[],{"trials":11831,"activeCount":103},[],{"intervention":1591,"totalTrials":437,"cells":11833},{"EARLY_PHASE1":11834,"PHASE1":11836,"PHASE2":11838,"PHASE3":11844,"PHASE4":11846,"NA":11848},{"trials":11835,"activeCount":103},[],{"trials":11837,"activeCount":103},[],{"trials":11839,"activeCount":437,"soonestReadout":1586},[11840],{"nctId":1583,"briefTitle":1584,"status":147,"phases":11841,"primaryCompletion":1586,"completion":1586,"start":1587,"enrollment":1562,"conditions":11842,"interventions":11843},[92],[1589],[1561,1591,1592],{"trials":11845,"activeCount":103},[],{"trials":11847,"activeCount":103},[],{"trials":11849,"activeCount":103},[],{"intervention":1592,"totalTrials":437,"cells":11851},{"EARLY_PHASE1":11852,"PHASE1":11854,"PHASE2":11856,"PHASE3":11862,"PHASE4":11864,"NA":11866},{"trials":11853,"activeCount":103},[],{"trials":11855,"activeCount":103},[],{"trials":11857,"activeCount":437,"soonestReadout":1586},[11858],{"nctId":1583,"briefTitle":1584,"status":147,"phases":11859,"primaryCompletion":1586,"completion":1586,"start":1587,"enrollment":1562,"conditions":11860,"interventions":11861},[92],[1589],[1561,1591,1592],{"trials":11863,"activeCount":103},[],{"trials":11865,"activeCount":103},[],{"trials":11867,"activeCount":103},[],{"intervention":9345,"totalTrials":437,"cells":11869},{"EARLY_PHASE1":11870,"PHASE1":11872,"PHASE2":11874,"PHASE3":11880,"PHASE4":11882,"NA":11884},{"trials":11871,"activeCount":103},[],{"trials":11873,"activeCount":103},[],{"trials":11875,"activeCount":437,"soonestReadout":9340},[11876],{"nctId":9337,"briefTitle":9338,"status":109,"phases":11877,"primaryCompletion":9340,"completion":9341,"start":8982,"enrollment":5080,"conditions":11878,"interventions":11879},[92],[9343],[9335,9345],{"trials":11881,"activeCount":103},[],{"trials":11883,"activeCount":103},[],{"trials":11885,"activeCount":103},[],{"intervention":11887,"totalTrials":437,"cells":11888},"Glycopyrronium bromide 25ug",{"EARLY_PHASE1":11889,"PHASE1":11891,"PHASE2":11893,"PHASE3":11904,"PHASE4":11906,"NA":11908},{"trials":11890,"activeCount":103},[],{"trials":11892,"activeCount":103},[],{"trials":11894,"activeCount":437,"soonestReadout":10336},[11895],{"nctId":11896,"briefTitle":11897,"status":109,"phases":11898,"primaryCompletion":10336,"completion":11899,"start":11900,"enrollment":25,"conditions":11901,"interventions":11902},"NCT05222529","Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma",[92],"2027-08-30","2022-08-29",[18],[11887,11903],"Glycopyrronium bromide 12.5ug",{"trials":11905,"activeCount":103},[],{"trials":11907,"activeCount":103},[],{"trials":11909,"activeCount":103},[],{"intervention":11903,"totalTrials":437,"cells":11911},{"EARLY_PHASE1":11912,"PHASE1":11914,"PHASE2":11916,"PHASE3":11922,"PHASE4":11924,"NA":11926},{"trials":11913,"activeCount":103},[],{"trials":11915,"activeCount":103},[],{"trials":11917,"activeCount":437,"soonestReadout":10336},[11918],{"nctId":11896,"briefTitle":11897,"status":109,"phases":11919,"primaryCompletion":10336,"completion":11899,"start":11900,"enrollment":25,"conditions":11920,"interventions":11921},[92],[18],[11887,11903],{"trials":11923,"activeCount":103},[],{"trials":11925,"activeCount":103},[],{"trials":11927,"activeCount":103},[],{"intervention":11403,"totalTrials":437,"cells":11929},{"EARLY_PHASE1":11930,"PHASE1":11932,"PHASE2":11934,"PHASE3":11940,"PHASE4":11942,"NA":11944},{"trials":11931,"activeCount":103},[],{"trials":11933,"activeCount":103},[],{"trials":11935,"activeCount":437,"soonestReadout":2541},[11936],{"nctId":11395,"briefTitle":11396,"status":147,"phases":11937,"primaryCompletion":2541,"completion":2541,"start":2005,"enrollment":597,"conditions":11938,"interventions":11939},[91,92],[11399,11400,4681,3204,11401],[11403,8161],{"trials":11941,"activeCount":103},[],{"trials":11943,"activeCount":103},[],{"trials":11945,"activeCount":103},[],{"intervention":11947,"totalTrials":437,"cells":11948},"ARV-766 Part A&B",{"EARLY_PHASE1":11949,"PHASE1":11951,"PHASE2":11953,"PHASE3":11965,"PHASE4":11967,"NA":11969},{"trials":11950,"activeCount":103},[],{"trials":11952,"activeCount":103},[],{"trials":11954,"activeCount":437,"soonestReadout":11959},[11955],{"nctId":11956,"briefTitle":11957,"status":147,"phases":11958,"primaryCompletion":11959,"completion":11959,"start":11960,"enrollment":5892,"conditions":11961,"interventions":11963},"NCT05067140","A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer",[91,92],"2027-05-25","2021-09-02",[11962],"Prostate Cancer Metastatic",[11947,11964],"ARV-766 + Abiraterone Part C&D",{"trials":11966,"activeCount":103},[],{"trials":11968,"activeCount":103},[],{"trials":11970,"activeCount":103},[],{"intervention":11964,"totalTrials":437,"cells":11972},{"EARLY_PHASE1":11973,"PHASE1":11975,"PHASE2":11977,"PHASE3":11983,"PHASE4":11985,"NA":11987},{"trials":11974,"activeCount":103},[],{"trials":11976,"activeCount":103},[],{"trials":11978,"activeCount":437,"soonestReadout":11959},[11979],{"nctId":11956,"briefTitle":11957,"status":147,"phases":11980,"primaryCompletion":11959,"completion":11959,"start":11960,"enrollment":5892,"conditions":11981,"interventions":11982},[91,92],[11962],[11947,11964],{"trials":11984,"activeCount":103},[],{"trials":11986,"activeCount":103},[],{"trials":11988,"activeCount":103},[],{"intervention":11990,"totalTrials":437,"cells":11991},"DJI136",{"EARLY_PHASE1":11992,"PHASE1":11994,"PHASE2":11996,"PHASE3":12007,"PHASE4":12009,"NA":12011},{"trials":11993,"activeCount":103},[],{"trials":11995,"activeCount":103},[],{"trials":11997,"activeCount":437,"soonestReadout":12002},[11998],{"nctId":11999,"briefTitle":12000,"status":109,"phases":12001,"primaryCompletion":12002,"completion":12002,"start":12003,"enrollment":4733,"conditions":12004,"interventions":12006},"NCT07564401","A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy",[91,92],"2031-03-03","2026-05-14",[12005],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)",[11990],{"trials":12008,"activeCount":103},[],{"trials":12010,"activeCount":103},[],{"trials":12012,"activeCount":103},[],{"intervention":9838,"totalTrials":437,"cells":12014},{"EARLY_PHASE1":12015,"PHASE1":12017,"PHASE2":12019,"PHASE3":12025,"PHASE4":12027,"NA":12029},{"trials":12016,"activeCount":103},[],{"trials":12018,"activeCount":103},[],{"trials":12020,"activeCount":437,"soonestReadout":9832},[12021],{"nctId":9829,"briefTitle":9830,"status":593,"phases":12022,"primaryCompletion":9832,"completion":9833,"start":221,"enrollment":2579,"conditions":12023,"interventions":12024},[91,92],[3204,9835,9836],[9838,9839,5747,1169,8231,4064,7443,9840,9841],{"trials":12026,"activeCount":103},[],{"trials":12028,"activeCount":103},[],{"trials":12030,"activeCount":103},[],{"intervention":9839,"totalTrials":437,"cells":12032},{"EARLY_PHASE1":12033,"PHASE1":12035,"PHASE2":12037,"PHASE3":12043,"PHASE4":12045,"NA":12047},{"trials":12034,"activeCount":103},[],{"trials":12036,"activeCount":103},[],{"trials":12038,"activeCount":437,"soonestReadout":9832},[12039],{"nctId":9829,"briefTitle":9830,"status":593,"phases":12040,"primaryCompletion":9832,"completion":9833,"start":221,"enrollment":2579,"conditions":12041,"interventions":12042},[91,92],[3204,9835,9836],[9838,9839,5747,1169,8231,4064,7443,9840,9841],{"trials":12044,"activeCount":103},[],{"trials":12046,"activeCount":103},[],{"trials":12048,"activeCount":103},[],{"intervention":9840,"totalTrials":437,"cells":12050},{"EARLY_PHASE1":12051,"PHASE1":12053,"PHASE2":12055,"PHASE3":12061,"PHASE4":12063,"NA":12065},{"trials":12052,"activeCount":103},[],{"trials":12054,"activeCount":103},[],{"trials":12056,"activeCount":437,"soonestReadout":9832},[12057],{"nctId":9829,"briefTitle":9830,"status":593,"phases":12058,"primaryCompletion":9832,"completion":9833,"start":221,"enrollment":2579,"conditions":12059,"interventions":12060},[91,92],[3204,9835,9836],[9838,9839,5747,1169,8231,4064,7443,9840,9841],{"trials":12062,"activeCount":103},[],{"trials":12064,"activeCount":103},[],{"trials":12066,"activeCount":103},[],{"intervention":589,"totalTrials":437,"cells":12068},{"EARLY_PHASE1":12069,"PHASE1":12071,"PHASE2":12073,"PHASE3":12079,"PHASE4":12081,"NA":12083},{"trials":12070,"activeCount":103},[],{"trials":12072,"activeCount":103},[],{"trials":12074,"activeCount":437,"soonestReadout":583},[12075],{"nctId":580,"briefTitle":581,"status":109,"phases":12076,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":12077,"interventions":12078},[91,92],[303,304,587],[589,119,249],{"trials":12080,"activeCount":103},[],{"trials":12082,"activeCount":103},[],{"trials":12084,"activeCount":103},[],{"intervention":12086,"totalTrials":437,"cells":12087},"DII235",{"EARLY_PHASE1":12088,"PHASE1":12090,"PHASE2":12092,"PHASE3":12105,"PHASE4":12107,"NA":12109},{"trials":12089,"activeCount":103},[],{"trials":12091,"activeCount":103},[],{"trials":12093,"activeCount":437,"soonestReadout":12098},[12094],{"nctId":12095,"briefTitle":12096,"status":109,"phases":12097,"primaryCompletion":12098,"completion":12099,"start":12100,"enrollment":919,"conditions":12101,"interventions":12103},"NCT07235046","A Study of DII235 in Adults With Elevated Lipoprotein(a)",[92],"2027-09-08","2028-09-08","2025-12-02",[12102],"Lipoprotein Disorder",[12086,12104],"Saline",{"trials":12106,"activeCount":103},[],{"trials":12108,"activeCount":103},[],{"trials":12110,"activeCount":103},[],{"intervention":12104,"totalTrials":437,"cells":12112},{"EARLY_PHASE1":12113,"PHASE1":12115,"PHASE2":12117,"PHASE3":12123,"PHASE4":12125,"NA":12127},{"trials":12114,"activeCount":103},[],{"trials":12116,"activeCount":103},[],{"trials":12118,"activeCount":437,"soonestReadout":12098},[12119],{"nctId":12095,"briefTitle":12096,"status":109,"phases":12120,"primaryCompletion":12098,"completion":12099,"start":12100,"enrollment":919,"conditions":12121,"interventions":12122},[92],[12102],[12086,12104],{"trials":12124,"activeCount":103},[],{"trials":12126,"activeCount":103},[],{"trials":12128,"activeCount":103},[],{"intervention":9605,"totalTrials":437,"cells":12130},{"EARLY_PHASE1":12131,"PHASE1":12133,"PHASE2":12135,"PHASE3":12141,"PHASE4":12143,"NA":12145},{"trials":12132,"activeCount":103},[],{"trials":12134,"activeCount":103},[],{"trials":12136,"activeCount":437,"soonestReadout":9328},[12137],{"nctId":9598,"briefTitle":9599,"status":147,"phases":12138,"primaryCompletion":9328,"completion":3948,"start":9601,"enrollment":630,"conditions":12139,"interventions":12140},[91,92],[9603],[9418,9605,9578],{"trials":12142,"activeCount":103},[],{"trials":12144,"activeCount":103},[],{"trials":12146,"activeCount":103},[],{"intervention":601,"totalTrials":437,"cells":12148},{"EARLY_PHASE1":12149,"PHASE1":12151,"PHASE2":12153,"PHASE3":12159,"PHASE4":12161,"NA":12163},{"trials":12150,"activeCount":103},[],{"trials":12152,"activeCount":103},[],{"trials":12154,"activeCount":437,"soonestReadout":595},[12155],{"nctId":591,"briefTitle":592,"status":593,"phases":12156,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":12157,"interventions":12158},[91,92],[303,304,599],[601,119,249],{"trials":12160,"activeCount":103},[],{"trials":12162,"activeCount":103},[],{"trials":12164,"activeCount":103},[],{"intervention":12166,"totalTrials":437,"cells":12167},"68Ga-FAP-2286",{"EARLY_PHASE1":12168,"PHASE1":12170,"PHASE2":12172,"PHASE3":12183,"PHASE4":12185,"NA":12187},{"trials":12169,"activeCount":103},[],{"trials":12171,"activeCount":103},[],{"trials":12173,"activeCount":437,"soonestReadout":596},[12174],{"nctId":12175,"briefTitle":12176,"status":109,"phases":12177,"primaryCompletion":596,"completion":12178,"start":12179,"enrollment":258,"conditions":12180,"interventions":12181},"NCT04939610","A Study of 177Lu-FAP-2286 in Advanced Solid Tumors",[91,92],"2028-06-30","2021-07-30",[1317],[12166,12182],"177Lu-FAP-2286",{"trials":12184,"activeCount":103},[],{"trials":12186,"activeCount":103},[],{"trials":12188,"activeCount":103},[],{"intervention":12182,"totalTrials":437,"cells":12190},{"EARLY_PHASE1":12191,"PHASE1":12193,"PHASE2":12195,"PHASE3":12201,"PHASE4":12203,"NA":12205},{"trials":12192,"activeCount":103},[],{"trials":12194,"activeCount":103},[],{"trials":12196,"activeCount":437,"soonestReadout":596},[12197],{"nctId":12175,"briefTitle":12176,"status":109,"phases":12198,"primaryCompletion":596,"completion":12178,"start":12179,"enrollment":258,"conditions":12199,"interventions":12200},[91,92],[1317],[12166,12182],{"trials":12202,"activeCount":103},[],{"trials":12204,"activeCount":103},[],{"trials":12206,"activeCount":103},[],{"intervention":12208,"totalTrials":437,"cells":12209},"Pelacarsen (TQJ230) 80mg",{"EARLY_PHASE1":12210,"PHASE1":12212,"PHASE2":12214,"PHASE3":12224,"PHASE4":12226,"NA":12228},{"trials":12211,"activeCount":103},[],{"trials":12213,"activeCount":103},[],{"trials":12215,"activeCount":437,"soonestReadout":12220},[12216],{"nctId":12217,"briefTitle":12218,"status":109,"phases":12219,"primaryCompletion":12220,"completion":12220,"start":10923,"enrollment":340,"conditions":12221,"interventions":12223},"NCT05646381","A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis",[92],"2030-03-12",[12222],"Aortic Stenosis",[12208],{"trials":12225,"activeCount":103},[],{"trials":12227,"activeCount":103},[],{"trials":12229,"activeCount":103},[],{"intervention":12231,"totalTrials":437,"cells":12232},"LXE408",{"EARLY_PHASE1":12233,"PHASE1":12235,"PHASE2":12237,"PHASE3":12249,"PHASE4":12251,"NA":12253},{"trials":12234,"activeCount":103},[],{"trials":12236,"activeCount":103},[],{"trials":12238,"activeCount":437,"soonestReadout":12243},[12239],{"nctId":12240,"briefTitle":12241,"status":109,"phases":12242,"primaryCompletion":12243,"completion":12244,"start":6513,"enrollment":3975,"conditions":12245,"interventions":12247},"NCT06632600","A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.",[92],"2027-03-22","2030-09-21",[12246],"Chagas Disease",[12231,12248],"Benznidazole",{"trials":12250,"activeCount":103},[],{"trials":12252,"activeCount":103},[],{"trials":12254,"activeCount":103},[],{"intervention":12248,"totalTrials":437,"cells":12256},{"EARLY_PHASE1":12257,"PHASE1":12259,"PHASE2":12261,"PHASE3":12267,"PHASE4":12269,"NA":12271},{"trials":12258,"activeCount":103},[],{"trials":12260,"activeCount":103},[],{"trials":12262,"activeCount":437,"soonestReadout":12243},[12263],{"nctId":12240,"briefTitle":12241,"status":109,"phases":12264,"primaryCompletion":12243,"completion":12244,"start":6513,"enrollment":3975,"conditions":12265,"interventions":12266},[92],[12246],[12231,12248],{"trials":12268,"activeCount":103},[],{"trials":12270,"activeCount":103},[],{"trials":12272,"activeCount":103},[],{"intervention":9562,"totalTrials":437,"cells":12274},{"EARLY_PHASE1":12275,"PHASE1":12277,"PHASE2":12279,"PHASE3":12285,"PHASE4":12287,"NA":12289},{"trials":12276,"activeCount":103},[],{"trials":12278,"activeCount":103},[],{"trials":12280,"activeCount":437,"soonestReadout":9557},[12281],{"nctId":9554,"briefTitle":9555,"status":109,"phases":12282,"primaryCompletion":9557,"completion":9557,"start":1523,"enrollment":9558,"conditions":12283,"interventions":12284},[91,92],[9560],[9523,9562,9494],{"trials":12286,"activeCount":103},[],{"trials":12288,"activeCount":103},[],{"trials":12290,"activeCount":103},[],{"intervention":9508,"totalTrials":437,"cells":12292},{"EARLY_PHASE1":12293,"PHASE1":12295,"PHASE2":12297,"PHASE3":12303,"PHASE4":12305,"NA":12307},{"trials":12294,"activeCount":103},[],{"trials":12296,"activeCount":103},[],{"trials":12298,"activeCount":437,"soonestReadout":9502},[12299],{"nctId":9499,"briefTitle":9500,"status":109,"phases":12300,"primaryCompletion":9502,"completion":9503,"start":9504,"enrollment":9331,"conditions":12301,"interventions":12302},[91,92],[9506],[9508,9479,9494],{"trials":12304,"activeCount":103},[],{"trials":12306,"activeCount":103},[],{"trials":12308,"activeCount":103},[],{"intervention":5845,"totalTrials":437,"cells":12310},{"EARLY_PHASE1":12311,"PHASE1":12313,"PHASE2":12315,"PHASE3":12321,"PHASE4":12323,"NA":12325},{"trials":12312,"activeCount":103},[],{"trials":12314,"activeCount":103},[],{"trials":12316,"activeCount":437,"soonestReadout":5838},[12317],{"nctId":5835,"briefTitle":5836,"status":109,"phases":12318,"primaryCompletion":5838,"completion":5839,"start":5840,"enrollment":5841,"conditions":12319,"interventions":12320},[92],[5822,5843],[5785,5845],{"trials":12322,"activeCount":103},[],{"trials":12324,"activeCount":103},[],{"trials":12326,"activeCount":103},[],{"intervention":1389,"totalTrials":437,"cells":12328},{"EARLY_PHASE1":12329,"PHASE1":12331,"PHASE2":12333,"PHASE3":12339,"PHASE4":12341,"NA":12343},{"trials":12330,"activeCount":103},[],{"trials":12332,"activeCount":103},[],{"trials":12334,"activeCount":437,"soonestReadout":1381},[12335],{"nctId":1378,"briefTitle":1379,"status":593,"phases":12336,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":12337,"interventions":12338},[92],[1386],[1388,1356,1389,1390],{"trials":12340,"activeCount":103},[],{"trials":12342,"activeCount":103},[],{"trials":12344,"activeCount":103},[],{"intervention":1390,"totalTrials":437,"cells":12346},{"EARLY_PHASE1":12347,"PHASE1":12349,"PHASE2":12351,"PHASE3":12357,"PHASE4":12359,"NA":12361},{"trials":12348,"activeCount":103},[],{"trials":12350,"activeCount":103},[],{"trials":12352,"activeCount":437,"soonestReadout":1381},[12353],{"nctId":1378,"briefTitle":1379,"status":593,"phases":12354,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":12355,"interventions":12356},[92],[1386],[1388,1356,1389,1390],{"trials":12358,"activeCount":103},[],{"trials":12360,"activeCount":103},[],{"trials":12362,"activeCount":103},[],{"intervention":1195,"totalTrials":437,"cells":12364},{"EARLY_PHASE1":12365,"PHASE1":12367,"PHASE2":12369,"PHASE3":12375,"PHASE4":12377,"NA":12379},{"trials":12366,"activeCount":103},[],{"trials":12368,"activeCount":103},[],{"trials":12370,"activeCount":437,"soonestReadout":1188},[12371],{"nctId":1185,"briefTitle":1186,"status":593,"phases":12372,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":709,"conditions":12373,"interventions":12374},[91,92],[1192,1193],[1195,211,156,236,1196],{"trials":12376,"activeCount":103},[],{"trials":12378,"activeCount":103},[],{"trials":12380,"activeCount":103},[],{"intervention":12382,"totalTrials":437,"cells":12383},"PKN605",{"EARLY_PHASE1":12384,"PHASE1":12386,"PHASE2":12388,"PHASE3":12398,"PHASE4":12400,"NA":12402},{"trials":12385,"activeCount":103},[],{"trials":12387,"activeCount":103},[],{"trials":12389,"activeCount":437,"soonestReadout":12394},[12390],{"nctId":12391,"briefTitle":12392,"status":109,"phases":12393,"primaryCompletion":12394,"completion":12394,"start":6789,"enrollment":1302,"conditions":12395,"interventions":12397},"NCT07217067","A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation",[92],"2027-09-09",[12396],"Atrial Fibrillation",[12382],{"trials":12399,"activeCount":103},[],{"trials":12401,"activeCount":103},[],{"trials":12403,"activeCount":103},[],{"intervention":12405,"totalTrials":437,"cells":12406},"ITU512",{"EARLY_PHASE1":12407,"PHASE1":12409,"PHASE2":12411,"PHASE3":12422,"PHASE4":12424,"NA":12426},{"trials":12408,"activeCount":103},[],{"trials":12410,"activeCount":103},[],{"trials":12412,"activeCount":437,"soonestReadout":12417},[12413],{"nctId":12414,"briefTitle":12415,"status":109,"phases":12416,"primaryCompletion":12417,"completion":12418,"start":12419,"enrollment":1829,"conditions":12420,"interventions":12421},"NCT06546670","A Phase I\u002FII Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease",[91,92],"2028-05-01","2030-02-19","2024-08-15",[3952],[12405],{"trials":12423,"activeCount":103},[],{"trials":12425,"activeCount":103},[],{"trials":12427,"activeCount":103},[],{"intervention":12429,"totalTrials":437,"cells":12430},"FWY003",{"EARLY_PHASE1":12431,"PHASE1":12433,"PHASE2":12435,"PHASE3":12447,"PHASE4":12449,"NA":12451},{"trials":12432,"activeCount":103},[],{"trials":12434,"activeCount":103},[],{"trials":12436,"activeCount":437,"soonestReadout":12441},[12437],{"nctId":12438,"briefTitle":12439,"status":109,"phases":12440,"primaryCompletion":12441,"completion":12442,"start":10373,"enrollment":12443,"conditions":12444,"interventions":12446},"NCT07441642","A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration",[92],"2029-08-21","2029-08-22",272,[12445],"Geographic Atrophy Secondary to Age-related Macular Degeneration",[12429],{"trials":12448,"activeCount":103},[],{"trials":12450,"activeCount":103},[],{"trials":12452,"activeCount":103},[],{"intervention":306,"totalTrials":437,"cells":12454},{"EARLY_PHASE1":12455,"PHASE1":12457,"PHASE2":12459,"PHASE3":12465,"PHASE4":12467,"NA":12469},{"trials":12456,"activeCount":103},[],{"trials":12458,"activeCount":103},[],{"trials":12460,"activeCount":437,"soonestReadout":299},[12461],{"nctId":296,"briefTitle":297,"status":109,"phases":12462,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":12463,"interventions":12464},[91,92],[303,304],[306,157,307],{"trials":12466,"activeCount":103},[],{"trials":12468,"activeCount":103},[],{"trials":12470,"activeCount":103},[],{"intervention":12472,"totalTrials":437,"cells":12473},"GHZ339",{"EARLY_PHASE1":12474,"PHASE1":12476,"PHASE2":12478,"PHASE3":12490,"PHASE4":12492,"NA":12494},{"trials":12475,"activeCount":103},[],{"trials":12477,"activeCount":103},[],{"trials":12479,"activeCount":437,"soonestReadout":12484},[12480],{"nctId":12481,"briefTitle":12482,"status":109,"phases":12483,"primaryCompletion":12484,"completion":12485,"start":12486,"enrollment":12487,"conditions":12488,"interventions":12489},"NCT06947993","Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis",[92],"2028-11-27","2028-12-22","2025-05-16",224,[10365],[12472],{"trials":12491,"activeCount":103},[],{"trials":12493,"activeCount":103},[],{"trials":12495,"activeCount":103},[],{"intervention":12497,"totalTrials":437,"cells":12498},"ABL001\u002FAsciminib",{"EARLY_PHASE1":12499,"PHASE1":12501,"PHASE2":12503,"PHASE3":12515,"PHASE4":12517,"NA":12519},{"trials":12500,"activeCount":103},[],{"trials":12502,"activeCount":103},[],{"trials":12504,"activeCount":437,"soonestReadout":12509},[12505],{"nctId":12506,"briefTitle":12507,"status":109,"phases":12508,"primaryCompletion":12509,"completion":12510,"start":12511,"enrollment":1611,"conditions":12512,"interventions":12514},"NCT06514534","Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.",[92],"2029-02-17","2029-02-18","2025-02-18",[12513],"Chronic Myeloid Leukemia (CML)",[12497],{"trials":12516,"activeCount":103},[],{"trials":12518,"activeCount":103},[],{"trials":12520,"activeCount":103},[],{"intervention":12522,"totalTrials":437,"cells":12523},"CPK850",{"EARLY_PHASE1":12524,"PHASE1":12526,"PHASE2":12528,"PHASE3":12538,"PHASE4":12540,"NA":12542},{"trials":12525,"activeCount":103},[],{"trials":12527,"activeCount":103},[],{"trials":12529,"activeCount":437,"soonestReadout":6858},[12530],{"nctId":12531,"briefTitle":12532,"status":147,"phases":12533,"primaryCompletion":6858,"completion":6858,"start":12534,"enrollment":138,"conditions":12535,"interventions":12537},"NCT03374657","A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa",[91,92],"2018-08-22",[12536],"Retinitis Pigmentosa",[12522],{"trials":12539,"activeCount":103},[],{"trials":12541,"activeCount":103},[],{"trials":12543,"activeCount":103},[],{"intervention":12545,"totalTrials":437,"cells":12546},"GXV813",{"EARLY_PHASE1":12547,"PHASE1":12549,"PHASE2":12551,"PHASE3":12562,"PHASE4":12564,"NA":12566},{"trials":12548,"activeCount":103},[],{"trials":12550,"activeCount":103},[],{"trials":12552,"activeCount":437,"soonestReadout":12557},[12553],{"nctId":12554,"briefTitle":12555,"status":109,"phases":12556,"primaryCompletion":12557,"completion":12557,"start":12558,"enrollment":3713,"conditions":12559,"interventions":12561},"NCT07467993","Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia",[92],"2027-04-22","2026-03-16",[12560],"Schizophrenia",[12545],{"trials":12563,"activeCount":103},[],{"trials":12565,"activeCount":103},[],{"trials":12567,"activeCount":103},[],{"intervention":12569,"totalTrials":437,"cells":12570},"EYU688",{"EARLY_PHASE1":12571,"PHASE1":12573,"PHASE2":12575,"PHASE3":12588,"PHASE4":12590,"NA":12592},{"trials":12572,"activeCount":103},[],{"trials":12574,"activeCount":103},[],{"trials":12576,"activeCount":437,"soonestReadout":12581},[12577],{"nctId":12578,"briefTitle":12579,"status":109,"phases":12580,"primaryCompletion":12581,"completion":12582,"start":12583,"enrollment":12584,"conditions":12585,"interventions":12587},"NCT06006559","A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever",[92],"2027-01-07","2027-01-15","2024-02-20",108,[12586],"Dengue",[12569],{"trials":12589,"activeCount":103},[],{"trials":12591,"activeCount":103},[],{"trials":12593,"activeCount":103},[],{"intervention":6006,"totalTrials":437,"cells":12595},{"EARLY_PHASE1":12596,"PHASE1":12598,"PHASE2":12600,"PHASE3":12606,"PHASE4":12608,"NA":12610},{"trials":12597,"activeCount":103},[],{"trials":12599,"activeCount":103},[],{"trials":12601,"activeCount":437,"soonestReadout":6001},[12602],{"nctId":5998,"briefTitle":5999,"status":109,"phases":12603,"primaryCompletion":6001,"completion":6002,"start":6003,"enrollment":467,"conditions":12604,"interventions":12605},[92],[1800],[5936,5936,6006],{"trials":12607,"activeCount":103},[],{"trials":12609,"activeCount":103},[],{"trials":12611,"activeCount":103},[],{"intervention":12613,"totalTrials":437,"cells":12614},"LTP",{"EARLY_PHASE1":12615,"PHASE1":12617,"PHASE2":12619,"PHASE3":12630,"PHASE4":12632,"NA":12634},{"trials":12616,"activeCount":103},[],{"trials":12618,"activeCount":103},[],{"trials":12620,"activeCount":437,"soonestReadout":12625},[12621],{"nctId":12622,"briefTitle":12623,"status":109,"phases":12624,"primaryCompletion":12625,"completion":12626,"start":1442,"enrollment":6350,"conditions":12627,"interventions":12629},"NCT06649110","A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)",[91,92],"2028-11-29","2028-12-31",[12628],"Healthy Volunteers, Pulmonary Arterial Hypertension",[12613],{"trials":12631,"activeCount":103},[],{"trials":12633,"activeCount":103},[],{"trials":12635,"activeCount":103},[],{"intervention":9867,"totalTrials":437,"cells":12637},{"EARLY_PHASE1":12638,"PHASE1":12640,"PHASE2":12642,"PHASE3":12648,"PHASE4":12650,"NA":12652},{"trials":12639,"activeCount":103},[],{"trials":12641,"activeCount":103},[],{"trials":12643,"activeCount":437,"soonestReadout":6371},[12644],{"nctId":9858,"briefTitle":9859,"status":147,"phases":12645,"primaryCompletion":6371,"completion":9861,"start":9862,"enrollment":2633,"conditions":12646,"interventions":12647},[92],[9864],[9866,9867,7443,9868,9869,9870],{"trials":12649,"activeCount":103},[],{"trials":12651,"activeCount":103},[],{"trials":12653,"activeCount":103},[],{"intervention":9868,"totalTrials":437,"cells":12655},{"EARLY_PHASE1":12656,"PHASE1":12658,"PHASE2":12660,"PHASE3":12666,"PHASE4":12668,"NA":12670},{"trials":12657,"activeCount":103},[],{"trials":12659,"activeCount":103},[],{"trials":12661,"activeCount":437,"soonestReadout":6371},[12662],{"nctId":9858,"briefTitle":9859,"status":147,"phases":12663,"primaryCompletion":6371,"completion":9861,"start":9862,"enrollment":2633,"conditions":12664,"interventions":12665},[92],[9864],[9866,9867,7443,9868,9869,9870],{"trials":12667,"activeCount":103},[],{"trials":12669,"activeCount":103},[],{"trials":12671,"activeCount":103},[],{"intervention":9869,"totalTrials":437,"cells":12673},{"EARLY_PHASE1":12674,"PHASE1":12676,"PHASE2":12678,"PHASE3":12684,"PHASE4":12686,"NA":12688},{"trials":12675,"activeCount":103},[],{"trials":12677,"activeCount":103},[],{"trials":12679,"activeCount":437,"soonestReadout":6371},[12680],{"nctId":9858,"briefTitle":9859,"status":147,"phases":12681,"primaryCompletion":6371,"completion":9861,"start":9862,"enrollment":2633,"conditions":12682,"interventions":12683},[92],[9864],[9866,9867,7443,9868,9869,9870],{"trials":12685,"activeCount":103},[],{"trials":12687,"activeCount":103},[],{"trials":12689,"activeCount":103},[],{"intervention":9870,"totalTrials":437,"cells":12691},{"EARLY_PHASE1":12692,"PHASE1":12694,"PHASE2":12696,"PHASE3":12702,"PHASE4":12704,"NA":12706},{"trials":12693,"activeCount":103},[],{"trials":12695,"activeCount":103},[],{"trials":12697,"activeCount":437,"soonestReadout":6371},[12698],{"nctId":9858,"briefTitle":9859,"status":147,"phases":12699,"primaryCompletion":6371,"completion":9861,"start":9862,"enrollment":2633,"conditions":12700,"interventions":12701},[92],[9864],[9866,9867,7443,9868,9869,9870],{"trials":12703,"activeCount":103},[],{"trials":12705,"activeCount":103},[],{"trials":12707,"activeCount":103},[],{"intervention":1626,"totalTrials":437,"cells":12709},{"EARLY_PHASE1":12710,"PHASE1":12712,"PHASE2":12714,"PHASE3":12720,"PHASE4":12722,"NA":12724},{"trials":12711,"activeCount":103},[],{"trials":12713,"activeCount":103},[],{"trials":12715,"activeCount":437,"soonestReadout":1620},[12716],{"nctId":1617,"briefTitle":1618,"status":147,"phases":12717,"primaryCompletion":1620,"completion":1620,"start":1621,"enrollment":1622,"conditions":12718,"interventions":12719},[92],[1624],[1561,1626,1627,1628,1629],{"trials":12721,"activeCount":103},[],{"trials":12723,"activeCount":103},[],{"trials":12725,"activeCount":103},[],{"intervention":1627,"totalTrials":437,"cells":12727},{"EARLY_PHASE1":12728,"PHASE1":12730,"PHASE2":12732,"PHASE3":12738,"PHASE4":12740,"NA":12742},{"trials":12729,"activeCount":103},[],{"trials":12731,"activeCount":103},[],{"trials":12733,"activeCount":437,"soonestReadout":1620},[12734],{"nctId":1617,"briefTitle":1618,"status":147,"phases":12735,"primaryCompletion":1620,"completion":1620,"start":1621,"enrollment":1622,"conditions":12736,"interventions":12737},[92],[1624],[1561,1626,1627,1628,1629],{"trials":12739,"activeCount":103},[],{"trials":12741,"activeCount":103},[],{"trials":12743,"activeCount":103},[],{"intervention":12745,"totalTrials":437,"cells":12746},"DFT383",{"EARLY_PHASE1":12747,"PHASE1":12749,"PHASE2":12751,"PHASE3":12763,"PHASE4":12765,"NA":12767},{"trials":12748,"activeCount":103},[],{"trials":12750,"activeCount":103},[],{"trials":12752,"activeCount":437,"soonestReadout":12757},[12753],{"nctId":12754,"briefTitle":12755,"status":109,"phases":12756,"primaryCompletion":12757,"completion":12758,"start":12759,"enrollment":2439,"conditions":12760,"interventions":12762},"NCT06910813","DFT383 in Pediatric Participants With Nephropathic Cystinosis",[91,92],"2031-03-14","2044-03-14","2025-06-02",[12761],"Nephropathic Cystinosis",[12745],{"trials":12764,"activeCount":103},[],{"trials":12766,"activeCount":103},[],{"trials":12768,"activeCount":103},[],{"intervention":12770,"totalTrials":437,"cells":12771},"BION-1301 Single Dose",{"EARLY_PHASE1":12772,"PHASE1":12774,"PHASE2":12776,"PHASE3":12787,"PHASE4":12789,"NA":12791},{"trials":12773,"activeCount":103},[],{"trials":12775,"activeCount":103},[],{"trials":12777,"activeCount":437,"soonestReadout":12782},[12778],{"nctId":12779,"briefTitle":12780,"status":147,"phases":12781,"primaryCompletion":12782,"completion":12782,"start":2622,"enrollment":12783,"conditions":12784,"interventions":12785},"NCT03945318","Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)",[91,92],"2026-04-30",103,[6761],[12770,12786,12770],"BION-1301 Multiple Doses",{"trials":12788,"activeCount":103},[],{"trials":12790,"activeCount":103},[],{"trials":12792,"activeCount":103},[],{"intervention":12786,"totalTrials":437,"cells":12794},{"EARLY_PHASE1":12795,"PHASE1":12797,"PHASE2":12799,"PHASE3":12805,"PHASE4":12807,"NA":12809},{"trials":12796,"activeCount":103},[],{"trials":12798,"activeCount":103},[],{"trials":12800,"activeCount":437,"soonestReadout":12782},[12801],{"nctId":12779,"briefTitle":12780,"status":147,"phases":12802,"primaryCompletion":12782,"completion":12782,"start":2622,"enrollment":12783,"conditions":12803,"interventions":12804},[91,92],[6761],[12770,12786,12770],{"trials":12806,"activeCount":103},[],{"trials":12808,"activeCount":103},[],{"trials":12810,"activeCount":103},[],{"intervention":3124,"totalTrials":437,"cells":12812},{"EARLY_PHASE1":12813,"PHASE1":12815,"PHASE2":12817,"PHASE3":12823,"PHASE4":12825,"NA":12827},{"trials":12814,"activeCount":103},[],{"trials":12816,"activeCount":103},[],{"trials":12818,"activeCount":437,"soonestReadout":3117},[12819],{"nctId":3114,"briefTitle":3115,"status":109,"phases":12820,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":3120,"conditions":12821,"interventions":12822},[91,92],[3122],[3124,3125,3126,3127,3128,3129,3130,3131,3017],{"trials":12824,"activeCount":103},[],{"trials":12826,"activeCount":103},[],{"trials":12828,"activeCount":103},[],{"intervention":3125,"totalTrials":437,"cells":12830},{"EARLY_PHASE1":12831,"PHASE1":12833,"PHASE2":12835,"PHASE3":12841,"PHASE4":12843,"NA":12845},{"trials":12832,"activeCount":103},[],{"trials":12834,"activeCount":103},[],{"trials":12836,"activeCount":437,"soonestReadout":3117},[12837],{"nctId":3114,"briefTitle":3115,"status":109,"phases":12838,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":3120,"conditions":12839,"interventions":12840},[91,92],[3122],[3124,3125,3126,3127,3128,3129,3130,3131,3017],{"trials":12842,"activeCount":103},[],{"trials":12844,"activeCount":103},[],{"trials":12846,"activeCount":103},[],{"intervention":3126,"totalTrials":437,"cells":12848},{"EARLY_PHASE1":12849,"PHASE1":12851,"PHASE2":12853,"PHASE3":12859,"PHASE4":12861,"NA":12863},{"trials":12850,"activeCount":103},[],{"trials":12852,"activeCount":103},[],{"trials":12854,"activeCount":437,"soonestReadout":3117},[12855],{"nctId":3114,"briefTitle":3115,"status":109,"phases":12856,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":3120,"conditions":12857,"interventions":12858},[91,92],[3122],[3124,3125,3126,3127,3128,3129,3130,3131,3017],{"trials":12860,"activeCount":103},[],{"trials":12862,"activeCount":103},[],{"trials":12864,"activeCount":103},[],{"intervention":3127,"totalTrials":437,"cells":12866},{"EARLY_PHASE1":12867,"PHASE1":12869,"PHASE2":12871,"PHASE3":12877,"PHASE4":12879,"NA":12881},{"trials":12868,"activeCount":103},[],{"trials":12870,"activeCount":103},[],{"trials":12872,"activeCount":437,"soonestReadout":3117},[12873],{"nctId":3114,"briefTitle":3115,"status":109,"phases":12874,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":3120,"conditions":12875,"interventions":12876},[91,92],[3122],[3124,3125,3126,3127,3128,3129,3130,3131,3017],{"trials":12878,"activeCount":103},[],{"trials":12880,"activeCount":103},[],{"trials":12882,"activeCount":103},[],{"intervention":3128,"totalTrials":437,"cells":12884},{"EARLY_PHASE1":12885,"PHASE1":12887,"PHASE2":12889,"PHASE3":12895,"PHASE4":12897,"NA":12899},{"trials":12886,"activeCount":103},[],{"trials":12888,"activeCount":103},[],{"trials":12890,"activeCount":437,"soonestReadout":3117},[12891],{"nctId":3114,"briefTitle":3115,"status":109,"phases":12892,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":3120,"conditions":12893,"interventions":12894},[91,92],[3122],[3124,3125,3126,3127,3128,3129,3130,3131,3017],{"trials":12896,"activeCount":103},[],{"trials":12898,"activeCount":103},[],{"trials":12900,"activeCount":103},[],{"intervention":3129,"totalTrials":437,"cells":12902},{"EARLY_PHASE1":12903,"PHASE1":12905,"PHASE2":12907,"PHASE3":12913,"PHASE4":12915,"NA":12917},{"trials":12904,"activeCount":103},[],{"trials":12906,"activeCount":103},[],{"trials":12908,"activeCount":437,"soonestReadout":3117},[12909],{"nctId":3114,"briefTitle":3115,"status":109,"phases":12910,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":3120,"conditions":12911,"interventions":12912},[91,92],[3122],[3124,3125,3126,3127,3128,3129,3130,3131,3017],{"trials":12914,"activeCount":103},[],{"trials":12916,"activeCount":103},[],{"trials":12918,"activeCount":103},[],{"intervention":3130,"totalTrials":437,"cells":12920},{"EARLY_PHASE1":12921,"PHASE1":12923,"PHASE2":12925,"PHASE3":12931,"PHASE4":12933,"NA":12935},{"trials":12922,"activeCount":103},[],{"trials":12924,"activeCount":103},[],{"trials":12926,"activeCount":437,"soonestReadout":3117},[12927],{"nctId":3114,"briefTitle":3115,"status":109,"phases":12928,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":3120,"conditions":12929,"interventions":12930},[91,92],[3122],[3124,3125,3126,3127,3128,3129,3130,3131,3017],{"trials":12932,"activeCount":103},[],{"trials":12934,"activeCount":103},[],{"trials":12936,"activeCount":103},[],{"intervention":3131,"totalTrials":437,"cells":12938},{"EARLY_PHASE1":12939,"PHASE1":12941,"PHASE2":12943,"PHASE3":12949,"PHASE4":12951,"NA":12953},{"trials":12940,"activeCount":103},[],{"trials":12942,"activeCount":103},[],{"trials":12944,"activeCount":437,"soonestReadout":3117},[12945],{"nctId":3114,"briefTitle":3115,"status":109,"phases":12946,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":3120,"conditions":12947,"interventions":12948},[91,92],[3122],[3124,3125,3126,3127,3128,3129,3130,3131,3017],{"trials":12950,"activeCount":103},[],{"trials":12952,"activeCount":103},[],{"trials":12954,"activeCount":103},[],{"intervention":8070,"totalTrials":2367,"cells":12956},{"EARLY_PHASE1":12957,"PHASE1":12959,"PHASE2":12965,"PHASE3":13030,"PHASE4":13040,"NA":13042},{"trials":12958,"activeCount":103},[],{"trials":12960,"activeCount":103},[12961],{"nctId":10567,"briefTitle":10568,"status":134,"phases":12962,"primaryCompletion":10570,"completion":10570,"start":1808,"enrollment":2776,"conditions":12963,"interventions":12964},[91],[10572],[10574,10125,10575,10576,10577,10578],{"trials":12966,"activeCount":437,"soonestReadout":10336},[12967,12971,12975,12984,12988,12992,13001,13010,13014,13021],{"nctId":10615,"briefTitle":10616,"status":134,"phases":12968,"primaryCompletion":10618,"completion":10619,"start":1120,"enrollment":827,"conditions":12969,"interventions":12970},[92],[227],[212,8070,10622],{"nctId":10333,"briefTitle":10334,"status":147,"phases":12972,"primaryCompletion":10336,"completion":10336,"start":10337,"enrollment":1053,"conditions":12973,"interventions":12974},[92],[10339],[8070,10341,10312,10342],{"nctId":12976,"briefTitle":12977,"status":123,"phases":12978,"primaryCompletion":12979,"completion":2044,"start":12980,"enrollment":12981,"conditions":12982,"interventions":12983},"NCT02414139","Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)",[92],"2023-04-12","2015-06-11",373,[227],[8070],{"nctId":11480,"briefTitle":11481,"status":134,"phases":12985,"primaryCompletion":11175,"completion":11175,"start":11483,"enrollment":446,"conditions":12986,"interventions":12987},[91,92],[1316],[8070,10341],{"nctId":8064,"briefTitle":8065,"status":123,"phases":12989,"primaryCompletion":8067,"completion":8067,"start":2853,"enrollment":3343,"conditions":12990,"interventions":12991},[92],[227],[8070,212,5252],{"nctId":12993,"briefTitle":12994,"status":134,"phases":12995,"primaryCompletion":12996,"completion":12997,"start":12998,"enrollment":485,"conditions":12999,"interventions":13000},"NCT04139317","Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%",[92],"2022-01-14","2023-02-07","2020-01-22",[5282],[8070,8153],{"nctId":13002,"briefTitle":13003,"status":390,"phases":13004,"primaryCompletion":13005,"completion":13005,"start":13006,"enrollment":103,"conditions":13007,"interventions":13009},"NCT04460729","A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases",[92],"2023-11-17","2020-11-11",[13008],"Non-small Cell Lung Carcinoma (NSCLC)",[8070],{"nctId":10638,"briefTitle":10639,"status":123,"phases":13011,"primaryCompletion":10641,"completion":1465,"start":4677,"enrollment":3568,"conditions":13012,"interventions":13013},[91,92],[10643],[212,8070],{"nctId":13015,"briefTitle":13016,"status":134,"phases":13017,"primaryCompletion":13018,"completion":13018,"start":6003,"enrollment":1630,"conditions":13019,"interventions":13020},"NCT04926831","Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC",[92],"2024-03-13",[128],[10576],{"nctId":13022,"briefTitle":13023,"status":123,"phases":13024,"primaryCompletion":13025,"completion":6153,"start":13026,"enrollment":792,"conditions":13027,"interventions":13029},"NCT04677595","Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation",[92],"2023-10-12","2021-05-17",[13028],"Non-Small Cell Lung Cancer (NSCLC)",[8070],{"trials":13031,"activeCount":103},[13032,13036],{"nctId":8097,"briefTitle":8098,"status":134,"phases":13033,"primaryCompletion":8100,"completion":8101,"start":5089,"enrollment":2633,"conditions":13034,"interventions":13035},[93],[227],[8070,5252],{"nctId":10969,"briefTitle":10970,"status":134,"phases":13037,"primaryCompletion":137,"completion":137,"start":10972,"enrollment":2379,"conditions":13038,"interventions":13039},[93],[227],[8070,10342,4375,5262,1168],{"trials":13041,"activeCount":103},[],{"trials":13043,"activeCount":103},[13044,13051],{"nctId":13045,"briefTitle":13046,"status":123,"phases":13047,"primaryCompletion":2277,"completion":2277,"start":1806,"enrollment":16,"conditions":13048,"interventions":13050},"NCT05675683","Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib",[],[13049],"Metastatic Non-Small Cell Lung Cancer",[8070],{"nctId":13052,"briefTitle":13053,"status":1326,"phases":13054,"conditions":13055,"interventions":13056},"NCT04741789","Managed Access Programs for INC280, Capmatinib",[],[182],[8070],{"intervention":9866,"totalTrials":814,"cells":13058},{"EARLY_PHASE1":13059,"PHASE1":13061,"PHASE2":13076,"PHASE3":13117,"PHASE4":13133,"NA":13135},{"trials":13060,"activeCount":103},[],{"trials":13062,"activeCount":103},[13063,13067],{"nctId":9817,"briefTitle":9818,"status":123,"phases":13064,"primaryCompletion":2034,"completion":2034,"start":9820,"enrollment":557,"conditions":13065,"interventions":13066},[91],[5598],[9823,9824,9825],{"nctId":13068,"briefTitle":13069,"status":123,"phases":13070,"primaryCompletion":13071,"completion":13072,"start":13073,"enrollment":4557,"conditions":13074,"interventions":13075},"NCT01429337","PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function",[91],"2020-04-13","2020-05-09","2011-03-07",[2625],[9866,9866],{"trials":13077,"activeCount":437,"soonestReadout":6371},[13078,13082,13092,13099,13105,13113],{"nctId":9843,"briefTitle":9844,"status":390,"phases":13079,"primaryCompletion":6372,"completion":2938,"start":9846,"enrollment":103,"conditions":13080,"interventions":13081},[91,92],[9848],[4393,9823,9850,9825,9851,9852,5207],{"nctId":13083,"briefTitle":13084,"status":123,"phases":13085,"primaryCompletion":13086,"completion":13087,"start":13088,"enrollment":13089,"conditions":13090,"interventions":13091},"NCT00782067","Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia",[92],"2014-12-01","2017-08-24","2008-10-13",116,[3422],[9866],{"nctId":13093,"briefTitle":13094,"status":123,"phases":13095,"primaryCompletion":3680,"completion":3680,"start":13096,"enrollment":1423,"conditions":13097,"interventions":13098},"NCT01883362","Standard of Care +\u002F- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML",[92],"2014-02-06",[2569],[9866],{"nctId":13100,"briefTitle":13101,"status":134,"phases":13102,"primaryCompletion":812,"completion":812,"start":4975,"enrollment":2633,"conditions":13103,"interventions":13104},"NCT00866281","A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia",[91,92],[2569,3204],[9825],{"nctId":13106,"briefTitle":13107,"status":123,"phases":13108,"primaryCompletion":13109,"completion":13109,"start":13110,"enrollment":10526,"conditions":13111,"interventions":13112},"NCT03280030","A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML",[92],"2022-11-14","2018-04-06",[2569],[9866],{"nctId":9858,"briefTitle":9859,"status":147,"phases":13114,"primaryCompletion":6371,"completion":9861,"start":9862,"enrollment":2633,"conditions":13115,"interventions":13116},[92],[9864],[9866,9867,7443,9868,9869,9870],{"trials":13118,"activeCount":103},[13119,13123],{"nctId":9874,"briefTitle":9875,"status":123,"phases":13120,"primaryCompletion":9877,"completion":9877,"start":9878,"enrollment":4670,"conditions":13121,"interventions":13122},[93],[2569],[9866,7443,9881],{"nctId":13124,"briefTitle":13125,"status":123,"phases":13126,"primaryCompletion":13127,"completion":13127,"start":13128,"enrollment":13129,"conditions":13130,"interventions":13131},"NCT03512197","A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)",[93],"2021-02-12","2018-07-20",511,[5598],[9866,13132],"Chemotherapy",{"trials":13134,"activeCount":103},[],{"trials":13136,"activeCount":103},[13137,13143,13152,13160],{"nctId":13138,"briefTitle":13139,"status":1326,"phases":13140,"conditions":13141,"interventions":13142},"NCT03114228","An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)",[],[9864],[9866],{"nctId":13144,"briefTitle":13145,"status":123,"phases":13146,"primaryCompletion":13147,"completion":13147,"start":13148,"enrollment":13149,"conditions":13150,"interventions":13151},"NCT05488613","Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)",[],"2021-01-26","2020-09-24",81,[5598],[9866],{"nctId":13153,"briefTitle":13154,"status":1326,"phases":13155,"conditions":13156,"interventions":13159},"NCT02624570","Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy",[],[13157,13158],"Acute Myeloid Leukemia (AML) With","FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)",[9866],{"nctId":13161,"briefTitle":13162,"status":1326,"phases":13163,"conditions":13164,"interventions":13169},"NCT05219266","Managed Access Programs for PKC412, Midostaurin",[],[13165,2569,13166,13167,13168],"FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia","Aggressive Systemic Mastocytosis","Mast Cell Leukemia","Systemic Mastocytosis With an Associated Hematologic Neoplasm",[9825],{"intervention":13171,"totalTrials":317,"cells":13172},"Atrasentan",{"EARLY_PHASE1":13173,"PHASE1":13175,"PHASE2":13177,"PHASE3":13200,"PHASE4":13202,"NA":13204},{"trials":13174,"activeCount":103},[],{"trials":13176,"activeCount":103},[],{"trials":13178,"activeCount":437,"soonestReadout":11657},[13179,13188],{"nctId":13180,"briefTitle":13181,"status":123,"phases":13182,"primaryCompletion":13183,"completion":13184,"start":13185,"enrollment":271,"conditions":13186,"interventions":13187},"NCT05834738","Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy",[92],"2025-06-30","2025-10-29","2023-07-20",[6761,5971],[13171,13171],{"nctId":13189,"briefTitle":13190,"status":147,"phases":13191,"primaryCompletion":11657,"completion":13192,"start":13193,"enrollment":12783,"conditions":13194,"interventions":13199},"NCT04573920","Atrasentan in Patients With Proteinuric Glomerular Diseases",[92],"2026-10-27","2021-03-15",[6761,13195,13196,13197,13198,5971],"Focal Segmental Glomerulosclerosis","Alport Syndrome","Diabetic Kidney Disease","Diabetic Nephropathy Type 2",[13171],{"trials":13201,"activeCount":103},[],{"trials":13203,"activeCount":103},[],{"trials":13205,"activeCount":103},[13206],{"nctId":13207,"briefTitle":13208,"status":491,"phases":13209,"conditions":13210,"interventions":13211},"NCT07319585","Managed Access Programs for EXV811, Atrasentan",[],[6761],[13171],{"intervention":13213,"totalTrials":317,"cells":13214},"PIT565",{"EARLY_PHASE1":13215,"PHASE1":13217,"PHASE2":13245,"PHASE3":13247,"PHASE4":13249,"NA":13251},{"trials":13216,"activeCount":103},[],{"trials":13218,"activeCount":317,"soonestReadout":13223},[13219,13228,13236],{"nctId":13220,"briefTitle":13221,"status":147,"phases":13222,"primaryCompletion":13223,"completion":13223,"start":7398,"enrollment":2354,"conditions":13224,"interventions":13227},"NCT05397496","Study of PIT565 in Relapsed and\u002For Refractory B-cell Malignancies",[91],"2026-08-20",[13225,13226],"B-cell Non-Hodgkin Lymphoma (B-NHL)","B-cell Acute Lymphoblastic Leukemia (B-ALL)",[13213],{"nctId":13229,"briefTitle":13230,"status":109,"phases":13231,"primaryCompletion":13232,"completion":13233,"start":707,"enrollment":3530,"conditions":13234,"interventions":13235},"NCT07029555","An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis",[91],"2028-05-15","2028-05-16",[1717],[13213],{"nctId":13237,"briefTitle":13238,"status":109,"phases":13239,"primaryCompletion":13240,"completion":13240,"start":13241,"enrollment":271,"conditions":13242,"interventions":13244},"NCT06335979","An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).",[91],"2027-11-17","2024-10-08",[13243],"Systemic Lupus Erythematosus, SLE",[13213],{"trials":13246,"activeCount":103},[],{"trials":13248,"activeCount":103},[],{"trials":13250,"activeCount":103},[],{"trials":13252,"activeCount":103},[],{"intervention":4389,"totalTrials":827,"cells":13254},{"EARLY_PHASE1":13255,"PHASE1":13266,"PHASE2":13426,"PHASE3":13537,"PHASE4":13539,"NA":13541},{"trials":13256,"activeCount":103},[13257],{"nctId":13258,"briefTitle":13259,"status":134,"phases":13260,"primaryCompletion":1512,"completion":1512,"start":13261,"enrollment":1112,"conditions":13262,"interventions":13263},"NCT04237649","KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors",[90],"2020-02-20",[647],[13264,4389,10575,13265],"KAZ954","NZV930",{"trials":13267,"activeCount":213,"soonestReadout":13353},[13268,13278,13287,13297,13306,13315,13322,13330,13337,13345,13349,13359,13367,13376,13380,13384,13395,13403,13412],{"nctId":13269,"briefTitle":13270,"status":123,"phases":13271,"primaryCompletion":13272,"completion":13272,"start":3139,"enrollment":1384,"conditions":13273,"interventions":13277},"NCT02947165","Phase I\u002FIb Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.",[91],"2021-06-18",[15,6656,13274,209,13275,13276],"Hepatocellular Cancer","Pancreatic Cancer","Renal Cancer",[2411,4389],{"nctId":13279,"briefTitle":13280,"status":134,"phases":13281,"primaryCompletion":13282,"completion":13282,"start":2220,"enrollment":709,"conditions":13283,"interventions":13285},"NCT04895748","DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced\u002FRelapsed Renal Cancer & Other Malignancies",[91],"2026-02-13",[13284],"Carcinoma, Renal Cell",[13286,7711,4389,10575],"DFF332",{"nctId":13288,"briefTitle":13289,"status":134,"phases":13290,"primaryCompletion":13291,"completion":13291,"start":1064,"enrollment":13292,"conditions":13293,"interventions":13295},"NCT02936102","A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.",[91],"2024-11-22",154,[5614,9944,13294],"Chordoma and Alveolar Soft Part Sarcoma",[13296,4389],"FAZ053",{"nctId":13298,"briefTitle":13299,"status":134,"phases":13300,"primaryCompletion":13301,"completion":13301,"start":5131,"enrollment":437,"conditions":13302,"interventions":13303},"NCT03176264","PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer",[91],"2018-01-30",[9924],[4389,13304,13305],"bevacizumab","mFOLFOX6",{"nctId":13307,"briefTitle":13308,"status":123,"phases":13309,"primaryCompletion":13310,"completion":13310,"start":13311,"enrollment":4516,"conditions":13312,"interventions":13313},"NCT02740270","Phase I\u002FIb Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas",[91],"2020-03-03","2016-07-22",[647,10090],[13314,4389],"GWN323",{"nctId":13316,"briefTitle":13317,"status":134,"phases":13318,"primaryCompletion":6013,"completion":6013,"start":13319,"enrollment":2810,"conditions":13320,"interventions":13321},"NCT03064854","PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients",[91],"2017-05-24",[128],[4389,5262,9948,4375,1168,4321,3157],{"nctId":13323,"briefTitle":13324,"status":134,"phases":13325,"primaryCompletion":13326,"completion":13326,"start":2138,"enrollment":3043,"conditions":13327,"interventions":13329},"NCT02452268","A Phase I\u002FIb Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers",[91],"2022-03-07",[13328],"Metastatic and Advanced Solid Tumors",[9915,4389],{"nctId":13331,"briefTitle":13332,"status":147,"phases":13333,"primaryCompletion":7176,"completion":7176,"start":13334,"enrollment":1384,"conditions":13335,"interventions":13336},"NCT04058756","Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments",[91],"2019-10-30",[5614],[4389],{"nctId":13338,"briefTitle":13339,"status":123,"phases":13340,"primaryCompletion":13341,"completion":13341,"start":13342,"enrollment":37,"conditions":13343,"interventions":13344},"NCT03111992","Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",[91],"2020-03-02","2017-12-18",[5636],[4389,1686,4390],{"nctId":10278,"briefTitle":10279,"status":134,"phases":13346,"primaryCompletion":10281,"completion":10282,"start":5132,"enrollment":3713,"conditions":13347,"interventions":13348},[91],[10284,6375,36,10285],[158,4389],{"nctId":13350,"briefTitle":13351,"status":147,"phases":13352,"primaryCompletion":13353,"completion":13354,"start":10595,"enrollment":6014,"conditions":13355,"interventions":13357},"NCT03891953","Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.",[91],"2026-10-30","2026-10-31",[227,36,10653,13356,9944],"Microsatellite Stable Colorectal Cancer",[13358,4389],"DKY709",{"nctId":13360,"briefTitle":13361,"status":123,"phases":13362,"primaryCompletion":13363,"completion":13363,"start":13364,"enrollment":3343,"conditions":13365,"interventions":13366},"NCT02678260","Phase I Study of PDR001 in Patients With Advanced Malignancies.",[91],"2017-09-01","2016-02-19",[6437],[4389],{"nctId":13368,"briefTitle":13369,"status":134,"phases":13370,"primaryCompletion":13371,"completion":13371,"start":13372,"enrollment":2405,"conditions":13373,"interventions":13374},"NCT03301896","Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",[91],"2022-06-30","2018-01-31",[647],[13375,4389],"LHC165",{"nctId":4381,"briefTitle":4382,"status":123,"phases":13377,"primaryCompletion":4384,"completion":4384,"start":4385,"enrollment":3741,"conditions":13378,"interventions":13379},[91],[4387],[4389,4390,196,4391,4392,4393],{"nctId":10694,"briefTitle":10695,"status":123,"phases":13381,"primaryCompletion":10697,"completion":10697,"start":10698,"enrollment":180,"conditions":13382,"interventions":13383},[91],[3422,10700,9848,5723,10701,10702,3335,5724],[10590,4389,10589,7513],{"nctId":13385,"briefTitle":13386,"status":123,"phases":13387,"primaryCompletion":13388,"completion":13388,"start":13389,"enrollment":13390,"conditions":13391,"interventions":13393},"NCT02900664","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)",[91],"2021-03-17","2016-08-23",283,[13392],"Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma",[4389,10126,1686,13394,155],"TMT212",{"nctId":13396,"briefTitle":13397,"status":123,"phases":13398,"primaryCompletion":9910,"completion":9910,"start":13399,"enrollment":1611,"conditions":13400,"interventions":13401},"NCT02988440","Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and\u002For Phase 2 Dose for This Combination in Advanced Hepatocellular Patients",[91],"2017-04-20",[4412],[4389,13402],"Sorafenib",{"nctId":13404,"briefTitle":13405,"status":134,"phases":13406,"primaryCompletion":9647,"completion":9647,"start":13407,"enrollment":1574,"conditions":13408,"interventions":13410},"NCT03172936","Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced\u002FMetastatic Solid Tumors or Lymphomas",[91],"2017-09-08",[13409],"Solid Tumors and Lymphomas",[13411,4389],"MIW815",{"nctId":13413,"briefTitle":13414,"status":123,"phases":13415,"primaryCompletion":10641,"completion":13416,"start":13417,"enrollment":2910,"conditions":13418,"interventions":13424},"NCT01351103","A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",[91],"2024-06-17","2011-12-01",[13275,13419,36,9944,13420,13421,13422,13423],"BRAF Mutant Colorectal Cancer","Head and Neck Squamous Cell Cancer","Cervical Squamous Cell Cancer","Esophageal Squamous Cell Cancer","Lung Squamous Cell Cancer",[13425,4389],"LGK974",{"trials":13427,"activeCount":103},[13428,13438,13453,13469,13477,13488,13501,13505,13509,13517,13525],{"nctId":13429,"briefTitle":13430,"status":134,"phases":13431,"primaryCompletion":13432,"completion":13432,"start":13433,"enrollment":13434,"conditions":13435,"interventions":13436},"NCT02829723","A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors",[91,92],"2022-12-01","2016-10-21",192,[5614],[13437,4389],"BLZ945",{"nctId":13439,"briefTitle":13440,"status":123,"phases":13441,"primaryCompletion":2417,"completion":13442,"start":13443,"enrollment":485,"conditions":13444,"interventions":13452},"NCT03365791","PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies",[92],"2020-09-17","2018-01-24",[13445,13446,13447,13448,13449,13450,13451,9517],"Small Cell Lung Cancer","Gastric Adenocarcinoma","Esophageal Adenocarcinoma","Castration Resistant Prostate Adenocarcinoma","Soft Tissue Sarcoma","Ovarian Adenocarcinoma","Advanced Well-differentiated Neuroendocrine Tumors",[4389,10125],{"nctId":13454,"briefTitle":13455,"status":134,"phases":13456,"primaryCompletion":5309,"completion":13457,"start":13458,"enrollment":3950,"conditions":13459,"interventions":13468},"NCT03207867","A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma",[92],"2023-02-14","2017-08-28",[13460,13461,13275,13462,13463,13464,13465,13466,36,13467],"NSCLC, Non Small Cell Lung Cancer","RCC, Renal Cell Cancer","Urothelial Cancer","Head and Neck Cancer","DLBCL, Diffused Large B Cell Lymphoma","MSS, Microsatellite Stable Colon Cancer","TNBC, Triple Negative Breast Cancer","mCRPC, Metastatic Castration Resistant Prostate Cancer",[10575,4389],{"nctId":13470,"briefTitle":13471,"status":123,"phases":13472,"primaryCompletion":7902,"completion":7902,"start":166,"enrollment":1434,"conditions":13473,"interventions":13476},"NCT02807844","Phase Ib\u002FII Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies",[91,92],[9944,13474,36,13475],"Pancreatic Carcinoma","Endometrial Carcinoma",[10577,4389],{"nctId":13478,"briefTitle":13479,"status":123,"phases":13480,"primaryCompletion":13481,"completion":13481,"start":13482,"enrollment":13483,"conditions":13484,"interventions":13487},"NCT02404441","Phase I\u002FII Study of PDR001 in Patients With Advanced Malignancies",[91,92],"2020-07-21","2015-04-27",319,[36,13485,9944,13486,10285],"Non-small Sell Lung Cancer (NSCLC)","Anaplastic Thyroid Cancer",[4389],{"nctId":13489,"briefTitle":13490,"status":123,"phases":13491,"primaryCompletion":13492,"completion":13493,"start":13494,"enrollment":13089,"conditions":13495,"interventions":13500},"NCT02955069","Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)",[92],"2018-08-10","2020-05-13","2017-02-14",[13496,13497,13498,13499],"Well-differentiated Non-functional NET of Thoracic Origin","Well-differentiated Non-functional NET of Gastrointestinal Origin","Well-differentiated Non-functional NET of Pancreatic Origin","Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma",[4389],{"nctId":10119,"briefTitle":10120,"status":123,"phases":13502,"primaryCompletion":5881,"completion":5881,"start":10122,"enrollment":2249,"conditions":13503,"interventions":13504},[92],[36],[4389,10125,159,10126,515],{"nctId":11284,"briefTitle":11285,"status":134,"phases":13506,"primaryCompletion":3576,"completion":3576,"start":11287,"enrollment":11288,"conditions":13507,"interventions":13508},[91,92],[6437],[10589,4389,10590],{"nctId":13510,"briefTitle":13511,"status":123,"phases":13512,"primaryCompletion":1351,"completion":1351,"start":13513,"enrollment":13514,"conditions":13515,"interventions":13516},"NCT02460224","Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.",[91,92],"2015-06-17",490,[5614],[10125,4389],{"nctId":13518,"briefTitle":13519,"status":123,"phases":13520,"primaryCompletion":9910,"completion":13521,"start":4445,"enrollment":534,"conditions":13522,"interventions":13524},"NCT03499899","A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer",[92],"2021-11-24",[13523],"Triple-negative Breast Cancer",[10125,4389,1168],{"nctId":13526,"briefTitle":13527,"status":123,"phases":13528,"primaryCompletion":13529,"completion":13529,"start":13530,"enrollment":13531,"conditions":13532,"interventions":13535},"NCT02325739","FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression",[91,92],"2019-05-30","2014-12-29",172,[13533,13534],"Hepatocellular Carcinoma (HCC)","Solid Malignancies",[13536,4389],"FGF401",{"trials":13538,"activeCount":103},[],{"trials":13540,"activeCount":103},[],{"trials":13542,"activeCount":103},[],{"intervention":1578,"totalTrials":213,"cells":13544},{"EARLY_PHASE1":13545,"PHASE1":13547,"PHASE2":13557,"PHASE3":13559,"PHASE4":13561,"NA":13563},{"trials":13546,"activeCount":103},[],{"trials":13548,"activeCount":213,"soonestReadout":9412},[13549,13553],{"nctId":1569,"briefTitle":1570,"status":109,"phases":13550,"primaryCompletion":1572,"completion":1572,"start":1573,"enrollment":1574,"conditions":13551,"interventions":13552},[91],[1576],[1561,1578,1579],{"nctId":9409,"briefTitle":9410,"status":147,"phases":13554,"primaryCompletion":9412,"completion":9412,"start":9413,"enrollment":827,"conditions":13555,"interventions":13556},[91],[9415],[6907,9417,117,6696,9418,118,9419,1578,9420,9421,9422],{"trials":13558,"activeCount":103},[],{"trials":13560,"activeCount":103},[],{"trials":13562,"activeCount":103},[],{"trials":13564,"activeCount":103},[],{"intervention":8153,"totalTrials":5594,"cells":13566},{"EARLY_PHASE1":13567,"PHASE1":13569,"PHASE2":13604,"PHASE3":13622,"PHASE4":13640,"NA":13642},{"trials":13568,"activeCount":103},[],{"trials":13570,"activeCount":213,"soonestReadout":13575},[13571,13583,13587],{"nctId":13572,"briefTitle":13573,"status":147,"phases":13574,"primaryCompletion":13575,"completion":13575,"start":13576,"enrollment":9331,"conditions":13577,"interventions":13579},"NCT05838768","Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.",[91],"2027-08-31","2023-06-27",[13578],"MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers",[13580,13581,13582],"HRO761","pembrolizumab","irinotecan",{"nctId":8146,"briefTitle":8147,"status":123,"phases":13584,"primaryCompletion":8149,"completion":8149,"start":8150,"enrollment":138,"conditions":13585,"interventions":13586},[91],[4681],[8139,8153],{"nctId":13588,"briefTitle":13589,"status":147,"phases":13590,"primaryCompletion":13591,"completion":13591,"start":13592,"enrollment":5080,"conditions":13593,"interventions":13602},"NCT05544929","A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers",[91],"2027-09-01","2022-10-26",[227,13594,13284,13595,10653,13596,13597,13598,13599,13600,13601,6340],"Cutaneous Melanoma","Carcinoma, Ovarian Epithelial","Carcinoma, Thymic","Anal Cancer","Mesothelioma","Esophagogastric Cancer","High Microsatellite Instability Colorectal Carcinoma","Squamous Cell Carcinoma of Head and Neck",[13603,13581],"KFA115",{"trials":13605,"activeCount":103},[13606,13610,13618],{"nctId":12993,"briefTitle":12994,"status":134,"phases":13607,"primaryCompletion":12996,"completion":12997,"start":12998,"enrollment":485,"conditions":13608,"interventions":13609},[92],[5282],[8070,8153],{"nctId":13611,"briefTitle":13612,"status":134,"phases":13613,"primaryCompletion":13614,"completion":13615,"start":10649,"enrollment":534,"conditions":13616,"interventions":13617},"NCT03968419","This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.",[92],"2022-04-20","2022-08-15",[128],[3157,8153],{"nctId":9938,"briefTitle":9939,"status":390,"phases":13619,"primaryCompletion":9941,"completion":9942,"start":1512,"enrollment":103,"conditions":13620,"interventions":13621},[92],[9944],[9946,1079,4321,9947,1168,8153,9948],{"trials":13623,"activeCount":103},[13624,13628],{"nctId":9952,"briefTitle":9953,"status":390,"phases":13625,"primaryCompletion":9955,"completion":9956,"start":9957,"enrollment":103,"conditions":13626,"interventions":13627},[93],[5282],[9946,1079,8153,1168,5262,4375,4321,9947],{"nctId":13629,"briefTitle":13630,"status":134,"phases":13631,"primaryCompletion":13632,"completion":13633,"start":13634,"enrollment":13635,"conditions":13636,"interventions":13637},"NCT03631199","Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects",[93],"2021-08-09","2026-01-26","2018-12-21",673,[128],[10578,13581,7871,13638,7872,6342,13639],"cisplatin","pemetrexed",{"trials":13641,"activeCount":103},[],{"trials":13643,"activeCount":103},[13644,13658],{"nctId":13645,"briefTitle":13646,"status":123,"phases":13647,"primaryCompletion":13648,"completion":13648,"start":13649,"enrollment":13650,"conditions":13651,"interventions":13653},"NCT05611229","Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden",[],"2021-12-03","2020-06-16",1975,[13652],"Metastatic Melanoma",[5187,8153,13654,13655,13656,13657],"Dabrafenib+Trametinib","Ipilimumab+Nivolumab","Vemurafenib+Cobimetinib","Encorafenib+Binimetinib",{"nctId":13659,"briefTitle":13660,"status":123,"phases":13661,"primaryCompletion":6327,"completion":6327,"start":13662,"enrollment":13663,"conditions":13664,"interventions":13665},"NCT05714371","Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma",[],"2021-10-02",618,[36],[5187,13666,8153,13667],"Ipilimumab + nivolumab","Dabrafenib + trametinib",{"intervention":13669,"totalTrials":213,"cells":13670},"Androgen Deprivation Therapy",{"EARLY_PHASE1":13671,"PHASE1":13673,"PHASE2":13679,"PHASE3":13681,"PHASE4":13690,"NA":13692},{"trials":13672,"activeCount":103},[],{"trials":13674,"activeCount":437,"soonestReadout":9489},[13675],{"nctId":9486,"briefTitle":9487,"status":109,"phases":13676,"primaryCompletion":9489,"completion":9489,"start":9490,"enrollment":6024,"conditions":13677,"interventions":13678},[91],[599],[9493,9479,9494,9495],{"trials":13680,"activeCount":103},[],{"trials":13682,"activeCount":103},[13683],{"nctId":13684,"briefTitle":13685,"status":123,"phases":13686,"primaryCompletion":1732,"completion":1732,"start":835,"enrollment":13687,"conditions":13688,"interventions":13689},"NCT00242567","Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer",[93],522,[1654],[955,13669],{"trials":13691,"activeCount":103},[],{"trials":13693,"activeCount":103},[],{"intervention":159,"totalTrials":1672,"cells":13695},{"EARLY_PHASE1":13696,"PHASE1":13698,"PHASE2":13760,"PHASE3":13816,"PHASE4":13818,"NA":13820},{"trials":13697,"activeCount":103},[],{"trials":13699,"activeCount":437,"soonestReadout":149},[13700,13708,13712,13723,13733,13737,13745,13754],{"nctId":13701,"briefTitle":13702,"status":123,"phases":13703,"primaryCompletion":7522,"completion":7522,"start":13704,"enrollment":13705,"conditions":13706,"interventions":13707},"NCT01324479","Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors",[91],"2012-02-29",131,[647],[159],{"nctId":10227,"briefTitle":10228,"status":134,"phases":13709,"primaryCompletion":10230,"completion":10230,"start":10231,"enrollment":734,"conditions":13710,"interventions":13711},[91],[10233,9924],[159,236],{"nctId":13713,"briefTitle":13714,"status":123,"phases":13715,"primaryCompletion":3418,"completion":13716,"start":13717,"enrollment":5612,"conditions":13718,"interventions":13720},"NCT02520752","A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors",[91],"2017-09-12","2015-12-10",[13719],"cMET-dysregulated Advanced Solid Tumors",[159,13721,13722],"Midazolam","Caffeine",{"nctId":13724,"briefTitle":13725,"status":123,"phases":13726,"primaryCompletion":13727,"completion":8338,"start":13728,"enrollment":7257,"conditions":13729,"interventions":13730},"NCT02626234","A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors",[91],"2017-02-28","2015-12-08",[13719],[159,13731,13732],"digoxin","rosuvastatin",{"nctId":145,"briefTitle":146,"status":147,"phases":13734,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":13735,"interventions":13736},[91],[153],[155,156,157,158,159,160],{"nctId":13738,"briefTitle":13739,"status":123,"phases":13740,"primaryCompletion":13741,"completion":13716,"start":13742,"enrollment":827,"conditions":13743,"interventions":13744},"NCT02474537","INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function",[91],"2017-08-14","2015-06-12",[2625],[159],{"nctId":13746,"briefTitle":13747,"status":123,"phases":13748,"primaryCompletion":13749,"completion":13749,"start":13750,"enrollment":792,"conditions":13751,"interventions":13753},"NCT02925104","A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.",[91],"2018-05-16","2016-12-14",[13752],"cMET Dysegulation Advanced Solid Tumors",[159],{"nctId":13755,"briefTitle":13756,"status":123,"phases":13757,"primaryCompletion":9061,"completion":9061,"start":1671,"enrollment":22,"conditions":13758,"interventions":13759},"NCT01546428","A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors",[91],[9516],[159],{"trials":13761,"activeCount":103},[13762,13771,13775,13784,13793,13800,13808,13812],{"nctId":13763,"briefTitle":13764,"status":134,"phases":13765,"primaryCompletion":6069,"completion":13766,"start":13767,"enrollment":5948,"conditions":13768,"interventions":13770},"NCT01737827","Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.",[92],"2023-05-24","2013-03-25",[13769],"Advanced Hepatocellular Carcinoma With c-MET Dysregulation",[159],{"nctId":10325,"briefTitle":10326,"status":123,"phases":13772,"primaryCompletion":10328,"completion":3031,"start":10329,"enrollment":1829,"conditions":13773,"interventions":13774},[92],[128],[159,10312],{"nctId":13776,"briefTitle":13777,"status":134,"phases":13778,"primaryCompletion":13779,"completion":13780,"start":13781,"enrollment":2776,"conditions":13782,"interventions":13783},"NCT02323126","Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer",[92],"2019-09-23","2021-02-05","2015-02-09",[1316],[155,159,5187],{"nctId":13785,"briefTitle":13786,"status":134,"phases":13787,"primaryCompletion":13788,"completion":13788,"start":13789,"enrollment":4557,"conditions":13790,"interventions":13792},"NCT01870726","Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma",[91,92],"2016-12-23","2014-01-09",[13791],"c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM",[159,738],{"nctId":13794,"briefTitle":13795,"status":390,"phases":13796,"primaryCompletion":13797,"completion":13797,"start":5634,"enrollment":103,"conditions":13798,"interventions":13799},"NCT01964235","Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma",[92],"2019-07",[10643],[159],{"nctId":13801,"briefTitle":13802,"status":390,"phases":13803,"primaryCompletion":13804,"completion":13804,"start":13805,"enrollment":103,"conditions":13806,"interventions":13807},"NCT03240393","Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)",[92],"2021-10-26","2018-07-31",[4571,1178],[159],{"nctId":10119,"briefTitle":10120,"status":123,"phases":13809,"primaryCompletion":5881,"completion":5881,"start":10122,"enrollment":2249,"conditions":13810,"interventions":13811},[92],[36],[4389,10125,159,10126,515],{"nctId":11063,"briefTitle":11064,"status":123,"phases":13813,"primaryCompletion":11066,"completion":11066,"start":11067,"enrollment":11068,"conditions":13814,"interventions":13815},[92],[11070],[516,159,11072,11073],{"trials":13817,"activeCount":103},[],{"trials":13819,"activeCount":103},[],{"trials":13821,"activeCount":103},[],{"intervention":5207,"totalTrials":422,"cells":13823},{"EARLY_PHASE1":13824,"PHASE1":13826,"PHASE2":13881,"PHASE3":13887,"PHASE4":13889,"NA":13891},{"trials":13825,"activeCount":103},[],{"trials":13827,"activeCount":437,"soonestReadout":6433},[13828,13843,13851,13855,13859,13866,13870],{"nctId":13829,"briefTitle":13830,"status":123,"phases":13831,"primaryCompletion":13832,"completion":13832,"start":13833,"enrollment":114,"conditions":13834,"interventions":13835},"NCT05236530","Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir",[91],"2022-10-17","2022-03-09",[11177],[13721,13836,13837,13838,13839,13840,13841,13842,13839,13840],"Repaglinide","Dextromethorphan","Metformin","Ganaplacide","Lumefantrine","Rosuvastatin","Dolutegravir",{"nctId":13844,"briefTitle":13845,"status":123,"phases":13846,"primaryCompletion":13847,"completion":13847,"start":13848,"enrollment":4360,"conditions":13849,"interventions":13850},"NCT01456689","A Study of Oral LGH447 in Patients With Relapsed and\u002For Refractory Multiple Myeloma",[91],"2019-06-05","2012-04-25",[5636],[11039,5207],{"nctId":13713,"briefTitle":13714,"status":123,"phases":13852,"primaryCompletion":3418,"completion":13716,"start":13717,"enrollment":5612,"conditions":13853,"interventions":13854},[91],[13719],[159,13721,13722],{"nctId":6430,"briefTitle":6431,"status":593,"phases":13856,"primaryCompletion":6433,"completion":6434,"start":6435,"enrollment":630,"conditions":13857,"interventions":13858},[91],[6437],[6424,6439,5207,6440,6441],{"nctId":13860,"briefTitle":13861,"status":123,"phases":13862,"primaryCompletion":2623,"completion":2623,"start":754,"enrollment":2342,"conditions":13863,"interventions":13865},"NCT02607774","Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis",[91],[13864],"Moderate to Severe Plaque Psoriasis",[13721,11428],{"nctId":5198,"briefTitle":5199,"status":123,"phases":13867,"primaryCompletion":5201,"completion":5201,"start":5202,"enrollment":99,"conditions":13868,"interventions":13869},[91],[5204],[5178,5206,5207],{"nctId":13871,"briefTitle":13872,"status":123,"phases":13873,"primaryCompletion":3409,"completion":3409,"start":5733,"enrollment":28,"conditions":13874,"interventions":13876},"NCT01596647","Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors",[91],[13875],"Advanced Solid Tumors, Excluding Breast Cancer",[13877,13878,13879,5207,13880],"caffeine","diclofenac","omeprazole","TKI258",{"trials":13882,"activeCount":103},[13883],{"nctId":9843,"briefTitle":9844,"status":390,"phases":13884,"primaryCompletion":6372,"completion":2938,"start":9846,"enrollment":103,"conditions":13885,"interventions":13886},[91,92],[9848],[4393,9823,9850,9825,9851,9852,5207],{"trials":13888,"activeCount":103},[],{"trials":13890,"activeCount":103},[],{"trials":13892,"activeCount":103},[],{"intervention":3036,"totalTrials":2379,"cells":13894},{"EARLY_PHASE1":13895,"PHASE1":13897,"PHASE2":13906,"PHASE3":13941,"PHASE4":13943,"NA":13945},{"trials":13896,"activeCount":103},[],{"trials":13898,"activeCount":437,"soonestReadout":6903},[13899],{"nctId":13900,"briefTitle":13901,"status":147,"phases":13902,"primaryCompletion":6903,"completion":6903,"start":10710,"enrollment":2149,"conditions":13903,"interventions":13905},"NCT05552469","Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases",[91],[13904],"Myeloid Diseases",[3036],{"trials":13907,"activeCount":103},[13908,13912,13921,13929,13937],{"nctId":3026,"briefTitle":3027,"status":123,"phases":13909,"primaryCompletion":3029,"completion":3030,"start":3031,"enrollment":3032,"conditions":13910,"interventions":13911},[92],[3034],[3036,3017],{"nctId":13913,"briefTitle":13914,"status":123,"phases":13915,"primaryCompletion":13916,"completion":13917,"start":6816,"enrollment":4992,"conditions":13918,"interventions":13920},"NCT04886258","Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis",[92],"2024-12-14","2024-12-23",[13919],"Symptomatic Knee Osteoarthritis",[3036],{"nctId":13922,"briefTitle":13923,"status":123,"phases":13924,"primaryCompletion":9330,"completion":13917,"start":13925,"enrollment":630,"conditions":13926,"interventions":13927},"NCT06031844","A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP",[92],"2023-10-16",[3180],[3036,13928],"DFV890 Placebo",{"nctId":13930,"briefTitle":13931,"status":123,"phases":13932,"primaryCompletion":13933,"completion":6904,"start":6816,"enrollment":1630,"conditions":13934,"interventions":13936},"NCT04868968","Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)",[92],"2022-12-13",[13935],"Familial Cold Autoinflammatory Syndrome",[3036],{"nctId":9665,"briefTitle":9666,"status":123,"phases":13938,"primaryCompletion":9668,"completion":6640,"start":9669,"enrollment":827,"conditions":13939,"interventions":13940},[92],[3180,9671],[3090,9673,3036,9674],{"trials":13942,"activeCount":103},[],{"trials":13944,"activeCount":103},[],{"trials":13946,"activeCount":103},[],{"intervention":155,"totalTrials":1630,"cells":13948},{"EARLY_PHASE1":13949,"PHASE1":13951,"PHASE2":13961,"PHASE3":13976,"PHASE4":13978,"NA":13980},{"trials":13950,"activeCount":103},[],{"trials":13952,"activeCount":437,"soonestReadout":149},[13953,13957],{"nctId":145,"briefTitle":146,"status":147,"phases":13954,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":13955,"interventions":13956},[91],[153],[155,156,157,158,159,160],{"nctId":13385,"briefTitle":13386,"status":123,"phases":13958,"primaryCompletion":13388,"completion":13388,"start":13389,"enrollment":13390,"conditions":13959,"interventions":13960},[91],[13392],[4389,10126,1686,13394,155],{"trials":13962,"activeCount":103},[13963,13972],{"nctId":13964,"briefTitle":13965,"status":123,"phases":13966,"primaryCompletion":939,"completion":13967,"start":13968,"enrollment":3420,"conditions":13969,"interventions":13971},"NCT02108964","A Phase I\u002FII, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies",[91,92],"2023-08-15","2014-06-06",[13970],"Advanced Non-small Cell Lung Cancer",[155],{"nctId":13776,"briefTitle":13777,"status":134,"phases":13973,"primaryCompletion":13779,"completion":13780,"start":13781,"enrollment":2776,"conditions":13974,"interventions":13975},[92],[1316],[155,159,5187],{"trials":13977,"activeCount":103},[],{"trials":13979,"activeCount":103},[],{"trials":13981,"activeCount":103},[],{"intervention":8043,"totalTrials":317,"cells":13983},{"EARLY_PHASE1":13984,"PHASE1":13986,"PHASE2":13996,"PHASE3":14002,"PHASE4":14004,"NA":14006},{"trials":13985,"activeCount":103},[],{"trials":13987,"activeCount":437,"soonestReadout":13575},[13988,13992],{"nctId":8036,"briefTitle":8037,"status":123,"phases":13989,"primaryCompletion":8039,"completion":8039,"start":3673,"enrollment":114,"conditions":13990,"interventions":13991},[91],[8041],[7886,516,4321,5252,8043],{"nctId":13572,"briefTitle":13573,"status":147,"phases":13993,"primaryCompletion":13575,"completion":13575,"start":13576,"enrollment":9331,"conditions":13994,"interventions":13995},[91],[13578],[13580,13581,13582],{"trials":13997,"activeCount":103},[13998],{"nctId":8081,"briefTitle":8082,"status":123,"phases":13999,"primaryCompletion":5733,"completion":5733,"start":4081,"enrollment":16,"conditions":14000,"interventions":14001},[92],[4439,8085],[7913,5252,8043],{"trials":14003,"activeCount":103},[],{"trials":14005,"activeCount":103},[],{"trials":14007,"activeCount":103},[],{"intervention":14009,"totalTrials":213,"cells":14010},"OTQ923",{"EARLY_PHASE1":14011,"PHASE1":14013,"PHASE2":14031,"PHASE3":14033,"PHASE4":14035,"NA":14037},{"trials":14012,"activeCount":103},[],{"trials":14014,"activeCount":437,"soonestReadout":14027},[14015,14023],{"nctId":14016,"briefTitle":14017,"status":134,"phases":14018,"primaryCompletion":14019,"completion":14019,"start":14020,"enrollment":1630,"conditions":14021,"interventions":14022},"NCT04443907","Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)",[91],"2025-01-06","2020-08-25",[3952],[14009,14009],{"nctId":14024,"briefTitle":14025,"status":147,"phases":14026,"primaryCompletion":14027,"completion":14027,"start":14028,"enrollment":1630,"conditions":14029,"interventions":14030},"NCT06155500","Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)",[91],"2039-01-11","2024-04-16",[3952],[14009],{"trials":14032,"activeCount":103},[],{"trials":14034,"activeCount":103},[],{"trials":14036,"activeCount":103},[],{"trials":14038,"activeCount":103},[],{"intervention":13836,"totalTrials":213,"cells":14040},{"EARLY_PHASE1":14041,"PHASE1":14043,"PHASE2":14053,"PHASE3":14055,"PHASE4":14057,"NA":14059},{"trials":14042,"activeCount":103},[],{"trials":14044,"activeCount":437,"soonestReadout":6433},[14045,14049],{"nctId":13829,"briefTitle":13830,"status":123,"phases":14046,"primaryCompletion":13832,"completion":13832,"start":13833,"enrollment":114,"conditions":14047,"interventions":14048},[91],[11177],[13721,13836,13837,13838,13839,13840,13841,13842,13839,13840],{"nctId":6430,"briefTitle":6431,"status":593,"phases":14050,"primaryCompletion":6433,"completion":6434,"start":6435,"enrollment":630,"conditions":14051,"interventions":14052},[91],[6437],[6424,6439,5207,6440,6441],{"trials":14054,"activeCount":103},[],{"trials":14056,"activeCount":103},[],{"trials":14058,"activeCount":103},[],{"trials":14060,"activeCount":103},[],{"intervention":43,"totalTrials":213,"cells":14062},{"EARLY_PHASE1":14063,"PHASE1":14065,"PHASE2":14081,"PHASE3":14083,"PHASE4":14085,"NA":14087},{"trials":14064,"activeCount":103},[],{"trials":14066,"activeCount":437,"soonestReadout":42},[14067,14074],{"nctId":40,"briefTitle":41,"status":147,"phases":14068,"primaryCompletion":42,"completion":14069,"start":14070,"enrollment":1100,"conditions":14071,"interventions":14073},[91],"2030-10-31","2015-03-06",[14072],"Advanced Malignancies That Harbor IDHR132 Mutations",[43],{"nctId":14075,"briefTitle":14076,"status":390,"phases":14077,"primaryCompletion":14078,"completion":14078,"start":7109,"enrollment":103,"conditions":14079,"interventions":14080},"NCT02826642","A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia",[91],"2016-11-29",[5598],[43],{"trials":14082,"activeCount":103},[],{"trials":14084,"activeCount":103},[],{"trials":14086,"activeCount":103},[],{"trials":14088,"activeCount":103},[],{"intervention":14090,"totalTrials":437,"cells":14091},"[68Ga]Ga-NNS309",{"EARLY_PHASE1":14092,"PHASE1":14094,"PHASE2":14108,"PHASE3":14110,"PHASE4":14112,"NA":14114},{"trials":14093,"activeCount":103},[],{"trials":14095,"activeCount":437,"soonestReadout":14100},[14096],{"nctId":14097,"briefTitle":14098,"status":109,"phases":14099,"primaryCompletion":14100,"completion":14101,"start":14102,"enrollment":3705,"conditions":14103,"interventions":14106},"NCT06562192","Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",[91],"2031-01-15","2031-01-16","2024-10-15",[14104,128,14105,9944,209],"Pancreatic Ductal Adenocarcinoma","HR+\u002FHER2- Ductal and Lobular Breast Cancer",[14090,14107],"[177Lu]Lu-NNS309",{"trials":14109,"activeCount":103},[],{"trials":14111,"activeCount":103},[],{"trials":14113,"activeCount":103},[],{"trials":14115,"activeCount":103},[],{"intervention":14107,"totalTrials":437,"cells":14117},{"EARLY_PHASE1":14118,"PHASE1":14120,"PHASE2":14126,"PHASE3":14128,"PHASE4":14130,"NA":14132},{"trials":14119,"activeCount":103},[],{"trials":14121,"activeCount":437,"soonestReadout":14100},[14122],{"nctId":14097,"briefTitle":14098,"status":109,"phases":14123,"primaryCompletion":14100,"completion":14101,"start":14102,"enrollment":3705,"conditions":14124,"interventions":14125},[91],[14104,128,14105,9944,209],[14090,14107],{"trials":14127,"activeCount":103},[],{"trials":14129,"activeCount":103},[],{"trials":14131,"activeCount":103},[],{"trials":14133,"activeCount":103},[],{"intervention":1579,"totalTrials":437,"cells":14135},{"EARLY_PHASE1":14136,"PHASE1":14138,"PHASE2":14144,"PHASE3":14146,"PHASE4":14148,"NA":14150},{"trials":14137,"activeCount":103},[],{"trials":14139,"activeCount":437,"soonestReadout":1572},[14140],{"nctId":1569,"briefTitle":1570,"status":109,"phases":14141,"primaryCompletion":1572,"completion":1572,"start":1573,"enrollment":1574,"conditions":14142,"interventions":14143},[91],[1576],[1561,1578,1579],{"trials":14145,"activeCount":103},[],{"trials":14147,"activeCount":103},[],{"trials":14149,"activeCount":103},[],{"trials":14151,"activeCount":103},[],{"intervention":13580,"totalTrials":437,"cells":14153},{"EARLY_PHASE1":14154,"PHASE1":14156,"PHASE2":14162,"PHASE3":14164,"PHASE4":14166,"NA":14168},{"trials":14155,"activeCount":103},[],{"trials":14157,"activeCount":437,"soonestReadout":13575},[14158],{"nctId":13572,"briefTitle":13573,"status":147,"phases":14159,"primaryCompletion":13575,"completion":13575,"start":13576,"enrollment":9331,"conditions":14160,"interventions":14161},[91],[13578],[13580,13581,13582],{"trials":14163,"activeCount":103},[],{"trials":14165,"activeCount":103},[],{"trials":14167,"activeCount":103},[],{"trials":14169,"activeCount":103},[],{"intervention":14171,"totalTrials":437,"cells":14172},"68Ga-NNS309",{"EARLY_PHASE1":14173,"PHASE1":14175,"PHASE2":14186,"PHASE3":14188,"PHASE4":14190,"NA":14192},{"trials":14174,"activeCount":103},[],{"trials":14176,"activeCount":437,"soonestReadout":14181},[14177],{"nctId":14178,"briefTitle":14179,"status":109,"phases":14180,"primaryCompletion":14181,"completion":14181,"start":14182,"enrollment":2981,"conditions":14183,"interventions":14184},"NCT07261631","Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors",[91],"2029-05-09","2025-11-24",[14104,182,14105,9944,209,13449],[14171,14185],"177Lu-DFC413",{"trials":14187,"activeCount":103},[],{"trials":14189,"activeCount":103},[],{"trials":14191,"activeCount":103},[],{"trials":14193,"activeCount":103},[],{"intervention":14185,"totalTrials":437,"cells":14195},{"EARLY_PHASE1":14196,"PHASE1":14198,"PHASE2":14204,"PHASE3":14206,"PHASE4":14208,"NA":14210},{"trials":14197,"activeCount":103},[],{"trials":14199,"activeCount":437,"soonestReadout":14181},[14200],{"nctId":14178,"briefTitle":14179,"status":109,"phases":14201,"primaryCompletion":14181,"completion":14181,"start":14182,"enrollment":2981,"conditions":14202,"interventions":14203},[91],[14104,182,14105,9944,209,13449],[14171,14185],{"trials":14205,"activeCount":103},[],{"trials":14207,"activeCount":103},[],{"trials":14209,"activeCount":103},[],{"trials":14211,"activeCount":103},[],{"intervention":9419,"totalTrials":437,"cells":14213},{"EARLY_PHASE1":14214,"PHASE1":14216,"PHASE2":14222,"PHASE3":14224,"PHASE4":14226,"NA":14228},{"trials":14215,"activeCount":103},[],{"trials":14217,"activeCount":437,"soonestReadout":9412},[14218],{"nctId":9409,"briefTitle":9410,"status":147,"phases":14219,"primaryCompletion":9412,"completion":9412,"start":9413,"enrollment":827,"conditions":14220,"interventions":14221},[91],[9415],[6907,9417,117,6696,9418,118,9419,1578,9420,9421,9422],{"trials":14223,"activeCount":103},[],{"trials":14225,"activeCount":103},[],{"trials":14227,"activeCount":103},[],{"trials":14229,"activeCount":103},[],{"intervention":9420,"totalTrials":437,"cells":14231},{"EARLY_PHASE1":14232,"PHASE1":14234,"PHASE2":14240,"PHASE3":14242,"PHASE4":14244,"NA":14246},{"trials":14233,"activeCount":103},[],{"trials":14235,"activeCount":437,"soonestReadout":9412},[14236],{"nctId":9409,"briefTitle":9410,"status":147,"phases":14237,"primaryCompletion":9412,"completion":9412,"start":9413,"enrollment":827,"conditions":14238,"interventions":14239},[91],[9415],[6907,9417,117,6696,9418,118,9419,1578,9420,9421,9422],{"trials":14241,"activeCount":103},[],{"trials":14243,"activeCount":103},[],{"trials":14245,"activeCount":103},[],{"trials":14247,"activeCount":103},[],{"intervention":9421,"totalTrials":437,"cells":14249},{"EARLY_PHASE1":14250,"PHASE1":14252,"PHASE2":14258,"PHASE3":14260,"PHASE4":14262,"NA":14264},{"trials":14251,"activeCount":103},[],{"trials":14253,"activeCount":437,"soonestReadout":9412},[14254],{"nctId":9409,"briefTitle":9410,"status":147,"phases":14255,"primaryCompletion":9412,"completion":9412,"start":9413,"enrollment":827,"conditions":14256,"interventions":14257},[91],[9415],[6907,9417,117,6696,9418,118,9419,1578,9420,9421,9422],{"trials":14259,"activeCount":103},[],{"trials":14261,"activeCount":103},[],{"trials":14263,"activeCount":103},[],{"trials":14265,"activeCount":103},[],{"intervention":9422,"totalTrials":437,"cells":14267},{"EARLY_PHASE1":14268,"PHASE1":14270,"PHASE2":14276,"PHASE3":14278,"PHASE4":14280,"NA":14282},{"trials":14269,"activeCount":103},[],{"trials":14271,"activeCount":437,"soonestReadout":9412},[14272],{"nctId":9409,"briefTitle":9410,"status":147,"phases":14273,"primaryCompletion":9412,"completion":9412,"start":9413,"enrollment":827,"conditions":14274,"interventions":14275},[91],[9415],[6907,9417,117,6696,9418,118,9419,1578,9420,9421,9422],{"trials":14277,"activeCount":103},[],{"trials":14279,"activeCount":103},[],{"trials":14281,"activeCount":103},[],{"trials":14283,"activeCount":103},[],{"intervention":13358,"totalTrials":437,"cells":14285},{"EARLY_PHASE1":14286,"PHASE1":14288,"PHASE2":14294,"PHASE3":14296,"PHASE4":14298,"NA":14300},{"trials":14287,"activeCount":103},[],{"trials":14289,"activeCount":437,"soonestReadout":13353},[14290],{"nctId":13350,"briefTitle":13351,"status":147,"phases":14291,"primaryCompletion":13353,"completion":13354,"start":10595,"enrollment":6014,"conditions":14292,"interventions":14293},[91],[227,36,10653,13356,9944],[13358,4389],{"trials":14295,"activeCount":103},[],{"trials":14297,"activeCount":103},[],{"trials":14299,"activeCount":103},[],{"trials":14301,"activeCount":103},[],{"intervention":9493,"totalTrials":437,"cells":14303},{"EARLY_PHASE1":14304,"PHASE1":14306,"PHASE2":14312,"PHASE3":14314,"PHASE4":14316,"NA":14318},{"trials":14305,"activeCount":103},[],{"trials":14307,"activeCount":437,"soonestReadout":9489},[14308],{"nctId":9486,"briefTitle":9487,"status":109,"phases":14309,"primaryCompletion":9489,"completion":9489,"start":9490,"enrollment":6024,"conditions":14310,"interventions":14311},[91],[599],[9493,9479,9494,9495],{"trials":14313,"activeCount":103},[],{"trials":14315,"activeCount":103},[],{"trials":14317,"activeCount":103},[],{"trials":14319,"activeCount":103},[],{"intervention":14321,"totalTrials":437,"cells":14322},"IAG933",{"EARLY_PHASE1":14323,"PHASE1":14325,"PHASE2":14334,"PHASE3":14336,"PHASE4":14338,"NA":14340},{"trials":14324,"activeCount":103},[],{"trials":14326,"activeCount":437,"soonestReadout":14331},[14327],{"nctId":14328,"briefTitle":14329,"status":147,"phases":14330,"primaryCompletion":14331,"completion":14331,"start":3010,"enrollment":1890,"conditions":14332,"interventions":14333},"NCT04857372","A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors",[91],"2026-09-04",[13598],[14321],{"trials":14335,"activeCount":103},[],{"trials":14337,"activeCount":103},[],{"trials":14339,"activeCount":103},[],{"trials":14341,"activeCount":103},[],{"intervention":14343,"totalTrials":437,"cells":14344},"225Ac-ETN029",{"EARLY_PHASE1":14345,"PHASE1":14347,"PHASE2":14361,"PHASE3":14363,"PHASE4":14365,"NA":14367},{"trials":14346,"activeCount":103},[],{"trials":14348,"activeCount":437,"soonestReadout":14353},[14349],{"nctId":14350,"briefTitle":14351,"status":109,"phases":14352,"primaryCompletion":14353,"completion":14353,"start":14354,"enrollment":13089,"conditions":14355,"interventions":14359},"NCT07006727","Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors",[91],"2031-08-29","2025-10-16",[2736,14356,14357,14358],"Large Cell Neuroendocrine Carcinoma of the Lung","Neuroendocrine Prostate Cancer","Gastroenteropancreatic Neuroendocrine Carcinoma",[14343,14360],"111In-ETN029",{"trials":14362,"activeCount":103},[],{"trials":14364,"activeCount":103},[],{"trials":14366,"activeCount":103},[],{"trials":14368,"activeCount":103},[],{"intervention":14360,"totalTrials":437,"cells":14370},{"EARLY_PHASE1":14371,"PHASE1":14373,"PHASE2":14379,"PHASE3":14381,"PHASE4":14383,"NA":14385},{"trials":14372,"activeCount":103},[],{"trials":14374,"activeCount":437,"soonestReadout":14353},[14375],{"nctId":14350,"briefTitle":14351,"status":109,"phases":14376,"primaryCompletion":14353,"completion":14353,"start":14354,"enrollment":13089,"conditions":14377,"interventions":14378},[91],[2736,14356,14357,14358],[14343,14360],{"trials":14380,"activeCount":103},[],{"trials":14382,"activeCount":103},[],{"trials":14384,"activeCount":103},[],{"trials":14386,"activeCount":103},[],{"intervention":6440,"totalTrials":437,"cells":14388},{"EARLY_PHASE1":14389,"PHASE1":14391,"PHASE2":14397,"PHASE3":14399,"PHASE4":14401,"NA":14403},{"trials":14390,"activeCount":103},[],{"trials":14392,"activeCount":437,"soonestReadout":6433},[14393],{"nctId":6430,"briefTitle":6431,"status":593,"phases":14394,"primaryCompletion":6433,"completion":6434,"start":6435,"enrollment":630,"conditions":14395,"interventions":14396},[91],[6437],[6424,6439,5207,6440,6441],{"trials":14398,"activeCount":103},[],{"trials":14400,"activeCount":103},[],{"trials":14402,"activeCount":103},[],{"trials":14404,"activeCount":103},[],{"intervention":6441,"totalTrials":437,"cells":14406},{"EARLY_PHASE1":14407,"PHASE1":14409,"PHASE2":14415,"PHASE3":14417,"PHASE4":14419,"NA":14421},{"trials":14408,"activeCount":103},[],{"trials":14410,"activeCount":437,"soonestReadout":6433},[14411],{"nctId":6430,"briefTitle":6431,"status":593,"phases":14412,"primaryCompletion":6433,"completion":6434,"start":6435,"enrollment":630,"conditions":14413,"interventions":14414},[91],[6437],[6424,6439,5207,6440,6441],{"trials":14416,"activeCount":103},[],{"trials":14418,"activeCount":103},[],{"trials":14420,"activeCount":103},[],{"trials":14422,"activeCount":103},[],{"intervention":13603,"totalTrials":437,"cells":14424},{"EARLY_PHASE1":14425,"PHASE1":14427,"PHASE2":14433,"PHASE3":14435,"PHASE4":14437,"NA":14439},{"trials":14426,"activeCount":103},[],{"trials":14428,"activeCount":437,"soonestReadout":13591},[14429],{"nctId":13588,"briefTitle":13589,"status":147,"phases":14430,"primaryCompletion":13591,"completion":13591,"start":13592,"enrollment":5080,"conditions":14431,"interventions":14432},[91],[227,13594,13284,13595,10653,13596,13597,13598,13599,13600,13601,6340],[13603,13581],{"trials":14434,"activeCount":103},[],{"trials":14436,"activeCount":103},[],{"trials":14438,"activeCount":103},[],{"trials":14440,"activeCount":103},[],{"intervention":14442,"totalTrials":437,"cells":14443},"[68Ga]Ga-DWJ155",{"EARLY_PHASE1":14444,"PHASE1":14446,"PHASE2":14455,"PHASE3":14457,"PHASE4":14459,"NA":14461},{"trials":14445,"activeCount":103},[],{"trials":14447,"activeCount":437,"soonestReadout":1534},[14448],{"nctId":14449,"briefTitle":14450,"status":593,"phases":14451,"primaryCompletion":1534,"completion":1534,"start":14452,"enrollment":792,"conditions":14453,"interventions":14454},"NCT07117214","A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers",[91],"2025-08-20",[559,227],[14442],{"trials":14456,"activeCount":103},[],{"trials":14458,"activeCount":103},[],{"trials":14460,"activeCount":103},[],{"trials":14462,"activeCount":103},[],{"intervention":14464,"totalTrials":437,"cells":14465},"HJB647 low dose",{"EARLY_PHASE1":14466,"PHASE1":14468,"PHASE2":14478,"PHASE3":14480,"PHASE4":14482,"NA":14484},{"trials":14467,"activeCount":103},[],{"trials":14469,"activeCount":437,"soonestReadout":10439},[14470],{"nctId":14471,"briefTitle":14472,"status":109,"phases":14473,"primaryCompletion":10439,"completion":10439,"start":6985,"enrollment":138,"conditions":14474,"interventions":14476},"NCT07465653","A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction",[91],[14475],"Heart Failure With Reduced Ejection Fraction",[14464,14477],"HJB647 high dose",{"trials":14479,"activeCount":103},[],{"trials":14481,"activeCount":103},[],{"trials":14483,"activeCount":103},[],{"trials":14485,"activeCount":103},[],{"intervention":14477,"totalTrials":437,"cells":14487},{"EARLY_PHASE1":14488,"PHASE1":14490,"PHASE2":14496,"PHASE3":14498,"PHASE4":14500,"NA":14502},{"trials":14489,"activeCount":103},[],{"trials":14491,"activeCount":437,"soonestReadout":10439},[14492],{"nctId":14471,"briefTitle":14472,"status":109,"phases":14493,"primaryCompletion":10439,"completion":10439,"start":6985,"enrollment":138,"conditions":14494,"interventions":14495},[91],[14475],[14464,14477],{"trials":14497,"activeCount":103},[],{"trials":14499,"activeCount":103},[],{"trials":14501,"activeCount":103},[],{"trials":14503,"activeCount":103},[],{"intervention":527,"totalTrials":437,"cells":14505},{"EARLY_PHASE1":14506,"PHASE1":14508,"PHASE2":14514,"PHASE3":14516,"PHASE4":14518,"NA":14520},{"trials":14507,"activeCount":103},[],{"trials":14509,"activeCount":437,"soonestReadout":522},[14510],{"nctId":519,"briefTitle":520,"status":109,"phases":14511,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":14512,"interventions":14513},[91],[303],[527,119,249],{"trials":14515,"activeCount":103},[],{"trials":14517,"activeCount":103},[],{"trials":14519,"activeCount":103},[],{"trials":14521,"activeCount":103},[],{"intervention":14523,"totalTrials":437,"cells":14524},"NIO752",{"EARLY_PHASE1":14525,"PHASE1":14527,"PHASE2":14539,"PHASE3":14541,"PHASE4":14543,"NA":14545},{"trials":14526,"activeCount":103},[],{"trials":14528,"activeCount":437,"soonestReadout":221},[14529],{"nctId":14530,"briefTitle":14531,"status":147,"phases":14532,"primaryCompletion":221,"completion":14533,"start":14534,"enrollment":5948,"conditions":14535,"interventions":14538},"NCT05469360","Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants",[91],"2027-09-24","2023-02-23",[14536,14537],"Alzheimer Disease","Mild Cognitive Impairment",[14523,14523,14523,14523,14523],{"trials":14540,"activeCount":103},[],{"trials":14542,"activeCount":103},[],{"trials":14544,"activeCount":103},[],{"trials":14546,"activeCount":103},[],{"intervention":14548,"totalTrials":437,"cells":14549},"OJR520",{"EARLY_PHASE1":14550,"PHASE1":14552,"PHASE2":14563,"PHASE3":14565,"PHASE4":14567,"NA":14569},{"trials":14551,"activeCount":103},[],{"trials":14553,"activeCount":437,"soonestReadout":14558},[14554],{"nctId":14555,"briefTitle":14556,"status":109,"phases":14557,"primaryCompletion":14558,"completion":14558,"start":14559,"enrollment":1034,"conditions":14560,"interventions":14562},"NCT07235059","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease",[91],"2028-01-21","2025-11-20",[14561],"Chronic Kidney Disease",[14548],{"trials":14564,"activeCount":103},[],{"trials":14566,"activeCount":103},[],{"trials":14568,"activeCount":103},[],{"trials":14570,"activeCount":103},[],{"intervention":14572,"totalTrials":437,"cells":14573},"EDK060, dose A",{"EARLY_PHASE1":14574,"PHASE1":14576,"PHASE2":14590,"PHASE3":14592,"PHASE4":14594,"NA":14596},{"trials":14575,"activeCount":103},[],{"trials":14577,"activeCount":437,"soonestReadout":6193},[14578],{"nctId":14579,"briefTitle":14580,"status":109,"phases":14581,"primaryCompletion":6193,"completion":14582,"start":14583,"enrollment":2046,"conditions":14584,"interventions":14586},"NCT07140614","A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.",[91],"2028-02-26","2025-09-30",[14585],"Charcot-Marie-Tooth Disease, Type 1A",[14572,14587,14588,14589],"EDK060, dose B","EDK060, dose C","EDK060, dose D",{"trials":14591,"activeCount":103},[],{"trials":14593,"activeCount":103},[],{"trials":14595,"activeCount":103},[],{"trials":14597,"activeCount":103},[],{"intervention":14587,"totalTrials":437,"cells":14599},{"EARLY_PHASE1":14600,"PHASE1":14602,"PHASE2":14608,"PHASE3":14610,"PHASE4":14612,"NA":14614},{"trials":14601,"activeCount":103},[],{"trials":14603,"activeCount":437,"soonestReadout":6193},[14604],{"nctId":14579,"briefTitle":14580,"status":109,"phases":14605,"primaryCompletion":6193,"completion":14582,"start":14583,"enrollment":2046,"conditions":14606,"interventions":14607},[91],[14585],[14572,14587,14588,14589],{"trials":14609,"activeCount":103},[],{"trials":14611,"activeCount":103},[],{"trials":14613,"activeCount":103},[],{"trials":14615,"activeCount":103},[],{"intervention":14588,"totalTrials":437,"cells":14617},{"EARLY_PHASE1":14618,"PHASE1":14620,"PHASE2":14626,"PHASE3":14628,"PHASE4":14630,"NA":14632},{"trials":14619,"activeCount":103},[],{"trials":14621,"activeCount":437,"soonestReadout":6193},[14622],{"nctId":14579,"briefTitle":14580,"status":109,"phases":14623,"primaryCompletion":6193,"completion":14582,"start":14583,"enrollment":2046,"conditions":14624,"interventions":14625},[91],[14585],[14572,14587,14588,14589],{"trials":14627,"activeCount":103},[],{"trials":14629,"activeCount":103},[],{"trials":14631,"activeCount":103},[],{"trials":14633,"activeCount":103},[],{"intervention":14589,"totalTrials":437,"cells":14635},{"EARLY_PHASE1":14636,"PHASE1":14638,"PHASE2":14644,"PHASE3":14646,"PHASE4":14648,"NA":14650},{"trials":14637,"activeCount":103},[],{"trials":14639,"activeCount":437,"soonestReadout":6193},[14640],{"nctId":14579,"briefTitle":14580,"status":109,"phases":14641,"primaryCompletion":6193,"completion":14582,"start":14583,"enrollment":2046,"conditions":14642,"interventions":14643},[91],[14585],[14572,14587,14588,14589],{"trials":14645,"activeCount":103},[],{"trials":14647,"activeCount":103},[],{"trials":14649,"activeCount":103},[],{"trials":14651,"activeCount":103},[],{"intervention":14653,"totalTrials":437,"cells":14654},"DCY636",{"EARLY_PHASE1":14655,"PHASE1":14657,"PHASE2":14667,"PHASE3":14669,"PHASE4":14671,"NA":14673},{"trials":14656,"activeCount":103},[],{"trials":14658,"activeCount":437,"soonestReadout":14663},[14659],{"nctId":14660,"briefTitle":14661,"status":109,"phases":14662,"primaryCompletion":14663,"completion":1382,"start":6588,"enrollment":19,"conditions":14664,"interventions":14666},"NCT07604324","A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis",[91],"2028-01-27",[14665],"Dermatitis, Atopic",[14653],{"trials":14668,"activeCount":103},[],{"trials":14670,"activeCount":103},[],{"trials":14672,"activeCount":103},[],{"trials":14674,"activeCount":103},[],{"intervention":5187,"totalTrials":1630,"cells":14676},{"EARLY_PHASE1":14677,"PHASE1":14679,"PHASE2":14685,"PHASE3":14691,"PHASE4":14693,"NA":14695},{"trials":14678,"activeCount":103},[],{"trials":14680,"activeCount":437,"soonestReadout":5183},[14681],{"nctId":5180,"briefTitle":5181,"status":147,"phases":14682,"primaryCompletion":5183,"completion":5183,"start":2016,"enrollment":3530,"conditions":14683,"interventions":14684},[91],[5185],[130,5187],{"trials":14686,"activeCount":103},[14687],{"nctId":13776,"briefTitle":13777,"status":134,"phases":14688,"primaryCompletion":13779,"completion":13780,"start":13781,"enrollment":2776,"conditions":14689,"interventions":14690},[92],[1316],[155,159,5187],{"trials":14692,"activeCount":103},[],{"trials":14694,"activeCount":103},[],{"trials":14696,"activeCount":103},[14697,14701],{"nctId":13645,"briefTitle":13646,"status":123,"phases":14698,"primaryCompletion":13648,"completion":13648,"start":13649,"enrollment":13650,"conditions":14699,"interventions":14700},[],[13652],[5187,8153,13654,13655,13656,13657],{"nctId":13659,"briefTitle":13660,"status":123,"phases":14702,"primaryCompletion":6327,"completion":6327,"start":13662,"enrollment":13663,"conditions":14703,"interventions":14704},[],[36],[5187,13666,8153,13667],{"intervention":1403,"totalTrials":317,"cells":14706},{"EARLY_PHASE1":14707,"PHASE1":14709,"PHASE2":14711,"PHASE3":14713,"PHASE4":14719,"NA":14721},{"trials":14708,"activeCount":103},[],{"trials":14710,"activeCount":103},[],{"trials":14712,"activeCount":103},[],{"trials":14714,"activeCount":103},[14715],{"nctId":1394,"briefTitle":1395,"status":123,"phases":14716,"primaryCompletion":1397,"completion":1397,"start":1398,"enrollment":1399,"conditions":14717,"interventions":14718},[93],[1401],[1356,1403],{"trials":14720,"activeCount":103},[],{"trials":14722,"activeCount":437,"soonestReadout":1547},[14723,14727],{"nctId":5355,"briefTitle":5356,"status":123,"phases":14724,"primaryCompletion":2310,"completion":2310,"start":5358,"enrollment":5359,"conditions":14725,"interventions":14726},[],[1371],[5285,1403,1376],{"nctId":1544,"briefTitle":1545,"status":109,"phases":14728,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":14729,"interventions":14730},[],[1371],[1552,1553,1554,1403,1555,1556,1557,1558,1376,1559,1356],{"intervention":1376,"totalTrials":317,"cells":14732},{"EARLY_PHASE1":14733,"PHASE1":14735,"PHASE2":14737,"PHASE3":14743,"PHASE4":14745,"NA":14747},{"trials":14734,"activeCount":103},[],{"trials":14736,"activeCount":103},[],{"trials":14738,"activeCount":103},[14739],{"nctId":1365,"briefTitle":1366,"status":123,"phases":14740,"primaryCompletion":689,"completion":689,"start":1368,"enrollment":1369,"conditions":14741,"interventions":14742},[92],[1371,1372,1373,1374],[1356,1376],{"trials":14744,"activeCount":103},[],{"trials":14746,"activeCount":103},[],{"trials":14748,"activeCount":437,"soonestReadout":1547},[14749,14753],{"nctId":5355,"briefTitle":5356,"status":123,"phases":14750,"primaryCompletion":2310,"completion":2310,"start":5358,"enrollment":5359,"conditions":14751,"interventions":14752},[],[1371],[5285,1403,1376],{"nctId":1544,"briefTitle":1545,"status":109,"phases":14754,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":14755,"interventions":14756},[],[1371],[1552,1553,1554,1403,1555,1556,1557,1558,1376,1559,1356],{"intervention":1557,"totalTrials":213,"cells":14758},{"EARLY_PHASE1":14759,"PHASE1":14761,"PHASE2":14763,"PHASE3":14774,"PHASE4":14776,"NA":14778},{"trials":14760,"activeCount":103},[],{"trials":14762,"activeCount":103},[],{"trials":14764,"activeCount":103},[14765],{"nctId":14766,"briefTitle":14767,"status":123,"phases":14768,"primaryCompletion":2033,"completion":2033,"start":4524,"enrollment":3064,"conditions":14769,"interventions":14771},"NCT01594983","A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia",[92],[14770],"Non Familial Chylocmicronemia Syndrome (Non-FCS)",[14772,1557,14773],"LCQ908","Fish Oil",{"trials":14775,"activeCount":103},[],{"trials":14777,"activeCount":103},[],{"trials":14779,"activeCount":437,"soonestReadout":1547},[14780],{"nctId":1544,"briefTitle":1545,"status":109,"phases":14781,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":14782,"interventions":14783},[],[1371],[1552,1553,1554,1403,1555,1556,1557,1558,1376,1559,1356],{"intervention":14785,"totalTrials":437,"cells":14786},"Ilaris",{"EARLY_PHASE1":14787,"PHASE1":14789,"PHASE2":14791,"PHASE3":14793,"PHASE4":14795,"NA":14797},{"trials":14788,"activeCount":103},[],{"trials":14790,"activeCount":103},[],{"trials":14792,"activeCount":103},[],{"trials":14794,"activeCount":103},[],{"trials":14796,"activeCount":103},[],{"trials":14798,"activeCount":437,"soonestReadout":2884},[14799],{"nctId":14800,"briefTitle":14801,"status":109,"phases":14802,"primaryCompletion":2884,"completion":2884,"start":14803,"enrollment":2342,"conditions":14804,"interventions":14811},"NCT06838143","Ilaris NIS in Korea",[],"2025-03-29",[14805,14806,14807,14808,14809,14810],"Hereditary Periodic Fever Syndromes","Cryopyrin-associated Periodic Syndromes (CAPS)","Colchicine Resistance Familial Mediterranean Fever (crFMF)","TNF Receptor Associated Periodic Syndrome (TRAPS)","Hyper-IgD Syndrome \u002F Mevalonate Kinase Deficiency (HIDS\u002FMKD)","Systemic Juvenile Idiopathic Arthritis (sJIA)",[14785],{"intervention":14813,"totalTrials":437,"cells":14814},"Tafinlar\u002FMekinist",{"EARLY_PHASE1":14815,"PHASE1":14817,"PHASE2":14819,"PHASE3":14821,"PHASE4":14823,"NA":14825},{"trials":14816,"activeCount":103},[],{"trials":14818,"activeCount":103},[],{"trials":14820,"activeCount":103},[],{"trials":14822,"activeCount":103},[],{"trials":14824,"activeCount":103},[],{"trials":14826,"activeCount":437,"soonestReadout":14831},[14827],{"nctId":14828,"briefTitle":14829,"status":109,"phases":14830,"primaryCompletion":14831,"completion":14831,"start":14832,"enrollment":11504,"conditions":14833,"interventions":14835},"NCT06262919","Special Drug Use-results Surveillance of Tafinlar\u002FMekinist",[],"2031-12-31","2024-02-09",[14834],"BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor",[14813],{"intervention":14837,"totalTrials":437,"cells":14838},"ribociclib + AI ± LHRH",{"EARLY_PHASE1":14839,"PHASE1":14841,"PHASE2":14843,"PHASE3":14845,"PHASE4":14847,"NA":14849},{"trials":14840,"activeCount":103},[],{"trials":14842,"activeCount":103},[],{"trials":14844,"activeCount":103},[],{"trials":14846,"activeCount":103},[],{"trials":14848,"activeCount":103},[],{"trials":14850,"activeCount":437,"soonestReadout":6032},[14851],{"nctId":14852,"briefTitle":14853,"status":109,"phases":14854,"primaryCompletion":6032,"completion":6032,"start":14855,"enrollment":14856,"conditions":14857,"interventions":14858},"NCT06830720","A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+\u002FHER2- Early Breast Cancer at High Risk of Recurrence",[],"2025-02-20",3250,[559],[14837,14859,14860],"abemaciclib + ET ± LHRH","ET mono ± LHRH",{"intervention":14859,"totalTrials":437,"cells":14862},{"EARLY_PHASE1":14863,"PHASE1":14865,"PHASE2":14867,"PHASE3":14869,"PHASE4":14871,"NA":14873},{"trials":14864,"activeCount":103},[],{"trials":14866,"activeCount":103},[],{"trials":14868,"activeCount":103},[],{"trials":14870,"activeCount":103},[],{"trials":14872,"activeCount":103},[],{"trials":14874,"activeCount":437,"soonestReadout":6032},[14875],{"nctId":14852,"briefTitle":14853,"status":109,"phases":14876,"primaryCompletion":6032,"completion":6032,"start":14855,"enrollment":14856,"conditions":14877,"interventions":14878},[],[559],[14837,14859,14860],{"intervention":14860,"totalTrials":437,"cells":14880},{"EARLY_PHASE1":14881,"PHASE1":14883,"PHASE2":14885,"PHASE3":14887,"PHASE4":14889,"NA":14891},{"trials":14882,"activeCount":103},[],{"trials":14884,"activeCount":103},[],{"trials":14886,"activeCount":103},[],{"trials":14888,"activeCount":103},[],{"trials":14890,"activeCount":103},[],{"trials":14892,"activeCount":437,"soonestReadout":6032},[14893],{"nctId":14852,"briefTitle":14853,"status":109,"phases":14894,"primaryCompletion":6032,"completion":6032,"start":14855,"enrollment":14856,"conditions":14895,"interventions":14896},[],[559],[14837,14859,14860],{"intervention":1553,"totalTrials":437,"cells":14898},{"EARLY_PHASE1":14899,"PHASE1":14901,"PHASE2":14903,"PHASE3":14905,"PHASE4":14907,"NA":14909},{"trials":14900,"activeCount":103},[],{"trials":14902,"activeCount":103},[],{"trials":14904,"activeCount":103},[],{"trials":14906,"activeCount":103},[],{"trials":14908,"activeCount":103},[],{"trials":14910,"activeCount":437,"soonestReadout":1547},[14911],{"nctId":1544,"briefTitle":1545,"status":109,"phases":14912,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":14913,"interventions":14914},[],[1371],[1552,1553,1554,1403,1555,1556,1557,1558,1376,1559,1356],{"intervention":1554,"totalTrials":437,"cells":14916},{"EARLY_PHASE1":14917,"PHASE1":14919,"PHASE2":14921,"PHASE3":14923,"PHASE4":14925,"NA":14927},{"trials":14918,"activeCount":103},[],{"trials":14920,"activeCount":103},[],{"trials":14922,"activeCount":103},[],{"trials":14924,"activeCount":103},[],{"trials":14926,"activeCount":103},[],{"trials":14928,"activeCount":437,"soonestReadout":1547},[14929],{"nctId":1544,"briefTitle":1545,"status":109,"phases":14930,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":14931,"interventions":14932},[],[1371],[1552,1553,1554,1403,1555,1556,1557,1558,1376,1559,1356],{"intervention":1555,"totalTrials":437,"cells":14934},{"EARLY_PHASE1":14935,"PHASE1":14937,"PHASE2":14939,"PHASE3":14941,"PHASE4":14943,"NA":14945},{"trials":14936,"activeCount":103},[],{"trials":14938,"activeCount":103},[],{"trials":14940,"activeCount":103},[],{"trials":14942,"activeCount":103},[],{"trials":14944,"activeCount":103},[],{"trials":14946,"activeCount":437,"soonestReadout":1547},[14947],{"nctId":1544,"briefTitle":1545,"status":109,"phases":14948,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":14949,"interventions":14950},[],[1371],[1552,1553,1554,1403,1555,1556,1557,1558,1376,1559,1356],{"intervention":1556,"totalTrials":437,"cells":14952},{"EARLY_PHASE1":14953,"PHASE1":14955,"PHASE2":14957,"PHASE3":14959,"PHASE4":14961,"NA":14963},{"trials":14954,"activeCount":103},[],{"trials":14956,"activeCount":103},[],{"trials":14958,"activeCount":103},[],{"trials":14960,"activeCount":103},[],{"trials":14962,"activeCount":103},[],{"trials":14964,"activeCount":437,"soonestReadout":1547},[14965],{"nctId":1544,"briefTitle":1545,"status":109,"phases":14966,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":14967,"interventions":14968},[],[1371],[1552,1553,1554,1403,1555,1556,1557,1558,1376,1559,1356],{"intervention":1558,"totalTrials":437,"cells":14970},{"EARLY_PHASE1":14971,"PHASE1":14973,"PHASE2":14975,"PHASE3":14977,"PHASE4":14979,"NA":14981},{"trials":14972,"activeCount":103},[],{"trials":14974,"activeCount":103},[],{"trials":14976,"activeCount":103},[],{"trials":14978,"activeCount":103},[],{"trials":14980,"activeCount":103},[],{"trials":14982,"activeCount":437,"soonestReadout":1547},[14983],{"nctId":1544,"briefTitle":1545,"status":109,"phases":14984,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":14985,"interventions":14986},[],[1371],[1552,1553,1554,1403,1555,1556,1557,1558,1376,1559,1356],{"intervention":1559,"totalTrials":437,"cells":14988},{"EARLY_PHASE1":14989,"PHASE1":14991,"PHASE2":14993,"PHASE3":14995,"PHASE4":14997,"NA":14999},{"trials":14990,"activeCount":103},[],{"trials":14992,"activeCount":103},[],{"trials":14994,"activeCount":103},[],{"trials":14996,"activeCount":103},[],{"trials":14998,"activeCount":103},[],{"trials":15000,"activeCount":437,"soonestReadout":1547},[15001],{"nctId":1544,"briefTitle":1545,"status":109,"phases":15002,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":15003,"interventions":15004},[],[1371],[1552,1553,1554,1403,1555,1556,1557,1558,1376,1559,1356],{"intervention":15006,"totalTrials":437,"cells":15007},"Zolgensma",{"EARLY_PHASE1":15008,"PHASE1":15010,"PHASE2":15012,"PHASE3":15014,"PHASE4":15016,"NA":15018},{"trials":15009,"activeCount":103},[],{"trials":15011,"activeCount":103},[],{"trials":15013,"activeCount":103},[],{"trials":15015,"activeCount":103},[],{"trials":15017,"activeCount":103},[],{"trials":15019,"activeCount":437,"soonestReadout":15024},[15020],{"nctId":15021,"briefTitle":15022,"status":109,"phases":15023,"primaryCompletion":15024,"completion":15024,"start":15025,"enrollment":1652,"conditions":15026,"interventions":15027},"NCT04174157","Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)",[],"2038-06-30","2018-09-25",[8661],[15006],{"intervention":15029,"totalTrials":4557,"cells":15030},"vildagliptin",{"EARLY_PHASE1":15031,"PHASE1":15033,"PHASE2":15035,"PHASE3":15052,"PHASE4":15256,"NA":15349},{"trials":15032,"activeCount":103},[],{"trials":15034,"activeCount":103},[],{"trials":15036,"activeCount":103},[15037,15044],{"nctId":15038,"briefTitle":15039,"status":123,"phases":15040,"primaryCompletion":5063,"completion":5063,"start":15041,"enrollment":5948,"conditions":15042,"interventions":15043},"NCT00099957","A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes",[92],"2003-09",[30],[15029],{"nctId":15045,"briefTitle":15046,"status":123,"phases":15047,"primaryCompletion":3410,"start":3552,"enrollment":1750,"conditions":15048,"interventions":15050},"NCT00818571","Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients",[91,92],[2635,15049],"Diabetes",[15051,15051,15051,15051],"Vildagliptin",{"trials":15053,"activeCount":103},[15054,15061,15069,15076,15082,15089,15097,15105,15113,15120,15128,15135,15141,15150,15156,15162,15170,15178,15184,15192,15199,15206,15212,15221,15228,15235,15242,15248],{"nctId":15055,"briefTitle":15056,"status":123,"phases":15057,"primaryCompletion":917,"completion":917,"start":15058,"enrollment":6165,"conditions":15059,"interventions":15060},"NCT00099853","Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes",[93],"2004-05",[30],[15051,10531],{"nctId":15062,"briefTitle":15063,"status":123,"phases":15064,"primaryCompletion":949,"completion":949,"start":15065,"enrollment":6234,"conditions":15066,"interventions":15067},"NCT00102466","Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes",[93],"2005-01",[30],[15029,15068,13838],"Gliclazide",{"nctId":15070,"briefTitle":15071,"status":123,"phases":15072,"primaryCompletion":8091,"completion":8091,"start":4071,"enrollment":2094,"conditions":15073,"interventions":15074},"NCT00101712","Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia",[93],[30],[15029,15075],"Vildagliptin Placebo",{"nctId":15077,"briefTitle":15078,"status":123,"phases":15079,"primaryCompletion":4621,"completion":4621,"start":15065,"enrollment":927,"conditions":15080,"interventions":15081},"NCT00101803","Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes",[93],[30],[15029],{"nctId":15083,"briefTitle":15084,"status":123,"phases":15085,"primaryCompletion":5063,"completion":5063,"start":15058,"enrollment":15086,"conditions":15087,"interventions":15088},"NCT00099931","Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes",[93],254,[30],[15029],{"nctId":15090,"briefTitle":15091,"status":123,"phases":15092,"primaryCompletion":895,"completion":895,"start":926,"enrollment":630,"conditions":15093,"interventions":15095},"NCT01262586","Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.",[93],[15094],"Type II Diabetes Mellitus",[15051,15096],"Glimepiride",{"nctId":15098,"briefTitle":15099,"status":123,"phases":15100,"primaryCompletion":3272,"completion":3272,"start":15101,"enrollment":6608,"conditions":15102,"interventions":15103},"NCT00099866","Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes",[93],"2004-01",[30],[15029,15104],"Metformin Comparator",{"nctId":15106,"briefTitle":15107,"status":123,"phases":15108,"primaryCompletion":15109,"completion":15109,"start":9096,"enrollment":15110,"conditions":15111,"interventions":15112},"NCT00099905","A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes",[93],"2005-10",639,[30],[15029],{"nctId":15114,"briefTitle":15115,"status":123,"phases":15116,"primaryCompletion":1025,"start":15065,"enrollment":15117,"conditions":15118,"interventions":15119},"NCT00102388","Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes",[93],1092,[30],[15029,15068],{"nctId":15121,"briefTitle":15122,"status":123,"phases":15123,"primaryCompletion":15109,"completion":15109,"start":15058,"enrollment":15124,"conditions":15125,"interventions":15126},"NCT00099944","Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes",[93],515,[30],[15029,15096,15127],"LAF237 placebo",{"nctId":15129,"briefTitle":15130,"status":123,"phases":15131,"primaryCompletion":1670,"completion":1670,"start":3383,"enrollment":2566,"conditions":15132,"interventions":15134},"NCT01357252","Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes",[93],[15133],"Type 2 Diabetes Mellitus",[15029],{"nctId":15136,"briefTitle":15137,"status":123,"phases":15138,"primaryCompletion":966,"completion":966,"start":3255,"enrollment":5594,"conditions":15139,"interventions":15140},"NCT00351507","A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes",[93],[30],[15051],{"nctId":15142,"briefTitle":15143,"status":123,"phases":15144,"primaryCompletion":2458,"completion":2458,"start":1682,"enrollment":25,"conditions":15145,"interventions":15147},"NCT01871558","Vildagliptin\u002FMetformin in T2DM Patients Starting Basal Insulin",[93],[15146],"Type 2 Diabetes Mellitus (T2DM)",[15051,13838,15148,15149],"sulfonylurea","Basal Insulin",{"nctId":15151,"briefTitle":15152,"status":123,"phases":15153,"primaryCompletion":4642,"start":825,"enrollment":2633,"conditions":15154,"interventions":15155},"NCT00396071","Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin",[93],[30],[15029],{"nctId":15157,"briefTitle":15158,"status":123,"phases":15159,"primaryCompletion":5063,"completion":5063,"start":845,"enrollment":10408,"conditions":15160,"interventions":15161},"NCT00101673","Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%",[93],[30],[15029],{"nctId":15163,"briefTitle":15164,"status":123,"phases":15165,"primaryCompletion":3447,"start":825,"enrollment":15166,"conditions":15167,"interventions":15168},"NCT00396227","Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone",[93],2665,[30],[15029,15169],"thiazolidinedione",{"nctId":15171,"briefTitle":15172,"status":123,"phases":15173,"primaryCompletion":5062,"start":825,"enrollment":15174,"conditions":15175,"interventions":15176},"NCT00396357","Efficacy\u002FSafety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone",[93],914,[30],[15051,15177],"metformin",{"nctId":15179,"briefTitle":15180,"status":123,"phases":15181,"primaryCompletion":2795,"completion":2795,"start":4372,"enrollment":4935,"conditions":15182,"interventions":15183},"NCT01257451","Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients",[93],[15133],[15051],{"nctId":15185,"briefTitle":15186,"status":123,"phases":15187,"primaryCompletion":938,"completion":938,"start":4034,"enrollment":15188,"conditions":15189,"interventions":15190},"NCT00382096","Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes",[93],1179,[30],[15051,13838,15191],"Vildagliptin + Metformin",{"nctId":15193,"briefTitle":15194,"status":123,"phases":15195,"primaryCompletion":8370,"completion":8370,"start":15058,"enrollment":15196,"conditions":15197,"interventions":15198},"NCT00099918","Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes",[93],717,[30],[15029],{"nctId":15200,"briefTitle":15201,"status":123,"phases":15202,"primaryCompletion":2793,"completion":2793,"start":4301,"enrollment":15203,"conditions":15204,"interventions":15205},"NCT01497522","Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes",[93],183,[30],[15051],{"nctId":15207,"briefTitle":15208,"status":123,"phases":15209,"primaryCompletion":8370,"completion":8370,"start":15058,"enrollment":1809,"conditions":15210,"interventions":15211},"NCT00099892","Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes",[93],[30],[15029],{"nctId":15213,"briefTitle":15214,"status":123,"phases":15215,"primaryCompletion":5696,"completion":15216,"start":996,"enrollment":15217,"conditions":15218,"interventions":15219},"NCT00106340","Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes",[93],"2008-05-20",3118,[30],[15029,15220,13838],"glimepiride",{"nctId":15222,"briefTitle":15223,"status":123,"phases":15224,"primaryCompletion":5114,"completion":5114,"start":607,"enrollment":15225,"conditions":15226,"interventions":15227},"NCT01582230","Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus",[93],293,[15133],[15051],{"nctId":15229,"briefTitle":15230,"status":123,"phases":15231,"primaryCompletion":1732,"completion":1732,"start":3351,"enrollment":8122,"conditions":15232,"interventions":15234},"NCT01159249","Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes",[93],[15233],"Type 2 Diabetes",[15051],{"nctId":15236,"briefTitle":15237,"status":123,"phases":15238,"primaryCompletion":825,"completion":825,"start":854,"enrollment":15239,"conditions":15240,"interventions":15241},"NCT00110240","Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes",[93],594,[30],[15029],{"nctId":15243,"briefTitle":15244,"status":123,"phases":15245,"primaryCompletion":3552,"completion":3552,"start":918,"enrollment":3322,"conditions":15246,"interventions":15247},"NCT00260156","A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes",[93],[30],[15029],{"nctId":15249,"briefTitle":15250,"status":123,"phases":15251,"primaryCompletion":895,"completion":895,"start":3612,"enrollment":15252,"conditions":15253,"interventions":15254},"NCT00860288","Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes",[92,93],1988,[30],[15051,13838,15255],"Sitagliptin",{"trials":15257,"activeCount":103},[15258,15265,15273,15279,15286,15294,15300,15308,15314,15321,15328,15334,15342],{"nctId":15259,"briefTitle":15260,"status":123,"phases":15261,"primaryCompletion":3799,"completion":3799,"start":1670,"enrollment":15262,"conditions":15263,"interventions":15264},"NCT01758380","Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan",[94],557,[15133],[15051,15068,13838],{"nctId":15266,"briefTitle":15267,"status":123,"phases":15268,"primaryCompletion":4524,"completion":4524,"start":2034,"enrollment":15269,"conditions":15270,"interventions":15272},"NCT01398592","Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy",[94],187,[15271],"Diabetes Mellitus Type 2",[15051,15255],{"nctId":15274,"briefTitle":15275,"status":123,"phases":15276,"primaryCompletion":812,"completion":812,"start":3712,"enrollment":2428,"conditions":15277,"interventions":15278},"NCT01686932","Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function",[94],[15271],[15051,15255],{"nctId":15280,"briefTitle":15281,"status":123,"phases":15282,"primaryCompletion":3861,"completion":3861,"start":15283,"enrollment":709,"conditions":15284,"interventions":15285},"NCT01582243","Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients",[94],"2013-04",[30],[15051],{"nctId":15287,"briefTitle":15288,"status":123,"phases":15289,"primaryCompletion":3383,"start":3760,"enrollment":630,"conditions":15290,"interventions":15291},"NCT01309698","Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes",[94],[15233],[15051,15292,15293],"Voglibose","Vildagliptin and Voglibose",{"nctId":15295,"briefTitle":15296,"status":134,"phases":15297,"primaryCompletion":812,"completion":812,"start":2033,"enrollment":167,"conditions":15298,"interventions":15299},"NCT01910441","Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients",[94],[15133],[15051,15096,13838],{"nctId":15301,"briefTitle":15302,"status":123,"phases":15303,"primaryCompletion":15304,"completion":15304,"start":4898,"enrollment":15305,"conditions":15306,"interventions":15307},"NCT01528254","VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus",[94],"2019-04-04",2004,[15133],[15029,13838],{"nctId":15309,"briefTitle":15310,"status":123,"phases":15311,"primaryCompletion":3383,"completion":3383,"start":5620,"enrollment":9531,"conditions":15312,"interventions":15313},"NCT01426802","Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin",[94],[15133],[15029],{"nctId":15315,"briefTitle":15316,"status":134,"phases":15317,"primaryCompletion":3511,"completion":3511,"start":5114,"enrollment":3411,"conditions":15318,"interventions":15319},"NCT01862263","Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes",[94],[15133],[15051,15320],"Insulin",{"nctId":15322,"briefTitle":15323,"status":123,"phases":15324,"primaryCompletion":1714,"completion":1714,"start":1671,"enrollment":15325,"conditions":15326,"interventions":15327},"NCT01541956","Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)",[94],3091,[15233],[13838,15029],{"nctId":15329,"briefTitle":15330,"status":123,"phases":15331,"primaryCompletion":2458,"completion":2458,"start":1714,"enrollment":5236,"conditions":15332,"interventions":15333},"NCT02002221","Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients",[94],[15146],[15051,15320,13838],{"nctId":15335,"briefTitle":15336,"status":123,"phases":15337,"primaryCompletion":3482,"completion":3482,"start":3410,"enrollment":15338,"conditions":15339,"interventions":15341},"NCT00894868","Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure",[94],798,[15340,15094],"Congestive Heart Failure",[15029],{"nctId":15343,"briefTitle":15344,"status":123,"phases":15345,"primaryCompletion":15346,"completion":15346,"start":3383,"enrollment":4557,"conditions":15347,"interventions":15348},"NCT01356381","Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes",[94],"2013-08",[15133],[15051],{"trials":15350,"activeCount":103},[],{"intervention":4321,"totalTrials":34,"cells":15352},{"EARLY_PHASE1":15353,"PHASE1":15355,"PHASE2":15424,"PHASE3":15458,"PHASE4":15512,"NA":15521},{"trials":15354,"activeCount":103},[],{"trials":15356,"activeCount":103},[15357,15361,15365,15369,15373,15377,15390,15396,15406,15412,15420],{"nctId":7861,"briefTitle":7862,"status":123,"phases":15358,"primaryCompletion":7864,"completion":7865,"start":7866,"enrollment":827,"conditions":15359,"interventions":15360},[91],[7868],[7870,7871,4780,7872],{"nctId":8036,"briefTitle":8037,"status":123,"phases":15362,"primaryCompletion":8039,"completion":8039,"start":3673,"enrollment":114,"conditions":15363,"interventions":15364},[91],[8041],[7886,516,4321,5252,8043],{"nctId":10990,"briefTitle":10991,"status":123,"phases":15366,"primaryCompletion":10993,"completion":10993,"start":10994,"enrollment":1065,"conditions":15367,"interventions":15368},[91],[10996],[516,4321],{"nctId":4314,"briefTitle":4315,"status":123,"phases":15370,"primaryCompletion":4093,"completion":4093,"start":4317,"enrollment":534,"conditions":15371,"interventions":15372},[91],[435],[196,4320,4321],{"nctId":13316,"briefTitle":13317,"status":134,"phases":15374,"primaryCompletion":6013,"completion":6013,"start":13319,"enrollment":2810,"conditions":15375,"interventions":15376},[91],[128],[4389,5262,9948,4375,1168,4321,3157],{"nctId":15378,"briefTitle":15379,"status":123,"phases":15380,"primaryCompletion":15381,"completion":5818,"start":15382,"enrollment":15383,"conditions":15384,"interventions":15386},"NCT03798626","Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",[91],"2023-03-01","2019-05-22",167,[209,15385,4403],"Gastroesophageal Cancer",[15387,9926,9927,9928,15388,4321,15389],"Gevokizumab","Ramucirumab","Cabozantinib",{"nctId":15391,"briefTitle":15392,"status":123,"phases":15393,"primaryCompletion":4410,"completion":4410,"start":4669,"enrollment":1495,"conditions":15394,"interventions":15395},"NCT01968915","Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors",[91],[4362],[4390,4321],{"nctId":15397,"briefTitle":15398,"status":134,"phases":15399,"primaryCompletion":15400,"completion":15400,"start":15401,"enrollment":2379,"conditions":15402,"interventions":15404},"NCT01820325","Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer",[91],"2014-06-18","2013-09-09",[15403],"Non-Small Cell Lunch Cancer",[738,15405,1168,4321],"Buparlisib placebo",{"nctId":15407,"briefTitle":15408,"status":123,"phases":15409,"primaryCompletion":10055,"completion":10055,"start":3383,"enrollment":485,"conditions":15410,"interventions":15411},"NCT01240655","A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors",[91],[647],[4390,4321],{"nctId":15413,"briefTitle":15414,"status":123,"phases":15415,"primaryCompletion":15416,"completion":15416,"start":1817,"enrollment":1053,"conditions":15417,"interventions":15418},"NCT02240212","Study of Afuresertib Combined With Paclitaxel in Gastric Cancer",[91],"2017-02-07",[1102],[15419,4321],"Afuresertib",{"nctId":7888,"briefTitle":7889,"status":123,"phases":15421,"primaryCompletion":3845,"start":3552,"enrollment":2367,"conditions":15422,"interventions":15423},[91],[7892,435],[7894,7895,4780,7872],{"trials":15425,"activeCount":103},[15426,15433,15437,15445,15454],{"nctId":15427,"briefTitle":15428,"status":123,"phases":15429,"primaryCompletion":812,"completion":812,"start":3482,"enrollment":15430,"conditions":15431,"interventions":15432},"NCT01617668","A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer",[92],209,[15],[4390,7872],{"nctId":7919,"briefTitle":7920,"status":123,"phases":15434,"primaryCompletion":2391,"completion":2391,"start":7922,"enrollment":2579,"conditions":15435,"interventions":15436},[92],[7924],[517,4320,4321,7926],{"nctId":15438,"briefTitle":15439,"status":134,"phases":15440,"primaryCompletion":15441,"completion":15441,"start":15442,"enrollment":3002,"conditions":15443,"interventions":15444},"NCT01852292","Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy",[92],"2017-03-30","2013-10-01",[206],[738,4321],{"nctId":15446,"briefTitle":15447,"status":134,"phases":15448,"primaryCompletion":511,"completion":511,"start":15449,"enrollment":3343,"conditions":15450,"interventions":15453},"NCT01495247","Phase Ib\u002FII Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer",[91,92],"2012-01-30",[15451,15452],"Inoperable Locally Advanced Breast Cancer","Metastatic Breast Cancer (MBC)",[4609,4321],{"nctId":9938,"briefTitle":9939,"status":390,"phases":15455,"primaryCompletion":9941,"completion":9942,"start":1512,"enrollment":103,"conditions":15456,"interventions":15457},[92],[9944],[9946,1079,4321,9947,1168,8153,9948],{"trials":15459,"activeCount":103},[15460,15467,15471,15478,15482,15486,15490,15494,15504,15508],{"nctId":15461,"briefTitle":15462,"status":123,"phases":15463,"primaryCompletion":4410,"completion":4410,"start":3482,"enrollment":15464,"conditions":15465,"interventions":15466},"NCT01572727","A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",[92,93],416,[15],[4321,517],{"nctId":7968,"briefTitle":7969,"status":123,"phases":15468,"primaryCompletion":7971,"completion":5830,"start":7972,"enrollment":7973,"conditions":15469,"interventions":15470},[93],[15],[4780,6673,7976,7872],{"nctId":15472,"briefTitle":15473,"status":134,"phases":15474,"primaryCompletion":853,"completion":853,"start":4070,"enrollment":15475,"conditions":15476,"interventions":15477},"NCT00662597","ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb\u002FIV Non-Small Cell Lung Cancer",[93],1285,[182],[8115,7871,4321],{"nctId":9952,"briefTitle":9953,"status":390,"phases":15479,"primaryCompletion":9955,"completion":9956,"start":9957,"enrollment":103,"conditions":15480,"interventions":15481},[93],[5282],[9946,1079,8153,1168,5262,4375,4321,9947],{"nctId":13629,"briefTitle":13630,"status":134,"phases":15483,"primaryCompletion":13632,"completion":13633,"start":13634,"enrollment":13635,"conditions":15484,"interventions":15485},[93],[128],[10578,13581,7871,13638,7872,6342,13639],{"nctId":6368,"briefTitle":6369,"status":134,"phases":15487,"primaryCompletion":5902,"completion":6371,"start":6372,"enrollment":6373,"conditions":15488,"interventions":15489},[93],[6375],[88,6377,4321,6378],{"nctId":8004,"briefTitle":8005,"status":123,"phases":15491,"primaryCompletion":8007,"completion":8008,"start":8009,"enrollment":7042,"conditions":15492,"interventions":15493},[93],[7868],[944,4320,4321],{"nctId":15495,"briefTitle":15496,"status":123,"phases":15497,"primaryCompletion":15498,"completion":6142,"start":15499,"enrollment":15500,"conditions":15501,"interventions":15502},"NCT00281658","Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2",[93],"2010-06-18","2006-01-02",444,[7868],[15503,4321],"Lapatinib (GW572016) oral",{"nctId":4922,"briefTitle":4923,"status":123,"phases":15505,"primaryCompletion":4925,"completion":2533,"start":4926,"enrollment":4794,"conditions":15506,"interventions":15507},[93],[15],[196,4320,4321],{"nctId":8017,"briefTitle":8018,"status":134,"phases":15509,"primaryCompletion":8020,"completion":8021,"start":8022,"enrollment":19,"conditions":15510,"interventions":15511},[93],[7868],[7870,7872,4780],{"trials":15513,"activeCount":103},[15514],{"nctId":15515,"briefTitle":15516,"status":123,"phases":15517,"primaryCompletion":2509,"completion":2509,"start":3383,"enrollment":1622,"conditions":15518,"interventions":15520},"NCT01317615","RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation",[94],[15519,4903],"Carcinoma, Large Cell",[7711,4321,1168],{"trials":15522,"activeCount":103},[],{"intervention":15524,"totalTrials":2633,"cells":15525},"QVA149",{"EARLY_PHASE1":15526,"PHASE1":15528,"PHASE2":15530,"PHASE3":15532,"PHASE4":15661,"NA":15702},{"trials":15527,"activeCount":103},[],{"trials":15529,"activeCount":103},[],{"trials":15531,"activeCount":103},[],{"trials":15533,"activeCount":103},[15534,15543,15549,15557,15566,15574,15581,15589,15596,15606,15611,15618,15624,15631,15638,15647,15653],{"nctId":15535,"briefTitle":15536,"status":123,"phases":15537,"primaryCompletion":3604,"completion":3604,"start":5733,"enrollment":15538,"conditions":15539,"interventions":15540},"NCT01529632","Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[93],193,[24],[15524,15541,15542],"NVA237","QAB149",{"nctId":15544,"briefTitle":15545,"status":123,"phases":15546,"primaryCompletion":2458,"completion":2458,"start":1781,"enrollment":524,"conditions":15547,"interventions":15548},"NCT01996319","Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.",[93],[24],[15524],{"nctId":15550,"briefTitle":15551,"status":123,"phases":15552,"primaryCompletion":3731,"completion":3731,"start":1761,"enrollment":15553,"conditions":15554,"interventions":15556},"NCT01682863","A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation",[93],614,[15555],"Chronic Obstructive Pulmonary Disease (COPD)",[15524,15524,15542],{"nctId":15558,"briefTitle":15559,"status":123,"phases":15560,"primaryCompletion":3759,"completion":3759,"start":4081,"enrollment":15561,"conditions":15562,"interventions":15563},"NCT01120691","Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations",[93],2224,[24],[15524,15541,15564,15565],"tiotropium","Salbutamol\u002Falbuterol",{"nctId":15567,"briefTitle":15568,"status":123,"phases":15569,"primaryCompletion":3861,"completion":3861,"start":2033,"enrollment":15570,"conditions":15571,"interventions":15572},"NCT01782326","QVA vs. Salmeterol\u002FFluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)",[93],3362,[15555],[15524,15573],"Long acting B2 agonist",{"nctId":15575,"briefTitle":15576,"status":390,"phases":15577,"primaryCompletion":812,"completion":812,"start":1714,"enrollment":103,"conditions":15578,"interventions":15579},"NCT01860066","A 12 Week Study of QVA149 Compared to Fluticasone\u002FSalmeterol (Advair) for Treatment of COPD",[93],[24],[15524,15580],"fluticasone\u002Fsalmeterol",{"nctId":15582,"briefTitle":15583,"status":123,"phases":15584,"primaryCompletion":3482,"completion":3482,"start":1715,"enrollment":15585,"conditions":15586,"interventions":15587},"NCT01490125","The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[93],247,[24],[15524,15588,15565],"Tiotropium",{"nctId":15590,"briefTitle":15591,"status":123,"phases":15592,"primaryCompletion":1723,"completion":1723,"start":3712,"enrollment":15593,"conditions":15594,"interventions":15595},"NCT01727141","A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate \u002F Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",[93],1042,[15555],[15524,15542,15541],{"nctId":15597,"briefTitle":15598,"status":123,"phases":15599,"primaryCompletion":15600,"completion":15600,"start":15601,"enrollment":15602,"conditions":15603,"interventions":15604},"NCT02487498","Efficacy and Safety Study of Indacaterol Maleate\u002FGlycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.",[93],"2016-09-06","2015-07-27",355,[24],[15524,15605],"Umeclidinium\u002Fvilanterol",{"nctId":15607,"briefTitle":15576,"status":390,"phases":15608,"primaryCompletion":812,"completion":812,"start":1714,"enrollment":103,"conditions":15609,"interventions":15610},"NCT01834885",[93],[24],[15524,15580],{"nctId":15612,"briefTitle":15613,"status":123,"phases":15614,"primaryCompletion":1723,"completion":1723,"start":3604,"enrollment":15615,"conditions":15616,"interventions":15617},"NCT01712516","A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate \u002F Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",[93],1001,[15555],[15524,15542,15541],{"nctId":15619,"briefTitle":15620,"status":123,"phases":15621,"primaryCompletion":4301,"completion":4301,"start":4081,"enrollment":4960,"conditions":15622,"interventions":15623},"NCT01120717","A Study to Assess the Long-term Safety of QVA149",[93],[24],[15524],{"nctId":15625,"briefTitle":15626,"status":123,"phases":15627,"primaryCompletion":15283,"completion":15283,"start":5733,"enrollment":15628,"conditions":15629,"interventions":15630},"NCT01574651","The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[93],934,[15555],[15524,15588,7842],{"nctId":15632,"briefTitle":15633,"status":123,"phases":15634,"primaryCompletion":2458,"completion":2458,"start":1761,"enrollment":15635,"conditions":15636,"interventions":15637},"NCT01610037","Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation",[93],1215,[15555],[15524,15588],{"nctId":15639,"briefTitle":15640,"status":123,"phases":15641,"primaryCompletion":15642,"completion":15642,"start":15643,"enrollment":15644,"conditions":15645,"interventions":15646},"NCT02487446","Efficacy and Safety Study of QVA149 in COPD Patients",[93],"2016-09-12","2015-07-28",357,[24],[15524,15605],{"nctId":15648,"briefTitle":15649,"status":123,"phases":15650,"primaryCompletion":3243,"completion":3243,"start":4598,"enrollment":4532,"conditions":15651,"interventions":15652},"NCT01285492","Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)",[93],[15555],[15524,15588],{"nctId":15654,"briefTitle":15655,"status":123,"phases":15656,"primaryCompletion":1723,"completion":1723,"start":3712,"enrollment":15657,"conditions":15658,"interventions":15659},"NCT01709903","A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149",[93],744,[24],[15524,15660],"Fluticasone\u002Fsalmeterol",{"trials":15662,"activeCount":103},[15663,15671,15680,15689,15696],{"nctId":15664,"briefTitle":15665,"status":123,"phases":15666,"primaryCompletion":13399,"completion":15667,"start":2176,"enrollment":2149,"conditions":15668,"interventions":15670},"NCT02442206","Effect of QVA149 (Indacaterol Maleate\u002FGlycopyrronium Bromide) on Cardiac Function in COPD Patients",[94],"2017-05-15",[15669],"Chronic Obstructive Pulmonary Disease, COPD",[15524],{"nctId":15672,"briefTitle":15673,"status":123,"phases":15674,"primaryCompletion":15675,"completion":15675,"start":15676,"enrollment":3846,"conditions":15677,"interventions":15678},"NCT02603393","Evaluation of the Efficacy and Safety of QVA149 (110\u002F50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol\u002FFluticasone Propionate FDC (50\u002F500 µg b.i.d.) in Patients With Moderate to Severe COPD",[94],"2017-07-18","2015-11-20",[15555],[15524,15588,15679],"Salmeterol\u002Ffluticasone",{"nctId":15681,"briefTitle":15682,"status":123,"phases":15683,"primaryCompletion":15684,"completion":15684,"start":15685,"enrollment":5948,"conditions":15686,"interventions":15687},"NCT02233543","A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)",[94],"2016-06-26","2014-11-30",[24],[15524,15688],"QVA149 Placebo",{"nctId":15690,"briefTitle":15691,"status":123,"phases":15692,"primaryCompletion":15693,"completion":15693,"start":8039,"enrollment":827,"conditions":15694,"interventions":15695},"NCT02634983","QVA Mechanistic Efficacy Study (Receptor Effects, Etc)",[94],"2017-09-26",[24],[15524],{"nctId":15697,"briefTitle":15698,"status":123,"phases":15699,"primaryCompletion":10055,"completion":10055,"start":1781,"enrollment":534,"conditions":15700,"interventions":15701},"NCT02125734","Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients",[94],[24,8267],[15524,15588],{"trials":15703,"activeCount":103},[],{"intervention":5447,"totalTrials":2633,"cells":15705},{"EARLY_PHASE1":15706,"PHASE1":15708,"PHASE2":15717,"PHASE3":15757,"PHASE4":15840,"NA":15892},{"trials":15707,"activeCount":103},[],{"trials":15709,"activeCount":103},[15710],{"nctId":15711,"briefTitle":15712,"status":123,"phases":15713,"primaryCompletion":1715,"completion":1715,"start":1724,"enrollment":138,"conditions":15714,"interventions":15716},"NCT01447485","Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients",[91],[21,14561,15715],"Nephrotic Syndrome",[5447],{"trials":15718,"activeCount":103},[15719,15728,15736,15744,15750],{"nctId":15720,"briefTitle":15721,"status":123,"phases":15722,"primaryCompletion":10499,"completion":10499,"start":3194,"enrollment":15723,"conditions":15724,"interventions":15725},"NCT00549770","Efficacy and Safety of LCZ696A in Patients With Essential Hypertension",[92],1334,[21],[15726,5447,15727],"LCZ696","AHU377",{"nctId":15729,"briefTitle":15730,"status":123,"phases":15731,"primaryCompletion":4301,"completion":4301,"start":4335,"enrollment":15732,"conditions":15733,"interventions":15735},"NCT00887588","LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction",[92],307,[15734],"Chronic Heart Failure",[15726,5447],{"nctId":15737,"briefTitle":15738,"status":123,"phases":15739,"primaryCompletion":4301,"completion":4301,"start":4598,"enrollment":15740,"conditions":15741,"interventions":15743},"NCT01281306","An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension",[92],910,[15742],"Systolic Hypertension",[15726,5447,15727],{"nctId":15745,"briefTitle":15746,"status":123,"phases":15747,"primaryCompletion":3482,"completion":3482,"start":895,"enrollment":7257,"conditions":15748,"interventions":15749},"NCT01353508","Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers",[92],[21],[15726,5447],{"nctId":15751,"briefTitle":15752,"status":123,"phases":15753,"primaryCompletion":813,"completion":813,"start":3482,"enrollment":774,"conditions":15754,"interventions":15756},"NCT01681576","Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension",[92],[15755],"Salt-sensitive Hypertension",[5447,15726],{"trials":15758,"activeCount":103},[15759,15770,15778,15790,15796,15804,15812,15822,15832],{"nctId":15760,"briefTitle":15761,"status":123,"phases":15762,"primaryCompletion":15763,"completion":15763,"start":15764,"enrollment":15765,"conditions":15766,"interventions":15768},"NCT02924727","Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI",[93],"2021-02-26","2016-12-09",5669,[15767],"Acute Myocardial Infarction",[15726,15769,5447],"Ramipril",{"nctId":15771,"briefTitle":15772,"status":123,"phases":15773,"primaryCompletion":3861,"completion":3861,"start":1724,"enrollment":9531,"conditions":15774,"interventions":15775},"NCT01365481","Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age",[93],[21,14561],[5447,15776,15777],"amlodipine","Hydrochlorothiazide",{"nctId":15779,"briefTitle":15780,"status":123,"phases":15781,"primaryCompletion":15782,"completion":15782,"start":15783,"enrollment":15784,"conditions":15785,"interventions":15787},"NCT03066804","A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients",[93],"2019-10-28","2017-08-22",2572,[15786],"Heart Failure With Preserved Ejection Fraction",[15788,15789,5447],"sacubitril\u002Fvalsartan","Enalapril",{"nctId":15791,"briefTitle":15792,"status":123,"phases":15793,"primaryCompletion":3612,"completion":3612,"start":3254,"enrollment":967,"conditions":15794,"interventions":15795},"NCT00433836","Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure",[93],[21],[5447,15789],{"nctId":15797,"briefTitle":15798,"status":123,"phases":15799,"primaryCompletion":1024,"completion":1024,"start":15800,"enrollment":15801,"conditions":15802,"interventions":15803},"NCT00446511","Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",[93],"2007-06",250,[21],[5447,15789],{"nctId":15805,"briefTitle":15806,"status":123,"phases":15807,"primaryCompletion":15808,"completion":15808,"start":15809,"enrollment":11068,"conditions":15810,"interventions":15811},"NCT00457626","A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension",[93],"2009-05-25","2007-04-09",[21],[5447],{"nctId":15813,"briefTitle":15814,"status":123,"phases":15815,"primaryCompletion":10618,"completion":10618,"start":15816,"enrollment":15817,"conditions":15818,"interventions":15820},"NCT03988634","Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)",[93],"2019-06-29",467,[15819],"Heart Failure With Preserved Ejection Fraction (HFpEF)",[15788,15821],"valsartan",{"nctId":15823,"briefTitle":15824,"status":123,"phases":15825,"primaryCompletion":15826,"completion":15826,"start":15827,"enrollment":15828,"conditions":15829,"interventions":15831},"NCT02884206","Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction",[93],"2022-05-16","2016-11-23",592,[15830],"Chronic Heart Failure (CHF)",[15726,5447],{"nctId":15833,"briefTitle":15834,"status":123,"phases":15835,"primaryCompletion":2111,"completion":2111,"start":15836,"enrollment":15837,"conditions":15838,"interventions":15839},"NCT01920711","Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction",[93],"2014-07-18",4822,[15786],[15726,5447],{"trials":15841,"activeCount":103},[15842,15851,15857,15863,15873,15877,15885],{"nctId":15843,"briefTitle":15844,"status":123,"phases":15845,"primaryCompletion":1024,"completion":1024,"start":4070,"enrollment":15846,"conditions":15847,"interventions":15848},"NCT00698646","Efficacy and Safety of Valsartan\u002FHydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.",[94],384,[21],[15849,5447,15850],"Valsartan + HCTZ","HCTZ",{"nctId":15852,"briefTitle":15853,"status":134,"phases":15854,"primaryCompletion":996,"start":15101,"enrollment":13149,"conditions":15855,"interventions":15856},"NCT00171119","A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril",[94],[21,3045],[15821],{"nctId":15858,"briefTitle":15859,"status":123,"phases":15860,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":919,"conditions":15861,"interventions":15862},"NCT01541189","Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.",[94],[21],[5447],{"nctId":15864,"briefTitle":15865,"status":123,"phases":15866,"primaryCompletion":15867,"completion":15867,"start":15868,"enrollment":2112,"conditions":15869,"interventions":15871},"NCT03300427","The Effects of Sacubitril\u002FValsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients",[94],"2022-03-23","2018-07-05",[15870],"Heart Failure",[15872,15821],"sacubitril\u002Fvalsatran",{"nctId":5439,"briefTitle":5440,"status":123,"phases":15874,"primaryCompletion":4620,"completion":4620,"start":4845,"enrollment":5442,"conditions":15875,"interventions":15876},[94],[21],[5445,5446,5415,5447,5448],{"nctId":15878,"briefTitle":15879,"status":123,"phases":15880,"primaryCompletion":3473,"completion":3473,"start":3447,"enrollment":15881,"conditions":15882,"interventions":15883},"NCT00700271","Efficacy of a Combination of Amlodipine\u002FValsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day",[94],478,[21],[15884,5447],"Amlodipine",{"nctId":15886,"briefTitle":15887,"status":123,"phases":15888,"primaryCompletion":917,"completion":917,"start":3195,"enrollment":7023,"conditions":15889,"interventions":15891},"NCT00523549","The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction",[94],[21,15890],"Diastolic Dysfunction",[15821,15776],{"trials":15893,"activeCount":103},[],{"intervention":4432,"totalTrials":4118,"cells":15895},{"EARLY_PHASE1":15896,"PHASE1":15898,"PHASE2":15900,"PHASE3":15983,"PHASE4":16020,"NA":16050},{"trials":15897,"activeCount":103},[],{"trials":15899,"activeCount":103},[],{"trials":15901,"activeCount":103},[15902,15908,15916,15924,15934,15938,15945,15951,15958,15964,15972,15979],{"nctId":15903,"briefTitle":15904,"status":123,"phases":15905,"primaryCompletion":4093,"completion":4093,"start":3473,"enrollment":192,"conditions":15906,"interventions":15907},"NCT01172548","Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)",[92],[208],[4432],{"nctId":15909,"briefTitle":15910,"status":123,"phases":15911,"primaryCompletion":1682,"completion":1682,"start":905,"enrollment":7438,"conditions":15912,"interventions":15914},"NCT00237185","A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene",[92],[15913],"Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)",[15915],"Imatinib mesylate",{"nctId":15917,"briefTitle":15918,"status":123,"phases":15919,"primaryCompletion":15920,"start":950,"enrollment":774,"conditions":15921,"interventions":15922},"NCT00237172","Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)",[92],"2005-07",[208],[15923],"Imatinib Mesylate",{"nctId":15925,"briefTitle":15926,"status":123,"phases":15927,"primaryCompletion":15283,"completion":15928,"start":15929,"enrollment":15930,"conditions":15931,"interventions":15933},"NCT00171158","An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis",[92],"2013-04-22","1999-07-26",260,[15932],"Philadelphia Chromosome Positive CML",[4432],{"nctId":4427,"briefTitle":4428,"status":123,"phases":15935,"primaryCompletion":3210,"completion":3210,"start":4047,"conditions":15936,"interventions":15937},[91,92],[3422],[4305,4432],{"nctId":15939,"briefTitle":15940,"status":123,"phases":15941,"primaryCompletion":2623,"completion":2623,"start":15942,"enrollment":9106,"conditions":15943,"interventions":15944},"NCT00867113","Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)",[92],"2009-07-22",[3403],[4432],{"nctId":15946,"briefTitle":15947,"status":134,"phases":15948,"primaryCompletion":4317,"start":950,"enrollment":630,"conditions":15949,"interventions":15950},"NCT00171860","A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome",[92],[3247],[4432],{"nctId":15952,"briefTitle":15953,"status":123,"phases":15954,"primaryCompletion":988,"completion":988,"start":4540,"enrollment":422,"conditions":15955,"interventions":15957},"NCT00154349","Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia",[92],[15956],"Philadelphia Chromosome Positive Acute Lymphocytic Leukemia",[15923],{"nctId":15959,"briefTitle":15960,"status":123,"phases":15961,"primaryCompletion":1732,"completion":1732,"start":5062,"enrollment":2439,"conditions":15962,"interventions":15963},"NCT01483014","Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)",[92],[208],[4432],{"nctId":15965,"briefTitle":15966,"status":123,"phases":15967,"primaryCompletion":3254,"completion":3254,"start":15968,"enrollment":2910,"conditions":15969,"interventions":15971},"NCT00154388","Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases",[92],"2001-02",[15970],"Life Threatening Diseases",[15915],{"nctId":15973,"briefTitle":15974,"status":123,"phases":15975,"primaryCompletion":1732,"completion":1732,"start":4810,"enrollment":5948,"conditions":15976,"interventions":15978},"NCT00171912","Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes",[92],[3247,3248,5724,15977],"Dermatofibrosarcoma",[4432],{"nctId":10523,"briefTitle":10524,"status":123,"phases":15980,"primaryCompletion":4410,"completion":8048,"start":988,"enrollment":10526,"conditions":15981,"interventions":15982},[92],[1654],[4432,10529,10530,10531,5639],{"trials":15984,"activeCount":103},[15985,15993,16000,16006,16013],{"nctId":15986,"briefTitle":15987,"status":134,"phases":15988,"primaryCompletion":926,"completion":926,"start":5063,"enrollment":15989,"conditions":15990,"interventions":15992},"NCT00124748","Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)",[93],476,[15991],"Leukemia, Myeloid, Chronic Phase",[15915],{"nctId":15994,"briefTitle":15995,"status":123,"phases":15996,"primaryCompletion":3473,"start":4071,"enrollment":467,"conditions":15997,"interventions":15998},"NCT00154375","Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma",[93],[4508,1147],[15915,15999],"Hydroxyurea",{"nctId":16001,"briefTitle":16002,"status":123,"phases":16003,"primaryCompletion":3784,"completion":3784,"start":4975,"enrollment":757,"conditions":16004,"interventions":16005},"NCT00902174","Imatinib (QTI571) in Pulmonary Arterial Hypertension",[93],[3305],[4432],{"nctId":16007,"briefTitle":16008,"status":123,"phases":16009,"primaryCompletion":3559,"completion":3559,"start":16010,"enrollment":3322,"conditions":16011,"interventions":16012},"NCT00477269","Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension",[92,93],"2006-04",[3305],[15915],{"nctId":16014,"briefTitle":16015,"status":134,"phases":16016,"primaryCompletion":4707,"start":8091,"enrollment":4148,"conditions":16017,"interventions":16019},"NCT00427583","Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors",[92,93],[16018],"Malignant Peripheral Nerve Sheath Tumors",[4432],{"trials":16021,"activeCount":103},[16022,16031,16038,16044],{"nctId":16023,"briefTitle":16024,"status":123,"phases":16025,"primaryCompletion":16026,"completion":16026,"start":16027,"enrollment":7500,"conditions":16028,"interventions":16030},"NCT01742299","Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator",[94],"2026-04-20","2013-03-26",[16029],"GIST and CML",[4432],{"nctId":16032,"briefTitle":16033,"status":123,"phases":16034,"primaryCompletion":3712,"completion":3712,"start":825,"enrollment":2046,"conditions":16035,"interventions":16037},"NCT00510354","Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate",[94],[16036],"Progressive Gastrointestinal Stromal Tumor",[15915],{"nctId":16039,"briefTitle":16040,"status":123,"phases":16041,"primaryCompletion":15800,"completion":15800,"start":854,"enrollment":4733,"conditions":16042,"interventions":16043},"NCT00171899","Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)",[94],[3228],[4432],{"nctId":16045,"briefTitle":16046,"status":123,"phases":16047,"primaryCompletion":4707,"start":4061,"enrollment":2776,"conditions":16048,"interventions":16049},"NCT00171977","Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)",[94],[208],[15923],{"trials":16051,"activeCount":103},[],{"intervention":15541,"totalTrials":1611,"cells":16053},{"EARLY_PHASE1":16054,"PHASE1":16056,"PHASE2":16064,"PHASE3":16072,"PHASE4":16172,"NA":16190},{"trials":16055,"activeCount":103},[],{"trials":16057,"activeCount":103},[16058],{"nctId":16059,"briefTitle":16060,"status":123,"phases":16061,"primaryCompletion":926,"completion":926,"start":3351,"enrollment":114,"conditions":16062,"interventions":16063},"NCT01613690","Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment",[91],[2635],[15541],{"trials":16065,"activeCount":103},[16066],{"nctId":16067,"briefTitle":16068,"status":123,"phases":16069,"primaryCompletion":4556,"start":4317,"enrollment":3043,"conditions":16070,"interventions":16071},"NCT00501852","Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium",[92],[24],[15541,15588],{"trials":16073,"activeCount":103},[16074,16078,16085,16091,16098,16105,16109,16116,16120,16127,16135,16141,16147,16151,16158,16166],{"nctId":15535,"briefTitle":15536,"status":123,"phases":16075,"primaryCompletion":3604,"completion":3604,"start":5733,"enrollment":15538,"conditions":16076,"interventions":16077},[93],[24],[15524,15541,15542],{"nctId":16079,"briefTitle":16080,"status":123,"phases":16081,"primaryCompletion":813,"completion":813,"start":3712,"enrollment":16082,"conditions":16083,"interventions":16084},"NCT01709864","NVA237 Versus Placebo 12-week Efficacy Study",[93],440,[24],[15541],{"nctId":16086,"briefTitle":16087,"status":123,"phases":16088,"primaryCompletion":1682,"completion":1682,"start":2795,"enrollment":2130,"conditions":16089,"interventions":16090},"NCT01566604","Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease",[93],[15555],[15541],{"nctId":16092,"briefTitle":16093,"status":123,"phases":16094,"primaryCompletion":2467,"completion":2467,"start":16095,"enrollment":7438,"conditions":16096,"interventions":16097},"NCT03137784","Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma",[92,93],"2017-05-04",[18],[15541],{"nctId":16099,"briefTitle":16100,"status":390,"phases":16101,"primaryCompletion":3730,"completion":3730,"start":2509,"enrollment":103,"conditions":16102,"interventions":16103},"NCT02127697","Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma",[93],[18],[15541,16104],"salbutamol\u002F albuterol",{"nctId":15558,"briefTitle":15559,"status":123,"phases":16106,"primaryCompletion":3759,"completion":3759,"start":4081,"enrollment":15561,"conditions":16107,"interventions":16108},[93],[24],[15524,15541,15564,15565],{"nctId":16110,"briefTitle":16111,"status":123,"phases":16112,"primaryCompletion":3382,"completion":3382,"start":1761,"enrollment":13129,"conditions":16113,"interventions":16114},"NCT01697696","Long Term Safety Study of NVA237 vs QAB149 in COPD Patients",[93],[15555],[15541,16115],"Long-acting beta 2-agonist",{"nctId":15590,"briefTitle":15591,"status":123,"phases":16117,"primaryCompletion":1723,"completion":1723,"start":3712,"enrollment":15593,"conditions":16118,"interventions":16119},[93],[15555],[15524,15542,15541],{"nctId":16121,"briefTitle":16122,"status":123,"phases":16123,"primaryCompletion":3800,"start":853,"enrollment":16124,"conditions":16125,"interventions":16126},"NCT01119937","Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients",[93],211,[24],[15541,15588],{"nctId":16128,"briefTitle":16129,"status":123,"phases":16130,"primaryCompletion":1670,"completion":1670,"start":4524,"enrollment":16131,"conditions":16132,"interventions":16133},"NCT01613326","Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[93],657,[24],[15541,15588,16134],"salbutamol\u002Falbuterol",{"nctId":16136,"briefTitle":16137,"status":123,"phases":16138,"primaryCompletion":3760,"completion":3760,"start":3351,"enrollment":12584,"conditions":16139,"interventions":16140},"NCT01154127","Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[93],[24],[15541],{"nctId":16142,"briefTitle":16143,"status":390,"phases":16144,"primaryCompletion":1781,"completion":1781,"start":15283,"enrollment":103,"conditions":16145,"interventions":16146},"NCT01757015","Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA\u002FICS",[93],[24],[15541],{"nctId":15612,"briefTitle":15613,"status":123,"phases":16148,"primaryCompletion":1723,"completion":1723,"start":3604,"enrollment":15615,"conditions":16149,"interventions":16150},[93],[15555],[15524,15542,15541],{"nctId":16152,"briefTitle":16153,"status":123,"phases":16154,"primaryCompletion":3731,"completion":3731,"start":3712,"enrollment":4360,"conditions":16155,"interventions":16157},"NCT01699685","Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.",[93],[16156],"Chronic Obstructive Pulmonary Disease: COPD",[15542,15541],{"nctId":16159,"briefTitle":16160,"status":390,"phases":16161,"primaryCompletion":1780,"completion":1780,"start":1781,"enrollment":103,"conditions":16162,"interventions":16164},"NCT01837927","Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.",[93],[16163],"Pulmonary Disease, Chronic Obstructive",[15541,16165],"Tiotropium Respimat®",{"nctId":16167,"briefTitle":16168,"status":123,"phases":16169,"primaryCompletion":1714,"completion":1714,"start":3712,"enrollment":677,"conditions":16170,"interventions":16171},"NCT01715298","NVA237 BID Versus Placebo Twelve-week Efficacy Study",[93],[24],[15541],{"trials":16173,"activeCount":103},[16174,16181],{"nctId":16175,"briefTitle":16176,"status":123,"phases":16177,"primaryCompletion":3559,"completion":3559,"start":15346,"enrollment":5892,"conditions":16178,"interventions":16179},"NCT01922271","Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[94],[24],[15541,15588,16180],"Salbutamol",{"nctId":16182,"briefTitle":16183,"status":123,"phases":16184,"primaryCompletion":16185,"completion":16185,"start":16186,"enrollment":16187,"conditions":16188,"interventions":16189},"NCT02371629","A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD",[94],"2016-11-16","2015-06-24",776,[24],[15541,16180],{"trials":16191,"activeCount":103},[],{"intervention":15588,"totalTrials":1611,"cells":16193},{"EARLY_PHASE1":16194,"PHASE1":16196,"PHASE2":16198,"PHASE3":16211,"PHASE4":16273,"NA":16315},{"trials":16195,"activeCount":103},[],{"trials":16197,"activeCount":103},[],{"trials":16199,"activeCount":103},[16200,16204],{"nctId":16067,"briefTitle":16068,"status":123,"phases":16201,"primaryCompletion":4556,"start":4317,"enrollment":3043,"conditions":16202,"interventions":16203},[92],[24],[15541,15588],{"nctId":16205,"briefTitle":16206,"status":123,"phases":16207,"primaryCompletion":3845,"completion":3845,"start":3551,"enrollment":2149,"conditions":16208,"interventions":16209},"NCT01068613","Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients",[92],[24],[16210,16210,15588],"QAX028",{"trials":16212,"activeCount":103},[16213,16220,16224,16228,16232,16236,16243,16247,16257,16261,16269],{"nctId":16214,"briefTitle":16215,"status":123,"phases":16216,"primaryCompletion":3800,"completion":3800,"start":3760,"enrollment":2685,"conditions":16217,"interventions":16218},"NCT01294787","Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[93],[8267],[16219,15564],"indacaterol and glycopyrronium bromide",{"nctId":15558,"briefTitle":15559,"status":123,"phases":16221,"primaryCompletion":3759,"completion":3759,"start":4081,"enrollment":15561,"conditions":16222,"interventions":16223},[93],[24],[15524,15541,15564,15565],{"nctId":15582,"briefTitle":15583,"status":123,"phases":16225,"primaryCompletion":3482,"completion":3482,"start":1715,"enrollment":15585,"conditions":16226,"interventions":16227},[93],[24],[15524,15588,15565],{"nctId":16121,"briefTitle":16122,"status":123,"phases":16229,"primaryCompletion":3800,"start":853,"enrollment":16124,"conditions":16230,"interventions":16231},[93],[24],[15541,15588],{"nctId":16128,"briefTitle":16129,"status":123,"phases":16233,"primaryCompletion":1670,"completion":1670,"start":4524,"enrollment":16131,"conditions":16234,"interventions":16235},[93],[24],[15541,15588,16134],{"nctId":16237,"briefTitle":16238,"status":123,"phases":16239,"primaryCompletion":4598,"start":4335,"enrollment":16240,"conditions":16241,"interventions":16242},"NCT01012765","Effect of Indacaterol on Inspiratory Capacity (IC)",[93],173,[24],[7850,15588],{"nctId":15625,"briefTitle":15626,"status":123,"phases":16244,"primaryCompletion":15283,"completion":15283,"start":5733,"enrollment":15628,"conditions":16245,"interventions":16246},[93],[15555],[15524,15588,7842],{"nctId":16248,"briefTitle":16249,"status":123,"phases":16250,"primaryCompletion":1671,"completion":2795,"start":7931,"enrollment":16251,"conditions":16252,"interventions":16253},"NCT01202188","A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[93],2144,[15555],[16254,16255,16256,15564],"indacaterol and glycopyrronium","glycopyrronium","indacaterol",{"nctId":15632,"briefTitle":15633,"status":123,"phases":16258,"primaryCompletion":2458,"completion":2458,"start":1761,"enrollment":15635,"conditions":16259,"interventions":16260},[93],[15555],[15524,15588],{"nctId":16262,"briefTitle":16263,"status":123,"phases":16264,"primaryCompletion":3759,"completion":3759,"start":3400,"enrollment":16265,"conditions":16266,"interventions":16267},"NCT00845728","Exacerbation Study",[93],3439,[24],[16268,15588],"Indacaterol 150 µg",{"nctId":15648,"briefTitle":15649,"status":123,"phases":16270,"primaryCompletion":3243,"completion":3243,"start":4598,"enrollment":4532,"conditions":16271,"interventions":16272},[93],[15555],[15524,15588],{"trials":16274,"activeCount":103},[16275,16279,16283,16292,16298,16304,16311],{"nctId":16175,"briefTitle":16176,"status":123,"phases":16276,"primaryCompletion":3559,"completion":3559,"start":15346,"enrollment":5892,"conditions":16277,"interventions":16278},[94],[24],[15541,15588,16180],{"nctId":15672,"briefTitle":15673,"status":123,"phases":16280,"primaryCompletion":15675,"completion":15675,"start":15676,"enrollment":3846,"conditions":16281,"interventions":16282},[94],[15555],[15524,15588,15679],{"nctId":16284,"briefTitle":16285,"status":123,"phases":16286,"primaryCompletion":16287,"completion":16287,"start":16288,"enrollment":2992,"conditions":16289,"interventions":16290},"NCT02566031","A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate\u002FGlycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients",[94],"2018-06-04","2013-03-23",[8267],[16291,15588],"Indacaterol and glycopyrronium",{"nctId":16293,"briefTitle":16294,"status":123,"phases":16295,"primaryCompletion":2794,"completion":2794,"start":15283,"enrollment":3087,"conditions":16296,"interventions":16297},"NCT01727024","Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients",[94],[15555],[15588,7850],{"nctId":16299,"briefTitle":16300,"status":390,"phases":16301,"primaryCompletion":3799,"completion":3799,"start":3712,"enrollment":103,"conditions":16302,"interventions":16303},"NCT01715311","Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control",[94],[15555],[7850,15588],{"nctId":16305,"briefTitle":16306,"status":123,"phases":16307,"primaryCompletion":1817,"completion":1817,"start":1723,"enrollment":3288,"conditions":16308,"interventions":16309},"NCT01959516","Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD",[94],[8267],[16310,15588],"Glycopyrronium",{"nctId":15697,"briefTitle":15698,"status":123,"phases":16312,"primaryCompletion":10055,"completion":10055,"start":1781,"enrollment":534,"conditions":16313,"interventions":16314},[94],[24,8267],[15524,15588],{"trials":16316,"activeCount":103},[],{"intervention":7850,"totalTrials":1065,"cells":16318},{"EARLY_PHASE1":16319,"PHASE1":16321,"PHASE2":16323,"PHASE3":16362,"PHASE4":16400,"NA":16447},{"trials":16320,"activeCount":103},[],{"trials":16322,"activeCount":103},[],{"trials":16324,"activeCount":103},[16325,16334,16341,16347,16355],{"nctId":16326,"briefTitle":16327,"status":123,"phases":16328,"primaryCompletion":4070,"completion":4070,"start":3447,"enrollment":16329,"conditions":16330,"interventions":16331},"NCT00545272","A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma",[92],392,[18],[16256,16332,16333],"formoterol","short acting β2-agonist",{"nctId":16335,"briefTitle":16336,"status":123,"phases":16337,"primaryCompletion":864,"start":964,"enrollment":3411,"conditions":16338,"interventions":16340},"NCT01156844","Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol",[92],[16339],"Persistent Asthma",[7850],{"nctId":16342,"briefTitle":16343,"status":123,"phases":16344,"primaryCompletion":4642,"completion":4642,"start":3195,"enrollment":4506,"conditions":16345,"interventions":16346},"NCT00403754","Dose Ranging Study for Indacaterol in Japanese Asthma Patients",[92],[18],[7850,7851],{"nctId":16348,"briefTitle":16349,"status":123,"phases":16350,"primaryCompletion":2033,"completion":2033,"start":3482,"enrollment":16351,"conditions":16352,"interventions":16353},"NCT01609478","Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma",[92],335,[18],[16256,16354],"mometasone furoate",{"nctId":16356,"briefTitle":16357,"status":123,"phases":16358,"primaryCompletion":3279,"completion":3279,"start":4556,"enrollment":13292,"conditions":16359,"interventions":16360},"NCT00570778","Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],[15555],[16361,16256],"indacaterol\u002Fglycopyrrolate",{"trials":16363,"activeCount":103},[16364,16371,16377,16384,16388,16392],{"nctId":16365,"briefTitle":16366,"status":123,"phases":16367,"primaryCompletion":864,"completion":864,"start":964,"enrollment":1290,"conditions":16368,"interventions":16369},"NCT01089127","Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)",[93],[24],[7850,16370],"Salmeterol 50 μg",{"nctId":16372,"briefTitle":16373,"status":123,"phases":16374,"primaryCompletion":864,"start":880,"enrollment":13129,"conditions":16375,"interventions":16376},"NCT01079130","Efficacy and Safety of Different Doses of Indacaterol",[93],[18],[7850,7851],{"nctId":16378,"briefTitle":16379,"status":123,"phases":16380,"primaryCompletion":5733,"completion":5733,"start":895,"enrollment":5882,"conditions":16381,"interventions":16382},"NCT01232894","12-week Open-label Evaluation of Efficacy and Safety of Indacaterol",[93],[15555],[7850,16383],"Long-acting beta2-agonist",{"nctId":16237,"briefTitle":16238,"status":123,"phases":16385,"primaryCompletion":4598,"start":4335,"enrollment":16240,"conditions":16386,"interventions":16387},[93],[24],[7850,15588],{"nctId":16248,"briefTitle":16249,"status":123,"phases":16389,"primaryCompletion":1671,"completion":2795,"start":7931,"enrollment":16251,"conditions":16390,"interventions":16391},[93],[15555],[16254,16255,16256,15564],{"nctId":16393,"briefTitle":16394,"status":123,"phases":16395,"primaryCompletion":812,"completion":812,"start":2793,"enrollment":2948,"conditions":16396,"interventions":16398},"NCT01778062","Indacaterol EfectIveness In COPD Patients With Tuberculosis History",[93],[16397],"Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis",[7850,16399],"Control",{"trials":16401,"activeCount":103},[16402,16409,16415,16422,16426,16433,16437,16443],{"nctId":16403,"briefTitle":16404,"status":123,"phases":16405,"primaryCompletion":11147,"completion":11147,"start":16406,"enrollment":630,"conditions":16407,"interventions":16408},"NCT02418468","Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations",[94],"2015-04-28",[24],[7850],{"nctId":16410,"briefTitle":16411,"status":390,"phases":16412,"primaryCompletion":1671,"completion":1671,"start":1818,"enrollment":103,"conditions":16413,"interventions":16414},"NCT01377428","Efficacy of Indacaterol 150 µg Versus Formoterol",[94],[15555],[7850,7842],{"nctId":16416,"briefTitle":16417,"status":123,"phases":16418,"primaryCompletion":1723,"completion":1723,"start":1671,"enrollment":16419,"conditions":16420,"interventions":16421},"NCT01555138","Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol\u002FFluticasone Propionate 50 mcg\u002F500 mcg Twice Daily (b.i.d.)",[94],581,[24],[7850,7851],{"nctId":16293,"briefTitle":16294,"status":123,"phases":16423,"primaryCompletion":2794,"completion":2794,"start":15283,"enrollment":3087,"conditions":16424,"interventions":16425},[94],[15555],[15588,7850],{"nctId":16427,"briefTitle":16428,"status":123,"phases":16429,"primaryCompletion":5733,"completion":5733,"start":4081,"enrollment":16430,"conditions":16431,"interventions":16432},"NCT01272362","To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol",[94],625,[15555],[7850],{"nctId":16299,"briefTitle":16300,"status":390,"phases":16434,"primaryCompletion":3799,"completion":3799,"start":3712,"enrollment":103,"conditions":16435,"interventions":16436},[94],[15555],[7850,15588],{"nctId":16438,"briefTitle":16439,"status":123,"phases":16440,"primaryCompletion":2795,"completion":2795,"start":1732,"enrollment":709,"conditions":16441,"interventions":16442},"NCT01543828","Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",[94],[8267],[16256],{"nctId":7844,"briefTitle":7845,"status":123,"phases":16444,"primaryCompletion":5246,"completion":5246,"start":4925,"enrollment":258,"conditions":16445,"interventions":16446},[94],[24],[7811,7849,7850,7851],{"trials":16448,"activeCount":103},[],{"intervention":7711,"totalTrials":3343,"cells":16450},{"EARLY_PHASE1":16451,"PHASE1":16453,"PHASE2":16495,"PHASE3":16542,"PHASE4":16573,"NA":16596},{"trials":16452,"activeCount":103},[],{"trials":16454,"activeCount":103},[16455,16459,16466,16472,16481,16488],{"nctId":13279,"briefTitle":13280,"status":134,"phases":16456,"primaryCompletion":13282,"completion":13282,"start":2220,"enrollment":709,"conditions":16457,"interventions":16458},[91],[13284],[13286,7711,4389,10575],{"nctId":16460,"briefTitle":16461,"status":123,"phases":16462,"primaryCompletion":895,"start":5063,"enrollment":3475,"conditions":16463,"interventions":16464},"NCT00456833","Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy",[91],[1316],[7711,16465],"erlotinib",{"nctId":16467,"briefTitle":16468,"status":123,"phases":16469,"primaryCompletion":4335,"completion":4335,"start":988,"enrollment":557,"conditions":16470,"interventions":16471},"NCT00457119","Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients",[91],[1316],[7711],{"nctId":16473,"briefTitle":16474,"status":123,"phases":16475,"primaryCompletion":16476,"completion":16476,"start":16477,"enrollment":3343,"conditions":16478,"interventions":16479},"NCT01590199","Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs",[91],"2018-09-11","2012-05-18",[4903],[7711,16480],"SOM230",{"nctId":16482,"briefTitle":16483,"status":134,"phases":16484,"primaryCompletion":2034,"completion":2034,"start":3552,"enrollment":3975,"conditions":16485,"interventions":16486},"NCT00828594","Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma",[91],[4412],[7711,16487],"RAD001, sorafenib",{"nctId":16489,"briefTitle":16490,"status":123,"phases":16491,"primaryCompletion":3731,"completion":3731,"start":4372,"enrollment":1672,"conditions":16492,"interventions":16494},"NCT01324492","Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor",[91],[16493],"Lung Neuroendocrine Neoplasm",[7711],{"trials":16496,"activeCount":103},[16497,16511,16517,16524,16532],{"nctId":16498,"briefTitle":16499,"status":123,"phases":16500,"primaryCompletion":16501,"completion":3456,"start":16502,"enrollment":16503,"conditions":16504,"interventions":16509},"NCT00719264","Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer",[92],"2011-12-31","2008-11-12",365,[4571,16505,16506,16507,16508],"Adenocarcinoma","Renal Cell","Nephroid Carcinoma","Hypernephroid",[7711,16510,13304],"interferon alfa-2a",{"nctId":16512,"briefTitle":16513,"status":123,"phases":16514,"primaryCompletion":1760,"completion":1760,"start":3800,"enrollment":292,"conditions":16515,"interventions":16516},"NCT01491672","Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma",[92],[4352],[7711],{"nctId":16518,"briefTitle":16519,"status":123,"phases":16520,"primaryCompletion":3447,"start":15920,"enrollment":2685,"conditions":16521,"interventions":16523},"NCT00124280","Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)",[92],[16522],"Non-small-cell Lung Carcinoma",[7711],{"nctId":16525,"briefTitle":16526,"status":123,"phases":16527,"primaryCompletion":1817,"completion":1817,"start":4845,"enrollment":4516,"conditions":16528,"interventions":16531},"NCT00688753","RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe",[92],[4571,16506,16529,16530,16505],"Non Clear Cell Renal Carcinoma","Papillary Cell Renal Carcinoma",[7711],{"nctId":16533,"briefTitle":16534,"status":123,"phases":16535,"primaryCompletion":16536,"completion":16536,"start":16537,"enrollment":3939,"conditions":16538,"interventions":16539},"NCT01275222","Everolimus in Combination With Imatinib in Patients With Glivec Refractory\u002FResistant Gastrointestinal Stromal Tumors",[91,92],"2008-09-03","2002-11-13",[208],[7711,16540,16541],"Imatinib 600mg\u002Fday","Imatinib 800mg\u002Fday",{"trials":16543,"activeCount":103},[16544,16554,16566],{"nctId":16545,"briefTitle":16546,"status":123,"phases":16547,"primaryCompletion":2006,"completion":16548,"start":16549,"enrollment":1574,"conditions":16550,"interventions":16552},"NCT01544491","Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients",[93],"2018-09-24","2012-08-17",[16551],"Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant",[7711,16553],"MMF",{"nctId":16555,"briefTitle":16556,"status":123,"phases":16557,"primaryCompletion":16558,"completion":16558,"start":16559,"enrollment":16560,"conditions":16561,"interventions":16563},"NCT01713946","A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures",[93],"2017-10-25","2013-04-29",366,[16562],"Tuberous Sclerosis Complex-associated Refractory Seizures",[7711,16564,16565],"Antiepileptic drug","open label RAD001",{"nctId":16567,"briefTitle":16568,"status":123,"phases":16569,"primaryCompletion":16570,"completion":1715,"start":3195,"enrollment":15464,"conditions":16571,"interventions":16572},"NCT00410124","RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and\u002For Sunitinib",[93],"2008-02",[4352],[7711],{"trials":16574,"activeCount":103},[16575,16579,16588,16592],{"nctId":7705,"briefTitle":7706,"status":134,"phases":16576,"primaryCompletion":4967,"completion":4967,"start":4845,"enrollment":1444,"conditions":16577,"interventions":16578},[94],[4701],[4804,7710,7711,4766,4769],{"nctId":16580,"briefTitle":16581,"status":123,"phases":16582,"primaryCompletion":16583,"completion":16584,"start":16585,"enrollment":3032,"conditions":16586,"interventions":16587},"NCT01206764","A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.",[94],"2017-06-06","2017-07-01","2009-11-11",[4403],[7711],{"nctId":7800,"briefTitle":7801,"status":123,"phases":16589,"primaryCompletion":7803,"completion":7803,"start":7804,"enrollment":3605,"conditions":16590,"interventions":16591},[94],[7806],[7711,195],{"nctId":15515,"briefTitle":15516,"status":123,"phases":16593,"primaryCompletion":2509,"completion":2509,"start":3383,"enrollment":1622,"conditions":16594,"interventions":16595},[94],[15519,4903],[7711,4321,1168],{"trials":16597,"activeCount":103},[],{"intervention":13838,"totalTrials":3343,"cells":16599},{"EARLY_PHASE1":16600,"PHASE1":16602,"PHASE2":16608,"PHASE3":16618,"PHASE4":16652,"NA":16712},{"trials":16601,"activeCount":103},[],{"trials":16603,"activeCount":103},[16604],{"nctId":13829,"briefTitle":13830,"status":123,"phases":16605,"primaryCompletion":13832,"completion":13832,"start":13833,"enrollment":114,"conditions":16606,"interventions":16607},[91],[11177],[13721,13836,13837,13838,13839,13840,13841,13842,13839,13840],{"trials":16609,"activeCount":103},[16610],{"nctId":16611,"briefTitle":16612,"status":123,"phases":16613,"primaryCompletion":3351,"completion":3351,"start":4707,"enrollment":16614,"conditions":16615,"interventions":16616},"NCT00901979","A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)",[92],693,[15133],[16617,16617,16617,16617,16617,15255,15177],"LCQ908A",{"trials":16619,"activeCount":103},[16620,16624,16628,16632,16640,16644,16648],{"nctId":15062,"briefTitle":15063,"status":123,"phases":16621,"primaryCompletion":949,"completion":949,"start":15065,"enrollment":6234,"conditions":16622,"interventions":16623},[93],[30],[15029,15068,13838],{"nctId":15142,"briefTitle":15143,"status":123,"phases":16625,"primaryCompletion":2458,"completion":2458,"start":1682,"enrollment":25,"conditions":16626,"interventions":16627},[93],[15146],[15051,13838,15148,15149],{"nctId":15171,"briefTitle":15172,"status":123,"phases":16629,"primaryCompletion":5062,"start":825,"enrollment":15174,"conditions":16630,"interventions":16631},[93],[30],[15051,15177],{"nctId":16633,"briefTitle":16634,"status":123,"phases":16635,"primaryCompletion":880,"start":5062,"enrollment":16636,"conditions":16637,"interventions":16638},"NCT00728351","Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25\u002F1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)",[93],317,[30],[16639,15177],"vildagliptin + metformin",{"nctId":15185,"briefTitle":15186,"status":123,"phases":16641,"primaryCompletion":938,"completion":938,"start":4034,"enrollment":15188,"conditions":16642,"interventions":16643},[93],[30],[15051,13838,15191],{"nctId":15213,"briefTitle":15214,"status":123,"phases":16645,"primaryCompletion":5696,"completion":15216,"start":996,"enrollment":15217,"conditions":16646,"interventions":16647},[93],[30],[15029,15220,13838],{"nctId":15249,"briefTitle":15250,"status":123,"phases":16649,"primaryCompletion":895,"completion":895,"start":3612,"enrollment":15252,"conditions":16650,"interventions":16651},[92,93],[30],[15051,13838,15255],{"trials":16653,"activeCount":103},[16654,16658,16662,16666,16674,16684,16694,16704,16708],{"nctId":15259,"briefTitle":15260,"status":123,"phases":16655,"primaryCompletion":3799,"completion":3799,"start":1670,"enrollment":15262,"conditions":16656,"interventions":16657},[94],[15133],[15051,15068,13838],{"nctId":15295,"briefTitle":15296,"status":134,"phases":16659,"primaryCompletion":812,"completion":812,"start":2033,"enrollment":167,"conditions":16660,"interventions":16661},[94],[15133],[15051,15096,13838],{"nctId":15301,"briefTitle":15302,"status":123,"phases":16663,"primaryCompletion":15304,"completion":15304,"start":4898,"enrollment":15305,"conditions":16664,"interventions":16665},[94],[15133],[15029,13838],{"nctId":16667,"briefTitle":16668,"status":123,"phases":16669,"primaryCompletion":1761,"completion":1761,"start":1732,"enrollment":2149,"conditions":16670,"interventions":16671},"NCT01518101","Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications",[94],[15233],[16672,16673,13838],"Vildagliptin\u002F Metformin","Liraglutide",{"nctId":16675,"briefTitle":16676,"status":123,"phases":16677,"primaryCompletion":8329,"completion":16678,"start":6556,"enrollment":16679,"conditions":16680,"interventions":16682},"NCT02060383","Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly",[94],"2018-03-26",249,[16681,8385],"Cushing's Disease",[16683,15255,16673,15320,4424,13838],"Pasireotide s.c.",{"nctId":16685,"briefTitle":16686,"status":123,"phases":16687,"primaryCompletion":16688,"completion":16688,"start":16689,"enrollment":3939,"conditions":16690,"interventions":16692},"NCT01766778","Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin",[94],"2015-10-22","2013-05-13",[16691],"Type-2 Diabetes Mellitus",[16693,13838],"LAF237",{"nctId":16695,"briefTitle":16696,"status":123,"phases":16697,"primaryCompletion":16698,"completion":16698,"start":16699,"enrollment":709,"conditions":16700,"interventions":16702},"NCT02007278","Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride",[94],"2016-02-22","2014-01-03",[15233,16701],"Hypoglycemia",[16703,15220,13838],"vildagliptin and metformin",{"nctId":15322,"briefTitle":15323,"status":123,"phases":16705,"primaryCompletion":1714,"completion":1714,"start":1671,"enrollment":15325,"conditions":16706,"interventions":16707},[94],[15233],[13838,15029],{"nctId":15329,"briefTitle":15330,"status":123,"phases":16709,"primaryCompletion":2458,"completion":2458,"start":1714,"enrollment":5236,"conditions":16710,"interventions":16711},[94],[15146],[15051,15320,13838],{"trials":16713,"activeCount":103},[],{"intervention":16715,"totalTrials":837,"cells":16716},"Aliskiren",{"EARLY_PHASE1":16717,"PHASE1":16719,"PHASE2":16727,"PHASE3":16767,"PHASE4":16828,"NA":16852},{"trials":16718,"activeCount":103},[],{"trials":16720,"activeCount":103},[16721],{"nctId":16722,"briefTitle":16723,"status":123,"phases":16724,"primaryCompletion":3271,"start":1024,"enrollment":3288,"conditions":16725,"interventions":16726},"NCT00933920","Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension",[91],[21],[16715,16715],{"trials":16728,"activeCount":103},[16729,16736,16743,16751,16758],{"nctId":16730,"briefTitle":16731,"status":134,"phases":16732,"primaryCompletion":4301,"completion":4301,"start":4598,"enrollment":422,"conditions":16733,"interventions":16735},"NCT01302899","To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy",[92],[16734],"Non-diabetic Nephropathy",[16715,15777,15769],{"nctId":16737,"briefTitle":16738,"status":134,"phases":16739,"primaryCompletion":3760,"completion":3760,"start":3279,"enrollment":28,"conditions":16740,"interventions":16742},"NCT00768040","Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema",[92],[16741],"Diabetic Macular Edema",[16715],{"nctId":16744,"briefTitle":16745,"status":123,"phases":16746,"primaryCompletion":4343,"completion":4343,"start":4071,"enrollment":16747,"conditions":16748,"interventions":16749},"NCT00097955","Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria",[92],496,[3045],[16750],"aliskiren",{"nctId":16752,"briefTitle":16753,"status":123,"phases":16754,"primaryCompletion":3760,"completion":3760,"start":3410,"enrollment":9331,"conditions":16755,"interventions":16756},"NCT00923156","Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure",[92],[15870],[16750,16757],"ramipril",{"nctId":16759,"briefTitle":16760,"status":123,"phases":16761,"primaryCompletion":864,"completion":864,"start":3447,"enrollment":114,"conditions":16762,"interventions":16766},"NCT00417170","Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome",[92],[16763,2225,16764,16765],"High Blood Pressure","Insulin Resistance","Endothelial Dysfunction",[16715,15884],{"trials":16768,"activeCount":103},[16769,16776,16782,16791,16799,16806,16814,16820],{"nctId":16770,"briefTitle":16771,"status":123,"phases":16772,"primaryCompletion":16570,"completion":16570,"start":4034,"enrollment":16773,"conditions":16774,"interventions":16775},"NCT00368277","A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",[93],901,[21],[16715,15769,15777,15884],{"nctId":16777,"briefTitle":16778,"status":123,"phases":16779,"primaryCompletion":7939,"completion":7939,"start":3351,"enrollment":3498,"conditions":16780,"interventions":16781},"NCT01150357","Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age",[93],[21],[16715,16715,16715],{"nctId":16783,"briefTitle":16784,"status":123,"phases":16785,"primaryCompletion":1670,"completion":1670,"start":3400,"enrollment":16786,"conditions":16787,"interventions":16790},"NCT00853827","Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients",[93],613,[16788,16789],"Coronary Artery Disease (CAD)","Coronary Atherosclerosis",[16715],{"nctId":16792,"briefTitle":16793,"status":134,"phases":16794,"primaryCompletion":3712,"completion":3712,"start":4598,"enrollment":16795,"conditions":16796,"interventions":16798},"NCT01259297","A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People",[93],2336,[16797],"Cardiovascular Events",[16715,15884,15777],{"nctId":16800,"briefTitle":16801,"status":123,"phases":16802,"primaryCompletion":1681,"completion":1681,"start":3400,"enrollment":16803,"conditions":16804,"interventions":16805},"NCT00853658","Efficacy and Safety of Aliskiren and Aliskiren\u002FEnalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure",[93],7064,[15734],[15789,16715],{"nctId":16807,"briefTitle":16808,"status":134,"phases":16809,"primaryCompletion":2793,"completion":2793,"start":3447,"enrollment":16810,"conditions":16811,"interventions":16813},"NCT00549757","Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)",[93],8606,[15133,16812],"Cardiovascular Disease",[16715],{"nctId":16815,"briefTitle":16816,"status":123,"phases":16817,"primaryCompletion":8048,"completion":8048,"start":3845,"enrollment":6024,"conditions":16818,"interventions":16819},"NCT01151410","An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age",[93],[21],[16715,15789],{"nctId":16821,"briefTitle":16822,"status":123,"phases":16823,"primaryCompletion":3482,"completion":3482,"start":3410,"enrollment":16824,"conditions":16825,"interventions":16827},"NCT00894387","Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure",[93],1639,[16826,15340],"Acute Decompensated Heart Failure",[16715],{"trials":16829,"activeCount":103},[16830,16838,16845],{"nctId":16831,"briefTitle":16832,"status":123,"phases":16833,"primaryCompletion":15283,"completion":15283,"start":3351,"enrollment":223,"conditions":16834,"interventions":16836},"NCT01176032","ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling",[94],[21,16835],"Left Ventricle Hypertrophy",[16715,16837,15884,15777],"Losartan",{"nctId":16839,"briefTitle":16840,"status":123,"phases":16841,"primaryCompletion":3712,"completion":3712,"start":607,"enrollment":16842,"conditions":16843,"interventions":16844},"NCT01570686","8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension",[94],589,[21],[16715],{"nctId":16846,"briefTitle":16847,"status":390,"phases":16848,"primaryCompletion":16849,"completion":16849,"start":1760,"enrollment":103,"conditions":16850,"interventions":16851},"NCT01922141","Aliskiren Study of Safety and Efficacy in Senior Hypertensives",[94],"2018-06",[21],[16715,15884,15769,15777],{"trials":16853,"activeCount":103},[],{"intervention":16855,"totalTrials":1672,"cells":16856},"Enteric-Coated Mycophenolate Sodium",{"EARLY_PHASE1":16857,"PHASE1":16859,"PHASE2":16861,"PHASE3":16863,"PHASE4":16916,"NA":16976},{"trials":16858,"activeCount":103},[],{"trials":16860,"activeCount":103},[],{"trials":16862,"activeCount":103},[],{"trials":16864,"activeCount":103},[16865,16873,16881,16887,16895,16903,16909],{"nctId":16866,"briefTitle":16867,"status":123,"phases":16868,"primaryCompletion":1024,"completion":1024,"start":745,"enrollment":2810,"conditions":16869,"interventions":16871},"NCT00351377","Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate",[93],[16870],"Autoimmune Disease",[16872],"Enteric-coated Mycophenolate Sodium",{"nctId":16874,"briefTitle":16875,"status":134,"phases":16876,"primaryCompletion":3210,"start":9096,"enrollment":1423,"conditions":16877,"interventions":16879},"NCT00284921","MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive",[93],[16878],"De Novo Kidney Transplant",[16880],"Enteric-coated Mycophenolate sodium",{"nctId":16882,"briefTitle":16883,"status":123,"phases":16884,"primaryCompletion":3279,"completion":3279,"start":3254,"enrollment":31,"conditions":16885,"interventions":16886},"NCT00405652","Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients",[93],[4645],[16880],{"nctId":16888,"briefTitle":16889,"status":123,"phases":16890,"primaryCompletion":917,"completion":917,"start":918,"enrollment":827,"conditions":16891,"interventions":16893},"NCT00267150","Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants",[93],[16892,4691],"Pancreas Transplantation",[16894],"Enteric-coated mycophenolate sodium",{"nctId":16896,"briefTitle":16897,"status":123,"phases":16898,"primaryCompletion":15920,"start":16899,"enrollment":4082,"conditions":16900,"interventions":16902},"NCT00238992","Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.",[93],"2002-12",[16901],"Kidney de Novo Transplant",[16880],{"nctId":16904,"briefTitle":16905,"status":123,"phases":16906,"primaryCompletion":3552,"completion":3552,"start":745,"enrollment":3587,"conditions":16907,"interventions":16908},"NCT00369278","Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients",[93],[4701],[16894],{"nctId":16910,"briefTitle":16911,"status":123,"phases":16912,"primaryCompletion":15920,"start":16899,"enrollment":709,"conditions":16913,"interventions":16915},"NCT00239044","An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients",[93],[16914],"Kidney Transplant Recipients",[16880],{"trials":16917,"activeCount":103},[16918,16925,16932,16940,16946,16952,16958,16964,16970],{"nctId":16919,"briefTitle":16920,"status":123,"phases":16921,"primaryCompletion":5026,"start":16922,"enrollment":2579,"conditions":16923,"interventions":16924},"NCT00238979","A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)",[94],"2003-01",[4701],[16855],{"nctId":16926,"briefTitle":16927,"status":123,"phases":16928,"primaryCompletion":9096,"start":16929,"enrollment":3705,"conditions":16930,"interventions":16931},"NCT00574743","Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients",[94],"2002-01",[4744],[16872],{"nctId":16933,"briefTitle":16934,"status":123,"phases":16935,"primaryCompletion":5063,"start":16936,"enrollment":16351,"conditions":16937,"interventions":16939},"NCT00150007","Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)",[94],"2004-06",[16938],"Kidney Maintenance Transplant",[16880],{"nctId":16941,"briefTitle":16942,"status":123,"phases":16943,"primaryCompletion":15800,"start":3657,"enrollment":919,"conditions":16944,"interventions":16945},"NCT00529269","Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms",[94],[4985],[16855],{"nctId":16947,"briefTitle":16948,"status":123,"phases":16949,"primaryCompletion":988,"start":8091,"enrollment":919,"conditions":16950,"interventions":16951},"NCT00537862","Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients",[94],[5042],[16855],{"nctId":16953,"briefTitle":16954,"status":123,"phases":16955,"primaryCompletion":3254,"start":4810,"enrollment":2367,"conditions":16956,"interventions":16957},"NCT00154206","Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients",[94],[4691],[16855],{"nctId":16959,"briefTitle":16960,"status":123,"phases":16961,"primaryCompletion":5062,"start":825,"enrollment":1466,"conditions":16962,"interventions":16963},"NCT00400400","Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance",[94],[4701],[16894,4768],{"nctId":16965,"briefTitle":16966,"status":123,"phases":16967,"primaryCompletion":996,"start":16936,"enrollment":3098,"conditions":16968,"interventions":16969},"NCT00154232","Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)",[94],[4701],[16855],{"nctId":16971,"briefTitle":16972,"status":123,"phases":16973,"primaryCompletion":1025,"start":8370,"enrollment":292,"conditions":16974,"interventions":16975},"NCT00239005","Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation",[94],[4985],[16855,7647],{"trials":16977,"activeCount":103},[],{"intervention":15884,"totalTrials":1672,"cells":16979},{"EARLY_PHASE1":16980,"PHASE1":16982,"PHASE2":16984,"PHASE3":17028,"PHASE4":17056,"NA":17084},{"trials":16981,"activeCount":103},[],{"trials":16983,"activeCount":103},[],{"trials":16985,"activeCount":103},[16986,16993,17002,17009,17017,17024],{"nctId":16987,"briefTitle":16988,"status":123,"phases":16989,"primaryCompletion":4410,"completion":4410,"start":813,"enrollment":4992,"conditions":16990,"interventions":16991},"NCT01870739","A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension",[92],[21],[15788,16992,15884],"olmesartan",{"nctId":16994,"briefTitle":16995,"status":123,"phases":16996,"primaryCompletion":606,"completion":606,"start":3604,"enrollment":16997,"conditions":16998,"interventions":16999},"NCT01692301","Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension",[92],454,[21],[15726,17000,15776,17001],"Olmesartan","hydrochlorothiazide",{"nctId":17003,"briefTitle":17004,"status":123,"phases":17005,"primaryCompletion":607,"completion":607,"start":926,"enrollment":1922,"conditions":17006,"interventions":17008},"NCT01256411","A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension",[92],[17007],"Essential Hypertension",[15726,15884,15777],{"nctId":17010,"briefTitle":17011,"status":134,"phases":17012,"primaryCompletion":926,"completion":926,"start":880,"enrollment":827,"conditions":17013,"interventions":17015},"NCT01080768","Assessment of Aliskiren\u002FAmlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension",[92],[21,17014],"Ankle Edema",[17016,15884],"Aliskiren\u002Famlodipine",{"nctId":17018,"briefTitle":17019,"status":123,"phases":17020,"primaryCompletion":2033,"completion":2033,"start":1761,"enrollment":6014,"conditions":17021,"interventions":17023},"NCT01631864","Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects",[92],[21,17022],"Concurrent Obesity",[15726,15776],{"nctId":16759,"briefTitle":16760,"status":123,"phases":17025,"primaryCompletion":864,"completion":864,"start":3447,"enrollment":114,"conditions":17026,"interventions":17027},[92],[16763,2225,16764,16765],[16715,15884],{"trials":17029,"activeCount":103},[17030,17034,17038,17042,17049],{"nctId":15771,"briefTitle":15772,"status":123,"phases":17031,"primaryCompletion":3861,"completion":3861,"start":1724,"enrollment":9531,"conditions":17032,"interventions":17033},[93],[21,14561],[5447,15776,15777],{"nctId":16770,"briefTitle":16771,"status":123,"phases":17035,"primaryCompletion":16570,"completion":16570,"start":4034,"enrollment":16773,"conditions":17036,"interventions":17037},[93],[21],[16715,15769,15777,15884],{"nctId":16792,"briefTitle":16793,"status":134,"phases":17039,"primaryCompletion":3712,"completion":3712,"start":4598,"enrollment":16795,"conditions":17040,"interventions":17041},[93],[16797],[16715,15884,15777],{"nctId":17043,"briefTitle":17044,"status":123,"phases":17045,"primaryCompletion":5114,"completion":5114,"start":3482,"enrollment":17046,"conditions":17047,"interventions":17048},"NCT01663233","Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine",[93],266,[17007],[15726,15884],{"nctId":17050,"briefTitle":17051,"status":390,"phases":17052,"primaryCompletion":606,"completion":606,"start":1781,"enrollment":103,"conditions":17053,"interventions":17054},"NCT01865188","Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension",[93],[21],[15726,15884,17055],"LCZ696 and amlodipine combination",{"trials":17057,"activeCount":103},[17058,17068,17072,17076,17080],{"nctId":17059,"briefTitle":17060,"status":134,"phases":17061,"primaryCompletion":1671,"completion":1671,"start":3784,"enrollment":17062,"conditions":17063,"interventions":17065},"NCT01368536","Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes",[94],975,[21,17064,15049],"Stage 2 Hypertension",[17066,15884,17067],"Valturna","Chlorthalidone",{"nctId":16831,"briefTitle":16832,"status":123,"phases":17069,"primaryCompletion":15283,"completion":15283,"start":3351,"enrollment":223,"conditions":17070,"interventions":17071},[94],[21,16835],[16715,16837,15884,15777],{"nctId":16846,"briefTitle":16847,"status":390,"phases":17073,"primaryCompletion":16849,"completion":16849,"start":1760,"enrollment":103,"conditions":17074,"interventions":17075},[94],[21],[16715,15884,15769,15777],{"nctId":15878,"briefTitle":15879,"status":123,"phases":17077,"primaryCompletion":3473,"completion":3473,"start":3447,"enrollment":15881,"conditions":17078,"interventions":17079},[94],[21],[15884,5447],{"nctId":15886,"briefTitle":15887,"status":123,"phases":17081,"primaryCompletion":917,"completion":917,"start":3195,"enrollment":7023,"conditions":17082,"interventions":17083},[94],[21,15890],[15821,15776],{"trials":17085,"activeCount":103},[],{"intervention":1168,"totalTrials":2367,"cells":17087},{"EARLY_PHASE1":17088,"PHASE1":17090,"PHASE2":17114,"PHASE3":17138,"PHASE4":17169,"NA":17175},{"trials":17089,"activeCount":103},[],{"trials":17091,"activeCount":103},[17092,17096,17100,17104],{"nctId":7861,"briefTitle":7862,"status":123,"phases":17093,"primaryCompletion":7864,"completion":7865,"start":7866,"enrollment":827,"conditions":17094,"interventions":17095},[91],[7868],[7870,7871,4780,7872],{"nctId":13316,"briefTitle":13317,"status":134,"phases":17097,"primaryCompletion":6013,"completion":6013,"start":13319,"enrollment":2810,"conditions":17098,"interventions":17099},[91],[128],[4389,5262,9948,4375,1168,4321,3157],{"nctId":15397,"briefTitle":15398,"status":134,"phases":17101,"primaryCompletion":15400,"completion":15400,"start":15401,"enrollment":2379,"conditions":17102,"interventions":17103},[91],[15403],[738,15405,1168,4321],{"nctId":17105,"briefTitle":17106,"status":123,"phases":17107,"primaryCompletion":17108,"completion":17108,"start":17109,"enrollment":906,"conditions":17110,"interventions":17112},"NCT01934361","Phase Ib\u002FII Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme",[91],"2016-07-07","2014-02-28",[17111],"Recurrent Glioblastoma Multiforme",[6263,7871,17113],"lomustine",{"trials":17115,"activeCount":103},[17116,17126,17130,17134],{"nctId":17117,"briefTitle":17118,"status":123,"phases":17119,"primaryCompletion":17120,"completion":17121,"start":17122,"enrollment":2579,"conditions":17123,"interventions":17125},"NCT02435680","Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)",[92],"2020-01-04","2020-03-23","2015-08-10",[17124],"Advanced Triple Negative Breast Cancer (TNBC) With High TAMs",[10577,7871,10632],{"nctId":1137,"briefTitle":1138,"status":123,"phases":17127,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":1143,"conditions":17128,"interventions":17129},[92],[1145,1146,1147,1148,1149,1150,1151,1152,1153,1154,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166],[1078,156,1168,1169],{"nctId":13518,"briefTitle":13519,"status":123,"phases":17131,"primaryCompletion":9910,"completion":13521,"start":4445,"enrollment":534,"conditions":17132,"interventions":17133},[92],[13523],[10125,4389,1168],{"nctId":9938,"briefTitle":9939,"status":390,"phases":17135,"primaryCompletion":9941,"completion":9942,"start":1512,"enrollment":103,"conditions":17136,"interventions":17137},[92],[9944],[9946,1079,4321,9947,1168,8153,9948],{"trials":17139,"activeCount":103},[17140,17149,17153,17157,17161,17165],{"nctId":17141,"briefTitle":17142,"status":123,"phases":17143,"primaryCompletion":3447,"completion":3447,"start":9096,"enrollment":15801,"conditions":17144,"interventions":17146},"NCT00086268","Non-small Cell Lung Cancer Study US75 (Z-PACT)",[93],[17145],"Non Small Cell Lung Carcinoma",[17147,17148,1168],"zoledronic acid","Taxotere",{"nctId":15472,"briefTitle":15473,"status":134,"phases":17150,"primaryCompletion":853,"completion":853,"start":4070,"enrollment":15475,"conditions":17151,"interventions":17152},[93],[182],[8115,7871,4321],{"nctId":9952,"briefTitle":9953,"status":390,"phases":17154,"primaryCompletion":9955,"completion":9956,"start":9957,"enrollment":103,"conditions":17155,"interventions":17156},[93],[5282],[9946,1079,8153,1168,5262,4375,4321,9947],{"nctId":13629,"briefTitle":13630,"status":134,"phases":17158,"primaryCompletion":13632,"completion":13633,"start":13634,"enrollment":13635,"conditions":17159,"interventions":17160},[93],[128],[10578,13581,7871,13638,7872,6342,13639],{"nctId":10969,"briefTitle":10970,"status":134,"phases":17162,"primaryCompletion":137,"completion":137,"start":10972,"enrollment":2379,"conditions":17163,"interventions":17164},[93],[227],[8070,10342,4375,5262,1168],{"nctId":5254,"briefTitle":5255,"status":123,"phases":17166,"primaryCompletion":5257,"completion":5258,"start":5259,"enrollment":282,"conditions":17167,"interventions":17168},[93],[182],[130,4375,5262,1168],{"trials":17170,"activeCount":103},[17171],{"nctId":15515,"briefTitle":15516,"status":123,"phases":17172,"primaryCompletion":2509,"completion":2509,"start":3383,"enrollment":1622,"conditions":17173,"interventions":17174},[94],[15519,4903],[7711,4321,1168],{"trials":17176,"activeCount":103},[],{"intervention":4765,"totalTrials":2367,"cells":17178},{"EARLY_PHASE1":17179,"PHASE1":17181,"PHASE2":17183,"PHASE3":17193,"PHASE4":17215,"NA":17262},{"trials":17180,"activeCount":103},[],{"trials":17182,"activeCount":103},[],{"trials":17184,"activeCount":103},[17185,17189],{"nctId":7622,"briefTitle":7623,"status":123,"phases":17186,"primaryCompletion":7625,"completion":7625,"start":542,"enrollment":3322,"conditions":17187,"interventions":17188},[91,92],[4691],[6519,4765,4768,4769,7628],{"nctId":7639,"briefTitle":7640,"status":123,"phases":17190,"primaryCompletion":483,"completion":483,"start":7642,"enrollment":7643,"conditions":17191,"interventions":17192},[92],[4691],[7646,7647,4769,4765,7648,7649,7650,7651],{"trials":17194,"activeCount":103},[17195,17199,17203,17207,17211],{"nctId":4757,"briefTitle":4758,"status":123,"phases":17196,"primaryCompletion":4760,"completion":4760,"start":4761,"enrollment":4762,"conditions":17197,"interventions":17198},[93],[4691,4701],[196,4765,4766,4767,4768,4769,4770],{"nctId":4791,"briefTitle":4792,"status":123,"phases":17200,"primaryCompletion":607,"completion":607,"start":917,"enrollment":4794,"conditions":17201,"interventions":17202},[93],[4645],[4765,4765,4765,196,196,4769],{"nctId":4798,"briefTitle":4799,"status":123,"phases":17204,"primaryCompletion":2509,"completion":2509,"start":3604,"enrollment":3120,"conditions":17205,"interventions":17206},[93],[4645],[4803,4305,4804,4805,4769],{"nctId":4815,"briefTitle":4816,"status":123,"phases":17208,"primaryCompletion":4818,"completion":4818,"start":4819,"enrollment":1352,"conditions":17209,"interventions":17210},[93],[4645],[196,4765],{"nctId":4906,"briefTitle":4907,"status":123,"phases":17212,"primaryCompletion":4909,"completion":4909,"start":4910,"enrollment":4911,"conditions":17213,"interventions":17214},[93],[4913],[4765,196,4765,196,4765,4769],{"trials":17216,"activeCount":103},[17217,17221,17225,17229,17233,17243,17247,17254],{"nctId":4955,"briefTitle":4956,"status":123,"phases":17218,"primaryCompletion":4958,"completion":4958,"start":4959,"enrollment":4960,"conditions":17219,"interventions":17220},[94],[4645],[196,4765,4769],{"nctId":4964,"briefTitle":4965,"status":134,"phases":17222,"primaryCompletion":4967,"completion":4967,"start":918,"enrollment":1016,"conditions":17223,"interventions":17224},[94],[4701],[196,4766,4765,4970,4769],{"nctId":4981,"briefTitle":4982,"status":123,"phases":17226,"primaryCompletion":4093,"completion":4093,"start":3845,"enrollment":1660,"conditions":17227,"interventions":17228},[94],[4985],[196,4765,4987],{"nctId":5016,"briefTitle":5017,"status":123,"phases":17230,"primaryCompletion":1682,"completion":1682,"start":3271,"enrollment":792,"conditions":17231,"interventions":17232},[94],[5020],[196,4765,4804,4767,4769],{"nctId":17234,"briefTitle":17235,"status":134,"phases":17236,"primaryCompletion":7931,"start":4621,"enrollment":17237,"conditions":17238,"interventions":17241},"NCT00260208","Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus",[94],361,[17239,17240],"Liver Transplant","Hepatitis C",[17242,4765],"Cyclosporine A",{"nctId":5067,"briefTitle":5068,"status":123,"phases":17244,"primaryCompletion":5070,"completion":5070,"start":5071,"enrollment":3705,"conditions":17245,"interventions":17246},[94],[4744],[196,5074,4803,5075,4626,4769],{"nctId":17248,"briefTitle":17249,"status":123,"phases":17250,"primaryCompletion":5114,"completion":5114,"start":4975,"enrollment":4516,"conditions":17251,"interventions":17252},"NCT00938860","Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C",[94],[17240,4645],[17253,4803],"cyclosporin",{"nctId":17255,"briefTitle":17256,"status":123,"phases":17257,"primaryCompletion":4556,"completion":4556,"start":16899,"enrollment":3544,"conditions":17258,"interventions":17259},"NCT00149994","Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients",[94],[17239],[17242,4765,4804,17260,17261],"Methylprednisolone","Prednisone",{"trials":17263,"activeCount":103},[],{"intervention":15789,"totalTrials":814,"cells":17265},{"EARLY_PHASE1":17266,"PHASE1":17268,"PHASE2":17270,"PHASE3":17272,"PHASE4":17330,"NA":17379},{"trials":17267,"activeCount":103},[],{"trials":17269,"activeCount":103},[],{"trials":17271,"activeCount":103},[],{"trials":17273,"activeCount":103},[17274,17282,17286,17295,17299,17303,17312,17316,17320],{"nctId":17275,"briefTitle":17276,"status":123,"phases":17277,"primaryCompletion":7450,"completion":7450,"start":5310,"enrollment":34,"conditions":17278,"interventions":17281},"NCT03917459","COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure",[93],[15870,17279,17280],"Heart Failure, Systolic","Erectile Dysfunction",[15726,15789],{"nctId":15779,"briefTitle":15780,"status":123,"phases":17283,"primaryCompletion":15782,"completion":15782,"start":15783,"enrollment":15784,"conditions":17284,"interventions":17285},[93],[15786],[15788,15789,5447],{"nctId":17287,"briefTitle":17288,"status":123,"phases":17289,"primaryCompletion":17290,"completion":17290,"start":2623,"enrollment":17291,"conditions":17292,"interventions":17294},"NCT02900378","randOmized stUdy Using acceleromeTry to Compare Sacubitril\u002FvalsarTan and Enalapril in Patients With Heart Failure",[93],"2018-04-11",621,[17293],"Chronic Heart Failure With Reduced Ejection Fraction",[15726,15789],{"nctId":16800,"briefTitle":16801,"status":123,"phases":17296,"primaryCompletion":1681,"completion":1681,"start":3400,"enrollment":16803,"conditions":17297,"interventions":17298},[93],[15734],[15789,16715],{"nctId":15791,"briefTitle":15792,"status":123,"phases":17300,"primaryCompletion":3612,"completion":3612,"start":3254,"enrollment":967,"conditions":17301,"interventions":17302},[93],[21],[5447,15789],{"nctId":17304,"briefTitle":17305,"status":123,"phases":17306,"primaryCompletion":17307,"completion":17307,"start":9177,"enrollment":17308,"conditions":17309,"interventions":17311},"NCT02678312","Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure",[92,93],"2022-01-03",393,[17310],"Pediatric Heart Failure",[15726,15789,15726],{"nctId":16815,"briefTitle":16816,"status":123,"phases":17313,"primaryCompletion":8048,"completion":8048,"start":3845,"enrollment":6024,"conditions":17314,"interventions":17315},[93],[21],[16715,15789],{"nctId":15797,"briefTitle":15798,"status":123,"phases":17317,"primaryCompletion":1024,"completion":1024,"start":15800,"enrollment":15801,"conditions":17318,"interventions":17319},[93],[21],[5447,15789],{"nctId":17321,"briefTitle":17322,"status":123,"phases":17323,"primaryCompletion":17324,"completion":17325,"start":17326,"enrollment":3420,"conditions":17327,"interventions":17329},"NCT02468232","Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction",[93],"2019-02-08","2021-02-18","2015-06-15",[17328],"Heart Failure With Reduced Ejection Fraction (HF-rEF)",[15726,15789],{"trials":17331,"activeCount":103},[17332,17342,17351,17362,17370],{"nctId":17333,"briefTitle":17334,"status":123,"phases":17335,"primaryCompletion":17336,"completion":17336,"start":17337,"enrollment":3087,"conditions":17338,"interventions":17340},"NCT02970669","Study on the Effects of Sacubitril\u002FValsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.",[94],"2018-03-19","2016-12-16",[17339],"Heart Failure, Reduced Ejection Fraction",[15788,17341],"enalapril",{"nctId":17343,"briefTitle":17344,"status":123,"phases":17345,"primaryCompletion":17346,"completion":6099,"start":3063,"enrollment":17347,"conditions":17348,"interventions":17349},"NCT04023227","Efficacy and Safety of Sacubitril\u002FValsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC",[94],"2025-03-16",922,[12246,15870],[17350,15789],"Sacubitril\u002Fvalsartan",{"nctId":17352,"briefTitle":17353,"status":123,"phases":17354,"primaryCompletion":17355,"completion":17356,"start":17357,"enrollment":17358,"conditions":17359,"interventions":17361},"NCT02874794","Study of Effects of Sacubitril\u002FValsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction",[94],"2018-12-13","2019-01-26","2016-08-17",465,[17360],"Heart Failure and Reduced Ejection Fraction",[15726,15789],{"nctId":17363,"briefTitle":17364,"status":123,"phases":17365,"primaryCompletion":17366,"completion":17366,"start":2055,"enrollment":17367,"conditions":17368,"interventions":17369},"NCT02768298","Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.",[94],"2019-11-25",201,[17293],[15726,15789],{"nctId":17371,"briefTitle":17372,"status":123,"phases":17373,"primaryCompletion":17374,"completion":2425,"start":1848,"enrollment":17375,"conditions":17376,"interventions":17378},"NCT02554890","Comparison of Sacubitril\u002FValsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.",[94],"2018-06-29",887,[17377],"Acute Heart Failure",[15788,15789],{"trials":17380,"activeCount":103},[],{"intervention":17382,"totalTrials":4148,"cells":17383},"Telbivudine",{"EARLY_PHASE1":17384,"PHASE1":17386,"PHASE2":17388,"PHASE3":17390,"PHASE4":17443,"NA":17482},{"trials":17385,"activeCount":103},[],{"trials":17387,"activeCount":103},[],{"trials":17389,"activeCount":103},[],{"trials":17391,"activeCount":103},[17392,17403,17412,17421,17428,17436],{"nctId":17393,"briefTitle":17394,"status":123,"phases":17395,"primaryCompletion":3271,"start":17396,"enrollment":6350,"conditions":17397,"interventions":17401},"NCT00076336","Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis",[93],"2003-12",[17398,17399,17400],"Hepatitis","Hepatitis B, Chronic","Cirrhosis",[17382,17402],"Lamivudine",{"nctId":17404,"briefTitle":17405,"status":123,"phases":17406,"primaryCompletion":4372,"start":3490,"enrollment":3043,"conditions":17407,"interventions":17409},"NCT00805675","Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB",[93],[17408],"Hepatitis B Virus",[17382,17410,17411],"Tenofovir","Telbivudine plus tenofovir",{"nctId":17413,"briefTitle":17414,"status":123,"phases":17415,"primaryCompletion":16570,"start":3657,"enrollment":22,"conditions":17416,"interventions":17419},"NCT00412529","Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B",[93],[17417,17418],"Hepatitis B","Chronic Hepatitis B",[17420,17382],"Entecavir",{"nctId":17422,"briefTitle":17423,"status":123,"phases":17424,"primaryCompletion":3271,"completion":3271,"start":1025,"enrollment":2439,"conditions":17425,"interventions":17426},"NCT00640588","Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine",[93],[17399],[17382,17427],"oral adefovir",{"nctId":17429,"briefTitle":17430,"status":134,"phases":17431,"primaryCompletion":1837,"completion":1837,"start":17432,"enrollment":17433,"conditions":17434,"interventions":17435},"NCT02058108","Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection",[93],"2014-10-31",53,[17418],[17382],{"nctId":17437,"briefTitle":17438,"status":123,"phases":17439,"primaryCompletion":4335,"completion":4335,"start":996,"enrollment":17440,"conditions":17441,"interventions":17442},"NCT00142298","Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies",[93],1869,[17418],[17382],{"trials":17444,"activeCount":103},[17445,17452,17458,17467,17475],{"nctId":17446,"briefTitle":17447,"status":123,"phases":17448,"primaryCompletion":4975,"completion":4975,"start":4343,"enrollment":22,"conditions":17449,"interventions":17450},"NCT00467545","An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B",[94],[17418],[17451],"telbivudine",{"nctId":17453,"briefTitle":17454,"status":123,"phases":17455,"primaryCompletion":2034,"start":4437,"enrollment":1314,"conditions":17456,"interventions":17457},"NCT00537537","To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)",[94],[17399],[17382],{"nctId":17459,"briefTitle":17460,"status":123,"phases":17461,"primaryCompletion":17462,"completion":17462,"start":17463,"enrollment":17464,"conditions":17465,"interventions":17466},"NCT00781105","Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B",[94],"2010-09-16","2008-08-01",2200,[17418],[17382],{"nctId":17468,"briefTitle":17469,"status":123,"phases":17470,"primaryCompletion":13717,"completion":13717,"start":17471,"enrollment":180,"conditions":17472,"interventions":17473},"NCT01379508","Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept",[94],"2011-03-21",[17418],[17451,17474],"tenofovir disoproxil fumarate",{"nctId":17476,"briefTitle":17477,"status":390,"phases":17478,"primaryCompletion":895,"enrollment":103,"conditions":17479,"interventions":17480},"NCT00409019","Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy",[94],[17418],[17382,17481,17410],"Adefovir",{"trials":17483,"activeCount":103},[],{"intervention":17485,"totalTrials":4148,"cells":17486},"FTY720",{"EARLY_PHASE1":17487,"PHASE1":17489,"PHASE2":17491,"PHASE3":17515,"PHASE4":17563,"NA":17574},{"trials":17488,"activeCount":103},[],{"trials":17490,"activeCount":103},[],{"trials":17492,"activeCount":103},[17493,17502,17510],{"nctId":17494,"briefTitle":17495,"status":123,"phases":17496,"primaryCompletion":17497,"start":17498,"enrollment":17499,"conditions":17500,"interventions":17501},"NCT00239902","Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients",[92],"2004-11","2002-05",396,[4701],[17485],{"nctId":17503,"briefTitle":17504,"status":390,"phases":17505,"primaryCompletion":1817,"completion":1817,"start":4669,"enrollment":103,"conditions":17506,"interventions":17508},"NCT01791192","Study of FTY720 in Patients With Uveitis",[92],[17507],"Acute Noninfectious Posterior, Intermediate, or Pan Uveitis",[17485,17509],"Oral Corticosteroid",{"nctId":17511,"briefTitle":17495,"status":123,"phases":17512,"primaryCompletion":3195,"start":17497,"enrollment":805,"conditions":17513,"interventions":17514},"NCT00239798",[92],[4701],[17485],{"trials":17516,"activeCount":103},[17517,17524,17534,17540,17546,17552,17557],{"nctId":17518,"briefTitle":17519,"status":123,"phases":17520,"primaryCompletion":8091,"start":9096,"enrollment":17521,"conditions":17522,"interventions":17523},"NCT00239811","Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients",[93],684,[4701],[17485],{"nctId":17525,"briefTitle":17526,"status":134,"phases":17527,"primaryCompletion":17528,"completion":17528,"start":17529,"enrollment":17530,"conditions":17531,"interventions":17533},"NCT00731692","This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",[93],"2015-06-22","2008-07-28",970,[17532],"Primary Progressive Multiple Sclerosis",[17485],{"nctId":17535,"briefTitle":17536,"status":123,"phases":17537,"primaryCompletion":16010,"start":9096,"enrollment":3087,"conditions":17538,"interventions":17539},"NCT00098735","Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation",[93],[4691],[17485],{"nctId":17541,"briefTitle":17495,"status":123,"phases":17542,"primaryCompletion":854,"start":17543,"enrollment":17521,"conditions":17544,"interventions":17545},"NCT00239785",[93],"2003-04",[4701],[17485],{"nctId":17547,"briefTitle":17548,"status":123,"phases":17549,"primaryCompletion":8091,"start":15058,"enrollment":17521,"conditions":17550,"interventions":17551},"NCT00239863","Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients",[93],[4701],[17485],{"nctId":17553,"briefTitle":17495,"status":123,"phases":17554,"primaryCompletion":835,"start":3255,"enrollment":3087,"conditions":17555,"interventions":17556},"NCT00239876",[93],[4701],[17485],{"nctId":17558,"briefTitle":17559,"status":123,"phases":17560,"primaryCompletion":865,"completion":865,"start":15065,"conditions":17561,"interventions":17562},"NCT00099801","Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant",[93],[4691],[17485],{"trials":17564,"activeCount":103},[17565],{"nctId":17566,"briefTitle":17567,"status":123,"phases":17568,"primaryCompletion":17569,"completion":17569,"start":17570,"enrollment":17571,"conditions":17572,"interventions":17573},"NCT01585298","STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)",[94],"2016-12-12","2012-04-29",6998,[27],[17485],{"trials":17575,"activeCount":103},[],{"intervention":4768,"totalTrials":5594,"cells":17577},{"EARLY_PHASE1":17578,"PHASE1":17580,"PHASE2":17582,"PHASE3":17592,"PHASE4":17602,"NA":17631},{"trials":17579,"activeCount":103},[],{"trials":17581,"activeCount":103},[],{"trials":17583,"activeCount":103},[17584,17588],{"nctId":7622,"briefTitle":7623,"status":123,"phases":17585,"primaryCompletion":7625,"completion":7625,"start":542,"enrollment":3322,"conditions":17586,"interventions":17587},[91,92],[4691],[6519,4765,4768,4769,7628],{"nctId":7639,"briefTitle":7640,"status":123,"phases":17589,"primaryCompletion":483,"completion":483,"start":7642,"enrollment":7643,"conditions":17590,"interventions":17591},[92],[4691],[7646,7647,4769,4765,7648,7649,7650,7651],{"trials":17593,"activeCount":103},[17594,17598],{"nctId":4617,"briefTitle":4618,"status":123,"phases":17595,"primaryCompletion":4620,"completion":4620,"start":4621,"enrollment":4622,"conditions":17596,"interventions":17597},[93],[4624],[4305,4626,4627,4628],{"nctId":4757,"briefTitle":4758,"status":123,"phases":17599,"primaryCompletion":4760,"completion":4760,"start":4761,"enrollment":4762,"conditions":17600,"interventions":17601},[93],[4691,4701],[196,4765,4766,4767,4768,4769,4770],{"trials":17603,"activeCount":103},[17604,17608,17612,17619,17623,17627],{"nctId":4989,"briefTitle":4990,"status":123,"phases":17605,"primaryCompletion":3604,"completion":3604,"start":4335,"enrollment":4992,"conditions":17606,"interventions":17607},[94],[4994],[4875,4768,4769,196,4996],{"nctId":5067,"briefTitle":5068,"status":123,"phases":17609,"primaryCompletion":5070,"completion":5070,"start":5071,"enrollment":3705,"conditions":17610,"interventions":17611},[94],[4744],[196,5074,4803,5075,4626,4769],{"nctId":17613,"briefTitle":17614,"status":134,"phases":17615,"primaryCompletion":3400,"completion":3400,"start":1025,"enrollment":2439,"conditions":17616,"interventions":17617},"NCT00658333","A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms",[94],[4701],[17618,7647],"Enteric-coated Mycophenolate Acid",{"nctId":16959,"briefTitle":16960,"status":123,"phases":17620,"primaryCompletion":5062,"start":825,"enrollment":1466,"conditions":17621,"interventions":17622},[94],[4701],[16894,4768],{"nctId":5128,"briefTitle":5129,"status":123,"phases":17624,"primaryCompletion":5131,"completion":5131,"start":5132,"enrollment":167,"conditions":17625,"interventions":17626},[94],[4744],[196,4875,4768,4769],{"nctId":16971,"briefTitle":16972,"status":123,"phases":17628,"primaryCompletion":1025,"start":8370,"enrollment":292,"conditions":17629,"interventions":17630},[94],[4985],[16855,7647],{"trials":17632,"activeCount":103},[],{"intervention":17634,"totalTrials":5594,"cells":17635},"Ranibizumab 0.5 mg",{"EARLY_PHASE1":17636,"PHASE1":17638,"PHASE2":17640,"PHASE3":17651,"PHASE4":17698,"NA":17731},{"trials":17637,"activeCount":103},[],{"trials":17639,"activeCount":103},[],{"trials":17641,"activeCount":103},[17642],{"nctId":17643,"briefTitle":17644,"status":123,"phases":17645,"primaryCompletion":383,"completion":17646,"start":17647,"enrollment":6514,"conditions":17648,"interventions":17650},"NCT01594281","Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)",[92],"2017-12-05","2012-12-11",[17649],"Proliferative Diabetic Retinopathy (PDR)",[17634],{"trials":17652,"activeCount":103},[17653,17661,17670,17677,17689],{"nctId":17654,"briefTitle":17655,"status":134,"phases":17656,"primaryCompletion":4620,"completion":4620,"start":3351,"enrollment":3587,"conditions":17657,"interventions":17659},"NCT01131585","Safety and Efficacy of Ranibizumab in Diabetic Macular Edema",[93],[17658],"Visual Impairment Due to Diabetic Macular Edema",[17660,17634],"Sham injections",{"nctId":17662,"briefTitle":17663,"status":123,"phases":17664,"primaryCompletion":17665,"completion":17665,"start":17666,"enrollment":13390,"conditions":17667,"interventions":17669},"NCT01976338","Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)",[93],"2016-03-28","2013-11-12",[17668],"Macular Edema Secondary to Branch Retinal Vein Occlusion",[17634],{"nctId":17671,"briefTitle":17672,"status":123,"phases":17673,"primaryCompletion":4944,"completion":4944,"start":17666,"enrollment":11288,"conditions":17674,"interventions":17676},"NCT01976312","Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)",[93],[17675],"Central Retinal Vein Occlusion",[17634],{"nctId":17678,"briefTitle":17679,"status":123,"phases":17680,"primaryCompletion":17681,"completion":17681,"start":17682,"enrollment":17683,"conditions":17684,"interventions":17686},"NCT01922102","Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia",[93],"2016-09-14","2013-09-11",457,[17685],"Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)",[17687,17634,17688],"Ranibizumab 0.5mg","Verteporfin PDT",{"nctId":17690,"briefTitle":17691,"status":123,"phases":17692,"primaryCompletion":864,"start":949,"enrollment":17693,"conditions":17694,"interventions":17696},"NCT00826371","Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients",[93],114,[17695],"Age Related Macular Degeneration",[17697],"ranibizumab 0.5 mg",{"trials":17699,"activeCount":103},[17700,17706,17715,17724],{"nctId":17701,"briefTitle":17702,"status":123,"phases":17703,"primaryCompletion":607,"completion":607,"start":880,"enrollment":2796,"conditions":17704,"interventions":17705},"NCT01148511","Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus \"Treat and Extend\" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)",[94],[4458],[17634],{"nctId":17707,"briefTitle":17708,"status":123,"phases":17709,"primaryCompletion":17710,"completion":1951,"start":7581,"enrollment":4506,"conditions":17711,"interventions":17713},"NCT02257632","Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration",[94],"2017-03-20",[17712],"Wet Age-Related Macular Degeneration",[17634,17714],"Aflibercept 2 mg",{"nctId":17716,"briefTitle":17717,"status":123,"phases":17718,"primaryCompletion":17719,"completion":17719,"start":17720,"enrollment":12,"conditions":17721,"interventions":17722},"NCT02130024","A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients",[94],"2017-11-15","2014-04-11",[5961],[17634,17723],"Aflibercept 2.0 mg",{"nctId":17725,"briefTitle":17726,"status":123,"phases":17727,"primaryCompletion":1951,"completion":1951,"start":1876,"enrollment":4049,"conditions":17728,"interventions":17730},"NCT02366468","Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema",[94],[17729],"Diabetic Retinopathy",[17697],{"trials":17732,"activeCount":103},[],{"intervention":17734,"totalTrials":5594,"cells":17735},"BAF312",{"EARLY_PHASE1":17736,"PHASE1":17738,"PHASE2":17752,"PHASE3":17808,"PHASE4":17819,"NA":17831},{"trials":17737,"activeCount":103},[],{"trials":17739,"activeCount":103},[17740,17746],{"nctId":17741,"briefTitle":17742,"status":123,"phases":17743,"primaryCompletion":3382,"completion":3382,"start":2033,"enrollment":1672,"conditions":17744,"interventions":17745},"NCT01904214","A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function",[91],[2635],[17734],{"nctId":17747,"briefTitle":17748,"status":123,"phases":17749,"primaryCompletion":4093,"completion":4093,"start":1761,"enrollment":709,"conditions":17750,"interventions":17751},"NCT01565902","Pharmacokinetics of BAF312 in Patients With Hepatic Impairment",[91],[2625],[17734],{"trials":17753,"activeCount":103},[17754,17763,17773,17782,17790,17798],{"nctId":17755,"briefTitle":17756,"status":134,"phases":17757,"primaryCompletion":17758,"completion":17758,"start":17759,"enrollment":837,"conditions":17760,"interventions":17762},"NCT02029274","Safety and Efficacy of BAF312 in Dermatomyositis",[92],"2016-02-17","2013-08-25",[17761],"Active Dermatomyositis",[17734],{"nctId":17764,"briefTitle":17765,"status":134,"phases":17766,"primaryCompletion":17767,"completion":17767,"start":17768,"enrollment":3343,"conditions":17769,"interventions":17772},"NCT01148810","Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis",[92],"2012-06-13","2010-06-15",[17770,17771],"Polymyositis","Dermatomyositis",[17734],{"nctId":17774,"briefTitle":17775,"status":123,"phases":17776,"primaryCompletion":17777,"completion":17777,"start":17778,"enrollment":17779,"conditions":17780,"interventions":17781},"NCT00879658","Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",[92],"2011-05-04","2009-03-30",297,[3762],[17734],{"nctId":17783,"briefTitle":17784,"status":134,"phases":17785,"primaryCompletion":17786,"completion":17786,"start":17787,"enrollment":814,"conditions":17788,"interventions":17789},"NCT01801917","Efficacy and Tolerability of BAF312 in Patients With Polymyositis",[92],"2016-08-05","2013-04-24",[17770],[17734],{"nctId":17791,"briefTitle":17792,"status":123,"phases":17793,"primaryCompletion":17794,"completion":17794,"start":17795,"enrollment":2910,"conditions":17796,"interventions":17797},"NCT01185821","Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",[92],"2016-10-10","2010-08-30",[3743],[17734],{"nctId":17799,"briefTitle":17800,"status":123,"phases":17801,"primaryCompletion":13493,"completion":13493,"start":17802,"enrollment":7257,"conditions":17803,"interventions":17806},"NCT03338998","Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).",[92],"2017-12-24",[17804,17805],"Hemorrhagic Stroke","Intracerebral Hemorrhage (ICH)",[17807,17734],"BAF312 solution",{"trials":17809,"activeCount":103},[17810],{"nctId":17811,"briefTitle":17812,"status":123,"phases":17813,"primaryCompletion":1848,"completion":17814,"start":3297,"enrollment":17815,"conditions":17816,"interventions":17818},"NCT01665144","Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)",[93],"2023-03-31",1651,[17817],"Secondary Progressive Multiple Sclerosis",[17734],{"trials":17820,"activeCount":103},[17821],{"nctId":17822,"briefTitle":17823,"status":123,"phases":17824,"primaryCompletion":17825,"completion":13615,"start":1110,"enrollment":4506,"conditions":17826,"interventions":17827},"NCT04792567","Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)",[94],"2021-09-06",[17817],[17734,17828,17829,17830],"Baseline disease modifying therapies","BNT162","mRNA-1273",{"trials":17832,"activeCount":103},[],{"intervention":4424,"totalTrials":1495,"cells":17834},{"EARLY_PHASE1":17835,"PHASE1":17837,"PHASE2":17845,"PHASE3":17883,"PHASE4":17904,"NA":17910},{"trials":17836,"activeCount":103},[],{"trials":17838,"activeCount":103},[17839],{"nctId":17840,"briefTitle":17841,"status":123,"phases":17842,"primaryCompletion":1780,"completion":1780,"start":1724,"enrollment":1053,"conditions":17843,"interventions":17844},"NCT01364415","Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)",[91],[4903],[4424],{"trials":17846,"activeCount":103},[17847,17851,17860,17864,17875],{"nctId":4416,"briefTitle":4417,"status":123,"phases":17848,"primaryCompletion":4419,"completion":4419,"start":4420,"enrollment":3288,"conditions":17849,"interventions":17850},[92],[4422],[4424,196,4425],{"nctId":17852,"briefTitle":17853,"status":123,"phases":17854,"primaryCompletion":17855,"completion":17855,"start":17856,"enrollment":99,"conditions":17857,"interventions":17859},"NCT01673646","Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism",[92],"2017-04-10","2012-10-16",[8385,17858],"Pituitary Gigantism",[4424],{"nctId":4529,"briefTitle":4530,"status":134,"phases":17861,"primaryCompletion":2458,"completion":2458,"start":2034,"enrollment":4532,"conditions":17862,"interventions":17863},[92],[4534],[196,4424],{"nctId":17865,"briefTitle":17866,"status":134,"phases":17867,"primaryCompletion":4410,"completion":4410,"start":4975,"enrollment":4708,"conditions":17868,"interventions":17873},"NCT00958841","Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin",[92],[17869,17870,17871,17872],"Pancreatic Neoplasm","Pituitary Neoplasm","Nelson Syndrome","Ectopic ACTH Syndrome",[17874],"pasireotide LAR",{"nctId":17876,"briefTitle":17877,"status":123,"phases":17878,"primaryCompletion":13716,"completion":13716,"start":17879,"enrollment":1611,"conditions":17880,"interventions":17882},"NCT01283542","Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.",[92],"2012-11-26",[17881],"Non-functioning Pituitary Adenoma",[4424],{"trials":17884,"activeCount":103},[17885,17894],{"nctId":17886,"briefTitle":17887,"status":123,"phases":17888,"primaryCompletion":17889,"completion":17890,"start":17891,"enrollment":9331,"conditions":17892,"interventions":17893},"NCT02354508","Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues",[93],"2018-01-08","2018-09-27","2015-03-31",[8385],[4424],{"nctId":17895,"briefTitle":17896,"status":123,"phases":17897,"primaryCompletion":17898,"completion":17898,"start":17899,"enrollment":9531,"conditions":17900,"interventions":17901},"NCT01374906","Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease",[93],"2016-12-21","2011-11-04",[16681],[17874,17902,17903],"SOM230 LAR 30 mg","SOM230 LAR 10 mg",{"trials":17905,"activeCount":103},[17906],{"nctId":16675,"briefTitle":16676,"status":123,"phases":17907,"primaryCompletion":8329,"completion":16678,"start":6556,"enrollment":16679,"conditions":17908,"interventions":17909},[94],[16681,8385],[16683,15255,16673,15320,4424,13838],{"trials":17911,"activeCount":103},[],{"intervention":4875,"totalTrials":422,"cells":17913},{"EARLY_PHASE1":17914,"PHASE1":17916,"PHASE2":17918,"PHASE3":17924,"PHASE4":17934,"NA":17961},{"trials":17915,"activeCount":103},[],{"trials":17917,"activeCount":103},[],{"trials":17919,"activeCount":103},[17920],{"nctId":7484,"briefTitle":7485,"status":123,"phases":17921,"primaryCompletion":7420,"completion":7487,"start":7488,"enrollment":271,"conditions":17922,"interventions":17923},[92],[7490],[7403,4875],{"trials":17925,"activeCount":103},[17926,17930],{"nctId":4617,"briefTitle":4618,"status":123,"phases":17927,"primaryCompletion":4620,"completion":4620,"start":4621,"enrollment":4622,"conditions":17928,"interventions":17929},[93],[4624],[4305,4626,4627,4628],{"nctId":4869,"briefTitle":4870,"status":123,"phases":17931,"primaryCompletion":2762,"completion":2762,"start":3800,"enrollment":568,"conditions":17932,"interventions":17933},[93],[4691],[196,4874,4875,4649],{"trials":17935,"activeCount":103},[17936,17942,17946,17953,17957],{"nctId":17937,"briefTitle":17938,"status":123,"phases":17939,"primaryCompletion":4070,"completion":949,"start":8091,"enrollment":31,"conditions":17940,"interventions":17941},"NCT00332462","A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients",[94],[4645],[4875,4875],{"nctId":4989,"briefTitle":4990,"status":123,"phases":17943,"primaryCompletion":3604,"completion":3604,"start":4335,"enrollment":4992,"conditions":17944,"interventions":17945},[94],[4994],[4875,4768,4769,196,4996],{"nctId":17947,"briefTitle":17948,"status":123,"phases":17949,"primaryCompletion":4642,"start":16936,"enrollment":6547,"conditions":17950,"interventions":17952},"NCT00154193","Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels",[94],[17951],"Heart and Lung Transplant",[4627],{"nctId":5077,"briefTitle":5078,"status":123,"phases":17954,"primaryCompletion":4524,"completion":4524,"start":865,"enrollment":5080,"conditions":17955,"interventions":17956},[94],[5082],[196,4875,5084,4874],{"nctId":5128,"briefTitle":5129,"status":123,"phases":17958,"primaryCompletion":5131,"completion":5131,"start":5132,"enrollment":167,"conditions":17959,"interventions":17960},[94],[4744],[196,4875,4768,4769],{"trials":17962,"activeCount":103},[],{"intervention":17964,"totalTrials":422,"cells":17965},"Secukinumab 300 mg",{"EARLY_PHASE1":17966,"PHASE1":17968,"PHASE2":17970,"PHASE3":17972,"PHASE4":18020,"NA":18047},{"trials":17967,"activeCount":103},[],{"trials":17969,"activeCount":103},[],{"trials":17971,"activeCount":103},[],{"trials":17973,"activeCount":103},[17974,17982,17992,18003,18013],{"nctId":17975,"briefTitle":17976,"status":123,"phases":17977,"primaryCompletion":17978,"completion":17978,"start":3812,"enrollment":2268,"conditions":17979,"interventions":17981},"NCT02267135","Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis",[93],"2015-12-07",[17980],"Chronic Scalp Psoriasis",[17964],{"nctId":17983,"briefTitle":17984,"status":123,"phases":17985,"primaryCompletion":9077,"completion":9077,"start":17986,"enrollment":585,"conditions":17987,"interventions":17989},"NCT01806597","Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",[93],"2013-06-19",[17988],"Moderate to Severe Palmoplantar Psoriasis",[17990,17991],"secukinumab 150 mg","secukinumab 300 mg",{"nctId":17993,"briefTitle":17994,"status":123,"phases":17995,"primaryCompletion":17996,"completion":17997,"start":3390,"enrollment":17998,"conditions":17999,"interventions":18001},"NCT04930094","Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)",[93],"2025-04-11","2026-02-18",354,[18000],"Giant Cell Arteritis (GCA)",[17964,18002],"Secukinumab 150 mg",{"nctId":18004,"briefTitle":18005,"status":123,"phases":18006,"primaryCompletion":18007,"completion":18008,"start":18009,"enrollment":18010,"conditions":18011,"interventions":18012},"NCT05767034","Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)",[93],"2025-09-10","2026-02-16","2023-03-22",381,[1696],[17964,18002],{"nctId":18014,"briefTitle":18015,"status":123,"phases":18016,"primaryCompletion":339,"completion":339,"start":18017,"enrollment":446,"conditions":18018,"interventions":18019},"NCT01555125","First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks",[93],"2012-05-08",[2068],[17990,17991],{"trials":18021,"activeCount":103},[18022,18031,18039],{"nctId":18023,"briefTitle":18024,"status":123,"phases":18025,"primaryCompletion":18026,"completion":18026,"start":18027,"enrollment":18028,"conditions":18029,"interventions":18030},"NCT02798211","Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo",[94],"2018-12-05","2016-06-27",258,[1821],[17964,18002],{"nctId":18032,"briefTitle":18033,"status":123,"phases":18034,"primaryCompletion":9136,"completion":18035,"start":18036,"enrollment":9106,"conditions":18037,"interventions":18038},"NCT02690701","Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis",[94],"2018-02-19","2016-02-10",[2037],[17964],{"nctId":18040,"briefTitle":18041,"status":390,"phases":18042,"primaryCompletion":18043,"completion":18043,"start":18044,"enrollment":103,"conditions":18045,"interventions":18046},"NCT04488185","An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound",[94],"2021-03-24","2020-11-02",[1675],[17964],{"trials":18048,"activeCount":103},[],{"intervention":4831,"totalTrials":422,"cells":18050},{"EARLY_PHASE1":18051,"PHASE1":18053,"PHASE2":18055,"PHASE3":18072,"PHASE4":18102,"NA":18110},{"trials":18052,"activeCount":103},[],{"trials":18054,"activeCount":103},[],{"trials":18056,"activeCount":103},[18057,18064,18068],{"nctId":18058,"briefTitle":18059,"status":123,"phases":18060,"primaryCompletion":5620,"start":8370,"enrollment":2342,"conditions":18061,"interventions":18063},"NCT00332969","Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma",[92],[18062],"Thymoma",[4831],{"nctId":8367,"briefTitle":8368,"status":123,"phases":18065,"primaryCompletion":3279,"completion":3279,"start":8370,"enrollment":2776,"conditions":18066,"interventions":18067},[92],[8372,8373,8374],[8358,4831,8376],{"nctId":10804,"briefTitle":10805,"status":134,"phases":18069,"primaryCompletion":10807,"completion":10807,"start":5002,"enrollment":2149,"conditions":18070,"interventions":18071},[92],[1102],[944,4451,4831],{"trials":18073,"activeCount":103},[18074,18082,18090,18094],{"nctId":18075,"briefTitle":18076,"status":123,"phases":18077,"primaryCompletion":7960,"completion":7960,"start":18078,"enrollment":6373,"conditions":18079,"interventions":18080},"NCT00600886","Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly",[93],"2008-02-11",[8385],[18081,4831],"Pasireotide",{"nctId":18083,"briefTitle":18084,"status":123,"phases":18085,"primaryCompletion":15109,"completion":15109,"start":18086,"enrollment":18087,"conditions":18088,"interventions":18089},"NCT00241020","Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma",[93],"2002-06",270,[10643],[4831],{"nctId":4823,"briefTitle":4824,"status":123,"phases":18091,"primaryCompletion":4081,"completion":1682,"start":3657,"enrollment":4826,"conditions":18092,"interventions":18093},[93],[4828,4829],[4831,196],{"nctId":18095,"briefTitle":18096,"status":123,"phases":18097,"primaryCompletion":607,"completion":607,"start":4070,"enrollment":18098,"conditions":18099,"interventions":18101},"NCT00690430","Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease",[93],186,[18100],"Symptomatic Refractory Resistant Carcinoid Disease",[18081,4831],{"trials":18103,"activeCount":103},[18104],{"nctId":18105,"briefTitle":18106,"status":123,"phases":18107,"primaryCompletion":8091,"completion":8091,"start":904,"enrollment":1611,"conditions":18108,"interventions":18109},"NCT00171886","Octreotide Efficacy and Safety in First-line Acromegalic Patients",[94],[8385],[4831],{"trials":18111,"activeCount":103},[],{"intervention":15777,"totalTrials":422,"cells":18113},{"EARLY_PHASE1":18114,"PHASE1":18116,"PHASE2":18118,"PHASE3":18132,"PHASE4":18146,"NA":18156},{"trials":18115,"activeCount":103},[],{"trials":18117,"activeCount":103},[],{"trials":18119,"activeCount":103},[18120,18124,18128],{"nctId":16730,"briefTitle":16731,"status":134,"phases":18121,"primaryCompletion":4301,"completion":4301,"start":4598,"enrollment":422,"conditions":18122,"interventions":18123},[92],[16734],[16715,15777,15769],{"nctId":16994,"briefTitle":16995,"status":123,"phases":18125,"primaryCompletion":606,"completion":606,"start":3604,"enrollment":16997,"conditions":18126,"interventions":18127},[92],[21],[15726,17000,15776,17001],{"nctId":17003,"briefTitle":17004,"status":123,"phases":18129,"primaryCompletion":607,"completion":607,"start":926,"enrollment":1922,"conditions":18130,"interventions":18131},[92],[17007],[15726,15884,15777],{"trials":18133,"activeCount":103},[18134,18138,18142],{"nctId":15771,"briefTitle":15772,"status":123,"phases":18135,"primaryCompletion":3861,"completion":3861,"start":1724,"enrollment":9531,"conditions":18136,"interventions":18137},[93],[21,14561],[5447,15776,15777],{"nctId":16770,"briefTitle":16771,"status":123,"phases":18139,"primaryCompletion":16570,"completion":16570,"start":4034,"enrollment":16773,"conditions":18140,"interventions":18141},[93],[21],[16715,15769,15777,15884],{"nctId":16792,"briefTitle":16793,"status":134,"phases":18143,"primaryCompletion":3712,"completion":3712,"start":4598,"enrollment":16795,"conditions":18144,"interventions":18145},[93],[16797],[16715,15884,15777],{"trials":18147,"activeCount":103},[18148,18152],{"nctId":16831,"briefTitle":16832,"status":123,"phases":18149,"primaryCompletion":15283,"completion":15283,"start":3351,"enrollment":223,"conditions":18150,"interventions":18151},[94],[21,16835],[16715,16837,15884,15777],{"nctId":16846,"briefTitle":16847,"status":390,"phases":18153,"primaryCompletion":16849,"completion":16849,"start":1760,"enrollment":103,"conditions":18154,"interventions":18155},[94],[21],[16715,15884,15769,15777],{"trials":18157,"activeCount":103},[],{"intervention":17990,"totalTrials":1562,"cells":18159},{"EARLY_PHASE1":18160,"PHASE1":18162,"PHASE2":18164,"PHASE3":18166,"PHASE4":18202,"NA":18208},{"trials":18161,"activeCount":103},[],{"trials":18163,"activeCount":103},[],{"trials":18165,"activeCount":103},[],{"trials":18167,"activeCount":103},[18168,18172,18176,18180,18187,18191],{"nctId":17983,"briefTitle":17984,"status":123,"phases":18169,"primaryCompletion":9077,"completion":9077,"start":17986,"enrollment":585,"conditions":18170,"interventions":18171},[93],[17988],[17990,17991],{"nctId":17993,"briefTitle":17994,"status":123,"phases":18173,"primaryCompletion":17996,"completion":17997,"start":3390,"enrollment":17998,"conditions":18174,"interventions":18175},[93],[18000],[17964,18002],{"nctId":18004,"briefTitle":18005,"status":123,"phases":18177,"primaryCompletion":18007,"completion":18008,"start":18009,"enrollment":18010,"conditions":18178,"interventions":18179},[93],[1696],[17964,18002],{"nctId":18181,"briefTitle":18182,"status":123,"phases":18183,"primaryCompletion":15283,"completion":15283,"start":2034,"enrollment":18184,"conditions":18185,"interventions":18186},"NCT01365455","Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year",[93],738,[2068],[17990],{"nctId":18014,"briefTitle":18015,"status":123,"phases":18188,"primaryCompletion":339,"completion":339,"start":18017,"enrollment":446,"conditions":18189,"interventions":18190},[93],[2068],[17990,17991],{"nctId":18192,"briefTitle":18193,"status":123,"phases":18194,"primaryCompletion":18195,"completion":18196,"start":18197,"enrollment":18198,"conditions":18199,"interventions":18201},"NCT03504852","Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate\u002FSevere Chronic Plaque Psoriasis",[93],"2019-09-13","2020-07-15","2018-06-25",331,[18200],"Moderate to Severe Chronic Plaque-type Psoriasis",[17990],{"trials":18203,"activeCount":103},[18204],{"nctId":18023,"briefTitle":18024,"status":123,"phases":18205,"primaryCompletion":18026,"completion":18026,"start":18027,"enrollment":18028,"conditions":18206,"interventions":18207},[94],[1821],[17964,18002],{"trials":18209,"activeCount":103},[],{"intervention":15255,"totalTrials":1562,"cells":18211},{"EARLY_PHASE1":18212,"PHASE1":18214,"PHASE2":18216,"PHASE3":18238,"PHASE4":18244,"NA":18258},{"trials":18213,"activeCount":103},[],{"trials":18215,"activeCount":103},[],{"trials":18217,"activeCount":103},[18218,18226,18230],{"nctId":18219,"briefTitle":18220,"status":390,"phases":18221,"primaryCompletion":18222,"completion":18222,"start":2794,"enrollment":103,"conditions":18223,"interventions":18224},"NCT01824264","Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes",[92],"2016-11",[15133],[18225,15255],"LIK066",{"nctId":16611,"briefTitle":16612,"status":123,"phases":18227,"primaryCompletion":3351,"completion":3351,"start":4707,"enrollment":16614,"conditions":18228,"interventions":18229},[92],[15133],[16617,16617,16617,16617,16617,15255,15177],{"nctId":18231,"briefTitle":18232,"status":123,"phases":18233,"primaryCompletion":3799,"completion":3799,"start":2795,"enrollment":7269,"conditions":18234,"interventions":18236},"NCT01619332","Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763",[91,92],[18235],"Type II Diabetes",[15255,18237],"LEZ763",{"trials":18239,"activeCount":103},[18240],{"nctId":15249,"briefTitle":15250,"status":123,"phases":18241,"primaryCompletion":895,"completion":895,"start":3612,"enrollment":15252,"conditions":18242,"interventions":18243},[92,93],[30],[15051,13838,15255],{"trials":18245,"activeCount":103},[18246,18250,18254],{"nctId":15266,"briefTitle":15267,"status":123,"phases":18247,"primaryCompletion":4524,"completion":4524,"start":2034,"enrollment":15269,"conditions":18248,"interventions":18249},[94],[15271],[15051,15255],{"nctId":15274,"briefTitle":15275,"status":123,"phases":18251,"primaryCompletion":812,"completion":812,"start":3712,"enrollment":2428,"conditions":18252,"interventions":18253},[94],[15271],[15051,15255],{"nctId":16675,"briefTitle":16676,"status":123,"phases":18255,"primaryCompletion":8329,"completion":16678,"start":6556,"enrollment":16679,"conditions":18256,"interventions":18257},[94],[16681,8385],[16683,15255,16673,15320,4424,13838],{"trials":18259,"activeCount":103},[],{"intervention":18261,"totalTrials":2379,"cells":18262},"Tobramycin Inhalation Powder",{"EARLY_PHASE1":18263,"PHASE1":18265,"PHASE2":18267,"PHASE3":18269,"PHASE4":18304,"NA":18320},{"trials":18264,"activeCount":103},[],{"trials":18266,"activeCount":103},[],{"trials":18268,"activeCount":103},[],{"trials":18270,"activeCount":103},[18271,18277,18287,18295],{"nctId":18272,"briefTitle":18273,"status":123,"phases":18274,"primaryCompletion":3784,"completion":3784,"start":1024,"enrollment":2149,"conditions":18275,"interventions":18276},"NCT00918957","A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo",[93],[9233],[18261],{"nctId":18278,"briefTitle":18279,"status":123,"phases":18280,"primaryCompletion":1715,"completion":18281,"start":18282,"enrollment":2112,"conditions":18283,"interventions":18285},"NCT00982930","Open Label Extension to Bridging Study CTBM100C2303",[93],"2011-10-06","2009-08-12",[18284,9233],"Pseudomonas Aeruginosa",[18286],"Tobramycin inhalation powder",{"nctId":18288,"briefTitle":18289,"status":123,"phases":18290,"primaryCompletion":3400,"completion":3400,"start":966,"enrollment":18291,"conditions":18292,"interventions":18293},"NCT00388505","Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis",[93],517,[9233],[18261,18294],"Tobramycin Solution for Inhalation",{"nctId":18296,"briefTitle":18297,"status":123,"phases":18298,"primaryCompletion":18299,"completion":18299,"start":18300,"enrollment":1622,"conditions":18301,"interventions":18303},"NCT01069705","Second Open Label Extension to Bridging Study CTBM100C2303",[93],"2012-03-19","2010-02-12",[18302,18284],"Pulmonary Infections",[18286],{"trials":18305,"activeCount":103},[18306,18314],{"nctId":18307,"briefTitle":18308,"status":123,"phases":18309,"primaryCompletion":1681,"completion":1681,"start":15346,"enrollment":1423,"conditions":18310,"interventions":18311},"NCT01844778","Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)",[94],[9233],[18261,18312,18313],"Tobramycin inhalation solution","Colistimethate",{"nctId":18315,"briefTitle":18316,"status":134,"phases":18317,"primaryCompletion":1731,"completion":1731,"start":3559,"enrollment":7257,"conditions":18318,"interventions":18319},"NCT02015663","Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on \u002F 28 Day Off Cycles",[94],[9233],[18261],{"trials":18321,"activeCount":103},[],{"intervention":17714,"totalTrials":2379,"cells":18323},{"EARLY_PHASE1":18324,"PHASE1":18326,"PHASE2":18328,"PHASE3":18330,"PHASE4":18375,"NA":18381},{"trials":18325,"activeCount":103},[],{"trials":18327,"activeCount":103},[],{"trials":18329,"activeCount":103},[],{"trials":18331,"activeCount":103},[18332,18342,18351,18358,18367],{"nctId":18333,"briefTitle":18334,"status":134,"phases":18335,"primaryCompletion":18336,"completion":18336,"start":18337,"enrollment":18338,"conditions":18339,"interventions":18340},"NCT03810313","Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion",[93],"2021-07-26","2019-07-03",493,[17675],[18341,17714],"Brolucizumab 6 mg",{"nctId":18343,"briefTitle":18344,"status":123,"phases":18345,"primaryCompletion":326,"completion":326,"start":18346,"enrollment":1839,"conditions":18347,"interventions":18349},"NCT04047472","Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration",[93],"2019-11-29",[18348],"Neovascular Age-Related Macular Degeneration",[18350,17714],"Brolucizumab 6mg",{"nctId":18352,"briefTitle":18353,"status":123,"phases":18354,"primaryCompletion":7021,"completion":7021,"start":6568,"enrollment":18355,"conditions":18356,"interventions":18357},"NCT04005352","Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)",[93],734,[4458],[18341,17714],{"nctId":18359,"briefTitle":18360,"status":123,"phases":18361,"primaryCompletion":18362,"completion":18362,"start":18363,"enrollment":1143,"conditions":18364,"interventions":18366},"NCT03386474","Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD",[93],"2018-09-06","2018-01-15",[18365],"Neovascular Age-related Macular Degeneration",[18341,17714],{"nctId":18368,"briefTitle":18369,"status":134,"phases":18370,"primaryCompletion":18336,"completion":18336,"start":18371,"enrollment":1514,"conditions":18372,"interventions":18374},"NCT03802630","Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion",[93],"2019-07-02",[18373],"Branch Retinal Vein Occlusion",[18341,17714],{"trials":18376,"activeCount":103},[18377],{"nctId":17707,"briefTitle":17708,"status":123,"phases":18378,"primaryCompletion":17710,"completion":1951,"start":7581,"enrollment":4506,"conditions":18379,"interventions":18380},[94],[17712],[17634,17714],{"trials":18382,"activeCount":103},[],{"intervention":4804,"totalTrials":2379,"cells":18384},{"EARLY_PHASE1":18385,"PHASE1":18387,"PHASE2":18389,"PHASE3":18391,"PHASE4":18401,"NA":18419},{"trials":18386,"activeCount":103},[],{"trials":18388,"activeCount":103},[],{"trials":18390,"activeCount":103},[],{"trials":18392,"activeCount":103},[18393,18397],{"nctId":4798,"briefTitle":4799,"status":123,"phases":18394,"primaryCompletion":2509,"completion":2509,"start":3604,"enrollment":3120,"conditions":18395,"interventions":18396},[93],[4645],[4803,4305,4804,4805,4769],{"nctId":4833,"briefTitle":4834,"status":123,"phases":18398,"primaryCompletion":1670,"completion":1670,"start":3210,"enrollment":4836,"conditions":18399,"interventions":18400},[93],[4645],[4305,4839,4840],{"trials":18402,"activeCount":103},[18403,18407,18411,18415],{"nctId":5016,"briefTitle":5017,"status":123,"phases":18404,"primaryCompletion":1682,"completion":1682,"start":3271,"enrollment":792,"conditions":18405,"interventions":18406},[94],[5020],[196,4765,4804,4767,4769],{"nctId":7705,"briefTitle":7706,"status":134,"phases":18408,"primaryCompletion":4967,"completion":4967,"start":4845,"enrollment":1444,"conditions":18409,"interventions":18410},[94],[4701],[4804,7710,7711,4766,4769],{"nctId":17255,"briefTitle":17256,"status":123,"phases":18412,"primaryCompletion":4556,"completion":4556,"start":16899,"enrollment":3544,"conditions":18413,"interventions":18414},[94],[17239],[17242,4765,4804,17260,17261],{"nctId":5111,"briefTitle":5112,"status":123,"phases":18416,"primaryCompletion":5114,"completion":5114,"start":1025,"enrollment":1941,"conditions":18417,"interventions":18418},[94],[5116],[4305,5074,4767,4628,4804],{"trials":18420,"activeCount":103},[],{"intervention":17242,"totalTrials":2379,"cells":18422},{"EARLY_PHASE1":18423,"PHASE1":18425,"PHASE2":18427,"PHASE3":18440,"PHASE4":18442,"NA":18460},{"trials":18424,"activeCount":103},[],{"trials":18426,"activeCount":103},[],{"trials":18428,"activeCount":103},[18429,18436],{"nctId":18430,"briefTitle":18431,"status":123,"phases":18432,"primaryCompletion":5193,"completion":5193,"start":18433,"enrollment":2633,"conditions":18434,"interventions":18435},"NCT01552629","A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients",[92],"2012-01-05",[10365],[9064,17242],{"nctId":7463,"briefTitle":7464,"status":123,"phases":18437,"primaryCompletion":7466,"completion":7467,"start":7468,"enrollment":792,"conditions":18438,"interventions":18439},[92],[7470],[7403,7472,5074],{"trials":18441,"activeCount":103},[],{"trials":18443,"activeCount":103},[18444,18448,18452,18456],{"nctId":17234,"briefTitle":17235,"status":134,"phases":18445,"primaryCompletion":7931,"start":4621,"enrollment":17237,"conditions":18446,"interventions":18447},[94],[17239,17240],[17242,4765],{"nctId":5067,"briefTitle":5068,"status":123,"phases":18449,"primaryCompletion":5070,"completion":5070,"start":5071,"enrollment":3705,"conditions":18450,"interventions":18451},[94],[4744],[196,5074,4803,5075,4626,4769],{"nctId":17255,"briefTitle":17256,"status":123,"phases":18453,"primaryCompletion":4556,"completion":4556,"start":16899,"enrollment":3544,"conditions":18454,"interventions":18455},[94],[17239],[17242,4765,4804,17260,17261],{"nctId":5111,"briefTitle":5112,"status":123,"phases":18457,"primaryCompletion":5114,"completion":5114,"start":1025,"enrollment":1941,"conditions":18458,"interventions":18459},[94],[5116],[4305,5074,4767,4628,4804],{"trials":18461,"activeCount":103},[],{"intervention":4649,"totalTrials":637,"cells":18463},{"EARLY_PHASE1":18464,"PHASE1":18466,"PHASE2":18468,"PHASE3":18470,"PHASE4":18488,"NA":18498},{"trials":18465,"activeCount":103},[],{"trials":18467,"activeCount":103},[],{"trials":18469,"activeCount":103},[],{"trials":18471,"activeCount":103},[18472,18480,18484],{"nctId":18473,"briefTitle":18474,"status":123,"phases":18475,"primaryCompletion":3410,"start":825,"enrollment":2439,"conditions":18476,"interventions":18477},"NCT00425308","Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.",[93],[4701],[18478,18479,4649],"Everolimus + Cyclosporine","Everolimus + Enteric-coated Mycophenolate Sodium",{"nctId":4639,"briefTitle":4640,"status":123,"phases":18481,"primaryCompletion":4642,"completion":4642,"start":918,"enrollment":4643,"conditions":18482,"interventions":18483},[93],[4645],[196,4647,4648,4649],{"nctId":4869,"briefTitle":4870,"status":123,"phases":18485,"primaryCompletion":2762,"completion":2762,"start":3800,"enrollment":568,"conditions":18486,"interventions":18487},[93],[4691],[196,4874,4875,4649],{"trials":18489,"activeCount":103},[18490,18494],{"nctId":5030,"briefTitle":5031,"status":123,"phases":18491,"primaryCompletion":880,"completion":880,"start":835,"enrollment":5033,"conditions":18492,"interventions":18493},[94],[5035],[196,4987,4647,4649],{"nctId":5051,"briefTitle":5052,"status":123,"phases":18495,"primaryCompletion":4400,"completion":4400,"start":5026,"enrollment":5054,"conditions":18496,"interventions":18497},[94],[4701],[196,5057,4648,4649],{"trials":18499,"activeCount":103},[],{"intervention":4874,"totalTrials":637,"cells":18501},{"EARLY_PHASE1":18502,"PHASE1":18504,"PHASE2":18506,"PHASE3":18514,"PHASE4":18533,"NA":18539},{"trials":18503,"activeCount":103},[],{"trials":18505,"activeCount":103},[],{"trials":18507,"activeCount":103},[18508],{"nctId":18509,"briefTitle":18510,"status":123,"phases":18511,"primaryCompletion":4335,"completion":4335,"start":988,"enrollment":13149,"conditions":18512,"interventions":18513},"NCT00423098","Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare",[92],[1800],[4874,17261,17260],{"trials":18515,"activeCount":103},[18516,18523,18527],{"nctId":18517,"briefTitle":18518,"status":123,"phases":18519,"primaryCompletion":9096,"start":18520,"enrollment":1223,"conditions":18521,"interventions":18522},"NCT00149916","Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107",[93],"2000-04",[4985],[4874],{"nctId":4869,"briefTitle":4870,"status":123,"phases":18524,"primaryCompletion":2762,"completion":2762,"start":3800,"enrollment":568,"conditions":18525,"interventions":18526},[93],[4691],[196,4874,4875,4649],{"nctId":18528,"briefTitle":18529,"status":123,"phases":18530,"primaryCompletion":745,"start":15065,"enrollment":967,"conditions":18531,"interventions":18532},"NCT00149903","Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients",[93],[4985],[4874],{"trials":18534,"activeCount":103},[18535],{"nctId":5077,"briefTitle":5078,"status":123,"phases":18536,"primaryCompletion":4524,"completion":4524,"start":865,"enrollment":5080,"conditions":18537,"interventions":18538},[94],[5082],[196,4875,5084,4874],{"trials":18540,"activeCount":103},[],{"intervention":18542,"totalTrials":637,"cells":18543},"Amlodipine 5 mg",{"EARLY_PHASE1":18544,"PHASE1":18546,"PHASE2":18548,"PHASE3":18550,"PHASE4":18595,"NA":18606},{"trials":18545,"activeCount":103},[],{"trials":18547,"activeCount":103},[],{"trials":18549,"activeCount":103},[],{"trials":18551,"activeCount":103},[18552,18561,18573,18587],{"nctId":18553,"briefTitle":18554,"status":123,"phases":18555,"primaryCompletion":3410,"completion":3410,"start":5696,"enrollment":18556,"conditions":18557,"interventions":18558},"NCT00699192","Safety, Tolerability, and Efficacy of Once Daily Amlodipine\u002FValsartan 5\u002F80 as Compared to Amlodipine\u002FValsartan 5\u002F40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension",[93],965,[21],[18542,18559,18560],"Valsartan 80 mg","Valsartan 40 mg",{"nctId":18562,"briefTitle":18563,"status":123,"phases":18564,"primaryCompletion":1025,"completion":1025,"start":3195,"enrollment":18565,"conditions":18566,"interventions":18567},"NCT00425373","Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension",[92,93],1474,[17007],[18568,18569,18570,18571,18560,18559,18572,18542],"Valsartan + amlodipine 40\u002F2.5 mg","Valsartan + amlodipine 40\u002F5 mg","Valsartan + amlodipine 80\u002F2.5 mg","Valsartan + amlodipine 80\u002F5 mg","Amlodipine 2.5 mg",{"nctId":18574,"briefTitle":18575,"status":123,"phases":18576,"primaryCompletion":3410,"completion":3410,"start":3279,"enrollment":18577,"conditions":18578,"interventions":18579},"NCT00739973","Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension",[93],2694,[21],[18580,18581,18542,18582,18583,18584,18585,18586],"Aliskiren 150 mg","Aliskiren 300 mg","Amlodipine 10 mg","Aliskiren\u002Famlodipine 150\u002F5 mg","Aliskiren\u002Famlodipine 150\u002F10 mg","Aliskiren\u002Famlodipine 300\u002F5 mg","Aliskiren\u002Famlodipine 300\u002F10 mg",{"nctId":18588,"briefTitle":18589,"status":123,"phases":18590,"primaryCompletion":4642,"completion":4642,"start":3254,"enrollment":18591,"conditions":18592,"interventions":18593},"NCT00437645","Efficacy and Safety of Valsartan\u002FAmlodipine Compared to Amlodipine in Patients With Essential Hypertension",[93],1183,[17007],[18594,18542],"Valsartan 160 mg",{"trials":18596,"activeCount":103},[18597],{"nctId":18598,"briefTitle":18599,"status":123,"phases":18600,"primaryCompletion":949,"completion":949,"start":917,"enrollment":17308,"conditions":18601,"interventions":18602},"NCT00687973","Effect of the Fixed Dose Combination Amlodipine\u002FValsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg",[94],[21],[18603,18542,18582,18604,18605],"Valsartan\u002Famlodipine 80\u002F5 mg","Atenolol 50 mg","Atenolol 100 mg",{"trials":18607,"activeCount":103},[],{"intervention":15769,"totalTrials":637,"cells":18609},{"EARLY_PHASE1":18610,"PHASE1":18612,"PHASE2":18614,"PHASE3":18624,"PHASE4":18634,"NA":18640},{"trials":18611,"activeCount":103},[],{"trials":18613,"activeCount":103},[],{"trials":18615,"activeCount":103},[18616,18620],{"nctId":16730,"briefTitle":16731,"status":134,"phases":18617,"primaryCompletion":4301,"completion":4301,"start":4598,"enrollment":422,"conditions":18618,"interventions":18619},[92],[16734],[16715,15777,15769],{"nctId":16752,"briefTitle":16753,"status":123,"phases":18621,"primaryCompletion":3760,"completion":3760,"start":3410,"enrollment":9331,"conditions":18622,"interventions":18623},[92],[15870],[16750,16757],{"trials":18625,"activeCount":103},[18626,18630],{"nctId":15760,"briefTitle":15761,"status":123,"phases":18627,"primaryCompletion":15763,"completion":15763,"start":15764,"enrollment":15765,"conditions":18628,"interventions":18629},[93],[15767],[15726,15769,5447],{"nctId":16770,"briefTitle":16771,"status":123,"phases":18631,"primaryCompletion":16570,"completion":16570,"start":4034,"enrollment":16773,"conditions":18632,"interventions":18633},[93],[21],[16715,15769,15777,15884],{"trials":18635,"activeCount":103},[18636],{"nctId":16846,"briefTitle":16847,"status":390,"phases":18637,"primaryCompletion":16849,"completion":16849,"start":1760,"enrollment":103,"conditions":18638,"interventions":18639},[94],[21],[16715,15884,15769,15777],{"trials":18641,"activeCount":103},[],{"intervention":15096,"totalTrials":637,"cells":18643},{"EARLY_PHASE1":18644,"PHASE1":18646,"PHASE2":18648,"PHASE3":18650,"PHASE4":18664,"NA":18674},{"trials":18645,"activeCount":103},[],{"trials":18647,"activeCount":103},[],{"trials":18649,"activeCount":103},[],{"trials":18651,"activeCount":103},[18652,18656,18660],{"nctId":15090,"briefTitle":15091,"status":123,"phases":18653,"primaryCompletion":895,"completion":895,"start":926,"enrollment":630,"conditions":18654,"interventions":18655},[93],[15094],[15051,15096],{"nctId":15121,"briefTitle":15122,"status":123,"phases":18657,"primaryCompletion":15109,"completion":15109,"start":15058,"enrollment":15124,"conditions":18658,"interventions":18659},[93],[30],[15029,15096,15127],{"nctId":15213,"briefTitle":15214,"status":123,"phases":18661,"primaryCompletion":5696,"completion":15216,"start":996,"enrollment":15217,"conditions":18662,"interventions":18663},[93],[30],[15029,15220,13838],{"trials":18665,"activeCount":103},[18666,18670],{"nctId":15295,"briefTitle":15296,"status":134,"phases":18667,"primaryCompletion":812,"completion":812,"start":2033,"enrollment":167,"conditions":18668,"interventions":18669},[94],[15133],[15051,15096,13838],{"nctId":16695,"briefTitle":16696,"status":123,"phases":18671,"primaryCompletion":16698,"completion":16698,"start":16699,"enrollment":709,"conditions":18672,"interventions":18673},[94],[15233,16701],[16703,15220,13838],{"trials":18675,"activeCount":103},[],{"intervention":7842,"totalTrials":637,"cells":18677},{"EARLY_PHASE1":18678,"PHASE1":18680,"PHASE2":18682,"PHASE3":18688,"PHASE4":18694,"NA":18711},{"trials":18679,"activeCount":103},[],{"trials":18681,"activeCount":103},[],{"trials":18683,"activeCount":103},[18684],{"nctId":16326,"briefTitle":16327,"status":123,"phases":18685,"primaryCompletion":4070,"completion":4070,"start":3447,"enrollment":16329,"conditions":18686,"interventions":18687},[92],[18],[16256,16332,16333],{"trials":18689,"activeCount":103},[18690],{"nctId":15625,"briefTitle":15626,"status":123,"phases":18691,"primaryCompletion":15283,"completion":15283,"start":5733,"enrollment":15628,"conditions":18692,"interventions":18693},[93],[15555],[15524,15588,7842],{"trials":18695,"activeCount":103},[18696,18703,18707],{"nctId":18697,"briefTitle":18698,"status":123,"phases":18699,"primaryCompletion":918,"completion":918,"start":4071,"enrollment":18700,"conditions":18701,"interventions":18702},"NCT00134979","Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease",[94],847,[24],[7842],{"nctId":16410,"briefTitle":16411,"status":390,"phases":18704,"primaryCompletion":1671,"completion":1671,"start":1818,"enrollment":103,"conditions":18705,"interventions":18706},[94],[15555],[7850,7842],{"nctId":7833,"briefTitle":7834,"status":134,"phases":18708,"primaryCompletion":7836,"completion":7837,"start":7838,"enrollment":1034,"conditions":18709,"interventions":18710},[94],[7840],[6218,7811,7842,7811,7842],{"trials":18712,"activeCount":103},[],{"intervention":18714,"totalTrials":637,"cells":18715},"ICL670",{"EARLY_PHASE1":18716,"PHASE1":18718,"PHASE2":18720,"PHASE3":18736,"PHASE4":18747,"NA":18766},{"trials":18717,"activeCount":103},[],{"trials":18719,"activeCount":103},[],{"trials":18721,"activeCount":103},[18722,18728],{"nctId":18723,"briefTitle":18724,"status":123,"phases":18725,"primaryCompletion":4845,"start":4061,"enrollment":2910,"conditions":18726,"interventions":18727},"NCT01090323","Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).",[92],[3952],[18714],{"nctId":18729,"briefTitle":18730,"status":123,"phases":18731,"primaryCompletion":4556,"start":18732,"enrollment":2439,"conditions":18733,"interventions":18735},"NCT01044186","A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity",[92],"2003-06",[18734],"Transfusional Iron Overload",[18714],{"trials":18737,"activeCount":103},[18738],{"nctId":18739,"briefTitle":18740,"status":123,"phases":18741,"primaryCompletion":17497,"start":881,"enrollment":18742,"conditions":18743,"interventions":18745},"NCT00061750","Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions",[93],595,[18744],"Beta-Thalassemia",[18714,18746],"deferoxamine",{"trials":18748,"activeCount":103},[18749,18756],{"nctId":18750,"briefTitle":18751,"status":123,"phases":18752,"primaryCompletion":1681,"completion":1681,"start":3799,"enrollment":34,"conditions":18753,"interventions":18755},"NCT01610297","Post Hematopoietic Stem Cell Transplantation",[94],[18754],"Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major",[18714],{"nctId":18757,"briefTitle":18758,"status":134,"phases":18759,"primaryCompletion":18760,"completion":18760,"start":18761,"enrollment":2367,"conditions":18762,"interventions":18763},"NCT01818726","Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients",[94],"2016-10-17","2014-06-23",[7412],[18714,18764,18765],"Chelation","No chelation",{"trials":18767,"activeCount":103},[],{"intervention":18769,"totalTrials":637,"cells":18770},"Rivastigmine transdermal patch",{"EARLY_PHASE1":18771,"PHASE1":18773,"PHASE2":18775,"PHASE3":18777,"PHASE4":18795,"NA":18817},{"trials":18772,"activeCount":103},[],{"trials":18774,"activeCount":103},[],{"trials":18776,"activeCount":103},[],{"trials":18778,"activeCount":103},[18779,18788],{"nctId":18780,"briefTitle":18781,"status":123,"phases":18782,"completion":4621,"start":4732,"enrollment":18783,"conditions":18784,"interventions":18786},"NCT00099242","Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease",[93],1040,[10401,18785],"Dementia, Alzheimer Type",[18787],"rivastigmine transdermal patch",{"nctId":18789,"briefTitle":18790,"status":123,"phases":18791,"primaryCompletion":3400,"completion":4081,"start":3254,"enrollment":18792,"conditions":18793,"interventions":18794},"NCT00423085","Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease",[93],859,[10401],[18769],{"trials":18796,"activeCount":103},[18797,18803,18810],{"nctId":18798,"briefTitle":18799,"status":123,"phases":18800,"primaryCompletion":1714,"completion":1714,"start":2795,"enrollment":3605,"conditions":18801,"interventions":18802},"NCT01529619","Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors",[94],[10401],[18769],{"nctId":18804,"briefTitle":18805,"status":134,"phases":18806,"primaryCompletion":4598,"completion":4598,"start":4707,"enrollment":1901,"conditions":18807,"interventions":18809},"NCT00881205","Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment",[94],[27,18808],"Cognitive Impairment",[18769],{"nctId":18811,"briefTitle":18812,"status":123,"phases":18813,"primaryCompletion":1715,"completion":1715,"start":10499,"enrollment":18814,"conditions":18815,"interventions":18816},"NCT00731224","Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.",[94],380,[10401],[18769],{"trials":18818,"activeCount":103},[],{"intervention":7851,"totalTrials":637,"cells":18820},{"EARLY_PHASE1":18821,"PHASE1":18823,"PHASE2":18825,"PHASE3":18835,"PHASE4":18841,"NA":18851},{"trials":18822,"activeCount":103},[],{"trials":18824,"activeCount":103},[],{"trials":18826,"activeCount":103},[18827,18831],{"nctId":8262,"briefTitle":8263,"status":123,"phases":18828,"primaryCompletion":3799,"completion":3799,"start":3712,"enrollment":8265,"conditions":18829,"interventions":18830},[92],[8267],[3057,7851],{"nctId":16342,"briefTitle":16343,"status":123,"phases":18832,"primaryCompletion":4642,"completion":4642,"start":3195,"enrollment":4506,"conditions":18833,"interventions":18834},[92],[18],[7850,7851],{"trials":18836,"activeCount":103},[18837],{"nctId":16372,"briefTitle":16373,"status":123,"phases":18838,"primaryCompletion":864,"start":880,"enrollment":13129,"conditions":18839,"interventions":18840},[93],[18],[7850,7851],{"trials":18842,"activeCount":103},[18843,18847],{"nctId":16416,"briefTitle":16417,"status":123,"phases":18844,"primaryCompletion":1723,"completion":1723,"start":1671,"enrollment":16419,"conditions":18845,"interventions":18846},[94],[24],[7850,7851],{"nctId":7844,"briefTitle":7845,"status":123,"phases":18848,"primaryCompletion":5246,"completion":5246,"start":4925,"enrollment":258,"conditions":18849,"interventions":18850},[94],[24],[7811,7849,7850,7851],{"trials":18852,"activeCount":103},[],{"intervention":18854,"totalTrials":637,"cells":18855},"Erenumab",{"EARLY_PHASE1":18856,"PHASE1":18858,"PHASE2":18860,"PHASE3":18862,"PHASE4":18883,"NA":18913},{"trials":18857,"activeCount":103},[],{"trials":18859,"activeCount":103},[],{"trials":18861,"activeCount":103},[],{"trials":18863,"activeCount":103},[18864,18873],{"nctId":18865,"briefTitle":18866,"status":123,"phases":18867,"primaryCompletion":18868,"completion":18868,"start":18869,"enrollment":8112,"conditions":18870,"interventions":18872},"NCT03333109","Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients",[93],"2020-01-13","2018-02-08",[18871],"Episodic Migraine",[18854],{"nctId":18874,"briefTitle":18875,"status":123,"phases":18876,"primaryCompletion":18877,"completion":18878,"start":18879,"enrollment":15262,"conditions":18880,"interventions":18882},"NCT03867201","Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients",[93],"2021-08-11","2024-04-30","2019-08-26",[18881],"Migraine",[18854],{"trials":18884,"activeCount":103},[18885,18894,18904],{"nctId":18886,"briefTitle":18887,"status":123,"phases":18888,"primaryCompletion":18889,"completion":18889,"start":202,"enrollment":2149,"conditions":18890,"interventions":18892},"NCT03977649","A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients",[94],"2021-07-05",[18891],"Migraine Disorders",[18893],"erenumab",{"nctId":18895,"briefTitle":18896,"status":123,"phases":18897,"primaryCompletion":14534,"completion":18898,"start":18899,"enrollment":18900,"conditions":18901,"interventions":18903},"NCT04084314","Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study",[94],"2023-03-13","2019-09-30",701,[18881,18891,18902],"Migraine Headache",[18854],{"nctId":18905,"briefTitle":18906,"status":123,"phases":18907,"primaryCompletion":2774,"completion":2774,"start":18908,"enrollment":18909,"conditions":18910,"interventions":18911},"NCT03828539","Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine",[94],"2019-02-22",777,[18881],[18854,18912],"Topiramate",{"trials":18914,"activeCount":103},[],{"intervention":4767,"totalTrials":637,"cells":18916},{"EARLY_PHASE1":18917,"PHASE1":18919,"PHASE2":18921,"PHASE3":18923,"PHASE4":18929,"NA":18949},{"trials":18918,"activeCount":103},[],{"trials":18920,"activeCount":103},[],{"trials":18922,"activeCount":103},[],{"trials":18924,"activeCount":103},[18925],{"nctId":4757,"briefTitle":4758,"status":123,"phases":18926,"primaryCompletion":4760,"completion":4760,"start":4761,"enrollment":4762,"conditions":18927,"interventions":18928},[93],[4691,4701],[196,4765,4766,4767,4768,4769,4770],{"trials":18930,"activeCount":103},[18931,18935,18941,18945],{"nctId":5016,"briefTitle":5017,"status":123,"phases":18932,"primaryCompletion":1682,"completion":1682,"start":3271,"enrollment":792,"conditions":18933,"interventions":18934},[94],[5020],[196,4765,4804,4767,4769],{"nctId":18936,"briefTitle":18937,"status":134,"phases":18938,"primaryCompletion":5696,"completion":5696,"start":3474,"enrollment":5594,"conditions":18939,"interventions":18940},"NCT00434590","Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients",[94],[4691],[5075],{"nctId":5067,"briefTitle":5068,"status":123,"phases":18942,"primaryCompletion":5070,"completion":5070,"start":5071,"enrollment":3705,"conditions":18943,"interventions":18944},[94],[4744],[196,5074,4803,5075,4626,4769],{"nctId":5111,"briefTitle":5112,"status":123,"phases":18946,"primaryCompletion":5114,"completion":5114,"start":1025,"enrollment":1941,"conditions":18947,"interventions":18948},[94],[5116],[4305,5074,4767,4628,4804],{"trials":18950,"activeCount":103},[],{"intervention":18952,"totalTrials":637,"cells":18953},"INC424",{"EARLY_PHASE1":18954,"PHASE1":18956,"PHASE2":18966,"PHASE3":18992,"PHASE4":19003,"NA":19013},{"trials":18955,"activeCount":103},[],{"trials":18957,"activeCount":103},[18958],{"nctId":18959,"briefTitle":18960,"status":134,"phases":18961,"primaryCompletion":18962,"completion":18962,"start":18963,"enrollment":19,"conditions":18964,"interventions":18965},"NCT01730248","A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis",[91],"2017-09-28","2012-12-18",[2369],[18952,517],{"trials":18967,"activeCount":103},[18968,18983],{"nctId":18969,"briefTitle":18970,"status":123,"phases":18971,"primaryCompletion":18972,"completion":18972,"start":18973,"enrollment":2579,"conditions":18974,"interventions":18981},"NCT01787552","A Phase Ib\u002FII Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF",[91,92],"2018-04-10","2013-05-08",[2430,18975,18976,2470,18977,10702,3335,18978,18979,18980],"Thrombocytosis","Essential Thrombocythemia","Myeloproliferative Disorders","Blood Coagulation Disorders","Blood Platelet Disorders","Hemorrhagic Disorders",[18982,18952],"LDE225",{"nctId":18984,"briefTitle":18985,"status":123,"phases":18986,"primaryCompletion":18987,"completion":3095,"start":18988,"enrollment":3098,"conditions":18989,"interventions":18991},"NCT03774082","Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant",[92],"2022-02-25","2020-05-20",[18990],"Graft vs Host Disease",[18952],{"trials":18993,"activeCount":103},[18994],{"nctId":18995,"briefTitle":18996,"status":123,"phases":18997,"primaryCompletion":18998,"completion":18998,"start":18999,"enrollment":19000,"conditions":19001,"interventions":19002},"NCT01493414","INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.",[93],"2017-01-26","2011-08-16",2233,[2369],[18952],{"trials":19004,"activeCount":103},[19005],{"nctId":19006,"briefTitle":19007,"status":123,"phases":19008,"primaryCompletion":3559,"completion":3559,"start":5733,"enrollment":114,"conditions":19009,"interventions":19012},"NCT01558739","Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)",[94],[2381,19010,19011],"Post Polycythaemia Myelofibrosis (PPV MF)","Post Essential Thrombocythaemia Myelofibrosis (PET-MF)",[18952],{"trials":19014,"activeCount":103},[],{"intervention":4987,"totalTrials":1630,"cells":19016},{"EARLY_PHASE1":19017,"PHASE1":19019,"PHASE2":19021,"PHASE3":19030,"PHASE4":19036,"NA":19046},{"trials":19018,"activeCount":103},[],{"trials":19020,"activeCount":103},[],{"trials":19022,"activeCount":103},[19023],{"nctId":19024,"briefTitle":19025,"status":123,"phases":19026,"primaryCompletion":5696,"completion":5696,"start":825,"enrollment":19027,"conditions":19028,"interventions":19029},"NCT00403416","Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients",[91,92],215,[4691],[4330,4805],{"trials":19031,"activeCount":103},[19032],{"nctId":4798,"briefTitle":4799,"status":123,"phases":19033,"primaryCompletion":2509,"completion":2509,"start":3604,"enrollment":3120,"conditions":19034,"interventions":19035},[93],[4645],[4803,4305,4804,4805,4769],{"trials":19037,"activeCount":103},[19038,19042],{"nctId":4981,"briefTitle":4982,"status":123,"phases":19039,"primaryCompletion":4093,"completion":4093,"start":3845,"enrollment":1660,"conditions":19040,"interventions":19041},[94],[4985],[196,4765,4987],{"nctId":5030,"briefTitle":5031,"status":123,"phases":19043,"primaryCompletion":880,"completion":880,"start":835,"enrollment":5033,"conditions":19044,"interventions":19045},[94],[5035],[196,4987,4647,4649],{"trials":19047,"activeCount":103},[],{"intervention":17261,"totalTrials":1630,"cells":19049},{"EARLY_PHASE1":19050,"PHASE1":19052,"PHASE2":19054,"PHASE3":19073,"PHASE4":19075,"NA":19081},{"trials":19051,"activeCount":103},[],{"trials":19053,"activeCount":103},[],{"trials":19055,"activeCount":103},[19056,19060,19069],{"nctId":8055,"briefTitle":8056,"status":123,"phases":19057,"primaryCompletion":3243,"completion":3243,"start":4034,"enrollment":2910,"conditions":19058,"interventions":19059},[92],[8059],[8061,8062,6673],{"nctId":19061,"briefTitle":19062,"status":134,"phases":19063,"primaryCompletion":19064,"completion":19064,"start":19065,"enrollment":1672,"conditions":19066,"interventions":19068},"NCT01364389","A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica",[92],"2013-01-29","2011-02-14",[1696,19067],"Inflammatory Diseases",[11428,10126,17261],{"nctId":18509,"briefTitle":18510,"status":123,"phases":19070,"primaryCompletion":4335,"completion":4335,"start":988,"enrollment":13149,"conditions":19071,"interventions":19072},[92],[1800],[4874,17261,17260],{"trials":19074,"activeCount":103},[],{"trials":19076,"activeCount":103},[19077],{"nctId":17255,"briefTitle":17256,"status":123,"phases":19078,"primaryCompletion":4556,"completion":4556,"start":16899,"enrollment":3544,"conditions":19079,"interventions":19080},[94],[17239],[17242,4765,4804,17260,17261],{"trials":19082,"activeCount":103},[],{"intervention":19084,"totalTrials":1630,"cells":19085},"OAV101",{"EARLY_PHASE1":19086,"PHASE1":19088,"PHASE2":19090,"PHASE3":19092,"PHASE4":19118,"NA":19129},{"trials":19087,"activeCount":103},[],{"trials":19089,"activeCount":103},[],{"trials":19091,"activeCount":103},[],{"trials":19093,"activeCount":103},[19094,19103,19110],{"nctId":19095,"briefTitle":19096,"status":123,"phases":19097,"primaryCompletion":566,"completion":19098,"start":19099,"enrollment":5080,"conditions":19100,"interventions":19102},"NCT05089656","Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)",[93],"2025-04-29","2022-02-01",[19101],"Type 2 Spinal Muscular Atrophy",[19084],{"nctId":19104,"briefTitle":19105,"status":123,"phases":19106,"primaryCompletion":2938,"completion":2938,"start":19107,"enrollment":630,"conditions":19108,"interventions":19109},"NCT04851873","Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)",[93],"2021-09-08",[5472],[19084],{"nctId":19111,"briefTitle":19112,"status":123,"phases":19113,"primaryCompletion":19114,"completion":19114,"start":19115,"enrollment":34,"conditions":19116,"interventions":19117},"NCT05386680","Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam",[93],"2024-11-29","2023-01-12",[5472],[19084],{"trials":19119,"activeCount":103},[19120],{"nctId":19121,"briefTitle":19122,"status":123,"phases":19123,"primaryCompletion":19124,"completion":19124,"start":19125,"enrollment":1672,"conditions":19126,"interventions":19128},"NCT05073133","Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)",[94],"2023-08-08","2021-11-04",[19127],"Muscular Atrophy, Spinal",[19084],{"trials":19130,"activeCount":103},[],{"intervention":19132,"totalTrials":317,"cells":19133},"ENA713",{"EARLY_PHASE1":19134,"PHASE1":19136,"PHASE2":19138,"PHASE3":19140,"PHASE4":19150,"NA":19165},{"trials":19135,"activeCount":103},[],{"trials":19137,"activeCount":103},[],{"trials":19139,"activeCount":103},[],{"trials":19141,"activeCount":103},[19142],{"nctId":19143,"briefTitle":19144,"status":123,"phases":19145,"primaryCompletion":4515,"completion":4515,"start":3759,"enrollment":19146,"conditions":19147,"interventions":19148},"NCT01614886","Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)",[93],216,[10401],[19149,19132],"Active Comparator",{"trials":19151,"activeCount":103},[19152,19158],{"nctId":19153,"briefTitle":19154,"status":123,"phases":19155,"primaryCompletion":3861,"completion":3861,"start":7939,"enrollment":258,"conditions":19156,"interventions":19157},"NCT01948791","16w Interventional Study on Titration and Dose\u002FEfficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients",[94],[10401],[19132],{"nctId":19159,"briefTitle":19160,"status":123,"phases":19161,"primaryCompletion":4410,"completion":4410,"start":3482,"enrollment":7571,"conditions":19162,"interventions":19164},"NCT01585272","Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia",[94],[19163],"Alzheimer's Dementia",[19132],{"trials":19166,"activeCount":103},[],{"intervention":4647,"totalTrials":317,"cells":19168},{"EARLY_PHASE1":19169,"PHASE1":19171,"PHASE2":19173,"PHASE3":19175,"PHASE4":19181,"NA":19191},{"trials":19170,"activeCount":103},[],{"trials":19172,"activeCount":103},[],{"trials":19174,"activeCount":103},[],{"trials":19176,"activeCount":103},[19177],{"nctId":4639,"briefTitle":4640,"status":123,"phases":19178,"primaryCompletion":4642,"completion":4642,"start":918,"enrollment":4643,"conditions":19179,"interventions":19180},[93],[4645],[196,4647,4648,4649],{"trials":19182,"activeCount":103},[19183,19187],{"nctId":5030,"briefTitle":5031,"status":123,"phases":19184,"primaryCompletion":880,"completion":880,"start":835,"enrollment":5033,"conditions":19185,"interventions":19186},[94],[5035],[196,4987,4647,4649],{"nctId":5051,"briefTitle":5052,"status":123,"phases":19188,"primaryCompletion":4400,"completion":4400,"start":5026,"enrollment":5054,"conditions":19189,"interventions":19190},[94],[4701],[196,5057,4648,4649],{"trials":19192,"activeCount":103},[],{"intervention":17688,"totalTrials":317,"cells":19194},{"EARLY_PHASE1":19195,"PHASE1":19197,"PHASE2":19199,"PHASE3":19201,"PHASE4":19216,"NA":19229},{"trials":19196,"activeCount":103},[],{"trials":19198,"activeCount":103},[],{"trials":19200,"activeCount":103},[],{"trials":19202,"activeCount":103},[19203,19212],{"nctId":19204,"briefTitle":19205,"status":123,"phases":19206,"primaryCompletion":3482,"completion":3482,"start":5620,"enrollment":11,"conditions":19207,"interventions":19209},"NCT01217944","Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia",[93],[19208],"Pathological Myopia",[4460,17688,19210,19211],"Sham Ranibizumab","Sham verteporfin PDT",{"nctId":17678,"briefTitle":17679,"status":123,"phases":19213,"primaryCompletion":17681,"completion":17681,"start":17682,"enrollment":17683,"conditions":19214,"interventions":19215},[93],[17685],[17687,17634,17688],{"trials":19217,"activeCount":103},[19218],{"nctId":19219,"briefTitle":19220,"status":123,"phases":19221,"primaryCompletion":7960,"completion":19222,"start":19223,"enrollment":19224,"conditions":19225,"interventions":19227},"NCT01846273","Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)",[94],"2017-03-02","2013-08-07",321,[4458,19226],"Polypoidal Choroidal Vasculopathy",[4460,17688,19228],"Sham PDT",{"trials":19230,"activeCount":103},[],{"intervention":15068,"totalTrials":317,"cells":19232},{"EARLY_PHASE1":19233,"PHASE1":19235,"PHASE2":19237,"PHASE3":19239,"PHASE4":19249,"NA":19255},{"trials":19234,"activeCount":103},[],{"trials":19236,"activeCount":103},[],{"trials":19238,"activeCount":103},[],{"trials":19240,"activeCount":103},[19241,19245],{"nctId":15062,"briefTitle":15063,"status":123,"phases":19242,"primaryCompletion":949,"completion":949,"start":15065,"enrollment":6234,"conditions":19243,"interventions":19244},[93],[30],[15029,15068,13838],{"nctId":15114,"briefTitle":15115,"status":123,"phases":19246,"primaryCompletion":1025,"start":15065,"enrollment":15117,"conditions":19247,"interventions":19248},[93],[30],[15029,15068],{"trials":19250,"activeCount":103},[19251],{"nctId":15259,"briefTitle":15260,"status":123,"phases":19252,"primaryCompletion":3799,"completion":3799,"start":1670,"enrollment":15262,"conditions":19253,"interventions":19254},[94],[15133],[15051,15068,13838],{"trials":19256,"activeCount":103},[],{"intervention":19258,"totalTrials":317,"cells":19259},"Rivastigmine",{"EARLY_PHASE1":19260,"PHASE1":19262,"PHASE2":19264,"PHASE3":19266,"PHASE4":19285,"NA":19296},{"trials":19261,"activeCount":103},[],{"trials":19263,"activeCount":103},[],{"trials":19265,"activeCount":103},[],{"trials":19267,"activeCount":103},[19268,19276],{"nctId":19269,"briefTitle":19270,"status":123,"phases":19271,"primaryCompletion":5114,"completion":5114,"start":4620,"enrollment":19272,"conditions":19273,"interventions":19274},"NCT01399125","A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease",[93],501,[10401],[19275,19258],"Rivastigmine Patch",{"nctId":19277,"briefTitle":19278,"status":123,"phases":19279,"primaryCompletion":918,"completion":918,"start":19280,"enrollment":19281,"conditions":19282,"interventions":19284},"NCT00099216","Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia",[93],"2001-08",708,[19283],"Vascular Dementia",[19258],{"trials":19286,"activeCount":103},[19287],{"nctId":19288,"briefTitle":19289,"status":123,"phases":19290,"primaryCompletion":19291,"completion":19292,"start":19293,"enrollment":1314,"conditions":19294,"interventions":19295},"NCT02989402","A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.",[94],"2022-12-07","2022-12-08","2018-12-31",[10401],[19258],{"trials":19297,"activeCount":103},[],{"intervention":19299,"totalTrials":317,"cells":19300},"Diclofenac potassium",{"EARLY_PHASE1":19301,"PHASE1":19303,"PHASE2":19305,"PHASE3":19307,"PHASE4":19318,"NA":19337},{"trials":19302,"activeCount":103},[],{"trials":19304,"activeCount":103},[],{"trials":19306,"activeCount":103},[],{"trials":19308,"activeCount":103},[19309],{"nctId":19310,"briefTitle":19311,"status":123,"phases":19312,"primaryCompletion":8048,"completion":8048,"start":606,"enrollment":19313,"conditions":19314,"interventions":19316},"NCT02476422","A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain",[93],328,[19315],"Post Operative Dental Pain",[19299,19317],"Ibuprofen",{"trials":19319,"activeCount":103},[19320,19328],{"nctId":19321,"briefTitle":19322,"status":134,"phases":19323,"primaryCompletion":964,"start":964,"enrollment":213,"conditions":19324,"interventions":19326},"NCT01019980","Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections",[94],[19325],"Fever",[19299,19327],"Acetaminophen",{"nctId":19329,"briefTitle":19330,"status":390,"phases":19331,"primaryCompletion":4301,"start":3383,"enrollment":103,"conditions":19332,"interventions":19334},"NCT01257126","Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection",[94],[19333],"Upper Respiratory Tract Infections",[19335,19336],"diclofenac potassium","nimesulide",{"trials":19338,"activeCount":103},[],{"intervention":17410,"totalTrials":317,"cells":19340},{"EARLY_PHASE1":19341,"PHASE1":19343,"PHASE2":19345,"PHASE3":19347,"PHASE4":19353,"NA":19365},{"trials":19342,"activeCount":103},[],{"trials":19344,"activeCount":103},[],{"trials":19346,"activeCount":103},[],{"trials":19348,"activeCount":103},[19349],{"nctId":17404,"briefTitle":17405,"status":123,"phases":19350,"primaryCompletion":4372,"start":3490,"enrollment":3043,"conditions":19351,"interventions":19352},[93],[17408],[17382,17410,17411],{"trials":19354,"activeCount":103},[19355,19359],{"nctId":17476,"briefTitle":17477,"status":390,"phases":19356,"primaryCompletion":895,"enrollment":103,"conditions":19357,"interventions":19358},[94],[17418],[17382,17481,17410],{"nctId":19360,"briefTitle":19361,"status":123,"phases":19362,"primaryCompletion":4301,"start":16570,"enrollment":151,"conditions":19363,"interventions":19364},"NCT00651209","A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)",[94],[17399],[17410],{"trials":19366,"activeCount":103},[],{"intervention":19368,"totalTrials":317,"cells":19369},"Carbidopa\u002Flevodopa\u002Fentacapone",{"EARLY_PHASE1":19370,"PHASE1":19372,"PHASE2":19374,"PHASE3":19376,"PHASE4":19387,"NA":19405},{"trials":19371,"activeCount":103},[],{"trials":19373,"activeCount":103},[],{"trials":19375,"activeCount":103},[],{"trials":19377,"activeCount":103},[19378],{"nctId":19379,"briefTitle":19380,"status":123,"phases":19381,"primaryCompletion":3490,"completion":3490,"start":4810,"enrollment":19382,"conditions":19383,"interventions":19385},"NCT00099268","Efficacy and Safety of Carbidopa\u002FLevodopa\u002FEntacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy",[93],747,[19384],"Parkinson's Disease",[19368,19386],"Immediate release carbidopa\u002Flevodopa",{"trials":19388,"activeCount":103},[19389,19397],{"nctId":19390,"briefTitle":19391,"status":390,"phases":19392,"primaryCompletion":4335,"completion":4335,"start":3473,"enrollment":103,"conditions":19393,"interventions":19394},"NCT00601978","Carbidopa\u002FLevodopa Versus Carbidopa\u002FLevodopa\u002FEntacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off",[94],[19384],[19395,19396],"carbidopa\u002Flevodopa","Carbidopa\u002FLevodopa\u002FEntacapone",{"nctId":19398,"briefTitle":19399,"status":123,"phases":19400,"primaryCompletion":10499,"completion":10499,"start":15065,"enrollment":19401,"conditions":19402,"interventions":19404},"NCT00219284","Effects of Carbidopa\u002FLevodopa\u002FEntacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease",[94],359,[19403],"Parkinson's Disease With End of Dose Wearing Off",[19368],{"trials":19406,"activeCount":103},[],{"intervention":4766,"totalTrials":317,"cells":19408},{"EARLY_PHASE1":19409,"PHASE1":19411,"PHASE2":19413,"PHASE3":19415,"PHASE4":19421,"NA":19431},{"trials":19410,"activeCount":103},[],{"trials":19412,"activeCount":103},[],{"trials":19414,"activeCount":103},[],{"trials":19416,"activeCount":103},[19417],{"nctId":4757,"briefTitle":4758,"status":123,"phases":19418,"primaryCompletion":4760,"completion":4760,"start":4761,"enrollment":4762,"conditions":19419,"interventions":19420},[93],[4691,4701],[196,4765,4766,4767,4768,4769,4770],{"trials":19422,"activeCount":103},[19423,19427],{"nctId":4964,"briefTitle":4965,"status":134,"phases":19424,"primaryCompletion":4967,"completion":4967,"start":918,"enrollment":1016,"conditions":19425,"interventions":19426},[94],[4701],[196,4766,4765,4970,4769],{"nctId":7705,"briefTitle":7706,"status":134,"phases":19428,"primaryCompletion":4967,"completion":4967,"start":4845,"enrollment":1444,"conditions":19429,"interventions":19430},[94],[4701],[4804,7710,7711,4766,4769],{"trials":19432,"activeCount":103},[],{"intervention":16310,"totalTrials":317,"cells":19434},{"EARLY_PHASE1":19435,"PHASE1":19437,"PHASE2":19439,"PHASE3":19441,"PHASE4":19447,"NA":19467},{"trials":19436,"activeCount":103},[],{"trials":19438,"activeCount":103},[],{"trials":19440,"activeCount":103},[],{"trials":19442,"activeCount":103},[19443],{"nctId":16248,"briefTitle":16249,"status":123,"phases":19444,"primaryCompletion":1671,"completion":2795,"start":7931,"enrollment":16251,"conditions":19445,"interventions":19446},[93],[15555],[16254,16255,16256,15564],{"trials":19448,"activeCount":103},[19449,19463],{"nctId":19450,"briefTitle":19451,"status":123,"phases":19452,"primaryCompletion":1848,"completion":1848,"start":19453,"enrollment":19454,"conditions":19455,"interventions":19456},"NCT01985334","Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen",[94],"2014-02-14",4389,[8267],[16310,19457,19458,19459,19460,19461,19462],"SABA","LABA","Indacaterol maleate and glycopyrronium bromide","LAMA","SAMA","ICS",{"nctId":16305,"briefTitle":16306,"status":123,"phases":19464,"primaryCompletion":1817,"completion":1817,"start":1723,"enrollment":3288,"conditions":19465,"interventions":19466},[94],[8267],[16310,15588],{"trials":19468,"activeCount":103},[],{"intervention":7849,"totalTrials":317,"cells":19470},{"EARLY_PHASE1":19471,"PHASE1":19473,"PHASE2":19475,"PHASE3":19485,"PHASE4":19491,"NA":19497},{"trials":19472,"activeCount":103},[],{"trials":19474,"activeCount":103},[],{"trials":19476,"activeCount":103},[19477],{"nctId":19478,"briefTitle":19479,"status":123,"phases":19480,"primaryCompletion":3760,"start":1024,"enrollment":906,"conditions":19481,"interventions":19483},"NCT00929968","Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis",[92],[19482],"Allergic Rhinitis",[19484,7849],"VAK694",{"trials":19486,"activeCount":103},[19487],{"nctId":9093,"briefTitle":9094,"status":123,"phases":19488,"primaryCompletion":1025,"completion":1025,"start":9096,"enrollment":9097,"conditions":19489,"interventions":19490},[93],[18],[6218,7849],{"trials":19492,"activeCount":103},[19493],{"nctId":7844,"briefTitle":7845,"status":123,"phases":19494,"primaryCompletion":5246,"completion":5246,"start":4925,"enrollment":258,"conditions":19495,"interventions":19496},[94],[24],[7811,7849,7850,7851],{"trials":19498,"activeCount":103},[],{"intervention":19500,"totalTrials":317,"cells":19501},"Nateglinide",{"EARLY_PHASE1":19502,"PHASE1":19504,"PHASE2":19506,"PHASE3":19508,"PHASE4":19510,"NA":19532},{"trials":19503,"activeCount":103},[],{"trials":19505,"activeCount":103},[],{"trials":19507,"activeCount":103},[],{"trials":19509,"activeCount":103},[],{"trials":19511,"activeCount":103},[19512,19519,19526],{"nctId":19513,"briefTitle":19514,"status":123,"phases":19515,"primaryCompletion":3760,"completion":3760,"start":3271,"enrollment":12783,"conditions":19516,"interventions":19517},"NCT01030952","Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion",[94],[30],[19500,19518],"Acarbose",{"nctId":19520,"briefTitle":19521,"status":123,"phases":19522,"primaryCompletion":5063,"completion":5063,"start":881,"enrollment":630,"conditions":19523,"interventions":19524},"NCT00238472","A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion",[94],[30],[19525],"nateglinide",{"nctId":19527,"briefTitle":19528,"status":123,"phases":19529,"primaryCompletion":4437,"completion":4437,"start":3195,"enrollment":2046,"conditions":19530,"interventions":19531},"NCT00402909","Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and\u002For Pioglitazone or Rosiglitazone",[94],[15233],[19500],{"trials":19533,"activeCount":103},[],{"intervention":9236,"totalTrials":317,"cells":19535},{"EARLY_PHASE1":19536,"PHASE1":19538,"PHASE2":19549,"PHASE3":19560,"PHASE4":19562,"NA":19568},{"trials":19537,"activeCount":103},[],{"trials":19539,"activeCount":103},[19540],{"nctId":19541,"briefTitle":19542,"status":123,"phases":19543,"primaryCompletion":19544,"completion":19545,"start":19546,"enrollment":1065,"conditions":19547,"interventions":19548},"NCT05084651","Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole",[91],"2022-05-13","2022-05-14","2021-11-18",[11177],[13839,13840,9236],{"trials":19550,"activeCount":103},[19551],{"nctId":19552,"briefTitle":19553,"status":123,"phases":19554,"primaryCompletion":19555,"completion":19555,"start":19556,"enrollment":4082,"conditions":19557,"interventions":19558},"NCT00045942","PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)",[91,92],"2008-03-27","2002-01-30",[2569,5723],[9236,19559],"PKC412",{"trials":19561,"activeCount":103},[],{"trials":19563,"activeCount":103},[19564],{"nctId":9229,"briefTitle":9230,"status":134,"phases":19565,"primaryCompletion":864,"completion":864,"start":3490,"enrollment":814,"conditions":19566,"interventions":19567},[94],[9233,9234],[6218,9236],{"trials":19569,"activeCount":103},[],{"intervention":17260,"totalTrials":317,"cells":19571},{"EARLY_PHASE1":19572,"PHASE1":19574,"PHASE2":19576,"PHASE3":19586,"PHASE4":19588,"NA":19594},{"trials":19573,"activeCount":103},[],{"trials":19575,"activeCount":103},[],{"trials":19577,"activeCount":103},[19578,19582],{"nctId":8367,"briefTitle":8368,"status":123,"phases":19579,"primaryCompletion":3279,"completion":3279,"start":8370,"enrollment":2776,"conditions":19580,"interventions":19581},[92],[8372,8373,8374],[8358,4831,8376],{"nctId":18509,"briefTitle":18510,"status":123,"phases":19583,"primaryCompletion":4335,"completion":4335,"start":988,"enrollment":13149,"conditions":19584,"interventions":19585},[92],[1800],[4874,17261,17260],{"trials":19587,"activeCount":103},[],{"trials":19589,"activeCount":103},[19590],{"nctId":17255,"briefTitle":17256,"status":123,"phases":19591,"primaryCompletion":4556,"completion":4556,"start":16899,"enrollment":3544,"conditions":19592,"interventions":19593},[94],[17239],[17242,4765,4804,17260,17261],{"trials":19595,"activeCount":103},[],{"intervention":16254,"totalTrials":317,"cells":19597},{"EARLY_PHASE1":19598,"PHASE1":19600,"PHASE2":19602,"PHASE3":19604,"PHASE4":19617,"NA":19623},{"trials":19599,"activeCount":103},[],{"trials":19601,"activeCount":103},[],{"trials":19603,"activeCount":103},[],{"trials":19605,"activeCount":103},[19606,19613],{"nctId":19607,"briefTitle":19608,"status":123,"phases":19609,"primaryCompletion":2795,"completion":2795,"start":895,"enrollment":19610,"conditions":19611,"interventions":19612},"NCT01315249","QVA149 Versus Fluticasone\u002FSalmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[93],523,[15555],[16254,15580],{"nctId":16248,"briefTitle":16249,"status":123,"phases":19614,"primaryCompletion":1671,"completion":2795,"start":7931,"enrollment":16251,"conditions":19615,"interventions":19616},[93],[15555],[16254,16255,16256,15564],{"trials":19618,"activeCount":103},[19619],{"nctId":16284,"briefTitle":16285,"status":123,"phases":19620,"primaryCompletion":16287,"completion":16287,"start":16288,"enrollment":2992,"conditions":19621,"interventions":19622},[94],[8267],[16291,15588],{"trials":19624,"activeCount":103},[],{"intervention":15320,"totalTrials":317,"cells":19626},{"EARLY_PHASE1":19627,"PHASE1":19629,"PHASE2":19631,"PHASE3":19633,"PHASE4":19635,"NA":19649},{"trials":19628,"activeCount":103},[],{"trials":19630,"activeCount":103},[],{"trials":19632,"activeCount":103},[],{"trials":19634,"activeCount":103},[],{"trials":19636,"activeCount":103},[19637,19641,19645],{"nctId":16675,"briefTitle":16676,"status":123,"phases":19638,"primaryCompletion":8329,"completion":16678,"start":6556,"enrollment":16679,"conditions":19639,"interventions":19640},[94],[16681,8385],[16683,15255,16673,15320,4424,13838],{"nctId":15315,"briefTitle":15316,"status":134,"phases":19642,"primaryCompletion":3511,"completion":3511,"start":5114,"enrollment":3411,"conditions":19643,"interventions":19644},[94],[15133],[15051,15320],{"nctId":15329,"briefTitle":15330,"status":123,"phases":19646,"primaryCompletion":2458,"completion":2458,"start":1714,"enrollment":5236,"conditions":19647,"interventions":19648},[94],[15146],[15051,15320,13838],{"trials":19650,"activeCount":103},[],{"intervention":19652,"totalTrials":317,"cells":19653},"Pimecrolimus",{"EARLY_PHASE1":19654,"PHASE1":19656,"PHASE2":19658,"PHASE3":19660,"PHASE4":19662,"NA":19684},{"trials":19655,"activeCount":103},[],{"trials":19657,"activeCount":103},[],{"trials":19659,"activeCount":103},[],{"trials":19661,"activeCount":103},[],{"trials":19663,"activeCount":103},[19664,19670,19678],{"nctId":19665,"briefTitle":19666,"status":123,"phases":19667,"primaryCompletion":3194,"start":854,"enrollment":919,"conditions":19668,"interventions":19669},"NCT00509990","Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting",[94],[10365],[19652],{"nctId":19671,"briefTitle":19672,"status":134,"phases":19673,"primaryCompletion":917,"completion":3490,"start":4540,"enrollment":19674,"conditions":19675,"interventions":19676},"NCT00124709","Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification",[94],1091,[10365],[19652,19677],"Corticosteroid",{"nctId":19679,"briefTitle":19680,"status":123,"phases":19681,"primaryCompletion":4621,"start":4741,"enrollment":3939,"conditions":19682,"interventions":19683},"NCT00510003","Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old",[94],[10365],[19652],{"trials":19685,"activeCount":103},[],{"intervention":16180,"totalTrials":213,"cells":19687},{"EARLY_PHASE1":19688,"PHASE1":19690,"PHASE2":19692,"PHASE3":19694,"PHASE4":19696,"NA":19706},{"trials":19689,"activeCount":103},[],{"trials":19691,"activeCount":103},[],{"trials":19693,"activeCount":103},[],{"trials":19695,"activeCount":103},[],{"trials":19697,"activeCount":103},[19698,19702],{"nctId":16175,"briefTitle":16176,"status":123,"phases":19699,"primaryCompletion":3559,"completion":3559,"start":15346,"enrollment":5892,"conditions":19700,"interventions":19701},[94],[24],[15541,15588,16180],{"nctId":16182,"briefTitle":16183,"status":123,"phases":19703,"primaryCompletion":16185,"completion":16185,"start":16186,"enrollment":16187,"conditions":19704,"interventions":19705},[94],[24],[15541,16180],{"trials":19707,"activeCount":103},[],{"intervention":3746,"totalTrials":213,"cells":19709},{"EARLY_PHASE1":19710,"PHASE1":19712,"PHASE2":19714,"PHASE3":19716,"PHASE4":19722,"NA":19728},{"trials":19711,"activeCount":103},[],{"trials":19713,"activeCount":103},[],{"trials":19715,"activeCount":103},[],{"trials":19717,"activeCount":103},[19718],{"nctId":3677,"briefTitle":3678,"status":134,"phases":19719,"primaryCompletion":3680,"completion":3680,"start":3681,"enrollment":3682,"conditions":19720,"interventions":19721},[93],[3684],[3686,3687],{"trials":19723,"activeCount":103},[19724],{"nctId":3738,"briefTitle":3739,"status":123,"phases":19725,"primaryCompletion":1682,"completion":1682,"start":1732,"enrollment":3741,"conditions":19726,"interventions":19727},[94],[3743],[2836,3745,3746],{"trials":19729,"activeCount":103},[],{"intervention":4648,"totalTrials":213,"cells":19731},{"EARLY_PHASE1":19732,"PHASE1":19734,"PHASE2":19736,"PHASE3":19738,"PHASE4":19744,"NA":19750},{"trials":19733,"activeCount":103},[],{"trials":19735,"activeCount":103},[],{"trials":19737,"activeCount":103},[],{"trials":19739,"activeCount":103},[19740],{"nctId":4639,"briefTitle":4640,"status":123,"phases":19741,"primaryCompletion":4642,"completion":4642,"start":918,"enrollment":4643,"conditions":19742,"interventions":19743},[93],[4645],[196,4647,4648,4649],{"trials":19745,"activeCount":103},[19746],{"nctId":5051,"briefTitle":5052,"status":123,"phases":19747,"primaryCompletion":4400,"completion":4400,"start":5026,"enrollment":5054,"conditions":19748,"interventions":19749},[94],[4701],[196,5057,4648,4649],{"trials":19751,"activeCount":103},[],{"intervention":18603,"totalTrials":213,"cells":19753},{"EARLY_PHASE1":19754,"PHASE1":19756,"PHASE2":19758,"PHASE3":19760,"PHASE4":19769,"NA":19775},{"trials":19755,"activeCount":103},[],{"trials":19757,"activeCount":103},[],{"trials":19759,"activeCount":103},[],{"trials":19761,"activeCount":103},[19762],{"nctId":19763,"briefTitle":19764,"status":123,"phases":19765,"primaryCompletion":4642,"completion":4642,"start":3254,"enrollment":19766,"conditions":19767,"interventions":19768},"NCT00413413","Efficacy\u002FSafety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension",[93],1134,[21],[18603,18559,18594],{"trials":19770,"activeCount":103},[19771],{"nctId":18598,"briefTitle":18599,"status":123,"phases":19772,"primaryCompletion":949,"completion":949,"start":917,"enrollment":17308,"conditions":19773,"interventions":19774},[94],[21],[18603,18542,18582,18604,18605],{"trials":19776,"activeCount":103},[],{"intervention":18582,"totalTrials":213,"cells":19778},{"EARLY_PHASE1":19779,"PHASE1":19781,"PHASE2":19783,"PHASE3":19785,"PHASE4":19791,"NA":19797},{"trials":19780,"activeCount":103},[],{"trials":19782,"activeCount":103},[],{"trials":19784,"activeCount":103},[],{"trials":19786,"activeCount":103},[19787],{"nctId":18574,"briefTitle":18575,"status":123,"phases":19788,"primaryCompletion":3410,"completion":3410,"start":3279,"enrollment":18577,"conditions":19789,"interventions":19790},[93],[21],[18580,18581,18542,18582,18583,18584,18585,18586],{"trials":19792,"activeCount":103},[19793],{"nctId":18598,"briefTitle":18599,"status":123,"phases":19794,"primaryCompletion":949,"completion":949,"start":917,"enrollment":17308,"conditions":19795,"interventions":19796},[94],[21],[18603,18542,18582,18604,18605],{"trials":19798,"activeCount":103},[],{"intervention":19275,"totalTrials":213,"cells":19800},{"EARLY_PHASE1":19801,"PHASE1":19803,"PHASE2":19805,"PHASE3":19807,"PHASE4":19813,"NA":19824},{"trials":19802,"activeCount":103},[],{"trials":19804,"activeCount":103},[],{"trials":19806,"activeCount":103},[],{"trials":19808,"activeCount":103},[19809],{"nctId":19269,"briefTitle":19270,"status":123,"phases":19810,"primaryCompletion":5114,"completion":5114,"start":4620,"enrollment":19272,"conditions":19811,"interventions":19812},[93],[10401],[19275,19258],{"trials":19814,"activeCount":103},[19815],{"nctId":19816,"briefTitle":19817,"status":123,"phases":19818,"primaryCompletion":19819,"completion":19819,"start":19820,"enrollment":4708,"conditions":19821,"interventions":19823},"NCT02703636","NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.",[94],"2018-05-07","2016-05-09",[19822],"Mild to Moderate Alzheimer's Disease",[19275],{"trials":19825,"activeCount":103},[],{"intervention":19827,"totalTrials":213,"cells":19828},"Standard Therapy",{"EARLY_PHASE1":19829,"PHASE1":19831,"PHASE2":19833,"PHASE3":19835,"PHASE4":19841,"NA":19851},{"trials":19830,"activeCount":103},[],{"trials":19832,"activeCount":103},[],{"trials":19834,"activeCount":103},[],{"trials":19836,"activeCount":103},[19837],{"nctId":4859,"briefTitle":4860,"status":123,"phases":19838,"primaryCompletion":4862,"completion":4862,"start":4863,"enrollment":3975,"conditions":19839,"interventions":19840},[93],[4865],[4867,196],{"trials":19842,"activeCount":103},[19843],{"nctId":19844,"briefTitle":19845,"status":123,"phases":19846,"primaryCompletion":3482,"completion":3482,"start":3351,"enrollment":22,"conditions":19847,"interventions":19850},"NCT01129336","Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients",[94],[19848,19849],"First or Second Line HER2-negative Breast Cancer","Metastatic Disease Without Bone Metastasis",[886,19827],{"trials":19852,"activeCount":103},[],{"intervention":19854,"totalTrials":213,"cells":19855},"Lumiracoxib",{"EARLY_PHASE1":19856,"PHASE1":19858,"PHASE2":19860,"PHASE3":19862,"PHASE4":19864,"NA":19884},{"trials":19857,"activeCount":103},[],{"trials":19859,"activeCount":103},[],{"trials":19861,"activeCount":103},[],{"trials":19863,"activeCount":103},[],{"trials":19865,"activeCount":103},[19866,19874],{"nctId":19867,"briefTitle":19868,"status":123,"phases":19869,"primaryCompletion":8091,"start":966,"enrollment":19870,"conditions":19871,"interventions":19873},"NCT00348491","Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib",[94],364,[19872],"Pain",[19854],{"nctId":19875,"briefTitle":19876,"status":123,"phases":19877,"primaryCompletion":4034,"start":918,"enrollment":19878,"conditions":19879,"interventions":19882},"NCT00267176","Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension",[94],1020,[19880,19881],"Osteoarthritis","Controlled Hypertension",[19883],"lumiracoxib",{"trials":19885,"activeCount":103},[],{"intervention":19887,"totalTrials":213,"cells":19888},"Artemether-lumefantrine",{"EARLY_PHASE1":19889,"PHASE1":19891,"PHASE2":19893,"PHASE3":19895,"PHASE4":19904,"NA":19914},{"trials":19890,"activeCount":103},[],{"trials":19892,"activeCount":103},[],{"trials":19894,"activeCount":103},[],{"trials":19896,"activeCount":103},[19897],{"nctId":19898,"briefTitle":19899,"status":123,"phases":19900,"primaryCompletion":3409,"completion":3409,"start":1761,"enrollment":1611,"conditions":19901,"interventions":19903},"NCT01619878","Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants \u003C 5 kg",[92,93],[19902],"Acute Uncomplicated Falciparum Malaria",[19887],{"trials":19905,"activeCount":103},[19906],{"nctId":19907,"briefTitle":19908,"status":134,"phases":19909,"primaryCompletion":918,"completion":918,"start":5063,"enrollment":19910,"conditions":19911,"interventions":19913},"NCT00386750","Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory Function",[94],265,[11177,19912],"Falciparum",[19887],{"trials":19915,"activeCount":103},[],{"intervention":15679,"totalTrials":213,"cells":19917},{"EARLY_PHASE1":19918,"PHASE1":19920,"PHASE2":19922,"PHASE3":19924,"PHASE4":19939,"NA":19945},{"trials":19919,"activeCount":103},[],{"trials":19921,"activeCount":103},[],{"trials":19923,"activeCount":103},[],{"trials":19925,"activeCount":103},[19926],{"nctId":19927,"briefTitle":19928,"status":123,"phases":19929,"primaryCompletion":19930,"completion":19930,"start":13728,"enrollment":19931,"conditions":19932,"interventions":19933},"NCT02571777","Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma",[93],"2019-06-14",3092,[18],[19934,19935,19936,19937,19938],"QVM149 150\u002F50\u002F160","QVM149 150\u002F50\u002F80","QMF149 150\u002F320","QMF149 150\u002F160","salmeterol\u002Ffluticasone",{"trials":19940,"activeCount":103},[19941],{"nctId":15672,"briefTitle":15673,"status":123,"phases":19942,"primaryCompletion":15675,"completion":15675,"start":15676,"enrollment":3846,"conditions":19943,"interventions":19944},[94],[15555],[15524,15588,15679],{"trials":19946,"activeCount":103},[],{"intervention":19327,"totalTrials":213,"cells":19948},{"EARLY_PHASE1":19949,"PHASE1":19951,"PHASE2":19953,"PHASE3":19955,"PHASE4":19957,"NA":19971},{"trials":19950,"activeCount":103},[],{"trials":19952,"activeCount":103},[],{"trials":19954,"activeCount":103},[],{"trials":19956,"activeCount":103},[],{"trials":19958,"activeCount":103},[19959,19963],{"nctId":19321,"briefTitle":19322,"status":134,"phases":19960,"primaryCompletion":964,"start":964,"enrollment":213,"conditions":19961,"interventions":19962},[94],[19325],[19299,19327],{"nctId":19964,"briefTitle":19965,"status":123,"phases":19966,"primaryCompletion":4556,"completion":4556,"start":15800,"enrollment":19967,"conditions":19968,"interventions":19969},"NCT00489424","Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass",[94],793,[953],[19327,19970],"Fluvastatin",{"trials":19972,"activeCount":103},[],{"intervention":19970,"totalTrials":213,"cells":19974},{"EARLY_PHASE1":19975,"PHASE1":19977,"PHASE2":19979,"PHASE3":19981,"PHASE4":19983,"NA":19997},{"trials":19976,"activeCount":103},[],{"trials":19978,"activeCount":103},[],{"trials":19980,"activeCount":103},[],{"trials":19982,"activeCount":103},[],{"trials":19984,"activeCount":103},[19985,19989],{"nctId":19964,"briefTitle":19965,"status":123,"phases":19986,"primaryCompletion":4556,"completion":4556,"start":15800,"enrollment":19967,"conditions":19987,"interventions":19988},[94],[953],[19327,19970],{"nctId":19990,"briefTitle":19991,"status":123,"phases":19992,"primaryCompletion":3447,"start":19993,"enrollment":5982,"conditions":19994,"interventions":19996},"NCT00565474","Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant",[94],"2001-09",[19995],"Graft Vasculopathy",[19970],{"trials":19998,"activeCount":103},[],{"intervention":16673,"totalTrials":213,"cells":20000},{"EARLY_PHASE1":20001,"PHASE1":20003,"PHASE2":20005,"PHASE3":20007,"PHASE4":20009,"NA":20019},{"trials":20002,"activeCount":103},[],{"trials":20004,"activeCount":103},[],{"trials":20006,"activeCount":103},[],{"trials":20008,"activeCount":103},[],{"trials":20010,"activeCount":103},[20011,20015],{"nctId":16667,"briefTitle":16668,"status":123,"phases":20012,"primaryCompletion":1761,"completion":1761,"start":1732,"enrollment":2149,"conditions":20013,"interventions":20014},[94],[15233],[16672,16673,13838],{"nctId":16675,"briefTitle":16676,"status":123,"phases":20016,"primaryCompletion":8329,"completion":16678,"start":6556,"enrollment":16679,"conditions":20017,"interventions":20018},[94],[16681,8385],[16683,15255,16673,15320,4424,13838],{"trials":20020,"activeCount":103},[],{"intervention":15999,"totalTrials":213,"cells":20022},{"EARLY_PHASE1":20023,"PHASE1":20025,"PHASE2":20027,"PHASE3":20029,"PHASE4":20035,"NA":20044},{"trials":20024,"activeCount":103},[],{"trials":20026,"activeCount":103},[],{"trials":20028,"activeCount":103},[],{"trials":20030,"activeCount":103},[20031],{"nctId":15994,"briefTitle":15995,"status":123,"phases":20032,"primaryCompletion":3473,"start":4071,"enrollment":467,"conditions":20033,"interventions":20034},[93],[4508,1147],[15915,15999],{"trials":20036,"activeCount":103},[20037],{"nctId":20038,"briefTitle":20039,"status":134,"phases":20040,"primaryCompletion":20041,"completion":20041,"start":9957,"enrollment":485,"conditions":20042,"interventions":20043},"NCT05853458","Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors",[94],"2026-02-26",[2470],[15999],{"trials":20045,"activeCount":103},[],{"intervention":20047,"totalTrials":213,"cells":20048},"TBM100",{"EARLY_PHASE1":20049,"PHASE1":20051,"PHASE2":20053,"PHASE3":20055,"PHASE4":20057,"NA":20073},{"trials":20050,"activeCount":103},[],{"trials":20052,"activeCount":103},[],{"trials":20054,"activeCount":103},[],{"trials":20056,"activeCount":103},[],{"trials":20058,"activeCount":103},[20059,20066],{"nctId":20060,"briefTitle":20061,"status":123,"phases":20062,"primaryCompletion":3559,"completion":3559,"start":1732,"enrollment":3002,"conditions":20063,"interventions":20065},"NCT01519661","Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis",[94],[18302,20064],"Pseudomonas Aeruginosa in Cystic Fibrosis",[20047],{"nctId":20067,"briefTitle":20068,"status":123,"phases":20069,"primaryCompletion":3382,"completion":3382,"start":2793,"enrollment":2405,"conditions":20070,"interventions":20072},"NCT01775137","Ext. Long-term Safety Study in CF Patients: Single Arm TIP",[94],[20071],"Long-term Safety of TIP",[20047],{"trials":20074,"activeCount":103},[],{"intervention":20076,"totalTrials":213,"cells":20077},"Sandostatin LAR",{"EARLY_PHASE1":20078,"PHASE1":20080,"PHASE2":20082,"PHASE3":20084,"PHASE4":20086,"NA":20103},{"trials":20079,"activeCount":103},[],{"trials":20081,"activeCount":103},[],{"trials":20083,"activeCount":103},[],{"trials":20085,"activeCount":103},[],{"trials":20087,"activeCount":103},[20088,20095],{"nctId":20089,"briefTitle":20090,"status":123,"phases":20091,"primaryCompletion":15920,"start":845,"enrollment":1423,"conditions":20092,"interventions":20094},"NCT00076362","Pediatric Hypothalamic Obesity",[94],[20093],"Obesity",[20076],{"nctId":20096,"briefTitle":20097,"status":123,"phases":20098,"primaryCompletion":4335,"completion":4335,"start":4034,"enrollment":512,"conditions":20099,"interventions":20100},"NCT01278342","Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients",[94],[8385],[20076,20101,20102],"pegvisomant","cabergoline",{"trials":20104,"activeCount":103},[],{"intervention":10557,"totalTrials":213,"cells":20106},{"EARLY_PHASE1":20107,"PHASE1":20109,"PHASE2":20111,"PHASE3":20120,"PHASE4":20122,"NA":20128},{"trials":20108,"activeCount":103},[],{"trials":20110,"activeCount":103},[],{"trials":20112,"activeCount":103},[20113],{"nctId":20114,"briefTitle":20115,"status":123,"phases":20116,"primaryCompletion":3482,"completion":3482,"start":4335,"enrollment":3043,"conditions":20117,"interventions":20119},"NCT00901186","Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema",[92],[16741,20118],"Visual Impairment",[10557],{"trials":20121,"activeCount":103},[],{"trials":20123,"activeCount":103},[20124],{"nctId":10551,"briefTitle":10552,"status":123,"phases":20125,"primaryCompletion":1817,"completion":1817,"start":5733,"enrollment":8659,"conditions":20126,"interventions":20127},[94],[10555],[10557,5747],{"trials":20129,"activeCount":103},[],{"intervention":16693,"totalTrials":213,"cells":20131},{"EARLY_PHASE1":20132,"PHASE1":20134,"PHASE2":20136,"PHASE3":20138,"PHASE4":20140,"NA":20153},{"trials":20133,"activeCount":103},[],{"trials":20135,"activeCount":103},[],{"trials":20137,"activeCount":103},[],{"trials":20139,"activeCount":103},[],{"trials":20141,"activeCount":103},[20142,20146],{"nctId":16685,"briefTitle":16686,"status":123,"phases":20143,"primaryCompletion":16688,"completion":16688,"start":16689,"enrollment":3939,"conditions":20144,"interventions":20145},[94],[16691],[16693,13838],{"nctId":20147,"briefTitle":20148,"status":123,"phases":20149,"primaryCompletion":813,"completion":813,"start":3482,"enrollment":3705,"conditions":20150,"interventions":20151},"NCT01649466","Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.",[94],[15133],[16693,20152],"Protaphane",{"trials":20154,"activeCount":103},[],{"intervention":5109,"totalTrials":213,"cells":20156},{"EARLY_PHASE1":20157,"PHASE1":20159,"PHASE2":20161,"PHASE3":20163,"PHASE4":20165,"NA":20179},{"trials":20158,"activeCount":103},[],{"trials":20160,"activeCount":103},[],{"trials":20162,"activeCount":103},[],{"trials":20164,"activeCount":103},[],{"trials":20166,"activeCount":103},[20167,20171],{"nctId":5103,"briefTitle":5104,"status":123,"phases":20168,"primaryCompletion":3320,"completion":3320,"start":5106,"enrollment":31,"conditions":20169,"interventions":20170},[94],[4362],[196,5109],{"nctId":20172,"briefTitle":20173,"status":123,"phases":20174,"completion":20175,"start":16899,"enrollment":9531,"conditions":20176,"interventions":20178},"NCT00050635","STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea",[94],"2003-07",[4362,20177],"Diarrhea",[5109],{"trials":20180,"activeCount":103},[],{"intervention":20182,"totalTrials":437,"cells":20183},"amlodipine\u002Fvalsartan",{"EARLY_PHASE1":20184,"PHASE1":20186,"PHASE2":20188,"PHASE3":20190,"PHASE4":20192,"NA":20200},{"trials":20185,"activeCount":103},[],{"trials":20187,"activeCount":103},[],{"trials":20189,"activeCount":103},[],{"trials":20191,"activeCount":103},[],{"trials":20193,"activeCount":103},[20194],{"nctId":20195,"briefTitle":20196,"status":123,"phases":20197,"primaryCompletion":3861,"completion":3861,"start":1723,"enrollment":4992,"conditions":20198,"interventions":20199},"NCT02062645","Study of Efficacy and Safety of CVAA489 in Hypertensive Patients",[94],[17007],[20182],{"trials":20201,"activeCount":103},[],{"intervention":20203,"totalTrials":437,"cells":20204},"Fingolimod 0.5mg",{"EARLY_PHASE1":20205,"PHASE1":20207,"PHASE2":20209,"PHASE3":20211,"PHASE4":20213,"NA":20223},{"trials":20206,"activeCount":103},[],{"trials":20208,"activeCount":103},[],{"trials":20210,"activeCount":103},[],{"trials":20212,"activeCount":103},[],{"trials":20214,"activeCount":103},[20215],{"nctId":20216,"briefTitle":20217,"status":123,"phases":20218,"primaryCompletion":20219,"completion":20219,"start":20220,"enrollment":6014,"conditions":20221,"interventions":20222},"NCT04667949","Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients",[94],"2025-03-25","2021-02-20",[2960],[20203],{"trials":20224,"activeCount":103},[],{"intervention":17828,"totalTrials":437,"cells":20226},{"EARLY_PHASE1":20227,"PHASE1":20229,"PHASE2":20231,"PHASE3":20233,"PHASE4":20235,"NA":20241},{"trials":20228,"activeCount":103},[],{"trials":20230,"activeCount":103},[],{"trials":20232,"activeCount":103},[],{"trials":20234,"activeCount":103},[],{"trials":20236,"activeCount":103},[20237],{"nctId":17822,"briefTitle":17823,"status":123,"phases":20238,"primaryCompletion":17825,"completion":13615,"start":1110,"enrollment":4506,"conditions":20239,"interventions":20240},[94],[17817],[17734,17828,17829,17830],{"trials":20242,"activeCount":103},[],{"intervention":17829,"totalTrials":437,"cells":20244},{"EARLY_PHASE1":20245,"PHASE1":20247,"PHASE2":20249,"PHASE3":20251,"PHASE4":20253,"NA":20259},{"trials":20246,"activeCount":103},[],{"trials":20248,"activeCount":103},[],{"trials":20250,"activeCount":103},[],{"trials":20252,"activeCount":103},[],{"trials":20254,"activeCount":103},[20255],{"nctId":17822,"briefTitle":17823,"status":123,"phases":20256,"primaryCompletion":17825,"completion":13615,"start":1110,"enrollment":4506,"conditions":20257,"interventions":20258},[94],[17817],[17734,17828,17829,17830],{"trials":20260,"activeCount":103},[],{"intervention":17830,"totalTrials":437,"cells":20262},{"EARLY_PHASE1":20263,"PHASE1":20265,"PHASE2":20267,"PHASE3":20269,"PHASE4":20271,"NA":20277},{"trials":20264,"activeCount":103},[],{"trials":20266,"activeCount":103},[],{"trials":20268,"activeCount":103},[],{"trials":20270,"activeCount":103},[],{"trials":20272,"activeCount":103},[20273],{"nctId":17822,"briefTitle":17823,"status":123,"phases":20274,"primaryCompletion":17825,"completion":13615,"start":1110,"enrollment":4506,"conditions":20275,"interventions":20276},[94],[17817],[17734,17828,17829,17830],{"trials":20278,"activeCount":103},[],{"intervention":3745,"totalTrials":437,"cells":20280},{"EARLY_PHASE1":20281,"PHASE1":20283,"PHASE2":20285,"PHASE3":20287,"PHASE4":20289,"NA":20295},{"trials":20282,"activeCount":103},[],{"trials":20284,"activeCount":103},[],{"trials":20286,"activeCount":103},[],{"trials":20288,"activeCount":103},[],{"trials":20290,"activeCount":103},[20291],{"nctId":3738,"briefTitle":3739,"status":123,"phases":20292,"primaryCompletion":1682,"completion":1682,"start":1732,"enrollment":3741,"conditions":20293,"interventions":20294},[94],[3743],[2836,3745,3746],{"trials":20296,"activeCount":103},[],{"intervention":15849,"totalTrials":437,"cells":20298},{"EARLY_PHASE1":20299,"PHASE1":20301,"PHASE2":20303,"PHASE3":20305,"PHASE4":20307,"NA":20313},{"trials":20300,"activeCount":103},[],{"trials":20302,"activeCount":103},[],{"trials":20304,"activeCount":103},[],{"trials":20306,"activeCount":103},[],{"trials":20308,"activeCount":103},[20309],{"nctId":15843,"briefTitle":15844,"status":123,"phases":20310,"primaryCompletion":1024,"completion":1024,"start":4070,"enrollment":15846,"conditions":20311,"interventions":20312},[94],[21],[15849,5447,15850],{"trials":20314,"activeCount":103},[],{"intervention":15850,"totalTrials":437,"cells":20316},{"EARLY_PHASE1":20317,"PHASE1":20319,"PHASE2":20321,"PHASE3":20323,"PHASE4":20325,"NA":20331},{"trials":20318,"activeCount":103},[],{"trials":20320,"activeCount":103},[],{"trials":20322,"activeCount":103},[],{"trials":20324,"activeCount":103},[],{"trials":20326,"activeCount":103},[20327],{"nctId":15843,"briefTitle":15844,"status":123,"phases":20328,"primaryCompletion":1024,"completion":1024,"start":4070,"enrollment":15846,"conditions":20329,"interventions":20330},[94],[21],[15849,5447,15850],{"trials":20332,"activeCount":103},[],{"intervention":19228,"totalTrials":437,"cells":20334},{"EARLY_PHASE1":20335,"PHASE1":20337,"PHASE2":20339,"PHASE3":20341,"PHASE4":20343,"NA":20349},{"trials":20336,"activeCount":103},[],{"trials":20338,"activeCount":103},[],{"trials":20340,"activeCount":103},[],{"trials":20342,"activeCount":103},[],{"trials":20344,"activeCount":103},[20345],{"nctId":19219,"briefTitle":19220,"status":123,"phases":20346,"primaryCompletion":7960,"completion":19222,"start":19223,"enrollment":19224,"conditions":20347,"interventions":20348},[94],[4458,19226],[4460,17688,19228],{"trials":20350,"activeCount":103},[],{"intervention":20352,"totalTrials":437,"cells":20353},"LABA based treatment: indacaterol",{"EARLY_PHASE1":20354,"PHASE1":20356,"PHASE2":20358,"PHASE3":20360,"PHASE4":20362,"NA":20378},{"trials":20355,"activeCount":103},[],{"trials":20357,"activeCount":103},[],{"trials":20359,"activeCount":103},[],{"trials":20361,"activeCount":103},[],{"trials":20363,"activeCount":103},[20364],{"nctId":20365,"briefTitle":20366,"status":123,"phases":20367,"primaryCompletion":20368,"completion":20368,"start":20369,"enrollment":20370,"conditions":20371,"interventions":20372},"NCT01794780","A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator",[94],"2015-05-25","2013-02-05",2229,[8267],[20352,20373,20374,20375,20376,20377],"LAMA based treatment: tiotropium","LABA\u002FICS based treatment: salmeterol\u002Ffluticasone","LABA\u002FICS based treatment: budesonide\u002Fformoterol","theophylline based treatment","Other treatment",{"trials":20379,"activeCount":103},[],{"intervention":20373,"totalTrials":437,"cells":20381},{"EARLY_PHASE1":20382,"PHASE1":20384,"PHASE2":20386,"PHASE3":20388,"PHASE4":20390,"NA":20396},{"trials":20383,"activeCount":103},[],{"trials":20385,"activeCount":103},[],{"trials":20387,"activeCount":103},[],{"trials":20389,"activeCount":103},[],{"trials":20391,"activeCount":103},[20392],{"nctId":20365,"briefTitle":20366,"status":123,"phases":20393,"primaryCompletion":20368,"completion":20368,"start":20369,"enrollment":20370,"conditions":20394,"interventions":20395},[94],[8267],[20352,20373,20374,20375,20376,20377],{"trials":20397,"activeCount":103},[],{"intervention":20374,"totalTrials":437,"cells":20399},{"EARLY_PHASE1":20400,"PHASE1":20402,"PHASE2":20404,"PHASE3":20406,"PHASE4":20408,"NA":20414},{"trials":20401,"activeCount":103},[],{"trials":20403,"activeCount":103},[],{"trials":20405,"activeCount":103},[],{"trials":20407,"activeCount":103},[],{"trials":20409,"activeCount":103},[20410],{"nctId":20365,"briefTitle":20366,"status":123,"phases":20411,"primaryCompletion":20368,"completion":20368,"start":20369,"enrollment":20370,"conditions":20412,"interventions":20413},[94],[8267],[20352,20373,20374,20375,20376,20377],{"trials":20415,"activeCount":103},[],{"intervention":20375,"totalTrials":437,"cells":20417},{"EARLY_PHASE1":20418,"PHASE1":20420,"PHASE2":20422,"PHASE3":20424,"PHASE4":20426,"NA":20432},{"trials":20419,"activeCount":103},[],{"trials":20421,"activeCount":103},[],{"trials":20423,"activeCount":103},[],{"trials":20425,"activeCount":103},[],{"trials":20427,"activeCount":103},[20428],{"nctId":20365,"briefTitle":20366,"status":123,"phases":20429,"primaryCompletion":20368,"completion":20368,"start":20369,"enrollment":20370,"conditions":20430,"interventions":20431},[94],[8267],[20352,20373,20374,20375,20376,20377],{"trials":20433,"activeCount":103},[],{"intervention":20376,"totalTrials":437,"cells":20435},{"EARLY_PHASE1":20436,"PHASE1":20438,"PHASE2":20440,"PHASE3":20442,"PHASE4":20444,"NA":20450},{"trials":20437,"activeCount":103},[],{"trials":20439,"activeCount":103},[],{"trials":20441,"activeCount":103},[],{"trials":20443,"activeCount":103},[],{"trials":20445,"activeCount":103},[20446],{"nctId":20365,"briefTitle":20366,"status":123,"phases":20447,"primaryCompletion":20368,"completion":20368,"start":20369,"enrollment":20370,"conditions":20448,"interventions":20449},[94],[8267],[20352,20373,20374,20375,20376,20377],{"trials":20451,"activeCount":103},[],{"intervention":20377,"totalTrials":437,"cells":20453},{"EARLY_PHASE1":20454,"PHASE1":20456,"PHASE2":20458,"PHASE3":20460,"PHASE4":20462,"NA":20468},{"trials":20455,"activeCount":103},[],{"trials":20457,"activeCount":103},[],{"trials":20459,"activeCount":103},[],{"trials":20461,"activeCount":103},[],{"trials":20463,"activeCount":103},[20464],{"nctId":20365,"briefTitle":20366,"status":123,"phases":20465,"primaryCompletion":20368,"completion":20368,"start":20369,"enrollment":20370,"conditions":20466,"interventions":20467},[94],[8267],[20352,20373,20374,20375,20376,20377],{"trials":20469,"activeCount":103},[],{"intervention":18604,"totalTrials":437,"cells":20471},{"EARLY_PHASE1":20472,"PHASE1":20474,"PHASE2":20476,"PHASE3":20478,"PHASE4":20480,"NA":20486},{"trials":20473,"activeCount":103},[],{"trials":20475,"activeCount":103},[],{"trials":20477,"activeCount":103},[],{"trials":20479,"activeCount":103},[],{"trials":20481,"activeCount":103},[20482],{"nctId":18598,"briefTitle":18599,"status":123,"phases":20483,"primaryCompletion":949,"completion":949,"start":917,"enrollment":17308,"conditions":20484,"interventions":20485},[94],[21],[18603,18542,18582,18604,18605],{"trials":20487,"activeCount":103},[],{"intervention":18605,"totalTrials":437,"cells":20489},{"EARLY_PHASE1":20490,"PHASE1":20492,"PHASE2":20494,"PHASE3":20496,"PHASE4":20498,"NA":20504},{"trials":20491,"activeCount":103},[],{"trials":20493,"activeCount":103},[],{"trials":20495,"activeCount":103},[],{"trials":20497,"activeCount":103},[],{"trials":20499,"activeCount":103},[20500],{"nctId":18598,"briefTitle":18599,"status":123,"phases":20501,"primaryCompletion":949,"completion":949,"start":917,"enrollment":17308,"conditions":20502,"interventions":20503},[94],[21],[18603,18542,18582,18604,18605],{"trials":20505,"activeCount":103},[],{"intervention":20507,"totalTrials":437,"cells":20508},"Co-artemether",{"EARLY_PHASE1":20509,"PHASE1":20511,"PHASE2":20513,"PHASE3":20515,"PHASE4":20517,"NA":20527},{"trials":20510,"activeCount":103},[],{"trials":20512,"activeCount":103},[],{"trials":20514,"activeCount":103},[],{"trials":20516,"activeCount":103},[],{"trials":20518,"activeCount":103},[20519],{"nctId":20520,"briefTitle":20521,"status":123,"phases":20522,"primaryCompletion":3272,"completion":3272,"start":20523,"conditions":20524,"interventions":20526},"NCT00233337","Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers",[94],"2001-05",[20525],"Acute Uncomplicated P. Falciparum Malaria",[20507],{"trials":20528,"activeCount":103},[],{"intervention":20530,"totalTrials":437,"cells":20531},"deferasirox:",{"EARLY_PHASE1":20532,"PHASE1":20534,"PHASE2":20536,"PHASE3":20538,"PHASE4":20540,"NA":20549},{"trials":20533,"activeCount":103},[],{"trials":20535,"activeCount":103},[],{"trials":20537,"activeCount":103},[],{"trials":20539,"activeCount":103},[],{"trials":20541,"activeCount":103},[20542],{"nctId":20543,"briefTitle":20544,"status":123,"phases":20545,"primaryCompletion":3845,"completion":3845,"start":3410,"enrollment":1524,"conditions":20546,"interventions":20548},"NCT00845871","Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food",[94],[20547],"Transfusional Hemosiderosis",[20530],{"trials":20550,"activeCount":103},[],{"intervention":20552,"totalTrials":437,"cells":20553},"omalizumab at a dose of 0.016mg\u002Fkg\u002FIU\u002FmL",{"EARLY_PHASE1":20554,"PHASE1":20556,"PHASE2":20558,"PHASE3":20560,"PHASE4":20562,"NA":20570},{"trials":20555,"activeCount":103},[],{"trials":20557,"activeCount":103},[],{"trials":20559,"activeCount":103},[],{"trials":20561,"activeCount":103},[],{"trials":20563,"activeCount":103},[20564],{"nctId":20565,"briefTitle":20566,"status":123,"phases":20567,"primaryCompletion":3800,"completion":3800,"start":4070,"enrollment":792,"conditions":20568,"interventions":20569},"NCT00670930","Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists",[94],[9070],[20552],{"trials":20571,"activeCount":103},[],{"intervention":20573,"totalTrials":437,"cells":20574},"telbivudine\u002FLDT600",{"EARLY_PHASE1":20575,"PHASE1":20577,"PHASE2":20579,"PHASE3":20581,"PHASE4":20583,"NA":20592},{"trials":20576,"activeCount":103},[],{"trials":20578,"activeCount":103},[],{"trials":20580,"activeCount":103},[],{"trials":20582,"activeCount":103},[],{"trials":20584,"activeCount":103},[20585],{"nctId":20586,"briefTitle":20587,"status":123,"phases":20588,"primaryCompletion":3383,"start":3400,"enrollment":4733,"conditions":20589,"interventions":20591},"NCT00877149","Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B",[94],[20590],"Compensated Chronic Hepatitis B",[20573],{"trials":20593,"activeCount":103},[],{"intervention":19395,"totalTrials":437,"cells":20595},{"EARLY_PHASE1":20596,"PHASE1":20598,"PHASE2":20600,"PHASE3":20602,"PHASE4":20604,"NA":20610},{"trials":20597,"activeCount":103},[],{"trials":20599,"activeCount":103},[],{"trials":20601,"activeCount":103},[],{"trials":20603,"activeCount":103},[],{"trials":20605,"activeCount":103},[20606],{"nctId":19390,"briefTitle":19391,"status":390,"phases":20607,"primaryCompletion":4335,"completion":4335,"start":3473,"enrollment":103,"conditions":20608,"interventions":20609},[94],[19384],[19395,19396],{"trials":20611,"activeCount":103},[],{"intervention":20613,"totalTrials":437,"cells":20614},"Pre-LASIK 0.3% hypromellose",{"EARLY_PHASE1":20615,"PHASE1":20617,"PHASE2":20619,"PHASE3":20621,"PHASE4":20623,"NA":20635},{"trials":20616,"activeCount":103},[],{"trials":20618,"activeCount":103},[],{"trials":20620,"activeCount":103},[],{"trials":20622,"activeCount":103},[],{"trials":20624,"activeCount":103},[20625],{"nctId":20626,"briefTitle":20627,"status":123,"phases":20628,"primaryCompletion":20629,"completion":20629,"start":20630,"enrollment":5959,"conditions":20631,"interventions":20633},"NCT00909324","Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery",[94],"2010-01-01","2009-08-01",[20632],"Dry Eye",[20613,20634],"Post-LASIK 0.3% hypromellose",{"trials":20636,"activeCount":103},[],{"intervention":20634,"totalTrials":437,"cells":20638},{"EARLY_PHASE1":20639,"PHASE1":20641,"PHASE2":20643,"PHASE3":20645,"PHASE4":20647,"NA":20653},{"trials":20640,"activeCount":103},[],{"trials":20642,"activeCount":103},[],{"trials":20644,"activeCount":103},[],{"trials":20646,"activeCount":103},[],{"trials":20648,"activeCount":103},[20649],{"nctId":20626,"briefTitle":20627,"status":123,"phases":20650,"primaryCompletion":20629,"completion":20629,"start":20630,"enrollment":5959,"conditions":20651,"interventions":20652},[94],[20632],[20613,20634],{"trials":20654,"activeCount":103},[],{"intervention":20656,"totalTrials":437,"cells":20657},"Injection Brolucizumab",{"EARLY_PHASE1":20658,"PHASE1":20660,"PHASE2":20662,"PHASE3":20664,"PHASE4":20666,"NA":20676},{"trials":20659,"activeCount":103},[],{"trials":20661,"activeCount":103},[],{"trials":20663,"activeCount":103},[],{"trials":20665,"activeCount":103},[],{"trials":20667,"activeCount":103},[20668],{"nctId":20669,"briefTitle":20670,"status":123,"phases":20671,"primaryCompletion":20672,"completion":20672,"start":13833,"enrollment":151,"conditions":20673,"interventions":20675},"NCT05269966","Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)",[94],"2023-08-29",[20674],"Neovascular Age-related Macular Degeneration (nAMD)",[20656],{"trials":20677,"activeCount":103},[],{"intervention":20679,"totalTrials":437,"cells":20680},"Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks",{"EARLY_PHASE1":20681,"PHASE1":20683,"PHASE2":20685,"PHASE3":20687,"PHASE4":20689,"NA":20699},{"trials":20682,"activeCount":103},[],{"trials":20684,"activeCount":103},[],{"trials":20686,"activeCount":103},[],{"trials":20688,"activeCount":103},[],{"trials":20690,"activeCount":103},[20691],{"nctId":20692,"briefTitle":20693,"status":123,"phases":20694,"primaryCompletion":3400,"completion":3400,"start":10499,"enrollment":20695,"conditions":20696,"interventions":20697},"NCT00739596","Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans",[94],332,[21],[20679,20698],"Amlodipine: 8 weeks",{"trials":20700,"activeCount":103},[],{"intervention":20698,"totalTrials":437,"cells":20702},{"EARLY_PHASE1":20703,"PHASE1":20705,"PHASE2":20707,"PHASE3":20709,"PHASE4":20711,"NA":20717},{"trials":20704,"activeCount":103},[],{"trials":20706,"activeCount":103},[],{"trials":20708,"activeCount":103},[],{"trials":20710,"activeCount":103},[],{"trials":20712,"activeCount":103},[20713],{"nctId":20692,"briefTitle":20693,"status":123,"phases":20714,"primaryCompletion":3400,"completion":3400,"start":10499,"enrollment":20695,"conditions":20715,"interventions":20716},[94],[21],[20679,20698],{"trials":20718,"activeCount":103},[],{"intervention":4970,"totalTrials":437,"cells":20720},{"EARLY_PHASE1":20721,"PHASE1":20723,"PHASE2":20725,"PHASE3":20727,"PHASE4":20729,"NA":20735},{"trials":20722,"activeCount":103},[],{"trials":20724,"activeCount":103},[],{"trials":20726,"activeCount":103},[],{"trials":20728,"activeCount":103},[],{"trials":20730,"activeCount":103},[20731],{"nctId":4964,"briefTitle":4965,"status":134,"phases":20732,"primaryCompletion":4967,"completion":4967,"start":918,"enrollment":1016,"conditions":20733,"interventions":20734},[94],[4701],[196,4766,4765,4970,4769],{"trials":20736,"activeCount":103},[],{"intervention":20738,"totalTrials":437,"cells":20739},"Zoledronic acid in combination with therapy",{"EARLY_PHASE1":20740,"PHASE1":20742,"PHASE2":20744,"PHASE3":20746,"PHASE4":20748,"NA":20756},{"trials":20741,"activeCount":103},[],{"trials":20743,"activeCount":103},[],{"trials":20745,"activeCount":103},[],{"trials":20747,"activeCount":103},[],{"trials":20749,"activeCount":103},[20750],{"nctId":20751,"briefTitle":20752,"status":123,"phases":20753,"primaryCompletion":3552,"completion":3552,"start":17498,"enrollment":11092,"conditions":20754,"interventions":20755},"NCT00171964","Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions",[94],[19872,4311,1102],[20738],{"trials":20757,"activeCount":103},[],{"intervention":19457,"totalTrials":437,"cells":20759},{"EARLY_PHASE1":20760,"PHASE1":20762,"PHASE2":20764,"PHASE3":20766,"PHASE4":20768,"NA":20774},{"trials":20761,"activeCount":103},[],{"trials":20763,"activeCount":103},[],{"trials":20765,"activeCount":103},[],{"trials":20767,"activeCount":103},[],{"trials":20769,"activeCount":103},[20770],{"nctId":19450,"briefTitle":19451,"status":123,"phases":20771,"primaryCompletion":1848,"completion":1848,"start":19453,"enrollment":19454,"conditions":20772,"interventions":20773},[94],[8267],[16310,19457,19458,19459,19460,19461,19462],{"trials":20775,"activeCount":103},[],{"intervention":19458,"totalTrials":437,"cells":20777},{"EARLY_PHASE1":20778,"PHASE1":20780,"PHASE2":20782,"PHASE3":20784,"PHASE4":20786,"NA":20792},{"trials":20779,"activeCount":103},[],{"trials":20781,"activeCount":103},[],{"trials":20783,"activeCount":103},[],{"trials":20785,"activeCount":103},[],{"trials":20787,"activeCount":103},[20788],{"nctId":19450,"briefTitle":19451,"status":123,"phases":20789,"primaryCompletion":1848,"completion":1848,"start":19453,"enrollment":19454,"conditions":20790,"interventions":20791},[94],[8267],[16310,19457,19458,19459,19460,19461,19462],{"trials":20793,"activeCount":103},[],{"intervention":19459,"totalTrials":437,"cells":20795},{"EARLY_PHASE1":20796,"PHASE1":20798,"PHASE2":20800,"PHASE3":20802,"PHASE4":20804,"NA":20810},{"trials":20797,"activeCount":103},[],{"trials":20799,"activeCount":103},[],{"trials":20801,"activeCount":103},[],{"trials":20803,"activeCount":103},[],{"trials":20805,"activeCount":103},[20806],{"nctId":19450,"briefTitle":19451,"status":123,"phases":20807,"primaryCompletion":1848,"completion":1848,"start":19453,"enrollment":19454,"conditions":20808,"interventions":20809},[94],[8267],[16310,19457,19458,19459,19460,19461,19462],{"trials":20811,"activeCount":103},[],{"intervention":19460,"totalTrials":437,"cells":20813},{"EARLY_PHASE1":20814,"PHASE1":20816,"PHASE2":20818,"PHASE3":20820,"PHASE4":20822,"NA":20828},{"trials":20815,"activeCount":103},[],{"trials":20817,"activeCount":103},[],{"trials":20819,"activeCount":103},[],{"trials":20821,"activeCount":103},[],{"trials":20823,"activeCount":103},[20824],{"nctId":19450,"briefTitle":19451,"status":123,"phases":20825,"primaryCompletion":1848,"completion":1848,"start":19453,"enrollment":19454,"conditions":20826,"interventions":20827},[94],[8267],[16310,19457,19458,19459,19460,19461,19462],{"trials":20829,"activeCount":103},[],{"intervention":19461,"totalTrials":437,"cells":20831},{"EARLY_PHASE1":20832,"PHASE1":20834,"PHASE2":20836,"PHASE3":20838,"PHASE4":20840,"NA":20846},{"trials":20833,"activeCount":103},[],{"trials":20835,"activeCount":103},[],{"trials":20837,"activeCount":103},[],{"trials":20839,"activeCount":103},[],{"trials":20841,"activeCount":103},[20842],{"nctId":19450,"briefTitle":19451,"status":123,"phases":20843,"primaryCompletion":1848,"completion":1848,"start":19453,"enrollment":19454,"conditions":20844,"interventions":20845},[94],[8267],[16310,19457,19458,19459,19460,19461,19462],{"trials":20847,"activeCount":103},[],{"intervention":19462,"totalTrials":437,"cells":20849},{"EARLY_PHASE1":20850,"PHASE1":20852,"PHASE2":20854,"PHASE3":20856,"PHASE4":20858,"NA":20864},{"trials":20851,"activeCount":103},[],{"trials":20853,"activeCount":103},[],{"trials":20855,"activeCount":103},[],{"trials":20857,"activeCount":103},[],{"trials":20859,"activeCount":103},[20860],{"nctId":19450,"briefTitle":19451,"status":123,"phases":20861,"primaryCompletion":1848,"completion":1848,"start":19453,"enrollment":19454,"conditions":20862,"interventions":20863},[94],[8267],[16310,19457,19458,19459,19460,19461,19462],{"trials":20865,"activeCount":103},[],{"intervention":20867,"totalTrials":437,"cells":20868},"Reclast",{"EARLY_PHASE1":20869,"PHASE1":20871,"PHASE2":20873,"PHASE3":20875,"PHASE4":20877,"NA":20887},{"trials":20870,"activeCount":103},[],{"trials":20872,"activeCount":103},[],{"trials":20874,"activeCount":103},[],{"trials":20876,"activeCount":103},[],{"trials":20878,"activeCount":103},[20879],{"nctId":20880,"briefTitle":20881,"status":123,"phases":20882,"primaryCompletion":3712,"completion":3712,"start":5696,"enrollment":13149,"conditions":20883,"interventions":20886},"NCT00668200","Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®",[94],[20884,20885],"Paget's Disease of the Bone","Hypocalcemia",[20867],{"trials":20888,"activeCount":103},[],{"intervention":20890,"totalTrials":437,"cells":20891},"ARNI",{"EARLY_PHASE1":20892,"PHASE1":20894,"PHASE2":20896,"PHASE3":20898,"PHASE4":20900,"NA":20910},{"trials":20893,"activeCount":103},[],{"trials":20895,"activeCount":103},[],{"trials":20897,"activeCount":103},[],{"trials":20899,"activeCount":103},[],{"trials":20901,"activeCount":103},[20902],{"nctId":20903,"briefTitle":20904,"status":134,"phases":20905,"primaryCompletion":20906,"completion":20906,"start":13006,"enrollment":17367,"conditions":20907,"interventions":20908},"NCT04491136","Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)",[94],"2023-06-08",[15870],[20909,20890],"ACEI\u002FARB",{"trials":20911,"activeCount":103},[],{"intervention":4979,"totalTrials":437,"cells":20913},{"EARLY_PHASE1":20914,"PHASE1":20916,"PHASE2":20918,"PHASE3":20920,"PHASE4":20922,"NA":20928},{"trials":20915,"activeCount":103},[],{"trials":20917,"activeCount":103},[],{"trials":20919,"activeCount":103},[],{"trials":20921,"activeCount":103},[],{"trials":20923,"activeCount":103},[20924],{"nctId":4972,"briefTitle":4973,"status":123,"phases":20925,"primaryCompletion":1714,"completion":1714,"start":4975,"enrollment":4976,"conditions":20926,"interventions":20927},[94],[4812],[196,4979],{"trials":20929,"activeCount":103},[],{"intervention":17066,"totalTrials":437,"cells":20931},{"EARLY_PHASE1":20932,"PHASE1":20934,"PHASE2":20936,"PHASE3":20938,"PHASE4":20940,"NA":20946},{"trials":20933,"activeCount":103},[],{"trials":20935,"activeCount":103},[],{"trials":20937,"activeCount":103},[],{"trials":20939,"activeCount":103},[],{"trials":20941,"activeCount":103},[20942],{"nctId":17059,"briefTitle":17060,"status":134,"phases":20943,"primaryCompletion":1671,"completion":1671,"start":3784,"enrollment":17062,"conditions":20944,"interventions":20945},[94],[21,17064,15049],[17066,15884,17067],{"trials":20947,"activeCount":103},[],{"intervention":17067,"totalTrials":437,"cells":20949},{"EARLY_PHASE1":20950,"PHASE1":20952,"PHASE2":20954,"PHASE3":20956,"PHASE4":20958,"NA":20964},{"trials":20951,"activeCount":103},[],{"trials":20953,"activeCount":103},[],{"trials":20955,"activeCount":103},[],{"trials":20957,"activeCount":103},[],{"trials":20959,"activeCount":103},[20960],{"nctId":17059,"briefTitle":17060,"status":134,"phases":20961,"primaryCompletion":1671,"completion":1671,"start":3784,"enrollment":17062,"conditions":20962,"interventions":20963},[94],[21,17064,15049],[17066,15884,17067],{"trials":20965,"activeCount":103},[],{"intervention":20967,"totalTrials":437,"cells":20968},"Imatinib and Vinorelbine",{"EARLY_PHASE1":20969,"PHASE1":20971,"PHASE2":20973,"PHASE3":20975,"PHASE4":20977,"NA":20985},{"trials":20970,"activeCount":103},[],{"trials":20972,"activeCount":103},[],{"trials":20974,"activeCount":103},[],{"trials":20976,"activeCount":103},[],{"trials":20978,"activeCount":103},[20979],{"nctId":20980,"briefTitle":20981,"status":123,"phases":20982,"primaryCompletion":3759,"completion":3759,"start":745,"enrollment":99,"conditions":20983,"interventions":20984},"NCT00372476","Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer",[94],[15],[20967],{"trials":20986,"activeCount":103},[],{"intervention":5341,"totalTrials":437,"cells":20988},{"EARLY_PHASE1":20989,"PHASE1":20991,"PHASE2":20993,"PHASE3":20995,"PHASE4":20997,"NA":21003},{"trials":20990,"activeCount":103},[],{"trials":20992,"activeCount":103},[],{"trials":20994,"activeCount":103},[],{"trials":20996,"activeCount":103},[],{"trials":20998,"activeCount":103},[20999],{"nctId":5332,"briefTitle":5333,"status":123,"phases":21000,"primaryCompletion":5335,"completion":5336,"start":5337,"enrollment":5338,"conditions":21001,"interventions":21002},[94],[1401],[5285,5341],{"trials":21004,"activeCount":103},[],{"intervention":1009,"totalTrials":437,"cells":21006},{"EARLY_PHASE1":21007,"PHASE1":21009,"PHASE2":21011,"PHASE3":21013,"PHASE4":21015,"NA":21021},{"trials":21008,"activeCount":103},[],{"trials":21010,"activeCount":103},[],{"trials":21012,"activeCount":103},[],{"trials":21014,"activeCount":103},[],{"trials":21016,"activeCount":103},[21017],{"nctId":1001,"briefTitle":1002,"status":134,"phases":21018,"primaryCompletion":1004,"completion":1004,"start":1005,"enrollment":1006,"conditions":21019,"interventions":21020},[94],[559],[249,1009],{"trials":21022,"activeCount":103},[],{"intervention":4996,"totalTrials":437,"cells":21024},{"EARLY_PHASE1":21025,"PHASE1":21027,"PHASE2":21029,"PHASE3":21031,"PHASE4":21033,"NA":21039},{"trials":21026,"activeCount":103},[],{"trials":21028,"activeCount":103},[],{"trials":21030,"activeCount":103},[],{"trials":21032,"activeCount":103},[],{"trials":21034,"activeCount":103},[21035],{"nctId":4989,"briefTitle":4990,"status":123,"phases":21036,"primaryCompletion":3604,"completion":3604,"start":4335,"enrollment":4992,"conditions":21037,"interventions":21038},[94],[4994],[4875,4768,4769,196,4996],{"trials":21040,"activeCount":103},[],{"intervention":21042,"totalTrials":437,"cells":21043},"TIS or TIP",{"EARLY_PHASE1":21044,"PHASE1":21046,"PHASE2":21048,"PHASE3":21050,"PHASE4":21052,"NA":21062},{"trials":21045,"activeCount":103},[],{"trials":21047,"activeCount":103},[],{"trials":21049,"activeCount":103},[],{"trials":21051,"activeCount":103},[],{"trials":21053,"activeCount":103},[21054],{"nctId":21055,"briefTitle":21056,"status":134,"phases":21057,"primaryCompletion":17855,"completion":17855,"start":21058,"enrollment":837,"conditions":21059,"interventions":21061},"NCT02248922","Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa",[94],"2015-01-27",[21060],"Chronic Lung Infection With Pseudomonas Aeruginosa in Cystic Fibrosis",[21042],{"trials":21063,"activeCount":103},[],{"intervention":21065,"totalTrials":437,"cells":21066},"Fluvastatin sodium",{"EARLY_PHASE1":21067,"PHASE1":21069,"PHASE2":21071,"PHASE3":21073,"PHASE4":21075,"NA":21084},{"trials":21068,"activeCount":103},[],{"trials":21070,"activeCount":103},[],{"trials":21072,"activeCount":103},[],{"trials":21074,"activeCount":103},[],{"trials":21076,"activeCount":103},[21077],{"nctId":21078,"briefTitle":21079,"status":123,"phases":21080,"primaryCompletion":5114,"completion":5114,"start":1732,"enrollment":5855,"conditions":21081,"interventions":21083},"NCT01551173","Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia",[94],[21082],"Lipid Metabolism Disorders",[21065],{"trials":21085,"activeCount":103},[],{"intervention":1019,"totalTrials":437,"cells":21087},{"EARLY_PHASE1":21088,"PHASE1":21090,"PHASE2":21092,"PHASE3":21094,"PHASE4":21096,"NA":21102},{"trials":21089,"activeCount":103},[],{"trials":21091,"activeCount":103},[],{"trials":21093,"activeCount":103},[],{"trials":21095,"activeCount":103},[],{"trials":21097,"activeCount":103},[21098],{"nctId":1011,"briefTitle":1012,"status":134,"phases":21099,"primaryCompletion":1014,"start":1015,"enrollment":1016,"conditions":21100,"interventions":21101},[94],[435],[249,1019,249],{"trials":21103,"activeCount":103},[],{"intervention":19518,"totalTrials":437,"cells":21105},{"EARLY_PHASE1":21106,"PHASE1":21108,"PHASE2":21110,"PHASE3":21112,"PHASE4":21114,"NA":21120},{"trials":21107,"activeCount":103},[],{"trials":21109,"activeCount":103},[],{"trials":21111,"activeCount":103},[],{"trials":21113,"activeCount":103},[],{"trials":21115,"activeCount":103},[21116],{"nctId":19513,"briefTitle":19514,"status":123,"phases":21117,"primaryCompletion":3760,"completion":3760,"start":3271,"enrollment":12783,"conditions":21118,"interventions":21119},[94],[30],[19500,19518],{"trials":21121,"activeCount":103},[],{"intervention":3787,"totalTrials":437,"cells":21123},{"EARLY_PHASE1":21124,"PHASE1":21126,"PHASE2":21128,"PHASE3":21130,"PHASE4":21132,"NA":21138},{"trials":21125,"activeCount":103},[],{"trials":21127,"activeCount":103},[],{"trials":21129,"activeCount":103},[],{"trials":21131,"activeCount":103},[],{"trials":21133,"activeCount":103},[21134],{"nctId":3781,"briefTitle":3782,"status":123,"phases":21135,"primaryCompletion":3731,"completion":3731,"start":3784,"enrollment":2354,"conditions":21136,"interventions":21137},[94],[3743],[2836,3787],{"trials":21139,"activeCount":103},[],{"intervention":16837,"totalTrials":437,"cells":21141},{"EARLY_PHASE1":21142,"PHASE1":21144,"PHASE2":21146,"PHASE3":21148,"PHASE4":21150,"NA":21156},{"trials":21143,"activeCount":103},[],{"trials":21145,"activeCount":103},[],{"trials":21147,"activeCount":103},[],{"trials":21149,"activeCount":103},[],{"trials":21151,"activeCount":103},[21152],{"nctId":16831,"briefTitle":16832,"status":123,"phases":21153,"primaryCompletion":15283,"completion":15283,"start":3351,"enrollment":223,"conditions":21154,"interventions":21155},[94],[21,16835],[16715,16837,15884,15777],{"trials":21157,"activeCount":103},[],{"intervention":21159,"totalTrials":437,"cells":21160},"Glycopyrronium \u002FIndacaterol maleate",{"EARLY_PHASE1":21161,"PHASE1":21163,"PHASE2":21165,"PHASE3":21167,"PHASE4":21169,"NA":21180},{"trials":21162,"activeCount":103},[],{"trials":21164,"activeCount":103},[],{"trials":21166,"activeCount":103},[],{"trials":21168,"activeCount":103},[],{"trials":21170,"activeCount":103},[21171],{"nctId":21172,"briefTitle":21173,"status":123,"phases":21174,"primaryCompletion":21175,"completion":21175,"start":21176,"enrollment":21177,"conditions":21178,"interventions":21179},"NCT02202616","Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)",[94],"2017-04-05","2014-08-27",401,[24],[21159],{"trials":21181,"activeCount":103},[],{"intervention":15292,"totalTrials":437,"cells":21183},{"EARLY_PHASE1":21184,"PHASE1":21186,"PHASE2":21188,"PHASE3":21190,"PHASE4":21192,"NA":21198},{"trials":21185,"activeCount":103},[],{"trials":21187,"activeCount":103},[],{"trials":21189,"activeCount":103},[],{"trials":21191,"activeCount":103},[],{"trials":21193,"activeCount":103},[21194],{"nctId":15287,"briefTitle":15288,"status":123,"phases":21195,"primaryCompletion":3383,"start":3760,"enrollment":630,"conditions":21196,"interventions":21197},[94],[15233],[15051,15292,15293],{"trials":21199,"activeCount":103},[],{"intervention":15293,"totalTrials":437,"cells":21201},{"EARLY_PHASE1":21202,"PHASE1":21204,"PHASE2":21206,"PHASE3":21208,"PHASE4":21210,"NA":21216},{"trials":21203,"activeCount":103},[],{"trials":21205,"activeCount":103},[],{"trials":21207,"activeCount":103},[],{"trials":21209,"activeCount":103},[],{"trials":21211,"activeCount":103},[21212],{"nctId":15287,"briefTitle":15288,"status":123,"phases":21213,"primaryCompletion":3383,"start":3760,"enrollment":630,"conditions":21214,"interventions":21215},[94],[15233],[15051,15292,15293],{"trials":21217,"activeCount":103},[],{"intervention":21219,"totalTrials":437,"cells":21220},"Dex-methylphenidate hydrochloride extended-release",{"EARLY_PHASE1":21221,"PHASE1":21223,"PHASE2":21225,"PHASE3":21227,"PHASE4":21229,"NA":21238},{"trials":21222,"activeCount":103},[],{"trials":21224,"activeCount":103},[],{"trials":21226,"activeCount":103},[],{"trials":21228,"activeCount":103},[],{"trials":21230,"activeCount":103},[21231],{"nctId":21232,"briefTitle":21233,"status":123,"phases":21234,"primaryCompletion":4642,"completion":4642,"start":3447,"enrollment":1901,"conditions":21235,"interventions":21237},"NCT00564954","A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[94],[21236],"Attention Deficit Hyperactivity Disorder",[21219],{"trials":21239,"activeCount":103},[],{"intervention":17474,"totalTrials":437,"cells":21241},{"EARLY_PHASE1":21242,"PHASE1":21244,"PHASE2":21246,"PHASE3":21248,"PHASE4":21250,"NA":21256},{"trials":21243,"activeCount":103},[],{"trials":21245,"activeCount":103},[],{"trials":21247,"activeCount":103},[],{"trials":21249,"activeCount":103},[],{"trials":21251,"activeCount":103},[21252],{"nctId":17468,"briefTitle":17469,"status":123,"phases":21253,"primaryCompletion":13717,"completion":13717,"start":17471,"enrollment":180,"conditions":21254,"interventions":21255},[94],[17418],[17451,17474],{"trials":21257,"activeCount":103},[],{"intervention":21259,"totalTrials":437,"cells":21260},"Rivastigmine transdermal",{"EARLY_PHASE1":21261,"PHASE1":21263,"PHASE2":21265,"PHASE3":21267,"PHASE4":21269,"NA":21277},{"trials":21262,"activeCount":103},[],{"trials":21264,"activeCount":103},[],{"trials":21266,"activeCount":103},[],{"trials":21268,"activeCount":103},[],{"trials":21270,"activeCount":103},[21271],{"nctId":21272,"briefTitle":21273,"status":123,"phases":21274,"primaryCompletion":1732,"completion":1732,"start":4081,"enrollment":2428,"conditions":21275,"interventions":21276},"NCT01047579","A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease",[94],[10401],[21259],{"trials":21278,"activeCount":103},[],{"intervention":15688,"totalTrials":437,"cells":21280},{"EARLY_PHASE1":21281,"PHASE1":21283,"PHASE2":21285,"PHASE3":21287,"PHASE4":21289,"NA":21295},{"trials":21282,"activeCount":103},[],{"trials":21284,"activeCount":103},[],{"trials":21286,"activeCount":103},[],{"trials":21288,"activeCount":103},[],{"trials":21290,"activeCount":103},[21291],{"nctId":15681,"briefTitle":15682,"status":123,"phases":21292,"primaryCompletion":15684,"completion":15684,"start":15685,"enrollment":5948,"conditions":21293,"interventions":21294},[94],[24],[15524,15688],{"trials":21296,"activeCount":103},[],{"intervention":21298,"totalTrials":437,"cells":21299},"QVA149 110\u002F50 micrograms",{"EARLY_PHASE1":21300,"PHASE1":21302,"PHASE2":21304,"PHASE3":21306,"PHASE4":21308,"NA":21319},{"trials":21301,"activeCount":103},[],{"trials":21303,"activeCount":103},[],{"trials":21305,"activeCount":103},[],{"trials":21307,"activeCount":103},[],{"trials":21309,"activeCount":103},[21310],{"nctId":21311,"briefTitle":21312,"status":123,"phases":21313,"primaryCompletion":16095,"completion":16095,"start":21314,"enrollment":21315,"conditions":21316,"interventions":21317},"NCT02516592","Assessment of Switching From Salmeterol\u002FFluticasone to Indacaterol\u002FGlycopyrronium in a symtomaticCOPD Patient Cohort",[94],"2015-10-13",500,[8267],[21298,21318],"Salmeterol\u002Ffluticasone 50\u002F500 microgrammes",{"trials":21320,"activeCount":103},[],{"intervention":21318,"totalTrials":437,"cells":21322},{"EARLY_PHASE1":21323,"PHASE1":21325,"PHASE2":21327,"PHASE3":21329,"PHASE4":21331,"NA":21337},{"trials":21324,"activeCount":103},[],{"trials":21326,"activeCount":103},[],{"trials":21328,"activeCount":103},[],{"trials":21330,"activeCount":103},[],{"trials":21332,"activeCount":103},[21333],{"nctId":21311,"briefTitle":21312,"status":123,"phases":21334,"primaryCompletion":16095,"completion":16095,"start":21314,"enrollment":21315,"conditions":21335,"interventions":21336},[94],[8267],[21298,21318],{"trials":21338,"activeCount":103},[],{"intervention":21340,"totalTrials":437,"cells":21341},"Desferasirox",{"EARLY_PHASE1":21342,"PHASE1":21344,"PHASE2":21346,"PHASE3":21348,"PHASE4":21350,"NA":21359},{"trials":21343,"activeCount":103},[],{"trials":21345,"activeCount":103},[],{"trials":21347,"activeCount":103},[],{"trials":21349,"activeCount":103},[],{"trials":21351,"activeCount":103},[21352],{"nctId":21353,"briefTitle":21354,"status":123,"phases":21355,"primaryCompletion":4669,"completion":4669,"start":1715,"enrollment":2776,"conditions":21356,"interventions":21358},"NCT01546415","Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia",[94],[21357],"Iron Overload",[21340],{"trials":21360,"activeCount":103},[],{"intervention":21362,"totalTrials":437,"cells":21363},"Nateglinide 120 mg",{"EARLY_PHASE1":21364,"PHASE1":21366,"PHASE2":21368,"PHASE3":21370,"PHASE4":21372,"NA":21381},{"trials":21365,"activeCount":103},[],{"trials":21367,"activeCount":103},[],{"trials":21369,"activeCount":103},[],{"trials":21371,"activeCount":103},[],{"trials":21373,"activeCount":103},[21374],{"nctId":21375,"briefTitle":21376,"status":123,"phases":21377,"primaryCompletion":3351,"completion":3351,"start":4845,"enrollment":4532,"conditions":21378,"interventions":21379},"NCT00928889","Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors",[94],[30],[21362,21380],"Acarbose 50 mg",{"trials":21382,"activeCount":103},[],{"intervention":21380,"totalTrials":437,"cells":21384},{"EARLY_PHASE1":21385,"PHASE1":21387,"PHASE2":21389,"PHASE3":21391,"PHASE4":21393,"NA":21399},{"trials":21386,"activeCount":103},[],{"trials":21388,"activeCount":103},[],{"trials":21390,"activeCount":103},[],{"trials":21392,"activeCount":103},[],{"trials":21394,"activeCount":103},[21395],{"nctId":21375,"briefTitle":21376,"status":123,"phases":21396,"primaryCompletion":3351,"completion":3351,"start":4845,"enrollment":4532,"conditions":21397,"interventions":21398},[94],[30],[21362,21380],{"trials":21400,"activeCount":103},[],{"intervention":7710,"totalTrials":437,"cells":21402},{"EARLY_PHASE1":21403,"PHASE1":21405,"PHASE2":21407,"PHASE3":21409,"PHASE4":21411,"NA":21417},{"trials":21404,"activeCount":103},[],{"trials":21406,"activeCount":103},[],{"trials":21408,"activeCount":103},[],{"trials":21410,"activeCount":103},[],{"trials":21412,"activeCount":103},[21413],{"nctId":7705,"briefTitle":7706,"status":134,"phases":21414,"primaryCompletion":4967,"completion":4967,"start":4845,"enrollment":1444,"conditions":21415,"interventions":21416},[94],[4701],[4804,7710,7711,4766,4769],{"trials":21418,"activeCount":103},[],{"intervention":16672,"totalTrials":437,"cells":21420},{"EARLY_PHASE1":21421,"PHASE1":21423,"PHASE2":21425,"PHASE3":21427,"PHASE4":21429,"NA":21435},{"trials":21422,"activeCount":103},[],{"trials":21424,"activeCount":103},[],{"trials":21426,"activeCount":103},[],{"trials":21428,"activeCount":103},[],{"trials":21430,"activeCount":103},[21431],{"nctId":16667,"briefTitle":16668,"status":123,"phases":21432,"primaryCompletion":1761,"completion":1761,"start":1732,"enrollment":2149,"conditions":21433,"interventions":21434},[94],[15233],[16672,16673,13838],{"trials":21436,"activeCount":103},[],{"intervention":17723,"totalTrials":437,"cells":21438},{"EARLY_PHASE1":21439,"PHASE1":21441,"PHASE2":21443,"PHASE3":21445,"PHASE4":21447,"NA":21453},{"trials":21440,"activeCount":103},[],{"trials":21442,"activeCount":103},[],{"trials":21444,"activeCount":103},[],{"trials":21446,"activeCount":103},[],{"trials":21448,"activeCount":103},[21449],{"nctId":17716,"briefTitle":17717,"status":123,"phases":21450,"primaryCompletion":17719,"completion":17719,"start":17720,"enrollment":12,"conditions":21451,"interventions":21452},[94],[5961],[17634,17723],{"trials":21454,"activeCount":103},[],{"intervention":21456,"totalTrials":437,"cells":21457},"brinzolamide 1%\u002Fbrimonidine 0.2% fixed combination",{"EARLY_PHASE1":21458,"PHASE1":21460,"PHASE2":21462,"PHASE3":21464,"PHASE4":21466,"NA":21477},{"trials":21459,"activeCount":103},[],{"trials":21461,"activeCount":103},[],{"trials":21463,"activeCount":103},[],{"trials":21465,"activeCount":103},[],{"trials":21467,"activeCount":103},[21468],{"nctId":21469,"briefTitle":21470,"status":123,"phases":21471,"primaryCompletion":21472,"completion":21472,"start":675,"enrollment":437,"conditions":21473,"interventions":21475},"NCT03150160","Additive Effect of Twice-daily Brinzolamide 1%\u002FBrimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma",[94],"2017-12-04",[21474],"Glaucoma",[21456,21476],"travoprost 0.004% ophthalmic solution",{"trials":21478,"activeCount":103},[],{"intervention":21476,"totalTrials":437,"cells":21480},{"EARLY_PHASE1":21481,"PHASE1":21483,"PHASE2":21485,"PHASE3":21487,"PHASE4":21489,"NA":21495},{"trials":21482,"activeCount":103},[],{"trials":21484,"activeCount":103},[],{"trials":21486,"activeCount":103},[],{"trials":21488,"activeCount":103},[],{"trials":21490,"activeCount":103},[21491],{"nctId":21469,"briefTitle":21470,"status":123,"phases":21492,"primaryCompletion":21472,"completion":21472,"start":675,"enrollment":437,"conditions":21493,"interventions":21494},[94],[21474],[21456,21476],{"trials":21496,"activeCount":103},[],{"intervention":21498,"totalTrials":437,"cells":21499},"Egaten (Triclabendazole) 250 mg",{"EARLY_PHASE1":21500,"PHASE1":21502,"PHASE2":21504,"PHASE3":21506,"PHASE4":21508,"NA":21519},{"trials":21501,"activeCount":103},[],{"trials":21503,"activeCount":103},[],{"trials":21505,"activeCount":103},[],{"trials":21507,"activeCount":103},[],{"trials":21509,"activeCount":103},[21510],{"nctId":21511,"briefTitle":21512,"status":123,"phases":21513,"primaryCompletion":21514,"completion":21514,"start":21515,"enrollment":4670,"conditions":21516,"interventions":21518},"NCT04230148","Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).",[94],"2026-03-27","2022-02-11",[21517],"Fascioliasis",[21498],{"trials":21520,"activeCount":103},[],{"intervention":3804,"totalTrials":437,"cells":21522},{"EARLY_PHASE1":21523,"PHASE1":21525,"PHASE2":21527,"PHASE3":21529,"PHASE4":21531,"NA":21537},{"trials":21524,"activeCount":103},[],{"trials":21526,"activeCount":103},[],{"trials":21528,"activeCount":103},[],{"trials":21530,"activeCount":103},[],{"trials":21532,"activeCount":103},[21533],{"nctId":3796,"briefTitle":3797,"status":134,"phases":21534,"primaryCompletion":3799,"completion":3799,"start":3800,"enrollment":271,"conditions":21535,"interventions":21536},[94],[3802,3762],[3804,3805,3806,2836],{"trials":21538,"activeCount":103},[],{"intervention":3805,"totalTrials":437,"cells":21540},{"EARLY_PHASE1":21541,"PHASE1":21543,"PHASE2":21545,"PHASE3":21547,"PHASE4":21549,"NA":21555},{"trials":21542,"activeCount":103},[],{"trials":21544,"activeCount":103},[],{"trials":21546,"activeCount":103},[],{"trials":21548,"activeCount":103},[],{"trials":21550,"activeCount":103},[21551],{"nctId":3796,"briefTitle":3797,"status":134,"phases":21552,"primaryCompletion":3799,"completion":3799,"start":3800,"enrollment":271,"conditions":21553,"interventions":21554},[94],[3802,3762],[3804,3805,3806,2836],{"trials":21556,"activeCount":103},[],{"intervention":3806,"totalTrials":437,"cells":21558},{"EARLY_PHASE1":21559,"PHASE1":21561,"PHASE2":21563,"PHASE3":21565,"PHASE4":21567,"NA":21573},{"trials":21560,"activeCount":103},[],{"trials":21562,"activeCount":103},[],{"trials":21564,"activeCount":103},[],{"trials":21566,"activeCount":103},[],{"trials":21568,"activeCount":103},[21569],{"nctId":3796,"briefTitle":3797,"status":134,"phases":21570,"primaryCompletion":3799,"completion":3799,"start":3800,"enrollment":271,"conditions":21571,"interventions":21572},[94],[3802,3762],[3804,3805,3806,2836],{"trials":21574,"activeCount":103},[],{"intervention":21576,"totalTrials":437,"cells":21577},"Fingolimod 0.5 mg",{"EARLY_PHASE1":21578,"PHASE1":21580,"PHASE2":21582,"PHASE3":21584,"PHASE4":21586,"NA":21595},{"trials":21579,"activeCount":103},[],{"trials":21581,"activeCount":103},[],{"trials":21583,"activeCount":103},[],{"trials":21585,"activeCount":103},[],{"trials":21587,"activeCount":103},[21588],{"nctId":21589,"briefTitle":21590,"status":123,"phases":21591,"primaryCompletion":21592,"completion":21592,"start":17891,"enrollment":5080,"conditions":21593,"interventions":21594},"NCT02373098","Fingolimod Effect on Cytokine and Chemokine Levels",[94],"2017-01-18",[3743],[21576],{"trials":21596,"activeCount":103},[],{"intervention":21598,"totalTrials":437,"cells":21599},"Formoterol 12 mcg",{"EARLY_PHASE1":21600,"PHASE1":21602,"PHASE2":21604,"PHASE3":21606,"PHASE4":21608,"NA":21621},{"trials":21601,"activeCount":103},[],{"trials":21603,"activeCount":103},[],{"trials":21605,"activeCount":103},[],{"trials":21607,"activeCount":103},[],{"trials":21609,"activeCount":103},[21610],{"nctId":21611,"briefTitle":21612,"status":134,"phases":21613,"primaryCompletion":21614,"completion":21614,"start":5114,"enrollment":21615,"conditions":21616,"interventions":21617},"NCT01845025","Study of Safety of Foradil in Patients With Persistent Asthma",[94],"2016-05",827,[16339],[21598,21618,21619,21620],"Fluticasone propionate 100 mcg","Fluticasone propionate 250 mcg","Fluticasone propionate 500 mcg",{"trials":21622,"activeCount":103},[],{"intervention":21618,"totalTrials":437,"cells":21624},{"EARLY_PHASE1":21625,"PHASE1":21627,"PHASE2":21629,"PHASE3":21631,"PHASE4":21633,"NA":21639},{"trials":21626,"activeCount":103},[],{"trials":21628,"activeCount":103},[],{"trials":21630,"activeCount":103},[],{"trials":21632,"activeCount":103},[],{"trials":21634,"activeCount":103},[21635],{"nctId":21611,"briefTitle":21612,"status":134,"phases":21636,"primaryCompletion":21614,"completion":21614,"start":5114,"enrollment":21615,"conditions":21637,"interventions":21638},[94],[16339],[21598,21618,21619,21620],{"trials":21640,"activeCount":103},[],{"intervention":21619,"totalTrials":437,"cells":21642},{"EARLY_PHASE1":21643,"PHASE1":21645,"PHASE2":21647,"PHASE3":21649,"PHASE4":21651,"NA":21657},{"trials":21644,"activeCount":103},[],{"trials":21646,"activeCount":103},[],{"trials":21648,"activeCount":103},[],{"trials":21650,"activeCount":103},[],{"trials":21652,"activeCount":103},[21653],{"nctId":21611,"briefTitle":21612,"status":134,"phases":21654,"primaryCompletion":21614,"completion":21614,"start":5114,"enrollment":21615,"conditions":21655,"interventions":21656},[94],[16339],[21598,21618,21619,21620],{"trials":21658,"activeCount":103},[],{"intervention":21620,"totalTrials":437,"cells":21660},{"EARLY_PHASE1":21661,"PHASE1":21663,"PHASE2":21665,"PHASE3":21667,"PHASE4":21669,"NA":21675},{"trials":21662,"activeCount":103},[],{"trials":21664,"activeCount":103},[],{"trials":21666,"activeCount":103},[],{"trials":21668,"activeCount":103},[],{"trials":21670,"activeCount":103},[21671],{"nctId":21611,"briefTitle":21612,"status":134,"phases":21672,"primaryCompletion":21614,"completion":21614,"start":5114,"enrollment":21615,"conditions":21673,"interventions":21674},[94],[16339],[21598,21618,21619,21620],{"trials":21676,"activeCount":103},[],{"intervention":21678,"totalTrials":437,"cells":21679},"ICL670\u002FDeferasirox",{"EARLY_PHASE1":21680,"PHASE1":21682,"PHASE2":21684,"PHASE3":21686,"PHASE4":21688,"NA":21697},{"trials":21681,"activeCount":103},[],{"trials":21683,"activeCount":103},[],{"trials":21685,"activeCount":103},[],{"trials":21687,"activeCount":103},[],{"trials":21689,"activeCount":103},[21690],{"nctId":21691,"briefTitle":21692,"status":123,"phases":21693,"primaryCompletion":926,"start":4740,"enrollment":19,"conditions":21694,"interventions":21696},"NCT00481143","Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload",[94],[5723,21695],"Transfusion Dependent Iron Overload",[21678],{"trials":21698,"activeCount":103},[],{"intervention":21700,"totalTrials":437,"cells":21701},"0,5 mg Fingolimod",{"EARLY_PHASE1":21702,"PHASE1":21704,"PHASE2":21706,"PHASE3":21708,"PHASE4":21710,"NA":21721},{"trials":21703,"activeCount":103},[],{"trials":21705,"activeCount":103},[],{"trials":21707,"activeCount":103},[],{"trials":21709,"activeCount":103},[],{"trials":21711,"activeCount":103},[21712],{"nctId":21713,"briefTitle":21714,"status":134,"phases":21715,"primaryCompletion":21716,"completion":21716,"start":1919,"enrollment":1630,"conditions":21717,"interventions":21720},"NCT02575365","Effect of Fingolimod on Neurodegeneration",[94],"2017-01-27",[21718,21719],"Cognition","Brain Volume Loss",[21700],{"trials":21722,"activeCount":103},[],{"intervention":21724,"totalTrials":437,"cells":21725},"Octreotide acetate and cabergoline\u002FOctrotide and Somavert",{"EARLY_PHASE1":21726,"PHASE1":21728,"PHASE2":21730,"PHASE3":21732,"PHASE4":21734,"NA":21742},{"trials":21727,"activeCount":103},[],{"trials":21729,"activeCount":103},[],{"trials":21731,"activeCount":103},[],{"trials":21733,"activeCount":103},[],{"trials":21735,"activeCount":103},[21736],{"nctId":21737,"briefTitle":21738,"status":123,"phases":21739,"primaryCompletion":3551,"start":865,"enrollment":1611,"conditions":21740,"interventions":21741},"NCT00376064","Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly",[94],[8385],[21724],{"trials":21743,"activeCount":103},[],{"intervention":21745,"totalTrials":437,"cells":21746},"Prograf",{"EARLY_PHASE1":21747,"PHASE1":21749,"PHASE2":21751,"PHASE3":21753,"PHASE4":21755,"NA":21767},{"trials":21748,"activeCount":103},[],{"trials":21750,"activeCount":103},[],{"trials":21752,"activeCount":103},[],{"trials":21754,"activeCount":103},[],{"trials":21756,"activeCount":103},[21757],{"nctId":21758,"briefTitle":21759,"status":123,"phases":21760,"primaryCompletion":21761,"completion":21761,"start":21762,"enrollment":4568,"conditions":21763,"interventions":21765},"NCT01649427","Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients",[94],"2015-08-20","2012-10-17",[21764],"Pharmacokinetics Study in de Novo Kidney Transplantation",[21745,21766],"Tacrolimus Hexal",{"trials":21768,"activeCount":103},[],{"intervention":21766,"totalTrials":437,"cells":21770},{"EARLY_PHASE1":21771,"PHASE1":21773,"PHASE2":21775,"PHASE3":21777,"PHASE4":21779,"NA":21785},{"trials":21772,"activeCount":103},[],{"trials":21774,"activeCount":103},[],{"trials":21776,"activeCount":103},[],{"trials":21778,"activeCount":103},[],{"trials":21780,"activeCount":103},[21781],{"nctId":21758,"briefTitle":21759,"status":123,"phases":21782,"primaryCompletion":21761,"completion":21761,"start":21762,"enrollment":4568,"conditions":21783,"interventions":21784},[94],[21764],[21745,21766],{"trials":21786,"activeCount":103},[],{"intervention":18312,"totalTrials":437,"cells":21788},{"EARLY_PHASE1":21789,"PHASE1":21791,"PHASE2":21793,"PHASE3":21795,"PHASE4":21797,"NA":21803},{"trials":21790,"activeCount":103},[],{"trials":21792,"activeCount":103},[],{"trials":21794,"activeCount":103},[],{"trials":21796,"activeCount":103},[],{"trials":21798,"activeCount":103},[21799],{"nctId":18307,"briefTitle":18308,"status":123,"phases":21800,"primaryCompletion":1681,"completion":1681,"start":15346,"enrollment":1423,"conditions":21801,"interventions":21802},[94],[9233],[18261,18312,18313],{"trials":21804,"activeCount":103},[],{"intervention":18313,"totalTrials":437,"cells":21806},{"EARLY_PHASE1":21807,"PHASE1":21809,"PHASE2":21811,"PHASE3":21813,"PHASE4":21815,"NA":21821},{"trials":21808,"activeCount":103},[],{"trials":21810,"activeCount":103},[],{"trials":21812,"activeCount":103},[],{"trials":21814,"activeCount":103},[],{"trials":21816,"activeCount":103},[21817],{"nctId":18307,"briefTitle":18308,"status":123,"phases":21818,"primaryCompletion":1681,"completion":1681,"start":15346,"enrollment":1423,"conditions":21819,"interventions":21820},[94],[9233],[18261,18312,18313],{"trials":21822,"activeCount":103},[],{"intervention":3840,"totalTrials":437,"cells":21824},{"EARLY_PHASE1":21825,"PHASE1":21827,"PHASE2":21829,"PHASE3":21831,"PHASE4":21833,"NA":21839},{"trials":21826,"activeCount":103},[],{"trials":21828,"activeCount":103},[],{"trials":21830,"activeCount":103},[],{"trials":21832,"activeCount":103},[],{"trials":21834,"activeCount":103},[21835],{"nctId":3832,"briefTitle":3833,"status":123,"phases":21836,"primaryCompletion":3835,"completion":3835,"start":3836,"enrollment":3837,"conditions":21837,"interventions":21838},[94],[3743],[2836,3840],{"trials":21840,"activeCount":103},[],{"intervention":21842,"totalTrials":437,"cells":21843},"Pamidronate",{"EARLY_PHASE1":21844,"PHASE1":21846,"PHASE2":21848,"PHASE3":21850,"PHASE4":21852,"NA":21860},{"trials":21845,"activeCount":103},[],{"trials":21847,"activeCount":103},[],{"trials":21849,"activeCount":103},[],{"trials":21851,"activeCount":103},[],{"trials":21853,"activeCount":103},[21854],{"nctId":21855,"briefTitle":21856,"status":123,"phases":21857,"primaryCompletion":4741,"start":905,"enrollment":5080,"conditions":21858,"interventions":21859},"NCT00738257","A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.",[94],[884],[21842],{"trials":21861,"activeCount":103},[],{"intervention":3849,"totalTrials":437,"cells":21863},{"EARLY_PHASE1":21864,"PHASE1":21866,"PHASE2":21868,"PHASE3":21870,"PHASE4":21872,"NA":21878},{"trials":21865,"activeCount":103},[],{"trials":21867,"activeCount":103},[],{"trials":21869,"activeCount":103},[],{"trials":21871,"activeCount":103},[],{"trials":21873,"activeCount":103},[21874],{"nctId":3842,"briefTitle":3843,"status":123,"phases":21875,"primaryCompletion":3482,"completion":3482,"start":3845,"enrollment":3846,"conditions":21876,"interventions":21877},[94],[3013],[2836,3849],{"trials":21879,"activeCount":103},[],{"intervention":16683,"totalTrials":437,"cells":21881},{"EARLY_PHASE1":21882,"PHASE1":21884,"PHASE2":21886,"PHASE3":21888,"PHASE4":21890,"NA":21896},{"trials":21883,"activeCount":103},[],{"trials":21885,"activeCount":103},[],{"trials":21887,"activeCount":103},[],{"trials":21889,"activeCount":103},[],{"trials":21891,"activeCount":103},[21892],{"nctId":16675,"briefTitle":16676,"status":123,"phases":21893,"primaryCompletion":8329,"completion":16678,"start":6556,"enrollment":16679,"conditions":21894,"interventions":21895},[94],[16681,8385],[16683,15255,16673,15320,4424,13838],{"trials":21897,"activeCount":103},[],{"intervention":21899,"totalTrials":437,"cells":21900},"Capmatinib 150 mg",{"EARLY_PHASE1":21901,"PHASE1":21903,"PHASE2":21905,"PHASE3":21907,"PHASE4":21909,"NA":21920},{"trials":21902,"activeCount":103},[],{"trials":21904,"activeCount":103},[],{"trials":21906,"activeCount":103},[],{"trials":21908,"activeCount":103},[],{"trials":21910,"activeCount":103},[21911],{"nctId":21912,"briefTitle":21913,"status":123,"phases":21914,"primaryCompletion":21915,"completion":21915,"start":21916,"enrollment":2579,"conditions":21917,"interventions":21918},"NCT05110196","Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.",[94],"2025-08-04","2022-09-03",[228],[21899,21919],"Capmatinib 200 mg",{"trials":21921,"activeCount":103},[],{"intervention":21919,"totalTrials":437,"cells":21923},{"EARLY_PHASE1":21924,"PHASE1":21926,"PHASE2":21928,"PHASE3":21930,"PHASE4":21932,"NA":21938},{"trials":21925,"activeCount":103},[],{"trials":21927,"activeCount":103},[],{"trials":21929,"activeCount":103},[],{"trials":21931,"activeCount":103},[],{"trials":21933,"activeCount":103},[21934],{"nctId":21912,"briefTitle":21913,"status":123,"phases":21935,"primaryCompletion":21915,"completion":21915,"start":21916,"enrollment":2579,"conditions":21936,"interventions":21937},[94],[228],[21899,21919],{"trials":21939,"activeCount":103},[],{"intervention":5084,"totalTrials":437,"cells":21941},{"EARLY_PHASE1":21942,"PHASE1":21944,"PHASE2":21946,"PHASE3":21948,"PHASE4":21950,"NA":21956},{"trials":21943,"activeCount":103},[],{"trials":21945,"activeCount":103},[],{"trials":21947,"activeCount":103},[],{"trials":21949,"activeCount":103},[],{"trials":21951,"activeCount":103},[21952],{"nctId":5077,"briefTitle":5078,"status":123,"phases":21953,"primaryCompletion":4524,"completion":4524,"start":865,"enrollment":5080,"conditions":21954,"interventions":21955},[94],[5082],[196,4875,5084,4874],{"trials":21957,"activeCount":103},[],{"intervention":18912,"totalTrials":437,"cells":21959},{"EARLY_PHASE1":21960,"PHASE1":21962,"PHASE2":21964,"PHASE3":21966,"PHASE4":21968,"NA":21974},{"trials":21961,"activeCount":103},[],{"trials":21963,"activeCount":103},[],{"trials":21965,"activeCount":103},[],{"trials":21967,"activeCount":103},[],{"trials":21969,"activeCount":103},[21970],{"nctId":18905,"briefTitle":18906,"status":123,"phases":21971,"primaryCompletion":2774,"completion":2774,"start":18908,"enrollment":18909,"conditions":21972,"interventions":21973},[94],[18881],[18854,18912],{"trials":21975,"activeCount":103},[],{"intervention":17481,"totalTrials":437,"cells":21977},{"EARLY_PHASE1":21978,"PHASE1":21980,"PHASE2":21982,"PHASE3":21984,"PHASE4":21986,"NA":21992},{"trials":21979,"activeCount":103},[],{"trials":21981,"activeCount":103},[],{"trials":21983,"activeCount":103},[],{"trials":21985,"activeCount":103},[],{"trials":21987,"activeCount":103},[21988],{"nctId":17476,"briefTitle":17477,"status":390,"phases":21989,"primaryCompletion":895,"enrollment":103,"conditions":21990,"interventions":21991},[94],[17418],[17382,17481,17410],{"trials":21993,"activeCount":103},[],{"intervention":21995,"totalTrials":437,"cells":21996},"Conbercept",{"EARLY_PHASE1":21997,"PHASE1":21999,"PHASE2":22001,"PHASE3":22003,"PHASE4":22005,"NA":22016},{"trials":21998,"activeCount":103},[],{"trials":22000,"activeCount":103},[],{"trials":22002,"activeCount":103},[],{"trials":22004,"activeCount":103},[],{"trials":22006,"activeCount":103},[22007],{"nctId":22008,"briefTitle":22009,"status":123,"phases":22010,"primaryCompletion":22011,"completion":22011,"start":22012,"enrollment":138,"conditions":22013,"interventions":22014},"NCT02577107","Head to Head Study of Anti-VEGF Treatment.",[94],"2016-07-09","2016-01-13",[4458],[22015,21995],"ranibizumab",{"trials":22017,"activeCount":103},[],{"intervention":22019,"totalTrials":437,"cells":22020},"Ranibizumab Intravitreal injections",{"EARLY_PHASE1":22021,"PHASE1":22023,"PHASE2":22025,"PHASE3":22027,"PHASE4":22029,"NA":22038},{"trials":22022,"activeCount":103},[],{"trials":22024,"activeCount":103},[],{"trials":22026,"activeCount":103},[],{"trials":22028,"activeCount":103},[],{"trials":22030,"activeCount":103},[22031],{"nctId":22032,"briefTitle":22033,"status":123,"phases":22034,"primaryCompletion":17898,"completion":17898,"start":22035,"enrollment":4118,"conditions":22036,"interventions":22037},"NCT02140411","Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.",[94],"2015-04-25",[10555,17695],[22019],{"trials":22039,"activeCount":103},[],{"intervention":2962,"totalTrials":437,"cells":22041},{"EARLY_PHASE1":22042,"PHASE1":22044,"PHASE2":22046,"PHASE3":22048,"PHASE4":22050,"NA":22056},{"trials":22043,"activeCount":103},[],{"trials":22045,"activeCount":103},[],{"trials":22047,"activeCount":103},[],{"trials":22049,"activeCount":103},[],{"trials":22051,"activeCount":103},[22052],{"nctId":2954,"briefTitle":2955,"status":134,"phases":22053,"primaryCompletion":2957,"completion":2957,"start":2958,"enrollment":630,"conditions":22054,"interventions":22055},[94],[2960],[2752,2962,2963],{"trials":22057,"activeCount":103},[],{"intervention":2963,"totalTrials":437,"cells":22059},{"EARLY_PHASE1":22060,"PHASE1":22062,"PHASE2":22064,"PHASE3":22066,"PHASE4":22068,"NA":22074},{"trials":22061,"activeCount":103},[],{"trials":22063,"activeCount":103},[],{"trials":22065,"activeCount":103},[],{"trials":22067,"activeCount":103},[],{"trials":22069,"activeCount":103},[22070],{"nctId":2954,"briefTitle":2955,"status":134,"phases":22071,"primaryCompletion":2957,"completion":2957,"start":2958,"enrollment":630,"conditions":22072,"interventions":22073},[94],[2960],[2752,2962,2963],{"trials":22075,"activeCount":103},[],{"intervention":15872,"totalTrials":437,"cells":22077},{"EARLY_PHASE1":22078,"PHASE1":22080,"PHASE2":22082,"PHASE3":22084,"PHASE4":22086,"NA":22092},{"trials":22079,"activeCount":103},[],{"trials":22081,"activeCount":103},[],{"trials":22083,"activeCount":103},[],{"trials":22085,"activeCount":103},[],{"trials":22087,"activeCount":103},[22088],{"nctId":15864,"briefTitle":15865,"status":123,"phases":22089,"primaryCompletion":15867,"completion":15867,"start":15868,"enrollment":2112,"conditions":22090,"interventions":22091},[94],[15870],[15872,15821],{"trials":22093,"activeCount":103},[],{"intervention":22095,"totalTrials":437,"cells":22096},"Dex-Methylphenidate hydrochloride Extended Release",{"EARLY_PHASE1":22097,"PHASE1":22099,"PHASE2":22101,"PHASE3":22103,"PHASE4":22105,"NA":22114},{"trials":22098,"activeCount":103},[],{"trials":22100,"activeCount":103},[],{"trials":22102,"activeCount":103},[],{"trials":22104,"activeCount":103},[],{"trials":22106,"activeCount":103},[22107],{"nctId":22108,"briefTitle":22109,"status":123,"phases":22110,"primaryCompletion":3552,"completion":3552,"start":1014,"enrollment":1302,"conditions":22111,"interventions":22113},"NCT00776009","Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit\u002FHyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.",[94],[22112],"Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[22095],{"trials":22115,"activeCount":103},[],{"intervention":17253,"totalTrials":437,"cells":22117},{"EARLY_PHASE1":22118,"PHASE1":22120,"PHASE2":22122,"PHASE3":22124,"PHASE4":22126,"NA":22132},{"trials":22119,"activeCount":103},[],{"trials":22121,"activeCount":103},[],{"trials":22123,"activeCount":103},[],{"trials":22125,"activeCount":103},[],{"trials":22127,"activeCount":103},[22128],{"nctId":17248,"briefTitle":17249,"status":123,"phases":22129,"primaryCompletion":5114,"completion":5114,"start":4975,"enrollment":4516,"conditions":22130,"interventions":22131},[94],[17240,4645],[17253,4803],{"trials":22133,"activeCount":103},[],{"intervention":17618,"totalTrials":437,"cells":22135},{"EARLY_PHASE1":22136,"PHASE1":22138,"PHASE2":22140,"PHASE3":22142,"PHASE4":22144,"NA":22150},{"trials":22137,"activeCount":103},[],{"trials":22139,"activeCount":103},[],{"trials":22141,"activeCount":103},[],{"trials":22143,"activeCount":103},[],{"trials":22145,"activeCount":103},[22146],{"nctId":17613,"briefTitle":17614,"status":134,"phases":22147,"primaryCompletion":3400,"completion":3400,"start":1025,"enrollment":2439,"conditions":22148,"interventions":22149},[94],[4701],[17618,7647],{"trials":22151,"activeCount":103},[],{"intervention":22153,"totalTrials":437,"cells":22154},"Secukinumab (AIN457) 150 mg s.c.",{"EARLY_PHASE1":22155,"PHASE1":22157,"PHASE2":22159,"PHASE3":22161,"PHASE4":22163,"NA":22172},{"trials":22156,"activeCount":103},[],{"trials":22158,"activeCount":103},[],{"trials":22160,"activeCount":103},[],{"trials":22162,"activeCount":103},[],{"trials":22164,"activeCount":103},[22165],{"nctId":22166,"briefTitle":22167,"status":123,"phases":22168,"primaryCompletion":165,"completion":165,"start":22169,"enrollment":16124,"conditions":22170,"interventions":22171},"NCT02763046","Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis",[94],"2016-05-31",[1974],[22153,22153],{"trials":22173,"activeCount":103},[],{"intervention":5445,"totalTrials":437,"cells":22175},{"EARLY_PHASE1":22176,"PHASE1":22178,"PHASE2":22180,"PHASE3":22182,"PHASE4":22184,"NA":22190},{"trials":22177,"activeCount":103},[],{"trials":22179,"activeCount":103},[],{"trials":22181,"activeCount":103},[],{"trials":22183,"activeCount":103},[],{"trials":22185,"activeCount":103},[22186],{"nctId":5439,"briefTitle":5440,"status":123,"phases":22187,"primaryCompletion":4620,"completion":4620,"start":4845,"enrollment":5442,"conditions":22188,"interventions":22189},[94],[21],[5445,5446,5415,5447,5448],{"trials":22191,"activeCount":103},[],{"intervention":5446,"totalTrials":437,"cells":22193},{"EARLY_PHASE1":22194,"PHASE1":22196,"PHASE2":22198,"PHASE3":22200,"PHASE4":22202,"NA":22208},{"trials":22195,"activeCount":103},[],{"trials":22197,"activeCount":103},[],{"trials":22199,"activeCount":103},[],{"trials":22201,"activeCount":103},[],{"trials":22203,"activeCount":103},[22204],{"nctId":5439,"briefTitle":5440,"status":123,"phases":22205,"primaryCompletion":4620,"completion":4620,"start":4845,"enrollment":5442,"conditions":22206,"interventions":22207},[94],[21],[5445,5446,5415,5447,5448],{"trials":22209,"activeCount":103},[],{"intervention":5448,"totalTrials":437,"cells":22211},{"EARLY_PHASE1":22212,"PHASE1":22214,"PHASE2":22216,"PHASE3":22218,"PHASE4":22220,"NA":22226},{"trials":22213,"activeCount":103},[],{"trials":22215,"activeCount":103},[],{"trials":22217,"activeCount":103},[],{"trials":22219,"activeCount":103},[],{"trials":22221,"activeCount":103},[22222],{"nctId":5439,"briefTitle":5440,"status":123,"phases":22223,"primaryCompletion":4620,"completion":4620,"start":4845,"enrollment":5442,"conditions":22224,"interventions":22225},[94],[21],[5445,5446,5415,5447,5448],{"trials":22227,"activeCount":103},[],{"intervention":22229,"totalTrials":437,"cells":22230},"Foradil Combi",{"EARLY_PHASE1":22231,"PHASE1":22233,"PHASE2":22235,"PHASE3":22237,"PHASE4":22239,"NA":22247},{"trials":22232,"activeCount":103},[],{"trials":22234,"activeCount":103},[],{"trials":22236,"activeCount":103},[],{"trials":22238,"activeCount":103},[],{"trials":22240,"activeCount":103},[22241],{"nctId":22242,"briefTitle":22243,"status":390,"phases":22244,"primaryCompletion":864,"start":3351,"enrollment":103,"conditions":22245,"interventions":22246},"NCT00997477","Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics",[94],[18],[22229],{"trials":22248,"activeCount":103},[],{"intervention":7730,"totalTrials":437,"cells":22250},{"EARLY_PHASE1":22251,"PHASE1":22253,"PHASE2":22255,"PHASE3":22257,"PHASE4":22259,"NA":22265},{"trials":22252,"activeCount":103},[],{"trials":22254,"activeCount":103},[],{"trials":22256,"activeCount":103},[],{"trials":22258,"activeCount":103},[],{"trials":22260,"activeCount":103},[22261],{"nctId":7717,"briefTitle":7718,"status":123,"phases":22262,"primaryCompletion":7720,"completion":7721,"start":7722,"enrollment":7723,"conditions":22263,"interventions":22264},[94],[7725,7726,7727,7728,4701],[7730,4769,7731,7732],{"trials":22266,"activeCount":103},[],{"intervention":7731,"totalTrials":437,"cells":22268},{"EARLY_PHASE1":22269,"PHASE1":22271,"PHASE2":22273,"PHASE3":22275,"PHASE4":22277,"NA":22283},{"trials":22270,"activeCount":103},[],{"trials":22272,"activeCount":103},[],{"trials":22274,"activeCount":103},[],{"trials":22276,"activeCount":103},[],{"trials":22278,"activeCount":103},[22279],{"nctId":7717,"briefTitle":7718,"status":123,"phases":22280,"primaryCompletion":7720,"completion":7721,"start":7722,"enrollment":7723,"conditions":22281,"interventions":22282},[94],[7725,7726,7727,7728,4701],[7730,4769,7731,7732],{"trials":22284,"activeCount":103},[],{"intervention":7732,"totalTrials":437,"cells":22286},{"EARLY_PHASE1":22287,"PHASE1":22289,"PHASE2":22291,"PHASE3":22293,"PHASE4":22295,"NA":22301},{"trials":22288,"activeCount":103},[],{"trials":22290,"activeCount":103},[],{"trials":22292,"activeCount":103},[],{"trials":22294,"activeCount":103},[],{"trials":22296,"activeCount":103},[22297],{"nctId":7717,"briefTitle":7718,"status":123,"phases":22298,"primaryCompletion":7720,"completion":7721,"start":7722,"enrollment":7723,"conditions":22299,"interventions":22300},[94],[7725,7726,7727,7728,4701],[7730,4769,7731,7732],{"trials":22302,"activeCount":103},[],{"intervention":22304,"totalTrials":437,"cells":22305},"Zoledronic acid 5mg",{"EARLY_PHASE1":22306,"PHASE1":22308,"PHASE2":22310,"PHASE3":22312,"PHASE4":22314,"NA":22324},{"trials":22307,"activeCount":103},[],{"trials":22309,"activeCount":103},[],{"trials":22311,"activeCount":103},[],{"trials":22313,"activeCount":103},[],{"trials":22315,"activeCount":103},[22316],{"nctId":22317,"briefTitle":22318,"status":390,"phases":22319,"primaryCompletion":22320,"completion":22320,"start":5741,"enrollment":103,"conditions":22321,"interventions":22323},"NCT02333344","The Efficacy Study of Aclasta on Prosthetic Fixation in Postmenopausal Women After THA",[94],"2020-01-28",[22322],"Prosthetic Fixation After Cementless Total Hip Arthroplasty",[22304],{"trials":22325,"activeCount":103},[],{"intervention":22327,"totalTrials":437,"cells":22328},"Aldesleukin",{"EARLY_PHASE1":22329,"PHASE1":22331,"PHASE2":22333,"PHASE3":22335,"PHASE4":22337,"NA":22346},{"trials":22330,"activeCount":103},[],{"trials":22332,"activeCount":103},[],{"trials":22334,"activeCount":103},[],{"trials":22336,"activeCount":103},[],{"trials":22338,"activeCount":103},[22339],{"nctId":22340,"briefTitle":22341,"status":123,"phases":22342,"primaryCompletion":22343,"completion":22343,"start":16536,"enrollment":37,"conditions":22344,"interventions":22345},"NCT00414765","Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma",[94],"2010-03-28",[4352,13652],[22327],{"trials":22347,"activeCount":103},[],{"intervention":16703,"totalTrials":437,"cells":22349},{"EARLY_PHASE1":22350,"PHASE1":22352,"PHASE2":22354,"PHASE3":22356,"PHASE4":22358,"NA":22364},{"trials":22351,"activeCount":103},[],{"trials":22353,"activeCount":103},[],{"trials":22355,"activeCount":103},[],{"trials":22357,"activeCount":103},[],{"trials":22359,"activeCount":103},[22360],{"nctId":16695,"briefTitle":16696,"status":123,"phases":22361,"primaryCompletion":16698,"completion":16698,"start":16699,"enrollment":709,"conditions":22362,"interventions":22363},[94],[15233,16701],[16703,15220,13838],{"trials":22365,"activeCount":103},[],{"intervention":20101,"totalTrials":437,"cells":22367},{"EARLY_PHASE1":22368,"PHASE1":22370,"PHASE2":22372,"PHASE3":22374,"PHASE4":22376,"NA":22382},{"trials":22369,"activeCount":103},[],{"trials":22371,"activeCount":103},[],{"trials":22373,"activeCount":103},[],{"trials":22375,"activeCount":103},[],{"trials":22377,"activeCount":103},[22378],{"nctId":20096,"briefTitle":20097,"status":123,"phases":22379,"primaryCompletion":4335,"completion":4335,"start":4034,"enrollment":512,"conditions":22380,"interventions":22381},[94],[8385],[20076,20101,20102],{"trials":22383,"activeCount":103},[],{"intervention":20102,"totalTrials":437,"cells":22385},{"EARLY_PHASE1":22386,"PHASE1":22388,"PHASE2":22390,"PHASE3":22392,"PHASE4":22394,"NA":22400},{"trials":22387,"activeCount":103},[],{"trials":22389,"activeCount":103},[],{"trials":22391,"activeCount":103},[],{"trials":22393,"activeCount":103},[],{"trials":22395,"activeCount":103},[22396],{"nctId":20096,"briefTitle":20097,"status":123,"phases":22397,"primaryCompletion":4335,"completion":4335,"start":4034,"enrollment":512,"conditions":22398,"interventions":22399},[94],[8385],[20076,20101,20102],{"trials":22401,"activeCount":103},[],{"intervention":22403,"totalTrials":437,"cells":22404},"Octreotide acetate",{"EARLY_PHASE1":22405,"PHASE1":22407,"PHASE2":22409,"PHASE3":22411,"PHASE4":22413,"NA":22421},{"trials":22406,"activeCount":103},[],{"trials":22408,"activeCount":103},[],{"trials":22410,"activeCount":103},[],{"trials":22412,"activeCount":103},[],{"trials":22414,"activeCount":103},[22415],{"nctId":22416,"briefTitle":22417,"status":134,"phases":22418,"primaryCompletion":3272,"start":1015,"enrollment":2579,"conditions":22419,"interventions":22420},"NCT00242541","Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas",[94],[8385],[22403],{"trials":22422,"activeCount":103},[],{"intervention":3864,"totalTrials":437,"cells":22424},{"EARLY_PHASE1":22425,"PHASE1":22427,"PHASE2":22429,"PHASE3":22431,"PHASE4":22433,"NA":22439},{"trials":22426,"activeCount":103},[],{"trials":22428,"activeCount":103},[],{"trials":22430,"activeCount":103},[],{"trials":22432,"activeCount":103},[],{"trials":22434,"activeCount":103},[22435],{"nctId":3858,"briefTitle":3859,"status":123,"phases":22436,"primaryCompletion":3861,"completion":3861,"start":3784,"enrollment":1143,"conditions":22437,"interventions":22438},[94],[27],[2836,3864],{"trials":22440,"activeCount":103},[],{"intervention":22442,"totalTrials":437,"cells":22443},"EC-MPS, Tacrolimus",{"EARLY_PHASE1":22444,"PHASE1":22446,"PHASE2":22448,"PHASE3":22450,"PHASE4":22452,"NA":22461},{"trials":22445,"activeCount":103},[],{"trials":22447,"activeCount":103},[],{"trials":22449,"activeCount":103},[],{"trials":22451,"activeCount":103},[],{"trials":22453,"activeCount":103},[22454],{"nctId":22455,"briefTitle":22456,"status":123,"phases":22457,"primaryCompletion":3474,"completion":3474,"start":8370,"enrollment":22458,"conditions":22459,"interventions":22460},"NCT00229138","Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients",[94],291,[4691],[22442],{"trials":22462,"activeCount":103},[],{"intervention":18764,"totalTrials":437,"cells":22464},{"EARLY_PHASE1":22465,"PHASE1":22467,"PHASE2":22469,"PHASE3":22471,"PHASE4":22473,"NA":22479},{"trials":22466,"activeCount":103},[],{"trials":22468,"activeCount":103},[],{"trials":22470,"activeCount":103},[],{"trials":22472,"activeCount":103},[],{"trials":22474,"activeCount":103},[22475],{"nctId":18757,"briefTitle":18758,"status":134,"phases":22476,"primaryCompletion":18760,"completion":18760,"start":18761,"enrollment":2367,"conditions":22477,"interventions":22478},[94],[7412],[18714,18764,18765],{"trials":22480,"activeCount":103},[],{"intervention":18765,"totalTrials":437,"cells":22482},{"EARLY_PHASE1":22483,"PHASE1":22485,"PHASE2":22487,"PHASE3":22489,"PHASE4":22491,"NA":22497},{"trials":22484,"activeCount":103},[],{"trials":22486,"activeCount":103},[],{"trials":22488,"activeCount":103},[],{"trials":22490,"activeCount":103},[],{"trials":22492,"activeCount":103},[22493],{"nctId":18757,"briefTitle":18758,"status":134,"phases":22494,"primaryCompletion":18760,"completion":18760,"start":18761,"enrollment":2367,"conditions":22495,"interventions":22496},[94],[7412],[18714,18764,18765],{"trials":22498,"activeCount":103},[],{"intervention":2972,"totalTrials":437,"cells":22500},{"EARLY_PHASE1":22501,"PHASE1":22503,"PHASE2":22505,"PHASE3":22507,"PHASE4":22509,"NA":22515},{"trials":22502,"activeCount":103},[],{"trials":22504,"activeCount":103},[],{"trials":22506,"activeCount":103},[],{"trials":22508,"activeCount":103},[],{"trials":22510,"activeCount":103},[22511],{"nctId":2965,"briefTitle":2966,"status":123,"phases":22512,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":19,"conditions":22513,"interventions":22514},[94],[2778],[2972,2752,2973],{"trials":22516,"activeCount":103},[],{"intervention":2973,"totalTrials":437,"cells":22518},{"EARLY_PHASE1":22519,"PHASE1":22521,"PHASE2":22523,"PHASE3":22525,"PHASE4":22527,"NA":22533},{"trials":22520,"activeCount":103},[],{"trials":22522,"activeCount":103},[],{"trials":22524,"activeCount":103},[],{"trials":22526,"activeCount":103},[],{"trials":22528,"activeCount":103},[22529],{"nctId":2965,"briefTitle":2966,"status":123,"phases":22530,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":19,"conditions":22531,"interventions":22532},[94],[2778],[2972,2752,2973],{"trials":22534,"activeCount":103},[],{"intervention":22536,"totalTrials":437,"cells":22537},"amlodipine besylate\u002Fbenazepril hydrochloride",{"EARLY_PHASE1":22538,"PHASE1":22540,"PHASE2":22542,"PHASE3":22544,"PHASE4":22546,"NA":22555},{"trials":22539,"activeCount":103},[],{"trials":22541,"activeCount":103},[],{"trials":22543,"activeCount":103},[],{"trials":22545,"activeCount":103},[],{"trials":22547,"activeCount":103},[22548],{"nctId":22549,"briefTitle":22550,"status":123,"phases":22551,"primaryCompletion":15920,"completion":15920,"start":4741,"enrollment":22552,"conditions":22553,"interventions":22554},"NCT00136851","Study Comparing the Efficacy of Amlodipine Besylate\u002FBenazepril Versus Amlodipine in the Treatment of Severe Hypertension",[94],259,[21],[22536],{"trials":22556,"activeCount":103},[],{"intervention":22558,"totalTrials":437,"cells":22559},"Zometa",{"EARLY_PHASE1":22560,"PHASE1":22562,"PHASE2":22564,"PHASE3":22566,"PHASE4":22568,"NA":22576},{"trials":22561,"activeCount":103},[],{"trials":22563,"activeCount":103},[],{"trials":22565,"activeCount":103},[],{"trials":22567,"activeCount":103},[],{"trials":22569,"activeCount":103},[22570],{"nctId":22571,"briefTitle":22572,"status":123,"phases":22573,"primaryCompletion":15101,"completion":15101,"start":997,"enrollment":1026,"conditions":22574,"interventions":22575},"NCT00035997","Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis",[94],[1654],[22558],{"trials":22577,"activeCount":103},[],{"intervention":19336,"totalTrials":437,"cells":22579},{"EARLY_PHASE1":22580,"PHASE1":22582,"PHASE2":22584,"PHASE3":22586,"PHASE4":22588,"NA":22594},{"trials":22581,"activeCount":103},[],{"trials":22583,"activeCount":103},[],{"trials":22585,"activeCount":103},[],{"trials":22587,"activeCount":103},[],{"trials":22589,"activeCount":103},[22590],{"nctId":19329,"briefTitle":19330,"status":390,"phases":22591,"primaryCompletion":4301,"start":3383,"enrollment":103,"conditions":22592,"interventions":22593},[94],[19333],[19335,19336],{"trials":22595,"activeCount":103},[],{"intervention":22597,"totalTrials":437,"cells":22598},"HCTZ + Amlodipine",{"EARLY_PHASE1":22599,"PHASE1":22601,"PHASE2":22603,"PHASE3":22605,"PHASE4":22607,"NA":22617},{"trials":22600,"activeCount":103},[],{"trials":22602,"activeCount":103},[],{"trials":22604,"activeCount":103},[],{"trials":22606,"activeCount":103},[],{"trials":22608,"activeCount":103},[22609],{"nctId":22610,"briefTitle":22611,"status":123,"phases":22612,"primaryCompletion":4642,"start":3657,"enrollment":22613,"conditions":22614,"interventions":22615},"NCT00439738","Safety\u002FEfficacy of Valsartan\u002FHydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults",[94],412,[21],[22597,22616],"Valsartan\u002FHCTZ",{"trials":22618,"activeCount":103},[],{"intervention":22616,"totalTrials":437,"cells":22620},{"EARLY_PHASE1":22621,"PHASE1":22623,"PHASE2":22625,"PHASE3":22627,"PHASE4":22629,"NA":22635},{"trials":22622,"activeCount":103},[],{"trials":22624,"activeCount":103},[],{"trials":22626,"activeCount":103},[],{"trials":22628,"activeCount":103},[],{"trials":22630,"activeCount":103},[22631],{"nctId":22610,"briefTitle":22611,"status":123,"phases":22632,"primaryCompletion":4642,"start":3657,"enrollment":22613,"conditions":22633,"interventions":22634},[94],[21],[22597,22616],{"trials":22636,"activeCount":103},[],{"intervention":19677,"totalTrials":437,"cells":22638},{"EARLY_PHASE1":22639,"PHASE1":22641,"PHASE2":22643,"PHASE3":22645,"PHASE4":22647,"NA":22653},{"trials":22640,"activeCount":103},[],{"trials":22642,"activeCount":103},[],{"trials":22644,"activeCount":103},[],{"trials":22646,"activeCount":103},[],{"trials":22648,"activeCount":103},[22649],{"nctId":19671,"briefTitle":19672,"status":134,"phases":22650,"primaryCompletion":917,"completion":3490,"start":4540,"enrollment":19674,"conditions":22651,"interventions":22652},[94],[10365],[19652,19677],{"trials":22654,"activeCount":103},[],{"intervention":22656,"totalTrials":437,"cells":22657},"Telbivudine\u002FLDT600A",{"EARLY_PHASE1":22658,"PHASE1":22660,"PHASE2":22662,"PHASE3":22664,"PHASE4":22666,"NA":22674},{"trials":22659,"activeCount":103},[],{"trials":22661,"activeCount":103},[],{"trials":22663,"activeCount":103},[],{"trials":22665,"activeCount":103},[],{"trials":22667,"activeCount":103},[22668],{"nctId":22669,"briefTitle":22670,"status":390,"phases":22671,"primaryCompletion":3383,"completion":3383,"start":4707,"enrollment":103,"conditions":22672,"interventions":22673},"NCT00862706","Efficacy of Telbivudine in Blacks\u002FAfrican Americans and Hispanics\u002FLatinos With Compensated Chronic Hepatitis B During 52 Weeks",[94],[20590],[22656],{"trials":22675,"activeCount":103},[],{"intervention":22677,"totalTrials":437,"cells":22678},"1",{"EARLY_PHASE1":22679,"PHASE1":22681,"PHASE2":22683,"PHASE3":22685,"PHASE4":22687,"NA":22697},{"trials":22680,"activeCount":103},[],{"trials":22682,"activeCount":103},[],{"trials":22684,"activeCount":103},[],{"trials":22686,"activeCount":103},[],{"trials":22688,"activeCount":103},[22689],{"nctId":22690,"briefTitle":22691,"status":123,"phases":22692,"primaryCompletion":15283,"completion":15283,"start":853,"enrollment":3568,"conditions":22693,"interventions":22695},"NCT01056822","Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.",[94],[22694],"Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft",[22677,22696],"2",{"trials":22698,"activeCount":103},[],{"intervention":22696,"totalTrials":437,"cells":22700},{"EARLY_PHASE1":22701,"PHASE1":22703,"PHASE2":22705,"PHASE3":22707,"PHASE4":22709,"NA":22715},{"trials":22702,"activeCount":103},[],{"trials":22704,"activeCount":103},[],{"trials":22706,"activeCount":103},[],{"trials":22708,"activeCount":103},[],{"trials":22710,"activeCount":103},[22711],{"nctId":22690,"briefTitle":22691,"status":123,"phases":22712,"primaryCompletion":15283,"completion":15283,"start":853,"enrollment":3568,"conditions":22713,"interventions":22714},[94],[22694],[22677,22696],{"trials":22716,"activeCount":103},[],{"intervention":22718,"totalTrials":437,"cells":22719},"150 mg open-label secukinumab",{"EARLY_PHASE1":22720,"PHASE1":22722,"PHASE2":22724,"PHASE3":22726,"PHASE4":22728,"NA":22741},{"trials":22721,"activeCount":103},[],{"trials":22723,"activeCount":103},[],{"trials":22725,"activeCount":103},[],{"trials":22727,"activeCount":103},[],{"trials":22729,"activeCount":103},[22730],{"nctId":22731,"briefTitle":22732,"status":123,"phases":22733,"primaryCompletion":1847,"completion":22734,"start":22735,"enrollment":22736,"conditions":22737,"interventions":22738},"NCT03350815","Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis",[94],"2021-05-29","2018-03-13",322,[1974],[22718,22739,22740],"150 mg double-blinded secukinumab","300 mg double-blinded secukinumab",{"trials":22742,"activeCount":103},[],{"intervention":22739,"totalTrials":437,"cells":22744},{"EARLY_PHASE1":22745,"PHASE1":22747,"PHASE2":22749,"PHASE3":22751,"PHASE4":22753,"NA":22759},{"trials":22746,"activeCount":103},[],{"trials":22748,"activeCount":103},[],{"trials":22750,"activeCount":103},[],{"trials":22752,"activeCount":103},[],{"trials":22754,"activeCount":103},[22755],{"nctId":22731,"briefTitle":22732,"status":123,"phases":22756,"primaryCompletion":1847,"completion":22734,"start":22735,"enrollment":22736,"conditions":22757,"interventions":22758},[94],[1974],[22718,22739,22740],{"trials":22760,"activeCount":103},[],{"intervention":22740,"totalTrials":437,"cells":22762},{"EARLY_PHASE1":22763,"PHASE1":22765,"PHASE2":22767,"PHASE3":22769,"PHASE4":22771,"NA":22777},{"trials":22764,"activeCount":103},[],{"trials":22766,"activeCount":103},[],{"trials":22768,"activeCount":103},[],{"trials":22770,"activeCount":103},[],{"trials":22772,"activeCount":103},[22773],{"nctId":22731,"briefTitle":22732,"status":123,"phases":22774,"primaryCompletion":1847,"completion":22734,"start":22735,"enrollment":22736,"conditions":22775,"interventions":22776},[94],[1974],[22718,22739,22740],{"trials":22778,"activeCount":103},[],{"intervention":20152,"totalTrials":437,"cells":22780},{"EARLY_PHASE1":22781,"PHASE1":22783,"PHASE2":22785,"PHASE3":22787,"PHASE4":22789,"NA":22795},{"trials":22782,"activeCount":103},[],{"trials":22784,"activeCount":103},[],{"trials":22786,"activeCount":103},[],{"trials":22788,"activeCount":103},[],{"trials":22790,"activeCount":103},[22791],{"nctId":20147,"briefTitle":20148,"status":123,"phases":22792,"primaryCompletion":813,"completion":813,"start":3482,"enrollment":3705,"conditions":22793,"interventions":22794},[94],[15133],[16693,20152],{"trials":22796,"activeCount":103},[],{"intervention":11428,"totalTrials":1053,"cells":22798},{"EARLY_PHASE1":22799,"PHASE1":22801,"PHASE2":22807,"PHASE3":22926,"PHASE4":22996,"NA":22998},{"trials":22800,"activeCount":103},[],{"trials":22802,"activeCount":103},[22803],{"nctId":13860,"briefTitle":13861,"status":123,"phases":22804,"primaryCompletion":2623,"completion":2623,"start":754,"enrollment":2342,"conditions":22805,"interventions":22806},[91],[13864],[13721,11428],{"trials":22808,"activeCount":103},[22809,22815,22821,22829,22836,22842,22848,22858,22862,22868,22874,22880,22888,22892,22898,22904,22912,22918],{"nctId":22810,"briefTitle":22811,"status":123,"phases":22812,"primaryCompletion":4372,"completion":4372,"start":3400,"enrollment":25,"conditions":22813,"interventions":22814},"NCT00809614","Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis",[92],[1821],[11428],{"nctId":22816,"briefTitle":22817,"status":134,"phases":22818,"primaryCompletion":3382,"completion":3382,"start":2795,"enrollment":3098,"conditions":22819,"interventions":22820},"NCT01478360","Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma",[92],[18],[11428],{"nctId":22822,"briefTitle":22823,"status":123,"phases":22824,"primaryCompletion":4372,"completion":4372,"start":4845,"enrollment":22825,"conditions":22826,"interventions":22827},"NCT00941031","AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis",[92],404,[1684],[11428,22828,22828],"AIN457A",{"nctId":22830,"briefTitle":22831,"status":123,"phases":22832,"primaryCompletion":607,"completion":607,"start":3271,"enrollment":4568,"conditions":22833,"interventions":22835},"NCT01051817","POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler",[92],[3762,22834],"RRMS",[11428],{"nctId":22837,"briefTitle":22838,"status":123,"phases":22839,"primaryCompletion":3760,"completion":3760,"start":964,"enrollment":3491,"conditions":22840,"interventions":22841},"NCT01071252","A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis",[92],[1684],[11428],{"nctId":22843,"briefTitle":22844,"status":134,"phases":22845,"primaryCompletion":1781,"completion":1781,"start":1682,"enrollment":2046,"conditions":22846,"interventions":22847},"NCT01874340","Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis",[92],[27],[11428],{"nctId":22849,"briefTitle":22850,"status":134,"phases":22851,"primaryCompletion":22852,"completion":22852,"start":22853,"enrollment":1562,"conditions":22854,"interventions":22857},"NCT01009281","An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease",[92],"2010-08-19","2009-10-30",[22855,22856],"Crohn's Disease","Inflammatory Bowel Disease",[11428],{"nctId":19061,"briefTitle":19062,"status":134,"phases":22859,"primaryCompletion":19064,"completion":19064,"start":19065,"enrollment":1672,"conditions":22860,"interventions":22861},[92],[1696,19067],[11428,10126,17261],{"nctId":22863,"briefTitle":22864,"status":134,"phases":22865,"primaryCompletion":3845,"completion":3845,"start":3473,"enrollment":3322,"conditions":22866,"interventions":22867},"NCT00584740","Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease",[92],[22855],[11428],{"nctId":22869,"briefTitle":22870,"status":123,"phases":22871,"primaryCompletion":3731,"completion":3731,"start":1671,"enrollment":28,"conditions":22872,"interventions":22873},"NCT01433250","A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis",[92],[27],[11428,11428],{"nctId":22875,"briefTitle":22876,"status":123,"phases":22877,"primaryCompletion":7931,"completion":7931,"start":3552,"enrollment":3975,"conditions":22878,"interventions":22879},"NCT00805480","Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis",[92],[2037],[11428],{"nctId":22881,"briefTitle":22882,"status":123,"phases":22883,"primaryCompletion":3799,"completion":3799,"start":5062,"enrollment":485,"conditions":22884,"interventions":22886},"NCT00685399","Safety and Efficacy of AIN457 in Noninfectious Uveitis",[92],[22885],"Non-infectious Uveitis",[11428,22887,11428],"AIN 457",{"nctId":11423,"briefTitle":11424,"status":123,"phases":22889,"primaryCompletion":4335,"start":949,"enrollment":630,"conditions":22890,"interventions":22891},[91,92],[1674],[11428,11429],{"nctId":22893,"briefTitle":22894,"status":123,"phases":22895,"primaryCompletion":4642,"completion":4642,"start":988,"enrollment":792,"conditions":22896,"interventions":22897},"NCT00669916","A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis",[91,92],[1773],[11428],{"nctId":22899,"briefTitle":22900,"status":123,"phases":22901,"primaryCompletion":3490,"completion":3490,"start":835,"enrollment":314,"conditions":22902,"interventions":22903},"NCT00669942","Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients",[91,92],[1717],[11428],{"nctId":22905,"briefTitle":22906,"status":123,"phases":22907,"primaryCompletion":22908,"completion":22908,"start":22909,"enrollment":4733,"conditions":22910,"interventions":22911},"NCT00770965","Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis",[92],"2009-09-17","2008-09-10",[2037],[11428],{"nctId":22913,"briefTitle":22914,"status":123,"phases":22915,"primaryCompletion":3784,"completion":3784,"start":3400,"enrollment":1423,"conditions":22916,"interventions":22917},"NCT00809159","Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis",[92],[1974],[11428],{"nctId":22919,"briefTitle":22920,"status":123,"phases":22921,"primaryCompletion":1859,"completion":1859,"start":22922,"enrollment":1798,"conditions":22923,"interventions":22925},"NCT01132612","AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis",[92],"2010-05-11",[22924],"Plaque-type Psoriasis",[11428],{"trials":22927,"activeCount":103},[22928,22935,22942,22949,22955,22961,22969,22977,22982,22988],{"nctId":22929,"briefTitle":22930,"status":123,"phases":22931,"primaryCompletion":864,"completion":864,"start":4400,"enrollment":4708,"conditions":22932,"interventions":22934},"NCT00995709","Phase III Study in Refractory Behcet's Disease",[93],[22933],"Behcet Disease",[11428,11428],{"nctId":22936,"briefTitle":22937,"status":123,"phases":22938,"primaryCompletion":11175,"completion":11175,"start":22939,"enrollment":1100,"conditions":22940,"interventions":22941},"NCT02662985","Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)",[93],"2016-08-22",[1821],[11428],{"nctId":22943,"briefTitle":22944,"status":134,"phases":22945,"primaryCompletion":5620,"completion":5620,"start":4081,"enrollment":2439,"conditions":22946,"interventions":22948},"NCT01095250","Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis",[93],[22947],"Uveitis",[11428,11428,11428],{"nctId":22950,"briefTitle":22951,"status":134,"phases":22952,"primaryCompletion":4598,"completion":4598,"start":964,"enrollment":3322,"conditions":22953,"interventions":22954},"NCT01093846","38 Week Extension Study to CAIN457C2303",[93],[22947],[11428,11428],{"nctId":22956,"briefTitle":22957,"status":134,"phases":22958,"primaryCompletion":4620,"completion":4620,"start":3845,"enrollment":1901,"conditions":22959,"interventions":22960},"NCT01090310","Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis",[93],[22885],[11428],{"nctId":22962,"briefTitle":22963,"status":123,"phases":22964,"primaryCompletion":2426,"completion":2426,"start":1264,"enrollment":568,"conditions":22965,"interventions":22967},"NCT03136861","SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis",[93],[22966],"Spondyloarthritis",[11428,22968],"AIN457 Placebo",{"nctId":22970,"briefTitle":22971,"status":123,"phases":22972,"primaryCompletion":2458,"completion":2458,"start":1818,"enrollment":22973,"conditions":22974,"interventions":22975},"NCT01350804","Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)",[93],551,[1717],[11428,22976],"Abatacept",{"nctId":22978,"briefTitle":22957,"status":134,"phases":22979,"primaryCompletion":2034,"completion":2034,"start":880,"enrollment":3491,"conditions":22980,"interventions":22981},"NCT01032915",[93],[22885],[11428,11428,11428],{"nctId":22983,"briefTitle":22984,"status":390,"phases":22985,"primaryCompletion":4515,"start":895,"enrollment":103,"conditions":22986,"interventions":22987},"NCT01327664","Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis",[93],[22947],[11428],{"nctId":22989,"briefTitle":22990,"status":123,"phases":22991,"primaryCompletion":22992,"completion":22993,"start":1465,"enrollment":4506,"conditions":22994,"interventions":22995},"NCT04711902","Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.",[93],"2022-06-02","2023-03-10",[1821],[11428],{"trials":22997,"activeCount":103},[],{"trials":22999,"activeCount":103},[],{"intervention":517,"totalTrials":1065,"cells":23001},{"EARLY_PHASE1":23002,"PHASE1":23004,"PHASE2":23079,"PHASE3":23118,"PHASE4":23132,"NA":23134},{"trials":23003,"activeCount":103},[],{"trials":23005,"activeCount":103},[23006,23020,23026,23030,23036,23043,23047,23056,23064,23072],{"nctId":23007,"briefTitle":23008,"status":123,"phases":23009,"primaryCompletion":606,"completion":606,"start":3759,"enrollment":1384,"conditions":23010,"interventions":23019},"NCT01576666","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",[91],[23011,23012,23013,5614,435,23014,9924,17111,23015,23016,23017,23018],"Dose Escalation","Safety","Preliminary Efficacy","Advanced Pancreatic Adenocarcinoma","Gastric Cancer","Gastroesophageal Junction Cancer","Triple Negative Metastatic Breast Cancer","Hormone Receptor Positive (ER+\u002FPR+, and Her2-) Metastatic Breast Cancer",[18982,517],{"nctId":23021,"briefTitle":23022,"status":123,"phases":23023,"primaryCompletion":15346,"completion":15346,"start":1715,"enrollment":827,"conditions":23024,"interventions":23025},"NCT01727128","Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment",[91],[2625],[517],{"nctId":507,"briefTitle":508,"status":123,"phases":23027,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":23028,"interventions":23029},[91],[15],[515,516,307,517],{"nctId":23031,"briefTitle":23032,"status":123,"phases":23033,"primaryCompletion":1715,"completion":1715,"start":4400,"enrollment":2367,"conditions":23034,"interventions":23035},"NCT01283503","A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors",[91],[9516],[517],{"nctId":23037,"briefTitle":23038,"status":123,"phases":23039,"primaryCompletion":1781,"completion":1781,"start":3759,"enrollment":7257,"conditions":23040,"interventions":23042},"NCT01626209","A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors",[91],[23041],"Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology",[517],{"nctId":18959,"briefTitle":18960,"status":134,"phases":23044,"primaryCompletion":18962,"completion":18962,"start":18963,"enrollment":19,"conditions":23045,"interventions":23046},[91],[2369],[18952,517],{"nctId":23048,"briefTitle":23049,"status":123,"phases":23050,"primaryCompletion":23051,"completion":23051,"start":4465,"enrollment":1423,"conditions":23052,"interventions":23054},"NCT01468688","A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients",[91],"2016-07-29",[23053],"3rd Line GIST",[23055,517],"STI571",{"nctId":23057,"briefTitle":23058,"status":123,"phases":23059,"primaryCompletion":1818,"completion":3482,"start":3490,"enrollment":6514,"conditions":23060,"interventions":23063},"NCT01068483","Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients",[91],[15,23061,6375,23062],"Colon Cancer","Endometrium Cancer",[517],{"nctId":23065,"briefTitle":23066,"status":123,"phases":23067,"primaryCompletion":3382,"completion":3382,"start":4081,"enrollment":5721,"conditions":23068,"interventions":23070},"NCT01155453","A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients",[91],[23069],"Advanced and Selected Solid Tumors",[517,23071],"GSK1120212",{"nctId":23073,"briefTitle":23074,"status":123,"phases":23075,"primaryCompletion":3511,"completion":3511,"start":3243,"enrollment":4557,"conditions":23076,"interventions":23078},"NCT01634061","Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients",[91],[23077],"Castration-resistant Prostate Cancer",[4609,517,4609,517],{"trials":23080,"activeCount":103},[23081,23085,23093,23101,23105,23111],{"nctId":7919,"briefTitle":7920,"status":123,"phases":23082,"primaryCompletion":2391,"completion":2391,"start":7922,"enrollment":2579,"conditions":23083,"interventions":23084},[92],[7924],[517,4320,4321,7926],{"nctId":23086,"briefTitle":23087,"status":123,"phases":23088,"primaryCompletion":23089,"completion":23089,"start":3529,"enrollment":6061,"conditions":23090,"interventions":23092},"NCT01833169","BKM120 for Patients With PI3K-activated Tumors",[92],"2016-09-26",[23091],"PI3K Pathway Activated Tumors",[517],{"nctId":23094,"briefTitle":23095,"status":390,"phases":23096,"primaryCompletion":23097,"completion":23097,"start":2794,"enrollment":103,"conditions":23098,"interventions":23100},"NCT01613677","Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer",[92],"2017-09",[23099],"Treatment for Metastatic or Locally Advanced Cervical Cancer",[517],{"nctId":7936,"briefTitle":7937,"status":134,"phases":23102,"primaryCompletion":7939,"completion":7939,"start":853,"enrollment":774,"conditions":23103,"interventions":23104},[91,92],[435,7941],[517,4320,4451],{"nctId":23106,"briefTitle":23107,"status":123,"phases":23108,"primaryCompletion":1817,"completion":1817,"start":3784,"enrollment":19,"conditions":23109,"interventions":23110},"NCT01297491","Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer",[92],[128],[517],{"nctId":23112,"briefTitle":23113,"status":123,"phases":23114,"primaryCompletion":4093,"completion":4093,"start":3760,"enrollment":512,"conditions":23115,"interventions":23117},"NCT01289041","BKM120 as Second-line Therapy for Advanced Endometrial Cancer",[92],[23116],"Advanced Endometrial Cancer",[517],{"trials":23119,"activeCount":103},[23120,23124,23128],{"nctId":15461,"briefTitle":15462,"status":123,"phases":23121,"primaryCompletion":4410,"completion":4410,"start":3482,"enrollment":15464,"conditions":23122,"interventions":23123},[92,93],[15],[4321,517],{"nctId":661,"briefTitle":662,"status":123,"phases":23125,"primaryCompletion":664,"completion":665,"start":666,"enrollment":667,"conditions":23126,"interventions":23127},[93],[15],[119,517],{"nctId":671,"briefTitle":672,"status":134,"phases":23129,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":23130,"interventions":23131},[93],[435],[119,517],{"trials":23133,"activeCount":103},[],{"trials":23135,"activeCount":103},[],{"intervention":944,"totalTrials":1672,"cells":23137},{"EARLY_PHASE1":23138,"PHASE1":23140,"PHASE2":23154,"PHASE3":23185,"PHASE4":23223,"NA":23225},{"trials":23139,"activeCount":103},[],{"trials":23141,"activeCount":103},[23142,23146],{"nctId":7861,"briefTitle":7862,"status":123,"phases":23143,"primaryCompletion":7864,"completion":7865,"start":7866,"enrollment":827,"conditions":23144,"interventions":23145},[91],[7868],[7870,7871,4780,7872],{"nctId":23147,"briefTitle":23148,"status":123,"phases":23149,"primaryCompletion":10993,"completion":10993,"start":1014,"enrollment":21315,"conditions":23150,"interventions":23151},"NCT00790816","Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents",[91],[7868],[23152,944,23153],"Lapatinib in combination with an anti-cancer agent","Lapatinib in combination with an anti-cancer agent as specified by parent protocol",{"trials":23155,"activeCount":103},[23156,23160,23164,23173,23181],{"nctId":7899,"briefTitle":7900,"status":134,"phases":23157,"primaryCompletion":7902,"completion":7902,"start":7903,"enrollment":25,"conditions":23158,"interventions":23159},[92],[7868],[944,4320,7906],{"nctId":10794,"briefTitle":10795,"status":123,"phases":23161,"primaryCompletion":10797,"completion":10798,"start":10799,"enrollment":1034,"conditions":23162,"interventions":23163},[92],[1102],[10802,944,4451],{"nctId":23165,"briefTitle":23166,"status":123,"phases":23167,"primaryCompletion":23168,"completion":23169,"start":23170,"enrollment":3605,"conditions":23171,"interventions":23172},"NCT00444535","Lapatinib and Bevacizumab for Metastatic Breast Cancer",[92],"2008-07-22","2020-06-19","2007-02-27",[7868],[7870,13304],{"nctId":23174,"briefTitle":23175,"status":123,"phases":23176,"primaryCompletion":23177,"completion":2775,"start":23178,"enrollment":1762,"conditions":23179,"interventions":23180},"NCT00263588","Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer",[92],"2007-09-25","2005-12-02",[7868],[7870],{"nctId":10804,"briefTitle":10805,"status":134,"phases":23182,"primaryCompletion":10807,"completion":10807,"start":5002,"enrollment":2149,"conditions":23183,"interventions":23184},[92],[1102],[944,4451,4831],{"trials":23186,"activeCount":103},[23187,23191,23195,23199,23203,23207,23211,23215,23219],{"nctId":10821,"briefTitle":10822,"status":134,"phases":23188,"primaryCompletion":10824,"completion":10825,"start":10826,"enrollment":3605,"conditions":23189,"interventions":23190},[93],[7868],[7870,7955],{"nctId":7946,"briefTitle":7947,"status":123,"phases":23192,"primaryCompletion":7949,"completion":939,"start":7950,"enrollment":7951,"conditions":23193,"interventions":23194},[93],[7953],[7955,7870,4780],{"nctId":7957,"briefTitle":7958,"status":123,"phases":23196,"primaryCompletion":7960,"completion":7961,"start":7962,"enrollment":7963,"conditions":23197,"interventions":23198},[93],[7868],[944,4320,7966,944],{"nctId":10834,"briefTitle":10835,"status":123,"phases":23200,"primaryCompletion":10837,"completion":10838,"start":10839,"enrollment":2185,"conditions":23201,"interventions":23202},[93],[10841],[944,4451,10843],{"nctId":7978,"briefTitle":7979,"status":123,"phases":23204,"primaryCompletion":7981,"completion":7982,"start":7983,"enrollment":7984,"conditions":23205,"interventions":23206},[93],[7868],[944,4320],{"nctId":7992,"briefTitle":7993,"status":134,"phases":23208,"primaryCompletion":1212,"completion":7995,"start":7996,"enrollment":5612,"conditions":23209,"interventions":23210},[93],[1102],[944,4320],{"nctId":935,"briefTitle":936,"status":123,"phases":23212,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":23213,"interventions":23214},[93],[559],[944,249],{"nctId":8004,"briefTitle":8005,"status":123,"phases":23216,"primaryCompletion":8007,"completion":8008,"start":8009,"enrollment":7042,"conditions":23217,"interventions":23218},[93],[7868],[944,4320,4321],{"nctId":8017,"briefTitle":8018,"status":134,"phases":23220,"primaryCompletion":8020,"completion":8021,"start":8022,"enrollment":19,"conditions":23221,"interventions":23222},[93],[7868],[7870,7872,4780],{"trials":23224,"activeCount":103},[],{"trials":23226,"activeCount":103},[],{"intervention":23228,"totalTrials":2367,"cells":23229},"AFQ056",{"EARLY_PHASE1":23230,"PHASE1":23232,"PHASE2":23262,"PHASE3":23337,"PHASE4":23345,"NA":23347},{"trials":23231,"activeCount":103},[],{"trials":23233,"activeCount":103},[23234,23242,23249,23255],{"nctId":23235,"briefTitle":23236,"status":123,"phases":23237,"primaryCompletion":1724,"completion":1724,"start":4598,"enrollment":114,"conditions":23238,"interventions":23241},"NCT01442259","An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects",[91],[23239,23240],"Mild Moderate","or Severe Renal Impairment",[23228],{"nctId":23243,"briefTitle":23244,"status":390,"phases":23245,"primaryCompletion":17307,"completion":17307,"start":1889,"enrollment":103,"conditions":23246,"interventions":23248},"NCT04771143","Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056",[91],[23247],"Cocaine Use Disorder",[23228],{"nctId":23250,"briefTitle":23251,"status":123,"phases":23252,"primaryCompletion":3759,"completion":3759,"start":3784,"enrollment":4708,"conditions":23253,"interventions":23254},"NCT01456663","A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects",[91],[2625],[23228],{"nctId":23256,"briefTitle":23257,"status":123,"phases":23258,"primaryCompletion":813,"completion":813,"start":2795,"enrollment":4118,"conditions":23259,"interventions":23261},"NCT01482143","Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)",[91],[23260],"Fragile X Syndrome",[23228],{"trials":23263,"activeCount":103},[23264,23275,23281,23289,23295,23301,23307,23315,23323,23331],{"nctId":23265,"briefTitle":23266,"status":123,"phases":23267,"primaryCompletion":15283,"completion":15283,"start":607,"enrollment":13292,"conditions":23268,"interventions":23274},"NCT01491529","Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",[92],[23269,23270,23271,23272,23273],"Dyskinesias","Parkinson Disease","Movement Disorders","Parkinsonian Disorders","Anti-Dyskinesia Agents",[23228],{"nctId":23276,"briefTitle":23277,"status":123,"phases":23278,"primaryCompletion":15346,"completion":15346,"start":926,"enrollment":8659,"conditions":23279,"interventions":23280},"NCT01253629","Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome",[92],[23260],[23228],{"nctId":23282,"briefTitle":23283,"status":134,"phases":23284,"primaryCompletion":1724,"start":4335,"enrollment":22,"conditions":23285,"interventions":23288},"NCT01019473","Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea",[92],[23286,23287],"Huntington's Disease","Chorea",[23228],{"nctId":23290,"briefTitle":23291,"status":123,"phases":23292,"primaryCompletion":813,"completion":813,"start":2795,"enrollment":2832,"conditions":23293,"interventions":23294},"NCT01491932","Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",[92],[23269,23270,23271,23272,23273],[23228],{"nctId":23296,"briefTitle":23297,"status":123,"phases":23298,"primaryCompletion":3559,"completion":3559,"start":3784,"enrollment":1223,"conditions":23299,"interventions":23300},"NCT01357239","Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome",[92],[23260],[23228],{"nctId":23302,"briefTitle":23303,"status":134,"phases":23304,"primaryCompletion":812,"completion":812,"start":1724,"enrollment":7438,"conditions":23305,"interventions":23306},"NCT01348087","Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome",[92],[23260],[23228],{"nctId":23308,"briefTitle":23309,"status":134,"phases":23310,"primaryCompletion":3382,"completion":3382,"start":4669,"enrollment":2579,"conditions":23311,"interventions":23314},"NCT01813019","Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy",[92],[23312,23313],"Patient Diagnosed With OCD and Resistant to SSRI Treatment","Failed SSRI Over 12 Weeks at Appropriate Doses",[23228],{"nctId":23316,"briefTitle":23317,"status":123,"phases":23318,"primaryCompletion":23319,"completion":23319,"start":21472,"enrollment":16,"conditions":23320,"interventions":23322},"NCT03242928","Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)",[92],"2019-12-16",[23321],"Cocaine-related Disorder",[23228],{"nctId":23324,"briefTitle":23325,"status":123,"phases":23326,"primaryCompletion":813,"completion":813,"start":5620,"enrollment":11068,"conditions":23327,"interventions":23330},"NCT01173731","Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",[92],[23270,23328,23329],"Dyskinesia, Drug-Induced","Levodopa",[23228],{"nctId":23332,"briefTitle":23333,"status":123,"phases":23334,"primaryCompletion":3243,"completion":3243,"start":3800,"enrollment":1352,"conditions":23335,"interventions":23336},"NCT01385592","Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",[92],[23269,23270,23271,23272],[23228],{"trials":23338,"activeCount":103},[23339],{"nctId":23340,"briefTitle":23341,"status":134,"phases":23342,"primaryCompletion":812,"completion":812,"start":3800,"enrollment":1932,"conditions":23343,"interventions":23344},"NCT01433354","Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)",[92,93],[23260],[23228],{"trials":23346,"activeCount":103},[],{"trials":23348,"activeCount":103},[],{"intervention":10126,"totalTrials":814,"cells":23350},{"EARLY_PHASE1":23351,"PHASE1":23353,"PHASE2":23359,"PHASE3":23415,"PHASE4":23455,"NA":23457},{"trials":23352,"activeCount":103},[],{"trials":23354,"activeCount":103},[23355],{"nctId":13385,"briefTitle":13386,"status":123,"phases":23356,"primaryCompletion":13388,"completion":13388,"start":13389,"enrollment":13390,"conditions":23357,"interventions":23358},[91],[13392],[4389,10126,1686,13394,155],{"trials":23360,"activeCount":103},[23361,23365,23369,23376,23384,23393,23400,23408],{"nctId":19061,"briefTitle":19062,"status":134,"phases":23362,"primaryCompletion":19064,"completion":19064,"start":19065,"enrollment":1672,"conditions":23363,"interventions":23364},[92],[1696,19067],[11428,10126,17261],{"nctId":10119,"briefTitle":10120,"status":123,"phases":23366,"primaryCompletion":5881,"completion":5881,"start":10122,"enrollment":2249,"conditions":23367,"interventions":23368},[92],[36],[4389,10125,159,10126,515],{"nctId":23370,"briefTitle":23371,"status":123,"phases":23372,"primaryCompletion":3731,"completion":3731,"start":5620,"enrollment":1611,"conditions":23373,"interventions":23375},"NCT01242813","Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).",[92],[23374],"TNF-receptor Associated Periodic Syndromes (TRAPS)",[10126],{"nctId":23377,"briefTitle":23378,"status":123,"phases":23379,"primaryCompletion":23380,"completion":23380,"start":2632,"enrollment":709,"conditions":23381,"interventions":23383},"NCT02888080","Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis",[92],"2019-03-04",[23382],"Pulmonary Sarcoidosis",[10126],{"nctId":23385,"briefTitle":23386,"status":123,"phases":23387,"primaryCompletion":23388,"completion":23389,"start":21175,"enrollment":1622,"conditions":23390,"interventions":23392},"NCT02961218","Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia",[92],"2019-06-27","2020-04-27",[23391],"Sickle Cell Anemia",[10126],{"nctId":23394,"briefTitle":23395,"status":123,"phases":23396,"primaryCompletion":1723,"completion":1723,"start":3271,"enrollment":3854,"conditions":23397,"interventions":23399},"NCT00995930","Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients",[92],[30,3155,23398],"Prediabetic State",[10126],{"nctId":23401,"briefTitle":23402,"status":390,"phases":23403,"primaryCompletion":2034,"start":895,"enrollment":103,"conditions":23404,"interventions":23407},"NCT01322321","ACZ885 in Type 1 Diabetes Mellitus",[92],[23405,23406],"Diabetes Mellitus","Diabetes Type 1",[10126],{"nctId":23409,"briefTitle":23410,"status":134,"phases":23411,"primaryCompletion":1681,"completion":1681,"start":1714,"enrollment":1524,"conditions":23412,"interventions":23414},"NCT02007252","ACZ885 for the Treatment of Abdominal Aortic Aneurysm",[92],[23413],"Abdominal Aortic Aneurysm (AAA)",[10126],{"trials":23416,"activeCount":103},[23417,23426,23432,23440,23448],{"nctId":23418,"briefTitle":23419,"status":123,"phases":23420,"primaryCompletion":3382,"completion":3382,"start":926,"enrollment":837,"conditions":23421,"interventions":23425},"NCT01302860","Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease",[93],[23422,13935,23423,23424],"Cryopyrin-associated Periodic Syndromes","Muckle-Wells Syndrome","Neonatal Onset Multisystem Inflammatory Disease",[10126],{"nctId":23427,"briefTitle":23419,"status":123,"phases":23428,"primaryCompletion":21314,"completion":21314,"start":23429,"enrollment":837,"conditions":23430,"interventions":23431},"NCT01576367",[93],"2012-01-16",[23422,13935,23423,23424],[10126],{"nctId":23433,"briefTitle":23434,"status":390,"phases":23435,"primaryCompletion":3243,"completion":3243,"start":3243,"enrollment":103,"conditions":23436,"interventions":23438},"NCT01593527","Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease",[93],[23437],"Acute Gouty Arthritis",[10126,23439],"Triamcinelone acetonide",{"nctId":23441,"briefTitle":23442,"status":123,"phases":23443,"primaryCompletion":5114,"completion":5114,"start":3800,"enrollment":2948,"conditions":23444,"interventions":23446},"NCT01470989","β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)",[93],[23445],"Acute Gouty Arthritis Flares",[10126,23447],"Triamcinolone acetonide 40 mg",{"nctId":23449,"briefTitle":23450,"status":390,"phases":23451,"primaryCompletion":10055,"completion":10055,"start":1670,"enrollment":103,"conditions":23452,"interventions":23454},"NCT01676948","An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)",[93],[23453],"Systemic Juvenile Idiopathic Arthritis",[10126,3157,3157,3157],{"trials":23456,"activeCount":103},[],{"trials":23458,"activeCount":103},[],{"intervention":23460,"totalTrials":138,"cells":23461},"QAW039",{"EARLY_PHASE1":23462,"PHASE1":23464,"PHASE2":23476,"PHASE3":23531,"PHASE4":23561,"NA":23563},{"trials":23463,"activeCount":103},[],{"trials":23465,"activeCount":103},[23466],{"nctId":23467,"briefTitle":23468,"status":123,"phases":23469,"primaryCompletion":23470,"completion":23470,"start":23471,"enrollment":2405,"conditions":23472,"interventions":23473},"NCT03087942","Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects",[91],"2018-08-07","2017-07-05",[10518],[23460,23474,23475,23475],"QAW39A","QAW39A2107",{"trials":23477,"activeCount":103},[23478,23488,23494,23502,23510,23519,23525],{"nctId":23479,"briefTitle":23480,"status":390,"phases":23481,"primaryCompletion":565,"completion":565,"start":11066,"enrollment":103,"conditions":23482,"interventions":23487},"NCT03989635","Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.",[92],[18,23483,23484,23485,23486],"Asthma, Bronchial","Bronchial Asthma","Eosinophilia","Physiological Effects of Drugs",[23460],{"nctId":23489,"briefTitle":23490,"status":123,"phases":23491,"primaryCompletion":3382,"completion":3382,"start":1682,"enrollment":12783,"conditions":23492,"interventions":23493},"NCT01785602","Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.",[92],[10365],[23460],{"nctId":23495,"briefTitle":23496,"status":134,"phases":23497,"primaryCompletion":23498,"completion":23498,"start":23499,"enrollment":1495,"conditions":23500,"interventions":23501},"NCT03810183","A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia",[92],"2020-01-16","2019-05-21",[24],[23460],{"nctId":23503,"briefTitle":23504,"status":123,"phases":23505,"primaryCompletion":4669,"completion":4669,"start":1724,"enrollment":23506,"conditions":23507,"interventions":23508},"NCT01437735","Dose Finding Study for QAW039 in Asthma",[92],1043,[18],[23460,23509],"Montelukast",{"nctId":23511,"briefTitle":23512,"status":123,"phases":23513,"primaryCompletion":23514,"completion":23514,"start":5114,"enrollment":5322,"conditions":23515,"interventions":23516},"NCT01836471","A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients",[92],"2016-02",[18],[23460,23517,23518],"Fluticasone 250 mcg","Fluticasone 100 mcg",{"nctId":23520,"briefTitle":23521,"status":123,"phases":23522,"primaryCompletion":1682,"completion":1682,"start":1671,"enrollment":2354,"conditions":23523,"interventions":23524},"NCT01545726","Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma",[92],[18],[23460],{"nctId":23526,"briefTitle":23527,"status":123,"phases":23528,"primaryCompletion":813,"completion":813,"start":1761,"enrollment":3120,"conditions":23529,"interventions":23530},"NCT01804400","A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber",[92],[19482],[23460,23509],{"trials":23532,"activeCount":103},[23533,23541,23546,23553],{"nctId":23534,"briefTitle":23535,"status":123,"phases":23536,"primaryCompletion":18371,"completion":202,"start":23537,"enrollment":23538,"conditions":23539,"interventions":23540},"NCT03215758","Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma",[93],"2017-11-01",675,[18],[23460],{"nctId":23542,"briefTitle":23535,"status":123,"phases":23543,"primaryCompletion":7092,"completion":3311,"start":2447,"enrollment":1256,"conditions":23544,"interventions":23545},"NCT03226392",[93],[18],[23460],{"nctId":23547,"briefTitle":23548,"status":123,"phases":23549,"primaryCompletion":8021,"completion":1301,"start":5270,"enrollment":23550,"conditions":23551,"interventions":23552},"NCT02555683","Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.",[93],894,[18],[23460,23460],{"nctId":23554,"briefTitle":23548,"status":123,"phases":23555,"primaryCompletion":23556,"completion":1747,"start":23557,"enrollment":23558,"conditions":23559,"interventions":23560},"NCT02563067",[93],"2019-07-04","2015-12-03",877,[18],[23460,23460],{"trials":23562,"activeCount":103},[],{"trials":23564,"activeCount":103},[],{"intervention":18081,"totalTrials":5594,"cells":23566},{"EARLY_PHASE1":23567,"PHASE1":23569,"PHASE2":23585,"PHASE3":23616,"PHASE4":23642,"NA":23644},{"trials":23568,"activeCount":103},[],{"trials":23570,"activeCount":103},[23571,23577],{"nctId":23572,"briefTitle":23573,"status":123,"phases":23574,"primaryCompletion":4669,"completion":4669,"start":745,"enrollment":2685,"conditions":23575,"interventions":23576},"NCT00446082","Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease",[91],[4828,8385],[18081],{"nctId":23578,"briefTitle":23579,"status":123,"phases":23580,"primaryCompletion":4707,"start":10499,"enrollment":31,"conditions":23581,"interventions":23584},"NCT00698464","Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function",[91],[23582,23583],"Hepatic Cirrhosis","Alcoholism",[18081],{"trials":23586,"activeCount":103},[23587,23594,23603,23609],{"nctId":23588,"briefTitle":23589,"status":123,"phases":23590,"primaryCompletion":10499,"completion":10499,"start":15101,"enrollment":2405,"conditions":23591,"interventions":23593},"NCT00088595","Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors",[92],[23592],"Carcinoid Tumors",[18081],{"nctId":23595,"briefTitle":23596,"status":123,"phases":23597,"primaryCompletion":23598,"completion":23598,"start":23599,"enrollment":1065,"conditions":23600,"interventions":23602},"NCT00171951","Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease",[92],"2013-07-08","2004-08-13",[23601],"Cushing Disease",[18081],{"nctId":23604,"briefTitle":23605,"status":123,"phases":23606,"primaryCompletion":15109,"start":845,"enrollment":2149,"conditions":23607,"interventions":23608},"NCT00088582","Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients",[92],[8385],[18081],{"nctId":23610,"briefTitle":23611,"status":123,"phases":23612,"primaryCompletion":7981,"completion":7981,"start":23613,"enrollment":2439,"conditions":23614,"interventions":23615},"NCT00171730","An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly",[92],"2004-08-24",[8385],[18081],{"trials":23617,"activeCount":103},[23618,23622,23632,23638],{"nctId":18075,"briefTitle":18076,"status":123,"phases":23619,"primaryCompletion":7960,"completion":7960,"start":18078,"enrollment":6373,"conditions":23620,"interventions":23621},[93],[8385],[18081,4831],{"nctId":23623,"briefTitle":23624,"status":123,"phases":23625,"primaryCompletion":23626,"completion":13727,"start":23627,"enrollment":2166,"conditions":23628,"interventions":23629},"NCT01137682","Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly",[93],"2013-01-22","2010-07-19",[8385],[18081,23630,23631],"octreotide LAR 30mg","lanreotide ATG 120mg",{"nctId":23633,"briefTitle":23634,"status":123,"phases":23635,"primaryCompletion":964,"completion":4515,"start":3657,"enrollment":3705,"conditions":23636,"interventions":23637},"NCT00434148","Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease",[93],[16681],[18081],{"nctId":18095,"briefTitle":18096,"status":123,"phases":23639,"primaryCompletion":607,"completion":607,"start":4070,"enrollment":18098,"conditions":23640,"interventions":23641},[93],[18100],[18081,4831],{"trials":23643,"activeCount":103},[],{"trials":23645,"activeCount":103},[],{"intervention":4586,"totalTrials":422,"cells":23647},{"EARLY_PHASE1":23648,"PHASE1":23650,"PHASE2":23652,"PHASE3":23662,"PHASE4":23688,"NA":23690},{"trials":23649,"activeCount":103},[],{"trials":23651,"activeCount":103},[],{"trials":23653,"activeCount":103},[23654,23658],{"nctId":4407,"briefTitle":4408,"status":134,"phases":23655,"primaryCompletion":4410,"completion":4410,"start":2034,"enrollment":1524,"conditions":23656,"interventions":23657},[92],[4412],[4305,4414],{"nctId":4579,"briefTitle":4580,"status":123,"phases":23659,"primaryCompletion":241,"completion":241,"start":4582,"enrollment":4583,"conditions":23660,"interventions":23661},[92],[375],[196,195,4586],{"trials":23663,"activeCount":103},[23664,23668,23672,23676,23680,23684],{"nctId":4630,"briefTitle":4631,"status":123,"phases":23665,"primaryCompletion":4633,"completion":4633,"start":4634,"enrollment":4635,"conditions":23666,"interventions":23667},[93],[15],[196,195,4586],{"nctId":4658,"briefTitle":4659,"status":123,"phases":23669,"primaryCompletion":880,"completion":4093,"start":4317,"enrollment":4661,"conditions":23670,"interventions":23671},[93],[4663],[196,4586],{"nctId":4674,"briefTitle":4675,"status":123,"phases":23673,"primaryCompletion":4677,"completion":4677,"start":4678,"enrollment":4679,"conditions":23674,"interventions":23675},[93],[4681],[196,4586],{"nctId":4704,"briefTitle":4705,"status":123,"phases":23677,"primaryCompletion":2034,"completion":2794,"start":4707,"enrollment":4708,"conditions":23678,"interventions":23679},[93],[4710,4711],[196,4586],{"nctId":4714,"briefTitle":4715,"status":123,"phases":23681,"primaryCompletion":813,"completion":813,"start":4081,"enrollment":4717,"conditions":23682,"interventions":23683},[93],[4571],[196,4586],{"nctId":4842,"briefTitle":4843,"status":123,"phases":23685,"primaryCompletion":3559,"completion":3559,"start":4845,"enrollment":4846,"conditions":23686,"interventions":23687},[93],[4439],[196,4849,4850],{"trials":23689,"activeCount":103},[],{"trials":23691,"activeCount":103},[],{"intervention":611,"totalTrials":422,"cells":23693},{"EARLY_PHASE1":23694,"PHASE1":23696,"PHASE2":23711,"PHASE3":23737,"PHASE4":23750,"NA":23752},{"trials":23695,"activeCount":103},[],{"trials":23697,"activeCount":103},[23698,23705],{"nctId":23699,"briefTitle":23700,"status":123,"phases":23701,"primaryCompletion":7939,"completion":7939,"start":5114,"enrollment":2405,"conditions":23702,"interventions":23703},"NCT01700270","Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.",[91],[13875],[649,23704],"fluvoxamine",{"nctId":23706,"briefTitle":23707,"status":123,"phases":23708,"primaryCompletion":1817,"completion":1817,"start":3800,"enrollment":5948,"conditions":23709,"interventions":23710},"NCT01443481","Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function",[91],[647,2625],[611],{"trials":23712,"activeCount":103},[23713,23720,23724,23730],{"nctId":23714,"briefTitle":23715,"status":123,"phases":23716,"primaryCompletion":2762,"completion":2762,"start":15346,"enrollment":4733,"conditions":23717,"interventions":23719},"NCT01831726","Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib",[92],[23718],"Tumor Pathway Activations Inhibited by Dovitinib",[611],{"nctId":603,"briefTitle":604,"status":134,"phases":23721,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":23722,"interventions":23723},[92],[435],[611,119,612],{"nctId":23725,"briefTitle":23726,"status":123,"phases":23727,"primaryCompletion":3409,"completion":3409,"start":1732,"enrollment":28,"conditions":23728,"interventions":23729},"NCT01478373","Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and\u002For Intolerant to Imatinib",[92],[208],[611],{"nctId":23731,"briefTitle":23732,"status":123,"phases":23733,"primaryCompletion":1781,"completion":1781,"start":4620,"enrollment":3705,"conditions":23734,"interventions":23735},"NCT01232296","A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment",[92],[4412],[649,23736],"sorafenib",{"trials":23738,"activeCount":103},[23739,23746],{"nctId":23740,"briefTitle":23741,"status":123,"phases":23742,"primaryCompletion":3731,"completion":3731,"start":895,"enrollment":23743,"conditions":23744,"interventions":23745},"NCT01223027","Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma",[93],564,[4352],[611,13402],{"nctId":641,"briefTitle":642,"status":123,"phases":23747,"primaryCompletion":644,"completion":644,"start":645,"enrollment":138,"conditions":23748,"interventions":23749},[92,93],[647],[649,307],{"trials":23751,"activeCount":103},[],{"trials":23753,"activeCount":103},[],{"intervention":14772,"totalTrials":422,"cells":23755},{"EARLY_PHASE1":23756,"PHASE1":23758,"PHASE2":23772,"PHASE3":23798,"PHASE4":23814,"NA":23816},{"trials":23757,"activeCount":103},[],{"trials":23759,"activeCount":103},[23760,23766],{"nctId":23761,"briefTitle":23762,"status":123,"phases":23763,"primaryCompletion":4967,"completion":4967,"start":5733,"enrollment":3064,"conditions":23764,"interventions":23765},"NCT01558323","Pharmacokinetics of LCQ908 in Patients With Renal Impairment",[91],[2635],[14772],{"nctId":23767,"briefTitle":23768,"status":123,"phases":23769,"primaryCompletion":15283,"completion":15283,"start":607,"enrollment":17433,"conditions":23770,"interventions":23771},"NCT01594957","Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment",[91],[2625],[14772],{"trials":23773,"activeCount":103},[23774,23781,23787,23794],{"nctId":23775,"briefTitle":23776,"status":123,"phases":23777,"primaryCompletion":812,"completion":812,"start":1682,"enrollment":3605,"conditions":23778,"interventions":23780},"NCT01811472","Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients",[92],[23779],"Non-alcoholic Fatty Liver Disease (NAFLD)",[14772],{"nctId":23782,"briefTitle":23783,"status":134,"phases":23784,"primaryCompletion":1671,"completion":1671,"start":4620,"enrollment":7257,"conditions":23785,"interventions":23786},"NCT01387958","A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients",[92],[17240],[14772],{"nctId":23788,"briefTitle":23789,"status":123,"phases":23790,"primaryCompletion":1715,"completion":1715,"start":853,"enrollment":422,"conditions":23791,"interventions":23793},"NCT01146522","Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia",[91,92],[23792],"Hyperlipoproteinemia",[14772],{"nctId":14766,"briefTitle":14767,"status":123,"phases":23795,"primaryCompletion":2033,"completion":2033,"start":4524,"enrollment":3064,"conditions":23796,"interventions":23797},[92],[14770],[14772,1557,14773],{"trials":23799,"activeCount":103},[23800,23807],{"nctId":23801,"briefTitle":23802,"status":134,"phases":23803,"primaryCompletion":3511,"completion":3511,"start":2793,"enrollment":5948,"conditions":23804,"interventions":23806},"NCT01589237","Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.",[93],[23805],"Familial Chylomicronemia Syndrome (FCS) (HLP Type I)",[14772],{"nctId":23808,"briefTitle":23809,"status":123,"phases":23810,"primaryCompletion":4515,"completion":4515,"start":3759,"enrollment":2405,"conditions":23811,"interventions":23813},"NCT01514461","A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome",[93],[23812],"Familial Chylomicronemia Syndrome (FCS)",[14772],{"trials":23815,"activeCount":103},[],{"trials":23817,"activeCount":103},[],{"intervention":3145,"totalTrials":422,"cells":23819},{"EARLY_PHASE1":23820,"PHASE1":23822,"PHASE2":23832,"PHASE3":23870,"PHASE4":23884,"NA":23886},{"trials":23821,"activeCount":103},[],{"trials":23823,"activeCount":103},[23824],{"nctId":23825,"briefTitle":23826,"status":123,"phases":23827,"primaryCompletion":1714,"completion":1714,"start":15346,"enrollment":792,"conditions":23828,"interventions":23831},"NCT01875523","PK of Serelaxin in Severe Renal Impairment and ESRD",[91],[23829,23830],"Renal Failure, Chronic","End-Stage Renal Disease",[3145],{"trials":23833,"activeCount":103},[23834,23840,23848,23855,23862],{"nctId":23835,"briefTitle":23836,"status":123,"phases":23837,"primaryCompletion":7939,"completion":7939,"start":3559,"enrollment":3098,"conditions":23838,"interventions":23839},"NCT02002702","Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients",[92],[17377],[3145],{"nctId":23841,"briefTitle":23842,"status":134,"phases":23843,"primaryCompletion":23844,"completion":23844,"start":23845,"enrollment":37,"conditions":23846,"interventions":23847},"NCT02625922","Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure",[92],"2017-01-11","2016-02-05",[15734],[3145],{"nctId":23849,"briefTitle":23850,"status":134,"phases":23851,"primaryCompletion":2102,"completion":2102,"start":23852,"enrollment":138,"conditions":23853,"interventions":23854},"NCT02151383","Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure",[92],"2014-09-05",[17377],[3145],{"nctId":23856,"briefTitle":23857,"status":123,"phases":23858,"primaryCompletion":17357,"completion":17357,"start":23859,"enrollment":3064,"conditions":23860,"interventions":23861},"NCT01979614","Study of the Vascular Effects of Serelaxin",[92],"2014-02-03",[7145],[3145],{"nctId":23863,"briefTitle":23864,"status":123,"phases":23865,"primaryCompletion":1731,"completion":1731,"start":15283,"enrollment":846,"conditions":23866,"interventions":23868},"NCT01640964","An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension",[92],[23867],"Compensated Cirrhosis and Portal Hypertension",[23869,3145],"Terlipressin acetate",{"trials":23871,"activeCount":103},[23872,23876],{"nctId":3135,"briefTitle":3136,"status":134,"phases":23873,"primaryCompletion":3138,"completion":3139,"start":3140,"enrollment":3141,"conditions":23874,"interventions":23875},[93],[3143],[3145,3017],{"nctId":23877,"briefTitle":23878,"status":134,"phases":23879,"primaryCompletion":2248,"completion":23880,"start":1202,"enrollment":23881,"conditions":23882,"interventions":23883},"NCT02007720","Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF",[93],"2017-06-16",876,[17377],[3145],{"trials":23885,"activeCount":103},[],{"trials":23887,"activeCount":103},[],{"intervention":4375,"totalTrials":422,"cells":23889},{"EARLY_PHASE1":23890,"PHASE1":23892,"PHASE2":23902,"PHASE3":23908,"PHASE4":23930,"NA":23932},{"trials":23891,"activeCount":103},[],{"trials":23893,"activeCount":103},[23894,23898],{"nctId":13316,"briefTitle":13317,"status":134,"phases":23895,"primaryCompletion":6013,"completion":6013,"start":13319,"enrollment":2810,"conditions":23896,"interventions":23897},[91],[128],[4389,5262,9948,4375,1168,4321,3157],{"nctId":4369,"briefTitle":4370,"status":123,"phases":23899,"primaryCompletion":4372,"completion":4372,"start":3657,"enrollment":114,"conditions":23900,"interventions":23901},[91],[1316],[196,4375],{"trials":23903,"activeCount":103},[23904],{"nctId":8072,"briefTitle":8073,"status":134,"phases":23905,"primaryCompletion":8075,"completion":8075,"start":8076,"enrollment":3322,"conditions":23906,"interventions":23907},[92],[8078],[7913,5252,4375],{"trials":23909,"activeCount":103},[23910,23914,23918,23922,23926],{"nctId":9952,"briefTitle":9953,"status":390,"phases":23911,"primaryCompletion":9955,"completion":9956,"start":9957,"enrollment":103,"conditions":23912,"interventions":23913},[93],[5282],[9946,1079,8153,1168,5262,4375,4321,9947],{"nctId":13629,"briefTitle":13630,"status":134,"phases":23915,"primaryCompletion":13632,"completion":13633,"start":13634,"enrollment":13635,"conditions":23916,"interventions":23917},[93],[128],[10578,13581,7871,13638,7872,6342,13639],{"nctId":10969,"briefTitle":10970,"status":134,"phases":23919,"primaryCompletion":137,"completion":137,"start":10972,"enrollment":2379,"conditions":23920,"interventions":23921},[93],[227],[8070,10342,4375,5262,1168],{"nctId":5243,"briefTitle":5244,"status":123,"phases":23923,"primaryCompletion":5246,"completion":5247,"start":5248,"enrollment":5249,"conditions":23924,"interventions":23925},[93],[182],[130,4375,5252],{"nctId":5254,"briefTitle":5255,"status":123,"phases":23927,"primaryCompletion":5257,"completion":5258,"start":5259,"enrollment":282,"conditions":23928,"interventions":23929},[93],[182],[130,4375,5262,1168],{"trials":23931,"activeCount":103},[],{"trials":23933,"activeCount":103},[],{"intervention":2411,"totalTrials":1562,"cells":23935},{"EARLY_PHASE1":23936,"PHASE1":23938,"PHASE2":23955,"PHASE3":23969,"PHASE4":23977,"NA":23979},{"trials":23937,"activeCount":103},[],{"trials":23939,"activeCount":103},[23940,23944,23948],{"nctId":13269,"briefTitle":13270,"status":123,"phases":23941,"primaryCompletion":13272,"completion":13272,"start":3139,"enrollment":1384,"conditions":23942,"interventions":23943},[91],[15,6656,13274,209,13275,13276],[2411,4389],{"nctId":10580,"briefTitle":10581,"status":390,"phases":23945,"primaryCompletion":10583,"completion":10583,"start":10584,"enrollment":103,"conditions":23946,"interventions":23947},[91],[2430,2369,10586,2432,10587],[10589,2411,212,10590],{"nctId":23949,"briefTitle":23950,"status":134,"phases":23951,"primaryCompletion":23952,"completion":23952,"start":13272,"enrollment":99,"conditions":23953,"interventions":23954},"NCT04810611","Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS",[91],"2024-04-19",[5723],[10589,2411,10578],{"trials":23956,"activeCount":103},[23957,23961,23965],{"nctId":2399,"briefTitle":2400,"status":134,"phases":23958,"primaryCompletion":2402,"completion":2403,"start":2404,"enrollment":2405,"conditions":23959,"interventions":23960},[91,92],[2369],[2341,2408,63,2409,2410,2411],{"nctId":10624,"briefTitle":10625,"status":134,"phases":23962,"primaryCompletion":10627,"completion":10628,"start":7551,"enrollment":5841,"conditions":23963,"interventions":23964},[92],[10630],[2411,212,10632,6342],{"nctId":9919,"briefTitle":9920,"status":134,"phases":23966,"primaryCompletion":9922,"completion":9922,"start":1277,"enrollment":1941,"conditions":23967,"interventions":23968},[92],[9924],[2411,9926,9927,9928,1079],{"trials":23970,"activeCount":103},[23971],{"nctId":23972,"briefTitle":23973,"status":123,"phases":23974,"primaryCompletion":6451,"completion":6451,"start":10017,"enrollment":13129,"conditions":23975,"interventions":23976},"NCT04935359","Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2",[93],[10630],[2411,9947,9948],{"trials":23978,"activeCount":103},[],{"trials":23980,"activeCount":103},[],{"intervention":15542,"totalTrials":2379,"cells":23982},{"EARLY_PHASE1":23983,"PHASE1":23985,"PHASE2":23987,"PHASE3":23996,"PHASE4":24018,"NA":24020},{"trials":23984,"activeCount":103},[],{"trials":23986,"activeCount":103},[],{"trials":23988,"activeCount":103},[23989],{"nctId":23990,"briefTitle":23991,"status":123,"phases":23992,"primaryCompletion":4741,"completion":4741,"start":4061,"enrollment":23993,"conditions":23994,"interventions":23995},"NCT00098228","Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],686,[8267],[15542],{"trials":23997,"activeCount":103},[23998,24002,24006,24010,24014],{"nctId":15535,"briefTitle":15536,"status":123,"phases":23999,"primaryCompletion":3604,"completion":3604,"start":5733,"enrollment":15538,"conditions":24000,"interventions":24001},[93],[24],[15524,15541,15542],{"nctId":15550,"briefTitle":15551,"status":123,"phases":24003,"primaryCompletion":3731,"completion":3731,"start":1761,"enrollment":15553,"conditions":24004,"interventions":24005},[93],[15555],[15524,15524,15542],{"nctId":15590,"briefTitle":15591,"status":123,"phases":24007,"primaryCompletion":1723,"completion":1723,"start":3712,"enrollment":15593,"conditions":24008,"interventions":24009},[93],[15555],[15524,15542,15541],{"nctId":15612,"briefTitle":15613,"status":123,"phases":24011,"primaryCompletion":1723,"completion":1723,"start":3604,"enrollment":15615,"conditions":24012,"interventions":24013},[93],[15555],[15524,15542,15541],{"nctId":16152,"briefTitle":16153,"status":123,"phases":24015,"primaryCompletion":3731,"completion":3731,"start":3712,"enrollment":4360,"conditions":24016,"interventions":24017},[93],[16156],[15542,15541],{"trials":24019,"activeCount":103},[],{"trials":24021,"activeCount":103},[],{"intervention":6342,"totalTrials":2379,"cells":24023},{"EARLY_PHASE1":24024,"PHASE1":24026,"PHASE2":24028,"PHASE3":24038,"PHASE4":24056,"NA":24058},{"trials":24025,"activeCount":103},[],{"trials":24027,"activeCount":103},[],{"trials":24029,"activeCount":103},[24030,24034],{"nctId":10624,"briefTitle":10625,"status":134,"phases":24031,"primaryCompletion":10627,"completion":10628,"start":7551,"enrollment":5841,"conditions":24032,"interventions":24033},[92],[10630],[2411,212,10632,6342],{"nctId":9938,"briefTitle":9939,"status":390,"phases":24035,"primaryCompletion":9941,"completion":9942,"start":1512,"enrollment":103,"conditions":24036,"interventions":24037},[92],[9944],[9946,1079,4321,9947,1168,8153,9948],{"trials":24039,"activeCount":103},[24040,24044,24048,24052],{"nctId":6333,"briefTitle":6334,"status":134,"phases":24041,"primaryCompletion":6336,"completion":6337,"start":6338,"enrollment":1890,"conditions":24042,"interventions":24043},[93],[6340],[4366,6342],{"nctId":23972,"briefTitle":23973,"status":123,"phases":24045,"primaryCompletion":6451,"completion":6451,"start":10017,"enrollment":13129,"conditions":24046,"interventions":24047},[93],[10630],[2411,9947,9948],{"nctId":9952,"briefTitle":9953,"status":390,"phases":24049,"primaryCompletion":9955,"completion":9956,"start":9957,"enrollment":103,"conditions":24050,"interventions":24051},[93],[5282],[9946,1079,8153,1168,5262,4375,4321,9947],{"nctId":13629,"briefTitle":13630,"status":134,"phases":24053,"primaryCompletion":13632,"completion":13633,"start":13634,"enrollment":13635,"conditions":24054,"interventions":24055},[93],[128],[10578,13581,7871,13638,7872,6342,13639],{"trials":24057,"activeCount":103},[],{"trials":24059,"activeCount":103},[],{"intervention":8115,"totalTrials":2379,"cells":24061},{"EARLY_PHASE1":24062,"PHASE1":24064,"PHASE2":24093,"PHASE3":24095,"PHASE4":24105,"NA":24107},{"trials":24063,"activeCount":103},[],{"trials":24065,"activeCount":103},[24066,24074,24080,24087],{"nctId":24067,"briefTitle":24068,"status":134,"phases":24069,"primaryCompletion":4372,"start":3551,"enrollment":34,"conditions":24070,"interventions":24073},"NCT01240642","An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404",[91],[24071,24072],"Metastatic Cancer With Impaired Renal Function","Metastatic Cancer With Normal Renal Function",[8115],{"nctId":24075,"briefTitle":24076,"status":123,"phases":24077,"primaryCompletion":3400,"start":4070,"enrollment":2367,"conditions":24078,"interventions":24079},"NCT00674102","An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)",[91],[128],[8115],{"nctId":24081,"briefTitle":24082,"status":134,"phases":24083,"primaryCompletion":926,"start":3551,"enrollment":637,"conditions":24084,"interventions":24086},"NCT01278849","An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function",[91],[24085],"Histologically-proven and Radiologically-confirmed Solid Tumors",[8115],{"nctId":24088,"briefTitle":24089,"status":134,"phases":24090,"primaryCompletion":4845,"completion":4845,"start":3552,"enrollment":1562,"conditions":24091,"interventions":24092},"NCT01299701","A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors",[91],[5614],[8115],{"trials":24094,"activeCount":103},[],{"trials":24096,"activeCount":103},[24097,24101],{"nctId":15472,"briefTitle":15473,"status":134,"phases":24098,"primaryCompletion":853,"completion":853,"start":4070,"enrollment":15475,"conditions":24099,"interventions":24100},[93],[182],[8115,7871,4321],{"nctId":8109,"briefTitle":8110,"status":134,"phases":24102,"primaryCompletion":4372,"start":3552,"enrollment":8112,"conditions":24103,"interventions":24104},[93],[182],[8115,6673],{"trials":24106,"activeCount":103},[],{"trials":24108,"activeCount":103},[],{"intervention":17000,"totalTrials":2379,"cells":24110},{"EARLY_PHASE1":24111,"PHASE1":24113,"PHASE2":24115,"PHASE3":24125,"PHASE4":24153,"NA":24155},{"trials":24112,"activeCount":103},[],{"trials":24114,"activeCount":103},[],{"trials":24116,"activeCount":103},[24117,24121],{"nctId":16987,"briefTitle":16988,"status":123,"phases":24118,"primaryCompletion":4410,"completion":4410,"start":813,"enrollment":4992,"conditions":24119,"interventions":24120},[92],[21],[15788,16992,15884],{"nctId":16994,"briefTitle":16995,"status":123,"phases":24122,"primaryCompletion":606,"completion":606,"start":3604,"enrollment":16997,"conditions":24123,"interventions":24124},[92],[21],[15726,17000,15776,17001],{"trials":24126,"activeCount":103},[24127,24133,24140,24146],{"nctId":24128,"briefTitle":24129,"status":123,"phases":24130,"primaryCompletion":7939,"completion":7939,"start":3799,"enrollment":282,"conditions":24131,"interventions":24132},"NCT01876368","Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan",[93],[21],[15726,17000],{"nctId":24134,"briefTitle":24135,"status":123,"phases":24136,"primaryCompletion":15283,"completion":15283,"start":4524,"enrollment":24137,"conditions":24138,"interventions":24139},"NCT01599104","Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension",[93],1161,[17007],[15726,17000],{"nctId":24141,"briefTitle":24142,"status":123,"phases":24143,"primaryCompletion":2033,"completion":2033,"start":3482,"enrollment":7202,"conditions":24144,"interventions":24145},"NCT01615198","Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension",[93],[17007],[17000,15726],{"nctId":24147,"briefTitle":24148,"status":123,"phases":24149,"primaryCompletion":7939,"completion":7939,"start":15283,"enrollment":24150,"conditions":24151,"interventions":24152},"NCT01785472","Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension",[93],1438,[17007],[15726,17000],{"trials":24154,"activeCount":103},[],{"trials":24156,"activeCount":103},[],{"intervention":24158,"totalTrials":637,"cells":24159},"osilodrostat",{"EARLY_PHASE1":24160,"PHASE1":24162,"PHASE2":24180,"PHASE3":24198,"PHASE4":24217,"NA":24219},{"trials":24161,"activeCount":103},[],{"trials":24163,"activeCount":103},[24164,24172],{"nctId":24165,"briefTitle":24166,"status":123,"phases":24167,"primaryCompletion":24168,"completion":24168,"start":24169,"enrollment":2367,"conditions":24170,"interventions":24171},"NCT02399202","A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function",[91],"2016-03-21","2015-11-06",[2635],[24158],{"nctId":24173,"briefTitle":24174,"status":123,"phases":24175,"primaryCompletion":24176,"completion":24176,"start":24177,"enrollment":99,"conditions":24178,"interventions":24179},"NCT02372084","A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function",[91],"2016-05-19","2015-04-21",[2625],[24158],{"trials":24181,"activeCount":103},[24182],{"nctId":24183,"briefTitle":24184,"status":123,"phases":24185,"primaryCompletion":24186,"completion":24187,"start":24188,"enrollment":1495,"conditions":24189,"interventions":24196},"NCT02468193","Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome",[92],"2018-06-07","2018-10-29","2015-09-24",[24190,24191,24192,24193,24194,24195],"Cushing's Syndrome","Ectopic Corticotropin Syndrome","Adrenal Adenoma","Adrenal Carcinoma","AIMAH","PPNAD",[24197],"Osilodrostat",{"trials":24199,"activeCount":103},[24200,24208],{"nctId":24201,"briefTitle":24202,"status":123,"phases":24203,"primaryCompletion":24204,"completion":1351,"start":2006,"enrollment":4568,"conditions":24205,"interventions":24206},"NCT02697734","Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease",[93],"2019-06-19",[16681],[24158,24207],"osilodrostat Placebo",{"nctId":24209,"briefTitle":24210,"status":123,"phases":24211,"primaryCompletion":10139,"completion":24212,"start":24213,"enrollment":1890,"conditions":24214,"interventions":24216},"NCT02180217","Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease",[93],"2019-12-04","2014-10-06",[24215],"Cushings Disease",[24158],{"trials":24218,"activeCount":103},[],{"trials":24220,"activeCount":103},[],{"intervention":18341,"totalTrials":637,"cells":24222},{"EARLY_PHASE1":24223,"PHASE1":24225,"PHASE2":24227,"PHASE3":24229,"PHASE4":24257,"NA":24259},{"trials":24224,"activeCount":103},[],{"trials":24226,"activeCount":103},[],{"trials":24228,"activeCount":103},[],{"trials":24230,"activeCount":103},[24231,24241,24245,24249,24253],{"nctId":24232,"briefTitle":24233,"status":123,"phases":24234,"primaryCompletion":1503,"completion":24235,"start":24236,"enrollment":24237,"conditions":24238,"interventions":24240},"NCT04278417","Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy",[93],"2024-08-19","2020-11-19",689,[24239],"Proliferative Diabetic Retinopathy",[18341],{"nctId":18333,"briefTitle":18334,"status":134,"phases":24242,"primaryCompletion":18336,"completion":18336,"start":18337,"enrollment":18338,"conditions":24243,"interventions":24244},[93],[17675],[18341,17714],{"nctId":18352,"briefTitle":18353,"status":123,"phases":24246,"primaryCompletion":7021,"completion":7021,"start":6568,"enrollment":18355,"conditions":24247,"interventions":24248},[93],[4458],[18341,17714],{"nctId":18359,"briefTitle":18360,"status":123,"phases":24250,"primaryCompletion":18362,"completion":18362,"start":18363,"enrollment":1143,"conditions":24251,"interventions":24252},[93],[18365],[18341,17714],{"nctId":18368,"briefTitle":18369,"status":134,"phases":24254,"primaryCompletion":18336,"completion":18336,"start":18371,"enrollment":1514,"conditions":24255,"interventions":24256},[93],[18373],[18341,17714],{"trials":24258,"activeCount":103},[],{"trials":24260,"activeCount":103},[],{"intervention":24262,"totalTrials":637,"cells":24263},"RLX030",{"EARLY_PHASE1":24264,"PHASE1":24266,"PHASE2":24268,"PHASE3":24295,"PHASE4":24306,"NA":24308},{"trials":24265,"activeCount":103},[],{"trials":24267,"activeCount":103},[],{"trials":24269,"activeCount":103},[24270,24276,24282,24288],{"nctId":24271,"briefTitle":24272,"status":123,"phases":24273,"primaryCompletion":3604,"completion":3604,"start":1671,"enrollment":4708,"conditions":24274,"interventions":24275},"NCT01546532","Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)",[92],[15830],[24262],{"nctId":24277,"briefTitle":24278,"status":123,"phases":24279,"primaryCompletion":1670,"completion":1670,"start":2795,"enrollment":1660,"conditions":24280,"interventions":24281},"NCT01543854","Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure",[92],[17377],[24262],{"nctId":24283,"briefTitle":24284,"status":123,"phases":24285,"primaryCompletion":3861,"completion":3861,"start":4515,"enrollment":19224,"conditions":24286,"interventions":24287},"NCT01982292","Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure",[92],[15734],[24262],{"nctId":24289,"briefTitle":24290,"status":134,"phases":24291,"primaryCompletion":7939,"completion":7939,"start":5114,"enrollment":317,"conditions":24292,"interventions":24294},"NCT01566630","Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia",[92],[24293],"Pre-eclampsia",[24262],{"trials":24296,"activeCount":103},[24297],{"nctId":24298,"briefTitle":24299,"status":123,"phases":24300,"primaryCompletion":24301,"completion":7720,"start":24302,"enrollment":24303,"conditions":24304,"interventions":24305},"NCT01870778","Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",[93],"2017-01-23","2013-10-02",6600,[17377],[24262],{"trials":24307,"activeCount":103},[],{"trials":24309,"activeCount":103},[],{"intervention":9948,"totalTrials":637,"cells":24311},{"EARLY_PHASE1":24312,"PHASE1":24314,"PHASE2":24320,"PHASE3":24334,"PHASE4":24340,"NA":24342},{"trials":24313,"activeCount":103},[],{"trials":24315,"activeCount":103},[24316],{"nctId":13316,"briefTitle":13317,"status":134,"phases":24317,"primaryCompletion":6013,"completion":6013,"start":13319,"enrollment":2810,"conditions":24318,"interventions":24319},[91],[128],[4389,5262,9948,4375,1168,4321,3157],{"trials":24321,"activeCount":103},[24322,24326,24330],{"nctId":10624,"briefTitle":10625,"status":134,"phases":24323,"primaryCompletion":10627,"completion":10628,"start":7551,"enrollment":5841,"conditions":24324,"interventions":24325},[92],[10630],[2411,212,10632,6342],{"nctId":17117,"briefTitle":17118,"status":123,"phases":24327,"primaryCompletion":17120,"completion":17121,"start":17122,"enrollment":2579,"conditions":24328,"interventions":24329},[92],[17124],[10577,7871,10632],{"nctId":9938,"briefTitle":9939,"status":390,"phases":24331,"primaryCompletion":9941,"completion":9942,"start":1512,"enrollment":103,"conditions":24332,"interventions":24333},[92],[9944],[9946,1079,4321,9947,1168,8153,9948],{"trials":24335,"activeCount":103},[24336],{"nctId":23972,"briefTitle":23973,"status":123,"phases":24337,"primaryCompletion":6451,"completion":6451,"start":10017,"enrollment":13129,"conditions":24338,"interventions":24339},[93],[10630],[2411,9947,9948],{"trials":24341,"activeCount":103},[],{"trials":24343,"activeCount":103},[],{"intervention":10927,"totalTrials":637,"cells":24345},{"EARLY_PHASE1":24346,"PHASE1":24348,"PHASE2":24350,"PHASE3":24384,"PHASE4":24390,"NA":24392},{"trials":24347,"activeCount":103},[],{"trials":24349,"activeCount":103},[],{"trials":24351,"activeCount":103},[24352,24362,24366,24374],{"nctId":24353,"briefTitle":24354,"status":123,"phases":24355,"primaryCompletion":565,"completion":9252,"start":7881,"enrollment":24356,"conditions":24357,"interventions":24359},"NCT03167242","Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria",[92],524,[24358],"Acute Uncomplicated Plasmodium Falciparum Malaria",[24360,10927,24361],"KAF156","Lumefantrine Solid Dispersion Formulation",{"nctId":11194,"briefTitle":11195,"status":123,"phases":24363,"primaryCompletion":6743,"completion":6743,"start":11197,"enrollment":3120,"conditions":24364,"interventions":24365},[92],[11177],[10904,10927],{"nctId":24367,"briefTitle":24368,"status":123,"phases":24369,"primaryCompletion":6451,"completion":2403,"start":1505,"enrollment":24370,"conditions":24371,"interventions":24372},"NCT04546633","Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria",[92],295,[10902],[24360,24373,10927],"LUM-SDF",{"nctId":24375,"briefTitle":24376,"status":123,"phases":24377,"primaryCompletion":24378,"completion":14452,"start":13326,"enrollment":15086,"conditions":24379,"interventions":24381},"NCT04675931","To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria",[92],"2025-07-24",[24380],"Severe Malaria",[24382,24383,10927],"Cipargamin","IV Artesunate",{"trials":24385,"activeCount":103},[24386],{"nctId":10918,"briefTitle":10919,"status":123,"phases":24387,"primaryCompletion":10921,"completion":10922,"start":10923,"enrollment":10924,"conditions":24388,"interventions":24389},[93],[10902],[10887,10927],{"trials":24391,"activeCount":103},[],{"trials":24393,"activeCount":103},[],{"intervention":5649,"totalTrials":637,"cells":24395},{"EARLY_PHASE1":24396,"PHASE1":24398,"PHASE2":24400,"PHASE3":24418,"PHASE4":24424,"NA":24426},{"trials":24397,"activeCount":103},[],{"trials":24399,"activeCount":103},[],{"trials":24401,"activeCount":103},[24402,24406,24410,24414],{"nctId":5641,"briefTitle":5642,"status":123,"phases":24403,"primaryCompletion":1723,"completion":1723,"start":3351,"enrollment":2112,"conditions":24404,"interventions":24405},[92],[5645,5646,5647],[2360,5649,5639],{"nctId":10496,"briefTitle":10497,"status":123,"phases":24407,"primaryCompletion":4598,"completion":4598,"start":10499,"enrollment":1053,"conditions":24408,"interventions":24409},[91,92],[10501],[7913,5746,5747],{"nctId":10514,"briefTitle":10515,"status":123,"phases":24411,"primaryCompletion":5114,"completion":5114,"start":1732,"enrollment":1495,"conditions":24412,"interventions":24413},[92],[5636,10518],[10520,10521,5649,5639],{"nctId":10533,"briefTitle":10534,"status":123,"phases":24415,"primaryCompletion":2467,"completion":10536,"start":10537,"enrollment":827,"conditions":24416,"interventions":24417},[92],[10539],[10541,5649,5639],{"trials":24419,"activeCount":103},[24420],{"nctId":5738,"briefTitle":5739,"status":123,"phases":24421,"primaryCompletion":5741,"completion":5741,"start":5742,"enrollment":5743,"conditions":24422,"interventions":24423},[93],[5636],[4391,5746,5747],{"trials":24425,"activeCount":103},[],{"trials":24427,"activeCount":103},[],{"intervention":5262,"totalTrials":637,"cells":24429},{"EARLY_PHASE1":24430,"PHASE1":24432,"PHASE2":24438,"PHASE3":24440,"PHASE4":24458,"NA":24460},{"trials":24431,"activeCount":103},[],{"trials":24433,"activeCount":103},[24434],{"nctId":13316,"briefTitle":13317,"status":134,"phases":24435,"primaryCompletion":6013,"completion":6013,"start":13319,"enrollment":2810,"conditions":24436,"interventions":24437},[91],[128],[4389,5262,9948,4375,1168,4321,3157],{"trials":24439,"activeCount":103},[],{"trials":24441,"activeCount":103},[24442,24446,24450,24454],{"nctId":9952,"briefTitle":9953,"status":390,"phases":24443,"primaryCompletion":9955,"completion":9956,"start":9957,"enrollment":103,"conditions":24444,"interventions":24445},[93],[5282],[9946,1079,8153,1168,5262,4375,4321,9947],{"nctId":13629,"briefTitle":13630,"status":134,"phases":24447,"primaryCompletion":13632,"completion":13633,"start":13634,"enrollment":13635,"conditions":24448,"interventions":24449},[93],[128],[10578,13581,7871,13638,7872,6342,13639],{"nctId":10969,"briefTitle":10970,"status":134,"phases":24451,"primaryCompletion":137,"completion":137,"start":10972,"enrollment":2379,"conditions":24452,"interventions":24453},[93],[227],[8070,10342,4375,5262,1168],{"nctId":5254,"briefTitle":5255,"status":123,"phases":24455,"primaryCompletion":5257,"completion":5258,"start":5259,"enrollment":282,"conditions":24456,"interventions":24457},[93],[182],[130,4375,5262,1168],{"trials":24459,"activeCount":103},[],{"trials":24461,"activeCount":103},[],{"intervention":24463,"totalTrials":637,"cells":24464},"BYM338",{"EARLY_PHASE1":24465,"PHASE1":24467,"PHASE2":24469,"PHASE3":24499,"PHASE4":24508,"NA":24510},{"trials":24466,"activeCount":103},[],{"trials":24468,"activeCount":103},[],{"trials":24470,"activeCount":103},[24471,24478,24485,24492],{"nctId":24472,"briefTitle":24473,"status":123,"phases":24474,"primaryCompletion":1731,"completion":1731,"start":3243,"enrollment":10526,"conditions":24475,"interventions":24477},"NCT01669174","BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia",[92],[24476],"Chronic Obstructive Pulmonary Disease (COPD) With Cachexia",[24463],{"nctId":24479,"briefTitle":24480,"status":123,"phases":24481,"primaryCompletion":5733,"completion":5733,"start":1724,"enrollment":814,"conditions":24482,"interventions":24484},"NCT01423110","Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis",[92],[24483],"Sporadic Inclusion Body Myositis",[24463],{"nctId":24486,"briefTitle":24487,"status":390,"phases":24488,"primaryCompletion":10055,"completion":10055,"start":1781,"enrollment":103,"conditions":24489,"interventions":24491},"NCT01868685","Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients",[92],[24490],"Mechanical Ventilation",[24463],{"nctId":24493,"briefTitle":24494,"status":123,"phases":24495,"primaryCompletion":1714,"completion":1714,"start":1732,"enrollment":709,"conditions":24496,"interventions":24498},"NCT01601600","A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults",[92],[24497],"Skeletal Muscle",[24463],{"trials":24500,"activeCount":103},[24501],{"nctId":24502,"briefTitle":24503,"status":123,"phases":24504,"primaryCompletion":13389,"completion":13389,"start":6306,"enrollment":5594,"conditions":24505,"interventions":24507},"NCT02250443","Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis",[92,93],[24506],"Sporadic Inclusion Body Myositis (sIBM)",[24463],{"trials":24509,"activeCount":103},[],{"trials":24511,"activeCount":103},[],{"intervention":24513,"totalTrials":637,"cells":24514},"Indacaterol 150 μg",{"EARLY_PHASE1":24515,"PHASE1":24517,"PHASE2":24519,"PHASE3":24521,"PHASE4":24556,"NA":24558},{"trials":24516,"activeCount":103},[],{"trials":24518,"activeCount":103},[],{"trials":24520,"activeCount":103},[],{"trials":24522,"activeCount":103},[24523,24530,24538,24543,24549],{"nctId":24524,"briefTitle":24525,"status":123,"phases":24526,"primaryCompletion":4400,"completion":4400,"start":3490,"enrollment":3577,"conditions":24527,"interventions":24528},"NCT00794157","Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[93],[15555],[24513,24529],"Indacaterol 300 μg",{"nctId":24531,"briefTitle":24532,"status":123,"phases":24533,"primaryCompletion":880,"completion":880,"start":4707,"enrollment":24534,"conditions":24535,"interventions":24536},"NCT00877383","Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease",[93],1142,[15555],[24513,24537],"Tiotropium 18 μg",{"nctId":24539,"briefTitle":24532,"status":123,"phases":24540,"primaryCompletion":964,"completion":964,"start":3400,"enrollment":19766,"conditions":24541,"interventions":24542},"NCT00846586",[93],[15555],[24513,24537],{"nctId":24544,"briefTitle":24545,"status":123,"phases":24546,"primaryCompletion":964,"completion":964,"start":4400,"enrollment":271,"conditions":24547,"interventions":24548},"NCT00999908","Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity",[93],[24],[24513,24537],{"nctId":24550,"briefTitle":24551,"status":123,"phases":24552,"primaryCompletion":964,"completion":964,"start":1024,"enrollment":24553,"conditions":24554,"interventions":24555},"NCT00900731","A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)",[93],1598,[24],[24513,24537],{"trials":24557,"activeCount":103},[],{"trials":24559,"activeCount":103},[],{"intervention":24561,"totalTrials":1630,"cells":24562},"bimagrumab",{"EARLY_PHASE1":24563,"PHASE1":24565,"PHASE2":24567,"PHASE3":24595,"PHASE4":24605,"NA":24607},{"trials":24564,"activeCount":103},[],{"trials":24566,"activeCount":103},[],{"trials":24568,"activeCount":103},[24569,24578,24586],{"nctId":24570,"briefTitle":24571,"status":123,"phases":24572,"primaryCompletion":2843,"completion":24573,"start":24574,"enrollment":597,"conditions":24575,"interventions":24577},"NCT02333331","Dose Range Finding Study of Bimagrumab in Sarcopenia",[92],"2018-06-28","2014-12-09",[24576],"Sarcopenia",[24561],{"nctId":24579,"briefTitle":24580,"status":123,"phases":24581,"primaryCompletion":24582,"completion":24582,"start":24583,"enrollment":4532,"conditions":24584,"interventions":24585},"NCT02468674","A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study",[92],"2018-12-03","2015-07-22",[24576],[24561],{"nctId":24587,"briefTitle":24588,"status":123,"phases":24589,"primaryCompletion":1857,"completion":24590,"start":24591,"enrollment":10408,"conditions":24592,"interventions":24594},"NCT02152761","Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery",[92],"2018-10-25","2014-09-16",[24593],"Muscle Wasting (Atrophy) After Hip Fracture Surgery",[24561],{"trials":24596,"activeCount":103},[24597],{"nctId":24598,"briefTitle":24599,"status":123,"phases":24600,"primaryCompletion":17357,"completion":24601,"start":8957,"enrollment":16124,"conditions":24602,"interventions":24603},"NCT02573467","An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203",[93],"2017-02-13",[24483],[24604],"Bimagrumab",{"trials":24606,"activeCount":103},[],{"trials":24608,"activeCount":103},[],{"intervention":4405,"totalTrials":1630,"cells":24610},{"EARLY_PHASE1":24611,"PHASE1":24613,"PHASE2":24615,"PHASE3":24632,"PHASE4":24652,"NA":24654},{"trials":24612,"activeCount":103},[],{"trials":24614,"activeCount":103},[],{"trials":24616,"activeCount":103},[24617,24621],{"nctId":4397,"briefTitle":4398,"status":123,"phases":24618,"primaryCompletion":1760,"completion":1760,"start":4400,"enrollment":4401,"conditions":24619,"interventions":24620},[92],[4403],[4305,4405],{"nctId":24622,"briefTitle":24623,"status":123,"phases":24624,"primaryCompletion":5123,"completion":24625,"start":24626,"enrollment":24627,"conditions":24628,"interventions":24629},"NCT01147822","Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and\u002For Metastatic Renal Cell Carcinoma",[92],"2021-09-03","2010-05-19",367,[13284],[24630,24631],"Pazopanib","Sunitinib",{"trials":24633,"activeCount":103},[24634,24644],{"nctId":24635,"briefTitle":24636,"status":123,"phases":24637,"primaryCompletion":24638,"completion":11287,"start":24639,"enrollment":24640,"conditions":24641,"interventions":24642},"NCT01064310","Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer",[93],"2011-10-19","2010-05-17",169,[13284],[24643,4405],"pazopanib",{"nctId":24645,"briefTitle":24646,"status":123,"phases":24647,"primaryCompletion":5123,"completion":18043,"start":24648,"enrollment":24649,"conditions":24650,"interventions":24651},"NCT00720941","Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and\u002For Metastatic Renal Cell Carcinoma",[93],"2008-08-14",1110,[13284],[24630,24631],{"trials":24653,"activeCount":103},[],{"trials":24655,"activeCount":103},[],{"intervention":24657,"totalTrials":1630,"cells":24658},"Deferoxamine",{"EARLY_PHASE1":24659,"PHASE1":24661,"PHASE2":24663,"PHASE3":24692,"PHASE4":24698,"NA":24700},{"trials":24660,"activeCount":103},[],{"trials":24662,"activeCount":103},[],{"trials":24664,"activeCount":103},[24665,24677,24685],{"nctId":24666,"briefTitle":24667,"status":123,"phases":24668,"primaryCompletion":4967,"completion":4967,"start":4642,"enrollment":24669,"conditions":24670,"interventions":24671},"NCT00600938","Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload",[92],197,[18734,20547],[24672,24673,24674,24675,24676,24657],"Core Study: Deferasirox","Core Study: Deferoxamine","Extension: deferoxamine to deferasirox","Extension: deferasirox to deferoxamine","Deferasirox",{"nctId":24678,"briefTitle":24679,"status":134,"phases":24680,"primaryCompletion":3731,"completion":3731,"start":4598,"enrollment":7257,"conditions":24681,"interventions":24684},"NCT01459718","Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload",[92],[24682,24683],"Transfusion-dependent β-thalassemia Patients","Cardiac Iron Overload",[24676,24657],{"nctId":24686,"briefTitle":24687,"status":123,"phases":24688,"primaryCompletion":4070,"completion":4070,"start":3255,"enrollment":6175,"conditions":24689,"interventions":24691},"NCT00110617","Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients",[92],[3952,21357,24690],"Hemolytic Anemia",[24676,24657],{"trials":24693,"activeCount":103},[24694],{"nctId":18739,"briefTitle":18740,"status":123,"phases":24695,"primaryCompletion":17497,"start":881,"enrollment":18742,"conditions":24696,"interventions":24697},[93],[18744],[18714,18746],{"trials":24699,"activeCount":103},[],{"trials":24701,"activeCount":103},[],{"intervention":24529,"totalTrials":1630,"cells":24703},{"EARLY_PHASE1":24704,"PHASE1":24706,"PHASE2":24708,"PHASE3":24710,"PHASE4":24736,"NA":24738},{"trials":24705,"activeCount":103},[],{"trials":24707,"activeCount":103},[],{"trials":24709,"activeCount":103},[],{"trials":24711,"activeCount":103},[24712,24719,24723,24730],{"nctId":24713,"briefTitle":24714,"status":123,"phases":24715,"primaryCompletion":3473,"completion":3473,"start":3194,"enrollment":24716,"conditions":24717,"interventions":24718},"NCT00529529","Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma",[93],805,[18],[24529,16370],{"nctId":24524,"briefTitle":24525,"status":123,"phases":24720,"primaryCompletion":4400,"completion":4400,"start":3490,"enrollment":3577,"conditions":24721,"interventions":24722},[93],[15555],[24513,24529],{"nctId":24724,"briefTitle":24725,"status":123,"phases":24726,"primaryCompletion":880,"completion":880,"start":3490,"enrollment":24727,"conditions":24728,"interventions":24729},"NCT00792805","Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)",[93],563,[15555],[16268,24529],{"nctId":24731,"briefTitle":24732,"status":123,"phases":24733,"primaryCompletion":10499,"completion":10499,"start":917,"enrollment":16,"conditions":24734,"interventions":24735},"NCT00622635","A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",[93],[24],[24529,16370],{"trials":24737,"activeCount":103},[],{"trials":24739,"activeCount":103},[],{"intervention":3056,"totalTrials":1630,"cells":24741},{"EARLY_PHASE1":24742,"PHASE1":24744,"PHASE2":24746,"PHASE3":24763,"PHASE4":24775,"NA":24777},{"trials":24743,"activeCount":103},[],{"trials":24745,"activeCount":103},[],{"trials":24747,"activeCount":103},[24748,24752,24759],{"nctId":3049,"briefTitle":3050,"status":123,"phases":24749,"primaryCompletion":3052,"completion":3052,"start":3053,"enrollment":630,"conditions":24750,"interventions":24751},[92],[18],[3056,3057,3017],{"nctId":24753,"briefTitle":24754,"status":123,"phases":24755,"primaryCompletion":2033,"completion":2033,"start":3759,"enrollment":24756,"conditions":24757,"interventions":24758},"NCT01555151","Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma",[92],739,[18],[3056],{"nctId":16348,"briefTitle":16349,"status":123,"phases":24760,"primaryCompletion":2033,"completion":2033,"start":3482,"enrollment":16351,"conditions":24761,"interventions":24762},[92],[18],[16256,16354],{"trials":24764,"activeCount":103},[24765],{"nctId":24766,"briefTitle":24767,"status":123,"phases":24768,"primaryCompletion":11323,"completion":3827,"start":24769,"enrollment":24770,"conditions":24771,"interventions":24772},"NCT02554786","A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma",[93],"2015-12-29",2216,[18],[24773,3056,24774],"Indacaterol acetate\u002FMometasone furoate","Salmeterol xinafoate\u002Ffluticasone propionate",{"trials":24776,"activeCount":103},[],{"trials":24778,"activeCount":103},[],{"intervention":15580,"totalTrials":1630,"cells":24780},{"EARLY_PHASE1":24781,"PHASE1":24783,"PHASE2":24785,"PHASE3":24787,"PHASE4":24805,"NA":24807},{"trials":24782,"activeCount":103},[],{"trials":24784,"activeCount":103},[],{"trials":24786,"activeCount":103},[],{"trials":24788,"activeCount":103},[24789,24793,24797,24801],{"nctId":15575,"briefTitle":15576,"status":390,"phases":24790,"primaryCompletion":812,"completion":812,"start":1714,"enrollment":103,"conditions":24791,"interventions":24792},[93],[24],[15524,15580],{"nctId":19607,"briefTitle":19608,"status":123,"phases":24794,"primaryCompletion":2795,"completion":2795,"start":895,"enrollment":19610,"conditions":24795,"interventions":24796},[93],[15555],[16254,15580],{"nctId":15607,"briefTitle":15576,"status":390,"phases":24798,"primaryCompletion":812,"completion":812,"start":1714,"enrollment":103,"conditions":24799,"interventions":24800},[93],[24],[15524,15580],{"nctId":15654,"briefTitle":15655,"status":123,"phases":24802,"primaryCompletion":1723,"completion":1723,"start":3712,"enrollment":15657,"conditions":24803,"interventions":24804},[93],[24],[15524,15660],{"trials":24806,"activeCount":103},[],{"trials":24808,"activeCount":103},[],{"intervention":16268,"totalTrials":1630,"cells":24810},{"EARLY_PHASE1":24811,"PHASE1":24813,"PHASE2":24823,"PHASE3":24825,"PHASE4":24843,"NA":24845},{"trials":24812,"activeCount":103},[],{"trials":24814,"activeCount":103},[24815],{"nctId":24816,"briefTitle":24817,"status":123,"phases":24818,"primaryCompletion":3473,"start":4070,"enrollment":22825,"conditions":24819,"interventions":24820},"NCT01263808","Cardiac Safety of Indacaterol",[91],[9634,24],[16268,24821,24822],"Indacaterol 300 µg","Indacaterol 600 µg",{"trials":24824,"activeCount":103},[],{"trials":24826,"activeCount":103},[24827,24831,24835],{"nctId":16262,"briefTitle":16263,"status":123,"phases":24828,"primaryCompletion":3759,"completion":3759,"start":3400,"enrollment":16265,"conditions":24829,"interventions":24830},[93],[24],[16268,15588],{"nctId":24724,"briefTitle":24725,"status":123,"phases":24832,"primaryCompletion":880,"completion":880,"start":3490,"enrollment":24727,"conditions":24833,"interventions":24834},[93],[15555],[16268,24529],{"nctId":24836,"briefTitle":24837,"status":123,"phases":24838,"primaryCompletion":4400,"completion":4400,"start":949,"enrollment":24839,"conditions":24840,"interventions":24841},"NCT00821093","Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)",[93],1123,[15555],[16268,24842],"Salmeterol 50 µg",{"trials":24844,"activeCount":103},[],{"trials":24846,"activeCount":103},[],{"intervention":2788,"totalTrials":1630,"cells":24848},{"EARLY_PHASE1":24849,"PHASE1":24851,"PHASE2":24857,"PHASE3":24867,"PHASE4":24873,"NA":24875},{"trials":24850,"activeCount":103},[],{"trials":24852,"activeCount":103},[24853],{"nctId":2759,"briefTitle":2760,"status":123,"phases":24854,"primaryCompletion":2762,"completion":2762,"start":1670,"enrollment":2439,"conditions":24855,"interventions":24856},[91],[1102],[2765,2766],{"trials":24858,"activeCount":103},[24859,24863],{"nctId":2781,"briefTitle":2782,"status":123,"phases":24860,"primaryCompletion":2623,"completion":2623,"start":2784,"enrollment":1622,"conditions":24861,"interventions":24862},[92],[2786],[2752,2788],{"nctId":2790,"briefTitle":2791,"status":123,"phases":24864,"primaryCompletion":2793,"completion":2794,"start":2795,"enrollment":2796,"conditions":24865,"interventions":24866},[92],[2798,2799],[2752,2788],{"trials":24868,"activeCount":103},[24869],{"nctId":2849,"briefTitle":2850,"status":134,"phases":24870,"primaryCompletion":2852,"completion":2853,"start":2854,"enrollment":2855,"conditions":24871,"interventions":24872},[93],[2857],[2752,2788,2859,2788],{"trials":24874,"activeCount":103},[],{"trials":24876,"activeCount":103},[],{"intervention":24537,"totalTrials":1630,"cells":24878},{"EARLY_PHASE1":24879,"PHASE1":24881,"PHASE2":24883,"PHASE3":24885,"PHASE4":24903,"NA":24905},{"trials":24880,"activeCount":103},[],{"trials":24882,"activeCount":103},[],{"trials":24884,"activeCount":103},[],{"trials":24886,"activeCount":103},[24887,24891,24895,24899],{"nctId":24531,"briefTitle":24532,"status":123,"phases":24888,"primaryCompletion":880,"completion":880,"start":4707,"enrollment":24534,"conditions":24889,"interventions":24890},[93],[15555],[24513,24537],{"nctId":24539,"briefTitle":24532,"status":123,"phases":24892,"primaryCompletion":964,"completion":964,"start":3400,"enrollment":19766,"conditions":24893,"interventions":24894},[93],[15555],[24513,24537],{"nctId":24544,"briefTitle":24545,"status":123,"phases":24896,"primaryCompletion":964,"completion":964,"start":4400,"enrollment":271,"conditions":24897,"interventions":24898},[93],[24],[24513,24537],{"nctId":24550,"briefTitle":24551,"status":123,"phases":24900,"primaryCompletion":964,"completion":964,"start":1024,"enrollment":24553,"conditions":24901,"interventions":24902},[93],[24],[24513,24537],{"trials":24904,"activeCount":103},[],{"trials":24906,"activeCount":103},[],{"intervention":24908,"totalTrials":317,"cells":24909},"Licarbazepine",{"EARLY_PHASE1":24910,"PHASE1":24912,"PHASE2":24914,"PHASE3":24916,"PHASE4":24938,"NA":24940},{"trials":24911,"activeCount":103},[],{"trials":24913,"activeCount":103},[],{"trials":24915,"activeCount":103},[],{"trials":24917,"activeCount":103},[24918,24926,24932],{"nctId":24919,"briefTitle":24920,"status":123,"phases":24921,"primaryCompletion":4437,"completion":4437,"start":4071,"enrollment":24922,"conditions":24923,"interventions":24925},"NCT00107926","Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder",[93],343,[24924],"Bipolar Disorder",[24908],{"nctId":24927,"briefTitle":24920,"status":123,"phases":24928,"primaryCompletion":3210,"completion":3210,"start":17497,"enrollment":24929,"conditions":24930,"interventions":24931},"NCT00099229",[93],320,[24924],[24908],{"nctId":24933,"briefTitle":24920,"status":123,"phases":24934,"primaryCompletion":4343,"completion":4343,"start":17497,"enrollment":24935,"conditions":24936,"interventions":24937},"NCT00107939",[93],453,[24924],[24908],{"trials":24939,"activeCount":103},[],{"trials":24941,"activeCount":103},[],{"intervention":4755,"totalTrials":317,"cells":24943},{"EARLY_PHASE1":24944,"PHASE1":24946,"PHASE2":24948,"PHASE3":24954,"PHASE4":24964,"NA":24966},{"trials":24945,"activeCount":103},[],{"trials":24947,"activeCount":103},[],{"trials":24949,"activeCount":103},[24950],{"nctId":7630,"briefTitle":7631,"status":123,"phases":24951,"primaryCompletion":4967,"completion":4967,"start":2795,"enrollment":1672,"conditions":24952,"interventions":24953},[92],[4701],[4755,7635,7636,7637,4769],{"trials":24955,"activeCount":103},[24956,24960],{"nctId":7659,"briefTitle":7660,"status":123,"phases":24957,"primaryCompletion":4524,"completion":4524,"start":4975,"enrollment":524,"conditions":24958,"interventions":24959},[93],[7663],[7636,7665,4753,4755,4769],{"nctId":4747,"briefTitle":4748,"status":123,"phases":24961,"primaryCompletion":4410,"completion":4410,"start":4317,"enrollment":4750,"conditions":24962,"interventions":24963},[93],[4691],[196,4753,4754,4755],{"trials":24965,"activeCount":103},[],{"trials":24967,"activeCount":103},[],{"intervention":24969,"totalTrials":317,"cells":24970},"Famciclovir",{"EARLY_PHASE1":24971,"PHASE1":24973,"PHASE2":24975,"PHASE3":24977,"PHASE4":25003,"NA":25005},{"trials":24972,"activeCount":103},[],{"trials":24974,"activeCount":103},[],{"trials":24976,"activeCount":103},[],{"trials":24978,"activeCount":103},[24979,24988,24995],{"nctId":24980,"briefTitle":24981,"status":123,"phases":24982,"primaryCompletion":24983,"completion":24983,"start":24984,"enrollment":17433,"conditions":24985,"interventions":24987},"NCT00878072","Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis",[92,93],"2010-06-02","2009-03-25",[24986],"Herpes Labialis",[24969],{"nctId":24989,"briefTitle":24990,"status":123,"phases":24991,"primaryCompletion":4556,"completion":4556,"start":5026,"enrollment":223,"conditions":24992,"interventions":24994},"NCT00098059","Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection",[93],[24993],"Herpes Simplex",[24969],{"nctId":24996,"briefTitle":24997,"status":123,"phases":24998,"primaryCompletion":16570,"completion":16570,"start":865,"enrollment":15188,"conditions":24999,"interventions":25001},"NCT00306787","Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes",[93],[25000],"Genital Herpes",[24969,25002],"Valacyclovir",{"trials":25004,"activeCount":103},[],{"trials":25006,"activeCount":103},[],{"intervention":16370,"totalTrials":317,"cells":25008},{"EARLY_PHASE1":25009,"PHASE1":25011,"PHASE2":25013,"PHASE3":25015,"PHASE4":25029,"NA":25031},{"trials":25010,"activeCount":103},[],{"trials":25012,"activeCount":103},[],{"trials":25014,"activeCount":103},[],{"trials":25016,"activeCount":103},[25017,25021,25025],{"nctId":24713,"briefTitle":24714,"status":123,"phases":25018,"primaryCompletion":3473,"completion":3473,"start":3194,"enrollment":24716,"conditions":25019,"interventions":25020},[93],[18],[24529,16370],{"nctId":16365,"briefTitle":16366,"status":123,"phases":25022,"primaryCompletion":864,"completion":864,"start":964,"enrollment":1290,"conditions":25023,"interventions":25024},[93],[24],[7850,16370],{"nctId":24731,"briefTitle":24732,"status":123,"phases":25026,"primaryCompletion":10499,"completion":10499,"start":917,"enrollment":16,"conditions":25027,"interventions":25028},[93],[24],[24529,16370],{"trials":25030,"activeCount":103},[],{"trials":25032,"activeCount":103},[],{"intervention":25034,"totalTrials":317,"cells":25035},"Triamcinolone acetonide",{"EARLY_PHASE1":25036,"PHASE1":25038,"PHASE2":25040,"PHASE3":25042,"PHASE4":25073,"NA":25075},{"trials":25037,"activeCount":103},[],{"trials":25039,"activeCount":103},[],{"trials":25041,"activeCount":103},[],{"trials":25043,"activeCount":103},[25044,25054,25064],{"nctId":25045,"briefTitle":25046,"status":123,"phases":25047,"primaryCompletion":917,"start":8370,"enrollment":2810,"conditions":25048,"interventions":25051},"NCT00242580","A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib",[93],[25049,25050],"Macular Degeneration","Choroidal Neovascularization",[25052,25053,25034],"Verteporfin photodynamic therapy","Pegaptanib",{"nctId":25055,"briefTitle":25056,"status":134,"phases":25057,"primaryCompletion":25058,"completion":25058,"start":25059,"enrollment":2948,"conditions":25060,"interventions":25062},"NCT01362608","Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and\u002F or Colchicine Are Contraindicated, Not Tolerated or Ineffective",[93],"2015-05-19","2011-06-20",[25061],"Gouty Arthritis",[25063,25034],"Canakinumab, ACZ885",{"nctId":25065,"briefTitle":25066,"status":123,"phases":25067,"primaryCompletion":3243,"completion":3243,"start":3784,"enrollment":1839,"conditions":25068,"interventions":25069},"NCT01356602","Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients",[93],[23437],[25070,25071,25072],"Canakinumab pre-filled syringe","Canakinumab lyophilized powder","Triamcinolone Acetonide",{"trials":25074,"activeCount":103},[],{"trials":25076,"activeCount":103},[],{"intervention":13402,"totalTrials":317,"cells":25078},{"EARLY_PHASE1":25079,"PHASE1":25081,"PHASE2":25087,"PHASE3":25093,"PHASE4":25099,"NA":25101},{"trials":25080,"activeCount":103},[],{"trials":25082,"activeCount":103},[25083],{"nctId":13396,"briefTitle":13397,"status":123,"phases":25084,"primaryCompletion":9910,"completion":9910,"start":13399,"enrollment":1611,"conditions":25085,"interventions":25086},[91],[4412],[4389,13402],{"trials":25088,"activeCount":103},[25089],{"nctId":23731,"briefTitle":23732,"status":123,"phases":25090,"primaryCompletion":1781,"completion":1781,"start":4620,"enrollment":3705,"conditions":25091,"interventions":25092},[92],[4412],[649,23736],{"trials":25094,"activeCount":103},[25095],{"nctId":23740,"briefTitle":23741,"status":123,"phases":25096,"primaryCompletion":3731,"completion":3731,"start":895,"enrollment":23743,"conditions":25097,"interventions":25098},[93],[4352],[611,13402],{"trials":25100,"activeCount":103},[],{"trials":25102,"activeCount":103},[],{"intervention":25104,"totalTrials":317,"cells":25105},"Secukinumab 150mg",{"EARLY_PHASE1":25106,"PHASE1":25108,"PHASE2":25110,"PHASE3":25112,"PHASE4":25140,"NA":25142},{"trials":25107,"activeCount":103},[],{"trials":25109,"activeCount":103},[],{"trials":25111,"activeCount":103},[],{"trials":25113,"activeCount":103},[25114,25125,25133],{"nctId":25115,"briefTitle":25116,"status":123,"phases":25117,"primaryCompletion":25118,"completion":25119,"start":25120,"enrollment":4855,"conditions":25121,"interventions":25123},"NCT02008890","Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab",[93],"2014-11-24","2017-05-31","2013-12-26",[25122],"Palmoplantar Pustular Psoriasis",[25124,25104],"Secukinumab 300mg",{"nctId":25126,"briefTitle":25127,"status":123,"phases":25128,"primaryCompletion":15283,"completion":15283,"start":4301,"enrollment":4557,"conditions":25129,"interventions":25130},"NCT01412944","Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis",[93],[22924],[25131,25132],"secukinumab 150mg","secukinumab 10mg\u002Fkg i.v. regimen",{"nctId":25134,"briefTitle":25135,"status":123,"phases":25136,"primaryCompletion":25137,"completion":25137,"start":21762,"enrollment":4976,"conditions":25138,"interventions":25139},"NCT01636687","Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)",[93],"2016-10-27",[22924],[25104,25124],{"trials":25141,"activeCount":103},[],{"trials":25143,"activeCount":103},[],{"intervention":25145,"totalTrials":317,"cells":25146},"Vehicle",{"EARLY_PHASE1":25147,"PHASE1":25149,"PHASE2":25151,"PHASE3":25169,"PHASE4":25179,"NA":25181},{"trials":25148,"activeCount":103},[],{"trials":25150,"activeCount":103},[],{"trials":25152,"activeCount":103},[25153,25162],{"nctId":25154,"briefTitle":25155,"status":123,"phases":25156,"primaryCompletion":3845,"start":4845,"enrollment":3343,"conditions":25157,"interventions":25159},"NCT00961896","A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients",[92],[25158],"Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients",[25145,25160,25161],"LDE225 0.25%","LDE225 0.75%",{"nctId":25163,"briefTitle":25164,"status":134,"phases":25165,"primaryCompletion":3760,"completion":3760,"start":3271,"enrollment":2342,"conditions":25166,"interventions":25168},"NCT01033019","To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)",[92],[25167],"Sporadic Superficial and Nodular Skin Basal Cell Carcinomas",[25161,25145],{"trials":25170,"activeCount":103},[25171],{"nctId":25172,"briefTitle":25173,"status":390,"phases":25174,"enrollment":103,"conditions":25175,"interventions":25177},"NCT03070691","Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)",[92,93],[25176],"Basal Cell Carcinoma",[25178,25145],"LDE225B",{"trials":25180,"activeCount":103},[],{"trials":25182,"activeCount":103},[],{"intervention":18559,"totalTrials":317,"cells":25184},{"EARLY_PHASE1":25185,"PHASE1":25187,"PHASE2":25189,"PHASE3":25191,"PHASE4":25205,"NA":25207},{"trials":25186,"activeCount":103},[],{"trials":25188,"activeCount":103},[],{"trials":25190,"activeCount":103},[],{"trials":25192,"activeCount":103},[25193,25197,25201],{"nctId":19763,"briefTitle":19764,"status":123,"phases":25194,"primaryCompletion":4642,"completion":4642,"start":3254,"enrollment":19766,"conditions":25195,"interventions":25196},[93],[21],[18603,18559,18594],{"nctId":18553,"briefTitle":18554,"status":123,"phases":25198,"primaryCompletion":3410,"completion":3410,"start":5696,"enrollment":18556,"conditions":25199,"interventions":25200},[93],[21],[18542,18559,18560],{"nctId":18562,"briefTitle":18563,"status":123,"phases":25202,"primaryCompletion":1025,"completion":1025,"start":3195,"enrollment":18565,"conditions":25203,"interventions":25204},[92,93],[17007],[18568,18569,18570,18571,18560,18559,18572,18542],{"trials":25206,"activeCount":103},[],{"trials":25208,"activeCount":103},[],{"intervention":15565,"totalTrials":317,"cells":25210},{"EARLY_PHASE1":25211,"PHASE1":25213,"PHASE2":25215,"PHASE3":25217,"PHASE4":25231,"NA":25233},{"trials":25212,"activeCount":103},[],{"trials":25214,"activeCount":103},[],{"trials":25216,"activeCount":103},[],{"trials":25218,"activeCount":103},[25219,25223,25227],{"nctId":15558,"briefTitle":15559,"status":123,"phases":25220,"primaryCompletion":3759,"completion":3759,"start":4081,"enrollment":15561,"conditions":25221,"interventions":25222},[93],[24],[15524,15541,15564,15565],{"nctId":15582,"briefTitle":15583,"status":123,"phases":25224,"primaryCompletion":3482,"completion":3482,"start":1715,"enrollment":15585,"conditions":25225,"interventions":25226},[93],[24],[15524,15588,15565],{"nctId":16128,"briefTitle":16129,"status":123,"phases":25228,"primaryCompletion":1670,"completion":1670,"start":4524,"enrollment":16131,"conditions":25229,"interventions":25230},[93],[24],[15541,15588,16134],{"trials":25232,"activeCount":103},[],{"trials":25234,"activeCount":103},[],{"intervention":2494,"totalTrials":317,"cells":25236},{"EARLY_PHASE1":25237,"PHASE1":25239,"PHASE2":25241,"PHASE3":25243,"PHASE4":25257,"NA":25259},{"trials":25238,"activeCount":103},[],{"trials":25240,"activeCount":103},[],{"trials":25242,"activeCount":103},[],{"trials":25244,"activeCount":103},[25245,25249,25253],{"nctId":2484,"briefTitle":2485,"status":123,"phases":25246,"primaryCompletion":2487,"completion":2488,"start":2489,"enrollment":2490,"conditions":25247,"interventions":25248},[93],[2492],[2341,2494],{"nctId":2496,"briefTitle":2497,"status":123,"phases":25250,"primaryCompletion":2499,"completion":2500,"start":2501,"enrollment":2502,"conditions":25251,"interventions":25252},[93],[2470],[2494,2341],{"nctId":2522,"briefTitle":2523,"status":123,"phases":25254,"primaryCompletion":2525,"completion":2525,"start":2526,"enrollment":1983,"conditions":25255,"interventions":25256},[93],[2369],[2341,2494],{"trials":25258,"activeCount":103},[],{"trials":25260,"activeCount":103},[],{"intervention":17687,"totalTrials":317,"cells":25262},{"EARLY_PHASE1":25263,"PHASE1":25265,"PHASE2":25267,"PHASE3":25269,"PHASE4":25290,"NA":25292},{"trials":25264,"activeCount":103},[],{"trials":25266,"activeCount":103},[],{"trials":25268,"activeCount":103},[],{"trials":25270,"activeCount":103},[25271,25275,25283],{"nctId":17678,"briefTitle":17679,"status":123,"phases":25272,"primaryCompletion":17681,"completion":17681,"start":17682,"enrollment":17683,"conditions":25273,"interventions":25274},[93],[17685],[17687,17634,17688],{"nctId":25276,"briefTitle":25277,"status":123,"phases":25278,"primaryCompletion":25279,"completion":25279,"start":402,"enrollment":25280,"conditions":25281,"interventions":25282},"NCT01948830","Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD",[93],"2015-11-19",650,[4458,25050],[17687,17687],{"nctId":25284,"briefTitle":25285,"status":134,"phases":25286,"primaryCompletion":664,"completion":664,"start":511,"enrollment":827,"conditions":25287,"interventions":25289},"NCT02032173","Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase",[93],[25288,25049,15049],"Macular Edema",[17687],{"trials":25291,"activeCount":103},[],{"trials":25293,"activeCount":103},[],{"intervention":23447,"totalTrials":317,"cells":25295},{"EARLY_PHASE1":25296,"PHASE1":25298,"PHASE2":25300,"PHASE3":25302,"PHASE4":25323,"NA":25325},{"trials":25297,"activeCount":103},[],{"trials":25299,"activeCount":103},[],{"trials":25301,"activeCount":103},[],{"trials":25303,"activeCount":103},[25304,25313,25317],{"nctId":25305,"briefTitle":25306,"status":123,"phases":25307,"primaryCompletion":5620,"completion":5620,"start":3271,"enrollment":25308,"conditions":25309,"interventions":25311},"NCT01029652","Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and\u002For Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study",[93],230,[25310],"Acute Gout",[25312,23447],"Canakinumab 150 mg",{"nctId":23441,"briefTitle":23442,"status":123,"phases":25314,"primaryCompletion":5114,"completion":5114,"start":3800,"enrollment":2948,"conditions":25315,"interventions":25316},[93],[23445],[10126,23447],{"nctId":25318,"briefTitle":25319,"status":123,"phases":25320,"primaryCompletion":926,"completion":1715,"start":964,"enrollment":1879,"conditions":25321,"interventions":25322},"NCT01080131","Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and\u002For Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.",[93],[25310],[25312,23447],{"trials":25324,"activeCount":103},[],{"trials":25326,"activeCount":103},[],{"intervention":7636,"totalTrials":213,"cells":25328},{"EARLY_PHASE1":25329,"PHASE1":25331,"PHASE2":25333,"PHASE3":25339,"PHASE4":25345,"NA":25347},{"trials":25330,"activeCount":103},[],{"trials":25332,"activeCount":103},[],{"trials":25334,"activeCount":103},[25335],{"nctId":7630,"briefTitle":7631,"status":123,"phases":25336,"primaryCompletion":4967,"completion":4967,"start":2795,"enrollment":1672,"conditions":25337,"interventions":25338},[92],[4701],[4755,7635,7636,7637,4769],{"trials":25340,"activeCount":103},[25341],{"nctId":7659,"briefTitle":7660,"status":123,"phases":25342,"primaryCompletion":4524,"completion":4524,"start":4975,"enrollment":524,"conditions":25343,"interventions":25344},[93],[7663],[7636,7665,4753,4755,4769],{"trials":25346,"activeCount":103},[],{"trials":25348,"activeCount":103},[],{"intervention":7665,"totalTrials":213,"cells":25350},{"EARLY_PHASE1":25351,"PHASE1":25353,"PHASE2":25355,"PHASE3":25365,"PHASE4":25371,"NA":25373},{"trials":25352,"activeCount":103},[],{"trials":25354,"activeCount":103},[],{"trials":25356,"activeCount":103},[25357],{"nctId":25358,"briefTitle":25359,"status":123,"phases":25360,"primaryCompletion":3383,"completion":3383,"start":4317,"enrollment":25361,"conditions":25362,"interventions":25363},"NCT00504543","Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients",[92],311,[4691],[4330,25364,7665],"Certican",{"trials":25366,"activeCount":103},[25367],{"nctId":7659,"briefTitle":7660,"status":123,"phases":25368,"primaryCompletion":4524,"completion":4524,"start":4975,"enrollment":524,"conditions":25369,"interventions":25370},[93],[7663],[7636,7665,4753,4755,4769],{"trials":25372,"activeCount":103},[],{"trials":25374,"activeCount":103},[],{"intervention":25376,"totalTrials":213,"cells":25377},"CNP520",{"EARLY_PHASE1":25378,"PHASE1":25380,"PHASE2":25382,"PHASE3":25390,"PHASE4":25402,"NA":25404},{"trials":25379,"activeCount":103},[],{"trials":25381,"activeCount":103},[],{"trials":25383,"activeCount":103},[25384],{"nctId":25385,"briefTitle":25386,"status":123,"phases":25387,"primaryCompletion":7960,"completion":7960,"start":17122,"enrollment":3288,"conditions":25388,"interventions":25389},"NCT02576639","Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age",[92],[10401],[25376],{"trials":25391,"activeCount":103},[25392],{"nctId":25393,"briefTitle":25394,"status":134,"phases":25395,"primaryCompletion":25396,"completion":25396,"start":25397,"enrollment":2845,"conditions":25398,"interventions":25400},"NCT02565511","A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease",[92,93],"2020-04-30","2015-11-30",[25399],"Alzheimers Disease",[25401,25376],"CAD106 Immunotherapy",{"trials":25403,"activeCount":103},[],{"trials":25405,"activeCount":103},[],{"intervention":1775,"totalTrials":213,"cells":25407},{"EARLY_PHASE1":25408,"PHASE1":25410,"PHASE2":25412,"PHASE3":25414,"PHASE4":25424,"NA":25426},{"trials":25409,"activeCount":103},[],{"trials":25411,"activeCount":103},[],{"trials":25413,"activeCount":103},[],{"trials":25415,"activeCount":103},[25416,25420],{"nctId":1766,"briefTitle":1767,"status":123,"phases":25417,"primaryCompletion":1769,"completion":1769,"start":1770,"enrollment":1771,"conditions":25418,"interventions":25419},[93],[1773],[1659,1775],{"nctId":1927,"briefTitle":1928,"status":123,"phases":25421,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1932,"conditions":25422,"interventions":25423},[93],[1821],[1659,1775],{"trials":25425,"activeCount":103},[],{"trials":25427,"activeCount":103},[],{"intervention":10531,"totalTrials":213,"cells":25429},{"EARLY_PHASE1":25430,"PHASE1":25432,"PHASE2":25434,"PHASE3":25440,"PHASE4":25446,"NA":25448},{"trials":25431,"activeCount":103},[],{"trials":25433,"activeCount":103},[],{"trials":25435,"activeCount":103},[25436],{"nctId":10523,"briefTitle":10524,"status":123,"phases":25437,"primaryCompletion":4410,"completion":8048,"start":988,"enrollment":10526,"conditions":25438,"interventions":25439},[92],[1654],[4432,10529,10530,10531,5639],{"trials":25441,"activeCount":103},[25442],{"nctId":15055,"briefTitle":15056,"status":123,"phases":25443,"primaryCompletion":917,"completion":917,"start":15058,"enrollment":6165,"conditions":25444,"interventions":25445},[93],[30],[15051,10531],{"trials":25447,"activeCount":103},[],{"trials":25449,"activeCount":103},[],{"intervention":25451,"totalTrials":213,"cells":25452},"Agomelatine",{"EARLY_PHASE1":25453,"PHASE1":25455,"PHASE2":25457,"PHASE3":25459,"PHASE4":25475,"NA":25477},{"trials":25454,"activeCount":103},[],{"trials":25456,"activeCount":103},[],{"trials":25458,"activeCount":103},[],{"trials":25460,"activeCount":103},[25461,25468],{"nctId":25462,"briefTitle":25463,"status":123,"phases":25464,"primaryCompletion":2034,"completion":2034,"start":853,"enrollment":16842,"conditions":25465,"interventions":25467},"NCT01110902","Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)",[93],[25466],"Major Depressive Disorder",[25451],{"nctId":25469,"briefTitle":25470,"status":123,"phases":25471,"primaryCompletion":4620,"start":853,"enrollment":25472,"conditions":25473,"interventions":25474},"NCT01110889","Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder",[93],582,[25466],[25451,25451],{"trials":25476,"activeCount":103},[],{"trials":25478,"activeCount":103},[],{"intervention":10021,"totalTrials":213,"cells":25480},{"EARLY_PHASE1":25481,"PHASE1":25483,"PHASE2":25485,"PHASE3":25487,"PHASE4":25500,"NA":25502},{"trials":25482,"activeCount":103},[],{"trials":25484,"activeCount":103},[],{"trials":25486,"activeCount":103},[],{"trials":25488,"activeCount":103},[25489,25493],{"nctId":10013,"briefTitle":10014,"status":123,"phases":25490,"primaryCompletion":10016,"completion":10016,"start":10017,"enrollment":6547,"conditions":25491,"interventions":25492},[93],[6705,1654,10019],[10021,6907],{"nctId":25494,"briefTitle":25495,"status":123,"phases":25496,"primaryCompletion":6349,"completion":6349,"start":25497,"enrollment":1485,"conditions":25498,"interventions":25499},"NCT04838626","Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection",[92,93],"2021-09-07",[6705,1654],[10021],{"trials":25501,"activeCount":103},[],{"trials":25503,"activeCount":103},[],{"intervention":1270,"totalTrials":213,"cells":25505},{"EARLY_PHASE1":25506,"PHASE1":25508,"PHASE2":25510,"PHASE3":25512,"PHASE4":25526,"NA":25528},{"trials":25507,"activeCount":103},[],{"trials":25509,"activeCount":103},[],{"trials":25511,"activeCount":103},[],{"trials":25513,"activeCount":103},[25514,25522],{"nctId":25515,"briefTitle":25516,"status":123,"phases":25517,"primaryCompletion":13341,"completion":25518,"start":5234,"enrollment":5681,"conditions":25519,"interventions":25520},"NCT03851705","A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)",[93],"2021-09-09",[5315],[25521,1270],"Inclisiran Sodium for",{"nctId":1261,"briefTitle":1262,"status":123,"phases":25523,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":1267,"conditions":25524,"interventions":25525},[93],[36],[1078,173,1270],{"trials":25527,"activeCount":103},[],{"trials":25529,"activeCount":103},[],{"intervention":25531,"totalTrials":213,"cells":25532},"AGO178",{"EARLY_PHASE1":25533,"PHASE1":25535,"PHASE2":25545,"PHASE3":25547,"PHASE4":25556,"NA":25558},{"trials":25534,"activeCount":103},[],{"trials":25536,"activeCount":103},[25537],{"nctId":25538,"briefTitle":25539,"status":123,"phases":25540,"primaryCompletion":25541,"completion":25541,"start":25542,"enrollment":7257,"conditions":25543,"interventions":25544},"NCT01531309","Pharmacokinetics of AGO178 in Participants With Liver Impairment",[91],"2011-09-02","2011-02-08",[2625],[25531],{"trials":25546,"activeCount":103},[],{"trials":25548,"activeCount":103},[25549],{"nctId":25550,"briefTitle":25551,"status":134,"phases":25552,"primaryCompletion":1715,"completion":1715,"start":3351,"enrollment":25553,"conditions":25554,"interventions":25555},"NCT01156415","Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)",[93],837,[25466],[25531,25531],{"trials":25557,"activeCount":103},[],{"trials":25559,"activeCount":103},[],{"intervention":25561,"totalTrials":213,"cells":25562},"oxcarbazepine",{"EARLY_PHASE1":25563,"PHASE1":25565,"PHASE2":25567,"PHASE3":25569,"PHASE4":25584,"NA":25586},{"trials":25564,"activeCount":103},[],{"trials":25566,"activeCount":103},[],{"trials":25568,"activeCount":103},[],{"trials":25570,"activeCount":103},[25571,25578],{"nctId":25572,"briefTitle":25573,"status":123,"phases":25574,"primaryCompletion":9820,"completion":9820,"start":904,"enrollment":3483,"conditions":25575,"interventions":25577},"NCT00050947","Pediatric Epilepsy Study",[93],[25576],"Epilepsy",[25561],{"nctId":25579,"briefTitle":25573,"status":123,"phases":25580,"primaryCompletion":16936,"completion":16936,"start":18086,"enrollment":192,"conditions":25581,"interventions":25583},"NCT00050934",[93],[25576,25582],"Epilepsies, Partial",[25561],{"trials":25585,"activeCount":103},[],{"trials":25587,"activeCount":103},[],{"intervention":25589,"totalTrials":213,"cells":25590},"RTH258\u002FBrolucizumab",{"EARLY_PHASE1":25591,"PHASE1":25593,"PHASE2":25595,"PHASE3":25597,"PHASE4":25615,"NA":25617},{"trials":25592,"activeCount":103},[],{"trials":25594,"activeCount":103},[],{"trials":25596,"activeCount":103},[],{"trials":25598,"activeCount":103},[25599,25607],{"nctId":25600,"briefTitle":25601,"status":123,"phases":25602,"primaryCompletion":25603,"completion":2416,"start":13147,"enrollment":690,"conditions":25604,"interventions":25606},"NCT04239027","A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration",[93],"2022-05-23",[25605],"Neovascular Age Related Macular Degeneration",[25589],{"nctId":25608,"briefTitle":25609,"status":123,"phases":25610,"primaryCompletion":25611,"completion":256,"start":25612,"enrollment":24370,"conditions":25613,"interventions":25614},"NCT04264819","Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration",[93],"2022-10-05","2020-12-14",[18348],[25589],{"trials":25616,"activeCount":103},[],{"trials":25618,"activeCount":103},[],{"intervention":25620,"totalTrials":213,"cells":25621},"EPO906",{"EARLY_PHASE1":25622,"PHASE1":25624,"PHASE2":25632,"PHASE3":25634,"PHASE4":25645,"NA":25647},{"trials":25623,"activeCount":103},[],{"trials":25625,"activeCount":103},[25626],{"nctId":25627,"briefTitle":25628,"status":123,"phases":25629,"primaryCompletion":3195,"completion":3195,"start":4732,"enrollment":1423,"conditions":25630,"interventions":25631},"NCT00969046","Dose-Escalation Study in Advanced Colon Cancer Patients",[91],[23061],[25620],{"trials":25633,"activeCount":103},[],{"trials":25635,"activeCount":103},[25636],{"nctId":25637,"briefTitle":25638,"status":123,"phases":25639,"primaryCompletion":880,"start":918,"enrollment":25640,"conditions":25641,"interventions":25643},"NCT00262990","Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer",[93],829,[6375,25642,8372],"Fallopian Tube Cancer",[25620,25644],"doxorubicin",{"trials":25646,"activeCount":103},[],{"trials":25648,"activeCount":103},[],{"intervention":25124,"totalTrials":213,"cells":25650},{"EARLY_PHASE1":25651,"PHASE1":25653,"PHASE2":25655,"PHASE3":25657,"PHASE4":25667,"NA":25669},{"trials":25652,"activeCount":103},[],{"trials":25654,"activeCount":103},[],{"trials":25656,"activeCount":103},[],{"trials":25658,"activeCount":103},[25659,25663],{"nctId":25115,"briefTitle":25116,"status":123,"phases":25660,"primaryCompletion":25118,"completion":25119,"start":25120,"enrollment":4855,"conditions":25661,"interventions":25662},[93],[25122],[25124,25104],{"nctId":25134,"briefTitle":25135,"status":123,"phases":25664,"primaryCompletion":25137,"completion":25137,"start":21762,"enrollment":4976,"conditions":25665,"interventions":25666},[93],[22924],[25104,25124],{"trials":25668,"activeCount":103},[],{"trials":25670,"activeCount":103},[],{"intervention":25672,"totalTrials":213,"cells":25673},"Risedronate",{"EARLY_PHASE1":25674,"PHASE1":25676,"PHASE2":25678,"PHASE3":25680,"PHASE4":25696,"NA":25698},{"trials":25675,"activeCount":103},[],{"trials":25677,"activeCount":103},[],{"trials":25679,"activeCount":103},[],{"trials":25681,"activeCount":103},[25682,25690],{"nctId":25683,"briefTitle":25684,"status":123,"phases":25685,"primaryCompletion":17396,"completion":3383,"start":997,"enrollment":2910,"conditions":25686,"interventions":25688},"NCT00103740","Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",[93],[25687],"Paget's Disease of Bone",[17147,25672,25689],"Calcium and vitamin D supplements",{"nctId":25691,"briefTitle":25684,"status":123,"phases":25692,"primaryCompletion":845,"completion":3383,"start":25693,"enrollment":13531,"conditions":25694,"interventions":25695},"NCT00051636",[93],"2001-01",[25687],[955,25672],{"trials":25697,"activeCount":103},[],{"trials":25699,"activeCount":103},[],{"intervention":25701,"totalTrials":213,"cells":25702},"ABL001",{"EARLY_PHASE1":25703,"PHASE1":25705,"PHASE2":25715,"PHASE3":25717,"PHASE4":25726,"NA":25728},{"trials":25704,"activeCount":103},[],{"trials":25706,"activeCount":103},[25707],{"nctId":25708,"briefTitle":25709,"status":123,"phases":25710,"primaryCompletion":25711,"completion":25711,"start":25712,"enrollment":7257,"conditions":25713,"interventions":25714},"NCT02857868","A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects",[91],"2017-07-20","2016-05-03",[2625],[25701],{"trials":25716,"activeCount":103},[],{"trials":25718,"activeCount":103},[25719],{"nctId":25720,"briefTitle":25721,"status":123,"phases":25722,"primaryCompletion":25723,"completion":5828,"start":7450,"enrollment":5681,"conditions":25724,"interventions":25725},"NCT04666259","Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation",[93],"2023-06-20",[3345],[25701],{"trials":25727,"activeCount":103},[],{"trials":25729,"activeCount":103},[],{"intervention":25731,"totalTrials":213,"cells":25732},"AIN457 150 mg",{"EARLY_PHASE1":25733,"PHASE1":25735,"PHASE2":25737,"PHASE3":25739,"PHASE4":25759,"NA":25761},{"trials":25734,"activeCount":103},[],{"trials":25736,"activeCount":103},[],{"trials":25738,"activeCount":103},[],{"trials":25740,"activeCount":103},[25741,25750],{"nctId":25742,"briefTitle":25743,"status":123,"phases":25744,"primaryCompletion":16095,"completion":16095,"start":25745,"enrollment":23538,"conditions":25746,"interventions":25748},"NCT01640951","4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis",[93],"2012-09-16",[25747],"Moderate to Severe Chronic Plaque-Type Psoriasis",[25731,25749],"AIN457 300 mg",{"nctId":25751,"briefTitle":25752,"status":123,"phases":25753,"primaryCompletion":25754,"completion":2045,"start":25755,"enrollment":18792,"conditions":25756,"interventions":25757},"NCT03259074","Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)",[93],"2021-11-12","2017-11-30",[1974],[25758,25731],"GP2017",{"trials":25760,"activeCount":103},[],{"trials":25762,"activeCount":103},[],{"intervention":25749,"totalTrials":213,"cells":25764},{"EARLY_PHASE1":25765,"PHASE1":25767,"PHASE2":25769,"PHASE3":25771,"PHASE4":25787,"NA":25789},{"trials":25766,"activeCount":103},[],{"trials":25768,"activeCount":103},[],{"trials":25770,"activeCount":103},[],{"trials":25772,"activeCount":103},[25773,25777],{"nctId":25742,"briefTitle":25743,"status":123,"phases":25774,"primaryCompletion":16095,"completion":16095,"start":25745,"enrollment":23538,"conditions":25775,"interventions":25776},[93],[25747],[25731,25749],{"nctId":25778,"briefTitle":25779,"status":123,"phases":25780,"primaryCompletion":166,"completion":166,"start":25781,"enrollment":25782,"conditions":25783,"interventions":25785},"NCT02074982","Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis",[93],"2014-02-26",676,[25784],"Chronic Plaque Type Psoriasis",[25749,25786],"ustekinumab 45\u002F90 mg",{"trials":25788,"activeCount":103},[],{"trials":25790,"activeCount":103},[],{"intervention":18594,"totalTrials":213,"cells":25792},{"EARLY_PHASE1":25793,"PHASE1":25795,"PHASE2":25797,"PHASE3":25799,"PHASE4":25809,"NA":25811},{"trials":25794,"activeCount":103},[],{"trials":25796,"activeCount":103},[],{"trials":25798,"activeCount":103},[],{"trials":25800,"activeCount":103},[25801,25805],{"nctId":19763,"briefTitle":19764,"status":123,"phases":25802,"primaryCompletion":4642,"completion":4642,"start":3254,"enrollment":19766,"conditions":25803,"interventions":25804},[93],[21],[18603,18559,18594],{"nctId":18588,"briefTitle":18589,"status":123,"phases":25806,"primaryCompletion":4642,"completion":4642,"start":3254,"enrollment":18591,"conditions":25807,"interventions":25808},[93],[17007],[18594,18542],{"trials":25810,"activeCount":103},[],{"trials":25812,"activeCount":103},[],{"intervention":25814,"totalTrials":213,"cells":25815},"CDZ173",{"EARLY_PHASE1":25816,"PHASE1":25818,"PHASE2":25820,"PHASE3":25828,"PHASE4":25839,"NA":25841},{"trials":25817,"activeCount":103},[],{"trials":25819,"activeCount":103},[],{"trials":25821,"activeCount":103},[25822],{"nctId":25823,"briefTitle":25824,"status":123,"phases":25825,"primaryCompletion":4474,"completion":4474,"start":3319,"enrollment":2439,"conditions":25826,"interventions":25827},"NCT02775916","Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome",[92],[6558],[25814],{"trials":25829,"activeCount":103},[25830],{"nctId":25831,"briefTitle":25832,"status":123,"phases":25833,"primaryCompletion":25834,"completion":25834,"start":25835,"enrollment":5612,"conditions":25836,"interventions":25838},"NCT02435173","Study of Efficacy of CDZ173 in Patients With APDS\u002FPASLI",[92,93],"2021-08-16","2015-08-24",[25837],"Common Variable Immunodeficiency (CVID), APDS \u002F PASLI",[25814],{"trials":25840,"activeCount":103},[],{"trials":25842,"activeCount":103},[],{"intervention":18350,"totalTrials":213,"cells":25844},{"EARLY_PHASE1":25845,"PHASE1":25847,"PHASE2":25849,"PHASE3":25851,"PHASE4":25864,"NA":25866},{"trials":25846,"activeCount":103},[],{"trials":25848,"activeCount":103},[],{"trials":25850,"activeCount":103},[],{"trials":25852,"activeCount":103},[25853,25860],{"nctId":25854,"briefTitle":25855,"status":123,"phases":25856,"primaryCompletion":18007,"completion":18007,"start":10570,"enrollment":7438,"conditions":25857,"interventions":25859},"NCT05666804","Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy",[93],[25858],"Macular Polypoidal Choroidal Vasculopathy (PCV)",[18350,18350],{"nctId":18343,"briefTitle":18344,"status":123,"phases":25861,"primaryCompletion":326,"completion":326,"start":18346,"enrollment":1839,"conditions":25862,"interventions":25863},[93],[18348],[18350,17714],{"trials":25865,"activeCount":103},[],{"trials":25867,"activeCount":103},[],{"intervention":25869,"totalTrials":213,"cells":25870},"terbinafine",{"EARLY_PHASE1":25871,"PHASE1":25873,"PHASE2":25875,"PHASE3":25877,"PHASE4":25893,"NA":25895},{"trials":25872,"activeCount":103},[],{"trials":25874,"activeCount":103},[],{"trials":25876,"activeCount":103},[],{"trials":25878,"activeCount":103},[25879,25886],{"nctId":25880,"briefTitle":25881,"status":123,"phases":25882,"primaryCompletion":5062,"start":3657,"enrollment":6808,"conditions":25883,"interventions":25885},"NCT00443898","Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",[93],[25884],"Onychomycosis",[25869,25869],{"nctId":25887,"briefTitle":25888,"status":123,"phases":25889,"primaryCompletion":5062,"completion":5062,"start":3657,"enrollment":25890,"conditions":25891,"interventions":25892},"NCT00443820","Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",[93],526,[25884],[25869,25869],{"trials":25894,"activeCount":103},[],{"trials":25896,"activeCount":103},[],{"intervention":10802,"totalTrials":213,"cells":25898},{"EARLY_PHASE1":25899,"PHASE1":25901,"PHASE2":25903,"PHASE3":25909,"PHASE4":25915,"NA":25917},{"trials":25900,"activeCount":103},[],{"trials":25902,"activeCount":103},[],{"trials":25904,"activeCount":103},[25905],{"nctId":10794,"briefTitle":10795,"status":123,"phases":25906,"primaryCompletion":10797,"completion":10798,"start":10799,"enrollment":1034,"conditions":25907,"interventions":25908},[92],[1102],[10802,944,4451],{"trials":25910,"activeCount":103},[25911],{"nctId":4772,"briefTitle":4773,"status":123,"phases":25912,"primaryCompletion":4410,"completion":4410,"start":4400,"enrollment":4775,"conditions":25913,"interventions":25914},[93],[4777,435],[4305,4779,4780],{"trials":25916,"activeCount":103},[],{"trials":25918,"activeCount":103},[],{"intervention":25920,"totalTrials":213,"cells":25921},"Active comparator",{"EARLY_PHASE1":25922,"PHASE1":25924,"PHASE2":25926,"PHASE3":25938,"PHASE4":25944,"NA":25946},{"trials":25923,"activeCount":103},[],{"trials":25925,"activeCount":103},[],{"trials":25927,"activeCount":103},[25928],{"nctId":25929,"briefTitle":25930,"status":123,"phases":25931,"primaryCompletion":25932,"completion":25932,"start":2565,"enrollment":25933,"conditions":25934,"interventions":25936},"NCT02404389","Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients",[92],"2016-01-27",82,[25935],"Actinic Keratosis",[25937,25920],"Investigational Treatment",{"trials":25939,"activeCount":103},[25940],{"nctId":19143,"briefTitle":19144,"status":123,"phases":25941,"primaryCompletion":4515,"completion":4515,"start":3759,"enrollment":19146,"conditions":25942,"interventions":25943},[93],[10401],[19149,19132],{"trials":25945,"activeCount":103},[],{"trials":25947,"activeCount":103},[],{"intervention":25949,"totalTrials":213,"cells":25950},"Imatinib mesilate",{"EARLY_PHASE1":25951,"PHASE1":25953,"PHASE2":25955,"PHASE3":25964,"PHASE4":25970,"NA":25972},{"trials":25952,"activeCount":103},[],{"trials":25954,"activeCount":103},[],{"trials":25956,"activeCount":103},[25957],{"nctId":25958,"briefTitle":25959,"status":123,"phases":25960,"primaryCompletion":1024,"start":3272,"enrollment":1495,"conditions":25961,"interventions":25963},"NCT00417807","Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors",[91,92],[25962],"Refractory Desmoplastic Small Round Cell Tumors",[25949],{"trials":25965,"activeCount":103},[25966],{"nctId":9883,"briefTitle":9884,"status":123,"phases":25967,"primaryCompletion":2795,"completion":2795,"start":905,"enrollment":9886,"conditions":25968,"interventions":25969},[93],[3228],[9889,9890,9823],{"trials":25971,"activeCount":103},[],{"trials":25973,"activeCount":103},[],{"intervention":25975,"totalTrials":213,"cells":25976},"Daptomycin",{"EARLY_PHASE1":25977,"PHASE1":25979,"PHASE2":25981,"PHASE3":25983,"PHASE4":26003,"NA":26005},{"trials":25978,"activeCount":103},[],{"trials":25980,"activeCount":103},[],{"trials":25982,"activeCount":103},[],{"trials":25984,"activeCount":103},[25985,25995],{"nctId":25986,"briefTitle":25987,"status":134,"phases":25988,"primaryCompletion":1025,"start":16010,"enrollment":524,"conditions":25989,"interventions":25992},"NCT00430937","Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections",[93],[25990,25991],"Skin Diseases, Infectious","Soft Tissue Infections",[25975,25993,25994],"Vancomycin","Teicoplanin",{"nctId":25996,"briefTitle":25997,"status":123,"phases":25998,"primaryCompletion":895,"completion":895,"start":964,"enrollment":1384,"conditions":25999,"interventions":26001},"NCT01184872","Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections",[93],[26000],"Infections",[25975,26002],"Vancomycin or Semi-Synthetic Penicillins",{"trials":26004,"activeCount":103},[],{"trials":26006,"activeCount":103},[],{"intervention":25993,"totalTrials":213,"cells":26008},{"EARLY_PHASE1":26009,"PHASE1":26011,"PHASE2":26013,"PHASE3":26023,"PHASE4":26029,"NA":26031},{"trials":26010,"activeCount":103},[],{"trials":26012,"activeCount":103},[],{"trials":26014,"activeCount":103},[26015],{"nctId":26016,"briefTitle":26017,"status":123,"phases":26018,"primaryCompletion":2033,"completion":2033,"start":5620,"enrollment":8239,"conditions":26019,"interventions":26021},"NCT01232595","Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections",[92],[26020],"Moderate Clostridium Difficile Infection",[26022,25993],"LFF571",{"trials":26024,"activeCount":103},[26025],{"nctId":25986,"briefTitle":25987,"status":134,"phases":26026,"primaryCompletion":1025,"start":16010,"enrollment":524,"conditions":26027,"interventions":26028},[93],[25990,25991],[25975,25993,25994],{"trials":26030,"activeCount":103},[],{"trials":26032,"activeCount":103},[],{"intervention":24821,"totalTrials":213,"cells":26034},{"EARLY_PHASE1":26035,"PHASE1":26037,"PHASE2":26043,"PHASE3":26045,"PHASE4":26052,"NA":26054},{"trials":26036,"activeCount":103},[],{"trials":26038,"activeCount":103},[26039],{"nctId":24816,"briefTitle":24817,"status":123,"phases":26040,"primaryCompletion":3473,"start":4070,"enrollment":22825,"conditions":26041,"interventions":26042},[91],[9634,24],[16268,24821,24822],{"trials":26044,"activeCount":103},[],{"trials":26046,"activeCount":103},[26047],{"nctId":26048,"briefTitle":24525,"status":123,"phases":26049,"primaryCompletion":5620,"completion":5620,"start":3400,"enrollment":18098,"conditions":26050,"interventions":26051},"NCT00876694",[93],[15555],[24821,24842],{"trials":26053,"activeCount":103},[],{"trials":26055,"activeCount":103},[],{"intervention":26057,"totalTrials":213,"cells":26058},"ciclosporin",{"EARLY_PHASE1":26059,"PHASE1":26061,"PHASE2":26063,"PHASE3":26065,"PHASE4":26080,"NA":26082},{"trials":26060,"activeCount":103},[],{"trials":26062,"activeCount":103},[],{"trials":26064,"activeCount":103},[],{"trials":26066,"activeCount":103},[26067,26074],{"nctId":26068,"briefTitle":26069,"status":123,"phases":26070,"primaryCompletion":996,"start":15058,"conditions":26071,"interventions":26073},"NCT00232076","Verification Study of Ciclosporin for Atopic Dermatitis",[93],[26072],"Severe Atopic Dermatitis",[26057],{"nctId":26075,"briefTitle":26076,"status":123,"phases":26077,"primaryCompletion":918,"start":15058,"conditions":26078,"interventions":26079},"NCT00232063","Long-term Study of Ciclosporin for Atopic Dermatitis",[93],[26072],[26057],{"trials":26081,"activeCount":103},[],{"trials":26083,"activeCount":103},[],{"intervention":26085,"totalTrials":213,"cells":26086},"Octreotide acetate in microspheres",{"EARLY_PHASE1":26087,"PHASE1":26089,"PHASE2":26091,"PHASE3":26093,"PHASE4":26107,"NA":26109},{"trials":26088,"activeCount":103},[],{"trials":26090,"activeCount":103},[],{"trials":26092,"activeCount":103},[],{"trials":26094,"activeCount":103},[26095,26101],{"nctId":26096,"briefTitle":26097,"status":134,"phases":26098,"primaryCompletion":844,"completion":844,"start":918,"enrollment":15930,"conditions":26099,"interventions":26100},"NCT00248131","Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy",[93],[17729],[26085],{"nctId":26102,"briefTitle":26103,"status":134,"phases":26104,"primaryCompletion":8091,"completion":8091,"start":918,"enrollment":151,"conditions":26105,"interventions":26106},"NCT00248157","Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy",[93],[17729],[26085],{"trials":26108,"activeCount":103},[],{"trials":26110,"activeCount":103},[],{"intervention":15605,"totalTrials":213,"cells":26112},{"EARLY_PHASE1":26113,"PHASE1":26115,"PHASE2":26117,"PHASE3":26119,"PHASE4":26129,"NA":26131},{"trials":26114,"activeCount":103},[],{"trials":26116,"activeCount":103},[],{"trials":26118,"activeCount":103},[],{"trials":26120,"activeCount":103},[26121,26125],{"nctId":15597,"briefTitle":15598,"status":123,"phases":26122,"primaryCompletion":15600,"completion":15600,"start":15601,"enrollment":15602,"conditions":26123,"interventions":26124},[93],[24],[15524,15605],{"nctId":15639,"briefTitle":15640,"status":123,"phases":26126,"primaryCompletion":15642,"completion":15642,"start":15643,"enrollment":15644,"conditions":26127,"interventions":26128},[93],[24],[15524,15605],{"trials":26130,"activeCount":103},[],{"trials":26132,"activeCount":103},[],{"intervention":16639,"totalTrials":213,"cells":26134},{"EARLY_PHASE1":26135,"PHASE1":26137,"PHASE2":26139,"PHASE3":26141,"PHASE4":26151,"NA":26153},{"trials":26136,"activeCount":103},[],{"trials":26138,"activeCount":103},[],{"trials":26140,"activeCount":103},[],{"trials":26142,"activeCount":103},[26143,26147],{"nctId":16633,"briefTitle":16634,"status":123,"phases":26144,"primaryCompletion":880,"start":5062,"enrollment":16636,"conditions":26145,"interventions":26146},[93],[30],[16639,15177],{"nctId":15185,"briefTitle":15186,"status":123,"phases":26148,"primaryCompletion":938,"completion":938,"start":4034,"enrollment":15188,"conditions":26149,"interventions":26150},[93],[30],[15051,13838,15191],{"trials":26152,"activeCount":103},[],{"trials":26154,"activeCount":103},[],{"intervention":7098,"totalTrials":213,"cells":26156},{"EARLY_PHASE1":26157,"PHASE1":26159,"PHASE2":26161,"PHASE3":26163,"PHASE4":26173,"NA":26175},{"trials":26158,"activeCount":103},[],{"trials":26160,"activeCount":103},[],{"trials":26162,"activeCount":103},[],{"trials":26164,"activeCount":103},[26165,26169],{"nctId":7089,"briefTitle":7090,"status":123,"phases":26166,"primaryCompletion":7092,"completion":7093,"start":7094,"enrollment":7095,"conditions":26167,"interventions":26168},[93],[2778],[7098,6188],{"nctId":7104,"briefTitle":7105,"status":123,"phases":26170,"primaryCompletion":7107,"completion":7108,"start":7109,"enrollment":7110,"conditions":26171,"interventions":26172},[93],[7112],[7098,6188],{"trials":26174,"activeCount":103},[],{"trials":26176,"activeCount":103},[],{"intervention":18560,"totalTrials":213,"cells":26178},{"EARLY_PHASE1":26179,"PHASE1":26181,"PHASE2":26183,"PHASE3":26185,"PHASE4":26195,"NA":26197},{"trials":26180,"activeCount":103},[],{"trials":26182,"activeCount":103},[],{"trials":26184,"activeCount":103},[],{"trials":26186,"activeCount":103},[26187,26191],{"nctId":18553,"briefTitle":18554,"status":123,"phases":26188,"primaryCompletion":3410,"completion":3410,"start":5696,"enrollment":18556,"conditions":26189,"interventions":26190},[93],[21],[18542,18559,18560],{"nctId":18562,"briefTitle":18563,"status":123,"phases":26192,"primaryCompletion":1025,"completion":1025,"start":3195,"enrollment":18565,"conditions":26193,"interventions":26194},[92,93],[17007],[18568,18569,18570,18571,18560,18559,18572,18542],{"trials":26196,"activeCount":103},[],{"trials":26198,"activeCount":103},[],{"intervention":25312,"totalTrials":213,"cells":26200},{"EARLY_PHASE1":26201,"PHASE1":26203,"PHASE2":26205,"PHASE3":26207,"PHASE4":26217,"NA":26219},{"trials":26202,"activeCount":103},[],{"trials":26204,"activeCount":103},[],{"trials":26206,"activeCount":103},[],{"trials":26208,"activeCount":103},[26209,26213],{"nctId":25305,"briefTitle":25306,"status":123,"phases":26210,"primaryCompletion":5620,"completion":5620,"start":3271,"enrollment":25308,"conditions":26211,"interventions":26212},[93],[25310],[25312,23447],{"nctId":25318,"briefTitle":25319,"status":123,"phases":26214,"primaryCompletion":926,"completion":1715,"start":964,"enrollment":1879,"conditions":26215,"interventions":26216},[93],[25310],[25312,23447],{"trials":26218,"activeCount":103},[],{"trials":26220,"activeCount":103},[],{"intervention":9946,"totalTrials":213,"cells":26222},{"EARLY_PHASE1":26223,"PHASE1":26225,"PHASE2":26227,"PHASE3":26233,"PHASE4":26239,"NA":26241},{"trials":26224,"activeCount":103},[],{"trials":26226,"activeCount":103},[],{"trials":26228,"activeCount":103},[26229],{"nctId":9938,"briefTitle":9939,"status":390,"phases":26230,"primaryCompletion":9941,"completion":9942,"start":1512,"enrollment":103,"conditions":26231,"interventions":26232},[92],[9944],[9946,1079,4321,9947,1168,8153,9948],{"trials":26234,"activeCount":103},[26235],{"nctId":9952,"briefTitle":9953,"status":390,"phases":26236,"primaryCompletion":9955,"completion":9956,"start":9957,"enrollment":103,"conditions":26237,"interventions":26238},[93],[5282],[9946,1079,8153,1168,5262,4375,4321,9947],{"trials":26240,"activeCount":103},[],{"trials":26242,"activeCount":103},[],{"intervention":18580,"totalTrials":213,"cells":26244},{"EARLY_PHASE1":26245,"PHASE1":26247,"PHASE2":26249,"PHASE3":26258,"PHASE4":26264,"NA":26266},{"trials":26246,"activeCount":103},[],{"trials":26248,"activeCount":103},[],{"trials":26250,"activeCount":103},[26251],{"nctId":26252,"briefTitle":26253,"status":123,"phases":26254,"primaryCompletion":1724,"completion":1724,"start":853,"enrollment":5612,"conditions":26255,"interventions":26256},"NCT01125514","A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure",[92],[15870],[18580,26257,18581],"Furosemide 60 mg",{"trials":26259,"activeCount":103},[26260],{"nctId":18574,"briefTitle":18575,"status":123,"phases":26261,"primaryCompletion":3410,"completion":3410,"start":3279,"enrollment":18577,"conditions":26262,"interventions":26263},[93],[21],[18580,18581,18542,18582,18583,18584,18585,18586],{"trials":26265,"activeCount":103},[],{"trials":26267,"activeCount":103},[],{"intervention":18581,"totalTrials":213,"cells":26269},{"EARLY_PHASE1":26270,"PHASE1":26272,"PHASE2":26274,"PHASE3":26280,"PHASE4":26286,"NA":26288},{"trials":26271,"activeCount":103},[],{"trials":26273,"activeCount":103},[],{"trials":26275,"activeCount":103},[26276],{"nctId":26252,"briefTitle":26253,"status":123,"phases":26277,"primaryCompletion":1724,"completion":1724,"start":853,"enrollment":5612,"conditions":26278,"interventions":26279},[92],[15870],[18580,26257,18581],{"trials":26281,"activeCount":103},[26282],{"nctId":18574,"briefTitle":18575,"status":123,"phases":26283,"primaryCompletion":3410,"completion":3410,"start":3279,"enrollment":18577,"conditions":26284,"interventions":26285},[93],[21],[18580,18581,18542,18582,18583,18584,18585,18586],{"trials":26287,"activeCount":103},[],{"trials":26289,"activeCount":103},[],{"intervention":24842,"totalTrials":213,"cells":26291},{"EARLY_PHASE1":26292,"PHASE1":26294,"PHASE2":26296,"PHASE3":26298,"PHASE4":26308,"NA":26310},{"trials":26293,"activeCount":103},[],{"trials":26295,"activeCount":103},[],{"trials":26297,"activeCount":103},[],{"trials":26299,"activeCount":103},[26300,26304],{"nctId":26048,"briefTitle":24525,"status":123,"phases":26301,"primaryCompletion":5620,"completion":5620,"start":3400,"enrollment":18098,"conditions":26302,"interventions":26303},[93],[15555],[24821,24842],{"nctId":24836,"briefTitle":24837,"status":123,"phases":26305,"primaryCompletion":4400,"completion":4400,"start":949,"enrollment":24839,"conditions":26306,"interventions":26307},[93],[15555],[16268,24842],{"trials":26309,"activeCount":103},[],{"trials":26311,"activeCount":103},[],{"intervention":25364,"totalTrials":213,"cells":26313},{"EARLY_PHASE1":26314,"PHASE1":26316,"PHASE2":26318,"PHASE3":26324,"PHASE4":26332,"NA":26334},{"trials":26315,"activeCount":103},[],{"trials":26317,"activeCount":103},[],{"trials":26319,"activeCount":103},[26320],{"nctId":25358,"briefTitle":25359,"status":123,"phases":26321,"primaryCompletion":3383,"completion":3383,"start":4317,"enrollment":25361,"conditions":26322,"interventions":26323},[92],[4691],[4330,25364,7665],{"trials":26325,"activeCount":103},[26326],{"nctId":26327,"briefTitle":26328,"status":123,"phases":26329,"primaryCompletion":3474,"completion":3474,"start":905,"enrollment":2405,"conditions":26330,"interventions":26331},"NCT00098241","Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients",[93],[4691],[25364],{"trials":26333,"activeCount":103},[],{"trials":26335,"activeCount":103},[],{"intervention":4121,"totalTrials":213,"cells":26337},{"EARLY_PHASE1":26338,"PHASE1":26340,"PHASE2":26342,"PHASE3":26351,"PHASE4":26357,"NA":26359},{"trials":26339,"activeCount":103},[],{"trials":26341,"activeCount":103},[],{"trials":26343,"activeCount":103},[26344],{"nctId":26345,"briefTitle":26346,"status":123,"phases":26347,"primaryCompletion":1670,"completion":1670,"start":3243,"enrollment":2046,"conditions":26348,"interventions":26350},"NCT01601470","Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension",[92],[26349],"Mild to Moderate Hypertension",[15726,4121],{"trials":26352,"activeCount":103},[26353],{"nctId":4113,"briefTitle":4114,"status":123,"phases":26354,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":26355,"interventions":26356},[93],[3305],[83,4121,4122],{"trials":26358,"activeCount":103},[],{"trials":26360,"activeCount":103},[],{"intervention":274,"totalTrials":213,"cells":26362},{"EARLY_PHASE1":26363,"PHASE1":26365,"PHASE2":26367,"PHASE3":26373,"PHASE4":26379,"NA":26381},{"trials":26364,"activeCount":103},[],{"trials":26366,"activeCount":103},[],{"trials":26368,"activeCount":103},[26369],{"nctId":266,"briefTitle":267,"status":123,"phases":26370,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":26371,"interventions":26372},[92],[15],[98,274],{"trials":26374,"activeCount":103},[26375],{"nctId":388,"briefTitle":389,"status":390,"phases":26376,"primaryCompletion":392,"completion":392,"start":393,"enrollment":103,"conditions":26377,"interventions":26378},[93],[15],[98,274],{"trials":26380,"activeCount":103},[],{"trials":26382,"activeCount":103},[],{"intervention":11438,"totalTrials":213,"cells":26384},{"EARLY_PHASE1":26385,"PHASE1":26387,"PHASE2":26389,"PHASE3":26395,"PHASE4":26404,"NA":26406},{"trials":26386,"activeCount":103},[],{"trials":26388,"activeCount":103},[],{"trials":26390,"activeCount":103},[26391],{"nctId":11431,"briefTitle":11432,"status":123,"phases":26392,"primaryCompletion":11434,"completion":11434,"start":11435,"enrollment":3605,"conditions":26393,"interventions":26394},[92],[1695],[11438,9841],{"trials":26396,"activeCount":103},[26397],{"nctId":26398,"briefTitle":26399,"status":123,"phases":26400,"primaryCompletion":26401,"completion":26401,"start":532,"enrollment":1143,"conditions":26402,"interventions":26403},"NCT05380453","Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission",[93],"2026-02-24",[1695],[11438],{"trials":26405,"activeCount":103},[],{"trials":26407,"activeCount":103},[],{"intervention":9881,"totalTrials":437,"cells":26409},{"EARLY_PHASE1":26410,"PHASE1":26412,"PHASE2":26414,"PHASE3":26416,"PHASE4":26422,"NA":26424},{"trials":26411,"activeCount":103},[],{"trials":26413,"activeCount":103},[],{"trials":26415,"activeCount":103},[],{"trials":26417,"activeCount":103},[26418],{"nctId":9874,"briefTitle":9875,"status":123,"phases":26419,"primaryCompletion":9877,"completion":9877,"start":9878,"enrollment":4670,"conditions":26420,"interventions":26421},[93],[2569],[9866,7443,9881],{"trials":26423,"activeCount":103},[],{"trials":26425,"activeCount":103},[],{"intervention":26427,"totalTrials":437,"cells":26428},"VAL489",{"EARLY_PHASE1":26429,"PHASE1":26431,"PHASE2":26433,"PHASE3":26435,"PHASE4":26446,"NA":26448},{"trials":26430,"activeCount":103},[],{"trials":26432,"activeCount":103},[],{"trials":26434,"activeCount":103},[],{"trials":26436,"activeCount":103},[26437],{"nctId":26438,"briefTitle":26439,"status":123,"phases":26440,"primaryCompletion":26441,"completion":26441,"start":26442,"enrollment":1213,"conditions":26443,"interventions":26445},"NCT01617681","Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD",[93],"2017-01-24","2012-11-08",[26444],"Pediatric Hypertension With or Without CKD",[26427],{"trials":26447,"activeCount":103},[],{"trials":26449,"activeCount":103},[],{"intervention":17660,"totalTrials":437,"cells":26451},{"EARLY_PHASE1":26452,"PHASE1":26454,"PHASE2":26456,"PHASE3":26458,"PHASE4":26464,"NA":26466},{"trials":26453,"activeCount":103},[],{"trials":26455,"activeCount":103},[],{"trials":26457,"activeCount":103},[],{"trials":26459,"activeCount":103},[26460],{"nctId":17654,"briefTitle":17655,"status":134,"phases":26461,"primaryCompletion":4620,"completion":4620,"start":3351,"enrollment":3587,"conditions":26462,"interventions":26463},[93],[17658],[17660,17634],{"trials":26465,"activeCount":103},[],{"trials":26467,"activeCount":103},[],{"intervention":26469,"totalTrials":437,"cells":26470},"AIN457 150mg",{"EARLY_PHASE1":26471,"PHASE1":26473,"PHASE2":26475,"PHASE3":26477,"PHASE4":26487,"NA":26489},{"trials":26472,"activeCount":103},[],{"trials":26474,"activeCount":103},[],{"trials":26476,"activeCount":103},[],{"trials":26478,"activeCount":103},[26479],{"nctId":26480,"briefTitle":26481,"status":123,"phases":26482,"primaryCompletion":5114,"completion":5114,"start":1724,"enrollment":26483,"conditions":26484,"interventions":26485},"NCT01406938","Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens",[93],967,[2068],[26469,26486],"AIN457 300mg",{"trials":26488,"activeCount":103},[],{"trials":26490,"activeCount":103},[],{"intervention":26486,"totalTrials":437,"cells":26492},{"EARLY_PHASE1":26493,"PHASE1":26495,"PHASE2":26497,"PHASE3":26499,"PHASE4":26505,"NA":26507},{"trials":26494,"activeCount":103},[],{"trials":26496,"activeCount":103},[],{"trials":26498,"activeCount":103},[],{"trials":26500,"activeCount":103},[26501],{"nctId":26480,"briefTitle":26481,"status":123,"phases":26502,"primaryCompletion":5114,"completion":5114,"start":1724,"enrollment":26483,"conditions":26503,"interventions":26504},[93],[2068],[26469,26486],{"trials":26506,"activeCount":103},[],{"trials":26508,"activeCount":103},[],{"intervention":26510,"totalTrials":437,"cells":26511},"Octreotide Long Acting Release",{"EARLY_PHASE1":26512,"PHASE1":26514,"PHASE2":26516,"PHASE3":26518,"PHASE4":26527,"NA":26529},{"trials":26513,"activeCount":103},[],{"trials":26515,"activeCount":103},[],{"trials":26517,"activeCount":103},[],{"trials":26519,"activeCount":103},[26520],{"nctId":26521,"briefTitle":26522,"status":123,"phases":26523,"primaryCompletion":7931,"completion":7931,"start":4070,"enrollment":1223,"conditions":26524,"interventions":26526},"NCT00582426","Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea",[93],[26525],"Chemotherapy-induced Diarrhea",[26510],{"trials":26528,"activeCount":103},[],{"trials":26530,"activeCount":103},[],{"intervention":17402,"totalTrials":437,"cells":26532},{"EARLY_PHASE1":26533,"PHASE1":26535,"PHASE2":26537,"PHASE3":26539,"PHASE4":26545,"NA":26547},{"trials":26534,"activeCount":103},[],{"trials":26536,"activeCount":103},[],{"trials":26538,"activeCount":103},[],{"trials":26540,"activeCount":103},[26541],{"nctId":17393,"briefTitle":17394,"status":123,"phases":26542,"primaryCompletion":3271,"start":17396,"enrollment":6350,"conditions":26543,"interventions":26544},[93],[17398,17399,17400],[17382,17402],{"trials":26546,"activeCount":103},[],{"trials":26548,"activeCount":103},[],{"intervention":24207,"totalTrials":437,"cells":26550},{"EARLY_PHASE1":26551,"PHASE1":26553,"PHASE2":26555,"PHASE3":26557,"PHASE4":26563,"NA":26565},{"trials":26552,"activeCount":103},[],{"trials":26554,"activeCount":103},[],{"trials":26556,"activeCount":103},[],{"trials":26558,"activeCount":103},[26559],{"nctId":24201,"briefTitle":24202,"status":123,"phases":26560,"primaryCompletion":24204,"completion":1351,"start":2006,"enrollment":4568,"conditions":26561,"interventions":26562},[93],[16681],[24158,24207],{"trials":26564,"activeCount":103},[],{"trials":26566,"activeCount":103},[],{"intervention":26568,"totalTrials":437,"cells":26569},"Secukinumab 2 mL form",{"EARLY_PHASE1":26570,"PHASE1":26572,"PHASE2":26574,"PHASE3":26576,"PHASE4":26587,"NA":26589},{"trials":26571,"activeCount":103},[],{"trials":26573,"activeCount":103},[],{"trials":26575,"activeCount":103},[],{"trials":26577,"activeCount":103},[26578],{"nctId":26579,"briefTitle":26580,"status":123,"phases":26581,"primaryCompletion":4958,"completion":26582,"start":17569,"enrollment":26583,"conditions":26584,"interventions":26585},"NCT02748863","Study of Secukinumab With 2 mL Pre-filled Syringes",[93],"2018-06-08",214,[1675],[26568,26586],"Secukinumab 1 mL form",{"trials":26588,"activeCount":103},[],{"trials":26590,"activeCount":103},[],{"intervention":26586,"totalTrials":437,"cells":26592},{"EARLY_PHASE1":26593,"PHASE1":26595,"PHASE2":26597,"PHASE3":26599,"PHASE4":26605,"NA":26607},{"trials":26594,"activeCount":103},[],{"trials":26596,"activeCount":103},[],{"trials":26598,"activeCount":103},[],{"trials":26600,"activeCount":103},[26601],{"nctId":26579,"briefTitle":26580,"status":123,"phases":26602,"primaryCompletion":4958,"completion":26582,"start":17569,"enrollment":26583,"conditions":26603,"interventions":26604},[93],[1675],[26568,26586],{"trials":26606,"activeCount":103},[],{"trials":26608,"activeCount":103},[],{"intervention":18478,"totalTrials":437,"cells":26610},{"EARLY_PHASE1":26611,"PHASE1":26613,"PHASE2":26615,"PHASE3":26617,"PHASE4":26623,"NA":26625},{"trials":26612,"activeCount":103},[],{"trials":26614,"activeCount":103},[],{"trials":26616,"activeCount":103},[],{"trials":26618,"activeCount":103},[26619],{"nctId":18473,"briefTitle":18474,"status":123,"phases":26620,"primaryCompletion":3410,"start":825,"enrollment":2439,"conditions":26621,"interventions":26622},[93],[4701],[18478,18479,4649],{"trials":26624,"activeCount":103},[],{"trials":26626,"activeCount":103},[],{"intervention":18479,"totalTrials":437,"cells":26628},{"EARLY_PHASE1":26629,"PHASE1":26631,"PHASE2":26633,"PHASE3":26635,"PHASE4":26641,"NA":26643},{"trials":26630,"activeCount":103},[],{"trials":26632,"activeCount":103},[],{"trials":26634,"activeCount":103},[],{"trials":26636,"activeCount":103},[26637],{"nctId":18473,"briefTitle":18474,"status":123,"phases":26638,"primaryCompletion":3410,"start":825,"enrollment":2439,"conditions":26639,"interventions":26640},[93],[4701],[18478,18479,4649],{"trials":26642,"activeCount":103},[],{"trials":26644,"activeCount":103},[],{"intervention":26646,"totalTrials":437,"cells":26647},"Concept2 inhaler",{"EARLY_PHASE1":26648,"PHASE1":26650,"PHASE2":26652,"PHASE3":26654,"PHASE4":26665,"NA":26667},{"trials":26649,"activeCount":103},[],{"trials":26651,"activeCount":103},[],{"trials":26653,"activeCount":103},[],{"trials":26655,"activeCount":103},[26656],{"nctId":26657,"briefTitle":26658,"status":134,"phases":26659,"primaryCompletion":26660,"completion":26660,"start":26661,"enrollment":1562,"conditions":26662,"interventions":26663},"NCT03379233","A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational\u002FAdaptive Messaging on Treatment Adherence",[93],"2019-01-22","2018-07-11",[24],[26646,26664],"Concept2 inhaler with patient application",{"trials":26666,"activeCount":103},[],{"trials":26668,"activeCount":103},[],{"intervention":26664,"totalTrials":437,"cells":26670},{"EARLY_PHASE1":26671,"PHASE1":26673,"PHASE2":26675,"PHASE3":26677,"PHASE4":26683,"NA":26685},{"trials":26672,"activeCount":103},[],{"trials":26674,"activeCount":103},[],{"trials":26676,"activeCount":103},[],{"trials":26678,"activeCount":103},[26679],{"nctId":26657,"briefTitle":26658,"status":134,"phases":26680,"primaryCompletion":26660,"completion":26660,"start":26661,"enrollment":1562,"conditions":26681,"interventions":26682},[93],[24],[26646,26664],{"trials":26684,"activeCount":103},[],{"trials":26686,"activeCount":103},[],{"intervention":26688,"totalTrials":437,"cells":26689},"FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids",{"EARLY_PHASE1":26690,"PHASE1":26692,"PHASE2":26694,"PHASE3":26696,"PHASE4":26708,"NA":26710},{"trials":26691,"activeCount":103},[],{"trials":26693,"activeCount":103},[],{"trials":26695,"activeCount":103},[],{"trials":26697,"activeCount":103},[26698],{"nctId":26699,"briefTitle":26700,"status":123,"phases":26701,"primaryCompletion":26702,"completion":26702,"start":26703,"enrollment":7059,"conditions":26704,"interventions":26705},"NCT00099736","Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant",[93],"2005-09-19","2003-05-07",[4691],[26688,26706,26707],"FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids","MMF 2 g + full-dose Neoral (FDN) + corticosteroids",{"trials":26709,"activeCount":103},[],{"trials":26711,"activeCount":103},[],{"intervention":26706,"totalTrials":437,"cells":26713},{"EARLY_PHASE1":26714,"PHASE1":26716,"PHASE2":26718,"PHASE3":26720,"PHASE4":26726,"NA":26728},{"trials":26715,"activeCount":103},[],{"trials":26717,"activeCount":103},[],{"trials":26719,"activeCount":103},[],{"trials":26721,"activeCount":103},[26722],{"nctId":26699,"briefTitle":26700,"status":123,"phases":26723,"primaryCompletion":26702,"completion":26702,"start":26703,"enrollment":7059,"conditions":26724,"interventions":26725},[93],[4691],[26688,26706,26707],{"trials":26727,"activeCount":103},[],{"trials":26729,"activeCount":103},[],{"intervention":26707,"totalTrials":437,"cells":26731},{"EARLY_PHASE1":26732,"PHASE1":26734,"PHASE2":26736,"PHASE3":26738,"PHASE4":26744,"NA":26746},{"trials":26733,"activeCount":103},[],{"trials":26735,"activeCount":103},[],{"trials":26737,"activeCount":103},[],{"trials":26739,"activeCount":103},[26740],{"nctId":26699,"briefTitle":26700,"status":123,"phases":26741,"primaryCompletion":26702,"completion":26702,"start":26703,"enrollment":7059,"conditions":26742,"interventions":26743},[93],[4691],[26688,26706,26707],{"trials":26745,"activeCount":103},[],{"trials":26747,"activeCount":103},[],{"intervention":26749,"totalTrials":437,"cells":26750},"\"Secukinumab\" \"Cosentyx TM\"",{"EARLY_PHASE1":26751,"PHASE1":26753,"PHASE2":26755,"PHASE3":26757,"PHASE4":26766,"NA":26768},{"trials":26752,"activeCount":103},[],{"trials":26754,"activeCount":103},[],{"trials":26756,"activeCount":103},[],{"trials":26758,"activeCount":103},[26759],{"nctId":26760,"briefTitle":26761,"status":390,"phases":26762,"primaryCompletion":26763,"completion":26763,"start":1788,"enrollment":103,"conditions":26764,"interventions":26765},"NCT02795416","Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population",[93],"2017-03",[1675],[26749],{"trials":26767,"activeCount":103},[],{"trials":26769,"activeCount":103},[],{"intervention":26771,"totalTrials":437,"cells":26772},"OFC",{"EARLY_PHASE1":26773,"PHASE1":26775,"PHASE2":26777,"PHASE3":26779,"PHASE4":26789,"NA":26791},{"trials":26774,"activeCount":103},[],{"trials":26776,"activeCount":103},[],{"trials":26778,"activeCount":103},[],{"trials":26780,"activeCount":103},[26781],{"nctId":26782,"briefTitle":26783,"status":123,"phases":26784,"primaryCompletion":5002,"completion":16558,"start":26785,"enrollment":16503,"conditions":26786,"interventions":26787},"NCT00824265","Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia",[93],"2009-03-12",[2799],[26771,26788],"FC",{"trials":26790,"activeCount":103},[],{"trials":26792,"activeCount":103},[],{"intervention":26788,"totalTrials":437,"cells":26794},{"EARLY_PHASE1":26795,"PHASE1":26797,"PHASE2":26799,"PHASE3":26801,"PHASE4":26807,"NA":26809},{"trials":26796,"activeCount":103},[],{"trials":26798,"activeCount":103},[],{"trials":26800,"activeCount":103},[],{"trials":26802,"activeCount":103},[26803],{"nctId":26782,"briefTitle":26783,"status":123,"phases":26804,"primaryCompletion":5002,"completion":16558,"start":26785,"enrollment":16503,"conditions":26805,"interventions":26806},[93],[2799],[26771,26788],{"trials":26808,"activeCount":103},[],{"trials":26810,"activeCount":103},[],{"intervention":26812,"totalTrials":437,"cells":26813},"Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy",{"EARLY_PHASE1":26814,"PHASE1":26816,"PHASE2":26818,"PHASE3":26820,"PHASE4":26833,"NA":26835},{"trials":26815,"activeCount":103},[],{"trials":26817,"activeCount":103},[],{"trials":26819,"activeCount":103},[],{"trials":26821,"activeCount":103},[26822],{"nctId":26823,"briefTitle":26824,"status":123,"phases":26825,"primaryCompletion":26826,"completion":26827,"start":26828,"enrollment":26829,"conditions":26830,"interventions":26831},"NCT03570892","Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma",[93],"2021-05-06","2026-02-03","2019-05-09",330,[8170],[26812,26832],"Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant",{"trials":26834,"activeCount":103},[],{"trials":26836,"activeCount":103},[],{"intervention":26832,"totalTrials":437,"cells":26838},{"EARLY_PHASE1":26839,"PHASE1":26841,"PHASE2":26843,"PHASE3":26845,"PHASE4":26851,"NA":26853},{"trials":26840,"activeCount":103},[],{"trials":26842,"activeCount":103},[],{"trials":26844,"activeCount":103},[],{"trials":26846,"activeCount":103},[26847],{"nctId":26823,"briefTitle":26824,"status":123,"phases":26848,"primaryCompletion":26826,"completion":26827,"start":26828,"enrollment":26829,"conditions":26849,"interventions":26850},[93],[8170],[26812,26832],{"trials":26852,"activeCount":103},[],{"trials":26854,"activeCount":103},[],{"intervention":8333,"totalTrials":437,"cells":26856},{"EARLY_PHASE1":26857,"PHASE1":26859,"PHASE2":26861,"PHASE3":26863,"PHASE4":26869,"NA":26871},{"trials":26858,"activeCount":103},[],{"trials":26860,"activeCount":103},[],{"trials":26862,"activeCount":103},[],{"trials":26864,"activeCount":103},[26865],{"nctId":8325,"briefTitle":8326,"status":123,"phases":26866,"primaryCompletion":6143,"completion":8328,"start":8329,"enrollment":8330,"conditions":26867,"interventions":26868},[93],[18],[8314,8333],{"trials":26870,"activeCount":103},[],{"trials":26872,"activeCount":103},[],{"intervention":26874,"totalTrials":437,"cells":26875},"BYM338\u002Fbimagrumab",{"EARLY_PHASE1":26876,"PHASE1":26878,"PHASE2":26880,"PHASE3":26882,"PHASE4":26892,"NA":26894},{"trials":26877,"activeCount":103},[],{"trials":26879,"activeCount":103},[],{"trials":26881,"activeCount":103},[],{"trials":26883,"activeCount":103},[26884],{"nctId":26885,"briefTitle":26886,"status":123,"phases":26887,"primaryCompletion":26888,"completion":26888,"start":26889,"enrollment":10408,"conditions":26890,"interventions":26891},"NCT01925209","Efficacy and Safety of Bimagrumab\u002FBYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients",[92,93],"2016-01-06","2013-09-26",[24483],[26874],{"trials":26893,"activeCount":103},[],{"trials":26895,"activeCount":103},[],{"intervention":9617,"totalTrials":437,"cells":26897},{"EARLY_PHASE1":26898,"PHASE1":26900,"PHASE2":26902,"PHASE3":26904,"PHASE4":26910,"NA":26912},{"trials":26899,"activeCount":103},[],{"trials":26901,"activeCount":103},[],{"trials":26903,"activeCount":103},[],{"trials":26905,"activeCount":103},[26906],{"nctId":9609,"briefTitle":9610,"status":123,"phases":26907,"primaryCompletion":9612,"completion":9612,"start":9613,"enrollment":1660,"conditions":26908,"interventions":26909},[93],[9615],[9578,9617],{"trials":26911,"activeCount":103},[],{"trials":26913,"activeCount":103},[],{"intervention":8232,"totalTrials":437,"cells":26915},{"EARLY_PHASE1":26916,"PHASE1":26918,"PHASE2":26920,"PHASE3":26922,"PHASE4":26928,"NA":26930},{"trials":26917,"activeCount":103},[],{"trials":26919,"activeCount":103},[],{"trials":26921,"activeCount":103},[],{"trials":26923,"activeCount":103},[26924],{"nctId":8223,"briefTitle":8224,"status":390,"phases":26925,"primaryCompletion":8226,"completion":8227,"start":8228,"enrollment":103,"conditions":26926,"interventions":26927},[93],[3204],[8139,8231,8232],{"trials":26929,"activeCount":103},[],{"trials":26931,"activeCount":103},[],{"intervention":26933,"totalTrials":437,"cells":26934},"Dexamethasone implant and sham injections",{"EARLY_PHASE1":26935,"PHASE1":26937,"PHASE2":26939,"PHASE3":26941,"PHASE4":26950,"NA":26952},{"trials":26936,"activeCount":103},[],{"trials":26938,"activeCount":103},[],{"trials":26940,"activeCount":103},[],{"trials":26942,"activeCount":103},[26943],{"nctId":26944,"briefTitle":26945,"status":123,"phases":26946,"primaryCompletion":3559,"completion":3559,"start":1724,"enrollment":26947,"conditions":26948,"interventions":26949},"NCT01396083","Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)",[93],243,[20118,25288,17675],[4460,26933],{"trials":26951,"activeCount":103},[],{"trials":26953,"activeCount":103},[],{"intervention":26955,"totalTrials":437,"cells":26956},"Ritalin LA",{"EARLY_PHASE1":26957,"PHASE1":26959,"PHASE2":26961,"PHASE3":26963,"PHASE4":26973,"NA":26975},{"trials":26958,"activeCount":103},[],{"trials":26960,"activeCount":103},[],{"trials":26962,"activeCount":103},[],{"trials":26964,"activeCount":103},[26965],{"nctId":26966,"briefTitle":26967,"status":123,"phases":26968,"primaryCompletion":2793,"completion":2793,"start":3383,"enrollment":26969,"conditions":26970,"interventions":26972},"NCT01338818","Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit\u002FHyperactivity Disorder",[93],299,[26971],"Attention Deficit\u002FHyperactivity Disorder",[26955],{"trials":26974,"activeCount":103},[],{"trials":26976,"activeCount":103},[],{"intervention":26978,"totalTrials":437,"cells":26979},"Intervention A",{"EARLY_PHASE1":26980,"PHASE1":26982,"PHASE2":26984,"PHASE3":26986,"PHASE4":26995,"NA":26997},{"trials":26981,"activeCount":103},[],{"trials":26983,"activeCount":103},[],{"trials":26985,"activeCount":103},[],{"trials":26987,"activeCount":103},[26988],{"nctId":26989,"briefTitle":26990,"status":390,"phases":26991,"primaryCompletion":4410,"completion":4410,"start":813,"enrollment":103,"conditions":26992,"interventions":26993},"NCT01900782","Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.",[93],[1675],[26978,26994],"Intervention B",{"trials":26996,"activeCount":103},[],{"trials":26998,"activeCount":103},[],{"intervention":26994,"totalTrials":437,"cells":27000},{"EARLY_PHASE1":27001,"PHASE1":27003,"PHASE2":27005,"PHASE3":27007,"PHASE4":27013,"NA":27015},{"trials":27002,"activeCount":103},[],{"trials":27004,"activeCount":103},[],{"trials":27006,"activeCount":103},[],{"trials":27008,"activeCount":103},[27009],{"nctId":26989,"briefTitle":26990,"status":390,"phases":27010,"primaryCompletion":4410,"completion":4410,"start":813,"enrollment":103,"conditions":27011,"interventions":27012},[93],[1675],[26978,26994],{"trials":27014,"activeCount":103},[],{"trials":27016,"activeCount":103},[],{"intervention":16553,"totalTrials":437,"cells":27018},{"EARLY_PHASE1":27019,"PHASE1":27021,"PHASE2":27023,"PHASE3":27025,"PHASE4":27031,"NA":27033},{"trials":27020,"activeCount":103},[],{"trials":27022,"activeCount":103},[],{"trials":27024,"activeCount":103},[],{"trials":27026,"activeCount":103},[27027],{"nctId":16545,"briefTitle":16546,"status":123,"phases":27028,"primaryCompletion":2006,"completion":16548,"start":16549,"enrollment":1574,"conditions":27029,"interventions":27030},[93],[16551],[7711,16553],{"trials":27032,"activeCount":103},[],{"trials":27034,"activeCount":103},[],{"intervention":27036,"totalTrials":437,"cells":27037},"Octreotide acetate 30 mg suspension",{"EARLY_PHASE1":27038,"PHASE1":27040,"PHASE2":27042,"PHASE3":27044,"PHASE4":27052,"NA":27054},{"trials":27039,"activeCount":103},[],{"trials":27041,"activeCount":103},[],{"trials":27043,"activeCount":103},[],{"trials":27045,"activeCount":103},[27046],{"nctId":27047,"briefTitle":27048,"status":123,"phases":27049,"primaryCompletion":3447,"completion":3447,"start":835,"enrollment":2046,"conditions":27050,"interventions":27051},"NCT00372697","Efficacy\u002FSafety of Octreotide Acetate in Patients With Uncontrolled Acromegaly",[93],[8385],[27036],{"trials":27053,"activeCount":103},[],{"trials":27055,"activeCount":103},[],{"intervention":27057,"totalTrials":437,"cells":27058},"Sham",{"EARLY_PHASE1":27059,"PHASE1":27061,"PHASE2":27063,"PHASE3":27065,"PHASE4":27075,"NA":27077},{"trials":27060,"activeCount":103},[],{"trials":27062,"activeCount":103},[],{"trials":27064,"activeCount":103},[],{"trials":27066,"activeCount":103},[27067],{"nctId":27068,"briefTitle":27069,"status":123,"phases":27070,"primaryCompletion":27071,"completion":27071,"start":27072,"enrollment":15846,"conditions":27073,"interventions":27074},"NCT02259088","A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients",[93],"2017-01-17","2014-11-05",[16741,20118],[4460,27057],{"trials":27076,"activeCount":103},[],{"trials":27078,"activeCount":103},[],{"intervention":27080,"totalTrials":437,"cells":27081},"Minimisation of TAC",{"EARLY_PHASE1":27082,"PHASE1":27084,"PHASE2":27086,"PHASE3":27088,"PHASE4":27097,"NA":27099},{"trials":27083,"activeCount":103},[],{"trials":27085,"activeCount":103},[],{"trials":27087,"activeCount":103},[],{"trials":27089,"activeCount":103},[27090],{"nctId":27091,"briefTitle":27092,"status":123,"phases":27093,"primaryCompletion":18036,"completion":18036,"start":6538,"enrollment":597,"conditions":27094,"interventions":27095},"NCT02040584","A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.",[93],[17239],[27080,27096],"TAC + MMF + corticosteroids",{"trials":27098,"activeCount":103},[],{"trials":27100,"activeCount":103},[],{"intervention":27096,"totalTrials":437,"cells":27102},{"EARLY_PHASE1":27103,"PHASE1":27105,"PHASE2":27107,"PHASE3":27109,"PHASE4":27115,"NA":27117},{"trials":27104,"activeCount":103},[],{"trials":27106,"activeCount":103},[],{"trials":27108,"activeCount":103},[],{"trials":27110,"activeCount":103},[27111],{"nctId":27091,"briefTitle":27092,"status":123,"phases":27112,"primaryCompletion":18036,"completion":18036,"start":6538,"enrollment":597,"conditions":27113,"interventions":27114},[93],[17239],[27080,27096],{"trials":27116,"activeCount":103},[],{"trials":27118,"activeCount":103},[],{"intervention":27120,"totalTrials":437,"cells":27121},"Ali\u002FAmlo 150\u002F2.5 mg",{"EARLY_PHASE1":27122,"PHASE1":27124,"PHASE2":27126,"PHASE3":27128,"PHASE4":27136,"NA":27138},{"trials":27123,"activeCount":103},[],{"trials":27125,"activeCount":103},[],{"trials":27127,"activeCount":103},[],{"trials":27129,"activeCount":103},[27130],{"nctId":27131,"briefTitle":27132,"status":123,"phases":27133,"primaryCompletion":1671,"completion":1671,"start":4598,"enrollment":9531,"conditions":27134,"interventions":27135},"NCT01237873","Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren\u002FAmlodipine) in Patients With Essential Hypertension",[93],[17007],[27120],{"trials":27137,"activeCount":103},[],{"trials":27139,"activeCount":103},[],{"intervention":27141,"totalTrials":437,"cells":27142},"RTH258",{"EARLY_PHASE1":27143,"PHASE1":27145,"PHASE2":27147,"PHASE3":27149,"PHASE4":27158,"NA":27160},{"trials":27144,"activeCount":103},[],{"trials":27146,"activeCount":103},[],{"trials":27148,"activeCount":103},[],{"trials":27150,"activeCount":103},[27151],{"nctId":27152,"briefTitle":27153,"status":123,"phases":27154,"primaryCompletion":18371,"completion":18371,"start":27155,"enrollment":31,"conditions":27156,"interventions":27157},"NCT03930641","Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration",[93],"2019-05-23",[25605],[27141],{"trials":27159,"activeCount":103},[],{"trials":27161,"activeCount":103},[],{"intervention":19317,"totalTrials":437,"cells":27163},{"EARLY_PHASE1":27164,"PHASE1":27166,"PHASE2":27168,"PHASE3":27170,"PHASE4":27176,"NA":27178},{"trials":27165,"activeCount":103},[],{"trials":27167,"activeCount":103},[],{"trials":27169,"activeCount":103},[],{"trials":27171,"activeCount":103},[27172],{"nctId":19310,"briefTitle":19311,"status":123,"phases":27173,"primaryCompletion":8048,"completion":8048,"start":606,"enrollment":19313,"conditions":27174,"interventions":27175},[93],[19315],[19299,19317],{"trials":27177,"activeCount":103},[],{"trials":27179,"activeCount":103},[],{"intervention":15075,"totalTrials":437,"cells":27181},{"EARLY_PHASE1":27182,"PHASE1":27184,"PHASE2":27186,"PHASE3":27188,"PHASE4":27194,"NA":27196},{"trials":27183,"activeCount":103},[],{"trials":27185,"activeCount":103},[],{"trials":27187,"activeCount":103},[],{"trials":27189,"activeCount":103},[27190],{"nctId":15070,"briefTitle":15071,"status":123,"phases":27191,"primaryCompletion":8091,"completion":8091,"start":4071,"enrollment":2094,"conditions":27192,"interventions":27193},[93],[30],[15029,15075],{"trials":27195,"activeCount":103},[],{"trials":27197,"activeCount":103},[],{"intervention":17411,"totalTrials":437,"cells":27199},{"EARLY_PHASE1":27200,"PHASE1":27202,"PHASE2":27204,"PHASE3":27206,"PHASE4":27212,"NA":27214},{"trials":27201,"activeCount":103},[],{"trials":27203,"activeCount":103},[],{"trials":27205,"activeCount":103},[],{"trials":27207,"activeCount":103},[27208],{"nctId":17404,"briefTitle":17405,"status":123,"phases":27209,"primaryCompletion":4372,"start":3490,"enrollment":3043,"conditions":27210,"interventions":27211},[93],[17408],[17382,17410,17411],{"trials":27213,"activeCount":103},[],{"trials":27215,"activeCount":103},[],{"intervention":27217,"totalTrials":437,"cells":27218},"Aliskiren 150\u002F300 mg",{"EARLY_PHASE1":27219,"PHASE1":27221,"PHASE2":27223,"PHASE3":27225,"PHASE4":27238,"NA":27240},{"trials":27220,"activeCount":103},[],{"trials":27222,"activeCount":103},[],{"trials":27224,"activeCount":103},[],{"trials":27226,"activeCount":103},[27227],{"nctId":27228,"briefTitle":27229,"status":123,"phases":27230,"primaryCompletion":4642,"completion":4642,"start":15109,"enrollment":2130,"conditions":27231,"interventions":27234},"NCT00219141","Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension",[93],[21,27232,27233],"Left Ventricular Hypertrophy","Overweight",[27217,27235,27236,27237],"Losartan 50\u002F100 mg","Aliskiren placebo","Losartan 50\u002F100 mg placebo",{"trials":27239,"activeCount":103},[],{"trials":27241,"activeCount":103},[],{"intervention":27235,"totalTrials":437,"cells":27243},{"EARLY_PHASE1":27244,"PHASE1":27246,"PHASE2":27248,"PHASE3":27250,"PHASE4":27256,"NA":27258},{"trials":27245,"activeCount":103},[],{"trials":27247,"activeCount":103},[],{"trials":27249,"activeCount":103},[],{"trials":27251,"activeCount":103},[27252],{"nctId":27228,"briefTitle":27229,"status":123,"phases":27253,"primaryCompletion":4642,"completion":4642,"start":15109,"enrollment":2130,"conditions":27254,"interventions":27255},[93],[21,27232,27233],[27217,27235,27236,27237],{"trials":27257,"activeCount":103},[],{"trials":27259,"activeCount":103},[],{"intervention":27236,"totalTrials":437,"cells":27261},{"EARLY_PHASE1":27262,"PHASE1":27264,"PHASE2":27266,"PHASE3":27268,"PHASE4":27274,"NA":27276},{"trials":27263,"activeCount":103},[],{"trials":27265,"activeCount":103},[],{"trials":27267,"activeCount":103},[],{"trials":27269,"activeCount":103},[27270],{"nctId":27228,"briefTitle":27229,"status":123,"phases":27271,"primaryCompletion":4642,"completion":4642,"start":15109,"enrollment":2130,"conditions":27272,"interventions":27273},[93],[21,27232,27233],[27217,27235,27236,27237],{"trials":27275,"activeCount":103},[],{"trials":27277,"activeCount":103},[],{"intervention":27237,"totalTrials":437,"cells":27279},{"EARLY_PHASE1":27280,"PHASE1":27282,"PHASE2":27284,"PHASE3":27286,"PHASE4":27292,"NA":27294},{"trials":27281,"activeCount":103},[],{"trials":27283,"activeCount":103},[],{"trials":27285,"activeCount":103},[],{"trials":27287,"activeCount":103},[27288],{"nctId":27228,"briefTitle":27229,"status":123,"phases":27289,"primaryCompletion":4642,"completion":4642,"start":15109,"enrollment":2130,"conditions":27290,"interventions":27291},[93],[21,27232,27233],[27217,27235,27236,27237],{"trials":27293,"activeCount":103},[],{"trials":27295,"activeCount":103},[],{"intervention":27297,"totalTrials":437,"cells":27298},"LMF237 50\u002F250 mg",{"EARLY_PHASE1":27299,"PHASE1":27301,"PHASE2":27303,"PHASE3":27305,"PHASE4":27314,"NA":27316},{"trials":27300,"activeCount":103},[],{"trials":27302,"activeCount":103},[],{"trials":27304,"activeCount":103},[],{"trials":27306,"activeCount":103},[27307],{"nctId":27308,"briefTitle":27309,"status":123,"phases":27310,"primaryCompletion":1723,"completion":1723,"start":5114,"enrollment":3544,"conditions":27311,"interventions":27312},"NCT01811485","Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy",[93],[30],[27297,27313],"LMF237 50\u002F500 mg",{"trials":27315,"activeCount":103},[],{"trials":27317,"activeCount":103},[],{"intervention":27313,"totalTrials":437,"cells":27319},{"EARLY_PHASE1":27320,"PHASE1":27322,"PHASE2":27324,"PHASE3":27326,"PHASE4":27332,"NA":27334},{"trials":27321,"activeCount":103},[],{"trials":27323,"activeCount":103},[],{"trials":27325,"activeCount":103},[],{"trials":27327,"activeCount":103},[27328],{"nctId":27308,"briefTitle":27309,"status":123,"phases":27329,"primaryCompletion":1723,"completion":1723,"start":5114,"enrollment":3544,"conditions":27330,"interventions":27331},[93],[30],[27297,27313],{"trials":27333,"activeCount":103},[],{"trials":27335,"activeCount":103},[],{"intervention":27337,"totalTrials":437,"cells":27338},"artemether:lumefantrine",{"EARLY_PHASE1":27339,"PHASE1":27341,"PHASE2":27343,"PHASE3":27345,"PHASE4":27355,"NA":27357},{"trials":27340,"activeCount":103},[],{"trials":27342,"activeCount":103},[],{"trials":27344,"activeCount":103},[],{"trials":27346,"activeCount":103},[27347],{"nctId":27348,"briefTitle":27349,"status":134,"phases":27350,"primaryCompletion":27351,"completion":27352,"start":1931,"enrollment":2046,"conditions":27353,"interventions":27354},"NCT04300309","Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates \u003C5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria",[92,93],"2023-07-02","2024-05-10",[11184],[27337],{"trials":27356,"activeCount":103},[],{"trials":27358,"activeCount":103},[],{"intervention":16219,"totalTrials":437,"cells":27360},{"EARLY_PHASE1":27361,"PHASE1":27363,"PHASE2":27365,"PHASE3":27367,"PHASE4":27373,"NA":27375},{"trials":27362,"activeCount":103},[],{"trials":27364,"activeCount":103},[],{"trials":27366,"activeCount":103},[],{"trials":27368,"activeCount":103},[27369],{"nctId":16214,"briefTitle":16215,"status":123,"phases":27370,"primaryCompletion":3800,"completion":3800,"start":3760,"enrollment":2685,"conditions":27371,"interventions":27372},[93],[8267],[16219,15564],{"trials":27374,"activeCount":103},[],{"trials":27376,"activeCount":103},[],{"intervention":25521,"totalTrials":437,"cells":27378},{"EARLY_PHASE1":27379,"PHASE1":27381,"PHASE2":27383,"PHASE3":27385,"PHASE4":27391,"NA":27393},{"trials":27380,"activeCount":103},[],{"trials":27382,"activeCount":103},[],{"trials":27384,"activeCount":103},[],{"trials":27386,"activeCount":103},[27387],{"nctId":25515,"briefTitle":25516,"status":123,"phases":27388,"primaryCompletion":13341,"completion":25518,"start":5234,"enrollment":5681,"conditions":27389,"interventions":27390},[93],[5315],[25521,1270],{"trials":27392,"activeCount":103},[],{"trials":27394,"activeCount":103},[],{"intervention":27396,"totalTrials":437,"cells":27397},"AMG334",{"EARLY_PHASE1":27398,"PHASE1":27400,"PHASE2":27402,"PHASE3":27404,"PHASE4":27414,"NA":27416},{"trials":27399,"activeCount":103},[],{"trials":27401,"activeCount":103},[],{"trials":27403,"activeCount":103},[],{"trials":27405,"activeCount":103},[27406],{"nctId":27407,"briefTitle":27408,"status":123,"phases":27409,"primaryCompletion":27410,"completion":27411,"start":17710,"enrollment":5099,"conditions":27412,"interventions":27413},"NCT03096834","A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies",[93],"2018-01-18","2021-01-28",[18871],[27396],{"trials":27415,"activeCount":103},[],{"trials":27417,"activeCount":103},[],{"intervention":27419,"totalTrials":437,"cells":27420},"erenumab 70mg\u002FmL",{"EARLY_PHASE1":27421,"PHASE1":27423,"PHASE2":27425,"PHASE3":27427,"PHASE4":27436,"NA":27438},{"trials":27422,"activeCount":103},[],{"trials":27424,"activeCount":103},[],{"trials":27426,"activeCount":103},[],{"trials":27428,"activeCount":103},[27429],{"nctId":27430,"briefTitle":27431,"status":390,"phases":27432,"primaryCompletion":6961,"completion":27433,"start":13334,"enrollment":103,"conditions":27434,"interventions":27435},"NCT04114630","Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab",[93],"2022-01-07",[18881],[27419],{"trials":27437,"activeCount":103},[],{"trials":27439,"activeCount":103},[],{"intervention":1791,"totalTrials":437,"cells":27441},{"EARLY_PHASE1":27442,"PHASE1":27444,"PHASE2":27446,"PHASE3":27448,"PHASE4":27454,"NA":27456},{"trials":27443,"activeCount":103},[],{"trials":27445,"activeCount":103},[],{"trials":27447,"activeCount":103},[],{"trials":27449,"activeCount":103},[27450],{"nctId":1785,"briefTitle":1786,"status":123,"phases":27451,"primaryCompletion":1788,"completion":1788,"start":606,"enrollment":757,"conditions":27452,"interventions":27453},[93],[1675],[1659,1791],{"trials":27455,"activeCount":103},[],{"trials":27457,"activeCount":103},[],{"intervention":15104,"totalTrials":437,"cells":27459},{"EARLY_PHASE1":27460,"PHASE1":27462,"PHASE2":27464,"PHASE3":27466,"PHASE4":27472,"NA":27474},{"trials":27461,"activeCount":103},[],{"trials":27463,"activeCount":103},[],{"trials":27465,"activeCount":103},[],{"trials":27467,"activeCount":103},[27468],{"nctId":15098,"briefTitle":15099,"status":123,"phases":27469,"primaryCompletion":3272,"completion":3272,"start":15101,"enrollment":6608,"conditions":27470,"interventions":27471},[93],[30],[15029,15104],{"trials":27473,"activeCount":103},[],{"trials":27475,"activeCount":103},[],{"intervention":25052,"totalTrials":437,"cells":27477},{"EARLY_PHASE1":27478,"PHASE1":27480,"PHASE2":27482,"PHASE3":27484,"PHASE4":27490,"NA":27492},{"trials":27479,"activeCount":103},[],{"trials":27481,"activeCount":103},[],{"trials":27483,"activeCount":103},[],{"trials":27485,"activeCount":103},[27486],{"nctId":25045,"briefTitle":25046,"status":123,"phases":27487,"primaryCompletion":917,"start":8370,"enrollment":2810,"conditions":27488,"interventions":27489},[93],[25049,25050],[25052,25053,25034],{"trials":27491,"activeCount":103},[],{"trials":27493,"activeCount":103},[],{"intervention":25053,"totalTrials":437,"cells":27495},{"EARLY_PHASE1":27496,"PHASE1":27498,"PHASE2":27500,"PHASE3":27502,"PHASE4":27508,"NA":27510},{"trials":27497,"activeCount":103},[],{"trials":27499,"activeCount":103},[],{"trials":27501,"activeCount":103},[],{"trials":27503,"activeCount":103},[27504],{"nctId":25045,"briefTitle":25046,"status":123,"phases":27505,"primaryCompletion":917,"start":8370,"enrollment":2810,"conditions":27506,"interventions":27507},[93],[25049,25050],[25052,25053,25034],{"trials":27509,"activeCount":103},[],{"trials":27511,"activeCount":103},[],{"intervention":27513,"totalTrials":437,"cells":27514},"Previous treatment in DEB025 study",{"EARLY_PHASE1":27515,"PHASE1":27517,"PHASE2":27519,"PHASE3":27521,"PHASE4":27532,"NA":27534},{"trials":27516,"activeCount":103},[],{"trials":27518,"activeCount":103},[],{"trials":27520,"activeCount":103},[],{"trials":27522,"activeCount":103},[27523],{"nctId":27524,"briefTitle":27525,"status":134,"phases":27526,"primaryCompletion":27527,"completion":27527,"start":27528,"enrollment":151,"conditions":27529,"interventions":27531},"NCT02465203","3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025\u002FAlisporivir Study",[93],"2014-01-23","2012-09-06",[27530],"Hepatitis C, Chronic",[27513],{"trials":27533,"activeCount":103},[],{"trials":27535,"activeCount":103},[],{"intervention":27537,"totalTrials":437,"cells":27538},"NVA237 50µg once daily",{"EARLY_PHASE1":27539,"PHASE1":27541,"PHASE2":27543,"PHASE3":27545,"PHASE4":27557,"NA":27559},{"trials":27540,"activeCount":103},[],{"trials":27542,"activeCount":103},[],{"trials":27544,"activeCount":103},[],{"trials":27546,"activeCount":103},[27547],{"nctId":27548,"briefTitle":27549,"status":123,"phases":27550,"primaryCompletion":1714,"completion":1714,"start":607,"enrollment":27551,"conditions":27552,"interventions":27553},"NCT01513460","Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease",[93],773,[24],[27537,27554,27555,27556],"Tiotropium 18µg once daily","Flu\u002FSal","NVA237 placebo + Tiotropium placebo.",{"trials":27558,"activeCount":103},[],{"trials":27560,"activeCount":103},[],{"intervention":27554,"totalTrials":437,"cells":27562},{"EARLY_PHASE1":27563,"PHASE1":27565,"PHASE2":27567,"PHASE3":27569,"PHASE4":27575,"NA":27577},{"trials":27564,"activeCount":103},[],{"trials":27566,"activeCount":103},[],{"trials":27568,"activeCount":103},[],{"trials":27570,"activeCount":103},[27571],{"nctId":27548,"briefTitle":27549,"status":123,"phases":27572,"primaryCompletion":1714,"completion":1714,"start":607,"enrollment":27551,"conditions":27573,"interventions":27574},[93],[24],[27537,27554,27555,27556],{"trials":27576,"activeCount":103},[],{"trials":27578,"activeCount":103},[],{"intervention":27555,"totalTrials":437,"cells":27580},{"EARLY_PHASE1":27581,"PHASE1":27583,"PHASE2":27585,"PHASE3":27587,"PHASE4":27593,"NA":27595},{"trials":27582,"activeCount":103},[],{"trials":27584,"activeCount":103},[],{"trials":27586,"activeCount":103},[],{"trials":27588,"activeCount":103},[27589],{"nctId":27548,"briefTitle":27549,"status":123,"phases":27590,"primaryCompletion":1714,"completion":1714,"start":607,"enrollment":27551,"conditions":27591,"interventions":27592},[93],[24],[27537,27554,27555,27556],{"trials":27594,"activeCount":103},[],{"trials":27596,"activeCount":103},[],{"intervention":27556,"totalTrials":437,"cells":27598},{"EARLY_PHASE1":27599,"PHASE1":27601,"PHASE2":27603,"PHASE3":27605,"PHASE4":27611,"NA":27613},{"trials":27600,"activeCount":103},[],{"trials":27602,"activeCount":103},[],{"trials":27604,"activeCount":103},[],{"trials":27606,"activeCount":103},[27607],{"nctId":27548,"briefTitle":27549,"status":123,"phases":27608,"primaryCompletion":1714,"completion":1714,"start":607,"enrollment":27551,"conditions":27609,"interventions":27610},[93],[24],[27537,27554,27555,27556],{"trials":27612,"activeCount":103},[],{"trials":27614,"activeCount":103},[],{"intervention":25644,"totalTrials":437,"cells":27616},{"EARLY_PHASE1":27617,"PHASE1":27619,"PHASE2":27621,"PHASE3":27623,"PHASE4":27629,"NA":27631},{"trials":27618,"activeCount":103},[],{"trials":27620,"activeCount":103},[],{"trials":27622,"activeCount":103},[],{"trials":27624,"activeCount":103},[27625],{"nctId":25637,"briefTitle":25638,"status":123,"phases":27626,"primaryCompletion":880,"start":918,"enrollment":25640,"conditions":27627,"interventions":27628},[93],[6375,25642,8372],[25620,25644],{"trials":27630,"activeCount":103},[],{"trials":27632,"activeCount":103},[],{"intervention":19210,"totalTrials":437,"cells":27634},{"EARLY_PHASE1":27635,"PHASE1":27637,"PHASE2":27639,"PHASE3":27641,"PHASE4":27647,"NA":27649},{"trials":27636,"activeCount":103},[],{"trials":27638,"activeCount":103},[],{"trials":27640,"activeCount":103},[],{"trials":27642,"activeCount":103},[27643],{"nctId":19204,"briefTitle":19205,"status":123,"phases":27644,"primaryCompletion":3482,"completion":3482,"start":5620,"enrollment":11,"conditions":27645,"interventions":27646},[93],[19208],[4460,17688,19210,19211],{"trials":27648,"activeCount":103},[],{"trials":27650,"activeCount":103},[],{"intervention":19211,"totalTrials":437,"cells":27652},{"EARLY_PHASE1":27653,"PHASE1":27655,"PHASE2":27657,"PHASE3":27659,"PHASE4":27665,"NA":27667},{"trials":27654,"activeCount":103},[],{"trials":27656,"activeCount":103},[],{"trials":27658,"activeCount":103},[],{"trials":27660,"activeCount":103},[27661],{"nctId":19204,"briefTitle":19205,"status":123,"phases":27662,"primaryCompletion":3482,"completion":3482,"start":5620,"enrollment":11,"conditions":27663,"interventions":27664},[93],[19208],[4460,17688,19210,19211],{"trials":27666,"activeCount":103},[],{"trials":27668,"activeCount":103},[],{"intervention":17148,"totalTrials":437,"cells":27670},{"EARLY_PHASE1":27671,"PHASE1":27673,"PHASE2":27675,"PHASE3":27677,"PHASE4":27683,"NA":27685},{"trials":27672,"activeCount":103},[],{"trials":27674,"activeCount":103},[],{"trials":27676,"activeCount":103},[],{"trials":27678,"activeCount":103},[27679],{"nctId":17141,"briefTitle":17142,"status":123,"phases":27680,"primaryCompletion":3447,"completion":3447,"start":9096,"enrollment":15801,"conditions":27681,"interventions":27682},[93],[17145],[17147,17148,1168],{"trials":27684,"activeCount":103},[],{"trials":27686,"activeCount":103},[],{"intervention":27688,"totalTrials":437,"cells":27689},"QAW039 150 mg",{"EARLY_PHASE1":27690,"PHASE1":27692,"PHASE2":27694,"PHASE3":27696,"PHASE4":27709,"NA":27711},{"trials":27691,"activeCount":103},[],{"trials":27693,"activeCount":103},[],{"trials":27695,"activeCount":103},[],{"trials":27697,"activeCount":103},[27698],{"nctId":27699,"briefTitle":27700,"status":134,"phases":27701,"primaryCompletion":27702,"completion":27703,"start":27704,"enrollment":27705,"conditions":27706,"interventions":27707},"NCT03052517","Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment",[93],"2020-02-19","2020-03-16","2017-03-21",2538,[18],[27688,27708],"QAW039 450 mg",{"trials":27710,"activeCount":103},[],{"trials":27712,"activeCount":103},[],{"intervention":27708,"totalTrials":437,"cells":27714},{"EARLY_PHASE1":27715,"PHASE1":27717,"PHASE2":27719,"PHASE3":27721,"PHASE4":27727,"NA":27729},{"trials":27716,"activeCount":103},[],{"trials":27718,"activeCount":103},[],{"trials":27720,"activeCount":103},[],{"trials":27722,"activeCount":103},[27723],{"nctId":27699,"briefTitle":27700,"status":134,"phases":27724,"primaryCompletion":27702,"completion":27703,"start":27704,"enrollment":27705,"conditions":27725,"interventions":27726},[93],[18],[27688,27708],{"trials":27728,"activeCount":103},[],{"trials":27730,"activeCount":103},[],{"intervention":25689,"totalTrials":437,"cells":27732},{"EARLY_PHASE1":27733,"PHASE1":27735,"PHASE2":27737,"PHASE3":27739,"PHASE4":27745,"NA":27747},{"trials":27734,"activeCount":103},[],{"trials":27736,"activeCount":103},[],{"trials":27738,"activeCount":103},[],{"trials":27740,"activeCount":103},[27741],{"nctId":25683,"briefTitle":25684,"status":123,"phases":27742,"primaryCompletion":17396,"completion":3383,"start":997,"enrollment":2910,"conditions":27743,"interventions":27744},[93],[25687],[17147,25672,25689],{"trials":27746,"activeCount":103},[],{"trials":27748,"activeCount":103},[],{"intervention":7966,"totalTrials":437,"cells":27750},{"EARLY_PHASE1":27751,"PHASE1":27753,"PHASE2":27755,"PHASE3":27757,"PHASE4":27763,"NA":27765},{"trials":27752,"activeCount":103},[],{"trials":27754,"activeCount":103},[],{"trials":27756,"activeCount":103},[],{"trials":27758,"activeCount":103},[27759],{"nctId":7957,"briefTitle":7958,"status":123,"phases":27760,"primaryCompletion":7960,"completion":7961,"start":7962,"enrollment":7963,"conditions":27761,"interventions":27762},[93],[7868],[944,4320,7966,944],{"trials":27764,"activeCount":103},[],{"trials":27766,"activeCount":103},[],{"intervention":23630,"totalTrials":437,"cells":27768},{"EARLY_PHASE1":27769,"PHASE1":27771,"PHASE2":27773,"PHASE3":27775,"PHASE4":27781,"NA":27783},{"trials":27770,"activeCount":103},[],{"trials":27772,"activeCount":103},[],{"trials":27774,"activeCount":103},[],{"trials":27776,"activeCount":103},[27777],{"nctId":23623,"briefTitle":23624,"status":123,"phases":27778,"primaryCompletion":23626,"completion":13727,"start":23627,"enrollment":2166,"conditions":27779,"interventions":27780},[93],[8385],[18081,23630,23631],{"trials":27782,"activeCount":103},[],{"trials":27784,"activeCount":103},[],{"intervention":23631,"totalTrials":437,"cells":27786},{"EARLY_PHASE1":27787,"PHASE1":27789,"PHASE2":27791,"PHASE3":27793,"PHASE4":27799,"NA":27801},{"trials":27788,"activeCount":103},[],{"trials":27790,"activeCount":103},[],{"trials":27792,"activeCount":103},[],{"trials":27794,"activeCount":103},[27795],{"nctId":23623,"briefTitle":23624,"status":123,"phases":27796,"primaryCompletion":23626,"completion":13727,"start":23627,"enrollment":2166,"conditions":27797,"interventions":27798},[93],[8385],[18081,23630,23631],{"trials":27800,"activeCount":103},[],{"trials":27802,"activeCount":103},[],{"intervention":10843,"totalTrials":437,"cells":27804},{"EARLY_PHASE1":27805,"PHASE1":27807,"PHASE2":27809,"PHASE3":27811,"PHASE4":27817,"NA":27819},{"trials":27806,"activeCount":103},[],{"trials":27808,"activeCount":103},[],{"trials":27810,"activeCount":103},[],{"trials":27812,"activeCount":103},[27813],{"nctId":10834,"briefTitle":10835,"status":123,"phases":27814,"primaryCompletion":10837,"completion":10838,"start":10839,"enrollment":2185,"conditions":27815,"interventions":27816},[93],[10841],[944,4451,10843],{"trials":27818,"activeCount":103},[],{"trials":27820,"activeCount":103},[],{"intervention":4693,"totalTrials":437,"cells":27822},{"EARLY_PHASE1":27823,"PHASE1":27825,"PHASE2":27827,"PHASE3":27829,"PHASE4":27835,"NA":27837},{"trials":27824,"activeCount":103},[],{"trials":27826,"activeCount":103},[],{"trials":27828,"activeCount":103},[],{"trials":27830,"activeCount":103},[27831],{"nctId":4684,"briefTitle":4685,"status":123,"phases":27832,"primaryCompletion":4687,"completion":4687,"start":4688,"enrollment":4689,"conditions":27833,"interventions":27834},[93],[4691],[196,4693],{"trials":27836,"activeCount":103},[],{"trials":27838,"activeCount":103},[],{"intervention":27840,"totalTrials":437,"cells":27841},"CNP520 50mg",{"EARLY_PHASE1":27842,"PHASE1":27844,"PHASE2":27846,"PHASE3":27848,"PHASE4":27860,"NA":27862},{"trials":27843,"activeCount":103},[],{"trials":27845,"activeCount":103},[],{"trials":27847,"activeCount":103},[],{"trials":27849,"activeCount":103},[27850],{"nctId":27851,"briefTitle":27852,"status":134,"phases":27853,"primaryCompletion":27854,"completion":27854,"start":27855,"enrollment":27856,"conditions":27857,"interventions":27858},"NCT03131453","A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease",[92,93],"2020-03-26","2017-08-03",1145,[25399],[27840,27859],"CNP520 15mg",{"trials":27861,"activeCount":103},[],{"trials":27863,"activeCount":103},[],{"intervention":27859,"totalTrials":437,"cells":27865},{"EARLY_PHASE1":27866,"PHASE1":27868,"PHASE2":27870,"PHASE3":27872,"PHASE4":27878,"NA":27880},{"trials":27867,"activeCount":103},[],{"trials":27869,"activeCount":103},[],{"trials":27871,"activeCount":103},[],{"trials":27873,"activeCount":103},[27874],{"nctId":27851,"briefTitle":27852,"status":134,"phases":27875,"primaryCompletion":27854,"completion":27854,"start":27855,"enrollment":27856,"conditions":27876,"interventions":27877},[92,93],[25399],[27840,27859],{"trials":27879,"activeCount":103},[],{"trials":27881,"activeCount":103},[],{"intervention":27883,"totalTrials":437,"cells":27884},"EFG816",{"EARLY_PHASE1":27885,"PHASE1":27887,"PHASE2":27889,"PHASE3":27891,"PHASE4":27903,"NA":27905},{"trials":27886,"activeCount":103},[],{"trials":27888,"activeCount":103},[],{"trials":27890,"activeCount":103},[],{"trials":27892,"activeCount":103},[27893],{"nctId":27894,"briefTitle":27895,"status":390,"phases":27896,"primaryCompletion":27897,"completion":27898,"start":2425,"enrollment":103,"conditions":27899,"interventions":27901},"NCT03529084","Phase III Study of Nazartinib (EGF816) Versus Erlotinib\u002FGefitinib in First-line Locally Advanced \u002F Metastatic NSCLC With EGFR Activating Mutations",[93],"2020-08-13","2024-06-03",[27900],"Carcinoma, Non-small Cell Lung",[27883,27902],"erlotinib or gefitinib",{"trials":27904,"activeCount":103},[],{"trials":27906,"activeCount":103},[],{"intervention":27902,"totalTrials":437,"cells":27908},{"EARLY_PHASE1":27909,"PHASE1":27911,"PHASE2":27913,"PHASE3":27915,"PHASE4":27921,"NA":27923},{"trials":27910,"activeCount":103},[],{"trials":27912,"activeCount":103},[],{"trials":27914,"activeCount":103},[],{"trials":27916,"activeCount":103},[27917],{"nctId":27894,"briefTitle":27895,"status":390,"phases":27918,"primaryCompletion":27897,"completion":27898,"start":2425,"enrollment":103,"conditions":27919,"interventions":27920},[93],[27900],[27883,27902],{"trials":27922,"activeCount":103},[],{"trials":27924,"activeCount":103},[],{"intervention":16104,"totalTrials":437,"cells":27926},{"EARLY_PHASE1":27927,"PHASE1":27929,"PHASE2":27931,"PHASE3":27933,"PHASE4":27939,"NA":27941},{"trials":27928,"activeCount":103},[],{"trials":27930,"activeCount":103},[],{"trials":27932,"activeCount":103},[],{"trials":27934,"activeCount":103},[27935],{"nctId":16099,"briefTitle":16100,"status":390,"phases":27936,"primaryCompletion":3730,"completion":3730,"start":2509,"enrollment":103,"conditions":27937,"interventions":27938},[93],[18],[15541,16104],{"trials":27940,"activeCount":103},[],{"trials":27942,"activeCount":103},[],{"intervention":17420,"totalTrials":437,"cells":27944},{"EARLY_PHASE1":27945,"PHASE1":27947,"PHASE2":27949,"PHASE3":27951,"PHASE4":27957,"NA":27959},{"trials":27946,"activeCount":103},[],{"trials":27948,"activeCount":103},[],{"trials":27950,"activeCount":103},[],{"trials":27952,"activeCount":103},[27953],{"nctId":17413,"briefTitle":17414,"status":123,"phases":27954,"primaryCompletion":16570,"start":3657,"enrollment":22,"conditions":27955,"interventions":27956},[93],[17417,17418],[17420,17382],{"trials":27958,"activeCount":103},[],{"trials":27960,"activeCount":103},[],{"intervention":27962,"totalTrials":437,"cells":27963},"Vildagliptin AM",{"EARLY_PHASE1":27964,"PHASE1":27966,"PHASE2":27968,"PHASE3":27970,"PHASE4":27980,"NA":27982},{"trials":27965,"activeCount":103},[],{"trials":27967,"activeCount":103},[],{"trials":27969,"activeCount":103},[],{"trials":27971,"activeCount":103},[27972],{"nctId":27973,"briefTitle":27974,"status":123,"phases":27975,"primaryCompletion":4642,"start":8091,"enrollment":27976,"conditions":27977,"interventions":27978},"NCT00351884","Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes",[93],370,[30],[27962,27979],"vildagliptin pm",{"trials":27981,"activeCount":103},[],{"trials":27983,"activeCount":103},[],{"intervention":27979,"totalTrials":437,"cells":27985},{"EARLY_PHASE1":27986,"PHASE1":27988,"PHASE2":27990,"PHASE3":27992,"PHASE4":27998,"NA":28000},{"trials":27987,"activeCount":103},[],{"trials":27989,"activeCount":103},[],{"trials":27991,"activeCount":103},[],{"trials":27993,"activeCount":103},[27994],{"nctId":27973,"briefTitle":27974,"status":123,"phases":27995,"primaryCompletion":4642,"start":8091,"enrollment":27976,"conditions":27996,"interventions":27997},[93],[30],[27962,27979],{"trials":27999,"activeCount":103},[],{"trials":28001,"activeCount":103},[],{"intervention":15127,"totalTrials":437,"cells":28003},{"EARLY_PHASE1":28004,"PHASE1":28006,"PHASE2":28008,"PHASE3":28010,"PHASE4":28016,"NA":28018},{"trials":28005,"activeCount":103},[],{"trials":28007,"activeCount":103},[],{"trials":28009,"activeCount":103},[],{"trials":28011,"activeCount":103},[28012],{"nctId":15121,"briefTitle":15122,"status":123,"phases":28013,"primaryCompletion":15109,"completion":15109,"start":15058,"enrollment":15124,"conditions":28014,"interventions":28015},[93],[30],[15029,15096,15127],{"trials":28017,"activeCount":103},[],{"trials":28019,"activeCount":103},[],{"intervention":28021,"totalTrials":437,"cells":28022},"Fevipiprant 150 mg",{"EARLY_PHASE1":28023,"PHASE1":28025,"PHASE2":28027,"PHASE3":28029,"PHASE4":28042,"NA":28044},{"trials":28024,"activeCount":103},[],{"trials":28026,"activeCount":103},[],{"trials":28028,"activeCount":103},[],{"trials":28030,"activeCount":103},[28031],{"nctId":28032,"briefTitle":28033,"status":123,"phases":28034,"primaryCompletion":28035,"completion":28036,"start":28037,"enrollment":6014,"conditions":28038,"interventions":28040},"NCT03681093","Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma",[93],"2020-05-29","2020-06-10","2019-03-26",[28039],"Nasal Polyps",[28021,28041],"Fevipiprant 450 mg",{"trials":28043,"activeCount":103},[],{"trials":28045,"activeCount":103},[],{"intervention":28041,"totalTrials":437,"cells":28047},{"EARLY_PHASE1":28048,"PHASE1":28050,"PHASE2":28052,"PHASE3":28054,"PHASE4":28060,"NA":28062},{"trials":28049,"activeCount":103},[],{"trials":28051,"activeCount":103},[],{"trials":28053,"activeCount":103},[],{"trials":28055,"activeCount":103},[28056],{"nctId":28032,"briefTitle":28033,"status":123,"phases":28057,"primaryCompletion":28035,"completion":28036,"start":28037,"enrollment":6014,"conditions":28058,"interventions":28059},[93],[28039],[28021,28041],{"trials":28061,"activeCount":103},[],{"trials":28063,"activeCount":103},[],{"intervention":1259,"totalTrials":437,"cells":28065},{"EARLY_PHASE1":28066,"PHASE1":28068,"PHASE2":28070,"PHASE3":28072,"PHASE4":28078,"NA":28080},{"trials":28067,"activeCount":103},[],{"trials":28069,"activeCount":103},[],{"trials":28071,"activeCount":103},[],{"trials":28073,"activeCount":103},[28074],{"nctId":1250,"briefTitle":1251,"status":123,"phases":28075,"primaryCompletion":1253,"completion":1254,"start":1255,"enrollment":1256,"conditions":28076,"interventions":28077},[93],[36],[1078,1259,173],{"trials":28079,"activeCount":103},[],{"trials":28081,"activeCount":103},[],{"intervention":16564,"totalTrials":437,"cells":28083},{"EARLY_PHASE1":28084,"PHASE1":28086,"PHASE2":28088,"PHASE3":28090,"PHASE4":28096,"NA":28098},{"trials":28085,"activeCount":103},[],{"trials":28087,"activeCount":103},[],{"trials":28089,"activeCount":103},[],{"trials":28091,"activeCount":103},[28092],{"nctId":16555,"briefTitle":16556,"status":123,"phases":28093,"primaryCompletion":16558,"completion":16558,"start":16559,"enrollment":16560,"conditions":28094,"interventions":28095},[93],[16562],[7711,16564,16565],{"trials":28097,"activeCount":103},[],{"trials":28099,"activeCount":103},[],{"intervention":16565,"totalTrials":437,"cells":28101},{"EARLY_PHASE1":28102,"PHASE1":28104,"PHASE2":28106,"PHASE3":28108,"PHASE4":28114,"NA":28116},{"trials":28103,"activeCount":103},[],{"trials":28105,"activeCount":103},[],{"trials":28107,"activeCount":103},[],{"trials":28109,"activeCount":103},[28110],{"nctId":16555,"briefTitle":16556,"status":123,"phases":28111,"primaryCompletion":16558,"completion":16558,"start":16559,"enrollment":16560,"conditions":28112,"interventions":28113},[93],[16562],[7711,16564,16565],{"trials":28115,"activeCount":103},[],{"trials":28117,"activeCount":103},[],{"intervention":28119,"totalTrials":437,"cells":28120},"Everolimus and tacrolimus",{"EARLY_PHASE1":28121,"PHASE1":28123,"PHASE2":28125,"PHASE3":28127,"PHASE4":28136,"NA":28138},{"trials":28122,"activeCount":103},[],{"trials":28124,"activeCount":103},[],{"trials":28126,"activeCount":103},[],{"trials":28128,"activeCount":103},[28129],{"nctId":28130,"briefTitle":28131,"status":123,"phases":28132,"primaryCompletion":4967,"completion":4967,"start":3551,"enrollment":16786,"conditions":28133,"interventions":28134},"NCT01025817","Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients",[93],[5042],[28119,28135],"mycophenolate mofetil and tacrolimus",{"trials":28137,"activeCount":103},[],{"trials":28139,"activeCount":103},[],{"intervention":28135,"totalTrials":437,"cells":28141},{"EARLY_PHASE1":28142,"PHASE1":28144,"PHASE2":28146,"PHASE3":28148,"PHASE4":28154,"NA":28156},{"trials":28143,"activeCount":103},[],{"trials":28145,"activeCount":103},[],{"trials":28147,"activeCount":103},[],{"trials":28149,"activeCount":103},[28150],{"nctId":28130,"briefTitle":28131,"status":123,"phases":28151,"primaryCompletion":4967,"completion":4967,"start":3551,"enrollment":16786,"conditions":28152,"interventions":28153},[93],[5042],[28119,28135],{"trials":28155,"activeCount":103},[],{"trials":28157,"activeCount":103},[],{"intervention":28159,"totalTrials":437,"cells":28160},"LOU064 25 mg",{"EARLY_PHASE1":28161,"PHASE1":28163,"PHASE2":28165,"PHASE3":28167,"PHASE4":28177,"NA":28179},{"trials":28162,"activeCount":103},[],{"trials":28164,"activeCount":103},[],{"trials":28166,"activeCount":103},[],{"trials":28168,"activeCount":103},[28169],{"nctId":28170,"briefTitle":28171,"status":123,"phases":28172,"primaryCompletion":9909,"completion":28173,"start":2220,"enrollment":6215,"conditions":28174,"interventions":28175},"NCT05030311","A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines",[93],"2024-01-19",[33],[28159,28176],"LOU064 25 mg (b.i.d) as a tablet.",{"trials":28178,"activeCount":103},[],{"trials":28180,"activeCount":103},[],{"intervention":28176,"totalTrials":437,"cells":28182},{"EARLY_PHASE1":28183,"PHASE1":28185,"PHASE2":28187,"PHASE3":28189,"PHASE4":28195,"NA":28197},{"trials":28184,"activeCount":103},[],{"trials":28186,"activeCount":103},[],{"trials":28188,"activeCount":103},[],{"trials":28190,"activeCount":103},[28191],{"nctId":28170,"briefTitle":28171,"status":123,"phases":28192,"primaryCompletion":9909,"completion":28173,"start":2220,"enrollment":6215,"conditions":28193,"interventions":28194},[93],[33],[28159,28176],{"trials":28196,"activeCount":103},[],{"trials":28198,"activeCount":103},[],{"intervention":22968,"totalTrials":437,"cells":28200},{"EARLY_PHASE1":28201,"PHASE1":28203,"PHASE2":28205,"PHASE3":28207,"PHASE4":28213,"NA":28215},{"trials":28202,"activeCount":103},[],{"trials":28204,"activeCount":103},[],{"trials":28206,"activeCount":103},[],{"trials":28208,"activeCount":103},[28209],{"nctId":22962,"briefTitle":22963,"status":123,"phases":28210,"primaryCompletion":2426,"completion":2426,"start":1264,"enrollment":568,"conditions":28211,"interventions":28212},[93],[22966],[11428,22968],{"trials":28214,"activeCount":103},[],{"trials":28216,"activeCount":103},[],{"intervention":22976,"totalTrials":437,"cells":28218},{"EARLY_PHASE1":28219,"PHASE1":28221,"PHASE2":28223,"PHASE3":28225,"PHASE4":28231,"NA":28233},{"trials":28220,"activeCount":103},[],{"trials":28222,"activeCount":103},[],{"trials":28224,"activeCount":103},[],{"trials":28226,"activeCount":103},[28227],{"nctId":22970,"briefTitle":22971,"status":123,"phases":28228,"primaryCompletion":2458,"completion":2458,"start":1818,"enrollment":22973,"conditions":28229,"interventions":28230},[93],[1717],[11428,22976],{"trials":28232,"activeCount":103},[],{"trials":28234,"activeCount":103},[],{"intervention":28236,"totalTrials":437,"cells":28237},"Investigational Arm - secukinumab",{"EARLY_PHASE1":28238,"PHASE1":28240,"PHASE2":28242,"PHASE3":28244,"PHASE4":28254,"NA":28256},{"trials":28239,"activeCount":103},[],{"trials":28241,"activeCount":103},[],{"trials":28243,"activeCount":103},[],{"trials":28245,"activeCount":103},[28246],{"nctId":28247,"briefTitle":28248,"status":134,"phases":28249,"primaryCompletion":28250,"completion":2909,"start":27702,"enrollment":5594,"conditions":28251,"interventions":28252},"NCT04237116","A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)",[93],"2021-06-29",[1773,11368],[28236,28253],"Control Arm - placebo",{"trials":28255,"activeCount":103},[],{"trials":28257,"activeCount":103},[],{"intervention":28253,"totalTrials":437,"cells":28259},{"EARLY_PHASE1":28260,"PHASE1":28262,"PHASE2":28264,"PHASE3":28266,"PHASE4":28272,"NA":28274},{"trials":28261,"activeCount":103},[],{"trials":28263,"activeCount":103},[],{"trials":28265,"activeCount":103},[],{"trials":28267,"activeCount":103},[28268],{"nctId":28247,"briefTitle":28248,"status":134,"phases":28269,"primaryCompletion":28250,"completion":2909,"start":27702,"enrollment":5594,"conditions":28270,"interventions":28271},[93],[1773,11368],[28236,28253],{"trials":28273,"activeCount":103},[],{"trials":28275,"activeCount":103},[],{"intervention":15573,"totalTrials":437,"cells":28277},{"EARLY_PHASE1":28278,"PHASE1":28280,"PHASE2":28282,"PHASE3":28284,"PHASE4":28290,"NA":28292},{"trials":28279,"activeCount":103},[],{"trials":28281,"activeCount":103},[],{"trials":28283,"activeCount":103},[],{"trials":28285,"activeCount":103},[28286],{"nctId":15567,"briefTitle":15568,"status":123,"phases":28287,"primaryCompletion":3861,"completion":3861,"start":2033,"enrollment":15570,"conditions":28288,"interventions":28289},[93],[15555],[15524,15573],{"trials":28291,"activeCount":103},[],{"trials":28293,"activeCount":103},[],{"intervention":25401,"totalTrials":437,"cells":28295},{"EARLY_PHASE1":28296,"PHASE1":28298,"PHASE2":28300,"PHASE3":28302,"PHASE4":28308,"NA":28310},{"trials":28297,"activeCount":103},[],{"trials":28299,"activeCount":103},[],{"trials":28301,"activeCount":103},[],{"trials":28303,"activeCount":103},[28304],{"nctId":25393,"briefTitle":25394,"status":134,"phases":28305,"primaryCompletion":25396,"completion":25396,"start":25397,"enrollment":2845,"conditions":28306,"interventions":28307},[92,93],[25399],[25401,25376],{"trials":28309,"activeCount":103},[],{"trials":28311,"activeCount":103},[],{"intervention":7976,"totalTrials":437,"cells":28313},{"EARLY_PHASE1":28314,"PHASE1":28316,"PHASE2":28318,"PHASE3":28320,"PHASE4":28326,"NA":28328},{"trials":28315,"activeCount":103},[],{"trials":28317,"activeCount":103},[],{"trials":28319,"activeCount":103},[],{"trials":28321,"activeCount":103},[28322],{"nctId":7968,"briefTitle":7969,"status":123,"phases":28323,"primaryCompletion":7971,"completion":5830,"start":7972,"enrollment":7973,"conditions":28324,"interventions":28325},[93],[15],[4780,6673,7976,7872],{"trials":28327,"activeCount":103},[],{"trials":28329,"activeCount":103},[],{"intervention":25994,"totalTrials":437,"cells":28331},{"EARLY_PHASE1":28332,"PHASE1":28334,"PHASE2":28336,"PHASE3":28338,"PHASE4":28344,"NA":28346},{"trials":28333,"activeCount":103},[],{"trials":28335,"activeCount":103},[],{"trials":28337,"activeCount":103},[],{"trials":28339,"activeCount":103},[28340],{"nctId":25986,"briefTitle":25987,"status":134,"phases":28341,"primaryCompletion":1025,"start":16010,"enrollment":524,"conditions":28342,"interventions":28343},[93],[25990,25991],[25975,25993,25994],{"trials":28345,"activeCount":103},[],{"trials":28347,"activeCount":103},[],{"intervention":28349,"totalTrials":437,"cells":28350},"AIN457 6 mg\u002Fkg i.v.",{"EARLY_PHASE1":28351,"PHASE1":28353,"PHASE2":28355,"PHASE3":28357,"PHASE4":28367,"NA":28369},{"trials":28352,"activeCount":103},[],{"trials":28354,"activeCount":103},[],{"trials":28356,"activeCount":103},[],{"trials":28358,"activeCount":103},[28359],{"nctId":28360,"briefTitle":28361,"status":123,"phases":28362,"primaryCompletion":10689,"completion":10689,"start":28363,"enrollment":18010,"conditions":28364,"interventions":28365},"NCT04209205","Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis",[93],"2020-01-29",[1821],[28349,28366],"AIN457 3 mg\u002Fkg",{"trials":28368,"activeCount":103},[],{"trials":28370,"activeCount":103},[],{"intervention":28366,"totalTrials":437,"cells":28372},{"EARLY_PHASE1":28373,"PHASE1":28375,"PHASE2":28377,"PHASE3":28379,"PHASE4":28385,"NA":28387},{"trials":28374,"activeCount":103},[],{"trials":28376,"activeCount":103},[],{"trials":28378,"activeCount":103},[],{"trials":28380,"activeCount":103},[28381],{"nctId":28360,"briefTitle":28361,"status":123,"phases":28382,"primaryCompletion":10689,"completion":10689,"start":28363,"enrollment":18010,"conditions":28383,"interventions":28384},[93],[1821],[28349,28366],{"trials":28386,"activeCount":103},[],{"trials":28388,"activeCount":103},[],{"intervention":28390,"totalTrials":437,"cells":28391},"ACZ885 150 mg",{"EARLY_PHASE1":28392,"PHASE1":28394,"PHASE2":28396,"PHASE3":28398,"PHASE4":28408,"NA":28410},{"trials":28393,"activeCount":103},[],{"trials":28395,"activeCount":103},[],{"trials":28397,"activeCount":103},[],{"trials":28399,"activeCount":103},[28400],{"nctId":28401,"briefTitle":28402,"status":123,"phases":28403,"primaryCompletion":4385,"completion":5131,"start":28404,"enrollment":4976,"conditions":28405,"interventions":28407},"NCT02296424","ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab",[93],"2014-11-17",[28406],"Systemic Juvenile Idiopathic Arthritis (SJIA)",[28390],{"trials":28409,"activeCount":103},[],{"trials":28411,"activeCount":103},[],{"intervention":25063,"totalTrials":437,"cells":28413},{"EARLY_PHASE1":28414,"PHASE1":28416,"PHASE2":28418,"PHASE3":28420,"PHASE4":28426,"NA":28428},{"trials":28415,"activeCount":103},[],{"trials":28417,"activeCount":103},[],{"trials":28419,"activeCount":103},[],{"trials":28421,"activeCount":103},[28422],{"nctId":25055,"briefTitle":25056,"status":134,"phases":28423,"primaryCompletion":25058,"completion":25058,"start":25059,"enrollment":2948,"conditions":28424,"interventions":28425},[93],[25061],[25063,25034],{"trials":28427,"activeCount":103},[],{"trials":28429,"activeCount":103},[],{"intervention":15148,"totalTrials":437,"cells":28431},{"EARLY_PHASE1":28432,"PHASE1":28434,"PHASE2":28436,"PHASE3":28438,"PHASE4":28444,"NA":28446},{"trials":28433,"activeCount":103},[],{"trials":28435,"activeCount":103},[],{"trials":28437,"activeCount":103},[],{"trials":28439,"activeCount":103},[28440],{"nctId":15142,"briefTitle":15143,"status":123,"phases":28441,"primaryCompletion":2458,"completion":2458,"start":1682,"enrollment":25,"conditions":28442,"interventions":28443},[93],[15146],[15051,13838,15148,15149],{"trials":28445,"activeCount":103},[],{"trials":28447,"activeCount":103},[],{"intervention":15149,"totalTrials":437,"cells":28449},{"EARLY_PHASE1":28450,"PHASE1":28452,"PHASE2":28454,"PHASE3":28456,"PHASE4":28462,"NA":28464},{"trials":28451,"activeCount":103},[],{"trials":28453,"activeCount":103},[],{"trials":28455,"activeCount":103},[],{"trials":28457,"activeCount":103},[28458],{"nctId":15142,"briefTitle":15143,"status":123,"phases":28459,"primaryCompletion":2458,"completion":2458,"start":1682,"enrollment":25,"conditions":28460,"interventions":28461},[93],[15146],[15051,13838,15148,15149],{"trials":28463,"activeCount":103},[],{"trials":28465,"activeCount":103},[],{"intervention":13132,"totalTrials":437,"cells":28467},{"EARLY_PHASE1":28468,"PHASE1":28470,"PHASE2":28472,"PHASE3":28474,"PHASE4":28480,"NA":28482},{"trials":28469,"activeCount":103},[],{"trials":28471,"activeCount":103},[],{"trials":28473,"activeCount":103},[],{"trials":28475,"activeCount":103},[28476],{"nctId":13124,"briefTitle":13125,"status":123,"phases":28477,"primaryCompletion":13127,"completion":13127,"start":13128,"enrollment":13129,"conditions":28478,"interventions":28479},[93],[5598],[9866,13132],{"trials":28481,"activeCount":103},[],{"trials":28483,"activeCount":103},[],{"intervention":2823,"totalTrials":437,"cells":28485},{"EARLY_PHASE1":28486,"PHASE1":28488,"PHASE2":28490,"PHASE3":28492,"PHASE4":28498,"NA":28500},{"trials":28487,"activeCount":103},[],{"trials":28489,"activeCount":103},[],{"trials":28491,"activeCount":103},[],{"trials":28493,"activeCount":103},[28494],{"nctId":2814,"briefTitle":2815,"status":134,"phases":28495,"primaryCompletion":2817,"completion":2818,"start":2819,"enrollment":2820,"conditions":28496,"interventions":28497},[93],[2799],[2823,2824],{"trials":28499,"activeCount":103},[],{"trials":28501,"activeCount":103},[],{"intervention":28503,"totalTrials":437,"cells":28504},"Labeled regime arm",{"EARLY_PHASE1":28505,"PHASE1":28507,"PHASE2":28509,"PHASE3":28511,"PHASE4":28521,"NA":28523},{"trials":28506,"activeCount":103},[],{"trials":28508,"activeCount":103},[],{"trials":28510,"activeCount":103},[],{"trials":28512,"activeCount":103},[28513],{"nctId":28514,"briefTitle":28515,"status":123,"phases":28516,"primaryCompletion":13716,"completion":13716,"start":28517,"enrollment":3776,"conditions":28518,"interventions":28519},"NCT02262260","Compare Safety\u002FEfficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME",[93],"2014-12-12",[16741],[28503,28520],"Wait and Extend regime arm",{"trials":28522,"activeCount":103},[],{"trials":28524,"activeCount":103},[],{"intervention":28520,"totalTrials":437,"cells":28526},{"EARLY_PHASE1":28527,"PHASE1":28529,"PHASE2":28531,"PHASE3":28533,"PHASE4":28539,"NA":28541},{"trials":28528,"activeCount":103},[],{"trials":28530,"activeCount":103},[],{"trials":28532,"activeCount":103},[],{"trials":28534,"activeCount":103},[28535],{"nctId":28514,"briefTitle":28515,"status":123,"phases":28536,"primaryCompletion":13716,"completion":13716,"start":28517,"enrollment":3776,"conditions":28537,"interventions":28538},[93],[16741],[28503,28520],{"trials":28540,"activeCount":103},[],{"trials":28542,"activeCount":103},[],{"intervention":25758,"totalTrials":437,"cells":28544},{"EARLY_PHASE1":28545,"PHASE1":28547,"PHASE2":28549,"PHASE3":28551,"PHASE4":28557,"NA":28559},{"trials":28546,"activeCount":103},[],{"trials":28548,"activeCount":103},[],{"trials":28550,"activeCount":103},[],{"trials":28552,"activeCount":103},[28553],{"nctId":25751,"briefTitle":25752,"status":123,"phases":28554,"primaryCompletion":25754,"completion":2045,"start":25755,"enrollment":18792,"conditions":28555,"interventions":28556},[93],[1974],[25758,25731],{"trials":28558,"activeCount":103},[],{"trials":28560,"activeCount":103},[],{"intervention":16115,"totalTrials":437,"cells":28562},{"EARLY_PHASE1":28563,"PHASE1":28565,"PHASE2":28567,"PHASE3":28569,"PHASE4":28575,"NA":28577},{"trials":28564,"activeCount":103},[],{"trials":28566,"activeCount":103},[],{"trials":28568,"activeCount":103},[],{"trials":28570,"activeCount":103},[28571],{"nctId":16110,"briefTitle":16111,"status":123,"phases":28572,"primaryCompletion":3382,"completion":3382,"start":1761,"enrollment":13129,"conditions":28573,"interventions":28574},[93],[15555],[15541,16115],{"trials":28576,"activeCount":103},[],{"trials":28578,"activeCount":103},[],{"intervention":6801,"totalTrials":437,"cells":28580},{"EARLY_PHASE1":28581,"PHASE1":28583,"PHASE2":28585,"PHASE3":28587,"PHASE4":28593,"NA":28595},{"trials":28582,"activeCount":103},[],{"trials":28584,"activeCount":103},[],{"trials":28586,"activeCount":103},[],{"trials":28588,"activeCount":103},[28589],{"nctId":6793,"briefTitle":6794,"status":123,"phases":28590,"primaryCompletion":6796,"completion":6797,"start":6798,"enrollment":608,"conditions":28591,"interventions":28592},[93],[6080],[6722,6801,6802],{"trials":28594,"activeCount":103},[],{"trials":28596,"activeCount":103},[],{"intervention":6802,"totalTrials":437,"cells":28598},{"EARLY_PHASE1":28599,"PHASE1":28601,"PHASE2":28603,"PHASE3":28605,"PHASE4":28611,"NA":28613},{"trials":28600,"activeCount":103},[],{"trials":28602,"activeCount":103},[],{"trials":28604,"activeCount":103},[],{"trials":28606,"activeCount":103},[28607],{"nctId":6793,"briefTitle":6794,"status":123,"phases":28608,"primaryCompletion":6796,"completion":6797,"start":6798,"enrollment":608,"conditions":28609,"interventions":28610},[93],[6080],[6722,6801,6802],{"trials":28612,"activeCount":103},[],{"trials":28614,"activeCount":103},[],{"intervention":28616,"totalTrials":437,"cells":28617},"Zoledronic acid 5 mg iv",{"EARLY_PHASE1":28618,"PHASE1":28620,"PHASE2":28622,"PHASE3":28624,"PHASE4":28634,"NA":28636},{"trials":28619,"activeCount":103},[],{"trials":28621,"activeCount":103},[],{"trials":28623,"activeCount":103},[],{"trials":28625,"activeCount":103},[28626],{"nctId":28627,"briefTitle":28628,"status":123,"phases":28629,"primaryCompletion":5620,"completion":5620,"start":3657,"enrollment":28630,"conditions":28631,"interventions":28633},"NCT00439647","Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis",[93],1199,[28632],"Male Osteoporosis",[28616],{"trials":28635,"activeCount":103},[],{"trials":28637,"activeCount":103},[],{"intervention":28639,"totalTrials":437,"cells":28640},"NVA237 50 µg and indacaterol 150 µg",{"EARLY_PHASE1":28641,"PHASE1":28643,"PHASE2":28645,"PHASE3":28647,"PHASE4":28656,"NA":28658},{"trials":28642,"activeCount":103},[],{"trials":28644,"activeCount":103},[],{"trials":28646,"activeCount":103},[],{"trials":28648,"activeCount":103},[28649],{"nctId":28650,"briefTitle":28651,"status":123,"phases":28652,"primaryCompletion":1670,"completion":1670,"start":5733,"enrollment":28653,"conditions":28654,"interventions":28655},"NCT01604278","Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[93],449,[15555],[28639],{"trials":28657,"activeCount":103},[],{"trials":28659,"activeCount":103},[],{"intervention":28661,"totalTrials":437,"cells":28662},"Everolimus 0.25 and 0.75 mg",{"EARLY_PHASE1":28663,"PHASE1":28665,"PHASE2":28667,"PHASE3":28669,"PHASE4":28681,"NA":28683},{"trials":28664,"activeCount":103},[],{"trials":28666,"activeCount":103},[],{"trials":28668,"activeCount":103},[],{"trials":28670,"activeCount":103},[28671],{"nctId":28672,"briefTitle":28673,"status":123,"phases":28674,"primaryCompletion":3612,"completion":3612,"start":8091,"enrollment":28675,"conditions":28676,"interventions":28678},"NCT01276457","Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients",[93],223,[28677],"Transplantation Infection",[28661,28679,28680],"Cyclosporine very low dose (150-300 ng\u002FmL) microemulsion","Cyclosporine low dose (350-500 ng\u002FmL) microemulsion",{"trials":28682,"activeCount":103},[],{"trials":28684,"activeCount":103},[],{"intervention":28679,"totalTrials":437,"cells":28686},{"EARLY_PHASE1":28687,"PHASE1":28689,"PHASE2":28691,"PHASE3":28693,"PHASE4":28699,"NA":28701},{"trials":28688,"activeCount":103},[],{"trials":28690,"activeCount":103},[],{"trials":28692,"activeCount":103},[],{"trials":28694,"activeCount":103},[28695],{"nctId":28672,"briefTitle":28673,"status":123,"phases":28696,"primaryCompletion":3612,"completion":3612,"start":8091,"enrollment":28675,"conditions":28697,"interventions":28698},[93],[28677],[28661,28679,28680],{"trials":28700,"activeCount":103},[],{"trials":28702,"activeCount":103},[],{"intervention":28680,"totalTrials":437,"cells":28704},{"EARLY_PHASE1":28705,"PHASE1":28707,"PHASE2":28709,"PHASE3":28711,"PHASE4":28717,"NA":28719},{"trials":28706,"activeCount":103},[],{"trials":28708,"activeCount":103},[],{"trials":28710,"activeCount":103},[],{"trials":28712,"activeCount":103},[28713],{"nctId":28672,"briefTitle":28673,"status":123,"phases":28714,"primaryCompletion":3612,"completion":3612,"start":8091,"enrollment":28675,"conditions":28715,"interventions":28716},[93],[28677],[28661,28679,28680],{"trials":28718,"activeCount":103},[],{"trials":28720,"activeCount":103},[],{"intervention":4754,"totalTrials":437,"cells":28722},{"EARLY_PHASE1":28723,"PHASE1":28725,"PHASE2":28727,"PHASE3":28729,"PHASE4":28735,"NA":28737},{"trials":28724,"activeCount":103},[],{"trials":28726,"activeCount":103},[],{"trials":28728,"activeCount":103},[],{"trials":28730,"activeCount":103},[28731],{"nctId":4747,"briefTitle":4748,"status":123,"phases":28732,"primaryCompletion":4410,"completion":4410,"start":4317,"enrollment":4750,"conditions":28733,"interventions":28734},[93],[4691],[196,4753,4754,4755],{"trials":28736,"activeCount":103},[],{"trials":28738,"activeCount":103},[],{"intervention":28740,"totalTrials":437,"cells":28741},"Everolimus + reduced tacrolimus",{"EARLY_PHASE1":28742,"PHASE1":28744,"PHASE2":28746,"PHASE3":28748,"PHASE4":28761,"NA":28763},{"trials":28743,"activeCount":103},[],{"trials":28745,"activeCount":103},[],{"trials":28747,"activeCount":103},[],{"trials":28749,"activeCount":103},[28750],{"nctId":28751,"briefTitle":28752,"status":123,"phases":28753,"primaryCompletion":28754,"completion":28755,"start":28756,"enrollment":28757,"conditions":28758,"interventions":28759},"NCT01888432","Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants",[93],"2016-10-19","2018-04-21","2013-09-25",285,[4645],[28740,28760],"Standard tacrolimus",{"trials":28762,"activeCount":103},[],{"trials":28764,"activeCount":103},[],{"intervention":28760,"totalTrials":437,"cells":28766},{"EARLY_PHASE1":28767,"PHASE1":28769,"PHASE2":28771,"PHASE3":28773,"PHASE4":28779,"NA":28781},{"trials":28768,"activeCount":103},[],{"trials":28770,"activeCount":103},[],{"trials":28772,"activeCount":103},[],{"trials":28774,"activeCount":103},[28775],{"nctId":28751,"briefTitle":28752,"status":123,"phases":28776,"primaryCompletion":28754,"completion":28755,"start":28756,"enrollment":28757,"conditions":28777,"interventions":28778},[93],[4645],[28740,28760],{"trials":28780,"activeCount":103},[],{"trials":28782,"activeCount":103},[],{"intervention":28784,"totalTrials":437,"cells":28785},"LCZ696 200 mg BID",{"EARLY_PHASE1":28786,"PHASE1":28788,"PHASE2":28790,"PHASE3":28792,"PHASE4":28802,"NA":28804},{"trials":28787,"activeCount":103},[],{"trials":28789,"activeCount":103},[],{"trials":28791,"activeCount":103},[],{"trials":28793,"activeCount":103},[28794],{"nctId":28795,"briefTitle":28796,"status":134,"phases":28797,"primaryCompletion":4515,"completion":4515,"start":3271,"enrollment":28798,"conditions":28799,"interventions":28800},"NCT01035255","This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure",[93],8442,[14475],[28784,28801],"Enalapril 10 mg BID",{"trials":28803,"activeCount":103},[],{"trials":28805,"activeCount":103},[],{"intervention":28801,"totalTrials":437,"cells":28807},{"EARLY_PHASE1":28808,"PHASE1":28810,"PHASE2":28812,"PHASE3":28814,"PHASE4":28820,"NA":28822},{"trials":28809,"activeCount":103},[],{"trials":28811,"activeCount":103},[],{"trials":28813,"activeCount":103},[],{"trials":28815,"activeCount":103},[28816],{"nctId":28795,"briefTitle":28796,"status":134,"phases":28817,"primaryCompletion":4515,"completion":4515,"start":3271,"enrollment":28798,"conditions":28818,"interventions":28819},[93],[14475],[28784,28801],{"trials":28821,"activeCount":103},[],{"trials":28823,"activeCount":103},[],{"intervention":25070,"totalTrials":437,"cells":28825},{"EARLY_PHASE1":28826,"PHASE1":28828,"PHASE2":28830,"PHASE3":28832,"PHASE4":28838,"NA":28840},{"trials":28827,"activeCount":103},[],{"trials":28829,"activeCount":103},[],{"trials":28831,"activeCount":103},[],{"trials":28833,"activeCount":103},[28834],{"nctId":25065,"briefTitle":25066,"status":123,"phases":28835,"primaryCompletion":3243,"completion":3243,"start":3784,"enrollment":1839,"conditions":28836,"interventions":28837},[93],[23437],[25070,25071,25072],{"trials":28839,"activeCount":103},[],{"trials":28841,"activeCount":103},[],{"intervention":25071,"totalTrials":437,"cells":28843},{"EARLY_PHASE1":28844,"PHASE1":28846,"PHASE2":28848,"PHASE3":28850,"PHASE4":28856,"NA":28858},{"trials":28845,"activeCount":103},[],{"trials":28847,"activeCount":103},[],{"trials":28849,"activeCount":103},[],{"trials":28851,"activeCount":103},[28852],{"nctId":25065,"briefTitle":25066,"status":123,"phases":28853,"primaryCompletion":3243,"completion":3243,"start":3784,"enrollment":1839,"conditions":28854,"interventions":28855},[93],[23437],[25070,25071,25072],{"trials":28857,"activeCount":103},[],{"trials":28859,"activeCount":103},[],{"intervention":9124,"totalTrials":437,"cells":28861},{"EARLY_PHASE1":28862,"PHASE1":28864,"PHASE2":28866,"PHASE3":28868,"PHASE4":28874,"NA":28876},{"trials":28863,"activeCount":103},[],{"trials":28865,"activeCount":103},[],{"trials":28867,"activeCount":103},[],{"trials":28869,"activeCount":103},[28870],{"nctId":9119,"briefTitle":9120,"status":123,"phases":28871,"primaryCompletion":3473,"completion":3473,"start":966,"enrollment":3587,"conditions":28872,"interventions":28873},[93],[9070],[9124,6218],{"trials":28875,"activeCount":103},[],{"trials":28877,"activeCount":103},[],{"intervention":15169,"totalTrials":437,"cells":28879},{"EARLY_PHASE1":28880,"PHASE1":28882,"PHASE2":28884,"PHASE3":28886,"PHASE4":28892,"NA":28894},{"trials":28881,"activeCount":103},[],{"trials":28883,"activeCount":103},[],{"trials":28885,"activeCount":103},[],{"trials":28887,"activeCount":103},[28888],{"nctId":15163,"briefTitle":15164,"status":123,"phases":28889,"primaryCompletion":3447,"start":825,"enrollment":15166,"conditions":28890,"interventions":28891},[93],[30],[15029,15169],{"trials":28893,"activeCount":103},[],{"trials":28895,"activeCount":103},[],{"intervention":1459,"totalTrials":437,"cells":28897},{"EARLY_PHASE1":28898,"PHASE1":28900,"PHASE2":28902,"PHASE3":28904,"PHASE4":28910,"NA":28912},{"trials":28899,"activeCount":103},[],{"trials":28901,"activeCount":103},[],{"trials":28903,"activeCount":103},[],{"trials":28905,"activeCount":103},[28906],{"nctId":1449,"briefTitle":1450,"status":123,"phases":28907,"primaryCompletion":1452,"completion":1452,"start":1453,"enrollment":1454,"conditions":28908,"interventions":28909},[93],[1371,1456,1457],[1356,1459],{"trials":28911,"activeCount":103},[],{"trials":28913,"activeCount":103},[],{"intervention":1946,"totalTrials":437,"cells":28915},{"EARLY_PHASE1":28916,"PHASE1":28918,"PHASE2":28920,"PHASE3":28922,"PHASE4":28928,"NA":28930},{"trials":28917,"activeCount":103},[],{"trials":28919,"activeCount":103},[],{"trials":28921,"activeCount":103},[],{"trials":28923,"activeCount":103},[28924],{"nctId":1936,"briefTitle":1937,"status":123,"phases":28925,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":28926,"interventions":28927},[93],[1821,1943,1944],[1659,1946],{"trials":28929,"activeCount":103},[],{"trials":28931,"activeCount":103},[],{"intervention":23439,"totalTrials":437,"cells":28933},{"EARLY_PHASE1":28934,"PHASE1":28936,"PHASE2":28938,"PHASE3":28940,"PHASE4":28946,"NA":28948},{"trials":28935,"activeCount":103},[],{"trials":28937,"activeCount":103},[],{"trials":28939,"activeCount":103},[],{"trials":28941,"activeCount":103},[28942],{"nctId":23433,"briefTitle":23434,"status":390,"phases":28943,"primaryCompletion":3243,"completion":3243,"start":3243,"enrollment":103,"conditions":28944,"interventions":28945},[93],[23437],[10126,23439],{"trials":28947,"activeCount":103},[],{"trials":28949,"activeCount":103},[],{"intervention":28951,"totalTrials":437,"cells":28952},"Zoledronic acid 4 mg",{"EARLY_PHASE1":28953,"PHASE1":28955,"PHASE2":28957,"PHASE3":28959,"PHASE4":28968,"NA":28970},{"trials":28954,"activeCount":103},[],{"trials":28956,"activeCount":103},[],{"trials":28958,"activeCount":103},[],{"trials":28960,"activeCount":103},[28961],{"nctId":28962,"briefTitle":28963,"status":123,"phases":28964,"primaryCompletion":853,"completion":3351,"start":996,"enrollment":28965,"conditions":28966,"interventions":28967},"NCT00172042","A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)",[93],437,[1178],[28951],{"trials":28969,"activeCount":103},[],{"trials":28971,"activeCount":103},[],{"intervention":26002,"totalTrials":437,"cells":28973},{"EARLY_PHASE1":28974,"PHASE1":28976,"PHASE2":28978,"PHASE3":28980,"PHASE4":28986,"NA":28988},{"trials":28975,"activeCount":103},[],{"trials":28977,"activeCount":103},[],{"trials":28979,"activeCount":103},[],{"trials":28981,"activeCount":103},[28982],{"nctId":25996,"briefTitle":25997,"status":123,"phases":28983,"primaryCompletion":895,"completion":895,"start":964,"enrollment":1384,"conditions":28984,"interventions":28985},[93],[26000],[25975,26002],{"trials":28987,"activeCount":103},[],{"trials":28989,"activeCount":103},[],{"intervention":4770,"totalTrials":437,"cells":28991},{"EARLY_PHASE1":28992,"PHASE1":28994,"PHASE2":28996,"PHASE3":28998,"PHASE4":29004,"NA":29006},{"trials":28993,"activeCount":103},[],{"trials":28995,"activeCount":103},[],{"trials":28997,"activeCount":103},[],{"trials":28999,"activeCount":103},[29000],{"nctId":4757,"briefTitle":4758,"status":123,"phases":29001,"primaryCompletion":4760,"completion":4760,"start":4761,"enrollment":4762,"conditions":29002,"interventions":29003},[93],[4691,4701],[196,4765,4766,4767,4768,4769,4770],{"trials":29005,"activeCount":103},[],{"trials":29007,"activeCount":103},[],{"intervention":29009,"totalTrials":437,"cells":29010},"Rivastigmine 5 cm^2",{"EARLY_PHASE1":29011,"PHASE1":29013,"PHASE2":29015,"PHASE3":29017,"PHASE4":29028,"NA":29030},{"trials":29012,"activeCount":103},[],{"trials":29014,"activeCount":103},[],{"trials":29016,"activeCount":103},[],{"trials":29018,"activeCount":103},[29019],{"nctId":29020,"briefTitle":29021,"status":123,"phases":29022,"primaryCompletion":3784,"completion":3784,"start":15800,"enrollment":29023,"conditions":29024,"interventions":29025},"NCT00506415","Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",[93],1584,[14536],[29009,29026,29027],"Rivastigmine 10 cm^2","Rivastigmine 15 cm^2",{"trials":29029,"activeCount":103},[],{"trials":29031,"activeCount":103},[],{"intervention":29026,"totalTrials":437,"cells":29033},{"EARLY_PHASE1":29034,"PHASE1":29036,"PHASE2":29038,"PHASE3":29040,"PHASE4":29046,"NA":29048},{"trials":29035,"activeCount":103},[],{"trials":29037,"activeCount":103},[],{"trials":29039,"activeCount":103},[],{"trials":29041,"activeCount":103},[29042],{"nctId":29020,"briefTitle":29021,"status":123,"phases":29043,"primaryCompletion":3784,"completion":3784,"start":15800,"enrollment":29023,"conditions":29044,"interventions":29045},[93],[14536],[29009,29026,29027],{"trials":29047,"activeCount":103},[],{"trials":29049,"activeCount":103},[],{"intervention":29027,"totalTrials":437,"cells":29051},{"EARLY_PHASE1":29052,"PHASE1":29054,"PHASE2":29056,"PHASE3":29058,"PHASE4":29064,"NA":29066},{"trials":29053,"activeCount":103},[],{"trials":29055,"activeCount":103},[],{"trials":29057,"activeCount":103},[],{"trials":29059,"activeCount":103},[29060],{"nctId":29020,"briefTitle":29021,"status":123,"phases":29061,"primaryCompletion":3784,"completion":3784,"start":15800,"enrollment":29023,"conditions":29062,"interventions":29063},[93],[14536],[29009,29026,29027],{"trials":29065,"activeCount":103},[],{"trials":29067,"activeCount":103},[],{"intervention":25786,"totalTrials":437,"cells":29069},{"EARLY_PHASE1":29070,"PHASE1":29072,"PHASE2":29074,"PHASE3":29076,"PHASE4":29082,"NA":29084},{"trials":29071,"activeCount":103},[],{"trials":29073,"activeCount":103},[],{"trials":29075,"activeCount":103},[],{"trials":29077,"activeCount":103},[29078],{"nctId":25778,"briefTitle":25779,"status":123,"phases":29079,"primaryCompletion":166,"completion":166,"start":25781,"enrollment":25782,"conditions":29080,"interventions":29081},[93],[25784],[25749,25786],{"trials":29083,"activeCount":103},[],{"trials":29085,"activeCount":103},[],{"intervention":29087,"totalTrials":437,"cells":29088},"secukinumab low dose",{"EARLY_PHASE1":29089,"PHASE1":29091,"PHASE2":29093,"PHASE3":29095,"PHASE4":29106,"NA":29108},{"trials":29090,"activeCount":103},[],{"trials":29092,"activeCount":103},[],{"trials":29094,"activeCount":103},[],{"trials":29096,"activeCount":103},[29097],{"nctId":29098,"briefTitle":29099,"status":123,"phases":29100,"primaryCompletion":29101,"completion":29102,"start":243,"enrollment":5982,"conditions":29103,"interventions":29104},"NCT03668613","Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to \u003C18 Years, With Moderate to Severe Plaque Psoriasis",[93],"2019-09-19","2023-09-12",[18200],[29087,29105],"secukinumab high dose",{"trials":29107,"activeCount":103},[],{"trials":29109,"activeCount":103},[],{"intervention":29105,"totalTrials":437,"cells":29111},{"EARLY_PHASE1":29112,"PHASE1":29114,"PHASE2":29116,"PHASE3":29118,"PHASE4":29124,"NA":29126},{"trials":29113,"activeCount":103},[],{"trials":29115,"activeCount":103},[],{"trials":29117,"activeCount":103},[],{"trials":29119,"activeCount":103},[29120],{"nctId":29098,"briefTitle":29099,"status":123,"phases":29121,"primaryCompletion":29101,"completion":29102,"start":243,"enrollment":5982,"conditions":29122,"interventions":29123},[93],[18200],[29087,29105],{"trials":29125,"activeCount":103},[],{"trials":29127,"activeCount":103},[],{"intervention":17427,"totalTrials":437,"cells":29129},{"EARLY_PHASE1":29130,"PHASE1":29132,"PHASE2":29134,"PHASE3":29136,"PHASE4":29142,"NA":29144},{"trials":29131,"activeCount":103},[],{"trials":29133,"activeCount":103},[],{"trials":29135,"activeCount":103},[],{"trials":29137,"activeCount":103},[29138],{"nctId":17422,"briefTitle":17423,"status":123,"phases":29139,"primaryCompletion":3271,"completion":3271,"start":1025,"enrollment":2439,"conditions":29140,"interventions":29141},[93],[17399],[17382,17427],{"trials":29143,"activeCount":103},[],{"trials":29145,"activeCount":103},[],{"intervention":29147,"totalTrials":437,"cells":29148},"TRI476",{"EARLY_PHASE1":29149,"PHASE1":29151,"PHASE2":29153,"PHASE3":29155,"PHASE4":29165,"NA":29167},{"trials":29150,"activeCount":103},[],{"trials":29152,"activeCount":103},[],{"trials":29154,"activeCount":103},[],{"trials":29156,"activeCount":103},[29157],{"nctId":29158,"briefTitle":29159,"status":123,"phases":29160,"primaryCompletion":1761,"completion":1761,"start":4975,"enrollment":2796,"conditions":29161,"interventions":29163},"NCT00975715","Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures",[92,93],[29162],"Partial Onset Seizures",[29147,29164],"Benzodiazepines",{"trials":29166,"activeCount":103},[],{"trials":29168,"activeCount":103},[],{"intervention":29164,"totalTrials":437,"cells":29170},{"EARLY_PHASE1":29171,"PHASE1":29173,"PHASE2":29175,"PHASE3":29177,"PHASE4":29183,"NA":29185},{"trials":29172,"activeCount":103},[],{"trials":29174,"activeCount":103},[],{"trials":29176,"activeCount":103},[],{"trials":29178,"activeCount":103},[29179],{"nctId":29158,"briefTitle":29159,"status":123,"phases":29180,"primaryCompletion":1761,"completion":1761,"start":4975,"enrollment":2796,"conditions":29181,"interventions":29182},[92,93],[29162],[29147,29164],{"trials":29184,"activeCount":103},[],{"trials":29186,"activeCount":103},[],{"intervention":29188,"totalTrials":437,"cells":29189},"Ritalin LA 20 mg",{"EARLY_PHASE1":29190,"PHASE1":29192,"PHASE2":29194,"PHASE3":29196,"PHASE4":29206,"NA":29208},{"trials":29191,"activeCount":103},[],{"trials":29193,"activeCount":103},[],{"trials":29195,"activeCount":103},[],{"trials":29197,"activeCount":103},[29198],{"nctId":29199,"briefTitle":29200,"status":123,"phases":29201,"primaryCompletion":3482,"completion":3482,"start":926,"enrollment":29202,"conditions":29203,"interventions":29204},"NCT01259492","Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit\u002FHyperactivity Disorder (ADHD)",[93],725,[26971],[29188,29205],"Ritalin LA 30 mg",{"trials":29207,"activeCount":103},[],{"trials":29209,"activeCount":103},[],{"intervention":29205,"totalTrials":437,"cells":29211},{"EARLY_PHASE1":29212,"PHASE1":29214,"PHASE2":29216,"PHASE3":29218,"PHASE4":29224,"NA":29226},{"trials":29213,"activeCount":103},[],{"trials":29215,"activeCount":103},[],{"trials":29217,"activeCount":103},[],{"trials":29219,"activeCount":103},[29220],{"nctId":29199,"briefTitle":29200,"status":123,"phases":29221,"primaryCompletion":3482,"completion":3482,"start":926,"enrollment":29202,"conditions":29222,"interventions":29223},[93],[26971],[29188,29205],{"trials":29225,"activeCount":103},[],{"trials":29227,"activeCount":103},[],{"intervention":29229,"totalTrials":437,"cells":29230},"brolucuzumab 6 mg IVT",{"EARLY_PHASE1":29231,"PHASE1":29233,"PHASE2":29235,"PHASE3":29237,"PHASE4":29251,"NA":29253},{"trials":29232,"activeCount":103},[],{"trials":29234,"activeCount":103},[],{"trials":29236,"activeCount":103},[],{"trials":29238,"activeCount":103},[29239],{"nctId":29240,"briefTitle":29241,"status":123,"phases":29242,"primaryCompletion":29243,"completion":29244,"start":2111,"enrollment":814,"conditions":29245,"interventions":29250},"NCT03954626","Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD",[93],"2019-07-09","2019-07-31",[5961,25049,29246,29247,29248,29249],"Wet Macular Degeneration","Retinal Degeneration","Retinal Diseases","Eye Diseases",[29229],{"trials":29252,"activeCount":103},[],{"trials":29254,"activeCount":103},[],{"intervention":29256,"totalTrials":437,"cells":29257},"QAW039 150 mg once daily",{"EARLY_PHASE1":29258,"PHASE1":29260,"PHASE2":29262,"PHASE3":29264,"PHASE4":29274,"NA":29276},{"trials":29259,"activeCount":103},[],{"trials":29261,"activeCount":103},[],{"trials":29263,"activeCount":103},[],{"trials":29265,"activeCount":103},[29266],{"nctId":29267,"briefTitle":29268,"status":134,"phases":29269,"primaryCompletion":338,"completion":338,"start":17355,"enrollment":29270,"conditions":29271,"interventions":29272},"NCT03629249","Systemic Corticosteroids Avoidance Study in Severe Asthma Patients",[93],604,[18],[29256,29273],"QAW039 450 mg once daily",{"trials":29275,"activeCount":103},[],{"trials":29277,"activeCount":103},[],{"intervention":29273,"totalTrials":437,"cells":29279},{"EARLY_PHASE1":29280,"PHASE1":29282,"PHASE2":29284,"PHASE3":29286,"PHASE4":29292,"NA":29294},{"trials":29281,"activeCount":103},[],{"trials":29283,"activeCount":103},[],{"trials":29285,"activeCount":103},[],{"trials":29287,"activeCount":103},[29288],{"nctId":29267,"briefTitle":29268,"status":134,"phases":29289,"primaryCompletion":338,"completion":338,"start":17355,"enrollment":29270,"conditions":29290,"interventions":29291},[93],[18],[29256,29273],{"trials":29293,"activeCount":103},[],{"trials":29295,"activeCount":103},[],{"intervention":29297,"totalTrials":437,"cells":29298},"FTY 720",{"EARLY_PHASE1":29299,"PHASE1":29301,"PHASE2":29303,"PHASE3":29305,"PHASE4":29312,"NA":29314},{"trials":29300,"activeCount":103},[],{"trials":29302,"activeCount":103},[],{"trials":29304,"activeCount":103},[],{"trials":29306,"activeCount":103},[29307],{"nctId":29308,"briefTitle":17559,"status":123,"phases":29309,"primaryCompletion":16010,"start":4732,"enrollment":805,"conditions":29310,"interventions":29311},"NCT00099749",[92,93],[4691],[29297],{"trials":29313,"activeCount":103},[],{"trials":29315,"activeCount":103},[],{"intervention":25178,"totalTrials":437,"cells":29317},{"EARLY_PHASE1":29318,"PHASE1":29320,"PHASE2":29322,"PHASE3":29324,"PHASE4":29330,"NA":29332},{"trials":29319,"activeCount":103},[],{"trials":29321,"activeCount":103},[],{"trials":29323,"activeCount":103},[],{"trials":29325,"activeCount":103},[29326],{"nctId":25172,"briefTitle":25173,"status":390,"phases":29327,"enrollment":103,"conditions":29328,"interventions":29329},[92,93],[25176],[25178,25145],{"trials":29331,"activeCount":103},[],{"trials":29333,"activeCount":103},[],{"intervention":29335,"totalTrials":437,"cells":29336},"TAC withdrawal",{"EARLY_PHASE1":29337,"PHASE1":29339,"PHASE2":29341,"PHASE3":29343,"PHASE4":29353,"NA":29355},{"trials":29338,"activeCount":103},[],{"trials":29340,"activeCount":103},[],{"trials":29342,"activeCount":103},[],{"trials":29344,"activeCount":103},[29345],{"nctId":29346,"briefTitle":29347,"status":390,"phases":29348,"primaryCompletion":29349,"completion":29349,"start":3861,"enrollment":103,"conditions":29350,"interventions":29351},"NCT03596970","Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.",[93],"2020-12",[4645],[29335,29352],"Everolimus with reduced TAC",{"trials":29354,"activeCount":103},[],{"trials":29356,"activeCount":103},[],{"intervention":29352,"totalTrials":437,"cells":29358},{"EARLY_PHASE1":29359,"PHASE1":29361,"PHASE2":29363,"PHASE3":29365,"PHASE4":29371,"NA":29373},{"trials":29360,"activeCount":103},[],{"trials":29362,"activeCount":103},[],{"trials":29364,"activeCount":103},[],{"trials":29366,"activeCount":103},[29367],{"nctId":29346,"briefTitle":29347,"status":390,"phases":29368,"primaryCompletion":29349,"completion":29349,"start":3861,"enrollment":103,"conditions":29369,"interventions":29370},[93],[4645],[29335,29352],{"trials":29372,"activeCount":103},[],{"trials":29374,"activeCount":103},[],{"intervention":19934,"totalTrials":437,"cells":29376},{"EARLY_PHASE1":29377,"PHASE1":29379,"PHASE2":29381,"PHASE3":29383,"PHASE4":29389,"NA":29391},{"trials":29378,"activeCount":103},[],{"trials":29380,"activeCount":103},[],{"trials":29382,"activeCount":103},[],{"trials":29384,"activeCount":103},[29385],{"nctId":19927,"briefTitle":19928,"status":123,"phases":29386,"primaryCompletion":19930,"completion":19930,"start":13728,"enrollment":19931,"conditions":29387,"interventions":29388},[93],[18],[19934,19935,19936,19937,19938],{"trials":29390,"activeCount":103},[],{"trials":29392,"activeCount":103},[],{"intervention":19935,"totalTrials":437,"cells":29394},{"EARLY_PHASE1":29395,"PHASE1":29397,"PHASE2":29399,"PHASE3":29401,"PHASE4":29407,"NA":29409},{"trials":29396,"activeCount":103},[],{"trials":29398,"activeCount":103},[],{"trials":29400,"activeCount":103},[],{"trials":29402,"activeCount":103},[29403],{"nctId":19927,"briefTitle":19928,"status":123,"phases":29404,"primaryCompletion":19930,"completion":19930,"start":13728,"enrollment":19931,"conditions":29405,"interventions":29406},[93],[18],[19934,19935,19936,19937,19938],{"trials":29408,"activeCount":103},[],{"trials":29410,"activeCount":103},[],{"intervention":19936,"totalTrials":437,"cells":29412},{"EARLY_PHASE1":29413,"PHASE1":29415,"PHASE2":29417,"PHASE3":29419,"PHASE4":29425,"NA":29427},{"trials":29414,"activeCount":103},[],{"trials":29416,"activeCount":103},[],{"trials":29418,"activeCount":103},[],{"trials":29420,"activeCount":103},[29421],{"nctId":19927,"briefTitle":19928,"status":123,"phases":29422,"primaryCompletion":19930,"completion":19930,"start":13728,"enrollment":19931,"conditions":29423,"interventions":29424},[93],[18],[19934,19935,19936,19937,19938],{"trials":29426,"activeCount":103},[],{"trials":29428,"activeCount":103},[],{"intervention":19937,"totalTrials":437,"cells":29430},{"EARLY_PHASE1":29431,"PHASE1":29433,"PHASE2":29435,"PHASE3":29437,"PHASE4":29443,"NA":29445},{"trials":29432,"activeCount":103},[],{"trials":29434,"activeCount":103},[],{"trials":29436,"activeCount":103},[],{"trials":29438,"activeCount":103},[29439],{"nctId":19927,"briefTitle":19928,"status":123,"phases":29440,"primaryCompletion":19930,"completion":19930,"start":13728,"enrollment":19931,"conditions":29441,"interventions":29442},[93],[18],[19934,19935,19936,19937,19938],{"trials":29444,"activeCount":103},[],{"trials":29446,"activeCount":103},[],{"intervention":2011,"totalTrials":437,"cells":29448},{"EARLY_PHASE1":29449,"PHASE1":29451,"PHASE2":29453,"PHASE3":29455,"PHASE4":29461,"NA":29463},{"trials":29450,"activeCount":103},[],{"trials":29452,"activeCount":103},[],{"trials":29454,"activeCount":103},[],{"trials":29456,"activeCount":103},[29457],{"nctId":2002,"briefTitle":2003,"status":123,"phases":29458,"primaryCompletion":2005,"completion":2005,"start":2006,"enrollment":2007,"conditions":29459,"interventions":29460},[93],[2009],[1659,2011],{"trials":29462,"activeCount":103},[],{"trials":29464,"activeCount":103},[],{"intervention":29466,"totalTrials":437,"cells":29467},"Ligelizumab 120 mg",{"EARLY_PHASE1":29468,"PHASE1":29470,"PHASE2":29472,"PHASE3":29474,"PHASE4":29485,"NA":29487},{"trials":29469,"activeCount":103},[],{"trials":29471,"activeCount":103},[],{"trials":29473,"activeCount":103},[],{"trials":29475,"activeCount":103},[29476],{"nctId":29477,"briefTitle":29478,"status":134,"phases":29479,"primaryCompletion":10170,"completion":10170,"start":29480,"enrollment":2294,"conditions":29481,"interventions":29483},"NCT05678959","Long-term Extension Study of Ligelizumab in Food Allergy",[93],"2023-04-27",[29482],"Food Allergy",[29466,29484],"Ligelizumab 240 mg",{"trials":29486,"activeCount":103},[],{"trials":29488,"activeCount":103},[],{"intervention":29484,"totalTrials":437,"cells":29490},{"EARLY_PHASE1":29491,"PHASE1":29493,"PHASE2":29495,"PHASE3":29497,"PHASE4":29503,"NA":29505},{"trials":29492,"activeCount":103},[],{"trials":29494,"activeCount":103},[],{"trials":29496,"activeCount":103},[],{"trials":29498,"activeCount":103},[29499],{"nctId":29477,"briefTitle":29478,"status":134,"phases":29500,"primaryCompletion":10170,"completion":10170,"start":29480,"enrollment":2294,"conditions":29501,"interventions":29502},[93],[29482],[29466,29484],{"trials":29504,"activeCount":103},[],{"trials":29506,"activeCount":103},[],{"intervention":19386,"totalTrials":437,"cells":29508},{"EARLY_PHASE1":29509,"PHASE1":29511,"PHASE2":29513,"PHASE3":29515,"PHASE4":29521,"NA":29523},{"trials":29510,"activeCount":103},[],{"trials":29512,"activeCount":103},[],{"trials":29514,"activeCount":103},[],{"trials":29516,"activeCount":103},[29517],{"nctId":19379,"briefTitle":19380,"status":123,"phases":29518,"primaryCompletion":3490,"completion":3490,"start":4810,"enrollment":19382,"conditions":29519,"interventions":29520},[93],[19384],[19368,19386],{"trials":29522,"activeCount":103},[],{"trials":29524,"activeCount":103},[],{"intervention":16383,"totalTrials":437,"cells":29526},{"EARLY_PHASE1":29527,"PHASE1":29529,"PHASE2":29531,"PHASE3":29533,"PHASE4":29539,"NA":29541},{"trials":29528,"activeCount":103},[],{"trials":29530,"activeCount":103},[],{"trials":29532,"activeCount":103},[],{"trials":29534,"activeCount":103},[29535],{"nctId":16378,"briefTitle":16379,"status":123,"phases":29536,"primaryCompletion":5733,"completion":5733,"start":895,"enrollment":5882,"conditions":29537,"interventions":29538},[93],[15555],[7850,16383],{"trials":29540,"activeCount":103},[],{"trials":29542,"activeCount":103},[],{"intervention":29544,"totalTrials":437,"cells":29545},"Ranibizumab 0.5 mg\u002F0.05 ml",{"EARLY_PHASE1":29546,"PHASE1":29548,"PHASE2":29550,"PHASE3":29552,"PHASE4":29560,"NA":29562},{"trials":29547,"activeCount":103},[],{"trials":29549,"activeCount":103},[],{"trials":29551,"activeCount":103},[],{"trials":29553,"activeCount":103},[29554],{"nctId":29555,"briefTitle":29556,"status":123,"phases":29557,"primaryCompletion":2509,"completion":2509,"start":1671,"enrollment":15644,"conditions":29558,"interventions":29559},"NCT01535261","Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion",[93],[25288,17675],[29544],{"trials":29561,"activeCount":103},[],{"trials":29563,"activeCount":103},[],{"intervention":29565,"totalTrials":437,"cells":29566},"Valsartan 0.25 mg\u002Fkg",{"EARLY_PHASE1":29567,"PHASE1":29569,"PHASE2":29571,"PHASE3":29573,"PHASE4":29583,"NA":29585},{"trials":29568,"activeCount":103},[],{"trials":29570,"activeCount":103},[],{"trials":29572,"activeCount":103},[],{"trials":29574,"activeCount":103},[29575],{"nctId":29576,"briefTitle":29577,"status":123,"phases":29578,"primaryCompletion":949,"completion":949,"start":3474,"enrollment":223,"conditions":29579,"interventions":29580},"NCT00435162","Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure",[93],[21],[29565,29581,29582],"Valsartan 1.0 mg\u002Fkg","Valsartan 4.0 mg\u002Fkg",{"trials":29584,"activeCount":103},[],{"trials":29586,"activeCount":103},[],{"intervention":29581,"totalTrials":437,"cells":29588},{"EARLY_PHASE1":29589,"PHASE1":29591,"PHASE2":29593,"PHASE3":29595,"PHASE4":29601,"NA":29603},{"trials":29590,"activeCount":103},[],{"trials":29592,"activeCount":103},[],{"trials":29594,"activeCount":103},[],{"trials":29596,"activeCount":103},[29597],{"nctId":29576,"briefTitle":29577,"status":123,"phases":29598,"primaryCompletion":949,"completion":949,"start":3474,"enrollment":223,"conditions":29599,"interventions":29600},[93],[21],[29565,29581,29582],{"trials":29602,"activeCount":103},[],{"trials":29604,"activeCount":103},[],{"intervention":29582,"totalTrials":437,"cells":29606},{"EARLY_PHASE1":29607,"PHASE1":29609,"PHASE2":29611,"PHASE3":29613,"PHASE4":29619,"NA":29621},{"trials":29608,"activeCount":103},[],{"trials":29610,"activeCount":103},[],{"trials":29612,"activeCount":103},[],{"trials":29614,"activeCount":103},[29615],{"nctId":29576,"briefTitle":29577,"status":123,"phases":29616,"primaryCompletion":949,"completion":949,"start":3474,"enrollment":223,"conditions":29617,"interventions":29618},[93],[21],[29565,29581,29582],{"trials":29620,"activeCount":103},[],{"trials":29622,"activeCount":103},[],{"intervention":29624,"totalTrials":437,"cells":29625},"Vatalanib",{"EARLY_PHASE1":29626,"PHASE1":29628,"PHASE2":29630,"PHASE3":29632,"PHASE4":29643,"NA":29645},{"trials":29627,"activeCount":103},[],{"trials":29629,"activeCount":103},[],{"trials":29631,"activeCount":103},[],{"trials":29633,"activeCount":103},[29634],{"nctId":29635,"briefTitle":29636,"status":123,"phases":29637,"primaryCompletion":3254,"completion":3254,"start":16922,"enrollment":29638,"conditions":29639,"interventions":29642},"NCT00056446","Study of Oxaliplatin\u002F5-FU\u002FLeucovorin Plus Vatalanib Versus Oxaliplatin\u002F5-FU\u002FLeucovorin in Patients With Previously Treated Metastatic Colorectal Cancer",[93],855,[231,29640,29641],"Colonic Neoplasms","Rectal Neoplasms",[29624],{"trials":29644,"activeCount":103},[],{"trials":29646,"activeCount":103},[],{"intervention":29648,"totalTrials":437,"cells":29649},"Tegaserod",{"EARLY_PHASE1":29650,"PHASE1":29652,"PHASE2":29654,"PHASE3":29656,"PHASE4":29666,"NA":29668},{"trials":29651,"activeCount":103},[],{"trials":29653,"activeCount":103},[],{"trials":29655,"activeCount":103},[],{"trials":29657,"activeCount":103},[29658],{"nctId":29659,"briefTitle":29660,"status":134,"phases":29661,"primaryCompletion":8091,"completion":8091,"start":17497,"enrollment":1611,"conditions":29662,"interventions":29665},"NCT00171431","The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)",[93],[29663,29664],"Constipation Predominant","Irritable Bowel Syndrome (IBS-C)",[29648],{"trials":29667,"activeCount":103},[],{"trials":29669,"activeCount":103},[],{"intervention":4122,"totalTrials":437,"cells":29671},{"EARLY_PHASE1":29672,"PHASE1":29674,"PHASE2":29676,"PHASE3":29678,"PHASE4":29684,"NA":29686},{"trials":29673,"activeCount":103},[],{"trials":29675,"activeCount":103},[],{"trials":29677,"activeCount":103},[],{"trials":29679,"activeCount":103},[29680],{"nctId":4113,"briefTitle":4114,"status":123,"phases":29681,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":29682,"interventions":29683},[93],[3305],[83,4121,4122],{"trials":29685,"activeCount":103},[],{"trials":29687,"activeCount":103},[],{"intervention":29689,"totalTrials":437,"cells":29690},"Secukinumab 2 mL auto-injector",{"EARLY_PHASE1":29691,"PHASE1":29693,"PHASE2":29695,"PHASE3":29697,"PHASE4":29708,"NA":29710},{"trials":29692,"activeCount":103},[],{"trials":29694,"activeCount":103},[],{"trials":29696,"activeCount":103},[],{"trials":29698,"activeCount":103},[29699],{"nctId":29700,"briefTitle":29701,"status":123,"phases":29702,"primaryCompletion":29703,"completion":29704,"start":5791,"enrollment":203,"conditions":29705,"interventions":29706},"NCT03589885","Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis",[93],"2019-11-19","2020-08-05",[1773],[29689,29707],"Secukinumab 1 mL prefilled syringe",{"trials":29709,"activeCount":103},[],{"trials":29711,"activeCount":103},[],{"intervention":29707,"totalTrials":437,"cells":29713},{"EARLY_PHASE1":29714,"PHASE1":29716,"PHASE2":29718,"PHASE3":29720,"PHASE4":29726,"NA":29728},{"trials":29715,"activeCount":103},[],{"trials":29717,"activeCount":103},[],{"trials":29719,"activeCount":103},[],{"trials":29721,"activeCount":103},[29722],{"nctId":29700,"briefTitle":29701,"status":123,"phases":29723,"primaryCompletion":29703,"completion":29704,"start":5791,"enrollment":203,"conditions":29724,"interventions":29725},[93],[1773],[29689,29707],{"trials":29727,"activeCount":103},[],{"trials":29729,"activeCount":103},[],{"intervention":2039,"totalTrials":437,"cells":29731},{"EARLY_PHASE1":29732,"PHASE1":29734,"PHASE2":29736,"PHASE3":29738,"PHASE4":29744,"NA":29746},{"trials":29733,"activeCount":103},[],{"trials":29735,"activeCount":103},[],{"trials":29737,"activeCount":103},[],{"trials":29739,"activeCount":103},[29740],{"nctId":2030,"briefTitle":2031,"status":123,"phases":29741,"primaryCompletion":2033,"completion":2033,"start":2034,"enrollment":2035,"conditions":29742,"interventions":29743},[93],[2037],[73,2039],{"trials":29745,"activeCount":103},[],{"trials":29747,"activeCount":103},[],{"intervention":25132,"totalTrials":437,"cells":29749},{"EARLY_PHASE1":29750,"PHASE1":29752,"PHASE2":29754,"PHASE3":29756,"PHASE4":29762,"NA":29764},{"trials":29751,"activeCount":103},[],{"trials":29753,"activeCount":103},[],{"trials":29755,"activeCount":103},[],{"trials":29757,"activeCount":103},[29758],{"nctId":25126,"briefTitle":25127,"status":123,"phases":29759,"primaryCompletion":15283,"completion":15283,"start":4301,"enrollment":4557,"conditions":29760,"interventions":29761},[93],[22924],[25131,25132],{"trials":29763,"activeCount":103},[],{"trials":29765,"activeCount":103},[],{"intervention":2859,"totalTrials":437,"cells":29767},{"EARLY_PHASE1":29768,"PHASE1":29770,"PHASE2":29772,"PHASE3":29774,"PHASE4":29780,"NA":29782},{"trials":29769,"activeCount":103},[],{"trials":29771,"activeCount":103},[],{"trials":29773,"activeCount":103},[],{"trials":29775,"activeCount":103},[29776],{"nctId":2849,"briefTitle":2850,"status":134,"phases":29777,"primaryCompletion":2852,"completion":2853,"start":2854,"enrollment":2855,"conditions":29778,"interventions":29779},[93],[2857],[2752,2788,2859,2788],{"trials":29781,"activeCount":103},[],{"trials":29783,"activeCount":103},[],{"intervention":7527,"totalTrials":437,"cells":29785},{"EARLY_PHASE1":29786,"PHASE1":29788,"PHASE2":29790,"PHASE3":29792,"PHASE4":29798,"NA":29800},{"trials":29787,"activeCount":103},[],{"trials":29789,"activeCount":103},[],{"trials":29791,"activeCount":103},[],{"trials":29793,"activeCount":103},[29794],{"nctId":7519,"briefTitle":7520,"status":123,"phases":29795,"primaryCompletion":7522,"completion":7522,"start":7523,"enrollment":1495,"conditions":29796,"interventions":29797},[93],[7525],[5895,7527],{"trials":29799,"activeCount":103},[],{"trials":29801,"activeCount":103},[],{"intervention":4840,"totalTrials":437,"cells":29803},{"EARLY_PHASE1":29804,"PHASE1":29806,"PHASE2":29808,"PHASE3":29810,"PHASE4":29816,"NA":29818},{"trials":29805,"activeCount":103},[],{"trials":29807,"activeCount":103},[],{"trials":29809,"activeCount":103},[],{"trials":29811,"activeCount":103},[29812],{"nctId":4833,"briefTitle":4834,"status":123,"phases":29813,"primaryCompletion":1670,"completion":1670,"start":3210,"enrollment":4836,"conditions":29814,"interventions":29815},[93],[4645],[4305,4839,4840],{"trials":29817,"activeCount":103},[],{"trials":29819,"activeCount":103},[],{"intervention":2106,"totalTrials":437,"cells":29821},{"EARLY_PHASE1":29822,"PHASE1":29824,"PHASE2":29826,"PHASE3":29828,"PHASE4":29834,"NA":29836},{"trials":29823,"activeCount":103},[],{"trials":29825,"activeCount":103},[],{"trials":29827,"activeCount":103},[],{"trials":29829,"activeCount":103},[29830],{"nctId":2098,"briefTitle":2099,"status":123,"phases":29831,"primaryCompletion":2101,"completion":2101,"start":2102,"enrollment":2103,"conditions":29832,"interventions":29833},[93],[1821],[1659,2106],{"trials":29835,"activeCount":103},[],{"trials":29837,"activeCount":103},[],{"intervention":16399,"totalTrials":437,"cells":29839},{"EARLY_PHASE1":29840,"PHASE1":29842,"PHASE2":29844,"PHASE3":29846,"PHASE4":29852,"NA":29854},{"trials":29841,"activeCount":103},[],{"trials":29843,"activeCount":103},[],{"trials":29845,"activeCount":103},[],{"trials":29847,"activeCount":103},[29848],{"nctId":16393,"briefTitle":16394,"status":123,"phases":29849,"primaryCompletion":812,"completion":812,"start":2793,"enrollment":2948,"conditions":29850,"interventions":29851},[93],[16397],[7850,16399],{"trials":29853,"activeCount":103},[],{"trials":29855,"activeCount":103},[],{"intervention":29857,"totalTrials":437,"cells":29858},"ABL001 40mg BID",{"EARLY_PHASE1":29859,"PHASE1":29861,"PHASE2":29863,"PHASE3":29865,"PHASE4":29877,"NA":29879},{"trials":29860,"activeCount":103},[],{"trials":29862,"activeCount":103},[],{"trials":29864,"activeCount":103},[],{"trials":29866,"activeCount":103},[29867],{"nctId":29868,"briefTitle":29869,"status":123,"phases":29870,"primaryCompletion":1639,"completion":29871,"start":29872,"enrollment":4498,"conditions":29873,"interventions":29874},"NCT04948333","Asciminib Treatment Optimization in ≥ 3rd Line CML-CP",[93],"2026-02-25","2021-10-13",[3228],[29857,29875,29876],"ABL001 80mg QD","ABL001 200mg QD",{"trials":29878,"activeCount":103},[],{"trials":29880,"activeCount":103},[],{"intervention":29875,"totalTrials":437,"cells":29882},{"EARLY_PHASE1":29883,"PHASE1":29885,"PHASE2":29887,"PHASE3":29889,"PHASE4":29895,"NA":29897},{"trials":29884,"activeCount":103},[],{"trials":29886,"activeCount":103},[],{"trials":29888,"activeCount":103},[],{"trials":29890,"activeCount":103},[29891],{"nctId":29868,"briefTitle":29869,"status":123,"phases":29892,"primaryCompletion":1639,"completion":29871,"start":29872,"enrollment":4498,"conditions":29893,"interventions":29894},[93],[3228],[29857,29875,29876],{"trials":29896,"activeCount":103},[],{"trials":29898,"activeCount":103},[],{"intervention":29876,"totalTrials":437,"cells":29900},{"EARLY_PHASE1":29901,"PHASE1":29903,"PHASE2":29905,"PHASE3":29907,"PHASE4":29913,"NA":29915},{"trials":29902,"activeCount":103},[],{"trials":29904,"activeCount":103},[],{"trials":29906,"activeCount":103},[],{"trials":29908,"activeCount":103},[29909],{"nctId":29868,"briefTitle":29869,"status":123,"phases":29910,"primaryCompletion":1639,"completion":29871,"start":29872,"enrollment":4498,"conditions":29911,"interventions":29912},[93],[3228],[29857,29875,29876],{"trials":29914,"activeCount":103},[],{"trials":29916,"activeCount":103},[],{"intervention":4850,"totalTrials":437,"cells":29918},{"EARLY_PHASE1":29919,"PHASE1":29921,"PHASE2":29923,"PHASE3":29925,"PHASE4":29931,"NA":29933},{"trials":29920,"activeCount":103},[],{"trials":29922,"activeCount":103},[],{"trials":29924,"activeCount":103},[],{"trials":29926,"activeCount":103},[29927],{"nctId":4842,"briefTitle":4843,"status":123,"phases":29928,"primaryCompletion":3559,"completion":3559,"start":4845,"enrollment":4846,"conditions":29929,"interventions":29930},[93],[4439],[196,4849,4850],{"trials":29932,"activeCount":103},[],{"trials":29934,"activeCount":103},[],{"intervention":29936,"totalTrials":437,"cells":29937},"Canakinumab 150mg in prefilled syringe",{"EARLY_PHASE1":29938,"PHASE1":29940,"PHASE2":29942,"PHASE3":29944,"PHASE4":29954,"NA":29956},{"trials":29939,"activeCount":103},[],{"trials":29941,"activeCount":103},[],{"trials":29943,"activeCount":103},[],{"trials":29945,"activeCount":103},[29946],{"nctId":29947,"briefTitle":29948,"status":123,"phases":29949,"primaryCompletion":29950,"completion":29950,"start":29951,"enrollment":1839,"conditions":29952,"interventions":29953},"NCT01431638","Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients",[93],"2013-05-09","2011-08-25",[23437],[29936],{"trials":29955,"activeCount":103},[],{"trials":29957,"activeCount":103},[],{"intervention":29959,"totalTrials":437,"cells":29960},"Terbinafine hydrochloride",{"EARLY_PHASE1":29961,"PHASE1":29963,"PHASE2":29965,"PHASE3":29967,"PHASE4":29978,"NA":29980},{"trials":29962,"activeCount":103},[],{"trials":29964,"activeCount":103},[],{"trials":29966,"activeCount":103},[],{"trials":29968,"activeCount":103},[29969],{"nctId":29970,"briefTitle":29971,"status":123,"phases":29972,"primaryCompletion":865,"start":16936,"enrollment":29973,"conditions":29974,"interventions":29976},"NCT00117767","Terbinafine Compared to Griseofulvin in Children With Tinea Capitis",[93],720,[29975],"Tinea Capitis",[29959,29977],"Griseofulvin",{"trials":29979,"activeCount":103},[],{"trials":29981,"activeCount":103},[],{"intervention":29977,"totalTrials":437,"cells":29983},{"EARLY_PHASE1":29984,"PHASE1":29986,"PHASE2":29988,"PHASE3":29990,"PHASE4":29996,"NA":29998},{"trials":29985,"activeCount":103},[],{"trials":29987,"activeCount":103},[],{"trials":29989,"activeCount":103},[],{"trials":29991,"activeCount":103},[29992],{"nctId":29970,"briefTitle":29971,"status":123,"phases":29993,"primaryCompletion":865,"start":16936,"enrollment":29973,"conditions":29994,"interventions":29995},[93],[29975],[29959,29977],{"trials":29997,"activeCount":103},[],{"trials":29999,"activeCount":103},[],{"intervention":30001,"totalTrials":437,"cells":30002},"Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.",{"EARLY_PHASE1":30003,"PHASE1":30005,"PHASE2":30007,"PHASE3":30009,"PHASE4":30018,"NA":30020},{"trials":30004,"activeCount":103},[],{"trials":30006,"activeCount":103},[],{"trials":30008,"activeCount":103},[],{"trials":30010,"activeCount":103},[30011],{"nctId":30012,"briefTitle":30013,"status":123,"phases":30014,"primaryCompletion":23471,"completion":13749,"start":30015,"enrollment":2439,"conditions":30016,"interventions":30017},"NCT02750592","Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis",[93],"2016-03-22",[1974],[30001],{"trials":30019,"activeCount":103},[],{"trials":30021,"activeCount":103},[],{"intervention":30023,"totalTrials":437,"cells":30024},"Tifacogin",{"EARLY_PHASE1":30025,"PHASE1":30027,"PHASE2":30029,"PHASE3":30031,"PHASE4":30041,"NA":30043},{"trials":30026,"activeCount":103},[],{"trials":30028,"activeCount":103},[],{"trials":30030,"activeCount":103},[],{"trials":30032,"activeCount":103},[30033],{"nctId":30034,"briefTitle":30035,"status":123,"phases":30036,"primaryCompletion":10499,"completion":10499,"start":15058,"enrollment":30037,"conditions":30038,"interventions":30040},"NCT00084071","Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia",[93],2136,[30039],"Pneumonia",[30023],{"trials":30042,"activeCount":103},[],{"trials":30044,"activeCount":103},[],{"intervention":30046,"totalTrials":437,"cells":30047},"QTI571",{"EARLY_PHASE1":30048,"PHASE1":30050,"PHASE2":30052,"PHASE3":30054,"PHASE4":30064,"NA":30066},{"trials":30049,"activeCount":103},[],{"trials":30051,"activeCount":103},[],{"trials":30053,"activeCount":103},[],{"trials":30055,"activeCount":103},[30056],{"nctId":30057,"briefTitle":30058,"status":123,"phases":30059,"primaryCompletion":18760,"completion":18760,"start":30060,"enrollment":422,"conditions":30061,"interventions":30063},"NCT02042014","Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan",[93],"2014-01-22",[30062],"Severe Pulmonary Arterial Hypertension",[30046],{"trials":30065,"activeCount":103},[],{"trials":30067,"activeCount":103},[],{"intervention":6377,"totalTrials":437,"cells":30069},{"EARLY_PHASE1":30070,"PHASE1":30072,"PHASE2":30074,"PHASE3":30076,"PHASE4":30082,"NA":30084},{"trials":30071,"activeCount":103},[],{"trials":30073,"activeCount":103},[],{"trials":30075,"activeCount":103},[],{"trials":30077,"activeCount":103},[30078],{"nctId":6368,"briefTitle":6369,"status":134,"phases":30079,"primaryCompletion":5902,"completion":6371,"start":6372,"enrollment":6373,"conditions":30080,"interventions":30081},[93],[6375],[88,6377,4321,6378],{"trials":30083,"activeCount":103},[],{"trials":30085,"activeCount":103},[],{"intervention":6378,"totalTrials":437,"cells":30087},{"EARLY_PHASE1":30088,"PHASE1":30090,"PHASE2":30092,"PHASE3":30094,"PHASE4":30100,"NA":30102},{"trials":30089,"activeCount":103},[],{"trials":30091,"activeCount":103},[],{"trials":30093,"activeCount":103},[],{"trials":30095,"activeCount":103},[30096],{"nctId":6368,"briefTitle":6369,"status":134,"phases":30097,"primaryCompletion":5902,"completion":6371,"start":6372,"enrollment":6373,"conditions":30098,"interventions":30099},[93],[6375],[88,6377,4321,6378],{"trials":30101,"activeCount":103},[],{"trials":30103,"activeCount":103},[],{"intervention":30105,"totalTrials":437,"cells":30106},"Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.",{"EARLY_PHASE1":30107,"PHASE1":30109,"PHASE2":30111,"PHASE3":30113,"PHASE4":30121,"NA":30123},{"trials":30108,"activeCount":103},[],{"trials":30110,"activeCount":103},[],{"trials":30112,"activeCount":103},[],{"trials":30114,"activeCount":103},[30115],{"nctId":30116,"briefTitle":30117,"status":123,"phases":30118,"primaryCompletion":1788,"completion":1788,"start":1761,"enrollment":5681,"conditions":30119,"interventions":30120},"NCT01598987","Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.",[93],[5116,17239],[30105],{"trials":30122,"activeCount":103},[],{"trials":30124,"activeCount":103},[],{"intervention":30126,"totalTrials":437,"cells":30127},"ensovibep",{"EARLY_PHASE1":30128,"PHASE1":30130,"PHASE2":30132,"PHASE3":30134,"PHASE4":30144,"NA":30146},{"trials":30129,"activeCount":103},[],{"trials":30131,"activeCount":103},[],{"trials":30133,"activeCount":103},[],{"trials":30135,"activeCount":103},[30136],{"nctId":30137,"briefTitle":30138,"status":134,"phases":30139,"primaryCompletion":19546,"completion":6327,"start":30140,"enrollment":10399,"conditions":30141,"interventions":30143},"NCT04828161","A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19",[92,93],"2021-05-10",[30142],"COVID-19",[30126],{"trials":30145,"activeCount":103},[],{"trials":30147,"activeCount":103},[],{"intervention":24773,"totalTrials":437,"cells":30149},{"EARLY_PHASE1":30150,"PHASE1":30152,"PHASE2":30154,"PHASE3":30156,"PHASE4":30162,"NA":30164},{"trials":30151,"activeCount":103},[],{"trials":30153,"activeCount":103},[],{"trials":30155,"activeCount":103},[],{"trials":30157,"activeCount":103},[30158],{"nctId":24766,"briefTitle":24767,"status":123,"phases":30159,"primaryCompletion":11323,"completion":3827,"start":24769,"enrollment":24770,"conditions":30160,"interventions":30161},[93],[18],[24773,3056,24774],{"trials":30163,"activeCount":103},[],{"trials":30165,"activeCount":103},[],{"intervention":24774,"totalTrials":437,"cells":30167},{"EARLY_PHASE1":30168,"PHASE1":30170,"PHASE2":30172,"PHASE3":30174,"PHASE4":30180,"NA":30182},{"trials":30169,"activeCount":103},[],{"trials":30171,"activeCount":103},[],{"trials":30173,"activeCount":103},[],{"trials":30175,"activeCount":103},[30176],{"nctId":24766,"briefTitle":24767,"status":123,"phases":30177,"primaryCompletion":11323,"completion":3827,"start":24769,"enrollment":24770,"conditions":30178,"interventions":30179},[93],[18],[24773,3056,24774],{"trials":30181,"activeCount":103},[],{"trials":30183,"activeCount":103},[],{"intervention":18568,"totalTrials":437,"cells":30185},{"EARLY_PHASE1":30186,"PHASE1":30188,"PHASE2":30190,"PHASE3":30192,"PHASE4":30198,"NA":30200},{"trials":30187,"activeCount":103},[],{"trials":30189,"activeCount":103},[],{"trials":30191,"activeCount":103},[],{"trials":30193,"activeCount":103},[30194],{"nctId":18562,"briefTitle":18563,"status":123,"phases":30195,"primaryCompletion":1025,"completion":1025,"start":3195,"enrollment":18565,"conditions":30196,"interventions":30197},[92,93],[17007],[18568,18569,18570,18571,18560,18559,18572,18542],{"trials":30199,"activeCount":103},[],{"trials":30201,"activeCount":103},[],{"intervention":18569,"totalTrials":437,"cells":30203},{"EARLY_PHASE1":30204,"PHASE1":30206,"PHASE2":30208,"PHASE3":30210,"PHASE4":30216,"NA":30218},{"trials":30205,"activeCount":103},[],{"trials":30207,"activeCount":103},[],{"trials":30209,"activeCount":103},[],{"trials":30211,"activeCount":103},[30212],{"nctId":18562,"briefTitle":18563,"status":123,"phases":30213,"primaryCompletion":1025,"completion":1025,"start":3195,"enrollment":18565,"conditions":30214,"interventions":30215},[92,93],[17007],[18568,18569,18570,18571,18560,18559,18572,18542],{"trials":30217,"activeCount":103},[],{"trials":30219,"activeCount":103},[],{"intervention":18570,"totalTrials":437,"cells":30221},{"EARLY_PHASE1":30222,"PHASE1":30224,"PHASE2":30226,"PHASE3":30228,"PHASE4":30234,"NA":30236},{"trials":30223,"activeCount":103},[],{"trials":30225,"activeCount":103},[],{"trials":30227,"activeCount":103},[],{"trials":30229,"activeCount":103},[30230],{"nctId":18562,"briefTitle":18563,"status":123,"phases":30231,"primaryCompletion":1025,"completion":1025,"start":3195,"enrollment":18565,"conditions":30232,"interventions":30233},[92,93],[17007],[18568,18569,18570,18571,18560,18559,18572,18542],{"trials":30235,"activeCount":103},[],{"trials":30237,"activeCount":103},[],{"intervention":18571,"totalTrials":437,"cells":30239},{"EARLY_PHASE1":30240,"PHASE1":30242,"PHASE2":30244,"PHASE3":30246,"PHASE4":30252,"NA":30254},{"trials":30241,"activeCount":103},[],{"trials":30243,"activeCount":103},[],{"trials":30245,"activeCount":103},[],{"trials":30247,"activeCount":103},[30248],{"nctId":18562,"briefTitle":18563,"status":123,"phases":30249,"primaryCompletion":1025,"completion":1025,"start":3195,"enrollment":18565,"conditions":30250,"interventions":30251},[92,93],[17007],[18568,18569,18570,18571,18560,18559,18572,18542],{"trials":30253,"activeCount":103},[],{"trials":30255,"activeCount":103},[],{"intervention":18572,"totalTrials":437,"cells":30257},{"EARLY_PHASE1":30258,"PHASE1":30260,"PHASE2":30262,"PHASE3":30264,"PHASE4":30270,"NA":30272},{"trials":30259,"activeCount":103},[],{"trials":30261,"activeCount":103},[],{"trials":30263,"activeCount":103},[],{"trials":30265,"activeCount":103},[30266],{"nctId":18562,"briefTitle":18563,"status":123,"phases":30267,"primaryCompletion":1025,"completion":1025,"start":3195,"enrollment":18565,"conditions":30268,"interventions":30269},[92,93],[17007],[18568,18569,18570,18571,18560,18559,18572,18542],{"trials":30271,"activeCount":103},[],{"trials":30273,"activeCount":103},[],{"intervention":2538,"totalTrials":437,"cells":30275},{"EARLY_PHASE1":30276,"PHASE1":30278,"PHASE2":30280,"PHASE3":30282,"PHASE4":30288,"NA":30290},{"trials":30277,"activeCount":103},[],{"trials":30279,"activeCount":103},[],{"trials":30281,"activeCount":103},[],{"trials":30283,"activeCount":103},[30284],{"nctId":2530,"briefTitle":2531,"status":134,"phases":30285,"primaryCompletion":2533,"completion":2533,"start":2534,"enrollment":1622,"conditions":30286,"interventions":30287},[93],[2536],[2341,2538],{"trials":30289,"activeCount":103},[],{"trials":30291,"activeCount":103},[],{"intervention":30293,"totalTrials":437,"cells":30294},"Secukinumab\u002FAdalimumab-Biosimilar",{"EARLY_PHASE1":30295,"PHASE1":30297,"PHASE2":30299,"PHASE3":30301,"PHASE4":30312,"NA":30314},{"trials":30296,"activeCount":103},[],{"trials":30298,"activeCount":103},[],{"trials":30300,"activeCount":103},[],{"trials":30302,"activeCount":103},[30303],{"nctId":30304,"briefTitle":30305,"status":123,"phases":30306,"primaryCompletion":30307,"completion":30308,"start":30309,"enrollment":8347,"conditions":30310,"interventions":30311},"NCT03906136","AScalate: Treat-to-target in Axial Spondyloarthritis",[93],"2022-02-04","2022-09-22","2019-06-04",[1943],[30293],{"trials":30313,"activeCount":103},[],{"trials":30315,"activeCount":103},[],{"intervention":30317,"totalTrials":437,"cells":30318},"Cyclosporine A microemulsion",{"EARLY_PHASE1":30319,"PHASE1":30321,"PHASE2":30323,"PHASE3":30325,"PHASE4":30333,"NA":30335},{"trials":30320,"activeCount":103},[],{"trials":30322,"activeCount":103},[],{"trials":30324,"activeCount":103},[],{"trials":30326,"activeCount":103},[30327],{"nctId":30328,"briefTitle":30329,"status":123,"phases":30330,"primaryCompletion":4642,"completion":4642,"start":8091,"enrollment":26947,"conditions":30331,"interventions":30332},"NCT00438360","Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis",[93],[2037],[30317],{"trials":30334,"activeCount":103},[],{"trials":30336,"activeCount":103},[],{"intervention":17902,"totalTrials":437,"cells":30338},{"EARLY_PHASE1":30339,"PHASE1":30341,"PHASE2":30343,"PHASE3":30345,"PHASE4":30351,"NA":30353},{"trials":30340,"activeCount":103},[],{"trials":30342,"activeCount":103},[],{"trials":30344,"activeCount":103},[],{"trials":30346,"activeCount":103},[30347],{"nctId":17895,"briefTitle":17896,"status":123,"phases":30348,"primaryCompletion":17898,"completion":17898,"start":17899,"enrollment":9531,"conditions":30349,"interventions":30350},[93],[16681],[17874,17902,17903],{"trials":30352,"activeCount":103},[],{"trials":30354,"activeCount":103},[],{"intervention":17903,"totalTrials":437,"cells":30356},{"EARLY_PHASE1":30357,"PHASE1":30359,"PHASE2":30361,"PHASE3":30363,"PHASE4":30369,"NA":30371},{"trials":30358,"activeCount":103},[],{"trials":30360,"activeCount":103},[],{"trials":30362,"activeCount":103},[],{"trials":30364,"activeCount":103},[30365],{"nctId":17895,"briefTitle":17896,"status":123,"phases":30366,"primaryCompletion":17898,"completion":17898,"start":17899,"enrollment":9531,"conditions":30367,"interventions":30368},[93],[16681],[17874,17902,17903],{"trials":30370,"activeCount":103},[],{"trials":30372,"activeCount":103},[],{"intervention":17055,"totalTrials":437,"cells":30374},{"EARLY_PHASE1":30375,"PHASE1":30377,"PHASE2":30379,"PHASE3":30381,"PHASE4":30387,"NA":30389},{"trials":30376,"activeCount":103},[],{"trials":30378,"activeCount":103},[],{"trials":30380,"activeCount":103},[],{"trials":30382,"activeCount":103},[30383],{"nctId":17050,"briefTitle":17051,"status":390,"phases":30384,"primaryCompletion":606,"completion":606,"start":1781,"enrollment":103,"conditions":30385,"interventions":30386},[93],[21],[15726,15884,17055],{"trials":30388,"activeCount":103},[],{"trials":30390,"activeCount":103},[],{"intervention":30392,"totalTrials":437,"cells":30393},"EC-MPS",{"EARLY_PHASE1":30394,"PHASE1":30396,"PHASE2":30398,"PHASE3":30400,"PHASE4":30409,"NA":30411},{"trials":30395,"activeCount":103},[],{"trials":30397,"activeCount":103},[],{"trials":30399,"activeCount":103},[],{"trials":30401,"activeCount":103},[30402],{"nctId":30403,"briefTitle":30404,"status":123,"phases":30405,"primaryCompletion":745,"start":17543,"conditions":30406,"interventions":30408},"NCT00238446","Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients",[93],[30407],"Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS",[30392],{"trials":30410,"activeCount":103},[],{"trials":30412,"activeCount":103},[],{"intervention":2903,"totalTrials":437,"cells":30414},{"EARLY_PHASE1":30415,"PHASE1":30417,"PHASE2":30419,"PHASE3":30421,"PHASE4":30427,"NA":30429},{"trials":30416,"activeCount":103},[],{"trials":30418,"activeCount":103},[],{"trials":30420,"activeCount":103},[],{"trials":30422,"activeCount":103},[30423],{"nctId":2895,"briefTitle":2896,"status":123,"phases":30424,"primaryCompletion":1111,"completion":2898,"start":2899,"enrollment":203,"conditions":30425,"interventions":30426},[93],[2901],[2752,2903],{"trials":30428,"activeCount":103},[],{"trials":30430,"activeCount":103},[],{"intervention":16165,"totalTrials":437,"cells":30432},{"EARLY_PHASE1":30433,"PHASE1":30435,"PHASE2":30437,"PHASE3":30439,"PHASE4":30445,"NA":30447},{"trials":30434,"activeCount":103},[],{"trials":30436,"activeCount":103},[],{"trials":30438,"activeCount":103},[],{"trials":30440,"activeCount":103},[30441],{"nctId":16159,"briefTitle":16160,"status":390,"phases":30442,"primaryCompletion":1780,"completion":1780,"start":1781,"enrollment":103,"conditions":30443,"interventions":30444},[93],[16163],[15541,16165],{"trials":30446,"activeCount":103},[],{"trials":30448,"activeCount":103},[],{"intervention":9890,"totalTrials":437,"cells":30450},{"EARLY_PHASE1":30451,"PHASE1":30453,"PHASE2":30455,"PHASE3":30457,"PHASE4":30463,"NA":30465},{"trials":30452,"activeCount":103},[],{"trials":30454,"activeCount":103},[],{"trials":30456,"activeCount":103},[],{"trials":30458,"activeCount":103},[30459],{"nctId":9883,"briefTitle":9884,"status":123,"phases":30460,"primaryCompletion":2795,"completion":2795,"start":905,"enrollment":9886,"conditions":30461,"interventions":30462},[93],[3228],[9889,9890,9823],{"trials":30464,"activeCount":103},[],{"trials":30466,"activeCount":103},[],{"intervention":30468,"totalTrials":437,"cells":30469},"LCZ",{"EARLY_PHASE1":30470,"PHASE1":30472,"PHASE2":30474,"PHASE3":30476,"PHASE4":30490,"NA":30492},{"trials":30471,"activeCount":103},[],{"trials":30473,"activeCount":103},[],{"trials":30475,"activeCount":103},[],{"trials":30477,"activeCount":103},[30478],{"nctId":30479,"briefTitle":30480,"status":123,"phases":30481,"primaryCompletion":8189,"completion":30482,"start":30483,"enrollment":30484,"conditions":30485,"interventions":30486},"NCT06236061","Study of Efficacy and Safety of LCZ696\u002FAmlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy",[93],"2025-12-23","2024-04-08",718,[21],[30468,30487,30488,30489],"LCZ\u002FAML 200 mg\u002F2.5 mg","LCZ\u002FAML 200 mg\u002F5 mg","LCZ\u002FAML 200 mg\u002F10 mg",{"trials":30491,"activeCount":103},[],{"trials":30493,"activeCount":103},[],{"intervention":30487,"totalTrials":437,"cells":30495},{"EARLY_PHASE1":30496,"PHASE1":30498,"PHASE2":30500,"PHASE3":30502,"PHASE4":30508,"NA":30510},{"trials":30497,"activeCount":103},[],{"trials":30499,"activeCount":103},[],{"trials":30501,"activeCount":103},[],{"trials":30503,"activeCount":103},[30504],{"nctId":30479,"briefTitle":30480,"status":123,"phases":30505,"primaryCompletion":8189,"completion":30482,"start":30483,"enrollment":30484,"conditions":30506,"interventions":30507},[93],[21],[30468,30487,30488,30489],{"trials":30509,"activeCount":103},[],{"trials":30511,"activeCount":103},[],{"intervention":30488,"totalTrials":437,"cells":30513},{"EARLY_PHASE1":30514,"PHASE1":30516,"PHASE2":30518,"PHASE3":30520,"PHASE4":30526,"NA":30528},{"trials":30515,"activeCount":103},[],{"trials":30517,"activeCount":103},[],{"trials":30519,"activeCount":103},[],{"trials":30521,"activeCount":103},[30522],{"nctId":30479,"briefTitle":30480,"status":123,"phases":30523,"primaryCompletion":8189,"completion":30482,"start":30483,"enrollment":30484,"conditions":30524,"interventions":30525},[93],[21],[30468,30487,30488,30489],{"trials":30527,"activeCount":103},[],{"trials":30529,"activeCount":103},[],{"intervention":30489,"totalTrials":437,"cells":30531},{"EARLY_PHASE1":30532,"PHASE1":30534,"PHASE2":30536,"PHASE3":30538,"PHASE4":30544,"NA":30546},{"trials":30533,"activeCount":103},[],{"trials":30535,"activeCount":103},[],{"trials":30537,"activeCount":103},[],{"trials":30539,"activeCount":103},[30540],{"nctId":30479,"briefTitle":30480,"status":123,"phases":30541,"primaryCompletion":8189,"completion":30482,"start":30483,"enrollment":30484,"conditions":30542,"interventions":30543},[93],[21],[30468,30487,30488,30489],{"trials":30545,"activeCount":103},[],{"trials":30547,"activeCount":103},[],{"intervention":30549,"totalTrials":437,"cells":30550},"Valsartan 160 mg + nateglinide 60 mg",{"EARLY_PHASE1":30551,"PHASE1":30553,"PHASE2":30555,"PHASE3":30557,"PHASE4":30569,"NA":30571},{"trials":30552,"activeCount":103},[],{"trials":30554,"activeCount":103},[],{"trials":30556,"activeCount":103},[],{"trials":30558,"activeCount":103},[30559],{"nctId":30560,"briefTitle":30561,"status":123,"phases":30562,"primaryCompletion":4400,"completion":4400,"start":16929,"enrollment":30563,"conditions":30564,"interventions":30565},"NCT00097786","Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications",[93],9306,[30],[30549,30566,30567,30568],"Valsartan 160 mg + nateglinide placebo","Nateglinide 60 mg + valsartan placebo","Valsartan placebo + nateglinide placebo",{"trials":30570,"activeCount":103},[],{"trials":30572,"activeCount":103},[],{"intervention":30566,"totalTrials":437,"cells":30574},{"EARLY_PHASE1":30575,"PHASE1":30577,"PHASE2":30579,"PHASE3":30581,"PHASE4":30587,"NA":30589},{"trials":30576,"activeCount":103},[],{"trials":30578,"activeCount":103},[],{"trials":30580,"activeCount":103},[],{"trials":30582,"activeCount":103},[30583],{"nctId":30560,"briefTitle":30561,"status":123,"phases":30584,"primaryCompletion":4400,"completion":4400,"start":16929,"enrollment":30563,"conditions":30585,"interventions":30586},[93],[30],[30549,30566,30567,30568],{"trials":30588,"activeCount":103},[],{"trials":30590,"activeCount":103},[],{"intervention":30567,"totalTrials":437,"cells":30592},{"EARLY_PHASE1":30593,"PHASE1":30595,"PHASE2":30597,"PHASE3":30599,"PHASE4":30605,"NA":30607},{"trials":30594,"activeCount":103},[],{"trials":30596,"activeCount":103},[],{"trials":30598,"activeCount":103},[],{"trials":30600,"activeCount":103},[30601],{"nctId":30560,"briefTitle":30561,"status":123,"phases":30602,"primaryCompletion":4400,"completion":4400,"start":16929,"enrollment":30563,"conditions":30603,"interventions":30604},[93],[30],[30549,30566,30567,30568],{"trials":30606,"activeCount":103},[],{"trials":30608,"activeCount":103},[],{"intervention":30568,"totalTrials":437,"cells":30610},{"EARLY_PHASE1":30611,"PHASE1":30613,"PHASE2":30615,"PHASE3":30617,"PHASE4":30623,"NA":30625},{"trials":30612,"activeCount":103},[],{"trials":30614,"activeCount":103},[],{"trials":30616,"activeCount":103},[],{"trials":30618,"activeCount":103},[30619],{"nctId":30560,"briefTitle":30561,"status":123,"phases":30620,"primaryCompletion":4400,"completion":4400,"start":16929,"enrollment":30563,"conditions":30621,"interventions":30622},[93],[30],[30549,30566,30567,30568],{"trials":30624,"activeCount":103},[],{"trials":30626,"activeCount":103},[],{"intervention":18583,"totalTrials":437,"cells":30628},{"EARLY_PHASE1":30629,"PHASE1":30631,"PHASE2":30633,"PHASE3":30635,"PHASE4":30641,"NA":30643},{"trials":30630,"activeCount":103},[],{"trials":30632,"activeCount":103},[],{"trials":30634,"activeCount":103},[],{"trials":30636,"activeCount":103},[30637],{"nctId":18574,"briefTitle":18575,"status":123,"phases":30638,"primaryCompletion":3410,"completion":3410,"start":3279,"enrollment":18577,"conditions":30639,"interventions":30640},[93],[21],[18580,18581,18542,18582,18583,18584,18585,18586],{"trials":30642,"activeCount":103},[],{"trials":30644,"activeCount":103},[],{"intervention":18584,"totalTrials":437,"cells":30646},{"EARLY_PHASE1":30647,"PHASE1":30649,"PHASE2":30651,"PHASE3":30653,"PHASE4":30659,"NA":30661},{"trials":30648,"activeCount":103},[],{"trials":30650,"activeCount":103},[],{"trials":30652,"activeCount":103},[],{"trials":30654,"activeCount":103},[30655],{"nctId":18574,"briefTitle":18575,"status":123,"phases":30656,"primaryCompletion":3410,"completion":3410,"start":3279,"enrollment":18577,"conditions":30657,"interventions":30658},[93],[21],[18580,18581,18542,18582,18583,18584,18585,18586],{"trials":30660,"activeCount":103},[],{"trials":30662,"activeCount":103},[],{"intervention":18585,"totalTrials":437,"cells":30664},{"EARLY_PHASE1":30665,"PHASE1":30667,"PHASE2":30669,"PHASE3":30671,"PHASE4":30677,"NA":30679},{"trials":30666,"activeCount":103},[],{"trials":30668,"activeCount":103},[],{"trials":30670,"activeCount":103},[],{"trials":30672,"activeCount":103},[30673],{"nctId":18574,"briefTitle":18575,"status":123,"phases":30674,"primaryCompletion":3410,"completion":3410,"start":3279,"enrollment":18577,"conditions":30675,"interventions":30676},[93],[21],[18580,18581,18542,18582,18583,18584,18585,18586],{"trials":30678,"activeCount":103},[],{"trials":30680,"activeCount":103},[],{"intervention":18586,"totalTrials":437,"cells":30682},{"EARLY_PHASE1":30683,"PHASE1":30685,"PHASE2":30687,"PHASE3":30689,"PHASE4":30695,"NA":30697},{"trials":30684,"activeCount":103},[],{"trials":30686,"activeCount":103},[],{"trials":30688,"activeCount":103},[],{"trials":30690,"activeCount":103},[30691],{"nctId":18574,"briefTitle":18575,"status":123,"phases":30692,"primaryCompletion":3410,"completion":3410,"start":3279,"enrollment":18577,"conditions":30693,"interventions":30694},[93],[21],[18580,18581,18542,18582,18583,18584,18585,18586],{"trials":30696,"activeCount":103},[],{"trials":30698,"activeCount":103},[],{"intervention":30700,"totalTrials":437,"cells":30701},"eltrombopag olamine",{"EARLY_PHASE1":30702,"PHASE1":30704,"PHASE2":30706,"PHASE3":30708,"PHASE4":30716,"NA":30718},{"trials":30703,"activeCount":103},[],{"trials":30705,"activeCount":103},[],{"trials":30707,"activeCount":103},[],{"trials":30709,"activeCount":103},[30710],{"nctId":30711,"briefTitle":30712,"status":123,"phases":30713,"primaryCompletion":3511,"completion":3511,"start":745,"enrollment":4899,"conditions":30714,"interventions":30715},"NCT00351468","EXTEND (Eltrombopag Extended Dosing Study)",[93],[7555],[30700],{"trials":30717,"activeCount":103},[],{"trials":30719,"activeCount":103},[],{"intervention":15503,"totalTrials":437,"cells":30721},{"EARLY_PHASE1":30722,"PHASE1":30724,"PHASE2":30726,"PHASE3":30728,"PHASE4":30734,"NA":30736},{"trials":30723,"activeCount":103},[],{"trials":30725,"activeCount":103},[],{"trials":30727,"activeCount":103},[],{"trials":30729,"activeCount":103},[30730],{"nctId":15495,"briefTitle":15496,"status":123,"phases":30731,"primaryCompletion":15498,"completion":6142,"start":15499,"enrollment":15500,"conditions":30732,"interventions":30733},[93],[7868],[15503,4321],{"trials":30735,"activeCount":103},[],{"trials":30737,"activeCount":103},[],{"intervention":30739,"totalTrials":437,"cells":30740},"Pelacarsen (TQJ230) 80 mg s.c.",{"EARLY_PHASE1":30741,"PHASE1":30743,"PHASE2":30745,"PHASE3":30747,"PHASE4":30759,"NA":30761},{"trials":30742,"activeCount":103},[],{"trials":30744,"activeCount":103},[],{"trials":30746,"activeCount":103},[],{"trials":30748,"activeCount":103},[30749],{"nctId":30750,"briefTitle":30751,"status":123,"phases":30752,"primaryCompletion":30753,"completion":30753,"start":30754,"enrollment":2428,"conditions":30755,"interventions":30757},"NCT05305664","A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany",[93],"2025-01-28","2022-08-19",[30756],"Hyperlipoproteinemia(a)",[30739,30758],"Corresponding Placebo",{"trials":30760,"activeCount":103},[],{"trials":30762,"activeCount":103},[],{"intervention":30758,"totalTrials":437,"cells":30764},{"EARLY_PHASE1":30765,"PHASE1":30767,"PHASE2":30769,"PHASE3":30771,"PHASE4":30777,"NA":30779},{"trials":30766,"activeCount":103},[],{"trials":30768,"activeCount":103},[],{"trials":30770,"activeCount":103},[],{"trials":30772,"activeCount":103},[30773],{"nctId":30750,"briefTitle":30751,"status":123,"phases":30774,"primaryCompletion":30753,"completion":30753,"start":30754,"enrollment":2428,"conditions":30775,"interventions":30776},[93],[30756],[30739,30758],{"trials":30778,"activeCount":103},[],{"trials":30780,"activeCount":103},[],{"intervention":30782,"totalTrials":437,"cells":30783},"Experimental : Secukinumab low dose",{"EARLY_PHASE1":30784,"PHASE1":30786,"PHASE2":30788,"PHASE3":30790,"PHASE4":30802,"NA":30804},{"trials":30785,"activeCount":103},[],{"trials":30787,"activeCount":103},[],{"trials":30789,"activeCount":103},[],{"trials":30791,"activeCount":103},[30792],{"nctId":30793,"briefTitle":30794,"status":123,"phases":30795,"primaryCompletion":17355,"completion":30796,"start":2499,"enrollment":3705,"conditions":30797,"interventions":30799},"NCT02471144","Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis",[93],"2023-03-30",[30798],"Chronic Severe Plaque-type Psoriasis",[30782,30800,30801],"Experimental: Secukinumab high dose","Active Comparator: Etanercept",{"trials":30803,"activeCount":103},[],{"trials":30805,"activeCount":103},[],{"intervention":30800,"totalTrials":437,"cells":30807},{"EARLY_PHASE1":30808,"PHASE1":30810,"PHASE2":30812,"PHASE3":30814,"PHASE4":30820,"NA":30822},{"trials":30809,"activeCount":103},[],{"trials":30811,"activeCount":103},[],{"trials":30813,"activeCount":103},[],{"trials":30815,"activeCount":103},[30816],{"nctId":30793,"briefTitle":30794,"status":123,"phases":30817,"primaryCompletion":17355,"completion":30796,"start":2499,"enrollment":3705,"conditions":30818,"interventions":30819},[93],[30798],[30782,30800,30801],{"trials":30821,"activeCount":103},[],{"trials":30823,"activeCount":103},[],{"intervention":30801,"totalTrials":437,"cells":30825},{"EARLY_PHASE1":30826,"PHASE1":30828,"PHASE2":30830,"PHASE3":30832,"PHASE4":30838,"NA":30840},{"trials":30827,"activeCount":103},[],{"trials":30829,"activeCount":103},[],{"trials":30831,"activeCount":103},[],{"trials":30833,"activeCount":103},[30834],{"nctId":30793,"briefTitle":30794,"status":123,"phases":30835,"primaryCompletion":17355,"completion":30796,"start":2499,"enrollment":3705,"conditions":30836,"interventions":30837},[93],[30798],[30782,30800,30801],{"trials":30839,"activeCount":103},[],{"trials":30841,"activeCount":103},[],{"intervention":30843,"totalTrials":437,"cells":30844},"HCQ",{"EARLY_PHASE1":30845,"PHASE1":30847,"PHASE2":30849,"PHASE3":30851,"PHASE4":30863,"NA":30865},{"trials":30846,"activeCount":103},[],{"trials":30848,"activeCount":103},[],{"trials":30850,"activeCount":103},[],{"trials":30852,"activeCount":103},[30853],{"nctId":30854,"briefTitle":30855,"status":123,"phases":30856,"primaryCompletion":30857,"completion":30857,"start":30858,"enrollment":1611,"conditions":30859,"interventions":30861},"NCT04358081","Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",[93],"2020-07-27","2020-05-01",[30860],"Covid-19",[30843,30862],"HCQ+AZT",{"trials":30864,"activeCount":103},[],{"trials":30866,"activeCount":103},[],{"intervention":30862,"totalTrials":437,"cells":30868},{"EARLY_PHASE1":30869,"PHASE1":30871,"PHASE2":30873,"PHASE3":30875,"PHASE4":30881,"NA":30883},{"trials":30870,"activeCount":103},[],{"trials":30872,"activeCount":103},[],{"trials":30874,"activeCount":103},[],{"trials":30876,"activeCount":103},[30877],{"nctId":30854,"briefTitle":30855,"status":123,"phases":30878,"primaryCompletion":30857,"completion":30857,"start":30858,"enrollment":1611,"conditions":30879,"interventions":30880},[93],[30860],[30843,30862],{"trials":30882,"activeCount":103},[],{"trials":30884,"activeCount":103},[],{"intervention":30886,"totalTrials":437,"cells":30887},"Vildagliptin 100 mg qd",{"EARLY_PHASE1":30888,"PHASE1":30890,"PHASE2":30892,"PHASE3":30894,"PHASE4":30903,"NA":30905},{"trials":30889,"activeCount":103},[],{"trials":30891,"activeCount":103},[],{"trials":30893,"activeCount":103},[],{"trials":30895,"activeCount":103},[30896],{"nctId":30897,"briefTitle":30898,"status":123,"phases":30899,"primaryCompletion":5696,"start":4034,"enrollment":16351,"conditions":30900,"interventions":30901},"NCT00383578","Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes",[93],[30],[30886,30902],"Metformin 1500 mg daily",{"trials":30904,"activeCount":103},[],{"trials":30906,"activeCount":103},[],{"intervention":30902,"totalTrials":437,"cells":30908},{"EARLY_PHASE1":30909,"PHASE1":30911,"PHASE2":30913,"PHASE3":30915,"PHASE4":30921,"NA":30923},{"trials":30910,"activeCount":103},[],{"trials":30912,"activeCount":103},[],{"trials":30914,"activeCount":103},[],{"trials":30916,"activeCount":103},[30917],{"nctId":30897,"briefTitle":30898,"status":123,"phases":30918,"primaryCompletion":5696,"start":4034,"enrollment":16351,"conditions":30919,"interventions":30920},[93],[30],[30886,30902],{"trials":30922,"activeCount":103},[],{"trials":30924,"activeCount":103},[],{"intervention":2913,"totalTrials":437,"cells":30926},{"EARLY_PHASE1":30927,"PHASE1":30929,"PHASE2":30931,"PHASE3":30933,"PHASE4":30939,"NA":30941},{"trials":30928,"activeCount":103},[],{"trials":30930,"activeCount":103},[],{"trials":30932,"activeCount":103},[],{"trials":30934,"activeCount":103},[30935],{"nctId":2905,"briefTitle":2906,"status":123,"phases":30936,"primaryCompletion":2908,"completion":2908,"start":2909,"enrollment":2910,"conditions":30937,"interventions":30938},[93],[27],[2752,2913],{"trials":30940,"activeCount":103},[],{"trials":30942,"activeCount":103},[],{"intervention":30944,"totalTrials":437,"cells":30945},"Pasireotide sub-cutaneous",{"EARLY_PHASE1":30946,"PHASE1":30948,"PHASE2":30950,"PHASE3":30952,"PHASE4":30960,"NA":30962},{"trials":30947,"activeCount":103},[],{"trials":30949,"activeCount":103},[],{"trials":30951,"activeCount":103},[],{"trials":30953,"activeCount":103},[30954],{"nctId":30955,"briefTitle":30956,"status":123,"phases":30957,"primaryCompletion":18998,"completion":18998,"start":18999,"enrollment":314,"conditions":30958,"interventions":30959},"NCT01582061","An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.",[93],[16681],[30944],{"trials":30961,"activeCount":103},[],{"trials":30963,"activeCount":103},[],{"intervention":30965,"totalTrials":437,"cells":30966},"Secukinumab 150 mg s.c.",{"EARLY_PHASE1":30967,"PHASE1":30969,"PHASE2":30971,"PHASE3":30973,"PHASE4":30985,"NA":30987},{"trials":30968,"activeCount":103},[],{"trials":30970,"activeCount":103},[],{"trials":30972,"activeCount":103},[],{"trials":30974,"activeCount":103},[30975],{"nctId":30976,"briefTitle":30977,"status":123,"phases":30978,"primaryCompletion":30979,"completion":30980,"start":13727,"enrollment":30981,"conditions":30982,"interventions":30983},"NCT03066609","Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis",[93],"2017-12-21","2018-11-20",543,[1773],[30965,30984],"Secukinumab 300 mg s.c.",{"trials":30986,"activeCount":103},[],{"trials":30988,"activeCount":103},[],{"intervention":30984,"totalTrials":437,"cells":30990},{"EARLY_PHASE1":30991,"PHASE1":30993,"PHASE2":30995,"PHASE3":30997,"PHASE4":31003,"NA":31005},{"trials":30992,"activeCount":103},[],{"trials":30994,"activeCount":103},[],{"trials":30996,"activeCount":103},[],{"trials":30998,"activeCount":103},[30999],{"nctId":30976,"briefTitle":30977,"status":123,"phases":31000,"primaryCompletion":30979,"completion":30980,"start":13727,"enrollment":30981,"conditions":31001,"interventions":31002},[93],[1773],[30965,30984],{"trials":31004,"activeCount":103},[],{"trials":31006,"activeCount":103},[],{"intervention":25002,"totalTrials":437,"cells":31008},{"EARLY_PHASE1":31009,"PHASE1":31011,"PHASE2":31013,"PHASE3":31015,"PHASE4":31021,"NA":31023},{"trials":31010,"activeCount":103},[],{"trials":31012,"activeCount":103},[],{"trials":31014,"activeCount":103},[],{"trials":31016,"activeCount":103},[31017],{"nctId":24996,"briefTitle":24997,"status":123,"phases":31018,"primaryCompletion":16570,"completion":16570,"start":865,"enrollment":15188,"conditions":31019,"interventions":31020},[93],[25000],[24969,25002],{"trials":31022,"activeCount":103},[],{"trials":31024,"activeCount":103},[],{"intervention":31026,"totalTrials":437,"cells":31027},"QMF149 150\u002F80 μg",{"EARLY_PHASE1":31028,"PHASE1":31030,"PHASE2":31032,"PHASE3":31034,"PHASE4":31047,"NA":31049},{"trials":31029,"activeCount":103},[],{"trials":31031,"activeCount":103},[],{"trials":31033,"activeCount":103},[],{"trials":31035,"activeCount":103},[31036],{"nctId":31037,"briefTitle":31038,"status":123,"phases":31039,"primaryCompletion":31040,"completion":31041,"start":31042,"enrollment":4750,"conditions":31043,"interventions":31045},"NCT02892344","Study of QMF149 (150\u002F80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma",[93],"2018-11-05","2018-11-30","2017-01-16",[31044],"Mild Asthma",[31026,31046],"MF 200 μg",{"trials":31048,"activeCount":103},[],{"trials":31050,"activeCount":103},[],{"intervention":31046,"totalTrials":437,"cells":31052},{"EARLY_PHASE1":31053,"PHASE1":31055,"PHASE2":31057,"PHASE3":31059,"PHASE4":31065,"NA":31067},{"trials":31054,"activeCount":103},[],{"trials":31056,"activeCount":103},[],{"trials":31058,"activeCount":103},[],{"trials":31060,"activeCount":103},[31061],{"nctId":31037,"briefTitle":31038,"status":123,"phases":31062,"primaryCompletion":31040,"completion":31041,"start":31042,"enrollment":4750,"conditions":31063,"interventions":31064},[93],[31044],[31026,31046],{"trials":31066,"activeCount":103},[],{"trials":31068,"activeCount":103},[],{"intervention":31070,"totalTrials":437,"cells":31071},"TOBI",{"EARLY_PHASE1":31072,"PHASE1":31074,"PHASE2":31076,"PHASE3":31078,"PHASE4":31087,"NA":31089},{"trials":31073,"activeCount":103},[],{"trials":31075,"activeCount":103},[],{"trials":31077,"activeCount":103},[],{"trials":31079,"activeCount":103},[31080],{"nctId":31081,"briefTitle":31082,"status":123,"phases":31083,"primaryCompletion":4410,"completion":4410,"start":4081,"enrollment":2579,"conditions":31084,"interventions":31086},"NCT01082367","Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years",[93],[31085],"Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients",[31070],{"trials":31088,"activeCount":103},[],{"trials":31090,"activeCount":103},[],{"intervention":31092,"totalTrials":437,"cells":31093},"Certoparin",{"EARLY_PHASE1":31094,"PHASE1":31096,"PHASE2":31098,"PHASE3":31100,"PHASE4":31111,"NA":31113},{"trials":31095,"activeCount":103},[],{"trials":31097,"activeCount":103},[],{"trials":31099,"activeCount":103},[],{"trials":31101,"activeCount":103},[31102],{"nctId":31103,"briefTitle":31104,"status":123,"phases":31105,"primaryCompletion":4556,"start":966,"enrollment":31106,"conditions":31107,"interventions":31109},"NCT00311753","Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients",[93],342,[31108],"Embolism",[31092,31110],"Heparin",{"trials":31112,"activeCount":103},[],{"trials":31114,"activeCount":103},[],{"intervention":31110,"totalTrials":437,"cells":31116},{"EARLY_PHASE1":31117,"PHASE1":31119,"PHASE2":31121,"PHASE3":31123,"PHASE4":31129,"NA":31131},{"trials":31118,"activeCount":103},[],{"trials":31120,"activeCount":103},[],{"trials":31122,"activeCount":103},[],{"trials":31124,"activeCount":103},[31125],{"nctId":31103,"briefTitle":31104,"status":123,"phases":31126,"primaryCompletion":4556,"start":966,"enrollment":31106,"conditions":31127,"interventions":31128},[93],[31108],[31092,31110],{"trials":31130,"activeCount":103},[],{"trials":31132,"activeCount":103},[],{"intervention":10541,"totalTrials":837,"cells":31134},{"EARLY_PHASE1":31135,"PHASE1":31137,"PHASE2":31211,"PHASE3":31260,"PHASE4":31262,"NA":31264},{"trials":31136,"activeCount":103},[],{"trials":31138,"activeCount":103},[31139,31146,31153,31159,31165,31174,31180,31187,31193,31199,31205],{"nctId":31140,"briefTitle":31141,"status":134,"phases":31142,"start":8091,"enrollment":12584,"conditions":31143,"interventions":31145},"NCT00419536","Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone",[91],[31144],"Hormone Refractory Prostate Cancer Disease",[10541],{"nctId":31147,"briefTitle":31148,"status":123,"phases":31149,"primaryCompletion":5062,"start":4740,"enrollment":1630,"conditions":31150,"interventions":31152},"NCT00472368","A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589",[91],[31151],"Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies",[10541],{"nctId":31154,"briefTitle":31155,"status":123,"phases":31156,"primaryCompletion":3712,"completion":3712,"start":964,"enrollment":2342,"conditions":31157,"interventions":31158},"NCT01007968","Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function",[91],[5614],[10541],{"nctId":31160,"briefTitle":31161,"status":123,"phases":31162,"primaryCompletion":3760,"completion":3760,"start":4642,"enrollment":792,"conditions":31163,"interventions":31164},"NCT00570284","A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors",[91],[1102],[10541],{"nctId":31166,"briefTitle":31167,"status":123,"phases":31168,"primaryCompletion":31169,"completion":31169,"start":31170,"enrollment":3098,"conditions":31171,"interventions":31172},"NCT00532675","Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.",[91],"2017-11-08","2008-04-22",[5636],[10541,31173],"Lenalidomide",{"nctId":31175,"briefTitle":31176,"status":123,"phases":31177,"primaryCompletion":4335,"start":10499,"enrollment":814,"conditions":31178,"interventions":31179},"NCT00739414","Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors",[91],[1102,9516],[10541],{"nctId":31181,"briefTitle":31182,"status":134,"phases":31183,"primaryCompletion":10499,"start":8091,"enrollment":1672,"conditions":31184,"interventions":31186},"NCT00493766","Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone",[91],[31185],"Hormone Refractory Prostate Cancer",[10541],{"nctId":31188,"briefTitle":31189,"status":123,"phases":31190,"primaryCompletion":949,"start":4642,"enrollment":3343,"conditions":31191,"interventions":31192},"NCT00535951","Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma",[91],[227,13598],[10541],{"nctId":31194,"briefTitle":31195,"status":123,"phases":31196,"primaryCompletion":813,"completion":813,"start":3447,"enrollment":2149,"conditions":31197,"interventions":31198},"NCT00532389","Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma",[91],[5636],[10541],{"nctId":31200,"briefTitle":31201,"status":123,"phases":31202,"primaryCompletion":4081,"start":3194,"enrollment":814,"conditions":31203,"interventions":31204},"NCT00503451","A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors",[91],[8170,4362],[10541],{"nctId":31206,"briefTitle":31207,"status":123,"phases":31208,"primaryCompletion":4301,"start":16570,"enrollment":22,"conditions":31209,"interventions":31210},"NCT00663832","A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer",[91],[1654],[10541],{"trials":31212,"activeCount":103},[31213,31223,31232,31241,31249,31256],{"nctId":31214,"briefTitle":31215,"status":134,"phases":31216,"primaryCompletion":31217,"completion":31218,"start":31219,"enrollment":34,"conditions":31220,"interventions":31222},"NCT00449761","Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase",[92],"2008-01-29","2008-08-26","2007-02-23",[31221],"Leukemia, Myeloid, Chronic",[10541],{"nctId":31224,"briefTitle":31225,"status":134,"phases":31226,"primaryCompletion":31227,"completion":31228,"start":31229,"enrollment":1053,"conditions":31230,"interventions":31231},"NCT00451035","Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase",[92],"2008-04-13","2008-09-30","2007-02-19",[6997],[10541],{"nctId":31233,"briefTitle":31234,"status":134,"phases":31235,"primaryCompletion":31236,"completion":31237,"start":31238,"enrollment":5948,"conditions":31239,"interventions":31240},"NCT00445068","Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma",[92],"2008-05-19","2009-12-25","2007-04-16",[5636],[10541],{"nctId":31242,"briefTitle":31243,"status":123,"phases":31244,"primaryCompletion":31245,"completion":31245,"start":31246,"enrollment":8659,"conditions":31247,"interventions":31248},"NCT00621244","A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies",[91,92],"2009-12-03","2003-03-01",[7610,3422,5636],[10541],{"nctId":31250,"briefTitle":31251,"status":134,"phases":31252,"primaryCompletion":3482,"completion":3482,"start":4335,"enrollment":31,"conditions":31253,"interventions":31254},"NCT01034657","LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)",[92],[10713],[10541,31255],"Epoetin Alfa",{"nctId":10533,"briefTitle":10534,"status":123,"phases":31257,"primaryCompletion":2467,"completion":10536,"start":10537,"enrollment":827,"conditions":31258,"interventions":31259},[92],[10539],[10541,5649,5639],{"trials":31261,"activeCount":103},[],{"trials":31263,"activeCount":103},[],{"trials":31265,"activeCount":103},[],{"intervention":13880,"totalTrials":814,"cells":31267},{"EARLY_PHASE1":31268,"PHASE1":31270,"PHASE2":31323,"PHASE3":31369,"PHASE4":31371,"NA":31373},{"trials":31269,"activeCount":103},[],{"trials":31271,"activeCount":103},[31272,31280,31286,31293,31300,31306,31313,31319],{"nctId":31273,"briefTitle":31274,"status":123,"phases":31275,"primaryCompletion":4669,"completion":4669,"start":864,"enrollment":19,"conditions":31276,"interventions":31279},"NCT01155713","Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors",[91],[31277,1102,31278],"Neoplasm","Tumors",[13880],{"nctId":31281,"briefTitle":31282,"status":134,"phases":31283,"primaryCompletion":3447,"start":4810,"enrollment":31,"conditions":31284,"interventions":31285},"NCT00279773","Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia",[91],[2569],[13880],{"nctId":31287,"briefTitle":31288,"status":123,"phases":31289,"primaryCompletion":3551,"start":4070,"enrollment":734,"conditions":31290,"interventions":31292},"NCT00669097","Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies",[91],[31291],"Advanced Solid Malignancies",[13880],{"nctId":31294,"briefTitle":31295,"status":123,"phases":31296,"primaryCompletion":3409,"completion":3409,"start":4301,"enrollment":1100,"conditions":31297,"interventions":31299},"NCT01421004","Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors",[91],[5614,31298],"Excluding Breast Cancer",[13880],{"nctId":31301,"briefTitle":31302,"status":123,"phases":31303,"primaryCompletion":4524,"completion":4524,"start":880,"enrollment":1423,"conditions":31304,"interventions":31305},"NCT01030055","Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors",[91],[4362,1102,31278],[13880],{"nctId":31307,"briefTitle":31308,"status":123,"phases":31309,"primaryCompletion":3759,"completion":3759,"start":10499,"enrollment":3776,"conditions":31310,"interventions":31312},"NCT00715182","A Phase I\u002FII Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced\u002FMetastatic Renal Cell Cancer",[91],[31311],"Advanced\u002F Metastatic Renal Cell Cancer",[13880],{"nctId":31314,"briefTitle":31315,"status":123,"phases":31316,"primaryCompletion":5733,"completion":5733,"start":3279,"enrollment":827,"conditions":31317,"interventions":31318},"NCT01471548","Phase I Dose Escalating Study of TKI258",[91],[5614],[13880],{"nctId":13871,"briefTitle":13872,"status":123,"phases":31320,"primaryCompletion":3409,"completion":3409,"start":5733,"enrollment":28,"conditions":31321,"interventions":31322},[91],[13875],[13877,13878,13879,5207,13880],{"trials":31324,"activeCount":103},[31325,31334,31340,31346,31352,31363],{"nctId":31326,"briefTitle":31327,"status":123,"phases":31328,"primaryCompletion":4093,"completion":4093,"start":3800,"enrollment":17433,"conditions":31329,"interventions":31333},"NCT01379534","A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and\u002For Metastatic Endometrial Cancer",[92],[31330,856,31331,31332],"Solid Tumors and Advanced Endometrial Cancer","Second-line Treatment","VEGF",[13880],{"nctId":31335,"briefTitle":31336,"status":123,"phases":31337,"primaryCompletion":895,"completion":895,"start":4845,"enrollment":4557,"conditions":31338,"interventions":31339},"NCT00958971","Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer",[92],[435],[13880],{"nctId":31341,"briefTitle":31342,"status":123,"phases":31343,"primaryCompletion":2793,"completion":2793,"start":853,"enrollment":4557,"conditions":31344,"interventions":31345},"NCT01058434","Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation",[92],[10501],[13880],{"nctId":31347,"briefTitle":31348,"status":123,"phases":31349,"primaryCompletion":607,"completion":607,"start":964,"enrollment":22,"conditions":31350,"interventions":31351},"NCT00790426","Phase II Study of TKI258 in Advanced Urothelial Carcinoma",[92],[13462],[13880],{"nctId":31353,"briefTitle":31354,"status":123,"phases":31355,"primaryCompletion":3799,"completion":3799,"start":4524,"enrollment":4148,"conditions":31356,"interventions":31362},"NCT01576380","A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients",[92],[31357,31358,31359,31360,31361,4362],"Adenocarcinoma, Scirrhous","Linitis Plastica","Stomach Neoplasms","Stomach Diseases","Neoplasms by Site",[13880],{"nctId":31364,"briefTitle":31365,"status":123,"phases":31366,"primaryCompletion":4975,"start":16010,"enrollment":846,"conditions":31367,"interventions":31368},"NCT00303251","Safety of TKI258 in Advanced\u002FMetastatic Melanoma Subjects",[91,92],[36],[13880],{"trials":31370,"activeCount":103},[],{"trials":31372,"activeCount":103},[],{"trials":31374,"activeCount":103},[],{"intervention":18982,"totalTrials":138,"cells":31376},{"EARLY_PHASE1":31377,"PHASE1":31379,"PHASE2":31413,"PHASE3":31466,"PHASE4":31468,"NA":31470},{"trials":31378,"activeCount":103},[],{"trials":31380,"activeCount":103},[31381,31385,31393,31399,31407],{"nctId":23007,"briefTitle":23008,"status":123,"phases":31382,"primaryCompletion":606,"completion":606,"start":3759,"enrollment":1384,"conditions":31383,"interventions":31384},[91],[23011,23012,23013,5614,435,23014,9924,17111,23015,23016,23017,23018],[18982,517],{"nctId":31386,"briefTitle":31387,"status":123,"phases":31388,"primaryCompletion":813,"completion":813,"start":5620,"enrollment":2405,"conditions":31389,"interventions":31392},"NCT01208831","An East Asian Study of LDE225",[91],[31390,31391,25176],"Advanced Solid Tumor Cancers","Medulloblastoma",[18982],{"nctId":31394,"briefTitle":31395,"status":123,"phases":31396,"primaryCompletion":2509,"completion":2509,"start":4967,"enrollment":99,"conditions":31397,"interventions":31398},"NCT01764776","Effect of Hepatic Impairment on LDE225..",[91],[10048,10049],[18982],{"nctId":31400,"briefTitle":31401,"status":123,"phases":31402,"primaryCompletion":11025,"completion":11025,"start":15283,"enrollment":17693,"conditions":31403,"interventions":31404},"NCT01769768","Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients",[91],[9516],[18982,31405,31406],"Wafarin","Bupropion",{"nctId":31408,"briefTitle":31409,"status":123,"phases":31410,"primaryCompletion":2033,"completion":2033,"start":3400,"enrollment":12783,"conditions":31411,"interventions":31412},"NCT00880308","Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors",[91],[31390,31391,25176],[18982],{"trials":31414,"activeCount":103},[31415,31422,31430,31439,31446,31450,31457],{"nctId":31416,"briefTitle":31417,"status":123,"phases":31418,"primaryCompletion":5248,"completion":17374,"start":31419,"enrollment":25308,"conditions":31420,"interventions":31421},"NCT01327053","A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma",[92],"2011-06-29",[25176],[18982],{"nctId":31423,"briefTitle":31424,"status":123,"phases":31425,"primaryCompletion":1761,"completion":1761,"start":3383,"enrollment":5594,"conditions":31426,"interventions":31429},"NCT01350115","Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)",[92],[25176,31427,31428],"Gorlin Syndrome","Nevoid Basal Cell Carcinoma Syndrome",[18982],{"nctId":31431,"briefTitle":31432,"status":123,"phases":31433,"primaryCompletion":31434,"completion":31434,"start":31435,"enrollment":2633,"conditions":31436,"interventions":31437},"NCT01708174","A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)",[92],"2016-10-05","2013-05-06",[31391],[18982,31438],"TMZ",{"nctId":31440,"briefTitle":31441,"status":123,"phases":31442,"primaryCompletion":1760,"completion":1760,"start":5114,"enrollment":512,"conditions":31443,"interventions":31445},"NCT01826214","Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed\u002FRefractory Acute Leukemia",[92],[31444],"Acute Leukemias",[18982],{"nctId":18969,"briefTitle":18970,"status":123,"phases":31447,"primaryCompletion":18972,"completion":18972,"start":18973,"enrollment":2579,"conditions":31448,"interventions":31449},[91,92],[2430,18975,18976,2470,18977,10702,3335,18978,18979,18980],[18982,18952],{"nctId":31451,"briefTitle":31452,"status":134,"phases":31453,"primaryCompletion":2509,"completion":2509,"start":1723,"enrollment":5594,"conditions":31454,"interventions":31456},"NCT02002689","LDE225 for Patients With PTCH1 or SMO Mutated Tumors",[92],[31455],"PTCH1 or SMO Activated Solid and Hematologic Tumors",[18982],{"nctId":31458,"briefTitle":31459,"status":123,"phases":31460,"primaryCompletion":1817,"completion":1817,"start":3760,"enrollment":485,"conditions":31461,"interventions":31465},"NCT01125800","A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB",[91,92],[31391,31462,140,31463,31464,1147],"Rhabdomyosarcoma","Hepatoblastoma","Glioma",[18982],{"trials":31467,"activeCount":103},[],{"trials":31469,"activeCount":103},[],{"trials":31471,"activeCount":103},[],{"intervention":18225,"totalTrials":4148,"cells":31473},{"EARLY_PHASE1":31474,"PHASE1":31476,"PHASE2":31478,"PHASE3":31565,"PHASE4":31567,"NA":31569},{"trials":31475,"activeCount":103},[],{"trials":31477,"activeCount":103},[],{"trials":31479,"activeCount":103},[31480,31489,31499,31509,31513,31521,31529,31537,31543,31550,31559],{"nctId":31481,"briefTitle":31482,"status":123,"phases":31483,"primaryCompletion":31484,"completion":31485,"start":31486,"enrollment":2130,"conditions":31487,"interventions":31488},"NCT03100058","A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults",[92],"2018-03-02","2018-08-02","2017-05-06",[20093,27233],[18225],{"nctId":31490,"briefTitle":31491,"status":123,"phases":31492,"primaryCompletion":31493,"completion":31494,"start":31495,"enrollment":6514,"conditions":31496,"interventions":31498},"NCT03205150","Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients",[92],"2019-11-11","2019-11-14","2017-10-04",[31497],"Obese Patients With Non-alcoholic Steatohepatitis (NASH)",[18225],{"nctId":31500,"briefTitle":31501,"status":134,"phases":31502,"primaryCompletion":31503,"completion":31503,"start":31504,"enrollment":3491,"conditions":31505,"interventions":31507},"NCT03152552","A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure",[92],"2018-06-06","2017-07-25",[31506],"Diabetes Mellitus and Heart Failure",[18225,31508],"Empagliflozin",{"nctId":18219,"briefTitle":18220,"status":390,"phases":31510,"primaryCompletion":18222,"completion":18222,"start":2794,"enrollment":103,"conditions":31511,"interventions":31512},[92],[15133],[18225,15255],{"nctId":31514,"briefTitle":31515,"status":123,"phases":31516,"primaryCompletion":31517,"completion":31517,"start":31518,"enrollment":271,"conditions":31519,"interventions":31520},"NCT03198767","Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066",[92],"2017-09-04","2017-06-21",[20093],[18225],{"nctId":31522,"briefTitle":31523,"status":123,"phases":31524,"primaryCompletion":31525,"completion":31525,"start":31526,"enrollment":5080,"conditions":31527,"interventions":31528},"NCT03320941","A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity",[92],"2018-07-25","2017-12-07",[20093],[18225],{"nctId":31530,"briefTitle":31531,"status":123,"phases":31532,"primaryCompletion":18197,"completion":18197,"start":31533,"enrollment":1053,"conditions":31534,"interventions":31536},"NCT03152591","Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome",[92],"2017-07-24",[31535],"Polycystic Ovary Syndrome",[18225],{"nctId":31538,"briefTitle":31539,"status":123,"phases":31540,"primaryCompletion":2793,"completion":2793,"start":2034,"enrollment":1600,"conditions":31541,"interventions":31542},"NCT01407003","Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)",[91,92],[15146],[18225],{"nctId":31544,"briefTitle":31545,"status":123,"phases":31546,"primaryCompletion":31547,"completion":31547,"start":8338,"enrollment":17433,"conditions":31548,"interventions":31549},"NCT03131479","Study of PK\u002FPD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.",[92],"2018-01-16",[2635],[18225],{"nctId":31551,"briefTitle":31552,"status":123,"phases":31553,"primaryCompletion":31554,"completion":31554,"start":31555,"enrollment":9558,"conditions":31556,"interventions":31558},"NCT02470403","Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index",[92],"2016-04-04","2015-06-05",[31557],"Elevated Body Mass Index",[18225],{"nctId":31560,"briefTitle":31561,"status":123,"phases":31562,"primaryCompletion":3559,"completion":3559,"start":2033,"enrollment":814,"conditions":31563,"interventions":31564},"NCT01915849","Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus",[91,92],[15133],[18225],{"trials":31566,"activeCount":103},[],{"trials":31568,"activeCount":103},[],{"trials":31570,"activeCount":103},[],{"intervention":8061,"totalTrials":5594,"cells":31572},{"EARLY_PHASE1":31573,"PHASE1":31575,"PHASE2":31614,"PHASE3":31642,"PHASE4":31644,"NA":31646},{"trials":31574,"activeCount":103},[],{"trials":31576,"activeCount":103},[31577,31583,31589,31595,31602,31608],{"nctId":31578,"briefTitle":31579,"status":123,"phases":31580,"primaryCompletion":3195,"start":3210,"enrollment":637,"conditions":31581,"interventions":31582},"NCT00426140","Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.",[91],[6437,647],[8061],{"nctId":31584,"briefTitle":31585,"status":134,"phases":31586,"start":4740,"enrollment":138,"conditions":31587,"interventions":31588},"NCT00468260","The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies",[91],[6437],[8061],{"nctId":31590,"briefTitle":31591,"status":123,"phases":31592,"primaryCompletion":16570,"start":3474,"enrollment":837,"conditions":31593,"interventions":31594},"NCT00448396","Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies",[91],[6437],[8061],{"nctId":31596,"briefTitle":31597,"status":390,"phases":31598,"primaryCompletion":4317,"start":4317,"enrollment":103,"conditions":31599,"interventions":31600},"NCT00442741","Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)",[91],[647],[8061,31601],"Patupilone + Omeprazole",{"nctId":31603,"briefTitle":31604,"status":123,"phases":31605,"primaryCompletion":917,"start":3210,"enrollment":2367,"conditions":31606,"interventions":31607},"NCT00412789","Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan",[91],[31278],[8061],{"nctId":31609,"briefTitle":31610,"status":123,"phases":31611,"primaryCompletion":3845,"start":3210,"enrollment":114,"conditions":31612,"interventions":31613},"NCT00426582","Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors",[91],[5614],[8061],{"trials":31615,"activeCount":103},[31616,31625,31629,31635],{"nctId":31617,"briefTitle":31618,"status":123,"phases":31619,"primaryCompletion":31620,"completion":31620,"start":31621,"enrollment":2579,"conditions":31622,"interventions":31624},"NCT00219297","Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer",[92],"2010-06-24","2005-11-16",[31623,128],"Brain Metastasis",[8061],{"nctId":8055,"briefTitle":8056,"status":123,"phases":31626,"primaryCompletion":3243,"completion":3243,"start":4034,"enrollment":2910,"conditions":31627,"interventions":31628},[92],[8059],[8061,8062,6673],{"nctId":31630,"briefTitle":31631,"status":123,"phases":31632,"primaryCompletion":825,"start":4621,"enrollment":2342,"conditions":31633,"interventions":31634},"NCT00273312","Patupilone Activity in Advanced\u002FMetastatic Hepatocellular Carcinoma",[92],[4412],[8061],{"nctId":31636,"briefTitle":31637,"status":123,"phases":31638,"primaryCompletion":3279,"completion":3279,"start":31639,"enrollment":3568,"conditions":31640,"interventions":31641},"NCT00171834","Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer",[91,92],"2003-08",[227],[8061],{"trials":31643,"activeCount":103},[],{"trials":31645,"activeCount":103},[],{"trials":31647,"activeCount":103},[],{"intervention":738,"totalTrials":5594,"cells":31649},{"EARLY_PHASE1":31650,"PHASE1":31652,"PHASE2":31680,"PHASE3":31703,"PHASE4":31705,"NA":31707},{"trials":31651,"activeCount":103},[],{"trials":31653,"activeCount":103},[31654,31658,31662,31668,31672,31676],{"nctId":6254,"briefTitle":6255,"status":123,"phases":31655,"primaryCompletion":6257,"completion":6257,"start":6258,"enrollment":709,"conditions":31656,"interventions":31657},[91],[6260,6261],[4366,6263],{"nctId":15397,"briefTitle":15398,"status":134,"phases":31659,"primaryCompletion":15400,"completion":15400,"start":15401,"enrollment":2379,"conditions":31660,"interventions":31661},[91],[15403],[738,15405,1168,4321],{"nctId":31663,"briefTitle":31664,"status":123,"phases":31665,"primaryCompletion":2509,"completion":2509,"start":4093,"enrollment":1065,"conditions":31666,"interventions":31667},"NCT02048787","Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.",[91],[2635],[738],{"nctId":17105,"briefTitle":17106,"status":123,"phases":31669,"primaryCompletion":17108,"completion":17108,"start":17109,"enrollment":906,"conditions":31670,"interventions":31671},[91],[17111],[6263,7871,17113],{"nctId":8045,"briefTitle":8046,"status":134,"phases":31673,"primaryCompletion":8048,"completion":8048,"start":813,"enrollment":34,"conditions":31674,"interventions":31675},[91],[8050],[738,5252],{"nctId":729,"briefTitle":730,"status":123,"phases":31677,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":31678,"interventions":31679},[91],[736],[515,738,249],{"trials":31681,"activeCount":103},[31682,31686,31690,31694],{"nctId":13785,"briefTitle":13786,"status":134,"phases":31683,"primaryCompletion":13788,"completion":13788,"start":13789,"enrollment":4557,"conditions":31684,"interventions":31685},[91,92],[13791],[159,738],{"nctId":6301,"briefTitle":6302,"status":123,"phases":31687,"primaryCompletion":6304,"completion":6305,"start":6306,"enrollment":1411,"conditions":31688,"interventions":31689},[92],[15],[4366,6263],{"nctId":15438,"briefTitle":15439,"status":134,"phases":31691,"primaryCompletion":15441,"completion":15441,"start":15442,"enrollment":3002,"conditions":31692,"interventions":31693},[92],[206],[738,4321],{"nctId":31695,"briefTitle":31696,"status":123,"phases":31697,"primaryCompletion":31698,"completion":31698,"start":31699,"enrollment":774,"conditions":31700,"interventions":31702},"NCT01693614","Safety and Efficacy of BKM120 in Relapsed and Refractory NHL",[92],"2017-07-21","2013-02-28",[31701],"Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma",[738],{"trials":31704,"activeCount":103},[],{"trials":31706,"activeCount":103},[],{"trials":31708,"activeCount":103},[],{"intervention":4609,"totalTrials":1495,"cells":31710},{"EARLY_PHASE1":31711,"PHASE1":31713,"PHASE2":31733,"PHASE3":31769,"PHASE4":31771,"NA":31773},{"trials":31712,"activeCount":103},[],{"trials":31714,"activeCount":103},[31715,31723,31729],{"nctId":31716,"briefTitle":31717,"status":123,"phases":31718,"primaryCompletion":1266,"completion":1266,"start":31719,"enrollment":15203,"conditions":31720,"interventions":31722},"NCT00620594","A Phase I\u002FII Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer",[91],"2006-12-21",[15,5614,31721],"Cowden Syndrome",[4609],{"nctId":31724,"briefTitle":31725,"status":123,"phases":31726,"primaryCompletion":2033,"completion":2033,"start":5620,"enrollment":906,"conditions":31727,"interventions":31728},"NCT01195376","A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors",[91],[9516],[4609],{"nctId":23073,"briefTitle":23074,"status":123,"phases":31730,"primaryCompletion":3511,"completion":3511,"start":3243,"enrollment":4557,"conditions":31731,"interventions":31732},[91],[23077],[4609,517,4609,517],{"trials":31734,"activeCount":103},[31735,31742,31749,31755,31761,31765],{"nctId":31736,"briefTitle":31737,"status":390,"phases":31738,"primaryCompletion":812,"completion":31739,"start":2795,"enrollment":103,"conditions":31740,"interventions":31741},"NCT01290406","BEZ235 Trial in Patients With Advanced Endometrial Carcinoma",[92],"2017-12",[856],[4609],{"nctId":31743,"briefTitle":31744,"status":390,"phases":31745,"primaryCompletion":10055,"completion":10055,"start":3243,"enrollment":103,"conditions":31746,"interventions":31748},"NCT01690871","A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa",[92],[31747],"Malignant PEComa (Perivascular Epithelioid Cell Tumors)",[4609],{"nctId":31750,"briefTitle":31751,"status":123,"phases":31752,"primaryCompletion":3511,"completion":3511,"start":3712,"enrollment":827,"conditions":31753,"interventions":31754},"NCT01658436","BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.",[92],[4607],[4609],{"nctId":31756,"briefTitle":31757,"status":390,"phases":31758,"primaryCompletion":3861,"start":2795,"enrollment":103,"conditions":31759,"interventions":31760},"NCT01288092","BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) \u002FHR+ (Hormonal Receptor Positive) Metastatic Breast Cancer",[92],[435],[4609],{"nctId":4603,"briefTitle":4604,"status":134,"phases":31762,"primaryCompletion":812,"completion":812,"start":1761,"enrollment":2149,"conditions":31763,"interventions":31764},[92],[4607],[4609,196],{"nctId":15446,"briefTitle":15447,"status":134,"phases":31766,"primaryCompletion":511,"completion":511,"start":15449,"enrollment":3343,"conditions":31767,"interventions":31768},[91,92],[15451,15452],[4609,4321],{"trials":31770,"activeCount":103},[],{"trials":31772,"activeCount":103},[],{"trials":31774,"activeCount":103},[],{"intervention":7913,"totalTrials":1495,"cells":31776},{"EARLY_PHASE1":31777,"PHASE1":31779,"PHASE2":31798,"PHASE3":31827,"PHASE4":31829,"NA":31831},{"trials":31778,"activeCount":103},[],{"trials":31780,"activeCount":103},[31781,31788,31792],{"nctId":31782,"briefTitle":31783,"status":123,"phases":31784,"primaryCompletion":9061,"completion":9061,"start":1682,"enrollment":2633,"conditions":31785,"interventions":31787},"NCT01772797","Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer",[91],[31786,128],"Anaplastic Lymphoma Kinase (ALK)",[11072,7913],{"nctId":11007,"briefTitle":11008,"status":123,"phases":31789,"primaryCompletion":4093,"completion":4093,"start":3604,"enrollment":3343,"conditions":31790,"interventions":31791},[91],[11011],[7913,516],{"nctId":31793,"briefTitle":31794,"status":123,"phases":31795,"primaryCompletion":5733,"completion":5733,"start":3490,"enrollment":5612,"conditions":31796,"interventions":31797},"NCT01132625","Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan",[91],[5614],[7913],{"trials":31799,"activeCount":103},[31800,31804,31811,31815,31819,31823],{"nctId":7908,"briefTitle":7909,"status":134,"phases":31801,"primaryCompletion":1682,"completion":1682,"start":3800,"enrollment":4118,"conditions":31802,"interventions":31803},[92],[4439],[7913,4320],{"nctId":31805,"briefTitle":31806,"status":123,"phases":31807,"primaryCompletion":7939,"completion":7939,"start":5620,"enrollment":1278,"conditions":31808,"interventions":31810},"NCT01124864","A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.",[92],[31809],"Non-small-cell Lung Cancer",[7913],{"nctId":10496,"briefTitle":10497,"status":123,"phases":31812,"primaryCompletion":4598,"completion":4598,"start":10499,"enrollment":1053,"conditions":31813,"interventions":31814},[91,92],[10501],[7913,5746,5747],{"nctId":8072,"briefTitle":8073,"status":134,"phases":31816,"primaryCompletion":8075,"completion":8075,"start":8076,"enrollment":3322,"conditions":31817,"interventions":31818},[92],[8078],[7913,5252,4375],{"nctId":7928,"briefTitle":7929,"status":123,"phases":31820,"primaryCompletion":813,"completion":813,"start":7931,"enrollment":2405,"conditions":31821,"interventions":31822},[91,92],[7933],[7913,4320],{"nctId":8081,"briefTitle":8082,"status":123,"phases":31824,"primaryCompletion":5733,"completion":5733,"start":4081,"enrollment":16,"conditions":31825,"interventions":31826},[92],[4439,8085],[7913,5252,8043],{"trials":31828,"activeCount":103},[],{"trials":31830,"activeCount":103},[],{"trials":31832,"activeCount":103},[],{"intervention":31834,"totalTrials":1495,"cells":31835},"QAX576",{"EARLY_PHASE1":31836,"PHASE1":31838,"PHASE2":31848,"PHASE3":31902,"PHASE4":31904,"NA":31906},{"trials":31837,"activeCount":103},[],{"trials":31839,"activeCount":103},[31840],{"nctId":31841,"briefTitle":31842,"status":123,"phases":31843,"primaryCompletion":4620,"start":5620,"enrollment":2579,"conditions":31844,"interventions":31845},"NCT01568762","To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma",[91],[18],[19484,31846,31834,31847],"VAK694 placebo","QAX576 placebo",{"trials":31849,"activeCount":103},[31850,31857,31864,31870,31877,31883,31889,31895],{"nctId":31851,"briefTitle":31852,"status":123,"phases":31853,"primaryCompletion":4967,"completion":4967,"start":2034,"enrollment":5594,"conditions":31854,"interventions":31855},"NCT01355614","A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients",[92],[22855],[31834,31856],"Infliximab",{"nctId":31858,"briefTitle":31859,"status":123,"phases":31860,"primaryCompletion":1671,"start":4335,"enrollment":2342,"conditions":31861,"interventions":31863},"NCT01022970","Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis",[92],[31862],"Eosinophilic Esophagitis",[31847,31834],{"nctId":31865,"briefTitle":31866,"status":123,"phases":31867,"primaryCompletion":3551,"start":4845,"enrollment":2439,"conditions":31868,"interventions":31869},"NCT00940160","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients",[91,92],[18],[31834,31834,31834],{"nctId":31871,"briefTitle":31872,"status":134,"phases":31873,"primaryCompletion":4707,"start":4556,"enrollment":422,"conditions":31874,"interventions":31876},"NCT00581997","QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis",[92],[31875],"Pulmonary Fibrosis Secondary to Systemic Sclerosis",[31834],{"nctId":31878,"briefTitle":31879,"status":123,"phases":31880,"primaryCompletion":1024,"completion":1024,"start":3194,"enrollment":3605,"conditions":31881,"interventions":31882},"NCT00532233","SD, IL-13 Production Rate in IPF",[92],[3100],[31834],{"nctId":31884,"briefTitle":31885,"status":134,"phases":31886,"primaryCompletion":15283,"completion":15283,"start":4372,"enrollment":709,"conditions":31887,"interventions":31888},"NCT01266135","Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)",[92],[3100],[31834],{"nctId":31890,"briefTitle":31891,"status":123,"phases":31892,"primaryCompletion":607,"completion":607,"start":853,"enrollment":22552,"conditions":31893,"interventions":31894},"NCT01130064","Efficacy of QAX576 in Asthma",[92],[18],[31834],{"nctId":31896,"briefTitle":31897,"status":134,"phases":31898,"primaryCompletion":926,"completion":926,"start":1024,"enrollment":317,"conditions":31899,"interventions":31901},"NCT00987545","Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence",[92],[31900],"Keloids",[31834,31847],{"trials":31903,"activeCount":103},[],{"trials":31905,"activeCount":103},[],{"trials":31907,"activeCount":103},[],{"intervention":9064,"totalTrials":1495,"cells":31909},{"EARLY_PHASE1":31910,"PHASE1":31912,"PHASE2":31921,"PHASE3":31966,"PHASE4":31968,"NA":31970},{"trials":31911,"activeCount":103},[],{"trials":31913,"activeCount":103},[31914],{"nctId":31915,"briefTitle":31916,"status":123,"phases":31917,"primaryCompletion":3482,"completion":3482,"start":895,"enrollment":15430,"conditions":31918,"interventions":31920},"NCT01596712","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects",[91],[31919],"Allergy",[9064],{"trials":31922,"activeCount":103},[31923,31927,31931,31938,31942,31946,31953,31960],{"nctId":9058,"briefTitle":9059,"status":123,"phases":31924,"primaryCompletion":9061,"completion":9061,"start":3604,"enrollment":4401,"conditions":31925,"interventions":31926},[92],[18],[9064,6218],{"nctId":9066,"briefTitle":9067,"status":123,"phases":31928,"primaryCompletion":813,"completion":813,"start":3712,"enrollment":5612,"conditions":31929,"interventions":31930},[91,92],[9070],[9064,9072],{"nctId":31932,"briefTitle":31933,"status":134,"phases":31934,"primaryCompletion":2509,"completion":2509,"start":1670,"enrollment":1611,"conditions":31935,"interventions":31937},"NCT01688882","Safety, Efficacy and PK\u002FPD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment",[92],[31936],"Bullous Pemphigoid",[9064],{"nctId":18430,"briefTitle":18431,"status":123,"phases":31939,"primaryCompletion":5193,"completion":5193,"start":18433,"enrollment":2633,"conditions":31940,"interventions":31941},[92],[10365],[9064,17242],{"nctId":9074,"briefTitle":9075,"status":123,"phases":31943,"primaryCompletion":9077,"completion":9078,"start":9079,"enrollment":1369,"conditions":31944,"interventions":31945},[92],[33],[9064,6218],{"nctId":31947,"briefTitle":31948,"status":134,"phases":31949,"primaryCompletion":30015,"completion":30015,"start":31950,"enrollment":18087,"conditions":31951,"interventions":31952},"NCT02075008","Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201",[92],"2014-03-27",[18],[9064],{"nctId":31954,"briefTitle":31955,"status":390,"phases":31956,"enrollment":103,"conditions":31957,"interventions":31959},"NCT01451450","Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy",[92],[31958],"Peanut Allergy",[9064],{"nctId":31961,"briefTitle":31962,"status":134,"phases":31963,"primaryCompletion":4514,"completion":4514,"start":3861,"enrollment":5594,"conditions":31964,"interventions":31965},"NCT02336425","Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma",[92],[18],[9064],{"trials":31967,"activeCount":103},[],{"trials":31969,"activeCount":103},[],{"trials":31971,"activeCount":103},[],{"intervention":4330,"totalTrials":1495,"cells":31973},{"EARLY_PHASE1":31974,"PHASE1":31976,"PHASE2":31997,"PHASE3":32035,"PHASE4":32037,"NA":32039},{"trials":31975,"activeCount":103},[],{"trials":31977,"activeCount":103},[31978,31986,31990],{"nctId":31979,"briefTitle":31980,"status":123,"phases":31981,"primaryCompletion":15382,"completion":15382,"start":31982,"enrollment":1278,"conditions":31983,"interventions":31985},"NCT01430416","Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients",[91],"2011-12-20",[31984],"Uveal Melanoma",[4330],{"nctId":4323,"briefTitle":4324,"status":123,"phases":31987,"primaryCompletion":3319,"completion":3319,"start":4326,"enrollment":827,"conditions":31988,"interventions":31989},[91],[4328],[4330,196],{"nctId":31991,"briefTitle":31992,"status":134,"phases":31993,"primaryCompletion":1781,"completion":1781,"start":3800,"enrollment":2367,"conditions":31994,"interventions":31996},"NCT01402440","Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma",[91],[31995],"Diffuse Large B-Cell Lymphoma",[4330],{"trials":31998,"activeCount":103},[31999,32007,32011,32017,32024,32028],{"nctId":32000,"briefTitle":32001,"status":123,"phases":32002,"primaryCompletion":1724,"start":4707,"enrollment":32003,"conditions":32004,"interventions":32006},"NCT00885196","A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis",[92],336,[32005],"Moderate and Severe Plaque Psoriasis",[4330],{"nctId":19024,"briefTitle":19025,"status":123,"phases":32008,"primaryCompletion":5696,"completion":5696,"start":825,"enrollment":19027,"conditions":32009,"interventions":32010},[91,92],[4691],[4330,4805],{"nctId":32012,"briefTitle":32013,"status":123,"phases":32014,"primaryCompletion":5696,"start":3254,"enrollment":3288,"conditions":32015,"interventions":32016},"NCT00492869","Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation",[91,92],[4691],[4330],{"nctId":32018,"briefTitle":32019,"status":123,"phases":32020,"primaryCompletion":607,"completion":607,"start":4081,"enrollment":1423,"conditions":32021,"interventions":32023},"NCT00572585","Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis",[92],[32022],"Ulcerative Colitis",[4330],{"nctId":25358,"briefTitle":25359,"status":123,"phases":32025,"primaryCompletion":3383,"completion":3383,"start":4317,"enrollment":25361,"conditions":32026,"interventions":32027},[92],[4691],[4330,25364,7665],{"nctId":32029,"briefTitle":32030,"status":134,"phases":32031,"primaryCompletion":1025,"completion":1025,"start":3447,"enrollment":1890,"conditions":32032,"interventions":32033},"NCT00555789","24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients",[92],[4691],[4330,32034],"mycophenolic plus tacrolimus",{"trials":32036,"activeCount":103},[],{"trials":32038,"activeCount":103},[],{"trials":32040,"activeCount":103},[],{"intervention":10589,"totalTrials":422,"cells":32042},{"EARLY_PHASE1":32043,"PHASE1":32045,"PHASE2":32063,"PHASE3":32086,"PHASE4":32088,"NA":32090},{"trials":32044,"activeCount":103},[],{"trials":32046,"activeCount":103},[32047,32051,32055,32059],{"nctId":11240,"briefTitle":11241,"status":134,"phases":32048,"primaryCompletion":11243,"completion":11243,"start":2487,"enrollment":3605,"conditions":32049,"interventions":32050},[91],[5598,11245],[4393,10589,10731],{"nctId":10580,"briefTitle":10581,"status":390,"phases":32052,"primaryCompletion":10583,"completion":10583,"start":10584,"enrollment":103,"conditions":32053,"interventions":32054},[91],[2430,2369,10586,2432,10587],[10589,2411,212,10590],{"nctId":23949,"briefTitle":23950,"status":134,"phases":32056,"primaryCompletion":23952,"completion":23952,"start":13272,"enrollment":99,"conditions":32057,"interventions":32058},[91],[5723],[10589,2411,10578],{"nctId":10694,"briefTitle":10695,"status":123,"phases":32060,"primaryCompletion":10697,"completion":10697,"start":10698,"enrollment":180,"conditions":32061,"interventions":32062},[91],[3422,10700,9848,5723,10701,10702,3335,5724],[10590,4389,10589,7513],{"trials":32064,"activeCount":103},[32065,32074,32078,32082],{"nctId":32066,"briefTitle":32067,"status":134,"phases":32068,"primaryCompletion":32069,"completion":32070,"start":30309,"enrollment":1213,"conditions":32071,"interventions":32072},"NCT03946670","A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).",[92],"2022-04-26","2024-07-15",[5723],[10589,32073],"Hypomethylating agents",{"nctId":10724,"briefTitle":10725,"status":134,"phases":32075,"primaryCompletion":10727,"completion":10727,"start":10728,"enrollment":5882,"conditions":32076,"interventions":32077},[92],[2569],[10589,10731,7513],{"nctId":11284,"briefTitle":11285,"status":134,"phases":32079,"primaryCompletion":3576,"completion":3576,"start":11287,"enrollment":11288,"conditions":32080,"interventions":32081},[91,92],[6437],[10589,4389,10590],{"nctId":10745,"briefTitle":10746,"status":134,"phases":32083,"primaryCompletion":10748,"completion":10749,"start":10750,"enrollment":28,"conditions":32084,"interventions":32085},[92],[10713],[10589,7513,10590,10667],{"trials":32087,"activeCount":103},[],{"trials":32089,"activeCount":103},[],{"trials":32091,"activeCount":103},[],{"intervention":6737,"totalTrials":1562,"cells":32093},{"EARLY_PHASE1":32094,"PHASE1":32096,"PHASE2":32113,"PHASE3":32154,"PHASE4":32156,"NA":32158},{"trials":32095,"activeCount":103},[],{"trials":32097,"activeCount":103},[32098,32105],{"nctId":32099,"briefTitle":32100,"status":123,"phases":32101,"primaryCompletion":1818,"completion":1818,"start":926,"enrollment":630,"conditions":32102,"interventions":32104},"NCT01255462","Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration",[91],[32103],"Advanced Age-related Macular Degeneration",[6737,6737,6737,6737],{"nctId":32106,"briefTitle":32107,"status":123,"phases":32108,"primaryCompletion":32109,"completion":32109,"start":7109,"enrollment":422,"conditions":32110,"interventions":32111},"NCT02878616","Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316",[91],"2017-07-19",[4691],[6737,32112],"IVIG",{"trials":32114,"activeCount":103},[32115,32123,32129,32139,32143],{"nctId":32116,"briefTitle":32117,"status":123,"phases":32118,"primaryCompletion":2033,"completion":2033,"start":1671,"enrollment":4557,"conditions":32119,"interventions":32122},"NCT01535950","Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)",[92],[32120,32121],"Neovascular Age-elated Macular Degeneration (Wet AMD)","Exudative Macular Degeneration",[6737],{"nctId":32124,"briefTitle":32125,"status":134,"phases":32126,"primaryCompletion":5114,"completion":5114,"start":3604,"enrollment":437,"conditions":32127,"interventions":32128},"NCT01624636","Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).",[92],[18365],[6737,6737],{"nctId":32130,"briefTitle":32131,"status":123,"phases":32132,"primaryCompletion":16186,"completion":16186,"start":32133,"enrollment":32134,"conditions":32135,"interventions":32137},"NCT01527500","Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)",[92],"2012-01-25",158,[32136,4458],"Geographic Atrophy",[6737,32138],"LFG316 Lower dose",{"nctId":6731,"briefTitle":6732,"status":123,"phases":32140,"primaryCompletion":6734,"completion":6734,"start":2199,"enrollment":5594,"conditions":32141,"interventions":32142},[92],[6026],[6737,6722],{"nctId":32144,"briefTitle":32145,"status":123,"phases":32146,"primaryCompletion":32147,"completion":13087,"start":3297,"enrollment":2342,"conditions":32148,"interventions":32152},"NCT01526889","Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,",[92],"2017-02-16",[32149,32150,32151],"Non-infectious Intermediate Uveitis","Non-infectious Posterior Uveitis","Non-infectious Panuveitis",[6737,32153],"Conventional Therapy",{"trials":32155,"activeCount":103},[],{"trials":32157,"activeCount":103},[],{"trials":32159,"activeCount":103},[],{"intervention":32161,"totalTrials":2379,"cells":32162},"epothilone b",{"EARLY_PHASE1":32163,"PHASE1":32165,"PHASE2":32167,"PHASE3":32206,"PHASE4":32208,"NA":32210},{"trials":32164,"activeCount":103},[],{"trials":32166,"activeCount":103},[],{"trials":32168,"activeCount":103},[32169,32175,32181,32188,32194,32200],{"nctId":32170,"briefTitle":32171,"status":123,"phases":32172,"primaryCompletion":31639,"start":997,"enrollment":17433,"conditions":32173,"interventions":32174},"NCT00035243","EPO906 Therapy in Patients With Advanced Kidney Cancer",[92],[4363],[32161],{"nctId":32176,"briefTitle":32177,"status":123,"phases":32178,"primaryCompletion":881,"start":4048,"enrollment":2428,"conditions":32179,"interventions":32180},"NCT00035165","EPO906 Therapy in Patients With Advanced Melanoma",[92],[36],[32161],{"nctId":32182,"briefTitle":32183,"status":123,"phases":32184,"primaryCompletion":18732,"start":19993,"enrollment":271,"conditions":32185,"interventions":32187},"NCT00035100","EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer",[92],[11326,8372,32186],"Fallopian Tube Neoplasms",[32161],{"nctId":32189,"briefTitle":32190,"status":123,"phases":32191,"primaryCompletion":15101,"completion":15101,"start":16929,"enrollment":114,"conditions":32192,"interventions":32193},"NCT00035113","EPO906 Therapy in Patients With Prostate Cancer",[92],[6705],[32161],{"nctId":32195,"briefTitle":32196,"status":123,"phases":32197,"primaryCompletion":4732,"completion":4732,"start":16929,"enrollment":3098,"conditions":32198,"interventions":32199},"NCT00035126","EPO906 Therapy in Patients With Advanced Breast Cancer",[92],[559],[32161],{"nctId":32201,"briefTitle":32202,"status":123,"phases":32203,"primaryCompletion":1015,"completion":1015,"start":17498,"enrollment":2149,"conditions":32204,"interventions":32205},"NCT00035087","EPO906 Therapy in Patients With Advanced Colorectal Cancer",[92],[231,29640],[32161],{"trials":32207,"activeCount":103},[],{"trials":32209,"activeCount":103},[],{"trials":32211,"activeCount":103},[],{"intervention":1686,"totalTrials":2379,"cells":32213},{"EARLY_PHASE1":32214,"PHASE1":32216,"PHASE2":32230,"PHASE3":32257,"PHASE4":32259,"NA":32261},{"trials":32215,"activeCount":103},[],{"trials":32217,"activeCount":103},[32218,32222,32226],{"nctId":13338,"briefTitle":13339,"status":123,"phases":32219,"primaryCompletion":13341,"completion":13341,"start":13342,"enrollment":37,"conditions":32220,"interventions":32221},[91],[5636],[4389,1686,4390],{"nctId":1678,"briefTitle":1679,"status":123,"phases":32223,"primaryCompletion":1681,"completion":1681,"start":1682,"enrollment":167,"conditions":32224,"interventions":32225},[91],[1684],[1686,1659],{"nctId":13385,"briefTitle":13386,"status":123,"phases":32227,"primaryCompletion":13388,"completion":13388,"start":13389,"enrollment":13390,"conditions":32228,"interventions":32229},[91],[13392],[4389,10126,1686,13394,155],{"trials":32231,"activeCount":103},[32232,32240,32249],{"nctId":32233,"briefTitle":32234,"status":123,"phases":32235,"primaryCompletion":15827,"completion":15827,"start":32236,"enrollment":11068,"conditions":32237,"interventions":32239},"NCT02421172","Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients",[92],"2015-04-13",[32238],"Hidradenitis Suppurativa (Acne Inversa)",[1686],{"nctId":32241,"briefTitle":32242,"status":123,"phases":32243,"primaryCompletion":32244,"completion":32244,"start":32245,"enrollment":3605,"conditions":32246,"interventions":32248},"NCT02998671","Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne",[92],"2018-08-01","2016-12-22",[32247],"Acne Vulgaris",[1686],{"nctId":32250,"briefTitle":32251,"status":123,"phases":32252,"primaryCompletion":2622,"completion":32253,"start":32254,"enrollment":4708,"conditions":32255,"interventions":32256},"NCT03299686","Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma",[92],"2019-07-08","2017-11-06",[18],[1686],{"trials":32258,"activeCount":103},[],{"trials":32260,"activeCount":103},[],{"trials":32262,"activeCount":103},[],{"intervention":32264,"totalTrials":2379,"cells":32265},"LNA043",{"EARLY_PHASE1":32266,"PHASE1":32268,"PHASE2":32286,"PHASE3":32321,"PHASE4":32323,"NA":32325},{"trials":32267,"activeCount":103},[],{"trials":32269,"activeCount":103},[32270,32278],{"nctId":32271,"briefTitle":32272,"status":123,"phases":32273,"primaryCompletion":3029,"completion":3029,"start":32274,"enrollment":138,"conditions":32275,"interventions":32277},"NCT04564053","Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants",[91],"2020-09-23",[19880,32276],"Knee",[32264],{"nctId":32279,"briefTitle":32280,"status":123,"phases":32281,"primaryCompletion":6555,"completion":2389,"start":32282,"enrollment":2046,"conditions":32283,"interventions":32285},"NCT02491281","First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement",[91],"2015-11-16",[32284],"Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery",[32264],{"trials":32287,"activeCount":103},[32288,32297,32306,32314],{"nctId":32289,"briefTitle":32290,"status":134,"phases":32291,"primaryCompletion":32292,"completion":32292,"start":32293,"enrollment":496,"conditions":32294,"interventions":32296},"NCT04814368","A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)",[92],"2024-06-24","2021-08-27",[32295],"Knee Osteoarthritis",[10578,32264],{"nctId":32298,"briefTitle":32299,"status":134,"phases":32300,"primaryCompletion":32301,"completion":32302,"start":10711,"enrollment":32303,"conditions":32304,"interventions":32305},"NCT04864392","Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis",[92],"2024-09-29","2025-05-29",576,[19880],[32264],{"nctId":32307,"briefTitle":32308,"status":134,"phases":32309,"primaryCompletion":6768,"completion":6768,"start":32310,"enrollment":814,"conditions":32311,"interventions":32313},"NCT03334812","Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation",[92],"2017-10-18",[32312],"Knee Cartilage Lesion",[32264],{"nctId":32315,"briefTitle":32316,"status":123,"phases":32317,"primaryCompletion":32318,"completion":32318,"start":13716,"enrollment":3713,"conditions":32319,"interventions":32320},"NCT03275064","Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.",[92],"2022-09-06",[19880],[32264],{"trials":32322,"activeCount":103},[],{"trials":32324,"activeCount":103},[],{"trials":32326,"activeCount":103},[],{"intervention":4390,"totalTrials":2379,"cells":32328},{"EARLY_PHASE1":32329,"PHASE1":32331,"PHASE2":32355,"PHASE3":32361,"PHASE4":32363,"NA":32365},{"trials":32330,"activeCount":103},[],{"trials":32332,"activeCount":103},[32333,32339,32343,32347,32351],{"nctId":32334,"briefTitle":32335,"status":123,"phases":32336,"primaryCompletion":4598,"completion":4598,"start":3490,"enrollment":1660,"conditions":32337,"interventions":32338},"NCT01098838","Safety and Efficacy of LCL161 in Patients With Solid Tumors",[91],[5614],[4390],{"nctId":13338,"briefTitle":13339,"status":123,"phases":32340,"primaryCompletion":13341,"completion":13341,"start":13342,"enrollment":37,"conditions":32341,"interventions":32342},[91],[5636],[4389,1686,4390],{"nctId":15391,"briefTitle":15392,"status":123,"phases":32344,"primaryCompletion":4410,"completion":4410,"start":4669,"enrollment":1495,"conditions":32345,"interventions":32346},[91],[4362],[4390,4321],{"nctId":15407,"briefTitle":15408,"status":123,"phases":32348,"primaryCompletion":10055,"completion":10055,"start":3383,"enrollment":485,"conditions":32349,"interventions":32350},[91],[647],[4390,4321],{"nctId":4381,"briefTitle":4382,"status":123,"phases":32352,"primaryCompletion":4384,"completion":4384,"start":4385,"enrollment":3741,"conditions":32353,"interventions":32354},[91],[4387],[4389,4390,196,4391,4392,4393],{"trials":32356,"activeCount":103},[32357],{"nctId":15427,"briefTitle":15428,"status":123,"phases":32358,"primaryCompletion":812,"completion":812,"start":3482,"enrollment":15430,"conditions":32359,"interventions":32360},[92],[15],[4390,7872],{"trials":32362,"activeCount":103},[],{"trials":32364,"activeCount":103},[],{"trials":32366,"activeCount":103},[],{"intervention":10575,"totalTrials":637,"cells":32368},{"EARLY_PHASE1":32369,"PHASE1":32375,"PHASE2":32395,"PHASE3":32401,"PHASE4":32403,"NA":32405},{"trials":32370,"activeCount":103},[32371],{"nctId":13258,"briefTitle":13259,"status":134,"phases":32372,"primaryCompletion":1512,"completion":1512,"start":13261,"enrollment":1112,"conditions":32373,"interventions":32374},[90],[647],[13264,4389,10575,13265],{"trials":32376,"activeCount":103},[32377,32381,32391],{"nctId":13279,"briefTitle":13280,"status":134,"phases":32378,"primaryCompletion":13282,"completion":13282,"start":2220,"enrollment":709,"conditions":32379,"interventions":32380},[91],[13284],[13286,7711,4389,10575],{"nctId":32382,"briefTitle":32383,"status":134,"phases":32384,"primaryCompletion":13832,"completion":13832,"start":32385,"enrollment":1213,"conditions":32386,"interventions":32390},"NCT03549000","A Phase I\u002FIb Study of NZV930 Alone and in Combination With PDR001 and \u002For NIR178 in Patients With Advanced Malignancies.",[91],"2018-07-18",[5282,10572,32387,32388,6375,32389,1589],"Pancreatic Ductal Adenocarcinoma (PDAC)","Colorectal Cancer Microsatellite Stable (MSS)","Renal Cell Carcinoma (RCC)",[10575],{"nctId":10567,"briefTitle":10568,"status":134,"phases":32392,"primaryCompletion":10570,"completion":10570,"start":1808,"enrollment":2776,"conditions":32393,"interventions":32394},[91],[10572],[10574,10125,10575,10576,10577,10578],{"trials":32396,"activeCount":103},[32397],{"nctId":13454,"briefTitle":13455,"status":134,"phases":32398,"primaryCompletion":5309,"completion":13457,"start":13458,"enrollment":3950,"conditions":32399,"interventions":32400},[92],[13460,13461,13275,13462,13463,13464,13465,13466,36,13467],[10575,4389],{"trials":32402,"activeCount":103},[],{"trials":32404,"activeCount":103},[],{"trials":32406,"activeCount":103},[],{"intervention":10125,"totalTrials":637,"cells":32408},{"EARLY_PHASE1":32409,"PHASE1":32411,"PHASE2":32417,"PHASE3":32435,"PHASE4":32437,"NA":32439},{"trials":32410,"activeCount":103},[],{"trials":32412,"activeCount":103},[32413],{"nctId":10567,"briefTitle":10568,"status":134,"phases":32414,"primaryCompletion":10570,"completion":10570,"start":1808,"enrollment":2776,"conditions":32415,"interventions":32416},[91],[10572],[10574,10125,10575,10576,10577,10578],{"trials":32418,"activeCount":103},[32419,32423,32427,32431],{"nctId":13439,"briefTitle":13440,"status":123,"phases":32420,"primaryCompletion":2417,"completion":13442,"start":13443,"enrollment":485,"conditions":32421,"interventions":32422},[92],[13445,13446,13447,13448,13449,13450,13451,9517],[4389,10125],{"nctId":10119,"briefTitle":10120,"status":123,"phases":32424,"primaryCompletion":5881,"completion":5881,"start":10122,"enrollment":2249,"conditions":32425,"interventions":32426},[92],[36],[4389,10125,159,10126,515],{"nctId":13510,"briefTitle":13511,"status":123,"phases":32428,"primaryCompletion":1351,"completion":1351,"start":13513,"enrollment":13514,"conditions":32429,"interventions":32430},[91,92],[5614],[10125,4389],{"nctId":13518,"briefTitle":13519,"status":123,"phases":32432,"primaryCompletion":9910,"completion":13521,"start":4445,"enrollment":534,"conditions":32433,"interventions":32434},[92],[13523],[10125,4389,1168],{"trials":32436,"activeCount":103},[],{"trials":32438,"activeCount":103},[],{"trials":32440,"activeCount":103},[],{"intervention":13304,"totalTrials":637,"cells":32442},{"EARLY_PHASE1":32443,"PHASE1":32445,"PHASE2":32455,"PHASE3":32469,"PHASE4":32471,"NA":32473},{"trials":32444,"activeCount":103},[],{"trials":32446,"activeCount":103},[32447,32451],{"nctId":13298,"briefTitle":13299,"status":134,"phases":32448,"primaryCompletion":13301,"completion":13301,"start":5131,"enrollment":437,"conditions":32449,"interventions":32450},[91],[9924],[4389,13304,13305],{"nctId":15378,"briefTitle":15379,"status":123,"phases":32452,"primaryCompletion":15381,"completion":5818,"start":15382,"enrollment":15383,"conditions":32453,"interventions":32454},[91],[209,15385,4403],[15387,9926,9927,9928,15388,4321,15389],{"trials":32456,"activeCount":103},[32457,32461,32465],{"nctId":16498,"briefTitle":16499,"status":123,"phases":32458,"primaryCompletion":16501,"completion":3456,"start":16502,"enrollment":16503,"conditions":32459,"interventions":32460},[92],[4571,16505,16506,16507,16508],[7711,16510,13304],{"nctId":23165,"briefTitle":23166,"status":123,"phases":32462,"primaryCompletion":23168,"completion":23169,"start":23170,"enrollment":3605,"conditions":32463,"interventions":32464},[92],[7868],[7870,13304],{"nctId":9919,"briefTitle":9920,"status":134,"phases":32466,"primaryCompletion":9922,"completion":9922,"start":1277,"enrollment":1941,"conditions":32467,"interventions":32468},[92],[9924],[2411,9926,9927,9928,1079],{"trials":32470,"activeCount":103},[],{"trials":32472,"activeCount":103},[],{"trials":32474,"activeCount":103},[],{"intervention":10577,"totalTrials":637,"cells":32476},{"EARLY_PHASE1":32477,"PHASE1":32479,"PHASE2":32485,"PHASE3":32515,"PHASE4":32517,"NA":32519},{"trials":32478,"activeCount":103},[],{"trials":32480,"activeCount":103},[32481],{"nctId":10567,"briefTitle":10568,"status":134,"phases":32482,"primaryCompletion":10570,"completion":10570,"start":1808,"enrollment":2776,"conditions":32483,"interventions":32484},[91],[10572],[10574,10125,10575,10576,10577,10578],{"trials":32486,"activeCount":103},[32487,32491,32498,32511],{"nctId":13470,"briefTitle":13471,"status":123,"phases":32488,"primaryCompletion":7902,"completion":7902,"start":166,"enrollment":1434,"conditions":32489,"interventions":32490},[91,92],[9944,13474,36,13475],[10577,4389],{"nctId":32492,"briefTitle":32493,"status":134,"phases":32494,"primaryCompletion":4505,"completion":4505,"start":3279,"enrollment":317,"conditions":32495,"interventions":32497},"NCT00757757","A Phase I\u002FII Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases",[91,92],[1654,32496],"Bone Metastases",[10577],{"nctId":32499,"briefTitle":32500,"status":123,"phases":32501,"primaryCompletion":31526,"completion":13634,"start":32502,"enrollment":792,"conditions":32503,"interventions":32510},"NCT01643850","MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)",[92],"2012-04-23",[32504,32505,32506,32507,32508,32509],"Pigmented Villonodular Synovitis","PVNS","Giant Cell Tumor of the Tendon Sheath","GCCTS","Tenosynovial Giant Cell Tumor Localized or Diffused Type","GCTS",[10577],{"nctId":17117,"briefTitle":17118,"status":123,"phases":32512,"primaryCompletion":17120,"completion":17121,"start":17122,"enrollment":2579,"conditions":32513,"interventions":32514},[92],[17124],[10577,7871,10632],{"trials":32516,"activeCount":103},[],{"trials":32518,"activeCount":103},[],{"trials":32520,"activeCount":103},[],{"intervention":16480,"totalTrials":637,"cells":32522},{"EARLY_PHASE1":32523,"PHASE1":32525,"PHASE2":32546,"PHASE3":32563,"PHASE4":32565,"NA":32567},{"trials":32524,"activeCount":103},[],{"trials":32526,"activeCount":103},[32527,32536,32542],{"nctId":32528,"briefTitle":32529,"status":123,"phases":32530,"primaryCompletion":32531,"completion":32531,"start":32532,"enrollment":1495,"conditions":32533,"interventions":32535},"NCT01646684","Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer",[91],"2018-11-13","2013-03-08",[32534],"Castration Resistant Prostate Cancer",[16480],{"nctId":32537,"briefTitle":32538,"status":123,"phases":32539,"primaryCompletion":4515,"completion":4515,"start":5733,"enrollment":2579,"conditions":32540,"interventions":32541},"NCT01578928","A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers",[91],[2635],[16480],{"nctId":16473,"briefTitle":16474,"status":123,"phases":32543,"primaryCompletion":16476,"completion":16476,"start":16477,"enrollment":3343,"conditions":32544,"interventions":32545},[91],[4903],[7711,16480],{"trials":32547,"activeCount":103},[32548,32555],{"nctId":32549,"briefTitle":32550,"status":134,"phases":32551,"primaryCompletion":15025,"completion":15025,"start":3465,"enrollment":2046,"conditions":32552,"interventions":32554},"NCT02619617","Safety and Efficacy Study of SOM230 s.c. in Cluster Headache",[92],[32553],"Cluster Headache - Episodic and Chronic",[16480],{"nctId":32556,"briefTitle":32557,"status":123,"phases":32558,"primaryCompletion":32559,"completion":32559,"start":1266,"enrollment":4557,"conditions":32560,"interventions":32562},"NCT01637272","Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome",[92],"2015-08-07",[32561],"Dumping Syndrome",[16480],{"trials":32564,"activeCount":103},[],{"trials":32566,"activeCount":103},[],{"trials":32568,"activeCount":103},[],{"intervention":32570,"totalTrials":637,"cells":32571},"BGG492",{"EARLY_PHASE1":32572,"PHASE1":32574,"PHASE2":32576,"PHASE3":32615,"PHASE4":32617,"NA":32619},{"trials":32573,"activeCount":103},[],{"trials":32575,"activeCount":103},[],{"trials":32577,"activeCount":103},[32578,32584,32591,32599,32608],{"nctId":32579,"briefTitle":32580,"status":123,"phases":32581,"primaryCompletion":3759,"completion":3759,"start":2034,"enrollment":5681,"conditions":32582,"interventions":32583},"NCT01338805","Phase II BGG492 Capsule Extension for Partial Epilepsy",[92],[29162],[32570],{"nctId":32585,"briefTitle":32586,"status":390,"phases":32587,"primaryCompletion":18222,"completion":18222,"start":21614,"enrollment":103,"conditions":32588,"interventions":32590},"NCT01617941","A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention",[92],[32589],"Patients With Migraine Equal of \u002FMore Than 3 and Equal of\u002F Less Than 12 Migraine Attacks\u002F4 Weeks for Each of the Last 6 Months Preceding the Screening",[32570],{"nctId":32592,"briefTitle":32593,"status":123,"phases":32594,"primaryCompletion":3861,"completion":3861,"start":7939,"enrollment":3322,"conditions":32595,"interventions":32598},"NCT02150213","Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492",[92],[32596,32597],"Adrenocortical Adenoma","Endometrial Stromal Sarcomas",[32570],{"nctId":32600,"briefTitle":32601,"status":390,"phases":32602,"primaryCompletion":32603,"completion":32603,"start":32604,"enrollment":103,"conditions":32605,"interventions":32607},"NCT01649050","Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis",[92],"2018-03","2016-10",[32606],"Muscle Spasticity Due to Multiple Sclerosis",[32570],{"nctId":32609,"briefTitle":32610,"status":123,"phases":32611,"primaryCompletion":7931,"completion":7931,"start":1014,"enrollment":734,"conditions":32612,"interventions":32614},"NCT00784212","Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy",[92],[32613],"Photosensitive Epilepsy",[32570,32570],{"trials":32616,"activeCount":103},[],{"trials":32618,"activeCount":103},[],{"trials":32620,"activeCount":103},[],{"intervention":4393,"totalTrials":637,"cells":32622},{"EARLY_PHASE1":32623,"PHASE1":32625,"PHASE2":32648,"PHASE3":32654,"PHASE4":32656,"NA":32658},{"trials":32624,"activeCount":103},[],{"trials":32626,"activeCount":103},[32627,32631,32640,32644],{"nctId":11240,"briefTitle":11241,"status":134,"phases":32628,"primaryCompletion":11243,"completion":11243,"start":2487,"enrollment":3605,"conditions":32629,"interventions":32630},[91],[5598,11245],[4393,10589,10731],{"nctId":32632,"briefTitle":32633,"status":123,"phases":32634,"primaryCompletion":270,"completion":32635,"start":3439,"enrollment":6024,"conditions":32636,"interventions":32638},"NCT02143635","Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt",[91],"2020-06-09",[32637],"Advanced Solid and Hematological TP53wt Tumors",[4393,32639],"ancillary treatment",{"nctId":4381,"briefTitle":4382,"status":123,"phases":32641,"primaryCompletion":4384,"completion":4384,"start":4385,"enrollment":3741,"conditions":32642,"interventions":32643},[91],[4387],[4389,4390,196,4391,4392,4393],{"nctId":10101,"briefTitle":10102,"status":123,"phases":32645,"primaryCompletion":3917,"completion":3917,"start":7435,"enrollment":223,"conditions":32646,"interventions":32647},[91],[10105],[4393,515],{"trials":32649,"activeCount":103},[32650],{"nctId":9843,"briefTitle":9844,"status":390,"phases":32651,"primaryCompletion":6372,"completion":2938,"start":9846,"enrollment":103,"conditions":32652,"interventions":32653},[91,92],[9848],[4393,9823,9850,9825,9851,9852,5207],{"trials":32655,"activeCount":103},[],{"trials":32657,"activeCount":103},[],{"trials":32659,"activeCount":103},[],{"intervention":11029,"totalTrials":637,"cells":32661},{"EARLY_PHASE1":32662,"PHASE1":32664,"PHASE2":32693,"PHASE3":32712,"PHASE4":32714,"NA":32716},{"trials":32663,"activeCount":103},[],{"trials":32665,"activeCount":103},[32666,32675,32689],{"nctId":32667,"briefTitle":32668,"status":123,"phases":32669,"primaryCompletion":32670,"completion":32670,"start":32671,"enrollment":1495,"conditions":32672,"interventions":32674},"NCT01697605","A Phase I Study of Oral BGJ398 in Asian Patients",[91],"2019-02-07","2012-10-19",[32673],"Tumor With Alterations of the FGF-R",[11029],{"nctId":32676,"briefTitle":32677,"status":123,"phases":32678,"primaryCompletion":32679,"completion":32679,"start":32680,"enrollment":6024,"conditions":32681,"interventions":32688},"NCT01004224","A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies",[91],"2018-10-08","2009-12-11",[32682,32683,32684,32685,32686,32687],"Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3","Squamous Lung Cancer With FGFR1 Amplification","Bladder Cancer With FGFR3 Mutation or Fusion","Advanced Solid Tumors With FGFR1 Amplication","Advanced Solid Tumors With FGFR2 Amplication","Advanced Solid Tumors With FGFR3 Mutation",[11029],{"nctId":11022,"briefTitle":11023,"status":123,"phases":32690,"primaryCompletion":11025,"completion":11025,"start":813,"enrollment":2149,"conditions":32691,"interventions":32692},[91],[5614,11027],[11029,516],{"trials":32694,"activeCount":103},[32695,32704],{"nctId":32696,"briefTitle":32697,"status":123,"phases":32698,"primaryCompletion":32699,"completion":32699,"start":32700,"enrollment":37,"conditions":32701,"interventions":32703},"NCT01975701","A Phase 2 Study of BGJ398 in Patients With Recurrent GBM",[92],"2018-10-03","2013-12-09",[32702],"Recurrent Glioblastoma or Other Glioma Subtypes",[11029],{"nctId":32705,"briefTitle":32706,"status":134,"phases":32707,"primaryCompletion":3680,"completion":3680,"start":32708,"enrollment":5982,"conditions":32709,"interventions":32711},"NCT02160041","BGJ398 for Patients With Tumors With FGFR Genetic Alterations",[92],"2014-07-24",[1317,32710],"Hematologic Malignancies",[11029],{"trials":32713,"activeCount":103},[],{"trials":32715,"activeCount":103},[],{"trials":32717,"activeCount":103},[],{"intervention":32719,"totalTrials":637,"cells":32720},"QBW251",{"EARLY_PHASE1":32721,"PHASE1":32723,"PHASE2":32725,"PHASE3":32770,"PHASE4":32772,"NA":32774},{"trials":32722,"activeCount":103},[],{"trials":32724,"activeCount":103},[],{"trials":32726,"activeCount":103},[32727,32734,32742,32752,32761],{"nctId":32728,"briefTitle":32729,"status":134,"phases":32730,"primaryCompletion":25397,"completion":25397,"start":32731,"enrollment":1278,"conditions":32732,"interventions":32733},"NCT02190604","Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients",[91,92],"2012-07-31",[9233],[32719],{"nctId":32735,"briefTitle":32736,"status":123,"phases":32737,"primaryCompletion":32738,"completion":24301,"start":32739,"enrollment":4516,"conditions":32740,"interventions":32741},"NCT02449018","A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251",[92],"2016-12-27","2015-04-30",[15669],[32719],{"nctId":32743,"briefTitle":32744,"status":134,"phases":32745,"primaryCompletion":32746,"completion":32747,"start":32748,"enrollment":25,"conditions":32749,"interventions":32751},"NCT04396366","Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis",[92],"2023-06-15","2023-06-21","2021-02-02",[32750],"Bronchiectasis",[32719],{"nctId":32753,"briefTitle":32754,"status":123,"phases":32755,"primaryCompletion":32756,"completion":19099,"start":7865,"enrollment":32757,"conditions":32758,"interventions":32759},"NCT04072887","Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients",[92],"2021-10-08",974,[16163],[32719,32760],"COPD maintenance background therapy",{"nctId":32762,"briefTitle":32763,"status":134,"phases":32764,"primaryCompletion":32765,"completion":32766,"start":32767,"enrollment":271,"conditions":32768,"interventions":32769},"NCT04268823","Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],"2022-09-13","2022-09-20","2020-09-10",[24],[32719],{"trials":32771,"activeCount":103},[],{"trials":32773,"activeCount":103},[],{"trials":32775,"activeCount":103},[],{"intervention":32777,"totalTrials":1630,"cells":32778},"CSJ117",{"EARLY_PHASE1":32779,"PHASE1":32781,"PHASE2":32790,"PHASE3":32815,"PHASE4":32817,"NA":32819},{"trials":32780,"activeCount":103},[],{"trials":32782,"activeCount":103},[32783],{"nctId":32784,"briefTitle":32785,"status":123,"phases":32786,"primaryCompletion":32787,"completion":32787,"start":13342,"enrollment":2046,"conditions":32788,"interventions":32789},"NCT03138811","A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma",[91],"2019-07-16",[18],[32777],{"trials":32791,"activeCount":103},[32792,32800,32807],{"nctId":32793,"briefTitle":32794,"status":134,"phases":32795,"primaryCompletion":32796,"completion":32318,"start":32797,"enrollment":16351,"conditions":32798,"interventions":32799},"NCT04410523","Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma",[92],"2022-07-12","2020-09-09",[18],[32777],{"nctId":32801,"briefTitle":32802,"status":134,"phases":32803,"primaryCompletion":32804,"completion":32804,"start":19107,"enrollment":2948,"conditions":32805,"interventions":32806},"NCT04946318","Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma",[92],"2022-09-08",[18],[32777],{"nctId":32808,"briefTitle":32809,"status":123,"phases":32810,"primaryCompletion":32811,"completion":32811,"start":32812,"enrollment":5948,"conditions":32813,"interventions":32814},"NCT04882124","Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD",[92],"2022-09-15","2021-09-24",[16163],[32777],{"trials":32816,"activeCount":103},[],{"trials":32818,"activeCount":103},[],{"trials":32820,"activeCount":103},[],{"intervention":32822,"totalTrials":1630,"cells":32823},"AQW051",{"EARLY_PHASE1":32824,"PHASE1":32826,"PHASE2":32828,"PHASE3":32860,"PHASE4":32862,"NA":32864},{"trials":32825,"activeCount":103},[],{"trials":32827,"activeCount":103},[],{"trials":32829,"activeCount":103},[32830,32837,32846,32854],{"nctId":32831,"briefTitle":32832,"status":123,"phases":32833,"primaryCompletion":1714,"completion":1714,"start":3243,"enrollment":32834,"conditions":32835,"interventions":32836},"NCT01730768","A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients",[92],147,[12560],[32822],{"nctId":32838,"briefTitle":32839,"status":123,"phases":32840,"primaryCompletion":32841,"completion":32841,"start":32842,"enrollment":1660,"conditions":32843,"interventions":32845},"NCT01474421","Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease",[92],"2013-02-21","2011-09-15",[23269,32844],"Drug-induced",[32822,32822],{"nctId":32847,"briefTitle":32848,"status":134,"phases":32849,"primaryCompletion":3612,"start":4556,"enrollment":271,"conditions":32850,"interventions":32853},"NCT00582855","Effect of AQW051 in Patients With Memory Impairment",[92],[32851,32852],"Mild Alzheimer's Disease","Amnestic Mild Cognitive Impairment",[32822],{"nctId":32855,"briefTitle":32856,"status":123,"phases":32857,"primaryCompletion":3800,"completion":3800,"start":949,"enrollment":16,"conditions":32858,"interventions":32859},"NCT00825539","Pharmacodynamic\u002FPharmacokinetic Study of AQW051 in Schizophrenia",[91,92],[12560],[32822],{"trials":32861,"activeCount":103},[],{"trials":32863,"activeCount":103},[],{"trials":32865,"activeCount":103},[],{"intervention":7886,"totalTrials":1630,"cells":32867},{"EARLY_PHASE1":32868,"PHASE1":32870,"PHASE2":32889,"PHASE3":32895,"PHASE4":32897,"NA":32899},{"trials":32869,"activeCount":103},[],{"trials":32871,"activeCount":103},[32872,32876,32880],{"nctId":8036,"briefTitle":8037,"status":123,"phases":32873,"primaryCompletion":8039,"completion":8039,"start":3673,"enrollment":114,"conditions":32874,"interventions":32875},[91],[8041],[7886,516,4321,5252,8043],{"nctId":7878,"briefTitle":7879,"status":123,"phases":32877,"primaryCompletion":7881,"completion":7881,"start":7882,"enrollment":2776,"conditions":32878,"interventions":32879},[91],[7884],[7886,4320],{"nctId":32881,"briefTitle":32882,"status":123,"phases":32883,"primaryCompletion":4093,"completion":4093,"start":3759,"enrollment":271,"conditions":32884,"interventions":32888},"NCT01598077","A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer",[91],[32885,32886,32887,13601,8041],"HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma","HER2 + Breast Cancer","HER2 + Gastric Cancer",[7886],{"trials":32890,"activeCount":103},[32891],{"nctId":10255,"briefTitle":10256,"status":390,"phases":32892,"primaryCompletion":10258,"completion":10258,"start":2509,"enrollment":103,"conditions":32893,"interventions":32894},[91,92],[206],[7886,236],{"trials":32896,"activeCount":103},[],{"trials":32898,"activeCount":103},[],{"trials":32900,"activeCount":103},[],{"intervention":32902,"totalTrials":1630,"cells":32903},"HCD122",{"EARLY_PHASE1":32904,"PHASE1":32906,"PHASE2":32926,"PHASE3":32934,"PHASE4":32936,"NA":32938},{"trials":32905,"activeCount":103},[],{"trials":32907,"activeCount":103},[32908,32914,32920],{"nctId":32909,"briefTitle":32910,"status":123,"phases":32911,"primaryCompletion":5733,"completion":5733,"start":3760,"enrollment":437,"conditions":32912,"interventions":32913},"NCT01275209","Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma",[91],[8192],[32902],{"nctId":32915,"briefTitle":32916,"status":123,"phases":32917,"primaryCompletion":3410,"completion":3410,"start":8370,"enrollment":99,"conditions":32918,"interventions":32919},"NCT00231166","Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma",[91],[5636],[32902],{"nctId":32921,"briefTitle":32922,"status":134,"phases":32923,"primaryCompletion":5062,"completion":5062,"start":854,"enrollment":37,"conditions":32924,"interventions":32925},"NCT00108108","Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy",[91],[11399],[32902],{"trials":32927,"activeCount":103},[32928],{"nctId":32929,"briefTitle":32930,"status":123,"phases":32931,"primaryCompletion":2793,"completion":2793,"start":1025,"enrollment":2810,"conditions":32932,"interventions":32933},"NCT00670592","Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies",[91,92],[2877,5735],[32902],{"trials":32935,"activeCount":103},[],{"trials":32937,"activeCount":103},[],{"trials":32939,"activeCount":103},[],{"intervention":11371,"totalTrials":1630,"cells":32941},{"EARLY_PHASE1":32942,"PHASE1":32944,"PHASE2":32946,"PHASE3":32980,"PHASE4":32982,"NA":32984},{"trials":32943,"activeCount":103},[],{"trials":32945,"activeCount":103},[],{"trials":32947,"activeCount":103},[32948,32957,32966,32976],{"nctId":32949,"briefTitle":32950,"status":134,"phases":32951,"primaryCompletion":32952,"completion":32952,"start":32953,"enrollment":1399,"conditions":32954,"interventions":32956},"NCT02855164","Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)",[92],"2020-04-06","2016-08-01",[32955],"Non-alcoholic Steatohepatitis (NASH)",[11371],{"nctId":32958,"briefTitle":32959,"status":123,"phases":32960,"primaryCompletion":32961,"completion":32962,"start":16476,"enrollment":15538,"conditions":32963,"interventions":32964},"NCT03517540","Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis",[92],"2020-09-15","2020-10-15",[32955],[11371,32965],"Cenicriviroc",{"nctId":32967,"briefTitle":32968,"status":134,"phases":32969,"primaryCompletion":32970,"completion":32970,"start":2101,"enrollment":32971,"conditions":32972,"interventions":32974},"NCT04065841","Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.",[92],"2022-10-27",234,[32973],"Non Alcoholic Steatohepatitis (NASH)",[11371,32975],"Licogliflozin",{"nctId":11363,"briefTitle":11364,"status":134,"phases":32977,"primaryCompletion":11366,"completion":11366,"start":7902,"enrollment":4506,"conditions":32978,"interventions":32979},[92],[11368,11369],[6529,11371],{"trials":32981,"activeCount":103},[],{"trials":32983,"activeCount":103},[],{"trials":32985,"activeCount":103},[],{"intervention":2408,"totalTrials":1630,"cells":32987},{"EARLY_PHASE1":32988,"PHASE1":32990,"PHASE2":33003,"PHASE3":33016,"PHASE4":33018,"NA":33020},{"trials":32989,"activeCount":103},[],{"trials":32991,"activeCount":103},[32992,32999],{"nctId":32993,"briefTitle":32994,"status":123,"phases":32995,"primaryCompletion":32996,"completion":32996,"start":2148,"enrollment":5948,"conditions":32997,"interventions":32998},"NCT05599932","Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment",[91],"2023-09-18",[2625],[2408],{"nctId":10685,"briefTitle":10686,"status":123,"phases":33000,"primaryCompletion":10688,"completion":10688,"start":10689,"enrollment":814,"conditions":33001,"interventions":33002},[91],[2569],[10692,10666,10665],{"trials":33004,"activeCount":103},[33005,33009],{"nctId":2399,"briefTitle":2400,"status":134,"phases":33006,"primaryCompletion":2402,"completion":2403,"start":2404,"enrollment":2405,"conditions":33007,"interventions":33008},[91,92],[2369],[2341,2408,63,2409,2410,2411],{"nctId":33010,"briefTitle":33011,"status":134,"phases":33012,"primaryCompletion":10748,"completion":10748,"start":14534,"enrollment":422,"conditions":33013,"interventions":33015},"NCT05447663","A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant",[91,92],[2569,33014],"Allogeneic Stem Cell Transplantation",[2408],{"trials":33017,"activeCount":103},[],{"trials":33019,"activeCount":103},[],{"trials":33021,"activeCount":103},[],{"intervention":23071,"totalTrials":1630,"cells":33023},{"EARLY_PHASE1":33024,"PHASE1":33026,"PHASE2":33040,"PHASE3":33065,"PHASE4":33067,"NA":33069},{"trials":33025,"activeCount":103},[],{"trials":33027,"activeCount":103},[33028,33036],{"nctId":33029,"briefTitle":33030,"status":123,"phases":33031,"primaryCompletion":3075,"completion":3075,"start":5688,"enrollment":26583,"conditions":33032,"interventions":33033},"NCT01231594","A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors",[91],[1102],[33034,23071,33035],"GSK2118436","Other approved anti-cancer agent",{"nctId":23065,"briefTitle":23066,"status":123,"phases":33037,"primaryCompletion":3382,"completion":3382,"start":4081,"enrollment":5721,"conditions":33038,"interventions":33039},[91],[23069],[517,23071],{"trials":33041,"activeCount":103},[33042,33051],{"nctId":33043,"briefTitle":33044,"status":123,"phases":33045,"primaryCompletion":33046,"completion":33047,"start":33048,"enrollment":2543,"conditions":33049,"interventions":33050},"NCT01072175","Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212",[92],"2012-05-31","2018-02-27","2010-03-26",[1102],[33034,23071],{"nctId":33052,"briefTitle":33053,"status":134,"phases":33054,"primaryCompletion":27410,"completion":27410,"start":33055,"enrollment":4583,"conditions":33056,"interventions":33057},"NCT01376310","GSK1120212 Rollover Study",[92],"2010-11-02",[1102],[23071,33058,33059,33060,33061,33062,33063,33064],"Docetaxel + GSK1120212","Erlotinib + GSK1120212","Pemetrexed + GSK1120212","Carboplatin + GSK1120212","Nab-paclitaxel + GSK1120212","Gemcitabine + GSK1120212","Everolimus + GSK1120212",{"trials":33066,"activeCount":103},[],{"trials":33068,"activeCount":103},[],{"trials":33070,"activeCount":103},[],{"intervention":24360,"totalTrials":1630,"cells":33072},{"EARLY_PHASE1":33073,"PHASE1":33075,"PHASE2":33084,"PHASE3":33100,"PHASE4":33102,"NA":33104},{"trials":33074,"activeCount":103},[],{"trials":33076,"activeCount":103},[33077],{"nctId":33078,"briefTitle":33079,"status":123,"phases":33080,"primaryCompletion":7625,"completion":7625,"start":33081,"enrollment":1901,"conditions":33082,"interventions":33083},"NCT04072302","Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model",[91],"2014-09-15",[11177],[24360],{"trials":33085,"activeCount":103},[33086,33090,33096],{"nctId":24353,"briefTitle":24354,"status":123,"phases":33087,"primaryCompletion":565,"completion":9252,"start":7881,"enrollment":24356,"conditions":33088,"interventions":33089},[92],[24358],[24360,10927,24361],{"nctId":33091,"briefTitle":33092,"status":123,"phases":33093,"primaryCompletion":7939,"completion":7939,"start":4967,"enrollment":4557,"conditions":33094,"interventions":33095},"NCT01753323","Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection",[92],[11177],[24360],{"nctId":24367,"briefTitle":24368,"status":123,"phases":33097,"primaryCompletion":6451,"completion":2403,"start":1505,"enrollment":24370,"conditions":33098,"interventions":33099},[92],[10902],[24360,24373,10927],{"trials":33101,"activeCount":103},[],{"trials":33103,"activeCount":103},[],{"trials":33105,"activeCount":103},[],{"intervention":23055,"totalTrials":1630,"cells":33107},{"EARLY_PHASE1":33108,"PHASE1":33110,"PHASE2":33116,"PHASE3":33148,"PHASE4":33150,"NA":33152},{"trials":33109,"activeCount":103},[],{"trials":33111,"activeCount":103},[33112],{"nctId":23048,"briefTitle":23049,"status":123,"phases":33113,"primaryCompletion":23051,"completion":23051,"start":4465,"enrollment":1423,"conditions":33114,"interventions":33115},[91],[23053],[23055,517],{"trials":33117,"activeCount":103},[33118,33127,33136],{"nctId":33119,"briefTitle":33120,"status":123,"phases":33121,"primaryCompletion":33122,"completion":33122,"start":33123,"enrollment":34,"conditions":33124,"interventions":33126},"NCT00613171","Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis",[92],"2010-01-13","2008-01-02",[33125],"Systemic Sclerosis, Scleroderma",[23055],{"nctId":33128,"briefTitle":33129,"status":123,"phases":33130,"primaryCompletion":33131,"completion":33131,"start":33132,"enrollment":33133,"conditions":33134,"interventions":33135},"NCT00171223","An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha",[92],"2013-11-29","1999-12-06",532,[3579],[23055],{"nctId":33137,"briefTitle":33138,"status":123,"phases":33139,"primaryCompletion":864,"start":18732,"enrollment":2428,"conditions":33140,"interventions":33147},"NCT01316458","Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy",[92],[1624,33141,33142,33143,33144,33145,33146,83],"Genital Neoplasms, Male","Neoplasms, Abdominal","Urogenital Neoplasms","Genital Diseases, Male","Prostatic Diseases","Antineoplastic Agents",[23055],{"trials":33149,"activeCount":103},[],{"trials":33151,"activeCount":103},[],{"trials":33153,"activeCount":103},[],{"intervention":33155,"totalTrials":317,"cells":33156},"BVS857",{"EARLY_PHASE1":33157,"PHASE1":33159,"PHASE2":33167,"PHASE3":33184,"PHASE4":33186,"NA":33188},{"trials":33158,"activeCount":103},[],{"trials":33160,"activeCount":103},[33161],{"nctId":33162,"briefTitle":33163,"status":123,"phases":33164,"primaryCompletion":2795,"completion":2795,"start":895,"enrollment":4557,"conditions":33165,"interventions":33166},"NCT01435330","Safety and Tolerability of BVS857 in Subjects With Insulin Resistance",[91],[16764],[33155],{"trials":33168,"activeCount":103},[33169,33176],{"nctId":33170,"briefTitle":33171,"status":134,"phases":33172,"primaryCompletion":10055,"completion":10055,"start":1723,"enrollment":437,"conditions":33173,"interventions":33175},"NCT02074995","Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects",[92],[33174],"Hypercatabolic Status Related to Severe Burn",[33155],{"nctId":33177,"briefTitle":33178,"status":123,"phases":33179,"primaryCompletion":2918,"completion":2918,"start":33180,"enrollment":5612,"conditions":33181,"interventions":33183},"NCT02024932","Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy",[92],"2014-02-04",[33182],"Spinal and Bulbar Muscular Atrophy",[33155],{"trials":33185,"activeCount":103},[],{"trials":33187,"activeCount":103},[],{"trials":33189,"activeCount":103},[],{"intervention":22828,"totalTrials":317,"cells":33191},{"EARLY_PHASE1":33192,"PHASE1":33194,"PHASE2":33196,"PHASE3":33214,"PHASE4":33216,"NA":33218},{"trials":33193,"activeCount":103},[],{"trials":33195,"activeCount":103},[],{"trials":33197,"activeCount":103},[33198,33204,33208],{"nctId":33199,"briefTitle":33200,"status":123,"phases":33201,"primaryCompletion":3604,"completion":3604,"start":4081,"enrollment":28,"conditions":33202,"interventions":33203},"NCT01109940","Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis",[92],[1974],[22828],{"nctId":22822,"briefTitle":22823,"status":123,"phases":33205,"primaryCompletion":4372,"completion":4372,"start":4845,"enrollment":22825,"conditions":33206,"interventions":33207},[92],[1684],[11428,22828,22828],{"nctId":33209,"briefTitle":33210,"status":123,"phases":33211,"primaryCompletion":3712,"completion":3712,"start":3351,"enrollment":2046,"conditions":33212,"interventions":33213},"NCT01169844","Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis",[92],[1821],[22828],{"trials":33215,"activeCount":103},[],{"trials":33217,"activeCount":103},[],{"trials":33219,"activeCount":103},[],{"intervention":3102,"totalTrials":317,"cells":33221},{"EARLY_PHASE1":33222,"PHASE1":33224,"PHASE2":33226,"PHASE3":33246,"PHASE4":33248,"NA":33250},{"trials":33223,"activeCount":103},[],{"trials":33225,"activeCount":103},[],{"trials":33227,"activeCount":103},[33228,33236,33240],{"nctId":33229,"briefTitle":33230,"status":134,"phases":33231,"primaryCompletion":10627,"completion":33232,"start":33233,"enrollment":827,"conditions":33234,"interventions":33235},"NCT05764265","Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants",[92],"2024-05-14","2023-03-27",[3305],[3102],{"nctId":3092,"briefTitle":3093,"status":134,"phases":33237,"primaryCompletion":3095,"completion":3096,"start":3097,"enrollment":3098,"conditions":33238,"interventions":33239},[92],[3100],[3102,3017],{"nctId":33241,"briefTitle":33242,"status":134,"phases":33243,"primaryCompletion":87,"completion":7049,"start":13371,"enrollment":846,"conditions":33244,"interventions":33245},"NCT05135000","Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension",[92],[3305],[3102],{"trials":33247,"activeCount":103},[],{"trials":33249,"activeCount":103},[],{"trials":33251,"activeCount":103},[],{"intervention":33253,"totalTrials":317,"cells":33254},"SBR759",{"EARLY_PHASE1":33255,"PHASE1":33257,"PHASE2":33259,"PHASE3":33282,"PHASE4":33284,"NA":33286},{"trials":33256,"activeCount":103},[],{"trials":33258,"activeCount":103},[],{"trials":33260,"activeCount":103},[33261,33267,33275],{"nctId":33262,"briefTitle":33263,"status":123,"phases":33264,"primaryCompletion":917,"completion":917,"start":988,"enrollment":1423,"conditions":33265,"interventions":33266},"NCT00750295","A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis",[91,92],[14561],[33253,33253,33253,33253,33253,33253,33253],{"nctId":33268,"briefTitle":33269,"status":123,"phases":33270,"primaryCompletion":3351,"start":3473,"enrollment":33271,"conditions":33272,"interventions":33273},"NCT00704678","Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis",[92],203,[14561],[33253,33274,33274,33274],"Sevelamer HCl",{"nctId":33276,"briefTitle":33277,"status":123,"phases":33278,"primaryCompletion":3845,"start":10499,"enrollment":19224,"conditions":33279,"interventions":33281},"NCT00704483","Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis",[92],[33280],"Hyperphosphatemia Patients With Chronic Kidney Disease on 3x\u002FWeek Replacement Therapy",[33253,33274,33253,33274],{"trials":33283,"activeCount":103},[],{"trials":33285,"activeCount":103},[],{"trials":33287,"activeCount":103},[],{"intervention":31847,"totalTrials":317,"cells":33289},{"EARLY_PHASE1":33290,"PHASE1":33292,"PHASE2":33298,"PHASE3":33308,"PHASE4":33310,"NA":33312},{"trials":33291,"activeCount":103},[],{"trials":33293,"activeCount":103},[33294],{"nctId":31841,"briefTitle":31842,"status":123,"phases":33295,"primaryCompletion":4620,"start":5620,"enrollment":2579,"conditions":33296,"interventions":33297},[91],[18],[19484,31846,31834,31847],{"trials":33299,"activeCount":103},[33300,33304],{"nctId":31858,"briefTitle":31859,"status":123,"phases":33301,"primaryCompletion":1671,"start":4335,"enrollment":2342,"conditions":33302,"interventions":33303},[92],[31862],[31847,31834],{"nctId":31896,"briefTitle":31897,"status":134,"phases":33305,"primaryCompletion":926,"completion":926,"start":1024,"enrollment":317,"conditions":33306,"interventions":33307},[92],[31900],[31834,31847],{"trials":33309,"activeCount":103},[],{"trials":33311,"activeCount":103},[],{"trials":33313,"activeCount":103},[],{"intervention":33315,"totalTrials":317,"cells":33316},"SAF312",{"EARLY_PHASE1":33317,"PHASE1":33319,"PHASE2":33321,"PHASE3":33350,"PHASE4":33352,"NA":33354},{"trials":33318,"activeCount":103},[],{"trials":33320,"activeCount":103},[],{"trials":33322,"activeCount":103},[33323,33334,33342],{"nctId":33324,"briefTitle":33325,"status":134,"phases":33326,"primaryCompletion":3243,"completion":3243,"start":1732,"enrollment":1495,"conditions":33327,"interventions":33333},"NCT01598103","Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions",[92],[33328,33329,33330,33331,33332],"Neurogenic Urinary Bladder","Neurogenic Bladder Disorder","Neurogenic Dysfunction of the Urinary Bladder","Neurogenic Bladder, Uninhibited","Neurogenic Bladder, Spastic",[33315],{"nctId":33335,"briefTitle":33336,"status":123,"phases":33337,"primaryCompletion":18363,"completion":10139,"start":33338,"enrollment":709,"conditions":33339,"interventions":33341},"NCT02961062","Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery",[92],"2016-12-01",[33340],"Postoperative Ocular Pain After PRK Surgery",[33315],{"nctId":33343,"briefTitle":33344,"status":123,"phases":33345,"primaryCompletion":33346,"completion":20906,"start":3085,"enrollment":1278,"conditions":33347,"interventions":33349},"NCT04630158","Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)",[92],"2023-06-07",[33348],"Chronic Ocular Pain",[33315],{"trials":33351,"activeCount":103},[],{"trials":33353,"activeCount":103},[],{"trials":33355,"activeCount":103},[],{"intervention":4544,"totalTrials":317,"cells":33357},{"EARLY_PHASE1":33358,"PHASE1":33360,"PHASE2":33368,"PHASE3":33380,"PHASE4":33382,"NA":33384},{"trials":33359,"activeCount":103},[],{"trials":33361,"activeCount":103},[33362],{"nctId":33363,"briefTitle":33364,"status":123,"phases":33365,"primaryCompletion":917,"start":20175,"enrollment":3854,"conditions":33366,"interventions":33367},"NCT00118456","Study of Oral AEE788 in Adults With Advanced Cancer",[91],[1102],[4544],{"trials":33369,"activeCount":103},[33370,33374],{"nctId":4537,"briefTitle":4538,"status":123,"phases":33371,"primaryCompletion":745,"completion":745,"start":4540,"enrollment":1672,"conditions":33372,"interventions":33373},[91,92],[4542],[4544,4305],{"nctId":33375,"briefTitle":33376,"status":123,"phases":33377,"primaryCompletion":918,"completion":918,"start":15101,"enrollment":2776,"conditions":33378,"interventions":33379},"NCT00116376","Study of AEE788 in Patients With Recurrent\u002FRelapse Glioblastoma Multiforme (GBM)",[91,92],[4508],[4544],{"trials":33381,"activeCount":103},[],{"trials":33383,"activeCount":103},[],{"trials":33385,"activeCount":103},[],{"intervention":10520,"totalTrials":317,"cells":33387},{"EARLY_PHASE1":33388,"PHASE1":33390,"PHASE2":33399,"PHASE3":33412,"PHASE4":33414,"NA":33416},{"trials":33389,"activeCount":103},[],{"trials":33391,"activeCount":103},[33392],{"nctId":33393,"briefTitle":33394,"status":123,"phases":33395,"primaryCompletion":4301,"completion":4301,"start":949,"enrollment":2046,"conditions":33396,"interventions":33398},"NCT00741377","A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients",[91],[33397],"Multiple Myeloma Bone Disease",[10520,886],{"trials":33400,"activeCount":103},[33401,33408],{"nctId":33402,"briefTitle":33403,"status":123,"phases":33404,"primaryCompletion":4669,"completion":4669,"start":3784,"enrollment":4506,"conditions":33405,"interventions":33407},"NCT01302886","Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma",[92],[33406],"Smoldering Multiple Myeloma",[10520],{"nctId":10514,"briefTitle":10515,"status":123,"phases":33409,"primaryCompletion":5114,"completion":5114,"start":1732,"enrollment":1495,"conditions":33410,"interventions":33411},[92],[5636,10518],[10520,10521,5649,5639],{"trials":33413,"activeCount":103},[],{"trials":33415,"activeCount":103},[],{"trials":33417,"activeCount":103},[],{"intervention":33419,"totalTrials":317,"cells":33420},"LHW090",{"EARLY_PHASE1":33421,"PHASE1":33423,"PHASE2":33434,"PHASE3":33451,"PHASE4":33453,"NA":33455},{"trials":33422,"activeCount":103},[],{"trials":33424,"activeCount":103},[33425],{"nctId":33426,"briefTitle":33427,"status":123,"phases":33428,"primaryCompletion":33429,"completion":33429,"start":33430,"enrollment":585,"conditions":33431,"interventions":33433},"NCT01846468","An Ascending Dose Study to Assess Safety, Tolerability, PK\u002FPD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction",[91],"2014-06-28","2013-03-01",[33432],"Chronic Renal Insufficiency",[33419],{"trials":33435,"activeCount":103},[33436,33444],{"nctId":33437,"briefTitle":33438,"status":123,"phases":33439,"primaryCompletion":33440,"completion":33440,"start":8075,"enrollment":2776,"conditions":33441,"interventions":33443},"NCT02515331","Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients",[92],"2017-08-17",[33442],"Patients, Resistant Hypertension",[33419],{"nctId":33445,"briefTitle":33446,"status":123,"phases":33447,"primaryCompletion":33448,"completion":33448,"start":2489,"enrollment":5982,"conditions":33449,"interventions":33450},"NCT02678000","Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function",[92],"2018-10-11",[7726],[33419],{"trials":33452,"activeCount":103},[],{"trials":33454,"activeCount":103},[],{"trials":33456,"activeCount":103},[],{"intervention":33458,"totalTrials":317,"cells":33459},"QCC374",{"EARLY_PHASE1":33460,"PHASE1":33462,"PHASE2":33471,"PHASE3":33487,"PHASE4":33489,"NA":33491},{"trials":33461,"activeCount":103},[],{"trials":33463,"activeCount":103},[33464],{"nctId":33465,"briefTitle":33466,"status":123,"phases":33467,"primaryCompletion":2762,"completion":2762,"start":3409,"enrollment":11068,"conditions":33468,"interventions":33470},"NCT02245828","A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374",[91],[33469],"Healthy Subjects",[33458],{"trials":33472,"activeCount":103},[33473,33481],{"nctId":33474,"briefTitle":33475,"status":134,"phases":33476,"primaryCompletion":33477,"completion":33477,"start":33478,"enrollment":637,"conditions":33479,"interventions":33480},"NCT02939599","Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients",[92],"2018-11-06","2018-02-01",[3305],[33458],{"nctId":33482,"briefTitle":33483,"status":134,"phases":33484,"primaryCompletion":24186,"completion":24186,"start":3828,"enrollment":422,"conditions":33485,"interventions":33486},"NCT02927366","Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients",[92],[3305],[33458],{"trials":33488,"activeCount":103},[],{"trials":33490,"activeCount":103},[],{"trials":33492,"activeCount":103},[],{"intervention":6518,"totalTrials":213,"cells":33494},{"EARLY_PHASE1":33495,"PHASE1":33497,"PHASE2":33503,"PHASE3":33509,"PHASE4":33511,"NA":33513},{"trials":33496,"activeCount":103},[],{"trials":33498,"activeCount":103},[33499],{"nctId":6491,"briefTitle":6492,"status":123,"phases":33500,"primaryCompletion":6494,"completion":6494,"start":6495,"enrollment":1524,"conditions":33501,"interventions":33502},[91],[1717],[3112,6498],{"trials":33504,"activeCount":103},[33505],{"nctId":6510,"briefTitle":6511,"status":123,"phases":33506,"primaryCompletion":5830,"completion":6513,"start":5791,"enrollment":6514,"conditions":33507,"interventions":33508},[92],[6516],[3112,6518,6519,6520],{"trials":33510,"activeCount":103},[],{"trials":33512,"activeCount":103},[],{"trials":33514,"activeCount":103},[],{"intervention":33516,"totalTrials":213,"cells":33517},"Fevipiprant",{"EARLY_PHASE1":33518,"PHASE1":33520,"PHASE2":33529,"PHASE3":33538,"PHASE4":33540,"NA":33542},{"trials":33519,"activeCount":103},[],{"trials":33521,"activeCount":103},[33522],{"nctId":33523,"briefTitle":33524,"status":123,"phases":33525,"primaryCompletion":33526,"completion":33526,"start":25119,"enrollment":25,"conditions":33527,"interventions":33528},"NCT03048448","Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects",[91],"2019-04-22",[2625],[33516],{"trials":33530,"activeCount":103},[33531],{"nctId":33532,"briefTitle":33533,"status":134,"phases":33534,"primaryCompletion":23319,"completion":12998,"start":33535,"enrollment":4148,"conditions":33536,"interventions":33537},"NCT03650400","Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to \u003C 12 Years With Asthma",[92],"2019-05-01",[18],[33516],{"trials":33539,"activeCount":103},[],{"trials":33541,"activeCount":103},[],{"trials":33543,"activeCount":103},[],{"intervention":33545,"totalTrials":213,"cells":33546},"CSJ148",{"EARLY_PHASE1":33547,"PHASE1":33549,"PHASE2":33551,"PHASE3":33570,"PHASE4":33572,"NA":33574},{"trials":33548,"activeCount":103},[],{"trials":33550,"activeCount":103},[],{"trials":33552,"activeCount":103},[33553,33561],{"nctId":33554,"briefTitle":33555,"status":123,"phases":33556,"primaryCompletion":42,"completion":42,"start":33557,"enrollment":1901,"conditions":33558,"interventions":33560},"NCT02268526","Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients",[92],"2015-06-02",[33559],"HCMV",[33545],{"nctId":33562,"briefTitle":33563,"status":390,"phases":33564,"primaryCompletion":33565,"completion":33565,"start":33566,"enrollment":103,"conditions":33567,"interventions":33569},"NCT03369912","A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection",[92],"2022-11-15","2018-10-23",[33568],"HCMV Infection",[33545],{"trials":33571,"activeCount":103},[],{"trials":33573,"activeCount":103},[],{"trials":33575,"activeCount":103},[],{"intervention":33577,"totalTrials":213,"cells":33578},"LFF269",{"EARLY_PHASE1":33579,"PHASE1":33581,"PHASE2":33591,"PHASE3":33600,"PHASE4":33602,"NA":33604},{"trials":33580,"activeCount":103},[],{"trials":33582,"activeCount":103},[33583],{"nctId":33584,"briefTitle":33585,"status":134,"phases":33586,"primaryCompletion":7939,"completion":7939,"start":15346,"enrollment":1016,"conditions":33587,"interventions":33590},"NCT02047656","To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension",[91],[33588,33589],"Part 1 - Healthy Volunteers","Part 2 - Patients With Hypertension",[33577],{"trials":33592,"activeCount":103},[33593],{"nctId":33594,"briefTitle":33595,"status":134,"phases":33596,"primaryCompletion":1715,"completion":1715,"start":3784,"enrollment":1065,"conditions":33597,"interventions":33598},"NCT01373086","LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension",[92],[21],[33577,33599],"Eplerenone",{"trials":33601,"activeCount":103},[],{"trials":33603,"activeCount":103},[],{"trials":33605,"activeCount":103},[],{"intervention":13437,"totalTrials":213,"cells":33607},{"EARLY_PHASE1":33608,"PHASE1":33610,"PHASE2":33612,"PHASE3":33626,"PHASE4":33628,"NA":33630},{"trials":33609,"activeCount":103},[],{"trials":33611,"activeCount":103},[],{"trials":33613,"activeCount":103},[33614,33618],{"nctId":13429,"briefTitle":13430,"status":134,"phases":33615,"primaryCompletion":13432,"completion":13432,"start":13433,"enrollment":13434,"conditions":33616,"interventions":33617},[91,92],[5614],[13437,4389],{"nctId":33619,"briefTitle":33620,"status":134,"phases":33621,"primaryCompletion":33622,"completion":33622,"start":2101,"enrollment":2046,"conditions":33623,"interventions":33625},"NCT04066244","Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients",[92],"2024-02-01",[33624],"Amyotrophic Lateral Sclerosis",[13437],{"trials":33627,"activeCount":103},[],{"trials":33629,"activeCount":103},[],{"trials":33631,"activeCount":103},[],{"intervention":33633,"totalTrials":213,"cells":33634},"BGT226",{"EARLY_PHASE1":33635,"PHASE1":33637,"PHASE2":33647,"PHASE3":33655,"PHASE4":33657,"NA":33659},{"trials":33636,"activeCount":103},[],{"trials":33638,"activeCount":103},[33639],{"nctId":33640,"briefTitle":33641,"status":134,"phases":33642,"primaryCompletion":33643,"completion":33643,"start":33644,"enrollment":3343,"conditions":33645,"interventions":33646},"NCT00742105","Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan",[91],"2009-12-22","2008-11-17",[1102,1317,9516],[33633],{"trials":33648,"activeCount":103},[33649],{"nctId":33650,"briefTitle":33651,"status":123,"phases":33652,"primaryCompletion":964,"start":4556,"enrollment":3530,"conditions":33653,"interventions":33654},"NCT00600275","A Phase I\u002FII Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer",[91,92],[647,15,31721],[33633],{"trials":33656,"activeCount":103},[],{"trials":33658,"activeCount":103},[],{"trials":33660,"activeCount":103},[],{"intervention":33662,"totalTrials":213,"cells":33663},"APL180",{"EARLY_PHASE1":33664,"PHASE1":33666,"PHASE2":33674,"PHASE3":33682,"PHASE4":33684,"NA":33686},{"trials":33665,"activeCount":103},[],{"trials":33667,"activeCount":103},[33668],{"nctId":33669,"briefTitle":33670,"status":123,"phases":33671,"primaryCompletion":4400,"start":1024,"enrollment":314,"conditions":33672,"interventions":33673},"NCT00907998","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180",[91],[3180],[33662,33662],{"trials":33675,"activeCount":103},[33676],{"nctId":33677,"briefTitle":33678,"status":390,"phases":33679,"primaryCompletion":3612,"completion":3612,"start":4034,"enrollment":103,"conditions":33680,"interventions":33681},"NCT00751608","Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients",[92],[1374],[33662,33662],{"trials":33683,"activeCount":103},[],{"trials":33685,"activeCount":103},[],{"trials":33687,"activeCount":103},[],{"intervention":33689,"totalTrials":213,"cells":33690},"LYS228",{"EARLY_PHASE1":33691,"PHASE1":33693,"PHASE2":33695,"PHASE3":33713,"PHASE4":33715,"NA":33717},{"trials":33692,"activeCount":103},[],{"trials":33694,"activeCount":103},[],{"trials":33696,"activeCount":103},[33697,33705],{"nctId":33698,"briefTitle":33699,"status":390,"phases":33700,"primaryCompletion":15782,"completion":15782,"start":3692,"enrollment":103,"conditions":33701,"interventions":33703},"NCT03377426","LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)",[92],[33702],"Complicated Urinary Tract Infections",[33689,33704],"Standard of care therapy",{"nctId":33706,"briefTitle":33707,"status":134,"phases":33708,"primaryCompletion":16548,"completion":16548,"start":33709,"enrollment":317,"conditions":33710,"interventions":33712},"NCT03354754","LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)",[92],"2018-05-15",[33711],"Intra-abdominal Infections",[33689,33704],{"trials":33714,"activeCount":103},[],{"trials":33716,"activeCount":103},[],{"trials":33718,"activeCount":103},[],{"intervention":33704,"totalTrials":213,"cells":33720},{"EARLY_PHASE1":33721,"PHASE1":33723,"PHASE2":33725,"PHASE3":33735,"PHASE4":33737,"NA":33739},{"trials":33722,"activeCount":103},[],{"trials":33724,"activeCount":103},[],{"trials":33726,"activeCount":103},[33727,33731],{"nctId":33698,"briefTitle":33699,"status":390,"phases":33728,"primaryCompletion":15782,"completion":15782,"start":3692,"enrollment":103,"conditions":33729,"interventions":33730},[92],[33702],[33689,33704],{"nctId":33706,"briefTitle":33707,"status":134,"phases":33732,"primaryCompletion":16548,"completion":16548,"start":33709,"enrollment":317,"conditions":33733,"interventions":33734},[92],[33711],[33689,33704],{"trials":33736,"activeCount":103},[],{"trials":33738,"activeCount":103},[],{"trials":33740,"activeCount":103},[],{"intervention":33742,"totalTrials":213,"cells":33743},"Branaplam",{"EARLY_PHASE1":33744,"PHASE1":33746,"PHASE2":33748,"PHASE3":33767,"PHASE4":33769,"NA":33771},{"trials":33745,"activeCount":103},[],{"trials":33747,"activeCount":103},[],{"trials":33749,"activeCount":103},[33750,33758],{"nctId":33751,"briefTitle":33752,"status":134,"phases":33753,"primaryCompletion":5911,"completion":5911,"start":33754,"enrollment":37,"conditions":33755,"interventions":33757},"NCT05111249","A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070\u002FBranaplam in Early Manifest Huntington's Disease",[92],"2021-12-08",[33756],"Early Manifest Huntington Disease",[33742],{"nctId":33759,"briefTitle":33760,"status":123,"phases":33761,"primaryCompletion":33762,"completion":33762,"start":33763,"enrollment":709,"conditions":33764,"interventions":33765},"NCT02268552","An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)",[91,92],"2022-12-29","2015-04-02",[5472],[33766],"branaplam",{"trials":33768,"activeCount":103},[],{"trials":33770,"activeCount":103},[],{"trials":33772,"activeCount":103},[],{"intervention":33774,"totalTrials":213,"cells":33775},"LKA651",{"EARLY_PHASE1":33776,"PHASE1":33778,"PHASE2":33788,"PHASE3":33799,"PHASE4":33801,"NA":33803},{"trials":33777,"activeCount":103},[],{"trials":33779,"activeCount":103},[33780],{"nctId":33781,"briefTitle":33782,"status":123,"phases":33783,"primaryCompletion":6579,"completion":6579,"start":33784,"enrollment":2046,"conditions":33785,"interventions":33787},"NCT02867735","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema",[91],"2016-09-21",[25288,16741,18365,33786],"Retinal Vein Occlusions",[33774],{"trials":33789,"activeCount":103},[33790],{"nctId":33791,"briefTitle":33792,"status":123,"phases":33793,"primaryCompletion":33794,"completion":62,"start":33795,"enrollment":9106,"conditions":33796,"interventions":33797},"NCT03927690","Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema",[92],"2022-06-17","2019-05-24",[16741],[33774,33798],"Lucentis",{"trials":33800,"activeCount":103},[],{"trials":33802,"activeCount":103},[],{"trials":33804,"activeCount":103},[],{"intervention":33806,"totalTrials":213,"cells":33807},"TCH346",{"EARLY_PHASE1":33808,"PHASE1":33810,"PHASE2":33812,"PHASE3":33826,"PHASE4":33828,"NA":33830},{"trials":33809,"activeCount":103},[],{"trials":33811,"activeCount":103},[],{"trials":33813,"activeCount":103},[33814,33820],{"nctId":33815,"briefTitle":33816,"status":123,"phases":33817,"primaryCompletion":4741,"completion":4741,"start":15041,"enrollment":22973,"conditions":33818,"interventions":33819},"NCT00072709","Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)",[92],[33624],[33806],{"nctId":33821,"briefTitle":33822,"status":123,"phases":33823,"primaryCompletion":746,"completion":746,"start":16929,"enrollment":22,"conditions":33824,"interventions":33825},"NCT00036413","A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis",[92],[33624],[33806],{"trials":33827,"activeCount":103},[],{"trials":33829,"activeCount":103},[],{"trials":33831,"activeCount":103},[],{"intervention":33833,"totalTrials":213,"cells":33834},"AAE581",{"EARLY_PHASE1":33835,"PHASE1":33837,"PHASE2":33839,"PHASE3":33853,"PHASE4":33855,"NA":33857},{"trials":33836,"activeCount":103},[],{"trials":33838,"activeCount":103},[],{"trials":33840,"activeCount":103},[33841,33847],{"nctId":33842,"briefTitle":33843,"status":123,"phases":33844,"primaryCompletion":8370,"completion":8370,"start":9820,"enrollment":25782,"conditions":33845,"interventions":33846},"NCT00100607","Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis",[92],[953],[33833],{"nctId":33848,"briefTitle":33849,"status":123,"phases":33850,"primaryCompletion":835,"start":996,"enrollment":4532,"conditions":33851,"interventions":33852},"NCT00170911","Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia\u002FOsteoporosis.",[92],[953],[33833],{"trials":33854,"activeCount":103},[],{"trials":33856,"activeCount":103},[],{"trials":33858,"activeCount":103},[],{"intervention":33034,"totalTrials":213,"cells":33860},{"EARLY_PHASE1":33861,"PHASE1":33863,"PHASE2":33869,"PHASE3":33875,"PHASE4":33877,"NA":33879},{"trials":33862,"activeCount":103},[],{"trials":33864,"activeCount":103},[33865],{"nctId":33029,"briefTitle":33030,"status":123,"phases":33866,"primaryCompletion":3075,"completion":3075,"start":5688,"enrollment":26583,"conditions":33867,"interventions":33868},[91],[1102],[33034,23071,33035],{"trials":33870,"activeCount":103},[33871],{"nctId":33043,"briefTitle":33044,"status":123,"phases":33872,"primaryCompletion":33046,"completion":33047,"start":33048,"enrollment":2543,"conditions":33873,"interventions":33874},[92],[1102],[33034,23071],{"trials":33876,"activeCount":103},[],{"trials":33878,"activeCount":103},[],{"trials":33880,"activeCount":103},[],{"intervention":33882,"totalTrials":213,"cells":33883},"HSC835",{"EARLY_PHASE1":33884,"PHASE1":33886,"PHASE2":33888,"PHASE3":33918,"PHASE4":33920,"NA":33922},{"trials":33885,"activeCount":103},[],{"trials":33887,"activeCount":103},[],{"trials":33889,"activeCount":103},[33890,33908],{"nctId":33891,"briefTitle":33892,"status":123,"phases":33893,"primaryCompletion":2006,"completion":2006,"start":33894,"enrollment":34,"conditions":33895,"interventions":33907},"NCT01474681","Safety and Tolerability of HSC835 in Patients With Hematological Malignancies",[91,92],"2012-01-09",[33896,33897,3228,33898,11399,33899,33900,33901,33902,33903,33904,33905,33906],"Acute Myelocytic Leukemia","Acute Lymphocytic Leukemia","Myelodysplastic Syndrome","Marginal Zone Lymphoma","Follicular Lymphomas","Large-cell Lymphoma","Lymphoblastic Lymphoma","Burkitt's Lymphoma","High Grade Lymphomas","Mantle-cell Lymphoma","Lymphoplasmacytic Lymphoma",[33882],{"nctId":33909,"briefTitle":33910,"status":123,"phases":33911,"primaryCompletion":33912,"completion":33912,"start":33913,"enrollment":1495,"conditions":33914,"interventions":33917},"NCT01930162","Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant",[92],"2016-08-29","2014-10-07",[33915,33916,33897,33898,2877,5636,11399],"Single Umbilical Cord Blood Transplantation","Non-myeloablative Conditioning",[33882],{"trials":33919,"activeCount":103},[],{"trials":33921,"activeCount":103},[],{"trials":33923,"activeCount":103},[],{"intervention":33925,"totalTrials":213,"cells":33926},"TIN816 70 mg lyophilisate powder",{"EARLY_PHASE1":33927,"PHASE1":33929,"PHASE2":33931,"PHASE3":33949,"PHASE4":33951,"NA":33953},{"trials":33928,"activeCount":103},[],{"trials":33930,"activeCount":103},[],{"trials":33932,"activeCount":103},[33933,33941],{"nctId":33934,"briefTitle":33935,"status":123,"phases":33936,"primaryCompletion":7049,"completion":7049,"start":33937,"enrollment":1611,"conditions":33938,"interventions":33940},"NCT05507437","Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury",[92],"2022-11-22",[33939],"Acute Kidney Injury Due to Sepsis",[33925],{"nctId":33942,"briefTitle":33943,"status":123,"phases":33944,"primaryCompletion":29871,"completion":12003,"start":33945,"enrollment":33946,"conditions":33947,"interventions":33948},"NCT05996835","Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)",[92],"2024-01-18",316,[33939],[33925],{"trials":33950,"activeCount":103},[],{"trials":33952,"activeCount":103},[],{"trials":33954,"activeCount":103},[],{"intervention":15727,"totalTrials":213,"cells":33956},{"EARLY_PHASE1":33957,"PHASE1":33959,"PHASE2":33961,"PHASE3":33971,"PHASE4":33973,"NA":33975},{"trials":33958,"activeCount":103},[],{"trials":33960,"activeCount":103},[],{"trials":33962,"activeCount":103},[33963,33967],{"nctId":15720,"briefTitle":15721,"status":123,"phases":33964,"primaryCompletion":10499,"completion":10499,"start":3194,"enrollment":15723,"conditions":33965,"interventions":33966},[92],[21],[15726,5447,15727],{"nctId":15737,"briefTitle":15738,"status":123,"phases":33968,"primaryCompletion":4301,"completion":4301,"start":4598,"enrollment":15740,"conditions":33969,"interventions":33970},[92],[15742],[15726,5447,15727],{"trials":33972,"activeCount":103},[],{"trials":33974,"activeCount":103},[],{"trials":33976,"activeCount":103},[],{"intervention":25161,"totalTrials":213,"cells":33978},{"EARLY_PHASE1":33979,"PHASE1":33981,"PHASE2":33983,"PHASE3":33993,"PHASE4":33995,"NA":33997},{"trials":33980,"activeCount":103},[],{"trials":33982,"activeCount":103},[],{"trials":33984,"activeCount":103},[33985,33989],{"nctId":25154,"briefTitle":25155,"status":123,"phases":33986,"primaryCompletion":3845,"start":4845,"enrollment":3343,"conditions":33987,"interventions":33988},[92],[25158],[25145,25160,25161],{"nctId":25163,"briefTitle":25164,"status":134,"phases":33990,"primaryCompletion":3760,"completion":3760,"start":3271,"enrollment":2342,"conditions":33991,"interventions":33992},[92],[25167],[25161,25145],{"trials":33994,"activeCount":103},[],{"trials":33996,"activeCount":103},[],{"trials":33998,"activeCount":103},[],{"intervention":34000,"totalTrials":213,"cells":34001},"LJN452",{"EARLY_PHASE1":34002,"PHASE1":34004,"PHASE2":34012,"PHASE3":34023,"PHASE4":34025,"NA":34027},{"trials":34003,"activeCount":103},[],{"trials":34005,"activeCount":103},[34006],{"nctId":34007,"briefTitle":34008,"status":123,"phases":34009,"primaryCompletion":6568,"completion":6568,"start":16548,"enrollment":25,"conditions":34010,"interventions":34011},"NCT03681457","Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects",[91],[11368],[34000],{"trials":34013,"activeCount":103},[34014],{"nctId":34015,"briefTitle":34016,"status":123,"phases":34017,"primaryCompletion":34018,"completion":34018,"start":34019,"enrollment":1611,"conditions":34020,"interventions":34022},"NCT02713243","To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.",[92],"2018-01-25","2016-01-16",[34021],"Primary Bile Acid Diarrhea",[34000],{"trials":34024,"activeCount":103},[],{"trials":34026,"activeCount":103},[],{"trials":34028,"activeCount":103},[],{"intervention":34030,"totalTrials":213,"cells":34031},"CMK389",{"EARLY_PHASE1":34032,"PHASE1":34034,"PHASE2":34036,"PHASE3":34053,"PHASE4":34055,"NA":34057},{"trials":34033,"activeCount":103},[],{"trials":34035,"activeCount":103},[],{"trials":34037,"activeCount":103},[34038,34046],{"nctId":34039,"briefTitle":34040,"status":123,"phases":34041,"primaryCompletion":34042,"completion":34043,"start":32274,"enrollment":2149,"conditions":34044,"interventions":34045},"NCT04064242","Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis",[92],"2023-09-19","2023-12-12",[23382],[34030],{"nctId":34047,"briefTitle":34048,"status":123,"phases":34049,"primaryCompletion":8768,"completion":13933,"start":34050,"enrollment":1660,"conditions":34051,"interventions":34052},"NCT04836858","A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.",[92],"2021-04-20",[10365],[34030],{"trials":34054,"activeCount":103},[],{"trials":34056,"activeCount":103},[],{"trials":34058,"activeCount":103},[],{"intervention":13928,"totalTrials":213,"cells":34060},{"EARLY_PHASE1":34061,"PHASE1":34063,"PHASE2":34065,"PHASE3":34075,"PHASE4":34077,"NA":34079},{"trials":34062,"activeCount":103},[],{"trials":34064,"activeCount":103},[],{"trials":34066,"activeCount":103},[34067,34071],{"nctId":13922,"briefTitle":13923,"status":123,"phases":34068,"primaryCompletion":9330,"completion":13917,"start":13925,"enrollment":630,"conditions":34069,"interventions":34070},[92],[3180],[3036,13928],{"nctId":9665,"briefTitle":9666,"status":123,"phases":34072,"primaryCompletion":9668,"completion":6640,"start":9669,"enrollment":827,"conditions":34073,"interventions":34074},[92],[3180,9671],[3090,9673,3036,9674],{"trials":34076,"activeCount":103},[],{"trials":34078,"activeCount":103},[],{"trials":34080,"activeCount":103},[],{"intervention":34082,"totalTrials":213,"cells":34083},"LML134",{"EARLY_PHASE1":34084,"PHASE1":34086,"PHASE2":34094,"PHASE3":34105,"PHASE4":34107,"NA":34109},{"trials":34085,"activeCount":103},[],{"trials":34087,"activeCount":103},[34088],{"nctId":34089,"briefTitle":34090,"status":123,"phases":34091,"primaryCompletion":23514,"completion":23514,"start":2458,"enrollment":3871,"conditions":34092,"interventions":34093},"NCT02334449","First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers",[91],[9634],[34082],{"trials":34095,"activeCount":103},[34096],{"nctId":34097,"briefTitle":34098,"status":134,"phases":34099,"primaryCompletion":34100,"completion":11120,"start":34101,"enrollment":630,"conditions":34102,"interventions":34104},"NCT03141086","A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder",[92],"2018-08-30","2017-07-26",[34103],"Circadian Rhythm Disorders",[34082],{"trials":34106,"activeCount":103},[],{"trials":34108,"activeCount":103},[],{"trials":34110,"activeCount":103},[],{"intervention":34112,"totalTrials":213,"cells":34113},"CAD106",{"EARLY_PHASE1":34114,"PHASE1":34116,"PHASE2":34124,"PHASE3":34134,"PHASE4":34136,"NA":34138},{"trials":34115,"activeCount":103},[],{"trials":34117,"activeCount":103},[34118],{"nctId":34119,"briefTitle":34120,"status":123,"phases":34121,"primaryCompletion":3552,"completion":3552,"start":5063,"enrollment":3064,"conditions":34122,"interventions":34123},"NCT00411580","Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)",[91],[10401],[34112],{"trials":34125,"activeCount":103},[34126],{"nctId":34127,"briefTitle":34128,"status":123,"phases":34129,"primaryCompletion":3604,"completion":3604,"start":964,"enrollment":446,"conditions":34130,"interventions":34131},"NCT01097096","Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients",[92],[10401],[34112,34132,34133],"Alum","MF59",{"trials":34135,"activeCount":103},[],{"trials":34137,"activeCount":103},[],{"trials":34139,"activeCount":103},[],{"intervention":25937,"totalTrials":213,"cells":34141},{"EARLY_PHASE1":34142,"PHASE1":34144,"PHASE2":34146,"PHASE3":34160,"PHASE4":34162,"NA":34164},{"trials":34143,"activeCount":103},[],{"trials":34145,"activeCount":103},[],{"trials":34147,"activeCount":103},[34148,34152],{"nctId":25929,"briefTitle":25930,"status":123,"phases":34149,"primaryCompletion":25932,"completion":25932,"start":2565,"enrollment":25933,"conditions":34150,"interventions":34151},[92],[25935],[25937,25920],{"nctId":34153,"briefTitle":34154,"status":123,"phases":34155,"primaryCompletion":22169,"completion":22169,"start":7410,"enrollment":534,"conditions":34156,"interventions":34158},"NCT02482428","Efficacy and Tolerability of Topical LFX453 for External Genital Warts",[92],[34157],"External Genital Warts",[25937,34159],"Aldara",{"trials":34161,"activeCount":103},[],{"trials":34163,"activeCount":103},[],{"trials":34165,"activeCount":103},[],{"intervention":9927,"totalTrials":213,"cells":34167},{"EARLY_PHASE1":34168,"PHASE1":34170,"PHASE2":34176,"PHASE3":34182,"PHASE4":34184,"NA":34186},{"trials":34169,"activeCount":103},[],{"trials":34171,"activeCount":103},[34172],{"nctId":15378,"briefTitle":15379,"status":123,"phases":34173,"primaryCompletion":15381,"completion":5818,"start":15382,"enrollment":15383,"conditions":34174,"interventions":34175},[91],[209,15385,4403],[15387,9926,9927,9928,15388,4321,15389],{"trials":34177,"activeCount":103},[34178],{"nctId":9919,"briefTitle":9920,"status":134,"phases":34179,"primaryCompletion":9922,"completion":9922,"start":1277,"enrollment":1941,"conditions":34180,"interventions":34181},[92],[9924],[2411,9926,9927,9928,1079],{"trials":34183,"activeCount":103},[],{"trials":34185,"activeCount":103},[],{"trials":34187,"activeCount":103},[],{"intervention":9928,"totalTrials":213,"cells":34189},{"EARLY_PHASE1":34190,"PHASE1":34192,"PHASE2":34198,"PHASE3":34204,"PHASE4":34206,"NA":34208},{"trials":34191,"activeCount":103},[],{"trials":34193,"activeCount":103},[34194],{"nctId":15378,"briefTitle":15379,"status":123,"phases":34195,"primaryCompletion":15381,"completion":5818,"start":15382,"enrollment":15383,"conditions":34196,"interventions":34197},[91],[209,15385,4403],[15387,9926,9927,9928,15388,4321,15389],{"trials":34199,"activeCount":103},[34200],{"nctId":9919,"briefTitle":9920,"status":134,"phases":34201,"primaryCompletion":9922,"completion":9922,"start":1277,"enrollment":1941,"conditions":34202,"interventions":34203},[92],[9924],[2411,9926,9927,9928,1079],{"trials":34205,"activeCount":103},[],{"trials":34207,"activeCount":103},[],{"trials":34209,"activeCount":103},[],{"intervention":34211,"totalTrials":213,"cells":34212},"EMA401",{"EARLY_PHASE1":34213,"PHASE1":34215,"PHASE2":34217,"PHASE3":34235,"PHASE4":34237,"NA":34239},{"trials":34214,"activeCount":103},[],{"trials":34216,"activeCount":103},[],{"trials":34218,"activeCount":103},[34219,34227],{"nctId":34220,"briefTitle":34221,"status":134,"phases":34222,"primaryCompletion":34223,"completion":34223,"start":189,"enrollment":3713,"conditions":34224,"interventions":34226},"NCT03297294","Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)",[92],"2019-03-25",[34225],"Painful Diabetic Neuropathy",[34211],{"nctId":34228,"briefTitle":34229,"status":134,"phases":34230,"primaryCompletion":34231,"completion":34231,"start":6546,"enrollment":3975,"conditions":34232,"interventions":34234},"NCT03094195","Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)",[92],"2019-03-07",[34233],"Post-herpetic Neuralgia",[34211],{"trials":34236,"activeCount":103},[],{"trials":34238,"activeCount":103},[],{"trials":34240,"activeCount":103},[],{"intervention":7415,"totalTrials":213,"cells":34242},{"EARLY_PHASE1":34243,"PHASE1":34245,"PHASE2":34247,"PHASE3":34257,"PHASE4":34259,"NA":34261},{"trials":34244,"activeCount":103},[],{"trials":34246,"activeCount":103},[],{"trials":34248,"activeCount":103},[34249,34253],{"nctId":7405,"briefTitle":7406,"status":123,"phases":34250,"primaryCompletion":7408,"completion":7409,"start":7410,"enrollment":5594,"conditions":34251,"interventions":34252},[92],[7412],[5895,7414,7415],{"nctId":7474,"briefTitle":7475,"status":123,"phases":34254,"primaryCompletion":7477,"completion":7478,"start":7479,"enrollment":2428,"conditions":34255,"interventions":34256},[92],[7412],[5895,7482,7415],{"trials":34258,"activeCount":103},[],{"trials":34260,"activeCount":103},[],{"trials":34262,"activeCount":103},[],{"intervention":34264,"totalTrials":213,"cells":34265},"LRX712",{"EARLY_PHASE1":34266,"PHASE1":34268,"PHASE2":34278,"PHASE3":34289,"PHASE4":34291,"NA":34293},{"trials":34267,"activeCount":103},[],{"trials":34269,"activeCount":103},[34270],{"nctId":34271,"briefTitle":34272,"status":123,"phases":34273,"primaryCompletion":28037,"completion":28037,"start":34274,"enrollment":25,"conditions":34275,"interventions":34277},"NCT03355196","First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients",[91],"2017-11-20",[34276],"Patients With Moderate Knee Osteoarthritis (30 - 65 Years)",[34264],{"trials":34279,"activeCount":103},[34280],{"nctId":34281,"briefTitle":34282,"status":123,"phases":34283,"primaryCompletion":34284,"completion":34285,"start":7093,"enrollment":2405,"conditions":34286,"interventions":34288},"NCT04097379","Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA",[92],"2024-08-08","2025-01-17",[34287],"Osteoarthritis (OA)",[34264],{"trials":34290,"activeCount":103},[],{"trials":34292,"activeCount":103},[],{"trials":34294,"activeCount":103},[],{"intervention":34296,"totalTrials":213,"cells":34297},"LCI699",{"EARLY_PHASE1":34298,"PHASE1":34300,"PHASE2":34302,"PHASE3":34320,"PHASE4":34322,"NA":34324},{"trials":34299,"activeCount":103},[],{"trials":34301,"activeCount":103},[],{"trials":34303,"activeCount":103},[34304,34312],{"nctId":34305,"briefTitle":34306,"status":123,"phases":34307,"primaryCompletion":34308,"completion":34308,"start":34309,"enrollment":827,"conditions":34310,"interventions":34311},"NCT01331239","Safety and Efficacy of LCI699 in Cushing's Disease Patients",[92],"2019-10-22","2011-03-23",[24215,23601],[34296],{"nctId":34313,"briefTitle":34314,"status":123,"phases":34315,"primaryCompletion":34316,"completion":34316,"start":34317,"enrollment":9097,"conditions":34318,"interventions":34319},"NCT00758524","A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension",[92],"2009-07-02","2008-09-11",[17007],[34296,33599],{"trials":34321,"activeCount":103},[],{"trials":34323,"activeCount":103},[],{"trials":34325,"activeCount":103},[],{"intervention":19484,"totalTrials":213,"cells":34327},{"EARLY_PHASE1":34328,"PHASE1":34330,"PHASE2":34336,"PHASE3":34342,"PHASE4":34344,"NA":34346},{"trials":34329,"activeCount":103},[],{"trials":34331,"activeCount":103},[34332],{"nctId":31841,"briefTitle":31842,"status":123,"phases":34333,"primaryCompletion":4620,"start":5620,"enrollment":2579,"conditions":34334,"interventions":34335},[91],[18],[19484,31846,31834,31847],{"trials":34337,"activeCount":103},[34338],{"nctId":19478,"briefTitle":19479,"status":123,"phases":34339,"primaryCompletion":3760,"start":1024,"enrollment":906,"conditions":34340,"interventions":34341},[92],[19482],[19484,7849],{"trials":34343,"activeCount":103},[],{"trials":34345,"activeCount":103},[],{"trials":34347,"activeCount":103},[],{"intervention":34349,"totalTrials":213,"cells":34350},"ZPL389 30mg",{"EARLY_PHASE1":34351,"PHASE1":34353,"PHASE2":34355,"PHASE3":34376,"PHASE4":34378,"NA":34380},{"trials":34352,"activeCount":103},[],{"trials":34354,"activeCount":103},[],{"trials":34356,"activeCount":103},[34357,34368],{"nctId":34358,"briefTitle":34359,"status":134,"phases":34360,"primaryCompletion":18196,"completion":34361,"start":34362,"enrollment":15225,"conditions":34363,"interventions":34364},"NCT03517566","A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis",[92],"2020-08-06","2018-11-14",[10365],[34365,34366,34349,34367],"ZPL389 3mg","ZPL389 10mg","ZPL389 50mg",{"nctId":34369,"briefTitle":34370,"status":134,"phases":34371,"primaryCompletion":34372,"completion":14020,"start":15304,"enrollment":9331,"conditions":34373,"interventions":34374},"NCT03948334","A Study to Assess the Safety and Efficacy of ZPL389 With TCS\u002FTCI in Atopic Dermatitis Patients",[92],"2020-07-23",[10365],[34349,34367,34375],"TCS and\u002For TCI",{"trials":34377,"activeCount":103},[],{"trials":34379,"activeCount":103},[],{"trials":34381,"activeCount":103},[],{"intervention":34367,"totalTrials":213,"cells":34383},{"EARLY_PHASE1":34384,"PHASE1":34386,"PHASE2":34388,"PHASE3":34398,"PHASE4":34400,"NA":34402},{"trials":34385,"activeCount":103},[],{"trials":34387,"activeCount":103},[],{"trials":34389,"activeCount":103},[34390,34394],{"nctId":34358,"briefTitle":34359,"status":134,"phases":34391,"primaryCompletion":18196,"completion":34361,"start":34362,"enrollment":15225,"conditions":34392,"interventions":34393},[92],[10365],[34365,34366,34349,34367],{"nctId":34369,"briefTitle":34370,"status":134,"phases":34395,"primaryCompletion":34372,"completion":14020,"start":15304,"enrollment":9331,"conditions":34396,"interventions":34397},[92],[10365],[34349,34367,34375],{"trials":34399,"activeCount":103},[],{"trials":34401,"activeCount":103},[],{"trials":34403,"activeCount":103},[],{"intervention":33599,"totalTrials":213,"cells":34405},{"EARLY_PHASE1":34406,"PHASE1":34408,"PHASE2":34410,"PHASE3":34420,"PHASE4":34422,"NA":34424},{"trials":34407,"activeCount":103},[],{"trials":34409,"activeCount":103},[],{"trials":34411,"activeCount":103},[34412,34416],{"nctId":34313,"briefTitle":34314,"status":123,"phases":34413,"primaryCompletion":34316,"completion":34316,"start":34317,"enrollment":9097,"conditions":34414,"interventions":34415},[92],[17007],[34296,33599],{"nctId":33594,"briefTitle":33595,"status":134,"phases":34417,"primaryCompletion":1715,"completion":1715,"start":3784,"enrollment":1065,"conditions":34418,"interventions":34419},[92],[21],[33577,33599],{"trials":34421,"activeCount":103},[],{"trials":34423,"activeCount":103},[],{"trials":34425,"activeCount":103},[],{"intervention":33274,"totalTrials":213,"cells":34427},{"EARLY_PHASE1":34428,"PHASE1":34430,"PHASE2":34432,"PHASE3":34442,"PHASE4":34444,"NA":34446},{"trials":34429,"activeCount":103},[],{"trials":34431,"activeCount":103},[],{"trials":34433,"activeCount":103},[34434,34438],{"nctId":33268,"briefTitle":33269,"status":123,"phases":34435,"primaryCompletion":3351,"start":3473,"enrollment":33271,"conditions":34436,"interventions":34437},[92],[14561],[33253,33274,33274,33274],{"nctId":33276,"briefTitle":33277,"status":123,"phases":34439,"primaryCompletion":3845,"start":10499,"enrollment":19224,"conditions":34440,"interventions":34441},[92],[33280],[33253,33274,33253,33274],{"trials":34443,"activeCount":103},[],{"trials":34445,"activeCount":103},[],{"trials":34447,"activeCount":103},[],{"intervention":34449,"totalTrials":213,"cells":34450},"MIJ821",{"EARLY_PHASE1":34451,"PHASE1":34453,"PHASE2":34461,"PHASE3":34471,"PHASE4":34473,"NA":34475},{"trials":34452,"activeCount":103},[],{"trials":34454,"activeCount":103},[34455],{"nctId":34456,"briefTitle":34457,"status":123,"phases":34458,"primaryCompletion":11823,"completion":11823,"start":371,"enrollment":5594,"conditions":34459,"interventions":34460},"NCT05666687","An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain",[91],[25466],[34449],{"trials":34462,"activeCount":103},[34463],{"nctId":34464,"briefTitle":34465,"status":123,"phases":34466,"primaryCompletion":17121,"completion":17121,"start":17324,"enrollment":512,"conditions":34467,"interventions":34469},"NCT03756129","Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression",[92],[34468],"Depressive Disorder, Treatment-Resistant",[34449,34470],"Ketamine",{"trials":34472,"activeCount":103},[],{"trials":34474,"activeCount":103},[],{"trials":34476,"activeCount":103},[],{"intervention":34478,"totalTrials":213,"cells":34479},"PHE885",{"EARLY_PHASE1":34480,"PHASE1":34482,"PHASE2":34490,"PHASE3":34500,"PHASE4":34502,"NA":34504},{"trials":34481,"activeCount":103},[],{"trials":34483,"activeCount":103},[34484],{"nctId":34485,"briefTitle":34486,"status":134,"phases":34487,"primaryCompletion":19098,"completion":19098,"start":34372,"enrollment":1750,"conditions":34488,"interventions":34489},"NCT04318327","BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma",[91],[5636],[34478],{"trials":34491,"activeCount":103},[34492],{"nctId":34493,"briefTitle":34494,"status":134,"phases":34495,"primaryCompletion":34496,"completion":34496,"start":34497,"enrollment":6061,"conditions":34498,"interventions":34499},"NCT05172596","PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma",[92],"2025-05-21","2022-03-03",[5636],[34478],{"trials":34501,"activeCount":103},[],{"trials":34503,"activeCount":103},[],{"trials":34505,"activeCount":103},[],{"intervention":34507,"totalTrials":213,"cells":34508},"MAA868",{"EARLY_PHASE1":34509,"PHASE1":34511,"PHASE2":34513,"PHASE3":34535,"PHASE4":34537,"NA":34539},{"trials":34510,"activeCount":103},[],{"trials":34512,"activeCount":103},[],{"trials":34514,"activeCount":103},[34515,34525],{"nctId":34516,"briefTitle":34517,"status":390,"phases":34518,"primaryCompletion":34519,"completion":34520,"start":34521,"enrollment":103,"conditions":34522,"interventions":34523},"NCT03398434","Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation",[92],"2019-11-28","2020-01-30","2018-10-16",[12396],[34507,34524],"Apixaban",{"nctId":34526,"briefTitle":34527,"status":390,"phases":34528,"primaryCompletion":34529,"completion":34530,"start":32699,"enrollment":103,"conditions":34531,"interventions":34533},"NCT03393481","Prevention of Thromboembolic Events in Total Knee Replacement Patients",[92],"2020-01-08","2020-04-17",[34532],"Thrombotic Disorders",[34507,34534],"Enoxaparin",{"trials":34536,"activeCount":103},[],{"trials":34538,"activeCount":103},[],{"trials":34540,"activeCount":103},[],{"intervention":23509,"totalTrials":213,"cells":34542},{"EARLY_PHASE1":34543,"PHASE1":34545,"PHASE2":34547,"PHASE3":34557,"PHASE4":34559,"NA":34561},{"trials":34544,"activeCount":103},[],{"trials":34546,"activeCount":103},[],{"trials":34548,"activeCount":103},[34549,34553],{"nctId":23503,"briefTitle":23504,"status":123,"phases":34550,"primaryCompletion":4669,"completion":4669,"start":1724,"enrollment":23506,"conditions":34551,"interventions":34552},[92],[18],[23460,23509],{"nctId":23526,"briefTitle":23527,"status":123,"phases":34554,"primaryCompletion":813,"completion":813,"start":1761,"enrollment":3120,"conditions":34555,"interventions":34556},[92],[19482],[23460,23509],{"trials":34558,"activeCount":103},[],{"trials":34560,"activeCount":103},[],{"trials":34562,"activeCount":103},[],{"intervention":4392,"totalTrials":213,"cells":34564},{"EARLY_PHASE1":34565,"PHASE1":34567,"PHASE2":34573,"PHASE3":34581,"PHASE4":34583,"NA":34585},{"trials":34566,"activeCount":103},[],{"trials":34568,"activeCount":103},[34569],{"nctId":4381,"briefTitle":4382,"status":123,"phases":34570,"primaryCompletion":4384,"completion":4384,"start":4385,"enrollment":3741,"conditions":34571,"interventions":34572},[91],[4387],[4389,4390,196,4391,4392,4393],{"trials":34574,"activeCount":103},[34575],{"nctId":34576,"briefTitle":34577,"status":134,"phases":34578,"primaryCompletion":1760,"completion":1760,"start":4669,"enrollment":114,"conditions":34579,"interventions":34580},"NCT01972776","A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.",[92],[8267],[4392],{"trials":34582,"activeCount":103},[],{"trials":34584,"activeCount":103},[],{"trials":34586,"activeCount":103},[],{"intervention":8173,"totalTrials":437,"cells":34588},{"EARLY_PHASE1":34589,"PHASE1":34591,"PHASE2":34593,"PHASE3":34599,"PHASE4":34601,"NA":34603},{"trials":34590,"activeCount":103},[],{"trials":34592,"activeCount":103},[],{"trials":34594,"activeCount":103},[34595],{"nctId":8165,"briefTitle":8166,"status":123,"phases":34596,"primaryCompletion":6023,"completion":8168,"start":2426,"enrollment":31,"conditions":34597,"interventions":34598},[92],[8170],[8139,8172,8173],{"trials":34600,"activeCount":103},[],{"trials":34602,"activeCount":103},[],{"trials":34604,"activeCount":103},[],{"intervention":6520,"totalTrials":437,"cells":34606},{"EARLY_PHASE1":34607,"PHASE1":34609,"PHASE2":34611,"PHASE3":34617,"PHASE4":34619,"NA":34621},{"trials":34608,"activeCount":103},[],{"trials":34610,"activeCount":103},[],{"trials":34612,"activeCount":103},[34613],{"nctId":6510,"briefTitle":6511,"status":123,"phases":34614,"primaryCompletion":5830,"completion":6513,"start":5791,"enrollment":6514,"conditions":34615,"interventions":34616},[92],[6516],[3112,6518,6519,6520],{"trials":34618,"activeCount":103},[],{"trials":34620,"activeCount":103},[],{"trials":34622,"activeCount":103},[],{"intervention":1104,"totalTrials":437,"cells":34624},{"EARLY_PHASE1":34625,"PHASE1":34627,"PHASE2":34629,"PHASE3":34635,"PHASE4":34637,"NA":34639},{"trials":34626,"activeCount":103},[],{"trials":34628,"activeCount":103},[],{"trials":34630,"activeCount":103},[34631],{"nctId":1095,"briefTitle":1096,"status":123,"phases":34632,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":34633,"interventions":34634},[91,92],[1102],[1078,173,1104],{"trials":34636,"activeCount":103},[],{"trials":34638,"activeCount":103},[],{"trials":34640,"activeCount":103},[],{"intervention":34642,"totalTrials":437,"cells":34643},"Eltrombopag 12.5 mg",{"EARLY_PHASE1":34644,"PHASE1":34646,"PHASE2":34648,"PHASE3":34660,"PHASE4":34662,"NA":34664},{"trials":34645,"activeCount":103},[],{"trials":34647,"activeCount":103},[],{"trials":34649,"activeCount":103},[34650],{"nctId":34651,"briefTitle":34652,"status":123,"phases":34653,"primaryCompletion":34654,"completion":34655,"start":11035,"enrollment":4118,"conditions":34656,"interventions":34658},"NCT02148133","A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia",[92],"2015-09-10","2017-09-05",[34657],"Cytopaenia",[34642,34659],"Eltrombopag 25 mg",{"trials":34661,"activeCount":103},[],{"trials":34663,"activeCount":103},[],{"trials":34665,"activeCount":103},[],{"intervention":34659,"totalTrials":437,"cells":34667},{"EARLY_PHASE1":34668,"PHASE1":34670,"PHASE2":34672,"PHASE3":34678,"PHASE4":34680,"NA":34682},{"trials":34669,"activeCount":103},[],{"trials":34671,"activeCount":103},[],{"trials":34673,"activeCount":103},[34674],{"nctId":34651,"briefTitle":34652,"status":123,"phases":34675,"primaryCompletion":34654,"completion":34655,"start":11035,"enrollment":4118,"conditions":34676,"interventions":34677},[92],[34657],[34642,34659],{"trials":34679,"activeCount":103},[],{"trials":34681,"activeCount":103},[],{"trials":34683,"activeCount":103},[],{"intervention":34685,"totalTrials":437,"cells":34686},"Secukinumab 10 mg\u002Fkg",{"EARLY_PHASE1":34687,"PHASE1":34689,"PHASE2":34691,"PHASE3":34700,"PHASE4":34702,"NA":34704},{"trials":34688,"activeCount":103},[],{"trials":34690,"activeCount":103},[],{"trials":34692,"activeCount":103},[34693],{"nctId":34694,"briefTitle":34695,"status":123,"phases":34696,"primaryCompletion":1818,"completion":1818,"start":926,"enrollment":774,"conditions":34697,"interventions":34698},"NCT01250171","The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients",[92],[20632],[34685,34699],"Canakinumab 10 mg\u002Fkg",{"trials":34701,"activeCount":103},[],{"trials":34703,"activeCount":103},[],{"trials":34705,"activeCount":103},[],{"intervention":34699,"totalTrials":437,"cells":34707},{"EARLY_PHASE1":34708,"PHASE1":34710,"PHASE2":34712,"PHASE3":34718,"PHASE4":34720,"NA":34722},{"trials":34709,"activeCount":103},[],{"trials":34711,"activeCount":103},[],{"trials":34713,"activeCount":103},[34714],{"nctId":34694,"briefTitle":34695,"status":123,"phases":34715,"primaryCompletion":1818,"completion":1818,"start":926,"enrollment":774,"conditions":34716,"interventions":34717},[92],[20632],[34685,34699],{"trials":34719,"activeCount":103},[],{"trials":34721,"activeCount":103},[],{"trials":34723,"activeCount":103},[],{"intervention":34725,"totalTrials":437,"cells":34726},"SOM230 s.c.",{"EARLY_PHASE1":34727,"PHASE1":34729,"PHASE2":34731,"PHASE3":34739,"PHASE4":34741,"NA":34743},{"trials":34728,"activeCount":103},[],{"trials":34730,"activeCount":103},[],{"trials":34732,"activeCount":103},[34733],{"nctId":34734,"briefTitle":34735,"status":123,"phases":34736,"primaryCompletion":745,"start":9096,"enrollment":37,"conditions":34737,"interventions":34738},"NCT00088608","A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease",[92],[24190],[34725],{"trials":34740,"activeCount":103},[],{"trials":34742,"activeCount":103},[],{"trials":34744,"activeCount":103},[],{"intervention":34746,"totalTrials":437,"cells":34747},"UNR844-Cl",{"EARLY_PHASE1":34748,"PHASE1":34750,"PHASE2":34752,"PHASE3":34761,"PHASE4":34763,"NA":34765},{"trials":34749,"activeCount":103},[],{"trials":34751,"activeCount":103},[],{"trials":34753,"activeCount":103},[34754],{"nctId":34755,"briefTitle":34756,"status":123,"phases":34757,"primaryCompletion":23319,"completion":23319,"start":5192,"enrollment":3491,"conditions":34758,"interventions":34760},"NCT03809611","A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.",[92],[34759],"Presbyopia",[34746],{"trials":34762,"activeCount":103},[],{"trials":34764,"activeCount":103},[],{"trials":34766,"activeCount":103},[],{"intervention":24672,"totalTrials":437,"cells":34768},{"EARLY_PHASE1":34769,"PHASE1":34771,"PHASE2":34773,"PHASE3":34779,"PHASE4":34781,"NA":34783},{"trials":34770,"activeCount":103},[],{"trials":34772,"activeCount":103},[],{"trials":34774,"activeCount":103},[34775],{"nctId":24666,"briefTitle":24667,"status":123,"phases":34776,"primaryCompletion":4967,"completion":4967,"start":4642,"enrollment":24669,"conditions":34777,"interventions":34778},[92],[18734,20547],[24672,24673,24674,24675,24676,24657],{"trials":34780,"activeCount":103},[],{"trials":34782,"activeCount":103},[],{"trials":34784,"activeCount":103},[],{"intervention":24673,"totalTrials":437,"cells":34786},{"EARLY_PHASE1":34787,"PHASE1":34789,"PHASE2":34791,"PHASE3":34797,"PHASE4":34799,"NA":34801},{"trials":34788,"activeCount":103},[],{"trials":34790,"activeCount":103},[],{"trials":34792,"activeCount":103},[34793],{"nctId":24666,"briefTitle":24667,"status":123,"phases":34794,"primaryCompletion":4967,"completion":4967,"start":4642,"enrollment":24669,"conditions":34795,"interventions":34796},[92],[18734,20547],[24672,24673,24674,24675,24676,24657],{"trials":34798,"activeCount":103},[],{"trials":34800,"activeCount":103},[],{"trials":34802,"activeCount":103},[],{"intervention":24674,"totalTrials":437,"cells":34804},{"EARLY_PHASE1":34805,"PHASE1":34807,"PHASE2":34809,"PHASE3":34815,"PHASE4":34817,"NA":34819},{"trials":34806,"activeCount":103},[],{"trials":34808,"activeCount":103},[],{"trials":34810,"activeCount":103},[34811],{"nctId":24666,"briefTitle":24667,"status":123,"phases":34812,"primaryCompletion":4967,"completion":4967,"start":4642,"enrollment":24669,"conditions":34813,"interventions":34814},[92],[18734,20547],[24672,24673,24674,24675,24676,24657],{"trials":34816,"activeCount":103},[],{"trials":34818,"activeCount":103},[],{"trials":34820,"activeCount":103},[],{"intervention":24675,"totalTrials":437,"cells":34822},{"EARLY_PHASE1":34823,"PHASE1":34825,"PHASE2":34827,"PHASE3":34833,"PHASE4":34835,"NA":34837},{"trials":34824,"activeCount":103},[],{"trials":34826,"activeCount":103},[],{"trials":34828,"activeCount":103},[34829],{"nctId":24666,"briefTitle":24667,"status":123,"phases":34830,"primaryCompletion":4967,"completion":4967,"start":4642,"enrollment":24669,"conditions":34831,"interventions":34832},[92],[18734,20547],[24672,24673,24674,24675,24676,24657],{"trials":34834,"activeCount":103},[],{"trials":34836,"activeCount":103},[],{"trials":34838,"activeCount":103},[],{"intervention":34840,"totalTrials":437,"cells":34841},"cyclosporine (reduced exposure) \u002F everolimus",{"EARLY_PHASE1":34842,"PHASE1":34844,"PHASE2":34846,"PHASE3":34856,"PHASE4":34858,"NA":34860},{"trials":34843,"activeCount":103},[],{"trials":34845,"activeCount":103},[],{"trials":34847,"activeCount":103},[34848],{"nctId":34849,"briefTitle":34850,"status":123,"phases":34851,"primaryCompletion":3759,"completion":3759,"start":3279,"enrollment":8659,"conditions":34852,"interventions":34853},"NCT00820911","Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients",[92],[4691],[34840,34854,34855],"AEB071 300 mg b.i.d. \u002F everolimus","AEB071 200 mg b.i.d. \u002F everolimus",{"trials":34857,"activeCount":103},[],{"trials":34859,"activeCount":103},[],{"trials":34861,"activeCount":103},[],{"intervention":34854,"totalTrials":437,"cells":34863},{"EARLY_PHASE1":34864,"PHASE1":34866,"PHASE2":34868,"PHASE3":34874,"PHASE4":34876,"NA":34878},{"trials":34865,"activeCount":103},[],{"trials":34867,"activeCount":103},[],{"trials":34869,"activeCount":103},[34870],{"nctId":34849,"briefTitle":34850,"status":123,"phases":34871,"primaryCompletion":3759,"completion":3759,"start":3279,"enrollment":8659,"conditions":34872,"interventions":34873},[92],[4691],[34840,34854,34855],{"trials":34875,"activeCount":103},[],{"trials":34877,"activeCount":103},[],{"trials":34879,"activeCount":103},[],{"intervention":34855,"totalTrials":437,"cells":34881},{"EARLY_PHASE1":34882,"PHASE1":34884,"PHASE2":34886,"PHASE3":34892,"PHASE4":34894,"NA":34896},{"trials":34883,"activeCount":103},[],{"trials":34885,"activeCount":103},[],{"trials":34887,"activeCount":103},[34888],{"nctId":34849,"briefTitle":34850,"status":123,"phases":34889,"primaryCompletion":3759,"completion":3759,"start":3279,"enrollment":8659,"conditions":34890,"interventions":34891},[92],[4691],[34840,34854,34855],{"trials":34893,"activeCount":103},[],{"trials":34895,"activeCount":103},[],{"trials":34897,"activeCount":103},[],{"intervention":34899,"totalTrials":437,"cells":34900},"CLR325",{"EARLY_PHASE1":34901,"PHASE1":34903,"PHASE2":34905,"PHASE3":34916,"PHASE4":34918,"NA":34920},{"trials":34902,"activeCount":103},[],{"trials":34904,"activeCount":103},[],{"trials":34906,"activeCount":103},[34907],{"nctId":34908,"briefTitle":34909,"status":123,"phases":34910,"primaryCompletion":34911,"completion":34911,"start":34912,"enrollment":37,"conditions":34913,"interventions":34915},"NCT02696967","A Study of CLR325 in Chronic Stable Heart Failure Patients.",[92],"2019-01-14","2016-05-17",[34914],"Chronic Stable Heart Failure",[34899],{"trials":34917,"activeCount":103},[],{"trials":34919,"activeCount":103},[],{"trials":34921,"activeCount":103},[],{"intervention":34923,"totalTrials":437,"cells":34924},"RAD001, Letrozole 2.5mg",{"EARLY_PHASE1":34925,"PHASE1":34927,"PHASE2":34929,"PHASE3":34939,"PHASE4":34941,"NA":34943},{"trials":34926,"activeCount":103},[],{"trials":34928,"activeCount":103},[],{"trials":34930,"activeCount":103},[34931],{"nctId":34932,"briefTitle":34933,"status":123,"phases":34934,"primaryCompletion":4343,"completion":4343,"start":996,"enrollment":3498,"conditions":34935,"interventions":34937},"NCT00107016","Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women",[92],[34936],"Breast Neoplasm",[34923,34938],"Letrozole 2.5mg",{"trials":34940,"activeCount":103},[],{"trials":34942,"activeCount":103},[],{"trials":34944,"activeCount":103},[],{"intervention":34938,"totalTrials":437,"cells":34946},{"EARLY_PHASE1":34947,"PHASE1":34949,"PHASE2":34951,"PHASE3":34957,"PHASE4":34959,"NA":34961},{"trials":34948,"activeCount":103},[],{"trials":34950,"activeCount":103},[],{"trials":34952,"activeCount":103},[34953],{"nctId":34932,"briefTitle":34933,"status":123,"phases":34954,"primaryCompletion":4343,"completion":4343,"start":996,"enrollment":3498,"conditions":34955,"interventions":34956},[92],[34936],[34923,34938],{"trials":34958,"activeCount":103},[],{"trials":34960,"activeCount":103},[],{"trials":34962,"activeCount":103},[],{"intervention":3047,"totalTrials":437,"cells":34964},{"EARLY_PHASE1":34965,"PHASE1":34967,"PHASE2":34969,"PHASE3":34975,"PHASE4":34977,"NA":34979},{"trials":34966,"activeCount":103},[],{"trials":34968,"activeCount":103},[],{"trials":34970,"activeCount":103},[34971],{"nctId":3038,"briefTitle":3039,"status":123,"phases":34972,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":3043,"conditions":34973,"interventions":34974},[92],[3045],[3047,3017],{"trials":34976,"activeCount":103},[],{"trials":34978,"activeCount":103},[],{"trials":34980,"activeCount":103},[],{"intervention":7906,"totalTrials":437,"cells":34982},{"EARLY_PHASE1":34983,"PHASE1":34985,"PHASE2":34987,"PHASE3":34993,"PHASE4":34995,"NA":34997},{"trials":34984,"activeCount":103},[],{"trials":34986,"activeCount":103},[],{"trials":34988,"activeCount":103},[34989],{"nctId":7899,"briefTitle":7900,"status":134,"phases":34990,"primaryCompletion":7902,"completion":7902,"start":7903,"enrollment":25,"conditions":34991,"interventions":34992},[92],[7868],[944,4320,7906],{"trials":34994,"activeCount":103},[],{"trials":34996,"activeCount":103},[],{"trials":34998,"activeCount":103},[],{"intervention":35000,"totalTrials":437,"cells":35001},"Deferasirox and Deferoxamine",{"EARLY_PHASE1":35002,"PHASE1":35004,"PHASE2":35006,"PHASE3":35014,"PHASE4":35016,"NA":35018},{"trials":35003,"activeCount":103},[],{"trials":35005,"activeCount":103},[],{"trials":35007,"activeCount":103},[35008],{"nctId":35009,"briefTitle":35010,"status":123,"phases":35011,"primaryCompletion":4669,"completion":4669,"start":4598,"enrollment":1423,"conditions":35012,"interventions":35013},"NCT01254227","Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload",[92],[24683],[35000],{"trials":35015,"activeCount":103},[],{"trials":35017,"activeCount":103},[],{"trials":35019,"activeCount":103},[],{"intervention":10622,"totalTrials":437,"cells":35021},{"EARLY_PHASE1":35022,"PHASE1":35024,"PHASE2":35026,"PHASE3":35032,"PHASE4":35034,"NA":35036},{"trials":35023,"activeCount":103},[],{"trials":35025,"activeCount":103},[],{"trials":35027,"activeCount":103},[35028],{"nctId":10615,"briefTitle":10616,"status":134,"phases":35029,"primaryCompletion":10618,"completion":10619,"start":1120,"enrollment":827,"conditions":35030,"interventions":35031},[92],[227],[212,8070,10622],{"trials":35033,"activeCount":103},[],{"trials":35035,"activeCount":103},[],{"trials":35037,"activeCount":103},[],{"intervention":35039,"totalTrials":437,"cells":35040},"Deferasirox dispersible",{"EARLY_PHASE1":35041,"PHASE1":35043,"PHASE2":35045,"PHASE3":35057,"PHASE4":35059,"NA":35061},{"trials":35042,"activeCount":103},[],{"trials":35044,"activeCount":103},[],{"trials":35046,"activeCount":103},[35047],{"nctId":35048,"briefTitle":35049,"status":123,"phases":35050,"primaryCompletion":35051,"completion":35051,"start":35052,"enrollment":16240,"conditions":35053,"interventions":35055},"NCT02125877","Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)",[92],"2016-02-24","2014-07-08",[35054],"Chronic Iron Overload Due to Transfusion-dependant Anemias",[35039,35056],"Defearisox film-coated",{"trials":35058,"activeCount":103},[],{"trials":35060,"activeCount":103},[],{"trials":35062,"activeCount":103},[],{"intervention":35056,"totalTrials":437,"cells":35064},{"EARLY_PHASE1":35065,"PHASE1":35067,"PHASE2":35069,"PHASE3":35075,"PHASE4":35077,"NA":35079},{"trials":35066,"activeCount":103},[],{"trials":35068,"activeCount":103},[],{"trials":35070,"activeCount":103},[35071],{"nctId":35048,"briefTitle":35049,"status":123,"phases":35072,"primaryCompletion":35051,"completion":35051,"start":35052,"enrollment":16240,"conditions":35073,"interventions":35074},[92],[35054],[35039,35056],{"trials":35076,"activeCount":103},[],{"trials":35078,"activeCount":103},[],{"trials":35080,"activeCount":103},[],{"intervention":4425,"totalTrials":437,"cells":35082},{"EARLY_PHASE1":35083,"PHASE1":35085,"PHASE2":35087,"PHASE3":35093,"PHASE4":35095,"NA":35097},{"trials":35084,"activeCount":103},[],{"trials":35086,"activeCount":103},[],{"trials":35088,"activeCount":103},[35089],{"nctId":4416,"briefTitle":4417,"status":123,"phases":35090,"primaryCompletion":4419,"completion":4419,"start":4420,"enrollment":3288,"conditions":35091,"interventions":35092},[92],[4422],[4424,196,4425],{"trials":35094,"activeCount":103},[],{"trials":35096,"activeCount":103},[],{"trials":35098,"activeCount":103},[],{"intervention":35100,"totalTrials":437,"cells":35101},"Indacaterol maleate",{"EARLY_PHASE1":35102,"PHASE1":35104,"PHASE2":35106,"PHASE3":35115,"PHASE4":35117,"NA":35119},{"trials":35103,"activeCount":103},[],{"trials":35105,"activeCount":103},[],{"trials":35107,"activeCount":103},[35108],{"nctId":35109,"briefTitle":35110,"status":123,"phases":35111,"primaryCompletion":7721,"completion":27410,"start":34655,"enrollment":271,"conditions":35112,"interventions":35113},"NCT03257995","Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.",[92],[18],[35100,35114],"Indacaterol acetate",{"trials":35116,"activeCount":103},[],{"trials":35118,"activeCount":103},[],{"trials":35120,"activeCount":103},[],{"intervention":35114,"totalTrials":437,"cells":35122},{"EARLY_PHASE1":35123,"PHASE1":35125,"PHASE2":35127,"PHASE3":35133,"PHASE4":35135,"NA":35137},{"trials":35124,"activeCount":103},[],{"trials":35126,"activeCount":103},[],{"trials":35128,"activeCount":103},[35129],{"nctId":35109,"briefTitle":35110,"status":123,"phases":35130,"primaryCompletion":7721,"completion":27410,"start":34655,"enrollment":271,"conditions":35131,"interventions":35132},[92],[18],[35100,35114],{"trials":35134,"activeCount":103},[],{"trials":35136,"activeCount":103},[],{"trials":35138,"activeCount":103},[],{"intervention":35140,"totalTrials":437,"cells":35141},"Aliskiren\u002F Valsartan",{"EARLY_PHASE1":35142,"PHASE1":35144,"PHASE2":35146,"PHASE3":35155,"PHASE4":35157,"NA":35159},{"trials":35143,"activeCount":103},[],{"trials":35145,"activeCount":103},[],{"trials":35147,"activeCount":103},[35148],{"nctId":35149,"briefTitle":35150,"status":123,"phases":35151,"primaryCompletion":3271,"start":4845,"enrollment":534,"conditions":35152,"interventions":35153},"NCT00939588","Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients",[92],[21],[35140,35154],"Telmisartan\u002F Ramipril",{"trials":35156,"activeCount":103},[],{"trials":35158,"activeCount":103},[],{"trials":35160,"activeCount":103},[],{"intervention":35154,"totalTrials":437,"cells":35162},{"EARLY_PHASE1":35163,"PHASE1":35165,"PHASE2":35167,"PHASE3":35173,"PHASE4":35175,"NA":35177},{"trials":35164,"activeCount":103},[],{"trials":35166,"activeCount":103},[],{"trials":35168,"activeCount":103},[35169],{"nctId":35149,"briefTitle":35150,"status":123,"phases":35170,"primaryCompletion":3271,"start":4845,"enrollment":534,"conditions":35171,"interventions":35172},[92],[21],[35140,35154],{"trials":35174,"activeCount":103},[],{"trials":35176,"activeCount":103},[],{"trials":35178,"activeCount":103},[],{"intervention":35180,"totalTrials":437,"cells":35181},"Deferasirox DFX, DT",{"EARLY_PHASE1":35182,"PHASE1":35184,"PHASE2":35186,"PHASE3":35199,"PHASE4":35201,"NA":35203},{"trials":35183,"activeCount":103},[],{"trials":35185,"activeCount":103},[],{"trials":35187,"activeCount":103},[35188],{"nctId":35189,"briefTitle":35190,"status":123,"phases":35191,"primaryCompletion":35192,"completion":21175,"start":35193,"enrollment":2046,"conditions":35194,"interventions":35196},"NCT01868477","Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.",[92],"2017-03-22","2014-01-28",[35195],"Low and Int 1-risk Myelodysplastic Syndrome",[35180,35197,35198],"Erythropoietin alpha","Deferasirox DFX, FCT",{"trials":35200,"activeCount":103},[],{"trials":35202,"activeCount":103},[],{"trials":35204,"activeCount":103},[],{"intervention":35197,"totalTrials":437,"cells":35206},{"EARLY_PHASE1":35207,"PHASE1":35209,"PHASE2":35211,"PHASE3":35217,"PHASE4":35219,"NA":35221},{"trials":35208,"activeCount":103},[],{"trials":35210,"activeCount":103},[],{"trials":35212,"activeCount":103},[35213],{"nctId":35189,"briefTitle":35190,"status":123,"phases":35214,"primaryCompletion":35192,"completion":21175,"start":35193,"enrollment":2046,"conditions":35215,"interventions":35216},[92],[35195],[35180,35197,35198],{"trials":35218,"activeCount":103},[],{"trials":35220,"activeCount":103},[],{"trials":35222,"activeCount":103},[],{"intervention":35198,"totalTrials":437,"cells":35224},{"EARLY_PHASE1":35225,"PHASE1":35227,"PHASE2":35229,"PHASE3":35235,"PHASE4":35237,"NA":35239},{"trials":35226,"activeCount":103},[],{"trials":35228,"activeCount":103},[],{"trials":35230,"activeCount":103},[35231],{"nctId":35189,"briefTitle":35190,"status":123,"phases":35232,"primaryCompletion":35192,"completion":21175,"start":35193,"enrollment":2046,"conditions":35233,"interventions":35234},[92],[35195],[35180,35197,35198],{"trials":35236,"activeCount":103},[],{"trials":35238,"activeCount":103},[],{"trials":35240,"activeCount":103},[],{"intervention":5638,"totalTrials":437,"cells":35242},{"EARLY_PHASE1":35243,"PHASE1":35245,"PHASE2":35247,"PHASE3":35253,"PHASE4":35255,"NA":35257},{"trials":35244,"activeCount":103},[],{"trials":35246,"activeCount":103},[],{"trials":35248,"activeCount":103},[35249],{"nctId":5630,"briefTitle":5631,"status":390,"phases":35250,"primaryCompletion":5633,"completion":5633,"start":5634,"enrollment":103,"conditions":35251,"interventions":35252},[92],[5636],[2360,5638,5639],{"trials":35254,"activeCount":103},[],{"trials":35256,"activeCount":103},[],{"trials":35258,"activeCount":103},[],{"intervention":31856,"totalTrials":437,"cells":35260},{"EARLY_PHASE1":35261,"PHASE1":35263,"PHASE2":35265,"PHASE3":35271,"PHASE4":35273,"NA":35275},{"trials":35262,"activeCount":103},[],{"trials":35264,"activeCount":103},[],{"trials":35266,"activeCount":103},[35267],{"nctId":31851,"briefTitle":31852,"status":123,"phases":35268,"primaryCompletion":4967,"completion":4967,"start":2034,"enrollment":5594,"conditions":35269,"interventions":35270},[92],[22855],[31834,31856],{"trials":35272,"activeCount":103},[],{"trials":35274,"activeCount":103},[],{"trials":35276,"activeCount":103},[],{"intervention":11057,"totalTrials":437,"cells":35278},{"EARLY_PHASE1":35279,"PHASE1":35281,"PHASE2":35283,"PHASE3":35289,"PHASE4":35291,"NA":35293},{"trials":35280,"activeCount":103},[],{"trials":35282,"activeCount":103},[],{"trials":35284,"activeCount":103},[35285],{"nctId":11047,"briefTitle":11048,"status":134,"phases":35286,"primaryCompletion":11050,"completion":11051,"start":11052,"enrollment":846,"conditions":35287,"interventions":35288},[91,92],[11054,11055],[516,11057],{"trials":35290,"activeCount":103},[],{"trials":35292,"activeCount":103},[],{"trials":35294,"activeCount":103},[],{"intervention":35296,"totalTrials":437,"cells":35297},"LMB763",{"EARLY_PHASE1":35298,"PHASE1":35300,"PHASE2":35302,"PHASE3":35312,"PHASE4":35314,"NA":35316},{"trials":35299,"activeCount":103},[],{"trials":35301,"activeCount":103},[],{"trials":35303,"activeCount":103},[35304],{"nctId":35305,"briefTitle":35306,"status":134,"phases":35307,"primaryCompletion":35308,"completion":35308,"start":339,"enrollment":203,"conditions":35309,"interventions":35311},"NCT02913105","Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH",[92],"2018-09-19",[35310],"Non-alcoholic Steatohepatitis NASH",[35296],{"trials":35313,"activeCount":103},[],{"trials":35315,"activeCount":103},[],{"trials":35317,"activeCount":103},[],{"intervention":35319,"totalTrials":437,"cells":35320},"Panobinostat\u002FLBH589",{"EARLY_PHASE1":35321,"PHASE1":35323,"PHASE2":35325,"PHASE3":35335,"PHASE4":35337,"NA":35339},{"trials":35322,"activeCount":103},[],{"trials":35324,"activeCount":103},[],{"trials":35326,"activeCount":103},[35327],{"nctId":35328,"briefTitle":35329,"status":123,"phases":35330,"primaryCompletion":1671,"completion":1671,"start":4505,"enrollment":3322,"conditions":35331,"interventions":35334},"NCT00880269","Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)",[92],[35332,35333],"Refractory Leukemia","Acute Myelogenous Leukemia",[35319],{"trials":35336,"activeCount":103},[],{"trials":35338,"activeCount":103},[],{"trials":35340,"activeCount":103},[],{"intervention":2410,"totalTrials":437,"cells":35342},{"EARLY_PHASE1":35343,"PHASE1":35345,"PHASE2":35347,"PHASE3":35353,"PHASE4":35355,"NA":35357},{"trials":35344,"activeCount":103},[],{"trials":35346,"activeCount":103},[],{"trials":35348,"activeCount":103},[35349],{"nctId":2399,"briefTitle":2400,"status":134,"phases":35350,"primaryCompletion":2402,"completion":2403,"start":2404,"enrollment":2405,"conditions":35351,"interventions":35352},[91,92],[2369],[2341,2408,63,2409,2410,2411],{"trials":35354,"activeCount":103},[],{"trials":35356,"activeCount":103},[],{"trials":35358,"activeCount":103},[],{"intervention":3068,"totalTrials":437,"cells":35360},{"EARLY_PHASE1":35361,"PHASE1":35363,"PHASE2":35365,"PHASE3":35371,"PHASE4":35373,"NA":35375},{"trials":35362,"activeCount":103},[],{"trials":35364,"activeCount":103},[],{"trials":35366,"activeCount":103},[35367],{"nctId":3059,"briefTitle":3060,"status":123,"phases":35368,"primaryCompletion":3062,"completion":3062,"start":3063,"enrollment":3064,"conditions":35369,"interventions":35370},[92],[3066],[3068,3017],{"trials":35372,"activeCount":103},[],{"trials":35374,"activeCount":103},[],{"trials":35376,"activeCount":103},[],{"intervention":35378,"totalTrials":437,"cells":35379},"XXB750 drug",{"EARLY_PHASE1":35380,"PHASE1":35382,"PHASE2":35384,"PHASE3":35395,"PHASE4":35397,"NA":35399},{"trials":35381,"activeCount":103},[],{"trials":35383,"activeCount":103},[],{"trials":35385,"activeCount":103},[35386],{"nctId":35387,"briefTitle":35388,"status":123,"phases":35389,"primaryCompletion":11657,"completion":35390,"start":35391,"enrollment":3854,"conditions":35392,"interventions":35394},"NCT05562934","An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.",[92],"2024-08-27","2022-11-08",[35393],"Resistant Hypertension",[35378],{"trials":35396,"activeCount":103},[],{"trials":35398,"activeCount":103},[],{"trials":35400,"activeCount":103},[],{"intervention":31508,"totalTrials":437,"cells":35402},{"EARLY_PHASE1":35403,"PHASE1":35405,"PHASE2":35407,"PHASE3":35413,"PHASE4":35415,"NA":35417},{"trials":35404,"activeCount":103},[],{"trials":35406,"activeCount":103},[],{"trials":35408,"activeCount":103},[35409],{"nctId":31500,"briefTitle":31501,"status":134,"phases":35410,"primaryCompletion":31503,"completion":31503,"start":31504,"enrollment":3491,"conditions":35411,"interventions":35412},[92],[31506],[18225,31508],{"trials":35414,"activeCount":103},[],{"trials":35416,"activeCount":103},[],{"trials":35418,"activeCount":103},[],{"intervention":35420,"totalTrials":437,"cells":35421},"UNR844",{"EARLY_PHASE1":35422,"PHASE1":35424,"PHASE2":35426,"PHASE3":35436,"PHASE4":35438,"NA":35440},{"trials":35423,"activeCount":103},[],{"trials":35425,"activeCount":103},[],{"trials":35427,"activeCount":103},[35428],{"nctId":35429,"briefTitle":35430,"status":134,"phases":35431,"primaryCompletion":5830,"completion":35432,"start":35433,"enrollment":32971,"conditions":35434,"interventions":35435},"NCT04806503","A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.",[92],"2022-10-14","2021-06-30",[34759],[35420],{"trials":35437,"activeCount":103},[],{"trials":35439,"activeCount":103},[],{"trials":35441,"activeCount":103},[],{"intervention":24361,"totalTrials":437,"cells":35443},{"EARLY_PHASE1":35444,"PHASE1":35446,"PHASE2":35448,"PHASE3":35454,"PHASE4":35456,"NA":35458},{"trials":35445,"activeCount":103},[],{"trials":35447,"activeCount":103},[],{"trials":35449,"activeCount":103},[35450],{"nctId":24353,"briefTitle":24354,"status":123,"phases":35451,"primaryCompletion":565,"completion":9252,"start":7881,"enrollment":24356,"conditions":35452,"interventions":35453},[92],[24358],[24360,10927,24361],{"trials":35455,"activeCount":103},[],{"trials":35457,"activeCount":103},[],{"trials":35459,"activeCount":103},[],{"intervention":35461,"totalTrials":437,"cells":35462},"QAB149 75 mg Concept 1",{"EARLY_PHASE1":35463,"PHASE1":35465,"PHASE2":35467,"PHASE3":35476,"PHASE4":35478,"NA":35480},{"trials":35464,"activeCount":103},[],{"trials":35466,"activeCount":103},[],{"trials":35468,"activeCount":103},[35469],{"nctId":35470,"briefTitle":35471,"status":390,"phases":35472,"primaryCompletion":1714,"completion":1714,"start":15346,"enrollment":103,"conditions":35473,"interventions":35474},"NCT01845623","A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture",[92],[18],[35461,35475],"QAB149 75 mg Epic Test Fixture",{"trials":35477,"activeCount":103},[],{"trials":35479,"activeCount":103},[],{"trials":35481,"activeCount":103},[],{"intervention":35475,"totalTrials":437,"cells":35483},{"EARLY_PHASE1":35484,"PHASE1":35486,"PHASE2":35488,"PHASE3":35494,"PHASE4":35496,"NA":35498},{"trials":35485,"activeCount":103},[],{"trials":35487,"activeCount":103},[],{"trials":35489,"activeCount":103},[35490],{"nctId":35470,"briefTitle":35471,"status":390,"phases":35491,"primaryCompletion":1714,"completion":1714,"start":15346,"enrollment":103,"conditions":35492,"interventions":35493},[92],[18],[35461,35475],{"trials":35495,"activeCount":103},[],{"trials":35497,"activeCount":103},[],{"trials":35499,"activeCount":103},[],{"intervention":35501,"totalTrials":437,"cells":35502},"QVM149 150\u002F50\u002F80 μg o.d.",{"EARLY_PHASE1":35503,"PHASE1":35505,"PHASE2":35507,"PHASE3":35518,"PHASE4":35520,"NA":35522},{"trials":35504,"activeCount":103},[],{"trials":35506,"activeCount":103},[],{"trials":35508,"activeCount":103},[35509],{"nctId":35510,"briefTitle":35511,"status":123,"phases":35512,"primaryCompletion":31485,"completion":31485,"start":35513,"enrollment":13089,"conditions":35514,"interventions":35515},"NCT03063086","Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol\u002FFluticasone in Patients With Asthma.",[92],"2017-01-21",[18],[35501,35516,35517],"QVM149 150\u002F50\u002F160 μg o.d.","salmeterol\u002Ffluticasone FDC 50\u002F500 μg b.i.d.",{"trials":35519,"activeCount":103},[],{"trials":35521,"activeCount":103},[],{"trials":35523,"activeCount":103},[],{"intervention":35516,"totalTrials":437,"cells":35525},{"EARLY_PHASE1":35526,"PHASE1":35528,"PHASE2":35530,"PHASE3":35536,"PHASE4":35538,"NA":35540},{"trials":35527,"activeCount":103},[],{"trials":35529,"activeCount":103},[],{"trials":35531,"activeCount":103},[35532],{"nctId":35510,"briefTitle":35511,"status":123,"phases":35533,"primaryCompletion":31485,"completion":31485,"start":35513,"enrollment":13089,"conditions":35534,"interventions":35535},[92],[18],[35501,35516,35517],{"trials":35537,"activeCount":103},[],{"trials":35539,"activeCount":103},[],{"trials":35541,"activeCount":103},[],{"intervention":35517,"totalTrials":437,"cells":35543},{"EARLY_PHASE1":35544,"PHASE1":35546,"PHASE2":35548,"PHASE3":35554,"PHASE4":35556,"NA":35558},{"trials":35545,"activeCount":103},[],{"trials":35547,"activeCount":103},[],{"trials":35549,"activeCount":103},[35550],{"nctId":35510,"briefTitle":35511,"status":123,"phases":35551,"primaryCompletion":31485,"completion":31485,"start":35513,"enrollment":13089,"conditions":35552,"interventions":35553},[92],[18],[35501,35516,35517],{"trials":35555,"activeCount":103},[],{"trials":35557,"activeCount":103},[],{"trials":35559,"activeCount":103},[],{"intervention":35561,"totalTrials":437,"cells":35562},"sotrastaurin (Dose 1) + tacrolimus + standard of care medications",{"EARLY_PHASE1":35563,"PHASE1":35565,"PHASE2":35567,"PHASE3":35578,"PHASE4":35580,"NA":35582},{"trials":35564,"activeCount":103},[],{"trials":35566,"activeCount":103},[],{"trials":35568,"activeCount":103},[35569],{"nctId":35570,"briefTitle":35571,"status":123,"phases":35572,"primaryCompletion":3482,"completion":3482,"start":3271,"enrollment":3741,"conditions":35573,"interventions":35574},"NCT01064791","Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients",[92],[4701],[35561,35575,35576,35577],"sotrastaurin (Dose 2) + tacrolimus + standard of care medications","sotrastaurin (Dose 3) + tacrolimus + standard of care medications","mycophenolic acid + tacrolimus + standard of care medications",{"trials":35579,"activeCount":103},[],{"trials":35581,"activeCount":103},[],{"trials":35583,"activeCount":103},[],{"intervention":35575,"totalTrials":437,"cells":35585},{"EARLY_PHASE1":35586,"PHASE1":35588,"PHASE2":35590,"PHASE3":35596,"PHASE4":35598,"NA":35600},{"trials":35587,"activeCount":103},[],{"trials":35589,"activeCount":103},[],{"trials":35591,"activeCount":103},[35592],{"nctId":35570,"briefTitle":35571,"status":123,"phases":35593,"primaryCompletion":3482,"completion":3482,"start":3271,"enrollment":3741,"conditions":35594,"interventions":35595},[92],[4701],[35561,35575,35576,35577],{"trials":35597,"activeCount":103},[],{"trials":35599,"activeCount":103},[],{"trials":35601,"activeCount":103},[],{"intervention":35576,"totalTrials":437,"cells":35603},{"EARLY_PHASE1":35604,"PHASE1":35606,"PHASE2":35608,"PHASE3":35614,"PHASE4":35616,"NA":35618},{"trials":35605,"activeCount":103},[],{"trials":35607,"activeCount":103},[],{"trials":35609,"activeCount":103},[35610],{"nctId":35570,"briefTitle":35571,"status":123,"phases":35611,"primaryCompletion":3482,"completion":3482,"start":3271,"enrollment":3741,"conditions":35612,"interventions":35613},[92],[4701],[35561,35575,35576,35577],{"trials":35615,"activeCount":103},[],{"trials":35617,"activeCount":103},[],{"trials":35619,"activeCount":103},[],{"intervention":35577,"totalTrials":437,"cells":35621},{"EARLY_PHASE1":35622,"PHASE1":35624,"PHASE2":35626,"PHASE3":35632,"PHASE4":35634,"NA":35636},{"trials":35623,"activeCount":103},[],{"trials":35625,"activeCount":103},[],{"trials":35627,"activeCount":103},[35628],{"nctId":35570,"briefTitle":35571,"status":123,"phases":35629,"primaryCompletion":3482,"completion":3482,"start":3271,"enrollment":3741,"conditions":35630,"interventions":35631},[92],[4701],[35561,35575,35576,35577],{"trials":35633,"activeCount":103},[],{"trials":35635,"activeCount":103},[],{"trials":35637,"activeCount":103},[],{"intervention":35639,"totalTrials":437,"cells":35640},"MAU868",{"EARLY_PHASE1":35641,"PHASE1":35643,"PHASE2":35645,"PHASE3":35657,"PHASE4":35659,"NA":35661},{"trials":35642,"activeCount":103},[],{"trials":35644,"activeCount":103},[],{"trials":35646,"activeCount":103},[35647],{"nctId":35648,"briefTitle":35649,"status":390,"phases":35650,"primaryCompletion":35651,"completion":35652,"start":35653,"enrollment":103,"conditions":35654,"interventions":35656},"NCT03456999","Determine the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of BK Virus Infection in Kidney Transplant Recipients",[92],"2020-07-13","2020-11-16","2018-10-15",[35655],"BK Virus Nephropathy",[35639],{"trials":35658,"activeCount":103},[],{"trials":35660,"activeCount":103},[],{"trials":35662,"activeCount":103},[],{"intervention":25160,"totalTrials":437,"cells":35664},{"EARLY_PHASE1":35665,"PHASE1":35667,"PHASE2":35669,"PHASE3":35675,"PHASE4":35677,"NA":35679},{"trials":35666,"activeCount":103},[],{"trials":35668,"activeCount":103},[],{"trials":35670,"activeCount":103},[35671],{"nctId":25154,"briefTitle":25155,"status":123,"phases":35672,"primaryCompletion":3845,"start":4845,"enrollment":3343,"conditions":35673,"interventions":35674},[92],[25158],[25145,25160,25161],{"trials":35676,"activeCount":103},[],{"trials":35678,"activeCount":103},[],{"trials":35680,"activeCount":103},[],{"intervention":35682,"totalTrials":437,"cells":35683},"TIN816",{"EARLY_PHASE1":35684,"PHASE1":35686,"PHASE2":35688,"PHASE3":35699,"PHASE4":35701,"NA":35703},{"trials":35685,"activeCount":103},[],{"trials":35687,"activeCount":103},[],{"trials":35689,"activeCount":103},[35690],{"nctId":35691,"briefTitle":35692,"status":134,"phases":35693,"primaryCompletion":9717,"completion":35694,"start":35695,"enrollment":2268,"conditions":35696,"interventions":35698},"NCT05524051","A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.",[92],"2025-06-23","2023-03-03",[35697],"Acute Kidney Injury Following Cardiac Surgery",[35682],{"trials":35700,"activeCount":103},[],{"trials":35702,"activeCount":103},[],{"trials":35704,"activeCount":103},[],{"intervention":16333,"totalTrials":437,"cells":35706},{"EARLY_PHASE1":35707,"PHASE1":35709,"PHASE2":35711,"PHASE3":35717,"PHASE4":35719,"NA":35721},{"trials":35708,"activeCount":103},[],{"trials":35710,"activeCount":103},[],{"trials":35712,"activeCount":103},[35713],{"nctId":16326,"briefTitle":16327,"status":123,"phases":35714,"primaryCompletion":4070,"completion":4070,"start":3447,"enrollment":16329,"conditions":35715,"interventions":35716},[92],[18],[16256,16332,16333],{"trials":35718,"activeCount":103},[],{"trials":35720,"activeCount":103},[],{"trials":35722,"activeCount":103},[],{"intervention":35724,"totalTrials":437,"cells":35725},"Umbilical cord blood transplantation with HSC835",{"EARLY_PHASE1":35726,"PHASE1":35728,"PHASE2":35730,"PHASE3":35740,"PHASE4":35742,"NA":35744},{"trials":35727,"activeCount":103},[],{"trials":35729,"activeCount":103},[],{"trials":35731,"activeCount":103},[35732],{"nctId":35733,"briefTitle":35734,"status":390,"phases":35735,"primaryCompletion":3881,"completion":3881,"start":35736,"enrollment":103,"conditions":35737,"interventions":35739},"NCT02715505","Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)",[91,92],"2017-10-10",[35738],"Inherited Metabolic Disorders IMD",[35724],{"trials":35741,"activeCount":103},[],{"trials":35743,"activeCount":103},[],{"trials":35745,"activeCount":103},[],{"intervention":35747,"totalTrials":437,"cells":35748},"LYS006 20 mg",{"EARLY_PHASE1":35749,"PHASE1":35751,"PHASE2":35753,"PHASE3":35764,"PHASE4":35766,"NA":35768},{"trials":35750,"activeCount":103},[],{"trials":35752,"activeCount":103},[],{"trials":35754,"activeCount":103},[35755],{"nctId":35756,"briefTitle":35757,"status":123,"phases":35758,"primaryCompletion":35759,"completion":13833,"start":10122,"enrollment":11068,"conditions":35760,"interventions":35762},"NCT03497897","Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne",[92],"2022-02-24",[35761],"Inflammatory Acne",[35747,35763],"LYS006 2 mg",{"trials":35765,"activeCount":103},[],{"trials":35767,"activeCount":103},[],{"trials":35769,"activeCount":103},[],{"intervention":35763,"totalTrials":437,"cells":35771},{"EARLY_PHASE1":35772,"PHASE1":35774,"PHASE2":35776,"PHASE3":35782,"PHASE4":35784,"NA":35786},{"trials":35773,"activeCount":103},[],{"trials":35775,"activeCount":103},[],{"trials":35777,"activeCount":103},[35778],{"nctId":35756,"briefTitle":35757,"status":123,"phases":35779,"primaryCompletion":35759,"completion":13833,"start":10122,"enrollment":11068,"conditions":35780,"interventions":35781},[92],[35761],[35747,35763],{"trials":35783,"activeCount":103},[],{"trials":35785,"activeCount":103},[],{"trials":35787,"activeCount":103},[],{"intervention":35789,"totalTrials":437,"cells":35790},"Indacaterol 27.5 mcg",{"EARLY_PHASE1":35791,"PHASE1":35793,"PHASE2":35795,"PHASE3":35807,"PHASE4":35809,"NA":35811},{"trials":35792,"activeCount":103},[],{"trials":35794,"activeCount":103},[],{"trials":35796,"activeCount":103},[35797],{"nctId":35798,"briefTitle":35799,"status":123,"phases":35800,"primaryCompletion":4093,"completion":4093,"start":4669,"enrollment":9106,"conditions":35801,"interventions":35802},"NCT01959412","Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma",[92],[18],[35789,35803,35804,35805,35806],"Indacaterol 37.5","Indacaterol 55 mcg","Indacaterol 75 mcg","Indacaterol 150 mcg",{"trials":35808,"activeCount":103},[],{"trials":35810,"activeCount":103},[],{"trials":35812,"activeCount":103},[],{"intervention":35803,"totalTrials":437,"cells":35814},{"EARLY_PHASE1":35815,"PHASE1":35817,"PHASE2":35819,"PHASE3":35825,"PHASE4":35827,"NA":35829},{"trials":35816,"activeCount":103},[],{"trials":35818,"activeCount":103},[],{"trials":35820,"activeCount":103},[35821],{"nctId":35798,"briefTitle":35799,"status":123,"phases":35822,"primaryCompletion":4093,"completion":4093,"start":4669,"enrollment":9106,"conditions":35823,"interventions":35824},[92],[18],[35789,35803,35804,35805,35806],{"trials":35826,"activeCount":103},[],{"trials":35828,"activeCount":103},[],{"trials":35830,"activeCount":103},[],{"intervention":35804,"totalTrials":437,"cells":35832},{"EARLY_PHASE1":35833,"PHASE1":35835,"PHASE2":35837,"PHASE3":35843,"PHASE4":35845,"NA":35847},{"trials":35834,"activeCount":103},[],{"trials":35836,"activeCount":103},[],{"trials":35838,"activeCount":103},[35839],{"nctId":35798,"briefTitle":35799,"status":123,"phases":35840,"primaryCompletion":4093,"completion":4093,"start":4669,"enrollment":9106,"conditions":35841,"interventions":35842},[92],[18],[35789,35803,35804,35805,35806],{"trials":35844,"activeCount":103},[],{"trials":35846,"activeCount":103},[],{"trials":35848,"activeCount":103},[],{"intervention":35805,"totalTrials":437,"cells":35850},{"EARLY_PHASE1":35851,"PHASE1":35853,"PHASE2":35855,"PHASE3":35861,"PHASE4":35863,"NA":35865},{"trials":35852,"activeCount":103},[],{"trials":35854,"activeCount":103},[],{"trials":35856,"activeCount":103},[35857],{"nctId":35798,"briefTitle":35799,"status":123,"phases":35858,"primaryCompletion":4093,"completion":4093,"start":4669,"enrollment":9106,"conditions":35859,"interventions":35860},[92],[18],[35789,35803,35804,35805,35806],{"trials":35862,"activeCount":103},[],{"trials":35864,"activeCount":103},[],{"trials":35866,"activeCount":103},[],{"intervention":35806,"totalTrials":437,"cells":35868},{"EARLY_PHASE1":35869,"PHASE1":35871,"PHASE2":35873,"PHASE3":35879,"PHASE4":35881,"NA":35883},{"trials":35870,"activeCount":103},[],{"trials":35872,"activeCount":103},[],{"trials":35874,"activeCount":103},[35875],{"nctId":35798,"briefTitle":35799,"status":123,"phases":35876,"primaryCompletion":4093,"completion":4093,"start":4669,"enrollment":9106,"conditions":35877,"interventions":35878},[92],[18],[35789,35803,35804,35805,35806],{"trials":35880,"activeCount":103},[],{"trials":35882,"activeCount":103},[],{"trials":35884,"activeCount":103},[],{"intervention":35886,"totalTrials":437,"cells":35887},"XBD173",{"EARLY_PHASE1":35888,"PHASE1":35890,"PHASE2":35892,"PHASE3":35901,"PHASE4":35903,"NA":35905},{"trials":35889,"activeCount":103},[],{"trials":35891,"activeCount":103},[],{"trials":35893,"activeCount":103},[35894],{"nctId":35895,"briefTitle":35896,"status":123,"phases":35897,"completion":8091,"start":996,"enrollment":1466,"conditions":35898,"interventions":35900},"NCT00108836","Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder",[92],[35899],"Anxiety Disorders",[35886],{"trials":35902,"activeCount":103},[],{"trials":35904,"activeCount":103},[],{"trials":35906,"activeCount":103},[],{"intervention":32138,"totalTrials":437,"cells":35908},{"EARLY_PHASE1":35909,"PHASE1":35911,"PHASE2":35913,"PHASE3":35919,"PHASE4":35921,"NA":35923},{"trials":35910,"activeCount":103},[],{"trials":35912,"activeCount":103},[],{"trials":35914,"activeCount":103},[35915],{"nctId":32130,"briefTitle":32131,"status":123,"phases":35916,"primaryCompletion":16186,"completion":16186,"start":32133,"enrollment":32134,"conditions":35917,"interventions":35918},[92],[32136,4458],[6737,32138],{"trials":35920,"activeCount":103},[],{"trials":35922,"activeCount":103},[],{"trials":35924,"activeCount":103},[],{"intervention":35926,"totalTrials":437,"cells":35927},"EPO906 epothilone B",{"EARLY_PHASE1":35928,"PHASE1":35930,"PHASE2":35932,"PHASE3":35941,"PHASE4":35943,"NA":35945},{"trials":35929,"activeCount":103},[],{"trials":35931,"activeCount":103},[],{"trials":35933,"activeCount":103},[35934],{"nctId":35935,"briefTitle":35936,"status":123,"phases":35937,"primaryCompletion":4343,"completion":4343,"start":904,"enrollment":99,"conditions":35938,"interventions":35940},"NCT00050349","EPO906 in Carcinoid and Other Neuroendocrine Tumors",[92],[35939,4903],"Carcinoid",[35926],{"trials":35942,"activeCount":103},[],{"trials":35944,"activeCount":103},[],{"trials":35946,"activeCount":103},[],{"intervention":35948,"totalTrials":437,"cells":35949},"HSY244",{"EARLY_PHASE1":35950,"PHASE1":35952,"PHASE2":35954,"PHASE3":35963,"PHASE4":35965,"NA":35967},{"trials":35951,"activeCount":103},[],{"trials":35953,"activeCount":103},[],{"trials":35955,"activeCount":103},[35956],{"nctId":35957,"briefTitle":35958,"status":134,"phases":35959,"primaryCompletion":35960,"completion":35960,"start":10584,"enrollment":734,"conditions":35961,"interventions":35962},"NCT04582409","A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation",[92],"2022-07-11",[12396],[35948],{"trials":35964,"activeCount":103},[],{"trials":35966,"activeCount":103},[],{"trials":35968,"activeCount":103},[],{"intervention":16510,"totalTrials":437,"cells":35970},{"EARLY_PHASE1":35971,"PHASE1":35973,"PHASE2":35975,"PHASE3":35981,"PHASE4":35983,"NA":35985},{"trials":35972,"activeCount":103},[],{"trials":35974,"activeCount":103},[],{"trials":35976,"activeCount":103},[35977],{"nctId":16498,"briefTitle":16499,"status":123,"phases":35978,"primaryCompletion":16501,"completion":3456,"start":16502,"enrollment":16503,"conditions":35979,"interventions":35980},[92],[4571,16505,16506,16507,16508],[7711,16510,13304],{"trials":35982,"activeCount":103},[],{"trials":35984,"activeCount":103},[],{"trials":35986,"activeCount":103},[],{"intervention":761,"totalTrials":437,"cells":35988},{"EARLY_PHASE1":35989,"PHASE1":35991,"PHASE2":35993,"PHASE3":35999,"PHASE4":36001,"NA":36003},{"trials":35990,"activeCount":103},[],{"trials":35992,"activeCount":103},[],{"trials":35994,"activeCount":103},[35995],{"nctId":751,"briefTitle":752,"status":123,"phases":35996,"primaryCompletion":754,"completion":755,"start":756,"enrollment":757,"conditions":35997,"interventions":35998},[92],[759],[196,249,195,761,762],{"trials":36000,"activeCount":103},[],{"trials":36002,"activeCount":103},[],{"trials":36004,"activeCount":103},[],{"intervention":762,"totalTrials":437,"cells":36006},{"EARLY_PHASE1":36007,"PHASE1":36009,"PHASE2":36011,"PHASE3":36017,"PHASE4":36019,"NA":36021},{"trials":36008,"activeCount":103},[],{"trials":36010,"activeCount":103},[],{"trials":36012,"activeCount":103},[36013],{"nctId":751,"briefTitle":752,"status":123,"phases":36014,"primaryCompletion":754,"completion":755,"start":756,"enrollment":757,"conditions":36015,"interventions":36016},[92],[759],[196,249,195,761,762],{"trials":36018,"activeCount":103},[],{"trials":36020,"activeCount":103},[],{"trials":36022,"activeCount":103},[],{"intervention":36024,"totalTrials":437,"cells":36025},"Deferasirox dispersable",{"EARLY_PHASE1":36026,"PHASE1":36028,"PHASE2":36030,"PHASE3":36042,"PHASE4":36044,"NA":36046},{"trials":36027,"activeCount":103},[],{"trials":36029,"activeCount":103},[],{"trials":36031,"activeCount":103},[36032],{"nctId":36033,"briefTitle":36034,"status":123,"phases":36035,"primaryCompletion":28363,"completion":1847,"start":36036,"enrollment":7438,"conditions":36037,"interventions":36040},"NCT02993224","Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet",[92],"2017-07-27",[36038,36039],"Transfusion-dependent Thalassemia","Non-transfusion-dependent Thalassemia",[36024,36041],"Deferasirox film coated",{"trials":36043,"activeCount":103},[],{"trials":36045,"activeCount":103},[],{"trials":36047,"activeCount":103},[],{"intervention":36041,"totalTrials":437,"cells":36049},{"EARLY_PHASE1":36050,"PHASE1":36052,"PHASE2":36054,"PHASE3":36060,"PHASE4":36062,"NA":36064},{"trials":36051,"activeCount":103},[],{"trials":36053,"activeCount":103},[],{"trials":36055,"activeCount":103},[36056],{"nctId":36033,"briefTitle":36034,"status":123,"phases":36057,"primaryCompletion":28363,"completion":1847,"start":36036,"enrollment":7438,"conditions":36058,"interventions":36059},[92],[36038,36039],[36024,36041],{"trials":36061,"activeCount":103},[],{"trials":36063,"activeCount":103},[],{"trials":36065,"activeCount":103},[],{"intervention":36067,"totalTrials":437,"cells":36068},"Deferasirox FCT",{"EARLY_PHASE1":36069,"PHASE1":36071,"PHASE2":36073,"PHASE3":36083,"PHASE4":36085,"NA":36087},{"trials":36070,"activeCount":103},[],{"trials":36072,"activeCount":103},[],{"trials":36074,"activeCount":103},[36075],{"nctId":36076,"briefTitle":36077,"status":134,"phases":36078,"primaryCompletion":36079,"completion":36079,"start":2128,"enrollment":2405,"conditions":36080,"interventions":36082},"NCT03203850","Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)",[92],"2023-04-17",[36081],"Hereditary Hemochromatosis",[36067],{"trials":36084,"activeCount":103},[],{"trials":36086,"activeCount":103},[],{"trials":36088,"activeCount":103},[],{"intervention":10251,"totalTrials":437,"cells":36090},{"EARLY_PHASE1":36091,"PHASE1":36093,"PHASE2":36095,"PHASE3":36101,"PHASE4":36103,"NA":36105},{"trials":36092,"activeCount":103},[],{"trials":36094,"activeCount":103},[],{"trials":36096,"activeCount":103},[36097],{"nctId":10242,"briefTitle":10243,"status":134,"phases":36098,"primaryCompletion":10245,"completion":10245,"start":10246,"enrollment":9369,"conditions":36099,"interventions":36100},[91,92],[10248,10249],[10251,10252,236,10253],{"trials":36102,"activeCount":103},[],{"trials":36104,"activeCount":103},[],{"trials":36106,"activeCount":103},[],{"intervention":10252,"totalTrials":437,"cells":36108},{"EARLY_PHASE1":36109,"PHASE1":36111,"PHASE2":36113,"PHASE3":36119,"PHASE4":36121,"NA":36123},{"trials":36110,"activeCount":103},[],{"trials":36112,"activeCount":103},[],{"trials":36114,"activeCount":103},[36115],{"nctId":10242,"briefTitle":10243,"status":134,"phases":36116,"primaryCompletion":10245,"completion":10245,"start":10246,"enrollment":9369,"conditions":36117,"interventions":36118},[91,92],[10248,10249],[10251,10252,236,10253],{"trials":36120,"activeCount":103},[],{"trials":36122,"activeCount":103},[],{"trials":36124,"activeCount":103},[],{"intervention":10253,"totalTrials":437,"cells":36126},{"EARLY_PHASE1":36127,"PHASE1":36129,"PHASE2":36131,"PHASE3":36137,"PHASE4":36139,"NA":36141},{"trials":36128,"activeCount":103},[],{"trials":36130,"activeCount":103},[],{"trials":36132,"activeCount":103},[36133],{"nctId":10242,"briefTitle":10243,"status":134,"phases":36134,"primaryCompletion":10245,"completion":10245,"start":10246,"enrollment":9369,"conditions":36135,"interventions":36136},[91,92],[10248,10249],[10251,10252,236,10253],{"trials":36138,"activeCount":103},[],{"trials":36140,"activeCount":103},[],{"trials":36142,"activeCount":103},[],{"intervention":36144,"totalTrials":437,"cells":36145},"high-dose imatinib",{"EARLY_PHASE1":36146,"PHASE1":36148,"PHASE2":36150,"PHASE3":36158,"PHASE4":36160,"NA":36162},{"trials":36147,"activeCount":103},[],{"trials":36149,"activeCount":103},[],{"trials":36151,"activeCount":103},[36152],{"nctId":36153,"briefTitle":36154,"status":123,"phases":36155,"primaryCompletion":4620,"completion":4620,"start":3845,"enrollment":5594,"conditions":36156,"interventions":36157},"NCT01216085","An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints",[92],[3333,83],[36144],{"trials":36159,"activeCount":103},[],{"trials":36161,"activeCount":103},[],{"trials":36163,"activeCount":103},[],{"intervention":36165,"totalTrials":437,"cells":36166},"ECMPS-IEM",{"EARLY_PHASE1":36167,"PHASE1":36169,"PHASE2":36171,"PHASE3":36183,"PHASE4":36185,"NA":36187},{"trials":36168,"activeCount":103},[],{"trials":36170,"activeCount":103},[],{"trials":36172,"activeCount":103},[36173],{"nctId":36174,"briefTitle":36175,"status":123,"phases":36176,"primaryCompletion":36177,"completion":36177,"start":36178,"enrollment":2439,"conditions":36179,"interventions":36182},"NCT01320358","Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients",[92],"2011-11-18","2011-05-10",[36180,36181],"Detection Accuracy","Patient Compliance",[36165],{"trials":36184,"activeCount":103},[],{"trials":36186,"activeCount":103},[],{"trials":36188,"activeCount":103},[],{"intervention":36190,"totalTrials":437,"cells":36191},"QAU145",{"EARLY_PHASE1":36192,"PHASE1":36194,"PHASE2":36196,"PHASE3":36204,"PHASE4":36206,"NA":36208},{"trials":36193,"activeCount":103},[],{"trials":36195,"activeCount":103},[],{"trials":36197,"activeCount":103},[36198],{"nctId":36199,"briefTitle":36200,"status":123,"phases":36201,"primaryCompletion":3552,"completion":4335,"start":4317,"enrollment":1495,"conditions":36202,"interventions":36203},"NCT00506792","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis",[92],[9233],[36190],{"trials":36205,"activeCount":103},[],{"trials":36207,"activeCount":103},[],{"trials":36209,"activeCount":103},[],{"intervention":36211,"totalTrials":437,"cells":36212},"QAV680",{"EARLY_PHASE1":36213,"PHASE1":36215,"PHASE2":36217,"PHASE3":36226,"PHASE4":36228,"NA":36230},{"trials":36214,"activeCount":103},[],{"trials":36216,"activeCount":103},[],{"trials":36218,"activeCount":103},[36219],{"nctId":36220,"briefTitle":36221,"status":134,"phases":36222,"primaryCompletion":7931,"completion":7931,"start":964,"enrollment":422,"conditions":36223,"interventions":36224},"NCT01103037","Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma",[92],[18],[36211,36225],"QAV680 Placebo",{"trials":36227,"activeCount":103},[],{"trials":36229,"activeCount":103},[],{"trials":36231,"activeCount":103},[],{"intervention":36225,"totalTrials":437,"cells":36233},{"EARLY_PHASE1":36234,"PHASE1":36236,"PHASE2":36238,"PHASE3":36244,"PHASE4":36246,"NA":36248},{"trials":36235,"activeCount":103},[],{"trials":36237,"activeCount":103},[],{"trials":36239,"activeCount":103},[36240],{"nctId":36220,"briefTitle":36221,"status":134,"phases":36241,"primaryCompletion":7931,"completion":7931,"start":964,"enrollment":422,"conditions":36242,"interventions":36243},[92],[18],[36211,36225],{"trials":36245,"activeCount":103},[],{"trials":36247,"activeCount":103},[],{"trials":36249,"activeCount":103},[],{"intervention":36251,"totalTrials":437,"cells":36252},"QAW039 capsules once daily for 28 days",{"EARLY_PHASE1":36253,"PHASE1":36255,"PHASE2":36257,"PHASE3":36266,"PHASE4":36268,"NA":36270},{"trials":36254,"activeCount":103},[],{"trials":36256,"activeCount":103},[],{"trials":36258,"activeCount":103},[36259],{"nctId":36260,"briefTitle":36261,"status":123,"phases":36262,"primaryCompletion":1818,"completion":1818,"start":926,"enrollment":5959,"conditions":36263,"interventions":36264},"NCT01253603","Efficacy, Safety, and Pharmacokinetics of QAW039",[92],[16339],[36251,36265],"Fluticasone propionate inhaler twice daily for 28 days",{"trials":36267,"activeCount":103},[],{"trials":36269,"activeCount":103},[],{"trials":36271,"activeCount":103},[],{"intervention":36265,"totalTrials":437,"cells":36273},{"EARLY_PHASE1":36274,"PHASE1":36276,"PHASE2":36278,"PHASE3":36284,"PHASE4":36286,"NA":36288},{"trials":36275,"activeCount":103},[],{"trials":36277,"activeCount":103},[],{"trials":36279,"activeCount":103},[36280],{"nctId":36260,"briefTitle":36261,"status":123,"phases":36281,"primaryCompletion":1818,"completion":1818,"start":926,"enrollment":5959,"conditions":36282,"interventions":36283},[92],[16339],[36251,36265],{"trials":36285,"activeCount":103},[],{"trials":36287,"activeCount":103},[],{"trials":36289,"activeCount":103},[],{"intervention":36291,"totalTrials":437,"cells":36292},"XXB750 Low dose",{"EARLY_PHASE1":36293,"PHASE1":36295,"PHASE2":36297,"PHASE3":36308,"PHASE4":36310,"NA":36312},{"trials":36294,"activeCount":103},[],{"trials":36296,"activeCount":103},[],{"trials":36298,"activeCount":103},[36299],{"nctId":36300,"briefTitle":36301,"status":134,"phases":36302,"primaryCompletion":36303,"completion":36303,"start":34043,"enrollment":2948,"conditions":36304,"interventions":36305},"NCT06142383","A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure",[92],"2024-11-01",[15870],[36291,36306,36307,17350],"XXB750 Medium Dose","XXB750 High Dose",{"trials":36309,"activeCount":103},[],{"trials":36311,"activeCount":103},[],{"trials":36313,"activeCount":103},[],{"intervention":36306,"totalTrials":437,"cells":36315},{"EARLY_PHASE1":36316,"PHASE1":36318,"PHASE2":36320,"PHASE3":36326,"PHASE4":36328,"NA":36330},{"trials":36317,"activeCount":103},[],{"trials":36319,"activeCount":103},[],{"trials":36321,"activeCount":103},[36322],{"nctId":36300,"briefTitle":36301,"status":134,"phases":36323,"primaryCompletion":36303,"completion":36303,"start":34043,"enrollment":2948,"conditions":36324,"interventions":36325},[92],[15870],[36291,36306,36307,17350],{"trials":36327,"activeCount":103},[],{"trials":36329,"activeCount":103},[],{"trials":36331,"activeCount":103},[],{"intervention":36307,"totalTrials":437,"cells":36333},{"EARLY_PHASE1":36334,"PHASE1":36336,"PHASE2":36338,"PHASE3":36344,"PHASE4":36346,"NA":36348},{"trials":36335,"activeCount":103},[],{"trials":36337,"activeCount":103},[],{"trials":36339,"activeCount":103},[36340],{"nctId":36300,"briefTitle":36301,"status":134,"phases":36341,"primaryCompletion":36303,"completion":36303,"start":34043,"enrollment":2948,"conditions":36342,"interventions":36343},[92],[15870],[36291,36306,36307,17350],{"trials":36345,"activeCount":103},[],{"trials":36347,"activeCount":103},[],{"trials":36349,"activeCount":103},[],{"intervention":36351,"totalTrials":437,"cells":36352},"Ranolazine 500 mg",{"EARLY_PHASE1":36353,"PHASE1":36355,"PHASE2":36357,"PHASE3":36368,"PHASE4":36370,"NA":36372},{"trials":36354,"activeCount":103},[],{"trials":36356,"activeCount":103},[],{"trials":36358,"activeCount":103},[36359],{"nctId":36360,"briefTitle":36361,"status":134,"phases":36362,"primaryCompletion":36363,"completion":36363,"start":36364,"enrollment":814,"conditions":36365,"interventions":36367},"NCT01562041","Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease",[92],"2014-01-02","2012-03-09",[36366],"Atherosclerotic Coronary Vascular Disease",[36351],{"trials":36369,"activeCount":103},[],{"trials":36371,"activeCount":103},[],{"trials":36373,"activeCount":103},[],{"intervention":36375,"totalTrials":437,"cells":36376},"STI571 400 mg",{"EARLY_PHASE1":36377,"PHASE1":36379,"PHASE2":36381,"PHASE3":36393,"PHASE4":36395,"NA":36397},{"trials":36378,"activeCount":103},[],{"trials":36380,"activeCount":103},[],{"trials":36382,"activeCount":103},[36383],{"nctId":36384,"briefTitle":36385,"status":123,"phases":36386,"primaryCompletion":36387,"completion":36387,"start":36388,"enrollment":15225,"conditions":36389,"interventions":36391},"NCT00171249","An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia",[92],"2013-09-23","1999-08-09",[36390,3204,2569],"Philadelphia Positive Chronic Myeloid Leukemia",[36375,36392],"STI571 600 mg",{"trials":36394,"activeCount":103},[],{"trials":36396,"activeCount":103},[],{"trials":36398,"activeCount":103},[],{"intervention":36392,"totalTrials":437,"cells":36400},{"EARLY_PHASE1":36401,"PHASE1":36403,"PHASE2":36405,"PHASE3":36411,"PHASE4":36413,"NA":36415},{"trials":36402,"activeCount":103},[],{"trials":36404,"activeCount":103},[],{"trials":36406,"activeCount":103},[36407],{"nctId":36384,"briefTitle":36385,"status":123,"phases":36408,"primaryCompletion":36387,"completion":36387,"start":36388,"enrollment":15225,"conditions":36409,"interventions":36410},[92],[36390,3204,2569],[36375,36392],{"trials":36412,"activeCount":103},[],{"trials":36414,"activeCount":103},[],{"trials":36416,"activeCount":103},[],{"intervention":36418,"totalTrials":437,"cells":36419},"RAF265",{"EARLY_PHASE1":36420,"PHASE1":36422,"PHASE2":36424,"PHASE3":36432,"PHASE4":36434,"NA":36436},{"trials":36421,"activeCount":103},[],{"trials":36423,"activeCount":103},[],{"trials":36425,"activeCount":103},[36426],{"nctId":36427,"briefTitle":36428,"status":123,"phases":36429,"primaryCompletion":4669,"completion":4669,"start":16010,"enrollment":314,"conditions":36430,"interventions":36431},"NCT00304525","A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma",[91,92],[13652],[36418],{"trials":36433,"activeCount":103},[],{"trials":36435,"activeCount":103},[],{"trials":36437,"activeCount":103},[],{"intervention":36439,"totalTrials":437,"cells":36440},"KRP203 - 1.2mg",{"EARLY_PHASE1":36441,"PHASE1":36443,"PHASE2":36445,"PHASE3":36454,"PHASE4":36456,"NA":36458},{"trials":36442,"activeCount":103},[],{"trials":36444,"activeCount":103},[],{"trials":36446,"activeCount":103},[36447],{"nctId":36448,"briefTitle":36449,"status":123,"phases":36450,"primaryCompletion":1761,"completion":1761,"start":3760,"enrollment":5594,"conditions":36451,"interventions":36453},"NCT01294774","Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus",[92],[36452],"Subacute Cutaneous Lupus Erythematosus",[36439],{"trials":36455,"activeCount":103},[],{"trials":36457,"activeCount":103},[],{"trials":36459,"activeCount":103},[],{"intervention":16617,"totalTrials":437,"cells":36461},{"EARLY_PHASE1":36462,"PHASE1":36464,"PHASE2":36466,"PHASE3":36472,"PHASE4":36474,"NA":36476},{"trials":36463,"activeCount":103},[],{"trials":36465,"activeCount":103},[],{"trials":36467,"activeCount":103},[36468],{"nctId":16611,"briefTitle":16612,"status":123,"phases":36469,"primaryCompletion":3351,"completion":3351,"start":4707,"enrollment":16614,"conditions":36470,"interventions":36471},[92],[15133],[16617,16617,16617,16617,16617,15255,15177],{"trials":36473,"activeCount":103},[],{"trials":36475,"activeCount":103},[],{"trials":36477,"activeCount":103},[],{"intervention":31438,"totalTrials":437,"cells":36479},{"EARLY_PHASE1":36480,"PHASE1":36482,"PHASE2":36484,"PHASE3":36490,"PHASE4":36492,"NA":36494},{"trials":36481,"activeCount":103},[],{"trials":36483,"activeCount":103},[],{"trials":36485,"activeCount":103},[36486],{"nctId":31431,"briefTitle":31432,"status":123,"phases":36487,"primaryCompletion":31434,"completion":31434,"start":31435,"enrollment":2633,"conditions":36488,"interventions":36489},[92],[31391],[18982,31438],{"trials":36491,"activeCount":103},[],{"trials":36493,"activeCount":103},[],{"trials":36495,"activeCount":103},[],{"intervention":7414,"totalTrials":437,"cells":36497},{"EARLY_PHASE1":36498,"PHASE1":36500,"PHASE2":36502,"PHASE3":36508,"PHASE4":36510,"NA":36512},{"trials":36499,"activeCount":103},[],{"trials":36501,"activeCount":103},[],{"trials":36503,"activeCount":103},[36504],{"nctId":7405,"briefTitle":7406,"status":123,"phases":36505,"primaryCompletion":7408,"completion":7409,"start":7410,"enrollment":5594,"conditions":36506,"interventions":36507},[92],[7412],[5895,7414,7415],{"trials":36509,"activeCount":103},[],{"trials":36511,"activeCount":103},[],{"trials":36513,"activeCount":103},[],{"intervention":36515,"totalTrials":437,"cells":36516},"NVA237 12.5 µg once daily",{"EARLY_PHASE1":36517,"PHASE1":36519,"PHASE2":36521,"PHASE3":36536,"PHASE4":36538,"NA":36540},{"trials":36518,"activeCount":103},[],{"trials":36520,"activeCount":103},[],{"trials":36522,"activeCount":103},[36523],{"nctId":36524,"briefTitle":36525,"status":123,"phases":36526,"primaryCompletion":4372,"completion":4372,"start":4081,"enrollment":36527,"conditions":36528,"interventions":36529},"NCT01119950","Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],388,[24],[36515,36530,36531,36532,36533,36534,36535],"NVA237 25.0 µg once daily","NVA237 12.5 µg twice daily","NVA237 50.0 µg once daily","NVA237 25.0 µg twice daily","NVA237 100.0 µg once daily","NVA237 50.0 µg twice daily",{"trials":36537,"activeCount":103},[],{"trials":36539,"activeCount":103},[],{"trials":36541,"activeCount":103},[],{"intervention":36530,"totalTrials":437,"cells":36543},{"EARLY_PHASE1":36544,"PHASE1":36546,"PHASE2":36548,"PHASE3":36554,"PHASE4":36556,"NA":36558},{"trials":36545,"activeCount":103},[],{"trials":36547,"activeCount":103},[],{"trials":36549,"activeCount":103},[36550],{"nctId":36524,"briefTitle":36525,"status":123,"phases":36551,"primaryCompletion":4372,"completion":4372,"start":4081,"enrollment":36527,"conditions":36552,"interventions":36553},[92],[24],[36515,36530,36531,36532,36533,36534,36535],{"trials":36555,"activeCount":103},[],{"trials":36557,"activeCount":103},[],{"trials":36559,"activeCount":103},[],{"intervention":36531,"totalTrials":437,"cells":36561},{"EARLY_PHASE1":36562,"PHASE1":36564,"PHASE2":36566,"PHASE3":36572,"PHASE4":36574,"NA":36576},{"trials":36563,"activeCount":103},[],{"trials":36565,"activeCount":103},[],{"trials":36567,"activeCount":103},[36568],{"nctId":36524,"briefTitle":36525,"status":123,"phases":36569,"primaryCompletion":4372,"completion":4372,"start":4081,"enrollment":36527,"conditions":36570,"interventions":36571},[92],[24],[36515,36530,36531,36532,36533,36534,36535],{"trials":36573,"activeCount":103},[],{"trials":36575,"activeCount":103},[],{"trials":36577,"activeCount":103},[],{"intervention":36532,"totalTrials":437,"cells":36579},{"EARLY_PHASE1":36580,"PHASE1":36582,"PHASE2":36584,"PHASE3":36590,"PHASE4":36592,"NA":36594},{"trials":36581,"activeCount":103},[],{"trials":36583,"activeCount":103},[],{"trials":36585,"activeCount":103},[36586],{"nctId":36524,"briefTitle":36525,"status":123,"phases":36587,"primaryCompletion":4372,"completion":4372,"start":4081,"enrollment":36527,"conditions":36588,"interventions":36589},[92],[24],[36515,36530,36531,36532,36533,36534,36535],{"trials":36591,"activeCount":103},[],{"trials":36593,"activeCount":103},[],{"trials":36595,"activeCount":103},[],{"intervention":36533,"totalTrials":437,"cells":36597},{"EARLY_PHASE1":36598,"PHASE1":36600,"PHASE2":36602,"PHASE3":36608,"PHASE4":36610,"NA":36612},{"trials":36599,"activeCount":103},[],{"trials":36601,"activeCount":103},[],{"trials":36603,"activeCount":103},[36604],{"nctId":36524,"briefTitle":36525,"status":123,"phases":36605,"primaryCompletion":4372,"completion":4372,"start":4081,"enrollment":36527,"conditions":36606,"interventions":36607},[92],[24],[36515,36530,36531,36532,36533,36534,36535],{"trials":36609,"activeCount":103},[],{"trials":36611,"activeCount":103},[],{"trials":36613,"activeCount":103},[],{"intervention":36534,"totalTrials":437,"cells":36615},{"EARLY_PHASE1":36616,"PHASE1":36618,"PHASE2":36620,"PHASE3":36626,"PHASE4":36628,"NA":36630},{"trials":36617,"activeCount":103},[],{"trials":36619,"activeCount":103},[],{"trials":36621,"activeCount":103},[36622],{"nctId":36524,"briefTitle":36525,"status":123,"phases":36623,"primaryCompletion":4372,"completion":4372,"start":4081,"enrollment":36527,"conditions":36624,"interventions":36625},[92],[24],[36515,36530,36531,36532,36533,36534,36535],{"trials":36627,"activeCount":103},[],{"trials":36629,"activeCount":103},[],{"trials":36631,"activeCount":103},[],{"intervention":36535,"totalTrials":437,"cells":36633},{"EARLY_PHASE1":36634,"PHASE1":36636,"PHASE2":36638,"PHASE3":36644,"PHASE4":36646,"NA":36648},{"trials":36635,"activeCount":103},[],{"trials":36637,"activeCount":103},[],{"trials":36639,"activeCount":103},[36640],{"nctId":36524,"briefTitle":36525,"status":123,"phases":36641,"primaryCompletion":4372,"completion":4372,"start":4081,"enrollment":36527,"conditions":36642,"interventions":36643},[92],[24],[36515,36530,36531,36532,36533,36534,36535],{"trials":36645,"activeCount":103},[],{"trials":36647,"activeCount":103},[],{"trials":36649,"activeCount":103},[],{"intervention":11138,"totalTrials":437,"cells":36651},{"EARLY_PHASE1":36652,"PHASE1":36654,"PHASE2":36656,"PHASE3":36662,"PHASE4":36664,"NA":36666},{"trials":36653,"activeCount":103},[],{"trials":36655,"activeCount":103},[],{"trials":36657,"activeCount":103},[36658],{"nctId":11131,"briefTitle":11132,"status":134,"phases":36659,"primaryCompletion":351,"completion":351,"start":11134,"enrollment":2832,"conditions":36660,"interventions":36661},[92],[11136],[6519,11138],{"trials":36663,"activeCount":103},[],{"trials":36665,"activeCount":103},[],{"trials":36667,"activeCount":103},[],{"intervention":36669,"totalTrials":437,"cells":36670},"QUC398",{"EARLY_PHASE1":36671,"PHASE1":36673,"PHASE2":36675,"PHASE3":36687,"PHASE4":36689,"NA":36691},{"trials":36672,"activeCount":103},[],{"trials":36674,"activeCount":103},[],{"trials":36676,"activeCount":103},[36677],{"nctId":36678,"briefTitle":36679,"status":134,"phases":36680,"primaryCompletion":36681,"completion":36682,"start":382,"enrollment":36683,"conditions":36684,"interventions":36686},"NCT05462990","A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA",[92],"2024-08-02","2025-04-08",101,[36685],"Osteoarthritis, Knee",[36669],{"trials":36688,"activeCount":103},[],{"trials":36690,"activeCount":103},[],{"trials":36692,"activeCount":103},[],{"intervention":10510,"totalTrials":437,"cells":36694},{"EARLY_PHASE1":36695,"PHASE1":36697,"PHASE2":36699,"PHASE3":36705,"PHASE4":36707,"NA":36709},{"trials":36696,"activeCount":103},[],{"trials":36698,"activeCount":103},[],{"trials":36700,"activeCount":103},[36701],{"nctId":10504,"briefTitle":10505,"status":134,"phases":36702,"primaryCompletion":10507,"completion":10507,"start":313,"enrollment":2379,"conditions":36703,"interventions":36704},[92],[5636],[10510,10511,5639,10512],{"trials":36706,"activeCount":103},[],{"trials":36708,"activeCount":103},[],{"trials":36710,"activeCount":103},[],{"intervention":10511,"totalTrials":437,"cells":36712},{"EARLY_PHASE1":36713,"PHASE1":36715,"PHASE2":36717,"PHASE3":36723,"PHASE4":36725,"NA":36727},{"trials":36714,"activeCount":103},[],{"trials":36716,"activeCount":103},[],{"trials":36718,"activeCount":103},[36719],{"nctId":10504,"briefTitle":10505,"status":134,"phases":36720,"primaryCompletion":10507,"completion":10507,"start":313,"enrollment":2379,"conditions":36721,"interventions":36722},[92],[5636],[10510,10511,5639,10512],{"trials":36724,"activeCount":103},[],{"trials":36726,"activeCount":103},[],{"trials":36728,"activeCount":103},[],{"intervention":10512,"totalTrials":437,"cells":36730},{"EARLY_PHASE1":36731,"PHASE1":36733,"PHASE2":36735,"PHASE3":36741,"PHASE4":36743,"NA":36745},{"trials":36732,"activeCount":103},[],{"trials":36734,"activeCount":103},[],{"trials":36736,"activeCount":103},[36737],{"nctId":10504,"briefTitle":10505,"status":134,"phases":36738,"primaryCompletion":10507,"completion":10507,"start":313,"enrollment":2379,"conditions":36739,"interventions":36740},[92],[5636],[10510,10511,5639,10512],{"trials":36742,"activeCount":103},[],{"trials":36744,"activeCount":103},[],{"trials":36746,"activeCount":103},[],{"intervention":36748,"totalTrials":437,"cells":36749},"AQW051 2 mg",{"EARLY_PHASE1":36750,"PHASE1":36752,"PHASE2":36754,"PHASE3":36765,"PHASE4":36767,"NA":36769},{"trials":36751,"activeCount":103},[],{"trials":36753,"activeCount":103},[],{"trials":36755,"activeCount":103},[36756],{"nctId":36757,"briefTitle":36758,"status":123,"phases":36759,"primaryCompletion":1818,"completion":1818,"start":853,"enrollment":3530,"conditions":36760,"interventions":36762},"NCT01163227","Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia",[92],[36761],"Schizophrenia Disorders",[36748,36763,36764],"AQW051 15mg","AQW051 100mg",{"trials":36766,"activeCount":103},[],{"trials":36768,"activeCount":103},[],{"trials":36770,"activeCount":103},[],{"intervention":36763,"totalTrials":437,"cells":36772},{"EARLY_PHASE1":36773,"PHASE1":36775,"PHASE2":36777,"PHASE3":36783,"PHASE4":36785,"NA":36787},{"trials":36774,"activeCount":103},[],{"trials":36776,"activeCount":103},[],{"trials":36778,"activeCount":103},[36779],{"nctId":36757,"briefTitle":36758,"status":123,"phases":36780,"primaryCompletion":1818,"completion":1818,"start":853,"enrollment":3530,"conditions":36781,"interventions":36782},[92],[36761],[36748,36763,36764],{"trials":36784,"activeCount":103},[],{"trials":36786,"activeCount":103},[],{"trials":36788,"activeCount":103},[],{"intervention":36764,"totalTrials":437,"cells":36790},{"EARLY_PHASE1":36791,"PHASE1":36793,"PHASE2":36795,"PHASE3":36801,"PHASE4":36803,"NA":36805},{"trials":36792,"activeCount":103},[],{"trials":36794,"activeCount":103},[],{"trials":36796,"activeCount":103},[36797],{"nctId":36757,"briefTitle":36758,"status":123,"phases":36798,"primaryCompletion":1818,"completion":1818,"start":853,"enrollment":3530,"conditions":36799,"interventions":36800},[92],[36761],[36748,36763,36764],{"trials":36802,"activeCount":103},[],{"trials":36804,"activeCount":103},[],{"trials":36806,"activeCount":103},[],{"intervention":36808,"totalTrials":437,"cells":36809},"AUY922 2 mg\u002Fm2",{"EARLY_PHASE1":36810,"PHASE1":36812,"PHASE2":36814,"PHASE3":36822,"PHASE4":36824,"NA":36826},{"trials":36811,"activeCount":103},[],{"trials":36813,"activeCount":103},[],{"trials":36815,"activeCount":103},[36816],{"nctId":36817,"briefTitle":36818,"status":123,"phases":36819,"primaryCompletion":607,"completion":607,"start":4317,"enrollment":3939,"conditions":36820,"interventions":36821},"NCT00526045","Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients",[91,92],[15,5707],[36808],{"trials":36823,"activeCount":103},[],{"trials":36825,"activeCount":103},[],{"trials":36827,"activeCount":103},[],{"intervention":36829,"totalTrials":437,"cells":36830},"LLG783",{"EARLY_PHASE1":36831,"PHASE1":36833,"PHASE2":36835,"PHASE3":36847,"PHASE4":36849,"NA":36851},{"trials":36832,"activeCount":103},[],{"trials":36834,"activeCount":103},[],{"trials":36836,"activeCount":103},[36837],{"nctId":36838,"briefTitle":36839,"status":123,"phases":36840,"primaryCompletion":36841,"completion":36842,"start":36843,"enrollment":3098,"conditions":36844,"interventions":36846},"NCT03194776","Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication",[92],"2018-09-07","2018-12-27","2017-09-20",[36845],"Peripheral Artery Disease (PAD); Intermittent Claudication",[36829],{"trials":36848,"activeCount":103},[],{"trials":36850,"activeCount":103},[],{"trials":36852,"activeCount":103},[],{"intervention":36854,"totalTrials":437,"cells":36855},"ofatumumab with PRF",{"EARLY_PHASE1":36856,"PHASE1":36858,"PHASE2":36860,"PHASE3":36870,"PHASE4":36872,"NA":36874},{"trials":36857,"activeCount":103},[],{"trials":36859,"activeCount":103},[],{"trials":36861,"activeCount":103},[36862],{"nctId":36863,"briefTitle":36864,"status":123,"phases":36865,"primaryCompletion":18879,"completion":36866,"start":16476,"enrollment":4911,"conditions":36867,"interventions":36868},"NCT03560739","A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients",[92],"2020-05-05",[27],[36854,36869],"ofatumumab with AI",{"trials":36871,"activeCount":103},[],{"trials":36873,"activeCount":103},[],{"trials":36875,"activeCount":103},[],{"intervention":36869,"totalTrials":437,"cells":36877},{"EARLY_PHASE1":36878,"PHASE1":36880,"PHASE2":36882,"PHASE3":36888,"PHASE4":36890,"NA":36892},{"trials":36879,"activeCount":103},[],{"trials":36881,"activeCount":103},[],{"trials":36883,"activeCount":103},[36884],{"nctId":36863,"briefTitle":36864,"status":123,"phases":36885,"primaryCompletion":18879,"completion":36866,"start":16476,"enrollment":4911,"conditions":36886,"interventions":36887},[92],[27],[36854,36869],{"trials":36889,"activeCount":103},[],{"trials":36891,"activeCount":103},[],{"trials":36893,"activeCount":103},[],{"intervention":36895,"totalTrials":437,"cells":36896},"Part 1: LJN452",{"EARLY_PHASE1":36897,"PHASE1":36899,"PHASE2":36901,"PHASE3":36914,"PHASE4":36916,"NA":36918},{"trials":36898,"activeCount":103},[],{"trials":36900,"activeCount":103},[],{"trials":36902,"activeCount":103},[36903],{"nctId":36904,"briefTitle":36905,"status":123,"phases":36906,"primaryCompletion":31485,"completion":31485,"start":2199,"enrollment":2354,"conditions":36907,"interventions":36909},"NCT02516605","A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients",[92],[36908],"Primary Biliary Cholangitis",[36895,36910,36911,36912,36913],"Part 1: Placebo","Part 2: LJN452 Dose level 1","Part 2: Placebo","Part 2: LJN452 Dose level 2",{"trials":36915,"activeCount":103},[],{"trials":36917,"activeCount":103},[],{"trials":36919,"activeCount":103},[],{"intervention":36910,"totalTrials":437,"cells":36921},{"EARLY_PHASE1":36922,"PHASE1":36924,"PHASE2":36926,"PHASE3":36932,"PHASE4":36934,"NA":36936},{"trials":36923,"activeCount":103},[],{"trials":36925,"activeCount":103},[],{"trials":36927,"activeCount":103},[36928],{"nctId":36904,"briefTitle":36905,"status":123,"phases":36929,"primaryCompletion":31485,"completion":31485,"start":2199,"enrollment":2354,"conditions":36930,"interventions":36931},[92],[36908],[36895,36910,36911,36912,36913],{"trials":36933,"activeCount":103},[],{"trials":36935,"activeCount":103},[],{"trials":36937,"activeCount":103},[],{"intervention":36911,"totalTrials":437,"cells":36939},{"EARLY_PHASE1":36940,"PHASE1":36942,"PHASE2":36944,"PHASE3":36950,"PHASE4":36952,"NA":36954},{"trials":36941,"activeCount":103},[],{"trials":36943,"activeCount":103},[],{"trials":36945,"activeCount":103},[36946],{"nctId":36904,"briefTitle":36905,"status":123,"phases":36947,"primaryCompletion":31485,"completion":31485,"start":2199,"enrollment":2354,"conditions":36948,"interventions":36949},[92],[36908],[36895,36910,36911,36912,36913],{"trials":36951,"activeCount":103},[],{"trials":36953,"activeCount":103},[],{"trials":36955,"activeCount":103},[],{"intervention":36912,"totalTrials":437,"cells":36957},{"EARLY_PHASE1":36958,"PHASE1":36960,"PHASE2":36962,"PHASE3":36968,"PHASE4":36970,"NA":36972},{"trials":36959,"activeCount":103},[],{"trials":36961,"activeCount":103},[],{"trials":36963,"activeCount":103},[36964],{"nctId":36904,"briefTitle":36905,"status":123,"phases":36965,"primaryCompletion":31485,"completion":31485,"start":2199,"enrollment":2354,"conditions":36966,"interventions":36967},[92],[36908],[36895,36910,36911,36912,36913],{"trials":36969,"activeCount":103},[],{"trials":36971,"activeCount":103},[],{"trials":36973,"activeCount":103},[],{"intervention":36913,"totalTrials":437,"cells":36975},{"EARLY_PHASE1":36976,"PHASE1":36978,"PHASE2":36980,"PHASE3":36986,"PHASE4":36988,"NA":36990},{"trials":36977,"activeCount":103},[],{"trials":36979,"activeCount":103},[],{"trials":36981,"activeCount":103},[36982],{"nctId":36904,"briefTitle":36905,"status":123,"phases":36983,"primaryCompletion":31485,"completion":31485,"start":2199,"enrollment":2354,"conditions":36984,"interventions":36985},[92],[36908],[36895,36910,36911,36912,36913],{"trials":36987,"activeCount":103},[],{"trials":36989,"activeCount":103},[],{"trials":36991,"activeCount":103},[],{"intervention":36993,"totalTrials":437,"cells":36994},"ECF843",{"EARLY_PHASE1":36995,"PHASE1":36997,"PHASE2":36999,"PHASE3":37009,"PHASE4":37011,"NA":37013},{"trials":36996,"activeCount":103},[],{"trials":36998,"activeCount":103},[],{"trials":37000,"activeCount":103},[37001],{"nctId":37002,"briefTitle":37003,"status":123,"phases":37004,"primaryCompletion":37005,"completion":37005,"start":37006,"enrollment":30484,"conditions":37007,"interventions":37008},"NCT04391894","A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease",[92],"2021-05-13","2020-10-06",[20632],[36993],{"trials":37010,"activeCount":103},[],{"trials":37012,"activeCount":103},[],{"trials":37014,"activeCount":103},[],{"intervention":10722,"totalTrials":437,"cells":37016},{"EARLY_PHASE1":37017,"PHASE1":37019,"PHASE2":37021,"PHASE3":37027,"PHASE4":37029,"NA":37031},{"trials":37018,"activeCount":103},[],{"trials":37020,"activeCount":103},[],{"trials":37022,"activeCount":103},[37023],{"nctId":10716,"briefTitle":10717,"status":390,"phases":37024,"primaryCompletion":10431,"completion":10431,"start":10719,"enrollment":103,"conditions":37025,"interventions":37026},[91,92],[5723,2569],[2409,10722,7513],{"trials":37028,"activeCount":103},[],{"trials":37030,"activeCount":103},[],{"trials":37032,"activeCount":103},[],{"intervention":37034,"totalTrials":437,"cells":37035},"Indacaterol acetate 75 μg",{"EARLY_PHASE1":37036,"PHASE1":37038,"PHASE2":37040,"PHASE3":37050,"PHASE4":37052,"NA":37054},{"trials":37037,"activeCount":103},[],{"trials":37039,"activeCount":103},[],{"trials":37041,"activeCount":103},[37042],{"nctId":37043,"briefTitle":37044,"status":123,"phases":37045,"primaryCompletion":24204,"completion":37046,"start":2267,"enrollment":4360,"conditions":37047,"interventions":37048},"NCT02892019","Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma",[92],"2019-07-17",[18],[37034,37049],"Indacaterol acetate 150 μg",{"trials":37051,"activeCount":103},[],{"trials":37053,"activeCount":103},[],{"trials":37055,"activeCount":103},[],{"intervention":37049,"totalTrials":437,"cells":37057},{"EARLY_PHASE1":37058,"PHASE1":37060,"PHASE2":37062,"PHASE3":37068,"PHASE4":37070,"NA":37072},{"trials":37059,"activeCount":103},[],{"trials":37061,"activeCount":103},[],{"trials":37063,"activeCount":103},[37064],{"nctId":37043,"briefTitle":37044,"status":123,"phases":37065,"primaryCompletion":24204,"completion":37046,"start":2267,"enrollment":4360,"conditions":37066,"interventions":37067},[92],[18],[37034,37049],{"trials":37069,"activeCount":103},[],{"trials":37071,"activeCount":103},[],{"trials":37073,"activeCount":103},[],{"intervention":32965,"totalTrials":437,"cells":37075},{"EARLY_PHASE1":37076,"PHASE1":37078,"PHASE2":37080,"PHASE3":37086,"PHASE4":37088,"NA":37090},{"trials":37077,"activeCount":103},[],{"trials":37079,"activeCount":103},[],{"trials":37081,"activeCount":103},[37082],{"nctId":32958,"briefTitle":32959,"status":123,"phases":37083,"primaryCompletion":32961,"completion":32962,"start":16476,"enrollment":15538,"conditions":37084,"interventions":37085},[92],[32955],[11371,32965],{"trials":37087,"activeCount":103},[],{"trials":37089,"activeCount":103},[],{"trials":37091,"activeCount":103},[],{"intervention":24373,"totalTrials":437,"cells":37093},{"EARLY_PHASE1":37094,"PHASE1":37096,"PHASE2":37098,"PHASE3":37104,"PHASE4":37106,"NA":37108},{"trials":37095,"activeCount":103},[],{"trials":37097,"activeCount":103},[],{"trials":37099,"activeCount":103},[37100],{"nctId":24367,"briefTitle":24368,"status":123,"phases":37101,"primaryCompletion":6451,"completion":2403,"start":1505,"enrollment":24370,"conditions":37102,"interventions":37103},[92],[10902],[24360,24373,10927],{"trials":37105,"activeCount":103},[],{"trials":37107,"activeCount":103},[],{"trials":37109,"activeCount":103},[],{"intervention":37111,"totalTrials":437,"cells":37112},"Mycograb",{"EARLY_PHASE1":37113,"PHASE1":37115,"PHASE2":37117,"PHASE3":37126,"PHASE4":37128,"NA":37130},{"trials":37114,"activeCount":103},[],{"trials":37116,"activeCount":103},[],{"trials":37118,"activeCount":103},[37119],{"nctId":37120,"briefTitle":37121,"status":134,"phases":37122,"primaryCompletion":3194,"completion":3194,"start":3474,"enrollment":317,"conditions":37123,"interventions":37125},"NCT00324025","Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS",[92],[37124],"Cryptococcal Meningitis",[37111],{"trials":37127,"activeCount":103},[],{"trials":37129,"activeCount":103},[],{"trials":37131,"activeCount":103},[],{"intervention":37133,"totalTrials":437,"cells":37134},"KRP203",{"EARLY_PHASE1":37135,"PHASE1":37137,"PHASE2":37139,"PHASE3":37147,"PHASE4":37149,"NA":37151},{"trials":37136,"activeCount":103},[],{"trials":37138,"activeCount":103},[],{"trials":37140,"activeCount":103},[37141],{"nctId":37142,"briefTitle":37143,"status":134,"phases":37144,"primaryCompletion":5733,"completion":5733,"start":4372,"enrollment":34,"conditions":37145,"interventions":37146},"NCT01375179","Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients",[92],[32022],[37133],{"trials":37148,"activeCount":103},[],{"trials":37150,"activeCount":103},[],{"trials":37152,"activeCount":103},[],{"intervention":37154,"totalTrials":437,"cells":37155},"Iscalimab",{"EARLY_PHASE1":37156,"PHASE1":37158,"PHASE2":37160,"PHASE3":37170,"PHASE4":37172,"NA":37174},{"trials":37157,"activeCount":103},[],{"trials":37159,"activeCount":103},[],{"trials":37161,"activeCount":103},[37162],{"nctId":37163,"briefTitle":37164,"status":123,"phases":37165,"primaryCompletion":24235,"completion":24235,"start":37166,"enrollment":1203,"conditions":37167,"interventions":37169},"NCT04541589","Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome",[92],"2021-01-05",[37168],"Sjogren's Syndrome",[37154],{"trials":37171,"activeCount":103},[],{"trials":37173,"activeCount":103},[],{"trials":37175,"activeCount":103},[],{"intervention":9850,"totalTrials":437,"cells":37177},{"EARLY_PHASE1":37178,"PHASE1":37180,"PHASE2":37182,"PHASE3":37188,"PHASE4":37190,"NA":37192},{"trials":37179,"activeCount":103},[],{"trials":37181,"activeCount":103},[],{"trials":37183,"activeCount":103},[37184],{"nctId":9843,"briefTitle":9844,"status":390,"phases":37185,"primaryCompletion":6372,"completion":2938,"start":9846,"enrollment":103,"conditions":37186,"interventions":37187},[91,92],[9848],[4393,9823,9850,9825,9851,9852,5207],{"trials":37189,"activeCount":103},[],{"trials":37191,"activeCount":103},[],{"trials":37193,"activeCount":103},[],{"intervention":9851,"totalTrials":437,"cells":37195},{"EARLY_PHASE1":37196,"PHASE1":37198,"PHASE2":37200,"PHASE3":37206,"PHASE4":37208,"NA":37210},{"trials":37197,"activeCount":103},[],{"trials":37199,"activeCount":103},[],{"trials":37201,"activeCount":103},[37202],{"nctId":9843,"briefTitle":9844,"status":390,"phases":37203,"primaryCompletion":6372,"completion":2938,"start":9846,"enrollment":103,"conditions":37204,"interventions":37205},[91,92],[9848],[4393,9823,9850,9825,9851,9852,5207],{"trials":37207,"activeCount":103},[],{"trials":37209,"activeCount":103},[],{"trials":37211,"activeCount":103},[],{"intervention":9852,"totalTrials":437,"cells":37213},{"EARLY_PHASE1":37214,"PHASE1":37216,"PHASE2":37218,"PHASE3":37224,"PHASE4":37226,"NA":37228},{"trials":37215,"activeCount":103},[],{"trials":37217,"activeCount":103},[],{"trials":37219,"activeCount":103},[37220],{"nctId":9843,"briefTitle":9844,"status":390,"phases":37221,"primaryCompletion":6372,"completion":2938,"start":9846,"enrollment":103,"conditions":37222,"interventions":37223},[91,92],[9848],[4393,9823,9850,9825,9851,9852,5207],{"trials":37225,"activeCount":103},[],{"trials":37227,"activeCount":103},[],{"trials":37229,"activeCount":103},[],{"intervention":247,"totalTrials":437,"cells":37231},{"EARLY_PHASE1":37232,"PHASE1":37234,"PHASE2":37236,"PHASE3":37242,"PHASE4":37244,"NA":37246},{"trials":37233,"activeCount":103},[],{"trials":37235,"activeCount":103},[],{"trials":37237,"activeCount":103},[37238],{"nctId":238,"briefTitle":239,"status":123,"phases":37239,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":37240,"interventions":37241},[92],[15],[247,98,248,249,250],{"trials":37243,"activeCount":103},[],{"trials":37245,"activeCount":103},[],{"trials":37247,"activeCount":103},[],{"intervention":248,"totalTrials":437,"cells":37249},{"EARLY_PHASE1":37250,"PHASE1":37252,"PHASE2":37254,"PHASE3":37260,"PHASE4":37262,"NA":37264},{"trials":37251,"activeCount":103},[],{"trials":37253,"activeCount":103},[],{"trials":37255,"activeCount":103},[37256],{"nctId":238,"briefTitle":239,"status":123,"phases":37257,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":37258,"interventions":37259},[92],[15],[247,98,248,249,250],{"trials":37261,"activeCount":103},[],{"trials":37263,"activeCount":103},[],{"trials":37265,"activeCount":103},[],{"intervention":22887,"totalTrials":437,"cells":37267},{"EARLY_PHASE1":37268,"PHASE1":37270,"PHASE2":37272,"PHASE3":37278,"PHASE4":37280,"NA":37282},{"trials":37269,"activeCount":103},[],{"trials":37271,"activeCount":103},[],{"trials":37273,"activeCount":103},[37274],{"nctId":22881,"briefTitle":22882,"status":123,"phases":37275,"primaryCompletion":3799,"completion":3799,"start":5062,"enrollment":485,"conditions":37276,"interventions":37277},[92],[22885],[11428,22887,11428],{"trials":37279,"activeCount":103},[],{"trials":37281,"activeCount":103},[],{"trials":37283,"activeCount":103},[],{"intervention":37285,"totalTrials":437,"cells":37286},"albinterferon alfa-2b",{"EARLY_PHASE1":37287,"PHASE1":37289,"PHASE2":37291,"PHASE3":37300,"PHASE4":37302,"NA":37304},{"trials":37288,"activeCount":103},[],{"trials":37290,"activeCount":103},[],{"trials":37292,"activeCount":103},[37293],{"nctId":37294,"briefTitle":37295,"status":134,"phases":37296,"primaryCompletion":926,"start":4845,"enrollment":1434,"conditions":37297,"interventions":37298},"NCT00964665","Pharmacokinetic\u002FPharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects",[91,92],[17418],[37285,37285,37285,37285,37299],"Pegasys®",{"trials":37301,"activeCount":103},[],{"trials":37303,"activeCount":103},[],{"trials":37305,"activeCount":103},[],{"intervention":37299,"totalTrials":437,"cells":37307},{"EARLY_PHASE1":37308,"PHASE1":37310,"PHASE2":37312,"PHASE3":37318,"PHASE4":37320,"NA":37322},{"trials":37309,"activeCount":103},[],{"trials":37311,"activeCount":103},[],{"trials":37313,"activeCount":103},[37314],{"nctId":37294,"briefTitle":37295,"status":134,"phases":37315,"primaryCompletion":926,"start":4845,"enrollment":1434,"conditions":37316,"interventions":37317},[91,92],[17418],[37285,37285,37285,37285,37299],{"trials":37319,"activeCount":103},[],{"trials":37321,"activeCount":103},[],{"trials":37323,"activeCount":103},[],{"intervention":37325,"totalTrials":437,"cells":37326},"PTK787\u002FZK 222584",{"EARLY_PHASE1":37327,"PHASE1":37329,"PHASE2":37331,"PHASE3":37342,"PHASE4":37344,"NA":37346},{"trials":37328,"activeCount":103},[],{"trials":37330,"activeCount":103},[],{"trials":37332,"activeCount":103},[37333],{"nctId":37334,"briefTitle":37335,"status":123,"phases":37336,"primaryCompletion":745,"start":989,"enrollment":4148,"conditions":37337,"interventions":37341},"NCT00052013","Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787\u002FZK 222584",[92],[37338,37339,37340],"Von Hippel-Lindau Disease","CNS Hemangioblastoma","Retinal Hemangioblastoma",[37325],{"trials":37343,"activeCount":103},[],{"trials":37345,"activeCount":103},[],{"trials":37347,"activeCount":103},[],{"intervention":7628,"totalTrials":437,"cells":37349},{"EARLY_PHASE1":37350,"PHASE1":37352,"PHASE2":37354,"PHASE3":37360,"PHASE4":37362,"NA":37364},{"trials":37351,"activeCount":103},[],{"trials":37353,"activeCount":103},[],{"trials":37355,"activeCount":103},[37356],{"nctId":7622,"briefTitle":7623,"status":123,"phases":37357,"primaryCompletion":7625,"completion":7625,"start":542,"enrollment":3322,"conditions":37358,"interventions":37359},[91,92],[4691],[6519,4765,4768,4769,7628],{"trials":37361,"activeCount":103},[],{"trials":37363,"activeCount":103},[],{"trials":37365,"activeCount":103},[],{"intervention":37367,"totalTrials":437,"cells":37368},"Everolimus 10 mg",{"EARLY_PHASE1":37369,"PHASE1":37371,"PHASE2":37373,"PHASE3":37386,"PHASE4":37388,"NA":37390},{"trials":37370,"activeCount":103},[],{"trials":37372,"activeCount":103},[],{"trials":37374,"activeCount":103},[37375],{"nctId":37376,"briefTitle":37377,"status":123,"phases":37378,"primaryCompletion":917,"completion":607,"start":745,"enrollment":4532,"conditions":37379,"interventions":37384},"NCT00363051","Safety\u002FEfficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy",[92],[37380,37381,37382,37383],"Islet Cell Carcinoma","Neuroendocrine Carcinoma","Neuroendocrine Tumor","Pancreatic Neoplasms",[37367,37385],"Octreotide Depot",{"trials":37387,"activeCount":103},[],{"trials":37389,"activeCount":103},[],{"trials":37391,"activeCount":103},[],{"intervention":37385,"totalTrials":437,"cells":37393},{"EARLY_PHASE1":37394,"PHASE1":37396,"PHASE2":37398,"PHASE3":37404,"PHASE4":37406,"NA":37408},{"trials":37395,"activeCount":103},[],{"trials":37397,"activeCount":103},[],{"trials":37399,"activeCount":103},[37400],{"nctId":37376,"briefTitle":37377,"status":123,"phases":37401,"primaryCompletion":917,"completion":607,"start":745,"enrollment":4532,"conditions":37402,"interventions":37403},[92],[37380,37381,37382,37383],[37367,37385],{"trials":37405,"activeCount":103},[],{"trials":37407,"activeCount":103},[],{"trials":37409,"activeCount":103},[],{"intervention":37411,"totalTrials":437,"cells":37412},"Lapatinib\u002Fnab-Paclitaxel",{"EARLY_PHASE1":37413,"PHASE1":37415,"PHASE2":37417,"PHASE3":37427,"PHASE4":37429,"NA":37431},{"trials":37414,"activeCount":103},[],{"trials":37416,"activeCount":103},[],{"trials":37418,"activeCount":103},[37419],{"nctId":37420,"briefTitle":37421,"status":123,"phases":37422,"primaryCompletion":37423,"completion":2852,"start":37424,"enrollment":1423,"conditions":37425,"interventions":37426},"NCT00709761","Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC",[92],"2011-01-05","2008-07-02",[7868],[37411],{"trials":37428,"activeCount":103},[],{"trials":37430,"activeCount":103},[],{"trials":37432,"activeCount":103},[],{"intervention":37434,"totalTrials":437,"cells":37435},"Nilotinib followed by treatment-free",{"EARLY_PHASE1":37436,"PHASE1":37438,"PHASE2":37440,"PHASE3":37450,"PHASE4":37452,"NA":37454},{"trials":37437,"activeCount":103},[],{"trials":37439,"activeCount":103},[],{"trials":37441,"activeCount":103},[37442],{"nctId":37443,"briefTitle":37444,"status":123,"phases":37445,"primaryCompletion":22169,"completion":37446,"start":37447,"enrollment":19027,"conditions":37448,"interventions":37449},"NCT01784068","Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients",[92],"2025-01-23","2013-03-19",[3228],[37434],{"trials":37451,"activeCount":103},[],{"trials":37453,"activeCount":103},[],{"trials":37455,"activeCount":103},[],{"intervention":37457,"totalTrials":437,"cells":37458},"CGF166",{"EARLY_PHASE1":37459,"PHASE1":37461,"PHASE2":37463,"PHASE3":37472,"PHASE4":37474,"NA":37476},{"trials":37460,"activeCount":103},[],{"trials":37462,"activeCount":103},[],{"trials":37464,"activeCount":103},[37465],{"nctId":37466,"briefTitle":37467,"status":123,"phases":37468,"primaryCompletion":7459,"completion":7459,"start":18761,"enrollment":2633,"conditions":37469,"interventions":37471},"NCT02132130","Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss",[91,92],[37470],"Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss",[37457],{"trials":37473,"activeCount":103},[],{"trials":37475,"activeCount":103},[],{"trials":37477,"activeCount":103},[],{"intervention":4519,"totalTrials":437,"cells":37479},{"EARLY_PHASE1":37480,"PHASE1":37482,"PHASE2":37484,"PHASE3":37490,"PHASE4":37492,"NA":37494},{"trials":37481,"activeCount":103},[],{"trials":37483,"activeCount":103},[],{"trials":37485,"activeCount":103},[37486],{"nctId":4511,"briefTitle":4512,"status":123,"phases":37487,"primaryCompletion":4514,"completion":4514,"start":4515,"enrollment":4516,"conditions":37488,"interventions":37489},[92],[375],[4519,196,195],{"trials":37491,"activeCount":103},[],{"trials":37493,"activeCount":103},[],{"trials":37495,"activeCount":103},[],{"intervention":37497,"totalTrials":437,"cells":37498},"QBW276",{"EARLY_PHASE1":37499,"PHASE1":37501,"PHASE2":37503,"PHASE3":37514,"PHASE4":37516,"NA":37518},{"trials":37500,"activeCount":103},[],{"trials":37502,"activeCount":103},[],{"trials":37504,"activeCount":103},[37505],{"nctId":37506,"briefTitle":37507,"status":123,"phases":37508,"primaryCompletion":37509,"completion":37509,"start":37510,"enrollment":1672,"conditions":37511,"interventions":37513},"NCT02566044","Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis",[91,92],"2018-04-24","2017-09-27",[37512],"Pulmonary Cystic Fibrosis",[37497],{"trials":37515,"activeCount":103},[],{"trials":37517,"activeCount":103},[],{"trials":37519,"activeCount":103},[],{"intervention":37521,"totalTrials":437,"cells":37522},"Naproxen",{"EARLY_PHASE1":37523,"PHASE1":37525,"PHASE2":37527,"PHASE3":37535,"PHASE4":37537,"NA":37539},{"trials":37524,"activeCount":103},[],{"trials":37526,"activeCount":103},[],{"trials":37528,"activeCount":103},[37529],{"nctId":37530,"briefTitle":37531,"status":123,"phases":37532,"primaryCompletion":4620,"completion":4620,"start":4081,"enrollment":24640,"conditions":37533,"interventions":37534},"NCT01160822","To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee",[92],[19880],[3157,37521],{"trials":37536,"activeCount":103},[],{"trials":37538,"activeCount":103},[],{"trials":37540,"activeCount":103},[],{"intervention":32975,"totalTrials":437,"cells":37542},{"EARLY_PHASE1":37543,"PHASE1":37545,"PHASE2":37547,"PHASE3":37553,"PHASE4":37555,"NA":37557},{"trials":37544,"activeCount":103},[],{"trials":37546,"activeCount":103},[],{"trials":37548,"activeCount":103},[37549],{"nctId":32967,"briefTitle":32968,"status":134,"phases":37550,"primaryCompletion":32970,"completion":32970,"start":2101,"enrollment":32971,"conditions":37551,"interventions":37552},[92],[32973],[11371,32975],{"trials":37554,"activeCount":103},[],{"trials":37556,"activeCount":103},[],{"trials":37558,"activeCount":103},[],{"intervention":37560,"totalTrials":437,"cells":37561},"BFH772 1% ointment",{"EARLY_PHASE1":37562,"PHASE1":37564,"PHASE2":37566,"PHASE3":37577,"PHASE4":37579,"NA":37581},{"trials":37563,"activeCount":103},[],{"trials":37565,"activeCount":103},[],{"trials":37567,"activeCount":103},[37568],{"nctId":37569,"briefTitle":37570,"status":123,"phases":37571,"primaryCompletion":1671,"completion":1671,"start":1818,"enrollment":792,"conditions":37572,"interventions":37574},"NCT01449591","Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients",[92],[37573],"Erythemato-telangiectatic Rosacea",[37560,37575,37576],"Vehicle ointment","Noritate® 1% cream",{"trials":37578,"activeCount":103},[],{"trials":37580,"activeCount":103},[],{"trials":37582,"activeCount":103},[],{"intervention":37575,"totalTrials":437,"cells":37584},{"EARLY_PHASE1":37585,"PHASE1":37587,"PHASE2":37589,"PHASE3":37595,"PHASE4":37597,"NA":37599},{"trials":37586,"activeCount":103},[],{"trials":37588,"activeCount":103},[],{"trials":37590,"activeCount":103},[37591],{"nctId":37569,"briefTitle":37570,"status":123,"phases":37592,"primaryCompletion":1671,"completion":1671,"start":1818,"enrollment":792,"conditions":37593,"interventions":37594},[92],[37573],[37560,37575,37576],{"trials":37596,"activeCount":103},[],{"trials":37598,"activeCount":103},[],{"trials":37600,"activeCount":103},[],{"intervention":37576,"totalTrials":437,"cells":37602},{"EARLY_PHASE1":37603,"PHASE1":37605,"PHASE2":37607,"PHASE3":37613,"PHASE4":37615,"NA":37617},{"trials":37604,"activeCount":103},[],{"trials":37606,"activeCount":103},[],{"trials":37608,"activeCount":103},[37609],{"nctId":37569,"briefTitle":37570,"status":123,"phases":37610,"primaryCompletion":1671,"completion":1671,"start":1818,"enrollment":792,"conditions":37611,"interventions":37612},[92],[37573],[37560,37575,37576],{"trials":37614,"activeCount":103},[],{"trials":37616,"activeCount":103},[],{"trials":37618,"activeCount":103},[],{"intervention":261,"totalTrials":437,"cells":37620},{"EARLY_PHASE1":37621,"PHASE1":37623,"PHASE2":37625,"PHASE3":37631,"PHASE4":37633,"NA":37635},{"trials":37622,"activeCount":103},[],{"trials":37624,"activeCount":103},[],{"trials":37626,"activeCount":103},[37627],{"nctId":252,"briefTitle":253,"status":123,"phases":37628,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":37629,"interventions":37630},[92],[15],[261,262,263,98,264,250],{"trials":37632,"activeCount":103},[],{"trials":37634,"activeCount":103},[],{"trials":37636,"activeCount":103},[],{"intervention":262,"totalTrials":437,"cells":37638},{"EARLY_PHASE1":37639,"PHASE1":37641,"PHASE2":37643,"PHASE3":37649,"PHASE4":37651,"NA":37653},{"trials":37640,"activeCount":103},[],{"trials":37642,"activeCount":103},[],{"trials":37644,"activeCount":103},[37645],{"nctId":252,"briefTitle":253,"status":123,"phases":37646,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":37647,"interventions":37648},[92],[15],[261,262,263,98,264,250],{"trials":37650,"activeCount":103},[],{"trials":37652,"activeCount":103},[],{"trials":37654,"activeCount":103},[],{"intervention":263,"totalTrials":437,"cells":37656},{"EARLY_PHASE1":37657,"PHASE1":37659,"PHASE2":37661,"PHASE3":37667,"PHASE4":37669,"NA":37671},{"trials":37658,"activeCount":103},[],{"trials":37660,"activeCount":103},[],{"trials":37662,"activeCount":103},[37663],{"nctId":252,"briefTitle":253,"status":123,"phases":37664,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":37665,"interventions":37666},[92],[15],[261,262,263,98,264,250],{"trials":37668,"activeCount":103},[],{"trials":37670,"activeCount":103},[],{"trials":37672,"activeCount":103},[],{"intervention":264,"totalTrials":437,"cells":37674},{"EARLY_PHASE1":37675,"PHASE1":37677,"PHASE2":37679,"PHASE3":37685,"PHASE4":37687,"NA":37689},{"trials":37676,"activeCount":103},[],{"trials":37678,"activeCount":103},[],{"trials":37680,"activeCount":103},[37681],{"nctId":252,"briefTitle":253,"status":123,"phases":37682,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":37683,"interventions":37684},[92],[15],[261,262,263,98,264,250],{"trials":37686,"activeCount":103},[],{"trials":37688,"activeCount":103},[],{"trials":37690,"activeCount":103},[],{"intervention":7635,"totalTrials":437,"cells":37692},{"EARLY_PHASE1":37693,"PHASE1":37695,"PHASE2":37697,"PHASE3":37703,"PHASE4":37705,"NA":37707},{"trials":37694,"activeCount":103},[],{"trials":37696,"activeCount":103},[],{"trials":37698,"activeCount":103},[37699],{"nctId":7630,"briefTitle":7631,"status":123,"phases":37700,"primaryCompletion":4967,"completion":4967,"start":2795,"enrollment":1672,"conditions":37701,"interventions":37702},[92],[4701],[4755,7635,7636,7637,4769],{"trials":37704,"activeCount":103},[],{"trials":37706,"activeCount":103},[],{"trials":37708,"activeCount":103},[],{"intervention":7637,"totalTrials":437,"cells":37710},{"EARLY_PHASE1":37711,"PHASE1":37713,"PHASE2":37715,"PHASE3":37721,"PHASE4":37723,"NA":37725},{"trials":37712,"activeCount":103},[],{"trials":37714,"activeCount":103},[],{"trials":37716,"activeCount":103},[37717],{"nctId":7630,"briefTitle":7631,"status":123,"phases":37718,"primaryCompletion":4967,"completion":4967,"start":2795,"enrollment":1672,"conditions":37719,"interventions":37720},[92],[4701],[4755,7635,7636,7637,4769],{"trials":37722,"activeCount":103},[],{"trials":37724,"activeCount":103},[],{"trials":37726,"activeCount":103},[],{"intervention":37728,"totalTrials":437,"cells":37729},"MMF(1000mg bid) + tacrolimus + standard of care medications",{"EARLY_PHASE1":37730,"PHASE1":37732,"PHASE2":37734,"PHASE3":37744,"PHASE4":37746,"NA":37748},{"trials":37731,"activeCount":103},[],{"trials":37733,"activeCount":103},[],{"trials":37735,"activeCount":103},[37736],{"nctId":37737,"briefTitle":37738,"status":123,"phases":37739,"primaryCompletion":3759,"completion":3759,"start":4081,"enrollment":919,"conditions":37740,"interventions":37741},"NCT01128335","Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients",[92],[4645],[37728,37742,37742,37743],"sotrastaurin (200mg bid) + tacrolimus + standard of care medications","sotrastaurin (300 mg bid) + tacrolimus + standard of care medications",{"trials":37745,"activeCount":103},[],{"trials":37747,"activeCount":103},[],{"trials":37749,"activeCount":103},[],{"intervention":37742,"totalTrials":437,"cells":37751},{"EARLY_PHASE1":37752,"PHASE1":37754,"PHASE2":37756,"PHASE3":37762,"PHASE4":37764,"NA":37766},{"trials":37753,"activeCount":103},[],{"trials":37755,"activeCount":103},[],{"trials":37757,"activeCount":103},[37758],{"nctId":37737,"briefTitle":37738,"status":123,"phases":37759,"primaryCompletion":3759,"completion":3759,"start":4081,"enrollment":919,"conditions":37760,"interventions":37761},[92],[4645],[37728,37742,37742,37743],{"trials":37763,"activeCount":103},[],{"trials":37765,"activeCount":103},[],{"trials":37767,"activeCount":103},[],{"intervention":37743,"totalTrials":437,"cells":37769},{"EARLY_PHASE1":37770,"PHASE1":37772,"PHASE2":37774,"PHASE3":37780,"PHASE4":37782,"NA":37784},{"trials":37771,"activeCount":103},[],{"trials":37773,"activeCount":103},[],{"trials":37775,"activeCount":103},[37776],{"nctId":37737,"briefTitle":37738,"status":123,"phases":37777,"primaryCompletion":3759,"completion":3759,"start":4081,"enrollment":919,"conditions":37778,"interventions":37779},[92],[4645],[37728,37742,37742,37743],{"trials":37781,"activeCount":103},[],{"trials":37783,"activeCount":103},[],{"trials":37785,"activeCount":103},[],{"intervention":612,"totalTrials":437,"cells":37787},{"EARLY_PHASE1":37788,"PHASE1":37790,"PHASE2":37792,"PHASE3":37798,"PHASE4":37800,"NA":37802},{"trials":37789,"activeCount":103},[],{"trials":37791,"activeCount":103},[],{"trials":37793,"activeCount":103},[37794],{"nctId":603,"briefTitle":604,"status":134,"phases":37795,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":37796,"interventions":37797},[92],[435],[611,119,612],{"trials":37799,"activeCount":103},[],{"trials":37801,"activeCount":103},[],{"trials":37803,"activeCount":103},[],{"intervention":37805,"totalTrials":437,"cells":37806},"Indacaterol maleate 400 μg",{"EARLY_PHASE1":37807,"PHASE1":37809,"PHASE2":37811,"PHASE3":37821,"PHASE4":37823,"NA":37825},{"trials":37808,"activeCount":103},[],{"trials":37810,"activeCount":103},[],{"trials":37812,"activeCount":103},[37813],{"nctId":37814,"briefTitle":37815,"status":123,"phases":37816,"primaryCompletion":4335,"completion":4335,"start":1024,"enrollment":2439,"conditions":37817,"interventions":37818},"NCT00927901","Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma",[92],[18],[37805,37819,37820],"Indacaterol acetate 400 μg","Indacaterol xinafoate 400 μg",{"trials":37822,"activeCount":103},[],{"trials":37824,"activeCount":103},[],{"trials":37826,"activeCount":103},[],{"intervention":37819,"totalTrials":437,"cells":37828},{"EARLY_PHASE1":37829,"PHASE1":37831,"PHASE2":37833,"PHASE3":37839,"PHASE4":37841,"NA":37843},{"trials":37830,"activeCount":103},[],{"trials":37832,"activeCount":103},[],{"trials":37834,"activeCount":103},[37835],{"nctId":37814,"briefTitle":37815,"status":123,"phases":37836,"primaryCompletion":4335,"completion":4335,"start":1024,"enrollment":2439,"conditions":37837,"interventions":37838},[92],[18],[37805,37819,37820],{"trials":37840,"activeCount":103},[],{"trials":37842,"activeCount":103},[],{"trials":37844,"activeCount":103},[],{"intervention":37820,"totalTrials":437,"cells":37846},{"EARLY_PHASE1":37847,"PHASE1":37849,"PHASE2":37851,"PHASE3":37857,"PHASE4":37859,"NA":37861},{"trials":37848,"activeCount":103},[],{"trials":37850,"activeCount":103},[],{"trials":37852,"activeCount":103},[37853],{"nctId":37814,"briefTitle":37815,"status":123,"phases":37854,"primaryCompletion":4335,"completion":4335,"start":1024,"enrollment":2439,"conditions":37855,"interventions":37856},[92],[18],[37805,37819,37820],{"trials":37858,"activeCount":103},[],{"trials":37860,"activeCount":103},[],{"trials":37862,"activeCount":103},[],{"intervention":37864,"totalTrials":437,"cells":37865},"Colchicine",{"EARLY_PHASE1":37866,"PHASE1":37868,"PHASE2":37870,"PHASE3":37880,"PHASE4":37882,"NA":37884},{"trials":37867,"activeCount":103},[],{"trials":37869,"activeCount":103},[],{"trials":37871,"activeCount":103},[37872],{"nctId":37873,"briefTitle":37874,"status":123,"phases":37875,"primaryCompletion":3845,"completion":3845,"start":3552,"enrollment":677,"conditions":37876,"interventions":37878},"NCT00819585","A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)",[92],[37877],"Gout",[3157,37864,37879],"Allopurinol",{"trials":37881,"activeCount":103},[],{"trials":37883,"activeCount":103},[],{"trials":37885,"activeCount":103},[],{"intervention":37879,"totalTrials":437,"cells":37887},{"EARLY_PHASE1":37888,"PHASE1":37890,"PHASE2":37892,"PHASE3":37898,"PHASE4":37900,"NA":37902},{"trials":37889,"activeCount":103},[],{"trials":37891,"activeCount":103},[],{"trials":37893,"activeCount":103},[37894],{"nctId":37873,"briefTitle":37874,"status":123,"phases":37895,"primaryCompletion":3845,"completion":3845,"start":3552,"enrollment":677,"conditions":37896,"interventions":37897},[92],[37877],[3157,37864,37879],{"trials":37899,"activeCount":103},[],{"trials":37901,"activeCount":103},[],{"trials":37903,"activeCount":103},[],{"intervention":26022,"totalTrials":437,"cells":37905},{"EARLY_PHASE1":37906,"PHASE1":37908,"PHASE2":37910,"PHASE3":37916,"PHASE4":37918,"NA":37920},{"trials":37907,"activeCount":103},[],{"trials":37909,"activeCount":103},[],{"trials":37911,"activeCount":103},[37912],{"nctId":26016,"briefTitle":26017,"status":123,"phases":37913,"primaryCompletion":2033,"completion":2033,"start":5620,"enrollment":8239,"conditions":37914,"interventions":37915},[92],[26020],[26022,25993],{"trials":37917,"activeCount":103},[],{"trials":37919,"activeCount":103},[],{"trials":37921,"activeCount":103},[],{"intervention":37923,"totalTrials":437,"cells":37924},"Efungumab",{"EARLY_PHASE1":37925,"PHASE1":37927,"PHASE2":37929,"PHASE3":37938,"PHASE4":37940,"NA":37942},{"trials":37926,"activeCount":103},[],{"trials":37928,"activeCount":103},[],{"trials":37930,"activeCount":103},[37931],{"nctId":37932,"briefTitle":37121,"status":134,"phases":37933,"primaryCompletion":4642,"start":3210,"enrollment":5948,"conditions":37934,"interventions":37935},"NCT00847678",[92],[37124],[37923,37936,37937],"Amphotericin B","5 flucytosine",{"trials":37939,"activeCount":103},[],{"trials":37941,"activeCount":103},[],{"trials":37943,"activeCount":103},[],{"intervention":37936,"totalTrials":437,"cells":37945},{"EARLY_PHASE1":37946,"PHASE1":37948,"PHASE2":37950,"PHASE3":37956,"PHASE4":37958,"NA":37960},{"trials":37947,"activeCount":103},[],{"trials":37949,"activeCount":103},[],{"trials":37951,"activeCount":103},[37952],{"nctId":37932,"briefTitle":37121,"status":134,"phases":37953,"primaryCompletion":4642,"start":3210,"enrollment":5948,"conditions":37954,"interventions":37955},[92],[37124],[37923,37936,37937],{"trials":37957,"activeCount":103},[],{"trials":37959,"activeCount":103},[],{"trials":37961,"activeCount":103},[],{"intervention":37937,"totalTrials":437,"cells":37963},{"EARLY_PHASE1":37964,"PHASE1":37966,"PHASE2":37968,"PHASE3":37974,"PHASE4":37976,"NA":37978},{"trials":37965,"activeCount":103},[],{"trials":37967,"activeCount":103},[],{"trials":37969,"activeCount":103},[37970],{"nctId":37932,"briefTitle":37121,"status":134,"phases":37971,"primaryCompletion":4642,"start":3210,"enrollment":5948,"conditions":37972,"interventions":37973},[92],[37124],[37923,37936,37937],{"trials":37975,"activeCount":103},[],{"trials":37977,"activeCount":103},[],{"trials":37979,"activeCount":103},[],{"intervention":26257,"totalTrials":437,"cells":37981},{"EARLY_PHASE1":37982,"PHASE1":37984,"PHASE2":37986,"PHASE3":37992,"PHASE4":37994,"NA":37996},{"trials":37983,"activeCount":103},[],{"trials":37985,"activeCount":103},[],{"trials":37987,"activeCount":103},[37988],{"nctId":26252,"briefTitle":26253,"status":123,"phases":37989,"primaryCompletion":1724,"completion":1724,"start":853,"enrollment":5612,"conditions":37990,"interventions":37991},[92],[15870],[18580,26257,18581],{"trials":37993,"activeCount":103},[],{"trials":37995,"activeCount":103},[],{"trials":37997,"activeCount":103},[],{"intervention":32153,"totalTrials":437,"cells":37999},{"EARLY_PHASE1":38000,"PHASE1":38002,"PHASE2":38004,"PHASE3":38010,"PHASE4":38012,"NA":38014},{"trials":38001,"activeCount":103},[],{"trials":38003,"activeCount":103},[],{"trials":38005,"activeCount":103},[38006],{"nctId":32144,"briefTitle":32145,"status":123,"phases":38007,"primaryCompletion":32147,"completion":13087,"start":3297,"enrollment":2342,"conditions":38008,"interventions":38009},[92],[32149,32150,32151],[6737,32153],{"trials":38011,"activeCount":103},[],{"trials":38013,"activeCount":103},[],{"trials":38015,"activeCount":103},[],{"intervention":620,"totalTrials":437,"cells":38017},{"EARLY_PHASE1":38018,"PHASE1":38020,"PHASE2":38022,"PHASE3":38028,"PHASE4":38030,"NA":38032},{"trials":38019,"activeCount":103},[],{"trials":38021,"activeCount":103},[],{"trials":38023,"activeCount":103},[38024],{"nctId":614,"briefTitle":615,"status":134,"phases":38025,"primaryCompletion":256,"completion":256,"start":617,"enrollment":213,"conditions":38026,"interventions":38027},[92],[15],[88,119,620,621,622],{"trials":38029,"activeCount":103},[],{"trials":38031,"activeCount":103},[],{"trials":38033,"activeCount":103},[],{"intervention":621,"totalTrials":437,"cells":38035},{"EARLY_PHASE1":38036,"PHASE1":38038,"PHASE2":38040,"PHASE3":38046,"PHASE4":38048,"NA":38050},{"trials":38037,"activeCount":103},[],{"trials":38039,"activeCount":103},[],{"trials":38041,"activeCount":103},[38042],{"nctId":614,"briefTitle":615,"status":134,"phases":38043,"primaryCompletion":256,"completion":256,"start":617,"enrollment":213,"conditions":38044,"interventions":38045},[92],[15],[88,119,620,621,622],{"trials":38047,"activeCount":103},[],{"trials":38049,"activeCount":103},[],{"trials":38051,"activeCount":103},[],{"intervention":622,"totalTrials":437,"cells":38053},{"EARLY_PHASE1":38054,"PHASE1":38056,"PHASE2":38058,"PHASE3":38064,"PHASE4":38066,"NA":38068},{"trials":38055,"activeCount":103},[],{"trials":38057,"activeCount":103},[],{"trials":38059,"activeCount":103},[38060],{"nctId":614,"briefTitle":615,"status":134,"phases":38061,"primaryCompletion":256,"completion":256,"start":617,"enrollment":213,"conditions":38062,"interventions":38063},[92],[15],[88,119,620,621,622],{"trials":38065,"activeCount":103},[],{"trials":38067,"activeCount":103},[],{"trials":38069,"activeCount":103},[],{"intervention":38071,"totalTrials":437,"cells":38072},"secukinumab 300 mg Q4W",{"EARLY_PHASE1":38073,"PHASE1":38075,"PHASE2":38077,"PHASE3":38088,"PHASE4":38090,"NA":38092},{"trials":38074,"activeCount":103},[],{"trials":38076,"activeCount":103},[],{"trials":38078,"activeCount":103},[38079],{"nctId":38080,"briefTitle":38081,"status":123,"phases":38082,"primaryCompletion":38083,"completion":6627,"start":30857,"enrollment":2810,"conditions":38084,"interventions":38086},"NCT04300296","PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus",[92],"2021-11-16",[38085],"Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris",[38071,38087],"secukinumab 300 mg Q2W",{"trials":38089,"activeCount":103},[],{"trials":38091,"activeCount":103},[],{"trials":38093,"activeCount":103},[],{"intervention":38087,"totalTrials":437,"cells":38095},{"EARLY_PHASE1":38096,"PHASE1":38098,"PHASE2":38100,"PHASE3":38106,"PHASE4":38108,"NA":38110},{"trials":38097,"activeCount":103},[],{"trials":38099,"activeCount":103},[],{"trials":38101,"activeCount":103},[38102],{"nctId":38080,"briefTitle":38081,"status":123,"phases":38103,"primaryCompletion":38083,"completion":6627,"start":30857,"enrollment":2810,"conditions":38104,"interventions":38105},[92],[38085],[38071,38087],{"trials":38107,"activeCount":103},[],{"trials":38109,"activeCount":103},[],{"trials":38111,"activeCount":103},[],{"intervention":38113,"totalTrials":437,"cells":38114},"AAA602",{"EARLY_PHASE1":38115,"PHASE1":38117,"PHASE2":38119,"PHASE3":38135,"PHASE4":38137,"NA":38139},{"trials":38116,"activeCount":103},[],{"trials":38118,"activeCount":103},[],{"trials":38120,"activeCount":103},[38121],{"nctId":38122,"briefTitle":38123,"status":390,"phases":38124,"primaryCompletion":38125,"completion":38126,"start":38127,"enrollment":103,"conditions":38128,"interventions":38129},"NCT06881823","Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC",[91,92],"2030-03-31","2033-06-01","2026-06-29",[1654],[38113,38130,38131,38132,38133,38134],"AAA802","Gallium (68Ga) gozetotide","Piflufolastat","Flotufolastat F 18","18F-PSMA-1007",{"trials":38136,"activeCount":103},[],{"trials":38138,"activeCount":103},[],{"trials":38140,"activeCount":103},[],{"intervention":38130,"totalTrials":437,"cells":38142},{"EARLY_PHASE1":38143,"PHASE1":38145,"PHASE2":38147,"PHASE3":38153,"PHASE4":38155,"NA":38157},{"trials":38144,"activeCount":103},[],{"trials":38146,"activeCount":103},[],{"trials":38148,"activeCount":103},[38149],{"nctId":38122,"briefTitle":38123,"status":390,"phases":38150,"primaryCompletion":38125,"completion":38126,"start":38127,"enrollment":103,"conditions":38151,"interventions":38152},[91,92],[1654],[38113,38130,38131,38132,38133,38134],{"trials":38154,"activeCount":103},[],{"trials":38156,"activeCount":103},[],{"trials":38158,"activeCount":103},[],{"intervention":38131,"totalTrials":437,"cells":38160},{"EARLY_PHASE1":38161,"PHASE1":38163,"PHASE2":38165,"PHASE3":38171,"PHASE4":38173,"NA":38175},{"trials":38162,"activeCount":103},[],{"trials":38164,"activeCount":103},[],{"trials":38166,"activeCount":103},[38167],{"nctId":38122,"briefTitle":38123,"status":390,"phases":38168,"primaryCompletion":38125,"completion":38126,"start":38127,"enrollment":103,"conditions":38169,"interventions":38170},[91,92],[1654],[38113,38130,38131,38132,38133,38134],{"trials":38172,"activeCount":103},[],{"trials":38174,"activeCount":103},[],{"trials":38176,"activeCount":103},[],{"intervention":38132,"totalTrials":437,"cells":38178},{"EARLY_PHASE1":38179,"PHASE1":38181,"PHASE2":38183,"PHASE3":38189,"PHASE4":38191,"NA":38193},{"trials":38180,"activeCount":103},[],{"trials":38182,"activeCount":103},[],{"trials":38184,"activeCount":103},[38185],{"nctId":38122,"briefTitle":38123,"status":390,"phases":38186,"primaryCompletion":38125,"completion":38126,"start":38127,"enrollment":103,"conditions":38187,"interventions":38188},[91,92],[1654],[38113,38130,38131,38132,38133,38134],{"trials":38190,"activeCount":103},[],{"trials":38192,"activeCount":103},[],{"trials":38194,"activeCount":103},[],{"intervention":38133,"totalTrials":437,"cells":38196},{"EARLY_PHASE1":38197,"PHASE1":38199,"PHASE2":38201,"PHASE3":38207,"PHASE4":38209,"NA":38211},{"trials":38198,"activeCount":103},[],{"trials":38200,"activeCount":103},[],{"trials":38202,"activeCount":103},[38203],{"nctId":38122,"briefTitle":38123,"status":390,"phases":38204,"primaryCompletion":38125,"completion":38126,"start":38127,"enrollment":103,"conditions":38205,"interventions":38206},[91,92],[1654],[38113,38130,38131,38132,38133,38134],{"trials":38208,"activeCount":103},[],{"trials":38210,"activeCount":103},[],{"trials":38212,"activeCount":103},[],{"intervention":38134,"totalTrials":437,"cells":38214},{"EARLY_PHASE1":38215,"PHASE1":38217,"PHASE2":38219,"PHASE3":38225,"PHASE4":38227,"NA":38229},{"trials":38216,"activeCount":103},[],{"trials":38218,"activeCount":103},[],{"trials":38220,"activeCount":103},[38221],{"nctId":38122,"briefTitle":38123,"status":390,"phases":38222,"primaryCompletion":38125,"completion":38126,"start":38127,"enrollment":103,"conditions":38223,"interventions":38224},[91,92],[1654],[38113,38130,38131,38132,38133,38134],{"trials":38226,"activeCount":103},[],{"trials":38228,"activeCount":103},[],{"trials":38230,"activeCount":103},[],{"intervention":34365,"totalTrials":437,"cells":38232},{"EARLY_PHASE1":38233,"PHASE1":38235,"PHASE2":38237,"PHASE3":38243,"PHASE4":38245,"NA":38247},{"trials":38234,"activeCount":103},[],{"trials":38236,"activeCount":103},[],{"trials":38238,"activeCount":103},[38239],{"nctId":34358,"briefTitle":34359,"status":134,"phases":38240,"primaryCompletion":18196,"completion":34361,"start":34362,"enrollment":15225,"conditions":38241,"interventions":38242},[92],[10365],[34365,34366,34349,34367],{"trials":38244,"activeCount":103},[],{"trials":38246,"activeCount":103},[],{"trials":38248,"activeCount":103},[],{"intervention":34366,"totalTrials":437,"cells":38250},{"EARLY_PHASE1":38251,"PHASE1":38253,"PHASE2":38255,"PHASE3":38261,"PHASE4":38263,"NA":38265},{"trials":38252,"activeCount":103},[],{"trials":38254,"activeCount":103},[],{"trials":38256,"activeCount":103},[38257],{"nctId":34358,"briefTitle":34359,"status":134,"phases":38258,"primaryCompletion":18196,"completion":34361,"start":34362,"enrollment":15225,"conditions":38259,"interventions":38260},[92],[10365],[34365,34366,34349,34367],{"trials":38262,"activeCount":103},[],{"trials":38264,"activeCount":103},[],{"trials":38266,"activeCount":103},[],{"intervention":19559,"totalTrials":437,"cells":38268},{"EARLY_PHASE1":38269,"PHASE1":38271,"PHASE2":38273,"PHASE3":38279,"PHASE4":38281,"NA":38283},{"trials":38270,"activeCount":103},[],{"trials":38272,"activeCount":103},[],{"trials":38274,"activeCount":103},[38275],{"nctId":19552,"briefTitle":19553,"status":123,"phases":38276,"primaryCompletion":19555,"completion":19555,"start":19556,"enrollment":4082,"conditions":38277,"interventions":38278},[91,92],[2569,5723],[9236,19559],{"trials":38280,"activeCount":103},[],{"trials":38282,"activeCount":103},[],{"trials":38284,"activeCount":103},[],{"intervention":38286,"totalTrials":437,"cells":38287},"CTL019 T-cells",{"EARLY_PHASE1":38288,"PHASE1":38290,"PHASE2":38292,"PHASE3":38303,"PHASE4":38305,"NA":38307},{"trials":38289,"activeCount":103},[],{"trials":38291,"activeCount":103},[],{"trials":38293,"activeCount":103},[38294],{"nctId":38295,"briefTitle":7577,"status":123,"phases":38296,"primaryCompletion":38297,"completion":33795,"start":38298,"enrollment":11092,"conditions":38299,"interventions":38302},"NCT02228096",[92],"2018-05-29","2014-08-14",[7583,38300,38301],"Relapsed B-cell Acute Lymphoblastic Leukemia","Refractory B-cell Acute Lymphoblastic Leukemia",[38286],{"trials":38304,"activeCount":103},[],{"trials":38306,"activeCount":103},[],{"trials":38308,"activeCount":103},[],{"intervention":33058,"totalTrials":437,"cells":38310},{"EARLY_PHASE1":38311,"PHASE1":38313,"PHASE2":38315,"PHASE3":38321,"PHASE4":38323,"NA":38325},{"trials":38312,"activeCount":103},[],{"trials":38314,"activeCount":103},[],{"trials":38316,"activeCount":103},[38317],{"nctId":33052,"briefTitle":33053,"status":134,"phases":38318,"primaryCompletion":27410,"completion":27410,"start":33055,"enrollment":4583,"conditions":38319,"interventions":38320},[92],[1102],[23071,33058,33059,33060,33061,33062,33063,33064],{"trials":38322,"activeCount":103},[],{"trials":38324,"activeCount":103},[],{"trials":38326,"activeCount":103},[],{"intervention":33059,"totalTrials":437,"cells":38328},{"EARLY_PHASE1":38329,"PHASE1":38331,"PHASE2":38333,"PHASE3":38339,"PHASE4":38341,"NA":38343},{"trials":38330,"activeCount":103},[],{"trials":38332,"activeCount":103},[],{"trials":38334,"activeCount":103},[38335],{"nctId":33052,"briefTitle":33053,"status":134,"phases":38336,"primaryCompletion":27410,"completion":27410,"start":33055,"enrollment":4583,"conditions":38337,"interventions":38338},[92],[1102],[23071,33058,33059,33060,33061,33062,33063,33064],{"trials":38340,"activeCount":103},[],{"trials":38342,"activeCount":103},[],{"trials":38344,"activeCount":103},[],{"intervention":33060,"totalTrials":437,"cells":38346},{"EARLY_PHASE1":38347,"PHASE1":38349,"PHASE2":38351,"PHASE3":38357,"PHASE4":38359,"NA":38361},{"trials":38348,"activeCount":103},[],{"trials":38350,"activeCount":103},[],{"trials":38352,"activeCount":103},[38353],{"nctId":33052,"briefTitle":33053,"status":134,"phases":38354,"primaryCompletion":27410,"completion":27410,"start":33055,"enrollment":4583,"conditions":38355,"interventions":38356},[92],[1102],[23071,33058,33059,33060,33061,33062,33063,33064],{"trials":38358,"activeCount":103},[],{"trials":38360,"activeCount":103},[],{"trials":38362,"activeCount":103},[],{"intervention":33061,"totalTrials":437,"cells":38364},{"EARLY_PHASE1":38365,"PHASE1":38367,"PHASE2":38369,"PHASE3":38375,"PHASE4":38377,"NA":38379},{"trials":38366,"activeCount":103},[],{"trials":38368,"activeCount":103},[],{"trials":38370,"activeCount":103},[38371],{"nctId":33052,"briefTitle":33053,"status":134,"phases":38372,"primaryCompletion":27410,"completion":27410,"start":33055,"enrollment":4583,"conditions":38373,"interventions":38374},[92],[1102],[23071,33058,33059,33060,33061,33062,33063,33064],{"trials":38376,"activeCount":103},[],{"trials":38378,"activeCount":103},[],{"trials":38380,"activeCount":103},[],{"intervention":33062,"totalTrials":437,"cells":38382},{"EARLY_PHASE1":38383,"PHASE1":38385,"PHASE2":38387,"PHASE3":38393,"PHASE4":38395,"NA":38397},{"trials":38384,"activeCount":103},[],{"trials":38386,"activeCount":103},[],{"trials":38388,"activeCount":103},[38389],{"nctId":33052,"briefTitle":33053,"status":134,"phases":38390,"primaryCompletion":27410,"completion":27410,"start":33055,"enrollment":4583,"conditions":38391,"interventions":38392},[92],[1102],[23071,33058,33059,33060,33061,33062,33063,33064],{"trials":38394,"activeCount":103},[],{"trials":38396,"activeCount":103},[],{"trials":38398,"activeCount":103},[],{"intervention":33063,"totalTrials":437,"cells":38400},{"EARLY_PHASE1":38401,"PHASE1":38403,"PHASE2":38405,"PHASE3":38411,"PHASE4":38413,"NA":38415},{"trials":38402,"activeCount":103},[],{"trials":38404,"activeCount":103},[],{"trials":38406,"activeCount":103},[38407],{"nctId":33052,"briefTitle":33053,"status":134,"phases":38408,"primaryCompletion":27410,"completion":27410,"start":33055,"enrollment":4583,"conditions":38409,"interventions":38410},[92],[1102],[23071,33058,33059,33060,33061,33062,33063,33064],{"trials":38412,"activeCount":103},[],{"trials":38414,"activeCount":103},[],{"trials":38416,"activeCount":103},[],{"intervention":33064,"totalTrials":437,"cells":38418},{"EARLY_PHASE1":38419,"PHASE1":38421,"PHASE2":38423,"PHASE3":38429,"PHASE4":38431,"NA":38433},{"trials":38420,"activeCount":103},[],{"trials":38422,"activeCount":103},[],{"trials":38424,"activeCount":103},[38425],{"nctId":33052,"briefTitle":33053,"status":134,"phases":38426,"primaryCompletion":27410,"completion":27410,"start":33055,"enrollment":4583,"conditions":38427,"interventions":38428},[92],[1102],[23071,33058,33059,33060,33061,33062,33063,33064],{"trials":38430,"activeCount":103},[],{"trials":38432,"activeCount":103},[],{"trials":38434,"activeCount":103},[],{"intervention":38436,"totalTrials":437,"cells":38437},"NIM811",{"EARLY_PHASE1":38438,"PHASE1":38440,"PHASE2":38442,"PHASE3":38451,"PHASE4":38453,"NA":38455},{"trials":38439,"activeCount":103},[],{"trials":38441,"activeCount":103},[],{"trials":38443,"activeCount":103},[38444],{"nctId":38445,"briefTitle":38446,"status":123,"phases":38447,"primaryCompletion":3383,"start":4975,"enrollment":3322,"conditions":38448,"interventions":38450},"NCT00983060","Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients",[92],[38449],"Chronic Hepatitis C Genotype-1 Relapse",[38436],{"trials":38452,"activeCount":103},[],{"trials":38454,"activeCount":103},[],{"trials":38456,"activeCount":103},[],{"intervention":14773,"totalTrials":437,"cells":38458},{"EARLY_PHASE1":38459,"PHASE1":38461,"PHASE2":38463,"PHASE3":38469,"PHASE4":38471,"NA":38473},{"trials":38460,"activeCount":103},[],{"trials":38462,"activeCount":103},[],{"trials":38464,"activeCount":103},[38465],{"nctId":14766,"briefTitle":14767,"status":123,"phases":38466,"primaryCompletion":2033,"completion":2033,"start":4524,"enrollment":3064,"conditions":38467,"interventions":38468},[92],[14770],[14772,1557,14773],{"trials":38470,"activeCount":103},[],{"trials":38472,"activeCount":103},[],{"trials":38474,"activeCount":103},[],{"intervention":38476,"totalTrials":437,"cells":38477},"QBX258",{"EARLY_PHASE1":38478,"PHASE1":38480,"PHASE2":38482,"PHASE3":38490,"PHASE4":38492,"NA":38494},{"trials":38479,"activeCount":103},[],{"trials":38481,"activeCount":103},[],{"trials":38483,"activeCount":103},[38484],{"nctId":38485,"briefTitle":38486,"status":123,"phases":38487,"primaryCompletion":2458,"completion":2458,"start":1671,"enrollment":1524,"conditions":38488,"interventions":38489},"NCT01479595","A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma",[92],[18],[38476],{"trials":38491,"activeCount":103},[],{"trials":38493,"activeCount":103},[],{"trials":38495,"activeCount":103},[],{"intervention":38497,"totalTrials":437,"cells":38498},"BZF961",{"EARLY_PHASE1":38499,"PHASE1":38501,"PHASE2":38503,"PHASE3":38512,"PHASE4":38514,"NA":38516},{"trials":38500,"activeCount":103},[],{"trials":38502,"activeCount":103},[],{"trials":38504,"activeCount":103},[38505],{"nctId":38506,"briefTitle":38507,"status":123,"phases":38508,"primaryCompletion":1731,"completion":1731,"start":4967,"enrollment":271,"conditions":38509,"interventions":38510},"NCT01825980","Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients",[91,92],[17240],[38497,38511],"Ritonavir",{"trials":38513,"activeCount":103},[],{"trials":38515,"activeCount":103},[],{"trials":38517,"activeCount":103},[],{"intervention":38511,"totalTrials":437,"cells":38519},{"EARLY_PHASE1":38520,"PHASE1":38522,"PHASE2":38524,"PHASE3":38530,"PHASE4":38532,"NA":38534},{"trials":38521,"activeCount":103},[],{"trials":38523,"activeCount":103},[],{"trials":38525,"activeCount":103},[38526],{"nctId":38506,"briefTitle":38507,"status":123,"phases":38527,"primaryCompletion":1731,"completion":1731,"start":4967,"enrollment":271,"conditions":38528,"interventions":38529},[91,92],[17240],[38497,38511],{"trials":38531,"activeCount":103},[],{"trials":38533,"activeCount":103},[],{"trials":38535,"activeCount":103},[],{"intervention":7926,"totalTrials":437,"cells":38537},{"EARLY_PHASE1":38538,"PHASE1":38540,"PHASE2":38542,"PHASE3":38548,"PHASE4":38550,"NA":38552},{"trials":38539,"activeCount":103},[],{"trials":38541,"activeCount":103},[],{"trials":38543,"activeCount":103},[38544],{"nctId":7919,"briefTitle":7920,"status":123,"phases":38545,"primaryCompletion":2391,"completion":2391,"start":7922,"enrollment":2579,"conditions":38546,"interventions":38547},[92],[7924],[517,4320,4321,7926],{"trials":38549,"activeCount":103},[],{"trials":38551,"activeCount":103},[],{"trials":38553,"activeCount":103},[],{"intervention":38555,"totalTrials":437,"cells":38556},"balicatib",{"EARLY_PHASE1":38557,"PHASE1":38559,"PHASE2":38561,"PHASE3":38569,"PHASE4":38571,"NA":38573},{"trials":38558,"activeCount":103},[],{"trials":38560,"activeCount":103},[],{"trials":38562,"activeCount":103},[38563],{"nctId":38564,"briefTitle":38565,"status":123,"phases":38566,"primaryCompletion":844,"start":4741,"enrollment":28675,"conditions":38567,"interventions":38568},"NCT00371670","Safety\u002FEfficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee",[92],[32295],[38555],{"trials":38570,"activeCount":103},[],{"trials":38572,"activeCount":103},[],{"trials":38574,"activeCount":103},[],{"intervention":38576,"totalTrials":437,"cells":38577},"Deferasirox granule formulation",{"EARLY_PHASE1":38578,"PHASE1":38580,"PHASE2":38582,"PHASE3":38594,"PHASE4":38596,"NA":38598},{"trials":38579,"activeCount":103},[],{"trials":38581,"activeCount":103},[],{"trials":38583,"activeCount":103},[38584],{"nctId":38585,"briefTitle":38586,"status":123,"phases":38587,"primaryCompletion":38588,"completion":201,"start":38589,"enrollment":12487,"conditions":38590,"interventions":38592},"NCT02435212","Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-\u003C18 Years Old) With Iron Overload",[92],"2018-05-31","2015-10-21",[38591],"Transfusion-dependent Anemia",[38576,38593],"Deferasirox DT formulation",{"trials":38595,"activeCount":103},[],{"trials":38597,"activeCount":103},[],{"trials":38599,"activeCount":103},[],{"intervention":38593,"totalTrials":437,"cells":38601},{"EARLY_PHASE1":38602,"PHASE1":38604,"PHASE2":38606,"PHASE3":38612,"PHASE4":38614,"NA":38616},{"trials":38603,"activeCount":103},[],{"trials":38605,"activeCount":103},[],{"trials":38607,"activeCount":103},[38608],{"nctId":38585,"briefTitle":38586,"status":123,"phases":38609,"primaryCompletion":38588,"completion":201,"start":38589,"enrollment":12487,"conditions":38610,"interventions":38611},[92],[38591],[38576,38593],{"trials":38613,"activeCount":103},[],{"trials":38615,"activeCount":103},[],{"trials":38617,"activeCount":103},[],{"intervention":38619,"totalTrials":437,"cells":38620},"VAY736 lower dose",{"EARLY_PHASE1":38621,"PHASE1":38623,"PHASE2":38625,"PHASE3":38634,"PHASE4":38636,"NA":38638},{"trials":38622,"activeCount":103},[],{"trials":38624,"activeCount":103},[],{"trials":38626,"activeCount":103},[38627],{"nctId":38628,"briefTitle":38629,"status":390,"phases":38630,"primaryCompletion":23097,"completion":23097,"start":2762,"enrollment":103,"conditions":38631,"interventions":38632},"NCT02495129","Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome",[91,92],[6558],[38619,38633],"VAY736 higher dose",{"trials":38635,"activeCount":103},[],{"trials":38637,"activeCount":103},[],{"trials":38639,"activeCount":103},[],{"intervention":38633,"totalTrials":437,"cells":38641},{"EARLY_PHASE1":38642,"PHASE1":38644,"PHASE2":38646,"PHASE3":38652,"PHASE4":38654,"NA":38656},{"trials":38643,"activeCount":103},[],{"trials":38645,"activeCount":103},[],{"trials":38647,"activeCount":103},[38648],{"nctId":38628,"briefTitle":38629,"status":390,"phases":38649,"primaryCompletion":23097,"completion":23097,"start":2762,"enrollment":103,"conditions":38650,"interventions":38651},[91,92],[6558],[38619,38633],{"trials":38653,"activeCount":103},[],{"trials":38655,"activeCount":103},[],{"trials":38657,"activeCount":103},[],{"intervention":32073,"totalTrials":437,"cells":38659},{"EARLY_PHASE1":38660,"PHASE1":38662,"PHASE2":38664,"PHASE3":38670,"PHASE4":38672,"NA":38674},{"trials":38661,"activeCount":103},[],{"trials":38663,"activeCount":103},[],{"trials":38665,"activeCount":103},[38666],{"nctId":32066,"briefTitle":32067,"status":134,"phases":38667,"primaryCompletion":32069,"completion":32070,"start":30309,"enrollment":1213,"conditions":38668,"interventions":38669},[92],[5723],[10589,32073],{"trials":38671,"activeCount":103},[],{"trials":38673,"activeCount":103},[],{"trials":38675,"activeCount":103},[],{"intervention":38677,"totalTrials":437,"cells":38678},"Certoparin 3,000 IU Once Daily",{"EARLY_PHASE1":38679,"PHASE1":38681,"PHASE2":38683,"PHASE3":38694,"PHASE4":38696,"NA":38698},{"trials":38680,"activeCount":103},[],{"trials":38682,"activeCount":103},[],{"trials":38684,"activeCount":103},[38685],{"nctId":38686,"briefTitle":38687,"status":123,"phases":38688,"primaryCompletion":4524,"start":4301,"enrollment":7257,"conditions":38689,"interventions":38690},"NCT01660295","Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects",[91,92],[10518],[38677,38691,38692,38693],"Certoparin 3,000 IU Twice a Day","Certoparin 8,000 IU Once Daily","Certoparin 8,000 IU Twice a Day",{"trials":38695,"activeCount":103},[],{"trials":38697,"activeCount":103},[],{"trials":38699,"activeCount":103},[],{"intervention":38691,"totalTrials":437,"cells":38701},{"EARLY_PHASE1":38702,"PHASE1":38704,"PHASE2":38706,"PHASE3":38712,"PHASE4":38714,"NA":38716},{"trials":38703,"activeCount":103},[],{"trials":38705,"activeCount":103},[],{"trials":38707,"activeCount":103},[38708],{"nctId":38686,"briefTitle":38687,"status":123,"phases":38709,"primaryCompletion":4524,"start":4301,"enrollment":7257,"conditions":38710,"interventions":38711},[91,92],[10518],[38677,38691,38692,38693],{"trials":38713,"activeCount":103},[],{"trials":38715,"activeCount":103},[],{"trials":38717,"activeCount":103},[],{"intervention":38692,"totalTrials":437,"cells":38719},{"EARLY_PHASE1":38720,"PHASE1":38722,"PHASE2":38724,"PHASE3":38730,"PHASE4":38732,"NA":38734},{"trials":38721,"activeCount":103},[],{"trials":38723,"activeCount":103},[],{"trials":38725,"activeCount":103},[38726],{"nctId":38686,"briefTitle":38687,"status":123,"phases":38727,"primaryCompletion":4524,"start":4301,"enrollment":7257,"conditions":38728,"interventions":38729},[91,92],[10518],[38677,38691,38692,38693],{"trials":38731,"activeCount":103},[],{"trials":38733,"activeCount":103},[],{"trials":38735,"activeCount":103},[],{"intervention":38693,"totalTrials":437,"cells":38737},{"EARLY_PHASE1":38738,"PHASE1":38740,"PHASE2":38742,"PHASE3":38748,"PHASE4":38750,"NA":38752},{"trials":38739,"activeCount":103},[],{"trials":38741,"activeCount":103},[],{"trials":38743,"activeCount":103},[38744],{"nctId":38686,"briefTitle":38687,"status":123,"phases":38745,"primaryCompletion":4524,"start":4301,"enrollment":7257,"conditions":38746,"interventions":38747},[91,92],[10518],[38677,38691,38692,38693],{"trials":38749,"activeCount":103},[],{"trials":38751,"activeCount":103},[],{"trials":38753,"activeCount":103},[],{"intervention":38755,"totalTrials":437,"cells":38756},"TIP",{"EARLY_PHASE1":38757,"PHASE1":38759,"PHASE2":38761,"PHASE3":38773,"PHASE4":38775,"NA":38777},{"trials":38758,"activeCount":103},[],{"trials":38760,"activeCount":103},[],{"trials":38762,"activeCount":103},[38763],{"nctId":38764,"briefTitle":38765,"status":123,"phases":38766,"primaryCompletion":38767,"completion":38767,"start":38768,"enrollment":6514,"conditions":38769,"interventions":38771},"NCT02712983","Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection",[92],"2019-03-20","2017-02-08",[38770],"Non-cystic Fibrosis Bronchiectasis",[38755,38772],"TIP and placebo",{"trials":38774,"activeCount":103},[],{"trials":38776,"activeCount":103},[],{"trials":38778,"activeCount":103},[],{"intervention":38772,"totalTrials":437,"cells":38780},{"EARLY_PHASE1":38781,"PHASE1":38783,"PHASE2":38785,"PHASE3":38791,"PHASE4":38793,"NA":38795},{"trials":38782,"activeCount":103},[],{"trials":38784,"activeCount":103},[],{"trials":38786,"activeCount":103},[38787],{"nctId":38764,"briefTitle":38765,"status":123,"phases":38788,"primaryCompletion":38767,"completion":38767,"start":38768,"enrollment":6514,"conditions":38789,"interventions":38790},[92],[38770],[38755,38772],{"trials":38792,"activeCount":103},[],{"trials":38794,"activeCount":103},[],{"trials":38796,"activeCount":103},[],{"intervention":38798,"totalTrials":437,"cells":38799},"RKI983A",{"EARLY_PHASE1":38800,"PHASE1":38802,"PHASE2":38804,"PHASE3":38814,"PHASE4":38816,"NA":38818},{"trials":38801,"activeCount":103},[],{"trials":38803,"activeCount":103},[],{"trials":38805,"activeCount":103},[38806],{"nctId":38807,"briefTitle":38808,"status":123,"phases":38809,"primaryCompletion":4707,"completion":4707,"start":949,"enrollment":4836,"conditions":38810,"interventions":38812},"NCT00846989","Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension",[91,92],[21474,38811],"Ocular Hypertension",[38798,38798,38813],"Latanoprost",{"trials":38815,"activeCount":103},[],{"trials":38817,"activeCount":103},[],{"trials":38819,"activeCount":103},[],{"intervention":38813,"totalTrials":437,"cells":38821},{"EARLY_PHASE1":38822,"PHASE1":38824,"PHASE2":38826,"PHASE3":38832,"PHASE4":38834,"NA":38836},{"trials":38823,"activeCount":103},[],{"trials":38825,"activeCount":103},[],{"trials":38827,"activeCount":103},[38828],{"nctId":38807,"briefTitle":38808,"status":123,"phases":38829,"primaryCompletion":4707,"completion":4707,"start":949,"enrollment":4836,"conditions":38830,"interventions":38831},[91,92],[21474,38811],[38798,38798,38813],{"trials":38833,"activeCount":103},[],{"trials":38835,"activeCount":103},[],{"trials":38837,"activeCount":103},[],{"intervention":38839,"totalTrials":437,"cells":38840},"Pazopanib followed by everolimus",{"EARLY_PHASE1":38841,"PHASE1":38843,"PHASE2":38845,"PHASE3":38855,"PHASE4":38857,"NA":38859},{"trials":38842,"activeCount":103},[],{"trials":38844,"activeCount":103},[],{"trials":38846,"activeCount":103},[38847],{"nctId":38848,"briefTitle":38849,"status":134,"phases":38850,"primaryCompletion":38851,"completion":38851,"start":38852,"enrollment":223,"conditions":38853,"interventions":38854},"NCT01545817","Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma",[92],"2016-11-18","2012-04-19",[13284],[38839],{"trials":38856,"activeCount":103},[],{"trials":38858,"activeCount":103},[],{"trials":38860,"activeCount":103},[],{"intervention":38862,"totalTrials":437,"cells":38863},"QAV680 + Cetirizine Placebo",{"EARLY_PHASE1":38864,"PHASE1":38866,"PHASE2":38868,"PHASE3":38881,"PHASE4":38883,"NA":38885},{"trials":38865,"activeCount":103},[],{"trials":38867,"activeCount":103},[],{"trials":38869,"activeCount":103},[38870],{"nctId":38871,"briefTitle":38872,"status":123,"phases":38873,"primaryCompletion":38874,"completion":38874,"start":38875,"enrollment":1423,"conditions":38876,"interventions":38877},"NCT01103050","A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine",[92],"2010-07-28","2010-03-22",[19482],[38862,38878,38879,38880],"QAV680 + Cetirizine","Cetirizine + QAV680 Placebo","QAV680 Placebo + Cetirizine Placebo",{"trials":38882,"activeCount":103},[],{"trials":38884,"activeCount":103},[],{"trials":38886,"activeCount":103},[],{"intervention":38878,"totalTrials":437,"cells":38888},{"EARLY_PHASE1":38889,"PHASE1":38891,"PHASE2":38893,"PHASE3":38899,"PHASE4":38901,"NA":38903},{"trials":38890,"activeCount":103},[],{"trials":38892,"activeCount":103},[],{"trials":38894,"activeCount":103},[38895],{"nctId":38871,"briefTitle":38872,"status":123,"phases":38896,"primaryCompletion":38874,"completion":38874,"start":38875,"enrollment":1423,"conditions":38897,"interventions":38898},[92],[19482],[38862,38878,38879,38880],{"trials":38900,"activeCount":103},[],{"trials":38902,"activeCount":103},[],{"trials":38904,"activeCount":103},[],{"intervention":38879,"totalTrials":437,"cells":38906},{"EARLY_PHASE1":38907,"PHASE1":38909,"PHASE2":38911,"PHASE3":38917,"PHASE4":38919,"NA":38921},{"trials":38908,"activeCount":103},[],{"trials":38910,"activeCount":103},[],{"trials":38912,"activeCount":103},[38913],{"nctId":38871,"briefTitle":38872,"status":123,"phases":38914,"primaryCompletion":38874,"completion":38874,"start":38875,"enrollment":1423,"conditions":38915,"interventions":38916},[92],[19482],[38862,38878,38879,38880],{"trials":38918,"activeCount":103},[],{"trials":38920,"activeCount":103},[],{"trials":38922,"activeCount":103},[],{"intervention":38880,"totalTrials":437,"cells":38924},{"EARLY_PHASE1":38925,"PHASE1":38927,"PHASE2":38929,"PHASE3":38935,"PHASE4":38937,"NA":38939},{"trials":38926,"activeCount":103},[],{"trials":38928,"activeCount":103},[],{"trials":38930,"activeCount":103},[38931],{"nctId":38871,"briefTitle":38872,"status":123,"phases":38932,"primaryCompletion":38874,"completion":38874,"start":38875,"enrollment":1423,"conditions":38933,"interventions":38934},[92],[19482],[38862,38878,38879,38880],{"trials":38936,"activeCount":103},[],{"trials":38938,"activeCount":103},[],{"trials":38940,"activeCount":103},[],{"intervention":38942,"totalTrials":437,"cells":38943},"75 µg indacaterol maleate",{"EARLY_PHASE1":38944,"PHASE1":38946,"PHASE2":38948,"PHASE3":38957,"PHASE4":38959,"NA":38961},{"trials":38945,"activeCount":103},[],{"trials":38947,"activeCount":103},[],{"trials":38949,"activeCount":103},[38950],{"nctId":38951,"briefTitle":38952,"status":123,"phases":38953,"primaryCompletion":5733,"completion":5733,"start":3800,"enrollment":792,"conditions":38954,"interventions":38955},"NCT01484197","A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device",[92],[18],[38942,38942,38956],"37.5 µg indacaterol maleate",{"trials":38958,"activeCount":103},[],{"trials":38960,"activeCount":103},[],{"trials":38962,"activeCount":103},[],{"intervention":38956,"totalTrials":437,"cells":38964},{"EARLY_PHASE1":38965,"PHASE1":38967,"PHASE2":38969,"PHASE3":38975,"PHASE4":38977,"NA":38979},{"trials":38966,"activeCount":103},[],{"trials":38968,"activeCount":103},[],{"trials":38970,"activeCount":103},[38971],{"nctId":38951,"briefTitle":38952,"status":123,"phases":38972,"primaryCompletion":5733,"completion":5733,"start":3800,"enrollment":792,"conditions":38973,"interventions":38974},[92],[18],[38942,38942,38956],{"trials":38976,"activeCount":103},[],{"trials":38978,"activeCount":103},[],{"trials":38980,"activeCount":103},[],{"intervention":38982,"totalTrials":437,"cells":38983},"LCZ696A",{"EARLY_PHASE1":38984,"PHASE1":38986,"PHASE2":38988,"PHASE3":38999,"PHASE4":39001,"NA":39003},{"trials":38985,"activeCount":103},[],{"trials":38987,"activeCount":103},[],{"trials":38989,"activeCount":103},[38990],{"nctId":38991,"briefTitle":38992,"status":123,"phases":38993,"primaryCompletion":4975,"completion":4975,"start":3400,"enrollment":138,"conditions":38994,"interventions":38998},"NCT01569828","Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function",[92],[38995,38996,38997],"Pharmacokinetics","Renal Impaired","Healthy Volunteer",[38982,38982],{"trials":39000,"activeCount":103},[],{"trials":39002,"activeCount":103},[],{"trials":39004,"activeCount":103},[],{"intervention":34470,"totalTrials":437,"cells":39006},{"EARLY_PHASE1":39007,"PHASE1":39009,"PHASE2":39011,"PHASE3":39017,"PHASE4":39019,"NA":39021},{"trials":39008,"activeCount":103},[],{"trials":39010,"activeCount":103},[],{"trials":39012,"activeCount":103},[39013],{"nctId":34464,"briefTitle":34465,"status":123,"phases":39014,"primaryCompletion":17121,"completion":17121,"start":17324,"enrollment":512,"conditions":39015,"interventions":39016},[92],[34468],[34449,34470],{"trials":39018,"activeCount":103},[],{"trials":39020,"activeCount":103},[],{"trials":39022,"activeCount":103},[],{"intervention":9673,"totalTrials":437,"cells":39024},{"EARLY_PHASE1":39025,"PHASE1":39027,"PHASE2":39029,"PHASE3":39035,"PHASE4":39037,"NA":39039},{"trials":39026,"activeCount":103},[],{"trials":39028,"activeCount":103},[],{"trials":39030,"activeCount":103},[39031],{"nctId":9665,"briefTitle":9666,"status":123,"phases":39032,"primaryCompletion":9668,"completion":6640,"start":9669,"enrollment":827,"conditions":39033,"interventions":39034},[92],[3180,9671],[3090,9673,3036,9674],{"trials":39036,"activeCount":103},[],{"trials":39038,"activeCount":103},[],{"trials":39040,"activeCount":103},[],{"intervention":39042,"totalTrials":437,"cells":39043},"BGG492A",{"EARLY_PHASE1":39044,"PHASE1":39046,"PHASE2":39048,"PHASE3":39057,"PHASE4":39059,"NA":39061},{"trials":39045,"activeCount":103},[],{"trials":39047,"activeCount":103},[],{"trials":39049,"activeCount":103},[39050],{"nctId":39051,"briefTitle":39052,"status":123,"phases":39053,"primaryCompletion":1732,"completion":1732,"start":4598,"enrollment":1750,"conditions":39054,"interventions":39056},"NCT01302873","Study of BGG492 in Patients With Chronic Subjective Tinnitus",[92],[39055],"Chronic Subjective Tinnitus",[39042,39042],{"trials":39058,"activeCount":103},[],{"trials":39060,"activeCount":103},[],{"trials":39062,"activeCount":103},[],{"intervention":39064,"totalTrials":437,"cells":39065},"DNK333 5 mg",{"EARLY_PHASE1":39066,"PHASE1":39068,"PHASE2":39070,"PHASE3":39083,"PHASE4":39085,"NA":39087},{"trials":39067,"activeCount":103},[],{"trials":39069,"activeCount":103},[],{"trials":39071,"activeCount":103},[39072],{"nctId":39073,"briefTitle":39074,"status":123,"phases":39075,"primaryCompletion":4620,"completion":4620,"start":4335,"enrollment":4733,"conditions":39076,"interventions":39078},"NCT01033097","Safety and Efficacy of DNK333 in Atopic Dermatitis Patients",[92],[39077],"Pruritus in Patients With Atopic Dermatitis",[39064,39079,39080,39081,39082],"DNK333 25 mg","DNK333 100 mg","Betamethasone 4 mg","DNK333 1mg",{"trials":39084,"activeCount":103},[],{"trials":39086,"activeCount":103},[],{"trials":39088,"activeCount":103},[],{"intervention":39079,"totalTrials":437,"cells":39090},{"EARLY_PHASE1":39091,"PHASE1":39093,"PHASE2":39095,"PHASE3":39101,"PHASE4":39103,"NA":39105},{"trials":39092,"activeCount":103},[],{"trials":39094,"activeCount":103},[],{"trials":39096,"activeCount":103},[39097],{"nctId":39073,"briefTitle":39074,"status":123,"phases":39098,"primaryCompletion":4620,"completion":4620,"start":4335,"enrollment":4733,"conditions":39099,"interventions":39100},[92],[39077],[39064,39079,39080,39081,39082],{"trials":39102,"activeCount":103},[],{"trials":39104,"activeCount":103},[],{"trials":39106,"activeCount":103},[],{"intervention":39080,"totalTrials":437,"cells":39108},{"EARLY_PHASE1":39109,"PHASE1":39111,"PHASE2":39113,"PHASE3":39119,"PHASE4":39121,"NA":39123},{"trials":39110,"activeCount":103},[],{"trials":39112,"activeCount":103},[],{"trials":39114,"activeCount":103},[39115],{"nctId":39073,"briefTitle":39074,"status":123,"phases":39116,"primaryCompletion":4620,"completion":4620,"start":4335,"enrollment":4733,"conditions":39117,"interventions":39118},[92],[39077],[39064,39079,39080,39081,39082],{"trials":39120,"activeCount":103},[],{"trials":39122,"activeCount":103},[],{"trials":39124,"activeCount":103},[],{"intervention":39081,"totalTrials":437,"cells":39126},{"EARLY_PHASE1":39127,"PHASE1":39129,"PHASE2":39131,"PHASE3":39137,"PHASE4":39139,"NA":39141},{"trials":39128,"activeCount":103},[],{"trials":39130,"activeCount":103},[],{"trials":39132,"activeCount":103},[39133],{"nctId":39073,"briefTitle":39074,"status":123,"phases":39134,"primaryCompletion":4620,"completion":4620,"start":4335,"enrollment":4733,"conditions":39135,"interventions":39136},[92],[39077],[39064,39079,39080,39081,39082],{"trials":39138,"activeCount":103},[],{"trials":39140,"activeCount":103},[],{"trials":39142,"activeCount":103},[],{"intervention":39082,"totalTrials":437,"cells":39144},{"EARLY_PHASE1":39145,"PHASE1":39147,"PHASE2":39149,"PHASE3":39155,"PHASE4":39157,"NA":39159},{"trials":39146,"activeCount":103},[],{"trials":39148,"activeCount":103},[],{"trials":39150,"activeCount":103},[39151],{"nctId":39073,"briefTitle":39074,"status":123,"phases":39152,"primaryCompletion":4620,"completion":4620,"start":4335,"enrollment":4733,"conditions":39153,"interventions":39154},[92],[39077],[39064,39079,39080,39081,39082],{"trials":39156,"activeCount":103},[],{"trials":39158,"activeCount":103},[],{"trials":39160,"activeCount":103},[],{"intervention":39162,"totalTrials":437,"cells":39163},"MIJ821 Intravenous",{"EARLY_PHASE1":39164,"PHASE1":39166,"PHASE2":39168,"PHASE3":39178,"PHASE4":39180,"NA":39182},{"trials":39165,"activeCount":103},[],{"trials":39167,"activeCount":103},[],{"trials":39169,"activeCount":103},[39170],{"nctId":39171,"briefTitle":39172,"status":134,"phases":39173,"primaryCompletion":39174,"completion":39174,"start":8149,"enrollment":4498,"conditions":39175,"interventions":39177},"NCT04722666","Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent",[92],"2023-09-26",[39176],"Major Depressive Disorder With Suicidal Ideation With Intent",[39162],{"trials":39179,"activeCount":103},[],{"trials":39181,"activeCount":103},[],{"trials":39183,"activeCount":103},[],{"intervention":10144,"totalTrials":437,"cells":39185},{"EARLY_PHASE1":39186,"PHASE1":39188,"PHASE2":39190,"PHASE3":39196,"PHASE4":39198,"NA":39200},{"trials":39187,"activeCount":103},[],{"trials":39189,"activeCount":103},[],{"trials":39191,"activeCount":103},[39192],{"nctId":10136,"briefTitle":10137,"status":123,"phases":39193,"primaryCompletion":10139,"completion":10139,"start":10140,"enrollment":5594,"conditions":39194,"interventions":39195},[92],[10142],[515,10144],{"trials":39197,"activeCount":103},[],{"trials":39199,"activeCount":103},[],{"trials":39201,"activeCount":103},[],{"intervention":39203,"totalTrials":437,"cells":39204},"MIJ821 Subcutaneous Injection 1 mg",{"EARLY_PHASE1":39205,"PHASE1":39207,"PHASE2":39209,"PHASE3":39220,"PHASE4":39222,"NA":39224},{"trials":39206,"activeCount":103},[],{"trials":39208,"activeCount":103},[],{"trials":39210,"activeCount":103},[39211],{"nctId":39212,"briefTitle":39213,"status":123,"phases":39214,"primaryCompletion":82,"completion":82,"start":18898,"enrollment":1423,"conditions":39215,"interventions":39217},"NCT05454410","Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)",[92],[39216],"Treatment-Resistant Depression",[39203,39218,39219],"MIJ821 Subcutaneous Injection 4 mg","MIJ821 Subcutaneous Injection 10 mg",{"trials":39221,"activeCount":103},[],{"trials":39223,"activeCount":103},[],{"trials":39225,"activeCount":103},[],{"intervention":39218,"totalTrials":437,"cells":39227},{"EARLY_PHASE1":39228,"PHASE1":39230,"PHASE2":39232,"PHASE3":39238,"PHASE4":39240,"NA":39242},{"trials":39229,"activeCount":103},[],{"trials":39231,"activeCount":103},[],{"trials":39233,"activeCount":103},[39234],{"nctId":39212,"briefTitle":39213,"status":123,"phases":39235,"primaryCompletion":82,"completion":82,"start":18898,"enrollment":1423,"conditions":39236,"interventions":39237},[92],[39216],[39203,39218,39219],{"trials":39239,"activeCount":103},[],{"trials":39241,"activeCount":103},[],{"trials":39243,"activeCount":103},[],{"intervention":39219,"totalTrials":437,"cells":39245},{"EARLY_PHASE1":39246,"PHASE1":39248,"PHASE2":39250,"PHASE3":39256,"PHASE4":39258,"NA":39260},{"trials":39247,"activeCount":103},[],{"trials":39249,"activeCount":103},[],{"trials":39251,"activeCount":103},[39252],{"nctId":39212,"briefTitle":39213,"status":123,"phases":39253,"primaryCompletion":82,"completion":82,"start":18898,"enrollment":1423,"conditions":39254,"interventions":39255},[92],[39216],[39203,39218,39219],{"trials":39257,"activeCount":103},[],{"trials":39259,"activeCount":103},[],{"trials":39261,"activeCount":103},[],{"intervention":17807,"totalTrials":437,"cells":39263},{"EARLY_PHASE1":39264,"PHASE1":39266,"PHASE2":39268,"PHASE3":39274,"PHASE4":39276,"NA":39278},{"trials":39265,"activeCount":103},[],{"trials":39267,"activeCount":103},[],{"trials":39269,"activeCount":103},[39270],{"nctId":17799,"briefTitle":17800,"status":123,"phases":39271,"primaryCompletion":13493,"completion":13493,"start":17802,"enrollment":7257,"conditions":39272,"interventions":39273},[92],[17804,17805],[17807,17734],{"trials":39275,"activeCount":103},[],{"trials":39277,"activeCount":103},[],{"trials":39279,"activeCount":103},[],{"intervention":7442,"totalTrials":437,"cells":39281},{"EARLY_PHASE1":39282,"PHASE1":39284,"PHASE2":39286,"PHASE3":39292,"PHASE4":39294,"NA":39296},{"trials":39283,"activeCount":103},[],{"trials":39285,"activeCount":103},[],{"trials":39287,"activeCount":103},[39288],{"nctId":7432,"briefTitle":7433,"status":123,"phases":39289,"primaryCompletion":7435,"completion":7436,"start":7437,"enrollment":7438,"conditions":39290,"interventions":39291},[92],[7440],[7442,7443,5895],{"trials":39293,"activeCount":103},[],{"trials":39295,"activeCount":103},[],{"trials":39297,"activeCount":103},[],{"intervention":4561,"totalTrials":437,"cells":39299},{"EARLY_PHASE1":39300,"PHASE1":39302,"PHASE2":39304,"PHASE3":39310,"PHASE4":39312,"NA":39314},{"trials":39301,"activeCount":103},[],{"trials":39303,"activeCount":103},[],{"trials":39305,"activeCount":103},[39306],{"nctId":4553,"briefTitle":4554,"status":134,"phases":39307,"primaryCompletion":3551,"completion":3551,"start":4556,"enrollment":4557,"conditions":39308,"interventions":39309},[92],[4559],[4561,196],{"trials":39311,"activeCount":103},[],{"trials":39313,"activeCount":103},[],{"trials":39315,"activeCount":103},[],{"intervention":39317,"totalTrials":437,"cells":39318},"Indacaterol 150 μg via the Concept1 dry-powder inhaler",{"EARLY_PHASE1":39319,"PHASE1":39321,"PHASE2":39323,"PHASE3":39333,"PHASE4":39335,"NA":39337},{"trials":39320,"activeCount":103},[],{"trials":39322,"activeCount":103},[],{"trials":39324,"activeCount":103},[39325],{"nctId":39326,"briefTitle":39327,"status":123,"phases":39328,"primaryCompletion":964,"completion":964,"start":4400,"enrollment":906,"conditions":39329,"interventions":39330},"NCT01012739","Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices",[92],[18],[39317,39331,39332],"Indacaterol 60 μg via the Simoon dry-powder inhaler","Indacaterol 120 μg via the Simoon dry-powder inhaler",{"trials":39334,"activeCount":103},[],{"trials":39336,"activeCount":103},[],{"trials":39338,"activeCount":103},[],{"intervention":39331,"totalTrials":437,"cells":39340},{"EARLY_PHASE1":39341,"PHASE1":39343,"PHASE2":39345,"PHASE3":39351,"PHASE4":39353,"NA":39355},{"trials":39342,"activeCount":103},[],{"trials":39344,"activeCount":103},[],{"trials":39346,"activeCount":103},[39347],{"nctId":39326,"briefTitle":39327,"status":123,"phases":39348,"primaryCompletion":964,"completion":964,"start":4400,"enrollment":906,"conditions":39349,"interventions":39350},[92],[18],[39317,39331,39332],{"trials":39352,"activeCount":103},[],{"trials":39354,"activeCount":103},[],{"trials":39356,"activeCount":103},[],{"intervention":39332,"totalTrials":437,"cells":39358},{"EARLY_PHASE1":39359,"PHASE1":39361,"PHASE2":39363,"PHASE3":39369,"PHASE4":39371,"NA":39373},{"trials":39360,"activeCount":103},[],{"trials":39362,"activeCount":103},[],{"trials":39364,"activeCount":103},[39365],{"nctId":39326,"briefTitle":39327,"status":123,"phases":39366,"primaryCompletion":964,"completion":964,"start":4400,"enrollment":906,"conditions":39367,"interventions":39368},[92],[18],[39317,39331,39332],{"trials":39370,"activeCount":103},[],{"trials":39372,"activeCount":103},[],{"trials":39374,"activeCount":103},[],{"intervention":39376,"totalTrials":437,"cells":39377},"LFG316 active drug",{"EARLY_PHASE1":39378,"PHASE1":39380,"PHASE2":39382,"PHASE3":39393,"PHASE4":39395,"NA":39397},{"trials":39379,"activeCount":103},[],{"trials":39381,"activeCount":103},[],{"trials":39383,"activeCount":103},[39384],{"nctId":39385,"briefTitle":39386,"status":134,"phases":39387,"primaryCompletion":39388,"completion":1264,"start":39389,"enrollment":1562,"conditions":39390,"interventions":39392},"NCT02763644","Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients",[92],"2017-02-10","2016-04-22",[39391],"Transplant Associated Microangiopathy TAM",[39376],{"trials":39394,"activeCount":103},[],{"trials":39396,"activeCount":103},[],{"trials":39398,"activeCount":103},[],{"intervention":39400,"totalTrials":437,"cells":39401},"Zoledronic acid + Calcium\u002FVitamin D",{"EARLY_PHASE1":39402,"PHASE1":39404,"PHASE2":39406,"PHASE3":39415,"PHASE4":39417,"NA":39419},{"trials":39403,"activeCount":103},[],{"trials":39405,"activeCount":103},[],{"trials":39407,"activeCount":103},[39408],{"nctId":39409,"briefTitle":39410,"status":134,"phases":39411,"primaryCompletion":3490,"start":16929,"enrollment":1750,"conditions":39412,"interventions":39414},"NCT00172068","Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow",[92],[39413],"Primary Breast Cancer",[39400],{"trials":39416,"activeCount":103},[],{"trials":39418,"activeCount":103},[],{"trials":39420,"activeCount":103},[],{"intervention":3337,"totalTrials":437,"cells":39422},{"EARLY_PHASE1":39423,"PHASE1":39425,"PHASE2":39427,"PHASE3":39433,"PHASE4":39435,"NA":39437},{"trials":39424,"activeCount":103},[],{"trials":39426,"activeCount":103},[],{"trials":39428,"activeCount":103},[39429],{"nctId":3327,"briefTitle":3328,"status":123,"phases":39430,"primaryCompletion":3330,"completion":136,"start":3331,"enrollment":314,"conditions":39431,"interventions":39432},[92],[3333,3228,3334,3335],[3337,83,2395,3338],{"trials":39434,"activeCount":103},[],{"trials":39436,"activeCount":103},[],{"trials":39438,"activeCount":103},[],{"intervention":3338,"totalTrials":437,"cells":39440},{"EARLY_PHASE1":39441,"PHASE1":39443,"PHASE2":39445,"PHASE3":39451,"PHASE4":39453,"NA":39455},{"trials":39442,"activeCount":103},[],{"trials":39444,"activeCount":103},[],{"trials":39446,"activeCount":103},[39447],{"nctId":3327,"briefTitle":3328,"status":123,"phases":39448,"primaryCompletion":3330,"completion":136,"start":3331,"enrollment":314,"conditions":39449,"interventions":39450},[92],[3333,3228,3334,3335],[3337,83,2395,3338],{"trials":39452,"activeCount":103},[],{"trials":39454,"activeCount":103},[],{"trials":39456,"activeCount":103},[],{"intervention":34524,"totalTrials":437,"cells":39458},{"EARLY_PHASE1":39459,"PHASE1":39461,"PHASE2":39463,"PHASE3":39469,"PHASE4":39471,"NA":39473},{"trials":39460,"activeCount":103},[],{"trials":39462,"activeCount":103},[],{"trials":39464,"activeCount":103},[39465],{"nctId":34516,"briefTitle":34517,"status":390,"phases":39466,"primaryCompletion":34519,"completion":34520,"start":34521,"enrollment":103,"conditions":39467,"interventions":39468},[92],[12396],[34507,34524],{"trials":39470,"activeCount":103},[],{"trials":39472,"activeCount":103},[],{"trials":39474,"activeCount":103},[],{"intervention":39476,"totalTrials":437,"cells":39477},"BYM338 active drug",{"EARLY_PHASE1":39478,"PHASE1":39480,"PHASE2":39482,"PHASE3":39491,"PHASE4":39493,"NA":39495},{"trials":39479,"activeCount":103},[],{"trials":39481,"activeCount":103},[],{"trials":39483,"activeCount":103},[39484],{"nctId":39485,"briefTitle":39486,"status":123,"phases":39487,"primaryCompletion":1781,"completion":1781,"start":1724,"enrollment":3530,"conditions":39488,"interventions":39490},"NCT01433263","Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas",[92],[39489],"Cachexia",[39476],{"trials":39492,"activeCount":103},[],{"trials":39494,"activeCount":103},[],{"trials":39496,"activeCount":103},[],{"intervention":34375,"totalTrials":437,"cells":39498},{"EARLY_PHASE1":39499,"PHASE1":39501,"PHASE2":39503,"PHASE3":39509,"PHASE4":39511,"NA":39513},{"trials":39500,"activeCount":103},[],{"trials":39502,"activeCount":103},[],{"trials":39504,"activeCount":103},[39505],{"nctId":34369,"briefTitle":34370,"status":134,"phases":39506,"primaryCompletion":34372,"completion":14020,"start":15304,"enrollment":9331,"conditions":39507,"interventions":39508},[92],[10365],[34349,34367,34375],{"trials":39510,"activeCount":103},[],{"trials":39512,"activeCount":103},[],{"trials":39514,"activeCount":103},[],{"intervention":18237,"totalTrials":437,"cells":39516},{"EARLY_PHASE1":39517,"PHASE1":39519,"PHASE2":39521,"PHASE3":39527,"PHASE4":39529,"NA":39531},{"trials":39518,"activeCount":103},[],{"trials":39520,"activeCount":103},[],{"trials":39522,"activeCount":103},[39523],{"nctId":18231,"briefTitle":18232,"status":123,"phases":39524,"primaryCompletion":3799,"completion":3799,"start":2795,"enrollment":7269,"conditions":39525,"interventions":39526},[91,92],[18235],[15255,18237],{"trials":39528,"activeCount":103},[],{"trials":39530,"activeCount":103},[],{"trials":39532,"activeCount":103},[],{"intervention":39534,"totalTrials":437,"cells":39535},"IGE025",{"EARLY_PHASE1":39536,"PHASE1":39538,"PHASE2":39540,"PHASE3":39549,"PHASE4":39551,"NA":39553},{"trials":39537,"activeCount":103},[],{"trials":39539,"activeCount":103},[],{"trials":39541,"activeCount":103},[39542],{"nctId":39543,"briefTitle":39544,"status":123,"phases":39545,"primaryCompletion":3799,"completion":3799,"start":607,"enrollment":709,"conditions":39546,"interventions":39548},"NCT01599637","Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment",[92],[39547],"Chronic Idiopathic Urticaria",[39534],{"trials":39550,"activeCount":103},[],{"trials":39552,"activeCount":103},[],{"trials":39554,"activeCount":103},[],{"intervention":39556,"totalTrials":437,"cells":39557},"Secukinmab",{"EARLY_PHASE1":39558,"PHASE1":39560,"PHASE2":39562,"PHASE3":39570,"PHASE4":39572,"NA":39574},{"trials":39559,"activeCount":103},[],{"trials":39561,"activeCount":103},[],{"trials":39563,"activeCount":103},[39564],{"nctId":39565,"briefTitle":39566,"status":123,"phases":39567,"primaryCompletion":895,"completion":895,"start":4845,"enrollment":4855,"conditions":39568,"interventions":39569},"NCT00928512","Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)",[92],[1717],[39556],{"trials":39571,"activeCount":103},[],{"trials":39573,"activeCount":103},[],{"trials":39575,"activeCount":103},[],{"intervention":31255,"totalTrials":437,"cells":39577},{"EARLY_PHASE1":39578,"PHASE1":39580,"PHASE2":39582,"PHASE3":39588,"PHASE4":39590,"NA":39592},{"trials":39579,"activeCount":103},[],{"trials":39581,"activeCount":103},[],{"trials":39583,"activeCount":103},[39584],{"nctId":31250,"briefTitle":31251,"status":134,"phases":39585,"primaryCompletion":3482,"completion":3482,"start":4335,"enrollment":31,"conditions":39586,"interventions":39587},[92],[10713],[10541,31255],{"trials":39589,"activeCount":103},[],{"trials":39591,"activeCount":103},[],{"trials":39593,"activeCount":103},[],{"intervention":32760,"totalTrials":437,"cells":39595},{"EARLY_PHASE1":39596,"PHASE1":39598,"PHASE2":39600,"PHASE3":39606,"PHASE4":39608,"NA":39610},{"trials":39597,"activeCount":103},[],{"trials":39599,"activeCount":103},[],{"trials":39601,"activeCount":103},[39602],{"nctId":32753,"briefTitle":32754,"status":123,"phases":39603,"primaryCompletion":32756,"completion":19099,"start":7865,"enrollment":32757,"conditions":39604,"interventions":39605},[92],[16163],[32719,32760],{"trials":39607,"activeCount":103},[],{"trials":39609,"activeCount":103},[],{"trials":39611,"activeCount":103},[],{"intervention":39613,"totalTrials":437,"cells":39614},"MBL949",{"EARLY_PHASE1":39615,"PHASE1":39617,"PHASE2":39619,"PHASE3":39628,"PHASE4":39630,"NA":39632},{"trials":39616,"activeCount":103},[],{"trials":39618,"activeCount":103},[],{"trials":39620,"activeCount":103},[39621],{"nctId":39622,"briefTitle":39623,"status":134,"phases":39624,"primaryCompletion":7827,"completion":7827,"start":39625,"enrollment":5080,"conditions":39626,"interventions":39627},"NCT05199090","Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM",[92],"2022-02-10",[20093],[39613],{"trials":39629,"activeCount":103},[],{"trials":39631,"activeCount":103},[],{"trials":39633,"activeCount":103},[],{"intervention":32034,"totalTrials":437,"cells":39635},{"EARLY_PHASE1":39636,"PHASE1":39638,"PHASE2":39640,"PHASE3":39646,"PHASE4":39648,"NA":39650},{"trials":39637,"activeCount":103},[],{"trials":39639,"activeCount":103},[],{"trials":39641,"activeCount":103},[39642],{"nctId":32029,"briefTitle":32030,"status":134,"phases":39643,"primaryCompletion":1025,"completion":1025,"start":3447,"enrollment":1890,"conditions":39644,"interventions":39645},[92],[4691],[4330,32034],{"trials":39647,"activeCount":103},[],{"trials":39649,"activeCount":103},[],{"trials":39651,"activeCount":103},[],{"intervention":17509,"totalTrials":437,"cells":39653},{"EARLY_PHASE1":39654,"PHASE1":39656,"PHASE2":39658,"PHASE3":39664,"PHASE4":39666,"NA":39668},{"trials":39655,"activeCount":103},[],{"trials":39657,"activeCount":103},[],{"trials":39659,"activeCount":103},[39660],{"nctId":17503,"briefTitle":17504,"status":390,"phases":39661,"primaryCompletion":1817,"completion":1817,"start":4669,"enrollment":103,"conditions":39662,"interventions":39663},[92],[17507],[17485,17509],{"trials":39665,"activeCount":103},[],{"trials":39667,"activeCount":103},[],{"trials":39669,"activeCount":103},[],{"intervention":10655,"totalTrials":437,"cells":39671},{"EARLY_PHASE1":39672,"PHASE1":39674,"PHASE2":39676,"PHASE3":39682,"PHASE4":39684,"NA":39686},{"trials":39673,"activeCount":103},[],{"trials":39675,"activeCount":103},[],{"trials":39677,"activeCount":103},[39678],{"nctId":10646,"briefTitle":10647,"status":123,"phases":39679,"primaryCompletion":10649,"completion":10650,"start":10651,"enrollment":203,"conditions":39680,"interventions":39681},[92],[10653],[212,10655],{"trials":39683,"activeCount":103},[],{"trials":39685,"activeCount":103},[],{"trials":39687,"activeCount":103},[],{"intervention":17016,"totalTrials":437,"cells":39689},{"EARLY_PHASE1":39690,"PHASE1":39692,"PHASE2":39694,"PHASE3":39700,"PHASE4":39702,"NA":39704},{"trials":39691,"activeCount":103},[],{"trials":39693,"activeCount":103},[],{"trials":39695,"activeCount":103},[39696],{"nctId":17010,"briefTitle":17011,"status":134,"phases":39697,"primaryCompletion":926,"completion":926,"start":880,"enrollment":827,"conditions":39698,"interventions":39699},[92],[21,17014],[17016,15884],{"trials":39701,"activeCount":103},[],{"trials":39703,"activeCount":103},[],{"trials":39705,"activeCount":103},[],{"intervention":23869,"totalTrials":437,"cells":39707},{"EARLY_PHASE1":39708,"PHASE1":39710,"PHASE2":39712,"PHASE3":39718,"PHASE4":39720,"NA":39722},{"trials":39709,"activeCount":103},[],{"trials":39711,"activeCount":103},[],{"trials":39713,"activeCount":103},[39714],{"nctId":23863,"briefTitle":23864,"status":123,"phases":39715,"primaryCompletion":1731,"completion":1731,"start":15283,"enrollment":846,"conditions":39716,"interventions":39717},[92],[23867],[23869,3145],{"trials":39719,"activeCount":103},[],{"trials":39721,"activeCount":103},[],{"trials":39723,"activeCount":103},[],{"intervention":11073,"totalTrials":437,"cells":39725},{"EARLY_PHASE1":39726,"PHASE1":39728,"PHASE2":39730,"PHASE3":39736,"PHASE4":39738,"NA":39740},{"trials":39727,"activeCount":103},[],{"trials":39729,"activeCount":103},[],{"trials":39731,"activeCount":103},[39732],{"nctId":11063,"briefTitle":11064,"status":123,"phases":39733,"primaryCompletion":11066,"completion":11066,"start":11067,"enrollment":11068,"conditions":39734,"interventions":39735},[92],[11070],[516,159,11072,11073],{"trials":39737,"activeCount":103},[],{"trials":39739,"activeCount":103},[],{"trials":39741,"activeCount":103},[],{"intervention":39743,"totalTrials":437,"cells":39744},"ICL670, deferoxamine",{"EARLY_PHASE1":39745,"PHASE1":39747,"PHASE2":39749,"PHASE3":39758,"PHASE4":39760,"NA":39762},{"trials":39746,"activeCount":103},[],{"trials":39748,"activeCount":103},[],{"trials":39750,"activeCount":103},[39751],{"nctId":39752,"briefTitle":39753,"status":123,"phases":39754,"primaryCompletion":4317,"start":881,"enrollment":1485,"conditions":39755,"interventions":39757},"NCT00067080","Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions",[92],[39756],"Anemia, Sickle Cell",[39743],{"trials":39759,"activeCount":103},[],{"trials":39761,"activeCount":103},[],{"trials":39763,"activeCount":103},[],{"intervention":39765,"totalTrials":437,"cells":39766},"BFH772",{"EARLY_PHASE1":39767,"PHASE1":39769,"PHASE2":39771,"PHASE3":39781,"PHASE4":39783,"NA":39785},{"trials":39768,"activeCount":103},[],{"trials":39770,"activeCount":103},[],{"trials":39772,"activeCount":103},[39773],{"nctId":39774,"briefTitle":39775,"status":123,"phases":39776,"primaryCompletion":880,"start":4975,"enrollment":2367,"conditions":39777,"interventions":39779},"NCT00987870","Safety and Efficacy of BFH772 in Psoriasis Patients",[91,92],[1675,39778],"Arthritis",[39765,39765,39780],"calcipotriol\u002Fbetamethasone",{"trials":39782,"activeCount":103},[],{"trials":39784,"activeCount":103},[],{"trials":39786,"activeCount":103},[],{"intervention":39780,"totalTrials":437,"cells":39788},{"EARLY_PHASE1":39789,"PHASE1":39791,"PHASE2":39793,"PHASE3":39799,"PHASE4":39801,"NA":39803},{"trials":39790,"activeCount":103},[],{"trials":39792,"activeCount":103},[],{"trials":39794,"activeCount":103},[39795],{"nctId":39774,"briefTitle":39775,"status":123,"phases":39796,"primaryCompletion":880,"start":4975,"enrollment":2367,"conditions":39797,"interventions":39798},[91,92],[1675,39778],[39765,39765,39780],{"trials":39800,"activeCount":103},[],{"trials":39802,"activeCount":103},[],{"trials":39804,"activeCount":103},[],{"intervention":34159,"totalTrials":437,"cells":39806},{"EARLY_PHASE1":39807,"PHASE1":39809,"PHASE2":39811,"PHASE3":39817,"PHASE4":39819,"NA":39821},{"trials":39808,"activeCount":103},[],{"trials":39810,"activeCount":103},[],{"trials":39812,"activeCount":103},[39813],{"nctId":34153,"briefTitle":34154,"status":123,"phases":39814,"primaryCompletion":22169,"completion":22169,"start":7410,"enrollment":534,"conditions":39815,"interventions":39816},[92],[34157],[25937,34159],{"trials":39818,"activeCount":103},[],{"trials":39820,"activeCount":103},[],{"trials":39822,"activeCount":103},[],{"intervention":39824,"totalTrials":437,"cells":39825},"LOU064 100 mg",{"EARLY_PHASE1":39826,"PHASE1":39828,"PHASE2":39830,"PHASE3":39839,"PHASE4":39841,"NA":39843},{"trials":39827,"activeCount":103},[],{"trials":39829,"activeCount":103},[],{"trials":39831,"activeCount":103},[39832],{"nctId":39833,"briefTitle":39834,"status":134,"phases":39835,"primaryCompletion":23389,"completion":23389,"start":39836,"enrollment":485,"conditions":39837,"interventions":39838},"NCT03944707","Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients",[92],"2019-07-18",[18],[39824],{"trials":39840,"activeCount":103},[],{"trials":39842,"activeCount":103},[],{"trials":39844,"activeCount":103},[],{"intervention":16210,"totalTrials":437,"cells":39846},{"EARLY_PHASE1":39847,"PHASE1":39849,"PHASE2":39851,"PHASE3":39857,"PHASE4":39859,"NA":39861},{"trials":39848,"activeCount":103},[],{"trials":39850,"activeCount":103},[],{"trials":39852,"activeCount":103},[39853],{"nctId":16205,"briefTitle":16206,"status":123,"phases":39854,"primaryCompletion":3845,"completion":3845,"start":3551,"enrollment":2149,"conditions":39855,"interventions":39856},[92],[24],[16210,16210,15588],{"trials":39858,"activeCount":103},[],{"trials":39860,"activeCount":103},[],{"trials":39862,"activeCount":103},[],{"intervention":39864,"totalTrials":437,"cells":39865},"NGI226",{"EARLY_PHASE1":39866,"PHASE1":39868,"PHASE2":39870,"PHASE3":39880,"PHASE4":39882,"NA":39884},{"trials":39867,"activeCount":103},[],{"trials":39869,"activeCount":103},[],{"trials":39871,"activeCount":103},[39872],{"nctId":39873,"briefTitle":39874,"status":123,"phases":39875,"primaryCompletion":26827,"completion":26827,"start":39876,"enrollment":2405,"conditions":39877,"interventions":39879},"NCT05592990","A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy",[92],"2023-06-14",[39878],"Achilles Tendinopathy",[39864],{"trials":39881,"activeCount":103},[],{"trials":39883,"activeCount":103},[],{"trials":39885,"activeCount":103},[],{"intervention":7646,"totalTrials":437,"cells":39887},{"EARLY_PHASE1":39888,"PHASE1":39890,"PHASE2":39892,"PHASE3":39898,"PHASE4":39900,"NA":39902},{"trials":39889,"activeCount":103},[],{"trials":39891,"activeCount":103},[],{"trials":39893,"activeCount":103},[39894],{"nctId":7639,"briefTitle":7640,"status":123,"phases":39895,"primaryCompletion":483,"completion":483,"start":7642,"enrollment":7643,"conditions":39896,"interventions":39897},[92],[4691],[7646,7647,4769,4765,7648,7649,7650,7651],{"trials":39899,"activeCount":103},[],{"trials":39901,"activeCount":103},[],{"trials":39903,"activeCount":103},[],{"intervention":7648,"totalTrials":437,"cells":39905},{"EARLY_PHASE1":39906,"PHASE1":39908,"PHASE2":39910,"PHASE3":39916,"PHASE4":39918,"NA":39920},{"trials":39907,"activeCount":103},[],{"trials":39909,"activeCount":103},[],{"trials":39911,"activeCount":103},[39912],{"nctId":7639,"briefTitle":7640,"status":123,"phases":39913,"primaryCompletion":483,"completion":483,"start":7642,"enrollment":7643,"conditions":39914,"interventions":39915},[92],[4691],[7646,7647,4769,4765,7648,7649,7650,7651],{"trials":39917,"activeCount":103},[],{"trials":39919,"activeCount":103},[],{"trials":39921,"activeCount":103},[],{"intervention":7649,"totalTrials":437,"cells":39923},{"EARLY_PHASE1":39924,"PHASE1":39926,"PHASE2":39928,"PHASE3":39934,"PHASE4":39936,"NA":39938},{"trials":39925,"activeCount":103},[],{"trials":39927,"activeCount":103},[],{"trials":39929,"activeCount":103},[39930],{"nctId":7639,"briefTitle":7640,"status":123,"phases":39931,"primaryCompletion":483,"completion":483,"start":7642,"enrollment":7643,"conditions":39932,"interventions":39933},[92],[4691],[7646,7647,4769,4765,7648,7649,7650,7651],{"trials":39935,"activeCount":103},[],{"trials":39937,"activeCount":103},[],{"trials":39939,"activeCount":103},[],{"intervention":7650,"totalTrials":437,"cells":39941},{"EARLY_PHASE1":39942,"PHASE1":39944,"PHASE2":39946,"PHASE3":39952,"PHASE4":39954,"NA":39956},{"trials":39943,"activeCount":103},[],{"trials":39945,"activeCount":103},[],{"trials":39947,"activeCount":103},[39948],{"nctId":7639,"briefTitle":7640,"status":123,"phases":39949,"primaryCompletion":483,"completion":483,"start":7642,"enrollment":7643,"conditions":39950,"interventions":39951},[92],[4691],[7646,7647,4769,4765,7648,7649,7650,7651],{"trials":39953,"activeCount":103},[],{"trials":39955,"activeCount":103},[],{"trials":39957,"activeCount":103},[],{"intervention":7651,"totalTrials":437,"cells":39959},{"EARLY_PHASE1":39960,"PHASE1":39962,"PHASE2":39964,"PHASE3":39970,"PHASE4":39972,"NA":39974},{"trials":39961,"activeCount":103},[],{"trials":39963,"activeCount":103},[],{"trials":39965,"activeCount":103},[39966],{"nctId":7639,"briefTitle":7640,"status":123,"phases":39967,"primaryCompletion":483,"completion":483,"start":7642,"enrollment":7643,"conditions":39968,"interventions":39969},[92],[4691],[7646,7647,4769,4765,7648,7649,7650,7651],{"trials":39971,"activeCount":103},[],{"trials":39973,"activeCount":103},[],{"trials":39975,"activeCount":103},[],{"intervention":39977,"totalTrials":437,"cells":39978},"BYM338 10 mg\u002Fkg",{"EARLY_PHASE1":39979,"PHASE1":39981,"PHASE2":39983,"PHASE3":39993,"PHASE4":39995,"NA":39997},{"trials":39980,"activeCount":103},[],{"trials":39982,"activeCount":103},[],{"trials":39984,"activeCount":103},[39985],{"nctId":39986,"briefTitle":39987,"status":123,"phases":39988,"primaryCompletion":39989,"completion":39990,"start":7720,"enrollment":1352,"conditions":39991,"interventions":39992},"NCT03005288","Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes",[92],"2019-03-21","2019-05-08",[30],[39977],{"trials":39994,"activeCount":103},[],{"trials":39996,"activeCount":103},[],{"trials":39998,"activeCount":103},[],{"intervention":23517,"totalTrials":437,"cells":40000},{"EARLY_PHASE1":40001,"PHASE1":40003,"PHASE2":40005,"PHASE3":40011,"PHASE4":40013,"NA":40015},{"trials":40002,"activeCount":103},[],{"trials":40004,"activeCount":103},[],{"trials":40006,"activeCount":103},[40007],{"nctId":23511,"briefTitle":23512,"status":123,"phases":40008,"primaryCompletion":23514,"completion":23514,"start":5114,"enrollment":5322,"conditions":40009,"interventions":40010},[92],[18],[23460,23517,23518],{"trials":40012,"activeCount":103},[],{"trials":40014,"activeCount":103},[],{"trials":40016,"activeCount":103},[],{"intervention":23518,"totalTrials":437,"cells":40018},{"EARLY_PHASE1":40019,"PHASE1":40021,"PHASE2":40023,"PHASE3":40029,"PHASE4":40031,"NA":40033},{"trials":40020,"activeCount":103},[],{"trials":40022,"activeCount":103},[],{"trials":40024,"activeCount":103},[40025],{"nctId":23511,"briefTitle":23512,"status":123,"phases":40026,"primaryCompletion":23514,"completion":23514,"start":5114,"enrollment":5322,"conditions":40027,"interventions":40028},[92],[18],[23460,23517,23518],{"trials":40030,"activeCount":103},[],{"trials":40032,"activeCount":103},[],{"trials":40034,"activeCount":103},[],{"intervention":34534,"totalTrials":437,"cells":40036},{"EARLY_PHASE1":40037,"PHASE1":40039,"PHASE2":40041,"PHASE3":40047,"PHASE4":40049,"NA":40051},{"trials":40038,"activeCount":103},[],{"trials":40040,"activeCount":103},[],{"trials":40042,"activeCount":103},[40043],{"nctId":34526,"briefTitle":34527,"status":390,"phases":40044,"primaryCompletion":34529,"completion":34530,"start":32699,"enrollment":103,"conditions":40045,"interventions":40046},[92],[34532],[34507,34534],{"trials":40048,"activeCount":103},[],{"trials":40050,"activeCount":103},[],{"trials":40052,"activeCount":103},[],{"intervention":10521,"totalTrials":437,"cells":40054},{"EARLY_PHASE1":40055,"PHASE1":40057,"PHASE2":40059,"PHASE3":40065,"PHASE4":40067,"NA":40069},{"trials":40056,"activeCount":103},[],{"trials":40058,"activeCount":103},[],{"trials":40060,"activeCount":103},[40061],{"nctId":10514,"briefTitle":10515,"status":123,"phases":40062,"primaryCompletion":5114,"completion":5114,"start":1732,"enrollment":1495,"conditions":40063,"interventions":40064},[92],[5636,10518],[10520,10521,5649,5639],{"trials":40066,"activeCount":103},[],{"trials":40068,"activeCount":103},[],{"trials":40070,"activeCount":103},[],{"intervention":3354,"totalTrials":437,"cells":40072},{"EARLY_PHASE1":40073,"PHASE1":40075,"PHASE2":40077,"PHASE3":40083,"PHASE4":40085,"NA":40087},{"trials":40074,"activeCount":103},[],{"trials":40076,"activeCount":103},[],{"trials":40078,"activeCount":103},[40079],{"nctId":3348,"briefTitle":3349,"status":123,"phases":40080,"primaryCompletion":1731,"completion":1731,"start":3351,"enrollment":2112,"conditions":40081,"interventions":40082},[92],[36],[2395,3354],{"trials":40084,"activeCount":103},[],{"trials":40086,"activeCount":103},[],{"trials":40088,"activeCount":103},[],{"intervention":40090,"totalTrials":437,"cells":40091},"Treatment C: Placebo",{"EARLY_PHASE1":40092,"PHASE1":40094,"PHASE2":40096,"PHASE3":40105,"PHASE4":40107,"NA":40109},{"trials":40093,"activeCount":103},[],{"trials":40095,"activeCount":103},[],{"trials":40097,"activeCount":103},[40098],{"nctId":40099,"briefTitle":40100,"status":123,"phases":40101,"primaryCompletion":40102,"completion":40102,"start":2156,"enrollment":5948,"conditions":40103,"interventions":40104},"NCT03108027","Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma",[92],"2018-02-24",[18],[40090],{"trials":40106,"activeCount":103},[],{"trials":40108,"activeCount":103},[],{"trials":40110,"activeCount":103},[],{"intervention":40112,"totalTrials":437,"cells":40113},"Pasireotide with or without cabergoline",{"EARLY_PHASE1":40114,"PHASE1":40116,"PHASE2":40118,"PHASE3":40129,"PHASE4":40131,"NA":40133},{"trials":40115,"activeCount":103},[],{"trials":40117,"activeCount":103},[],{"trials":40119,"activeCount":103},[40120],{"nctId":40121,"briefTitle":40122,"status":134,"phases":40123,"primaryCompletion":40124,"completion":40125,"start":40126,"enrollment":16,"conditions":40127,"interventions":40128},"NCT01915303","Study of the Efficacy and Safety of Pasireotide s.c. +\u002F- Cabergoline in Patients With Cushing's Disease",[92],"2016-09-05","2019-09-04","2014-03-06",[24215],[40112],{"trials":40130,"activeCount":103},[],{"trials":40132,"activeCount":103},[],{"trials":40134,"activeCount":103},[],{"intervention":24382,"totalTrials":437,"cells":40136},{"EARLY_PHASE1":40137,"PHASE1":40139,"PHASE2":40141,"PHASE3":40147,"PHASE4":40149,"NA":40151},{"trials":40138,"activeCount":103},[],{"trials":40140,"activeCount":103},[],{"trials":40142,"activeCount":103},[40143],{"nctId":24375,"briefTitle":24376,"status":123,"phases":40144,"primaryCompletion":24378,"completion":14452,"start":13326,"enrollment":15086,"conditions":40145,"interventions":40146},[92],[24380],[24382,24383,10927],{"trials":40148,"activeCount":103},[],{"trials":40150,"activeCount":103},[],{"trials":40152,"activeCount":103},[],{"intervention":24383,"totalTrials":437,"cells":40154},{"EARLY_PHASE1":40155,"PHASE1":40157,"PHASE2":40159,"PHASE3":40165,"PHASE4":40167,"NA":40169},{"trials":40156,"activeCount":103},[],{"trials":40158,"activeCount":103},[],{"trials":40160,"activeCount":103},[40161],{"nctId":24375,"briefTitle":24376,"status":123,"phases":40162,"primaryCompletion":24378,"completion":14452,"start":13326,"enrollment":15086,"conditions":40163,"interventions":40164},[92],[24380],[24382,24383,10927],{"trials":40166,"activeCount":103},[],{"trials":40168,"activeCount":103},[],{"trials":40170,"activeCount":103},[],{"intervention":40172,"totalTrials":437,"cells":40173},"GSK2110183",{"EARLY_PHASE1":40174,"PHASE1":40176,"PHASE2":40178,"PHASE3":40188,"PHASE4":40190,"NA":40192},{"trials":40175,"activeCount":103},[],{"trials":40177,"activeCount":103},[],{"trials":40179,"activeCount":103},[40180],{"nctId":40181,"briefTitle":40182,"status":123,"phases":40183,"primaryCompletion":40184,"completion":40184,"start":40185,"enrollment":4148,"conditions":40186,"interventions":40187},"NCT01531894","Continuation Study of the Oral AKT Inhibitor GSK2110183",[92],"2018-06-20","2012-02-08",[1102],[40172],{"trials":40189,"activeCount":103},[],{"trials":40191,"activeCount":103},[],{"trials":40193,"activeCount":103},[],{"intervention":34132,"totalTrials":437,"cells":40195},{"EARLY_PHASE1":40196,"PHASE1":40198,"PHASE2":40200,"PHASE3":40206,"PHASE4":40208,"NA":40210},{"trials":40197,"activeCount":103},[],{"trials":40199,"activeCount":103},[],{"trials":40201,"activeCount":103},[40202],{"nctId":34127,"briefTitle":34128,"status":123,"phases":40203,"primaryCompletion":3604,"completion":3604,"start":964,"enrollment":446,"conditions":40204,"interventions":40205},[92],[10401],[34112,34132,34133],{"trials":40207,"activeCount":103},[],{"trials":40209,"activeCount":103},[],{"trials":40211,"activeCount":103},[],{"intervention":34133,"totalTrials":437,"cells":40213},{"EARLY_PHASE1":40214,"PHASE1":40216,"PHASE2":40218,"PHASE3":40224,"PHASE4":40226,"NA":40228},{"trials":40215,"activeCount":103},[],{"trials":40217,"activeCount":103},[],{"trials":40219,"activeCount":103},[40220],{"nctId":34127,"briefTitle":34128,"status":123,"phases":40221,"primaryCompletion":3604,"completion":3604,"start":964,"enrollment":446,"conditions":40222,"interventions":40223},[92],[10401],[34112,34132,34133],{"trials":40225,"activeCount":103},[],{"trials":40227,"activeCount":103},[],{"trials":40229,"activeCount":103},[],{"intervention":40231,"totalTrials":437,"cells":40232},"Fingolimod 0.5mg\u002Fdaily",{"EARLY_PHASE1":40233,"PHASE1":40235,"PHASE2":40237,"PHASE3":40246,"PHASE4":40248,"NA":40250},{"trials":40234,"activeCount":103},[],{"trials":40236,"activeCount":103},[],{"trials":40238,"activeCount":103},[40239],{"nctId":40240,"briefTitle":40241,"status":134,"phases":40242,"primaryCompletion":4515,"completion":4515,"start":15346,"enrollment":213,"conditions":40243,"interventions":40245},"NCT01757691","Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)",[92],[40244],"Acute Demylelinating Optic Neuritis",[40231],{"trials":40247,"activeCount":103},[],{"trials":40249,"activeCount":103},[],{"trials":40251,"activeCount":103},[],{"intervention":5726,"totalTrials":437,"cells":40253},{"EARLY_PHASE1":40254,"PHASE1":40256,"PHASE2":40258,"PHASE3":40264,"PHASE4":40266,"NA":40268},{"trials":40255,"activeCount":103},[],{"trials":40257,"activeCount":103},[],{"trials":40259,"activeCount":103},[40260],{"nctId":5716,"briefTitle":5717,"status":123,"phases":40261,"primaryCompletion":5719,"completion":5719,"start":5720,"enrollment":5721,"conditions":40262,"interventions":40263},[91,92],[5723,5724,2569],[4391,5726],{"trials":40265,"activeCount":103},[],{"trials":40267,"activeCount":103},[],{"trials":40269,"activeCount":103},[],{"intervention":40271,"totalTrials":437,"cells":40272},"pradigastat",{"EARLY_PHASE1":40273,"PHASE1":40275,"PHASE2":40277,"PHASE3":40286,"PHASE4":40288,"NA":40290},{"trials":40274,"activeCount":103},[],{"trials":40276,"activeCount":103},[],{"trials":40278,"activeCount":103},[40279],{"nctId":40280,"briefTitle":40281,"status":134,"phases":40282,"primaryCompletion":3731,"completion":3731,"start":4301,"enrollment":4506,"conditions":40283,"interventions":40285},"NCT01474434","Efficacy of LCQ908 on Cardiovascular Risk",[92],[7145,40284],"Hypertriglyceridemia",[40271],{"trials":40287,"activeCount":103},[],{"trials":40289,"activeCount":103},[],{"trials":40291,"activeCount":103},[],{"intervention":40293,"totalTrials":437,"cells":40294},"MHV370",{"EARLY_PHASE1":40295,"PHASE1":40297,"PHASE2":40299,"PHASE3":40309,"PHASE4":40311,"NA":40313},{"trials":40296,"activeCount":103},[],{"trials":40298,"activeCount":103},[],{"trials":40300,"activeCount":103},[40301],{"nctId":40302,"briefTitle":40303,"status":134,"phases":40304,"primaryCompletion":12997,"completion":40305,"start":2220,"enrollment":2439,"conditions":40306,"interventions":40308},"NCT04988087","A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)",[92],"2023-03-07",[5832,40307],"Mixed Connective Tissue Disease",[40293],{"trials":40310,"activeCount":103},[],{"trials":40312,"activeCount":103},[],{"trials":40314,"activeCount":103},[],{"intervention":10762,"totalTrials":437,"cells":40316},{"EARLY_PHASE1":40317,"PHASE1":40319,"PHASE2":40321,"PHASE3":40327,"PHASE4":40329,"NA":40331},{"trials":40318,"activeCount":103},[],{"trials":40320,"activeCount":103},[],{"trials":40322,"activeCount":103},[40323],{"nctId":10754,"briefTitle":10755,"status":134,"phases":40324,"primaryCompletion":10757,"completion":10757,"start":10758,"enrollment":437,"conditions":40325,"interventions":40326},[92],[10760],[7513,10762],{"trials":40328,"activeCount":103},[],{"trials":40330,"activeCount":103},[],{"trials":40332,"activeCount":103},[],{"intervention":7472,"totalTrials":437,"cells":40334},{"EARLY_PHASE1":40335,"PHASE1":40337,"PHASE2":40339,"PHASE3":40345,"PHASE4":40347,"NA":40349},{"trials":40336,"activeCount":103},[],{"trials":40338,"activeCount":103},[],{"trials":40340,"activeCount":103},[40341],{"nctId":7463,"briefTitle":7464,"status":123,"phases":40342,"primaryCompletion":7466,"completion":7467,"start":7468,"enrollment":792,"conditions":40343,"interventions":40344},[92],[7470],[7403,7472,5074],{"trials":40346,"activeCount":103},[],{"trials":40348,"activeCount":103},[],{"trials":40350,"activeCount":103},[],{"intervention":7482,"totalTrials":437,"cells":40352},{"EARLY_PHASE1":40353,"PHASE1":40355,"PHASE2":40357,"PHASE3":40363,"PHASE4":40365,"NA":40367},{"trials":40354,"activeCount":103},[],{"trials":40356,"activeCount":103},[],{"trials":40358,"activeCount":103},[40359],{"nctId":7474,"briefTitle":7475,"status":123,"phases":40360,"primaryCompletion":7477,"completion":7478,"start":7479,"enrollment":2428,"conditions":40361,"interventions":40362},[92],[7412],[5895,7482,7415],{"trials":40364,"activeCount":103},[],{"trials":40366,"activeCount":103},[],{"trials":40368,"activeCount":103},[],{"intervention":4065,"totalTrials":437,"cells":40370},{"EARLY_PHASE1":40371,"PHASE1":40373,"PHASE2":40375,"PHASE3":40381,"PHASE4":40383,"NA":40385},{"trials":40372,"activeCount":103},[],{"trials":40374,"activeCount":103},[],{"trials":40376,"activeCount":103},[40377],{"nctId":4058,"briefTitle":4059,"status":123,"phases":40378,"primaryCompletion":3272,"completion":3272,"start":4061,"enrollment":2579,"conditions":40379,"interventions":40380},[92],[1717],[83,4064,4065],{"trials":40382,"activeCount":103},[],{"trials":40384,"activeCount":103},[],{"trials":40386,"activeCount":103},[],{"intervention":40388,"totalTrials":437,"cells":40389},"Iloperidone crystalline formulation",{"EARLY_PHASE1":40390,"PHASE1":40392,"PHASE2":40394,"PHASE3":40404,"PHASE4":40406,"NA":40408},{"trials":40391,"activeCount":103},[],{"trials":40393,"activeCount":103},[],{"trials":40395,"activeCount":103},[40396],{"nctId":40397,"briefTitle":40398,"status":123,"phases":40399,"primaryCompletion":3759,"completion":3759,"start":3383,"enrollment":13149,"conditions":40400,"interventions":40401},"NCT01348100","Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients",[91,92],[12560],[40388,40402,40403],"Iloperidone microparticle formulation","Oral iloperidone",{"trials":40405,"activeCount":103},[],{"trials":40407,"activeCount":103},[],{"trials":40409,"activeCount":103},[],{"intervention":40402,"totalTrials":437,"cells":40411},{"EARLY_PHASE1":40412,"PHASE1":40414,"PHASE2":40416,"PHASE3":40422,"PHASE4":40424,"NA":40426},{"trials":40413,"activeCount":103},[],{"trials":40415,"activeCount":103},[],{"trials":40417,"activeCount":103},[40418],{"nctId":40397,"briefTitle":40398,"status":123,"phases":40419,"primaryCompletion":3759,"completion":3759,"start":3383,"enrollment":13149,"conditions":40420,"interventions":40421},[91,92],[12560],[40388,40402,40403],{"trials":40423,"activeCount":103},[],{"trials":40425,"activeCount":103},[],{"trials":40427,"activeCount":103},[],{"intervention":40403,"totalTrials":437,"cells":40429},{"EARLY_PHASE1":40430,"PHASE1":40432,"PHASE2":40434,"PHASE3":40440,"PHASE4":40442,"NA":40444},{"trials":40431,"activeCount":103},[],{"trials":40433,"activeCount":103},[],{"trials":40435,"activeCount":103},[40436],{"nctId":40397,"briefTitle":40398,"status":123,"phases":40437,"primaryCompletion":3759,"completion":3759,"start":3383,"enrollment":13149,"conditions":40438,"interventions":40439},[91,92],[12560],[40388,40402,40403],{"trials":40441,"activeCount":103},[],{"trials":40443,"activeCount":103},[],{"trials":40445,"activeCount":103},[],{"intervention":40447,"totalTrials":437,"cells":40448},"QMF149 Twisthaler®",{"EARLY_PHASE1":40449,"PHASE1":40451,"PHASE2":40453,"PHASE3":40463,"PHASE4":40465,"NA":40467},{"trials":40450,"activeCount":103},[],{"trials":40452,"activeCount":103},[],{"trials":40454,"activeCount":103},[40455],{"nctId":40456,"briefTitle":40457,"status":123,"phases":40458,"primaryCompletion":3784,"completion":3784,"start":4845,"enrollment":40459,"conditions":40460,"interventions":40461},"NCT00941798","Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma",[92],2283,[18],[40447,40462],"Mometasone Twisthaler®",{"trials":40464,"activeCount":103},[],{"trials":40466,"activeCount":103},[],{"trials":40468,"activeCount":103},[],{"intervention":40462,"totalTrials":437,"cells":40470},{"EARLY_PHASE1":40471,"PHASE1":40473,"PHASE2":40475,"PHASE3":40481,"PHASE4":40483,"NA":40485},{"trials":40472,"activeCount":103},[],{"trials":40474,"activeCount":103},[],{"trials":40476,"activeCount":103},[40477],{"nctId":40456,"briefTitle":40457,"status":123,"phases":40478,"primaryCompletion":3784,"completion":3784,"start":4845,"enrollment":40459,"conditions":40479,"interventions":40480},[92],[18],[40447,40462],{"trials":40482,"activeCount":103},[],{"trials":40484,"activeCount":103},[],{"trials":40486,"activeCount":103},[],{"intervention":10529,"totalTrials":437,"cells":40488},{"EARLY_PHASE1":40489,"PHASE1":40491,"PHASE2":40493,"PHASE3":40499,"PHASE4":40501,"NA":40503},{"trials":40490,"activeCount":103},[],{"trials":40492,"activeCount":103},[],{"trials":40494,"activeCount":103},[40495],{"nctId":10523,"briefTitle":10524,"status":123,"phases":40496,"primaryCompletion":4410,"completion":8048,"start":988,"enrollment":10526,"conditions":40497,"interventions":40498},[92],[1654],[4432,10529,10530,10531,5639],{"trials":40500,"activeCount":103},[],{"trials":40502,"activeCount":103},[],{"trials":40504,"activeCount":103},[],{"intervention":10530,"totalTrials":437,"cells":40506},{"EARLY_PHASE1":40507,"PHASE1":40509,"PHASE2":40511,"PHASE3":40517,"PHASE4":40519,"NA":40521},{"trials":40508,"activeCount":103},[],{"trials":40510,"activeCount":103},[],{"trials":40512,"activeCount":103},[40513],{"nctId":10523,"briefTitle":10524,"status":123,"phases":40514,"primaryCompletion":4410,"completion":8048,"start":988,"enrollment":10526,"conditions":40515,"interventions":40516},[92],[1654],[4432,10529,10530,10531,5639],{"trials":40518,"activeCount":103},[],{"trials":40520,"activeCount":103},[],{"trials":40522,"activeCount":103},[],{"intervention":40524,"totalTrials":437,"cells":40525},"LOU064 Arm 1",{"EARLY_PHASE1":40526,"PHASE1":40528,"PHASE2":40530,"PHASE3":40545,"PHASE4":40547,"NA":40549},{"trials":40527,"activeCount":103},[],{"trials":40529,"activeCount":103},[],{"trials":40531,"activeCount":103},[40532],{"nctId":40533,"briefTitle":40534,"status":123,"phases":40535,"primaryCompletion":2969,"completion":40536,"start":40537,"enrollment":25361,"conditions":40538,"interventions":40539},"NCT03926611","This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines",[92],"2021-04-15","2019-06-06",[33],[40524,40540,40541,40542,40543,40544],"LOU064 Arm 2","LOU064 Arm 3","LOU064 Arm 4","LOU064 Arm 5","LOU064 Arm 6",{"trials":40546,"activeCount":103},[],{"trials":40548,"activeCount":103},[],{"trials":40550,"activeCount":103},[],{"intervention":40540,"totalTrials":437,"cells":40552},{"EARLY_PHASE1":40553,"PHASE1":40555,"PHASE2":40557,"PHASE3":40563,"PHASE4":40565,"NA":40567},{"trials":40554,"activeCount":103},[],{"trials":40556,"activeCount":103},[],{"trials":40558,"activeCount":103},[40559],{"nctId":40533,"briefTitle":40534,"status":123,"phases":40560,"primaryCompletion":2969,"completion":40536,"start":40537,"enrollment":25361,"conditions":40561,"interventions":40562},[92],[33],[40524,40540,40541,40542,40543,40544],{"trials":40564,"activeCount":103},[],{"trials":40566,"activeCount":103},[],{"trials":40568,"activeCount":103},[],{"intervention":40541,"totalTrials":437,"cells":40570},{"EARLY_PHASE1":40571,"PHASE1":40573,"PHASE2":40575,"PHASE3":40581,"PHASE4":40583,"NA":40585},{"trials":40572,"activeCount":103},[],{"trials":40574,"activeCount":103},[],{"trials":40576,"activeCount":103},[40577],{"nctId":40533,"briefTitle":40534,"status":123,"phases":40578,"primaryCompletion":2969,"completion":40536,"start":40537,"enrollment":25361,"conditions":40579,"interventions":40580},[92],[33],[40524,40540,40541,40542,40543,40544],{"trials":40582,"activeCount":103},[],{"trials":40584,"activeCount":103},[],{"trials":40586,"activeCount":103},[],{"intervention":40542,"totalTrials":437,"cells":40588},{"EARLY_PHASE1":40589,"PHASE1":40591,"PHASE2":40593,"PHASE3":40599,"PHASE4":40601,"NA":40603},{"trials":40590,"activeCount":103},[],{"trials":40592,"activeCount":103},[],{"trials":40594,"activeCount":103},[40595],{"nctId":40533,"briefTitle":40534,"status":123,"phases":40596,"primaryCompletion":2969,"completion":40536,"start":40537,"enrollment":25361,"conditions":40597,"interventions":40598},[92],[33],[40524,40540,40541,40542,40543,40544],{"trials":40600,"activeCount":103},[],{"trials":40602,"activeCount":103},[],{"trials":40604,"activeCount":103},[],{"intervention":40543,"totalTrials":437,"cells":40606},{"EARLY_PHASE1":40607,"PHASE1":40609,"PHASE2":40611,"PHASE3":40617,"PHASE4":40619,"NA":40621},{"trials":40608,"activeCount":103},[],{"trials":40610,"activeCount":103},[],{"trials":40612,"activeCount":103},[40613],{"nctId":40533,"briefTitle":40534,"status":123,"phases":40614,"primaryCompletion":2969,"completion":40536,"start":40537,"enrollment":25361,"conditions":40615,"interventions":40616},[92],[33],[40524,40540,40541,40542,40543,40544],{"trials":40618,"activeCount":103},[],{"trials":40620,"activeCount":103},[],{"trials":40622,"activeCount":103},[],{"intervention":40544,"totalTrials":437,"cells":40624},{"EARLY_PHASE1":40625,"PHASE1":40627,"PHASE2":40629,"PHASE3":40635,"PHASE4":40637,"NA":40639},{"trials":40626,"activeCount":103},[],{"trials":40628,"activeCount":103},[],{"trials":40630,"activeCount":103},[40631],{"nctId":40533,"briefTitle":40534,"status":123,"phases":40632,"primaryCompletion":2969,"completion":40536,"start":40537,"enrollment":25361,"conditions":40633,"interventions":40634},[92],[33],[40524,40540,40541,40542,40543,40544],{"trials":40636,"activeCount":103},[],{"trials":40638,"activeCount":103},[],{"trials":40640,"activeCount":103},[],{"intervention":13536,"totalTrials":437,"cells":40642},{"EARLY_PHASE1":40643,"PHASE1":40645,"PHASE2":40647,"PHASE3":40653,"PHASE4":40655,"NA":40657},{"trials":40644,"activeCount":103},[],{"trials":40646,"activeCount":103},[],{"trials":40648,"activeCount":103},[40649],{"nctId":13526,"briefTitle":13527,"status":123,"phases":40650,"primaryCompletion":13529,"completion":13529,"start":13530,"enrollment":13531,"conditions":40651,"interventions":40652},[91,92],[13533,13534],[13536,4389],{"trials":40654,"activeCount":103},[],{"trials":40656,"activeCount":103},[],{"trials":40658,"activeCount":103},[],{"intervention":40660,"totalTrials":437,"cells":40661},"RHH646",{"EARLY_PHASE1":40662,"PHASE1":40664,"PHASE2":40666,"PHASE3":40674,"PHASE4":40676,"NA":40678},{"trials":40663,"activeCount":103},[],{"trials":40665,"activeCount":103},[],{"trials":40667,"activeCount":103},[40668],{"nctId":40669,"briefTitle":40670,"status":123,"phases":40671,"primaryCompletion":6484,"completion":6484,"start":6336,"enrollment":25933,"conditions":40672,"interventions":40673},"NCT05816395","Safety and Efficacy of RHH646 for Knee Osteoarthritis",[92],[36685],[40660],{"trials":40675,"activeCount":103},[],{"trials":40677,"activeCount":103},[],{"trials":40679,"activeCount":103},[],{"intervention":40681,"totalTrials":437,"cells":40682},"VAK694; Alutard Avanz SQ",{"EARLY_PHASE1":40683,"PHASE1":40685,"PHASE2":40687,"PHASE3":40697,"PHASE4":40699,"NA":40701},{"trials":40684,"activeCount":103},[],{"trials":40686,"activeCount":103},[],{"trials":40688,"activeCount":103},[40689],{"nctId":40690,"briefTitle":40691,"status":123,"phases":40692,"primaryCompletion":1715,"completion":1715,"start":4335,"enrollment":5612,"conditions":40693,"interventions":40694},"NCT01018693","A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance",[92],[9157],[40681,40695,40696],"VAK694 placebo infusion; Alutard Avanz SQ","VAK694 placebo infusion; Saline",{"trials":40698,"activeCount":103},[],{"trials":40700,"activeCount":103},[],{"trials":40702,"activeCount":103},[],{"intervention":40695,"totalTrials":437,"cells":40704},{"EARLY_PHASE1":40705,"PHASE1":40707,"PHASE2":40709,"PHASE3":40715,"PHASE4":40717,"NA":40719},{"trials":40706,"activeCount":103},[],{"trials":40708,"activeCount":103},[],{"trials":40710,"activeCount":103},[40711],{"nctId":40690,"briefTitle":40691,"status":123,"phases":40712,"primaryCompletion":1715,"completion":1715,"start":4335,"enrollment":5612,"conditions":40713,"interventions":40714},[92],[9157],[40681,40695,40696],{"trials":40716,"activeCount":103},[],{"trials":40718,"activeCount":103},[],{"trials":40720,"activeCount":103},[],{"intervention":40696,"totalTrials":437,"cells":40722},{"EARLY_PHASE1":40723,"PHASE1":40725,"PHASE2":40727,"PHASE3":40733,"PHASE4":40735,"NA":40737},{"trials":40724,"activeCount":103},[],{"trials":40726,"activeCount":103},[],{"trials":40728,"activeCount":103},[40729],{"nctId":40690,"briefTitle":40691,"status":123,"phases":40730,"primaryCompletion":1715,"completion":1715,"start":4335,"enrollment":5612,"conditions":40731,"interventions":40732},[92],[9157],[40681,40695,40696],{"trials":40734,"activeCount":103},[],{"trials":40736,"activeCount":103},[],{"trials":40738,"activeCount":103},[],{"intervention":40740,"totalTrials":437,"cells":40741},"AMN107- NILOTINIB",{"EARLY_PHASE1":40742,"PHASE1":40744,"PHASE2":40746,"PHASE3":40755,"PHASE4":40757,"NA":40759},{"trials":40743,"activeCount":103},[],{"trials":40745,"activeCount":103},[],{"trials":40747,"activeCount":103},[40748],{"nctId":40749,"briefTitle":40750,"status":123,"phases":40751,"primaryCompletion":853,"completion":853,"start":5062,"enrollment":1495,"conditions":40752,"interventions":40754},"NCT00633295","Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor",[92],[40753],"Gastrointestinal Stromal Tumors (GIST)",[40740],{"trials":40756,"activeCount":103},[],{"trials":40758,"activeCount":103},[],{"trials":40760,"activeCount":103},[],{"intervention":16361,"totalTrials":437,"cells":40762},{"EARLY_PHASE1":40763,"PHASE1":40765,"PHASE2":40767,"PHASE3":40773,"PHASE4":40775,"NA":40777},{"trials":40764,"activeCount":103},[],{"trials":40766,"activeCount":103},[],{"trials":40768,"activeCount":103},[40769],{"nctId":16356,"briefTitle":16357,"status":123,"phases":40770,"primaryCompletion":3279,"completion":3279,"start":4556,"enrollment":13292,"conditions":40771,"interventions":40772},[92],[15555],[16361,16256],{"trials":40774,"activeCount":103},[],{"trials":40776,"activeCount":103},[],{"trials":40778,"activeCount":103},[],{"intervention":40780,"totalTrials":437,"cells":40781},"CFZ533 active - Cohort 1",{"EARLY_PHASE1":40782,"PHASE1":40784,"PHASE2":40786,"PHASE3":40800,"PHASE4":40802,"NA":40804},{"trials":40783,"activeCount":103},[],{"trials":40785,"activeCount":103},[],{"trials":40787,"activeCount":103},[40788],{"nctId":40789,"briefTitle":40790,"status":123,"phases":40791,"primaryCompletion":17374,"completion":17374,"start":40792,"enrollment":557,"conditions":40793,"interventions":40794},"NCT02291029","Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome",[92],"2014-10-22",[6558],[40780,40795,40796,40797,40798,40799],"CFZ533 placebo- Cohort 1","CFZ533 active - Cohort 2","CFZ533 placebo - Cohort 2","CFZ533 active -Cohort 3","CFZ533 active - Cohort 3",{"trials":40801,"activeCount":103},[],{"trials":40803,"activeCount":103},[],{"trials":40805,"activeCount":103},[],{"intervention":40795,"totalTrials":437,"cells":40807},{"EARLY_PHASE1":40808,"PHASE1":40810,"PHASE2":40812,"PHASE3":40818,"PHASE4":40820,"NA":40822},{"trials":40809,"activeCount":103},[],{"trials":40811,"activeCount":103},[],{"trials":40813,"activeCount":103},[40814],{"nctId":40789,"briefTitle":40790,"status":123,"phases":40815,"primaryCompletion":17374,"completion":17374,"start":40792,"enrollment":557,"conditions":40816,"interventions":40817},[92],[6558],[40780,40795,40796,40797,40798,40799],{"trials":40819,"activeCount":103},[],{"trials":40821,"activeCount":103},[],{"trials":40823,"activeCount":103},[],{"intervention":40796,"totalTrials":437,"cells":40825},{"EARLY_PHASE1":40826,"PHASE1":40828,"PHASE2":40830,"PHASE3":40836,"PHASE4":40838,"NA":40840},{"trials":40827,"activeCount":103},[],{"trials":40829,"activeCount":103},[],{"trials":40831,"activeCount":103},[40832],{"nctId":40789,"briefTitle":40790,"status":123,"phases":40833,"primaryCompletion":17374,"completion":17374,"start":40792,"enrollment":557,"conditions":40834,"interventions":40835},[92],[6558],[40780,40795,40796,40797,40798,40799],{"trials":40837,"activeCount":103},[],{"trials":40839,"activeCount":103},[],{"trials":40841,"activeCount":103},[],{"intervention":40797,"totalTrials":437,"cells":40843},{"EARLY_PHASE1":40844,"PHASE1":40846,"PHASE2":40848,"PHASE3":40854,"PHASE4":40856,"NA":40858},{"trials":40845,"activeCount":103},[],{"trials":40847,"activeCount":103},[],{"trials":40849,"activeCount":103},[40850],{"nctId":40789,"briefTitle":40790,"status":123,"phases":40851,"primaryCompletion":17374,"completion":17374,"start":40792,"enrollment":557,"conditions":40852,"interventions":40853},[92],[6558],[40780,40795,40796,40797,40798,40799],{"trials":40855,"activeCount":103},[],{"trials":40857,"activeCount":103},[],{"trials":40859,"activeCount":103},[],{"intervention":40798,"totalTrials":437,"cells":40861},{"EARLY_PHASE1":40862,"PHASE1":40864,"PHASE2":40866,"PHASE3":40872,"PHASE4":40874,"NA":40876},{"trials":40863,"activeCount":103},[],{"trials":40865,"activeCount":103},[],{"trials":40867,"activeCount":103},[40868],{"nctId":40789,"briefTitle":40790,"status":123,"phases":40869,"primaryCompletion":17374,"completion":17374,"start":40792,"enrollment":557,"conditions":40870,"interventions":40871},[92],[6558],[40780,40795,40796,40797,40798,40799],{"trials":40873,"activeCount":103},[],{"trials":40875,"activeCount":103},[],{"trials":40877,"activeCount":103},[],{"intervention":40799,"totalTrials":437,"cells":40879},{"EARLY_PHASE1":40880,"PHASE1":40882,"PHASE2":40884,"PHASE3":40890,"PHASE4":40892,"NA":40894},{"trials":40881,"activeCount":103},[],{"trials":40883,"activeCount":103},[],{"trials":40885,"activeCount":103},[40886],{"nctId":40789,"briefTitle":40790,"status":123,"phases":40887,"primaryCompletion":17374,"completion":17374,"start":40792,"enrollment":557,"conditions":40888,"interventions":40889},[92],[6558],[40780,40795,40796,40797,40798,40799],{"trials":40891,"activeCount":103},[],{"trials":40893,"activeCount":103},[],{"trials":40895,"activeCount":103},[],{"intervention":16540,"totalTrials":437,"cells":40897},{"EARLY_PHASE1":40898,"PHASE1":40900,"PHASE2":40902,"PHASE3":40908,"PHASE4":40910,"NA":40912},{"trials":40899,"activeCount":103},[],{"trials":40901,"activeCount":103},[],{"trials":40903,"activeCount":103},[40904],{"nctId":16533,"briefTitle":16534,"status":123,"phases":40905,"primaryCompletion":16536,"completion":16536,"start":16537,"enrollment":3939,"conditions":40906,"interventions":40907},[91,92],[208],[7711,16540,16541],{"trials":40909,"activeCount":103},[],{"trials":40911,"activeCount":103},[],{"trials":40913,"activeCount":103},[],{"intervention":16541,"totalTrials":437,"cells":40915},{"EARLY_PHASE1":40916,"PHASE1":40918,"PHASE2":40920,"PHASE3":40926,"PHASE4":40928,"NA":40930},{"trials":40917,"activeCount":103},[],{"trials":40919,"activeCount":103},[],{"trials":40921,"activeCount":103},[40922],{"nctId":16533,"briefTitle":16534,"status":123,"phases":40923,"primaryCompletion":16536,"completion":16536,"start":16537,"enrollment":3939,"conditions":40924,"interventions":40925},[91,92],[208],[7711,16540,16541],{"trials":40927,"activeCount":103},[],{"trials":40929,"activeCount":103},[],{"trials":40931,"activeCount":103},[],{"intervention":11039,"totalTrials":1630,"cells":40933},{"EARLY_PHASE1":40934,"PHASE1":40936,"PHASE2":40962,"PHASE3":40964,"PHASE4":40966,"NA":40968},{"trials":40935,"activeCount":103},[],{"trials":40937,"activeCount":103},[40938,40948,40952,40956],{"nctId":40939,"briefTitle":40940,"status":123,"phases":40941,"primaryCompletion":40942,"completion":40942,"start":40943,"enrollment":512,"conditions":40944,"interventions":40946},"NCT02078609","A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)",[91],"2019-04-18","2014-03-20",[40945],"AML and High Risk MDS",[11039,40947],"LGH447 + midostaurin",{"nctId":13844,"briefTitle":13845,"status":123,"phases":40949,"primaryCompletion":13847,"completion":13847,"start":13848,"enrollment":4360,"conditions":40950,"interventions":40951},[91],[5636],[11039,5207],{"nctId":11031,"briefTitle":11032,"status":123,"phases":40953,"primaryCompletion":11034,"completion":11034,"start":11035,"enrollment":1611,"conditions":40954,"interventions":40955},[91],[11037],[11039,516],{"nctId":40957,"briefTitle":40958,"status":123,"phases":40959,"primaryCompletion":21614,"completion":21614,"start":812,"enrollment":734,"conditions":40960,"interventions":40961},"NCT02160951","Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and\u002For Refractory Hematologic Malignancies",[91],[5636],[11039],{"trials":40963,"activeCount":103},[],{"trials":40965,"activeCount":103},[],{"trials":40967,"activeCount":103},[],{"trials":40969,"activeCount":103},[],{"intervention":13839,"totalTrials":317,"cells":40971},{"EARLY_PHASE1":40972,"PHASE1":40974,"PHASE2":40992,"PHASE3":40994,"PHASE4":40996,"NA":40998},{"trials":40973,"activeCount":103},[],{"trials":40975,"activeCount":103},[40976,40980,40984],{"nctId":13829,"briefTitle":13830,"status":123,"phases":40977,"primaryCompletion":13832,"completion":13832,"start":13833,"enrollment":114,"conditions":40978,"interventions":40979},[91],[11177],[13721,13836,13837,13838,13839,13840,13841,13842,13839,13840],{"nctId":19541,"briefTitle":19542,"status":123,"phases":40981,"primaryCompletion":19544,"completion":19545,"start":19546,"enrollment":1065,"conditions":40982,"interventions":40983},[91],[11177],[13839,13840,9236],{"nctId":40985,"briefTitle":40986,"status":123,"phases":40987,"primaryCompletion":33937,"completion":33937,"start":40988,"enrollment":814,"conditions":40989,"interventions":40990},"NCT05330273","Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz",[91],"2022-04-28",[11177],[13839,13840,40991],"Efavirenz",{"trials":40993,"activeCount":103},[],{"trials":40995,"activeCount":103},[],{"trials":40997,"activeCount":103},[],{"trials":40999,"activeCount":103},[],{"intervention":13840,"totalTrials":317,"cells":41001},{"EARLY_PHASE1":41002,"PHASE1":41004,"PHASE2":41018,"PHASE3":41020,"PHASE4":41022,"NA":41024},{"trials":41003,"activeCount":103},[],{"trials":41005,"activeCount":103},[41006,41010,41014],{"nctId":13829,"briefTitle":13830,"status":123,"phases":41007,"primaryCompletion":13832,"completion":13832,"start":13833,"enrollment":114,"conditions":41008,"interventions":41009},[91],[11177],[13721,13836,13837,13838,13839,13840,13841,13842,13839,13840],{"nctId":19541,"briefTitle":19542,"status":123,"phases":41011,"primaryCompletion":19544,"completion":19545,"start":19546,"enrollment":1065,"conditions":41012,"interventions":41013},[91],[11177],[13839,13840,9236],{"nctId":40985,"briefTitle":40986,"status":123,"phases":41015,"primaryCompletion":33937,"completion":33937,"start":40988,"enrollment":814,"conditions":41016,"interventions":41017},[91],[11177],[13839,13840,40991],{"trials":41019,"activeCount":103},[],{"trials":41021,"activeCount":103},[],{"trials":41023,"activeCount":103},[],{"trials":41025,"activeCount":103},[],{"intervention":41027,"totalTrials":317,"cells":41028},"Gimatecan",{"EARLY_PHASE1":41029,"PHASE1":41031,"PHASE2":41052,"PHASE3":41054,"PHASE4":41056,"NA":41058},{"trials":41030,"activeCount":103},[],{"trials":41032,"activeCount":103},[41033,41040,41046],{"nctId":41034,"briefTitle":41035,"status":123,"phases":41036,"primaryCompletion":926,"completion":926,"start":865,"enrollment":1384,"conditions":41037,"interventions":41038},"NCT00420485","Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors",[91],[647],[41039],"gimatecan",{"nctId":41041,"briefTitle":41042,"status":123,"phases":41043,"primaryCompletion":16570,"start":745,"enrollment":1065,"conditions":41044,"interventions":41045},"NCT00410358","A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.",[91],[5614],[41027],{"nctId":41047,"briefTitle":41048,"status":123,"phases":41049,"primaryCompletion":4975,"start":3254,"enrollment":1630,"conditions":41050,"interventions":41051},"NCT00441610","An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor",[91],[5614],[41027],{"trials":41053,"activeCount":103},[],{"trials":41055,"activeCount":103},[],{"trials":41057,"activeCount":103},[],{"trials":41059,"activeCount":103},[],{"intervention":41061,"totalTrials":213,"cells":41062},"TAP311",{"EARLY_PHASE1":41063,"PHASE1":41065,"PHASE2":41081,"PHASE3":41083,"PHASE4":41085,"NA":41087},{"trials":41064,"activeCount":103},[],{"trials":41066,"activeCount":103},[41067,41074],{"nctId":41068,"briefTitle":41069,"status":123,"phases":41070,"primaryCompletion":3604,"completion":3604,"start":4524,"enrollment":2566,"conditions":41071,"interventions":41073},"NCT01632358","Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients",[91],[41072],"Dyslipidaemia",[41061],{"nctId":41075,"briefTitle":41076,"status":123,"phases":41077,"primaryCompletion":4524,"completion":4524,"start":3800,"enrollment":1890,"conditions":41078,"interventions":41080},"NCT01487460","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients",[91],[41079,9634],"Dyslipidemia",[41061],{"trials":41082,"activeCount":103},[],{"trials":41084,"activeCount":103},[],{"trials":41086,"activeCount":103},[],{"trials":41088,"activeCount":103},[],{"intervention":41090,"totalTrials":213,"cells":41091},"68Ga-FF58",{"EARLY_PHASE1":41092,"PHASE1":41105,"PHASE2":41115,"PHASE3":41117,"PHASE4":41119,"NA":41121},{"trials":41093,"activeCount":103},[41094],{"nctId":41095,"briefTitle":41096,"status":134,"phases":41097,"primaryCompletion":41098,"completion":41099,"start":41100,"enrollment":814,"conditions":41101,"interventions":41104},"NCT04712721","Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.",[90],"2024-06-18","2024-07-01","2021-10-14",[4508,41102,41103,14104],"Brain Neoplasms","Gastroesophageal Adenocarcinoma",[41090],{"trials":41106,"activeCount":103},[41107],{"nctId":41108,"briefTitle":41109,"status":134,"phases":41110,"primaryCompletion":2025,"completion":2025,"start":41111,"enrollment":630,"conditions":41112,"interventions":41113},"NCT05977322","A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.",[91],"2023-10-06",[14104,41103,4508],[41090,41114],"177Lu-FF58",{"trials":41116,"activeCount":103},[],{"trials":41118,"activeCount":103},[],{"trials":41120,"activeCount":103},[],{"trials":41122,"activeCount":103},[],{"intervention":41124,"totalTrials":213,"cells":41125},"MHS552",{"EARLY_PHASE1":41126,"PHASE1":41128,"PHASE2":41146,"PHASE3":41148,"PHASE4":41150,"NA":41152},{"trials":41127,"activeCount":103},[],{"trials":41129,"activeCount":103},[41130,41138],{"nctId":41131,"briefTitle":41132,"status":134,"phases":41133,"primaryCompletion":41134,"completion":41134,"start":41135,"enrollment":422,"conditions":41136,"interventions":41137},"NCT05203419","Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)",[91],"2023-06-04","2022-03-15",[9371],[41124],{"nctId":41139,"briefTitle":41140,"status":390,"phases":41141,"primaryCompletion":41142,"completion":41142,"start":41143,"enrollment":103,"conditions":41144,"interventions":41145},"NCT05272059","Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus",[91],"2025-04-14","2023-09-01",[1741],[41124],{"trials":41147,"activeCount":103},[],{"trials":41149,"activeCount":103},[],{"trials":41151,"activeCount":103},[],{"trials":41153,"activeCount":103},[],{"intervention":41155,"totalTrials":213,"cells":41156},"LFA102",{"EARLY_PHASE1":41157,"PHASE1":41159,"PHASE2":41175,"PHASE3":41177,"PHASE4":41179,"NA":41181},{"trials":41158,"activeCount":103},[],{"trials":41160,"activeCount":103},[41161,41168],{"nctId":41162,"briefTitle":41163,"status":123,"phases":41164,"primaryCompletion":4093,"completion":4093,"start":1818,"enrollment":4568,"conditions":41165,"interventions":41167},"NCT01338831","Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer",[91],[23077,435,41166],"Uterine Leiomyoma",[41155],{"nctId":41169,"briefTitle":41170,"status":123,"phases":41171,"primaryCompletion":1723,"completion":1723,"start":4524,"enrollment":814,"conditions":41172,"interventions":41174},"NCT01610050","A Phase I Study of LFA102 in Japanese Patients",[91],[41173],"Castration-resistant Prostate Cancer, Advanced Breast Cancer",[41155],{"trials":41176,"activeCount":103},[],{"trials":41178,"activeCount":103},[],{"trials":41180,"activeCount":103},[],{"trials":41182,"activeCount":103},[],{"intervention":41184,"totalTrials":213,"cells":41185},"Patupilone\u002FEPO906",{"EARLY_PHASE1":41186,"PHASE1":41188,"PHASE2":41201,"PHASE3":41203,"PHASE4":41205,"NA":41207},{"trials":41187,"activeCount":103},[],{"trials":41189,"activeCount":103},[41190,41196],{"nctId":41191,"briefTitle":41192,"status":123,"phases":41193,"primaryCompletion":864,"start":4621,"enrollment":792,"conditions":41194,"interventions":41195},"NCT00420524","A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function",[91],[6437,31278],[41184],{"nctId":41197,"briefTitle":41192,"status":123,"phases":41198,"primaryCompletion":16570,"start":8091,"enrollment":814,"conditions":41199,"interventions":41200},"NCT00421044",[91],[6437,31278],[41184],{"trials":41202,"activeCount":103},[],{"trials":41204,"activeCount":103},[],{"trials":41206,"activeCount":103},[],{"trials":41208,"activeCount":103},[],{"intervention":13841,"totalTrials":213,"cells":41210},{"EARLY_PHASE1":41211,"PHASE1":41213,"PHASE2":41223,"PHASE3":41225,"PHASE4":41227,"NA":41229},{"trials":41212,"activeCount":103},[],{"trials":41214,"activeCount":103},[41215,41219],{"nctId":13829,"briefTitle":13830,"status":123,"phases":41216,"primaryCompletion":13832,"completion":13832,"start":13833,"enrollment":114,"conditions":41217,"interventions":41218},[91],[11177],[13721,13836,13837,13838,13839,13840,13841,13842,13839,13840],{"nctId":13724,"briefTitle":13725,"status":123,"phases":41220,"primaryCompletion":13727,"completion":8338,"start":13728,"enrollment":7257,"conditions":41221,"interventions":41222},[91],[13719],[159,13731,13732],{"trials":41224,"activeCount":103},[],{"trials":41226,"activeCount":103},[],{"trials":41228,"activeCount":103},[],{"trials":41230,"activeCount":103},[],{"intervention":15419,"totalTrials":213,"cells":41232},{"EARLY_PHASE1":41233,"PHASE1":41235,"PHASE2":41250,"PHASE3":41252,"PHASE4":41254,"NA":41256},{"trials":41234,"activeCount":103},[],{"trials":41236,"activeCount":103},[41237,41246],{"nctId":41238,"briefTitle":41239,"status":134,"phases":41240,"primaryCompletion":1868,"completion":41241,"start":41242,"enrollment":1495,"conditions":41243,"interventions":41245},"NCT02177682","Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients",[91],"2019-08-14","2014-08-13",[41244],"Neoplasms, Haematologic",[15419],{"nctId":15413,"briefTitle":15414,"status":123,"phases":41247,"primaryCompletion":15416,"completion":15416,"start":1817,"enrollment":1053,"conditions":41248,"interventions":41249},[91],[1102],[15419,4321],{"trials":41251,"activeCount":103},[],{"trials":41253,"activeCount":103},[],{"trials":41255,"activeCount":103},[],{"trials":41257,"activeCount":103},[],{"intervention":9915,"totalTrials":213,"cells":41259},{"EARLY_PHASE1":41260,"PHASE1":41262,"PHASE2":41272,"PHASE3":41274,"PHASE4":41276,"NA":41278},{"trials":41261,"activeCount":103},[],{"trials":41263,"activeCount":103},[41264,41268],{"nctId":13323,"briefTitle":13324,"status":134,"phases":41265,"primaryCompletion":13326,"completion":13326,"start":2138,"enrollment":3043,"conditions":41266,"interventions":41267},[91],[13328],[9915,4389],{"nctId":9906,"briefTitle":9907,"status":134,"phases":41269,"primaryCompletion":9909,"completion":9909,"start":9910,"enrollment":1423,"conditions":41270,"interventions":41271},[91],[9912,9913],[9915,212,1079],{"trials":41273,"activeCount":103},[],{"trials":41275,"activeCount":103},[],{"trials":41277,"activeCount":103},[],{"trials":41279,"activeCount":103},[],{"intervention":41281,"totalTrials":213,"cells":41282},"HSP990",{"EARLY_PHASE1":41283,"PHASE1":41285,"PHASE2":41299,"PHASE3":41301,"PHASE4":41303,"NA":41305},{"trials":41284,"activeCount":103},[],{"trials":41286,"activeCount":103},[41287,41293],{"nctId":41288,"briefTitle":41289,"status":134,"phases":41290,"primaryCompletion":1732,"completion":1732,"start":880,"enrollment":837,"conditions":41291,"interventions":41292},"NCT01064089","Dose Escalation of HSP990 in Japan\u002FKorea",[91],[5614],[41281],{"nctId":41294,"briefTitle":41295,"status":123,"phases":41296,"primaryCompletion":3759,"completion":3759,"start":3410,"enrollment":2776,"conditions":41297,"interventions":41298},"NCT00879905","A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors",[91],[31291],[41281],{"trials":41300,"activeCount":103},[],{"trials":41302,"activeCount":103},[],{"trials":41304,"activeCount":103},[],{"trials":41306,"activeCount":103},[],{"intervention":41308,"totalTrials":213,"cells":41309},"XXB750",{"EARLY_PHASE1":41310,"PHASE1":41312,"PHASE2":41329,"PHASE3":41331,"PHASE4":41333,"NA":41335},{"trials":41311,"activeCount":103},[],{"trials":41313,"activeCount":103},[41314,41321],{"nctId":41315,"briefTitle":41316,"status":123,"phases":41317,"primaryCompletion":5854,"completion":17814,"start":2774,"enrollment":1112,"conditions":41318,"interventions":41320},"NCT06558097","Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants",[91],[41319],"XXB750 in Healthy Participants",[41308],{"nctId":41322,"briefTitle":41323,"status":123,"phases":41324,"primaryCompletion":33945,"completion":33945,"start":10689,"enrollment":34,"conditions":41325,"interventions":41328},"NCT05328752","Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF\u002FHFmrEF)",[91],[41326,41327],"Heart Failure With Reduced Ejection Fraction (HFrEF)","or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)",[41308],{"trials":41330,"activeCount":103},[],{"trials":41332,"activeCount":103},[],{"trials":41334,"activeCount":103},[],{"trials":41336,"activeCount":103},[],{"intervention":31173,"totalTrials":213,"cells":41338},{"EARLY_PHASE1":41339,"PHASE1":41341,"PHASE2":41351,"PHASE3":41353,"PHASE4":41355,"NA":41357},{"trials":41340,"activeCount":103},[],{"trials":41342,"activeCount":103},[41343,41347],{"nctId":31166,"briefTitle":31167,"status":123,"phases":41344,"primaryCompletion":31169,"completion":31169,"start":31170,"enrollment":3098,"conditions":41345,"interventions":41346},[91],[5636],[10541,31173],{"nctId":6481,"briefTitle":6482,"status":134,"phases":41348,"primaryCompletion":6484,"completion":6484,"start":6485,"enrollment":3343,"conditions":41349,"interventions":41350},[91],[6487],[3112,6489],{"trials":41352,"activeCount":103},[],{"trials":41354,"activeCount":103},[],{"trials":41356,"activeCount":103},[],{"trials":41358,"activeCount":103},[],{"intervention":13722,"totalTrials":213,"cells":41360},{"EARLY_PHASE1":41361,"PHASE1":41363,"PHASE2":41373,"PHASE3":41375,"PHASE4":41377,"NA":41379},{"trials":41362,"activeCount":103},[],{"trials":41364,"activeCount":103},[41365,41369],{"nctId":13713,"briefTitle":13714,"status":123,"phases":41366,"primaryCompletion":3418,"completion":13716,"start":13717,"enrollment":5612,"conditions":41367,"interventions":41368},[91],[13719],[159,13721,13722],{"nctId":13871,"briefTitle":13872,"status":123,"phases":41370,"primaryCompletion":3409,"completion":3409,"start":5733,"enrollment":28,"conditions":41371,"interventions":41372},[91],[13875],[13877,13878,13879,5207,13880],{"trials":41374,"activeCount":103},[],{"trials":41376,"activeCount":103},[],{"trials":41378,"activeCount":103},[],{"trials":41380,"activeCount":103},[],{"intervention":41382,"totalTrials":213,"cells":41383},"MIK665",{"EARLY_PHASE1":41384,"PHASE1":41386,"PHASE2":41407,"PHASE3":41409,"PHASE4":41411,"NA":41413},{"trials":41385,"activeCount":103},[],{"trials":41387,"activeCount":103},[41388,41399],{"nctId":41389,"briefTitle":41390,"status":134,"phases":41391,"primaryCompletion":41392,"completion":41392,"start":41393,"enrollment":5612,"conditions":41394,"interventions":41397},"NCT04702425","VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed\u002FRefractory Non-Hodgkin Lymphoma, Relapsed\u002FRefractory Acute Myeloid Leukemia, or Relapsed\u002FRefractory Multiple Myeloma)",[91],"2024-07-23","2021-06-23",[41395,5598,41396],"Non-Hodgkin Lymphoma (NHL)","Multiple Myeloma (MM)",[41398,41382],"VOB560",{"nctId":41400,"briefTitle":41401,"status":123,"phases":41402,"primaryCompletion":2111,"completion":2111,"start":41403,"enrollment":827,"conditions":41404,"interventions":41406},"NCT02992483","Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma",[91],"2017-07-12",[41405],"Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma",[41382],{"trials":41408,"activeCount":103},[],{"trials":41410,"activeCount":103},[],{"trials":41412,"activeCount":103},[],{"trials":41414,"activeCount":103},[],{"intervention":16465,"totalTrials":213,"cells":41416},{"EARLY_PHASE1":41417,"PHASE1":41419,"PHASE2":41433,"PHASE3":41435,"PHASE4":41437,"NA":41439},{"trials":41418,"activeCount":103},[],{"trials":41420,"activeCount":103},[41421,41425],{"nctId":16460,"briefTitle":16461,"status":123,"phases":41422,"primaryCompletion":895,"start":5063,"enrollment":3475,"conditions":41423,"interventions":41424},[91],[1316],[7711,16465],{"nctId":41426,"briefTitle":41427,"status":134,"phases":41428,"primaryCompletion":17719,"completion":18026,"start":41429,"enrollment":496,"conditions":41430,"interventions":41431},"NCT02468661","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced\u002FMetastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",[91],"2015-09-23",[182],[41432,16465],"INC280 single agent",{"trials":41434,"activeCount":103},[],{"trials":41436,"activeCount":103},[],{"trials":41438,"activeCount":103},[],{"trials":41440,"activeCount":103},[],{"intervention":41442,"totalTrials":437,"cells":41443},"FIA586",{"EARLY_PHASE1":41444,"PHASE1":41446,"PHASE2":41455,"PHASE3":41457,"PHASE4":41459,"NA":41461},{"trials":41445,"activeCount":103},[],{"trials":41447,"activeCount":103},[41448],{"nctId":41449,"briefTitle":41450,"status":123,"phases":41451,"primaryCompletion":41452,"completion":41452,"start":1201,"enrollment":271,"conditions":41453,"interventions":41454},"NCT04993157","Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment",[91],"2022-06-28",[2625],[41442],{"trials":41456,"activeCount":103},[],{"trials":41458,"activeCount":103},[],{"trials":41460,"activeCount":103},[],{"trials":41462,"activeCount":103},[],{"intervention":41464,"totalTrials":437,"cells":41465},"LFX453 H1",{"EARLY_PHASE1":41466,"PHASE1":41468,"PHASE2":41480,"PHASE3":41482,"PHASE4":41484,"NA":41486},{"trials":41467,"activeCount":103},[],{"trials":41469,"activeCount":103},[41470],{"nctId":41471,"briefTitle":41472,"status":123,"phases":41473,"primaryCompletion":3731,"completion":3731,"start":3559,"enrollment":4506,"conditions":41474,"interventions":41475},"NCT02052687","A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453",[91],[1674],[41464,41476,41477,41478,41479],"LFX453 L1","LFX453 H2","LFX453 L2","Imiquimod",{"trials":41481,"activeCount":103},[],{"trials":41483,"activeCount":103},[],{"trials":41485,"activeCount":103},[],{"trials":41487,"activeCount":103},[],{"intervention":41476,"totalTrials":437,"cells":41489},{"EARLY_PHASE1":41490,"PHASE1":41492,"PHASE2":41498,"PHASE3":41500,"PHASE4":41502,"NA":41504},{"trials":41491,"activeCount":103},[],{"trials":41493,"activeCount":103},[41494],{"nctId":41471,"briefTitle":41472,"status":123,"phases":41495,"primaryCompletion":3731,"completion":3731,"start":3559,"enrollment":4506,"conditions":41496,"interventions":41497},[91],[1674],[41464,41476,41477,41478,41479],{"trials":41499,"activeCount":103},[],{"trials":41501,"activeCount":103},[],{"trials":41503,"activeCount":103},[],{"trials":41505,"activeCount":103},[],{"intervention":41477,"totalTrials":437,"cells":41507},{"EARLY_PHASE1":41508,"PHASE1":41510,"PHASE2":41516,"PHASE3":41518,"PHASE4":41520,"NA":41522},{"trials":41509,"activeCount":103},[],{"trials":41511,"activeCount":103},[41512],{"nctId":41471,"briefTitle":41472,"status":123,"phases":41513,"primaryCompletion":3731,"completion":3731,"start":3559,"enrollment":4506,"conditions":41514,"interventions":41515},[91],[1674],[41464,41476,41477,41478,41479],{"trials":41517,"activeCount":103},[],{"trials":41519,"activeCount":103},[],{"trials":41521,"activeCount":103},[],{"trials":41523,"activeCount":103},[],{"intervention":41478,"totalTrials":437,"cells":41525},{"EARLY_PHASE1":41526,"PHASE1":41528,"PHASE2":41534,"PHASE3":41536,"PHASE4":41538,"NA":41540},{"trials":41527,"activeCount":103},[],{"trials":41529,"activeCount":103},[41530],{"nctId":41471,"briefTitle":41472,"status":123,"phases":41531,"primaryCompletion":3731,"completion":3731,"start":3559,"enrollment":4506,"conditions":41532,"interventions":41533},[91],[1674],[41464,41476,41477,41478,41479],{"trials":41535,"activeCount":103},[],{"trials":41537,"activeCount":103},[],{"trials":41539,"activeCount":103},[],{"trials":41541,"activeCount":103},[],{"intervention":41479,"totalTrials":437,"cells":41543},{"EARLY_PHASE1":41544,"PHASE1":41546,"PHASE2":41552,"PHASE3":41554,"PHASE4":41556,"NA":41558},{"trials":41545,"activeCount":103},[],{"trials":41547,"activeCount":103},[41548],{"nctId":41471,"briefTitle":41472,"status":123,"phases":41549,"primaryCompletion":3731,"completion":3731,"start":3559,"enrollment":4506,"conditions":41550,"interventions":41551},[91],[1674],[41464,41476,41477,41478,41479],{"trials":41553,"activeCount":103},[],{"trials":41555,"activeCount":103},[],{"trials":41557,"activeCount":103},[],{"trials":41559,"activeCount":103},[],{"intervention":40947,"totalTrials":437,"cells":41561},{"EARLY_PHASE1":41562,"PHASE1":41564,"PHASE2":41570,"PHASE3":41572,"PHASE4":41574,"NA":41576},{"trials":41563,"activeCount":103},[],{"trials":41565,"activeCount":103},[41566],{"nctId":40939,"briefTitle":40940,"status":123,"phases":41567,"primaryCompletion":40942,"completion":40942,"start":40943,"enrollment":512,"conditions":41568,"interventions":41569},[91],[40945],[11039,40947],{"trials":41571,"activeCount":103},[],{"trials":41573,"activeCount":103},[],{"trials":41575,"activeCount":103},[],{"trials":41577,"activeCount":103},[],{"intervention":41579,"totalTrials":437,"cells":41580},"ASA404, DMXAA or DXAA",{"EARLY_PHASE1":41581,"PHASE1":41583,"PHASE2":41592,"PHASE3":41594,"PHASE4":41596,"NA":41598},{"trials":41582,"activeCount":103},[],{"trials":41584,"activeCount":103},[41585],{"nctId":41586,"briefTitle":41587,"status":134,"phases":41588,"primaryCompletion":926,"start":964,"enrollment":1562,"conditions":41589,"interventions":41591},"NCT01278758","A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function",[91],[41590],"Metastatic Cancer",[41579],{"trials":41593,"activeCount":103},[],{"trials":41595,"activeCount":103},[],{"trials":41597,"activeCount":103},[],{"trials":41599,"activeCount":103},[],{"intervention":41601,"totalTrials":437,"cells":41602},"LDE225+gemcitabine",{"EARLY_PHASE1":41603,"PHASE1":41605,"PHASE2":41613,"PHASE3":41615,"PHASE4":41617,"NA":41619},{"trials":41604,"activeCount":103},[],{"trials":41606,"activeCount":103},[41607],{"nctId":41608,"briefTitle":41609,"status":123,"phases":41610,"primaryCompletion":3409,"completion":3409,"start":2795,"enrollment":3343,"conditions":41611,"interventions":41612},"NCT01487785","Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients",[91],[13275],[41601],{"trials":41614,"activeCount":103},[],{"trials":41616,"activeCount":103},[],{"trials":41618,"activeCount":103},[],{"trials":41620,"activeCount":103},[],{"intervention":9824,"totalTrials":437,"cells":41622},{"EARLY_PHASE1":41623,"PHASE1":41625,"PHASE2":41631,"PHASE3":41633,"PHASE4":41635,"NA":41637},{"trials":41624,"activeCount":103},[],{"trials":41626,"activeCount":103},[41627],{"nctId":9817,"briefTitle":9818,"status":123,"phases":41628,"primaryCompletion":2034,"completion":2034,"start":9820,"enrollment":557,"conditions":41629,"interventions":41630},[91],[5598],[9823,9824,9825],{"trials":41632,"activeCount":103},[],{"trials":41634,"activeCount":103},[],{"trials":41636,"activeCount":103},[],{"trials":41638,"activeCount":103},[],{"intervention":13286,"totalTrials":437,"cells":41640},{"EARLY_PHASE1":41641,"PHASE1":41643,"PHASE2":41649,"PHASE3":41651,"PHASE4":41653,"NA":41655},{"trials":41642,"activeCount":103},[],{"trials":41644,"activeCount":103},[41645],{"nctId":13279,"briefTitle":13280,"status":134,"phases":41646,"primaryCompletion":13282,"completion":13282,"start":2220,"enrollment":709,"conditions":41647,"interventions":41648},[91],[13284],[13286,7711,4389,10575],{"trials":41650,"activeCount":103},[],{"trials":41652,"activeCount":103},[],{"trials":41654,"activeCount":103},[],{"trials":41656,"activeCount":103},[],{"intervention":41658,"totalTrials":437,"cells":41659},"LGT209 50 mg",{"EARLY_PHASE1":41660,"PHASE1":41662,"PHASE2":41673,"PHASE3":41675,"PHASE4":41677,"NA":41679},{"trials":41661,"activeCount":103},[],{"trials":41663,"activeCount":103},[41664],{"nctId":41665,"briefTitle":41666,"status":123,"phases":41667,"primaryCompletion":3759,"completion":3759,"start":4620,"enrollment":2342,"conditions":41668,"interventions":41670},"NCT01859455","Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins",[91],[1401,41669],"LDL Cholesterol",[41658,41671,41672],"LGT209 300 mg","Statins",{"trials":41674,"activeCount":103},[],{"trials":41676,"activeCount":103},[],{"trials":41678,"activeCount":103},[],{"trials":41680,"activeCount":103},[],{"intervention":41671,"totalTrials":437,"cells":41682},{"EARLY_PHASE1":41683,"PHASE1":41685,"PHASE2":41691,"PHASE3":41693,"PHASE4":41695,"NA":41697},{"trials":41684,"activeCount":103},[],{"trials":41686,"activeCount":103},[41687],{"nctId":41665,"briefTitle":41666,"status":123,"phases":41688,"primaryCompletion":3759,"completion":3759,"start":4620,"enrollment":2342,"conditions":41689,"interventions":41690},[91],[1401,41669],[41658,41671,41672],{"trials":41692,"activeCount":103},[],{"trials":41694,"activeCount":103},[],{"trials":41696,"activeCount":103},[],{"trials":41698,"activeCount":103},[],{"intervention":41672,"totalTrials":437,"cells":41700},{"EARLY_PHASE1":41701,"PHASE1":41703,"PHASE2":41709,"PHASE3":41711,"PHASE4":41713,"NA":41715},{"trials":41702,"activeCount":103},[],{"trials":41704,"activeCount":103},[41705],{"nctId":41665,"briefTitle":41666,"status":123,"phases":41706,"primaryCompletion":3759,"completion":3759,"start":4620,"enrollment":2342,"conditions":41707,"interventions":41708},[91],[1401,41669],[41658,41671,41672],{"trials":41710,"activeCount":103},[],{"trials":41712,"activeCount":103},[],{"trials":41714,"activeCount":103},[],{"trials":41716,"activeCount":103},[],{"intervention":13296,"totalTrials":437,"cells":41718},{"EARLY_PHASE1":41719,"PHASE1":41721,"PHASE2":41727,"PHASE3":41729,"PHASE4":41731,"NA":41733},{"trials":41720,"activeCount":103},[],{"trials":41722,"activeCount":103},[41723],{"nctId":13288,"briefTitle":13289,"status":134,"phases":41724,"primaryCompletion":13291,"completion":13291,"start":1064,"enrollment":13292,"conditions":41725,"interventions":41726},[91],[5614,9944,13294],[13296,4389],{"trials":41728,"activeCount":103},[],{"trials":41730,"activeCount":103},[],{"trials":41732,"activeCount":103},[],{"trials":41734,"activeCount":103},[],{"intervention":41736,"totalTrials":437,"cells":41737},"NJH395",{"EARLY_PHASE1":41738,"PHASE1":41740,"PHASE2":41749,"PHASE3":41751,"PHASE4":41753,"NA":41755},{"trials":41739,"activeCount":103},[],{"trials":41741,"activeCount":103},[41742],{"nctId":41743,"briefTitle":41744,"status":123,"phases":41745,"primaryCompletion":2809,"completion":2809,"start":36842,"enrollment":3343,"conditions":41746,"interventions":41748},"NCT03696771","Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer",[91],[41747],"NON-breast HER2+ Malignancies",[41736],{"trials":41750,"activeCount":103},[],{"trials":41752,"activeCount":103},[],{"trials":41754,"activeCount":103},[],{"trials":41756,"activeCount":103},[],{"intervention":41758,"totalTrials":437,"cells":41759},"Imatinib\u002FAcetaminophen",{"EARLY_PHASE1":41760,"PHASE1":41762,"PHASE2":41770,"PHASE3":41772,"PHASE4":41774,"NA":41776},{"trials":41761,"activeCount":103},[],{"trials":41763,"activeCount":103},[41764],{"nctId":41765,"briefTitle":41766,"status":123,"phases":41767,"primaryCompletion":3473,"completion":3473,"start":3195,"enrollment":138,"conditions":41768,"interventions":41769},"NCT00428909","Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen\u002FParacetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)",[91],[12513],[41758],{"trials":41771,"activeCount":103},[],{"trials":41773,"activeCount":103},[],{"trials":41775,"activeCount":103},[],{"trials":41777,"activeCount":103},[],{"intervention":41779,"totalTrials":437,"cells":41780},"ABP688",{"EARLY_PHASE1":41781,"PHASE1":41783,"PHASE2":41791,"PHASE3":41793,"PHASE4":41795,"NA":41797},{"trials":41782,"activeCount":103},[],{"trials":41784,"activeCount":103},[41785],{"nctId":41786,"briefTitle":41787,"status":123,"phases":41788,"primaryCompletion":853,"completion":853,"start":3473,"enrollment":25,"conditions":41789,"interventions":41790},"NCT01528241","Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)",[91],[3802],[41779],{"trials":41792,"activeCount":103},[],{"trials":41794,"activeCount":103},[],{"trials":41796,"activeCount":103},[],{"trials":41798,"activeCount":103},[],{"intervention":41800,"totalTrials":437,"cells":41801},"AGO178C",{"EARLY_PHASE1":41802,"PHASE1":41804,"PHASE2":41812,"PHASE3":41814,"PHASE4":41816,"NA":41818},{"trials":41803,"activeCount":103},[],{"trials":41805,"activeCount":103},[41806],{"nctId":41807,"briefTitle":41808,"status":123,"phases":41809,"primaryCompletion":1724,"start":895,"enrollment":7257,"conditions":41810,"interventions":41811},"NCT01459250","Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects",[91],[2635],[41800],{"trials":41813,"activeCount":103},[],{"trials":41815,"activeCount":103},[],{"trials":41817,"activeCount":103},[],{"trials":41819,"activeCount":103},[],{"intervention":41821,"totalTrials":437,"cells":41822},"Treatment A",{"EARLY_PHASE1":41823,"PHASE1":41825,"PHASE2":41836,"PHASE3":41838,"PHASE4":41840,"NA":41842},{"trials":41824,"activeCount":103},[],{"trials":41826,"activeCount":103},[41827],{"nctId":41828,"briefTitle":41829,"status":123,"phases":41830,"primaryCompletion":382,"completion":382,"start":41831,"enrollment":99,"conditions":41832,"interventions":41833},"NCT05195892","Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers",[91],"2022-02-03",[9634],[41821,41834,41835],"Treatment B","Treatment C",{"trials":41837,"activeCount":103},[],{"trials":41839,"activeCount":103},[],{"trials":41841,"activeCount":103},[],{"trials":41843,"activeCount":103},[],{"intervention":41834,"totalTrials":437,"cells":41845},{"EARLY_PHASE1":41846,"PHASE1":41848,"PHASE2":41854,"PHASE3":41856,"PHASE4":41858,"NA":41860},{"trials":41847,"activeCount":103},[],{"trials":41849,"activeCount":103},[41850],{"nctId":41828,"briefTitle":41829,"status":123,"phases":41851,"primaryCompletion":382,"completion":382,"start":41831,"enrollment":99,"conditions":41852,"interventions":41853},[91],[9634],[41821,41834,41835],{"trials":41855,"activeCount":103},[],{"trials":41857,"activeCount":103},[],{"trials":41859,"activeCount":103},[],{"trials":41861,"activeCount":103},[],{"intervention":41835,"totalTrials":437,"cells":41863},{"EARLY_PHASE1":41864,"PHASE1":41866,"PHASE2":41872,"PHASE3":41874,"PHASE4":41876,"NA":41878},{"trials":41865,"activeCount":103},[],{"trials":41867,"activeCount":103},[41868],{"nctId":41828,"briefTitle":41829,"status":123,"phases":41869,"primaryCompletion":382,"completion":382,"start":41831,"enrollment":99,"conditions":41870,"interventions":41871},[91],[9634],[41821,41834,41835],{"trials":41873,"activeCount":103},[],{"trials":41875,"activeCount":103},[],{"trials":41877,"activeCount":103},[],{"trials":41879,"activeCount":103},[],{"intervention":41881,"totalTrials":437,"cells":41882},"CHIR-258",{"EARLY_PHASE1":41883,"PHASE1":41885,"PHASE2":41893,"PHASE3":41895,"PHASE4":41897,"NA":41899},{"trials":41884,"activeCount":103},[],{"trials":41886,"activeCount":103},[41887],{"nctId":41888,"briefTitle":41889,"status":134,"phases":41890,"primaryCompletion":825,"start":17396,"enrollment":906,"conditions":41891,"interventions":41892},"NCT01270906","Safety of CHIR-258 (TKI258) in Advanced Solid Tumors",[91],[4362,1102,31278],[41881],{"trials":41894,"activeCount":103},[],{"trials":41896,"activeCount":103},[],{"trials":41898,"activeCount":103},[],{"trials":41900,"activeCount":103},[],{"intervention":13305,"totalTrials":437,"cells":41902},{"EARLY_PHASE1":41903,"PHASE1":41905,"PHASE2":41911,"PHASE3":41913,"PHASE4":41915,"NA":41917},{"trials":41904,"activeCount":103},[],{"trials":41906,"activeCount":103},[41907],{"nctId":13298,"briefTitle":13299,"status":134,"phases":41908,"primaryCompletion":13301,"completion":13301,"start":5131,"enrollment":437,"conditions":41909,"interventions":41910},[91],[9924],[4389,13304,13305],{"trials":41912,"activeCount":103},[],{"trials":41914,"activeCount":103},[],{"trials":41916,"activeCount":103},[],{"trials":41918,"activeCount":103},[],{"intervention":41920,"totalTrials":437,"cells":41921},"RSV604",{"EARLY_PHASE1":41922,"PHASE1":41924,"PHASE2":41932,"PHASE3":41934,"PHASE4":41936,"NA":41938},{"trials":41923,"activeCount":103},[],{"trials":41925,"activeCount":103},[41926],{"nctId":41927,"briefTitle":41928,"status":123,"phases":41929,"primaryCompletion":3195,"start":825,"enrollment":114,"conditions":41930,"interventions":41931},"NCT00416442","Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.",[91],[1674],[41920],{"trials":41933,"activeCount":103},[],{"trials":41935,"activeCount":103},[],{"trials":41937,"activeCount":103},[],{"trials":41939,"activeCount":103},[],{"intervention":41941,"totalTrials":437,"cells":41942},"LDT600",{"EARLY_PHASE1":41943,"PHASE1":41945,"PHASE2":41953,"PHASE3":41955,"PHASE4":41957,"NA":41959},{"trials":41944,"activeCount":103},[],{"trials":41946,"activeCount":103},[41947],{"nctId":41948,"briefTitle":41949,"status":123,"phases":41950,"primaryCompletion":2795,"start":3612,"enrollment":2633,"conditions":41951,"interventions":41952},"NCT00907894","Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B",[91],[17418],[41941],{"trials":41954,"activeCount":103},[],{"trials":41956,"activeCount":103},[],{"trials":41958,"activeCount":103},[],{"trials":41960,"activeCount":103},[],{"intervention":41962,"totalTrials":437,"cells":41963},"Pasireotide sub-cutaneous formulation",{"EARLY_PHASE1":41964,"PHASE1":41966,"PHASE2":41976,"PHASE3":41978,"PHASE4":41980,"NA":41982},{"trials":41965,"activeCount":103},[],{"trials":41967,"activeCount":103},[41968],{"nctId":41969,"briefTitle":41970,"status":123,"phases":41971,"primaryCompletion":606,"completion":606,"start":3712,"enrollment":5594,"conditions":41972,"interventions":41974},"NCT01652547","A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma",[91],[41973],"Metastatic Melanoma and Merkel Cell Carcinoma",[41962,41975],"Pasireotide lon acting release formulation",{"trials":41977,"activeCount":103},[],{"trials":41979,"activeCount":103},[],{"trials":41981,"activeCount":103},[],{"trials":41983,"activeCount":103},[],{"intervention":41975,"totalTrials":437,"cells":41985},{"EARLY_PHASE1":41986,"PHASE1":41988,"PHASE2":41994,"PHASE3":41996,"PHASE4":41998,"NA":42000},{"trials":41987,"activeCount":103},[],{"trials":41989,"activeCount":103},[41990],{"nctId":41969,"briefTitle":41970,"status":123,"phases":41991,"primaryCompletion":606,"completion":606,"start":3712,"enrollment":5594,"conditions":41992,"interventions":41993},[91],[41973],[41962,41975],{"trials":41995,"activeCount":103},[],{"trials":41997,"activeCount":103},[],{"trials":41999,"activeCount":103},[],{"trials":42001,"activeCount":103},[],{"intervention":42003,"totalTrials":437,"cells":42004},"LOP628",{"EARLY_PHASE1":42005,"PHASE1":42007,"PHASE2":42017,"PHASE3":42019,"PHASE4":42021,"NA":42023},{"trials":42006,"activeCount":103},[],{"trials":42008,"activeCount":103},[42009],{"nctId":42010,"briefTitle":42011,"status":134,"phases":42012,"primaryCompletion":2509,"completion":2509,"start":1731,"enrollment":317,"conditions":42013,"interventions":42016},"NCT02221505","Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia",[91],[42014,42015],"cKIT-positive Solid Tumors","AML",[42003],{"trials":42018,"activeCount":103},[],{"trials":42020,"activeCount":103},[],{"trials":42022,"activeCount":103},[],{"trials":42024,"activeCount":103},[],{"intervention":42026,"totalTrials":437,"cells":42027},"CSJ137",{"EARLY_PHASE1":42028,"PHASE1":42030,"PHASE2":42040,"PHASE3":42042,"PHASE4":42044,"NA":42046},{"trials":42029,"activeCount":103},[],{"trials":42031,"activeCount":103},[42032],{"nctId":42033,"briefTitle":42034,"status":123,"phases":42035,"primaryCompletion":13493,"completion":13493,"start":42036,"enrollment":709,"conditions":42037,"interventions":42039},"NCT02570854","A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients",[91],"2015-09-22",[42038],"Anemia, Iron-Deficiency",[42026],{"trials":42041,"activeCount":103},[],{"trials":42043,"activeCount":103},[],{"trials":42045,"activeCount":103},[],{"trials":42047,"activeCount":103},[],{"intervention":142,"totalTrials":437,"cells":42049},{"EARLY_PHASE1":42050,"PHASE1":42052,"PHASE2":42058,"PHASE3":42060,"PHASE4":42062,"NA":42064},{"trials":42051,"activeCount":103},[],{"trials":42053,"activeCount":103},[42054],{"nctId":132,"briefTitle":133,"status":134,"phases":42055,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":42056,"interventions":42057},[91],[140],[142,143,98],{"trials":42059,"activeCount":103},[],{"trials":42061,"activeCount":103},[],{"trials":42063,"activeCount":103},[],{"trials":42065,"activeCount":103},[],{"intervention":143,"totalTrials":437,"cells":42067},{"EARLY_PHASE1":42068,"PHASE1":42070,"PHASE2":42076,"PHASE3":42078,"PHASE4":42080,"NA":42082},{"trials":42069,"activeCount":103},[],{"trials":42071,"activeCount":103},[42072],{"nctId":132,"briefTitle":133,"status":134,"phases":42073,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":42074,"interventions":42075},[91],[140],[142,143,98],{"trials":42077,"activeCount":103},[],{"trials":42079,"activeCount":103},[],{"trials":42081,"activeCount":103},[],{"trials":42083,"activeCount":103},[],{"intervention":42085,"totalTrials":437,"cells":42086},"AMN107, STI571",{"EARLY_PHASE1":42087,"PHASE1":42089,"PHASE2":42097,"PHASE3":42099,"PHASE4":42101,"NA":42103},{"trials":42088,"activeCount":103},[],{"trials":42090,"activeCount":103},[42091],{"nctId":42092,"briefTitle":42093,"status":123,"phases":42094,"primaryCompletion":3195,"completion":3195,"start":3272,"enrollment":3322,"conditions":42095,"interventions":42096},"NCT00135005","Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)",[91],[208],[42085],{"trials":42098,"activeCount":103},[],{"trials":42100,"activeCount":103},[],{"trials":42102,"activeCount":103},[],{"trials":42104,"activeCount":103},[],{"intervention":42106,"totalTrials":437,"cells":42107},"panobinostat\u002FLBH589B",{"EARLY_PHASE1":42108,"PHASE1":42110,"PHASE2":42118,"PHASE3":42120,"PHASE4":42122,"NA":42124},{"trials":42109,"activeCount":103},[],{"trials":42111,"activeCount":103},[42112],{"nctId":42113,"briefTitle":42114,"status":123,"phases":42115,"primaryCompletion":1671,"completion":1671,"start":4975,"enrollment":3322,"conditions":42116,"interventions":42117},"NCT01055483","A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia",[91],[2569],[42106],{"trials":42119,"activeCount":103},[],{"trials":42121,"activeCount":103},[],{"trials":42123,"activeCount":103},[],{"trials":42125,"activeCount":103},[],{"intervention":42127,"totalTrials":437,"cells":42128},"ST571 + BYL719",{"EARLY_PHASE1":42129,"PHASE1":42131,"PHASE2":42140,"PHASE3":42142,"PHASE4":42144,"NA":42146},{"trials":42130,"activeCount":103},[],{"trials":42132,"activeCount":103},[42133],{"nctId":42134,"briefTitle":42135,"status":123,"phases":42136,"primaryCompletion":3692,"completion":3692,"start":42137,"enrollment":5681,"conditions":42138,"interventions":42139},"NCT01735968","A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients",[91],"2013-02-27",[23053],[42127],{"trials":42141,"activeCount":103},[],{"trials":42143,"activeCount":103},[],{"trials":42145,"activeCount":103},[],{"trials":42147,"activeCount":103},[],{"intervention":42149,"totalTrials":437,"cells":42150},"MGY825",{"EARLY_PHASE1":42151,"PHASE1":42153,"PHASE2":42162,"PHASE3":42164,"PHASE4":42166,"NA":42168},{"trials":42152,"activeCount":103},[],{"trials":42154,"activeCount":103},[42155],{"nctId":42156,"briefTitle":42157,"status":134,"phases":42158,"primaryCompletion":42159,"completion":42159,"start":25611,"enrollment":4506,"conditions":42160,"interventions":42161},"NCT05275868","Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer",[91],"2025-10-13",[128],[42149],{"trials":42163,"activeCount":103},[],{"trials":42165,"activeCount":103},[],{"trials":42167,"activeCount":103},[],{"trials":42169,"activeCount":103},[],{"intervention":42171,"totalTrials":437,"cells":42172},"LGT209",{"EARLY_PHASE1":42173,"PHASE1":42175,"PHASE2":42183,"PHASE3":42185,"PHASE4":42187,"NA":42189},{"trials":42174,"activeCount":103},[],{"trials":42176,"activeCount":103},[42177],{"nctId":42178,"briefTitle":42179,"status":123,"phases":42180,"primaryCompletion":3800,"completion":3800,"start":4372,"enrollment":223,"conditions":42181,"interventions":42182},"NCT01979601","Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia",[91],[1401],[42171],{"trials":42184,"activeCount":103},[],{"trials":42186,"activeCount":103},[],{"trials":42188,"activeCount":103},[],{"trials":42190,"activeCount":103},[],{"intervention":42192,"totalTrials":437,"cells":42193},"TAS266",{"EARLY_PHASE1":42194,"PHASE1":42196,"PHASE2":42204,"PHASE3":42206,"PHASE4":42208,"NA":42210},{"trials":42195,"activeCount":103},[],{"trials":42197,"activeCount":103},[42198],{"nctId":42199,"briefTitle":42200,"status":134,"phases":42201,"primaryCompletion":3243,"completion":3243,"start":4524,"enrollment":2379,"conditions":42202,"interventions":42203},"NCT01529307","First in Human Trial of TAS266 in Patients With Advanced Solid Tumors",[91],[5614],[42192],{"trials":42205,"activeCount":103},[],{"trials":42207,"activeCount":103},[],{"trials":42209,"activeCount":103},[],{"trials":42211,"activeCount":103},[],{"intervention":42213,"totalTrials":437,"cells":42214},"MHU650",{"EARLY_PHASE1":42215,"PHASE1":42217,"PHASE2":42225,"PHASE3":42227,"PHASE4":42229,"NA":42231},{"trials":42216,"activeCount":103},[],{"trials":42218,"activeCount":103},[42219],{"nctId":42220,"briefTitle":42221,"status":123,"phases":42222,"primaryCompletion":6734,"completion":6734,"start":3029,"enrollment":4118,"conditions":42223,"interventions":42224},"NCT04635800","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients",[91],[25288,16741,18365,10555],[42213],{"trials":42226,"activeCount":103},[],{"trials":42228,"activeCount":103},[],{"trials":42230,"activeCount":103},[],{"trials":42232,"activeCount":103},[],{"intervention":2371,"totalTrials":437,"cells":42234},{"EARLY_PHASE1":42235,"PHASE1":42237,"PHASE2":42243,"PHASE3":42245,"PHASE4":42247,"NA":42249},{"trials":42236,"activeCount":103},[],{"trials":42238,"activeCount":103},[42239],{"nctId":2363,"briefTitle":2364,"status":123,"phases":42240,"primaryCompletion":1899,"completion":1899,"start":2366,"enrollment":2367,"conditions":42241,"interventions":42242},[91],[2369],[2371,2341,515],{"trials":42244,"activeCount":103},[],{"trials":42246,"activeCount":103},[],{"trials":42248,"activeCount":103},[],{"trials":42250,"activeCount":103},[],{"intervention":13314,"totalTrials":437,"cells":42252},{"EARLY_PHASE1":42253,"PHASE1":42255,"PHASE2":42261,"PHASE3":42263,"PHASE4":42265,"NA":42267},{"trials":42254,"activeCount":103},[],{"trials":42256,"activeCount":103},[42257],{"nctId":13307,"briefTitle":13308,"status":123,"phases":42258,"primaryCompletion":13310,"completion":13310,"start":13311,"enrollment":4516,"conditions":42259,"interventions":42260},[91],[647,10090],[13314,4389],{"trials":42262,"activeCount":103},[],{"trials":42264,"activeCount":103},[],{"trials":42266,"activeCount":103},[],{"trials":42268,"activeCount":103},[],{"intervention":41114,"totalTrials":437,"cells":42270},{"EARLY_PHASE1":42271,"PHASE1":42273,"PHASE2":42279,"PHASE3":42281,"PHASE4":42283,"NA":42285},{"trials":42272,"activeCount":103},[],{"trials":42274,"activeCount":103},[42275],{"nctId":41108,"briefTitle":41109,"status":134,"phases":42276,"primaryCompletion":2025,"completion":2025,"start":41111,"enrollment":630,"conditions":42277,"interventions":42278},[91],[14104,41103,4508],[41090,41114],{"trials":42280,"activeCount":103},[],{"trials":42282,"activeCount":103},[],{"trials":42284,"activeCount":103},[],{"trials":42286,"activeCount":103},[],{"intervention":42288,"totalTrials":437,"cells":42289},"RAD001 + BEZ235",{"EARLY_PHASE1":42290,"PHASE1":42292,"PHASE2":42300,"PHASE3":42302,"PHASE4":42304,"NA":42306},{"trials":42291,"activeCount":103},[],{"trials":42293,"activeCount":103},[42294],{"nctId":42295,"briefTitle":42296,"status":123,"phases":42297,"primaryCompletion":2458,"completion":2458,"start":1732,"enrollment":3098,"conditions":42298,"interventions":42299},"NCT01482156","Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors",[91],[5614,435,4352],[42288],{"trials":42301,"activeCount":103},[],{"trials":42303,"activeCount":103},[],{"trials":42305,"activeCount":103},[],{"trials":42307,"activeCount":103},[],{"intervention":1068,"totalTrials":437,"cells":42309},{"EARLY_PHASE1":42310,"PHASE1":42312,"PHASE2":42318,"PHASE3":42320,"PHASE4":42322,"NA":42324},{"trials":42311,"activeCount":103},[],{"trials":42313,"activeCount":103},[42314],{"nctId":1060,"briefTitle":1061,"status":123,"phases":42315,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":42316,"interventions":42317},[91],[647],[173,173,1068],{"trials":42319,"activeCount":103},[],{"trials":42321,"activeCount":103},[],{"trials":42323,"activeCount":103},[],{"trials":42325,"activeCount":103},[],{"intervention":42327,"totalTrials":437,"cells":42328},"INE 963",{"EARLY_PHASE1":42329,"PHASE1":42331,"PHASE2":42340,"PHASE3":42342,"PHASE4":42344,"NA":42346},{"trials":42330,"activeCount":103},[],{"trials":42332,"activeCount":103},[42333],{"nctId":42334,"briefTitle":42335,"status":134,"phases":42336,"primaryCompletion":42337,"completion":42337,"start":37005,"enrollment":2776,"conditions":42338,"interventions":42339},"NCT04896632","Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants",[91],"2022-11-24",[9634],[42327],{"trials":42341,"activeCount":103},[],{"trials":42343,"activeCount":103},[],{"trials":42345,"activeCount":103},[],{"trials":42347,"activeCount":103},[],{"intervention":13837,"totalTrials":437,"cells":42349},{"EARLY_PHASE1":42350,"PHASE1":42352,"PHASE2":42358,"PHASE3":42360,"PHASE4":42362,"NA":42364},{"trials":42351,"activeCount":103},[],{"trials":42353,"activeCount":103},[42354],{"nctId":13829,"briefTitle":13830,"status":123,"phases":42355,"primaryCompletion":13832,"completion":13832,"start":13833,"enrollment":114,"conditions":42356,"interventions":42357},[91],[11177],[13721,13836,13837,13838,13839,13840,13841,13842,13839,13840],{"trials":42359,"activeCount":103},[],{"trials":42361,"activeCount":103},[],{"trials":42363,"activeCount":103},[],{"trials":42365,"activeCount":103},[],{"intervention":13842,"totalTrials":437,"cells":42367},{"EARLY_PHASE1":42368,"PHASE1":42370,"PHASE2":42376,"PHASE3":42378,"PHASE4":42380,"NA":42382},{"trials":42369,"activeCount":103},[],{"trials":42371,"activeCount":103},[42372],{"nctId":13829,"briefTitle":13830,"status":123,"phases":42373,"primaryCompletion":13832,"completion":13832,"start":13833,"enrollment":114,"conditions":42374,"interventions":42375},[91],[11177],[13721,13836,13837,13838,13839,13840,13841,13842,13839,13840],{"trials":42377,"activeCount":103},[],{"trials":42379,"activeCount":103},[],{"trials":42381,"activeCount":103},[],{"trials":42383,"activeCount":103},[],{"intervention":42385,"totalTrials":437,"cells":42386},"lapatinib, docetaxel, trastuzumab",{"EARLY_PHASE1":42387,"PHASE1":42389,"PHASE2":42400,"PHASE3":42402,"PHASE4":42404,"NA":42406},{"trials":42388,"activeCount":103},[],{"trials":42390,"activeCount":103},[42391],{"nctId":42392,"briefTitle":42393,"status":134,"phases":42394,"primaryCompletion":42395,"completion":42396,"start":42397,"enrollment":17433,"conditions":42398,"interventions":42399},"NCT00251433","GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer",[91],"2010-06-10","2022-06-22","2005-09-26",[7868],[42385],{"trials":42401,"activeCount":103},[],{"trials":42403,"activeCount":103},[],{"trials":42405,"activeCount":103},[],{"trials":42407,"activeCount":103},[],{"intervention":15387,"totalTrials":437,"cells":42409},{"EARLY_PHASE1":42410,"PHASE1":42412,"PHASE2":42418,"PHASE3":42420,"PHASE4":42422,"NA":42424},{"trials":42411,"activeCount":103},[],{"trials":42413,"activeCount":103},[42414],{"nctId":15378,"briefTitle":15379,"status":123,"phases":42415,"primaryCompletion":15381,"completion":5818,"start":15382,"enrollment":15383,"conditions":42416,"interventions":42417},[91],[209,15385,4403],[15387,9926,9927,9928,15388,4321,15389],{"trials":42419,"activeCount":103},[],{"trials":42421,"activeCount":103},[],{"trials":42423,"activeCount":103},[],{"trials":42425,"activeCount":103},[],{"intervention":15388,"totalTrials":437,"cells":42427},{"EARLY_PHASE1":42428,"PHASE1":42430,"PHASE2":42436,"PHASE3":42438,"PHASE4":42440,"NA":42442},{"trials":42429,"activeCount":103},[],{"trials":42431,"activeCount":103},[42432],{"nctId":15378,"briefTitle":15379,"status":123,"phases":42433,"primaryCompletion":15381,"completion":5818,"start":15382,"enrollment":15383,"conditions":42434,"interventions":42435},[91],[209,15385,4403],[15387,9926,9927,9928,15388,4321,15389],{"trials":42437,"activeCount":103},[],{"trials":42439,"activeCount":103},[],{"trials":42441,"activeCount":103},[],{"trials":42443,"activeCount":103},[],{"intervention":15389,"totalTrials":437,"cells":42445},{"EARLY_PHASE1":42446,"PHASE1":42448,"PHASE2":42454,"PHASE3":42456,"PHASE4":42458,"NA":42460},{"trials":42447,"activeCount":103},[],{"trials":42449,"activeCount":103},[42450],{"nctId":15378,"briefTitle":15379,"status":123,"phases":42451,"primaryCompletion":15381,"completion":5818,"start":15382,"enrollment":15383,"conditions":42452,"interventions":42453},[91],[209,15385,4403],[15387,9926,9927,9928,15388,4321,15389],{"trials":42455,"activeCount":103},[],{"trials":42457,"activeCount":103},[],{"trials":42459,"activeCount":103},[],{"trials":42461,"activeCount":103},[],{"intervention":42463,"totalTrials":437,"cells":42464},"Everolmus",{"EARLY_PHASE1":42465,"PHASE1":42467,"PHASE2":42475,"PHASE3":42477,"PHASE4":42479,"NA":42481},{"trials":42466,"activeCount":103},[],{"trials":42468,"activeCount":103},[42469],{"nctId":42470,"briefTitle":42471,"status":123,"phases":42472,"primaryCompletion":3559,"completion":3559,"start":1025,"enrollment":734,"conditions":42473,"interventions":42474},"NCT00622258","A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[91],[2877],[42463],{"trials":42476,"activeCount":103},[],{"trials":42478,"activeCount":103},[],{"trials":42480,"activeCount":103},[],{"trials":42482,"activeCount":103},[],{"intervention":42484,"totalTrials":437,"cells":42485},"CLR457",{"EARLY_PHASE1":42486,"PHASE1":42488,"PHASE2":42498,"PHASE3":42500,"PHASE4":42502,"NA":42504},{"trials":42487,"activeCount":103},[],{"trials":42489,"activeCount":103},[42490],{"nctId":42491,"briefTitle":42492,"status":134,"phases":42493,"primaryCompletion":42494,"completion":42494,"start":42495,"enrollment":827,"conditions":42496,"interventions":42497},"NCT02189174","Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies",[91],"2015-11-12","2014-08-07",[9516],[42484],{"trials":42499,"activeCount":103},[],{"trials":42501,"activeCount":103},[],{"trials":42503,"activeCount":103},[],{"trials":42505,"activeCount":103},[],{"intervention":24822,"totalTrials":437,"cells":42507},{"EARLY_PHASE1":42508,"PHASE1":42510,"PHASE2":42516,"PHASE3":42518,"PHASE4":42520,"NA":42522},{"trials":42509,"activeCount":103},[],{"trials":42511,"activeCount":103},[42512],{"nctId":24816,"briefTitle":24817,"status":123,"phases":42513,"primaryCompletion":3473,"start":4070,"enrollment":22825,"conditions":42514,"interventions":42515},[91],[9634,24],[16268,24821,24822],{"trials":42517,"activeCount":103},[],{"trials":42519,"activeCount":103},[],{"trials":42521,"activeCount":103},[],{"trials":42523,"activeCount":103},[],{"intervention":42525,"totalTrials":437,"cells":42526},"Gleevec\u002FGlivec",{"EARLY_PHASE1":42527,"PHASE1":42529,"PHASE2":42539,"PHASE3":42541,"PHASE4":42543,"NA":42545},{"trials":42528,"activeCount":103},[],{"trials":42530,"activeCount":103},[42531],{"nctId":42532,"briefTitle":42533,"status":134,"phases":42534,"primaryCompletion":3784,"start":5620,"enrollment":317,"conditions":42535,"interventions":42538},"NCT01066468","Glivec\u002FGleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec\u002FGleevec® Indicated Hematological Disorders.",[91],[12513,42536,42537],"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)","Other Glivec\u002FGleevec Indicated Hematological Disorders (HES, CEL, MDS\u002F MPN)",[42525],{"trials":42540,"activeCount":103},[],{"trials":42542,"activeCount":103},[],{"trials":42544,"activeCount":103},[],{"trials":42546,"activeCount":103},[],{"intervention":15405,"totalTrials":437,"cells":42548},{"EARLY_PHASE1":42549,"PHASE1":42551,"PHASE2":42557,"PHASE3":42559,"PHASE4":42561,"NA":42563},{"trials":42550,"activeCount":103},[],{"trials":42552,"activeCount":103},[42553],{"nctId":15397,"briefTitle":15398,"status":134,"phases":42554,"primaryCompletion":15400,"completion":15400,"start":15401,"enrollment":2379,"conditions":42555,"interventions":42556},[91],[15403],[738,15405,1168,4321],{"trials":42558,"activeCount":103},[],{"trials":42560,"activeCount":103},[],{"trials":42562,"activeCount":103},[],{"trials":42564,"activeCount":103},[],{"intervention":42566,"totalTrials":437,"cells":42567},"IMJ995 single agent",{"EARLY_PHASE1":42568,"PHASE1":42570,"PHASE2":42580,"PHASE3":42582,"PHASE4":42584,"NA":42586},{"trials":42569,"activeCount":103},[],{"trials":42571,"activeCount":103},[42572],{"nctId":42573,"briefTitle":42574,"status":390,"phases":42575,"primaryCompletion":42576,"completion":42576,"start":42577,"enrollment":103,"conditions":42578,"interventions":42579},"NCT05168748","CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia",[91],"2026-08-13","2023-01-24",[3204],[42566],{"trials":42581,"activeCount":103},[],{"trials":42583,"activeCount":103},[],{"trials":42585,"activeCount":103},[],{"trials":42587,"activeCount":103},[],{"intervention":42589,"totalTrials":437,"cells":42590},"MAK683",{"EARLY_PHASE1":42591,"PHASE1":42593,"PHASE2":42601,"PHASE3":42603,"PHASE4":42605,"NA":42607},{"trials":42592,"activeCount":103},[],{"trials":42594,"activeCount":103},[42595],{"nctId":42596,"briefTitle":42597,"status":134,"phases":42598,"primaryCompletion":2864,"completion":2864,"start":2006,"enrollment":1223,"conditions":42599,"interventions":42600},"NCT02900651","Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies",[91],[4681],[42589],{"trials":42602,"activeCount":103},[],{"trials":42604,"activeCount":103},[],{"trials":42606,"activeCount":103},[],{"trials":42608,"activeCount":103},[],{"intervention":42610,"totalTrials":437,"cells":42611},"PCA062",{"EARLY_PHASE1":42612,"PHASE1":42614,"PHASE2":42624,"PHASE3":42626,"PHASE4":42628,"NA":42630},{"trials":42613,"activeCount":103},[],{"trials":42615,"activeCount":103},[42616],{"nctId":42617,"briefTitle":42618,"status":123,"phases":42619,"primaryCompletion":42620,"completion":42620,"start":42621,"enrollment":846,"conditions":42622,"interventions":42623},"NCT02375958","PCA062 in pCAD-positive Tumors.",[91],"2018-07-17","2015-04-15",[9944,5605,5606],[42610],{"trials":42625,"activeCount":103},[],{"trials":42627,"activeCount":103},[],{"trials":42629,"activeCount":103},[],{"trials":42631,"activeCount":103},[],{"intervention":42633,"totalTrials":437,"cells":42634},"CEE321",{"EARLY_PHASE1":42635,"PHASE1":42637,"PHASE2":42646,"PHASE3":42648,"PHASE4":42650,"NA":42652},{"trials":42636,"activeCount":103},[],{"trials":42638,"activeCount":103},[42639],{"nctId":42640,"briefTitle":42641,"status":123,"phases":42642,"primaryCompletion":42643,"completion":42643,"start":9910,"enrollment":2046,"conditions":42644,"interventions":42645},"NCT04612062","A First-in-Human Study of CEE321 in Adult Subjects",[91],"2021-05-16",[10365],[42633],{"trials":42647,"activeCount":103},[],{"trials":42649,"activeCount":103},[],{"trials":42651,"activeCount":103},[],{"trials":42653,"activeCount":103},[],{"intervention":42655,"totalTrials":437,"cells":42656},"triopifexor",{"EARLY_PHASE1":42657,"PHASE1":42659,"PHASE2":42668,"PHASE3":42670,"PHASE4":42672,"NA":42674},{"trials":42658,"activeCount":103},[],{"trials":42660,"activeCount":103},[42661],{"nctId":42662,"briefTitle":42663,"status":123,"phases":42664,"primaryCompletion":7468,"completion":7468,"start":28035,"enrollment":3568,"conditions":42665,"interventions":42667},"NCT04408937","The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.",[91],[42666],"Liver Disease",[42655],{"trials":42669,"activeCount":103},[],{"trials":42671,"activeCount":103},[],{"trials":42673,"activeCount":103},[],{"trials":42675,"activeCount":103},[],{"intervention":42677,"totalTrials":437,"cells":42678},"MK-3475",{"EARLY_PHASE1":42679,"PHASE1":42681,"PHASE2":42690,"PHASE3":42692,"PHASE4":42694,"NA":42696},{"trials":42680,"activeCount":103},[],{"trials":42682,"activeCount":103},[42683],{"nctId":42684,"briefTitle":42685,"status":123,"phases":42686,"primaryCompletion":6526,"completion":6526,"start":42687,"enrollment":25,"conditions":42688,"interventions":42689},"NCT02014636","Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)",[91],"2013-12-27",[13284],[24630,42677],{"trials":42691,"activeCount":103},[],{"trials":42693,"activeCount":103},[],{"trials":42695,"activeCount":103},[],{"trials":42697,"activeCount":103},[],{"intervention":42699,"totalTrials":437,"cells":42700},"CFG920",{"EARLY_PHASE1":42701,"PHASE1":42703,"PHASE2":42712,"PHASE3":42714,"PHASE4":42716,"NA":42718},{"trials":42702,"activeCount":103},[],{"trials":42704,"activeCount":103},[42705],{"nctId":42706,"briefTitle":42707,"status":134,"phases":42708,"primaryCompletion":2534,"completion":2534,"start":42709,"enrollment":827,"conditions":42710,"interventions":42711},"NCT01647789","A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer",[91],"2012-12-04",[6705],[42699],{"trials":42713,"activeCount":103},[],{"trials":42715,"activeCount":103},[],{"trials":42717,"activeCount":103},[],{"trials":42719,"activeCount":103},[],{"intervention":42721,"totalTrials":437,"cells":42722},"CGM097",{"EARLY_PHASE1":42723,"PHASE1":42725,"PHASE2":42735,"PHASE3":42737,"PHASE4":42739,"NA":42741},{"trials":42724,"activeCount":103},[],{"trials":42726,"activeCount":103},[42727],{"nctId":42728,"briefTitle":42729,"status":123,"phases":42730,"primaryCompletion":42731,"completion":42731,"start":2817,"enrollment":2428,"conditions":42732,"interventions":42734},"NCT01760525","A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors",[91],"2020-07-24",[42733],"Solid Tumor With p53 Wild Type Status",[42721],{"trials":42736,"activeCount":103},[],{"trials":42738,"activeCount":103},[],{"trials":42740,"activeCount":103},[],{"trials":42742,"activeCount":103},[],{"intervention":42744,"totalTrials":437,"cells":42745},"LEQ506",{"EARLY_PHASE1":42746,"PHASE1":42748,"PHASE2":42758,"PHASE3":42760,"PHASE4":42762,"NA":42764},{"trials":42747,"activeCount":103},[],{"trials":42749,"activeCount":103},[42750],{"nctId":42751,"briefTitle":42752,"status":123,"phases":42753,"primaryCompletion":4410,"completion":4410,"start":5620,"enrollment":3530,"conditions":42754,"interventions":42757},"NCT01106508","A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors",[91],[5614,42755,42756],"Recurrent or Refractory Medulloblastoma","Locally Advanced or Metastatic Basal Cell Carcinoma",[42744],{"trials":42759,"activeCount":103},[],{"trials":42761,"activeCount":103},[],{"trials":42763,"activeCount":103},[],{"trials":42765,"activeCount":103},[],{"intervention":23704,"totalTrials":437,"cells":42767},{"EARLY_PHASE1":42768,"PHASE1":42770,"PHASE2":42776,"PHASE3":42778,"PHASE4":42780,"NA":42782},{"trials":42769,"activeCount":103},[],{"trials":42771,"activeCount":103},[42772],{"nctId":23699,"briefTitle":23700,"status":123,"phases":42773,"primaryCompletion":7939,"completion":7939,"start":5114,"enrollment":2405,"conditions":42774,"interventions":42775},[91],[13875],[649,23704],{"trials":42777,"activeCount":103},[],{"trials":42779,"activeCount":103},[],{"trials":42781,"activeCount":103},[],{"trials":42783,"activeCount":103},[],{"intervention":31601,"totalTrials":437,"cells":42785},{"EARLY_PHASE1":42786,"PHASE1":42788,"PHASE2":42794,"PHASE3":42796,"PHASE4":42798,"NA":42800},{"trials":42787,"activeCount":103},[],{"trials":42789,"activeCount":103},[42790],{"nctId":31596,"briefTitle":31597,"status":390,"phases":42791,"primaryCompletion":4317,"start":4317,"enrollment":103,"conditions":42792,"interventions":42793},[91],[647],[8061,31601],{"trials":42795,"activeCount":103},[],{"trials":42797,"activeCount":103},[],{"trials":42799,"activeCount":103},[],{"trials":42801,"activeCount":103},[],{"intervention":42803,"totalTrials":437,"cells":42804},"HKT288",{"EARLY_PHASE1":42805,"PHASE1":42807,"PHASE2":42816,"PHASE3":42818,"PHASE4":42820,"NA":42822},{"trials":42806,"activeCount":103},[],{"trials":42808,"activeCount":103},[42809],{"nctId":42810,"briefTitle":42811,"status":134,"phases":42812,"primaryCompletion":10036,"completion":10036,"start":33338,"enrollment":1495,"conditions":42813,"interventions":42815},"NCT02947152","HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma",[91],[42814,4403],"Epithelial Ovarian Cancer",[42803],{"trials":42817,"activeCount":103},[],{"trials":42819,"activeCount":103},[],{"trials":42821,"activeCount":103},[],{"trials":42823,"activeCount":103},[],{"intervention":32639,"totalTrials":437,"cells":42825},{"EARLY_PHASE1":42826,"PHASE1":42828,"PHASE2":42834,"PHASE3":42836,"PHASE4":42838,"NA":42840},{"trials":42827,"activeCount":103},[],{"trials":42829,"activeCount":103},[42830],{"nctId":32632,"briefTitle":32633,"status":123,"phases":42831,"primaryCompletion":270,"completion":32635,"start":3439,"enrollment":6024,"conditions":42832,"interventions":42833},[91],[32637],[4393,32639],{"trials":42835,"activeCount":103},[],{"trials":42837,"activeCount":103},[],{"trials":42839,"activeCount":103},[],{"trials":42841,"activeCount":103},[],{"intervention":42843,"totalTrials":437,"cells":42844},"[68Ga]Ga-EVS459",{"EARLY_PHASE1":42845,"PHASE1":42847,"PHASE2":42858,"PHASE3":42860,"PHASE4":42862,"NA":42864},{"trials":42846,"activeCount":103},[],{"trials":42848,"activeCount":103},[42849],{"nctId":42850,"briefTitle":42851,"status":134,"phases":42852,"primaryCompletion":42853,"completion":42853,"start":42854,"enrollment":1630,"conditions":42855,"interventions":42856},"NCT06376253","A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers",[91],"2025-07-10","2024-09-08",[6375,6656],[42843,42857],"[177Lu]Lu-EVS459",{"trials":42859,"activeCount":103},[],{"trials":42861,"activeCount":103},[],{"trials":42863,"activeCount":103},[],{"trials":42865,"activeCount":103},[],{"intervention":42857,"totalTrials":437,"cells":42867},{"EARLY_PHASE1":42868,"PHASE1":42870,"PHASE2":42876,"PHASE3":42878,"PHASE4":42880,"NA":42882},{"trials":42869,"activeCount":103},[],{"trials":42871,"activeCount":103},[42872],{"nctId":42850,"briefTitle":42851,"status":134,"phases":42873,"primaryCompletion":42853,"completion":42853,"start":42854,"enrollment":1630,"conditions":42874,"interventions":42875},[91],[6375,6656],[42843,42857],{"trials":42877,"activeCount":103},[],{"trials":42879,"activeCount":103},[],{"trials":42881,"activeCount":103},[],{"trials":42883,"activeCount":103},[],{"intervention":40991,"totalTrials":437,"cells":42885},{"EARLY_PHASE1":42886,"PHASE1":42888,"PHASE2":42894,"PHASE3":42896,"PHASE4":42898,"NA":42900},{"trials":42887,"activeCount":103},[],{"trials":42889,"activeCount":103},[42890],{"nctId":40985,"briefTitle":40986,"status":123,"phases":42891,"primaryCompletion":33937,"completion":33937,"start":40988,"enrollment":814,"conditions":42892,"interventions":42893},[91],[11177],[13839,13840,40991],{"trials":42895,"activeCount":103},[],{"trials":42897,"activeCount":103},[],{"trials":42899,"activeCount":103},[],{"trials":42901,"activeCount":103},[],{"intervention":41398,"totalTrials":437,"cells":42903},{"EARLY_PHASE1":42904,"PHASE1":42906,"PHASE2":42912,"PHASE3":42914,"PHASE4":42916,"NA":42918},{"trials":42905,"activeCount":103},[],{"trials":42907,"activeCount":103},[42908],{"nctId":41389,"briefTitle":41390,"status":134,"phases":42909,"primaryCompletion":41392,"completion":41392,"start":41393,"enrollment":5612,"conditions":42910,"interventions":42911},[91],[41395,5598,41396],[41398,41382],{"trials":42913,"activeCount":103},[],{"trials":42915,"activeCount":103},[],{"trials":42917,"activeCount":103},[],{"trials":42919,"activeCount":103},[],{"intervention":42921,"totalTrials":437,"cells":42922},"Vadimezan™",{"EARLY_PHASE1":42923,"PHASE1":42925,"PHASE2":42933,"PHASE3":42935,"PHASE4":42937,"NA":42939},{"trials":42924,"activeCount":103},[],{"trials":42926,"activeCount":103},[42927],{"nctId":42928,"briefTitle":42929,"status":134,"phases":42930,"primaryCompletion":7931,"start":4505,"enrollment":837,"conditions":42931,"interventions":42932},"NCT01299415","Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor",[91],[647],[42921],{"trials":42934,"activeCount":103},[],{"trials":42936,"activeCount":103},[],{"trials":42938,"activeCount":103},[],{"trials":42940,"activeCount":103},[],{"intervention":13731,"totalTrials":437,"cells":42942},{"EARLY_PHASE1":42943,"PHASE1":42945,"PHASE2":42951,"PHASE3":42953,"PHASE4":42955,"NA":42957},{"trials":42944,"activeCount":103},[],{"trials":42946,"activeCount":103},[42947],{"nctId":13724,"briefTitle":13725,"status":123,"phases":42948,"primaryCompletion":13727,"completion":8338,"start":13728,"enrollment":7257,"conditions":42949,"interventions":42950},[91],[13719],[159,13731,13732],{"trials":42952,"activeCount":103},[],{"trials":42954,"activeCount":103},[],{"trials":42956,"activeCount":103},[],{"trials":42958,"activeCount":103},[],{"intervention":23152,"totalTrials":437,"cells":42960},{"EARLY_PHASE1":42961,"PHASE1":42963,"PHASE2":42969,"PHASE3":42971,"PHASE4":42973,"NA":42975},{"trials":42962,"activeCount":103},[],{"trials":42964,"activeCount":103},[42965],{"nctId":23147,"briefTitle":23148,"status":123,"phases":42966,"primaryCompletion":10993,"completion":10993,"start":1014,"enrollment":21315,"conditions":42967,"interventions":42968},[91],[7868],[23152,944,23153],{"trials":42970,"activeCount":103},[],{"trials":42972,"activeCount":103},[],{"trials":42974,"activeCount":103},[],{"trials":42976,"activeCount":103},[],{"intervention":23153,"totalTrials":437,"cells":42978},{"EARLY_PHASE1":42979,"PHASE1":42981,"PHASE2":42987,"PHASE3":42989,"PHASE4":42991,"NA":42993},{"trials":42980,"activeCount":103},[],{"trials":42982,"activeCount":103},[42983],{"nctId":23147,"briefTitle":23148,"status":123,"phases":42984,"primaryCompletion":10993,"completion":10993,"start":1014,"enrollment":21315,"conditions":42985,"interventions":42986},[91],[7868],[23152,944,23153],{"trials":42988,"activeCount":103},[],{"trials":42990,"activeCount":103},[],{"trials":42992,"activeCount":103},[],{"trials":42994,"activeCount":103},[],{"intervention":42996,"totalTrials":437,"cells":42997},"LXS196",{"EARLY_PHASE1":42998,"PHASE1":43000,"PHASE2":43010,"PHASE3":43012,"PHASE4":43014,"NA":43016},{"trials":42999,"activeCount":103},[],{"trials":43001,"activeCount":103},[43002],{"nctId":43003,"briefTitle":43004,"status":134,"phases":43005,"primaryCompletion":27433,"completion":27433,"start":43006,"enrollment":6514,"conditions":43007,"interventions":43008},"NCT02601378","A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.",[91],"2016-02-01",[31984],[42996,43009],"LXS196 and HDM201",{"trials":43011,"activeCount":103},[],{"trials":43013,"activeCount":103},[],{"trials":43015,"activeCount":103},[],{"trials":43017,"activeCount":103},[],{"intervention":43009,"totalTrials":437,"cells":43019},{"EARLY_PHASE1":43020,"PHASE1":43022,"PHASE2":43028,"PHASE3":43030,"PHASE4":43032,"NA":43034},{"trials":43021,"activeCount":103},[],{"trials":43023,"activeCount":103},[43024],{"nctId":43003,"briefTitle":43004,"status":134,"phases":43025,"primaryCompletion":27433,"completion":27433,"start":43006,"enrollment":6514,"conditions":43026,"interventions":43027},[91],[31984],[42996,43009],{"trials":43029,"activeCount":103},[],{"trials":43031,"activeCount":103},[],{"trials":43033,"activeCount":103},[],{"trials":43035,"activeCount":103},[],{"intervention":10083,"totalTrials":437,"cells":43037},{"EARLY_PHASE1":43038,"PHASE1":43040,"PHASE2":43046,"PHASE3":43048,"PHASE4":43050,"NA":43052},{"trials":43039,"activeCount":103},[],{"trials":43041,"activeCount":103},[43042],{"nctId":10076,"briefTitle":10077,"status":134,"phases":43043,"primaryCompletion":10079,"completion":10079,"start":313,"enrollment":4498,"conditions":43044,"interventions":43045},[91],[10081],[10083,515,516],{"trials":43047,"activeCount":103},[],{"trials":43049,"activeCount":103},[],{"trials":43051,"activeCount":103},[],{"trials":43053,"activeCount":103},[],{"intervention":17113,"totalTrials":437,"cells":43055},{"EARLY_PHASE1":43056,"PHASE1":43058,"PHASE2":43064,"PHASE3":43066,"PHASE4":43068,"NA":43070},{"trials":43057,"activeCount":103},[],{"trials":43059,"activeCount":103},[43060],{"nctId":17105,"briefTitle":17106,"status":123,"phases":43061,"primaryCompletion":17108,"completion":17108,"start":17109,"enrollment":906,"conditions":43062,"interventions":43063},[91],[17111],[6263,7871,17113],{"trials":43065,"activeCount":103},[],{"trials":43067,"activeCount":103},[],{"trials":43069,"activeCount":103},[],{"trials":43071,"activeCount":103},[],{"intervention":10599,"totalTrials":437,"cells":43073},{"EARLY_PHASE1":43074,"PHASE1":43076,"PHASE2":43082,"PHASE3":43084,"PHASE4":43086,"NA":43088},{"trials":43075,"activeCount":103},[],{"trials":43077,"activeCount":103},[43078],{"nctId":10592,"briefTitle":10593,"status":123,"phases":43079,"primaryCompletion":10595,"completion":10595,"start":10596,"enrollment":5594,"conditions":43080,"interventions":43081},[91],[9924],[10574,10599],{"trials":43083,"activeCount":103},[],{"trials":43085,"activeCount":103},[],{"trials":43087,"activeCount":103},[],{"trials":43089,"activeCount":103},[],{"intervention":10188,"totalTrials":437,"cells":43091},{"EARLY_PHASE1":43092,"PHASE1":43094,"PHASE2":43100,"PHASE3":43102,"PHASE4":43104,"NA":43106},{"trials":43093,"activeCount":103},[],{"trials":43095,"activeCount":103},[43096],{"nctId":10174,"briefTitle":10175,"status":134,"phases":43097,"primaryCompletion":10177,"completion":10177,"start":10178,"enrollment":10179,"conditions":43098,"interventions":43099},[91],[10181,10182,10183,10184,36,10185,10186],[211,10188],{"trials":43101,"activeCount":103},[],{"trials":43103,"activeCount":103},[],{"trials":43105,"activeCount":103},[],{"trials":43107,"activeCount":103},[],{"intervention":43109,"totalTrials":437,"cells":43110},"Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab",{"EARLY_PHASE1":43111,"PHASE1":43113,"PHASE2":43122,"PHASE3":43124,"PHASE4":43126,"NA":43128},{"trials":43112,"activeCount":103},[],{"trials":43114,"activeCount":103},[43115],{"nctId":43116,"briefTitle":43117,"status":134,"phases":43118,"primaryCompletion":4505,"start":3447,"enrollment":5594,"conditions":43119,"interventions":43121},"NCT01271166","Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer",[91],[43120],"Advanced Colorectal Cancer",[43109],{"trials":43123,"activeCount":103},[],{"trials":43125,"activeCount":103},[],{"trials":43127,"activeCount":103},[],{"trials":43129,"activeCount":103},[],{"intervention":13375,"totalTrials":437,"cells":43131},{"EARLY_PHASE1":43132,"PHASE1":43134,"PHASE2":43140,"PHASE3":43142,"PHASE4":43144,"NA":43146},{"trials":43133,"activeCount":103},[],{"trials":43135,"activeCount":103},[43136],{"nctId":13368,"briefTitle":13369,"status":134,"phases":43137,"primaryCompletion":13371,"completion":13371,"start":13372,"enrollment":2405,"conditions":43138,"interventions":43139},[91],[647],[13375,4389],{"trials":43141,"activeCount":103},[],{"trials":43143,"activeCount":103},[],{"trials":43145,"activeCount":103},[],{"trials":43147,"activeCount":103},[],{"intervention":43149,"totalTrials":437,"cells":43150},"Octreotide pamoate",{"EARLY_PHASE1":43151,"PHASE1":43153,"PHASE2":43162,"PHASE3":43164,"PHASE4":43166,"NA":43168},{"trials":43152,"activeCount":103},[],{"trials":43154,"activeCount":103},[43155],{"nctId":43156,"briefTitle":43157,"status":123,"phases":43158,"primaryCompletion":3351,"completion":3351,"start":3254,"enrollment":114,"conditions":43159,"interventions":43161},"NCT00432068","Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers",[91],[43160],"Healthy Cholecystectomized",[43149],{"trials":43163,"activeCount":103},[],{"trials":43165,"activeCount":103},[],{"trials":43167,"activeCount":103},[],{"trials":43169,"activeCount":103},[],{"intervention":43171,"totalTrials":437,"cells":43172},"Nilotinib, Imatinib",{"EARLY_PHASE1":43173,"PHASE1":43175,"PHASE2":43183,"PHASE3":43185,"PHASE4":43187,"NA":43189},{"trials":43174,"activeCount":103},[],{"trials":43176,"activeCount":103},[43177],{"nctId":43178,"briefTitle":43179,"status":123,"phases":43180,"primaryCompletion":4598,"completion":4598,"start":3195,"enrollment":814,"conditions":43181,"interventions":43182},"NCT00441155","Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib",[91],[208],[43171],{"trials":43184,"activeCount":103},[],{"trials":43186,"activeCount":103},[],{"trials":43188,"activeCount":103},[],{"trials":43190,"activeCount":103},[],{"intervention":43192,"totalTrials":437,"cells":43193},"QEQ278",{"EARLY_PHASE1":43194,"PHASE1":43196,"PHASE2":43205,"PHASE3":43207,"PHASE4":43209,"NA":43211},{"trials":43195,"activeCount":103},[],{"trials":43197,"activeCount":103},[43198],{"nctId":43199,"briefTitle":43200,"status":134,"phases":43201,"primaryCompletion":13633,"completion":13633,"start":43202,"enrollment":2439,"conditions":43203,"interventions":43204},"NCT05462873","A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors",[91],"2023-04-04",[227,13284,8041,13601],[43192],{"trials":43206,"activeCount":103},[],{"trials":43208,"activeCount":103},[],{"trials":43210,"activeCount":103},[],{"trials":43212,"activeCount":103},[],{"intervention":43214,"totalTrials":437,"cells":43215},"BPR277 ointment",{"EARLY_PHASE1":43216,"PHASE1":43218,"PHASE2":43228,"PHASE3":43230,"PHASE4":43232,"NA":43234},{"trials":43217,"activeCount":103},[],{"trials":43219,"activeCount":103},[43220],{"nctId":43221,"briefTitle":43222,"status":123,"phases":43223,"primaryCompletion":1723,"completion":1723,"start":3784,"enrollment":138,"conditions":43224,"interventions":43226},"NCT01428297","A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome",[91],[9634,10365,43225],"Netherton Syndrome",[43214,43214,43227],"BPR277",{"trials":43229,"activeCount":103},[],{"trials":43231,"activeCount":103},[],{"trials":43233,"activeCount":103},[],{"trials":43235,"activeCount":103},[],{"intervention":43227,"totalTrials":437,"cells":43237},{"EARLY_PHASE1":43238,"PHASE1":43240,"PHASE2":43246,"PHASE3":43248,"PHASE4":43250,"NA":43252},{"trials":43239,"activeCount":103},[],{"trials":43241,"activeCount":103},[43242],{"nctId":43221,"briefTitle":43222,"status":123,"phases":43243,"primaryCompletion":1723,"completion":1723,"start":3784,"enrollment":138,"conditions":43244,"interventions":43245},[91],[9634,10365,43225],[43214,43214,43227],{"trials":43247,"activeCount":103},[],{"trials":43249,"activeCount":103},[],{"trials":43251,"activeCount":103},[],{"trials":43253,"activeCount":103},[],{"intervention":43255,"totalTrials":437,"cells":43256},"QAK423A",{"EARLY_PHASE1":43257,"PHASE1":43259,"PHASE2":43267,"PHASE3":43269,"PHASE4":43271,"NA":43273},{"trials":43258,"activeCount":103},[],{"trials":43260,"activeCount":103},[43261],{"nctId":43262,"briefTitle":43263,"status":123,"phases":43264,"primaryCompletion":5026,"start":15058,"enrollment":485,"conditions":43265,"interventions":43266},"NCT01197287","Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients",[91],[24],[43255,43255,43255],{"trials":43268,"activeCount":103},[],{"trials":43270,"activeCount":103},[],{"trials":43272,"activeCount":103},[],{"trials":43274,"activeCount":103},[],{"intervention":43276,"totalTrials":437,"cells":43277},"Nilotinib + LDE225",{"EARLY_PHASE1":43278,"PHASE1":43280,"PHASE2":43289,"PHASE3":43291,"PHASE4":43293,"NA":43295},{"trials":43279,"activeCount":103},[],{"trials":43281,"activeCount":103},[43282],{"nctId":43283,"briefTitle":43284,"status":123,"phases":43285,"primaryCompletion":1723,"completion":1723,"start":1732,"enrollment":4148,"conditions":43286,"interventions":43288},"NCT01456676","Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy",[91],[43287],"Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",[43276],{"trials":43290,"activeCount":103},[],{"trials":43292,"activeCount":103},[],{"trials":43294,"activeCount":103},[],{"trials":43296,"activeCount":103},[],{"intervention":43298,"totalTrials":437,"cells":43299},"Iloperidone",{"EARLY_PHASE1":43300,"PHASE1":43302,"PHASE2":43310,"PHASE3":43312,"PHASE4":43314,"NA":43316},{"trials":43301,"activeCount":103},[],{"trials":43303,"activeCount":103},[43304],{"nctId":43305,"briefTitle":43306,"status":123,"phases":43307,"primaryCompletion":3759,"completion":3759,"start":3845,"enrollment":5882,"conditions":43308,"interventions":43309},"NCT01529294","Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers",[91],[2625],[43298],{"trials":43311,"activeCount":103},[],{"trials":43313,"activeCount":103},[],{"trials":43315,"activeCount":103},[],{"trials":43317,"activeCount":103},[],{"intervention":43319,"totalTrials":437,"cells":43320},"JBH492",{"EARLY_PHASE1":43321,"PHASE1":43323,"PHASE2":43333,"PHASE3":43335,"PHASE4":43337,"NA":43339},{"trials":43322,"activeCount":103},[],{"trials":43324,"activeCount":103},[43325],{"nctId":43326,"briefTitle":43327,"status":134,"phases":43328,"primaryCompletion":43329,"completion":43329,"start":8067,"enrollment":2342,"conditions":43330,"interventions":43332},"NCT04240704","Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL",[91],"2024-09-05",[43331,11399],"Non-Hodgkins Lymphoma",[43319],{"trials":43334,"activeCount":103},[],{"trials":43336,"activeCount":103},[],{"trials":43338,"activeCount":103},[],{"trials":43340,"activeCount":103},[],{"intervention":31405,"totalTrials":437,"cells":43342},{"EARLY_PHASE1":43343,"PHASE1":43345,"PHASE2":43351,"PHASE3":43353,"PHASE4":43355,"NA":43357},{"trials":43344,"activeCount":103},[],{"trials":43346,"activeCount":103},[43347],{"nctId":31400,"briefTitle":31401,"status":123,"phases":43348,"primaryCompletion":11025,"completion":11025,"start":15283,"enrollment":17693,"conditions":43349,"interventions":43350},[91],[9516],[18982,31405,31406],{"trials":43352,"activeCount":103},[],{"trials":43354,"activeCount":103},[],{"trials":43356,"activeCount":103},[],{"trials":43358,"activeCount":103},[],{"intervention":31406,"totalTrials":437,"cells":43360},{"EARLY_PHASE1":43361,"PHASE1":43363,"PHASE2":43369,"PHASE3":43371,"PHASE4":43373,"NA":43375},{"trials":43362,"activeCount":103},[],{"trials":43364,"activeCount":103},[43365],{"nctId":31400,"briefTitle":31401,"status":123,"phases":43366,"primaryCompletion":11025,"completion":11025,"start":15283,"enrollment":17693,"conditions":43367,"interventions":43368},[91],[9516],[18982,31405,31406],{"trials":43370,"activeCount":103},[],{"trials":43372,"activeCount":103},[],{"trials":43374,"activeCount":103},[],{"trials":43376,"activeCount":103},[],{"intervention":11186,"totalTrials":437,"cells":43378},{"EARLY_PHASE1":43379,"PHASE1":43381,"PHASE2":43387,"PHASE3":43389,"PHASE4":43391,"NA":43393},{"trials":43380,"activeCount":103},[],{"trials":43382,"activeCount":103},[43383],{"nctId":11180,"briefTitle":11181,"status":134,"phases":43384,"primaryCompletion":3861,"completion":3861,"start":3511,"enrollment":422,"conditions":43385,"interventions":43386},[91],[11184],[10904,11186],{"trials":43388,"activeCount":103},[],{"trials":43390,"activeCount":103},[],{"trials":43392,"activeCount":103},[],{"trials":43394,"activeCount":103},[],{"intervention":43396,"totalTrials":437,"cells":43397},"Part 1; LOU064",{"EARLY_PHASE1":43398,"PHASE1":43400,"PHASE2":43411,"PHASE3":43413,"PHASE4":43415,"NA":43417},{"trials":43399,"activeCount":103},[],{"trials":43401,"activeCount":103},[43402],{"nctId":43403,"briefTitle":43404,"status":123,"phases":43405,"primaryCompletion":43406,"completion":43407,"start":8199,"enrollment":5948,"conditions":43408,"interventions":43409},"NCT05753592","A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants",[91],"2023-12-14","2023-12-17",[2625],[43396,43410],"Part 2; LOU064",{"trials":43412,"activeCount":103},[],{"trials":43414,"activeCount":103},[],{"trials":43416,"activeCount":103},[],{"trials":43418,"activeCount":103},[],{"intervention":43410,"totalTrials":437,"cells":43420},{"EARLY_PHASE1":43421,"PHASE1":43423,"PHASE2":43429,"PHASE3":43431,"PHASE4":43433,"NA":43435},{"trials":43422,"activeCount":103},[],{"trials":43424,"activeCount":103},[43425],{"nctId":43403,"briefTitle":43404,"status":123,"phases":43426,"primaryCompletion":43406,"completion":43407,"start":8199,"enrollment":5948,"conditions":43427,"interventions":43428},[91],[2625],[43396,43410],{"trials":43430,"activeCount":103},[],{"trials":43432,"activeCount":103},[],{"trials":43434,"activeCount":103},[],{"trials":43436,"activeCount":103},[],{"intervention":23474,"totalTrials":437,"cells":43438},{"EARLY_PHASE1":43439,"PHASE1":43441,"PHASE2":43447,"PHASE3":43449,"PHASE4":43451,"NA":43453},{"trials":43440,"activeCount":103},[],{"trials":43442,"activeCount":103},[43443],{"nctId":23467,"briefTitle":23468,"status":123,"phases":43444,"primaryCompletion":23470,"completion":23470,"start":23471,"enrollment":2405,"conditions":43445,"interventions":43446},[91],[10518],[23460,23474,23475,23475],{"trials":43448,"activeCount":103},[],{"trials":43450,"activeCount":103},[],{"trials":43452,"activeCount":103},[],{"trials":43454,"activeCount":103},[],{"intervention":23475,"totalTrials":437,"cells":43456},{"EARLY_PHASE1":43457,"PHASE1":43459,"PHASE2":43465,"PHASE3":43467,"PHASE4":43469,"NA":43471},{"trials":43458,"activeCount":103},[],{"trials":43460,"activeCount":103},[43461],{"nctId":23467,"briefTitle":23468,"status":123,"phases":43462,"primaryCompletion":23470,"completion":23470,"start":23471,"enrollment":2405,"conditions":43463,"interventions":43464},[91],[10518],[23460,23474,23475,23475],{"trials":43466,"activeCount":103},[],{"trials":43468,"activeCount":103},[],{"trials":43470,"activeCount":103},[],{"trials":43472,"activeCount":103},[],{"intervention":43474,"totalTrials":437,"cells":43475},"LM716",{"EARLY_PHASE1":43476,"PHASE1":43478,"PHASE2":43486,"PHASE3":43488,"PHASE4":43490,"NA":43492},{"trials":43477,"activeCount":103},[],{"trials":43479,"activeCount":103},[43480],{"nctId":43481,"briefTitle":43482,"status":123,"phases":43483,"primaryCompletion":2509,"completion":2509,"start":3799,"enrollment":138,"conditions":43484,"interventions":43485},"NCT01911936","A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors",[91],[4362],[43474],{"trials":43487,"activeCount":103},[],{"trials":43489,"activeCount":103},[],{"trials":43491,"activeCount":103},[],{"trials":43493,"activeCount":103},[],{"intervention":43495,"totalTrials":437,"cells":43496},"RAD001, Cetuximab, Irinotecan",{"EARLY_PHASE1":43497,"PHASE1":43499,"PHASE2":43507,"PHASE3":43509,"PHASE4":43511,"NA":43513},{"trials":43498,"activeCount":103},[],{"trials":43500,"activeCount":103},[43501],{"nctId":43502,"briefTitle":43503,"status":123,"phases":43504,"primaryCompletion":4975,"completion":4975,"start":4740,"enrollment":1065,"conditions":43505,"interventions":43506},"NCT00478634","A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer",[91],[209,230,232,233],[43495],{"trials":43508,"activeCount":103},[],{"trials":43510,"activeCount":103},[],{"trials":43512,"activeCount":103},[],{"trials":43514,"activeCount":103},[],{"intervention":32112,"totalTrials":437,"cells":43516},{"EARLY_PHASE1":43517,"PHASE1":43519,"PHASE2":43525,"PHASE3":43527,"PHASE4":43529,"NA":43531},{"trials":43518,"activeCount":103},[],{"trials":43520,"activeCount":103},[43521],{"nctId":32106,"briefTitle":32107,"status":123,"phases":43522,"primaryCompletion":32109,"completion":32109,"start":7109,"enrollment":422,"conditions":43523,"interventions":43524},[91],[4691],[6737,32112],{"trials":43526,"activeCount":103},[],{"trials":43528,"activeCount":103},[],{"trials":43530,"activeCount":103},[],{"trials":43532,"activeCount":103},[],{"intervention":43534,"totalTrials":437,"cells":43535},"Study Part 1: KRP203",{"EARLY_PHASE1":43536,"PHASE1":43538,"PHASE2":43550,"PHASE3":43552,"PHASE4":43554,"NA":43556},{"trials":43537,"activeCount":103},[],{"trials":43539,"activeCount":103},[43540],{"nctId":43541,"briefTitle":43542,"status":123,"phases":43543,"primaryCompletion":43544,"completion":43544,"start":5248,"enrollment":496,"conditions":43545,"interventions":43547},"NCT01830010","A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies",[91],"2018-08-21",[43546],"Hematological Malignancies",[43534,43548,43549],"Study Part 2: KRP203 lower dose","Study Part 2: KRP203 higher dose",{"trials":43551,"activeCount":103},[],{"trials":43553,"activeCount":103},[],{"trials":43555,"activeCount":103},[],{"trials":43557,"activeCount":103},[],{"intervention":43548,"totalTrials":437,"cells":43559},{"EARLY_PHASE1":43560,"PHASE1":43562,"PHASE2":43568,"PHASE3":43570,"PHASE4":43572,"NA":43574},{"trials":43561,"activeCount":103},[],{"trials":43563,"activeCount":103},[43564],{"nctId":43541,"briefTitle":43542,"status":123,"phases":43565,"primaryCompletion":43544,"completion":43544,"start":5248,"enrollment":496,"conditions":43566,"interventions":43567},[91],[43546],[43534,43548,43549],{"trials":43569,"activeCount":103},[],{"trials":43571,"activeCount":103},[],{"trials":43573,"activeCount":103},[],{"trials":43575,"activeCount":103},[],{"intervention":43549,"totalTrials":437,"cells":43577},{"EARLY_PHASE1":43578,"PHASE1":43580,"PHASE2":43586,"PHASE3":43588,"PHASE4":43590,"NA":43592},{"trials":43579,"activeCount":103},[],{"trials":43581,"activeCount":103},[43582],{"nctId":43541,"briefTitle":43542,"status":123,"phases":43583,"primaryCompletion":43544,"completion":43544,"start":5248,"enrollment":496,"conditions":43584,"interventions":43585},[91],[43546],[43534,43548,43549],{"trials":43587,"activeCount":103},[],{"trials":43589,"activeCount":103},[],{"trials":43591,"activeCount":103},[],{"trials":43593,"activeCount":103},[],{"intervention":43595,"totalTrials":437,"cells":43596},"ASA404, DMXAA, DXAA",{"EARLY_PHASE1":43597,"PHASE1":43599,"PHASE2":43608,"PHASE3":43610,"PHASE4":43612,"NA":43614},{"trials":43598,"activeCount":103},[],{"trials":43600,"activeCount":103},[43601],{"nctId":43602,"briefTitle":43603,"status":134,"phases":43604,"primaryCompletion":926,"start":880,"enrollment":271,"conditions":43605,"interventions":43607},"NCT01290380","A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies",[91],[43606],"Solid Tumor Malignancies",[43595],{"trials":43609,"activeCount":103},[],{"trials":43611,"activeCount":103},[],{"trials":43613,"activeCount":103},[],{"trials":43615,"activeCount":103},[],{"intervention":43617,"totalTrials":437,"cells":43618},"vadimezan",{"EARLY_PHASE1":43619,"PHASE1":43621,"PHASE2":43630,"PHASE3":43632,"PHASE4":43634,"NA":43636},{"trials":43620,"activeCount":103},[],{"trials":43622,"activeCount":103},[43623],{"nctId":43624,"briefTitle":43625,"status":123,"phases":43626,"primaryCompletion":3271,"start":3400,"enrollment":1495,"conditions":43627,"interventions":43629},"NCT01285453","Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors",[91],[43628],"Advanced or Recurrent Solid Tumors",[43617],{"trials":43631,"activeCount":103},[],{"trials":43633,"activeCount":103},[],{"trials":43635,"activeCount":103},[],{"trials":43637,"activeCount":103},[],{"intervention":5206,"totalTrials":437,"cells":43639},{"EARLY_PHASE1":43640,"PHASE1":43642,"PHASE2":43648,"PHASE3":43650,"PHASE4":43652,"NA":43654},{"trials":43641,"activeCount":103},[],{"trials":43643,"activeCount":103},[43644],{"nctId":5198,"briefTitle":5199,"status":123,"phases":43645,"primaryCompletion":5201,"completion":5201,"start":5202,"enrollment":99,"conditions":43646,"interventions":43647},[91],[5204],[5178,5206,5207],{"trials":43649,"activeCount":103},[],{"trials":43651,"activeCount":103},[],{"trials":43653,"activeCount":103},[],{"trials":43655,"activeCount":103},[],{"intervention":43657,"totalTrials":437,"cells":43658},"RLX030A",{"EARLY_PHASE1":43659,"PHASE1":43661,"PHASE2":43669,"PHASE3":43671,"PHASE4":43673,"NA":43675},{"trials":43660,"activeCount":103},[],{"trials":43662,"activeCount":103},[43663],{"nctId":43664,"briefTitle":43665,"status":123,"phases":43666,"primaryCompletion":4301,"completion":4301,"start":4620,"enrollment":2112,"conditions":43667,"interventions":43668},"NCT01433458","Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects",[91],[2625],[43657],{"trials":43670,"activeCount":103},[],{"trials":43672,"activeCount":103},[],{"trials":43674,"activeCount":103},[],{"trials":43676,"activeCount":103},[],{"intervention":43678,"totalTrials":437,"cells":43679},"BCT194",{"EARLY_PHASE1":43680,"PHASE1":43682,"PHASE2":43690,"PHASE3":43692,"PHASE4":43694,"NA":43696},{"trials":43681,"activeCount":103},[],{"trials":43683,"activeCount":103},[43684],{"nctId":43685,"briefTitle":43686,"status":123,"phases":43687,"primaryCompletion":4642,"start":4343,"enrollment":138,"conditions":43688,"interventions":43689},"NCT01539915","Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients",[91],[1675],[43678],{"trials":43691,"activeCount":103},[],{"trials":43693,"activeCount":103},[],{"trials":43695,"activeCount":103},[],{"trials":43697,"activeCount":103},[],{"intervention":43699,"totalTrials":437,"cells":43700},"BKM120 + temozolomide",{"EARLY_PHASE1":43701,"PHASE1":43703,"PHASE2":43713,"PHASE3":43715,"PHASE4":43717,"NA":43719},{"trials":43702,"activeCount":103},[],{"trials":43704,"activeCount":103},[43705],{"nctId":43706,"briefTitle":43707,"status":123,"phases":43708,"primaryCompletion":4474,"completion":4474,"start":43709,"enrollment":5948,"conditions":43710,"interventions":43711},"NCT01473901","A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma",[91],"2011-12-30",[1150],[43699,43712],"BKM120 +temozolomide with\u002Fwithout radiotherapy",{"trials":43714,"activeCount":103},[],{"trials":43716,"activeCount":103},[],{"trials":43718,"activeCount":103},[],{"trials":43720,"activeCount":103},[],{"intervention":43712,"totalTrials":437,"cells":43722},{"EARLY_PHASE1":43723,"PHASE1":43725,"PHASE2":43731,"PHASE3":43733,"PHASE4":43735,"NA":43737},{"trials":43724,"activeCount":103},[],{"trials":43726,"activeCount":103},[43727],{"nctId":43706,"briefTitle":43707,"status":123,"phases":43728,"primaryCompletion":4474,"completion":4474,"start":43709,"enrollment":5948,"conditions":43729,"interventions":43730},[91],[1150],[43699,43712],{"trials":43732,"activeCount":103},[],{"trials":43734,"activeCount":103},[],{"trials":43736,"activeCount":103},[],{"trials":43738,"activeCount":103},[],{"intervention":43740,"totalTrials":437,"cells":43741},"Pasireotide LAR followed by Pasireotide LAR + Everolimus",{"EARLY_PHASE1":43742,"PHASE1":43744,"PHASE2":43754,"PHASE3":43756,"PHASE4":43758,"NA":43760},{"trials":43743,"activeCount":103},[],{"trials":43745,"activeCount":103},[43746],{"nctId":43747,"briefTitle":43748,"status":123,"phases":43749,"primaryCompletion":4093,"completion":4093,"start":926,"enrollment":792,"conditions":43750,"interventions":43752},"NCT01263353","Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs",[91],[43751],"Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System",[43740,43753],"Everolimus followed by Pasireotide LAR + Everolimus",{"trials":43755,"activeCount":103},[],{"trials":43757,"activeCount":103},[],{"trials":43759,"activeCount":103},[],{"trials":43761,"activeCount":103},[],{"intervention":43753,"totalTrials":437,"cells":43763},{"EARLY_PHASE1":43764,"PHASE1":43766,"PHASE2":43772,"PHASE3":43774,"PHASE4":43776,"NA":43778},{"trials":43765,"activeCount":103},[],{"trials":43767,"activeCount":103},[43768],{"nctId":43747,"briefTitle":43748,"status":123,"phases":43769,"primaryCompletion":4093,"completion":4093,"start":926,"enrollment":792,"conditions":43770,"interventions":43771},[91],[43751],[43740,43753],{"trials":43773,"activeCount":103},[],{"trials":43775,"activeCount":103},[],{"trials":43777,"activeCount":103},[],{"trials":43779,"activeCount":103},[],{"intervention":13878,"totalTrials":437,"cells":43781},{"EARLY_PHASE1":43782,"PHASE1":43784,"PHASE2":43790,"PHASE3":43792,"PHASE4":43794,"NA":43796},{"trials":43783,"activeCount":103},[],{"trials":43785,"activeCount":103},[43786],{"nctId":13871,"briefTitle":13872,"status":123,"phases":43787,"primaryCompletion":3409,"completion":3409,"start":5733,"enrollment":28,"conditions":43788,"interventions":43789},[91],[13875],[13877,13878,13879,5207,13880],{"trials":43791,"activeCount":103},[],{"trials":43793,"activeCount":103},[],{"trials":43795,"activeCount":103},[],{"trials":43797,"activeCount":103},[],{"intervention":13879,"totalTrials":437,"cells":43799},{"EARLY_PHASE1":43800,"PHASE1":43802,"PHASE2":43808,"PHASE3":43810,"PHASE4":43812,"NA":43814},{"trials":43801,"activeCount":103},[],{"trials":43803,"activeCount":103},[43804],{"nctId":13871,"briefTitle":13872,"status":123,"phases":43805,"primaryCompletion":3409,"completion":3409,"start":5733,"enrollment":28,"conditions":43806,"interventions":43807},[91],[13875],[13877,13878,13879,5207,13880],{"trials":43809,"activeCount":103},[],{"trials":43811,"activeCount":103},[],{"trials":43813,"activeCount":103},[],{"trials":43815,"activeCount":103},[],{"intervention":16487,"totalTrials":437,"cells":43817},{"EARLY_PHASE1":43818,"PHASE1":43820,"PHASE2":43826,"PHASE3":43828,"PHASE4":43830,"NA":43832},{"trials":43819,"activeCount":103},[],{"trials":43821,"activeCount":103},[43822],{"nctId":16482,"briefTitle":16483,"status":134,"phases":43823,"primaryCompletion":2034,"completion":2034,"start":3552,"enrollment":3975,"conditions":43824,"interventions":43825},[91],[4412],[7711,16487],{"trials":43827,"activeCount":103},[],{"trials":43829,"activeCount":103},[],{"trials":43831,"activeCount":103},[],{"trials":43833,"activeCount":103},[],{"intervention":7894,"totalTrials":437,"cells":43835},{"EARLY_PHASE1":43836,"PHASE1":43838,"PHASE2":43844,"PHASE3":43846,"PHASE4":43848,"NA":43850},{"trials":43837,"activeCount":103},[],{"trials":43839,"activeCount":103},[43840],{"nctId":7888,"briefTitle":7889,"status":123,"phases":43841,"primaryCompletion":3845,"start":3552,"enrollment":2367,"conditions":43842,"interventions":43843},[91],[7892,435],[7894,7895,4780,7872],{"trials":43845,"activeCount":103},[],{"trials":43847,"activeCount":103},[],{"trials":43849,"activeCount":103},[],{"trials":43851,"activeCount":103},[],{"intervention":7895,"totalTrials":437,"cells":43853},{"EARLY_PHASE1":43854,"PHASE1":43856,"PHASE2":43862,"PHASE3":43864,"PHASE4":43866,"NA":43868},{"trials":43855,"activeCount":103},[],{"trials":43857,"activeCount":103},[43858],{"nctId":7888,"briefTitle":7889,"status":123,"phases":43859,"primaryCompletion":3845,"start":3552,"enrollment":2367,"conditions":43860,"interventions":43861},[91],[7892,435],[7894,7895,4780,7872],{"trials":43863,"activeCount":103},[],{"trials":43865,"activeCount":103},[],{"trials":43867,"activeCount":103},[],{"trials":43869,"activeCount":103},[],{"intervention":43871,"totalTrials":437,"cells":43872},"Icenticaftor",{"EARLY_PHASE1":43873,"PHASE1":43875,"PHASE2":43884,"PHASE3":43886,"PHASE4":43888,"NA":43890},{"trials":43874,"activeCount":103},[],{"trials":43876,"activeCount":103},[43877],{"nctId":43878,"briefTitle":43879,"status":123,"phases":43880,"primaryCompletion":32811,"completion":32811,"start":291,"enrollment":709,"conditions":43881,"interventions":43883},"NCT04587622","Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment",[91],[43882],"Hepatic Failure",[43871],{"trials":43885,"activeCount":103},[],{"trials":43887,"activeCount":103},[],{"trials":43889,"activeCount":103},[],{"trials":43891,"activeCount":103},[],{"intervention":33035,"totalTrials":437,"cells":43893},{"EARLY_PHASE1":43894,"PHASE1":43896,"PHASE2":43902,"PHASE3":43904,"PHASE4":43906,"NA":43908},{"trials":43895,"activeCount":103},[],{"trials":43897,"activeCount":103},[43898],{"nctId":33029,"briefTitle":33030,"status":123,"phases":43899,"primaryCompletion":3075,"completion":3075,"start":5688,"enrollment":26583,"conditions":43900,"interventions":43901},[91],[1102],[33034,23071,33035],{"trials":43903,"activeCount":103},[],{"trials":43905,"activeCount":103},[],{"trials":43907,"activeCount":103},[],{"trials":43909,"activeCount":103},[],{"intervention":31846,"totalTrials":437,"cells":43911},{"EARLY_PHASE1":43912,"PHASE1":43914,"PHASE2":43920,"PHASE3":43922,"PHASE4":43924,"NA":43926},{"trials":43913,"activeCount":103},[],{"trials":43915,"activeCount":103},[43916],{"nctId":31841,"briefTitle":31842,"status":123,"phases":43917,"primaryCompletion":4620,"start":5620,"enrollment":2579,"conditions":43918,"interventions":43919},[91],[18],[19484,31846,31834,31847],{"trials":43921,"activeCount":103},[],{"trials":43923,"activeCount":103},[],{"trials":43925,"activeCount":103},[],{"trials":43927,"activeCount":103},[],{"intervention":43929,"totalTrials":437,"cells":43930},"BEZ235 + paclitaxel",{"EARLY_PHASE1":43931,"PHASE1":43933,"PHASE2":43945,"PHASE3":43947,"PHASE4":43949,"NA":43951},{"trials":43932,"activeCount":103},[],{"trials":43934,"activeCount":103},[43935],{"nctId":43936,"briefTitle":43937,"status":123,"phases":43938,"primaryCompletion":1817,"completion":1817,"start":4598,"enrollment":11504,"conditions":43939,"interventions":43941},"NCT01285466","A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab",[91],[43940],"Metastatic or Locally Advanced Solid Tumors",[43929,43942,43943,43944],"BKM120 + paclitaxel","BEZ235 + paclitaxel + trastuzumab","BKM120 + paclitaxel + trastuzumab",{"trials":43946,"activeCount":103},[],{"trials":43948,"activeCount":103},[],{"trials":43950,"activeCount":103},[],{"trials":43952,"activeCount":103},[],{"intervention":43942,"totalTrials":437,"cells":43954},{"EARLY_PHASE1":43955,"PHASE1":43957,"PHASE2":43963,"PHASE3":43965,"PHASE4":43967,"NA":43969},{"trials":43956,"activeCount":103},[],{"trials":43958,"activeCount":103},[43959],{"nctId":43936,"briefTitle":43937,"status":123,"phases":43960,"primaryCompletion":1817,"completion":1817,"start":4598,"enrollment":11504,"conditions":43961,"interventions":43962},[91],[43940],[43929,43942,43943,43944],{"trials":43964,"activeCount":103},[],{"trials":43966,"activeCount":103},[],{"trials":43968,"activeCount":103},[],{"trials":43970,"activeCount":103},[],{"intervention":43943,"totalTrials":437,"cells":43972},{"EARLY_PHASE1":43973,"PHASE1":43975,"PHASE2":43981,"PHASE3":43983,"PHASE4":43985,"NA":43987},{"trials":43974,"activeCount":103},[],{"trials":43976,"activeCount":103},[43977],{"nctId":43936,"briefTitle":43937,"status":123,"phases":43978,"primaryCompletion":1817,"completion":1817,"start":4598,"enrollment":11504,"conditions":43979,"interventions":43980},[91],[43940],[43929,43942,43943,43944],{"trials":43982,"activeCount":103},[],{"trials":43984,"activeCount":103},[],{"trials":43986,"activeCount":103},[],{"trials":43988,"activeCount":103},[],{"intervention":43944,"totalTrials":437,"cells":43990},{"EARLY_PHASE1":43991,"PHASE1":43993,"PHASE2":43999,"PHASE3":44001,"PHASE4":44003,"NA":44005},{"trials":43992,"activeCount":103},[],{"trials":43994,"activeCount":103},[43995],{"nctId":43936,"briefTitle":43937,"status":123,"phases":43996,"primaryCompletion":1817,"completion":1817,"start":4598,"enrollment":11504,"conditions":43997,"interventions":43998},[91],[43940],[43929,43942,43943,43944],{"trials":44000,"activeCount":103},[],{"trials":44002,"activeCount":103},[],{"trials":44004,"activeCount":103},[],{"trials":44006,"activeCount":103},[],{"intervention":41432,"totalTrials":437,"cells":44008},{"EARLY_PHASE1":44009,"PHASE1":44011,"PHASE2":44017,"PHASE3":44019,"PHASE4":44021,"NA":44023},{"trials":44010,"activeCount":103},[],{"trials":44012,"activeCount":103},[44013],{"nctId":41426,"briefTitle":41427,"status":134,"phases":44014,"primaryCompletion":17719,"completion":18026,"start":41429,"enrollment":496,"conditions":44015,"interventions":44016},[91],[182],[41432,16465],{"trials":44018,"activeCount":103},[],{"trials":44020,"activeCount":103},[],{"trials":44022,"activeCount":103},[],{"trials":44024,"activeCount":103},[],{"intervention":44026,"totalTrials":437,"cells":44027},"antisense oligonucleotide",{"EARLY_PHASE1":44028,"PHASE1":44030,"PHASE2":44039,"PHASE3":44041,"PHASE4":44043,"NA":44045},{"trials":44029,"activeCount":103},[],{"trials":44031,"activeCount":103},[44032],{"nctId":44033,"briefTitle":44034,"status":123,"phases":44035,"primaryCompletion":1909,"completion":1909,"start":1505,"enrollment":3322,"conditions":44036,"interventions":44038},"NCT04539041","Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy",[91],[44037],"Progressive Supranuclear Palsy (PSP)",[44026],{"trials":44040,"activeCount":103},[],{"trials":44042,"activeCount":103},[],{"trials":44044,"activeCount":103},[],{"trials":44046,"activeCount":103},[],{"intervention":44048,"totalTrials":437,"cells":44049},"WVT078",{"EARLY_PHASE1":44050,"PHASE1":44052,"PHASE2":44062,"PHASE3":44064,"PHASE4":44066,"NA":44068},{"trials":44051,"activeCount":103},[],{"trials":44053,"activeCount":103},[44054],{"nctId":44055,"briefTitle":44056,"status":134,"phases":44057,"primaryCompletion":6902,"completion":6902,"start":44058,"enrollment":5681,"conditions":44059,"interventions":44060},"NCT04123418","A Study of WVT078 in Patients With Multiple Myeloma (MM)",[91],"2019-12-05",[41396],[44048,44061],"WHG626",{"trials":44063,"activeCount":103},[],{"trials":44065,"activeCount":103},[],{"trials":44067,"activeCount":103},[],{"trials":44069,"activeCount":103},[],{"intervention":44061,"totalTrials":437,"cells":44071},{"EARLY_PHASE1":44072,"PHASE1":44074,"PHASE2":44080,"PHASE3":44082,"PHASE4":44084,"NA":44086},{"trials":44073,"activeCount":103},[],{"trials":44075,"activeCount":103},[44076],{"nctId":44055,"briefTitle":44056,"status":134,"phases":44077,"primaryCompletion":6902,"completion":6902,"start":44058,"enrollment":5681,"conditions":44078,"interventions":44079},[91],[41396],[44048,44061],{"trials":44081,"activeCount":103},[],{"trials":44083,"activeCount":103},[],{"trials":44085,"activeCount":103},[],{"trials":44087,"activeCount":103},[],{"intervention":13394,"totalTrials":437,"cells":44089},{"EARLY_PHASE1":44090,"PHASE1":44092,"PHASE2":44098,"PHASE3":44100,"PHASE4":44102,"NA":44104},{"trials":44091,"activeCount":103},[],{"trials":44093,"activeCount":103},[44094],{"nctId":13385,"briefTitle":13386,"status":123,"phases":44095,"primaryCompletion":13388,"completion":13388,"start":13389,"enrollment":13390,"conditions":44096,"interventions":44097},[91],[13392],[4389,10126,1686,13394,155],{"trials":44099,"activeCount":103},[],{"trials":44101,"activeCount":103},[],{"trials":44103,"activeCount":103},[],{"trials":44105,"activeCount":103},[],{"intervention":44107,"totalTrials":437,"cells":44108},"LMI070",{"EARLY_PHASE1":44109,"PHASE1":44111,"PHASE2":44120,"PHASE3":44122,"PHASE4":44124,"NA":44126},{"trials":44110,"activeCount":103},[],{"trials":44112,"activeCount":103},[44113],{"nctId":44114,"briefTitle":44115,"status":134,"phases":44116,"primaryCompletion":30754,"completion":30754,"start":44117,"enrollment":1495,"conditions":44118,"interventions":44119},"NCT05330286","Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.",[91],"2022-04-13",[9634],[44107,44107,44107,44107],{"trials":44121,"activeCount":103},[],{"trials":44123,"activeCount":103},[],{"trials":44125,"activeCount":103},[],{"trials":44127,"activeCount":103},[],{"intervention":44129,"totalTrials":437,"cells":44130},"sotrastaurin",{"EARLY_PHASE1":44131,"PHASE1":44133,"PHASE2":44142,"PHASE3":44144,"PHASE4":44146,"NA":44148},{"trials":44132,"activeCount":103},[],{"trials":44134,"activeCount":103},[44135],{"nctId":44136,"briefTitle":44137,"status":123,"phases":44138,"primaryCompletion":4975,"start":4845,"enrollment":1314,"conditions":44139,"interventions":44140},"NCT01594255","CAEB071 Thorough QTc Study in Healthy Volunteers",[91],[1674],[44129,44129,44141],"Avelox",{"trials":44143,"activeCount":103},[],{"trials":44145,"activeCount":103},[],{"trials":44147,"activeCount":103},[],{"trials":44149,"activeCount":103},[],{"intervention":44141,"totalTrials":437,"cells":44151},{"EARLY_PHASE1":44152,"PHASE1":44154,"PHASE2":44160,"PHASE3":44162,"PHASE4":44164,"NA":44166},{"trials":44153,"activeCount":103},[],{"trials":44155,"activeCount":103},[44156],{"nctId":44136,"briefTitle":44137,"status":123,"phases":44157,"primaryCompletion":4975,"start":4845,"enrollment":1314,"conditions":44158,"interventions":44159},[91],[1674],[44129,44129,44141],{"trials":44161,"activeCount":103},[],{"trials":44163,"activeCount":103},[],{"trials":44165,"activeCount":103},[],{"trials":44167,"activeCount":103},[],{"intervention":44169,"totalTrials":437,"cells":44170},"Patupilone and Omeprazole",{"EARLY_PHASE1":44171,"PHASE1":44173,"PHASE2":44182,"PHASE3":44184,"PHASE4":44186,"NA":44188},{"trials":44172,"activeCount":103},[],{"trials":44174,"activeCount":103},[44175],{"nctId":44176,"briefTitle":44177,"status":123,"phases":44178,"primaryCompletion":3473,"start":3657,"enrollment":31,"conditions":44179,"interventions":44180},"NCT00420615","Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies",[91],[647],[44169,44181],"Patupilone + Midalzolam",{"trials":44183,"activeCount":103},[],{"trials":44185,"activeCount":103},[],{"trials":44187,"activeCount":103},[],{"trials":44189,"activeCount":103},[],{"intervention":44181,"totalTrials":437,"cells":44191},{"EARLY_PHASE1":44192,"PHASE1":44194,"PHASE2":44200,"PHASE3":44202,"PHASE4":44204,"NA":44206},{"trials":44193,"activeCount":103},[],{"trials":44195,"activeCount":103},[44196],{"nctId":44176,"briefTitle":44177,"status":123,"phases":44197,"primaryCompletion":3473,"start":3657,"enrollment":31,"conditions":44198,"interventions":44199},[91],[647],[44169,44181],{"trials":44201,"activeCount":103},[],{"trials":44203,"activeCount":103},[],{"trials":44205,"activeCount":103},[],{"trials":44207,"activeCount":103},[],{"intervention":44209,"totalTrials":437,"cells":44210},"Cutaneous Cream application",{"EARLY_PHASE1":44211,"PHASE1":44213,"PHASE2":44223,"PHASE3":44225,"PHASE4":44227,"NA":44229},{"trials":44212,"activeCount":103},[],{"trials":44214,"activeCount":103},[44215],{"nctId":44216,"briefTitle":44217,"status":134,"phases":44218,"primaryCompletion":44219,"completion":44219,"start":1749,"enrollment":709,"conditions":44220,"interventions":44222},"NCT03333694","Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)",[91],"2018-11-01",[44221],"Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)",[44209],{"trials":44224,"activeCount":103},[],{"trials":44226,"activeCount":103},[],{"trials":44228,"activeCount":103},[],{"trials":44230,"activeCount":103},[],{"intervention":44232,"totalTrials":437,"cells":44233},"BCL201",{"EARLY_PHASE1":44234,"PHASE1":44236,"PHASE2":44247,"PHASE3":44249,"PHASE4":44251,"NA":44253},{"trials":44235,"activeCount":103},[],{"trials":44237,"activeCount":103},[44238],{"nctId":44239,"briefTitle":44240,"status":123,"phases":44241,"primaryCompletion":44242,"completion":44242,"start":32282,"enrollment":1611,"conditions":44243,"interventions":44245},"NCT02603445","Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL",[91],"2018-07-10",[44244],"Follicular Lymphoma, Mantle Cell Lymphoma",[44232,44246],"Idelalisib",{"trials":44248,"activeCount":103},[],{"trials":44250,"activeCount":103},[],{"trials":44252,"activeCount":103},[],{"trials":44254,"activeCount":103},[],{"intervention":44246,"totalTrials":437,"cells":44256},{"EARLY_PHASE1":44257,"PHASE1":44259,"PHASE2":44265,"PHASE3":44267,"PHASE4":44269,"NA":44271},{"trials":44258,"activeCount":103},[],{"trials":44260,"activeCount":103},[44261],{"nctId":44239,"briefTitle":44240,"status":123,"phases":44262,"primaryCompletion":44242,"completion":44242,"start":32282,"enrollment":1611,"conditions":44263,"interventions":44264},[91],[44244],[44232,44246],{"trials":44266,"activeCount":103},[],{"trials":44268,"activeCount":103},[],{"trials":44270,"activeCount":103},[],{"trials":44272,"activeCount":103},[],{"intervention":13411,"totalTrials":437,"cells":44274},{"EARLY_PHASE1":44275,"PHASE1":44277,"PHASE2":44283,"PHASE3":44285,"PHASE4":44287,"NA":44289},{"trials":44276,"activeCount":103},[],{"trials":44278,"activeCount":103},[44279],{"nctId":13404,"briefTitle":13405,"status":134,"phases":44280,"primaryCompletion":9647,"completion":9647,"start":13407,"enrollment":1574,"conditions":44281,"interventions":44282},[91],[13409],[13411,4389],{"trials":44284,"activeCount":103},[],{"trials":44286,"activeCount":103},[],{"trials":44288,"activeCount":103},[],{"trials":44290,"activeCount":103},[],{"intervention":44292,"totalTrials":437,"cells":44293},"BEZ235 + Trastuzumab Phase l\u002FPhase ll)",{"EARLY_PHASE1":44294,"PHASE1":44296,"PHASE2":44306,"PHASE3":44308,"PHASE4":44310,"NA":44312},{"trials":44295,"activeCount":103},[],{"trials":44297,"activeCount":103},[44298],{"nctId":44299,"briefTitle":44300,"status":123,"phases":44301,"primaryCompletion":4524,"completion":4524,"start":1671,"enrollment":637,"conditions":44302,"interventions":44304},"NCT01471847","A Phase Ib\u002FII Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab",[91],[44303,15452],"Locally Advance Breast Cancer (LABC)",[44292,44305],"Lapatinib + Capecitabine",{"trials":44307,"activeCount":103},[],{"trials":44309,"activeCount":103},[],{"trials":44311,"activeCount":103},[],{"trials":44313,"activeCount":103},[],{"intervention":44305,"totalTrials":437,"cells":44315},{"EARLY_PHASE1":44316,"PHASE1":44318,"PHASE2":44324,"PHASE3":44326,"PHASE4":44328,"NA":44330},{"trials":44317,"activeCount":103},[],{"trials":44319,"activeCount":103},[44320],{"nctId":44299,"briefTitle":44300,"status":123,"phases":44321,"primaryCompletion":4524,"completion":4524,"start":1671,"enrollment":637,"conditions":44322,"interventions":44323},[91],[44303,15452],[44292,44305],{"trials":44325,"activeCount":103},[],{"trials":44327,"activeCount":103},[],{"trials":44329,"activeCount":103},[],{"trials":44331,"activeCount":103},[],{"intervention":44333,"totalTrials":437,"cells":44334},"LLF580",{"EARLY_PHASE1":44335,"PHASE1":44337,"PHASE2":44347,"PHASE3":44349,"PHASE4":44351,"NA":44353},{"trials":44336,"activeCount":103},[],{"trials":44338,"activeCount":103},[44339],{"nctId":44340,"briefTitle":44341,"status":123,"phases":44342,"primaryCompletion":44343,"completion":44343,"start":44344,"enrollment":2354,"conditions":44345,"interventions":44346},"NCT03466203","Safety Study of LLF580 in Obese Volunteers",[91],"2019-11-13","2018-02-26",[20093],[44333],{"trials":44348,"activeCount":103},[],{"trials":44350,"activeCount":103},[],{"trials":44352,"activeCount":103},[],{"trials":44354,"activeCount":103},[],{"intervention":13425,"totalTrials":437,"cells":44356},{"EARLY_PHASE1":44357,"PHASE1":44359,"PHASE2":44365,"PHASE3":44367,"PHASE4":44369,"NA":44371},{"trials":44358,"activeCount":103},[],{"trials":44360,"activeCount":103},[44361],{"nctId":13413,"briefTitle":13414,"status":123,"phases":44362,"primaryCompletion":10641,"completion":13416,"start":13417,"enrollment":2910,"conditions":44363,"interventions":44364},[91],[13275,13419,36,9944,13420,13421,13422,13423],[13425,4389],{"trials":44366,"activeCount":103},[],{"trials":44368,"activeCount":103},[],{"trials":44370,"activeCount":103},[],{"trials":44372,"activeCount":103},[],{"intervention":44374,"totalTrials":437,"cells":44375},"100 mg inclisiran sodium",{"EARLY_PHASE1":44376,"PHASE1":44378,"PHASE2":44389,"PHASE3":44391,"PHASE4":44393,"NA":44395},{"trials":44377,"activeCount":103},[],{"trials":44379,"activeCount":103},[44380],{"nctId":44381,"briefTitle":44382,"status":123,"phases":44383,"primaryCompletion":44384,"completion":44384,"start":15763,"enrollment":709,"conditions":44385,"interventions":44387},"NCT04774003","Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C",[91],"2021-10-18",[44386],"Hyperlipidemia",[44374,44388],"300 mg inclisiran sodium",{"trials":44390,"activeCount":103},[],{"trials":44392,"activeCount":103},[],{"trials":44394,"activeCount":103},[],{"trials":44396,"activeCount":103},[],{"intervention":44388,"totalTrials":437,"cells":44398},{"EARLY_PHASE1":44399,"PHASE1":44401,"PHASE2":44407,"PHASE3":44409,"PHASE4":44411,"NA":44413},{"trials":44400,"activeCount":103},[],{"trials":44402,"activeCount":103},[44403],{"nctId":44381,"briefTitle":44382,"status":123,"phases":44404,"primaryCompletion":44384,"completion":44384,"start":15763,"enrollment":709,"conditions":44405,"interventions":44406},[91],[44386],[44374,44388],{"trials":44408,"activeCount":103},[],{"trials":44410,"activeCount":103},[],{"trials":44412,"activeCount":103},[],{"trials":44414,"activeCount":103},[],{"intervention":44416,"totalTrials":437,"cells":44417},"Nilotinib, interferon-alfa",{"EARLY_PHASE1":44418,"PHASE1":44420,"PHASE2":44428,"PHASE3":44430,"PHASE4":44432,"NA":44434},{"trials":44419,"activeCount":103},[],{"trials":44421,"activeCount":103},[44422],{"nctId":44423,"briefTitle":44424,"status":123,"phases":44425,"primaryCompletion":3559,"completion":3559,"start":607,"enrollment":1630,"conditions":44426,"interventions":44427},"NCT01220648","Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)",[91],[2393],[44416],{"trials":44429,"activeCount":103},[],{"trials":44431,"activeCount":103},[],{"trials":44433,"activeCount":103},[],{"trials":44435,"activeCount":103},[],{"intervention":13264,"totalTrials":437,"cells":44437},{"EARLY_PHASE1":44438,"PHASE1":44444,"PHASE2":44446,"PHASE3":44448,"PHASE4":44450,"NA":44452},{"trials":44439,"activeCount":103},[44440],{"nctId":13258,"briefTitle":13259,"status":134,"phases":44441,"primaryCompletion":1512,"completion":1512,"start":13261,"enrollment":1112,"conditions":44442,"interventions":44443},[90],[647],[13264,4389,10575,13265],{"trials":44445,"activeCount":103},[],{"trials":44447,"activeCount":103},[],{"trials":44449,"activeCount":103},[],{"trials":44451,"activeCount":103},[],{"trials":44453,"activeCount":103},[],{"intervention":13265,"totalTrials":437,"cells":44455},{"EARLY_PHASE1":44456,"PHASE1":44462,"PHASE2":44464,"PHASE3":44466,"PHASE4":44468,"NA":44470},{"trials":44457,"activeCount":103},[44458],{"nctId":13258,"briefTitle":13259,"status":134,"phases":44459,"primaryCompletion":1512,"completion":1512,"start":13261,"enrollment":1112,"conditions":44460,"interventions":44461},[90],[647],[13264,4389,10575,13265],{"trials":44463,"activeCount":103},[],{"trials":44465,"activeCount":103},[],{"trials":44467,"activeCount":103},[],{"trials":44469,"activeCount":103},[],{"trials":44471,"activeCount":103},[],{"intervention":886,"totalTrials":3605,"cells":44473},{"EARLY_PHASE1":44474,"PHASE1":44476,"PHASE2":44488,"PHASE3":44507,"PHASE4":44667,"NA":44796},{"trials":44475,"activeCount":103},[],{"trials":44477,"activeCount":103},[44478,44484],{"nctId":44479,"briefTitle":44480,"status":123,"phases":44481,"primaryCompletion":4335,"completion":4335,"start":3195,"enrollment":3343,"conditions":44482,"interventions":44483},"NCT00424983","Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year",[91],[5636,15],[886],{"nctId":33393,"briefTitle":33394,"status":123,"phases":44485,"primaryCompletion":4301,"completion":4301,"start":949,"enrollment":2046,"conditions":44486,"interventions":44487},[91],[33397],[10520,886],{"trials":44489,"activeCount":103},[44490,44497,44503],{"nctId":44491,"briefTitle":44492,"status":123,"phases":44493,"primaryCompletion":4740,"completion":4740,"start":18732,"enrollment":32134,"conditions":44494,"interventions":44496},"NCT00063479","Bisphosphonate Treatment of Osteogenesis Imperfecta",[92],[44495],"Osteogenesis Imperfecta",[955],{"nctId":44498,"briefTitle":44499,"status":123,"phases":44500,"primaryCompletion":4740,"completion":4740,"start":4061,"enrollment":1213,"conditions":44501,"interventions":44502},"NCT00131118","Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta",[92],[44495],[955],{"nctId":8088,"briefTitle":8089,"status":134,"phases":44504,"primaryCompletion":3195,"start":8091,"enrollment":437,"conditions":44505,"interventions":44506},[92],[1654],[955,5252],{"trials":44508,"activeCount":103},[44509,44517,44523,44527,44534,44538,44547,44551,44555,44561,44568,44574,44580,44587,44594,44602,44606,44612,44616,44623,44627,44633,44639,44646,44653,44659],{"nctId":44510,"briefTitle":44511,"status":123,"phases":44512,"primaryCompletion":4301,"completion":44513,"start":4335,"enrollment":4708,"conditions":44514,"interventions":44516},"NCT00909961","A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years",[93],"2011-12-16",[44515],"Postmenopausal Osteoporosis",[886],{"nctId":44518,"briefTitle":44519,"status":123,"phases":44520,"primaryCompletion":2033,"completion":2033,"start":966,"enrollment":15464,"conditions":44521,"interventions":44522},"NCT00320710","Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer",[93],[15],[886],{"nctId":17141,"briefTitle":17142,"status":123,"phases":44524,"primaryCompletion":3447,"completion":3447,"start":9096,"enrollment":15801,"conditions":44525,"interventions":44526},[93],[17145],[17147,17148,1168],{"nctId":44528,"briefTitle":44529,"status":123,"phases":44530,"primaryCompletion":4845,"completion":4845,"start":4741,"enrollment":9169,"conditions":44531,"interventions":44533},"NCT00172055","Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy",[93],[44532],"Cancer Prostate",[886],{"nctId":25683,"briefTitle":25684,"status":123,"phases":44535,"primaryCompletion":17396,"completion":3383,"start":997,"enrollment":2910,"conditions":44536,"interventions":44537},[93],[25687],[17147,25672,25689],{"nctId":44539,"briefTitle":44540,"status":123,"phases":44541,"primaryCompletion":988,"completion":988,"start":44542,"enrollment":44543,"conditions":44544,"interventions":44546},"NCT00046254","Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture",[93],"2002-02",2127,[953,44545],"Hip Fracture",[955],{"nctId":877,"briefTitle":878,"status":123,"phases":44548,"primaryCompletion":880,"completion":880,"start":881,"enrollment":882,"conditions":44549,"interventions":44550},[93],[884,15],[886,249],{"nctId":13684,"briefTitle":13685,"status":123,"phases":44552,"primaryCompletion":1732,"completion":1732,"start":835,"enrollment":13687,"conditions":44553,"interventions":44554},[93],[1654],[955,13669],{"nctId":44556,"briefTitle":44557,"status":123,"phases":44558,"primaryCompletion":4317,"start":5063,"enrollment":2354,"conditions":44559,"interventions":44560},"NCT00375648","Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer",[93],[19872],[886],{"nctId":44562,"briefTitle":44563,"status":123,"phases":44564,"primaryCompletion":15283,"completion":15283,"start":5696,"enrollment":6547,"conditions":44565,"interventions":44567},"NCT00718861","3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs",[93],[44566],"Post-menopausal Osteoporosis",[886],{"nctId":44569,"briefTitle":44570,"status":123,"phases":44571,"primaryCompletion":4437,"completion":4437,"start":9096,"enrollment":5903,"conditions":44572,"interventions":44573},"NCT00097825","Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men",[93],[953],[955],{"nctId":44575,"briefTitle":44576,"status":123,"phases":44577,"primaryCompletion":5063,"completion":5063,"start":16936,"enrollment":1384,"conditions":44578,"interventions":44579},"NCT00100555","A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate",[93],[953],[17147],{"nctId":44581,"briefTitle":44582,"status":123,"phases":44583,"primaryCompletion":745,"start":16929,"enrollment":44584,"conditions":44585,"interventions":44586},"NCT00049829","HORIZON-PFT: Pivotal Fracture Trial",[93],7700,[953],[955],{"nctId":44588,"briefTitle":44589,"status":134,"phases":44590,"primaryCompletion":1015,"completion":1015,"start":44591,"enrollment":1809,"conditions":44592,"interventions":44593},"NCT00005073","Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms",[93],"1999-09",[1654],[17147],{"nctId":44595,"briefTitle":44596,"status":123,"phases":44597,"primaryCompletion":44598,"completion":44598,"start":44599,"enrollment":31,"conditions":44600,"interventions":44601},"NCT00799266","An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids",[93],"2018-03-05","2008-12-04",[953],[886],{"nctId":923,"briefTitle":924,"status":123,"phases":44603,"primaryCompletion":926,"start":845,"enrollment":927,"conditions":44604,"interventions":44605},[93],[15],[886,249],{"nctId":44607,"briefTitle":44608,"status":123,"phases":44609,"primaryCompletion":4343,"completion":4343,"start":16936,"enrollment":4750,"conditions":44610,"interventions":44611},"NCT00100620","Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis",[93],[953],[955],{"nctId":25691,"briefTitle":25684,"status":123,"phases":44613,"primaryCompletion":845,"completion":3383,"start":25693,"enrollment":13531,"conditions":44614,"interventions":44615},[93],[25687],[955,25672],{"nctId":44617,"briefTitle":44618,"status":123,"phases":44619,"primaryCompletion":6526,"completion":6526,"start":44620,"enrollment":2342,"conditions":44621,"interventions":44622},"NCT01197300","1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids",[93],"2010-10-25",[953],[886],{"nctId":946,"briefTitle":947,"status":123,"phases":44624,"primaryCompletion":949,"completion":949,"start":950,"enrollment":951,"conditions":44625,"interventions":44626},[93],[559,953],[955,249],{"nctId":44628,"briefTitle":44629,"status":123,"phases":44630,"primaryCompletion":3474,"completion":3474,"start":16936,"enrollment":2046,"conditions":44631,"interventions":44632},"NCT00171639","The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis",[93],[1654],[17147],{"nctId":44634,"briefTitle":44635,"status":123,"phases":44636,"primaryCompletion":4515,"completion":4515,"start":15109,"enrollment":512,"conditions":44637,"interventions":44638},"NCT00375505","The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss",[93],[15],[886],{"nctId":44640,"briefTitle":44641,"status":123,"phases":44642,"primaryCompletion":16570,"completion":16570,"start":4061,"enrollment":16419,"conditions":44643,"interventions":44645},"NCT00132808","Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older",[93],[44644],"Osteopenia",[955],{"nctId":44647,"briefTitle":44648,"status":123,"phases":44649,"primaryCompletion":880,"start":966,"enrollment":2543,"conditions":44650,"interventions":44652},"NCT00375427","Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions",[93],[44651],"Breast Cancer With Bone Metastasis",[886],{"nctId":44654,"briefTitle":44655,"status":123,"phases":44656,"primaryCompletion":835,"completion":835,"start":15058,"enrollment":7269,"conditions":44657,"interventions":44658},"NCT00097812","Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid",[93],[953],[17147],{"nctId":44660,"briefTitle":44661,"status":134,"phases":44662,"primaryCompletion":3490,"completion":3490,"start":44663,"enrollment":3032,"conditions":44664,"interventions":44666},"NCT00171925","Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I",[93],"2000-08",[44665],"Multiple Myeloma Stage I",[886],{"trials":44668,"activeCount":103},[44669,44676,44683,44690,44696,44703,44711,44717,44723,44727,44734,44742,44748,44754,44760,44767,44773,44780,44788],{"nctId":44670,"briefTitle":44671,"status":123,"phases":44672,"primaryCompletion":4621,"start":15041,"enrollment":7438,"conditions":44673,"interventions":44675},"NCT00241111","Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis",[94],[44674],"Prostate Cancer With Bone Metastasis",[17147],{"nctId":44677,"briefTitle":44678,"status":123,"phases":44679,"primaryCompletion":835,"start":746,"enrollment":4911,"conditions":44680,"interventions":44682},"NCT00237159","Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis",[94],[44681],"Prostate Cancer Patients With Bone Metastasis",[886],{"nctId":44684,"briefTitle":44685,"status":123,"phases":44686,"primaryCompletion":4975,"start":3657,"enrollment":4568,"conditions":44687,"interventions":44689},"NCT00434447","Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases",[94],[44688],"Bone Neoplasms",[886],{"nctId":44691,"briefTitle":44692,"status":123,"phases":44693,"primaryCompletion":865,"start":845,"enrollment":1423,"conditions":44694,"interventions":44695},"NCT00346242","Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events",[94],[2570],[955],{"nctId":44697,"briefTitle":44698,"status":134,"phases":44699,"primaryCompletion":1714,"completion":1714,"start":865,"enrollment":4148,"conditions":44700,"interventions":44702},"NCT00333229","A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss",[94],[44701],"Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women",[955],{"nctId":44704,"briefTitle":44705,"status":123,"phases":44706,"primaryCompletion":44707,"completion":44707,"start":44708,"enrollment":1495,"conditions":44709,"interventions":44710},"NCT00774020","Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)",[94],"2011-01-14","2008-10-30",[25687],[886],{"nctId":44712,"briefTitle":44713,"status":123,"phases":44714,"primaryCompletion":1025,"completion":1025,"start":4732,"enrollment":5948,"conditions":44715,"interventions":44716},"NCT00237146","Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy",[94],[1654],[886],{"nctId":44718,"briefTitle":44719,"status":123,"phases":44720,"primaryCompletion":3447,"completion":3447,"start":4071,"enrollment":9369,"conditions":44721,"interventions":44722},"NCT00104104","A Multiple Myeloma Trial in Patients With Bone Metastases",[94],[5636],[17147],{"nctId":19844,"briefTitle":19845,"status":123,"phases":44724,"primaryCompletion":3482,"completion":3482,"start":3351,"enrollment":22,"conditions":44725,"interventions":44726},[94],[19848,19849],[886,19827],{"nctId":44728,"briefTitle":44729,"status":123,"phases":44730,"primaryCompletion":4845,"completion":4845,"start":4810,"enrollment":2579,"conditions":44731,"interventions":44733},"NCT00172003","Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis",[94],[44732,4311],"Renal Cell Cancer",[886],{"nctId":44735,"briefTitle":44736,"status":123,"phases":44737,"primaryCompletion":4845,"completion":4845,"start":8091,"enrollment":44738,"conditions":44739,"interventions":44741},"NCT00334139","Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer",[94],411,[1654,15,44740],"Bone Metastasis",[955],{"nctId":44743,"briefTitle":44744,"status":123,"phases":44745,"primaryCompletion":864,"start":3473,"enrollment":18098,"conditions":44746,"interventions":44747},"NCT00745485","Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid",[94],[953],[17147],{"nctId":44749,"briefTitle":44750,"status":123,"phases":44751,"primaryCompletion":4317,"start":746,"enrollment":9531,"conditions":44752,"interventions":44753},"NCT00242554","Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases",[94],[1654],[886],{"nctId":44755,"briefTitle":44756,"status":123,"phases":44757,"completion":854,"start":17543,"enrollment":919,"conditions":44758,"interventions":44759},"NCT00063609","The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy",[94],[1654],[17147],{"nctId":44761,"briefTitle":44762,"status":123,"phases":44763,"primaryCompletion":854,"start":15101,"enrollment":4557,"conditions":44764,"interventions":44766},"NCT00172016","A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates",[94],[44765],"Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated",[886],{"nctId":44768,"briefTitle":44769,"status":123,"phases":44770,"primaryCompletion":4975,"completion":4975,"start":15041,"enrollment":1423,"conditions":44771,"interventions":44772},"NCT00219271","Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer",[94],[1654],[886],{"nctId":44774,"briefTitle":44775,"status":123,"phases":44776,"completion":4642,"start":17497,"enrollment":967,"conditions":44777,"interventions":44779},"NCT00099541","Non-small Cell Lung Cancer Registry",[94],[1178,44778],"Pleural Effusion, Malignant",[17147],{"nctId":44781,"briefTitle":44782,"status":123,"phases":44783,"primaryCompletion":44784,"completion":44784,"start":44785,"enrollment":7571,"conditions":44786,"interventions":44787},"NCT00622505","Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants",[94],"2012-04-03","2007-11-07",[5636],[17147],{"nctId":44789,"briefTitle":44790,"status":123,"phases":44791,"primaryCompletion":44792,"completion":44792,"start":44793,"enrollment":2379,"conditions":44794,"interventions":44795},"NCT00740129","Re-treatment of Participants With Paget's Disease Using Zoledronic Acid",[94],"2011-03-14","2008-10-21",[20884],[955],{"trials":44797,"activeCount":103},[44798,44804],{"nctId":44799,"briefTitle":44800,"status":123,"phases":44801,"completion":4740,"start":17396,"conditions":44802,"interventions":44803},"NCT00087659","A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy",[95],[1654],[17147],{"nctId":44805,"briefTitle":44806,"status":123,"phases":44807,"primaryCompletion":1781,"completion":1781,"start":3490,"enrollment":44808,"conditions":44809,"interventions":44811},"NCT00984893","Intra-venous Zoledronic Acid Once Yearly",[],1551,[44810],"Post-Menopausal Osteoporosis",[17147,44812],"Any oral bisphosphonates marketed in Canada",{"intervention":15726,"totalTrials":5948,"cells":44814},{"EARLY_PHASE1":44815,"PHASE1":44817,"PHASE2":44826,"PHASE3":44898,"PHASE4":44980,"NA":45015},{"trials":44816,"activeCount":103},[],{"trials":44818,"activeCount":103},[44819],{"nctId":44820,"briefTitle":44821,"status":123,"phases":44822,"primaryCompletion":7939,"completion":7939,"start":3612,"enrollment":7257,"conditions":44823,"interventions":44825},"NCT01569815","Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function",[91],[44824],"Mild and Moderate Renal Impairment",[15726],{"trials":44827,"activeCount":103},[44828,44836,44843,44847,44851,44855,44861,44865,44869,44876,44880,44886,44890,44894],{"nctId":44829,"briefTitle":44830,"status":123,"phases":44831,"primaryCompletion":44832,"completion":44832,"start":34529,"enrollment":3098,"conditions":44833,"interventions":44835},"NCT04164732","Study of Efficacy of Oral Sacubitril\u002FValsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy",[92],"2023-08-22",[44834],"Cardiomyopathy, Hypertrophic",[15726],{"nctId":44837,"briefTitle":44838,"status":123,"phases":44839,"primaryCompletion":3383,"completion":3383,"start":3845,"enrollment":44840,"conditions":44841,"interventions":44842},"NCT01193101","Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension",[92],389,[21],[15726],{"nctId":15720,"briefTitle":15721,"status":123,"phases":44844,"primaryCompletion":10499,"completion":10499,"start":3194,"enrollment":15723,"conditions":44845,"interventions":44846},[92],[21],[15726,5447,15727],{"nctId":16994,"briefTitle":16995,"status":123,"phases":44848,"primaryCompletion":606,"completion":606,"start":3604,"enrollment":16997,"conditions":44849,"interventions":44850},[92],[21],[15726,17000,15776,17001],{"nctId":15729,"briefTitle":15730,"status":123,"phases":44852,"primaryCompletion":4301,"completion":4301,"start":4335,"enrollment":15732,"conditions":44853,"interventions":44854},[92],[15734],[15726,5447],{"nctId":44856,"briefTitle":44857,"status":123,"phases":44858,"primaryCompletion":4845,"start":3410,"enrollment":2439,"conditions":44859,"interventions":44860},"NCT00913653","Safety\u002FTolerability, Pharmacokinetics\u002FPharmacodynamics (PK\u002FPD) of LCZ696 in Patients With Stable Heart Failure",[92],[15870],[15726],{"nctId":15737,"briefTitle":15738,"status":123,"phases":44862,"primaryCompletion":4301,"completion":4301,"start":4598,"enrollment":15740,"conditions":44863,"interventions":44864},[92],[15742],[15726,5447,15727],{"nctId":15745,"briefTitle":15746,"status":123,"phases":44866,"primaryCompletion":3482,"completion":3482,"start":895,"enrollment":7257,"conditions":44867,"interventions":44868},[92],[21],[15726,5447],{"nctId":44870,"briefTitle":44871,"status":123,"phases":44872,"primaryCompletion":7939,"completion":7939,"start":4669,"enrollment":44873,"conditions":44874,"interventions":44875},"NCT01922089","Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients",[92],498,[14475],[15726],{"nctId":17003,"briefTitle":17004,"status":123,"phases":44877,"primaryCompletion":607,"completion":607,"start":926,"enrollment":1922,"conditions":44878,"interventions":44879},[92],[17007],[15726,15884,15777],{"nctId":44881,"briefTitle":44882,"status":123,"phases":44883,"primaryCompletion":1670,"completion":1670,"start":3243,"enrollment":7257,"conditions":44884,"interventions":44885},"NCT01621633","A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers",[92],[2625],[15726],{"nctId":26345,"briefTitle":26346,"status":123,"phases":44887,"primaryCompletion":1670,"completion":1670,"start":3243,"enrollment":2046,"conditions":44888,"interventions":44889},[92],[26349],[15726,4121],{"nctId":15751,"briefTitle":15752,"status":123,"phases":44891,"primaryCompletion":813,"completion":813,"start":3482,"enrollment":774,"conditions":44892,"interventions":44893},[92],[15755],[5447,15726],{"nctId":17018,"briefTitle":17019,"status":123,"phases":44895,"primaryCompletion":2033,"completion":2033,"start":1761,"enrollment":6014,"conditions":44896,"interventions":44897},[92],[21,17022],[15726,15776],{"trials":44899,"activeCount":103},[44900,44904,44908,44912,44920,44924,44928,44934,44938,44942,44946,44950,44954,44958,44962,44969,44976],{"nctId":17275,"briefTitle":17276,"status":123,"phases":44901,"primaryCompletion":7450,"completion":7450,"start":5310,"enrollment":34,"conditions":44902,"interventions":44903},[93],[15870,17279,17280],[15726,15789],{"nctId":15760,"briefTitle":15761,"status":123,"phases":44905,"primaryCompletion":15763,"completion":15763,"start":15764,"enrollment":15765,"conditions":44906,"interventions":44907},[93],[15767],[15726,15769,5447],{"nctId":24128,"briefTitle":24129,"status":123,"phases":44909,"primaryCompletion":7939,"completion":7939,"start":3799,"enrollment":282,"conditions":44910,"interventions":44911},[93],[21],[15726,17000],{"nctId":44913,"briefTitle":44914,"status":123,"phases":44915,"primaryCompletion":1142,"completion":1142,"start":44916,"enrollment":44917,"conditions":44918,"interventions":44919},"NCT02226120","Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction",[93],"2014-10-16",1980,[17293],[15726],{"nctId":17287,"briefTitle":17288,"status":123,"phases":44921,"primaryCompletion":17290,"completion":17290,"start":2623,"enrollment":17291,"conditions":44922,"interventions":44923},[93],[17293],[15726,15789],{"nctId":24134,"briefTitle":24135,"status":123,"phases":44925,"primaryCompletion":15283,"completion":15283,"start":4524,"enrollment":24137,"conditions":44926,"interventions":44927},[93],[17007],[15726,17000],{"nctId":44929,"briefTitle":44930,"status":134,"phases":44931,"primaryCompletion":29703,"completion":29703,"start":10595,"enrollment":3605,"conditions":44932,"interventions":44933},"NCT03909295","An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.",[93],[15819],[15726],{"nctId":24141,"briefTitle":24142,"status":123,"phases":44935,"primaryCompletion":2033,"completion":2033,"start":3482,"enrollment":7202,"conditions":44936,"interventions":44937},[93],[17007],[17000,15726],{"nctId":17304,"briefTitle":17305,"status":123,"phases":44939,"primaryCompletion":17307,"completion":17307,"start":9177,"enrollment":17308,"conditions":44940,"interventions":44941},[92,93],[17310],[15726,15789,15726],{"nctId":17043,"briefTitle":17044,"status":123,"phases":44943,"primaryCompletion":5114,"completion":5114,"start":3482,"enrollment":17046,"conditions":44944,"interventions":44945},[93],[17007],[15726,15884],{"nctId":15823,"briefTitle":15824,"status":123,"phases":44947,"primaryCompletion":15826,"completion":15826,"start":15827,"enrollment":15828,"conditions":44948,"interventions":44949},[93],[15830],[15726,5447],{"nctId":15833,"briefTitle":15834,"status":123,"phases":44951,"primaryCompletion":2111,"completion":2111,"start":15836,"enrollment":15837,"conditions":44952,"interventions":44953},[93],[15786],[15726,5447],{"nctId":17050,"briefTitle":17051,"status":390,"phases":44955,"primaryCompletion":606,"completion":606,"start":1781,"enrollment":103,"conditions":44956,"interventions":44957},[93],[21],[15726,15884,17055],{"nctId":24147,"briefTitle":24148,"status":123,"phases":44959,"primaryCompletion":7939,"completion":7939,"start":15283,"enrollment":24150,"conditions":44960,"interventions":44961},[93],[17007],[15726,17000],{"nctId":44963,"briefTitle":44964,"status":123,"phases":44965,"primaryCompletion":2793,"completion":2793,"start":3759,"enrollment":906,"conditions":44966,"interventions":44968},"NCT01646671","Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients",[93],[44967],"Severe Hypertension",[15726,15726,15726],{"nctId":44970,"briefTitle":44971,"status":123,"phases":44972,"primaryCompletion":4967,"completion":4967,"start":5733,"enrollment":7257,"conditions":44973,"interventions":44975},"NCT01593787","Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction",[93],[44974],"Hypertension With Renal Dysfunction",[15726],{"nctId":17321,"briefTitle":17322,"status":123,"phases":44977,"primaryCompletion":17324,"completion":17325,"start":17326,"enrollment":3420,"conditions":44978,"interventions":44979},[93],[17328],[15726,15789],{"trials":44981,"activeCount":103},[44982,44990,44994,44998,45006],{"nctId":44983,"briefTitle":44984,"status":123,"phases":44985,"primaryCompletion":44986,"completion":40184,"start":44987,"enrollment":2312,"conditions":44988,"interventions":44989},"NCT02661217","Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event",[94],"2018-02-20","2016-02-12",[14475],[15726],{"nctId":17352,"briefTitle":17353,"status":123,"phases":44991,"primaryCompletion":17355,"completion":17356,"start":17357,"enrollment":17358,"conditions":44992,"interventions":44993},[94],[17360],[15726,15789],{"nctId":17363,"briefTitle":17364,"status":123,"phases":44995,"primaryCompletion":17366,"completion":17366,"start":2055,"enrollment":17367,"conditions":44996,"interventions":44997},[94],[17293],[15726,15789],{"nctId":44999,"briefTitle":45000,"status":123,"phases":45001,"primaryCompletion":421,"completion":7625,"start":45002,"enrollment":4899,"conditions":45003,"interventions":45005},"NCT02690974","Description of Tolerability of LCZ696 (Sacubitril \u002F Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting",[94],"2016-03-08",[45004],"Hearth Failure With Reduced Ejection Fraction (HFrEF)",[15726],{"nctId":45007,"briefTitle":45008,"status":123,"phases":45009,"primaryCompletion":45010,"completion":45010,"start":45011,"enrollment":45012,"conditions":45013,"interventions":45014},"NCT02887183","Effects of Sacubitril\u002FValsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.",[94],"2018-10-22","2016-10-25",794,[15870],[15726],{"trials":45016,"activeCount":103},[45017],{"nctId":45018,"briefTitle":45019,"status":1326,"phases":45020,"conditions":45021,"interventions":45022},"NCT02389933","Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)",[],[17328],[15726],{"intervention":24676,"totalTrials":906,"cells":45024},{"EARLY_PHASE1":45025,"PHASE1":45027,"PHASE2":45042,"PHASE3":45146,"PHASE4":45186,"NA":45261},{"trials":45026,"activeCount":103},[],{"trials":45028,"activeCount":103},[45029,45035],{"nctId":45030,"briefTitle":45031,"status":123,"phases":45032,"primaryCompletion":3845,"completion":3845,"start":3657,"enrollment":630,"conditions":45033,"interventions":45034},"NCT00432627","Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.",[91],[2625],[24676],{"nctId":45036,"briefTitle":45037,"status":123,"phases":45038,"primaryCompletion":607,"completion":607,"start":3194,"enrollment":4148,"conditions":45039,"interventions":45041},"NCT00560820","Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload",[91],[45040,18734],"β-thalassemia",[24676],{"trials":45043,"activeCount":103},[45044,45048,45055,45063,45067,45075,45081,45088,45092,45098,45108,45116,45122,45130,45139],{"nctId":24666,"briefTitle":24667,"status":123,"phases":45045,"primaryCompletion":4967,"completion":4967,"start":4642,"enrollment":24669,"conditions":45046,"interventions":45047},[92],[18734,20547],[24672,24673,24674,24675,24676,24657],{"nctId":45049,"briefTitle":45050,"status":123,"phases":45051,"primaryCompletion":3784,"start":3612,"enrollment":1611,"conditions":45052,"interventions":45054},"NCT00879242","Effect of Deferasirox on Patients With Cardiac MRI T2* \u003C 20 Msec",[92],[45053],"Beta Thalassemia Transfusion Dependent",[24676],{"nctId":45056,"briefTitle":45057,"status":134,"phases":45058,"primaryCompletion":45059,"completion":45059,"start":45060,"enrollment":437,"conditions":45061,"interventions":45062},"NCT02663752","A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.",[92],"2016-07-01","2016-05-30",[33898],[24676],{"nctId":24678,"briefTitle":24679,"status":134,"phases":45064,"primaryCompletion":3731,"completion":3731,"start":4598,"enrollment":7257,"conditions":45065,"interventions":45066},[92],[24682,24683],[24676,24657],{"nctId":45068,"briefTitle":45069,"status":123,"phases":45070,"primaryCompletion":2034,"completion":4524,"start":3490,"enrollment":1100,"conditions":45071,"interventions":45073},"NCT00873041","Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study",[92],[45072],"Non-transfusion Dependent Thalassemia",[45074],"deferasirox",{"nctId":45076,"briefTitle":45077,"status":123,"phases":45078,"primaryCompletion":17543,"completion":17543,"start":904,"enrollment":11068,"conditions":45079,"interventions":45080},"NCT00379483","Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload",[92],[18734],[24676],{"nctId":45082,"briefTitle":45083,"status":390,"phases":45084,"primaryCompletion":23514,"completion":23514,"start":1723,"enrollment":103,"conditions":45085,"interventions":45087},"NCT01948817","Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses",[92],[45086],"Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg\u002FkgQD",[24676],{"nctId":24686,"briefTitle":24687,"status":123,"phases":45089,"primaryCompletion":4070,"completion":4070,"start":3255,"enrollment":6175,"conditions":45090,"interventions":45091},[92],[3952,21357,24690],[24676,24657],{"nctId":45093,"briefTitle":45094,"status":123,"phases":45095,"primaryCompletion":4556,"completion":3400,"start":3210,"enrollment":1622,"conditions":45096,"interventions":45097},"NCT00395629","Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis",[91,92],[21357,36081],[24676],{"nctId":45099,"briefTitle":45100,"status":123,"phases":45101,"primaryCompletion":17497,"start":881,"enrollment":8659,"conditions":45102,"interventions":45107},"NCT00061763","Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias",[92],[45103,5723,45104,45105,45106],"Beta-thalassemia","Fanconi Syndrome","Anemia, Diamond-Blackfan","Anemia, Aplastic",[24676],{"nctId":45109,"briefTitle":45110,"status":123,"phases":45111,"primaryCompletion":16570,"completion":16570,"start":15041,"enrollment":709,"conditions":45112,"interventions":45115},"NCT00390858","A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.",[92],[18734,45113,45114],"β-thalassemia Major","Pediatric Rare Anemia",[24676],{"nctId":45117,"briefTitle":45118,"status":123,"phases":45119,"primaryCompletion":33047,"completion":33047,"start":38875,"enrollment":3420,"conditions":45120,"interventions":45121},"NCT00940602","Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study",[92],[5723],[24676],{"nctId":45123,"briefTitle":45124,"status":123,"phases":45125,"primaryCompletion":45126,"completion":45126,"start":45127,"enrollment":4742,"conditions":45128,"interventions":45129},"NCT00110266","Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients",[92],"2008-03-28","2005-07-25",[33898,21357],[24676],{"nctId":45131,"briefTitle":45132,"status":123,"phases":45133,"primaryCompletion":1014,"completion":1014,"start":845,"enrollment":45134,"conditions":45135,"interventions":45138},"NCT00303329","Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients",[92],184,[45136,45137],"Anemia","Hemosiderosis",[24676],{"nctId":45140,"briefTitle":45141,"status":123,"phases":45142,"primaryCompletion":4598,"completion":1671,"start":3447,"enrollment":2268,"conditions":45143,"interventions":45145},"NCT00631163","Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis",[92],[45144,20547],"Chronic Anemia",[24676],{"trials":45147,"activeCount":103},[45148,45156,45163,45171,45178],{"nctId":45149,"briefTitle":45150,"status":123,"phases":45151,"primaryCompletion":1014,"completion":1014,"start":15109,"enrollment":45152,"conditions":45153,"interventions":45155},"NCT00235391","Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload",[93],1683,[2570,3952,45154,2369],"Diamond Blackfan Anemia",[24676],{"nctId":45157,"briefTitle":45158,"status":123,"phases":45159,"primaryCompletion":4070,"start":4071,"enrollment":6599,"conditions":45160,"interventions":45162},"NCT00171210","An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload",[93],[45161],"Transfusional Iron Overload in β-thalassemia",[24676],{"nctId":45164,"briefTitle":45165,"status":123,"phases":45166,"primaryCompletion":3410,"completion":864,"start":854,"enrollment":45167,"conditions":45168,"interventions":45170},"NCT00171821","A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload",[93],1784,[45169],"Transfusion-dependent Iron Overload",[24676],{"nctId":45172,"briefTitle":45173,"status":123,"phases":45174,"primaryCompletion":917,"completion":917,"start":989,"enrollment":512,"conditions":45175,"interventions":45177},"NCT01033747","Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study",[92,93],[45176],"Liver Iron Overload",[24676,24676],{"nctId":45179,"briefTitle":45180,"status":123,"phases":45181,"primaryCompletion":9135,"completion":9135,"start":45182,"enrollment":17433,"conditions":45183,"interventions":45185},"NCT02720536","Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation",[93],"2016-08-16",[45184],"Chronic Iron Overload",[24676],{"trials":45187,"activeCount":103},[45188,45194,45200,45206,45212,45218,45224,45230,45236,45245,45253],{"nctId":45189,"briefTitle":45190,"status":123,"phases":45191,"primaryCompletion":1732,"completion":1732,"start":16570,"enrollment":11092,"conditions":45192,"interventions":45193},"NCT00654589","Efficacy and Safety of Oral Deferasirox (20 mg\u002Fkg\u002Fd) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload",[94],[21357],[24676],{"nctId":45195,"briefTitle":45196,"status":123,"phases":45197,"primaryCompletion":3784,"start":3552,"enrollment":2439,"conditions":45198,"interventions":45199},"NCT01335035","Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload",[94],[21357],[45074],{"nctId":45201,"briefTitle":45202,"status":123,"phases":45203,"primaryCompletion":917,"completion":917,"start":8370,"enrollment":630,"conditions":45204,"interventions":45205},"NCT00117507","Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients",[94],[5723,21357],[24676],{"nctId":45207,"briefTitle":45208,"status":123,"phases":45209,"primaryCompletion":4620,"completion":1818,"start":3271,"enrollment":2810,"conditions":45210,"interventions":45211},"NCT01250951","This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.",[94],[33898,2570],[24676],{"nctId":45213,"briefTitle":45214,"status":123,"phases":45215,"primaryCompletion":44058,"completion":44058,"start":31547,"enrollment":22,"conditions":45216,"interventions":45217},"NCT03372083","Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis",[94],[21357],[24676],{"nctId":45219,"briefTitle":45220,"status":134,"phases":45221,"primaryCompletion":3243,"completion":3243,"start":4301,"enrollment":138,"conditions":45222,"interventions":45223},"NCT01326845","Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study",[94],[33898,18734],[24676],{"nctId":45225,"briefTitle":45226,"status":390,"phases":45227,"primaryCompletion":1781,"completion":1817,"start":1682,"enrollment":103,"conditions":45228,"interventions":45229},"NCT01724138","An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old",[94],[45113],[24676],{"nctId":45231,"briefTitle":45232,"status":123,"phases":45233,"primaryCompletion":4620,"completion":4620,"start":4556,"enrollment":4448,"conditions":45234,"interventions":45235},"NCT00564941","Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload",[94],[5723,18744],[45074],{"nctId":45237,"briefTitle":45238,"status":123,"phases":45239,"primaryCompletion":45240,"completion":45241,"start":45242,"enrollment":292,"conditions":45243,"interventions":45244},"NCT01709838","Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia",[94],"2015-01-03","2019-01-17","2012-12-06",[45072],[45074],{"nctId":45246,"briefTitle":45247,"status":390,"phases":45248,"primaryCompletion":45249,"completion":45249,"start":1731,"enrollment":103,"conditions":45250,"interventions":45252},"NCT02069886","Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia",[94],"2018-12",[45251],"Thalassemia (Transfusion Delendent)",[45074],{"nctId":45254,"briefTitle":45255,"status":123,"phases":45256,"primaryCompletion":5696,"completion":5696,"start":5063,"enrollment":4223,"conditions":45257,"interventions":45260},"NCT00171301","Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)",[94],[45258,45137,21357,45259],"Beta-thalassemia Major","Rare Anemia",[24676],{"trials":45262,"activeCount":103},[45263,45269],{"nctId":45264,"briefTitle":45265,"status":123,"phases":45266,"primaryCompletion":1681,"completion":1681,"start":4620,"enrollment":1384,"conditions":45267,"interventions":45268},"NCT01394029","Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox",[],[20547],[45074],{"nctId":45270,"briefTitle":45271,"status":123,"phases":45272,"primaryCompletion":3511,"completion":3511,"start":4740,"enrollment":12584,"conditions":45273,"interventions":45274},"NCT00466063","ENTRUST, a 5 Year Surveillance of Children Aged 2 to \u003C6 Years With Transfusional Iron Overload Treated With Deferasirox",[],[45136],[24676],{"intervention":3157,"totalTrials":31,"cells":45276},{"EARLY_PHASE1":45277,"PHASE1":45279,"PHASE2":45293,"PHASE3":45378,"PHASE4":45492,"NA":45494},{"trials":45278,"activeCount":103},[],{"trials":45280,"activeCount":103},[45281,45285,45289],{"nctId":13316,"briefTitle":13317,"status":134,"phases":45282,"primaryCompletion":6013,"completion":6013,"start":13319,"enrollment":2810,"conditions":45283,"interventions":45284},[91],[128],[4389,5262,9948,4375,1168,4321,3157],{"nctId":10567,"briefTitle":10568,"status":134,"phases":45286,"primaryCompletion":10570,"completion":10570,"start":1808,"enrollment":2776,"conditions":45287,"interventions":45288},[91],[10572],[10574,10125,10575,10576,10577,10578],{"nctId":23949,"briefTitle":23950,"status":134,"phases":45290,"primaryCompletion":23952,"completion":23952,"start":13272,"enrollment":99,"conditions":45291,"interventions":45292},[91],[5723],[10589,2411,10578],{"trials":45294,"activeCount":103},[45295,45302,45309,45317,45321,45328,45335,45339,45343,45352,45359,45367,45371],{"nctId":45296,"briefTitle":45297,"status":123,"phases":45298,"primaryCompletion":10499,"completion":10499,"start":15065,"enrollment":31,"conditions":45299,"interventions":45301},"NCT00487708","Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms",[92],[45300],"NALP3 Mutation",[10578],{"nctId":45303,"briefTitle":45304,"status":123,"phases":45305,"primaryCompletion":1724,"completion":1724,"start":4081,"enrollment":5594,"conditions":45306,"interventions":45308},"NCT01088880","Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever",[92],[45307],"Familial Mediterranean Fever",[3157],{"nctId":45310,"briefTitle":45311,"status":390,"phases":45312,"primaryCompletion":25755,"completion":25755,"start":45313,"enrollment":103,"conditions":45314,"interventions":45316},"NCT02980263","Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease",[92],"2016-11-15",[45315],"Kawasaki Disease",[3157],{"nctId":32289,"briefTitle":32290,"status":134,"phases":45318,"primaryCompletion":32292,"completion":32292,"start":32293,"enrollment":496,"conditions":45319,"interventions":45320},[92],[32295],[10578,32264],{"nctId":45322,"briefTitle":45323,"status":123,"phases":45324,"primaryCompletion":1671,"start":4372,"enrollment":2367,"conditions":45325,"interventions":45327},"NCT01148797","Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)",[92],[45326],"Colchicine Resistant\u002FIntolerant Familial Mediterranean Fever",[3157],{"nctId":45329,"briefTitle":45330,"status":123,"phases":45331,"primaryCompletion":1808,"completion":1808,"start":45332,"enrollment":422,"conditions":45333,"interventions":45334},"NCT02756650","1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement",[92],"2016-06-23",[22933],[3157],{"nctId":37530,"briefTitle":37531,"status":123,"phases":45336,"primaryCompletion":4620,"completion":4620,"start":4081,"enrollment":24640,"conditions":45337,"interventions":45338},[92],[19880],[3157,37521],{"nctId":37873,"briefTitle":37874,"status":123,"phases":45340,"primaryCompletion":3845,"completion":3845,"start":3552,"enrollment":677,"conditions":45341,"interventions":45342},[92],[37877],[3157,37864,37879],{"nctId":45344,"briefTitle":45345,"status":134,"phases":45346,"primaryCompletion":45347,"completion":45347,"start":45348,"enrollment":5948,"conditions":45349,"interventions":45351},"NCT01731990","Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease",[92],"2016-08-04","2012-10-30",[45350],"Peripheral Artery Disease",[3157],{"nctId":45353,"briefTitle":45354,"status":123,"phases":45355,"primaryCompletion":3409,"completion":3409,"start":895,"enrollment":1495,"conditions":45356,"interventions":45358},"NCT01303380","Canakinumab in Patients With Active Hyper-IgD Syndrome",[92],[45357],"Mevalonate Kinase Deficiency",[3157],{"nctId":45360,"briefTitle":45361,"status":123,"phases":45362,"primaryCompletion":45363,"completion":45363,"start":45364,"enrollment":1922,"conditions":45365,"interventions":45366},"NCT00927810","Long Term Study of Canakinumab (ACZ885) in Patients With Gout",[92],"2010-08-04","2009-06-05",[25061],[3157],{"nctId":13611,"briefTitle":13612,"status":134,"phases":45368,"primaryCompletion":13614,"completion":13615,"start":10649,"enrollment":534,"conditions":45369,"interventions":45370},[92],[128],[3157,8153],{"nctId":45372,"briefTitle":45373,"status":134,"phases":45374,"primaryCompletion":10923,"completion":10923,"start":45375,"enrollment":31,"conditions":45376,"interventions":45377},"NCT04795466","Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease",[92],"2021-10-28",[14537,14536],[3157],{"trials":45379,"activeCount":103},[45380,45387,45393,45400,45407,45415,45423,45432,45439,45445,45449,45455,45461,45465,45469,45473,45482],{"nctId":45381,"briefTitle":45382,"status":123,"phases":45383,"primaryCompletion":1818,"completion":1818,"start":4845,"enrollment":446,"conditions":45384,"interventions":45386},"NCT00889863","Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)",[93],[45385],"Systemic Juvenile Idiopathic Arthritis With Active Flare",[10578],{"nctId":45388,"briefTitle":45389,"status":123,"phases":45390,"primaryCompletion":1731,"completion":1731,"start":4975,"enrollment":18087,"conditions":45391,"interventions":45392},"NCT00891046","An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.",[93],[23453],[3157],{"nctId":45394,"briefTitle":45395,"status":134,"phases":45396,"primaryCompletion":10750,"completion":12997,"start":2092,"enrollment":45397,"conditions":45398,"interventions":45399},"NCT03447769","Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC\u002FUICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A",[93],1382,[182],[3157],{"nctId":45401,"briefTitle":45402,"status":123,"phases":45403,"primaryCompletion":45404,"completion":32244,"start":2139,"enrollment":1065,"conditions":45405,"interventions":45406},"NCT02396212","Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA",[93],"2017-03-07",[23453],[3157],{"nctId":45408,"briefTitle":45409,"status":123,"phases":45410,"primaryCompletion":45411,"completion":45411,"start":3845,"enrollment":1630,"conditions":45412,"interventions":45414},"NCT01105507","The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada",[93],"2012-05-12",[45413],"Cryopyrin Associated Periodic Syndrome",[10578],{"nctId":45416,"briefTitle":45417,"status":123,"phases":45418,"primaryCompletion":45419,"completion":5573,"start":25396,"enrollment":16997,"conditions":45420,"interventions":45422},"NCT04362813","Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia",[93],"2020-09-16",[45421],"Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia",[3157],{"nctId":45424,"briefTitle":45425,"status":123,"phases":45426,"primaryCompletion":45427,"completion":45427,"start":45428,"enrollment":827,"conditions":45429,"interventions":45431},"NCT02334748","A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies",[93],"2018-08-31","2014-11-03",[23453,45430],"Hereditary Periodic Fevers",[10578],{"nctId":45433,"briefTitle":45434,"status":123,"phases":45435,"primaryCompletion":21716,"completion":21716,"start":2006,"enrollment":1630,"conditions":45436,"interventions":45438},"NCT02911857","An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes",[93],[45437],"Periodic Fevers Syndrome",[3157],{"nctId":45440,"briefTitle":45441,"status":123,"phases":45442,"primaryCompletion":7522,"completion":7522,"start":733,"enrollment":33271,"conditions":45443,"interventions":45444},"NCT02059291","Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers",[93],[45430],[3157],{"nctId":3147,"briefTitle":3148,"status":123,"phases":45446,"primaryCompletion":3150,"completion":3151,"start":3152,"enrollment":3153,"conditions":45447,"interventions":45448},[93],[3155],[3157,3158],{"nctId":45450,"briefTitle":45451,"status":134,"phases":45452,"primaryCompletion":4372,"completion":4598,"start":4845,"enrollment":5982,"conditions":45453,"interventions":45454},"NCT00886769","Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)",[93],[23453],[3157],{"nctId":45456,"briefTitle":45457,"status":123,"phases":45458,"primaryCompletion":1671,"completion":1671,"start":4400,"enrollment":1065,"conditions":45459,"interventions":45460},"NCT00991146","Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase",[93],[23422,13935,23423,23424],[10578],{"nctId":13629,"briefTitle":13630,"status":134,"phases":45462,"primaryCompletion":13632,"completion":13633,"start":13634,"enrollment":13635,"conditions":45463,"interventions":45464},[93],[128],[10578,13581,7871,13638,7872,6342,13639],{"nctId":23449,"briefTitle":23450,"status":390,"phases":45466,"primaryCompletion":10055,"completion":10055,"start":1670,"enrollment":103,"conditions":45467,"interventions":45468},[93],[23453],[10126,3157,3157,3157],{"nctId":8117,"briefTitle":8118,"status":134,"phases":45470,"primaryCompletion":629,"completion":8120,"start":8121,"enrollment":8122,"conditions":45471,"interventions":45472},[93],[8124],[3157,5252],{"nctId":45474,"briefTitle":45475,"status":123,"phases":45476,"primaryCompletion":45477,"completion":45477,"start":45478,"enrollment":814,"conditions":45479,"interventions":45481},"NCT04717635","Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD",[93],"2025-04-16","2021-03-30",[45480],"Adult Onset Still's Disease",[3157],{"nctId":45483,"briefTitle":45484,"status":134,"phases":45485,"primaryCompletion":45486,"completion":45486,"start":45487,"enrollment":1562,"conditions":45488,"interventions":45491},"NCT00770601","Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease",[93],"2011-02-17","2009-01-26",[45489,45490],"NOMID","CINCA Syndrome",[3157],{"trials":45493,"activeCount":103},[],{"trials":45495,"activeCount":103},[45496],{"nctId":45497,"briefTitle":45498,"status":1326,"phases":45499,"conditions":45500,"interventions":45502},"NCT04476706","Canakinumab MAP in COVID-19 Pneumonia With CRS",[],[45501],"Cytokine Release Syndrome in COVID-19-induced Pneumonia",[10578],{"intervention":4460,"totalTrials":7257,"cells":45504},{"EARLY_PHASE1":45505,"PHASE1":45507,"PHASE2":45509,"PHASE3":45515,"PHASE4":45614,"NA":45713},{"trials":45506,"activeCount":103},[],{"trials":45508,"activeCount":103},[],{"trials":45510,"activeCount":103},[45511],{"nctId":4453,"briefTitle":4454,"status":134,"phases":45512,"primaryCompletion":864,"start":3612,"enrollment":1672,"conditions":45513,"interventions":45514},[92],[4457,4458],[196,4460],{"trials":45516,"activeCount":103},[45517,45524,45528,45532,45538,45542,45548,45554,45561,45567,45574,45583,45591,45598,45605],{"nctId":45518,"briefTitle":45519,"status":123,"phases":45520,"primaryCompletion":7837,"completion":7837,"start":26889,"enrollment":18087,"conditions":45521,"interventions":45523},"NCT01908816","An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.",[93],[25050,25288,45522,17729],"Glaucoma, Neovascular",[22015],{"nctId":26944,"briefTitle":26945,"status":123,"phases":45525,"primaryCompletion":3559,"completion":3559,"start":1724,"enrollment":26947,"conditions":45526,"interventions":45527},[93],[20118,25288,17675],[4460,26933],{"nctId":27068,"briefTitle":27069,"status":123,"phases":45529,"primaryCompletion":27071,"completion":27071,"start":27072,"enrollment":15846,"conditions":45530,"interventions":45531},[93],[16741,20118],[4460,27057],{"nctId":45533,"briefTitle":45534,"status":123,"phases":45535,"primaryCompletion":607,"completion":607,"start":2034,"enrollment":846,"conditions":45536,"interventions":45537},"NCT01377597","Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion",[93],[10555],[22015],{"nctId":19204,"briefTitle":19205,"status":123,"phases":45539,"primaryCompletion":3482,"completion":3482,"start":5620,"enrollment":11,"conditions":45540,"interventions":45541},[93],[19208],[4460,17688,19210,19211],{"nctId":45543,"briefTitle":45544,"status":123,"phases":45545,"primaryCompletion":1760,"completion":1760,"start":5733,"enrollment":7042,"conditions":45546,"interventions":45547},"NCT01599650","Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion",[93],[18373],[4460],{"nctId":45549,"briefTitle":45550,"status":123,"phases":45551,"primaryCompletion":4967,"completion":4967,"start":864,"enrollment":180,"conditions":45552,"interventions":45553},"NCT01135914","Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)",[93],[16741],[22015],{"nctId":45555,"briefTitle":45556,"status":123,"phases":45557,"primaryCompletion":2794,"completion":2794,"start":3799,"enrollment":15203,"conditions":45558,"interventions":45560},"NCT01840410","Assess the Efficacy\u002FSafety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.",[93],[45559],"Choroidal Neovascularization (CNV)",[4460],{"nctId":45562,"briefTitle":45563,"status":123,"phases":45564,"primaryCompletion":15283,"completion":15283,"start":7931,"enrollment":12981,"conditions":45565,"interventions":45566},"NCT01171976","Efficacy and Safety of Ranibizumab in Two \"Treat and Extend\" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus",[93],[16741],[4460],{"nctId":45568,"briefTitle":45569,"status":123,"phases":45570,"primaryCompletion":2084,"completion":2084,"start":7509,"enrollment":919,"conditions":45571,"interventions":45573},"NCT02034006","A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.",[93],[45572],"Choroidal Neovascularization Secondary to Pathologic Myopia",[4460],{"nctId":45575,"briefTitle":45576,"status":123,"phases":45577,"primaryCompletion":45578,"completion":45578,"start":45579,"enrollment":45580,"conditions":45581,"interventions":45582},"NCT01780935","Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and\u002For Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration",[93],"2015-07-09","2013-06-03",671,[18365],[4460],{"nctId":45584,"briefTitle":45585,"status":123,"phases":45586,"primaryCompletion":45587,"completion":45587,"start":5172,"enrollment":2981,"conditions":45588,"interventions":45590},"NCT02640664","Rainbow Extension Study",[93],"2022-04-21",[45589],"Retinopathy of Prematurity (ROP)",[4460],{"nctId":45592,"briefTitle":45593,"status":123,"phases":45594,"primaryCompletion":1682,"completion":1682,"start":4620,"enrollment":45595,"conditions":45596,"interventions":45597},"NCT01396057","Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)",[93],244,[20118,25288,18373],[4460],{"nctId":45599,"briefTitle":45600,"status":123,"phases":45601,"primaryCompletion":3861,"completion":3861,"start":813,"enrollment":9558,"conditions":45602,"interventions":45604},"NCT01846299","To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema",[93],[45603],"Macular Edema (ME)",[4460],{"nctId":45606,"briefTitle":45607,"status":123,"phases":45608,"primaryCompletion":45609,"completion":45609,"start":45610,"enrollment":12487,"conditions":45611,"interventions":45613},"NCT02375971","RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity",[93],"2017-12-14","2015-12-30",[45612],"Retinopathy of Prematurity",[4460],{"trials":45615,"activeCount":103},[45616,45620,45629,45636,45643,45650,45656,45665,45671,45682,45688,45692,45699,45706],{"nctId":19219,"briefTitle":19220,"status":123,"phases":45617,"primaryCompletion":7960,"completion":19222,"start":19223,"enrollment":19224,"conditions":45618,"interventions":45619},[94],[4458,19226],[4460,17688,19228],{"nctId":45621,"briefTitle":45622,"status":123,"phases":45623,"primaryCompletion":13727,"completion":13727,"start":45624,"enrollment":45625,"conditions":45626,"interventions":45628},"NCT01972789","Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and\u002For Sub-retinal Fluid >200µm at the Foveal Centre)",[94],"2013-10-31",349,[45627],"Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD",[4460],{"nctId":45630,"briefTitle":45631,"status":123,"phases":45632,"primaryCompletion":10036,"completion":10036,"start":45633,"enrollment":12783,"conditions":45634,"interventions":45635},"NCT02161575","Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD",[94],"2014-08-28",[18365],[4460],{"nctId":45637,"briefTitle":45638,"status":390,"phases":45639,"primaryCompletion":31739,"completion":31739,"start":4514,"enrollment":103,"conditions":45640,"interventions":45642},"NCT02634970","CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab",[94],[45641],"Wet Age-related Macular Degeneration (Wet AMD)",[4460],{"nctId":45644,"briefTitle":45645,"status":123,"phases":45646,"primaryCompletion":11287,"completion":11287,"start":45647,"enrollment":20695,"conditions":45648,"interventions":45649},"NCT01775124","Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)",[94],"2013-02-22",[18365],[4460],{"nctId":45651,"briefTitle":45652,"status":123,"phases":45653,"primaryCompletion":3482,"completion":3482,"start":3760,"enrollment":5054,"conditions":45654,"interventions":45655},"NCT01315275","A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema",[94],[20118,25288],[4460],{"nctId":45657,"briefTitle":45658,"status":123,"phases":45659,"primaryCompletion":4677,"completion":4677,"start":45660,"enrollment":45661,"conditions":45662,"interventions":45664},"NCT01986907","Safety and Tolerability of Ranibizumab in Mono\u002FBilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA\u003C2\u002F10 and\u002For 2nd Affected Eye",[94],"2014-03-04",1049,[45663],"Wet Age Related Macular Degeneration",[22015],{"nctId":45666,"briefTitle":45667,"status":123,"phases":45668,"primaryCompletion":3712,"completion":3712,"start":4598,"enrollment":1562,"conditions":45669,"interventions":45670},"NCT01297569","Ranibizumab \"Treat and Extend\" in Diabetic Macular Edma",[94],[16741],[4460],{"nctId":45672,"briefTitle":45673,"status":123,"phases":45674,"primaryCompletion":45675,"completion":45676,"start":45677,"enrollment":45678,"conditions":45679,"interventions":45680},"NCT01958918","Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD",[94],"2016-11-22","2017-05-29","2013-10-23",712,[18365],[4460,45681],"Aflibercept",{"nctId":45683,"briefTitle":45684,"status":390,"phases":45685,"primaryCompletion":32604,"completion":32604,"start":1681,"enrollment":103,"conditions":45686,"interventions":45687},"NCT02258009","Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema",[94],[17658],[4460,45681],{"nctId":22008,"briefTitle":22009,"status":123,"phases":45689,"primaryCompletion":22011,"completion":22011,"start":22012,"enrollment":138,"conditions":45690,"interventions":45691},[94],[4458],[22015,21995],{"nctId":45693,"briefTitle":45694,"status":123,"phases":45695,"primaryCompletion":2885,"completion":2885,"start":10114,"enrollment":3322,"conditions":45696,"interventions":45698},"NCT02953938","Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety",[94],[45697],"Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)",[4460],{"nctId":45700,"briefTitle":45701,"status":123,"phases":45702,"primaryCompletion":15283,"completion":15283,"start":4598,"enrollment":2810,"conditions":45703,"interventions":45705},"NCT01257815","Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment",[94],[17729,45704],"Macular Oedema",[4460],{"nctId":45707,"briefTitle":45708,"status":390,"phases":45709,"primaryCompletion":23097,"completion":23097,"start":45710,"enrollment":103,"conditions":45711,"interventions":45712},"NCT02878681","24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.",[94],"2016-09",[17658],[4460,45681],{"trials":45714,"activeCount":103},[45715,45725],{"nctId":45716,"briefTitle":45717,"status":123,"phases":45718,"primaryCompletion":45719,"completion":45719,"start":3541,"enrollment":45720,"conditions":45721,"interventions":45722},"NCT04662944","A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections",[],"2023-06-28",494,[18348],[45723,22015,45724],"brolucizumab","aflibercept",{"nctId":45726,"briefTitle":45727,"status":123,"phases":45728,"primaryCompletion":1780,"completion":1780,"start":895,"enrollment":45729,"conditions":45730,"interventions":45732},"NCT01318941","Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting",[],30490,[45731,45663,16741,10555],"Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion",[4460],{"intervention":15788,"totalTrials":837,"cells":45734},{"EARLY_PHASE1":45735,"PHASE1":45737,"PHASE2":45739,"PHASE3":45749,"PHASE4":45782,"NA":45796},{"trials":45736,"activeCount":103},[],{"trials":45738,"activeCount":103},[],{"trials":45740,"activeCount":103},[45741,45745],{"nctId":16987,"briefTitle":16988,"status":123,"phases":45742,"primaryCompletion":4410,"completion":4410,"start":813,"enrollment":4992,"conditions":45743,"interventions":45744},[92],[21],[15788,16992,15884],{"nctId":36300,"briefTitle":36301,"status":134,"phases":45746,"primaryCompletion":36303,"completion":36303,"start":34043,"enrollment":2948,"conditions":45747,"interventions":45748},[92],[15870],[36291,36306,36307,17350],{"trials":45750,"activeCount":103},[45751,45755,45764,45768,45774],{"nctId":15779,"briefTitle":15780,"status":123,"phases":45752,"primaryCompletion":15782,"completion":15782,"start":15783,"enrollment":15784,"conditions":45753,"interventions":45754},[93],[15786],[15788,15789,5447],{"nctId":45756,"briefTitle":45757,"status":390,"phases":45758,"primaryCompletion":45759,"completion":45759,"start":45760,"enrollment":103,"conditions":45761,"interventions":45763},"NCT04637555","Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)",[93],"2023-06-01","2021-05-26",[45762],"Post Myocardial Infarction",[15788],{"nctId":15813,"briefTitle":15814,"status":123,"phases":45765,"primaryCompletion":10618,"completion":10618,"start":15816,"enrollment":15817,"conditions":45766,"interventions":45767},[93],[15819],[15788,15821],{"nctId":45769,"briefTitle":45770,"status":123,"phases":45771,"primaryCompletion":9439,"completion":9439,"start":3001,"enrollment":422,"conditions":45772,"interventions":45773},"NCT06149104","A Safety Study of Sacubitril\u002FValsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study",[93],[15870],[15788],{"nctId":45775,"briefTitle":45776,"status":123,"phases":45777,"primaryCompletion":45778,"completion":45778,"start":45779,"enrollment":19146,"conditions":45780,"interventions":45781},"NCT03785405","Open-label Extension Study to Evaluate Long-term Safety of Sacubitril\u002FValsartan in Pediatric Patients With HF",[93],"2023-12-29","2019-05-02",[15870],[15788],{"trials":45783,"activeCount":103},[45784,45788,45792],{"nctId":17333,"briefTitle":17334,"status":123,"phases":45785,"primaryCompletion":17336,"completion":17336,"start":17337,"enrollment":3087,"conditions":45786,"interventions":45787},[94],[17339],[15788,17341],{"nctId":17343,"briefTitle":17344,"status":123,"phases":45789,"primaryCompletion":17346,"completion":6099,"start":3063,"enrollment":17347,"conditions":45790,"interventions":45791},[94],[12246,15870],[17350,15789],{"nctId":17371,"briefTitle":17372,"status":123,"phases":45793,"primaryCompletion":17374,"completion":2425,"start":1848,"enrollment":17375,"conditions":45794,"interventions":45795},[94],[17377],[15788,15789],{"trials":45797,"activeCount":103},[45798,45807,45817,45826,45835,45844,45853],{"nctId":45799,"briefTitle":45800,"status":123,"phases":45801,"primaryCompletion":45802,"completion":45802,"start":45803,"enrollment":5338,"conditions":45804,"interventions":45805},"NCT03387163","Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril\u002FValsartan) in Heart Failure",[],"2019-06-21","2018-02-09",[17279],[45806],"Sacubitril\u002FValsartan",{"nctId":45808,"briefTitle":45809,"status":123,"phases":45810,"primaryCompletion":45811,"completion":45811,"start":45812,"enrollment":45813,"conditions":45814,"interventions":45815},"NCT05096039","Role of Sacubitril\u002FValsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models",[],"2020-09-30","2020-04-10",1614719,[15870],[17350,45816],"ACEI or ARB and no sacubitril\u002Fvalsartan",{"nctId":45818,"briefTitle":45819,"status":123,"phases":45820,"primaryCompletion":45821,"completion":45821,"start":45822,"enrollment":45823,"conditions":45824,"interventions":45825},"NCT02957409","PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada",[],"2020-10-24","2016-05-20",1009,[15870],[15788],{"nctId":45827,"briefTitle":45828,"status":123,"phases":45829,"primaryCompletion":45830,"completion":45830,"start":45831,"enrollment":45832,"conditions":45833,"interventions":45834},"NCT05613140","Sacubitril\u002FValsartan Treated Adult Patients With Chronic Heart Failure",[],"2021-11-05","2021-08-02",9230,[15734],[15788],{"nctId":45836,"briefTitle":45837,"status":123,"phases":45838,"primaryCompletion":45839,"completion":45839,"start":45840,"enrollment":45841,"conditions":45842,"interventions":45843},"NCT04735354","Sacubitril\u002FValsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India",[],"2022-06-01","2020-10-27",268,[15870],[15788],{"nctId":45845,"briefTitle":45846,"status":123,"phases":45847,"primaryCompletion":2809,"completion":2809,"start":45848,"enrollment":45849,"conditions":45850,"interventions":45851},"NCT05096143","A Cohort Study to Compare the Hospitalization Between Naive Sacubitril\u002FValsartan and Naive ACEi\u002FARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data",[],"2020-06-03",42269,[15870],[17350,45852],"ACEi\u002FARB",{"nctId":45854,"briefTitle":45855,"status":123,"phases":45856,"primaryCompletion":45857,"completion":45857,"start":45858,"enrollment":45859,"conditions":45860,"interventions":45861},"NCT05448872","Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc\u002FvaL.",[],"2021-09-15","2020-11-23",924,[15870],[45806],{"intervention":45863,"totalTrials":837,"cells":45864},"Brolucizumab",{"EARLY_PHASE1":45865,"PHASE1":45867,"PHASE2":45869,"PHASE3":45871,"PHASE4":45935,"NA":45959},{"trials":45866,"activeCount":103},[],{"trials":45868,"activeCount":103},[],{"trials":45870,"activeCount":103},[],{"trials":45872,"activeCount":103},[45873,45881,45889,45897,45905,45914,45921,45929],{"nctId":45874,"briefTitle":45875,"status":123,"phases":45876,"primaryCompletion":13006,"completion":44384,"start":45877,"enrollment":45878,"conditions":45879,"interventions":45880},"NCT03481634","Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema",[93],"2018-07-23",566,[16741],[45863,45681],{"nctId":45882,"briefTitle":45883,"status":123,"phases":45884,"primaryCompletion":45885,"completion":45885,"start":45886,"enrollment":17046,"conditions":45887,"interventions":45888},"NCT04058067","To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema",[93],"2023-01-31","2019-08-23",[16741],[45863,45681],{"nctId":45890,"briefTitle":45891,"status":134,"phases":45892,"primaryCompletion":1931,"completion":7982,"start":45893,"enrollment":45894,"conditions":45895,"interventions":45896},"NCT03710564","Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections",[93],"2018-10-30",535,[5961],[45863,45681],{"nctId":45898,"briefTitle":45899,"status":390,"phases":45900,"primaryCompletion":45885,"completion":45885,"start":45901,"enrollment":103,"conditions":45902,"interventions":45904},"NCT04079231","Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema",[93],"2021-02-01",[45903],"Diabetic Macula Edema",[45863,45681],{"nctId":45906,"briefTitle":45907,"status":390,"phases":45908,"primaryCompletion":45909,"completion":45910,"start":10711,"enrollment":103,"conditions":45911,"interventions":45913},"NCT04697953","Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)",[93],"2021-06-21","2025-05-31",[45912],"Age-related Macular Degeneration (AMD)",[45723],{"nctId":45915,"briefTitle":45916,"status":123,"phases":45917,"primaryCompletion":2258,"completion":2258,"start":45918,"enrollment":3475,"conditions":45919,"interventions":45920},"NCT04597632","An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study",[93],"2020-12-16",[18365],[45723],{"nctId":45922,"briefTitle":45923,"status":123,"phases":45924,"primaryCompletion":45925,"completion":11434,"start":45926,"enrollment":8498,"conditions":45927,"interventions":45928},"NCT03481660","A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema",[93],"2020-06-29","2018-07-27",[16741],[45863,45681],{"nctId":45930,"briefTitle":45931,"status":123,"phases":45932,"primaryCompletion":18043,"completion":18043,"start":37046,"enrollment":18291,"conditions":45933,"interventions":45934},"NCT03917472","Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema",[93],[16741],[45863,45681],{"trials":45936,"activeCount":103},[45937,45945,45951],{"nctId":45938,"briefTitle":45939,"status":123,"phases":45940,"primaryCompletion":45941,"completion":45941,"start":45942,"enrollment":3605,"conditions":45943,"interventions":45944},"NCT04679935","Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration",[94],"2024-01-31","2021-07-13",[4458],[45863],{"nctId":45946,"briefTitle":45947,"status":123,"phases":45948,"primaryCompletion":392,"completion":392,"start":1910,"enrollment":11068,"conditions":45949,"interventions":45950},"NCT05959304","Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.",[94],[16741],[45723],{"nctId":45952,"briefTitle":45953,"status":123,"phases":45954,"primaryCompletion":45955,"completion":45955,"start":45956,"enrollment":203,"conditions":45957,"interventions":45958},"NCT04774926","Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.",[94],"2023-10-04","2021-10-15",[18365],[45863],{"trials":45960,"activeCount":103},[45961,45965,45974,45982,45989,45997],{"nctId":45716,"briefTitle":45717,"status":123,"phases":45962,"primaryCompletion":45719,"completion":45719,"start":3541,"enrollment":45720,"conditions":45963,"interventions":45964},[],[18348],[45723,22015,45724],{"nctId":45966,"briefTitle":45967,"status":123,"phases":45968,"primaryCompletion":45969,"completion":45969,"start":45970,"enrollment":45971,"conditions":45972,"interventions":45973},"NCT05037396","Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab",[],"2020-08-01","2020-03-05",9457,[45912],[45863],{"nctId":45975,"briefTitle":45976,"status":123,"phases":45977,"primaryCompletion":9647,"completion":9647,"start":45978,"enrollment":45979,"conditions":45980,"interventions":45981},"NCT05111743","Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)",[],"2020-06-17",9261,[45912],[45863],{"nctId":45983,"briefTitle":45984,"status":134,"phases":45985,"primaryCompletion":45986,"completion":45986,"start":30140,"enrollment":13149,"conditions":45987,"interventions":45988},"NCT04764656","Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal",[],"2024-02-16",[20674],[45863],{"nctId":45990,"briefTitle":45991,"status":123,"phases":45992,"primaryCompletion":45993,"completion":45993,"start":45848,"enrollment":45994,"conditions":45995,"interventions":45996},"NCT05082415","Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)",[],"2020-12-15",9456,[45912],[45863],{"nctId":45998,"briefTitle":45999,"status":123,"phases":46000,"primaryCompletion":392,"completion":392,"start":46001,"enrollment":657,"conditions":46002,"interventions":46004},"NCT04543331","Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema",[],"2020-11-05",[20674,46003],"Diabetic Macular Edema (DME)",[45723],{"intervention":9191,"totalTrials":5594,"cells":46006},{"EARLY_PHASE1":46007,"PHASE1":46009,"PHASE2":46019,"PHASE3":46035,"PHASE4":46077,"NA":46079},{"trials":46008,"activeCount":103},[],{"trials":46010,"activeCount":103},[46011],{"nctId":46012,"briefTitle":46013,"status":134,"phases":46014,"primaryCompletion":2184,"completion":2184,"start":29704,"enrollment":4148,"conditions":46015,"interventions":46018},"NCT04513548","Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria",[91],[33,46016,46017],"Cholinergic Urticaria","Cold Urticaria",[9191],{"trials":46020,"activeCount":103},[46021,46028],{"nctId":46022,"briefTitle":46023,"status":123,"phases":46024,"primaryCompletion":46025,"completion":2302,"start":32244,"enrollment":1622,"conditions":46026,"interventions":46027},"NCT03437278","Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)",[92],"2020-10-23",[33],[9191],{"nctId":46029,"briefTitle":46030,"status":123,"phases":46031,"primaryCompletion":45779,"completion":45779,"start":46032,"enrollment":1879,"conditions":46033,"interventions":46034},"NCT02649218","A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients",[92],"2016-05-24",[33],[9191],{"trials":46036,"activeCount":103},[46037,46043,46052,46060,46064,46073],{"nctId":46038,"briefTitle":46039,"status":134,"phases":46040,"primaryCompletion":708,"completion":708,"start":38083,"enrollment":28,"conditions":46041,"interventions":46042},"NCT05024058","Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines",[93],[6167],[9191],{"nctId":46044,"briefTitle":46045,"status":134,"phases":46046,"primaryCompletion":46047,"completion":46047,"start":46048,"enrollment":46049,"conditions":46050,"interventions":46051},"NCT04210843","Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab",[93],"2022-09-01","2020-04-08",1033,[33],[9191],{"nctId":46053,"briefTitle":46054,"status":123,"phases":46055,"primaryCompletion":46056,"completion":46056,"start":46057,"enrollment":11068,"conditions":46058,"interventions":46059},"NCT03907878","A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines",[93],"2022-01-26","2019-04-13",[33],[9191],{"nctId":9183,"briefTitle":9184,"status":123,"phases":46061,"primaryCompletion":7457,"completion":9186,"start":9187,"enrollment":9188,"conditions":46062,"interventions":46063},[93],[33],[9191,6218],{"nctId":46065,"briefTitle":46066,"status":134,"phases":46067,"primaryCompletion":46068,"completion":46068,"start":46069,"enrollment":16124,"conditions":46070,"interventions":46071},"NCT04984876","Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy",[93],"2023-11-27","2021-12-07",[6136],[46072],"ligelizumab",{"nctId":9193,"briefTitle":9194,"status":123,"phases":46074,"primaryCompletion":6759,"completion":9186,"start":9154,"enrollment":9196,"conditions":46075,"interventions":46076},[93],[33],[9191,6218],{"trials":46078,"activeCount":103},[],{"trials":46080,"activeCount":103},[46081],{"nctId":46082,"briefTitle":46083,"status":1326,"phases":46084,"conditions":46085,"interventions":46086},"NCT04903613","Global Managed Access Program Cohort for Ligelizumab in CSU",[],[33],[9191],{"intervention":45681,"totalTrials":5594,"cells":46088},{"EARLY_PHASE1":46089,"PHASE1":46091,"PHASE2":46093,"PHASE3":46095,"PHASE4":46121,"NA":46135},{"trials":46090,"activeCount":103},[],{"trials":46092,"activeCount":103},[],{"trials":46094,"activeCount":103},[],{"trials":46096,"activeCount":103},[46097,46101,46105,46109,46113,46117],{"nctId":45874,"briefTitle":45875,"status":123,"phases":46098,"primaryCompletion":13006,"completion":44384,"start":45877,"enrollment":45878,"conditions":46099,"interventions":46100},[93],[16741],[45863,45681],{"nctId":45882,"briefTitle":45883,"status":123,"phases":46102,"primaryCompletion":45885,"completion":45885,"start":45886,"enrollment":17046,"conditions":46103,"interventions":46104},[93],[16741],[45863,45681],{"nctId":45890,"briefTitle":45891,"status":134,"phases":46106,"primaryCompletion":1931,"completion":7982,"start":45893,"enrollment":45894,"conditions":46107,"interventions":46108},[93],[5961],[45863,45681],{"nctId":45898,"briefTitle":45899,"status":390,"phases":46110,"primaryCompletion":45885,"completion":45885,"start":45901,"enrollment":103,"conditions":46111,"interventions":46112},[93],[45903],[45863,45681],{"nctId":45922,"briefTitle":45923,"status":123,"phases":46114,"primaryCompletion":45925,"completion":11434,"start":45926,"enrollment":8498,"conditions":46115,"interventions":46116},[93],[16741],[45863,45681],{"nctId":45930,"briefTitle":45931,"status":123,"phases":46118,"primaryCompletion":18043,"completion":18043,"start":37046,"enrollment":18291,"conditions":46119,"interventions":46120},[93],[16741],[45863,45681],{"trials":46122,"activeCount":103},[46123,46127,46131],{"nctId":45672,"briefTitle":45673,"status":123,"phases":46124,"primaryCompletion":45675,"completion":45676,"start":45677,"enrollment":45678,"conditions":46125,"interventions":46126},[94],[18365],[4460,45681],{"nctId":45683,"briefTitle":45684,"status":390,"phases":46128,"primaryCompletion":32604,"completion":32604,"start":1681,"enrollment":103,"conditions":46129,"interventions":46130},[94],[17658],[4460,45681],{"nctId":45707,"briefTitle":45708,"status":390,"phases":46132,"primaryCompletion":23097,"completion":23097,"start":45710,"enrollment":103,"conditions":46133,"interventions":46134},[94],[17658],[4460,45681],{"trials":46136,"activeCount":103},[46137],{"nctId":45716,"briefTitle":45717,"status":123,"phases":46138,"primaryCompletion":45719,"completion":45719,"start":3541,"enrollment":45720,"conditions":46139,"interventions":46140},[],[18348],[45723,22015,45724],{"intervention":11072,"totalTrials":5594,"cells":46142},{"EARLY_PHASE1":46143,"PHASE1":46145,"PHASE2":46172,"PHASE3":46206,"PHASE4":46208,"NA":46210},{"trials":46144,"activeCount":103},[],{"trials":46146,"activeCount":103},[46147,46155,46159,46165],{"nctId":46148,"briefTitle":46149,"status":123,"phases":46150,"primaryCompletion":25712,"completion":25712,"start":46151,"enrollment":8347,"conditions":46152,"interventions":46154},"NCT01283516","A Dose Escalation\u002FExpansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase",[91],"2011-01-24",[46153],"Tumors Characterized by Genetic Abnormalities of ALK",[11072],{"nctId":31782,"briefTitle":31783,"status":123,"phases":46156,"primaryCompletion":9061,"completion":9061,"start":1682,"enrollment":2633,"conditions":46157,"interventions":46158},[91],[31786,128],[11072,7913],{"nctId":46160,"briefTitle":46161,"status":123,"phases":46162,"primaryCompletion":45710,"completion":45710,"start":3559,"enrollment":792,"conditions":46163,"interventions":46164},"NCT01950481","Effect of Hepatic Impairment on LDK378 Pharmacokinetics",[91],[10048,10049],[11072],{"nctId":46166,"briefTitle":46167,"status":123,"phases":46168,"primaryCompletion":9061,"completion":9061,"start":4524,"enrollment":2633,"conditions":46169,"interventions":46171},"NCT01634763","Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)",[91],[46170],"Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)",[11072],{"trials":46173,"activeCount":103},[46174,46181,46187,46194,46202],{"nctId":46175,"briefTitle":46176,"status":123,"phases":46177,"primaryCompletion":36036,"completion":36036,"start":46178,"enrollment":12783,"conditions":46179,"interventions":46180},"NCT02040870","LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib",[91,92],"2014-03-07",[182],[11072],{"nctId":46182,"briefTitle":46183,"status":123,"phases":46184,"primaryCompletion":6494,"completion":6494,"start":3297,"enrollment":3288,"conditions":46185,"interventions":46186},"NCT01685138","LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer",[92],[182],[11072],{"nctId":46188,"briefTitle":46189,"status":123,"phases":46190,"primaryCompletion":46191,"completion":46191,"start":17879,"enrollment":3087,"conditions":46192,"interventions":46193},"NCT01685060","LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib",[92],"2016-03-29",[182],[11072],{"nctId":46195,"briefTitle":46196,"status":123,"phases":46197,"primaryCompletion":11155,"completion":46198,"start":46199,"enrollment":1611,"conditions":46200,"interventions":46201},"NCT02450903","LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.",[92],"2018-05-24","2015-08-21",[1178],[11072],{"nctId":11063,"briefTitle":11064,"status":123,"phases":46203,"primaryCompletion":11066,"completion":11066,"start":11067,"enrollment":11068,"conditions":46204,"interventions":46205},[92],[11070],[516,159,11072,11073],{"trials":46207,"activeCount":103},[],{"trials":46209,"activeCount":103},[],{"trials":46211,"activeCount":103},[46212],{"nctId":46213,"briefTitle":46214,"status":1326,"phases":46215,"conditions":46216,"interventions":46217},"NCT01947608","Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC",[],[5282],[11072],{"intervention":24630,"totalTrials":5594,"cells":46219},{"EARLY_PHASE1":46220,"PHASE1":46222,"PHASE2":46237,"PHASE3":46260,"PHASE4":46288,"NA":46290},{"trials":46221,"activeCount":103},[],{"trials":46223,"activeCount":103},[46224,46228],{"nctId":42684,"briefTitle":42685,"status":123,"phases":46225,"primaryCompletion":6526,"completion":6526,"start":42687,"enrollment":25,"conditions":46226,"interventions":46227},[91],[13284],[24630,42677],{"nctId":46229,"briefTitle":46230,"status":123,"phases":46231,"primaryCompletion":46232,"completion":46233,"start":46234,"enrollment":3120,"conditions":46235,"interventions":46236},"NCT00387205","Study To Assess Long Term Safety Of Pazopanib",[91],"2013-02-13","2018-03-08","2006-06-20",[13284],[24630],{"trials":46238,"activeCount":103},[46239,46248,46252],{"nctId":46240,"briefTitle":46241,"status":123,"phases":46242,"primaryCompletion":46243,"completion":46243,"start":46244,"enrollment":2149,"conditions":46245,"interventions":46247},"NCT03200717","Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and\u002For Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment",[92],"2021-08-10","2017-11-14",[46246,4352],"Advanced Renal Cell Carcinoma",[24630],{"nctId":24622,"briefTitle":24623,"status":123,"phases":46249,"primaryCompletion":5123,"completion":24625,"start":24626,"enrollment":24627,"conditions":46250,"interventions":46251},[92],[13284],[24630,24631],{"nctId":46253,"briefTitle":46254,"status":123,"phases":46255,"primaryCompletion":10649,"completion":10649,"start":46256,"enrollment":3530,"conditions":46257,"interventions":46259},"NCT01956669","Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors",[92],"2014-10-08",[46258],"Solid Tumours",[24630],{"trials":46261,"activeCount":103},[46262,46272,46276,46284],{"nctId":46263,"briefTitle":46264,"status":123,"phases":46265,"primaryCompletion":46266,"completion":46267,"start":46268,"enrollment":46269,"conditions":46270,"interventions":46271},"NCT01235962","A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)",[93],"2015-10-15","2019-04-15","2010-11-30",1538,[32389,1102],[24643,24643],{"nctId":24635,"briefTitle":24636,"status":123,"phases":46273,"primaryCompletion":24638,"completion":11287,"start":24639,"enrollment":24640,"conditions":46274,"interventions":46275},[93],[13284],[24643,4405],{"nctId":46277,"briefTitle":46278,"status":123,"phases":46279,"primaryCompletion":46280,"completion":13087,"start":46281,"enrollment":3166,"conditions":46282,"interventions":46283},"NCT00866697","Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[93],"2012-07-08","2009-05-26",[6375],[24630],{"nctId":24645,"briefTitle":24646,"status":123,"phases":46285,"primaryCompletion":5123,"completion":18043,"start":24648,"enrollment":24649,"conditions":46286,"interventions":46287},[93],[13284],[24630,24631],{"trials":46289,"activeCount":103},[],{"trials":46291,"activeCount":103},[46292],{"nctId":46293,"briefTitle":46294,"status":123,"phases":46295,"primaryCompletion":46296,"completion":46296,"start":46297,"enrollment":46298,"conditions":46299,"interventions":46300},"NCT01649778","Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma",[],"2017-07-03","2012-07-19",662,[13284],[24630],{"intervention":4753,"totalTrials":1630,"cells":46302},{"EARLY_PHASE1":46303,"PHASE1":46305,"PHASE2":46307,"PHASE3":46309,"PHASE4":46325,"NA":46327},{"trials":46304,"activeCount":103},[],{"trials":46306,"activeCount":103},[],{"trials":46308,"activeCount":103},[],{"trials":46310,"activeCount":103},[46311,46315,46321],{"nctId":7659,"briefTitle":7660,"status":123,"phases":46312,"primaryCompletion":4524,"completion":4524,"start":4975,"enrollment":524,"conditions":46313,"interventions":46314},[93],[7663],[7636,7665,4753,4755,4769],{"nctId":46316,"briefTitle":46317,"status":123,"phases":46318,"primaryCompletion":3255,"completion":3255,"start":1015,"enrollment":31106,"conditions":46319,"interventions":46320},"NCT00101738","Freedom Study: Myfortic in Kidney Transplant Patients",[93],[4691],[4753],{"nctId":4747,"briefTitle":4748,"status":123,"phases":46322,"primaryCompletion":4410,"completion":4410,"start":4317,"enrollment":4750,"conditions":46323,"interventions":46324},[93],[4691],[196,4753,4754,4755],{"trials":46326,"activeCount":103},[],{"trials":46328,"activeCount":103},[46329],{"nctId":46330,"briefTitle":46331,"status":123,"phases":46332,"primaryCompletion":3000,"completion":3000,"start":46333,"enrollment":774,"conditions":46334,"interventions":46335},"NCT04645589","Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis",[],"2021-03-16",[1800],[4753],{"intervention":46337,"totalTrials":1630,"cells":46338},"AMN107",{"EARLY_PHASE1":46339,"PHASE1":46341,"PHASE2":46343,"PHASE3":46351,"PHASE4":46359,"NA":46368},{"trials":46340,"activeCount":103},[],{"trials":46342,"activeCount":103},[],{"trials":46344,"activeCount":103},[46345],{"nctId":46346,"briefTitle":46347,"status":123,"phases":46348,"primaryCompletion":2033,"completion":2033,"start":3279,"enrollment":906,"conditions":46349,"interventions":46350},"NCT00718562","Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib",[92],[208],[46337],{"trials":46352,"activeCount":103},[46353],{"nctId":46354,"briefTitle":46355,"status":123,"phases":46356,"primaryCompletion":3490,"completion":4505,"start":8091,"enrollment":792,"conditions":46357,"interventions":46358},"NCT00264160","Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and\u002For Intolerant to Imatinib Mesylate Therapy",[92,93],[31221],[46337],{"trials":46360,"activeCount":103},[46361],{"nctId":46362,"briefTitle":46363,"status":390,"phases":46364,"primaryCompletion":46365,"completion":46365,"start":1723,"enrollment":103,"conditions":46366,"interventions":46367},"NCT01605981","Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.",[94],"2017-01",[12513],[46337],{"trials":46369,"activeCount":103},[46370],{"nctId":46371,"briefTitle":46372,"status":1326,"phases":46373,"primaryCompletion":3490,"start":4621,"conditions":46374,"interventions":46375},"NCT00302016","Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia",[],[2393],[46337],{"intervention":1330,"totalTrials":213,"cells":46377},{"EARLY_PHASE1":46378,"PHASE1":46380,"PHASE2":46382,"PHASE3":46384,"PHASE4":46386,"NA":46388},{"trials":46379,"activeCount":103},[],{"trials":46381,"activeCount":103},[],{"trials":46383,"activeCount":103},[],{"trials":46385,"activeCount":103},[],{"trials":46387,"activeCount":103},[],{"trials":46389,"activeCount":103},[46390,46394],{"nctId":1324,"briefTitle":1325,"status":1326,"phases":46391,"conditions":46392,"interventions":46393},[],[36],[1330,1078,173],{"nctId":1332,"briefTitle":1333,"status":1326,"phases":46395,"conditions":46396,"interventions":46397},[],[36,1336],[1330,1078,173],{"intervention":46399,"totalTrials":213,"cells":46400},"dabrafenib + trametinib",{"EARLY_PHASE1":46401,"PHASE1":46403,"PHASE2":46405,"PHASE3":46407,"PHASE4":46409,"NA":46411},{"trials":46402,"activeCount":103},[],{"trials":46404,"activeCount":103},[],{"trials":46406,"activeCount":103},[],{"trials":46408,"activeCount":103},[],{"trials":46410,"activeCount":103},[],{"trials":46412,"activeCount":103},[46413,46420],{"nctId":46414,"briefTitle":46415,"status":123,"phases":46416,"primaryCompletion":46417,"completion":46417,"start":45956,"enrollment":317,"conditions":46418,"interventions":46419},"NCT04547946","Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)",[],"2022-06-07",[1292],[46399],{"nctId":13659,"briefTitle":13660,"status":123,"phases":46421,"primaryCompletion":6327,"completion":6327,"start":13662,"enrollment":13663,"conditions":46422,"interventions":46423},[],[36],[5187,13666,8153,13667],{"intervention":46425,"totalTrials":213,"cells":46426},"Entresto",{"EARLY_PHASE1":46427,"PHASE1":46429,"PHASE2":46431,"PHASE3":46433,"PHASE4":46435,"NA":46437},{"trials":46428,"activeCount":103},[],{"trials":46430,"activeCount":103},[],{"trials":46432,"activeCount":103},[],{"trials":46434,"activeCount":103},[],{"trials":46436,"activeCount":103},[],{"trials":46438,"activeCount":103},[46439,46447],{"nctId":46440,"briefTitle":46441,"status":123,"phases":46442,"primaryCompletion":5902,"completion":5902,"start":46443,"enrollment":46444,"conditions":46445,"interventions":46446},"NCT04781881","Special Drug Use Surveillance for Entresto Tablets",[],"2021-03-04",688,[15734],[46425],{"nctId":46448,"briefTitle":46449,"status":123,"phases":46450,"primaryCompletion":32302,"completion":32302,"start":46451,"enrollment":46452,"conditions":46453,"interventions":46454},"NCT05976230","Special Drug Use Surveillance of Entresto Tablets (Hypertension)",[],"2023-09-04",1125,[21],[46425],{"intervention":20909,"totalTrials":213,"cells":46456},{"EARLY_PHASE1":46457,"PHASE1":46459,"PHASE2":46461,"PHASE3":46463,"PHASE4":46465,"NA":46471},{"trials":46458,"activeCount":103},[],{"trials":46460,"activeCount":103},[],{"trials":46462,"activeCount":103},[],{"trials":46464,"activeCount":103},[],{"trials":46466,"activeCount":103},[46467],{"nctId":20903,"briefTitle":20904,"status":134,"phases":46468,"primaryCompletion":20906,"completion":20906,"start":13006,"enrollment":17367,"conditions":46469,"interventions":46470},[94],[15870],[20909,20890],{"trials":46472,"activeCount":103},[46473],{"nctId":45845,"briefTitle":45846,"status":123,"phases":46474,"primaryCompletion":2809,"completion":2809,"start":45848,"enrollment":45849,"conditions":46475,"interventions":46476},[],[15870],[17350,45852],{"intervention":46478,"totalTrials":213,"cells":46479},"Tobramycin solution for inhalation",{"EARLY_PHASE1":46480,"PHASE1":46482,"PHASE2":46484,"PHASE3":46486,"PHASE4":46492,"NA":46494},{"trials":46481,"activeCount":103},[],{"trials":46483,"activeCount":103},[],{"trials":46485,"activeCount":103},[],{"trials":46487,"activeCount":103},[46488],{"nctId":18288,"briefTitle":18289,"status":123,"phases":46489,"primaryCompletion":3400,"completion":3400,"start":966,"enrollment":18291,"conditions":46490,"interventions":46491},[93],[9233],[18261,18294],{"trials":46493,"activeCount":103},[],{"trials":46495,"activeCount":103},[46496],{"nctId":46497,"briefTitle":46498,"status":123,"phases":46499,"primaryCompletion":5620,"start":4081,"conditions":46500,"interventions":46501},"NCT01460836","Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis",[],[9233],[46478,46502],"Aztreonam lysine for inhalation",{"intervention":46504,"totalTrials":213,"cells":46505},"Gleevec",{"EARLY_PHASE1":46506,"PHASE1":46508,"PHASE2":46510,"PHASE3":46512,"PHASE4":46514,"NA":46522},{"trials":46507,"activeCount":103},[],{"trials":46509,"activeCount":103},[],{"trials":46511,"activeCount":103},[],{"trials":46513,"activeCount":103},[],{"trials":46515,"activeCount":103},[46516],{"nctId":46517,"briefTitle":46518,"status":123,"phases":46519,"completion":3474,"start":4540,"enrollment":1034,"conditions":46520,"interventions":46521},"NCT00081926","Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",[94],[3228],[46504],{"trials":46523,"activeCount":103},[46524],{"nctId":46525,"briefTitle":46526,"status":123,"phases":46527,"primaryCompletion":2509,"completion":2509,"start":4598,"enrollment":1630,"conditions":46528,"interventions":46530},"NCT01289054","A Global Imatinib and Nilotinib Pregnancy Exposure Registry",[],[46529],"All Indications for Glivec\u002FGleevec and Tasigna",[46531,46504],"Tasigna",{"intervention":46531,"totalTrials":213,"cells":46533},{"EARLY_PHASE1":46534,"PHASE1":46536,"PHASE2":46544,"PHASE3":46546,"PHASE4":46548,"NA":46550},{"trials":46535,"activeCount":103},[],{"trials":46537,"activeCount":103},[46538],{"nctId":46539,"briefTitle":46540,"status":123,"phases":46541,"primaryCompletion":1714,"completion":1714,"start":3351,"enrollment":1065,"conditions":46542,"interventions":46543},"NCT01223898","To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib",[91],[2393],[46531],{"trials":46545,"activeCount":103},[],{"trials":46547,"activeCount":103},[],{"trials":46549,"activeCount":103},[],{"trials":46551,"activeCount":103},[46552],{"nctId":46525,"briefTitle":46526,"status":123,"phases":46553,"primaryCompletion":2509,"completion":2509,"start":4598,"enrollment":1630,"conditions":46554,"interventions":46555},[],[46529],[46531,46504],{"intervention":459,"totalTrials":213,"cells":46557},{"EARLY_PHASE1":46558,"PHASE1":46560,"PHASE2":46562,"PHASE3":46564,"PHASE4":46566,"NA":46568},{"trials":46559,"activeCount":103},[],{"trials":46561,"activeCount":103},[],{"trials":46563,"activeCount":103},[],{"trials":46565,"activeCount":103},[],{"trials":46567,"activeCount":103},[],{"trials":46569,"activeCount":103},[46570,46574],{"nctId":451,"briefTitle":452,"status":123,"phases":46571,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":46572,"interventions":46573},[],[435],[98,459,460],{"nctId":46575,"briefTitle":46576,"status":123,"phases":46577,"primaryCompletion":46578,"completion":46578,"start":46579,"enrollment":46580,"conditions":46581,"interventions":46582},"NCT05141240","A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4\u002F6 Inhibitors",[],"2020-06-15","2020-04-15",4650,[435],[46583,459,460],"Ribiciclib",{"intervention":460,"totalTrials":213,"cells":46585},{"EARLY_PHASE1":46586,"PHASE1":46588,"PHASE2":46590,"PHASE3":46592,"PHASE4":46594,"NA":46596},{"trials":46587,"activeCount":103},[],{"trials":46589,"activeCount":103},[],{"trials":46591,"activeCount":103},[],{"trials":46593,"activeCount":103},[],{"trials":46595,"activeCount":103},[],{"trials":46597,"activeCount":103},[46598,46602],{"nctId":451,"briefTitle":452,"status":123,"phases":46599,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":46600,"interventions":46601},[],[435],[98,459,460],{"nctId":46575,"briefTitle":46576,"status":123,"phases":46603,"primaryCompletion":46578,"completion":46578,"start":46579,"enrollment":46580,"conditions":46604,"interventions":46605},[],[435],[46583,459,460],{"intervention":33798,"totalTrials":213,"cells":46607},{"EARLY_PHASE1":46608,"PHASE1":46610,"PHASE2":46612,"PHASE3":46618,"PHASE4":46620,"NA":46622},{"trials":46609,"activeCount":103},[],{"trials":46611,"activeCount":103},[],{"trials":46613,"activeCount":103},[46614],{"nctId":33791,"briefTitle":33792,"status":123,"phases":46615,"primaryCompletion":33794,"completion":62,"start":33795,"enrollment":9106,"conditions":46616,"interventions":46617},[92],[16741],[33774,33798],{"trials":46619,"activeCount":103},[],{"trials":46621,"activeCount":103},[],{"trials":46623,"activeCount":103},[46624],{"nctId":46625,"briefTitle":46626,"status":123,"phases":46627,"primaryCompletion":2301,"completion":2301,"start":46628,"enrollment":46629,"conditions":46630,"interventions":46632},"NCT04847895","Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications",[],"2015-06-01",5500,[46631],"Neovascular (Wet) Age-related Macular Degeneration",[33798],{"intervention":46634,"totalTrials":437,"cells":46635},"Tabrecta",{"EARLY_PHASE1":46636,"PHASE1":46638,"PHASE2":46640,"PHASE3":46642,"PHASE4":46644,"NA":46646},{"trials":46637,"activeCount":103},[],{"trials":46639,"activeCount":103},[],{"trials":46641,"activeCount":103},[],{"trials":46643,"activeCount":103},[],{"trials":46645,"activeCount":103},[],{"trials":46647,"activeCount":103},[46648],{"nctId":46649,"briefTitle":46650,"status":123,"phases":46651,"primaryCompletion":46652,"completion":46652,"start":18044,"enrollment":8239,"conditions":46653,"interventions":46654},"NCT04575025","Special Drug Use-results Surveillance of Tabrecta Tablets",[],"2024-10-26",[128],[46634],{"intervention":46656,"totalTrials":437,"cells":46657},"Lamprene®\u002FClofazimine",{"EARLY_PHASE1":46658,"PHASE1":46660,"PHASE2":46662,"PHASE3":46664,"PHASE4":46666,"NA":46668},{"trials":46659,"activeCount":103},[],{"trials":46661,"activeCount":103},[],{"trials":46663,"activeCount":103},[],{"trials":46665,"activeCount":103},[],{"trials":46667,"activeCount":103},[],{"trials":46669,"activeCount":103},[46670],{"nctId":46671,"briefTitle":46672,"status":491,"phases":46673,"conditions":46674,"interventions":46676},"NCT04334070","Lamprene Multiple Patient Program",[],[46675],"Non-Tuberculous Mycobacterial (NTM) Infections",[46656],{"intervention":46678,"totalTrials":437,"cells":46679},"Lutetium-177 DOTATATE",{"EARLY_PHASE1":46680,"PHASE1":46682,"PHASE2":46684,"PHASE3":46686,"PHASE4":46688,"NA":46690},{"trials":46681,"activeCount":103},[],{"trials":46683,"activeCount":103},[],{"trials":46685,"activeCount":103},[],{"trials":46687,"activeCount":103},[],{"trials":46689,"activeCount":103},[],{"trials":46691,"activeCount":103},[46692],{"nctId":46693,"briefTitle":46694,"status":123,"phases":46695,"primaryCompletion":8201,"completion":8201,"start":46696,"enrollment":827,"conditions":46697,"interventions":46698},"NCT05816720","Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)",[],"2021-09-01",[37382],[46678],{"intervention":45816,"totalTrials":437,"cells":46700},{"EARLY_PHASE1":46701,"PHASE1":46703,"PHASE2":46705,"PHASE3":46707,"PHASE4":46709,"NA":46711},{"trials":46702,"activeCount":103},[],{"trials":46704,"activeCount":103},[],{"trials":46706,"activeCount":103},[],{"trials":46708,"activeCount":103},[],{"trials":46710,"activeCount":103},[],{"trials":46712,"activeCount":103},[46713],{"nctId":45808,"briefTitle":45809,"status":123,"phases":46714,"primaryCompletion":45811,"completion":45811,"start":45812,"enrollment":45813,"conditions":46715,"interventions":46716},[],[15870],[17350,45816],{"intervention":2738,"totalTrials":437,"cells":46718},{"EARLY_PHASE1":46719,"PHASE1":46721,"PHASE2":46723,"PHASE3":46725,"PHASE4":46727,"NA":46729},{"trials":46720,"activeCount":103},[],{"trials":46722,"activeCount":103},[],{"trials":46724,"activeCount":103},[],{"trials":46726,"activeCount":103},[],{"trials":46728,"activeCount":103},[],{"trials":46730,"activeCount":103},[46731],{"nctId":2732,"briefTitle":2733,"status":1326,"phases":46732,"conditions":46733,"interventions":46734},[],[2736],[1078,2738],{"intervention":46502,"totalTrials":437,"cells":46736},{"EARLY_PHASE1":46737,"PHASE1":46739,"PHASE2":46741,"PHASE3":46743,"PHASE4":46745,"NA":46747},{"trials":46738,"activeCount":103},[],{"trials":46740,"activeCount":103},[],{"trials":46742,"activeCount":103},[],{"trials":46744,"activeCount":103},[],{"trials":46746,"activeCount":103},[],{"trials":46748,"activeCount":103},[46749],{"nctId":46497,"briefTitle":46498,"status":123,"phases":46750,"primaryCompletion":5620,"start":4081,"conditions":46751,"interventions":46752},[],[9233],[46478,46502],{"intervention":3894,"totalTrials":437,"cells":46754},{"EARLY_PHASE1":46755,"PHASE1":46757,"PHASE2":46759,"PHASE3":46761,"PHASE4":46763,"NA":46765},{"trials":46756,"activeCount":103},[],{"trials":46758,"activeCount":103},[],{"trials":46760,"activeCount":103},[],{"trials":46762,"activeCount":103},[],{"trials":46764,"activeCount":103},[],{"trials":46766,"activeCount":103},[46767],{"nctId":3886,"briefTitle":3887,"status":123,"phases":46768,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":3891,"conditions":46769,"interventions":46770},[],[27],[3894,2836],{"intervention":46772,"totalTrials":437,"cells":46773},"Nelarabine",{"EARLY_PHASE1":46774,"PHASE1":46776,"PHASE2":46778,"PHASE3":46780,"PHASE4":46782,"NA":46784},{"trials":46775,"activeCount":103},[],{"trials":46777,"activeCount":103},[],{"trials":46779,"activeCount":103},[],{"trials":46781,"activeCount":103},[],{"trials":46783,"activeCount":103},[],{"trials":46785,"activeCount":103},[46786],{"nctId":46787,"briefTitle":46788,"status":123,"phases":46789,"primaryCompletion":46790,"completion":46790,"start":46791,"enrollment":24922,"conditions":46792,"interventions":46793},"NCT01376115","Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg",[],"2017-10-24","2008-01-18",[1102],[46772],{"intervention":46795,"totalTrials":437,"cells":46796},"Indacaterol (Onbrez®) \u002FQAB149",{"EARLY_PHASE1":46797,"PHASE1":46799,"PHASE2":46801,"PHASE3":46803,"PHASE4":46805,"NA":46807},{"trials":46798,"activeCount":103},[],{"trials":46800,"activeCount":103},[],{"trials":46802,"activeCount":103},[],{"trials":46804,"activeCount":103},[],{"trials":46806,"activeCount":103},[],{"trials":46808,"activeCount":103},[46809],{"nctId":46810,"briefTitle":46811,"status":123,"phases":46812,"primaryCompletion":1714,"start":607,"enrollment":12783,"conditions":46813,"interventions":46814},"NCT02123199","Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD",[],[24],[46795],{"intervention":46816,"totalTrials":437,"cells":46817},"Lutathera®",{"EARLY_PHASE1":46818,"PHASE1":46820,"PHASE2":46822,"PHASE3":46824,"PHASE4":46826,"NA":46828},{"trials":46819,"activeCount":103},[],{"trials":46821,"activeCount":103},[],{"trials":46823,"activeCount":103},[],{"trials":46825,"activeCount":103},[],{"trials":46827,"activeCount":103},[],{"trials":46829,"activeCount":103},[46830],{"nctId":46831,"briefTitle":46832,"status":123,"phases":46833,"primaryCompletion":46834,"completion":46834,"start":46835,"enrollment":5841,"conditions":46836,"interventions":46838},"NCT04727723","Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs",[],"2026-03-10","2021-03-09",[46837],"Gastroenteropancreatic Neuroendocrine Tumor",[46816],{"intervention":46583,"totalTrials":437,"cells":46840},{"EARLY_PHASE1":46841,"PHASE1":46843,"PHASE2":46845,"PHASE3":46847,"PHASE4":46849,"NA":46851},{"trials":46842,"activeCount":103},[],{"trials":46844,"activeCount":103},[],{"trials":46846,"activeCount":103},[],{"trials":46848,"activeCount":103},[],{"trials":46850,"activeCount":103},[],{"trials":46852,"activeCount":103},[46853],{"nctId":46575,"briefTitle":46576,"status":123,"phases":46854,"primaryCompletion":46578,"completion":46578,"start":46579,"enrollment":46580,"conditions":46855,"interventions":46856},[],[435],[46583,459,460],{"intervention":46858,"totalTrials":437,"cells":46859},"Mayzent",{"EARLY_PHASE1":46860,"PHASE1":46862,"PHASE2":46864,"PHASE3":46866,"PHASE4":46868,"NA":46870},{"trials":46861,"activeCount":103},[],{"trials":46863,"activeCount":103},[],{"trials":46865,"activeCount":103},[],{"trials":46867,"activeCount":103},[],{"trials":46869,"activeCount":103},[],{"trials":46871,"activeCount":103},[46872],{"nctId":46873,"briefTitle":46874,"status":123,"phases":46875,"primaryCompletion":46876,"completion":46876,"start":46877,"enrollment":46878,"conditions":46879,"interventions":46880},"NCT04593927","Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients",[],"2023-08-30","2020-10-28",451,[6228],[46858],{"intervention":46882,"totalTrials":437,"cells":46883},"Secikinumab",{"EARLY_PHASE1":46884,"PHASE1":46886,"PHASE2":46888,"PHASE3":46890,"PHASE4":46892,"NA":46894},{"trials":46885,"activeCount":103},[],{"trials":46887,"activeCount":103},[],{"trials":46889,"activeCount":103},[],{"trials":46891,"activeCount":103},[],{"trials":46893,"activeCount":103},[],{"trials":46895,"activeCount":103},[46896],{"nctId":46897,"briefTitle":46898,"status":123,"phases":46899,"primaryCompletion":46900,"completion":46900,"start":46901,"enrollment":46902,"conditions":46903,"interventions":46904},"NCT02786186","A Registry of Patients With Moderate to Severe Plaque Psoriasis",[],"2026-01-22","2015-12-23",2376,[1675],[46882],{"intervention":46906,"totalTrials":437,"cells":46907},"lifitegrast",{"EARLY_PHASE1":46908,"PHASE1":46910,"PHASE2":46912,"PHASE3":46914,"PHASE4":46916,"NA":46918},{"trials":46909,"activeCount":103},[],{"trials":46911,"activeCount":103},[],{"trials":46913,"activeCount":103},[],{"trials":46915,"activeCount":103},[],{"trials":46917,"activeCount":103},[],{"trials":46919,"activeCount":103},[46920],{"nctId":46921,"briefTitle":46922,"status":390,"phases":46923,"primaryCompletion":46924,"completion":46924,"start":1265,"enrollment":103,"conditions":46925,"interventions":46927},"NCT05857748","Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Utilization of Patients With Dry Eye Disease",[],"2024-12-30",[46926],"Dry Eye Disease",[46906],{"intervention":46929,"totalTrials":437,"cells":46930},"Glivec",{"EARLY_PHASE1":46931,"PHASE1":46933,"PHASE2":46935,"PHASE3":46937,"PHASE4":46939,"NA":46941},{"trials":46932,"activeCount":103},[],{"trials":46934,"activeCount":103},[],{"trials":46936,"activeCount":103},[],{"trials":46938,"activeCount":103},[],{"trials":46940,"activeCount":103},[],{"trials":46942,"activeCount":103},[46943],{"nctId":46944,"briefTitle":46945,"status":1326,"phases":46946,"conditions":46947,"interventions":46948},"NCT01613053","Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination",[],[3281],[46929],{"intervention":44812,"totalTrials":437,"cells":46950},{"EARLY_PHASE1":46951,"PHASE1":46953,"PHASE2":46955,"PHASE3":46957,"PHASE4":46959,"NA":46961},{"trials":46952,"activeCount":103},[],{"trials":46954,"activeCount":103},[],{"trials":46956,"activeCount":103},[],{"trials":46958,"activeCount":103},[],{"trials":46960,"activeCount":103},[],{"trials":46962,"activeCount":103},[46963],{"nctId":44805,"briefTitle":44806,"status":123,"phases":46964,"primaryCompletion":1781,"completion":1781,"start":3490,"enrollment":44808,"conditions":46965,"interventions":46966},[],[44810],[17147,44812],{"intervention":46968,"totalTrials":437,"cells":46969},"First-line Ribociclib + endocrine therapy",{"EARLY_PHASE1":46970,"PHASE1":46972,"PHASE2":46974,"PHASE3":46976,"PHASE4":46978,"NA":46980},{"trials":46971,"activeCount":103},[],{"trials":46973,"activeCount":103},[],{"trials":46975,"activeCount":103},[],{"trials":46977,"activeCount":103},[],{"trials":46979,"activeCount":103},[],{"trials":46981,"activeCount":103},[46982],{"nctId":46983,"briefTitle":46984,"status":123,"phases":46985,"primaryCompletion":46986,"completion":46986,"start":46987,"enrollment":46988,"conditions":46989,"interventions":46990},"NCT06311383","A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI\u002FFUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment",[],"2025-03-10","2017-10-09",2610,[15],[46968,46991,46992],"First-line endocrine therapy","First-line chemtherapy",{"intervention":46991,"totalTrials":437,"cells":46994},{"EARLY_PHASE1":46995,"PHASE1":46997,"PHASE2":46999,"PHASE3":47001,"PHASE4":47003,"NA":47005},{"trials":46996,"activeCount":103},[],{"trials":46998,"activeCount":103},[],{"trials":47000,"activeCount":103},[],{"trials":47002,"activeCount":103},[],{"trials":47004,"activeCount":103},[],{"trials":47006,"activeCount":103},[47007],{"nctId":46983,"briefTitle":46984,"status":123,"phases":47008,"primaryCompletion":46986,"completion":46986,"start":46987,"enrollment":46988,"conditions":47009,"interventions":47010},[],[15],[46968,46991,46992],{"intervention":46992,"totalTrials":437,"cells":47012},{"EARLY_PHASE1":47013,"PHASE1":47015,"PHASE2":47017,"PHASE3":47019,"PHASE4":47021,"NA":47023},{"trials":47014,"activeCount":103},[],{"trials":47016,"activeCount":103},[],{"trials":47018,"activeCount":103},[],{"trials":47020,"activeCount":103},[],{"trials":47022,"activeCount":103},[],{"trials":47024,"activeCount":103},[47025],{"nctId":46983,"briefTitle":46984,"status":123,"phases":47026,"primaryCompletion":46986,"completion":46986,"start":46987,"enrollment":46988,"conditions":47027,"interventions":47028},[],[15],[46968,46991,46992],{"intervention":47030,"totalTrials":437,"cells":47031},"Xolair",{"EARLY_PHASE1":47032,"PHASE1":47034,"PHASE2":47036,"PHASE3":47038,"PHASE4":47040,"NA":47042},{"trials":47033,"activeCount":103},[],{"trials":47035,"activeCount":103},[],{"trials":47037,"activeCount":103},[],{"trials":47039,"activeCount":103},[],{"trials":47041,"activeCount":103},[],{"trials":47043,"activeCount":103},[47044],{"nctId":47045,"briefTitle":47046,"status":123,"phases":47047,"primaryCompletion":47048,"completion":47048,"start":1433,"enrollment":2579,"conditions":47049,"interventions":47050},"NCT04648930","Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and \u003C 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies",[],"2022-11-03",[19482],[47030],{"intervention":47052,"totalTrials":437,"cells":47053},"Beovu",{"EARLY_PHASE1":47054,"PHASE1":47056,"PHASE2":47058,"PHASE3":47060,"PHASE4":47062,"NA":47064},{"trials":47055,"activeCount":103},[],{"trials":47057,"activeCount":103},[],{"trials":47059,"activeCount":103},[],{"trials":47061,"activeCount":103},[],{"trials":47063,"activeCount":103},[],{"trials":47065,"activeCount":103},[47066],{"nctId":47067,"briefTitle":47068,"status":123,"phases":47069,"primaryCompletion":3097,"completion":3097,"start":35652,"enrollment":47070,"conditions":47071,"interventions":47072},"NCT04632056","A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD",[],329,[18365],[47052],{"intervention":47074,"totalTrials":437,"cells":47075},"Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant",{"EARLY_PHASE1":47076,"PHASE1":47078,"PHASE2":47080,"PHASE3":47082,"PHASE4":47084,"NA":47086},{"trials":47077,"activeCount":103},[],{"trials":47079,"activeCount":103},[],{"trials":47081,"activeCount":103},[],{"trials":47083,"activeCount":103},[],{"trials":47085,"activeCount":103},[],{"trials":47087,"activeCount":103},[47088],{"nctId":47089,"briefTitle":47090,"status":123,"phases":47091,"primaryCompletion":13432,"completion":13432,"start":2120,"enrollment":16082,"conditions":47092,"interventions":47094},"NCT02753686","Treatment of Canadian Men and Pre\u002FPeri\u002FPost-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy",[],[47093],"HR+ HER2- Men, Pre\u002FPostmenopausal Advanced Breast Cancer",[47074,47095],"Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4\u002F6 inhibitor plus endocrine therapy",{"intervention":47095,"totalTrials":437,"cells":47097},{"EARLY_PHASE1":47098,"PHASE1":47100,"PHASE2":47102,"PHASE3":47104,"PHASE4":47106,"NA":47108},{"trials":47099,"activeCount":103},[],{"trials":47101,"activeCount":103},[],{"trials":47103,"activeCount":103},[],{"trials":47105,"activeCount":103},[],{"trials":47107,"activeCount":103},[],{"trials":47109,"activeCount":103},[47110],{"nctId":47089,"briefTitle":47090,"status":123,"phases":47111,"primaryCompletion":13432,"completion":13432,"start":2120,"enrollment":16082,"conditions":47112,"interventions":47113},[],[47093],[47074,47095],{"intervention":47115,"totalTrials":437,"cells":47116},"MF\u002FIND\u002FGLY plus sensor system",{"EARLY_PHASE1":47117,"PHASE1":47119,"PHASE2":47121,"PHASE3":47123,"PHASE4":47125,"NA":47127},{"trials":47118,"activeCount":103},[],{"trials":47120,"activeCount":103},[],{"trials":47122,"activeCount":103},[],{"trials":47124,"activeCount":103},[],{"trials":47126,"activeCount":103},[],{"trials":47128,"activeCount":103},[47129],{"nctId":47130,"briefTitle":47131,"status":123,"phases":47132,"primaryCompletion":6742,"completion":6742,"start":47133,"enrollment":1953,"conditions":47134,"interventions":47135},"NCT04656223","Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions",[],"2020-12-17",[18],[47115,47136],"FDC therapy",{"intervention":47136,"totalTrials":437,"cells":47138},{"EARLY_PHASE1":47139,"PHASE1":47141,"PHASE2":47143,"PHASE3":47145,"PHASE4":47147,"NA":47149},{"trials":47140,"activeCount":103},[],{"trials":47142,"activeCount":103},[],{"trials":47144,"activeCount":103},[],{"trials":47146,"activeCount":103},[],{"trials":47148,"activeCount":103},[],{"trials":47150,"activeCount":103},[47151],{"nctId":47130,"briefTitle":47131,"status":123,"phases":47152,"primaryCompletion":6742,"completion":6742,"start":47133,"enrollment":1953,"conditions":47153,"interventions":47154},[],[18],[47115,47136],{"intervention":47156,"totalTrials":437,"cells":47157},"Pasireotide long acting release formulation",{"EARLY_PHASE1":47158,"PHASE1":47160,"PHASE2":47162,"PHASE3":47164,"PHASE4":47166,"NA":47168},{"trials":47159,"activeCount":103},[],{"trials":47161,"activeCount":103},[],{"trials":47163,"activeCount":103},[],{"trials":47165,"activeCount":103},[],{"trials":47167,"activeCount":103},[],{"trials":47169,"activeCount":103},[47170],{"nctId":47171,"briefTitle":47172,"status":3636,"phases":47173,"conditions":47174,"interventions":47175},"NCT01995734","An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly",[],[8385],[47156],{"intervention":13654,"totalTrials":437,"cells":47177},{"EARLY_PHASE1":47178,"PHASE1":47180,"PHASE2":47182,"PHASE3":47184,"PHASE4":47186,"NA":47188},{"trials":47179,"activeCount":103},[],{"trials":47181,"activeCount":103},[],{"trials":47183,"activeCount":103},[],{"trials":47185,"activeCount":103},[],{"trials":47187,"activeCount":103},[],{"trials":47189,"activeCount":103},[47190],{"nctId":13645,"briefTitle":13646,"status":123,"phases":47191,"primaryCompletion":13648,"completion":13648,"start":13649,"enrollment":13650,"conditions":47192,"interventions":47193},[],[13652],[5187,8153,13654,13655,13656,13657],{"intervention":13655,"totalTrials":437,"cells":47195},{"EARLY_PHASE1":47196,"PHASE1":47198,"PHASE2":47200,"PHASE3":47202,"PHASE4":47204,"NA":47206},{"trials":47197,"activeCount":103},[],{"trials":47199,"activeCount":103},[],{"trials":47201,"activeCount":103},[],{"trials":47203,"activeCount":103},[],{"trials":47205,"activeCount":103},[],{"trials":47207,"activeCount":103},[47208],{"nctId":13645,"briefTitle":13646,"status":123,"phases":47209,"primaryCompletion":13648,"completion":13648,"start":13649,"enrollment":13650,"conditions":47210,"interventions":47211},[],[13652],[5187,8153,13654,13655,13656,13657],{"intervention":13656,"totalTrials":437,"cells":47213},{"EARLY_PHASE1":47214,"PHASE1":47216,"PHASE2":47218,"PHASE3":47220,"PHASE4":47222,"NA":47224},{"trials":47215,"activeCount":103},[],{"trials":47217,"activeCount":103},[],{"trials":47219,"activeCount":103},[],{"trials":47221,"activeCount":103},[],{"trials":47223,"activeCount":103},[],{"trials":47225,"activeCount":103},[47226],{"nctId":13645,"briefTitle":13646,"status":123,"phases":47227,"primaryCompletion":13648,"completion":13648,"start":13649,"enrollment":13650,"conditions":47228,"interventions":47229},[],[13652],[5187,8153,13654,13655,13656,13657],{"intervention":13657,"totalTrials":437,"cells":47231},{"EARLY_PHASE1":47232,"PHASE1":47234,"PHASE2":47236,"PHASE3":47238,"PHASE4":47240,"NA":47242},{"trials":47233,"activeCount":103},[],{"trials":47235,"activeCount":103},[],{"trials":47237,"activeCount":103},[],{"trials":47239,"activeCount":103},[],{"trials":47241,"activeCount":103},[],{"trials":47243,"activeCount":103},[47244],{"nctId":13645,"briefTitle":13646,"status":123,"phases":47245,"primaryCompletion":13648,"completion":13648,"start":13649,"enrollment":13650,"conditions":47246,"interventions":47247},[],[13652],[5187,8153,13654,13655,13656,13657],{"intervention":13666,"totalTrials":437,"cells":47249},{"EARLY_PHASE1":47250,"PHASE1":47252,"PHASE2":47254,"PHASE3":47256,"PHASE4":47258,"NA":47260},{"trials":47251,"activeCount":103},[],{"trials":47253,"activeCount":103},[],{"trials":47255,"activeCount":103},[],{"trials":47257,"activeCount":103},[],{"trials":47259,"activeCount":103},[],{"trials":47261,"activeCount":103},[47262],{"nctId":13659,"briefTitle":13660,"status":123,"phases":47263,"primaryCompletion":6327,"completion":6327,"start":13662,"enrollment":13663,"conditions":47264,"interventions":47265},[],[36],[5187,13666,8153,13667]]